PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Yokoh, H; Kobayashi, K; Sato, Y; Takemoto, M; Uchida, D; Kanatsuka, A; Kuribayashi, N; Terano, T; Hashimoto, N; Sakurai, K; Hanaoka, H; Ishikawa, K; Onishi, S; Yokote, K				Yokoh, Hidetaka; Kobayashi, Kazuki; Sato, Yasunori; Takemoto, Minoru; Uchida, Daigaku; Kanatsuka, Azuma; Kuribayashi, Nobuichi; Terano, Takashi; Hashimoto, Naotake; Sakurai, Kenichi; Hanaoka, Hideki; Ishikawa, Ko; Onishi, Shunichiro; Yokote, Koutaro		SUCCESS Study Grp	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial	JOURNAL OF DIABETES INVESTIGATION			English	Article						Alpha-glucosidase inhibitor; Combination drug therapy; Sitagliptin	GLUCAGON-LIKE PEPTIDE-1; DOUBLE-BLIND TRIAL; GLYCEMIC CONTROL; CLINICAL-TRIAL; PARALLEL-GROUP; MIXED MEAL; MELLITUS; ACARBOSE; INSULIN; MONOTHERAPY	Aims/IntroductionTo assess the efficacy and safety of sitagliptin compared with -glucosidase inhibitors in Japanese patients with type2 diabetes inadequately controlled by metformin or pioglitazone alone. Materials and MethodsIn the present multicenter, randomized, open-label, parallel-group, active-controlled, non-inferiority trial, 119 patients aged 20-79years with type2 diabetes who had glycated hemoglobin 6.9-8.8% on stable metformin (500-1,500mg/day) or pioglitazone (15-30mg/day) alone were randomly assigned (1:1) to receive the addition of sitagliptin (50mg/day) or an -glucosidase inhibitor (0.6mg/day voglibose or 150mg/day miglitol) for 24weeks. The primary end-point was change in glycated hemoglobin from baseline to week12. All data were analyzed according to the intention-to-treat principle. ResultsAfter 12weeks, reductions in adjusted mean glycated hemoglobin from baseline were -0.70% in sitagliptin and -0.21% in the -glucosidase inhibitor groups respectively; between-group difference was -0.49% (95% confidence interval -0.66 to -0.32, P<0.0001), meeting the predefined non-inferiority criterion (0.25%) and showing statistical significance. This statistical significance also continued after 24weeks. Although sitagliptin did not affect bodyweight, -glucosidase inhibitors decreased bodyweight significantly from baseline (-0.39kg; P=0.0079). Gastrointestinal disorders were significantly lower with sitagliptin than with an -glucosidase inhibitor (6 [10.3%] patients vs 23 [39.7%]; P=0.0003). Minor hypoglycemia occurred in two patients (3.5%) in each group. ConclusionsSitagliptin showed greater efficacy and better tolerability than an -glucosidase inhibitor when added to stable doses of metformin or pioglitazone. These findings support the use of sitagliptin in Japanese patients with type2 diabetes inadequately controlled by insulin-sensitizing agents. This trial was registered with UMIN (no. 000004675).	[Yokoh, Hidetaka; Takemoto, Minoru; Sakurai, Kenichi; Ishikawa, Ko; Onishi, Shunichiro; Yokote, Koutaro] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan; [Kobayashi, Kazuki] Chiba Univ, Grad Sch Med, Dept Reg Disaster Med, Chiba, Japan; [Yokoh, Hidetaka; Kobayashi, Kazuki; Takemoto, Minoru; Sakurai, Kenichi; Ishikawa, Ko; Onishi, Shunichiro; Yokote, Koutaro] Chiba Univ Hosp, Dept Diabet Metab & Endocrinol, Chiba, Japan; [Yokoh, Hidetaka; Sato, Yasunori; Hanaoka, Hideki] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan; [Uchida, Daigaku] Hotaruno Cent Clin, Chiba, Japan; [Kanatsuka, Azuma] Chiba Cent Med Ctr, Chiba, Japan; [Kuribayashi, Nobuichi] Misaki Naika Clin, Chiba, Japan; [Terano, Takashi] Chiba Aoba Municipal Hosp, Chiba, Japan; [Hashimoto, Naotake] Tokyo Womens Med Univ, Yachiyo Med Ctr, Chiba, Japan	Yokote, K (reprint author), Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan.	kyokote@faculty.chiba-u.jp			Waksman Foundation of Japan Inc., Tokyo; Japanese Ministry of Health, Labor and Welfare; Ministry of Education, Culture, Sports, Science and Technology	This study was designed and led by a steering committee of the SUCCESS study group, funded by the Waksman Foundation of Japan Inc., Tokyo, the Grant-in-Aid from the Japanese Ministry of Health, Labor and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology. KY has received research endowment for his Department from MSD (Merck). The sponsors played no role in the design and management of the study, collection and analysis of the data, interpretation of the results, or the writing of the report. The authors declare no conflict of interest. The authors thank the SUCCESS investigators for participating in this study (see the list of investigators in Appendix 1) and the staff of the Chiba University Hospital Clinical Research Center for their assistance in the performance of this study: Junpei Kamimoto, Ami Kuninobu, Ayumi Miura, Yumiko Imai, Asako Kohno, Nanae Tanemura, Asuka Nemoto, Nobuko Yamaguchi and Yasuhisa Fujii.	Ahren B, 2007, REGUL PEPTIDES, V143, P97, DOI 10.1016/j.regpep.2007.03.008; American Diabetes Association, 2011, DIABETES CARE S1, V34, pS11, DOI DOI 10.2337/DC11-S011; Pospisilik JA, 2003, DIABETES, V52, P741, DOI 10.2337/diabetes.52.3.741; Rosenstock J, 2006, CLIN THER, V28, P1556, DOI 10.1016/j.clinthera.2006.10.007; Patil HR, 2012, AM J CARDIOL, V110, P826, DOI 10.1016/j.amjcard.2012.04.061; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Hucking K, 2005, DIABETIC MED, V22, P470, DOI 10.1111/j.1464-5491.2005.01451.x; van de Laar FA, 2005, DIABETES CARE, V28, P154, DOI 10.2337/diacare.28.1.154; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Nonaka K, 2008, DIABETES RES CLIN PR, V79, P291, DOI 10.1016/j.diabres.2007.08.021; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Lamers D, 2011, DIABETES, V60, P1917, DOI 10.2337/db10-1707; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009; Charbonnel B, 2006, DIABETES CARE, V29, P2638, DOI 10.2337/dc06-0706; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Sasaki T, 2013, ENDOCR J, V60, P1117, DOI 10.1507/endocrj.EJ13-0333; Narita T, 2009, DIABETIC MED, V26, P187, DOI 10.1111/j.1464-5491.2008.02651.x; Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8; Maida A, 2011, DIABETOLOGIA, V54, P339, DOI 10.1007/s00125-010-1937-z; Migoya EM, 2010, CLIN PHARMACOL THER, V88, P801, DOI 10.1038/clpt.2010.184; Solis-Herrera C, 2013, DIABETES CARE, V36, P2756, DOI 10.2337/dc12-2072; Skyler JS, 2009, CIRCULATION, V119, P351, DOI 10.1161/CIRCULATIONAHA.108.191305; Yamanouchi T, 1996, LANCET, V347, P1514, DOI 10.1016/S0140-6736(96)90672-8; Horton ES, 2010, DIABETES CARE, V33, P1759, DOI 10.2337/dc09-2062; Narita T, 2012, DIABETES OBES METAB, V14, P283, DOI 10.1111/j.1463-1326.2011.01526.x; Raz I, 2006, DIABETOLOGIA, V49, P2564, DOI 10.1007/s00125-006-0416-z; DeLeon MJ, 2002, DIABETES RES CLIN PR, V56, P101, DOI 10.1016/S0168-8227(01)00359-X; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Hanefeld M, 2004, EUR HEART J, V25, P10, DOI 10.1016/S0195-668X(03)00468-8; Lee A, 2002, DIABETES OBES METAB, V4, P329, DOI 10.1046/j.1463-1326.2002.00219.x; Kawamori R, 2009, LANCET, V373, P1607, DOI 10.1016/S0140-6736(09)60222-1; Miyazaki Y, 2002, J CLIN ENDOCR METAB, V87, P2784, DOI 10.1210/jc.87.6.2784; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI [10.2337/dc12-0413, 10.2337/dc12-041.3]; Iwamoto Y, 2010, DIABETES OBES METAB, V12, P613, DOI 10.1111/j.1463-1326.2010.01197.x; Kadowaki T, 2008, P 68 ADA SCI SESS SA; Kanatsuka Azuma, 2006, Journal of the Japan Diabetes Society, V49, P409; Kashiwagi A, 2008, P 68 ADA SCI SESS SA; Kobayashi K, 2014, DIABETES OBES METAB, V16, P761, DOI 10.1111/dom.12264; Turner RC, 1998, LANCET, V352, P854; UK Prospective Diabetes Study (UKPDS) Group, 1998, LANCET, V352, P837, DOI DOI 10.1016/S0140-6736(98)07019-6; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	46	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					182	191		10.1111/jdi.12282		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700011		
J	Takeshita, Y; Takamura, T; Kita, Y; Otoda, T; Kato, K; Wakakuri, H; Yamada, M; Misu, H; Matsushima, Y; Kaneko, S				Takeshita, Yumie; Takamura, Toshinari; Kita, Yuki; Otoda, Toshiki; Kato, Ken-ichiro; Wakakuri, Hitomi; Yamada, Masayuki; Misu, Hirofumi; Matsushima, Yukiko; Kaneko, Shuichi		Estab Rationale Antiaging Diabetic	Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study	JOURNAL OF DIABETES INVESTIGATION			English	Article						Dipeptidyl peptidase-4 inhibitor; Glucagon-like peptide-1 receptor agonists; Pleiotropic effects	DIPEPTIDYL PEPTIDASE-4 INHIBITORS; BETA-CELL FUNCTION; HUMAN GLP-1 ANALOG; OPEN-LABEL TRIAL; GLYCEMIC CONTROL; RECEPTOR AGONISTS; DOUBLE-BLIND; GLUCOSE; METAANALYSIS; METFORMIN	IntroductionA step-up strategy for dipeptidyl peptidase (DPP)-4 inhibitor-based regimens has not yet been established. In addition, similarities and differences between DPP-4 inhibitors and glucagon-like peptide (GLP)-1 receptor agonists remain to be elucidated in humans. We investigated the pleiotropic effects of vildagliptin vs liraglutide in patients with type 2 diabetes on sitagliptin-based regimens in an open-label, randomized, clinical trial. Materials and MethodsA total of 122 patients with type 2 diabetes that was inadequately controlled by sitagliptin-based regimens were randomly assigned to either vildagliptin (50mg, twice daily) or liraglutide treatment (0.9mg, once daily) for 12weeks. The primary outcomes were glycated hemoglobin and body mass index. ResultsBoth vildagliptin and liraglutide significantly lowered glycated hemoglobin within 12weeks after switching from sitagliptin, but liraglutide produced a greater reduction (-0.670.12% vs -0.36 +/- 0.53%). Liraglutide lowered body mass index, whereas vildagliptin did not affect body mass index. Vildagliptin lowered fasting C-peptide immunoreactivity, but liraglutide did not. Vildagliptin increased serum levels of adiponectin, arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, whereas liraglutide had no effect on these levels. Quality of life, assessed using the diabetes treatment satisfaction questionnaire, was not impaired in either group. The most common adverse events were gastrointestinal symptoms, which occurred with similar frequencies in both groups. ConclusionsVildagliptin-mediated improvements in glycemic control did not correlate with indices for insulin secretion and insulin sensitivity. Switching from sitagliptin to liraglutide is useful in managing hyperglycemia and weight. Each agent exerts unique pleiotropic effects. This trial was registered with the University Hospital Medical Information Network Clinical Trials Registry (no. 000004953).	[Takeshita, Yumie; Takamura, Toshinari; Kita, Yuki; Otoda, Toshiki; Kato, Ken-ichiro; Wakakuri, Hitomi; Yamada, Masayuki; Misu, Hirofumi; Matsushima, Yukiko; Kaneko, Shuichi; Estab Rationale Antiaging Diabetic] Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan	Takamura, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Dis Control & Homeostasis, Kanazawa, Ishikawa, Japan.	ttakamura@m-kanazawa.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan; Novo Nordisk; Novartis	This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and research grants from Novo Nordisk and Novartis (to TT and SK). Clinical Centers for the Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group: Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science (Kanazawa, Ishikawa): Yumie Takeshita MD PhD, Toshinari Takamura MD PhD, Toshiki Otoda MD PhD; Kenichiro Kato MD, Hitomi Wakakuri MD, Masayuki Yamada MD, Hirofumi Misu MD PhD, Shuichi Kaneko MD PhD, Tsuguhito Ota MD PhD, Takehiro Kanamori MD, Yukiko Matsushima (coordinator), Shima Kitakata (coordinator); Handa Medical Clinic (Kanazawa, Ishikawa): Yumie Takeshita MD PhD; Public Hakui Hospital (Hakui, Ishikawa): Toshiki Otoda MD PhD; Japanese Red Cross Kanazawa Hospital (Kanazawa, Ishikawa): Erika Hamaguchi MD PhD and Yasuyuki Nishimura MD PhD; Toyama City Hospital (Toyama, Toyama), Akiko Shimizu MD PhD; Public Central Hospital of Matto Ishikawa (Matto, Ishikawa): Yuki Kita MD and Kozo Kawai MD PhD; Kahoku Central Hospital (Kahoku, Ishikawa), Kensuke Mouri MD; Fukui Saiseikai Hospital (Fukui, Fukui): Kosuke R Shima MD and Yukihiro Bando MD PhD; Kanazawa Municipal Hospital (Kanazawa, Ishikawa): Nobuhiko Koike MD PhD.	Ray KK, 2009, LANCET, V373, P1765, DOI 10.1016/S0140-6736(09)60697-8; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Rizzo MR, 2012, DIABETES CARE, V35, P2076, DOI 10.2337/dc12-0199; Esposito K, 2011, DIABETES OBES METAB, V13, P594, DOI 10.1111/j.1463-1326.2011.01380.x; Aschner P, 2006, DIABETES CARE, V29, P2632, DOI 10.2337/dc06-0703; Buse JB, 2007, CLIN THER, V29, P139, DOI 10.1016/j.clintera.2007.01.015; Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5; He H, 2009, DRUG METAB DISPOS, V37, P536, DOI 10.1124/dmd.108.023010; BRADLEY C, 1994, DIABETIC MED, V11, P510; Puavilai G, 1999, DIABETES RES CLIN PR, V44, P21, DOI 10.1016/S0168-8227(99)00008-X; Yang W, 2011, DIABETES OBES METAB, V13, P81, DOI 10.1111/j.1463-1326.2010.01323.x; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Lamers D, 2011, DIABETES, V60, P1917, DOI 10.2337/db10-1707; Degn KB, 2004, DIABETES, V53, P1187, DOI 10.2337/diabetes.53.5.1187; Kothny W, 2012, DIABETES OBES METAB, V14, P1032, DOI 10.1111/j.1463-1326.2012.01634.x; Pratley RE, 2010, LANCET, V375, P1447, DOI 10.1016/S0140-6736(10)60307-8; Marre M, 2009, DIABETIC MED, V26, P268, DOI 10.1111/j.1464-5491.2009.02666.x; Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402; Nauck M, 2009, DIABETES CARE, V32, P84, DOI 10.2337/dc08-1355; Garber A, 2009, LANCET, V373, P473, DOI 10.1016/S0140-6736(08)61246-5; Aroda VR, 2012, CLIN THER, V34, P1247, DOI 10.1016/j.clinthera.2012.04.013; Buse John B, 2009, Lancet, V374, P39, DOI 10.1016/S0140-6736(09)60659-0; Bradley C, 1994, HDB PSYCHOL DIABETES, P111; Cuthbertson DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050117; Inzucchi SE, 2012, DIABETES CARE, V35, P1364, DOI [10.2337/dc12-0413, 10.2337/dc12-041.3]; Ishii H, 2000, J CLIN EXP MED, V192, P809; Morishita M, 2008, J CONTROL RELEASE, V132, P99, DOI 10.1016/j.jconrel.2008.09.001; Peyrot M, 2009, DIABETES CARE, V32, P1411, DOI 10.2337/dc08-2256; Schmidt WE, 2009, DIABETOLOGIA, V52, pS289; Senmaru T, 2012, J DIABETES INVEST, V3, P498, DOI 10.1111/j.2040-1124.2012.00220.x; Tushuizen ME, 2006, LIVER INT, V26, P1015, DOI 10.1111/j.1478-3231.2006.01315.x; vansGenugten RE, 2013, DIABETES OBES METAB, V15, P593	32	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					192	200		10.1111/jdi.12269		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700012		
J	Onishi, Y; Niemoeller, E; Ikeda, Y; Takagi, H; Yabe, D; Seino, Y				Onishi, Yukiko; Niemoeller, Elisabeth; Ikeda, Yukio; Takagi, Hiroki; Yabe, Daisuke; Seino, Yutaka			Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S	JOURNAL OF DIABETES INVESTIGATION			English	Article						Glucagon-like peptide-1 receptor; Japanese; Lixisenatide	RECEPTOR AGONIST LIXISENATIDE; PLACEBO-CONTROLLED TRIAL; ONCE-DAILY LIXISENATIDE; BETA-CELL FUNCTION; BASAL INSULIN; DOUBLE-BLIND; GLYCEMIC CONTROL; LIRAGLUTIDE; SECRETION; 24-WEEK	Aims/IntroductionThis was a subanalysis of Japanese patients included in the glucagon-like peptide-1 receptor agonist AVE0010 in patients with type2 diabetes mellitus for glycemic control and safety evaluation (GetGoal-S) study - a 24-week, randomized, placebo-controlled study of lixisenatide in patients with type2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin. Materials and MethodsIn GetGoal-S, 127 Japanese patients received the once-daily prandial glucagon-like peptide-1 receptor agonist lixisenatide 20g/day or a matching placebo. The primary outcome was change in glycated hemoglobin. ResultsAt week24, lixisenatide significantly reduced mean glycated hemoglobin (least squares mean difference vs the placebo -1.1% [12mmol/mol, P<0.0001]), and significantly more lixisenatide patients reached glycated hemoglobin targets of <7% (53mmol/mol) and 6.5% (48mmol/mol) vs the placebo. Lixisenatide produced statistically significant reductions in 2-h postprandial plasma glucose (least squares mean difference vs the placebo -8.51mmol/L, P<0.0001) and glucose excursion vs the placebo, and significantly reduced fasting plasma glucose (least squares mean difference vs the placebo -0.65mmol/L, P=0.0454). Bodyweight decreased with both lixisenatide and the placebo (least squares mean change -1.12kg for lixisenatide, -1.02kg for placebo). The overall incidence of adverse events was similar for lixisenatide and the placebo (84.2 and 82.4%, respectively), the most frequent being gastrointestinal disorders (52.6% for lixisenatide vs 29.4% for placebo). The incidence of symptomatic hypoglycemia was higher with lixisenatide vs the placebo (17.1 and 9.8%, respectively), with no cases of severe symptomatic hypoglycemia in either group. ConclusionsIn the Japanese subpopulation of the GetGoal-S study, lixisenatide produced a significant and clinically relevant improvement in glycated hemoglobin, with a pronounced improvement in postprandial plasma glucose, and a good safety and tolerability profile.	[Onishi, Yukiko] Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan; [Ikeda, Yukio; Takagi, Hiroki] Sanofi, Tokyo, Japan; [Yabe, Daisuke; Seino, Yutaka] Kansai Elect Power Hosp, Osaka, Japan; [Niemoeller, Elisabeth] Sanofi R&D, Frankfurt, Germany	Onishi, Y (reprint author), Asahi Life Fdn, Inst Adult Dis, Tokyo, Japan.	y-ohnishi@asahi-life.or.jp	Yabe, Daisuke/J-6682-2014	Yabe, Daisuke/0000-0002-5334-7687	Sanofi; Eli Lilly; MSD; Novo Nordisk; Takeda	The study was supported by Sanofi. Editorial support was provided by Medicus International London (UK) and Caudex Medical, and was funded by Sanofi. Yukiko Onishi has acted as medical advisor for Sanofi, Novo Nordisk Pharma Ltd and Astra-Zeneca. Daisuke Yabe has received consulting and/or speaker fees from Eli Lilly, MSD, Sanofi, Novo Nordisk and Takeda. Yutaka Seino has acted as medical advisor for Eli Lilly, Sanofi, Novo Nordisk, GlaxoSmithKline, Taisho Pharmaceuticals, Astellas Pharmaceuticals, Becton, Dickinson & Company, Boerhringer Ingelheim, Johnson & Johnson, Takeda Pharmaceuticals and Otsuka Pharmaceuticals. Elisabeth Niemoeller, Yukio Ikeda and Hiroki Takagi are employees of Sanofi. Sanofi was responsible for the design and implementation of this study. Yukiko Onishi was one of the principle investigators of this study. All authors contributed to the interpretation of the data and provided comments on the report at various stages in its development. Hiroki Takagi undertook statistical analyses. Elisabeth Niemoeller made significant suggestions to analysis and interpretation of data. Yukio Ikeda drafted the manuscript. All authors were involved in developing the manuscript, providing critical review of the content and final approval of the version to be published.	Ahren B, 2014, J DIABETES COMPLICAT, V28, P735, DOI 10.1016/j.jdiacomp.2014.05.012; Anichini Roberto, 2013, Diabetes Metab Syndr Obes, V6, P123, DOI 10.2147/DMSO.S42729; Kadowaki T, 2011, J DIABETES INVEST, V2, P210, DOI 10.1111/j.2040-1124.2010.00084.x; Meier JJ, 2012, NAT REV ENDOCRINOL, V8, P728, DOI 10.1038/nrendo.2012.140; Ratner RE, 2010, DIABETIC MED, V27, P1024, DOI 10.1111/j.1464-5491.2010.03020.x; Pearce KL, 2008, AM J CLIN NUTR, V87, P638; Kobayashi M, 2006, DIABETES RES CLIN PR, V73, P198, DOI 10.1016/j.diabres.2006.01.013; Yabe D, 2010, J DIABETES INVEST, V1, P56, DOI 10.1111/j.2040-1124.2010.00010.x; Seino Y, 2012, DIABETES OBES METAB, V14, P910, DOI 10.1111/j.1463-1326.2012.01618.x; Morimoto A, 2013, DIABETOLOGIA, V56, P1671, DOI 10.1007/s00125-013-2932-y; Rosenstock J, 2014, J DIABETES COMPLICAT, V28, P386, DOI 10.1016/j.jdiacomp.2014.01.012; Fonseca VA, 2012, DIABETES CARE, V35, P1225, DOI 10.2337/dc11-1935; Usui R, 2013, J DIABETES INVEST, V4, P585, DOI 10.1111/jdi.12111; Yabe D, 2012, J DIABETES INVEST, V3, P70, DOI 10.1111/j.2040-1124.2011.00141.x; Seino Y, 2010, J DIABETES INVEST, V1, P1, DOI 10.1111/j.2040-1124.2010.00005.x; Whiting DR, 2011, DIABETES RES CLIN PR, V94, P311, DOI 10.1016/j.diabres.2011.10.029; Riddle MC, 2013, DIABETES CARE, V36, P2489, DOI 10.2337/dc12-2454; Riddle MC, 2013, DIABETES CARE, V36, P2497, DOI 10.2337/dc12-2462; Kaku K, 2010, DIABETES OBES METAB, V12, P341, DOI 10.1111/j.1463-1326.2009.01194.x; Garber AJ, 2012, EXPERT OPIN INV DRUG, V21, P45, DOI 10.1517/13543784.2012.638282; Nauck MA, 2011, DIABETES, V60, P1561, DOI 10.2337/db10-0474; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Deacon CF, 2012, DIABETES OBES METAB, V14, P762, DOI 10.1111/j.1463-1326.2012.01603.x; Monnier L, 2007, DIABETES CARE, V30, P263, DOI 10.2337/dc06-1612; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Rosenstock J, 2013, DIABETES CARE, V36, P2945, DOI 10.2337/dc12-2709; Zhang P, 2010, DIABETES RES CLIN PR, V87, P293, DOI 10.1016/j.diabres.2010.01.026; Ahren B, 2013, DIABETES CARE, V36, P2543, DOI 10.2337/dc12-2006; Kapitza C, 2013, DIABETES OBES METAB, V15, P642, DOI 10.1111/dom.12076; Kozawa J, 2012, J DIABETES INVEST, V3, P294, DOI 10.1111/j.2040-1124.2011.00168.x; Seino Y, 2011, J DIABETES INVEST, V2, P280, DOI 10.1111/j.2040-1124.2011.00103.x; Barnett Anthony H, 2011, Core Evid, V6, P67, DOI 10.2147/CE.S15525; Becker RHA, 2014, DIABETES OBES METAB, V16, P793, DOI 10.1111/dom.12278; Bolli GB, 2014, DIABETIC MED, V31, P176, DOI 10.1111/dme.12328; Funakoshi S, 2011, J DIABETES INVEST, V2, P429, DOI 10.1111/j.2040-1124.2011.00126.x; Funakoshi S, 2008, DIABETES RES CLIN PR, V82, P353, DOI 10.1016/j.diabres.2008.09.010; International Diabetes Federation, 2013, IDF DIABETES ATLAS; Kim YG, 2014, DIABETES OBES METAB, V16, P900, DOI 10.1111/dom.12293; Meier JJ, 2011, DIABETOLOGIA S1, V54, P1; Meier JJ, 2013, DIABETOLOGIA, V56, pS1; Onishi Y, 2010, J DIABETES INVEST, V1, P191, DOI 10.1111/j.2040-1124.2010.00041.x; Pinget M, 2013, DIABETES OBES METAB, V15, P1000, DOI 10.1111/dom.12121; Seino Y, 2014, DIABETES OBES METAB, V16, P739, DOI 10.1111/dom.12276; Usui R, 2001, J DIABETES INVEST, V4, P585	44	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					201	209		10.1111/jdi.12275		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700013		
J	Inagaki, N; Kondo, K; Yoshinari, T; Kuki, H				Inagaki, Nobuya; Kondo, Kazuoki; Yoshinari, Toru; Kuki, Hideki			Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study	JOURNAL OF DIABETES INVESTIGATION			English	Article						Canagliflozin; Sodium-glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus	GLUCOSE-HOMEOSTASIS; RANDOMIZED-TRIAL; DOUBLE-BLIND; MELLITUS; PLACEBO; WEIGHT; INHIBITOR; THERAPY; SITAGLIPTIN; MONOTHERAPY	Aims/IntroductionCanagliflozin is a sodium-glucose cotransporter 2 inhibitor under development for the treatment of type 2 diabetes. Our aim was to examine its efficacy and safety as monotherapy or in combination with commonly used oral antihyperglycemic drugs in Japanese patients with type 2 diabetes. Materials and MethodsPatients on diet/exercise alone or diet/exercise plus an oral antihyperglycemic drug (sulfonylurea, glinide, -glucosidase inhibitor, biguanide, thiazolidinedione or dipeptidyl peptidase-4 inhibitor) were randomized to either 100 or 200mg canagliflozin while continuing prior therapy. Patients were treated for 52weeks in an open-label manner. ResultsCanagliflozin significantly reduced hemoglobin A1c, fasting plasma glucose and bodyweight in all the study groups. Improvements were apparent by 4weeks of treatment, and were maintained for 52weeks. The reduction in hemoglobin A1c ranged from -0.80 to -1.06%, and from -0.93 to -1.26% in the 100 and 200mg canagliflozin groups, respectively. Drug-related adverse events occurred in approximately one-third of patients, and included hypoglycemia/asymptomatic hypoglycemia and pollakiuria. Hypoglycemia/asymptomatic hypoglycemia was most common in patients treated with a sulfonylurea. Most adverse events were classified as mild or moderate in severity. ConclusionsThe results of the present study confirmed that treatment with canagliflozin resulted in significant reductions in glycemic control and bodyweight that were maintained for 52weeks of treatment irrespective of whether it was administered as monotherapy or in combination with another oral antihyperglycemic drug. Canagliflozin was well tolerated, with a low incidence of drug-related adverse events. This trial was registered with ClinicalTrials.gov (no. NCT01387737).	[Inagaki, Nobuya] Kyoto Univ, Grad Sch Med, Dept Diabet Endocrinol & Nutr, Kyoto, Japan; [Kondo, Kazuoki; Yoshinari, Toru; Kuki, Hideki] Mitsubishi Tanabe Pharma Corp, Tokyo, Japan	Yoshinari, T (reprint author), Mitsubishi Tanabe Pharma Corp, Tokyo, Japan.	yoshinari.toru@mm.mt-pharma.co.jp			Mitsubishi Tanabe Pharma Corporation; MSD; Daiichi Sankyo Company, Ltd.; Astellas Pharma Inc.; Nippon Boehringer Ingelheim Co., Ltd.; AstraZeneca; Novartis Pharma	Canagliflozin is being developed by Mitsubishi Tanabe Pharma Corporation in collaboration with Janssen Research & Development, LLC. This study was funded by Mitsubishi Tanabe Pharma Corporation. We thank all of the staff at each institution for participating in this study, as listed in the Supporting Information online. We thank Nicholas D Smith, PhD, for providing medical writing assistance. Nobuya Inagaki has received honoraria for lectures, clinical commissioned/joint research grants and scholarship grants from Mitsubishi Tanabe Pharma Corporation. Nobuya Inagaki has also received honoraria for lectures from MSD K.K., Novartis Pharma K.K., Sanofi K.K. and Nippon Boehringer Ingelheim Co., Ltd.; clinical commissioned/joint research grants from MSD K.K. and Eli Lilly Japan K.K.; and scholarship grants from MSD K.K., Daiichi Sankyo Company, Ltd., Astellas Pharma Inc., Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K. and Novartis Pharma K.K. Kazuoki Kondo, Toru Yoshinari and Hideki Kuki are employees of Mitsubishi Tanabe Pharma Corporation. The authors declare that they have no conflict of interest.	Abdul-Ghani Muhammad A, 2008, Endocr Pract, V14, P782; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; van Dieren S, 2012, DIABETES OBES METAB, V14, P464, DOI 10.1111/j.1463-1326.2012.01556.x; Campbell IW, 2010, INT J CLIN PRACT, V64, P791, DOI 10.1111/j.1742-1241.2009.02292.x; Inagaki N, 2013, DIABETES OBES METAB, V15, P1136, DOI 10.1111/dom.12149; Imagawa A, 2012, J DIABETES INVEST, V3, P536, DOI 10.1111/jdi.12024; Rosenstock J, 2012, DIABETES CARE, V35, P1232, DOI 10.2337/dc11-1926; Stenlof K, 2013, DIABETES OBES METAB, V15, P372, DOI 10.1111/dom.12054; Inagaki N, 2014, EXPERT OPIN PHARMACO, V15, P1501, DOI 10.1517/14656566.2014.935764; Chen LH, 2013, DIABETES OBES METAB, V15, P392, DOI 10.1111/dom.12064; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Meneghini LF, 2011, J CLIN ENDOCR METAB, V96, P3337, DOI 10.1210/jc.2011-1074; Schernthaner G, 2013, DIABETES CARE, V36, P2508, DOI 10.2337/dc12-2491; Nair S, 2010, J CLIN ENDOCR METAB, V95, P34, DOI 10.1210/jc.2009-0473; DeFronzo RA, 2012, DIABETES OBES METAB, V14, P5, DOI 10.1111/j.1463-1326.2011.01511.x; Nicolle LE, 2012, CURR MED RES OPIN, V28, P1167, DOI 10.1185/03007995.2012.689956; Solomon TPJ, 2012, J CLIN ENDOCR METAB, V97, P4682, DOI 10.1210/jc.2012-2097; Jurczak MJ, 2011, DIABETES, V60, P890, DOI 10.2337/db10-1328; Morgan CL, 2012, DIABETES OBES METAB, V14, P424, DOI 10.1111/j.1463-1326.2011.01552.x; Neal B, 2013, AM HEART J, V166, P217, DOI 10.1016/j.ahj.2013.05.007; Nyirjesy P, 2012, CURR MED RES OPIN, V28, P1173, DOI 10.1185/03007995.2012.697053; [Anonymous], 2013, MED LETT DRUGS THER, V55, P5; Marchetti P, 2008, REGUL PEPTIDES, V146, P4, DOI 10.1016/j.regpep.2007.08.017; Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP, 2014, FULL PRESCR INF FARX; Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau Ministry of Health Labour and Welfare, 2010, GUID CLIN EV OR HYP; Kashiwagi A, 2012, J DIABETES INVEST, V3, P8; Lavalle-Gonzalez FJ, 2013, DIABETOLOGIA, V56, P2582, DOI 10.1007/s00125-013-3039-1; McIntosh B, 2011, OPEN MED, V5, pe35; The Japan Diabetes Society, 2013, TREATM GUID DIAB 201	29	5	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					210	218		10.1111/jdi.12266		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700014		
J	Heianza, Y; Arase, Y; Kodama, S; Tsuji, H; Fujihara, K; Saito, K; Hara, S; Sone, H				Heianza, Yoriko; Arase, Yasuji; Kodama, Satoru; Tsuji, Hiroshi; Fujihara, Kazuya; Saito, Kazumi; Hara, Shigeko; Sone, Hirohito			Simple self-reported behavioral or psychological characteristics as risk factors for future type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 14	JOURNAL OF DIABETES INVESTIGATION			English	Article						Behavioral or psychological risk factors; Type 2 diabetes	COGNITIVE DYSFUNCTION; INSULIN-RESISTANCE; DEPRESSION; MELLITUS; METAANALYSIS; HOSTILITY; STRESS; POPULATION	Aims/IntroductionDepression, anger, sleep disorders and cognitive impairment are regarded as presenting a high risk for diabetes. We investigated whether responses to single statements on a self-report questionnaire on the presence of each of these four factors were associated with the development of type 2 diabetes. Materials and MethodsWe investigated 3,211 Japanese individuals without diabetes. Cumulative incidence rate and hazard ratios (HRs) for future type 2 diabetes over 7-13years were evaluated according to the presence of lack of perseverance, anger, memory loss or sleep disorders. ResultsResults of Cox regression analysis showed that lack of perseverance (age- and sex-adjusted HR 1.41, 95% confidence interval 1.07-1.84), anger, (HR 1.51, 95% confidence interval 1.07-2.12) or memory loss (HR 1.47, 95% confidence interval 1.14-1.90) was predictive of the development of diabetes. Even after adjustment for metabolic factors including glycemic measurements, anger was significantly associated with an increased risk of future diabetes. Individuals with both anger and memory loss had a 1.94-fold (95% confidence interval 1.19-3.15) increased risk of type2 diabetes than those without those two symptoms. ConclusionsResponses to a simple self-report questionnaire as to whether individuals were aware of anger or memory loss were associated with the development of type2 diabetes independent of traditional risk factors for diabetes in this cohort of Japanese individuals.	[Heianza, Yoriko; Kodama, Satoru; Fujihara, Kazuya; Sone, Hirohito] Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan; [Heianza, Yoriko; Arase, Yasuji; Kodama, Satoru; Tsuji, Hiroshi; Saito, Kazumi; Hara, Shigeko; Sone, Hirohito] Toranomon Gen Hosp, Hlth Management Ctr, Tokyo, Japan; [Arase, Yasuji; Tsuji, Hiroshi; Hara, Shigeko] Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Tokyo, Japan; [Saito, Kazumi] Ibaraki Prefectural Univ, Hlth Sci Hosp, Ibaraki, Japan	Sone, H (reprint author), Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan.	sone@med.niigata-u.ac.jp			Ministry of Health, Labor and Welfare, Japan; Japan Society for the Promotion of Science (JSPS)	This work is financially supported in part by the Ministry of Health, Labor and Welfare, Japan. H Sone and Y Heianza are recipients of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS). YH is a Research Fellow of the JSPS. The sponsor had no role in the design and conduct of the study. All authors sincerely thank the late Professor and Director Kinori Kosaka MD PhD, the Health Management Center, Toranomon Hospital, who established the foundation and framework of this project, and was always the foremost pillar of spiritual support of the TOPICS project. Parts of this study were presented at the 70th Scientific Sessions of the American Diabetes Association, June 2010, Orlando, Florida. The authors declare no conflict of interest.	American Diabetes Association, 2010, DIABETES CARE S1, V33, pS62, DOI DOI 10.2337/DC10-S062; Reijmer YD, 2010, DIABETES-METAB RES, V26, P507, DOI 10.1002/dmrr.1112; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; Mezuk B, 2008, DIABETES CARE, V31, P2383, DOI 10.2337/dc08-0985; Ruis C, 2009, DIABETES CARE, V32, P1261, DOI 10.2337/dc08-2143; Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124; Strachan MWJ, 2011, NAT REV ENDOCRINOL, V7, P108, DOI 10.1038/nrendo.2010.228; Strachan MWJ, 1997, DIABETES CARE, V20, P438, DOI 10.2337/diacare.20.3.438; Sanz CM, 2013, DIABETES CARE, V36, P1512, DOI 10.2337/dc12-1017; Ikeda N, 2011, LANCET, V378, P1094, DOI 10.1016/S0140-6736(11)61055-6; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Rod NH, 2009, J INTERN MED, V266, P467, DOI 10.1111/j.1365-2796.2009.02124.x; McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2; Knol MJ, 2006, DIABETOLOGIA, V49, P837, DOI 10.1007/s00125-006-0159-x; Björntorp P, 2001, Obes Rev, V2, P73, DOI 10.1046/j.1467-789x.2001.00027.x; Golden SH, 2006, PSYCHONEUROENDOCRINO, V31, P325, DOI 10.1016/j.psyneuen.2005.08.008; MAHONEY J, 1994, J AM GERIATR SOC, V42, P1006; Pouwer F, 2010, DISCOV MED, V45, P112; Shen BJ, 2008, DIABETES CARE, V31, P1293, DOI 10.2337/dc07-1945; Surwit RS, 2002, DIABETES CARE, V25, P835, DOI 10.2337/diacare.25.5.835; Zhang JP, 2006, PSYCHOSOM MED, V68, P718, DOI 10.1097/01.psy.0000228343.89466.11	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					236	241		10.1111/jdi.12274		6	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700017		
J	Haneda, M; Utsunomiya, K; Koya, D; Babazono, T; Moriya, T; Makino, H; Kimura, K; Suzuki, Y; Wada, T; Ogawa, S; Inaba, M; Kanno, Y; Shigematsu, T; Masakane, I; Tsuchiya, K; Honda, K; Ichikawa, K; Shide, K				Haneda, Masakazu; Utsunomiya, Kazunori; Koya, Daisuke; Babazono, Tetsuya; Moriya, Tatsumi; Makino, Hirofumi; Kimura, Kenjiro; Suzuki, Yoshiki; Wada, Takashi; Ogawa, Susumu; Inaba, Masaaki; Kanno, Yoshihiko; Shigematsu, Takashi; Masakane, Ikuto; Tsuchiya, Ken; Honda, Keiko; Ichikawa, Kazuko; Shide, Kenichiro		Joint Comm Diabetic Nephropathy	A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy	JOURNAL OF DIABETES INVESTIGATION			English	Article						Albuminuria; Diabetic nephropathy; Glomerular filtration rate		The Joint Committee on Diabetic Nephropathy has revised its Classification of Diabetic Nephropathy (Classification of Diabetic Nephropathy 2014) in line with the widespread use of key concepts, such as the estimated glomerular filtration rate (eGFR) and chronic kidney disease (CKD). In revising the Classification, the Committee carefully evaluated, as relevant to current revision, the report of a study conducted by the Research Group of Diabetic Nephropathy, Ministry of Health, Labor and Welfare of Japan. Major revisions to the Classification are summarized as follows: (i) eGFR is substituted for GFR in the Classification; (ii) the subdivisions A and B in stage3 (overt nephropathy) have been reintegrated; (iii) stage4 (kidney failure) has been redefined as a GFR <30mL/min/1.73m(2), regardless of the extent of albuminuria; and (iv) stress has been placed on the differential diagnosis of diabetic nephropathy versus non-diabetic kidney disease as being crucial in all stages of diabetic nephropathy.	[Haneda, Masakazu] Asahikawa Med Univ, Dept Med, Sapporo, Hokkaido, Japan; [Utsunomiya, Kazunori] Jikei Univ, Sch Med, Tokyo, Japan; [Babazono, Tetsuya; Tsuchiya, Ken] Tokyo Womens Med Univ, Tokyo, Japan; [Kimura, Kenjiro] St Marianna Univ, Sch Med, Tokyo, Japan; [Kanno, Yoshihiko] Tokyo Med Univ, Tokyo 1608402, Japan; [Koya, Daisuke] Kanazawa Med Univ, Kanazawa, Ishikawa, Japan; [Wada, Takashi] Kanazawa Univ, Kanazawa, Ishikawa, Japan; [Moriya, Tatsumi] Kitasato Univ, Sagamihara, Kanagawa, Japan; [Makino, Hirofumi] Okayama Univ Hosp, Okayama, Japan; [Suzuki, Yoshiki] Niigata Univ, Niigata, Japan; [Ogawa, Susumu] Tohoku Univ Hosp, Sendai, Miyagi, Japan; [Inaba, Masaaki] Osaka City Univ, Grad Sch Med, Osaka 558, Japan; [Shigematsu, Takashi] Wakayama Med Univ, Wakayama, Japan; [Masakane, Ikuto] Yabuki Hosp, Yamagata, Japan; [Honda, Keiko] Kagawa Nutr Univ, Saitama, Japan; [Ichikawa, Kazuko] Kawasaki Med Sch Hosp, Hiroshima, Japan; [Shide, Kenichiro] Kyoto Univ Hosp, Kyoto 606, Japan	Haneda, M (reprint author), Asahikawa Med Univ, Dept Med, Sapporo, Hokkaido, Japan.	haneda@asahikawa-med.ac.jp			Astellas Pharma Inc.; Daiichi-Sankyo Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Takeda Pharmaceutical Co., Ltd.; Novo Nordisk Pharma Ltd.; Merck Sharp Dohme; Boehringer Ingelheim GmbH; Eli Lilly and Company; Japan Tabacco Inc.; Ono Pharmaceutical Co., Ltd.; Project for accelerating Practice and Research on Community Medicine in Okayama Prefecture; Kyowa Hakko Kirin Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Teijin Pharma Limited.; Baxter International Inc.; Sekisui Medical Co., Ltd.; Chugai pharmaceutical Co., Ltd.; Bayer Yakuhin, Ltd.	The Joint Committee on Diabetic Nephropathy would like to extend its heartfelt thanks to all investigators in the Research Group of Diabetic Nephropathy, Ministry of Health, Labor and Welfare of Japan for their contributions, which provided the basis for the current revision. Masakazu Haneda has received speaker honoraria from pharmaceutical companies Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Daiichi-Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Sanofi K.K., Merck Sharp & Dohme, Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Kowa Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; and scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Merck Sharp & Dohme, Boehringer Ingelheim GmbH, and Eli Lilly and Company, Daisuke Koya has received speaker honoraria from pharmaceutical companies Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, and Eli Lilly and Company; and research grants from Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Japan Tabacco Inc., Eli Lilly and Company, and Ono Pharmaceutical Co., Ltd. Tetsuya Babazono has received speaker honoraria from pharmaceutical company Merck Sharp & Dohme. Tatsumi Moriya has received travel expenses from pharmaceutical companies Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd. and Daiichi-Sankyo Co., Ltd. Hirofumi Makino has received speaker honoraria from pharmaceutical companies AbbVie GK, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Daiichi-Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Novartis Pharma K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co. and Mitsubishi Tanabe Pharma Corporation; research grants from Project for accelerating Practice and Research on Community Medicine in Okayama Prefecture; scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Takeda Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. Kenjiro Kimura has received research grants from pharmaceutical companies Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Limited., Boehringer Ingelheim GmbH, Baxter International Inc. and Sekisui Medical Co., Ltd. Takashi Wada has received speaker honoraria from pharmaceutical company Daiichi-Sankyo Co., Ltd. and scholarship grants from Chugai pharmaceutical Co., Ltd. Susumu Ogawa has received speaker honoraria from pharmaceutical companies Daiichi-Sankyo Co., Ltd., Eli Lilly and Company, and Novo Nordisk Pharma Ltd.; and research grants from Daiichi-Sankyo Co., Ltd. Masaaki Inaba has received speaker honoraria from pharmaceutical companies Bayer Yakuhin, Ltd., Takeda Pharmaceutical Co., Ltd., Merck Sharp & Dohme, Kyowa Hakko Kirin Co., Ltd. and Asahi Kasei Pharma Corporation; and research grants from Bayer Yakuhin, Ltd., Kyowa Hakko Kirin Co., Ltd., and Eli Lilly and Company. Yoshihiko Kanno has received scholarship grants from pharmaceutical company Chugai Pharmaceutical Co., Ltd., and travel expenses from Abbott Japan Co., Ltd. Takashi Shigemats has received research grants from the pharmaceutical company Bayer Yakuhin, Ltd. Kazunori Utsunomiya, Yoshiki Suzuki, Ikuto Masakane, Ken Tsuchiya, Keiko Honda, Kazuko Ichikawa, Kenichiro Shide have no conflict of interest.	[Anonymous], 2007, JPN J NEPHROL, V49, P767; [Anonymous], 2014, DIABETES CARE S1, V37, pS4; [Anonymous], 2013, DIABETES CARE S1, V36, pS3; [Anonymous], 2012, JPN J NEPHROL, V54, P1047; Wada T, 2014, CLIN EXP NEPHROL, V18, P613, DOI 10.1007/s10157-013-0879-4; [Anonymous], 1997, JPN J NEPHROL, V102, P1; [Anonymous], 2012, SYST RES REP RES GRO, P1; [Anonymous], 1991, DIAB SURV RES REP, P320; Committee for Statistical Surveys Japanese Society for Dialysis Therapy (JSDT), 2013, CURR STAT DIAL THER; Haneda M, 2014, J JPN SOC DIAL THER, V47, P415; Haneda M, 2014, JPN J NEPHROL, V56, P547; Haneda M, 2014, CLIN NUTR, V17, P325; Haneda M, 2014, J JAPAN DIAB SOC, V57, P529; Yoshikawa R, 2001, J JPN DIAB SOC, V44, P623	14	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2040-1116	2040-1124		J DIABETES INVEST	J. Diabetes Investig.	MAR	2015	6	2					242	246		10.1111/jdi.12319		5	Endocrinology & Metabolism	Endocrinology & Metabolism	CC8VM	WOS:000350646700018		
J	Sunakawa, T				Sunakawa, Takeki			A quantitative analysis of optimal sustainable monetary policies	JOURNAL OF ECONOMIC DYNAMICS & CONTROL			English	Article						Optimal monetary policy; Time inconsistency; Sustainable plans; Timeless perspective	NOMINAL INTEREST-RATES; TIMELESS PERSPECTIVE; RULES; DISCRETION; COMMITMENT; RATHER; MODELS; PLANS	This study examines the quantitative properties of optimal sustainable monetary policies using a monetary model with a stabilization bias. As in Kurozumi (2008), the optimal sustainable policy is a strategy considered in the absence of commitment technologies; however it is implemented following an optimal quasi-sustainable policy derived by assuming that the commitment technologies are present. This study finds that solving for the policy function of the optimal quasi-sustainable policy yields a result basically identical to the Ramsey-optimal commitment policy under a set of parameters commonly used in the literature. The simulation shows two further results: policymakers have incentive to deviate from the Ramsey-optimal commitment policy when the lagged output gap is large and the optimal quasi-sustainable policy endogenously diminishes the steadfastness of policymakers' commitment. (C) 2014 Elsevier B.V. All rights reserved.	Univ Tokyo, Grad Sch Publ Policy, Bunkyo Ku, Tokyo 1138654, Japan	Sunakawa, T (reprint author), Univ Tokyo, Grad Sch Publ Policy, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138654, Japan.	sunakawa@pp.u-tokyo.ac.jp					Nakov A, 2008, INT J CENT BANK, V4, P73; Christiano LJ, 2000, J ECON DYN CONTROL, V24, P1179, DOI 10.1016/S0165-1889(99)00016-0; KYDLAND FE, 1977, J POLIT ECON, V85, P473, DOI 10.1086/260580; Kehoe PJ, 2002, ECONOMETRICA, V70, P907, DOI 10.1111/1468-0262.00314; ABREU D, 1988, ECONOMETRICA, V56, P383, DOI 10.2307/1911077; Adam K, 2006, J MONEY CREDIT BANK, V38, P1877, DOI 10.1353/mcb.2006.0089; TAUCHEN G, 1986, ECON LETT, V20, P177, DOI 10.1016/0165-1765(86)90168-0; Rotemberg JJ, 1997, NBER MACROECON ANNU, V12, P297, DOI 10.2307/3585236; Bodenstein M, 2012, J MONETARY ECON, V59, P135, DOI 10.1016/j.jmoneco.2012.01.002; Adam K, 2007, J MONETARY ECON, V54, P728, DOI 10.1016/j.jmoneco.2005.11.003; CHARI VV, 1990, J POLIT ECON, V98, P783, DOI 10.1086/261706; Dennis R, 2010, J MONETARY ECON, V57, P266, DOI 10.1016/j.jmoneco.2010.02.006; Gali J, 2008, MONETARY POLICY, INFLATION, AND THE BUSINESS CYCLE: AN INTRODUCTION TO THE NEW KEYNESIAN FRAMEWORK, P1; Giannoni M.P., 2010, NBER WORKING PAPER 1; Ireland PN, 1997, J ECON DYN CONTROL, V22, P87, DOI 10.1016/S0165-1889(97)00051-1; Jensen C, 2002, ECON LETT, V77, P163, DOI 10.1016/S0165-1765(02)00096-4; JUDD KL, 1992, J ECON THEORY, V58, P410, DOI 10.1016/0022-0531(92)90061-L; Kurozumi T, 2008, J MONETARY ECON, V55, P1277, DOI 10.1016/j.jmoneco.2008.08.003; Loisel O, 2008, J ECON DYN CONTROL, V32, P3718, DOI 10.1016/j.jedc.2008.03.003; Marcet A., 2011, EUI WORKING PAPERS, VECO 2011/15; Marimon R., 1998, EUI WORKING PAPERS, VECO 1998/37; Marimon R., 1994, ECONOMICS WORKING PA, V337; Nakata T., 2014, FEDS WORKING PAPER 2; Sauer S, 2010, ECON LETT, V107, P128, DOI 10.1016/j.econlet.2010.01.003; Sauer S, 2010, INT J CENT BANK, V6, P1; Van Zandweghe W., 2010, WORKING PAPER RWP 10; Woodford M., 1999, NEW CHALLENGES FOR M; Woodford M, 2003, INTEREST AND PRICES: FOUNDATIONS OF A THEORY OF MONETARY POLICY, P1	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-1889	1879-1743		J ECON DYN CONTROL	J. Econ. Dyn. Control	MAR	2015	52						119	135		10.1016/j.jedc.2014.12.002		17	Economics	Business & Economics	CD1KT	WOS:000350834500008		
J	Hiraguchi, R; Shibata, A				Hiraguchi, Ryoji; Shibata, Akihisa			Taxing capital is a good idea: The role of idiosyncratic risk in an OLG model	JOURNAL OF ECONOMIC DYNAMICS & CONTROL			English	Article						Idiosyncratic risk; Capital tax; Incomplete markets; Overlapping generations	NEOCLASSICAL GROWTH-MODEL; PERFECT-FORESIGHT MODEL; OVERLAPPING GENERATIONS; OPTIMAL TAXATION; INCOME; DEBT	We investigate an overlapping generations (OLG) model in which agents who live for two periods receive idiosyncratic productivity shocks when they are old. We show that, around zero tax equilibria, we can always construct a combination of a small capital tax and a lump-sum transfer that are Pareto-improving. As Davila et al. (Econometrica (2012)) show, a capital reduction in one period raises the welfare level of agents who are old in that period, but lowers that of the young agents, because it reduces their wages. We show that the government can compensate for these wage losses by additionally taxing the old agents, such that their welfare gains remain positive. Our result is unchanged when earnings are uncertain at young age. (C) 2014 Elsevier B.V. All rights reserved.	[Hiraguchi, Ryoji] Chiba Univ, Fac Law & Econ, Inage Ku, Chiba, Japan; [Shibata, Akihisa] Kyoto Univ, Inst Econ Res, Sakyo Ku, Kyoto 6068501, Japan	Hiraguchi, R (reprint author), Chiba Univ, Fac Law & Econ, Inage Ku, 1-33 Yayoi Cho, Chiba, Japan.	ryojih@chiba-u.jp; shibata@kier.kyoto-u.ac.jp	Shibata, Akihisa/F-1214-2010	Shibata, Akihisa/0000-0002-2284-1332	Osaka University;  [23000001]	This research is financially supported by Grant-in-Aid for Specially Promoted Research (No. 23000001) and the G-COE program of Osaka University, "Human Behavior and Socioeconomic Dynamics."	Song Z, 2012, ECONOMETRICA, V80, P2785, DOI 10.3982/ECTA8910; Davila J, 2012, ECONOMETRICA, V80, P2431, DOI 10.3982/ECTA5989; Carvajal A, 2011, J ECON THEORY, V146, P1569, DOI 10.1016/j.jet.2011.03.012; CHAMLEY C, 1986, ECONOMETRICA, V54, P607, DOI 10.2307/1911310; TIROLE J, 1985, ECONOMETRICA, V53, P1499, DOI 10.2307/1913232; AIYAGARI SR, 1995, J POLIT ECON, V103, P1158; Conesa JC, 2009, AM ECON REV, V99, P25, DOI 10.1257/aer.99.1.25; Atkeson A., 1999, FEDERAL RESERVE BANK, V23, P3; Chari V. V., 1999, HDB MACROECONOMICS, V1C; Davila J, 2012, J MACROECON, V34, P441, DOI 10.1016/j.jmacro.2011.12.010; DIAMOND PA, 1965, AM ECON REV, V55, P1126; Erosa A, 2002, J ECON THEORY, V105, P338, DOI 10.1006/jeth.2001.2877; Fiorini LC, 2008, J MATH ECON, V44, P1312, DOI 10.1016/j.jmateco.2008.07.010; Garriga C., 2003, OPTIMAL FISCAL UNPUB; Gottardi P., 2012, 694 KIER KYOT U; IHORI T, 1978, AM ECON REV, V68, P389; JUDD KL, 1985, J PUBLIC ECON, V28, P59, DOI 10.1016/0047-2727(85)90020-9; JUDD KL, 1987, J POLIT ECON, V95, P675, DOI 10.1086/261481	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-1889	1879-1743		J ECON DYN CONTROL	J. Econ. Dyn. Control	MAR	2015	52						258	269		10.1016/j.jedc.2014.12.003		12	Economics	Business & Economics	CD1KT	WOS:000350834500016		
J	Takahashi, M; Morita, S; Ishidu, K				Takahashi, Miho; Morita, Shinichiro; Ishidu, Kazuko			stigma and mental health in japanese unemployed individuals	JOURNAL OF EMPLOYMENT COUNSELING			English	Article						depression; Japan; mental health; scale of stigma; stigma; unemployed	ILL-HEALTH; IMPACT; SHAME	An Internet-based survey was administered in Japan to compare mental health of and stigma toward unemployed individuals, workers with regular employment, and workers with irregular employment. Unemployed individuals showed higher scores for both anxiety/depression and disturbance of activities, as well as faced more stigma than did employed individuals. In addition, the factor structure of stigma that unemployed individuals have toward the unemployed was the same as that previously found for university students and employed individuals. Financial strain and stigma were the factors with the greatest influence on the mental health of unemployed individuals.	[Takahashi, Miho; Morita, Shinichiro] Univ Tokyo, Grad Sch Educ, Tokyo 1130033, Japan; [Ishidu, Kazuko] Komazawa Womens Univ, Dept Psychol, Tokyo, Japan	Takahashi, M (reprint author), Univ Tokyo, Grad Sch Educ, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miho-t@p.u-tokyo.ac.jp			MEXT KAKENHI [23402057]	This work was supported by MEXT KAKENHI Grant Number 23402057. Correspondence concerning this article should be addressed to Miho Takahashi, Graduate School of Education, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan (e-mail: miho-t@p.u-tokyo.ac.jp).	BROMAN CL, 1990, AM J COMMUN PSYCHOL, V18, P643, DOI 10.1007/BF00931235; KESSLER RC, 1988, J SOC ISSUES, V44, P69; SHAMIR B, 1986, SOC PSYCHOL QUART, V49, P61, DOI 10.2307/2786857; JACKSON PR, 1984, PSYCHOL MED, V14, P605; Blau G, 2013, CAREER DEV INT, V18, P257, DOI 10.1108/CDI-10-2012-0095; Paul KI, 2009, J VOCAT BEHAV, V74, P264, DOI 10.1016/j.jvb.2009.01.001; Benedict R. F., 1954, CHRYSANTHEMUM SWORD; Breakwell G. M., 1985, NEW APPROACHES EC LI, P137; EALES MJ, 1989, SOC SCI MED, V28, P783, DOI 10.1016/0277-9536(89)90107-X; Goffman E., 1963, STIGMA NOTES MANAGEM; Goldberg DP, 1972, DETECTION PSYCHIAT I; GORE S, 1978, J HEALTH SOC BEHAV, V19, P157, DOI 10.2307/2136531; Hisata M., 2003, JAPAN I LABOR POLICY, V516, P78; Ho G. C., 2011, STIGMA UNEMPLOYMENT; Inoue T, 1977, SEKENTEI NO KOUZOU S; Ishitake T., 2000, J OCCUP HEALTH, V42, P404; Kaufman H. G, 1982, PROFESSIONALS SEARCH; Kawase T., 2002, B MIYAZAKI MUNICIPAL, V10, P39; KESSLER RC, 1987, PSYCHOL MED, V17, P949; Liem J. H., 1990, STRESS WORK FAMILY, P175; Ministry of Public Management Home Affairs Posts and Telecommunications, 2012, ROUD; National Police Agency, 2010, HEIS NIJ NI OK JIS N; Niiro M, 2001, CLIN PSYCHIATR, V43, P431; Rantakeisu U, 1997, SCAND J SOC WELFARE, V6, P13; Takahashi M., 2012, JAPANESE J PSYCHOL, V83, P100; Yamada K., 2006, B SCH HLTH NURSING S, V2, P27	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-0787	2161-1920		J EMPLOYMENT COUNS	J. Employ. Couns.	MAR	2015	52	1					18	28		10.1002/j.2161-1920.2015.00053.x		11	Psychology, Applied	Psychology	CC7JB	WOS:000350542400002		
J	Gulis, G; Fujino, Y				Gulis, Gabriel; Fujino, Yoshihisa			Epidemiology, Population Health, and Health Impact Assessment	JOURNAL OF EPIDEMIOLOGY			English	Editorial Material						health impact assessment; social determinants of health; health inequity			[Gulis, Gabriel] Univ Southern Denmark, DK-6700 Esbjerg, Denmark; [Fujino, Yoshihisa] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan	Gulis, G (reprint author), Univ Southern Denmark, Niels Bohrsvej 9-10, DK-6700 Esbjerg, Denmark.	GGulis@health.sdu.dk	Fujino, Yoshihisa/F-3054-2010	Fujino, Yoshihisa/0000-0002-9126-206X			Winslow CEA, 1920, SCIENCE, V51, P23, DOI 10.1126/science.51.1306.23; Barton H, 2006, J R SOC PROMO HEALTH, V126, P252, DOI 10.1177/1466424006070466; Dahlgren G, 1991, POLICIES STRATEGIES; European Centre for Health Policy, 1999, HLTH IMP ASS MAIN CO; Fehr R, 2014, HLTH IMPACT ASSESSME; Grandjean P., 2013, LATE LESSONS EARLY W; Kemm J, 2013, HLTH IMPACT ASSESSME; O'Mullane M., 2013, INTEGRATING HLTH IMP; Ross CL, 2014, HLTH IMPACT ASSESSME	9	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					179	180		10.2188/jea.JE20140212		2	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100001		
J	Tanihara, S				Tanihara, Shinichi			Assessment of Text Documentation Accompanying Uncoded Diagnoses in Computerized Health Insurance Claims in Japan	JOURNAL OF EPIDEMIOLOGY			English	Article						coding; health insurance claim; ICD-10; uncoded diagnoses	RULE-OUT DIAGNOSES; MEDICAL EXPENDITURES; DISEASE; OUTPATIENT; PHARMACY; CARE	Background: Uncoded diagnoses in health insurance claims (HICs) may introduce bias into Japanese health statistics dependent on computerized HICs. This study's aim was to identify the causes and characteristics of uncoded diagnoses. Methods: Uncoded diagnoses from computerized HICs (outpatient, inpatient, and the diagnosis procedure-combination per-diem payment system [DPC/PDPS]) submitted to the National Health Insurance Organization of Kumamoto Prefecture in May 2010 were analyzed. The text documentation accompanying the uncoded diagnoses was used to classify diagnoses in accordance with the International Classification of Diseases-10 (ICD-10). The text documentation was also classified into four categories using the standard descriptions of diagnoses defined in the master files of the computerized HIC system: 1) standard descriptions of diagnoses, 2) standard descriptions with a modifier, 3) non-standard descriptions of diagnoses, and 4) unclassifiable text documentation. Using these classifications, the proportions of uncoded diagnoses by ICD-10 disease category were calculated. Results: Of the uncoded diagnoses analyzed (n = 363 753), non-standard descriptions of diagnoses for outpatient, inpatient, and DPC/PDPS HICs comprised 12.1%, 14.6%, and 1.0% of uncoded diagnoses, respectively. The proportion of uncoded diagnoses with standard descriptions with a modifier for Diseases of the eye and adnexa was significantly higher than the overall proportion of uncoded diagnoses among every HIC type. Conclusions: The pattern of uncoded diagnoses differed by HIC type and disease category. Evaluating the proportion of uncoded diagnoses in all medical facilities and developing effective coding methods for diagnoses with modifiers, prefixes, and suffixes should reduce number of uncoded diagnoses in computerized HICs and improve the quality of HIC databases.	[Tanihara, Shinichi] Fukuoka Univ, Sch Med, Dept Publ Hlth & Prevent Med, Fukuoka 8140180, Japan	Tanihara, S (reprint author), Fukuoka Univ, Sch Med, Dept Publ Hlth & Prevent Med, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	taniyan@cis.fukuoka-u.ac.jp			Ministry of Science and Education [21119006, 25460646]; Ministry of Health, Labour and Welfare of Japan [H23-Jisedaishitei-007]	This work was partly funded by Grants-in-Aid for Scientific Research (No. 21119006 and 25460646) from the Ministry of Science and Education and the Research Project for Patients Aged 20 and Over with Intractable Chronic Diseases approved by Medical Aid for Children (No. H23-Jisedaishitei-007) from the Ministry of Health, Labour and Welfare of Japan.	Allen LA, 2014, MED CARE, V52, pe30, DOI 10.1097/MLR.0b013e31825a8c22; Tanihara S, 2011, EPIDEMIOL INFECT, V139, P516, DOI 10.1017/S095026881000244X; Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895-4356(03)00246-4; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Funch D, 2013, VACCINE, V31, P2075, DOI 10.1016/j.vaccine.2013.02.009; Kisa K, 2012, GENDER MED, V13, P77; Kolodner K, 2004, J CLIN EPIDEMIOL, V57, P962, DOI 10.1016/j.jclinepi.2004.01.014; Kumamaru H, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-302; Maeda T, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-337; Ministry of Health Labour and Welfare of Japan, MAN SPEC COMP HLTH I; Okamoto E, 2013, J EPIDEMIOL, V23, P262, DOI 10.2188/jea.JE20120136; Tanihara S, 2014, J EPIDEMIOL, V24, P392, DOI 10.2188/jea.JE20130194; Tanihara S, 2013, KOUSEI NO SHIHYO, V60, P20; Tanihara S, 2012, J EVAL CLIN PRACT, V18, P426, DOI 10.1111/j.1365-2753.2010.01601.x; Tanihara S, 2011, J EVAL CLIN PRACT, V17, P1070, DOI 10.1111/j.1365-2753.2010.01482.x; Tanihara S, 2012, J EVAL CLIN PRACT, V18, P616, DOI 10.1111/j.1365-2753.2011.01643.x; Tanihara Shinichi, 2008, Nihon Eiseigaku Zasshi, V63, P29, DOI 10.1265/jjh.63.29; Tanihara S, 2014, ACTA MED OKAYAMA, V68, P1; Tomio J, 2010, J EVAL CLIN PRACT, V16, P1164, DOI 10.1111/j.1365-2753.2009.01287.x	19	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					181	188		10.2188/jea.JE20140105		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100002		
J	Kuwabara, M; Yashiro, M; Kotani, K; Tsuboi, S; Ae, R; Nakamura, Y; Yanagawa, H; Kawasaki, T				Kuwabara, Masanari; Yashiro, Mayumi; Kotani, Kazuhiko; Tsuboi, Satoshi; Ae, Ryusuke; Nakamura, Yosikazu; Yanagawa, Hiroshi; Kawasaki, Tomisaku			Cardiac Lesions and Initial Laboratory Data in Kawasaki Disease: a Nationwide Survey in Japan	JOURNAL OF EPIDEMIOLOGY			English	Article						mucocutaneous lymph node syndrome; coronary disease; coronary aneurysm; valvular lesion; epidemiology	LYMPH-NODE SYNDROME; SECTIONAL ECHOCARDIOGRAPHIC DIAGNOSIS; CORONARY-ARTERY ANEURYSMS; C-REACTIVE PROTEIN; EPIDEMIOLOGIC FEATURES; YOUNG-CHILDREN; RISK-FACTOR; INFANTS; LEVEL	Background: Cardiac lesions, such as coronary dilatation, aneurysms, narrowing, myocardial infarction, and valvular lesions, sometimes occur in Kawasaki disease, but most studies have only evaluated cardiac lesions in the later phase of the disease. This study was undertaken to clarify the related factors between cardiac lesions and laboratory data in the initial phase of Kawasaki disease. Methods: We conducted a cross-sectional study using data for 26 691 patients from the 22nd nationwide survey of Kawasaki disease in Japan, the observation period of which was from January 2011 through December 2012. We excluded patients with recurrent Kawasaki disease and who were more than seven days from the start of symptoms at admission. We analyzed 23 155 cases (13 353 boys; mean age: 923 +/- 734 days) with available laboratory data for white blood cell count, platelet count, serum albumin, and C-reactive protein (CRP). Results: Cardiac lesions were detected in 984 cases (656 boys and 328 girls); lesions were classified as coronary dilatation (764 cases), coronary aneurysm (40), giant coronary aneurysm (6), coronary narrowing (3), and valvular lesions (204). The significant related factors of initial coronary dilatation were male sex (odds ratio [OR] 1.73), older age (OR per 100 days increase 1.03), higher platelet count (OR per 10 000 cells/mu L increase 1.006), lower albumin (OR per 1 g/dL increase 0.66), and higher CRP (OR per 1 mg/dL increase 1.02). The factors related to coronary aneurysm were higher platelet count (OR 1.01) and lower albumin (OR 0.34). No factors were significantly related to giant coronary aneurysm. The related factors of valvular lesions were age (OR 0.98), and higher CRP (OR 1.05). Conclusions: Clinicians should consider male sex, older age, higher platelet count, lower albumin levels, and higher CRP levels when assessing risk of cardiac lesions in the initial phase of Kawasaki disease.	[Kuwabara, Masanari; Yashiro, Mayumi; Kotani, Kazuhiko; Tsuboi, Satoshi; Ae, Ryusuke; Nakamura, Yosikazu; Yanagawa, Hiroshi] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi 3290498, Japan; [Kuwabara, Masanari] Toranomon Gen Hosp, Dept Cardiol, Tokyo, Japan; [Kawasaki, Tomisaku] Japan Kawasaki Dis Res Ctr, Tokyo, Japan	Kuwabara, M (reprint author), Jichi Med Univ, Dept Publ Hlth, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	kuwamasa728@gmail.com			non-profit Japan Kawasaki Disease Research Center	The authors thank all of the pediatric doctors who have supported the nationwide surveys of Kawasaki disease in Japan. This study was partly supported by the non-profit Japan Kawasaki Disease Research Center.	AKAGI T, 1992, J PEDIATR-US, V121, P689, DOI 10.1016/S0022-3476(05)81894-3; Luca NJC, 2012, DRUGS, V72, P1029, DOI 10.2165/11631440-000000000-00000; Lin YHT, 2010, PEDIATR INT, V52, P699, DOI 10.1111/j.1442-200X.2010.03092.x; Yanagawa H, 2006, PEDIATR INT, V48, P356, DOI 10.1111/j.1442-200X.2006.02221.x; Nakamura Y, 2008, PEDIATR INT, V50, P287, DOI 10.1111/j.1442-200X.2008.02572.x; Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235; KAWASAKI T, 1974, PEDIATRICS, V54, P271; Kuo HC, 2010, ACTA PAEDIATR, V99, P1578, DOI 10.1111/j.1651-2227.2010.01875.x; Nakamura Y, 2010, J EPIDEMIOL, V20, P302, DOI 10.2188/jea.JE20090180; Kato H, 1996, CIRCULATION, V94, P1379; Koyanagi H, 1998, ACTA PAEDIATR, V87, P32, DOI 10.1080/08035259850157831; Nakamura Y, 2012, J EPIDEMIOL, V22, P216, DOI 10.2188/jea.JE20110126; Uehara R, 2012, J EPIDEMIOL, V22, P79, DOI 10.2188/jea.JE20110131; Harnden A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1514; HIRAISHI S, 1979, AM J CARDIOL, V43, P1225, DOI 10.1016/0002-9149(79)90157-7; KATO H, 1975, J PEDIATR-US, V86, P892, DOI 10.1016/S0022-3476(75)80220-4; KATO H, 1995, CORONARY ARTERY DIS, V6, P194; Kawasaki T, 1967, Arerugi, V16, P178; Koyanagi H, 1997, ACTA PAEDIATR, V86, P613, DOI 10.1111/j.1651-2227.1997.tb08944.x; Muta H, 2004, PEDIATRICS, V114, P751, DOI 10.1542/peds.2003-0118-F; Nakamura Y, 2008, J EPIDEMIOL, V18, P167, DOI 10.2188/jea.JE2008001; Nakamura Y, 2004, PEDIATR INT, V46, P33, DOI 10.1111/j.1442-200X.2004.01840.x; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; ONOUCHI Z, 1975, CHEST, V68, P297, DOI 10.1378/chest.68.3.297; Rowley Anne H, 2010, Curr Infect Dis Rep, V12, P96, DOI 10.1007/s11908-010-0091-6; YANAGISA.M, 1974, PEDIATRICS, V54, P277; Yellen ES, 2010, PEDIATRICS, V125, pE234, DOI 10.1542/peds.2009-0606; YOSHIDA H, 1979, AM J DIS CHILD, V133, P1244; YOSHIKAWA J, 1979, CIRCULATION, V59, P133	29	1	2	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					189	193		10.2188/jea.JE20140128		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100003		
J	Yasui, T; Hayashi, K; Nagai, K; Mizunuma, H; Kubota, T; Lee, JS; Suzuki, S				Yasui, Toshiyuki; Hayashi, Kunihiko; Nagai, Kazue; Mizunuma, Hideki; Kubota, Toshiro; Lee, Jung-Su; Suzuki, Shosuke			Risk Profiles for Endometriosis in Japanese Women: Results From a Repeated Survey of Self-Reports	JOURNAL OF EPIDEMIOLOGY			English	Article						endometriosis; risk factors; validation	DIAGNOSTIC LAPAROSCOPY; MENSTRUAL CHARACTERISTICS; INFERTILITY; ACCURACY; SMOKING; DESIGN; AGE	Background: The prevalence and risk factors for endometriosis may differ according to diagnosis methodologies, such as study populations and diagnostic accuracy. We examined risk profiles in imaging-diagnosed endometriosis with and without surgical confirmation in a large population of Japanese women, as well as the differences in risk profiles of endometriosis based on history of infertility. Methods: Questionnaires that included items on sites of endometriosis determined by imaging techniques and surgical procedure were mailed to 1025 women who self-reported endometriosis in a baseline survey of the Japan Nurses' Health Study (n = 15 019). Results: Two hundred and ten women had surgically confirmed endometriosis (Group A), 120 had imaging-diagnosed endometriosis without a surgical procedure (Group B), and 264 had adenomyosis (Group C). A short menstrual cycle at 18-22 years of age and cigarette smoking at 30 years of age were associated with significantly increased risk of endometriosis (Group A plus Group B), while older age was associated with risk of adenomyosis (Group C). In women with a history of infertility, a short menstrual cycle was associated with a significantly increased risk of endometriosis in both Group A and Group B, but risk profiles of endometriosis were different between Group A and Group B in women without a history of infertility. Conclusions: Women with surgically confirmed endometriosis and those with imaging-diagnosed endometriosis without surgery have basically common risk profiles, but these risk profiles are different from those with adenomyosis. The presence of a history of infertility should be taken into consideration for evaluation of risk profiles.	[Yasui, Toshiyuki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Reprod Technol, Tokushima 7708503, Japan; [Hayashi, Kunihiko; Nagai, Kazue] Gunma Univ, Sch Hlth Sci, Dept Basic Med Sci, Maebashi, Gumma 371, Japan; [Mizunuma, Hideki] Hirosaki Univ, Sch Med, Dept Obstet & Gynecol, Hirosaki, Aomori 036, Japan; [Kubota, Toshiro] Tokyo Med & Dent Univ, Dept Comprehens Reprod Med, Tokyo, Japan; [Lee, Jung-Su] Univ Tokyo, Sch Publ Hlth, Dept Hlth Promot Sci, Tokyo, Japan; [Suzuki, Shosuke] Gunma Univ, Fac Med, Maebashi, Gumma 371, Japan	Yasui, T (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Reprod Technol, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	yasui@medsci.tokushima-u.ac.jp			Japanese Nursing Association; Japan Menopause Society	The authors appreciate the support and cooperation of all of the Japanese nurses who participated in the present study, the Japanese Nursing Association, and the Japan Menopause Society for their cooperation with the study. The authors thank Dr. Fumie Tokuda at the JNHS Data Center for help with data management. The authors are grateful to Drs. Walter Willett and Karin Michels for their valuable advice in order to initiate the JNHS.	Missmer SA, 2004, OBSTET GYNECOL, V104, P965, DOI 10.1097/01.AOG.0000142714.54857.f8; Stratton P, 2003, FERTIL STERIL, V79, P1078, DOI 10.1016/S0015-0282(03)00155-9; Hayashi K, 2007, IND HEALTH, V45, P679, DOI 10.2486/indhealth.45.679; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Yeniel O, 2007, CLIN EXP OBSTET GYN, V34, P163; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Missmer SA, 2004, AM J EPIDEMIOL, V160, P784, DOI 10.1093/aje/kwh275; Zondervan KT, 2002, HUM REPROD, V17, P1415, DOI 10.1093/humrep/17.6.1415; Eskenazi B, 2001, FERTIL STERIL, V76, P929, DOI 10.1016/S0015-0282(01)02736-4; CANDIANI GB, 1991, FERTIL STERIL, V56, P230; Nnoaham KE, 2012, FERTIL STERIL, V98, P702, DOI 10.1016/j.fertnstert.2012.05.035; Louis GMB, 2011, FERTIL STERIL, V96, P360, DOI 10.1016/j.fertnstert.2011.05.087; HASSON HM, 1976, J REPROD MED, V16, P135; Arumugam K, 1997, BRIT J OBSTET GYNAEC, V104, P948, DOI 10.1111/j.1471-0528.1997.tb14357.x; Chapron C, 2010, FERTIL STERIL, V94, P2353, DOI 10.1016/j.fertnstert.2010.04.020; CRAMER DW, 1986, JAMA-J AM MED ASSOC, V255, P1904; DUIGNAN NM, 1972, J OBSTET GYN BR COMM, V79, P1016; Ministry of Health Labour and Welfare, 2003, NAT HLTH NUTR SURV J, P206; Missmer SA, 2006, FERTIL STERIL, V85, P866, DOI 10.1016/j.fertnstert.2005.12.008; Peterson CM, 2013, AM J OBSTET GYNECOL, V208; Shrestha A, 2012, J Nepal Health Res Counc, V10, P229; Tanahatoe SJ, 2003, FERTIL STERIL, V79, P361, DOI 10.1016/S0015-0282(02)04686-1; Vitonis AF, 2010, HUM REPROD, V25, P1325, DOI 10.1093/humrep/deq039; Yasui T, 2011, MATURITAS, V69, P279, DOI 10.1016/j.maturitas.2011.04.009; Zanardi R, 2003, ABDOM IMAGING, V28, P733, DOI 10.1007/s00261-003-0005-2	25	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					194	203		10.2188/jea.JE20140124		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100004		
J	Ojima, M; Amano, A; Kurata, S				Ojima, Miki; Amano, Atsuo; Kurata, Shu			Relationship Between Decayed Teeth and Metabolic Syndrome: Data From 4716 Middle-Aged Male Japanese Employees	JOURNAL OF EPIDEMIOLOGY			English	Article						dental caries; dyslipidemia; hyperglycemia; hypertension; obesity	JOINT EFP/AAP WORKSHOP; ADULT ORAL-HEALTH; DENTAL-CARIES; SYSTEMIC-DISEASES; CONSENSUS REPORT; NHANES 1999-2002; UNITED-STATES; TOOTH LOSS; RISK; PERIODONTITIS	Background: Epidemiological findings regarding the relationship between decayed teeth (DT) and metabolic syndrome (MetS) are scarce. We evaluated the relationship of DT with MetS, obesity, and MetS components in early middle-aged male Japanese employees. Methods: We cross-sectionally analyzed dental and medical health checkup results from a total of 4716 participants aged 42 or 46 years. Logistic regression models were employed to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) after adjustment for age, breakfast consumption frequency, drinking habits, smoking status, and physical activity. Results: Significant differences in the prevalence of MetS, obesity determined by body mass index, and the components of MetS between participating men with and without DT were detected (all P < 0.01). The adjusted OR of MetS was 1.41 (95% CI, 1.14-1.74) for those with 1 or 2 DT, and 1.66 (95% CI, 1.28-2.16) for those with >= 3 DT (P for trend = 0.01), and this significant relationship was observed even in those without periodontal pocket formation (P for trend = 0.03) or missing teeth (P for trend = 0.02). DT was significantly related to overweight/obesity and the MetS components of hypertension, dyslipidemia, and hyperglycemia, with adjusted ORs of 1.35 (95% CI, 1.19-1.53), 1.22 (95% CI, 1.07-1.39), 1.18 (95% CI, 1.03-1.34), and 1.33 (95% CI, 1.13-1.56), respectively. In addition, even in non-overweight/non-obese men, DT was found to be related to dyslipidemia and hyperglycemia, though with marginal significance (P < 0.05). Conclusions: Our findings suggest that having DT is related to MetS in early middle-aged Japanese men directly and through obesity and is independent of health behaviors, periodontal condition, and tooth loss.	[Ojima, Miki; Amano, Atsuo] Osaka Univ, Grad Sch Dent, Dept Prevent Dent, Suita, Osaka 5650871, Japan; [Kurata, Shu] Sumitomo Mitsui Banking Corp, Osaka Hlth Support Ctr, Dent Clin, Osaka, Japan	Ojima, M (reprint author), Osaka Univ, Grad Sch Dent, Dept Prevent Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	ojima@dent.osaka-u.ac.jp			Osaka University [24593148]	This study was supported by a Grant-in-Aid for Scientific Research (C) (No. 24593148) and a Grant-in-Aid for Challenge to Intractable Oral Diseases of Osaka University. The authors declare that there are no conflicts of interest with respect to the authorship and/or publication of this article. We thank Dr. Haruhito Tatsuma, Dr. Gentaro Watanabe, Dr. Fumitaka Goto, and Dr. Kyohei Kajiwara, as well as other staff at the Health Support Center, Sumitomo Mitsui Banking Corporation, for their valuable contributions.	von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; Glodny B, 2013, CLINICS, V68, P946, DOI 10.6061/clinics/2013(07)10; Elani HW, 2012, J DENT RES, V91, P865, DOI 10.1177/0022034512455062; Han YW, 2013, J DENT RES, V92, P485, DOI 10.1177/0022034513487559; Kozarov E, 2006, MICROBES INFECT, V8, P687, DOI 10.1016/j.micinf.2005.09.004; Loucks EB, 2007, ANN EPIDEMIOL, V17, P782, DOI 10.1016/j.annepidem.2007.05.003; Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5; Nibali L, 2013, J CLIN ENDOCR METAB, V98, P913, DOI 10.1210/jc.2012-3552; Nagata E, 2011, MOL ORAL MICROBIOL, V26, P78, DOI 10.1111/j.2041-1014.2010.00597.x; Crocombe LA, 2009, AUST DENT J, V54, P147, DOI 10.1111/j.1834-7819.2009.01108.x; AINAMO J, 1982, INT DENT J, V32, P281; Flink H, 2008, COMMUNITY DENT ORAL, V36, P523, DOI [10.1111/j.1600-0528.2008.00432.x, 10.1111/j.1600-0528.2008.00440.x]; Kobayashi Y, 2012, J DENT RES, V91, P479, DOI 10.1177/0022034512440707; Deshmukh-Taskar PR, 2010, J AM COLL NUTR, V29, P407; Selwitz RH, 2007, LANCET, V369, P51, DOI 10.1016/S0140-6736(07)60031-2; Aida J, 2006, J EPIDEMIOL, V16, P214, DOI 10.2188/jea.16.214; Timonen P, 2010, J DENT RES, V89, P1068, DOI 10.1177/0022034510376542; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Sanders AE, 2005, COMMUNITY DENT ORAL, V33, P370, DOI 10.1111/j.1600-0528.2005.00237.x; Song S, 2014, J ACAD NUTR DIET, V114, P54, DOI 10.1016/j.jand.2013.08.025; Ylostalo PV, 2006, J CLIN PERIODONTOL, V33, P92, DOI 10.1111/j.1600.051X2005.00875.x; Kesavalu L, 2012, J DENT RES, V91, P255, DOI 10.1177/0022034511435101; Griffin SO, 2009, J AM DENT ASSOC, V140, P1266; Schwahn C, 2013, INT J CARDIOL, V167, P1430, DOI [10.1016/j.ijcard.2012.04.061, 10.1016/j.ijcard.012.04.061]; Nakano K, 2009, ORAL MICROBIOL IMMUN, V24, P64, DOI 10.1111/j.1399-302X.2008.00479.x; Tonetti MS, 2013, J CLIN PERIODONTOL, V40, pS24, DOI 10.1111/jcpe.12089; Ando A, 2013, J EPIDEMIOL, V23, P301, DOI 10.2188/jea.JE20120180; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Otsuka R, 2006, J EPIDEMIOL, V16, P117, DOI 10.2188/jea.16.117; Chapple ILC, 2013, J CLIN PERIODONTOL, V40, pS106, DOI [10.1111/jcpe.12077, 10.1902/jop.2013.1340011]; CPMP (Committee for Proprietary Medicinal Products), 2002, POINTS CONS MULT ISS; Decerle N, 2013, CARIES RES, V47, P330, DOI 10.1159/000348397; Dental Health Division of Health Policy Bueau Ministry of Health, 2013, REP SURV DENT DIS 20; Fernandez-Garcia JC, 2013, CURR VASC PHARMACOL, V11, P906, DOI 10.2174/15701611113116660175; Garton BJ, 2012, AUST DENT J, V57, P114, DOI 10.1111/j.1834-7819.2012.01690.x; Kantovitz Kamila Rosamilia, 2006, Oral Health Prev Dent, V4, P137; Kaur J., 2014, CARDIOL RES PRACT, DOI [10.1155/2014/943162, DOI 10.1155/2014/943162]; Montero-Martin J, 2009, MED ORAL PATOL ORAL, V14, pE44; SAKKI TK, 1994, COMMUNITY DENT ORAL, V22, P298; Tremblay M, 2011, J CAN DENT ASSOC, V77, P1; Watt RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030797; White DA, 2011, 2 DIS RELATED DISORD; World Health Organization, 1997, OR HLTH SURV BAS MET	43	0	0	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					204	211		10.2188/jea.JE20140132		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100005		
J	Makino, N; Nakamura, Y; Yashiro, M; Ae, R; Tsuboi, S; Aoyama, Y; Kojo, T; Uehara, R; Kotani, K; Yanagawa, H				Makino, Nobuko; Nakamura, Yosikazu; Yashiro, Mayumi; Ae, Ryusuke; Tsuboi, Satoshi; Aoyama, Yasuko; Kojo, Takao; Uehara, Ritei; Kotani, Kazuhiko; Yanagawa, Hiroshi			Descriptive Epidemiology of Kawasaki Disease in Japan, 2011-2012: From the Results of the 22nd Nationwide Survey	JOURNAL OF EPIDEMIOLOGY			English	Article						mucocutaneous lymph node syndrome; incidence; cardiovascular disease; intravenous immunoglobulin; epidemiology	FEATURES; GUIDELINES; HISTORY; VERSION; CHILD	Background: The number of patients and incidence rate of Kawasaki disease (KD) are increasing in Japan. We have therefore characterized the latest epidemiological information on KD. Methods: The 22nd nationwide survey of KD, which targeted patients diagnosed with KD in 2011 and 2012, was conducted in 2013 and included a total of 1983 departments and hospitals. In order to report on all patients with KD during the 2 survey years, we targeted hospitals of 100 beds or more with pediatric departments, or specialized pediatric hospitals. Results: From a total of 1420 hospitals and departments (71.6% response rate), 26 691 KD patients were reported (12 774 in 2011 and 13 917 in 2012; 15 442 males and 11 249 females). The annual incidence rates were 243.1 per 100 000 population aged 0 to 4 years in 2011 and 264.8 in 2012. The number of cases of KD recorded in 2012 was the highest ever reported in Japan. The incidence rate of complete cases was also the highest ever reported in Japan and contributed to the increase in the rate of total cases in recent years. The number of patients diagnosed per month peaked in January, and additional peaks were noted during summer months, although these peaks were lower than those seen in winter. Age-specific incidence rate showed a monomodal distribution with a peak in the latter half of the year in which patients were born. Conclusions: The number of patients and the incidence rate of KD in Japan continue to increase. A similar trend has also been seen for patients with complete KD.	[Makino, Nobuko; Nakamura, Yosikazu; Yashiro, Mayumi; Ae, Ryusuke; Tsuboi, Satoshi; Aoyama, Yasuko; Kojo, Takao; Uehara, Ritei; Kotani, Kazuhiko; Yanagawa, Hiroshi] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi 3290498, Japan	Makino, N (reprint author), Jichi Med Univ, Dept Publ Hlth, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	n-makino@jichi.ac.jp			Japanese Kawasaki Disease Research Center; nationwide survey of Kawasaki disease in Japan	The authors would like thank all pediatricians that supported the nationwide survey of Kawasaki disease in Japan. Part of this research was supported financially by the Japanese Kawasaki Disease Research Center, a non-profit organization.	Yu HR, 2010, PEDIATR CARDIOL, V31, P1151, DOI 10.1007/s00246-010-9769-7; Yanagawa H, 2006, PEDIATR INT, V48, P356, DOI 10.1111/j.1442-200X.2006.02221.x; Nakamura Y, 2008, PEDIATR INT, V50, P287, DOI 10.1111/j.1442-200X.2008.02572.x; Fukazawa R, 2010, CURR OPIN PEDIATR, V22, P587, DOI 10.1097/MOP.0b013e32833e12f7; Tsuda E, 2011, CARDIOL YOUNG, V21, P74, DOI 10.1017/S1047951110001502; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Huang WC, 2009, PEDIATRICS, V123, pe401, DOI 10.1542/peds.2008-2187; Girard MP, 2010, VACCINE, V28, P4895, DOI 10.1016/j.vaccine.2010.05.031; Nakamura Y, 2010, J EPIDEMIOL, V20, P302, DOI 10.2188/jea.JE20090180; Nakamura Y, 2012, J EPIDEMIOL, V22, P216, DOI 10.2188/jea.JE20110126; FUJITA Y, 1989, PEDIATRICS, V84, P666; Ogawa S, 2010, CIRC J, V74, P1989, DOI 10.1253/circj.CJ-10-74-0903; Nakamura Y, 2008, J EPIDEMIOL, V18, P167, DOI 10.2188/jea.JE2008001; Nakamura Y, 2008, J EPIDEMIOL, V18, P273, DOI 10.2188/jea.JE2008030; Nakamura Y, 2013, J EPIDEMIOL, V23, P429, DOI 10.2188/jea.JE20130048; Neuwirth CA, 2010, J VASC INTERV RADIOL, V21, P952, DOI 10.1016/j.jvir.2010.01.045; Saji T, 2014, PEDIATR INT, V56, P135, DOI 10.1111/ped.12317; Shulman ST, 2004, EUR J PEDIATR, V163, P285, DOI 10.1007/s00431-004-1431-z; Statistics and Information Department Minister's Secretariat Ministry of Health Labour and Welfare, 2011, VIT STAT JAP 2009, V1, P517; Sudo D, 2012, EUR J PEDIATR, V171, P651, DOI 10.1007/s00431-011-1630-3; Uehara R, 2011, PEDIATR INT, V53, P511, DOI 10.1111/j.1442-200X.2010.03267.x; Watanabe T, 2002, NIPPON SHONIKA GAKKA, V106, P1892; Wu MH, 2008, PEDIAT HLTH, V2, P405, DOI 10.2217/17455111.2.4.405; Yanagawa H, 2004, EPIDEMIOLOGY KAWASAK, P33; Yanagawa H, 2004, EPIDEMIOLOGY KAWASAK	25	2	2	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					239	245		10.2188/jea.JE20140089		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100009		
J	Honjo, K; Iso, H; Nakaya, T; Hanibuchi, T; Ikeda, A; Inoue, M; Sawada, N; Tsugane, S				Honjo, Kaori; Iso, Hiroyasu; Nakaya, Tomoki; Hanibuchi, Tomoya; Ikeda, Ai; Inoue, Manami; Sawada, Norie; Tsugane, Shoichiro		Japan Public Hlth Ctr Based Prospe	Impact of Neighborhood Socioeconomic Conditions on the Risk of Stroke in Japan	JOURNAL OF EPIDEMIOLOGY			English	Article						neighborhood; stroke; socioeconomic status; poverty areas; Japan	CORONARY-HEART-DISEASE; AREA-BASED DEPRIVATION; ISCHEMIC-STROKE; CARDIOVASCULAR-DISEASE; HEALTHY FOODS; MORTALITY; POPULATION; COHORT; WOMEN; ENVIRONMENT	Background: Neighborhood deprivation has been shown in many studies to be an influential factor in cardiovascular disease risk. However, no previous studies have examined the effect of neighborhood socioeconomic conditions on the risk of stroke in Asian countries. Methods: This study investigated whether neighborhood deprivation was associated with the risk of stroke and stroke death using data from the Japan Public Health Center-based Prospective Study. We calculated the adjusted hazard ratios of stroke mortality (mean follow-up, 16.4 years) and stroke incidence (mean follow-up, 15.4 years) according to the area deprivation index (ADI) among 90 843 Japanese men and women aged 40-69 years. A Cox proportional-hazard regression model using a shared frailty model was applied. Results: The adjusted hazard ratios of stroke incidence, in order of increasing deprivation with reference to the least deprived area, were 1.16 (95% CI, 1.04-1.29), 1.12 (95% CI, 1.00-1.26), 1.18 (95% CI, 1.02-1.35), and 1.19 (95% CI, 1.01-1.41), after adjustment for individual socioeconomic conditions. Behavioral and psychosocial factors attenuated the association, but the association remained significant. The associations were explained by adjusting for biological cardiovascular risk factors. No significant association with stroke mortality was identified. Conclusions: Our results indicate that the neighborhood deprivation level influences stroke incidence in Japan, suggesting that area socioeconomic conditions could be a potential target for public health intervention to reduce the risk of stroke.	[Honjo, Kaori] Osaka Univ, Global Collaborat Ctr, Osaka, Japan; [Iso, Hiroyasu] Osaka Univ, Grad Sch Med, Dept Social Med, Osaka, Japan; [Nakaya, Tomoki] Ritsumeikan Univ, Dept Geog, Kyoto, Japan; [Nakaya, Tomoki] Ritsumeikan Univ, Res Inst Disaster Mitigat Urban Cultural Heritage, Kyoto, Japan; [Hanibuchi, Tomoya] Chukyo Univ, Sch Int Liberal Studies, Nagoya, Aichi, Japan; [Ikeda, Ai] Juntendo Univ, Grad Sch Med, Dept Publ Hlth, Tokyo, Japan; [Inoue, Manami; Sawada, Norie; Tsugane, Shoichiro] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Grp, Tokyo 104, Japan; [Inoue, Manami] Univ Tokyo, Grad Sch Med, Tokyo, Japan	Iso, H (reprint author), Osaka Univ, Grad Sch Med, Dept Social & Environm Hlth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	iso@pbhel.med.osaka-u.ac.jp			National Cancer Center Research and Development Fund [23-A-31[toku], 26-A-2]; Ministry of Health, Labour and Welfare of Japan; JSPS KAKENHI [20590793]	This study was supported by National Cancer Center Research and Development Fund (23-A-31[toku] and 26-A-2) (since 2011) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan (from 1989 to 2010). This work was also supported by JSPS KAKENHI Grant Numbers 20590793.	Roux AVD, 2003, J URBAN HEALTH, V80, P569, DOI 10.1093/jurban/jtg065; Lisabeth LD, 2007, AM J EPIDEMIOL, V165, P279, DOI 10.1093/aje/kwk005; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; Honjo K, 2008, STROKE, V39, P2886, DOI 10.1161/STROKEAHA.108.514067; Honjo K, 2010, INT J BEHAV MED, V17, P58, DOI 10.1007/s12529-009-9051-7; Hilmers A, 2012, AM J PUBLIC HEALTH, V102, P1644, DOI 10.2105/AJPH.2012.300865; Fukuda Y, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-53; Reijneveld SA, 2002, J EPIDEMIOL COMMUN H, V56, P935, DOI 10.1136/jech.56.12.935; Aslanyan S, 2003, STROKE, V34, P2623, DOI 10.1161/01.STR.0000097610.12803.D7; Auchincloss AH, 2009, ARCH INTERN MED, V169, P1698, DOI 10.1001/archinternmed.2009.302; Engstrom G, 2001, STROKE, V32, P1098; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399; Grimaud O, 2011, STROKE, V42, P1201, DOI 10.1161/STROKEAHA.110.596429; Thrift AG, 2006, STROKE, V37, P877, DOI 10.1161/01.STR.0000202588.95876.a7; Kagamimori S, 2009, SOC SCI MED, V68, P2152, DOI 10.1016/j.socscimed.2009.03.030; Brown AF, 2011, STROKE, V42, P3363, DOI 10.1161/STROKEAHA.111.622134; Collett D., 2003, MODELLING SURVIVAL D; Fujino Y, 2005, PREV MED, V40, P444, DOI 10.1016/j.ypmed.2004.07.002; Fukuda Y, 2005, INT J EPIDEMIOL, V34, P100; Fukuda Y, 2004, SOC SCI MED, V59, P2435, DOI 10.1016/j.socscimed.2004.04.012; Hirokawa K, 2006, EUR J EPIDEMIOL, V21, P641, DOI 10.1007/s10654-006-9049-2; Honjo K, 2014, INT J BEHAV MED, V21, P737, DOI 10.1007/s12529-013-9337-7; Macintyre S., 2003, NEIGHBORHOODS HLTH, P20; Mair C., 2010, ANN NY ACAD SCI, V1186, P125, DOI DOI 10.1111/J.1749-6632.2009.05333.X; Murakami K, 2009, NUTRITION, V25, P745, DOI 10.1016/j.nut.2009.01.010; Nakaya T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097802; Nakaya T, 2005, SOC SCI MED, V60, P2865, DOI 10.1016/j.socscimed.2004.11.007; Nakaya T, 2011, P I STAT MATH, V59, P239; Nishi N, 2004, SOC SCI MED, V58, P1159, DOI 10.1016/S0277-9536(03)00287-9; Smits J, 2002, J EPIDEMIOL COMMUN H, V56, P637, DOI 10.1136/jech.56.8.637; Sundquist K, 2004, AM J EPIDEMIOL, V159, P655, DOI 10.1093/aje/kwh096; Tsugane S, 2001, J Epidemiol, V11, pS24; Walker AE, 1981, CLIN FINDINGS STROKE, V12, pI13	33	1	1	JAPAN EPIDEMIOLOGICAL ASSOC	TOKYO	C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0917-5040	1349-9092		J EPIDEMIOL	J. Epidemiol.	MAR	2015	25	3					254	260		10.2188/jea.JE20140117		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CC4XM	WOS:000350359100011		
J	Motokawa, T; Fuchigami, Y				Motokawa, Tatsuo; Fuchigami, Yoshiro			Coordination between catch connective tissue and muscles through nerves in the spine joint of the sea urchin Diadema setosum	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						Catch apparatus; Mutable collagenous tissue; Nervous control; Mechanical properties; Sea urchin; Shadow reaction	MECHANICAL-PROPERTIES; ANTILLARUM PHILIPPI; SHADOW REACTION; BODY-WALL; ECHINODERMATA; APPARATUS; CONTRIBUTE; MORPHOLOGY; CUCUMBERS; MOVEMENT	Echinoderms have catch connective tissues that change their stiffness as a result of nervous control. The coordination between catch connective tissue and muscles was studied in the spine joint of the sea urchin Diadema setosum. Spine joints are equipped with two kinds of effector: spine muscles and a kind of catch connective tissue, which is called the catch apparatus (CA). The former is responsible for spine movements and the latter for maintenance of spine posture. Diadema show a shadow reaction in which they wave spines when a shadow falls on them, which is a reflex involving the radial nerves. Dynamic mechanical tests were performed on the CA in a joint at which the muscles were severed so as not to interfere with the mechanical measurements. The joint was on a piece of the test that contained other spines and a radial nerve. Darkening of the preparation invoked softening of the CA and spine waving (the shadow reaction). Electrical stimulation of the radial nerve invoked a similar response. These responses were abolished after the nerve pathways from the radial nerve to spines had been cut. A touch applied to the CA stiffened it and the adjacent spines inclined toward the touched CA. A touch to the base of the adjacent spine softened the CA and the spines around the touched spine inclined towards it. The softening of the CA can be interpreted as a response that reduces the resistance of the ligaments to spine movements. Our results clearly show coordination between catch connective tissue and muscles through nerves.	[Motokawa, Tatsuo; Fuchigami, Yoshiro] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Meguro Ku, Tokyo 1528551, Japan	Motokawa, T (reprint author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Meguro Ku, Tokyo 1528551, Japan.	tmotokawa@t06.itscom.net			Ministry of Education, Culture, Sports, Science and Technology, Japan [21570075]	Supported by the Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (grant number 21570075) to T.M.	Byrne M, 2001, J EXP BIOL, V204, P849; Thurmond FA, 1996, J EXP BIOL, V199, P1817; BIRENHEIDE R, 1994, MAR BIOL, V121, P273, DOI 10.1007/BF00346736; BULLOCK TH, 1965, AM ZOOL, V5, P545; Cavey Michael J., 1994, P345; COBB JLS, 1989, NATO ADV SCI I A-LIF, V188, P329; Diaz-Balzac CA, 2007, BIOL BULL-US, V213, P28; FRICKE HW, 1971, MAR BIOL, V9, P328, DOI 10.1007/BF00372827; HIDAKA M, 1983, J EXP BIOL, V103, P15; HIDAKA M, 1983, J EXP BIOL, V103, P1; Hyman L., 1955, THE INVERTEBRATES, V4; Inoue M, 1999, P ROY SOC B-BIOL SCI, V266, P993; Kawaguti S., 1965, ANNOT ZOOL JPN, V37, P147; Kinosita H., 1941, Japanese Journal of Zoology, V9, P221; Millott N., 1966, P465; YOSHIDA M, 1960, J EXP BIOL, V37, P390; MILLOTT N, 1963, PHILOS T ROY SOC B, V246, P437, DOI 10.1098/rstb.1963.0011; Motokawa T, 2003, BIOL BULL-US, V205, P261, DOI 10.2307/1543290; MOTOKAWA T, 1983, J ZOOL, V201, P223; Motokawa T, 2012, BIOL BULL-US, V222, P150; MOTOKAWA T, 1987, COMP BIOCHEM PHYS C, V86, P333, DOI 10.1016/0742-8413(87)90089-2; PETERS BH, 1985, CELL TISSUE RES, V239, P219, DOI 10.1007/BF00214922; SHINGYOJI C, 1995, COMP BIOCHEM PHYS C, V111, P23, DOI 10.1016/0742-8413(95)00027-5; SMITH DS, 1981, TISSUE CELL, V13, P299, DOI 10.1016/0040-8166(81)90007-0; Takahashi K, 1967, J FS U TOKYO, V11, P121; TAKAHASHI K, 1964, NATURE, V201, P1343, DOI 10.1038/2011343a0; Takahashi K., 1967, Journal of the Faculty of Science Tokyo University Zoology, V11, P109; Takehana Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085644; Takemae N, 2009, BIOL BULL-US, V216, P45; Takemae N, 2005, BIOL BULL-US, V208, P29, DOI 10.2307/3593098; Tipper J., 2003, MATRIX BIOL, V21, P625; von Uexkull J, 1900, Z BIOL-MUNICH, V39, P73; Wainwright S. A., 1976, MECH DESIGN ORGANISM; Welsch U, 1995, ECHINODERM RESEARCH 1995, P129; Wilkie I. C., 2005, PROG MOL SUBCELL BIO, V21, P224; WILKIE IC, 1979, CELL TISSUE RES, V197, P515; Yamada A, 2010, J EXP BIOL, V213, P3416, DOI 10.1242/jeb.044149	37	1	1	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	MAR	2015	218	5					703	710		10.1242/jeb.115972		8	Biology	Life Sciences & Biomedicine - Other Topics	CD0HR	WOS:000350751900015		
J	Allam, R; Maillard, MH; Tardivel, A; Chennupati, V; Bega, H; Yu, CW; Velin, D; Schneider, P; Maslowski, KM				Allam, Ramanjaneyulu; Maillard, Michel H.; Tardivel, Aubry; Chennupati, Vijaykumar; Bega, Hristina; Yu, Chi Wang; Velin, Dominique; Schneider, Pascal; Maslowski, Kendle M.			Epithelial NAIPs protect against colonic tumorigenesis	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							APOPTOSIS-INHIBITORY PROTEIN; INFLAMMASOME ACTIVATION; INTESTINAL INFLAMMATION; LEGIONELLA-PNEUMOPHILA; ULCERATIVE-COLITIS; STAT3 ACTIVATION; NEEDLE PROTEIN; IN-VIVO; MICE; CANCER	NLR family apoptosis inhibitory proteins (NAIPs) belong to both the Nod-like receptor (NLR) and the inhibitor of apoptosis (IAP) families. NAIPs are known to form an inflammasome with NLRC4, but other in vivo functions remain unexplored. Using mice deficient for all NAIP paralogs (Naip1-6(Delta/Delta)), we show that NAIPs are key regulators of colorectal tumorigenesis. Naip1-6(Delta/Delta) mice developed increased colorectal tumors, in an epithelial-intrinsic manner, in a model of colitis-associated cancer. Increased tumorigenesis, however, was not driven by an exacerbated inflammatory response. Instead, Naip1-6(Delta/Delta) mice were protected from severe colitis and displayed increased antiapoptotic and proliferation-related gene expression. Naip1-6(Delta/Delta) mice also displayed increased tumorigenesis in an inflammation-independent model of colorectal cancer. Moreover, Naip1-6(Delta/Delta) mice, but not Nlrc4-null mice, displayed hyper-activation of STAT3 and failed to activate p53 18 h after carcinogen exposure. This suggests that NAIPs protect against tumor initiation in the colon by promoting the removal of carcinogen-elicited epithelium, likely in a NLRC4 inflammasome-independent manner. Collectively, we demonstrate a novel epithelial-intrinsic function of NAIPs in protecting the colonic epithelium against tumorigenesis.	[Allam, Ramanjaneyulu; Tardivel, Aubry; Yu, Chi Wang; Schneider, Pascal; Maslowski, Kendle M.] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland; [Chennupati, Vijaykumar] Univ Lausanne, Ludwig Ctr Canc Res, CH-1066 Epalinges, Switzerland; [Maillard, Michel H.; Bega, Hristina; Velin, Dominique] Univ Lausanne Hosp, Dept Med, Serv Gastroenterol & Hepatol, CH-1015 Lausanne, Switzerland; [Maslowski, Kendle M.] RIKEN Ctr Integrat Med Sci, Lab Intestinal Ecosyst, Yokohama, Kanagawa 2300045, Japan; [Allam, Ramanjaneyulu] Inselspital Univ Spital, Univ Klin Hematol & Hamatol Zentrallabor, CH-3010 Bern, Switzerland	Maslowski, KM (reprint author), Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland.	kendle.maslowski@riken.jp		Allam, Ramanjaneyulu/0000-0002-2789-3596	Swiss National Science Foundation; Institute of Arthritis Research; National Center of Competence in Research Molecular Oncology; Louis-Jeantet foundation; EMBO long-term fellowship an Australian NHMRC overseas post-doctoral fellowship; RIKEN's Programs for Junior Scientists	This work was funded by grants from the Swiss National Science Foundation, the Institute of Arthritis Research, the National Center of Competence in Research Molecular Oncology, and the Louis-Jeantet foundation (to Jurg Tschopp). K.M. Maslowski was funded by an EMBO long-term fellowship an Australian NHMRC overseas post-doctoral fellowship and is currently supported by RIKEN's Programs for Junior Scientists. C.W. Yu is currently employed by Roche.	Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; Endo T, 2004, CANCER IMMUNOL IMMUN, V53, P770, DOI 10.1007/s00262-004-0534-8; Broz P, 2010, J EXP MED, V207, P1745, DOI 10.1084/jem.20100257; Maier JKX, 2002, J NEUROSCI, V22, P2035; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; von Moltke J, 2012, NATURE, V490, P107, DOI 10.1038/nature11351; Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Kim YS, 2012, BMB REP, V45, P623, DOI 10.5483/BMBRep.2012.45.11.233; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394; Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Rayamajhi M, 2013, J IMMUNOL, V191, P3986, DOI 10.4049/jimmunol.1301549; Sellin ME, 2014, CELL HOST MICROBE, V16, P237, DOI 10.1016/j.chom.2014.07.001; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ayres JS, 2012, NAT MED, V18, P799, DOI 10.1038/nm.2729; Davoodi J, 2010, INT J BIOCHEM CELL B, V42, P958, DOI 10.1016/j.biocel.2010.02.008; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Rubin DT, 2013, CLIN GASTROENTEROL H, V11, P1601, DOI 10.1016/j.cgh.2013.06.023; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Miyatsuka T, 2006, GENE DEV, V20, P1435, DOI 10.1101/gad.1412806; Drexler SK, 2012, P NATL ACAD SCI USA, V109, P18384, DOI 10.1073/pnas.1209171109; Yang JL, 2013, P NATL ACAD SCI USA, V110, P14408, DOI 10.1073/pnas.1306376110; Ubeda C, 2012, J EXP MED, V209, P1445, DOI 10.1084/jem.20120504; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; COOPER HS, 1993, LAB INVEST, V69, P238; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510; Schmutz J, 2004, NATURE, V431, P268, DOI 10.1038/nature02919; Carvalho FA, 2012, MUCOSAL IMMUNOL, V5, P288, DOI 10.1038/mi.2012.8; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Diez E, 2000, J IMMUNOL, V164, P1470; Endrizzi MG, 2000, GENOME RES, V10, P1095, DOI 10.1101/gr.10.8.1095; Hu Y, 2002, CARCINOGENESIS, V23, P1131, DOI 10.1093/carcin/23.7.1131; Kerr Caroline A., 2013, BMC Physiology, V13, P2, DOI 10.1186/1472-6793-13-2; Kim DJ, 2009, CANCER RES, V69, P7587, DOI 10.1158/0008-5472.CAN-09-1180; Kofoed EM, 2012, BIOESSAYS, V34, P589, DOI 10.1002/bies.201200013; Mueller C, 2012, DIGEST DIS, V30, P40, DOI 10.1159/000342600; Romanish MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005761; Shuman Moss LA, 2012, AM J PATHOL, V181, P1895, DOI DOI 10.1016/J.AJPATH.2012.08.044; Vieira AT, 2005, BRIT J PHARMACOL, V146, P244, DOI 10.1038/sj.bjp.0706321; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378	59	1	1	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	MAR	2015	212	3					369	383		10.1084/jem.20140474		15	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	CD1ZN	WOS:000350873300009		
J	Hachinohe, M; Okunishi, T; Hagiwara, S; Todoriki, S; Kawamoto, S; Hamamatsu, S				Hachinohe, Mayumi; Okunishi, Tomoya; Hagiwara, Shoji; Todoriki, Setsuko; Kawamoto, Shinichi; Hamamatsu, Shioka			Distribution of Radioactive Cesium (Cs-134 plus Cs-137) in Rice Fractions during Polishing and Cooking	JOURNAL OF FOOD PROTECTION			English	Article							UDON NOODLES; RADIOCESIUM; DYNAMICS	We investigated the distribution of cesium-134 (Cs-134) and cesium-137 (Cs-137) during polishing and cooking of rice to obtain their processing factors (Pf) and food processing retention factors (Fr) to make the information available for an adequate understanding of radioactive Cs dynamics. Polishing brown rice resulted in a decreased radioactive Cs concentration of the polished rice, but the bran and germ (outer layers) exhibited higher concentrations than brown rice. The Pf values for 100% polished rice and outer layers ranged from 0.47 to 0.48 and 6.5 to 7.8, respectively. The Fr values for 100% polished rice and outer layers were 0.43 and 0.58 to 0.60, respectively. The distribution of radioactive Cs in polished rice and outer layers was estimated at approximately 40 and 60%, respectively. On the other hand, cooked rice showed significantly lower levels of radioactive Cs than polished rice, and transfer of radioactive Cs into wash water was observed. The Pf and Fr values for cooked rice were 0.28 and 0.65 to 0.66, respectively. From these results, we can calculate that if the radioactive Cs concentration in brown rice is 100 Bq/kg, the concentrations of Cs in polished rice and cooked rice will be 47 to 48 Bq/kg and 13 Bq/kg, respectively.	[Hachinohe, Mayumi; Okunishi, Tomoya; Hagiwara, Shoji; Todoriki, Setsuko; Kawamoto, Shinichi; Hamamatsu, Shioka] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	Hamamatsu, S (reprint author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	shioka@affrc.go.jp					Yasunari TJ, 2011, P NATL ACAD SCI USA, V108, P19530, DOI 10.1073/pnas.1112058108; Chino M, 2011, J NUCL SCI TECHNOL, V48, P1129, DOI 10.3327/jnst.48.1129; Council for Science and Technology, 2010, STAND TABL FOOD COMP; Fukushima Association for Securing Safety of Agricultural Products, 2013, FUK ASS SEC SAF AGR; Fukushima Council on Safety Measures for Local Produce, 2013, INF TEST RES RAD CES; Gopalakrishna A. G., 2012, BEVERAGE FOOD WORLD, V39, P31; Hachinohe M, 2014, J JPN SOC FOOD SCI, V61, P34, DOI 10.3136/nskkk.61.34; Hachinohe M, 2013, J FOOD PROTECT, V76, P1021, DOI 10.4315/0362-028X.JFP-12-441; International Rice Research Institute, RIC MILL; Juliano B. O., 1993, RICE HUMAN NUTR GRAI; Kimura K, 2012, J FOOD PROTECT, V75, P1823, DOI 10.4315/0362-028X.JFP-12-166; Ministry of Agriculture Forestry and Fisheries, 2011, TREND REP DOM RIC; Ministry of Agriculture Forestry and Fisheries, 2011, REG US RIC BRAN; Ministry of Health Labor and Welfare, 2013, CONC INSP PLANN EST; Ministry of Health Labor and Welfare, 2012, NEW STAND LIM RAD FO; YOSHIDA S, 1994, J ENVIRON RADIOACTIV, V22, P141, DOI 10.1016/0265-931X(94)90019-1; Okuda M, 2012, J BIOSCI BIOENG, V114, P600, DOI 10.1016/j.jbiosc.2012.07.003; Rosen K, 1996, SCI TOTAL ENVIRON, V182, P117, DOI 10.1016/0048-9697(95)05056-6; Tagami Keiko, 2012, Radioisotopes, V61, P223; Tsukada K., 2002, ENVIRON POLLUT, V117, P403	20	0	0	INT ASSOC FOOD PROTECTION	DES MOINES	6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA	0362-028X	1944-9097		J FOOD PROTECT	J. Food Prot.	MAR	2015	78	3					561	566		10.4315/0362-028X.JFP-14-275		6	Biotechnology & Applied Microbiology; Food Science & Technology	Biotechnology & Applied Microbiology; Food Science & Technology	CC7EU	WOS:000350531300012		
J	Sakuma, A; Saitoh, H; Ishii, N; Iwase, H				Sakuma, Ayaka; Saitoh, Hisako; Ishii, Namiko; Iwase, Hirotaro			The Effects of Racemization Rate for Age Estimation of Pink Teeth	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; age estimation; racemization; aspartic acid; pink teeth; odontology	ASPARTIC-ACID RACEMIZATION; DENTIN; TOOTH	Pink teeth is thought to result from the seepage of hemoglobin caused by dental pulp decomposition. We investigated whether racemization can be applied for age estimation in cases of pink teeth where the whole tooth is used. The pink teeth used were three cases and the normal teeth for control were five mandibular canines of known age. Age of the pink teeth was calculated on the basis of regression formula obtained from the five control teeth. Only a slight error was noted between the actual and estimated ages of the pink teeth (R-2=0.980, r=0.990): Cases 1-3 actually aged 23, 53, and 59years were estimated to be 26, 52, and 60years. Based on our results of testing pink teeth of known age, we suggest that racemization techniques allow for the age estimation of pink teeth using the same methods for normally colored teeth.	[Sakuma, Ayaka; Saitoh, Hisako; Ishii, Namiko; Iwase, Hirotaro] Chiba Univ, Grad Sch Med, Dept Legal Med, Chuo Ku, Chiba, Chiba 2608670, Japan	Sakuma, A (reprint author), Chiba Univ, Grad Sch Med, Dept Legal Med, Chuo Ku, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan.	a.sakuma@chiba-u.jp					Ohtani S, 2010, J FORENSIC SCI, V55, P1630, DOI 10.1111/j.1556-4029.2010.01472.x; BORRMAN H, 1994, INT J LEGAL MED, V106, P225, DOI 10.1007/BF01225410; Campobasso CP, 2006, AM J FOREN MED PATH, V27, P313, DOI 10.1097/01.paf.0000233544.58567.81; HELFMAN PM, 1975, P NATL ACAD SCI USA, V72, P2891, DOI 10.1073/pnas.72.8.2891; Ohtani S, 1998, AM J FOREN MED PATH, V19, P77, DOI 10.1097/00000433-199803000-00015; Ohtani S, 2003, INT J LEGAL MED, V117, P149, DOI 10.1007/s00414-003-0365-8; Ortmann C, 1998, INT J LEGAL MED, V111, P35; Sakuma A, 2012, FORENSIC SCI INT, V223, P198, DOI 10.1016/j.forsciint.2012.08.043; Soriano EP, 2009, MED ORAL PATOL ORAL, V14, P337	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	MAR	2015	60	2					450	452		10.1111/1556-4029.12653		3	Medicine, Legal	Legal Medicine	CD0LM	WOS:000350764300025		
J	Sato, T; Nishio, H; Suzuki, K				Sato, Takako; Nishio, Hajime; Suzuki, Koichi			Identification of Arrhythmogenic Right Ventricular Cardiomyopathy-Causing Gene Mutations in Young Sudden Unexpected Death Autopsy Cases	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic pathology; arrhythmogenic right ventricular cardiomyopathy; molecular autopsy; desmoplakin; sudden death	DESMOPLAKIN; DYSPLASIA/CARDIOMYOPATHY; DISEASE; PLAKOGLOBIN; DESMOSOME; DIAGNOSIS; DELETION	Arrhythmogenic right ventricular cardiomyopathy (ARVC) results in an increased risk of sudden death. We sought mutations of desmoglein-2 (DSG2), desmoplakin (DSP), and plakophilin-2 (PKP2) in 15 cases of sudden death whose causes of death could not be determined at autopsy. In three victims, mutations were identified in DSP. Two of these mutations were novel; one had previously been reported in a patient with ARVC that had been diagnosed clinically. Histological findings were not typical of ARVC; however, it was notable that these mutations were present in three of 15 cases, a relatively high proportion. The causal relationship between the mutations and ARVC is unclear, but the mutations might have been associated with faulty desmosomal proteins resulting in fatal arrhythmia. Combining information gathered by the traditional means of gross and histological examination with postmortem genetic analysis of young victims would assist in identifying their cause of death.	[Sato, Takako; Suzuki, Koichi] Osaka Med Coll, Dept Legal Med, Takatsuki, Osaka 5698686, Japan; [Nishio, Hajime] Hyogo Coll Med, Dept Legal Med, Nishinomiya, Hyogo 6638501, Japan	Sato, T (reprint author), Osaka Med Coll, Dept Legal Med, 2-7 Daigaku, Takatsuki, Osaka 5698686, Japan.	leg017@art.osaka-med.ac.jp					Yang Z, 2006, CIRC RES, V99, P646, DOI 10.1161/01.RES.0000241482.19382.c6; Quarta G, 2012, EUR HEART J, V33, P1128, DOI 10.1093/eurheartj/ehr451; Taylor M, 2011, CIRCULATION, V124, P876, DOI 10.1161/CIRCULATIONAHA.110.005405; Beffagna G, 2005, CARDIOVASC RES, V65, P366, DOI 10.1016/j.cardiores.2004.10.005; Bauce B, 2010, HEART RHYTHM, V7, P22, DOI 10.1016/j.hrthm.2009.09.070; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Awad MM, 2008, NAT CLIN PRACT CARD, V5, P258, DOI 10.1038/ncpcardio1182; Corrado D, 2006, CIRCULATION, V113, P1634, DOI 10.1161/CIRCULATIONAHA.105.616490; Xu TH, 2010, J AM COLL CARDIOL, V55, P587, DOI 10.1016/j.jacc.2009.11.020; Meurs KM, 2010, HUM GENET, V128, P315, DOI 10.1007/s00439-010-0855-y; Marcus FI, 2010, CIRCULATION, V121, P1533, DOI 10.1161/CIRCULATIONAHA.108.840827; Merner ND, 2008, AM J HUM GENET, V82, P809, DOI 10.1016/j.ajhg.2008.01.010; Basso C, 2012, NAT REV CARDIOL, V9, P223, DOI 10.1038/nrcardio.2011.173; Hamilton RM, 2009, PACE, V32, pS44, DOI 10.1111/j.1540-8159.2009.02384.x; Herren T, 2009, CLIN RES CARDIOL, V98, P141, DOI 10.1007/s00392-009-0751-4; Klauke B, 2010, HUM MOL GENET, V19, P4595, DOI 10.1093/hmg/ddq387; Lapouge K, 2006, J CELL SCI, V119, P4974, DOI 10.1242/jcs.03255; Larsen MK, 2012, J FORENSIC SCI, V57, P658, DOI 10.1111/j.1556-4029.2011.02028.x; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; Nishio Hajime, 2009, Legal Medicine, V11, P142, DOI 10.1016/j.legalmed.2008.12.004; Nishio Hajime, 2009, Leg Med (Tokyo), V11 Suppl 1, pS119, DOI 10.1016/j.legalmed.2009.01.031; Nishio H, 2009, INT J LEGAL MED, V123, P253, DOI 10.1007/s00414-009-0321-3; Rampazzo A, 2002, AM J HUM GENET, V71, P1200, DOI 10.1086/344208; RAMPAZZO A, 1995, HUM MOL GENET, V4, P2151, DOI 10.1093/hmg/4.11.2151; Sato T, 2010, FORENSIC SCI INT, V194, P77, DOI 10.1016/j.forsciint.2009.10.014; Sato T, 2011, LEGAL MED-TOKYO, V13, P298, DOI 10.1016/j.legalmed.2011.08.004; Yu CC, 2008, J FORMOS MED ASSOC, V107, P548, DOI 10.1016/S0929-6646(08)60168-0; Zhang MC, 2012, CIRC J, V76, P189, DOI 10.1253/circj.CJ-11-0747	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	MAR	2015	60	2					457	461		10.1111/1556-4029.12657		5	Medicine, Legal	Legal Medicine	CD0LM	WOS:000350764300027		
J	Kadooka, K; Fujii, K; Matsumoto, T; Sato, M; Morimatsu, F; Tashiro, K; Kuhara, S; Katakura, Y				Kadooka, Keishi; Fujii, Kaoru; Matsumoto, Takashi; Sato, Mikako; Morimatsu, Fumiki; Tashiro, Kosuke; Kuhara, Satoru; Katakura, Yoshinori			Mechanisms and consequences of carnosine-induced activation of intestinal epithelial cells	JOURNAL OF FUNCTIONAL FOODS			English	Article						Camosine; Intestinal epithelial cells; Microarray; Brain-gut interaction	LARGE GENE LISTS; NEUROTROPHIC FACTOR; RETINOIC ACID; ALZHEIMERS-DISEASE; SH-SY5Y CELLS; MUSCLE; BRAIN; EXPRESSION; ANSERINE; MODEL	The molecular basis for the camosine-induced activation of intestinal epithelial cells was studied and subsequently we focused on whether camosine stimulates a brain-gut interaction. To assess this, we investigated changes in intestinal epithelial cells induced by camosine. Our results showed that camosine activated Caco-2 cells, resulting in the secretion of various factors (including neurotrophic factors), and leading to the induction of neurite growth in SY-SY5Y cells. We then conducted DNA microarray analysis to reveal global changes in Caco-2 cells via treatment with camosine. The expression of 745 genes significantly changed upon camosine treatment. Furthermore, cluster analysis showed that several of these genes were related to secretory proteins, membrane protein/transporters, and calcium channel/transport protein. Some of these genes would explain the mechanism of camosine action, especially considering stimulation of the brain-gut interaction. (C) 2014 Elsevier Ltd. All rights reserved.	[Kadooka, Keishi; Tashiro, Kosuke; Kuhara, Satoru; Katakura, Yoshinori] Kyushu Univ, Fac Agr, Fukuoka 8128581, Japan; [Fujii, Kaoru] Kyushu Univ, Grad Sch Syst Life Sci, Fukuoka 8128581, Japan; [Matsumoto, Takashi; Sato, Mikako; Morimatsu, Fumiki] Nippon Meat Packers Inc, R&D Ctr, Tsukuba, Ibaraki 3002646, Japan	Katakura, Y (reprint author), Kyushu Univ, Fac Agr, Fukuoka 8128581, Japan.	katakura@grt.kyushu-u.ac.jp			JSPS KAKENHI Grant [12J02731]	The authors like to thank N. Oshima (GE Healthcare) for her expert assistance with the IN Cell Analyzer 1000, Dr. M. Udono and Mr. M. Deguchi for their technical assistance, and Dr. K. Yasuda for her expert assistance with DNA microarray analysis. This work was supported by JSPS KAKENHI Grant Number 12J02731.	Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Fujiki T, 2007, ONCOGENE, V26, P5258, DOI 10.1038/sj.onc.1210331; Batrukova MA, 1997, BBA-BIOMEMBRANES, V1324, P142, DOI 10.1016/S0005-2736(96)00216-7; Culbertson JY, 2010, NUTRIENTS, V2, P75, DOI 10.3390/nu2010075; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Perego S, 2013, J FUNCT FOODS, V5, P847, DOI 10.1016/j.jff.2013.01.032; Jamsa A, 2004, BIOCHEM BIOPH RES CO, V319, P993, DOI 10.1016/j.bbrc.2004.05.075; Kou W, 2008, EUR J NUTR, V47, P104, DOI 10.1007/s00394-008-0703-1; Herculano B, 2013, J ALZHEIMERS DIS, V33, P983, DOI 10.3233/JAD-2012-121324; Tomonaga S, 2008, PHARMACOL BIOCHEM BE, V89, P627, DOI 10.1016/j.pbb.2008.02.021; Saeed AI, 2003, BIOTECHNIQUES, V34, P374; LAMONT C, 1992, J PHYSIOL-LONDON, V454, P421; Budzen S, 2013, ADV CLIN EXP MED, V22, P739; CHASOVNIKOVA LV, 1990, BIOCHEM INT, V20, P1097; Corona C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017971; DAVEY CL, 1960, ARCH BIOCHEM BIOPHYS, V89, P296, DOI 10.1016/0003-9861(60)90058-8; DeMarchis S, 1997, NEUROSCI LETT, V237, P37, DOI 10.1016/S0304-3940(97)00800-8; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; JOHNSON P, 1984, COMP BIOCHEM PHYS B, V78, P331, DOI 10.1016/0305-0491(84)90039-7; Maemura H., 2006, INT J SPORT HLTH SCI, V4, P86, DOI 10.5432/ijshs.4.86; Miyahara E, 2014, TOXICOLOGY, V317, P50, DOI 10.1016/j.tox.2014.01.007; Samaranayaka AGP, 2011, J FUNCT FOODS, V3, P229, DOI 10.1016/j.jff.2011.05.006	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1756-4646			J FUNCT FOODS	J. Funct. Food.	MAR	2015	13						32	37		10.1016/j.jff.2014.12.024		6	Food Science & Technology	Food Science & Technology	CC8IX	WOS:000350612800004		
J	Zhu, QC; Nakagawa, T; Kishikawa, A; Ohnuki, K; Shimizu, K				Zhu, Qinchang; Nakagawa, Toshinori; Kishikawa, Asuka; Ohnuki, Koichiro; Shimizu, Kuniyoshi			In vitro bioactivities and phytochemical profile of various parts of the strawberry (Fragaria x ananassa var. Amaou)	JOURNAL OF FUNCTIONAL FOODS			English	Article						Strawberry; Antioxidant; Anti-obesity; Anti-allergy; Skin lightening; Phytochemicals	TOTAL ANTIOXIDANT CAPACITY; PHENOLIC-COMPOUNDS; MELANIN BIOSYNTHESIS; DIGESTIVE ENZYMES; BERRY POLYPHENOLS; 3T3-L1 ADIPOCYTE; ELLAGIC ACID; HUMAN HEALTH; FRUITS; EXTRACTS	The in vitro antioxidant, anti-obesity, anti-allergy and skin-lightening effects of extracts from strawberry fruits (ripe and unripe) and nine other plant parts of Amaou strawberry (Fragaria x ananassa var. Amaou) were comparatively investigated by using the antioxidant assay and inhibition assays of lipase, adipocyte differentiation, beta-hexosaminidase release, melanogenesis and tyrosinase. Their total phenolic content and the main phenolic compounds were also determined. The ripe strawberry fruits were found to possess potential anti-obesity and skin-lightening effects. The ethanol extracts from unripe strawberry fruits and several other parts like the crown, stolon leaf and flower showed more strong activities in the bioactivity assays conducted. The phytochemical profile varied among extracts from various parts of the plant. Ellagic acid was found in every part of the strawberry plant except the root. Our study provides valuable evidence that strawberry fruit is a food with potential anti-obesity and skin-lightening functions. The findings also support that several inedible parts of the strawberry plant have great potential to be used as the ingredients of functional food products. (C) 2014 Elsevier Ltd. All rights reserved.	[Zhu, Qinchang; Nakagawa, Toshinori; Kishikawa, Asuka; Shimizu, Kuniyoshi] Kyushu Univ, Dept Agroenvironm Sci, Fac Agr, Higashi Ku, Fukuoka 8128581, Japan; [Ohnuki, Koichiro] Kinki Univ, Dept Biol & Environm Chem, Iizuka, Fukuoka 8208555, Japan	Shimizu, K (reprint author), Kyushu Univ, Dept Agroenvironm Sci, Fac Agr, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	shimizu@agr.kyushu-u.ac.jp			KAKENHI Grant [26252037]; Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University	We thank Mr. Toshiro Nagata for the help in preparing the extracts. We thank the Research Support Center, Kyushu University Graduate School of Medical Sciences for providing the instrument of Flex Station 3 Reader. This work was supported by KAKENHI Grant Number 26252037. The publication of this study was supported in part by the Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University.	LERNER AB, 1950, PHYSIOL REV, V30, P91; Liu CJ, 2013, INT IMMUNOPHARMACOL, V16, P165, DOI 10.1016/j.intimp.2013.03.032; Aaby K, 2007, J AGR FOOD CHEM, V55, P4395, DOI 10.1021/jf0702592; Olsson ME, 2004, J AGR FOOD CHEM, V52, P2490, DOI 10.1021/jf030461e; Tanaka A, 2014, MOLECULES, V19, P8238, DOI 10.3390/molecules19068238; Giampieri F, 2012, NUTRITION, V28, P9, DOI 10.1016/j.nut.2011.08.009; Wang SY, 2000, J AGR FOOD CHEM, V48, P140, DOI 10.1021/jf9908345; Fernandes VC, 2012, FOOD CHEM, V134, P1926, DOI 10.1016/j.foodchem.2012.03.130; McDougall GJ, 2009, FOOD CHEM, V115, P193, DOI 10.1016/j.foodchem.2008.11.093; Pineli LDD, 2011, J FOOD COMPOS ANAL, V24, P11, DOI 10.1016/j.jfca.2010.05.004; Gunduz K, 2014, FOOD CHEM, V155, P298, DOI 10.1016/j.foodchem.2014.01.064; Chen YM, 2013, J FUNCT FOODS, V5, P395, DOI 10.1016/j.jff.2012.11.012; Wu D, 2013, J FUNCT FOODS, V5, P633, DOI 10.1016/j.jff.2013.01.005; Shimizu K, 2007, J WOOD SCI, V53, P153, DOI 10.1007/s10086-006-0824-1; Rendon MI, 2005, DERMATOL SURG, V31, P886; Huang C, 2006, BIOCHEM BIOPH RES CO, V348, P571, DOI 10.1016/j.bbrc.2006.07.095; Liu CJ, 2012, FOOD CHEM TOXICOL, V50, P3032, DOI 10.1016/j.fct.2012.06.016; Zunino SJ, 2012, BRIT J NUTR, V108, P900, DOI 10.1017/S0007114511006027; Giampieri F, 2014, J AGR FOOD CHEM, V62, P3867, DOI 10.1021/jf405455n; Arung ET, 2006, BIOL PHARM BULL, V29, P1966, DOI 10.1248/bpb.29.1966; Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1016/jf047814+; Wang LX, 2013, 2013 14TH ACIS INTERNATIONAL CONFERENCE ON SOFTWARE ENGINEERING, ARTIFICIAL INTELLIGENCE, NETWORKING AND PARALLEL/DISTRIBUTED COMPUTING (SNPD 2013), P3, DOI [10.1109/MWSYM.2013.6697441, 10.1109/SNPD.2013.34]; Mira A, 2013, J ETHNOPHARMACOL, V148, P980, DOI 10.1016/j.jep.2013.06.008; Pinto MDS, 2008, J AGR FOOD CHEM, V56, P4386, DOI 10.1021/jf0732758; Wang H, 1996, J AGR FOOD CHEM, V44, P701, DOI 10.1021/jf950579y; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Maeda K, 1996, J PHARMACOL EXP THER, V276, P765; Zhang XH, 2012, NUTR RES PRACT, V6, P286, DOI 10.4162/nrp.2012.6.4.286; Aiyer HS, 2012, J AGR FOOD CHEM, V60, P5693, DOI 10.1021/jf204084f; Aaby K, 2012, FOOD CHEM, V132, P86, DOI 10.1016/j.foodchem.2011.10.037; Boivin D, 2007, ANTICANCER RES, V27, P937; Kosar M, 2004, J AGR FOOD CHEM, V52, P1586, DOI 10.1021/jf035093t; Podsedek A, 2014, J AGR FOOD CHEM, V62, P4610, DOI 10.1021/jf5008264; McDougall GJ, 2005, BIOFACTORS, V23, P189; Wang SY, 2009, J AGR FOOD CHEM, V57, P9651, DOI 10.1021/jf9020575; Atkinson CJ, 2006, ANN BOT-LONDON, V97, P429, DOI 10.1093/aob/mcj046; Choi SP, 2007, J FOOD SCI, V72, pS719, DOI 10.1111/j.1750-3841.2007.00562.x; Chung MJ, 2002, CANCER LETT, V182, P1, DOI 10.1016/S0304-3835(02)00076-9; Pinto MD, 2010, J MED FOOD, V13, P1027, DOI 10.1089/jmf.2009.0257; El-Mesallamy A. M. D., 2013, NATURAL PRODUCTS IND, V9, P251; Goto K., 2011, J ISSAAS INT SOC SE, V17, P274; Inaba Yukio, 2006, Horticultural Research (Japan), V5, P219, DOI 10.2503/hrj.5.219; Iwamoto A, 2013, J FUNCT FOODS, V5, P1947, DOI 10.1016/j.jff.2013.09.016; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Rodriguez-Mateos A, 2013, J AGR FOOD CHEM, V62, P3842; Sato K., 2007, B FUKUOKA AGR RES CT, V26, P45; Shimogaki H., 2000, International Journal of Cosmetic Science, V22, P291, DOI 10.1046/j.1467-2494.2000.00023.x; Song NY, 2013, NAT PROD RES, V27, P2219, DOI 10.1080/14786419.2013.805330; Tanaka Y., 2001, HDB COSMETIC SCI TEC, V40, P473	49	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1756-4646			J FUNCT FOODS	J. Funct. Food.	MAR	2015	13						38	49		10.1016/j.jff.2014.12.026		12	Food Science & Technology	Food Science & Technology	CC8IX	WOS:000350612800005		
J	Kobayashi, S; Kato, T; Azuma, T; Kikuzaki, H; Abe, K				Kobayashi, Shoko; Kato, Taro; Azuma, Toshiaki; Kikuzaki, Hiroe; Abe, Keiko			Anti-allergenic activity of polymethoxyflavones from Kaempferia parviflora	JOURNAL OF FUNCTIONAL FOODS			English	Article						Antiallergic activity; Degranulation; Kaempferia parviflora; Polymethoxyflavone; RBL-2H3; Zingiberaceae	ANTIGEN-INDUCED DEGRANULATION; BASOPHILIC LEUKEMIA RBL-2H3; MAST-CELL ACTIVATION; INHIBITION; FLAVONOIDS; CHEMISTRY; CATECHINS; RECEPTOR; BINDING; ALPHA	The inhibitory effects of 13 polymethoxyflavones (PMFs) obtained from Kaempferia paruiflora extracts were evaluated on RBL-2H3 cell degranulation. These flavones suppressed antigeninduced degranulation in RBL-2H3 cells. 5-Hydroxy-3,7,4',-trimethoxyflavone (KP02) and 5,3'-dihydroxy-3,7,4',-trimethoxyflavone (KP10) showed potent inhibitory activities. KP10 significantly suppressed calcium ionophores, such as A23187 and 2,5-ditert-butylhydroquinone, which promoted calcium influx from the outside of cells and from the endoplasmic reticulum, respectively. However, these activities did not fully explain the PMFs' effects. Immunoblot analysis of KPO2 and KP10 showed that the inhibitory effects were attributable to the downregulation of PLC gamma 1 kinase phosphorylation in the signaling pathways involved in degranulation. The phosphorylation levels of Syk were also suppressed by the addition of KP10. KP02 and KP10 treatment to the cells did not affect the high affinity IgE receptor (Fc epsilon RI) levels inside RBL-2H3 cells, but they suppressed the Fc epsilon RI levels in the plasma membrane. Therefore, K. parviflora PMFs have multiple degranulation mechanisms to suppress RBL-2H3 cells and would be beneficial for alleviating type I allergy symptoms. (C) 2014 Elsevier Ltd. All rights reserved.	[Kobayashi, Shoko; Kato, Taro] Univ Tokyo, Res Ctr Food Safety, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; [Azuma, Toshiaki] Osaka City Univ, Grad Sch Human Life Sci, Div Food & Hlth Sci, Sumiyoshi Ku, Osaka 5588585, Japan; [Kikuzaki, Hiroe] Nara Womens Univ, Dept Food Sci & Nutr, Nara 6308506, Japan; [Abe, Keiko] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; [Abe, Keiko] Kanagawa Acad Sci & Technol, Kawasaki, Kanagawa, Japan; [Abe, Keiko] Life Sci & Environm Res Ctr, Kawasaki, Kanagawa, Japan	Kobayashi, S (reprint author), Univ Tokyo, Res Ctr Food Safety, Grad Sch Agr & Life Sci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ashoko@mail.ecc.u-tokyo.ac.jp			Council for Science, Technology and Innovation (CSTI); Cross-ministerial Strategic Innovation Promotion Program (SIP), "Technologies for creating nextgeneration agriculture, forestry and fisheries"	This work was supported by Council for Science, Technology and Innovation (CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP), "Technologies for creating nextgeneration agriculture, forestry and fisheries"	Abramson J, 2006, EMBO J, V25, P323, DOI 10.1038/sj.emboj.7600932; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Li SM, 2014, J FUNCT FOODS, V6, P2, DOI 10.1016/j.jff.2013.12.011; Li SM, 2009, J FUNCT FOOD, V1, P2, DOI 10.1016/j.jff.2008.09.003; Mastuda H, 2002, BIOORGAN MED CHEM, V10, P3123, DOI 10.1016/S0968-0896(02)00227-4; Maeda-Yamamoto M, 2004, J IMMUNOL, V172, P4486; Itoh T, 2009, BIOORGAN MED CHEM, V17, P5374, DOI 10.1016/j.bmc.2009.06.050; Tanifuji S, 2010, INT IMMUNOPHARMACOL, V10, P769, DOI 10.1016/j.intimp.2010.04.007; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Azuma T, 2008, PHYTOCHEMISTRY, V69, P2743, DOI 10.1016/j.phytochem.2008.09.001; Azuma T, 2011, FOOD CHEM, V125, P471, DOI 10.1016/j.foodchem.2010.09.033; Campbell DE, 1998, PEDIATR ALLERGY IMMU, V9, P68, DOI 10.1111/j.1399-3038.1998.tb00306.x; Chinapongtitiwat V, 2013, J FUNCT FOODS, V5, P1151, DOI 10.1016/j.jff.2013.03.012; Coureau B, 2008, ANN PHARMACOTHER, V42, P1903, DOI 10.1345/aph.1L067; Fujimura Y, 2008, ARCH BIOCHEM BIOPHYS, V476, P133, DOI 10.1016/j.abb.2008.03.002; Kaneko M, 2010, IMMUNOPHARM IMMUNOT, V32, P454, DOI 10.3109/08923970903513139; Kobayashi S, 2006, INT J MOL MED, V17, P511; Kopec A, 2006, ARCH IMMUNOL THER EX, V54, P393, DOI 10.1007/s00005-006-0049-4; Lee ACL, 2013, J FUNCT FOODS, V5, P616, DOI 10.1016/j.jff.2013.01.003; Shichijo M, 2003, BIOL PHARM BULL, V26, P1685, DOI 10.1248/bpb.26.1685; Tedeschi A, 2000, INT J IMMUNOPHARMACO, V22, P797, DOI 10.1016/S0192-0561(00)00041-2; Tewtrakul S, 2008, J ETHNOPHARMACOL, V116, P191, DOI 10.1016/j.jep.2007.10.042; Yamada T, 2014, J ALLERGY CLIN IMMUN, V133, P632, DOI 10.1016/j.jaci.2013.11.002; Yenjai C, 2004, FITOTERAPIA, V75, P89, DOI 10.1016/j.fitote.2003.08.017	27	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1756-4646			J FUNCT FOODS	J. Funct. Food.	MAR	2015	13						100	107		10.1016/j.jff.2014.12.029		8	Food Science & Technology	Food Science & Technology	CC8IX	WOS:000350612800011		
J	Watanabe, M				Watanabe, Mamoru			Recent dramatic evolution of the Journal of Gastroenterology (JG): a note from current Editorial Director and former Editor-in-Chief of JG	JOURNAL OF GASTROENTEROLOGY			English	Editorial Material									Tokyo Med Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan	Watanabe, M (reprint author), Tokyo Med Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan.	mamoru.gast@tmd.ac.jp						0	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					249	251		10.1007/s00535-015-1047-2		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200001		
J	Tanaka, S; Saitoh, Y; Matsuda, T; Igarashi, M; Matsumoto, T; Iwao, Y; Suzuki, Y; Nishida, H; Watanabe, T; Sugai, T; Sugihara, K; Tsuruta, O; Hirata, I; Hiwatashi, N; Saito, H; Watanabe, M; Sugano, K; Shimosegawa, T				Tanaka, Shinji; Saitoh, Yusuke; Matsuda, Takahisa; Igarashi, Masahiro; Matsumoto, Takayuki; Iwao, Yasushi; Suzuki, Yasumoto; Nishida, Hiroshi; Watanabe, Toshiaki; Sugai, Tamotsu; Sugihara, Ken-ichi; Tsuruta, Osamu; Hirata, Ichiro; Hiwatashi, Nobuo; Saito, Hiroshi; Watanabe, Mamoru; Sugano, Kentaro; Shimosegawa, Tooru			Evidence-based clinical practice guidelines for management of colorectal polyps	JOURNAL OF GASTROENTEROLOGY			English	Article						Colorectal polyp; Colorectal tumor; Polyposis; GRADE system	ENDOSCOPIC SUBMUCOSAL DISSECTION; LATERALLY SPREADING TUMORS; HIGH-GRADE DYSPLASIA; MUCOSAL RESECTION; RISK-FACTORS; CLINICOPATHOLOGICAL FEATURES; HYPERPLASTIC POLYPS; INVASIVE-CARCINOMA; TREATMENT STRATEGY; COLONIC POLYPS	Recently in Japan, the morbidity of colorectal polyp has been increasing. As a result, a large number of cases of colorectal polyps that are diagnosed and treated using colonoscopy has now increased, and clinical guidelines are needed for endoscopic management and surveillance after treatment. Three committees [the professional committee for making clinical questions (CQs) and statements by Japanese specialists, the expert panelist committee for rating statements by the modified Delphi method, and the evaluating committee by moderators] were organized. Ten specialists for colorectal polyp management extracted the specific clinical statements from articles published between 1983 and September 2011 obtained from PubMed and a secondary database, and developed the CQs and statements. Basically, statements were made according to the GRADE system. The expert panel individually rated the clinical statements using a modified Delphi approach, in which a clinical statement receiving a median score greater than seven on a nine-point scale from the panel was regarded as valid. The professional committee created 91CQs and statements for the current concept and diagnosis/treatment of various colorectal polyps including epidemiology, screening, pathophysiology, definition and classification, diagnosis, treatment/management, practical treatment, complications and surveillance after treatment, and other colorectal lesions (submucosal tumors, nonneoplastic polyps, polyposis, hereditary tumors, ulcerative colitis-associated tumor/carcinoma). After evaluation by the moderators, evidence-based clinical guidelines for management of colorectal polyps have been proposed for 2014.	[Tanaka, Shinji; Saitoh, Yusuke; Matsuda, Takahisa; Igarashi, Masahiro; Matsumoto, Takayuki; Iwao, Yasushi; Suzuki, Yasumoto; Nishida, Hiroshi; Watanabe, Toshiaki; Sugai, Tamotsu; Sugihara, Ken-ichi; Tsuruta, Osamu; Hirata, Ichiro; Hiwatashi, Nobuo; Saito, Hiroshi; Watanabe, Mamoru; Sugano, Kentaro; Shimosegawa, Tooru] Japanese Soc Gastroenterol JSGE, Guidelines Comm Creating & Evaluating Evidence Ba, Chuo Ku, Tokyo 1040061, Japan	Tanaka, S (reprint author), Japanese Soc Gastroenterol JSGE, Guidelines Comm Creating & Evaluating Evidence Ba, Chuo Ku, K-18 Bldg 8F,8-9-13 Ginza, Tokyo 1040061, Japan.	colon@hiroshima-u.ac.jp			JSGE	This article was supported by a Grant-in-Aid from the JSGE. The authors thank Dr. Shiro Oka (Hiroshima University Hospital) and Dr. Toshiaki Tanaka (University of Tokyo) for great assistance for data collection, data analysis, and manuscript preparation.	Ahlawat SK, 2011, J CLIN GASTROENTEROL, V45, P347, DOI 10.1097/MCG.0b013e3181f3a2e0; Aldridge AJ, 2001, EUR J SURG, V167, P777; Saito Y, 2010, SURG ENDOSC, V24, P343, DOI 10.1007/s00464-009-0562-8; Mannath J, 2011, DIGEST DIS SCI, V56, P2389, DOI 10.1007/s10620-011-1609-y; Tamura S, 2004, ENDOSCOPY, V36, P306, DOI 10.1055/s-2004-814204; Laiyemo AO, 2009, CLIN GASTROENTEROL H, V7, P192, DOI 10.1016/j.cgh.2008.08.031; Ikematsu H, 2013, GASTROENTEROLOGY, V144, P551, DOI 10.1053/j.gastro.2012.12.003; Terasaki M, 2012, J GASTROEN HEPATOL, V27, P734, DOI 10.1111/j.1440-1746.2011.06977.x; Yamaji Y, 2004, GUT, V53, P568, DOI 10.1136/gut.2003.026112; Kudo SE, 2008, GASTROINTEST ENDOSC, V68, pS3, DOI 10.1016/j.gie.2008.07.052; Tanaka S, 2006, GASTROINTEST ENDOSC, V64, P604, DOI 10.1016/j.gie.2006.06.007; Bretagne JF, 2010, DIS COLON RECTUM, V53, P339, DOI 10.1007/DCR.0b013e3181c37f9c; Tanaka S, 2007, GASTROINTEST ENDOSC, V66, P100, DOI 10.1016/j.gie.2007.02.032; Tanaka S, 2008, J GASTROENTEROL, V43, P641, DOI 10.1007/s00535-008-2223-4; Atkin WS, 2012, ENDOSCOPY, V44, pSE151, DOI 10.1055/s-0032-1309821; Kuroki Y, 2010, J GASTROEN HEPATOL, V25, P1747, DOI 10.1111/j.1440-1746.2010.06331.x; Suh JH, 2012, ENDOSCOPY, V44, P590, DOI 10.1055/s-0031-1291665; Son HJ, 2008, HEPATO-GASTROENTEROL, V55, P1293; Tanaka S, 2013, DIGEST ENDOSC, V25, P107, DOI 10.1111/den.12016; Nakajima T, 2013, SURG ENDOSC, V27, P3262, DOI 10.1007/s00464-013-2903-x; Saitoh Y, 2001, GASTROENTEROLOGY, V120, P1657, DOI 10.1053/gast.2001.24886; Uraoka T, 2006, GUT, V55, P1592, DOI 10.1136/gut.2005.087452; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; Kim JH, 2008, DIGEST DIS SCI, V53, P2941, DOI 10.1007/s10620-008-0248-4; Lieberman DA, 2012, GASTROENTEROLOGY, V143, P844, DOI 10.1053/j.gastro.2012.06.001; Nakadoi K, 2012, J GASTROEN HEPATOL, V27, P1057, DOI 10.1111/j.1440-1746.2011.07041.x; Puli SR, 2009, ANN SURG ONCOL, V16, P2147, DOI 10.1245/s10434-009-0520-7; Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/S0016-5085(04)00717-6; COVERLIZZA S, 1989, CANCER, V64, P1937, DOI 10.1002/1097-0142(19891101)64:9<1937::AID-CNCR2820640929>3.0.CO;2-X; Puli SR, 2009, WORLD J GASTROENTERO, V15, P4273, DOI 10.3748/wjg.15.4273; [Anonymous], 2014, JSCCR GUID 201 UNPUB; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Gschwantler M, 2002, EUR J GASTROEN HEPAT, V14, P183, DOI 10.1097/00042737-200202000-00013; Bensen SP, 1999, LANCET, V354, P1873, DOI 10.1016/S0140-6736(99)04469-4; Saito Y, 2001, ENDOSCOPY, V33, P682, DOI 10.1055/s-2001-16213; Asano M, 2006, DIG MED, V43, P299; De Jesus-Monge Wilfredo E, 2009, Curr Gastroenterol Rep, V11, P420; DEYHLE P, 1973, ENDOSCOPY, V5, P38; DIRSCHMID K, 1993, AM J SURG PATHOL, V17, P1262, DOI 10.1097/00000478-199312000-00007; Fukutomi Y, 2002, J CANCER RES CLIN, V128, P569, DOI 10.1007/s00432-002-0375-9; Hasegawa S, 2011, STOMACH INTESTINE, V46, P394; Hurlstone DP, 2008, COLORECTAL DIS, V10, P891, DOI 10.1111/j.1463-1318.2008.01510.x; Hurlstone DP, 2004, GUT, V53, P1334, DOI 10.1136/gut.2003.036913; Igarashi M, 1997, FOLLOW RESIDUAL COLO, P155; Kashida H, 2006, J CLIN EXPT MED IG S, P628; Kawamura T, 2006, DIG MED, V43, P307; Kobayashi N, 2009, J GASTROEN HEPATOL, V24, P1387, DOI 10.1111/j.1440-1746.2009.05893.x; Kodaira Susumu, 1994, Stomach and Intestine, V29, P1137; KUDO S, 1993, ENDOSCOPY, V25, P455, DOI 10.1055/s-2007-1010367; Luigiano C, 2009, ENDOSCOPY, V41, P829, DOI 10.1055/s-0029-1215091; Matsuda T, 2009, JPN J CLIN ONCOL, V39, P435, DOI 10.1093/jjco/hyp047; Matumoto T, 1999, J CLIN PATHOL, V52, P513; Meining A, 2011, CLIN GASTROENTEROL H, V9, P590, DOI 10.1016/j.cgh.2011.02.002; Nishiyama H, 2010, SURG ENDOSC, V24, P2881, DOI 10.1007/s00464-010-1071-5; Nozaki R, 1997, DIS COLON RECTUM, V40, pS16, DOI 10.1007/BF02062015; Nusko G, 2008, INT J COLORECTAL DIS, V23, P1065, DOI 10.1007/s00384-008-0508-y; Oka S, 2011, DIGEST ENDOSC, V23, P190, DOI 10.1111/j.1443-1661.2010.01072.x; Okabe S, 1998, SURG TODAY, V28, P687; Onoue K, 2008, J GASTROINTEST CANC, V46, P729; Saitoh Y, 2009, STOMACH INTESTINE, V44, P1047; Sawada T, 1995, LABOR WELF H, VH6, P66; Suzuki Y, 1997, THER RES, V18, pS362; Tanaka S, 2001, GASTROINTEST ENDOSC, V54, P62, DOI 10.1067/mge.2001.115729; Tanaka S, 2000, ONCOL REP, V7, P783; TANAKA S, 1995, DIS COLON RECTUM, V38, P959, DOI 10.1007/BF02049732; Tanaka S, 2014, GASTROENTEROL ENDOSC, V56, P1598; Togashi K, 2008, DIS COLON RECTUM, V51, P196, DOI 10.1007/s10350-007-9106-2; Toyonaga N, 2009, GASTROENTEROL ENDOSC, V51, P1121; Uraoka T, 2011, STOMACH INTESTINE, V46, P406; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; Yoda Y, 2011, STOMACH INTESTINE, V46, P1442; Yoshida M, 2015, J GASTROENTEROL, V50, P4, DOI 10.1007/s00535-014-1016-1; Yoshimori K, 2006, EARLY COLORECTAL CAN, V10, P291	73	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					252	260		10.1007/s00535-014-1021-4		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200002		
J	Goto, K; Kato, N				Goto, Kaku; Kato, Naoya			MICA SNPs and the NKG2D system in virus-induced HCC	JOURNAL OF GASTROENTEROLOGY			English	Review						MHC class I polypeptide-related sequence A; Single nucleotide polymorphism; Hepatitis C virus; Hepatitis B virus; Hepatocellular carcinoma; Natural killer	HEPATITIS-B-VIRUS; NATURAL-KILLER-CELLS; I-RELATED CHAIN; INDUCED HEPATOCELLULAR-CARCINOMA; GENOME-WIDE ASSOCIATION; CHRONIC VIRAL-HEPATITIS; C VIRUS; NK CELLS; SUSCEPTIBILITY LOCUS; ACTIVATING RECEPTOR	Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death globally. Above well-known risk factors for HCC development ranging from various toxins to diseases such as diabetes mellitus, chronic infection with hepatitis B virus and hepatitis C virus (HCV) poses the most serious threat, constituting the cause in more than 80 % of cases. In addition to the viral genes intensively investigated, the pathophysiological importance of host genetic factors has also been greatly and increasingly appreciated. Genome-wide association studies (GWAS) comprehensively search the host genome at the single-nucleotide level, and have successfully identified the genomic region associated with a whole variety of diseases. With respect to HCC, there have been reports from several groups on single nucleotide polymorphisms (SNPs) associated with hepatocarcinogenesis, among which was our GWAS discovering MHC class I polypeptide-related sequence A (MICA) as a susceptibility gene for HCV-induced HCC. MICA is a natural killer (NK) group 2D (NKG2D) ligand, whose interaction with NKG2D triggers NK cell-mediated cytotoxicity toward the target cells, and is a key molecule in tumor immune surveillance as its expression is induced on stressed cells such as transformed tumor cells for the detection by NK cells. In this review, the latest understanding of the MICA-NKG2D system in viral HCC, particularly focused on its antitumor properties and the involvement of MICA SNPs, is summarized, followed by a discussion of targets for state-of-the-art cancer immunotherapy with personalized medicine in view.	[Goto, Kaku; Kato, Naoya] Univ Tokyo, Div Adv Genome Med, Adv Clin Res Ctr, Inst Med Sci, Tokyo 1088639, Japan; [Goto, Kaku] Japan Soc Promot Sci, Tokyo 1028472, Japan	Kato, N (reprint author), Univ Tokyo, Div Adv Genome Med, Adv Clin Res Ctr, Inst Med Sci, Tokyo 1088639, Japan.	kato-2im@ims.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science (JSPS)	N.K. is supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan. K.G. is a recipient of Research Fellowships of the Japan Society for the Promotion of Science (JSPS) for Young Scientists. The authors appreciate critical reading of the manuscript and comments by Dr. Masahisa Jinushi, Center for Infection-Associated Cancer, Institute for Genetic Medicine, Hokkaido University, Hokkaido, Japan.	Ahlenstiel G., 2010, GASTROENTEROLOGY, V138, pe1; Al-Qahtani AA, 2013, EXP MOL PATHOL, V95, P255, DOI 10.1016/j.yexmp.2013.08.005; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gast.2004.09.014; Salih HR, 2002, J IMMUNOL, V169, P4098; Varchetta S, 2012, HEPATOLOGY, V56, P841, DOI 10.1002/hep.25723; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Sun DH, 2011, CELL BIOL INT, V35, P569, DOI 10.1042/CBI20100431; Boukouaci W, 2009, BLOOD, V114, P5216, DOI 10.1182/blood-2009-04-217430; Lange CM, 2013, J HEPATOL, V59, P504, DOI 10.1016/j.jhep.2013.04.032; Tsai WL, 2010, ONCOGENE, V29, P2309, DOI 10.1038/onc.2010.36; Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523; Cai L, 2008, CLIN IMMUNOL, V129, P428, DOI 10.1016/j.clim.2008.08.012; Schmidt N, 2012, DIGEST DIS, V30, P483, DOI 10.1159/000341697; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Kim GP, 2012, INVEST NEW DRUG, V30, P387, DOI 10.1007/s10637-010-9532-1; Castello G, 2010, CLIN IMMUNOL, V134, P237, DOI 10.1016/j.clim.2009.10.007; Han ZG, 2012, ANNU REV GENOM HUM G, V13, P171, DOI 10.1146/annurev-genom-090711-163752; Kahraman A, 2010, HEPATOLOGY, V51, P92, DOI 10.1002/hep.23253; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Korangy F, 2010, DIGEST DIS, V28, P150, DOI 10.1159/000282079; Thomas DL, 2013, NAT MED, V19, P850, DOI 10.1038/nm.3184; Jinushi M, 2005, J HEPATOL, V43, P1013, DOI 10.1016/j.jhep.2005.05.026; Abu-Amara M, 2013, SEMIN LIVER DIS, V33, P157, DOI 10.1055/s-0033-1345719; Miki D, 2012, CANCER SCI, V103, P846, DOI 10.1111/j.1349-7006.2012.02242.x; Rehermann B, 2013, NAT MED, V19, P859, DOI 10.1038/nm.3251; Li JJ, 2013, CHIN J CANCER, V32, P141, DOI 10.5732/cjc.012.10025; Marten A, 2006, INT J CANCER, V119, P2359, DOI 10.1002/ijc.22186; Mizuki N, 1997, P NATL ACAD SCI USA, V94, P1298, DOI 10.1073/pnas.94.4.1298; Karacki PS, 2004, GENES IMMUN, V5, P261, DOI 10.1038/sj.gene.6364065; Shabani Z, 2014, ARCH VIROL, V159, P1555, DOI 10.1007/s00705-013-1965-3; Morgan RL, 2013, ANN INTERN MED, V158, P329, DOI 10.7326/0003-4819-158-5-201303050-00005; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Van Belle TL, 2009, MOL IMMUNOL, V47, P8, DOI 10.1016/j.molimm.2009.02.023; Miletic A, 2013, EUR J IMMUNOL, V43, P867, DOI 10.1002/eji.201243101; Negrini M, 2011, ANTI-CANCER AGENT ME, V11, P500; Ou DP, 2007, INT J CANCER, V120, P1208, DOI 10.1002/ijc.22452; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Chotiyaputta W, 2009, NAT REV GASTRO HEPAT, V6, P453, DOI 10.1038/nrgastro.2009.107; Bjorkstrom NK, 2013, IMMUNOLOGY, V139, P416, DOI 10.1111/imm.12098; Kasahara M, 2012, IMMUNOGENETICS, V64, P855, DOI 10.1007/s00251-012-0638-9; Dunn C, 2007, J EXP MED, V204, P667, DOI 10.1084/jem.20061287; Lopez-Hernandez R, 2010, HUM IMMUNOL, V71, P512, DOI 10.1016/j.humimm.2010.02.003; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Goto K, 2013, J HEPATOL, V59, P942, DOI 10.1016/j.jhep.2013.06.025; Caldwell S, 2009, J GASTROENTEROL, V44, P96, DOI 10.1007/s00535-008-2258-6; Lavanchy D, 2012, J CLIN VIROL, V55, P296, DOI 10.1016/j.jcv.2012.08.022; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; Kim JR, 2004, INT J BIOCHEM CELL B, V36, P2293, DOI 10.1016/j.biocel.2004.04.022; Steinle A, 2001, IMMUNOGENETICS, V53, P279, DOI 10.1007/s002510100325; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Ogawa E, 2013, J HEPATOL, V58, P495, DOI 10.1016/j.jhep.2012.10.017; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Marcus A, 2014, ADV IMMUNOL, V122, P91, DOI 10.1016/B978-0-12-800267-4.00003-1; Fletcher SP, 2013, SEMIN LIVER DIS, V33, P130, DOI 10.1055/s-0033-1345713; Tamaki S, 2009, CLIN IMMUNOL, V130, P331, DOI 10.1016/j.clim.2008.09.004; Zou Y, 2010, J IMMUNOL, V184, P466, DOI 10.4049/jimmunol.0900687; Nishida N, 2013, ONCOLOGY-BASEL, V84, P93, DOI 10.1159/000345897; Manns MP, 2013, NAT REV DRUG DISCOV, V12, P595, DOI 10.1038/nrd4050; Zhang Z, 2011, HEPATOLOGY, V53, P73, DOI 10.1002/hep.23977; Zhang C, 2008, HUM IMMUNOL, V69, P490, DOI 10.1016/j.humimm.2008.06.004; Glassner A, 2012, LAB INVEST, V92, P967, DOI 10.1038/labinvest.2012.54; Liu G, 2010, J IMMUNOL, V184, P3346, DOI 10.4049/jimmunol.0903789; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Zwirner NW, 2007, CYTOKINE GROWTH F R, V18, P159, DOI 10.1016/j.cytogfr.2007.01.013; Kohga K, 2010, HEPATOLOGY, V51, P1264, DOI 10.1002/hep.23456; Lunemann S, 2014, J INFECT DIS, V209, P1362, DOI 10.1093/infdis/jit561; Gong Z, 2012, BRAZ J MED BIOL RES, V45, P222, DOI 10.1590/S0100-879X2012007500024; Shlomai A, 2014, SEMIN CANCER BIOL, V26, P78, DOI 10.1016/j.semcancer.2014.01.004; Kurokawa M, 2012, J GASTROENTEROL, V47, P577, DOI 10.1007/s00535-011-0522-7; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Cox ST, 2014, TISSUE ANTIGENS, V84, P293, DOI 10.1111/tan.12400; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Armeanu S, 2008, CLIN CANCER RES, V14, P3520, DOI 10.1158/1078-0432.CCR-07-4744; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Tinto N, 2008, DIGEST LIVER DIS, V40, P248, DOI 10.1016/j.dld.2007.11.028; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Chen YY, 2007, HEPATOLOGY, V46, P706, DOI 10.1002/hep.21872; Waldhauer I, 2008, CANCER RES, V68, P6368, DOI 10.1158/0008-5472.CAN-07-6768; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Delaney WE, 2013, ANTIVIR RES, V99, P34, DOI 10.1016/j.antiviral.2013.04.010; Jinushi M, 2003, J IMMUNOL, V171, P5423; Raache R, 2012, CLIN VACCINE IMMUNOL, V19, P557, DOI 10.1128/CVI.05473-11; Papatheodoridis GV, 2011, GUT, V60, P1109, DOI 10.1136/gut.2010.221846; Chitadze G, 2013, SCAND J IMMUNOL, V78, P120, DOI 10.1111/sji.12072; Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Ohira M, 2012, CELL TRANSPLANT, V21, P1397, DOI 10.3727/096368911X627589; Chaiteerakij R, 2015, CLIN GASTROENTEROL H, V13, P237, DOI 10.1016/j.cgh.2013.10.038; Chan CJ, 2013, CELL DEATH DIFFER, V21, P5, DOI DOI 10.1038/CDD.2013.26; Chang CJ, 2007, HEPATOLOGY, V45, P746, DOI 10.1002/hep.21560; Chen KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077315; Chen YY, 2006, CELL MOL IMMUNOL, V3, P373; Chen YY, 2005, INT IMMUNOPHARMACOL, V5, P1839, DOI 10.1016/j.intimp.2005.06.004; Della Corte C, 2013, WORLD J GASTROENTERO, V19, P1359, DOI 10.3748/wjg.v19.i9.1359; EAftSot Liver, 2014, J HEPATOL, V60, P392; Feitelson MA, 2014, EXPERT OPIN THER TAR, V18, P293, DOI 10.1517/14728222.2014.867947; Gao B, 2010, HEPATOLOGY, V51, P8, DOI 10.1002/hep.23320; Gao Qiang, 2012, Front Med, V6, P122, DOI 10.1007/s11684-012-0193-7; Gerlich WH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-239; Guan YS, 2013, ANTI-CANCER DRUG, V24, P337, DOI 10.1097/CAD.0b013e32835ec39a; Hoshida Y, 2012, J HEPATOL, V56, P729, DOI 10.1016/j.jhep.2011.08.015; Jeong Soung Won, 2012, Clin Mol Hepatol, V18, P347, DOI 10.3350/cmh.2012.18.4.347; Jiang X, 2011, TISSUE ANTIGENS, V78, P143, DOI 10.1111/j.1399-0039.2011.01693.x; Kahraman A, 2012, LIVER INT, V32, P370, DOI 10.1111/j.1478-3231.2011.02608.x; Kamimura H, 2012, J HEPATOL, V56, P381, DOI [10.1016/j.jhep.2011.06.017, 10.1016/j.jhep.2011.07.008]; Kato N, 2005, HEPATOLOGY, V42, P846, DOI 10.1002/hep.20860; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kim H, 2014, J VIROL, V88, P2564, DOI 10.1128/JVI.02988-13; Kirsten H, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2683; Kishikawa T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02739; Kohga K, 2009, CANCER RES, V69, P8050, DOI 10.1158/0008-5472.CAN-09-0789; Kumar V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044743; Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086927; Lo PHY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061279; Lopez-Soto A, 2015, INT J CANCER, V136, P1741, DOI 10.1002/ijc.28775; Lopez-Vazquez A, 2004, J INFECT DIS, V189, P957; Lu M, 2009, IMMUNOLOGY, V128, pe230, DOI 10.1111/j.1365-2567.2008.02953.x; Miamen Alexander G, 2012, Liver Cancer, V1, P226, DOI 10.1159/000343837; Mok JW, 2003, HUM IMMUNOL, V64, P1190, DOI 10.1016/j.humimm.2003.09.010; Motomura T, 2012, HPB SURG, V2012; Ngamruengphong S, 2014, DIGEST DIS SCI, V59, P986, DOI 10.1007/s10620-013-2984-3; Otsuka M, 2013, J GASTROENTEROL, V49, P173; Park Y, 2001, DIABETES CARE, V24, P33, DOI 10.2337/diacare.24.1.33; Peppa D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001227; Rosmorduc O, 2012, CLIN RES HEPATOL GAS, V36, P202, DOI 10.1016/j.clinre.2011.12.011; Salvatierra Karina, 2013, World J Virol, V2, P6, DOI 10.5501/wjv.v2.i1.6; Sene D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001184; Spear Paul, 2013, Cancer Immun, V13, P8; Sun C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002594; Tang KF, 2009, MED MICROBIOL IMMUN, V198, P27, DOI 10.1007/s00430-008-0101-6; Tong HV, 2013, J VIRAL HEPATITIS, V20, P687, DOI 10.1111/jvh.12089; Tonnerre P, 2013, J AM SOC NEPHROL, V24, P954, DOI 10.1681/ASN.2012080814; Ullrich E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26097; Okamoto Y, 2014, GASTROENTEROLOGY, V146, P562, DOI 10.1053/j.gastro.2013.10.056; Watzl C, 2003, MICROBES INFECT, V5, P31, DOI 10.1016/S1286-4579(02)00057-6; Wen CY, 2008, CELL MOL IMMUNOL, V5, P475, DOI 10.1038/cmi.2008.60; Wendt Astrid, 2014, Clin Pharmacol, V6, P1, DOI 10.2147/CPAA.S30338; Worns MA, 2013, DIGEST DIS, V31, P104, DOI 10.1159/000347202; Wu J., 2013, CARCINOGENESIS, V35, P155; Xia XW, 2013, ACTA RADIOL, V54, P684, DOI 10.1177/0284185113480072; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031	147	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					261	272		10.1007/s00535-014-1000-9		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200003		
J	Kamisawa, T; Kuruma, S; Tabata, T; Chiba, K; Iwasaki, S; Koizumi, S; Kurata, M; Honda, G; Itoi, T				Kamisawa, Terumi; Kuruma, Sawako; Tabata, Taku; Chiba, Kazuro; Iwasaki, Susumu; Koizumi, Satomi; Kurata, Masanao; Honda, Goro; Itoi, Takao			Pancreaticobiliary maljunction and biliary cancer	JOURNAL OF GASTROENTEROLOGY			English	Review						Pancreaticobiliary maljunction; Congenital biliary dilatation; Gallbladder cancer; Bile duct cancer	EXTRAHEPATIC BILE-DUCT; LONG COMMON CHANNEL; MR CHOLANGIOPANCREATOGRAPHY; CHOLEDOCHAL CYSTS; ENDOSCOPIC ULTRASONOGRAPHY; GALLBLADDER; JUNCTION; SYSTEM; CARCINOMA; UNION	Pancreaticobiliary maljunction (PBM) is a congenital malformation in which the pancreatic and bile ducts join anatomically outside the duodenal wall. Japanese clinical practice guidelines on how to deal with PBM were made in 2012, representing a world first. According to the 2013 revision to the diagnostic criteria for PBM, in addition to direct cholangiography, diagnosis can be made by magnetic resonance cholangiopancreatography (MRCP), 3-dimensional drip infusion cholangiography computed tomography, endoscopic ultrasonography (US), or multiplanar reconstruction images by multidetector row computed tomography. In PBM, the common channel is so long that sphincter action does not affect the pancreaticobiliary junction, and pancreatic juice frequently refluxes into the biliary tract. Persistence of refluxed pancreatic juice injures epithelium of the biliary tract and promotes cancer development, resulting in higher rates of carcinogenesis in the biliary tract. In a nationwide survey, biliary cancer was detected in 21.6 % of adult patients with congenital biliary dilatation (bile duct cancer, 32.1 % vs. gallbladder cancer, 62.3 %) and in 42.4 % of PBM patients without biliary dilatation (bile duct cancer, 7.3 % vs. gallbladder cancer, 88.1 %). Pathophysiological conditions due to pancreatobiliary reflux occur in patients with high confluence of pancreaticobiliary ducts, a common channel a parts per thousand yen6 mm long, and occlusion of communication during contraction of the sphincter. Once the diagnosis of PBM is established, immediate prophylactic surgery is recommended. However, the surgical strategy for PBM without biliary dilatation remains controversial. To detect PBM without biliary dilatation early, MRCP is recommended for patients showing gallbladder wall thickening on screening US under suspicion of PBM.	[Kamisawa, Terumi; Kuruma, Sawako; Tabata, Taku; Chiba, Kazuro; Iwasaki, Susumu; Koizumi, Satomi] Tokyo Metropolitan Komagome Hosp, Dept Internal Med, Bunkyo Ku, Tokyo 1138677, Japan; [Kurata, Masanao; Honda, Goro] Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; [Itoi, Takao] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Tokyo 1608402, Japan	Kamisawa, T (reprint author), Tokyo Metropolitan Komagome Hosp, Dept Internal Med, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	kamisawa@cick.jp					Yusuf TE, 2004, J GASTROEN HEPATOL, V19, P243, DOI 10.1111/j.1440-1746.2003.03142.x; Kamisawa T, 2014, J HEPATO-BIL-PAN SCI, V21, P159, DOI 10.1002/jhbp.57; Matos C, 1998, RADIOLOGY, V209, P443; Kim MJ, 2002, AM J ROENTGENOL, V179, P209; Sugiyama M, 1998, SURGERY, V123, P391, DOI 10.1067/msy.1998.86581; Matsuda T, 2009, JPN J CLIN ONCOL, V39, P850, DOI 10.1093/jjco/hyp106; Watanabe H, 1999, ANN ONCOL, V10, P136, DOI 10.1023/A:1008330012536; DOWDY GS, 1962, ARCH SURG-CHICAGO, V84, P229; Itoi T, 2013, J GASTROENTEROL, V48, P1045, DOI 10.1007/s00535-012-0702-0; Kamisawa T, 2002, PANCREATOLOGY, V2, P122, DOI 10.1159/000055902; Aoki T, 2002, PANCREATICOBILIARY M, P295; Deng YL, 2011, HEPATOB PANCREAT DIS, V10, P570, DOI 10.1016/S1499-3872(11)60098-2; Fujii T, 2004, J HEPATO-BILIARY-PAN, V11, P280, DOI 10.1007/s00534-003-0880-5; Funabiki T, 2009, LANGENBECK ARCH SURG, V394, P159, DOI 10.1007/s00423-008-0336-0; Hamada Y, 2010, TAN TO SUI, V31, P1269; Hirohashi S, 1997, RADIOLOGY, V203, P411; Hori H, 2006, JPN J CLIN ONCOL, V36, P638, DOI 10.1093/jjco/hyl077; Itoh T, 2008, J HEPATO-BILIARY-PAN, V15, P338, DOI 10.1007/s00534-007-1245-2; Kamisawa T, 2007, ABDOM IMAGING, V32, P129, DOI 10.1007/s00261-006-9005-3; Kamisawa T, 2009, CLIN GASTROENTEROL H, V7, pS84, DOI 10.1016/j.cgh.2009.08.024; Kamisawa T, 2012, J GASTROENTEROL, V47, P731, DOI 10.1007/s00535-012-0611-2; Kamisawa T, 2006, DIGEST ENDOSC, V18, P192, DOI 10.1111/j.0915-5635.2006.00603.x; Kamisawa T, 2014, J HEPATO-BIL-PAN SCI, V21, P87, DOI 10.1002/jhbp.8; Kamisawa T, 2004, GASTROINTEST ENDOSC, V60, P56, DOI 10.1016/S0016-5107(04)01290-8; KOZUKA S, 1982, CANCER, V50, P2226, DOI 10.1002/1097-0142(19821115)50:10<2226::AID-CNCR2820501043>3.0.CO;2-3; Li Y, 2013, SCI WORLD J, DOI 10.1155/2013/618670; Matsubara Toshiki, 2002, J Hepatobiliary Pancreat Surg, V9, P312, DOI 10.1007/s005340200035; Matsuda M, 2007, J JAPAN BILIARY ASS, V21, P119; Miyazaki M, 2008, J HEPATO-BILIARY-PAN, V15, P15, DOI 10.1007/s00534-007-1276-8; Morine Y, 2013, J HEPATO-BIL-PAN SCI, V20, P472, DOI 10.1007/s00534-013-0606-2; Ogawa A, 2001, J Hepatobiliary Pancreat Surg, V8, P374, DOI 10.1007/s005340170011; Okamoto A, 2003, J AM COLL SURGEONS, V196, P394, DOI 10.1016/S1072-7515(02)01664-2; SHIMADA K, 1991, HEPATOLOGY, V13, P438, DOI 10.1016/0270-9139(91)90296-8; Sugiyama M, 1997, GASTROINTEST ENDOSC, V45, P261, DOI 10.1016/S0016-5107(97)70268-2; Sugiyama M, 1998, BRIT J SURG, V85, P911; Takuma K, 2012, WORLD J GASTROENTERO, V18, P3409, DOI 10.3748/wjg.v18.i26.3409; Tanno S, 1998, CANCER, V83, P267; Tashiro Seiki, 2003, J Hepatobiliary Pancreat Surg, V10, P345, DOI 10.1007/s00534-002-0741-7; The Japanese Study Group on Pancreaticobiliary Maljunction (JSGPM) Committee for Diagnostic Criteria for Pancreaticobiliary Maljunction, 1987, TAN TO SUI, V8, P115; The Japanese Study Group on Pancreaticobiliary Maljunction (JSPBM) The Committee of JSPBM for Diagnostic Criteria, 1994, J HEPATOBILIARY PANC, V1, P219; TODANI T, 1995, EUR J PEDIATR SURG, V5, P143, DOI 10.1055/s-2008-1066189; Tsuchida Akihiko, 2010, World J Gastrointest Oncol, V2, P130, DOI 10.4251/wjgo.v2.i3.130; Tsuchida A, 2004, ONCOL REP, V11, P269; YAMAMOTO M, 1991, PATHOL RES PRACT, V187, P241	44	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					273	279		10.1007/s00535-014-1015-2		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200004		
J	Nagaishi, K; Arimura, Y; Fujimiya, M				Nagaishi, Kanna; Arimura, Yoshiaki; Fujimiya, Mineko			Stem cell therapy for inflammatory bowel disease	JOURNAL OF GASTROENTEROLOGY			English	Review						Inflammatory bowel disease; Immune-mediated inflammatory disease; Mesenchymal stem cells; Hematopoietic stem cell transplantation; MSC-conditioned medium	REFRACTORY CROHNS-DISEASE; TERM-FOLLOW-UP; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; COMPLEX PERIANAL FISTULA; NON-HODGKINS-LYMPHOMA; VERSUS-HOST-DISEASE; HEMATOPOIETIC STEM; CLINICAL-TRIAL; IPS CELLS	Inflammatory bowel disease (IBD) could be curable by "immune rest" and correction of the genetic predisposition inherent in allogeneic hematopoietic stem cell transplantation. However, balancing risks against benefits remains challenging. The application of mesenchymal stem cells (MSCs) serving as a site-regulated "drugstore" is a recent concept, which suggests the possibility of an alternative treatment for many intractable diseases such as IBD. Depending on the required function of MSC, such as a cell provider, immune moderator, and/or trophic resource, MSC therapy should be optimized to maximize its therapeutic benefit. Therapeutic effects do not always require full engraftment of MSCs. Therefore, optimization of pleiotropic gut trophic factors produced by MSCs, which favoring not only regulating immune responses but also promoting tissue repair, must directly enhance new drug discoveries for treatment of IBD. Stem cell biology holds great promise for a new era of cell-based therapy, sparking considerable interest among scientists, clinicians, and patients. However, the translational arm of stem cell science remains in a relatively primitive state. Although several clinical studies using MSCs have been initiated, early results suggest several inherent problems. In each study, optimization of MSC therapy appears to be the most urgent problem, and can be resolved only by scientifically unveiling the mechanisms of therapeutic action. In the present review, the authors outline how such information would facilitate the critical steps in the paradigm shift from basic research on stem cell biology to clinical practice of regenerative medicine for conquering IBD in the near future.	[Nagaishi, Kanna; Fujimiya, Mineko] Sapporo Med Univ, Dept Anat 2, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Arimura, Yoshiaki] Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido 0608556, Japan	Nagaishi, K (reprint author), Sapporo Med Univ, Dept Anat 2, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	kanna@sapmed.ac.jp; arimura0330@gmail.com; fujimiya@sapmed.ac.jp					Wu SM, 2011, NAT CELL BIOL, V13, P497, DOI 10.1038/ncb0511-497; Grigoriadis AE, 2010, BLOOD, V115, P2769, DOI 10.1182/blood-2009-07-234690; Burt RK, 2010, BLOOD, V116, P6123, DOI 10.1182/blood-2010-06-292391; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Garcia-Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350-0052-6; Otsu K, 2012, STEM CELLS DEV, V21, P1156, DOI 10.1089/scd.2011.0210; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; Lee WY, 2013, STEM CELLS, V31, P2575, DOI 10.1002/stem.1357; Herreros MD, 2012, DIS COLON RECTUM, V55, P762, DOI 10.1097/DCR.0b013e318255364a; Uccelli A, 2011, LANCET NEUROL, V10, P649, DOI 10.1016/S1474-4422(11)70121-1; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Hawkey CJ, 2004, BEST PRACT RES CL HA, V17, P317, DOI 10.1016/j.beha.2004.05.006; Kashyap A, 1998, BRIT J HAEMATOL, V103, P651, DOI 10.1046/j.1365-2141.1998.01059.x; Tanaka H, 2011, J GASTROENTEROL, V46, P143, DOI 10.1007/s00535-010-0320-7; Liang J, 2012, GUT, V61, P468, DOI 10.1136/gutjnl-2011-300083; Hasselblatt P, 2012, ALIMENT PHARM THER, V36, P725, DOI 10.1111/apt.12032; Hawkey CJ, 2012, DIGEST DIS, V30, P134, DOI 10.1159/000342740; Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841; Griffin MD, 2010, HUM GENE THER, V21, P1641, DOI 10.1089/hum.2010.156; Guadalajara H, 2012, INT J COLORECTAL DIS, V27, P595, DOI 10.1007/s00384-011-1350-1; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Oyama Y, 2005, GASTROENTEROLOGY, V128, P552, DOI 10.1053/j.gastrop.2004.11.051; Kreisel W, 2003, BONE MARROW TRANSPL, V32, P337, DOI 10.1038/sj.bmt.1704134; Lopez-Cubero SO, 1998, GASTROENTEROLOGY, V114, P433, DOI 10.1016/S0016-5085(98)70525-6; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Ditschkowski M, 2003, TRANSPLANTATION, V75, P1745, DOI 10.1097/01.TP.0000062540.29757.E9; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Cassinotti A, 2008, GUT, V57, P211, DOI 10.1136/gut.2007.128694; Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681; Villa-Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084; Raelson JV, 2007, P NATL ACAD SCI USA, V104, P14747, DOI 10.1073/pnas.0706645104; Forbes GM, 2014, CLIN GASTROENTEROL H, V12, P64, DOI 10.1016/j.cgh.2013.06.021; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695; Hansson EM, 2009, CELL STEM CELL, V5, P364, DOI 10.1016/j.stem.2009.09.004; Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Van Limbergen J, 2009, ANNU REV GENOM HUM G, V10, P89, DOI 10.1146/annurev-genom-082908-150013; Sonwalkar SA, 2003, GUT, V52, P1518, DOI 10.1136/gut.52.10.1518; de la Portilla F, 2013, INT J COLORECTAL DIS, V28, P313, DOI 10.1007/s00384-012-1581-9; Garcia-Olmo D, 2009, DIS COLON RECTUM, V52, P79, DOI 10.1007/DCR.0b013e3181973487; Yabana T, 2009, J PATHOL, V218, P350, DOI 10.1002/path.2535; Chen YS, 2012, STEM CELL TRANSL MED, V1, P83, DOI 10.5966/sctm.2011-0022; Richardson SM, 2010, J CELL PHYSIOL, V222, P23, DOI 10.1002/jcp.21915; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Cho JH, 2011, GASTROENTEROLOGY, V140, P1704, DOI 10.1053/j.gastro.2011.02.046; Giuliani M, 2011, BLOOD, V118, P3254, DOI 10.1182/blood-2010-12-325324; Anumakonda V, 2007, GUT, V56, P1325, DOI 10.1136/gut.2006.111377; Bohgaki T, 2007, NEW ENGL J MED, V357, P2734, DOI 10.1056/NEJMc076383; Burt RK, 2003, BLOOD, V101, P2064, DOI 10.1182/blood-2002-07-2122; Clerici M, 2011, DIGEST LIVER DIS, V43, P946, DOI 10.1016/j.dld.2011.07.021; Carbonare LD, 2009, ARTHRITIS RHEUM-US, V60, P3356, DOI 10.1002/art.24884; DRAKOS PE, 1993, AM J HEMATOL, V43, P157, DOI 10.1002/ajh.2830430223; Eberle I, 2013, ADV BIOCHEM ENG BIOT, V130, P1, DOI 10.1007/10_2012_156; Hommes DW, 2011, J CROHNS COLITIS, V5, P543, DOI 10.1016/j.crohns.2011.05.004; Inoue-Yokoo T, 2013, STEM CELL REV REP, V9, P422, DOI 10.1007/s12015-012-9388-1; Kim EM, 2013, BLOOD, V121, P5167, DOI 10.1182/blood-2012-11-467753; Klump H, 2013, CURR MOL MED, V13, P815; Kountouras J, 2011, J CROHNS COLITIS, V5, P275, DOI 10.1016/j.crohns.2011.03.004; Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559; Lengerke C, 2009, ANN NY ACAD SCI, V1176, P219, DOI 10.1111/j.1749-6632.2009.04606.x; Liu YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033225; Marmont AM, 2001, HAEMATOLOGICA, V86, P337; Marti JL, 2001, BONE MARROW TRANSPL, V28, P109, DOI 10.1038/sj.bmt.1703103; Mazurier C, 2011, CURR OPIN HEMATOL, V18, P249, DOI 10.1097/MOH.0b013e3283476129; Musso M, 2000, BONE MARROW TRANSPL, V26, P921, DOI 10.1038/sj.bmt.1702621; Nasuno M, 2014, STEM CELLS, V3, P13; Scimè Rosanna, 2004, Inflamm Bowel Dis, V10, P892, DOI 10.1097/00054725-200411000-00027; Soderholm JD, 2002, SCAND J GASTROENTERO, V37, P613, DOI 10.1080/00365520252903198; Stadelmann WK, 1998, AM J SURG, V176, p26S, DOI 10.1016/S0002-9610(98)00183-4; Talbot DC, 1998, HOSP MED, V59, P580; Teramura Takeshi, 2010, Cell Reprogram, V12, P249, DOI 10.1089/cell.2009.0086; Watanabe M, 2014, J GASTROEN HEPATOL, DOI [10.1111/jgh.12555, DOI 10.1111/JGH.12555]; Watanabe S, 2014, J GASTROENTEROL, V49, P270, DOI 10.1007/s00535-013-0901-3	76	4	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					280	286		10.1007/s00535-015-1040-9		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200005		
J	Takemoto, K; Shiozaki, A; Ichikawa, D; Komatsu, S; Konishi, H; Nako, Y; Murayama, Y; Kuriu, Y; Nakanishi, M; Fujiwara, H; Okamoto, K; Sakakura, C; Nakahari, T; Marunaka, Y; Otuji, E				Takemoto, Kenichi; Shiozaki, Atsushi; Ichikawa, Daisuke; Komatsu, Shuhei; Konishi, Hirotaka; Nako, Yoshito; Murayama, Yasutoshi; Kuriu, Yoshiaki; Nakanishi, Masayoshi; Fujiwara, Hitoshi; Okamoto, Kazuma; Sakakura, Chouhei; Nakahari, Takashi; Marunaka, Yoshinori; Otuji, Eigo			Evaluation of the efficacy of peritoneal lavage with distilled water in colorectal cancer surgery: in vitro and in vivo study	JOURNAL OF GASTROENTEROLOGY			English	Article						Colorectal cancer; Distilled water; Peritoneal lavage; Regulatory volume decrease; Chloride ion transport	CELL-VOLUME REGULATION; HYPOTONIC SOLUTION; CHLORIDE CHANNELS; INVASION; DECREASE; CARCINOMATOSIS; MECHANISMS; BLOCKER; ORIGIN; CYCLE	Peritoneal lavage with distilled water has been performed during colorectal cancer surgery. This study investigated the cytocidal effects of hypotonic shock in vitro and in vivo in colorectal cancer cells. Three human colorectal cancer cell lines, DLD1, HT29, and CACO2, were exposed to distilled water, and morphological changes were observed under a differential interference contrast microscope connected to a high-speed digital video camera. Cell volume changes were assessed using a high-resolution flow cytometer. Re-incubation experiments were performed to investigate the cytocidal effects of distilled water. In the in vivo experiment, cancer cells after hypotonic shock were injected intraperitoneally into mice and the degree of established peritoneal metastasis was subsequently evaluated. The effects of the blockade of Cl- channels on these cells during hypotonic shock were also analyzed. Morphological observations revealed a rapid cell swelling followed by cell rupture. Measurements of cell volume changes showed that mild hypotonic shock induced regulatory volume decrease (RVD) while severe hypotonic shock broke cells into fragments. Re-incubation experiments demonstrated the cytocidal effects of hypotonicity. In vivo experiments revealed the absence of peritoneal dissemination in mice in the distilled water group, and its presence in all mice in the control group. The blockade of Cl- channels increased cell volume by inhibiting RVD and enhanced cytocidal effects during mild hypotonic shock. These results clearly support the efficacy of peritoneal lavage with distilled water during colorectal cancer surgery and suggest that regulating of Cl- transport may enhance the cytocidal effects of hypotonic shock.	[Takemoto, Kenichi; Shiozaki, Atsushi; Ichikawa, Daisuke; Komatsu, Shuhei; Konishi, Hirotaka; Nako, Yoshito; Murayama, Yasutoshi; Kuriu, Yoshiaki; Nakanishi, Masayoshi; Fujiwara, Hitoshi; Okamoto, Kazuma; Sakakura, Chouhei; Otuji, Eigo] Kyoto Prefectural Univ Med, Div Digest Surg, Dept Surg, Kamigyo Ku, Kyoto 6028566, Japan; [Nakahari, Takashi] Osaka Med Coll, Dept Physiol, Takatsuki, Osaka 5698686, Japan; [Marunaka, Yoshinori] Kyoto Prefectural Univ Med, Dept Mol Cell Physiol, Grad Sch Med Sci, Kyoto 6028566, Japan; [Marunaka, Yoshinori] Kyoto Prefectural Univ Med, Dept Bioion, Grad Sch Med Sci, Kyoto 6028566, Japan; [Marunaka, Yoshinori] Heian Jogakuin St Agnes Univ, Japan Inst Food Educ & Hlth, Kyoto 6028013, Japan	Shiozaki, A (reprint author), Kyoto Prefectural Univ Med, Div Digest Surg, Dept Surg, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	shiozaki@koto.kpu-m.ac.jp			Japan Society for the Promotion of Science [22791295, 23791557, 22591464]; Kyoto Preventive Medical Center	This work was supported by Grants-in-Aid for Young Scientists (B) (22791295, 23791557), a Grant-in-Aid for Scientific Research (C) (22591464) from the Japan Society for the Promotion of Science, and Research Grant Awards from Kyoto Preventive Medical Center to Dr. Atsushi Shiozaki.	Ernest NJ, 2005, AM J PHYSIOL-CELL PH, V288, pC1451, DOI 10.1152/ajpcell.00503.2004; Koppe MJ, 2006, ANN SURG, V243, P212, DOI 10.1097/01.sla.0000197702.46394.16; Lemmens VE, 2011, INT J CANCER, V128, P2717, DOI 10.1002/ijc.25596; House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; Wang P, 2012, MOL CELL BIOCHEM, V365, P313, DOI 10.1007/s11010-012-1271-5; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Bosanquet DC, 2013, BRIT J SURG, V100, P853, DOI 10.1002/bjs.9118; Miyazaki H, 2008, BIOCHEM BIOPH RES CO, V366, P506, DOI 10.1016/j.bbrc.2007.11.144; Shiozaki A, 2011, AM J PATHOL, V178, P391, DOI 10.1016/j.ajpath.2010.11.024; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Watkins S, 2011, J NEUROSCI, V31, P17250, DOI 10.1523/JNEUROSCI.3938-11.2011; Antico S, 2013, CELL PHYSIOL BIOCHEM, V32, P1551, DOI 10.1159/000356592; Brenner H, 2013, LANCET, V383, P1490; Brundell SM, 2002, SURG ENDOSC, V16, P1064, DOI 10.1007/s00464-001-9111-9; Chua TC, 2013, J SURG ONCOL, V107, P566, DOI 10.1002/jso.23189; Del Monte SR, 2012, J SURG ONCOL, V106, P17, DOI 10.1002/jso.23052; Homma Y, 2013, SURG TODAY, V44, P1084; Huguet EL, 2004, DIS COLON RECTUM, V47, P2114, DOI 10.1007/s10350-004-0788-4; Iitaka D, 2012, J SURG RES, V176, P524, DOI 10.1016/j.jss.2011.10.039; Ito F, 2011, ANN SURG ONCOL, V18, P2357, DOI 10.1245/s10434-011-1588-4; Kosuga T, 2011, ONCOL REP, V26, P577, DOI 10.3892/or.2011.1307; Nako Y, 2012, PANCREATOLOGY, V12, P440, DOI 10.1016/j.pan.2012.08.003; Ozawa H, 2013, SURG TODAY; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232=-005-0782-3; Shiozaki A, 2006, J PHYSIOL SCI, V56, P401, DOI 10.2170/physiolsci.RP10806; Waldegger S, 1998, NEPHROL DIAL TRANSPL, V13, P867, DOI 10.1093/ndt/13.4.867; Wang LW, 2002, J CELL PHYSIOL, V193, P110, DOI 10.1002/jcp.10156; Whiteside OJH, 2005, ANN ROY COLL SURG, V87, P255, DOI 10.1308/1478708051847; Yang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060861	30	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					287	297		10.1007/s00535-014-0971-x		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200006		
J	Kusano, M; Hosaka, H; Kawamura, O; Kawada, A; Kuribayashi, S; Shimoyama, Y; Yasuoka, H; Mizuide, M; Tomizawa, T; Sagawa, T; Sato, K; Yamada, M				Kusano, Motoyasu; Hosaka, Hiroko; Kawamura, Osamu; Kawada, Akiyo; Kuribayashi, Shiko; Shimoyama, Yasuyuki; Yasuoka, Hidetoshi; Mizuide, Masafumi; Tomizawa, Taku; Sagawa, Toshihiko; Sato, Ken; Yamada, Masanobu			More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy	JOURNAL OF GASTROENTEROLOGY			English	Article						Gastroesophageal reflux disease; Non-erosive reflux disease; Proton pump inhibitor; Upper GI symptoms; Questionnaire	COMPETITIVE ACID BLOCKER; FREQUENCY SCALE; CLINICAL-TRIAL; NERD PATIENTS; ESOPHAGITIS; GERD; MANAGEMENT; ESOMEPRAZOLE; METAANALYSIS; PROKINETICS	During maintenance proton pump inhibitor (PPI) therapy, patients with gastroesophageal reflux disease (GERD) sometimes complain of upper gastrointestinal symptoms. To evaluate upper gastrointestinal symptoms in patients on maintenance PPI therapy for erosive GERD or non-erosive reflux disease (NERD) without endoscopic mucosal breaks by using a new questionnaire. At Gunma University Hospital over a 12-month period during 2011-2012, we enrolled 30 consecutive patients with erosive GERD and 46 patients with NERD. All patients had been on maintenance PPI therapy for more than 1 year. We used the modified frequency scale for the symptoms of GERD (mFSSG) questionnaire to assess upper gastrointestinal symptoms. We also asked patients about their satisfaction with maintenance therapy and whether they wished to change their current PPI. The NERD patients had significantly higher symptom scores than the erosive GERD patients. There was no difference in the treatment satisfaction rate between patients with erosive GERD and NERD, but more patients with NERD wanted to change their PPI therapy. There was no difference in the mFSSG score between NERD patients who wished to change their current PPI therapy and those who were satisfied with it. During maintenance PPI therapy, upper gastrointestinal symptoms were more severe in NERD patients than in patients with erosive GERD. NERD patients often wished to change their PPI therapy, but this was not dependent on the severity of their upper GI symptoms.	[Kusano, Motoyasu; Hosaka, Hiroko; Kawamura, Osamu; Kawada, Akiyo; Kuribayashi, Shiko; Shimoyama, Yasuyuki; Yasuoka, Hidetoshi; Mizuide, Masafumi; Tomizawa, Taku; Sagawa, Toshihiko; Sato, Ken; Yamada, Masanobu] Gunma Univ Hosp, Dept Gastroenterol, Maebashi, Gunma 3718511, Japan; [Kusano, Motoyasu; Kawamura, Osamu; Tomizawa, Taku] Gunma Univ Hosp, Dept Endoscopy & Endoscop Surg, Maebashi, Gunma 3718511, Japan	Kusano, M (reprint author), Gunma Univ Hosp, Dept Endoscopy & Endoscop Surg, 3-39-15 Showamachi, Maebashi, Gunma 3718511, Japan.	mkusano@gunma-u.ac.jp			Eisai Co., Ltd.; Astellas Co., Ltd.; AstraZeneca Co., Ltd.; Daiichi-Sankyo Co., Ltd.; Given Imaging., Ltd.	Kusano M received lecture fees from Eisai Co., Ltd., Astellas Co., Ltd., and AstraZeneca Co., Ltd.. Motoyasu Kusano received commercial research funding from Eisai Co., Ltd., Astellas Co., Ltd., Daiichi-Sankyo Co., Ltd., and Given Imaging., Ltd. The following authors have nothing to declare: Osamu Kawamura, Hiroko Hosaka, Akiyo Kawada, Shikou Kuribayashi, Yasuyuki Shimoyama, Hidetoshi Yasuoka, Masafumi Mizuide, Taku Tomizawa, Toshihiko Sagawa, Ken Sato and Masanobu Yamada.	Modlin IM, 2009, DIGESTION, V80, P74, DOI 10.1159/000219365; Bytzer P, 2009, CLIN GASTROENTEROL H, V7, P816, DOI 10.1016/j.cgh.2009.03.006; Furuta T, 2011, J GASTROENTEROL, V46, P1273, DOI 10.1007/s00535-011-0446-2; Fass R, 2005, ALIMENT PHARM THERAP, V22, P79, DOI 10.1111/j.1365-2036.2005.02531.x; Liker HR, 2009, DIGEST DIS, V27, P62, DOI 10.1159/000210106; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Chiba N, 1997, GASTROENTEROLOGY, V112, P1798, DOI 10.1053/gast.1997.v112.pm9178669; Kusano M, 2008, DIGEST DIS SCI, V53, P3082, DOI 10.1007/s10620-008-0290-2; Mainie I, 2006, GUT, V55, P1398, DOI 10.1136/gut.2005.087668; Fass R, 2009, ALIMENT PHARM THER, V29, P1261, DOI 10.1111/j.1365-2036.2009.04013.x; Kusano M, 2004, J GASTROENTEROL, V39, P888, DOI 10.1007/s00535-004-1417-7; Armstrong D, 1996, GASTROENTEROLOGY, V111, P85, DOI 10.1053/gast.1996.v111.pm8698230; BELL NJV, 1992, DIGESTION, V51, P59; Dent J, 2008, AM J GASTROENTEROL, V103, P20, DOI 10.1111/j.1572-0241.2007.01544.x; Miyamoto M, 2010, INTERNAL MED, V49, P1469, DOI 10.2169/internalmedicine.49.3615; Savarino E, 2013, J GASTROENTEROL, V48, P473, DOI 10.1007/s00535-012-0672-2; Dean BB, 2004, CLIN GASTROENTEROL H, V2, P656, DOI 10.1053/S1542-3565(04)00288-5; Armstrong D, 2004, ALIMENT PHARM THERAP, V20, P413, DOI 10.1111/j.1365-2036.2004.02085.x; Tominaga K, 2012, J GASTROENTEROL, V47, P284, DOI 10.1007/s00535-011-0488-5; Coron E, 2007, CURR OPIN GASTROEN, V23, P434; Dickman R, 2007, ALIMENT PHARM THER, V26, P1333, DOI 10.1111/j.1365-2036.2007.03520.x; Hershcovici Tiberiu, 2010, J Neurogastroenterol Motil, V16, P8, DOI 10.5056/jnm.2010.16.1.8; Hori Y, 2011, J PHARMACOL EXP THER, V337, P797, DOI 10.1124/jpet.111.179556; HUNT RH, 1995, ALIMENT PHARM THERAP, V9, P3; Iwakiri K, 2009, J GASTROENTEROL, V44, P708, DOI 10.1007/s00535-009-0070-6; Jones R, 2006, CURR MED RES OPIN, V22, P657, DOI 10.1185/030079906X100032; Kawamura O, 2014, DDW 2014 IN PRESS; Khan M, 2007, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003244.PUB2; Kusano M, 2012, J GASTROEN HEPATOL, V27, P1187, DOI 10.1111/j.1440-1746.2012.07121.x; Kusano M, 2012, DIGESTION, V85, P282, DOI 10.1159/000336715; Miyamoto M, 2008, J GASTROEN HEPATOL, V23, P746, DOI 10.1111/j.1440-1746.2007.05218.x; Patrick Lyn, 2011, Altern Med Rev, V16, P116; Quigley EMM, 2004, ALIMENT PHARM THERAP, V20, P56, DOI 10.1111/j.1365-2036.2004.02186.x; Tominaga K, 2014, J GASTROENTEROL; VIGNERI S, 1995, NEW ENGL J MED, V333, P1106, DOI 10.1056/NEJM199510263331703; Weijenborg PW, 2012, NEUROGASTROENT MOTIL, V24, P747, DOI 10.1111/j.1365-2982.2012.01888.x; Wu JCY, 2007, CLIN GASTROENTEROL H, V5, P690, DOI 10.1016/j.cgh.2007.02.023	37	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					298	304		10.1007/s00535-014-0972-9		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200007		
J	Iijima, K; Koike, T; Ara, N; Nakagawa, K; Kondo, Y; Uno, K; Hatta, W; Asano, N; Imatani, A; Shimosegawa, T				Iijima, K.; Koike, T.; Ara, N.; Nakagawa, K.; Kondo, Y.; Uno, K.; Hatta, W.; Asano, N.; Imatani, A.; Shimosegawa, T.			Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H-pylori-infected subjects	JOURNAL OF GASTROENTEROLOGY			English	Article						Gastric ulcer; H. pylori; Low-dose aspirin; Serum pepsinogen	GASTRIC-ACID-SECRETION; HELICOBACTER-PYLORI; CELLULAR-LOCALIZATION; JAPANESE SUBJECTS; CONTROLLED-TRIAL; MUCUS SECRETION; PEPTIC-ULCERS; MUCOSA; IMMUNOFLUORESCENCE; ESOMEPRAZOLE	We recently demonstrated in humans that the extent of low-dose aspirin (LDA)-induced gastropathy was directly related to the individual gastric acid secretion level. We also established reliable cutoff serum pepsinogen (PG) values to predict gastric acid secretion status. In this study, we investigated the clinical usefulness of measuring the serum pepsinogen values for identifying a high-risk group for gastric mucosal injury among chronic LDA users. One hundred long-term LDA users were enrolled in this analysis. Serum from each subject was subjected to determination of H. pylori status and measurement of pepsinogen values. According to our recent report, a PG I value a parts per thousand yen 50 ng/mL was defined as estimated hyperchlorhydria in H. pylori-negative subjects, while a PG I/II a parts per thousand yen 3.3 was defined as estimated hyperchlorhydria in H. pylori-positive subjects. The grade of gastric mucosal injury was assessed endoscopically, and multiple logistic regression analyses were used to estimate the risk. Estimated hyperchlorhydria was a strong independent risk for intensive gastric mucosal injury with an OR (95 % CI): 34.0 (4.5-259) and for gastric ulcer with an OR (95 % CI): 10.2 (1.8-58.3) in H. pylori-positive subjects, while it was not a significant risk in H. pylori-negative subjects. The association persisted even after excluding those with conventional risks for LDA-gastropathy such as ulcer histories. Using simple serum measurement of H. pylori antibody and pepsinogen concentrations, an extremely high-risk group for LDA-induced gastropathy could be extracted, and these patients should become a therapeutic target for prevention of LDA-induced gastropathy.	[Iijima, K.; Koike, T.; Ara, N.; Nakagawa, K.; Kondo, Y.; Uno, K.; Hatta, W.; Asano, N.; Imatani, A.; Shimosegawa, T.] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 9808574, Japan	Iijima, K (reprint author), Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kiijima@med.tohoku.ac.jp					Elliott SL, 1996, CLIN EXP PHARMACOL P, V23, P432, DOI 10.1111/j.1440-1681.1996.tb02754.x; KONTUREK JW, 1994, GUT, V35, P1197, DOI 10.1136/gut.35.9.1197; SAMLOFF IM, 1973, GASTROENTEROLOGY, V65, P36; Scheiman JM, 2011, HEART, V97, P797, DOI 10.1136/hrt.2010.217547; Iijima K, 2004, SCAND J GASTROENTERO, V39, P709, DOI 10.1080/00365520410005911; Shiotani A, 2009, J GASTROENTEROL, V44, P717, DOI 10.1007/s00535-009-0068-0; Iijima K, 2011, J GASTROENTEROL, V46, P612, DOI 10.1007/s00535-011-0385-y; Iijima K, 2014, TOHOKU J EXP MED, V232, P293; Lanas A, 2013, ALIMENT PHARM THER, V37, P738, DOI 10.1111/apt.12240; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; Iijima K, 2012, J GASTROENTEROL, V47, P1290, DOI 10.1007/s00535-012-0598-8; Valkhoff VE, 2012, BEST PRACT RES CL GA, V26, P125, DOI 10.1016/j.bpg.2012.01.011; Kikuchi R, 2011, TOHOKU J EXP MED, V223, P35, DOI 10.1620/tjem.223.35; Sugano K, 2011, J GASTROENTEROL, V46, P724, DOI 10.1007/s00535-011-0397-7; ROWE PH, 1987, GASTROENTEROLOGY, V93, P863; Chan FKL, 2013, GASTROENTEROLOGY, V144, P528, DOI 10.1053/j.gastro.2012.12.038; Sanuki T, 2012, J GASTROENTEROL, V47, P1186, DOI 10.1007/s00535-012-0588-x; Yeomans N, 2008, AM J GASTROENTEROL, V103, P2465, DOI [10.1111/j.1572-0241.2008.01995.x, 10.1111/j.1572-2008.01995.x]; Laine L, 2006, ALIMENT PHARM THERAP, V24, P897, DOI 10.1111/j.1365-2036.03077.x; Iijima K, 2013, DIGEST DIS SCI, V58, P2266, DOI 10.1007/s10620-013-2660-7; Sugano K, 2014, GUT, V63, P1061, DOI 10.1136/gutjnl-2013-304722; Ho CW, 2013, ALIMENT PHARM THER, V37, P819, DOI 10.1111/apt.12259; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; SAMLOFF IM, 1971, GASTROENTEROLOGY, V61, P185; Sostres C, 2012, BEST PRACT RES CL GA, V26, P141, DOI 10.1016/j.bpg.2012.01.016; ASAKA M, 1992, GASTROENTEROLOGY, V102, P760; Naito Y, 2010, EXPERT REV GASTROENT, V4, P261, DOI [10.1586/egh.10.25, 10.1586/EGH.10.25]; Fujisawa T, 1999, AM J GASTROENTEROL, V94, P2094; Abraham NS, 2010, AM J GASTROENTEROL, V105, P2533, DOI 10.1038/ajg.2010.445; Bhatt DL, 2008, AM J GASTROENTEROL, V2008, P2890; Derakhshan MH, 2006, J CLIN PATHOL, V59, P1293, DOI 10.1136/jcp.2005.036111; Iijima K, 2012, J GASTROENTEROL, V47, P150, DOI 10.1007/s00535-011-0478-7; Iijima K, 2005, J GASTROENTEROL, V40, P938, DOI 10.1007/s00535-005-1677-x; LANZA FL, 1990, DIGEST DIS SCI, V35, P1494, DOI 10.1007/BF01540567; SAMLOFF IM, 1975, GASTROENTEROLOGY, V69, P1196; Tozawa K, 2014, DIG DIS SCI	36	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					305	312		10.1007/s00535-014-0976-5		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200008		
J	Oze, T; Hiramatsu, N; Yakushijin, T; Yamada, R; Harada, N; Morishita, N; Yamada, A; Oshita, M; Kaneko, A; Suzuki, K; Inui, Y; Tamura, S; Yoshihara, H; Imai, Y; Miyagi, T; Yoshida, Y; Tatsumi, T; Kasahara, A; Hayashi, N; Takehara, T				Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Yamada, Ryoko; Harada, Naoki; Morishita, Naoki; Yamada, Akira; Oshita, Masahide; Kaneko, Akira; Suzuki, Kunio; Inui, Yoshiaki; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu; Miyagi, Takuya; Yoshida, Yuichi; Tatsumi, Tomohide; Kasahara, Akinori; Hayashi, Norio; Takehara, Tetsuo			The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1	JOURNAL OF GASTROENTEROLOGY			English	Article						Chronic hepatitis C; Telaprevir; Pegylated interferon plus ribavirin; Dose reduction	CHRONIC HEPATITIS-C; TREATMENT-EXPERIENCED PATIENTS; VIRUS-INFECTION; PEGINTERFERON	Triple therapy with telaprevir (TVR), pegylated interferon and ribavirin has improved antiviral efficacy in patients with chronic hepatitis C (CH-C). However, the severe adverse effects caused by TVR are important to resolve. In this prospective, randomized, multicenter, open-label study, the antiviral efficacy and safety in the reduced administration of TVR were examined. A total of 81 CH-C Japanese patients with HCV genotype 1 were randomized into two regimens of TVR 2250 mg (TVR-2250) or 1500 mg (TVR-1500) and treated with triple therapy for 24 weeks. The mean HCV RNA at start, 2 and 4 weeks of treatment were 6.69 +/- A 0.70, 1.05 +/- A 0.74, 0.22 +/- A 0.48 log(10) IU/ml in the TVR-2250 group and 6.70 +/- A 0.62, 1.02 +/- A 0.62, 0.13 +/- A 0.41 log(10) IU/ml in the TVR-1500 group. The SVR rates were 85 % in both groups (35/41 and 34/40, respectively). There were no patients with viral breakthrough in either group. As for adverse effects, rash more than moderate and severe anemia with < 8.5 g/dl of hemoglobin were higher in the TVR-2250 group than in the TVR-1500 group (p = 0.046, p < 0.001, respectively). The increase in serum creatinine levels and decrease in estimated glomerular filtration rates were higher in the TVR-2250 group than in the TVR-1500 group. The lower dose of TVR (1500 mg/day) can result in similar SVR rates and lower treatment-related adverse effects compared to the higher dose of TVR (2250 mg/day) in triple therapy (UMIN: 000007313, 000007330).	[Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Yamada, Ryoko; Harada, Naoki; Morishita, Naoki; Miyagi, Takuya; Yoshida, Yuichi; Tatsumi, Tomohide; Takehara, Tetsuo] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan; [Yamada, Akira] Sumitomo Hosp, Osaka, Osaka, Japan; [Oshita, Masahide] Osaka Police Hosp, Osaka, Osaka, Japan; [Kaneko, Akira] NTT West Osaka Hosp, Osaka, Osaka, Japan; [Suzuki, Kunio] Saiseikai Senri Hosp, Suita, Osaka, Japan; [Inui, Yoshiaki] Hyogo Prefectural Nishinomiya Hosp, Nishinomiya, Hyogo, Japan; [Tamura, Shinji] Minoh City Hosp, Osaka, Japan; [Yoshihara, Harumasa] Osaka Rosai Hosp, Sakai, Osaka, Japan; [Imai, Yasuharu] Ikeda Municipal Hosp, Ikeda, Osaka, Japan; [Kasahara, Akinori] Osaka Univ Hosp, Dept Gen Med, Suita, Osaka, Japan; [Hayashi, Norio] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan	Hiramatsu, N (reprint author), Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	t-oze@gh.med.osaka-u.ac.jp; hiramatsu@gh.med.osaka-u.ac.jp			Ministry of Health Labour and Welfare of Japan; Ministry of Education, Science, and Culture of Japan	This work was supported by a Grant-in-Aid for Research on Hepatitis and BSE from the Ministry of Health Labour and Welfare of Japan and a Scientific Research from the Ministry of Education, Science, and Culture of Japan.	Hezode C, 2009, NEW ENGL J MED, V360, P1839, DOI 10.1056/NEJMoa0807650; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013; McHutchison JG, 2010, NEW ENGL J MED, V362, P1292, DOI 10.1056/NEJMoa0908014; Sherman KE, 2011, NEW ENGL J MED, V365, P1014, DOI 10.1056/NEJMoa1014463; Hezode C, 2013, J HEPATOL, V59, P434, DOI 10.1016/j.jhep.2013.04.035; Akuta N, 2010, HEPATOLOGY, V52, P421, DOI 10.1002/hep.23690; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; McHutchison JG, 2009, NEW ENGL J MED, V360, P1827, DOI 10.1056/NEJMoa0806104; Fried MW, 2013, HEPATOLOGY, V58, P1918, DOI 10.1002/hep.26641; Ghany MG, 2011, HEPATOLOGY, V54, P1433, DOI 10.1002/hep.24641; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016; Hayashi N, 2014, J GASTROENTEROL, V49, P138, DOI 10.1007/s00535-013-0875-1; Hayashi N, 2012, J VIRAL HEPATITUS, V19, P134; Kawakami Y, 2013, ANTIVIR THER, DOI [10.3851/IMP2706, DOI 10.3851/IMP2706]; Suzuki F, 2009, HEPATOL RES, V39, P1056, DOI 10.1111/j.1872-034X.2009.00548.x; Suzuki F, 2013, HEPATOL RES, V43, P691, DOI 10.1111/hepr.12009; Zeuzem S, 2014, GASTROENTEROLOGY, V146, P430, DOI 10.1053/j.gastro.2013.10.058	19	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					313	322		10.1007/s00535-014-0965-8		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200009		
J	Iritani, S; Imai, K; Takai, K; Hanai, T; Ideta, T; Miyazaki, T; Suetsugu, A; Shiraki, M; Shimizu, M; Moriwaki, H				Iritani, Soichi; Imai, Kenji; Takai, Koji; Hanai, Tatsunori; Ideta, Takayasu; Miyazaki, Tsuneyuki; Suetsugu, Atsushi; Shiraki, Makoto; Shimizu, Masahito; Moriwaki, Hisataka			Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma	JOURNAL OF GASTROENTEROLOGY			English	Article						Hepatocellular carcinoma; Skeletal muscle depletion; Total body fat-free mass; Sarcopenia; Prognostic factor	LIVER-CIRRHOSIS; SARCOPENIC OBESITY; NUTRITIONAL-STATUS; BODY-COMPOSITION; CANCER; SURVIVAL; CONSEQUENCES; MALNUTRITION; TOMOGRAPHY; DEFINITION	Skeletal muscle depletion or sarcopenia has been identified as a poor prognostic factor for various diseases. The aim of this study is to determine whether muscle depletion is a prognostic factor for hepatocellular carcinoma (HCC). We evaluated 217 consecutive patients with primary HCC. The skeletal muscle cross-sectional area was measured by computed tomography at the third lumbar vertebra (L3), from which the total body fat-free mass (FFM) and L3 skeletal muscle index (L3 SMI) were obtained. The factors contributing to overall survival (OS) were analyzed by univariate and multivariate Cox proportional hazards model. In univariate analysis, FFM (P = 0.0422), Child-Pugh classification (P = 0.0058), serum albumin level (P < 0.0001), serum AFP level (P < 0.0001), serum proteins induced by vitamin K absence or antagonist-II level (P < 0.0001), cancer stage (P < 0.0001), and curability of the initial treatment (P < 0.0001) were significantly associated with the prognosis of HCC. Multivariate analysis indicated that FFM (P = 0.0499), albumin level (P = 0.0398), and curability of the initial treatment (P = 0.0008) were independent prognostic factors. Sarcopenia was defined as an L3 SMI value of a parts per thousand currency sign29.0 cm(2)/m(2) for women and a parts per thousand currency sign36.0 cm(2)/m(2) for men, and 24 patients (11.1 %) have sarcopenia. Sarcopenic patients showed a significantly lower OS than those without sarcopenia (P = 0.0043). Sarcopenic patients who were overweight (BMI > 22) died earlier (P = 0.0129). Skeletal muscle depletion is an independent prognostic factor. Intervention to prevent muscle wasting might be an effective strategy for improving the outcome of HCC.	[Iritani, Soichi; Imai, Kenji; Takai, Koji; Hanai, Tatsunori; Ideta, Takayasu; Miyazaki, Tsuneyuki; Suetsugu, Atsushi; Shiraki, Makoto; Shimizu, Masahito; Moriwaki, Hisataka] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, Gifu 5011194, Japan	Shimizu, M (reprint author), Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, 1-1 Yanagido, Gifu 5011194, Japan.	shimim-gif@umin.ac.jp					Periyalwar P, 2012, CLIN LIVER DIS, V16, P95, DOI 10.1016/j.cld.2011.12.009; Merli M, 1996, HEPATOLOGY, V23, P1041; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Montano-Loza AJ, 2012, CLIN GASTROENTEROL H, V10, P166, DOI 10.1016/j.cgh.2011.08.028; Ikai I, 2010, HEPATOL RES, V40, P1043, DOI 10.1111/j.1872-034X.2010.00731.x; Shimizu M, 2013, SEMIN IMMUNOPATHOL, V35, P191, DOI 10.1007/s00281-012-0336-6; Dodson RM, 2013, J GASTROINTEST SURG, V17, P2123, DOI 10.1007/s11605-013-2348-5; Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08-075; Prado CMM, 2012, CLIN NUTR, V31, P583, DOI 10.1016/j.clnu.2012.06.010; [Anonymous], 1989, JPN J SURG, V19, P98; Stenholm S, 2008, CURR OPIN CLIN NUTR, V11, P693, DOI 10.1097/MCO.0b013e328312c37d; Mitsiopoulos N, 1998, J APPL PHYSIOL, V85, P115; Vincent HK, 2012, AGEING RES REV, V11, P361, DOI 10.1016/j.arr.2012.03.002; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; Tan BHL, 2009, CLIN CANCER RES, V15, P6973, DOI 10.1158/1078-0432.CCR-09-1525; van Vledder MG, 2012, BRIT J SURG, V99, P550, DOI 10.1002/bjs.7823; Poon RTP, 2011, HEPATOLOGY, V54, P757, DOI 10.1002/hep.24569; Marchesini G, 2003, GASTROENTEROLOGY, V124, P1792, DOI 10.1016/S0016-5085(03)00323-8; Moriwaki H, 2008, HEPATOL RES, V38, pS102, DOI 10.1111/j.1872-034X.2008.00434.x; Kaido T, 2013, AM J TRANSPLANT, V13, P1549, DOI 10.1111/ajt.12221; Harimoto N, 2013, BRIT J SURG, V100, P1523, DOI 10.1002/bjs.9258; Jones JC, 2012, LIVER TRANSPLANT, V18, P146, DOI 10.1002/lt.22472; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Plauth M, 2006, CLIN NUTR, V25, P285, DOI 10.1016/j.clnu.2006.01.018; Kudo M, 2010, HEPATOL RES, V40, P686, DOI 10.1111/j.1872-034X.2010.00674.x; Shiraki M, 2013, HEPATOL RES, V43, P106, DOI 10.1111/hepr.12004; Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1053/S1542-3565(05)00017-0; Prado CMM, 2008, LANCET ONCOL, V9, P629, DOI [10.1016/S1470-2045(08)70153-0, 10.1016/51470-2045(08)70153-0]; [Anonymous], 2010, HEPATOL RES S1, V40, P2; Sabel MS, 2011, ANN SURG ONCOL, V18, P3579, DOI 10.1245/s10434-011-1976-9; Lutz CT, 2012, AGING-US, V4, P535; Imai K, 2010, HEPATOL RES, V40, P376, DOI 10.1111/j.1872-034X.2009.00616.x; Meza-Junco J, 2013, J CLIN GASTROENTEROL, V47, P861, DOI 10.1097/MCG.0b013e318293a825; Mir O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037563; Nagel D., 2012, PLOS ONE, V7; Rosenberg IH, 1997, J NUTR, V127, pS990; Tajika M, 2002, NUTRITION, V18, P229, DOI 10.1016/S0899-9007(01)00754-7	37	5	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					323	332		10.1007/s00535-014-0964-9		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200010		
J	Kawaguchi, T; Kohjima, M; Ichikawa, T; Seike, M; Ide, Y; Mizuta, T; Honda, K; Nakao, K; Nakamuta, M; Sata, M				Kawaguchi, Takumi; Kohjima, Motoyuki; Ichikawa, Tatsuki; Seike, Masataka; Ide, Yasushi; Mizuta, Toshihiko; Honda, Koichi; Nakao, Kazuhiko; Nakamuta, Makoto; Sata, Michio			The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey	JOURNAL OF GASTROENTEROLOGY			English	Article						Diabetes mellitus; Chronic liver disease; Morbidity; Risk factor	POPULATION-BASED COHORT; ALL-CAUSE MORTALITY; HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; UP-REGULATION; COLON-CANCER; METAANALYSIS; INSULIN; DIAGNOSIS	Diabetes mellitus is associated with various cancers; however, little is known of the relationship between cancer and diabetes in chronic liver disease (CLD) patients. The aim of this study is to investigate the morbidity and associated factors of cancer, including the use of anti-diabetics, in CLD patients with diabetes. We performed a multicenter survey in 2012 and 478 CLD patients with diabetes were enrolled (age 64.3 +/- A 12.1 years, female/male 187/291). A frequency analysis of cancer and antidiabetic use was performed. Independent factors for cancer were analyzed using logistic regression and decision-tree analysis. The morbidity of cancer was 33.3 %. Hepatocellular carcinoma (HCC) and extra-hepatic cancer were diagnosed in 24.7 and 11.3 % of enrolled patients, respectively. The frequency of antidiabetic use was 66.5 %. Of prescribed antidiabetics, 39 % were dipeptidyl-peptidase 4 inhibitors; however, their use was not significantly associated with cancer. In contrast, the use of exogenous insulin (OR 2.21; 95 % CI 1.16-4.21, P = 0.0165) and sulfonylurea (OR 2.08; 95 % CI 1.05-3.97, P = 0.0353) were independently associated with HCC and extra-hepatic cancer, respectively. In decision-tree analysis, exogenous insulin and sulfonylurea were also identified as a divergence factor for HCC and extra-hepatic cancer, respectively. We found a high morbidity of not only HCC, but also extra-hepatic cancer in CLD patients with diabetes. We also showed a possible association between the use of antidiabetics and the morbidity of cancer. Thus, a large-scale cohort study is needed to establish a therapeutic strategy for diabetes to suppress carcinogenesis in CLD patients.	[Kawaguchi, Takumi; Sata, Michio] Kurume Univ, Sch Med, Div Gastroenterol, Dept Med, Kurume, Fukuoka 8300011, Japan; [Kawaguchi, Takumi; Sata, Michio] Kurume Univ, Sch Med, Dept Digest Dis Informat & Res, Kurume, Fukuoka 8300011, Japan; [Kohjima, Motoyuki; Nakamuta, Makoto] Kyushu Med Ctr, Dept Gastroenterol, Fukuoka, Japan; [Ichikawa, Tatsuki; Nakao, Kazuhiko] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki 852, Japan; [Seike, Masataka; Honda, Koichi] Oita Univ, Fac Med, Dept Gastroenterol, Hasama, Yuhu, Japan; [Ide, Yasushi; Mizuta, Toshihiko] Saga Univ, Saga Med Sch, Div Hepatol Diabet Metab & Endocrinol, Dept Internal Med,Fac Med, Saga 840, Japan	Kawaguchi, T (reprint author), Kurume Univ, Sch Med, Div Gastroenterol, Dept Med, Kurume, Fukuoka 8300011, Japan.	takumi@med.kurume-u.ac.jp					Ahmadieh H, 2013, ISRN ENDOCRINOL, V2013; Hsieh MC, 2012, EXP DIABETES RES, DOI 10.1155/2012/413782; Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322; Castillo JJ, 2012, BLOOD, V119, P4845, DOI 10.1182/blood-2011-06-362830; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Yokoyama H, 2009, NEPHROL DIAL TRANSPL, V24, P1212, DOI 10.1093/ndt/gfn603; Chevaliez S, 2008, BEST PRACT RES CL GA, V22, P1031, DOI 10.1016/j.bpg.2008.11.004; Yuhara H, 2011, AM J GASTROENTEROL, V106, P1911, DOI 10.1038/ajg.2011.301; Chalasani N, 2012, GASTROENTEROLOGY, V142, P1592, DOI 10.1053/j.gastro.2012.04.001; Kawaguchi T, 2004, AM J PATHOL, V165, P1499, DOI 10.1016/S0002-9440(10)63408-6; Kubo M, 2003, STROKE, V34, P2349, DOI 10.1161/01.STR.0000090348.52943.A2; Lee JY, 2013, EUR J CANCER, V49, P2411, DOI 10.1016/j.ejca.2013.02.025; Stamler J, 2000, JAMA-J AM MED ASSOC, V284, P311, DOI 10.1001/jama.284.3.311; Kawaguchi T, 2010, LIVER INT, V30, P479, DOI 10.1111/j.1478-3231.2009.02191.x; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Kawasaki R, 2011, DIABETOLOGIA, V54, P2288, DOI 10.1007/s00125-011-2199-0; Ben QW, 2011, EUR J CANCER, V47, P1928, DOI 10.1016/j.ejca.2011.03.003; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Kawaguchi T, 2011, HEPATOLOGY, V54, P1063, DOI 10.1002/hep.24412; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Singh S, 2013, AM J GASTROENTEROL, V108, P881, DOI 10.1038/ajg.2013.5; Morimoto A, 2013, DIABETOLOGIA, V56, P2171, DOI 10.1007/s00125-013-3001-2; Sayeed A, 2012, J CELL PHYSIOL, V227, P751, DOI 10.1002/jcp.22784; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Kissow H, 2012, REGUL PEPTIDES, V179, P91, DOI 10.1016/j.regpep.2012.08.016; White WB, 2013, NEW ENGL J MED, V369, P1327, DOI 10.1056/NEJMoa1305889; Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6; BARKER BE, 1964, EXP CELL RES, V35, P437, DOI 10.1016/0014-4827(64)90134-X; Charvat H, 2013, PREV MED, V57, P685, DOI 10.1016/j.ypmed.2013.08.030; Ito Hiroyuki, 2013, Nephron Extra, V3, P66, DOI 10.1159/000353592; Kawaguchi T, 2011, HEPATOL RES, V41, P564, DOI 10.1111/j.1872-034X.2011.00799.x; Kiderlen M, 2013, ANN ONCOL, V24, P3011, DOI 10.1093/annonc/mdt367; KUZUYA T, 1994, DIABETES RES CLIN PR, V24, pS159, DOI 10.1016/0168-8227(94)90244-5; Nakamura K, 2013, CANCER SCI, V104, P1362, DOI 10.1111/cas.12235; OOHASHI H, 1983, Tohoku Journal of Experimental Medicine, V141, P367; Park SH, 2008, GYNECOL ENDOCRINOL, V24, P250, DOI 10.1080/09513590801893315; Sakata M, 2013, J GASTROENTEROL, V48, P277, DOI 10.1007/s00535-012-0633-9; Sasazuki S, 2013, CANCER SCI, V104, P1499, DOI 10.1111/cas.12241; Satoh Jo, 2007, Journal of the Japan Diabetes Society, V50, P799; The Committee of 370 Japan Diabetes Society on the diagnostic criteria of diabetes mellitus, 2010, J JPN DIAB SOC, V53, P450; The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health LaWoJ, 2012, KANZO, V53, P633; Tsutsumi Mikihiro, 2012, Nihon Shokakibyo Gakkai Zasshi, V109, P1509; Yamada S, 2014, HEPATOL RES, V44, P837, DOI 10.1111/hepr.12192; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0	44	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					333	341		10.1007/s00535-014-0968-5		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200011		
J	Tateishi, R; Okanoue, T; Fujiwara, N; Okita, K; Kiyosawa, K; Omata, M; Kumada, H; Hayashi, N; Koike, K				Tateishi, Ryosuke; Okanoue, Takeshi; Fujiwara, Naoto; Okita, Kiwamu; Kiyosawa, Kendo; Omata, Masao; Kumada, Hiromitsu; Hayashi, Norio; Koike, Kazuhiko			Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study	JOURNAL OF GASTROENTEROLOGY			English	Article						Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Alcoholic liver disease; Retrospective study	CHRONIC HEPATITIS-B; VIRUS-INFECTION; LIVER-DISEASE; CANCER; JAPAN; RISK; CIRRHOSIS	The number of hepatocellular carcinoma (HCC) patients with non-viral etiologies is increasing in Japan. We conducted a nation-wide survey to examine the characteristics of those patients. After we assessed the trend of patients who were first diagnosed with HCC at 53 tertiary care centers in Japan from 1991 to 2010, we collected detailed data of 5326 patients with non-viral etiology. The etiologies were categorized as autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), unclassified, and other. Baseline characteristics at initial diagnosis, the modality of the initial treatment, and survival status were collected via a website. Survival of the patients was assessed by the Kaplan-Meier method and Cox proportional hazard regression. The proportion of patients with non-viral etiologies increased from 10.0 % in 1991 to 24.1 % in 2010. Of the patients, 92 % were categorized as ALD, NAFLD, or unclassified. Body mass index (BMI) was a parts per thousand yen 25 kg/m(2) in 39 %. Diabetes was most prevalent in NAFLD (63 %), followed by unclassified etiology (46 %) and ALD (45 %). Approximately 80 % of patients underwent radical therapy, including resection, ablation, or transarterial chemoembolization. Survival rates at 3, 5, 10, 15, and 20 years were 58.2, 42.6, 21.5, 15.2, and 15.2 %, respectively. Multivariate analysis revealed that patients with BMI > 22 and a parts per thousand currency sign 25 kg/m(2) showed the best prognosis versus other BMI categories, after adjusting by age, gender, tumor-related factors, and Child-Pugh score. Most cases of non-B, non-C HCC are related to lifestyle factors, including obesity and diabetes. Slightly overweight patients showed the best prognosis.	[Tateishi, Ryosuke; Fujiwara, Naoto; Koike, Kazuhiko] Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; [Okanoue, Takeshi] Saiseikai Suita Hosp, Suita, Osaka, Japan; [Okita, Kiwamu] Ajisu Kyoritsu Hosp, Yamaguchi, Japan; [Kiyosawa, Kendo] Shironishi Hosp, Matsumoto, Nagano, Japan; [Omata, Masao] Yamanashi Prefectural Hosp Org, Kofu, Yamanashi, Japan; [Kumada, Hiromitsu] Toranomon Gen Hosp, Tokyo, Japan; [Hayashi, Norio] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan	Tateishi, R (reprint author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	tateishi-tky@umin.ac.jp	Tateishi, Ryosuke/G-7758-2014	Tateishi, Ryosuke/0000-0003-3021-2517	Ministry of Health, Labour and Welfare of Japan; Eisai Co.	This work was supported partly by Health Sciences Research Grants of The Ministry of Health, Labour and Welfare of Japan (Research on Hepatitis). Eisai Co. supported the maintenance fee of the website for the data registration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; IIZUKA H, 1992, VOX SANG, V63, P107; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Tanaka H, 2008, ANN INTERN MED, V148, P820; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Tandon P, 2009, LIVER INT, V29, P502, DOI 10.1111/j.1478-3231.2008.01957.x; Simonetti J, 2010, HEPATOLOGY, V51, P1531, DOI 10.1002/hep.23464; [Anonymous], 2010, HEPATOL RES, V40, P16; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Ertle J, 2011, INT J CANCER, V128, P2436, DOI 10.1002/ijc.25797; Ikai I, 2007, HEPATOL RES, V37, P676, DOI 10.1111/j.1872-034X.2007.00119.x; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; El-Serag HB, 2006, CLIN GASTROENTEROL H, V4, P369, DOI 10.1016/j.cgh.2005.12.007; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Yokosuka O, 2010, J HEPATOL, V52, P791, DOI 10.1016/j.jhep.2009.12.036; Yoshida H, 1999, ANN INTERN MED, V131, P174; Abe H, 2008, J GASTROENTEROL, V43, P967, DOI 10.1007/s00535-008-2264-8; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Montano-Loza AJ, 2008, AM J GASTROENTEROL, V103, P1944, DOI 10.1111/j.1572-0241.2008.01922.x; Cancer Statistics in Japan, 2012, FDN PROM CANC RES; Cancer Study Group of Japan, 2003, GEN RUL CLIN PATH ST; Higuchi S, 2007, ADDICTION, V102, P1849, DOI 10.1111/j.1360-0443.2007.01902.x; Kondo R, 2013, HEPATOL RES; Lai MS, 2006, HEPATOLOGY, V43, P1295, DOI 10.1002/hep.21208; Liang Y, 2012, HEPATOLOGY, V56, P1409, DOI 10.1002/hep.25788; Sola R, 2006, LIVER INT, V26, P62, DOI 10.1111/j.1478-3231.2005.01181.x; Yang WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027326; Yoshizawa H, 2002, ONCOLOGY-BASEL, V62, P8, DOI 10.1159/000048270; YU MC, 1991, J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820	31	4	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0944-1174	1435-5922		J GASTROENTEROL	J. Gastroenterol.	MAR	2015	50	3					350	360		10.1007/s00535-014-0973-8		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD5XN	WOS:000351162200013		
J	Aida, Y; Abe, H; Tomita, Y; Nagano, T; Seki, N; Sugita, T; Itagaki, M; Ishiguro, H; Sutoh, S; Aizawa, Y				Aida, Yuta; Abe, Hiroshi; Tomita, Yoichi; Nagano, Tomohisa; Seki, Nobuyoshi; Sugita, Tomonori; Itagaki, Munenori; Ishiguro, Haruya; Sutoh, Satoshi; Aizawa, Yoshio			Serum Immunoreactive Collagen IV detected by Monoclonal Antibodies as a Marker of Severe Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease	JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES			English	Article						non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; collagen IV; FIB-4; hepatitis C virus; liver fibrosis	CHRONIC HEPATITIS-C; SANDWICH ENZYME-IMMUNOASSAY; NATURAL-HISTORY; STEATOHEPATITIS; CIRRHOSIS; BIOPSY; JAPAN	Background & Aims: The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We evaluated serum collagen IV as a direct non-invasive marker of severe liver fibrosis in NAFLD. Methods: The study included 148 NAFLD and 187 chronic hepatitis C patients in whom histological severity of liver fibrosis was evaluated. The utility of serum collagen IV measured by immune-mediated agglutination using two types of monoclonal antibodies for distinguishing severe fibrosis (>= stage 3 and >= F3) from non-to-moderate fibrosis in NAFLD or chronic hepatitis C was assessed in comparison to serum hyaluronic acid or other indirect fibrosis markers. Results: Multiple logistic regression analysis showed that serum collagen IV was significantly associated with severe fibrosis in NAFLD (odds ratio: 1.21, p<0.001) but not in chronic hepatitis C. For distinguishing severe fibrosis in NAFLD, collagen IV showed the largest area under the receiver-operating characteristic curve (0.827, 95% CI: 0.746-0.908) followed by FIB-4 (0.805, 95%CI: 0.728-0.890); in chronic hepatitis C, those for FIB-4 (0.813, 95%CI: 0.748-0.878) and collagen IV (0.770, 95%CI: 0.683-0.857) were the largest and smallest, respectively. To detect severe fibrosis in NAFLD, a cutoff of collagen IV > 177 exhibited 77.1% sensitivity, 84.0% specificity, 76.5% positive predictive value, and 84.0% negative predictive value. Combined with a cutoff of FIB-4 > 2.09, the negative and positive predictive values, and specificity for detecting severe fibrosis in NAFLD increased further. Conclusion: Collagen IV is a reliable marker for distinguishing severe liver fibrosis from non-to-moderate fibrosis in NAFLD but not chronic hepatitis C.	[Aida, Yuta; Abe, Hiroshi; Tomita, Yoichi; Nagano, Tomohisa; Seki, Nobuyoshi; Sugita, Tomonori; Itagaki, Munenori; Ishiguro, Haruya; Sutoh, Satoshi; Aizawa, Yoshio] Jikei Univ, Dept Internal Med, Katsushika Med Ctr, Div Gastroenterol & Hepatol,Sch Med,Katsushika Ku, Tokyo 1258506, Japan	Aida, Y (reprint author), Jikei Univ, Dept Internal Med, Katsushika Med Ctr, Div Gastroenterol & Hepatol,Sch Med,Katsushika Ku, 6-41-2 Aoto, Tokyo 1258506, Japan.	aidajik@jikei.ac.jp					Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Amarapurkar DN, 2007, J GASTROEN HEPATOL, V22, P788, DOI 10.1111/j.1440-1746.2007.05042.x; Kopelman PG, 2000, NATURE, V404, P635; [Anonymous], 1980, WHO TECH REP SER, V646, P1; Leeming DJ, 2012, HEPATOL RES, V42, P482, DOI 10.1111/j.1872-034X.2011.00946.x; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Lin ZH, 2011, HEPATOLOGY, V53, P726, DOI 10.1002/hep.24105; Kojima S, 2003, J GASTROENTEROL, V38, P954, DOI 10.1007/s00535-003-1178-8; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Tsochatzis EA, 2014, HEPATOLOGY, V60, P832, DOI 10.1002/hep.27296; Leeming DJ, 2013, LIVER INT, V33, P439, DOI 10.1111/liv.12044; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Nishie A, 2012, J MAGN RESON IMAGING, V36, P664, DOI 10.1002/jmri.23691; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Hui JM, 2003, HEPATOLOGY, V38, P420, DOI 10.1053/jhep.2003.50320; Merriman RB, 2006, HEPATOLOGY, V44, P874, DOI 10.1002/hep.21346; Muwaki Y, 1996, J HEPATOL, V24, P148, DOI [10.1016/s0168-8278(96)80023-7, DOI 10.1016/S0168-8278(96)80023-7]; OBATA K, 1989, CLIN CHIM ACTA, V181, P293, DOI 10.1016/0009-8981(89)90235-0; Sakugawa H, 2003, HEPATO-GASTROENTEROL, V50, P2005; Sand JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084934; Santos V N Dos, 2005, Braz J Med Biol Res, V38, P747; Seko Y, 2014, HEPATOL RES, DOI [10.1111/hepr.12407, DOI 10.1111/HEPR.12407]; Shimada M, 2002, HEPATOL RES, V24, P429, DOI 10.1016/S1386-6346(02)00246-2; UENO T, 1992, SCAND J GASTROENTERO, V27, P513, DOI 10.3109/00365529209000114; Walsh KM, 2000, J HEPATOL, V32, P325, DOI 10.1016/S0168-8278(00)80079-3	31	0	0	MEDICAL UNIV PRESS	CLUJ-NAPOCA	3RD MEDICAL CLINIC, STR CROITORILOR NO 19-21, CLUJ-NAPOCA, 400162, ROMANIA	1841-8724	1842-1121		J GASTROINTEST LIVER	J. Gastrointest. Liver Dis.	MAR	2015	24	1					61	68				8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD1OM	WOS:000350844200012		
J	Mori, H; Kobara, H; Nishiyama, N; Fujihara, S; Masaki, T				Mori, Hirohito; Kobara, Hideki; Nishiyama, Noriko; Fujihara, Shintaro; Masaki, Tsutomu			Open Biopsy guided by Endoscopic Ultrasonography from a Gastric Submucosal Tumor growing Outside the Stomach	JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES			English	Article						submucosal tunneling biopsy; submucosal tumor; outside growth; endoscopic ultrasonography	BLOC BIOPSY; DISSECTION; SAFETY; TUNNEL	Submucosal tunneling bloc biopsy for submucosal tumors growing inside the gastric wall is a safe and reliable method. However, it is difficult for an endoscopist to perform submucosal tunneling bloc biopsy and detect the demarcation line between the proper muscular layer and the capsule layer of submucosal tumors growing outside the gastric wall. A submucosal tumor in the lesser curvature of the stomach was identified in a 74-year-old man by esophagogastroduodenoscopy. Computed tomography revealed hetero-density with partial calcification of the tumor growing outside the gastric wall, that connected to approximately 10 mm of the muscular layer. Almost all of the tumor body was located outside the stomach. After the small connecting area was detected by endoscopic ultrasonography, two markings were placed at the opposite ends of the tumor. The tumor was removed via snare resection between the markings located immediately above the top of the tumor. After the biopsy site was reconfirmed using endoscopic ultrasonography, a large bloc biopsy was conducted. This new "open biopsy under endoscopic ultrasonography" is a simple, safe, and reliable method to obtain samples from any type of submucosal tumor growing inside or outside the stomach.	[Mori, Hirohito; Kobara, Hideki; Nishiyama, Noriko; Fujihara, Shintaro; Masaki, Tsutomu] Kagawa Univ, Dept Gastroenterol & Neurol, Kita Ku, Miki, Kagawa 7610793, Japan	Mori, H (reprint author), Kagawa Univ, Dept Gastroenterol & Neurol, Sch Med, Kita Ku, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hiro4884@med.kagawa-u.ac.jp					Akagi T, 2012, SURG INNOV, V19, P415, DOI 10.1177/1553350611432721; Levy MJ, 2003, GASTROINTEST ENDOSC, V57, P101, DOI 10.1067/mge.2003.49; Lee CK, 2010, GASTROINTEST ENDOSC, V71, P188, DOI 10.1016/j.gie.2009.07.029; Sumiyama K, 2007, GASTROINTEST ENDOSC, V65, P688, DOI 10.1016/j.gie.2006.07.030; Mori H, 2014, GASTROENTEROLOGY, V147, P278, DOI 10.1053/j.gastro.2014.06.030; Lee IL, 2006, ENDOSCOPY, V38, P1024, DOI 10.1055/s-2006-944814; Kobara H, 2012, ENDOSCOPY, V44, pE197, DOI 10.1055/s-0031-1291821; Kobara H, 2013, GASTROINTEST ENDOSC, V77, P141, DOI 10.1016/j.gie.2012.08.008; Linghu E, 2013, ENDOSCOPY, V45, P60, DOI 10.1055/s-0032-1325965; Mekky MA, 2010, GASTROINTEST ENDOSC, V71, P913, DOI 10.1016/j.gie.2009.11.044; Mori H, 2011, ENDOSCOPY, V43, P631, DOI 10.1055/s-0030-1256227; Nishida T, 2013, DIGEST ENDOSC, V25, P479, DOI 10.1111/den.12149; Papanikolaou Ioannis S, 2011, World J Gastrointest Endosc, V3, P86, DOI 10.4253/wjge.v3.i5.86; Ponsaing LG, 2007, WORLD J GASTROENTERO, V13, P3311; Suzuki T, 2011, ISRN GASTROENTEROL, V2011, DOI DOI 10.5402/2011/619128	15	0	0	MEDICAL UNIV PRESS	CLUJ-NAPOCA	3RD MEDICAL CLINIC, STR CROITORILOR NO 19-21, CLUJ-NAPOCA, 400162, ROMANIA	1841-8724	1842-1121		J GASTROINTEST LIVER	J. Gastrointest. Liver Dis.	MAR	2015	24	1					105	108				4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CD1OM	WOS:000350844200018		
J	Miyazaki, M; Ohtsuka, M; Miyakawa, S; Nagino, M; Yamamoto, M; Kokudo, N; Sano, K; Endo, I; Unno, M; Chijiiwa, K; Horiguchi, A; Kinoshita, H; Oka, M; Kubota, K; Sugiyama, M; Uemoto, S; Shimada, M; Suzuki, Y; Inui, K; Tazuma, S; Furuse, J; Yanagisawa, A; Nakanuma, Y; Kijima, H; Takada, T				Miyazaki, Masaru; Ohtsuka, Masayuki; Miyakawa, Shuichi; Nagino, Masato; Yamamoto, Masakazu; Kokudo, Norihiro; Sano, Keiji; Endo, Itaru; Unno, Michiaki; Chijiiwa, Kazuo; Horiguchi, Akihiko; Kinoshita, Hisafumi; Oka, Masaaki; Kubota, Keiichi; Sugiyama, Masanori; Uemoto, Shinji; Shimada, Mitsuo; Suzuki, Yasuyuki; Inui, Kazuo; Tazuma, Susumu; Furuse, Junji; Yanagisawa, Akio; Nakanuma, Yasuni; Kijima, Hiroshi; Takada, Tadahiro			Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Biliary tract cancers; Internationalization; Japanese classification; UICC/AJCC staging system		The 3rd English edition of the Japanese classification of biliary tract cancers was released approximately 10 years after the 5th Japanese edition and the 2nd English edition. Since the first Japanese edition was published in 1981, the Japanese classification has been in extensive use, particularly among Japanese surgeons and pathologists, because the cancer status and clinical outcomes in surgically resected cases have been the main objects of interest. However, recent advances in the diagnosis, management and research of the disease prompted the revision of the classification that can be used by not only surgeons and pathologists but also by all clinicians and researchers, for the evaluation of current disease status, the determination of current appropriate treatment, and the future development of medical practice for biliary tract cancers. Furthermore, during the past 10 years, globalization has advanced rapidly, and therefore, internationalization of the classification was an important issue to revise the Japanese original staging system, which would facilitate to compare the disease information among institutions worldwide. In order to achieve these objectives, the new Japanese classification of the biliary tract cancers principally adopted the 7th edition of staging system developed by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer ( AJCC). However, because there are some points pending in these systems, several distinctive points were also included for the purpose of collection of information for the future optimization of the staging system. Free mobile application of the new Japanese classification of the biliary tract cancers is available via http://www.jshbps.jp/en/classification/cbt15.html.	[Miyazaki, Masaru; Ohtsuka, Masayuki] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba 2608670, Japan; [Miyakawa, Shuichi] Fujita Hlth Univ, Dept Biliary Pancreat Surg, Toyoake, Aichi, Japan; [Nagino, Masato] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan; [Yamamoto, Masakazu] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan; [Kokudo, Norihiro] Univ Tokyo, Dept Surg, Div Hepatobiliary Pancreat Surg, Tokyo, Japan; [Sano, Keiji; Takada, Tadahiro] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan; [Endo, Itaru] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Yokohama, Kanagawa 232, Japan; [Unno, Michiaki] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi 980, Japan; [Chijiiwa, Kazuo] Miyazaki Univ, Sch Med, Dept Surg Oncol & Regulat Organ Funct, Miyazaki, Japan; [Horiguchi, Akihiko] Fujita Hlth Univ, Dept Gen Surg Pancreat Surg, Toyoake, Aichi, Japan; [Kinoshita, Hisafumi] Kurume Univ, Sch Med, Dept Surg, Fukuoka, Japan; [Oka, Masaaki] Yamaguchi Univ, Grad Sch Med, Dept Digest Surg & Surg Oncol, Yamaguchi, Japan; [Kubota, Keiichi] Dokkyo Med Univ, Dept Surg 2, Shimotsuga, Tochigi, Japan; [Sugiyama, Masanori] Kyorin Univ, Dept Surg, Tokyo, Japan; [Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Div Hepatobiliary Pancreat Surg & Transplantat, Kyoto, Japan; [Shimada, Mitsuo] Univ Tokushima, Dept Surg, Tokushima 770, Japan; [Suzuki, Yasuyuki] Kagawa Univ, Fac Med, Dept Surg Gastroenterol, Takamatsu, Kagawa 760, Japan; [Inui, Kazuo] Fujita Hlth Univ, Teaching Hosp 2, Dept Gastroenterol, Nagoya, Aichi, Japan; [Tazuma, Susumu] Hiroshima Univ, Grad Sch, Dept Gen Internal Med, Hiroshima, Japan; [Furuse, Junji] Kyorin Univ, Sch Med, Dept Med Oncol, Tokyo, Japan; [Yanagisawa, Akio] Kyoto Prefectural Univ Med, Dept Pathol, Kyoto 602, Japan; [Nakanuma, Yasuni] Kanazawa Univ, Grad Sch Sci, Dept Human Pathol, Kanazawa, Ishikawa, Japan; [Kijima, Hiroshi] Hirosaki Univ, Sch Med, Dept Pathol & Biosci, Aomori, Japan	Miyazaki, M (reprint author), Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuoh Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	masaru@faculy.chiba-u.jp	Unno, Michiaki/A-8633-2010	Unno, Michiaki/0000-0002-2145-6416			AJCC, 2010, CANC STAGING MANUAL; Nagino M, 2012, J GASTROENTEROL, V47, P1165, DOI 10.1007/s00535-012-0628-6; Ebata T, 2014, BRIT J SURG, V101, P79, DOI 10.1002/bjs.9379; Japanese Society of Hepato-Biliary-Pancreatic Surgery, 2013, GEN RUL CLIN PATH ST; Liver Cancer Study Group of Japan, 2010, GEN RUL CLIN PATH ST; Sobins LH, 2010, TNM CLASSIFICATION M	6	3	4	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					181	196		10.1002/jhbp.211		16	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900002		
J	Ohtsuka, M; Miyakawa, S; Nagino, M; Takada, T; Miyazaki, M				Ohtsuka, Masayuki; Miyakawa, Shuichi; Nagino, Masato; Takada, Tadahiro; Miyazaki, Masaru			Revision concepts and distinctive points of the new Japanese classification for biliary tract cancers in comparison with the 7th edition of the Union for International Cancer Control and the American Joint Committee on Cancer staging system	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Biliary tract cancers; Japanese classification; Staging system; UICC/AJCC staging system	GALLBLADDER CARCINOMA; CHOLANGIOCARCINOMA; RESECTION; SURGERY; NODES	BackgroundThe 3(rd) English edition of the Japanese classification of the biliary tract cancers (JC) is now available in this journal. The primary aim of this revision is to provide all clinicians and researchers with a common language of cancer staging at an international level. On the other hand, there are several important issues that should be solved for the optimization of the staging system. MethodsRevision concepts and major revision points of the 3(rd) English edition of the JC were reviewed. Furthermore, comparing with the 7(th) edition of staging system developed by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC), distinctive points in the JC was discussed. ResultsIn this edition of the JC, the same stage groupings as those in the UICC/AJCC staging system were basically adopted. T, N, and M categories were also identical in principle with those in the UICC/AJCC staging system, although slight modifications were proposed as the Japanese rules. As distinctive points, perihilar cholangiocarcinomas and ampullary region carcinomas were clearly defined. Intraepithelial tumor was discriminated from invasive carcinoma at ductal resection margins. Classifications of site-specific surgical margin status remained in this edition. Histological classification was based on that in the former editions of the JC, but adopted some parts of the World Health Organization classification. ConclusionsThe JC now share its staging system of the biliary tact carcinomas with the UICC/AJCC staging system. Future validation of the Japanese rules could provide important evidence to make globally standardized staging system. (c) Japanese Society of Hepato-Biliary-Pancreatic Surgery	[Ohtsuka, Masayuki; Miyazaki, Masaru] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuoh Ku, Chiba 2608670, Japan; [Miyakawa, Shuichi] Fujita Hlth Univ, Dept Biliary Pancreat Surg, Toyoake, Aichi, Japan; [Nagino, Masato] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan; [Takada, Tadahiro] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan	Miyazaki, M (reprint author), Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuoh Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	masaru@faculty.chiba-u.jp					BISMUTH H, 1992, ANN SURG, V215, P31; Igami T, 2009, ANN SURG, V249, P296, DOI 10.1097/SLA.0b013e318190a647; Ebata T, 2014, BRIT J SURG, V101, P79, DOI 10.1002/bjs.9379; Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Aoba T, 2013, ANN SURG, V257, P718, DOI 10.1097/SLA.0b013e3182822277; Shimizu H, 2007, J HEPATO-BILIARY-PAN, V14, P358, DOI 10.1007/s00534-006-1188-z; Negi SS, 2011, J GASTROINTEST SURG, V15, P1017, DOI 10.1007/s11605-011-1528-4; Sakata J, 2011, WORLD J SURG, V35, P2118, DOI 10.1007/s00268-011-1175-7; Bosmans FT, 2010, WHO CLASSIFICATION T, V4th; Edges SB, 2010, AM JOINT COMMITTEE C; Higuchi R, 2014, ANN SURG ONCOL, V21, P4308, DOI 10.1245/s10434-014-3885-1; Japanese society of Biliary Surgery, 2004, CLASS BIL TRACT CARC; Japanese Society of Hepato-Biliary-Pancreatic Surgery, 2013, GEN RUL CLIN PATH ST; Kishi Y, 2012, ANN SURG ONCOL, V19, P3567, DOI 10.1245/s10434-012-2599-5; Lius GJ, 2013, WORLD J GASTROENTERO, V19, P5150; Miyazaki M, 2015, J HEPATO-BIL-PAN SCI, V22, P181, DOI 10.1002/jhbp.211; Miyazaki M, 1996, BRIT J SURG, V83, P478, DOI 10.1002/bjs.1800830413; Nakeebs A, 1996, ANN SURG, V4, P463; Regimbeaus JM, 2011, EUR J SURG ONCOL, V37, P505; Sobins LH, 2010, INT UNION CANC UICC; Wakai T, 2005, CANCER, V103, P1210, DOI 10.1002/cncr.20906	21	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					197	201		10.1002/jhbp.212		5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900003		
J	Ueda, J; Miyasaka, Y; Ohtsuka, T; Takahata, S; Tanaka, M				Ueda, Junji; Miyasaka, Yoshihiro; Ohtsuka, Takao; Takahata, Shunichi; Tanaka, Masao			Short- and long-term results of the Frey procedure for chronic pancreatitis	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Chronic pancreatitis; Frey procedure	RANDOMIZED-TRIAL; LONGITUDINAL PANCREATICOJEJUNOSTOMY; SURGICAL DRAINAGE; PANCREATICODUODENECTOMY; RESECTION; DUCT; HEAD; SURGERY; EXPERIENCE; OUTCOMES	BackgroundThe aim of this study was to determine the short- and long-term results of the Frey procedure for chronic pancreatitis. MethodsFrom November 1998 to December 2013, 41 patients underwent the Frey procedure for painful chronic pancreatitis at Kyushu University Hospital. The short- and long-term results of the Frey procedure including mortality, morbidity, pain relief, weight gain and pancreatic endocrine function were analyzed. The long-term results were analyzed in 29 patients who had been followed-up for more than 12 months. The long-term follow-up rate was 85%. ResultsThere was no mortality. Early postoperative complications occurred in seven patients (17%), including pancreatic fistula in four (10%, International Study Group of Pancreatic Fistula ISGPF grade B) and hemorrhage in three (7%). Long-term relief of abdominal pain was achieved in 90% (26/29) of cases. One patient developed relapse of inflammation of the head of pancreas during the follow-up period, necessitating pylorus-resecting pancreatoduodenectomy. Only two patients (7%) developed new-onset diabetes mellitus after the Frey procedure during the follow-up period. ConclusionsThe Frey procedure for painful chronic pancreatitis may be safe and pancreatic endocrine function is preserved. Complete decompression of the pancreatic ducts in the head of pancreas and full length drainage of the main pancreatic duct from the head of pancreas to the tail may be important in the Frey procedure to prevent recurrence of acute inflammation.	[Ueda, Junji; Miyasaka, Yoshihiro; Ohtsuka, Takao; Takahata, Shunichi; Tanaka, Masao] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Higashi Ku, Fukuoka 8128582, Japan	Tanaka, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	masaotan@med.kyushu-u.ac.jp					Cahen DL, 2011, GASTROENTEROLOGY, V141, P1690, DOI 10.1053/j.gastro.2011.07.049; Izbicki JR, 1998, ANN SURG, V228, P771, DOI 10.1097/00000658-199812000-00008; Gouma DJ, 2000, ANN SURG, V232, P786, DOI 10.1097/00000658-200012000-00007; Cahen DL, 2007, NEW ENGL J MED, V356, P676, DOI 10.1056/NEJMoa060610; Huang JJ, 2000, ANN SURG, V231, P890, DOI 10.1097/00000658-200006000-00014; GREENLEE HB, 1990, WORLD J SURG, V14, P70; PRINZ RA, 1981, ANN SURG, V194, P313, DOI 10.1097/00000658-198109000-00009; PARTINGTON PF, 1960, ANN SURG, V152, P1037; Dite P, 2003, ENDOSCOPY, V35, P553; Sakata N, 2009, SURG TODAY, V39, P120, DOI 10.1007/s00595-008-3816-5; Strate T, 2008, GASTROENTEROLOGY, V134, P1406, DOI 10.1053/j.gastro.2008.02.056; Whitcomb DC, 2010, AM J GASTROENTEROL, V105, P2276, DOI 10.1038/ajg.2010.201; Jimenez RE, 2000, ANN SURG, V231, P293, DOI 10.1097/00000658-200003000-00001; Braganza JM, 2011, LANCET, V377, P1184, DOI 10.1016/S0140-6736(10)61852-1; Egawa S, 2010, J HEPATO-BIL-PAN SCI, V17, P745, DOI 10.1007/s00534-009-0185-4; Falconi M, 2006, J GASTROINTEST SURG, V10, P504, DOI 10.1016/j.gassur.2005.09.011; FREY CF, 1987, PANCREAS, V2, P701, DOI 10.1097/00006676-198711000-00014; FREY CF, 1994, ANN SURG, V220, P492, DOI 10.1097/00000658-199410000-00008; HART MJ, 1983, AM J SURG, V145, P567, DOI 10.1016/0002-9610(83)90092-2; Hildebrand Philipp, 2011, JOP, V12, P364; HOLMBERG JT, 1985, SURG GYNECOL OBSTET, V160, P339; Isaji S, 2010, J HEPATO-BIL-PAN SCI, V17, P763, DOI 10.1007/s00534-009-0181-8; Muller MW, 2008, AM J SURG, V196, P364, DOI 10.1016/j.amjsurg.2007.08.065; Roch AMD, 2012, J GASTROINTEST SURG, V16, P1362, DOI 10.1007/s11605-012-1904-8; Sakorafas GH, 2000, INT J PANCREATOL, V27, P131, DOI 10.1385/IJGC:27:2:131; Sudo T, 2014, J HEPATO-BIL-PAN SCI, V21, P426, DOI 10.1002/jhbp.48; Yeos CJ, 1997, ANN SURG, V226, P248	27	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					211	216		10.1002/jhbp.176		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900005		
J	Kondo, R; Kage, M; Ogata, T; Nakashima, O; Akiba, J; Nomura, Y; Yano, H				Kondo, Reiichiro; Kage, Masayoshi; Ogata, Toshiro; Nakashima, Osamu; Akiba, Jun; Nomura, Yoriko; Yano, Hirohisa			Therapeutic efficacy of splenectomy is attenuated by necroinflammation of the liver in patients with liver cirrhosis	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Alanine aminotransferase; Hepatitis C; Hypersplenism; Immunohistochemical analysis; Platelet	TUMOR-NECROSIS-FACTOR; C VIRUS-INFECTION; CHRONIC HEPATITIS; THROMBOCYTOPENIA; HYPERSPLENISM; PLATELETS; MECHANISMS; KINETICS; DISEASE; SPLEEN	BackgroundSplenectomy is a therapy for thrombocytopenia caused by hypersplenism with liver cirrhosis. However, the determinant of therapeutic outcomes for this complication has not yet been fully clarified. MethodsWe studied the laboratory findings of 55 patients who underwent splenectomy for hypersplenism with liver cirrhosis. In addition, we examined the histopathological findings of hepatosplenic tissues of nine patients who underwent hepatectomy for hepatocellular carcinoma and splenectomy for hypersplenism with liver cirrhosis on one stage surgery. The locations of platelets in hepatosplenic tissues were identified by immunohistochemistry. We used monoclonal antibody against CD41. ResultsAmong 55 patients, 40 patients had high serum alanine aminotransferase (ALT) level (38IU/l). Blood platelet count after splenectomy of patients with high serum ALT level were significantly lower than those of patients with low serum ALT level (P = 0.02). Histopathologically, platelet area of the liver tissues was positively correlated with hepatic inflammation (P = 0.02). Platelet area of the liver tissues was negatively correlated with blood platelet count after splenectomy (P = 0.03). ConclusionsHepatic inflammation contributes to the accumulation of platelets in liver; therefore, in patients with high serum ALT level, improvement of thrombocytopenia by the elimination of hypersplenism was limited.	[Kondo, Reiichiro; Akiba, Jun; Nomura, Yoriko; Yano, Hirohisa] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan; [Kondo, Reiichiro; Kage, Masayoshi] Kurume Univ Hosp, Ctr Canc, Kurume, Fukuoka, Japan; [Kondo, Reiichiro; Kage, Masayoshi; Nomura, Yoriko] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan; [Ogata, Toshiro] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan; [Nakashima, Osamu] Kurume Univ Hosp, Dept Clin Lab Med, Kurume, Fukuoka, Japan	Kondo, R (reprint author), Kurume Univ, Sch Med, Dept Pathol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	kondou_reiichirou@kurume-u.ac.jp			Ministry of Health, Labor and Welfare Japan	This study was partially supported by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare Japan, regarding Research on Intractable Diseases, Portal Hemodynamic Abnormalities.	ASTER RH, 1966, J CLIN INVEST, V45, P645, DOI 10.1172/JCI105380; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; Dolganiuc A, 2007, GASTROENTEROLOGY, V133, P1627, DOI 10.1053/j.gastro.2007.08.003; AOKI Y, 1993, EUR J NUCL MED, V20, P123; Noguchi H, 1995, HEPATOLOGY, V22, P1682, DOI 10.1016/0270-9139(95)90191-4; Ueda S, 2003, LAB INVEST, V83, P1595, DOI 10.1097/01.LAB.0000095686.10639.C8; Giannini E, 2003, AM J GASTROENTEROL, V98, P2516, DOI 10.1016/S0002-9270(03)01698-8; Akahoshi T, 2002, J GASTROEN HEPATOL, V17, P59, DOI 10.1046/j.1440-1746.2002.02667.x; Nakamura M, 1998, J HEPATOL, V28, P991, DOI 10.1016/S0168-8278(98)80348-6; Sata M, 1997, J GASTROENTEROL, V32, P206, DOI 10.1007/BF02936369; Sugawara Y, 2000, J AM COLL SURGEONS, V190, P446, DOI 10.1016/S1072-7515(99)00294-X; SANGRO B, 1993, HEPATOLOGY, V18, P309, DOI 10.1016/0270-9139(93)90013-D; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; COON WW, 1988, ARCH SURG-CHICAGO, V123, P369; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DUPERRAY A, 1989, BLOOD, V74, P1603; Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082; Itoh H, 1996, THROMB RES, V83, P405, DOI 10.1016/0049-3848(96)00151-X; Kercher KW, 2004, J GASTROINTEST SURG, V8, P120, DOI 10.1016/j.gassur.2003.10.009; Kinuya K, 2003, ANN NUCL MED, V17, P161, DOI 10.1007/BF02988457; Kondo R, 2013, J GASTROENTEROL, V48, P526, DOI 10.1007/s00535-012-0656-2; Miyazawa Y, 1998, HEPATOLOGY, V27, P497, DOI 10.1002/hep.510270225; Morinaga A, 2010, HPB, V12, P22, DOI 10.1111/j.1477-2574.2009.00116.x; Nomura Y, 2014, HEPATOL RES, V44, pE100, DOI 10.1111/hepr.12234; PEARSON JM, 1995, SHOCK, V4, P178, DOI 10.1097/00024382-199509000-00005; Peck-Radosavljevic M, 2000, Can J Gastroenterol, V14 Suppl D, p60D; Pockros PJ, 2002, AM J GASTROENTEROL, V97, P2040; SCHMIDT KG, 1985, SCAND J HAEMATOL, V34, P39	28	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					217	224		10.1002/jhbp.177		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900006		
J	Fujiwara, K; Yasui, S; Yonemitsu, Y; Arai, M; Kanda, T; Nakano, M; Oda, S; Yokosuka, O				Fujiwara, Keiichi; Yasui, Shin; Yonemitsu, Yutaka; Arai, Makoto; Kanda, Tatsuo; Nakano, Masayuki; Oda, Shigeto; Yokosuka, Osamu			Fixed point observation of etiology of acute liver failure according to the novel Japanese diagnostic criteria	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Acute liver failure; Etiology; Fulminant hepatitis; Late onset hepatic failure; Novel Japanese diagnostic criteria	ONSET AUTOIMMUNE HEPATITIS; DISEASES STUDY-GROUP; FULMINANT-HEPATITIS; PROGNOSIS; TRANSPLANTATION; EXPERIENCE; ADULTS	BackgroundThere has existed important differences in the definition of acute liver failure (ALF) between Japanese criteria and those of other countries. The novel diagnostic criteria for ALF in Japanese patients were established by the Intractable Hepato-Biliary Diseases Study Group of Japan, in order to correspond to those for ALF in Europe and the USA. We prospectively diagnosed our ALF patients based on this novel criteria, and discussed the etiology by a fixed point observation. MethodsWe investigated the etiology of 54 adult inpatients and outpatients with ALF between 2010 and 2012. ResultsOf 54 patients, 36 were ALF without coma, 17 ALF with coma and one late onset hepatic failure. The etiology was due to viral infections in 38.9%, autoimmune hepatitis in 11.1%, drug-induced liver injury in 13.0%, etiologies without hepatitis in 29.6% (circulatory disturbance in 18.5%, infiltration of the liver by malignant cells in 7.4%, and metabolic diseases in 3.7%) and indeterminate causes in 7.4%. ConclusionsCirculatory disturbance was the most frequent etiology according to the novel criteria. Indeterminate etiology was less observed in our study than the nation-wide survey with significance (P = 0.0014).	[Fujiwara, Keiichi; Yasui, Shin; Yonemitsu, Yutaka; Arai, Makoto; Kanda, Tatsuo; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuo Ku, Chiba 2608670, Japan; [Nakano, Masayuki] Ofuna Chuo Hosp, Div Pathol, Kamakura, Kanagawa, Japan; [Oda, Shigeto] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba 2608670, Japan	Fujiwara, K (reprint author), Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	fujiwara-cib@umin.ac.jp			Ministry of Health, Labor and Welfare of Japan by Intractable Hepato-Biliary Disease Study Group	We are indebted to all our colleagues at the liver unit of our hospital who cared for the patients described herein. This study was supported in part by Health Labour Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan as a project by the Intractable Hepato-Biliary Disease Study Group, the Ministry of Health, Labor and Welfare of Japan.	Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Oketani M, 2013, HEPATOL RES, V43, P97, DOI 10.1111/j.1872-034X.2012.01105.x; Mochida S, 2011, HEPATOL RES, V41, P805, DOI 10.1111/j.1872-034X.2011.00860.x; Stravitz RT, 2011, HEPATOLOGY, V53, P517, DOI 10.1002/hep.24080; Ostapowicz G, 2002, ANN INTERN MED, V137, P947; Fujiwara K, 2014, HEPATOL RES, V44, P491, DOI 10.1111/hepr.12148; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439; Fujiwara K, 2008, HEPATOL RES, V38, P646, DOI 10.1111/j.1872-034X.2008.00322.x; Polson J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/hep.20703; Fujiwara K, 2011, HEPATOLOGY, V54, P371, DOI 10.1002/hep.24331; Takikawa Y, 2008, HEPATOL RES, V38, pS14, DOI 10.1111/j.1872-034X.2008.00421.x; Fujiwara K, 2013, HEPATOL INT, V7, P335, DOI 10.1007/s12072-012-9402-3; OGRADY JG, 1993, LANCET, V342, P273; [Anonymous], 1982, P 12 IN S HEP TYP A; Yasui S, 2011, J GASTROENTEROL, V46, P378, DOI 10.1007/s00535-010-0316-3; Mochida S, 2014, HEPATOL RES, V44, P365, DOI 10.1111/hepr.12295; Fujiwara K, 2011, HEPATOL RES, V41, P133, DOI 10.1111/j.1872-034X.2010.00755.x; NIKIAS GA, 1994, J HEPATOL, V21, P866, DOI 10.1016/S0168-8278(94)80251-3; Fujiwara K, 2008, J GASTROENTEROL, V43, P951, DOI 10.1007/s00535-008-2254-x; Ichai P, 2008, LIVER TRANSPLANT, V14, pS67, DOI 10.1002/lt.21612; Fujiwara K, 2014, HEPATOLOGY, V60, P1447, DOI 10.1002/hep.27111; Lees WM, 2008, HEPATOLOGY, V47, P1401; Lees WM, 2012, BEST PRACT RES CLIN, V26, P3; Mochidas S, 2013, ACUTE LIVER FAILURE, P108; Mochidas S, 2014, ACUTE LIVER FAILURE; Mochidas S, 2012, ANN REPORT INTRACTAB, P101; Wigg AJ, 2005, LIVER TRANSPLANT, V11, P27, DOI 10.1002/lt.20289; WILLIAMS R, 1994, HEPATOLOGY, V20, pS5, DOI 10.1016/0270-9139(94)90265-8	28	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					225	229		10.1002/jhbp.178		5	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900007		
J	Tanaka, A; Tazuma, S; Okazaki, K; Tsubouchi, H; Inui, K; Takikawa, H				Tanaka, Atsushi; Tazuma, Susumu; Okazaki, Kazuichi; Tsubouchi, Hirohito; Inui, Kazuo; Takikawa, Hajime			Clinical profiles of patients with primary sclerosing cholangitis in the elderly	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Autoimmune pancreatitis; Inflammatory bowel diseases; Nationwide survey; Prednisolone; Ursodeoxycholic acid	PRIMARY BILIARY-CIRRHOSIS; PROGNOSTIC-FACTORS; NATURAL-HISTORY; POPULATION; JAPAN; EPIDEMIOLOGY; PREVALENCE; OUTCOMES; RISK	BackgroundIn 2012 we conducted a nationwide survey for primary sclerosing cholangitis (PSC) and isolated IgG4-related sclerosing cholangitis (IgG4-SC) in Japan, and demonstrated the young as well as the elderly individuals were at higher risk for development of PSC. In the current study we aimed to further clarify the clinical profiles of PSC in the elderly, compared with PSC in the young and IgG4-SC. MethodsThe design was a questionnaires-based, multi-center retrospective study. The enrolled subjects were patients with PSC and isolated IgG4-SC diagnosed after 2005. Since the median of age of patients with PSC was 48.1, we defined those who developed the disease at the age older than 48.1 as PSC in the elderly, and the rest as PSC in the young. ResultsWe defined 98 and 99 patients as PSC in the elderly and in the young, respectively. Although symptoms and biochemistries at presentation were similar, serum IgA and IgM levels were significantly higher and lower in the elderly PSC compared to the young PSC, respectively (P < 0.001, P < 0.001). The sensitivity and specificity of serum IgG4 levels were 89.5% and 88.9% for discriminating the elderly PSC and IgG4-SC. In terms of complications, prevalence of IBD was 12% in the elderly PSC and 57% in the young PSC, the latter being comparable to those in Europe and the USA. ConclusionIt is reasoned to conclude that PSC in the young resembles those in Europe and the USA in terms of the onset age and prevalence of IBD, while PSC in the elderly is really unique in Japan.	[Tanaka, Atsushi; Takikawa, Hajime] Teikyo Univ, Dept Med, Sch Med, Itabashi Ku, Tokyo 1738605, Japan; [Tazuma, Susumu] Hiroshima Univ, Grad Sch Med Sci, Dept Gen Med, Programs Appl Med,Clin Pharmacotherapy, Hiroshima, Japan; [Okazaki, Kazuichi] Kansai Med Univ, Dept Internal Med 3, Hirakata, Osaka, Japan; [Tsubouchi, Hirohito] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, Kagoshima 890, Japan; [Inui, Kazuo] Fujita Hlth Univ, Teaching Hosp 2, Dept Internal Med, Nagoya, Aichi, Japan	Tanaka, A (reprint author), Teikyo Univ, Dept Med, Sch Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	a-tanaka@med.teikyo-u.ac.jp			Intractable hepato-biliary disease Study Group in Japan; Research Committee to establish diagnostic criteria and development of treatment for systemic IgG4-related sclerosing disease by Research Program of Intractable Disease by Ministry of Health, Labor, and Welfare of Japan	This study was conducted and supported by the Intractable hepato-biliary disease Study Group in Japan and the Research Committee to establish diagnostic criteria and development of treatment for systemic IgG4-related sclerosing disease supported by the Research Program of Intractable Disease provided by the Ministry of Health, Labor, and Welfare of Japan.	Boberg KM, 1998, SCAND J GASTROENTERO, V33, P99; Bambha K, 2003, GASTROENTEROLOGY, V125, P1364, DOI 10.1053/S0016-5085(03)01356-8; SCHRUMPF E, 1994, J HEPATOL, V21, P1061, DOI 10.1016/S0168-8278(05)80618-X; Kikuchi K, 2005, GASTROENTEROLOGY, V128, P304, DOI 10.1053/j.gastro.2004.11.005; Kingham JGC, 2004, GASTROENTEROLOGY, V126, P1929, DOI 10.1053/j.gastro.2004.04.052; Card TR, 2008, J HEPATOL, V48, P939, DOI 10.1016/j.jhep.2008.02.017; Ohara H, 2012, J HEPATO-BIL-PAN SCI, V19, P536, DOI 10.1007/s00534-012-0521-y; Eaton JE, 2013, GASTROENTEROLOGY, V145, P521, DOI 10.1053/j.gastro.2013.06.052; Broome U, 1996, GUT, V38, P610, DOI 10.1136/gut.38.4.610; Boonstra K, 2013, HEPATOLOGY, V58, P2045, DOI 10.1002/hep.26565; Takikawa H, 2004, HEPATOL RES, V29, P153, DOI 10.1016/j.hepres.2004.03.006; WIESNER RH, 1989, HEPATOLOGY, V10, P430, DOI 10.1002/hep.1840100406; FARRANT JM, 1991, GASTROENTEROLOGY, V100, P1710; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Kaplan GG, 2007, AM J GASTROENTEROL, V102, P1042, DOI 10.1111/j.1572-0241.2007.01103.x; Takikawa H, 1997, J GASTROENTEROL, V32, P134, DOI 10.1007/BF01213311; ESCORSELL A, 1994, J HEPATOL, V21, P787, DOI 10.1016/S0168-8278(94)80240-8; Lindkvist B, 2010, HEPATOLOGY, V52, P571, DOI 10.1002/hep.23678; Hirano K, 2008, J GASTROENTEROL, V43, P729, DOI 10.1007/s00535-008-2216-3; Lindors K, 2007, SCHIFFS DIS LIVER, P673; Nakazawa T, 2006, PANCREAS, V32, P229, DOI 10.1097/01.mpa.0000202941.85955.07; Tanaka A, 2014, J HEPATO-BIL-PAN SCI, V21, P43, DOI 10.1002/jhbp.50; Tanaka A, 2008, LIVER INT, V28, P983, DOI 10.1111/j.1478-3231.2008.01726.x; Working Subgroup (English Version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis, 2014, HEPATOL RES SS1, V44, P71	24	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					230	236		10.1002/jhbp.194		7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900008		
J	Yane, K; Katanuma, A; Maguchi, H				Yane, Kei; Katanuma, Akio; Maguchi, Hiroyuki			Endoscopic cutting technique using scissors forceps after temporary endoscopic naso-gallbladder drainage for acute cholecystitis (with videos)	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Acute cholecystitis; Endoscopic naso-gallbladder drainage; Endoscopic retrograde cholangiopancreatography			[Yane, Kei; Katanuma, Akio; Maguchi, Hiroyuki] Teine Keijinkai Hosp, Ctr Gastroenterol, Teine Ku, Sapporo, Hokkaido 0068555, Japan	Yane, K (reprint author), Teine Keijinkai Hosp, Ctr Gastroenterol, Teine Ku, 1 Jo 12 Chome, Sapporo, Hokkaido 0068555, Japan.	k.yane3@gmail.com					Itoi T, 2008, GASTROINTEST ENDOSC, V68, P455, DOI 10.1016/j.gie.2008.02.052; Maekawa S, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-65; Uchida N, 2003, HEPATO-GASTROENTEROL, V50, P1891; Yane K, 2015, GUT LIVER, V9, P239, DOI 10.5009/gnl14070	4	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					244	245		10.1002/jhbp.202		2	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900010		
J	Fujiwara, K; Oda, S; Abe, R; Yokosuka, O				Fujiwara, Keiichi; Oda, Shigeto; Abe, Ryuzo; Yokosuka, Osamu			On-line hemodiafiltration or high-flow continuous hemodiafiltration is one of the most effective artificial liver support devices for acute liver failure in Japan	JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES			English	Article						Acute liver failure; Artificial liver support; High-flow continuous hemodiafiltration; On-line hemodiafiltration			[Fujiwara, Keiichi; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuo Ku, Chiba 2608670, Japan; [Oda, Shigeto; Abe, Ryuzo] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chiba 2608670, Japan	Fujiwara, K (reprint author), Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	fujiwara-cib@umin.ac.jp			Ministry of Health, Labor and Welfare of Japan by Intractable Hepato-Biliary Disease Study Group of Japan	This study was supported in part by a Health Labour Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan as a project by the Intractable Hepato-Biliary Disease Study Group of Japan.	Heemann U, 2002, HEPATOLOGY, V36, P949, DOI 10.1053/jhep.2002.36130; Arata Shinju, 2010, BMC Emerg Med, V10, P10, DOI 10.1186/1471-227X-10-10; Ferenci P, 2007, HEPATOLOGY, V46, P1682, DOI 10.1002/hep.22031; Fujiwaras K, 2012, KANZO, V53, P530; Inoue K, 2010, TRANSPL P, V42, P4109, DOI 10.1016/j.transproceed.2010.09.073; Yokoi T, 2009, TRANSFUS APHER SCI, V40, P61, DOI 10.1016/j.transci.2008.11.006	6	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1868-6974	1868-6982		J HEPATO-BIL-PAN SCI	J. Hepato-Biliary-Pancreat. Sci.	MAR	2015	22	3					246	247		10.1002/jhbp.204		2	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CC8UC	WOS:000350642900011		
J	Shimizu, T; Kumagai, T; Kobayashi, M; Tamai, K; Iida, S; Kabeya, N; Ikawa, R; Tateishi, M; Miyazawa, Y; Shimizu, A				Shimizu, Takanori; Kumagai, Tomo'omi; Kobayashi, Masahiro; Tamai, Koji; Iida, Shin'ichi; Kabeya, Naoki; Ikawa, Reo; Tateishi, Makiko; Miyazawa, Yoshiyuki; Shimizu, Akira			Estimation of annual forest evapotranspiration from a coniferous plantation watershed in Japan (2): Comparison of eddy covariance, water budget and sap-flow plus interception loss	JOURNAL OF HYDROLOGY			English	Article						Multi-method comparison; Patchy planted forest; Stand level flux; Water vapor exchange	MEAN RESIDENCE TIME; FLUX MEASUREMENTS; CATCHMENT-SCALE; CYPRESS FOREST; COMPONENTS; BALANCE; TRANSPIRATION; MODEL; EVAPORATION; DYNAMICS	Evapotranspiration (ET) was estimated from a planted coniferous forest in southwestern Japan by applying three methods: the eddy covariance method; the measurement of rainfall (P) and runoff (Q) in a small watershed; and a combination of rainfall interception loss (I-C), upper canopy transpiration based on a sap-flux density measurement in Japanese cedar (Cryptomeria Japonica D. Don) stands (E-UC), and modeled sub-canopy ET (E-SC). After inverse multiplication of the energy imbalance ratio, ET by the eddy covariance method (ETEC) was 839.9 mm in 2007 and 811.8 mm in 2008. The yearly values of P-Q were partially affected by Pin the previous autumn. After continuous data collection for more than 5 years, P-Q became stable. The 9-year (2000-2008) average P-Q which was considered most reliable in this study, was 897,5 mm y(-1). The cumulative ETEc during the daylight hours from the right stream bank, covered mainly with large Japanese cedars, was 894.1 mm from April 2007 to March 2008. The value was almost the same as that calculated as the components sum (ETCOMP = I-C + E-UC + E-SC: 911.4 mm), and the comparison suggested that the annual totals of ETEC with an energy imbalance correction provide a reliable estimate of ET in a forest stand on a complex topography. Spatial variation in the watershed was likely caused by differences in soil water retention at each slope position. The slight difference in annual ETEC in 2007 compared with 2008 was attributed to differences in the radiative energy input. In the monthly-weekly analysis, ETCOMP was frequently higher than ETEC after heavy rainfall, while ETEC was higher under dry conditions and during active ET. Even under dry canopy conditions, daily ETEC was often higher than E-UC + E-SC. The results suggested a time-lag in evaporation from the ecosystem and/or under-estimated ETEC after rainfall. (C) 2014 Elsevier B.V. All rights reserved.	[Shimizu, Takanori; Kobayashi, Masahiro; Tamai, Koji; Iida, Shin'ichi] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan; [Kumagai, Tomo'omi] Nagoya Univ, Hydrospher Atmospher Res Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Kabeya, Naoki; Shimizu, Akira] Forestry & Forest Prod Res Inst, Kyushu Res Ctr, Kurokami, Kumamoto 8600862, Japan; [Ikawa, Reo] Geol Survey Japan, AIST Tsukuba Cent 7, Tsukuba, Ibaraki 3058567, Japan; [Tateishi, Makiko] Kyushu Univ, Kasuya Res Forest, Fukuoka 8112415, Japan; [Tateishi, Makiko] Kyoto Univ, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan; [Miyazawa, Yoshiyuki] Kyushu Univ, Res Inst East Asia Environm, Motooka, Fukuoka 8110395, Japan; [Miyazawa, Yoshiyuki] Univ Hawaii Manoa, Dept Geog, Honolulu, HI 96822 USA	Shimizu, T (reprint author), Forestry & Forest Prod Res Inst, 1 Matsunosato, Tsukuba, Ibaraki 3058687, Japan.	simizuta@affrc.go.jp	Kabeya, Naoki/C-6543-2015; Kumagai, Tomo'omi/A-4791-2011; Iida, Shin'ichi/B-5963-2011	Kabeya, Naoki/0000-0002-0210-2508; 	Kyushu Research Center of the Forestry and Forest Products Research Institute (FFPRI); National Forests in Kyushu Office; Ministry of Agriculture, Forestry and Fisheries, Japan [A-8]; Ministry of Education, Science and Culture, Japan [17380096, 17510011]	Maintenance of the KHEW is supported by the Kyushu Research Center of the Forestry and Forest Products Research Institute (FFPRI) and the National Forests in Kyushu Office. This work was financially supported by the Ministry of Agriculture, Forestry and Fisheries, Japan through a research project entitled "Development of technologies for mitigation and adaptation to climate change in Agriculture, Forestry and Fisheries (A-8)" and also supported by Grants-in-Aid for Scientific Research (Nos. 17380096 and 17510011) from the Ministry of Education, Science and Culture, Japan. The authors are grateful to Prof. Masakazu Suzuki of The University of Tokyo, Prof. Delphis F. Levia of The University of Delaware, and Dr. Kazuki Nanko of FFPRI for support of this study. The authors also thank Dr. Yasuhiro Ohnuki and Dr. Shoji Noguchi of FFPRI for helpful instruction, and Dr. Hiroaki Hagino of FFPRI and Dr. Natsuko Yoshifuji of Kyoto University for providing field information. Further, we appreciate the thoughtful comments and advice of three anonymous reviewers.	Iida S, 2009, AGR FOREST METEOROL, V149, P1129, DOI 10.1016/j.agrformet.2009.02.003; Domec JC, 2012, FOREST SCI, V58, P497, DOI 10.5849/forsci.11-051; Scott RL, 2010, AGR FOREST METEOROL, V150, P219, DOI 10.1016/j.agrformet.2009.11.002; Holst J, 2010, INT J BIOMETEOROL, V54, P23, DOI 10.1007/s00484-009-0248-x; WEBB EK, 1980, Q J ROY METEOR SOC, V106, P85, DOI 10.1002/qj.49710644707; Noguchi S, 1999, SOIL SCI SOC AM J, V63, P1413; Murakami S, 2006, J HYDROL, V319, P72, DOI 10.1016/j.jhydrol.2005.07.002; Pearcy RW, 1996, OECOLOGIA, V108, P1, DOI 10.1007/BF00333208; Hui DF, 2004, AGR FOREST METEOROL, V121, P93, DOI 10.1016/S0168-1923(03)00158-8; Kosugi Y, 2007, J HYDROL, V334, P305, DOI 10.1016/j.jhydrol.2006.05.025; Iida S, 2012, HYDROL PROCESS, V26, P2445, DOI 10.1002/hyp.9462; Ibrom A, 2007, AGR FOREST METEOROL, V147, P140, DOI 10.1016/j.agrformet.2007.07.007; Katsuyama M, 2010, HYDROL PROCESS, V24, P2287, DOI 10.1002/hyp.7741; Ford CR, 2007, AGR FOREST METEOROL, V145, P176, DOI 10.1016/j.agrformet.2007.04.010; GRANIER A, 1987, TREE PHYSIOL, V3, P309; Oishi AC, 2008, AGR FOREST METEOROL, V148, P1719, DOI 10.1016/j.agrformet.2008.06.013; Sidle RC, 2000, HYDROL PROCESS, V14, P369, DOI 10.1002/(SICI)1099-1085(20000228)14:3<369::AID-HYP943>3.3.CO;2-G; Iida S, 2005, J HYDROL, V315, P154, DOI 10.1016/j.jhydrol.2005.03.024; Ding RS, 2010, AGR WATER MANAGE, V98, P87, DOI 10.1016/j.agwat.2010.08.001; Komatsu H, 2007, J HYDROL, V336, P361, DOI 10.1016/j.jhydrol.2007.01.009; Wilson KB, 2001, AGR FOREST METEOROL, V106, P153, DOI 10.1016/S0168-1923(00)00199-4; Barr AG, 2012, AGR FOREST METEOROL, V153, P3, DOI 10.1016/j.agrformet.2011.05.017; McGlynn B, 2003, HYDROL PROCESS, V17, P175, DOI 10.1002/hyp.5085; Dyer A. J., 1974, Boundary-Layer Meteorology, V7, DOI 10.1007/BF00240838; Foken T., 2012, EDDY COVARIANCE PRAC, P85, DOI [10.1007/978-94-007-2351-1_4, DOI 10.1007/978-94-007-2351-1_]; Forestry Agency of Japan, 2013, ANN REP FOR FOR JAP, P284; Hsieh CI, 2000, ADV WATER RESOUR, V23, P765, DOI 10.1016/S0309-1708(99)00042-1; Ikawa R., 2008, THESIS KUMAMOTO U, P45; Kobayashi M, 2007, HYDROL PROCESS, V21, P2356, DOI 10.1002/hyp.6754; Komatsu H, 2008, J HYDROL, V348, P330, DOI 10.1016/j.jhydrol.2007.10.006; Kosugi Y, 2007, J HYDROL, V337, P269, DOI 10.1016/j.jhydrol.2007.01.039; Kumagai T, 2007, TREE PHYSIOL, V27, P161; Kumagai T, 2014, J HYDROL, V508, P66, DOI 10.1016/j.jhydrol.2013.10.047; Manfroi OJ, 2006, J HYDROL, V329, P329, DOI 10.1016/j.jhydrol.2006.02.020; Matsumoto K., 2011, INT J EROS CONTROL E, V4, P10; Nagakura J, 2004, TREE PHYSIOL, V24, P1203; Ohnuki Y., 1998, B KYUSHU BRANCH JPN, V51, P105; Shimizu A, 2003, HYDROL PROCESS, V17, P3125, DOI 10.1002/hyp.1261; Shimizu A., 1994, P INT S FOR HYDROL, V1994, P367; Shimizu T, 1999, BOUND-LAY METEOROL, V93, P227, DOI 10.1023/A:1002053313130; Shimizu T, 2007, BOUND-LAY METEOROL, V122, P417, DOI 10.1007/s10546-006-9115-z; Shimizu T., BOUNDARY LAYER UNPUB; Siebicke L, 2012, THEOR APPL CLIMATOL, V109, P109, DOI 10.1007/s00704-011-0552-3; Tamai K., 2010, J FOR ENV, V52, P1; Waichler SR, 2005, HYDROL PROCESS, V19, P3177, DOI 10.1002/hyp.5841; Yamashita T, 2004, FOREST ECOL MANAG, V200, P215, DOI 10.1016/j.foreco.2004.06.022; Zhang I., 2001, WATER RESOUR RES, V37, P701	47	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-1694	1879-2707		J HYDROL	J. Hydrol.	MAR	2015	522						250	264		10.1016/j.jhydrol.2014.12.021		15	Engineering, Civil; Geosciences, Multidisciplinary; Water Resources	Engineering; Geology; Water Resources	CD2OZ	WOS:000350920200021		
J	Maruyama, T; Takimoto, H; Ogura, A; Yoshida, M				Maruyama, Toshisuke; Takimoto, Hiroshi; Ogura, Akira; Yoshida, Masashi			Analysis of snowpack accumulation and the melting process of wet snow using a heat balance approach that emphasizes the role of underground heat flux	JOURNAL OF HYDROLOGY			English	Article						Bulk transfer method; Heat flux from underground; Snowpack density; Roughness length; Water depth equivalent		Snowpack accumulation and melting, including the role of the heat flux underground, were investigated by employing the bulk transfer method and setting roughness lengths of Z(O) = Z(T) = 0.005 m and Z(T) = 0.007 m. Heat balance data were recorded for a period of 4 years, from the fall of 2009 to the spring of 2013, at a forest experiment station in the Hokuriku region, which lies along the Japan Sea. The findings of the research are as follows: (1) The observed temporal changes in the snowpack depth were well reproduced by our model using observed and estimated densities. (2) The importance and roles of the heat balance components were clarified. The total heat input during the 4 years was 252.2 MJ/m(2) on average; 41.4% was provided by net radiation (R-n), 37.8% by sensible heat flux (H), and 13.2% by underground heat flux (G). The total output was 120.7 MJ/m(2), of which 56.2% was accounted for by R-n and 31.1% by latent heat flux (lE). (3) Of the total heat input, 45.2% was released as freezing energy from the surface side and 2.6% was released from the bottom. (4) In the very cold season (December-February), the total input energy was 115.8 MJ/m(2) on average; 75.0% was supplied by the surface and the remaining 25.0% from underground. In an anomalous year, 40.8% of the energy was supplied from underground. (C) 2014 Elsevier B.V. All rights reserved.	[Maruyama, Toshisuke; Takimoto, Hiroshi; Yoshida, Masashi] Ishikawa Prefectural Univ, Nonoichi, Ishikawa 9218836, Japan; [Ogura, Akira] Res Ctr Agr & Forestry, Haku San, Ishikawa 9202114, Japan	Maruyama, T (reprint author), Ishikawa Prefectural Univ, 1-308 Suematsu, Nonoichi, Ishikawa 9218836, Japan.	maruyama@ishikawa-pu.ac.jp					WIERINGA J, 1992, J WIND ENG IND AEROD, V41, P357, DOI 10.1016/0167-6105(92)90434-C; Senese A, 2012, ARCT ANTARCT ALP RES, V44, P122, DOI 10.1657/1938-4246-44.1.122; Martin KA, 2013, WATER RESOUR RES, V49, P3243, DOI 10.1002/wrcr.20271; Arakawa H., 1965, STUDY ESTIMATION WAT, V2, P35; Boike J., 2003, J GEOPHYS RES-ATMOS, V108; Brock W.B., 2006, J GLACIOL, V52, P1; Ding BH, 2014, J HYDROL, V513, P154, DOI 10.1016/j.jhydrol.2014.03.038; Gromke C, 2011, BOUND-LAY METEOROL, V141, P21, DOI 10.1007/s10546-011-9623-3; Gromke C, 2009, ISSW 09 EUROPE: INTERNATIONAL SNOW SCIENCE WORKSHOP, PROCEEDINGS, P136; Kojima K., 1982, LOW TEMPERATURE SC A, V41, P99; Kojima K., 1970, LOW TEMP SCI A, V28, P175; Kondo J, 1996, BASIC KNOWLEDGE WATE, p[108, 128]; Kurashima E., 1991, J IRRIG DRAIN RURAL, V154, P99; Noto F., 2012, PADDY WATER ENV; Ohno H., 1998, SEPPYO, V60, P225; Storck P., 2002, WATER RESOUR RES, V38; Takayo M., 1984, STUDY MELTING SNOWFL, V8, P1; Takimoto H., 2014, J IRRIG DRAIN RURAL, V292, P9	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-1694	1879-2707		J HYDROL	J. Hydrol.	MAR	2015	522						369	381		10.1016/j.jhydrol.2014.12.036		13	Engineering, Civil; Geosciences, Multidisciplinary; Water Resources	Engineering; Geology; Water Resources	CD2OZ	WOS:000350920200031		
J	Nguyen, TT; Kawamura, A; Tong, TN; Nakagawa, N; Amaguchi, H; Gilbuena, R				Thuy Thanh Nguyen; Kawamura, Akira; Thanh Ngoc Tong; Nakagawa, Naoko; Amaguchi, Hideo; Gilbuena, Romeo, Jr.			Clustering spatio-seasonal hydrogeochemical data using self-organizing maps for groundwater quality assessment in the Red River Delta, Vietnam	JOURNAL OF HYDROLOGY			English	Article						SOM; Gibbs diagrams; Pleistocene confined aquifer; Major ions	WATER-QUALITY; STATISTICAL-ANALYSIS; CHEMISTRY DATA; CLASSIFICATION; AQUIFERS; BASIN; INDIA; PLAIN	The Red River Delta (RRD) is the second largest delta in Vietnam, and its local communities depend on groundwater sources for water supply. A clear understanding of the groundwater hydrogeochemical properties, particularly their changes from the dry to rainy seasons and spatial characteristics, is invaluable and indispensable for the management and protection of this important water resource. In this study, self-organizing maps was systematically applied for the first time to investigate the seasonal and spatial hydrogeochemical characteristics of groundwater in the Pleistocene confined aquifer of the RRD. The hydrogeochemical characteristics clustered by SOM were further examined using the Gibbs Diagrams. The groundwater chemistry dataset used in the analysis comprised eight major dissolved ions (i.e., Ca2+, Me2+, Na+, K+, HCO3-, Cl-, SO42-, and CO32-) and total dissolved solids that were collected from 52 groundwater monitoring wells within the study area during the dry and rainy seasons. Based on the results, the hydrogeochemical groundwater data of the confined aquifer monitoring wells for the delta were classified into 8 clusters, which revealed three basic representative water types: high salinity (2 clusters), low salinity (3 clusters), and freshwater (3 clusters). The high-salinity types were located in the middle-stream and coastal areas of the RRD, while the low-salinity types were observed near the western and northeastern boundaries of the delta. Cluster changes from the dry to rainy seasons were detected in approximately one-third of the observation wells. The increase in groundwater recharge during the rainy season is the main reason for these changes. Based on Gibbs diagrams, the source of soluble ions in the groundwater of the freshwater types was found to be the weathering of rock-forming minerals, while evaporation and marine activities (leaching from salty paleowater and salt water intrusion) were found to be the main factors affecting the chemistry of the groundwater characterized by the low- and high-salinity types, respectively. (C) 2015 Elsevier B.V. All rights reserved.	[Thuy Thanh Nguyen; Kawamura, Akira; Nakagawa, Naoko; Amaguchi, Hideo; Gilbuena, Romeo, Jr.] Tokyo Metropolitan Univ, Dept Civil & Environm Engn, Hachioji, Tokyo 1920397, Japan; [Thanh Ngoc Tong] Natl Ctr Water Resource Planning & Invest, Ho Chi Minh, Vietnam	Nguyen, TT (reprint author), Tokyo Metropolitan Univ, Dept Civil & Environm Engn, 1-1 Minami Oshawa, Hachioji, Tokyo 1920397, Japan.	nguyen-thanhthuy@ed.tmu.ac.jp			Tokyo Metropolitan Government, Japan	This study was carried out as a part of the research project "Solutions for the water related problems in Asian metropolitan areas" supported by the Tokyo Metropolitan Government, Japan (represented by Akira Kawamura). We would like to thank the Department of Geology and Minerals of Vietnam for supplying the necessary field data from the earlier feasibility studies.	Marghade D, 2012, ENVIRON MONIT ASSESS, V184, P2405, DOI 10.1007/s10661-011-2126-3; Drogue C, 2000, HYDROL EARTH SYST SC, V4, P332; Hall MJ, 1999, HYDROLOG SCI J, V44, P693, DOI 10.1080/02626669909492268; Nishiyama K, 2007, ATMOS RES, V83, P185, DOI 10.1016/j.atmosres.2005.10.015; Alberto WD, 2001, WATER RES, V35, P2881, DOI 10.1016/S0043-1354(00)00592-3; Hentati A, 2010, GEOMORPHOLOGY, V122, P56, DOI 10.1016/j.geomorph.2010.05.013; Guler C, 2002, HYDROGEOL J, V10, P455, DOI 10.1007/s10040-002-0196-6; Bui DD, 2012, HYDROGEOL J, V20, P1635, DOI 10.1007/s10040-012-0889-4; Jin YH, 2011, J ENVIRON MONITOR, V13, P2886, DOI 10.1039/c1em10132c; Jeong KS, 2010, ECOL INFORM, V5, P293, DOI 10.1016/j.ecoinf.2010.04.005; Astel A, 2004, ADV ENVIRON RES, V8, P337, DOI 10.1016/S1093-0191(02)00107-7; Nguyen TT, 2014, J ASIAN EARTH SCI, V93, P180, DOI 10.1016/j.jseaes.2014.07.035; Raju NJ, 2011, ENVIRON MONIT ASSESS, V173, P279, DOI 10.1007/s10661-010-1387-6; Guler C, 2004, WATER RESOUR RES, V40, DOI 10.1029/2004WR003299; Kalteh AM, 2008, ENVIRON MODELL SOFTW, V23, P835, DOI 10.1016/j.envsoft.2007.10.001; Vialle C, 2011, WATER RES, V45, P3765, DOI 10.1016/j.watres.2011.04.029; Srinivas VV, 2008, J HYDROL, V348, P148, DOI 10.1016/j.jhydrol.2007.09.046; Reghunath R, 2002, WATER RES, V36, P2437, DOI 10.1016/S0043-1354(01)00490-0; Zhang B, 2012, WATER RES, V46, P2737, DOI 10.1016/j.watres.2012.02.033; Leloup JA, 2007, CLIM DYNAM, V28, P147, DOI 10.1007/s00382-006-0173-1; Jalali M, 2009, ENVIRON GEOL, V56, P1479, DOI 10.1007/s00254-008-1245-9; Hong YST, 2003, WATER RES, V37, P1608, DOI 10.1016/S0043-1354(02)00494-3; Tanabe S, 2003, QUATERNARY SCI REV, V22, P2345, DOI 10.1016/S0277-3791(03)00138-0; Belkhiri L, 2011, INT J ENVIRON RES, V5, P537; Bui DuongDu, 2011, Geosciences Journal, V15, P323, DOI 10.1007/s12303-011-0024-x; El-Fiky A.A., 2009, EARTH SCI, V21, P79; Farsadnia E., 2014, J HYDROL, V509, P387; Gibbs R.J., 1970, SCIENCE, V17, P1970; Hilario L.G., 2004, ENG APPL ARTIF INTEL, V17, P215; Hussein MT, 2004, HYDROGEOL J, V12, P144, DOI 10.1007/s10040-003-0265-5; IMHE-MONRE, 2011, ANN REP HYDR OBS VIE; Iseri E., 2009, MEM FAC ENG KYUSHU U, V69, P37; Kohonen T., 2001, SELF ORGANIZING MAPS; Lambrakis N, 2004, WATER RES, V38, P1862, DOI 10.1016/j.watres.2004.01.009; Ministry of Natural Resources and Environment (MONRE), 2008, NAT TECHN REG UND WA; Su M.C., 2002, TAMKANG J SCI ENG, V5, P35; Subyani A.M., 2009, EARTH SCI, V21, P29; Tong T.N, 2004, NATL HYDROGEOLOGY DA; Tran LT, 2012, HYDROGEOL J, V20, P1295, DOI 10.1007/s10040-012-0874-y; Vesanto J., 2000, A57 HELS U TECHN; Vietnam General Statics Office, 2013, STAT HDB VIETN; Wagner F., 2012, EGU GEN ASSEM, V14, P2273; Wallner M, 2013, J HYDROL, V494, P59, DOI 10.1016/j.jhydrol.2013.04.022; Winkel LE, 2011, ARSENIC POLLUTION GR; Yidana SM, 2010, J AFR EARTH SCI, V58, P220, DOI 10.1016/j.jafrearsci.2010.03.003	45	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-1694	1879-2707		J HYDROL	J. Hydrol.	MAR	2015	522						661	673		10.1016/j.jhydrol.2015.01.023		13	Engineering, Civil; Geosciences, Multidisciplinary; Water Resources	Engineering; Geology; Water Resources	CD2OZ	WOS:000350920200054		
J	Peltokorpi, V				Peltokorpi, Vesa			Corporate Language Proficiency and Reverse Knowledge Transfer in Multinational Corporations: Interactive Effects of Communication Media Richness and Commitment to Headquarters	JOURNAL OF INTERNATIONAL MANAGEMENT			English	Article						Media richness; Knowledge transfer; Language; Headquarters commitment	SUBSIDIARY ABSORPTIVE-CAPACITY; FOREIGN SUBSIDIARIES; PERFORMANCE; FLOWS; ORGANIZATIONS; OPERATIONS; ATTENTION; BUSINESS; BEHAVIOR; ADOPTION	While corporate language proficiency provides the ability for employees in foreign subsidiaries to transfer knowledge to headquarters (HQ) in multinational corporations, this topic has received relatively little attention in international management research. In this paper, I link host country national (HCN) employee corporate language proficiency to reverse knowledge transfer. In addition to its direct effect, I draw on media richness theory and related research to hypothesize that communication media richness has a mediating effect between HCN corporate language proficiency and reverse knowledge transfer. As employees also need to be motivated to transfer knowledge to HQ, I draw on ability-motivation frameworks to hypothesize that HCN employee commitment to HQ has a moderating effect between communication media richness and reverse knowledge transfer. Data derived at two points in time from 661 functional departments of foreign subsidiaries in Japan provide support for the direct and interactive effects. (C) 2014 Elsevier Inc. All rights reserved.	Japan Adv Inst Sci & Technol, Nomi, Ishikawa 9231292, Japan	Peltokorpi, V (reprint author), Japan Adv Inst Sci & Technol, 1-1 Asahidai, Nomi, Ishikawa 9231292, Japan.	vesap@jaist.ac.jp					Aiken L. S., 1991, MULTIPLE REGRESSION; Michailova S, 2012, J WORLD BUS, V47, P383, DOI 10.1016/j.jwb.2011.05.006; Harzing AW, 2013, J WORLD BUS, V48, P87, DOI 10.1016/j.jwb.2012.06.011; Monteiro LF, 2008, ORGAN SCI, V19, P90, DOI 10.1287/orsc.1070.0264; Piekkari R, 2013, INT BUS REV, V22, P771, DOI 10.1016/j.ibusrev.2012.12.004; Takeuchi R, 2007, J APPL PSYCHOL, V92, P1069, DOI 10.1037/0021-9010.92.4.1069; Mudambi R, 2014, LONG RANGE PLANN, V47, P49, DOI 10.1016/j.lrp.2013.08.013; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; KOGUT B, 1988, J INT BUS STUD, V19, P411, DOI 10.1057/palgrave.jibs.8490394; GHOSHAL S, 1988, J INT BUS STUD, V19, P365, DOI 10.1057/palgrave.jibs.8490388; Nobel R, 1998, STRATEGIC MANAGE J, V19, P479, DOI 10.1002/(SICI)1097-0266(199805)19:5<479::AID-SMJ954>3.3.CO;2-L; Harzing AW, 2011, J WORLD BUS, V46, P279, DOI 10.1016/j.jwb.2010.07.005; Peltokorpi V, 2012, J INT BUS STUD, V43, P808, DOI 10.1057/jibs.2012.28; Gupta AK, 2000, STRATEGIC MANAGE J, V21, P473, DOI 10.1002/(SICI)1097-0266(200004)21:4<473::AID-SMJ84>3.0.CO;2-I; Cabrera A, 2002, ORGAN STUD, V23, P687, DOI 10.1177/0170840602235001; Tsai WP, 1998, ACAD MANAGE J, V41, P464, DOI 10.2307/257085; Chang YY, 2012, ACAD MANAGE J, V55, P927, DOI 10.5465/amj.2010.0985; Kostova T, 2002, ACAD MANAGE J, V45, P215, DOI 10.2307/3069293; Wu WY, 2007, J INF SCI, V33, P275, DOI 10.1177/0165551506070730; Noorderhaven N, 2009, J INT BUS STUD, V40, P719, DOI 10.1057/jibs.2008.106; Subramaniam M, 2001, STRATEGIC MANAGE J, V22, P359, DOI 10.1002/smj.163.abs; DAFT RL, 1986, MANAGE SCI, V32, P554, DOI 10.1287/mnsc.32.5.554; DAFT RL, 1984, RES ORGAN BEHAV, V6, P191; Govindarajan V, 2001, MIT SLOAN MANAGE REV, V42, P63; Ambos TC, 2006, INT BUS REV, V15, P294, DOI 10.1016/j.ibusrev.2006.01.002; Ambos TC, 2009, J INT MANAG, V15, P1, DOI 10.1016/j.intman.2008.02.002; Bouquet C, 2008, ACAD MANAGE J, V51, P577; Reiche BS, 2009, J INT BUS STUD, V40, P509, DOI 10.1057/jibs.2008.86; Rabbiosi L, 2011, J INT MANAG, V17, P97, DOI 10.1016/j.intman.2010.10.001; Welch DE, 2008, MANAGE INT REV, V48, P339, DOI 10.1007/s11575-008-0019-7; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Schomaker MS, 2014, J INT MANAG, V20, P55, DOI 10.1016/j.intman.2013.10.004; Bouquet C, 2009, J INT BUS STUD, V40, P108, DOI 10.1057/jibs.2008.64; Peltokorpi V, 2014, J INT BUS STUD, V45, P600, DOI 10.1057/jibs.2014.1; Neeley TB, 2013, ORGAN SCI, V24, P476, DOI 10.1287/orsc.1120.0739; Minbaeva D, 2003, J INT BUS STUD, V34, P586, DOI 10.1057/palgrave.jibs.8400056; Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185; Takeuchi R, 2002, INT J HUM RESOUR MAN, V13, P1224, DOI 10.1080/09585190210149493; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9101.88.5.879; JAMES LR, 1984, J APPL PSYCHOL, V69, P85, DOI 10.1037/0021-9010.69.1.85; KOGUT B, 1993, J INT BUS STUD, V24, P625, DOI 10.1057/palgrave.jibs.8490248; Golden TD, 2010, J ORGAN BEHAV, V31, P1061, DOI 10.1002/job.652; Barner-Rasmussen W., 2007, MANAGEMENT ORG REV, V3, P105, DOI 10.1111/j.1740-8784.2007.00060.x; Bliese P, 2000, MULTILEVEL THEORY RE, P349; Brislin R., 1980, HDB CROSS CULTURAL P, V2, P349; Buckley P., 2005, INT STUDIES MANAGEME, V35, P47; Charles M., 2002, BUSINESS COMMUNICATI, V65, P9, DOI 10.1177/108056990206500202; Clement R., 2002, NEW HDB LANGUAGE SOC, P489; Cohen J., 2003, APPL MULTIPLE REGRES; Fan X, 2008, FIELD METHOD, V20, P249; Foss N. J., 2002, J INT MANAG, V8, P49, DOI DOI 10.1016/S1075-4253(01)00054-0; Hair J. F. Jr., 1998, MULTIVARIATE DATA AN; Harzing Anne-Wil, 2008, Cross Cultural Management, V15, DOI 10.1108/13527600810848827; Hayes A. F., 2013, INTRO MEDIATION MODE; Hofstede G., 2001, CULTURES CONSEQUENCE; JETRO, 2003, BUS ENV SURR FOR AFF; JETRO, 2004, SURV FOR FIRMS JAP; Koo C, 2011, INT J INFORM MANAGE, V31, P445, DOI 10.1016/j.ijinfomgt.2011.01.003; Klitmoller A, 2013, J WORLD BUS, V48, P398, DOI 10.1016/j.jwb.2012.07.023; Lauring Jakob, 2008, INT J CROSS CULTURAL, V8, P343, DOI DOI 10.1177/1470595808096673; Louhiala-Salminen L., 2002, 330 HELS SCH EC; Marschan-Piekkari R., 1999, INT BUSINESS REV, V8, P421, DOI DOI 10.1016/S0969-5931(99)00015-3; Mudambi R., 2002, J INT MANAG, V8, P1, DOI 10.1016/S1075-4253(02)00050-9; Ng TWH, 2013, PERS PSYCHOL, V66, P645, DOI 10.1111/peps.12025; Nunnally J. C., 1978, PSYCHOMETRIC THEORY; Pedersen T., 2003, MANAGE INT REV, V43, P69; Peltokorpi V, 2010, SCAND J MANAG, V26, P176, DOI 10.1016/j.scaman.2010.02.003; Piekkari R., 2009, HDB BUSINESS DISCOUR, P269; Reade C., 2003, J MANAGERIAL PSYCHOL, V18, P208, DOI DOI 10.1037/0021-9010.88.3.391; Research Toyo Keizai, 2013, FOR AFF CO JAP COMPR; Slangen AHL, 2011, J MANAGE STUD, V48, P1699, DOI 10.1111/j.1467-6486.2011.01013.x; Sobel M.E., 1982, SOCIOL METHODOL, V13, P290, DOI DOI 10.2307/270723; Sunaoshi Y, 2005, J WORLD BUS, V40, P57, DOI 10.1016/j.jwb.2004.10.005; Teigland R, 2009, J INT MANAG, V15, P15, DOI 10.1016/j.intman.2008.02.001; TOEFL, 2014, TEST SCOR DAT SUMM T; Williams C, 2011, J MANAGE STUD, V48, P1243, DOI 10.1111/j.1467-6486.2010.00996.x; Woodrow L., 2006, RELC J, V37, P308, DOI [10.1177/0033688206071315, DOI 10.1177/033688206071315]; Wright P. M., 2002, J MANAGE, V28, P248; Yoshihara H., 2001, EIGO KEIEISURU JIDAI	79	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1075-4253	1873-0620		J INT MANAG	J. Int. Manag.	MAR	2015	21	1					49	62		10.1016/j.intman.2014.11.003		14	Management	Business & Economics	CD1CV	WOS:000350812400004		
J	Numata, M; Kandasamy, P; Nagashima, Y; Fickes, R; Murphy, RC; Voelker, DR				Numata, Mari; Kandasamy, Pitchaimani; Nagashima, Yoji; Fickes, Rachel; Murphy, Robert C.; Voelker, Dennis R.			Phosphatidylinositol inhibits respiratory syncytial virus infection	JOURNAL OF LIPID RESEARCH			English	Article						phospholipids; pulmonary surfactant; immunology; inflammation; lung; epithelium; innate immunity; prophylaxis	MYCOPLASMA-PNEUMONIAE; DISTRESS SYNDROME; SURFACTANT; ADULTS; PHOSPHOLIPIDS; PROTEIN; ACTIVATION; DISEASE; ASTHMA; LUNG	Respiratory syncytial virus (RSV) infects nearly all children under age 2, and reinfection occurs throughout life, seriously impacting adults with chronic pulmonary diseases. Recent data demonstrate that the anionic pulmonary surfactant lipid phosphatidylglycerol (PG) exerts a potent antiviral effect against RSV in vitro and in vivo. Phosphatidylinositol (PI) is also an anionic pulmonary surfactant phospholipid, and we tested its antiviral activity. PI liposomes completely suppress interleukin-8 production from BEAS2B epithelial cells challenged with RSV. The presence of PI during viral challenge in vitro reduces infection by a factor of >10(3). PI binds RSV with high affinity, preventing virus attachment to epithelial cells. Intranasal inoculation with PI along with RSV in mice reduces the viral burden 30-fold, eliminates the influx of inflammatory cells, and reduces tissue histopathology. Pharmacological doses of PI persist for > 6 h in mouse lung. Pretreatment of mice with PI at 2 h prior to viral infection effectively suppresses inflammation and reduces the viral burden by 85%. These data demonstrate that PI has potent antiviral properties, a long residence time in the extracellular bronchoalveolar compartment, and a significant prophylaxis window. The findings demonstrate PG and PI have complementary roles as intrinsic, innate immune antiviral mediators in the lung.	[Numata, Mari; Kandasamy, Pitchaimani; Fickes, Rachel; Voelker, Dennis R.] Natl Jewish Hlth, Dept Med, Program Cell Biol, Denver, CO 80206 USA; [Nagashima, Yoji] Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 232, Japan; [Murphy, Robert C.] Univ Colorado, Dept Pharmacol, Denver, CO 80045 USA	Voelker, DR (reprint author), Natl Jewish Hlth, Dept Med, Program Cell Biol, Denver, CO 80206 USA.	voelkerd@njhealth.org			National Institutes of Health [HL073907]; state of Colorado [CBDEG-2009, CBDEG-2012]	This work was supported by National Institutes of Health Grant HL073907 (D.R.V.) and by the state of Colorado CBDEG-2009 (D.R.V.) and CBDEG-2012 (M.N.).	McKimm-Breschkin JL, 2004, J VIROL METHODS, V120, P113, DOI 10.1016/j.jviromet.2004.02.020; Marr N, 2012, INNATE IMMUN-LONDON, V18, P856, DOI 10.1177/1753425912444479; Numata M, 2012, AM J RESP CELL MOL, V46, P479, DOI 10.1165/rcmb.2011-0194OC; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Wright SM, 2000, J APPL PHYSIOL, V89, P1283; Numata M, 2013, J LIPID RES, V54, P2133, DOI 10.1194/jlr.M037077; Numata M, 2010, P NATL ACAD SCI USA, V107, P320, DOI 10.1073/pnas.0909361107; Hallak LK, 2000, VIROLOGY, V271, P264, DOI 10.1006/viro.2000.0293; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; Mueller M, 2005, J IMMUNOL, V174, P1091; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Tayyari F, 2011, NAT MED, V17, P1132, DOI 10.1038/nm.2444; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Tripp RA, 2001, NAT IMMUNOL, V2, P732, DOI 10.1038/90675; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Hashimoto M, 2003, J BIOL CHEM, V278, P44205, DOI 10.1074/jbc.M306735200; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Whimbey E, 2000, CURR CLIN TOPICS INF, V20, P232; Kuronuma K, 2009, J BIOL CHEM, V284, P25488, DOI 10.1074/jbc.M109.040832; CIMOLAI N, 1992, MICROBIOL IMMUNOL, V36, P465; Erpenbeck VJ, 2005, AM J PHYSIOL-LUNG C, V288, pL692, DOI 10.1152/ajplung.00362.2004; Dakhama Azzeddine, 2005, Pediatr Infect Dis J, V24, pS159, DOI 10.1097/01.inf.0000188155.46381.15; Falsey AR, 2007, SEMIN RESP CRIT CARE, V28, P171, DOI 10.1055/s-2007-976489; Falsey AR, 2006, AM J RESP CRIT CARE, V173, P639, DOI 10.1164/rccm.200510-1681OC; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HALLMAN M, 1994, CLIN PHARMACOKINET, V26, P215, DOI 10.2165/00003088-199426030-00005; Kandasamy P, 2011, J BIOL CHEM, V286, P7841, DOI 10.1074/jbc.M110.170241; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Numata M, 2012, EXPERT REV RESP MED, V6, P243, DOI [10.1586/ers.12.21, 10.1586/ERS.12.21]; Numata M, 2013, INT J NANOMED, V8, P1417, DOI 10.2147/IJN.S39888; Schmidt R, 2002, AM J PHYSIOL-LUNG C, V283, pL1079, DOI 10.1152/ajplung.00484.2001; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; Wang PY, 1998, J BIOL CHEM, V273, P24309, DOI 10.1074/jbc.273.38.24309	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0022-2275	1539-7262		J LIPID RES	J. Lipid Res.	MAR	2015	56	3					578	587		10.1194/jlr.M055723		10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CC4TF	WOS:000350345900010		
J	Zhao, Y; Ishigami, M; Nagao, K; Hanada, K; Kono, N; Arai, H; Matsuo, M; Kioka, N; Ueda, K				Zhao, Yu; Ishigami, Masato; Nagao, Kohjiro; Hanada, Kentaro; Kono, Nozomu; Arai, Hiroyuki; Matsuo, Michinori; Kioka, Noriyuki; Ueda, Kazumitsu			ABCB4 exports phosphatidylcholine in a sphingomyelin-dependent manner	JOURNAL OF LIPID RESEARCH			English	Article						ATP binding cassette protein; ATP binding cassette transporter A1; myriosin; cholesterol; high density lipoprotein; (1R,3S)-N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecanamide; bile acid	FAMILIAL INTRAHEPATIC CHOLESTASIS; CHOLESTEROL EFFLUX; P-GLYCOPROTEIN; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID METABOLISM; CERAMIDE TRAFFICKING; CANALICULAR MEMBRANE; MULTIDRUG-RESISTANCE; LIPID EFFLUX; A-I	ABCB4, which is specifically expressed on the canalicular membrane of hepatocytes, exports phosphatidylcholine (PC) into bile. Because SM depletion increases cellular PC content and stimulates PC and cholesterol efflux by ABCA1, a key transporter involved in generation of HDL, we predicted that SM depletion also stimulates PC efflux through ABCB4. To test this prediction, we compared the lipid efflux activity of ABCB4 and ABCA1 under SM depletion induced by two different types of inhibitors for SM synthesis, myriocin and (1R, 3S)-N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide, in human embryonic kidney 293 and baby hamster kidney cells. Unexpectedly, SM depletion exerted opposite effects on ABCB4 and ABCA1, suppressing PC efflux through ABCB4 while stimulating efflux through ABCA1. Both ABCB4 and ABCA1 were recovered from Triton-X-100-soluble membranes, but ABCB4 was mainly recovered from CHAPS-insoluble SM-rich membranes, whereas ABCA1 was recovered from CHAPS-soluble membranes. These results suggest that a SM-rich membrane environment is required for ABCB4 to function. ABCB4 must have evolved to exert its maximum activity in the SM-rich membrane environment of the canalicular membrane, where it transports PC as the physiological substrate.	[Zhao, Yu; Nagao, Kohjiro; Ueda, Kazumitsu] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Kyoto 6068502, Japan; [Ishigami, Masato; Matsuo, Michinori; Kioka, Noriyuki; Ueda, Kazumitsu] Kyoto Univ, Grad Sch Agr, Lab Cellular Biochem, Div Appl Life Sci, Kyoto 6068502, Japan; [Hanada, Kentaro] Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; [Kono, Nozomu; Arai, Hiroyuki] Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo 1130033, Japan	Ueda, K (reprint author), Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation; World Premier International Research Center Initiative, MEXT	This work was supported by a Grant-in-Aid for Scientific Research (S) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation. This work was supported by the World Premier International Research Center Initiative, MEXT.	Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; ALVARO D, 1986, BIOMED BIOCHIM ACTA, V45, P761; Delgado A, 2006, BBA-BIOMEMBRANES, V1758, P1957, DOI 10.1016/j.bbamem.2006.08.017; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Kumagai K, 2005, J BIOL CHEM, V280, P6488, DOI 10.1074/jbc.M409290200; UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X; Duris A, 2011, ORG LETT, V13, P1642, DOI 10.1021/ol2001057; Deleuze JF, 1996, HEPATOLOGY, V23, P904, DOI 10.1002/hep.510230435; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Lucena JF, 2003, GASTROENTEROLOGY, V124, P1037, DOI 10.1053/gast.2003.50144; Hojjati MR, 2006, J LIPID RES, V47, P673, DOI 10.1194/jlr.D500040-JLR200; Morita S, 2007, HEPATOLOGY, V46, P188, DOI 10.1002/hep.21591; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Oram JF, 2001, J BIOL CHEM, V276, P39898, DOI 10.1074/jbc.M106984200; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Guyot C, 2011, J HEPATOL, V55, P1368, DOI 10.1016/j.jhep.2011.04.014; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Hirayama H, 2013, J LIPID RES, V54, P496, DOI 10.1194/jlr.M033209; Hozoji M, 2008, J BIOL CHEM, V283, P30057, DOI 10.1074/jbc.M804599200; Ismair MG, 2009, HEPATOLOGY, V49, P1673, DOI 10.1002/hep.22807; Kobayashi A, 2006, J LIPID RES, V47, P1791, DOI 10.1194/jlr.M500546-JLR200; Kudo N, 2010, J MOL BIOL, V396, P245, DOI 10.1016/j.jmb.2009.12.029; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; Morita S, 2013, J LIPID RES, V54, P1221, DOI 10.1194/jlr.M032425; Nagao K, 2007, J BIOL CHEM, V282, P14868, DOI 10.1074/jbc.M611230200; Nagao K, 2009, J LIPID RES, V50, P1165, DOI 10.1194/jlr.M800597-JLR200; OHTA K, 1993, J FERMENT BIOENG, V75, P155, DOI 10.1016/0922-338X(93)90229-2; Oude Elferink RP, 2007, PFLUGERS ARCH, V453, P601; Sano O, 2007, J LIPID RES, V48, P2377, DOI 10.1194/jlr.M700139-JLR200; Ueno K., 2013, ORG LETT, V15, P2869; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0022-2275	1539-7262		J LIPID RES	J. Lipid Res.	MAR	2015	56	3					644	652		10.1194/jlr.M056622		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CC4TF	WOS:000350345900016		
J	Morita, H				Morita, Hiroshi			State-dependent effects of fiscal policy in Japan: Do rule-of-thumb households increase the effects of fiscal policy?	JOURNAL OF MACROECONOMICS			English	Article						Fiscal policy; State-dependence; Rule-of-thumb household; Markov-switching	GOVERNMENT SPENDING SHOCKS; MONETARY-POLICY; CONSUMPTION; OUTPUT; MODEL	This study empirically investigates whether macroeconomic effects of fiscal polity are affected by the existence of rule-of-thumb households in Japan. Motivated by existing theoretical formulations, we estimate a consumption function as extended to a Markov switching model and divide the sample period into two parts depending on the share of rule-of-thumb (ROT) households. Subsequently, we estimate a Vector Autoregression (VAR) model to investigate the effects of two types of fiscal policy shock: unanticipated and anticipated. The results are subjected to robustness checks and reveal that the share of ROT households rises after large negative shocks (i.e., oil shock, economic bubble burst, Lehman shock), and then (unanticipated) fiscal policy shock stimulates private consumption more effectively in the high ROT households' period. (c) 2014 Elsevier Inc. All rights reserved.	Hitotsubashi Univ, Japan Soc Promot Sci, Res Fellowship Young Scientists, Inst Econ Res, Kunitachi, Tokyo 1868603, Japan	Morita, H (reprint author), Hitotsubashi Univ, Japan Soc Promot Sci, Res Fellowship Young Scientists, Inst Econ Res, Naka 2-1, Kunitachi, Tokyo 1868603, Japan.	hiroshi.morita1013@gmail.com			Japan Society for the Promotion of Science (JSPS)	I would like to thank William D. Lastrapes (the editor) and the referee for their valuable comments and suggestions. I also acknowledge Etsuro Shioji, Naohito Abe, Toshiaki Watanabe, Takashi Kano, Tatsuyoshi Okimoto, Mototsugu Fukushige and participants in The 2013 Asian Meeting of the Econometric Society, The Ninth Annual Conference of Asia-Pacific Economic Association and International Conference "Frontiers in Macroeconometrics" held in Hitotsubashi University for their helpful comments and encouragement. I would like to express gratitude to the research fellowships of the Japan Society for the Promotion of Science (JSPS) for Young Scientists for the grant that made it possible to complete this study. Of course, all errors are my own.	Fry R, 2011, J ECON LIT, V49, P938, DOI 10.1257/jel.49.4.938; Tagkalakis A, 2008, J PUBLIC ECON, V92, P1486, DOI 10.1016/j.jpubeco.2007.11.007; Kameda K, 2014, JPN WORLD ECON, V31, P14, DOI 10.1016/j.japwor.2014.04.003; Inoue A, 2013, J ECONOMETRICS, V177, P1, DOI 10.1016/j.jeconom.2013.02.009; Lo MC, 2005, J MONEY CREDIT BANK, V37, P865, DOI 10.1353/mcb.2005.0054; CAMPBELL JY, 1989, NBER MACROECON ANN, V4, P185, DOI 10.2307/3584973; Auerbach AJ, 2012, AM ECON J-ECON POLIC, V4, P1, DOI 10.1257/pol.4.2.1; Mountford A, 2009, J APPL ECONOM, V24, P960, DOI 10.1002/jae.1079; Gali J, 2007, J EUR ECON ASSOC, V5, P227, DOI 10.1162/JEEA.2007.5.1.227; BAXTER M, 1993, AM ECON REV, V83, P315; Blanchard O, 2002, Q J ECON, V117, P1329, DOI 10.1162/003355302320935043; Fazzari S. M., 2013, 2012ECON27B AUSTR SC; Fisher JDM, 2010, ECON J, V120, P414, DOI 10.1111/j.1468-0297.2010.02355.x; Geweke J., 1999, ECONOMET REV, V18, P1, DOI 10.1080/07474939908800428; Geweke J, 1992, BAYESIAN STATISTICS, V4, P169, DOI DOI 10.1371/J0URNAL.P0NE.0059328; Kim C. J., 1999, STATE SPACE MODELS R; Kim CJ, 2004, J ECONOMETRICS, V122, P127, DOI 10.1016/j.jeconom.2003.10.021; Nakajima J, 2011, J JPN INT ECON, V25, P225, DOI 10.1016/j.jjie.2011.07.004; Owyang MT, 2013, AM ECON REV, V103, P129, DOI 10.1257/aer.103.3.129; Ramey VA, 2011, Q J ECON, V126, P1, DOI 10.1093/qje/qjq008; Uhlig H, 2005, J MONETARY ECON, V52, P381, DOI 10.1016/j.jmoneco.2004.05.007	21	0	0	LOUISIANA STATE UNIV PR	BATON ROUGE	BATON ROUGE, LA 70893 USA	0164-0704			J MACROECON	J. Macroecon.	MAR	2015	43						49	61		10.1016/j.jmacro.2014.09.002		13	Economics	Business & Economics	CD2TH	WOS:000350931400004		
J	Kuo, CH; Miyamoto, H				Kuo, Chun-Hung; Miyamoto, Hiroaki			Fiscal stimuli in the form of job creation subsidies	JOURNAL OF MACROECONOMICS			English	Article						Fiscal policy; Hiring subsidy; Unemployment; Search and matching	CYCLICAL BEHAVIOR; LABOR-MARKET; EQUILIBRIUM UNEMPLOYMENT; VACANCIES; DESTRUCTION; CONSUMPTION; SEARCH; PUZZLE	This paper examines the effects of fiscal stimuli in the form of job creation subsidies in a DSGE model with search friction and endogenous job separation. We consider two types of job creation subsidies: a subsidy for the cost of posting vacancies and a hiring subsidy. This paper finds that the effects of job creation subsides on unemployment differ between models with and without endogenous job separation. While a positive job creation subsidy shock lowers unemployment in a model without endogenous job separation, it increases unemployment in a model with endogenous job separation. We also find that while qualitatively the effects of a vacancy cost subsidy on the economy are similar to those of a hiring subsidy, quantitatively they are different. (c) 2015 Elsevier Inc. All rights reserved.	[Kuo, Chun-Hung] Int Univ Japan, Minami Uonuma, Niigata 9497277, Japan; [Miyamoto, Hiroaki] Univ Tokyo, Bunkyo Ku, Tokyo 1130033, Japan	Miyamoto, H (reprint author), Univ Tokyo, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	chkuo@iuj.ac.jp; miyamoto@pp.u-tokyo.ac.jp			Kakenhi [26380248]; IUJ Research Institute research fund	Part of this research is supported by the Grant-in-Aid for Scientific Research (C) (Kakenhi No. 26380248) and IUJ Research Institute research fund.	Andolfatto D, 1996, AM ECON REV, V86, P112; Pissarides CA, 2009, ECONOMETRICA, V77, P1339; Monacelli T, 2010, J MONETARY ECON, V57, P531, DOI 10.1016/j.jmoneco.2010.05.009; Bruckner M, 2012, INT ECON REV, V53, P1205, DOI 10.1111/j.1468-2354.2012.00717.x; MORTENSEN DT, 1994, REV ECON STUD, V61, P397, DOI 10.2307/2297896; Linnemann L, 2006, J MONEY CREDIT BANK, V38, P1715, DOI 10.1353/mcb.2006.0094; Petrongolo B, 2001, J ECON LIT, V39, P390, DOI 10.1257/jel.39.2.390; Merz M, 1995, J MONETARY ECON, V36, P269, DOI 10.1016/0304-3932(95)01216-8; Mortensen DT, 2007, REV ECON DYNAM, V10, P327, DOI 10.1016/j.red.2007.01.004; Gali J, 2007, J EUR ECON ASSOC, V5, P227, DOI 10.1162/JEEA.2007.5.1.227; Shimer R, 2005, AM ECON REV, V95, P25, DOI 10.1257/0002828053828572; Hagedorn M, 2008, AM ECON REV, V98, P1692, DOI 10.1257/aer.98.4.1692; BAXTER M, 1993, AM ECON REV, V83, P315; Brown A., MACROECON D IN PRESS; Campolmi A., 2011, BE J MACROECON, V11; Davis S. J., 2006, 12167 NBER; Elsby M., 2008, 13777 NBER; Faia E, 2013, J ECON DYN CONTROL, V37, P483, DOI 10.1016/j.jedc.2012.09.004; Kitao S, 2011, ECON LETT, V113, P248, DOI 10.1016/j.econlet.2011.08.001; Lubik T. A., 2009, EC Q, V95, P101; Mortensen D. T., 1999, HDB MACROECONOMICS B, V1, P1171, DOI 10.1016/S1574-0048(99)10026-0; Nagypal E., 2004, WORKER REALLOC UNPUB; Pissarides C., 2000, EQUILIBRIUM UNEMPLOY; Pissarides C.A., 2007, 839 CEP; Silva JI, 2009, MACROECON DYN, V13, P76, DOI 10.1017/S1365100509080122	25	0	0	LOUISIANA STATE UNIV PR	BATON ROUGE	BATON ROUGE, LA 70893 USA	0164-0704			J MACROECON	J. Macroecon.	MAR	2015	43						267	284		10.1016/j.jmacro.2014.12.004		18	Economics	Business & Economics	CD2TH	WOS:000350931400019		
J	Umeda, N				Umeda, Naoya			Untitled	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Editorial Material									Osaka Univ, Dept Naval Architecture & Ocean Engn, Suita, Osaka 5650871, Japan	Umeda, N (reprint author), Osaka Univ, Dept Naval Architecture & Ocean Engn, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	umeda@naoe.eng.osaka-u.ac.jp						0	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					1	1		10.1007/s00773-015-0310-9		1	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500001		
J	Strasser, G; Takagi, K; Werner, S; Hollenbach, U; Tanaka, T; Yamamoto, K; Hirota, K				Strasser, Gerhard; Takagi, Ken; Werner, Sofia; Hollenbach, Uwe; Tanaka, Taichi; Yamamoto, Kotaku; Hirota, Kazuyoshi			A verification of the ITTC/ISO speed/power trials analysis	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Article						Speed/power trials; Propulsive performance; Current correction; Guideline		Speed and power (S/P) trials are most important to guarantee the ship's propulsive performance. However, it was pointed out that the existing procedures often give a good guideline, but are not specific and can introduce inconsistent results. Recently, ITTC and ISO have improved their S/P trials procedures and harmonized the two procedures. During the harmonization process, we have verified the 'Mean of Means' (MoM) method and the 'Iterative' method which are used as the current correction methods and the 'Direct Power Method' and the 'Extended Power Method' which are applied for the evaluation of the acquired data. The results of verification are presented in this paper. The results show that using the 'MoM' method for each power setting, two double runs should be made to keep the accuracy of S/P trials, and the 'Iterative' method leads to less errors in average of the tested cases when 1 + 2 + 2 double runs are used in the 'MoM' method, although the methods are equally adequate if the time periods between the runs are short enough. In specific cases, e.g. in case of large speed range and/or humps and hollows within the speed-power curve, the 'MoM' method has advantages over the 'Iterative' method. In case of current time history deviating from the assumed parabolic/sinusoidal trend and the change of the current within the time span of two double runs is very high, neither of the methods are applicable. Summarizing the results, the 'Iterative' method is fully compatible with the simple 'Direct Power Method'.	[Strasser, Gerhard; Takagi, Ken; Werner, Sofia; Hollenbach, Uwe; Tanaka, Taichi; Yamamoto, Kotaku; Hirota, Kazuyoshi] Univ Tokyo, Tokyo, Japan	Takagi, K (reprint author), Univ Tokyo, Tokyo, Japan.	takagi@k.u-tokyo.ac.jp					[Anonymous], 2012, 6323 MEPC; [Anonymous], 2006, REC PRACT SPEED TRIA; [Anonymous], 1969, P 12 ITTC APP 1 ROM, P194; [Anonymous], 2015, ISO15016; [Anonymous], 2014, MAR ENV PROT COMM 63; [Anonymous], 2013, MAR ENV PROT COMM 65; [Anonymous], 1996, P 21 ITTC APP 1 TRON, V1; [Anonymous], 2002, ISO15016; BSRA, 1978, 466 BSRA NS; ITTC, 2012, 64INF6 MEPC; ITTC, 2013, 65INF7 MEPC; Norway, 2011, 6255 MEPC; Society of Naval Architects and Marine Engineers Ship's Machinery Committee, 1989, SOC NAV ARCH MAR ENG; Society of Naval Architects and Marine Engineers Technical and Research Program, 1973, SOC NAV ARCH MAR ENG; The Specialist Committee on Speed and Powering Trials, 2002, P 23 ITTC, VII; The Specialist Committee on Trials and Monitoring, 1999, P 22 ITTC, VII	16	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					2	13		10.1007/s00773-015-0304-7		12	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500002		
J	Kaneko, F; Arima, T; Yoshida, K; Yuzui, T				Kaneko, Fujio; Arima, Toshiro; Yoshida, Koichi; Yuzui, Tomohiro			On a novel method for approximation of FN diagram and setting ALARP borders	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Article						FN diagram; Power law with maximum value; Approximation function; ALARP border	POWER-LAW DISTRIBUTIONS; EMPIRICAL-DATA	This article thoroughly reviews the state-of-the-art methods for setting ALARP upper border as a straight line in logarithmic graph, which is the common practice in the risk assessments of nuclear, chemical plants and maritime facilities. It also reviews methods for setting ALARP upper border based on economic importance of a considered ship type. As a result, inconsistency related to ALARP upper border has been identified and new methods to resolve such inconsistency are developed. Here, firstly a method for approximating FN diagrams of existing major ship types is proposed and it is applied to ship types which consist of ships above 100 gross tonnage. After that the approximated FN diagrams were checked by goodness-of-fit test by 5 % significance level, and it was validated that those approximated FN diagrams well express corresponding FN diagrams made from IHSF casualty and ship databases. This method can extrapolate FN diagrams made from those databases to the area of severer accidents with more fatalities, which have not been occurred yet, rationally. Secondly, problems that accompany with an existing method for setting ALARP upper border are discussed and methods for resolving the problems using the approximated FN diagrams are proposed. The methods can set ALARP upper border keeping consistency of ALARP upper border between individual risk and FN diagram. Lastly, the new method for safety analysis of ships using approximated FN diagrams of major ship types is introduced. The method is used in order to find ships' groups which should be considered preferentially. The method for approximating FN diagrams and the method for setting ALARP upper border proposed here is so general that they can be applied to risk analysis of the fields which have a lot of accident records like maritime field, such as aviation or automotive fields.	[Kaneko, Fujio; Arima, Toshiro; Yuzui, Tomohiro] Natl Maritime Res Inst, Mitaka, Tokyo, Japan; [Yoshida, Koichi] Yokohama Natl Univ, Ctr Ocean Studies & Integrated Educ, Yokohama, Kanagawa 240, Japan	Kaneko, F (reprint author), Natl Maritime Res Inst, Mitaka, Tokyo, Japan.	kaneko@nmri.go.jp					VRIJLING JK, 1995, J HAZARD MATER, V43, P245, DOI 10.1016/0304-3894(95)91197-V; Clauset A, 2009, SIAM REV, V51, P661, DOI 10.1137/070710111; IChemE, 2009, IND REV HSE METH ASS; IMO, 2013, MSCMEPC2CIRC IMO; Japan, 2002, 7552 MSC; Japan, 2006, 51101 FP; Japan, 2013, REV DAMAGE STABILITY; Japan, 2006, 5262 NAV; Jonkman SN, 2003, J HAZARD MATER, V99, P1, DOI 10.1016/S0304-3894(02)00283-2; Kaneko F, 2014, P 24 ISOPE BUS, V4, P579; KOWALIK J. S., 1968, METHODS UNCONSTRAINE; Papanikolaou AD, 2009, RISK BASED DESIGN ME; Quinn DJ, 2004, 283 HSE UK; Shao J, 2003, MATH STAT, P437; Train K. E., 2008, J CHOICE MODEL, V1, P40; UK, 2002, 7655 MSC; Virkar Y, 2014, ANN APPL STAT, V8, P89, DOI 10.1214/13-AOAS710	17	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					14	36		10.1007/s00773-015-0305-6		23	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500003		
J	Yasukawa, H; Yoshimura, Y				Yasukawa, H.; Yoshimura, Y.			Introduction of MMG standard method for ship maneuvering predictions	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Review						MMG standard method; MMG model; Maneuvering prediction; KVLCC2; Captive model tests		A lot of simulation methods based on Maneuvering Modeling Group (MMG) model for ship maneuvering have been presented. Many simulation methods sometimes harm the adaptability of hydrodynamic force data for the maneuvering simulations since one method may be not applicable to other method in general. To avoid this, basic part of the method should be common. Under such a background, research committee on "standardization of mathematical model for ship maneuvering predictions" was organized by the Japan Society of Naval Architects and Ocean Engineers and proposed a prototype of maneuvering prediction method for ships, called "MMG standard method". In this article, the MMG standard method is introduced. The MMG standard method is composed of 4 elements; maneuvering simulation model, procedure of the required captive model tests to capture the hydrodynamic force characteristics, analysis method for determining the hydrodynamic force coefficients for maneuvering simulations, and prediction method for maneuvering motions of a ship in fullscale. KVLCC2 tanker is selected as a sample ship and the captive mode test results are presented with a process of the data analysis. Using the hydrodynamic force coefficients presented, maneuvering simulations are carried out for KVLCC2 model and the fullscale ship for validation of the method. The present method can roughly capture the maneuvering motions and is useful for the maneuvering predictions in fullscale.	[Yasukawa, H.] Hiroshima Univ, Grad Sch Engn, Higashihiroshima 724, Japan; [Yoshimura, Y.] Hokkaido Univ, Grad Sch Fisheries Sci, Hakodate, Hokkaido, Japan	Yasukawa, H (reprint author), Hiroshima Univ, Grad Sch Engn, Higashihiroshima 724, Japan.	yasukawa@naoe.hiroshima-u.ac.jp					[Anonymous], 2013, REP RES COMM STAND M; [Anonymous], 2008, WORKSH VER VAL SHIP, V1, pB7; Fujii H, 1961, J SOC NAV ARCHIT JPN, V110, P31; Hess F, 1978, INT SHIPBUILD PROG, V25, P299; Hirano M, 1982, T W JPN SOC NAVAL AR, V64, P93; Inoue S., 1981, INT SHIPBUILD PROGR, V28, P207; Karasuno K, 1969, J KANSAI SOC NAVAL A, V133, P14; Kose K., 1981, P 3 S SHIP MAN SOC N, P27; Matsumoto K, 1980, J KANSAI SOC NAVAL A, V176, P11; Motora S, 1959, J SOC NAVAL ARCHITEC, V105, P83; Motora S., 1960, J SOC NAVAL ARCHITEC, V106, P59; Motora S, 1960, J SOC NAVAL ARCHITEC, V106, P63; Ogawa A, 1977, B SOC NAVAL ARCHIT J, V575, P22; Ogawa A., 1978, INT SHIPBUILD PROG, V25, P306; Yasukawa H, 1992, T W JPN SOC NAVAL AR, V84, P59; Yoshimura Y., 2008, P WORKSH VER VAL SHI, V1, pE80; Yoshimura Y, 1986, J KANSAI SOC NAVAL A, V200, P41	17	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					37	52		10.1007/s00773-014-0293-y		16	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500004		
J	Yudo, H; Yoshikawa, T				Yudo, Hartono; Yoshikawa, Takao			Buckling phenomenon for straight and curved pipe under pure bending	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Article						Buckling strength; Straight pipe; Curved pipe; Oval deformation; Pure bending	CYLINDRICAL-SHELLS	Not only straight pipes, but also the curved ones are used in an actual pipeline. In designing such a pipeline, it is important to know the buckling strength of the pipe under various kinds of loads. Especially, it is well known that the buckling moment will be reduced by increasing the pipe's length. However, comprehensive studies for the buckling strength of straight and curved pipe under bending loads are still limited. In this research, the previous research for the buckling strength of pipe under bending moments was reviewed. It is well known that the cross-sectional oval deformation takes place and the buckling strength of pipe is reduced due to this deformation. Therefore, secondly, the buckling phenomenon for a straight pipe under a pure bending moment was investigated by nonlinear FEA, considering the effect of a cross-sectional oval deformation by changing the varying of pipes, that is, the length-to-diameter ratio (L/D) varying from about 5 to 20 and the diameter-to-thickness ratio (D/t) varying from about 50 to 200. Thirdly, the buckling phenomenon for curved pipe was also investigated by changing the R/D from 50 to 200 where R is the curvature radius of curved pipe. From the results of the calculations for the straight pipe, the reduction rate of the buckling moment due to the oval deformation of pipe was clarified for various values of L/D and D/t, not only in elastic buckling, but also in elasto-plastic buckling. For the curved pipe, it was explained that the buckling moment will be reduced by lowering the value of R/D.	[Yudo, Hartono] Kyushu Univ, Grad Sch Engn, Dept Maritime Engn, Fukuoka 812, Japan; [Yoshikawa, Takao] Kyushu Univ, Fac Engn, Dept Marine Syst Engn, Fukuoka 812, Japan	Yudo, H (reprint author), Kyushu Univ, Grad Sch Engn, Dept Maritime Engn, Fukuoka 812, Japan.	hartono.yudo@kyudai.jp					JU GT, 1992, INT J SOLIDS STRUCT, V29, P1143, DOI 10.1016/0020-7683(92)90140-O; Brazier LG, 1927, P R SOC LOND A-CONTA, V116, P104, DOI 10.1098/rspa.1927.0125; Boussaa D, 1996, COMPUT STRUCT, V60, P1003, DOI 10.1016/0045-7949(96)00011-9; BOYLE JT, 1981, INT J SOLIDS STRUCT, V17, P515, DOI 10.1016/0020-7683(81)90058-5; Hauch S, 1999, OFFSHORE MECH ARCT E; Odland J, 1978, NORWEGIAN MARITIME R, V6, P2; Seide P, 1961, T ASME J APPL MECH, V28, P112; SUPERB, 1996, BUCKL COLL LIM STAT; Timoshenko S., 1959, THEORY PLATES SHELLS; Timoshenko S. P., 1961, THEORY ELASTIC STABI; Von Chwalla E, 1933, Z ANGEW MATH MECH, V13; Yudo H, 2012, P 26 AS TECHN EXCH A, P359; ZHANG LC, 1987, INT J PRES VES PIP, V30, P77, DOI 10.1016/0308-0161(87)90101-3	13	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					94	103		10.1007/s00773-014-0254-5		10	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500008		
J	Cho, H; Gu, J; Joe, H; Asada, A; Yu, SC				Cho, Hyeonwoo; Gu, Jeonghwe; Joe, Hangil; Asada, Akira; Yu, Son-Cheol			Acoustic beam profile-based rapid underwater object detection for an imaging sonar	JOURNAL OF MARINE SCIENCE AND TECHNOLOGY			English	Article						Underwater object detection; Imaging sonar; Rapid search; Acoustic beam profile; Cross-correlation	RECOGNITION; VEHICLE	In sonar applications, the ability to locate underwater structures such as pipelines and a wreckage of submerged airplane is important. To investigate extensive sections of the seabed within a limited time period, the scanning speed and the reliability of object detection alarms are the most critical factors for finding objects. In this paper, we propose a method to provide an automatic detection alarm indicating the presence of suspected underwater objects using high-speed imaging sonar. The proposed method is based on the cross-correlations between two successive acoustic beam profiles of imaging sonar. The alarm signal alerts human operators or automatic underwater vehicles to suspected objects, which may be a part of or all of the target object. Using this signal as a trigger, the object can then be examined in more detail to determine whether it is the target. We verified the feasibility of the proposed method by indoor and field experiments.	[Cho, Hyeonwoo] Pohang Univ Sci & Technol, Future IT Lab, Pohang 790784, Gyeongbuk, South Korea; [Gu, Jeonghwe; Joe, Hangil; Yu, Son-Cheol] Pohang Univ Sci & Technol, Dept Creat IT Engn, Pohang 790784, Gyeongbuk, South Korea; [Asada, Akira] Univ Tokyo, Institude Ind Sci, Tokyo 1538505, Japan	Yu, SC (reprint author), Pohang Univ Sci & Technol, Dept Creat IT Engn, Pohang 790784, Gyeongbuk, South Korea.	lighto@postech.ac.kr; bygu111@postech.ac.kr; roboticist@postech.ac.kr; asada@iis.u-tokyo.ac.jp; sncyu@postech.ac.kr			Ministry of Science, ICT and Future Planning, Korea, under the IT Consilience Creative Program [NIPA-2014-H0201-14-1001]; Civil Military Technology Cooperation Center; Ministry of Oceans and Fisheries, Korea	This research was supported by the Ministry of Science, ICT and Future Planning, Korea, under the IT Consilience Creative Program (NIPA-2014-H0201-14-1001), supervised by the NIPA National IT Industry Promotion Agency. This work was partly supported by the Civil Military Technology Cooperation Center. This research was a part of the project titled "Gyeongbuk Sea Grant Program", funded by the Ministry of Oceans and Fisheries, Korea.	Chaillan F, 2007, SIGNAL PROCESS, V87, P762, DOI 10.1016/j.sigpro.2006.08.001; Petillot Y, 2001, IEEE J OCEANIC ENG, V26, P240, DOI 10.1109/48.922790; Kondo H, 2004, CONTROL ENG PRACT, V12, P1551, DOI 10.1016/j.conengprac.2003.12.005; Mignotte M, 2000, IEEE T IMAGE PROCESS, V9, P1216, DOI 10.1109/83.847834; Aykin MD, 2012, OCEANS, V2012, P1; Belcher E.O., 2000, P UND INT 2000 C, P187; Caimi FM, 2008, OCEANS, V2008, P1; Daniel S, 1998, IEEE J OCEANIC ENG, V23, P245, DOI 10.1109/48.701197; Gu J-H, 2013, OC SAN DIEG, P1; Lee Y, 2013, INT CONF UBIQ ROBOT, P517; Nasahashi K, 2005, OCEANS EUR, V1, P557; Negahdaripour S., 2005, Proceedings. The 2nd Canadian Conference on Computer and Robot Vision; Orfanidis S.J., 1996, OPTIMUM SIGNAL PROCE; Zingaretti P, 1998, ENG APPL ARTIF INTEL, V11, P257, DOI 10.1016/S0952-1976(97)00001-8; Purcell M, 2011, OCEANS, V2011, P1; Reed S, 2003, IEEE J OCEANIC ENG, V28, P90, DOI 10.1109/JOE.2002.808199; Yu SC, 2006, OCEANS, V2006, P1; Yu SC, 2008, OCEAN ENG, V35, P90, DOI 10.1016/j.oceaneng.2007.07.010	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0948-4280	1437-8213		J MAR SCI TECH-JAPAN	J. Mar. Sci. Technol.	MAR	2015	20	1					180	197		10.1007/s00773-014-0294-x		18	Engineering, Marine; Engineering, Civil	Engineering	CC4MM	WOS:000350327500015		
J	Senthilkumar, R; Ravi, G; Sekar, C; Arivanandhan, M; Navaneethan, M; Hayakawa, Y				Senthilkumar, R.; Ravi, G.; Sekar, C.; Arivanandhan, M.; Navaneethan, M.; Hayakawa, Y.			Determination of gas sensing properties of thermally evaporated WO3 nanostructures	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN ELECTRONICS			English	Article							TUNGSTEN-OXIDE; ORIENTATION; SUBSTRATE; SENSORS; GROWTH; FILMS	Thin films of tungsten oxide (WO3) nano-structures were grown on indium tin oxide coated glass substrates by thermal evaporation technique under oxygen and argon (O-2/Ar) mixed gas atmosphere. The films were characterized by X-ray diffraction, Raman spectroscopy and field emission scanning electron microscopy to study the structural and morphological properties of the grown films. Three different shapes of nanostructures (one dimensional nanorods, two dimensional nanosheets and three dimensional nanosized orthorhombic structures) were formed due to the variations of growth conditions such as substrate temperature and oxygen/argon flow rate. In particular, the flow rate of oxygen plays an important role in controlling the nucleation and growth of WO3 nanostructures. The ethanol gas sensing properties of the films were investigated under different concentrations (10-50 ppm) at room temperature, which reveals that the sensitivity of the sensor was greatly enhanced with the increasing gas concentration. This result indicates that the WO3 films are good candidate for sensing ethanol gas in low concentration at room temperature.	[Senthilkumar, R.; Ravi, G.] Alagappa Univ, Dept Phys, Karaikkudi 630004, Tamil Nadu, India; [Sekar, C.] Alagappa Univ, Dept Bioelect & Biosensors, Karaikkudi 630004, Tamil Nadu, India; [Arivanandhan, M.; Navaneethan, M.; Hayakawa, Y.] Shizuoka Univ, Elect Res Inst, Hamamatsu, Shizuoka 4328011, Japan	Ravi, G (reprint author), Alagappa Univ, Dept Phys, Karaikkudi 630004, Tamil Nadu, India.	gravicrc@gmail.com	Arivanandhan, Mukannan/E-5411-2010				Baserga A, 2007, THIN SOLID FILMS, V515, P6465, DOI 10.1016/j.tsf.2006.11.067; Balazsi C, 2008, J EUR CERAM SOC, V28, P913, DOI 10.1016/j.jeurceramsoc.2007.09.001; Rahmani MB, 2010, SENSOR ACTUAT B-CHEM, V145, P13, DOI 10.1016/j.snb.2009.11.007; Baek Y, 2007, J PHYS CHEM C, V111, P1213, DOI 10.1021/jp0659857; Lee DS, 2000, THIN SOLID FILMS, V375, P142, DOI 10.1016/S0040-6090(00)01261-X; Li YN, 2010, CERAM INT, V36, P1917, DOI 10.1016/j.ceramint.2010.03.016; Guo YF, 2007, ENVIRON SCI TECHNOL, V41, P4422, DOI 10.1021/es062546c; Al-Sharab JF, 2009, CRYST GROWTH DES, V9, P4680, DOI 10.1021/cg900544k; Siciliano T, 2008, SENSOR ACTUAT B-CHEM, V133, P321, DOI 10.1016/j.snb.2008.02.028; Dai ZR, 2003, ADV FUNCT MATER, V13, P9, DOI 10.1002/adfm.200390013; Daothong S, 2010, J PHYS CHEM C, V114, P10, DOI 10.1021/jp9085975; Di Fonzo F, 2006, CATAL TODAY, V116, P69, DOI 10.1016/j.cattod.2006.02.080; Ghimbeu CM, 2010, MAT SCI SEMICON PROC, V13, P1, DOI 10.1016/j.mssp.2010.01.001; Huang K, 2007, APPL SURF SCI, V253, P8923, DOI 10.1016/j.apsusc.2007.05.006; Kim YS, 2009, SENSOR ACTUAT B-CHEM, V137, P297, DOI 10.1016/j.snb.2008.11.037; Li ZL, 2010, J CRYST GROWTH, V312, P520, DOI 10.1016/j.jcrysgro.2009.11.036; Lyashkov A. Yu., 2010, SENSOR ACTUAT B-CHEM, V148, P1; Senthil K, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/39/395604; Stankova M., 2005, Sensors and Actuators B (Chemical), V105, DOI 10.1016/j.snb.2004.06.009; Zhang H.X., 2008, J NE U, V1, P1; Zhang WD, 2009, J MATER SCI, V44, P4677, DOI 10.1007/s10853-009-3716-0	21	3	3	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4522	1573-482X		J MATER SCI-MATER EL	J. Mater. Sci.-Mater. Electron.	MAR	2015	26	3					1389	1394		10.1007/s10854-014-2552-4		6	Engineering, Electrical & Electronic; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Engineering; Materials Science; Physics	CC3CZ	WOS:000350223700015		
J	Xu, L; Zhu, KJ; Wang, J; Gu, QL; Cao, Y; Zheng, HJ; Liu, JS; Qiu, JH				Xu, Lan; Zhu, Kongjun; Wang, Jing; Gu, Qilin; Cao, Yang; Zheng, Hongjuan; Liu, Jinsong; Qiu, Jinhao			Microwave-assisted sol-hydrothermal synthesis of tetragonal barium titanate nanoparticles with hollow morphologies	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN ELECTRONICS			English	Article							BATIO3 NANOPARTICLES; GROWTH-MECHANISM; POWDERS; NANOCRYSTALS; NANOSTRUCTURES; PRECURSORS; ROUTE	Barium titanate (BaTiO3; BT) nanoparticles were synthesized via a sol-hydrothermal microwave method, which were tetragonal phase of BT nanoparticles with an average diameter of similar to 50 nm. The alkalinity of the initial hydrothermal solution considerably influenced the morphologies of the BT powders. Small amount of hollow and ring-like structure was observed at 5 M. The evolution of the time-dependent morphology revealed a possible formation mechanism. An aggregation, re-alignment, and ripening process is proposed to elucidate the formation of nanoparticles with different morphologies.	[Xu, Lan; Zhu, Kongjun; Wang, Jing; Gu, Qilin; Liu, Jinsong; Qiu, Jinhao] Nanjing Univ Aeronaut & Astronaut, Coll Aerosp Engn, State Key Lab Mech & Control Mech Struct, Nanjing 210016, Jiangsu, Peoples R China; [Cao, Yang] Tohoku Univ, Ctr Interdisciplinary Res, Sendai, Miyagi 9828578, Japan; [Zheng, Hongjuan] Kochi Univ, Res Lab Hydrothermal Chem, Fac Sci, Kochi 7808520, Japan	Zhu, KJ (reprint author), Nanjing Univ Aeronaut & Astronaut, Coll Aerosp Engn, State Key Lab Mech & Control Mech Struct, Nanjing 210016, Jiangsu, Peoples R China.	kjzhu@nuaa.edu.cn			National Nature Science Foundation of China (NSFC) [51372114, 51202118]; Doctoral Fund of the Ministry of Education of China [20120002120012]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); NUAA Fundamental Research Funds [NN2012018, NP2013301]	This work was supported by the National Nature Science Foundation of China (NSFC Nos. 51372114, 51202118), the Doctoral Fund of the Ministry of Education of China (Grant No. 20120002120012).), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the NUAA Fundamental Research Funds (Nos. NN2012018, NP2013301).	Penn RL, 2001, J PHYS CHEM B, V105, P2177, DOI 10.1021/jp003570u; KOMARNENI S, 1992, MATER RES BULL, V27, P1393, DOI 10.1016/0025-5408(92)90004-J; Bansal V, 2006, J AM CHEM SOC, V128, P11958, DOI 10.1021/ja063011m; Zhang MS, 2001, SOLID STATE COMMUN, V119, P659, DOI 10.1016/S0038-1098(01)00312-X; Ma Y, 1997, CHEM MATER, V9, P3023, DOI 10.1021/cm970371n; KAJIYOSHI K, 1991, J AM CERAM SOC, V74, P369, DOI 10.1111/j.1151-2916.1991.tb06889.x; Maxim F, 2008, CRYST GROWTH DES, V8, P3309, DOI 10.1021/cg800215r; Kang SO, 2008, CRYST GROWTH DES, V8, P3180, DOI 10.1021/cg700795q; Cao Y, 2014, MATER RES BULL, V57, P162, DOI 10.1016/j.materresbull.2014.05.043; Newalkar BL, 2001, MATER RES BULL, V36, P2347, DOI 10.1016/S0025-5408(01)00729-2; Zhang SC, 2004, MAT SCI ENG B-SOLID, V110, P11, DOI 10.1016/j.mseb.2004.01.017; Cao Y, 2014, ADV POWDER TECHNOL, V25, P853, DOI 10.1016/j.apt.2013.12.012; Yoon S, 2007, J AM CERAM SOC, V90, P311, DOI 10.1111/j.1551-2916.2006.01361.x; Asiaie R, 1996, CHEM MATER, V8, P226, DOI 10.1021/cm950327c; Komarneni S, 1999, MATER CHEM PHYS, V61, P50, DOI 10.1016/S0254-0584(99)00113-3; Pontes FM, 2003, J LUMIN, V104, P175, DOI 10.1016/S0022-2313(03)00014-0; Keyson D, 2007, J MATER PROCESS TECH, V189, P316, DOI 10.1016/j.jmatprotec.2007.02.001; Moreira ML, 2008, CHEM MATER, V20, P5381, DOI 10.1021/cm801638d; PERRY CH, 1965, PHYS REV LETT, V15, P700, DOI 10.1103/PhysRevLett.15.700; Zheng HJ, 2013, J CRYST GROWTH, V363, P300, DOI 10.1016/j.jcrysgro.2012.11.019; CHRISTEN.AN, 1970, ACTA CHEM SCAND, V24, P2447, DOI 10.3891/acta.chem.scand.24-2447; Feng Q, 2005, J AM CERAM SOC, V88, P1415, DOI 10.1111/j.1551-2916.2005.00298.x; Guo LT, 2006, MATER LETT, V60, P3011, DOI 10.1016/j.matlet.2006.02.035; Sun WA, 2006, J AM CERAM SOC, V89, P118, DOI 10.1111/j.1551-2916.2005.00649.x; Zhu XH, 2005, J CRYST GROWTH, V283, P553, DOI 10.1016/j.jcrysgro.2005.05.080	25	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4522	1573-482X		J MATER SCI-MATER EL	J. Mater. Sci.-Mater. Electron.	MAR	2015	26	3					1597	1601		10.1007/s10854-014-2581-z		5	Engineering, Electrical & Electronic; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Engineering; Materials Science; Physics	CC3CZ	WOS:000350223700044		
J	Hata, K; Minoda, Y; Ikebuchi, M; Mizokawa, S; Ohta, Y; Miyazaki, N; Miyake, Y; Nakamura, H				Hata, Kanako; Minoda, Yukihide; Ikebuchi, Mitsuhiko; Mizokawa, Shigekazu; Ohta, Yoichi; Miyazaki, Nobuyuki; Miyake, Yusuke; Nakamura, Hiroaki			In vivo wear particles of remelted highly crosslinked polyethylene after total hip arthroplasty: report of four cases	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE			English	Article							TISSUE-DIGESTION; UHMWPE PARTICLES; DEBRIS; OSTEOLYSIS; PROSTHESES	This is the first report of in vivo wear particles from four total hip arthroplasties using remelted highly crosslinked polyethylene. The number of particles was (1.51 +/- 0.45) x 10(7) g(-1) (mean +/- standard error); particle size (equivalent circle diameter), 0.72 +/- 0.15 mu m; and roundness, 1.45 +/- 0.05. Remelted highly crosslinked polyethylene generates fewer, rounder, equivalently sized particles compared with corresponding reported values for particles generated from conventional polyethylene.	[Hata, Kanako; Minoda, Yukihide; Ikebuchi, Mitsuhiko; Mizokawa, Shigekazu; Ohta, Yoichi; Nakamura, Hiroaki] Osaka City Univ, Grad Sch Med, Dept Orthopaed Surg, Abeno Ku, Osaka 5458585, Japan; [Miyazaki, Nobuyuki; Miyake, Yusuke] Wakayama Med Univ, Dept Orthopaed Surg, Wakayama 6410011, Japan	Minoda, Y (reprint author), Osaka City Univ, Grad Sch Med, Dept Orthopaed Surg, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	yminoda@msic.med.osaka-cu.ac.jp					AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7; Yang SY, 2002, BIOMATERIALS, V23, P3535, DOI 10.1016/S0142-9612(02)00032-7; Kadoya Y, 1996, J ORTHOPAED RES, V14, P473, DOI 10.1002/jor.1100140318; DeHeer DH, 2001, J BIOMED MATER RES, V54, P12, DOI 10.1002/1097-4636(200101)54:1<12::AID-JBM2>3.0.CO;2-X; Matthews JB, 2000, J BIOMED MATER RES, V52, P296, DOI 10.1002/1097-4636(200011)52:2<296::AID-JBM8>3.0.CO;2-9; CAMPBELL P, 1994, J BIOMED MATER RES, V28, P523, DOI 10.1002/jbm.820280415; Kobayashi A, 1997, J BONE JOINT SURG BR, V79B, P844, DOI 10.1302/0301-620X.79B5.7602; Zahiri CA, 1998, J ARTHROPLASTY, V13, P890, DOI 10.1016/S0883-5403(98)90195-4; Endo M, 2002, P I MECH ENG H, V216, P111, DOI 10.1243/0954411021536333; WILLERT HG, 1977, J BIOMED MATER RES, V11, P157, DOI 10.1002/jbm.820110202; HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46; Iwakiri K, 2009, J BIOMED MATER RES B, V91B, P799, DOI 10.1002/jbm.b.31458; Ries MD, 2001, J BONE JOINT SURG AM, V83A, P116; Saikko V, 2002, J BIOMED MATER RES, V63, P848, DOI 10.1002/jbm.10471	14	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4530	1573-4838		J MATER SCI-MATER M	J. Mater. Sci.-Mater. Med.	MAR	2015	26	3							133	10.1007/s10856-015-5472-9		4	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CC9AI	WOS:000350659300013		
J	Tsukanaka, M; Fujibayashi, S; Otsuki, B; Takemoto, M; Matsuda, S				Tsukanaka, Masako; Fujibayashi, Shunsuke; Otsuki, Bungo; Takemoto, Mitsuru; Matsuda, Shuichi			Osteoinductive potential of highly purified porous beta-TCP in mice	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE			English	Article							CALCIUM-PHOSPHATE CERAMICS; TRICALCIUM PHOSPHATE; BONE-FORMATION; HYDROXYAPATITE; INDUCTION; BIOMATERIALS; OSTEOGENESIS; OSTEOCLASTOGENESIS; INHIBITION; MUSCLES	Material-induced osteoinduction of calcium phosphate ceramics has been reported in specific animals. We previously reported that recruitment of tartrate-resistant acid phosphatase (TRAP)-positive cells might be one of the main factors responsible for the difference in the occurrence of material-induced osteoinduction between dogs and rats. In this study, we evaluated the osteoinductive potential of highly purified porous beta-tricalcium phosphate materials (HPP-beta-TCP) with two different porosities, 75 and 60 % (Olympus Terumo Biomaterials, Tokyo, Japan), implanted into subcutaneous pockets of FVB and C57BL/6 mice. Twelve weeks after implantation, histological examination and gene expression analysis using reverse transcription-polymerase chain reaction were performed. We observed osteoinduction in half of the HPP-beta-TCP materials with 60 % porosity implanted into FVB mice. This group of mice also exhibited the most TRAPpositive cells. Significantly more vessels were found in FVB mice than in C57BL/6 mice, but the greatest number of vessels was counted in implants from materials with 75 % porosity implanted into FVB mice, which did not show osteoinduction. These results indicate that recruitment of TRAP-positive cells is one factor responsible for osteoinduction caused by HPP-b-TCP materials in both FVB mice and dogs. Vessel formation seems to be necessary but appears to be less influential for osteoinduction than TRAP-positive cell recruitment.	[Tsukanaka, Masako] Univ Oslo, Ulleval Hosp, Ctr Implant & Radiostereometr Res Oslo, N-0407 Oslo, Norway; [Tsukanaka, Masako; Fujibayashi, Shunsuke; Otsuki, Bungo; Takemoto, Mitsuru; Matsuda, Shuichi] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 6068507, Japan	Tsukanaka, M (reprint author), Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kawahara Cho 54, Kyoto 6068507, Japan.	masakotsukanaka@gmail.com					Akita S, 2004, TISSUE ENG, V10, P789, DOI 10.1089/1076327041348338; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Geuze RE, 2012, TISSUE ENG PT A, V18, P2052, DOI [10.1089/ten.TEA.2011.0560, 10.1089/ten.tea.2011.0560]; Kondo N, 2006, BIOMATERIALS, V27, P4419, DOI 10.1016/j.biomaterials.2006.04.016; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Yuan HP, 2001, BIOMATERIALS, V22, P2617, DOI 10.1016/S0142-9612(00)00450-6; Barradas AMC, 2012, BIOMATERIALS, V33, P5696, DOI 10.1016/j.biomaterials.2012.04.021; Gotz W, 2010, FOLIA HISTOCHEM CYTO, V48, P589, DOI 10.2478/v10042-010-0096-x; Akiyama N, 2011, J BIOMED MATER RES A, V96A, P402, DOI 10.1002/jbm.a.32995; Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142-9612(99)00075-7; Wang L, 2010, BIOMATERIALS, V31, P9452, DOI 10.1016/j.biomaterials.2010.08.036; Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031; Cheng LJ, 2013, MAT SCI ENG C-MATER, V33, P1254, DOI 10.1016/j.msec.2012.12.023; Davison NL, 2014, BIOMATERIALS, V35, P5088, DOI 10.1016/j.biomaterials.2014.03.013; Fukuda C, 2012, J BIOMATER NANOBIOTE, V03, P169; Gosain AF, 2002, PLAST RECONSTR SURG, V109, P619, DOI 10.1097/00006534-200202000-00032; Ho MK, 2014, AUDIOL NEUROTOL EXTR, V4, P1; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Nasu T, 2009, J BIOMED MATER RES A, V89A, P601, DOI 10.1002/jbm.a.31984; Ripamonti U, 2010, BIOMATERIALS, V31, P6400, DOI 10.1016/j.biomaterials.2010.04.037; RIPAMONTI U, 1991, J ORAL MAXIL SURG, V49, P817, DOI 10.1016/0278-2391(91)90010-J; Sugawara T, 2011, SPINE, V36, P1509; Tanaka T, 2008, J BIOMED MATER RES B, V86B, P453, DOI 10.1002/jbm.b.31041; TORIYAMA M, 1987, NIPPON SERAM KYO GAK, V95, P741; Wang Z, 2013, J SPINAL DISORD TECH, V26, P40; Yang RN, 2011, J ZHEJIANG UNIV-SC B, V12, P582, DOI 10.1631/jzus.B1000204; Zhang MY, 2010, J PLAST RECONSTR AES, V63, P227, DOI 10.1016/j.bjps.2008.11.017	27	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4530	1573-4838		J MATER SCI-MATER M	J. Mater. Sci.-Mater. Med.	MAR	2015	26	3							132	10.1007/s10856-015-5469-4		9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CC9AI	WOS:000350659300012		
J	Ikeda, S; Kihira, K; Yokoi, A; Tamakoshi, K; Miyazaki, K; Furuhashi, M				Ikeda, Sayako; Kihira, Kana; Yokoi, Akira; Tamakoshi, Koji; Miyazaki, Ken; Furuhashi, Madoka			The levels of the neutrophil elastase in the amniotic fluid of pregnant women whose infants develop bronchopulmonary dysplasia	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE			English	Article						Amniotic fluid; bronchopulmonary dysplasia; chorioamnionitis; funisitis; neutrophil elastase	RESPIRATORY-DISTRESS-SYNDROME; CHRONIC LUNG-DISEASE; FETAL INFLAMMATORY RESPONSE; PRETERM INFANTS; CHORIOAMNIONITIS; INHIBITOR; PATHOGENESIS; PROTEINASES; PREMATURITY; SIVELESTAT	Objective: To clarify the association between amniotic neutrophil elastase levels and the development of bronchopulmonary dysplasia (BPD). Methods: The database between July 2001 and December 2012 was reviewed for women with amniocentesis on admission for amniotic fluid neutrophil elastase levels and with singleton deliveries between 22 + 0 and 31 + 6 weeks of gestation. Following deliveries, placentas were examined for histologic chorioamnionitis. The peripheral blood of the neonates was analyzed for acute phase reactants. Results: Among 294 infants, no, mild, moderate or severe BPD was observed in 126, 89, 40 and 39 infants, respectively. The medians of gestational age on admission, at premature rupture of membranes and at delivery were significantly smaller in BPD (+) when compared with BPD (-) (p<0.001). The median level of amniotic neutrophil elastase on admission was significantly greater in BPD (+) than that in BPD (-). Histologic chorioamnionitis and funisitis were both detected more frequently in BPD (+) patients than in BPD (-) patients. In a logistic regression model, the only variable that affected an increased chance of BPD was the gestational age at delivery (odds ratio, 0.58; 95% confidence interval, 0.36-0.92; p = 0.021). Conclusions: The level of amniotic neutrophil elastase cannot be a definitive risk factor for BPD.	[Ikeda, Sayako; Kihira, Kana; Yokoi, Akira; Miyazaki, Ken; Furuhashi, Madoka] Japanese Red Cross Nagoya Daiichi Hosp, Dept Obstet & Gynecol, Nagoya, Aichi, Japan; [Tamakoshi, Koji] Nagoya Univ, Dept Nursing, Grad Sch Med, Nagoya, Aichi 4648601, Japan	Furuhashi, M (reprint author), Japanese Red Cross Nagoya Daiichi Hosp, Dept Obstet & Gynecol, Nakamura Ku, 3-35 Michishita Cho, Nagoya, Aichi 4538511, Japan.	furuhashi-f@syd.odn.ne.jp					Nupponen I, 2002, PEDIATRICS, V110, P36, DOI 10.1542/peds.110.1.36; Gotsch F, 2007, CLIN OBSTET GYNECOL, V50, P652, DOI 10.1097/GRF.0b013e31811ebef6; Miyoshi S, 2013, DRUG DES DEV THER, V7, P305, DOI 10.2147/DDDT.S42004; Benitz WE, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.4.e41; Mehta R, 2006, ARCH DIS CHILD-FETAL, V91, pF415, DOI 10.1136/adc.2005.092288; Kunzmann S, 2013, AM J OBSTET GYNECOL, V208, P429, DOI 10.1016/j.ajog.2013.01.008; Yoon BH, 1999, AM J OBSTET GYNECOL, V181, P773, DOI 10.1016/S0002-9378(99)70299-1; CholletMartin S, 1996, AM J RESP CRIT CARE, V154, P594; Eber E, 2001, THORAX, V56, P317, DOI 10.1136/thorax.56.4.317; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; HAVEMANN K, 1984, ADV EXP MED BIOL, V167, P1; Kobaly K, 2008, PEDIATRICS, V121, P73, DOI 10.1542/peds.2007-1444; Watterberg KL, 1996, PEDIATRICS, V97, P210; Blanc WA, 1981, INT ACADEMY PATHOLOG, V22, P67; Cepinskas G, 1997, CIRC RES, V81, P618; Davies PL, 2010, THORAX, V65, P246, DOI 10.1136/thx.2009.116061; Helmig B R, 2002, J Matern Fetal Neonatal Med, V12, P237, DOI 10.1080/jmf.12.4.237.246; Jobe Alan H, 2003, Semin Neonatol, V8, P9, DOI 10.1016/S1084-2756(02)00188-4; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kidokoro K, 2006, ACTA OBSTET GYN SCAN, V85, P669, DOI 10.1080/01443610600604432; Manuck TA, 2009, AM J OBSTET GYNECOL, V201, P414, DOI DOI 10.1016/J/AJOG.2009.07.045; Melville JM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00079; MERRITT TA, 1983, J CLIN INVEST, V72, P656, DOI 10.1172/JCI111015; Miyazaki K, 2007, ACTA OBSTET GYN SCAN, V86, P191, DOI 10.1080/00016340601022793; Miyazaki K, 2012, ACTA OBSTET GYN SCAN, V91, P923, DOI 10.1111/j.1600-0412.2012.01432.x; Pacora P, 2002, J Matern Fetal Neonatal Med, V11, P18, DOI 10.1080/713605445; Rocha G., 2013, CRIT CARE RES PRACT, V2013; Stiskal JA, 1998, PEDIATRICS, V101, P89, DOI 10.1542/peds.101.1.89; Tsuboko Y, 2012, DRUG DES DEV THER, V6, P273, DOI 10.2147/DDDT.S36436; WIENERKRONISH JP, 1990, BRIT J ANAESTH, V65, P107, DOI 10.1093/bja/65.1.107	30	1	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1476-7058	1476-4954		J MATERN-FETAL NEO M	J. Matern.-Fetal Neonatal Med.	MAR	2015	28	4					479	483		10.3109/14767058.2014.921674		5	Obstetrics & Gynecology	Obstetrics & Gynecology	CD5MZ	WOS:000351133400021		
J	Iimura, Y; Onoe, H; Teshima, T; Heo, YJ; Yoshida, S; Morimoto, Y; Takeuchi, S				Iimura, Yoshinobu; Onoe, Hiroaki; Teshima, Tetsuhiko; Heo, Yun Jung; Yoshida, Shotaro; Morimoto, Yuya; Takeuchi, Shoji			Liquid-filled tunable lenticular lens	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						lenticular lens; varifocal lens; liquid-filled lens; naked-eye stereoscopic display; 2D/3D switching	MICROLENS; CRYSTAL; DISPLAY; CELL	This paper describes a liquid-filled tunable lenticular lens for switching between two-dimensional (2D) and three-dimensional (3D) images in naked-eye 3D displays. Compared with previous 2D/3D switchable displays, this tunable lenticular lens that is directly attached to a smartphone display can project both a 2D image with the original resolution of the smartphone display and a 3D image with high brightness. This lens is simply composed of transparent poly(dimethylsiloxane) (PDMS) microchannels. While the thin top membrane on the microchannels is normally flat to transmit light without deflection for displaying 2D images, applying pressure to the microchannel deforms the membrane to acquire characteristics of lenticular lenses for 3D images. We successfully demonstrate the switching between the 2D and 3D modes. We believe that our lens can be applied as a part of a portable 2D/3D naked-eye 3D display.	[Iimura, Yoshinobu; Onoe, Hiroaki; Teshima, Tetsuhiko; Heo, Yun Jung; Yoshida, Shotaro; Morimoto, Yuya; Takeuchi, Shoji] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; [Onoe, Hiroaki; Heo, Yun Jung; Morimoto, Yuya; Takeuchi, Shoji] Japan Sci & Technol Agcy, Komaba Open Lab, ERATO Takeuchi Biohybrid Innovat Project, Meguro Ku, Tokyo 1538505, Japan	Iimura, Y (reprint author), Univ Tokyo, Inst Ind Sci, Meguro Ku, Fw205,4-6-1 Komaba, Tokyo 1538505, Japan.	takeuchi@iis.u-tokyo.ac.jp			ERATO Takeuchi Biohybrid Innovation Project, JST, Japan	This work was partly supported by ERATO Takeuchi Biohybrid Innovation Project, JST, Japan.	Agarwall M, 2004, J MICROMECH MICROENG, V14, P1665, DOI 10.1088/0960-1317/14/12/010; Fuard D, 2008, MICROELECTRON ENG, V85, P1289, DOI 10.1016/j.mee.2008.02.004; Commander LG, 2000, OPT COMMUN, V177, P157, DOI 10.1016/S0030-4018(00)00596-4; Krupenkin T, 2003, APPL PHYS LETT, V82, P316, DOI 10.1063/1.1536033; Song C, 2009, LAB CHIP, V9, P1178, DOI 10.1039/b819158a; Song CL, 2010, OPT LETT, V35, P327, DOI 10.1364/OL.35.000327; Ren HW, 2004, OPT LETT, V29, P1608, DOI 10.1364/OL.29.001608; Na JH, 2012, OPT EXPRESS, V20, P864, DOI 10.1364/OE.20.000864; Chen CW, 2012, J DISP TECHNOL, V8, P559, DOI 10.1109/JDT.2012.2216856; Geng JS, 2013, ADV OPT PHOTONICS, V5, P456, DOI 10.1364/AOP.5.000456; Choi Y, 2003, OPT MATER, V21, P643, DOI 10.1016/S0925-3467(02)00215-X; Werber A, 2005, APPL OPTICS, V44, P3238, DOI 10.1364/AO.44.003238; Chronis N, 2003, OPT EXPRESS, V11, P2370, DOI 10.1364/OE.11.002370; Berge B, 2000, EUR PHYS J E, V3, P159, DOI 10.1007/s101890070029; Naumov AF, 1998, OPT LETT, V23, P992, DOI 10.1364/OL.23.000992; Chen J, 2004, J MICROMECH MICROENG, V14, P675, DOI 10.1088/0960-1317/14/5/003; Heo YJ, 2013, MICRO NANO LETT, V8, P865, DOI 10.1049/mnl.2013.0476; Chen CY, 2008, MICROW OPT TECHN LET, V50, P1610, DOI 10.1002/mop.23435; Hess W., 1915, U.S. patent, Patent No. [1,128,979, 1128979]; Ives F., 1903, U.S. Patent, Patent No. [725,567, 725567]; Takai Y, 2012, P IEEE MEMS, P632; Urruchi Del Pozo V, 2012, REV OPT ELECT, V20, P260; Xu M, 2012, J APPL PHYS, V111, DOI 10.1063/1.3694738	23	0	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	MAR	2015	25	3							035030	10.1088/0960-1317/25/3/035030		6	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CC3PQ	WOS:000350261800031		
J	Miki, H; Matsui, G; Kanda, M; Tsuchitani, S				Miki, Hirofumi; Matsui, G.; Kanda, M.; Tsuchitani, S.			Fabrication of microstructure array directly on beta-phase poly(vinylidene fluoride) thin film by O-2 reactive ion etching	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						beta-PVDF; microstructure array; high aspect ratio; flexible; tactile sensation; skin sensor; RIE; MEMS	POLY VINYLIDENE FLUORIDE; TACTILE SENSOR	The ability to pattern a thin film of poly(vinylidene fluoride) (PVDF), a piezoelectric, pyroelectric and ferroelectric polymer, has potential applications in the fields of microelectromechanical systems (MEMS), nonlinear optics and nonvolatile ferroelectric random access memory technology. Low pressure O-2 reactive ion etching (RIE) was employed to realize fine pitch microstructures on a beta-phase PVDF (beta-PVDF) film for the first time; a line and space (70/130 mu m) microstructure array with a height of over 30 mu m was fabricated. Different to the traditional method of PDMS molding, the proposed technology did not result in significant loss of piezoelectricity. Furthermore, unlike the x-ray photo-etching method, there was no etching saturation limit with the proposed method. Here, we introduce the fabrication process technology in detail and report on the etching properties of the beta-PVDF film under different process conditions. The effect of process variables, such as supplied gas flow, applied RF power and etch time, on the PVDF etching characteristics were investigated in detail. The RF power and etch time showed a more predominant influence on PVDF etching progress than the gas flow. The etched depth was linearly increased with the etch time and the amount of RF power. Etching rates over 10 mu m h(-1) were achieved and increased linearly with the applied RF power. By means of a responding photomask design and control of process conditions, much finer and higher microstructure arrays are also possible.	[Miki, Hirofumi; Matsui, G.; Kanda, M.; Tsuchitani, S.] Wakayama Univ, Fac Syst Engn, Dept Optomechatron, Wakayama 6408510, Japan	Miki, H (reprint author), Wakayama Univ, Dept Syst Engn, 930 Sakaedani, Wakayama 6408510, Japan.	hjs@sys.wakayama-u.ac.jp					Dahiya RS, 2010, IEEE T ROBOT, V26, P1, DOI 10.1109/TRO.2009.2033627; Puangmali P, 2008, IEEE SENS J, V8, P371, DOI 10.1109/JSEN.2008.917481; KAWAI H, 1969, JPN J APPL PHYS, V8, P975, DOI 10.1143/JJAP.8.975; Kang SJ, 2007, ADV MATER, V19, P581, DOI 10.1002/adma.200601474; Lee MH, 2000, INT J ROBOT RES, V19, P636; Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234; Bartnik A, 2012, APPL PHYS A-MATER, V106, P551, DOI 10.1007/s00339-011-6662-z; Sharma T, 2012, SENSOR ACTUAT A-PHYS, V177, P87, DOI 10.1016/j.sna.2011.08.019; Engel J, 2005, SENSOR ACTUAT A-PHYS, V117, P50, DOI 10.1016/j.sna.2004.05.037; Dargahi J., 2005, Industrial Robot, V32, DOI 10.1108/01439910510593965; Dario P, 1983, P 13 INT S IND ROB C, V2, P14; DARIO P, 1987, INT J ROBOT RES, V6, P25, DOI 10.1177/027836498700600302; Egitto F D, 1990, PLASMA DEPOSITION TR, P312; Han H, 2012, J MICROMECH MICROENG, V22, DOI 10.1088/0960-1317/22/8/085030; Han JS, 2004, J MICROMECH MICROENG, V14, P38, DOI 10.1088/0960-1317/14/1/306; HANSEN RH, 1965, J POLYM SCI PART A, V3, P2205, DOI 10.1002/pol.1965.100030609; Huang Y, 2011, J WUHAN UNIV TECHNOL, V26, P443, DOI 10.1007/s11595-011-0246-9; Kaynak A, 2013, MATERIALS, V6, P3482, DOI 10.3390/ma6083482; Kolesar ES, 1996, EIGHTH ANNUAL IEEE INTERNATIONAL CONFERENCE ON INNOVATIVE SYSTEMS IN SILICON, 1996 PROCEEDINGS, P372; KOLESAR ES, 1992, J ROBOTIC SYST, V9, P37, DOI 10.1002/rob.4620090104; Liu Y, 2010, OPT EXPRESS, V18, P22041, DOI 10.1364/OE.18.022041; Manohara HM, 1999, J MICROELECTROMECH S, V8, P417; Montazer-Rahamati P, 1991, P ISPC 10 BOCH GERM, V2.2, P1; Panescu D, 2006, IEEE ENG MED BIOL, V25, P19, DOI 10.1109/MEMB.2006.1705742; REGTIEN PPL, 1989, SENSOR ACTUATOR, V17, P91, DOI 10.1016/0250-6874(89)80068-X; Shida K, 1996, ISIE'96 - PROCEEDINGS OF THE IEEE INTERNATIONAL SYMPOSIUM ON INDUSTRIAL ELECTRONICS, VOLS 1 AND 2, P54, DOI 10.1109/ISIE.1996.548392; YongGang J, 2013, CHIN SCI B MECH ENG, V58, P2091; Yuji J, 2000, IEEE T INSTRUM MEAS, V49, P1091, DOI 10.1109/19.872935	28	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	MAR	2015	25	3							035026	10.1088/0960-1317/25/3/035026		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CC3PQ	WOS:000350261800027		
J	Samoto, T; Hirano, H; Somekawa, T; Hikichi, K; Fujita, M; Esashi, M; Tanaka, S				Samoto, Tetuo; Hirano, Hideki; Somekawa, Toshihiro; Hikichi, Kousuke; Fujita, Masayuki; Esashi, Masayoshi; Tanaka, Shuji			Wafer-to-wafer transfer process of barium strontium titanate for frequency tuning applications using laser pre-irradiation	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						wafer-to-wafer bonding; laser assisted transfer process; barium strontium titanate; metal-insulator-metal variable capacitor; lithium tantalate	LIFT-OFF TECHNIQUE; THIN-FILMS; LITHIUM-NIOBATE; GAN; PLATINUM; TEMPERATURE; TECHNOLOGY	This paper describes laser-assisted film transfer technology for barium strontium titanate (BST) deposited on a sapphire substrate. BST is a promising ferroelectric material for varactors, which are required for frequency-tunable RF applications. However, the deposition temperature of BST (600 similar to 700 degrees C) is too high for surface acoustic wave (SAW) substrates. In this study, BST grown on a sapphire substrate at 650 degrees C was transferred at low temperature (140 degrees C) to a borosilicate glass substrate as well as a LiTaO3 substrate. The transferred BST films were characterized as tunable capacitors. A key process in the BST film transfer technology is the laser pre-irradiation of a buffer Pt layer beneath BST from the backside of the sapphire substrate to weaken the BST-to-Pt adhesion. The mechanism of delamination at the BST/Pt interface is discussed using a simple 1D heat transfer model.	[Samoto, Tetuo; Hirano, Hideki; Hikichi, Kousuke; Tanaka, Shuji] Tohoku Univ, Grad Sch Engn, Sendai, Miyagi 980, Japan; [Somekawa, Toshihiro; Fujita, Masayuki] Inst Laser Technol, Osaka, Japan; [Esashi, Masayoshi] Tohoku Univ, Adv Inst Mat Res, Sendai, Miyagi 980, Japan	Samoto, T (reprint author), Tohoku Univ, Grad Sch Engn, Sendai, Miyagi 980, Japan.	samoto@mems.mech.tohoku.ac.jp			Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R and D on Science and Technology (FIRST) Program	This work was supported by the Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R and D on Science and Technology (FIRST) Program. The authors thank Mr T Kimura, Mr Y Kishimoto and Dr M Kadota at Murata Manufacturing Co, Ltd, Japan for their strong support on BST deposition.	Ueda T, 2003, APPL SURF SCI, V216, P512, DOI 10.1016/S0169-4332(03)00476-8; Lima MM, 2001, THERMOCHIM ACTA, V373, P69, DOI 10.1016/S0040-6031(01)00456-7; Bao P, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/6/063001; Taylor TR, 2002, APPL PHYS LETT, V80, P1978, DOI 10.1063/1.1459482; Chu CF, 2004, J APPL PHYS, V95, P3916, DOI 10.1063/1.1651338; Yasue T, 2012, SENSOR ACTUAT A-PHYS, V188, P456, DOI 10.1016/j.sna.2012.01.017; Ayguavives T, 2000, APPL FERR 2000 ISAF, V1, P365; Baldus O, 2005, APPL PHYS A-MATER, V80, P1553, DOI 10.1007/s00339-004-2904-7; BUNTIN SA, 1989, J CHEM PHYS, V91, P6429, DOI 10.1063/1.457411; Chakraborty T, 2009, INTEGR FERROELECTR, V106, P40, DOI 10.1080/10584580903213167; Chen M, 2012, ECS SOLID STATE LETT, V1, pQ26, DOI 10.1149/2.011202ssl; Despont M, 2004, J MICROELECTROMECH S, V13, P895, DOI 10.1109/JMEMS.2004.835769; Guerre R, 2008, J MICROELECTROMECH S, V17, P157, DOI 10.1109/JMEMS.2007.911370; Harada H., 2008, P 3 IEEE INT S NEW F, P1; Hirano H, 2013, J MICROMECH MICROENG, V23, DOI 10.1088/0960-1317/23/2/025005; Hirano H, 2014, P 2014 IEEE INT ULTR; Im J, 2000, APPL PHYS LETT, V76, P625, DOI 10.1063/1.125839; Inaba M, 2013, JPN J APPL PHYS, V52, DOI 10.7567/JJAP.52.07HD05; James C, 2009, J MATER SCI, V44, P5325, DOI 10.1007/s10853-009-3609-2; James CW, 2010, J EUR CERAM SOC, V30, P419, DOI 10.1016/j.jeurceramsoc.2009.06.022; Ji HF, 2009, SOLID STATE ELECTRON, V53, P526, DOI 10.1016/j.sse.2009.02.006; Jiang H, 2011, IEEE T MICROW THEORY, V59, P3068, DOI 10.1109/TMTT.2011.2170088; KATZ A, 1990, J APPL PHYS, V67, P6237, DOI 10.1063/1.345190; KIM YS, 1969, J APPL PHYS, V40, P4637, DOI 10.1063/1.1657244; Komatsu T, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.07HD24; Matsuda T., 2012, Proceedings of the 5th International Conference on Communications, Computers and Applications (MIC-CCA2012); Milkove KR, 1998, J VAC SCI TECHNOL A, V16, P1483, DOI 10.1116/1.581174; Ranpura HM, 1999, J ELECTROCHEM SOC, V146, P3114, DOI 10.1149/1.1392440; Samoto T, 2013, WAFER TO WAFER TRANS, P171; Shibano T, 1999, J VAC SCI TECHNOL A, V17, P799, DOI 10.1116/1.581650; Shye DC, 2003, JPN J APPL PHYS 1, V42, P1680, DOI 10.1143/JJAP.42.1680; Vetelino K, 2004, ULTRASON, P449; Wang YH, 2008, ELEC COMP C, P944, DOI 10.1109/ECTC.2008.4550089; Xu J, 2002, MATER LETT, V56, P43, DOI 10.1016/S0167-577X(02)00414-7; Zhang RT, 2008, APPL SURF SCI, V254, P6697, DOI 10.1016/j.apsusc.2008.05.233	35	2	2	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	MAR	2015	25	3							035015	10.1088/0960-1317/25/3/035015		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CC3PQ	WOS:000350261800016		
J	Wang, M; Tsukamoto, T; Tanaka, S				Wang, Min; Tsukamoto, Takashiro; Tanaka, Shuji			Infrared thermal detector array using Eu(TTA)(3)-based temperature sensitive paint for optical readable thermal imaging device	JOURNAL OF MICROMECHANICS AND MICROENGINEERING			English	Article						infrared thermal detector array; Eu(TTA)(3); temperature sensitive paint; temperature-dependent luminescence; optical readout; thermal imaging	EUROPIUM THENOYLTRIFLUOROACETONATE; RESOLUTION; SURFACE	This paper presents the design and fabrication of an infrared (IR) thermal detector array made of Eu(TTA)(3)-based temperature sensitive paint (TSP). The TSP emits 610 nm visible luminescence depending on temperature, and works as an IR-to-visible converter. An optical readout system was designed to excite and observe the detector array using a 355 nm light-emitting diode (LED) and a charge-coupled-device (CCD) camera, respectively. The temperature coefficient of the TSP was measured to be -1.58% K-1, and thermal images of a 400 degrees C object were successfully obtained. The noise analysis showed that the noise-equivalent temperature difference (NETD) of the imaging system was about 4.5 K.	[Wang, Min; Tsukamoto, Takashiro; Tanaka, Shuji] Tohoku Univ, Dept Bioengn & Robot, Aoba Ku, Sendai, Miyagi 9808579, Japan	Wang, M (reprint author), Tohoku Univ, Dept Bioengn & Robot, Aoba Ku, Aoba 6-6-01, Sendai, Miyagi 9808579, Japan.	wangmin@mems.mech.tohoku.ac.jp			Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program	The authors would like to thank Sekisui Chemical Co., Ltd for providing the PVB. This research was partly supported by Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program.	Alfaro M, 2012, APPL OPTICS, V51, P780, DOI 10.1364/AO.51.000780; Bean JA, 2009, J VAC SCI TECHNOL B, V27, P11, DOI 10.1116/1.3039684; Rogalski A, 2003, PROG QUANT ELECTRON, V27, P59, DOI 10.1016/S0079-6727(02)00024-1; Hunter SR, 2007, P SOC PHOTO-OPT INS, V6542, pF5421, DOI 10.1117/12.726316; Alfaro M, 2010, APPL OPTICS, V49, P5444, DOI 10.1364/AO.49.005444; Tsukamoto T, 2013, J MICROMECH MICROENG, V23, DOI 10.1088/0960-1317/23/11/114015; Bostrom T, 2007, SOL ENERG MAT SOL C, V91, P38, DOI 10.1016/j.solmat.2006.07.002; Basu BBJ, 2008, J LUMIN, V128, P1701, DOI 10.1016/j.jlumin.2008.03.024; KOLODNER P, 1982, APPL PHYS LETT, V40, P782, DOI 10.1063/1.93258; Barton DL, 1996, MICROELECTRON ENG, V31, P271, DOI 10.1016/0167-9317(95)00349-5; Fahy S, 1997, PHYS REV B, V56, P12573, DOI 10.1103/PhysRevB.56.12573; Hirota M, 2007, SENSOR ACTUAT A-PHYS, V135, P146, DOI 10.1016/j.sna.2006.06.058; Kimura M, 2008, NSTI NANOTECH 2008, VOL 1, TECHNICAL PROCEEDINGS, P642; Kruse P W, 2002, UNCOOLED THERMAL IMA, P49; Kruse P W, 1997, SEMICONDUCT SEMIMET, V47, P17; LIDDIARD KC, 1993, INFRARED PHYS, V34, P379, DOI 10.1016/0020-0891(93)90070-N; Lloyd J M, 1975, THERMAL IMAGING SYST, P1; Lucas TM, 2013, SENSOR ACTUAT A-PHYS, V198, P81, DOI 10.1016/j.sna.2013.04.033; Madonald G, 1980, THIN SOLID FILMS, V72, P83; Murphy D, 2007, P SOC PHOTO-OPT INS, V6542, pZ5421, DOI 10.1117/12.724345; PUTLEY EH, 1966, J SCI INSTRUM, V43, P857, DOI 10.1088/0950-7671/43/12/301; Sui Y, 2012, MRS P, V1452, P7; Teranishi N, 1997, SEMICONDUCT SEMIMET, V47, P203; Tsukamoto T, 2013, PROC IEEE MICR ELECT, P421, DOI 10.1109/MEMSYS.2013.6474268; Wood R. A., 1997, SEMICONDUCT SEMIMET, V47, P43	25	2	2	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0960-1317	1361-6439		J MICROMECH MICROENG	J. Micromech. Microeng.	MAR	2015	25	3							035012	10.1088/0960-1317/25/3/035012		8	Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Materials Science, Multidisciplinary; Mechanics	Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Materials Science; Mechanics	CC3PQ	WOS:000350261800013		
J	Singh, A; Liang, L; Kaneoke, Y; Cao, XB; Papa, SM				Singh, Arun; Liang, Li; Kaneoke, Yoshiki; Cao, Xuebing; Papa, Stella M.			Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates	JOURNAL OF NEUROPHYSIOLOGY			English	Article						basal ganglia; striatum; electrophysiology; bursts; pauses; Parkinson's disease; dyskinesias	MEDIUM SPINY NEURONS; LEVODOPA-INDUCED DYSKINESIAS; MPTP-INDUCED PARKINSONISM; GLOBUS-PALLIDUS NEURONS; CHOLINERGIC INTERNEURONS; BASAL GANGLIA; GLUTAMATERGIC TRANSMISSION; FUNCTIONAL-ORGANIZATION; STRIATOPALLIDAL NEURONS; SUBTHALAMIC NUCLEUS	Nigrostriatal dopamine denervation plays a major role in basal ganglia circuitry disarray and motor abnormalities of Parkinson's disease (PD). Studies in rodent and primate models have revealed that striatal projection neurons, namely, medium spiny neurons (MSNs), increase the firing frequency. However, their activity pattern changes and the effects of dopaminergic stimulation in such conditions are unknown. Using single-cell recordings in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates with advanced parkinsonism, we studied MSN activity patterns in the transition to different motor states following levodopa administration. In the "off" state (baseline parkinsonian disability), a burst-firing pattern accompanied by prolonged silences (pauses) was found in 34% of MSNs, and 80% of these exhibited a levodopa response compatible with dopamine D-1 receptor activation (direct pathway MSNs). This pattern was highly responsive to levodopa given that bursting/pausing almost disappeared in the "on" state (reversal of parkinsonism after levodopa injection), although this led to higher firing rates. Nonbursty MSNs fired irregularly with marked pausing that increased in the on state in the MSN subset with a levodopa response compatible with dopamine D-2 receptor activation (indirect pathway MSNs), although the pause increase was not sustained in some units during the appearance of dyskinesias. Data indicate that the MSN firing pattern in the advanced parkinsonian monkey is altered by bursting and pausing changes and that dopamine differentially and inefficiently regulates these behaviorally correlated patterns in MSN subpopulations. These findings may contribute to understand the impact of striatal dysfunction in the basal ganglia network and its role in motor symptoms of PD.	[Singh, Arun; Liang, Li; Cao, Xuebing; Papa, Stella M.] Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Liang, Li] SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; [Kaneoke, Yoshiki] Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi, Japan; [Cao, Xuebing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Hubei, Peoples R China; [Papa, Stella M.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA	Papa, SM (reprint author), Emory Univ, Sch Med, Dept Neurol, 954 Gatewood Rd, Atlanta, GA 30329 USA.	spapa@emory.edu			National Institutes of Health grants [NS045962, NS073994, RR000165, OD011132]; National Institutes of Health; Michael J. Fox Foundation; Pfizer, Inc.; EnVivo Pharmaceuticals, Inc.; FORUM Pharmaceuticals, Inc.; GeneGrafts, Ltd.; Key Neurosciences; National Natural Science Foundation of China [NSFC 81171193, 370700881]	This work was supported by National Institutes of Health grants NS045962 and NS073994 (to S. M. Papa) and RR000165 and OD011132 (to Yerkes National Primate Research Center). S. M. Papa has received research support from the National Institutes of Health, the Michael J. Fox Foundation, Pfizer, Inc., EnVivo Pharmaceuticals, Inc., FORUM Pharmaceuticals, Inc., GeneGrafts, Ltd., and Key Neurosciences. S. M. Papa is a consultant for Teva Neuroscience. X. Cao is supported by the National Natural Science Foundation of China grants NSFC 81171193 and 370700881.	Pisani A, 2007, TRENDS NEUROSCI, V30, P545, DOI 10.1016/j.tins.2007.07.008; Gerfen CR, 2011, ANNU REV NEUROSCI, V34, P441, DOI 10.1146/annurev-neuro-061010-113641; Raz A, 2000, J NEUROSCI, V20, P8559; Heimer G, 2002, J NEUROSCI, V22, P7850; Wilson CJ, 2006, J NEUROPHYSIOL, V95, P196, DOI 10.1152/jn.00630.2005; DELONG MR, 1985, J NEUROPHYSIOL, V53, P530; Adler A, 2012, J NEUROSCI, V32, P2473, DOI 10.1523/JNEUROSCI.4830-11.2012; Plenz D, 1998, J NEUROSCI, V18, P266; Wilson CJ, 1996, J NEUROSCI, V16, P2397; Ingham CA, 1998, J NEUROSCI, V18, P4732; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926; CRUTCHER MD, 1984, EXP BRAIN RES, V53, P244, DOI 10.1007/BF00238154; Taverna S, 2008, J NEUROSCI, V28, P5504, DOI 10.1523/JNEUROSCI.5493-07.2008; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Wang ZF, 2006, NEURON, V50, P443, DOI 10.1016/j.neuron.2006.04.010; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Calabresi P, 2000, PROG NEUROBIOL, V61, P231, DOI 10.1016/S0301-0082(99)00030-1; Gubellini P, 2002, J NEUROSCI, V22, P6900; Shen W, 2007, NAT NEUROSCI, V10, P1458, DOI 10.1038/nn1972; Bennett BD, 2000, J NEUROSCI, V20, P8493; Obeso JA, 2000, TRENDS NEUROSCI, V23, pS2, DOI 10.1016/S1471-1931(00)00031-8; Mallet N, 2008, J NEUROSCI, V28, P4795, DOI 10.1523/JNEUROSCI.0123-08.2008; Papa SM, 1996, ANN NEUROL, V39, P574, DOI 10.1002/ana.410390505; Papa SM, 1999, ANN NEUROL, V46, P732, DOI 10.1002/1531-8249(199911)46:5<732::AID-ANA8>3.0.CO;2-Q; Hashimoto K, 2006, EUR J NEUROSCI, V23, P443, DOI 10.1111/j.1460-9568.2005.04582.x; CRUTCHER MD, 1984, EXP BRAIN RES, V53, P233, DOI 10.1007/BF00238153; AOSAKI T, 1994, J NEUROSCI, V14, P3969; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; Jenner P, 2008, NAT REV NEUROSCI, V9, P665, DOI 10.1038/nrn2471; FILION M, 1991, BRAIN RES, V547, P142; West AR, 2002, J NEUROSCI, V22, P294; Hyland BI, 2002, NEUROSCIENCE, V114, P475, DOI 10.1016/S0306-4522(02)00267-1; Zhou FM, 2002, J NEUROBIOL, V53, P590, DOI 10.1002/neu.10150; Liang L, 2008, J NEUROSCI, V28, P7537, DOI 10.1523/JNEUROSCI.1176-08.2008; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; Day M, 2006, NAT NEUROSCI, V9, P251, DOI 10.1038/nn1632; Cao XB, 2007, J PHARMACOL EXP THER, V323, P318, DOI 10.1124/jpet.107.125666; Elias S, 2007, J NEUROSCI, V27, P2525, DOI 10.1523/JNEUROSCI.4156-06.2007; Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053; Gerfen CR, 2002, J NEUROSCI, V22, P5042; Kaneoke Y, 1996, J NEUROSCI METH, V68, P211; Tepper JM, 2004, TRENDS NEUROSCI, V27, P662, DOI 10.1016/j.tins.2004.08.007; Kitano K, 2002, J NEUROSCI, V22; Calabresi P, 2014, NAT NEUROSCI, V17, P1022, DOI 10.1038/nn.3743; Surmeier DJ, 1996, J NEUROSCI, V16, P6579; KIMURA M, 1992, BRAIN RES, V578, P204, DOI 10.1016/0006-8993(92)90249-9; Adler A, 2013, J NEUROSCI, V33, P4854, DOI 10.1523/JNEUROSCI.4791-12.2013; Guzman JN, 2003, J NEUROSCI, V23, P8931; Shen WX, 2005, J NEUROSCI, V25, P7449, DOI 10.1523/JNEUROSCI.1381-05.2005; Cepeda C, 1998, J NEUROPHYSIOL, V79, P82; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; Raz A, 1996, J NEUROPHYSIOL, V76, P2083; Calabresi P, 2010, LANCET NEUROL, V9, P1106, DOI 10.1016/S1474-4422(10)70218-0; Reynolds JNJ, 2004, J NEUROSCI, V24, P9870, DOI 10.1523/JNEUROSCI.3225-04.2004; Blesa J, 2010, NEUROBIOL DIS, V38, P456, DOI 10.1016/j.nbd.2010.03.006; BOLDRY RC, 1995, BRAIN RES, V692, P259, DOI 10.1016/0006-8993(95)00690-R; Cepeda C, 2001, J NEUROPHYSIOL, V85, P659; Chase TN, 1998, NEUROLOGY, V51, pS30; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Kita Hitoshi, 2011, Front Syst Neurosci, V5, P42, DOI 10.3389/fnsys.2011.00042; KITAI ST, 1993, ADV NEUROL, V60, P40; OVERTON P, 1992, SYNAPSE, V10, P131, DOI 10.1002/syn.890100208; Papa SM, 2004, ANN NEUROL, V56, P723, DOI 10.1002/ana.20279; Papa SM, 2008, EXP NEUROL, V211, P334, DOI 10.1016/j.expneurol.2008.03.009; PEREZOTANO I, 1994, NEUROSCI LETT, V175, P121, DOI 10.1016/0304-3940(94)91094-4; Perreault ML, 2011, FRONT NEUROANAT, V5, DOI 10.3389/fnana.2011.00031; Potts LF, 2014, EXP NEUROL, V256, P133, DOI 10.1016/j.expneurol.2013.09.014; Tepper JM, 2006, MICROCIRCUITS INTERF, P127	68	2	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAR 1	2015	113	5					1533	1544		10.1152/jn.00910.2014		12	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	CD0DK	WOS:000350740400023		
J	Li, ZS; Noda, K; Fujita, E; Manabe, Y; Hirata, T; Sugawara, T				Li, Zhuo-Si; Noda, Kenji; Fujita, Eriko; Manabe, Yuki; Hirata, Takashi; Sugawara, Tatsuya			The Green Algal Carotenoid Siphonaxanthin Inhibits Adipogenesis in 3T3-L1 Preadipocytes and the Accumulation of Lipids in White Adipose Tissue of KK-Ay Mice	JOURNAL OF NUTRITION			English	Article						siphonaxanthin; marine carotenoids; adipogenesis; 3T3-L1 cells; adipose tissue; KK-Ay mice	BINDING PROTEIN-BETA; DIET-INDUCED OBESITY; ADIPOCYTE DIFFERENTIATION; UNCOUPLING PROTEINS; KK-A(Y) MICE; WEIGHT-GAIN; C/EBP-BETA; EXPRESSION; FUCOXANTHIN; CELLS	Background: Siphonaxanthin, a xanthophyll present in green algae, has been shown to possess antiangiogenic and apoptosis-inducing activities. Objective: We evaluated the antiobesity effects of siphonaxanthin by using a 3T3-L1 cell culture system and in diabetic KK-Ay mice. Methods: 3T3-L1 cells were differentiated with or without 5 mu mol/L siphonaxanthin, and lipid accumulation and critical gene expressions for adipogenesis were examined. In vivo, 4-wk-old male KK-Ay mice were administered daily oral treatment of 1.3 mg siphonaxanthin for 6 wk and body weight, visceral fat weight, serum variables, and gene expressions involved in lipid metabolism were evaluated. Results: Compared with the other carotenoids evaluated, siphonaxanthin potently inhibited adipocyte differentiation. Siphonaxanthin significantly suppressed lipid accumulation at noncytotoxic concentrations of 2.5 and 5 mu mol/L by 29% and 43%, respectively. The effects of siphonaxanthin were largely limited to the early stages of adipogenesis. Siphonaxanthin significantly inhibited protein kinase B phosphorylation by 48% and 72% at 90 and 120 min, respectively. The expressions of key adipogenesis genes, including CCAAT/enhancer binding protein alpha (Cebpa), peroxisome proliferator activated receptor g (Pparg), fatty acid binding protein 4 (Fabp4), and stearoyl coenzyme A desaturase 1 (Scd1), were elevated by 1.6- to 166-fold during adipogenesis. After 8 d of adipocyte differentiation, siphonaxanthin significantly lowered gene expression of Cebpa, Pparg, Fabp4, and Scd1 by 94%, 83%, 95%, and 90%, respectively. Moreover, oral administration of siphonaxanthin to KK-Ay mice significantly reduced the total weight of white adipose tissue (WAT) by 13%, especially the mesenteric WAT by 28%. Furthermore, siphonaxanthin administration reduced lipogenesis and enhanced fatty acid oxidation in adipose tissue. Siphonaxanthin was observed to highly accumulate in mesenteric WAT, and the accumulation in the mesenteric WAT was almost 2- and 3-fold that in epididymal (P = 0.14) and perirenal (P < 0.05) WAT, respectively. Conclusion: These results provide evidence that siphonaxanthin may effectively regulate adipogenesis in 3T3-L1 cells and diabetic KK-Ay mice.	[Li, Zhuo-Si; Noda, Kenji; Fujita, Eriko; Manabe, Yuki; Hirata, Takashi; Sugawara, Tatsuya] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Kyoto, Japan; [Hirata, Takashi] Shijonawate Gakuen Univ, Dept Rehabil, Osaka, Japan	Sugawara, T (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Kyoto, Japan.	sugawara@kais.kyoto-u.ac.jp			Japan Society for the Promotion of Science [23380124]	Supported by Grant-in-Aid for Scientific Research (B) from Japan Society for the Promotion of Science (grant 23380124). Codium fragile was supplied by the NOF Corporation.	Shan TZ, 2013, FASEB J, V27, P277, DOI 10.1096/fj.12-211516; Kim CY, 2011, J NUTR BIOCHEM, V22, P910, DOI 10.1016/j.jnutbio.2010.08.003; REEVES PG, 1993, J NUTR, V123, P1939; Takaichi S, 2011, MAR DRUGS, V9, P1101, DOI 10.3390/md9061101; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; Ali AT, 2013, EUR J CELL BIOL, V92, P229, DOI 10.1016/j.ejcb.2013.06.001; Sugawara T, 2014, MAR DRUGS, V12, P3660, DOI 10.3390/md12063660; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Woo MN, 2009, MOL NUTR FOOD RES, V53, P1603, DOI 10.1002/mnfr.200900079; Ganesan P, 2011, BBA-GEN SUBJECTS, V1810, P497, DOI 10.1016/j.bbagen.2011.02.008; Manabe Y, 2014, J OLEO SCI, V63, P291, DOI 10.5650/jos.ess13169; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Harmon AW, 2002, BIOCHEM J, V367, P203, DOI 10.1042/BJ20020300; Semple RK, 2004, INT J OBESITY, V28, P176, DOI 10.1038/sj.ijo.0802482; Maeda H, 2007, J AGR FOOD CHEM, V55, P7701, DOI 10.1021/jf071569n; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Lee J, 2012, J BIOL CHEM, V287, P8839, DOI 10.1074/jbc.M111.263434; Pangestuti R, 2011, J FUNCT FOODS, V3, P255, DOI 10.1016/j.jff.2011.07.001; Strable MS, 2010, CRIT REV BIOCHEM MOL, V45, P199, DOI 10.3109/10409231003667500; IWATSUKA H, 1970, ENDOCRINOL JAPON, V17, P23; Ganesan P, 2013, MOL CELL BIOCHEM, V380, P1, DOI 10.1007/s11010-013-1651-5; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Ganesan P, 2010, PHYTOMEDICINE, V17, P1140, DOI 10.1016/j.phymed.2010.05.005; Xu JF, 2004, J BIOL CHEM, V279, P35914, DOI 10.1074/jbc.M402297200; Kohn AD, 1996, J BIOL CHEM, V271, P31372; Lefterova MI, 2009, TRENDS ENDOCRIN MET, V20, P107, DOI 10.1016/j.tem.2008.11.005; Maeda H, 2006, INT J MOL MED, V18, P147; Jeon SM, 2010, BIOTECHNOL J, V5, P961, DOI 10.1002/biot.201000215; Bluher M, 2013, BEST PRACT RES CL EN, V27, P163, DOI 10.1016/j.beem.2013.02.005; Maeda H, 2005, BIOCHEM BIOPH RES CO, V332, P392, DOI 10.1016/j.bbrc.2005.05.002; Gregoire FM, 2001, EXP BIOL MED, V226, P997; Beppu F, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-112; Boss O, 1998, FASEB J, V12, P335; Bray GA, 2006, J MED CHEM, V49, P4001, DOI 10.1021/jm0680124; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Enguix Natàlia, 2013, Mol Metab, V2, P215, DOI 10.1016/j.molmet.2013.05.004; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; Nakano R, 2006, BIOCHEM PHARMACOL, V72, P42, DOI 10.1016/j.bcp.2006.03.023; Okada T, 2008, J OLEO SCI, V57, P345, DOI 10.5650/jos.57.345; Shirakura Y, 2011, J NUTR SCI VITAMINOL, V57, P426; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Walton TJ, 1973, PHYTOCHEMISTRY, V9, P2545	45	0	0	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3166	1541-6100		J NUTR	J. Nutr.	MAR	2015	145	3					490	498		10.3945/jn.114.200931		9	Nutrition & Dietetics	Nutrition & Dietetics	CC5RM	WOS:000350420400017		
J	Mizoue, T; Kochi, T; Akter, S; Eguchi, M; Kurotani, K; Tsuruoka, H; Kuwahara, K; Ito, R; Kabe, I; Nanri, A				Mizoue, Tetsuya; Kochi, Takeshi; Akter, Shamima; Eguchi, Masafumi; Kurotani, Kayo; Tsuruoka, Hiroko; Kuwahara, Keisuke; Ito, Rie; Kabe, Isamu; Nanri, Akiko			Low Serum 25-Hydroxyvitamin D Concentrations Are Associated with Increased Likelihood of Having Depressive Symptoms among Japanese Workers	JOURNAL OF NUTRITION			English	Article						cross-sectional studies; depressive symptoms; Japanese; worker; 25-hydroxyvitamin D	VITAMIN-D LEVELS; MOOD DISORDERS; D DEFICIENCY; D-RECEPTOR; ADULTS; POPULATION; HEALTH; NUTRITION; SAMPLE; DIET	Background: Accumulating evidence suggests a protective role of vitamin D against mood disorders; however, epidemiologic studies are scarce in working populations. Objective: We investigated cross-sectionally the association of serum vitamin D status and depressive symptoms among Japanese workers. Methods: Participants were 1786 employees (9% women), aged 19-69 y, who received health check-ups and participated in a nutrition and health survey. Serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured with the use of a competitive protein binding assay. Depressive symptoms were assessed by using the Center for Epidemiologic Studies Depression (CES-D) scale. Logistic regression was used to estimate ORs with adjustment for potential confounding variables including dietary factors. Results: Overall, 92% of study participants had suboptimal vitamin D status [25(OH)D < 30 mu g/L]. Depressive symptoms were inversely associated with 25(OH) D. Compared with those with a 25(OH)D concentration of <20 mu g/L, multivariable-adjusted ORs (95% CIs) for depressive symptoms (CES-D scale score >= 16) were 0.75 (0.59, 0.95) and 0.66 (0.41, 1.06) for those with a 25(OH) D concentration of 20-29 mu g/L and >= 30 mu g/L, respectively (P-trend = 0.01). After further adjustment for leisure-time physical activity and shift work (factors closely related to photo-initiated vitamin D production), the OR (95% CI) for the highest category of 25(OH)D was 0.70 (0.43, 1.14). The association between 25(OH)D and depressive symptoms appears to be linear, according to restricted cubic spline regression. Conclusion: Results suggest that lower concentrations of circulating vitamin D are associated with increased likelihood of having depressive symptoms among apparently healthy workers.	[Mizoue, Tetsuya; Akter, Shamima; Kurotani, Kayo; Kuwahara, Keisuke; Nanri, Akiko] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan; [Kochi, Takeshi; Eguchi, Masafumi; Tsuruoka, Hiroko; Ito, Rie; Kabe, Isamu] Furukawa Elect Corp, Dept Hlth Adm, Tokyo, Japan; [Kuwahara, Keisuke] Teikyo Univ, Grad Sch Publ Hlth, Tokyo 173, Japan	Mizoue, T (reprint author), Natl Ctr Global Hlth & Med, Ctr Clin Sci, Dept Epidemiol & Prevent, Tokyo, Japan.	mizoue@ri.ncgm.go.jp			Industrial Health Foundation [25702006]; Uehara Memorial Foundation	Supported by Grant-in-Aid for Young Scientists (A) (25702006), the Industrial Health Foundation, and the Uehara Memorial Foundation.	Akter S, NUTRITION IN PRESS; Milaneschi Y, 2014, MOL PSYCHIATR, V19, P444, DOI 10.1038/mp.2013.36; Nanri A, 2009, EUR J CLIN NUTR, V63, P1444, DOI 10.1038/ejcn.2009.96; Black LJ, 2014, AUST NZ J PSYCHIAT, V48, P464, DOI 10.1177/0004867413512383; THOREN P, 1990, MED SCI SPORT EXER, V22, P417; Stewart R, 2010, PSYCHOSOM MED, V72, P608, DOI 10.1097/PSY.0b013e3181e9bf15; May HT, 2010, AM HEART J, V159, P1037, DOI 10.1016/j.ahj.2010.03.017; Kessler RC, 2006, AM J PSYCHIAT, V163, P1561, DOI 10.1176/appi.ajp.163.9.1561; Burne THJ, 2006, BRAIN RES BULL, V69, P74, DOI 10.1016/j.brainresbull.2005.10.014; Hoang MT, 2011, MAYO CLIN PROC, V86, P1050, DOI 10.4065/mcp.2011.0208; McClung CA, 2007, PHARMACOL THERAPEUT, V114, P222, DOI 10.1016/j.pharmthera.2007.02.003; Anglin RES, 2013, BRIT J PSYCHIAT, V202, P100, DOI 10.1192/bjp.bp.111.106666; Murakami K, 2008, NUTRITION, V24, P140, DOI 10.1016/j.nut.2007.10.013; Milaneschi Y, 2010, J CLIN ENDOCR METAB, V95, P3225, DOI 10.1210/jc.2010-0347; Ono Y, 2005, J BONE MINER METAB, V23, P147, DOI 10.1007/s00774-004-0553-8; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Nanri A, 2013, EUR J CLIN NUTR, V67, P1060, DOI 10.1038/ejcn.2013.115; Li GW, 2014, J CLIN ENDOCR METAB, V99, P757, DOI 10.1210/jc.2013-3450; Sanhueza C, 2013, J HUM NUTR DIET, V26, P56, DOI 10.1111/j.1365-277X.2012.01283.x; Jaddou HY, 2012, EUR ARCH PSY CLIN N, V262, P321, DOI 10.1007/s00406-011-0265-8; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI [10.2188/jeaJE20110075, 10.2188/jea.JE20110075]; Chan R, 2011, J AFFECT DISORDERS, V130, P251, DOI 10.1016/j.jad.2010.10.029; Maddock J, 2013, CLIN NUTR, V32, P758, DOI 10.1016/j.clnu.2013.01.006; Lee DM, 2011, J PSYCHOPHARMACOL, V25, P1320, DOI 10.1177/0269881110379287; Nanri A, 2014, PSYCHIAT RES, V220, P263, DOI 10.1016/j.psychres.2014.08.026; Bertone-Johnson ER, 2011, AM J CLIN NUTR, V94, P1104, DOI 10.3945/ajcn.111.017384; Chung HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099185; Ferrari AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069637; Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547; Ganji Vijay, 2010, Int Arch Med, V3, P29, DOI 10.1186/1755-7682-3-29; Jacka FN, 2009, AUST NZ J PSYCHIAT, V43, P45, DOI 10.1080/00048670802534408; Karasek R, 1998, J Occup Health Psychol, V3, P322, DOI 10.1037/1076-8998.3.4.322; Kim BK, 2013, CALCIFIED TISSUE INT, V93, P495, DOI 10.1007/s00223-013-9779-6; Kjaergaard M, 2011, PSYCHIAT RES, V190, P221; Lu HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047264; Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Shima S, 1985, CLIN PSYCHIATR, V27, P717; Yi S, 2011, PSYCHIAT RES, V189, P368, DOI 10.1016/j.psychres.2011.03.009	40	1	1	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3166	1541-6100		J NUTR	J. Nutr.	MAR	2015	145	3					541	546		10.3945/jn.114.204115		6	Nutrition & Dietetics	Nutrition & Dietetics	CC5RM	WOS:000350420400023		
J	Hoshuyama, T; Odashiro, K; Fukata, M; Maruyama, T; Saito, K; Wakana, C; Fukumitsu, M; Fujino, T				Hoshuyama, Tsutomu; Odashiro, Keita; Fukata, Mitsuhiro; Maruyama, Toru; Saito, Kazuyuki; Wakana, Chikako; Fukumitsu, Michiko; Fujino, Takehiko			Mortality Benefit of Participation in BOOCS Program A Follow-Up Study for 15 Years in a Japanese Working Population	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							CARDIOVASCULAR-DISEASE MORTALITY; SELF-DETERMINATION THEORY; ALL-CAUSE MORTALITY; METABOLIC SYNDROME; PHYSICAL-ACTIVITY; LIFE-STYLE; WORKING POPULATION; CONTROLLED-TRIAL; HIGH-RISK; INTERVENTION	Objective: This study aims to demonstrate the protective effect on mortality among participants of a health education program, Brain-Oriented Obesity Control System (BOOCS). Methods: A quasi-experimentally designed, 15-year (1993 to 2007) follow-up study was conducted with a total of 13,835 male and 7791 female Japanese workers. They were divided into three groups: participants in the program (1565 males and 742 females), nonparticipant comparative obese controls (1230 males and 605 females), and nonparticipant reference subjects (11,012 males and 6426 females). Hazard ratios were calculated with survival curves drawn to evaluate the mortality effects by the program participation. Results: The male participants showed significantly lower mortality risk for all causes of death at hazard ratio = 0.54 (95% confidence interval: 0.31 to 0.94) with significantly different survival curves (P = 0.014 by log-rank test) than obese controls. Conclusions: The results support a protective effect on mortality by participating in BOOCS program.	[Hoshuyama, Tsutomu] Ushibuka City Hosp, Kumamoto 8631901, Japan; [Odashiro, Keita; Fukata, Mitsuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 812, Japan; [Maruyama, Toru] Kyushu Univ, Fac Arts & Sci, Fukuoka 812, Japan; [Saito, Kazuyuki; Wakana, Chikako; Fukumitsu, Michiko; Fujino, Takehiko] BOOCS Clin, Fukuoka, Japan	Hoshuyama, T (reprint author), Ushibuka City Hosp, 3050 Ushibuka, Kumamoto 8631901, Japan.	goldmedal@hotmail.co.jp					Sawada SS, 2010, DIABETES CARE, V33, P1353, DOI 10.2337/dc09-1654; Caballero B, 2007, EPIDEMIOL REV, V29, P1, DOI 10.1093/epirev/mxm012; Arao T, 2007, PREV MED, V45, P146, DOI 10.1016/j.ypmed.2007.05.004; Deen D, 2004, AM FAM PHYSICIAN, V69, P2875; Chalmers J, 2008, NEW ENGL J MED, V359, P1618, DOI 10.1056/NEJMe0807625; Huang KC, 2008, OBESITY, V16, P684, DOI 10.1038/oby.2007.112; Teixeira PJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-78; Karlsson B, 2001, OCCUP ENVIRON MED, V58, P747, DOI 10.1136/oem.58.11.747; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Arena VC, 2006, J OCCUP ENVIRON MED, V48, P1118, DOI 10.1097/01.jom.0000241050.26059.2b; Ford ES, 2005, DIABETES CARE, V28, P1769, DOI 10.2337/diacare.28.7.1769; Cowey S, 2006, AM J PATHOL, V169, P1505, DOI 10.2353/ajpath.2006.051090; Groeneveld IF, 2010, SCAND J WORK ENV HEA, V36, P202; Naito M, 2008, ATHEROSCLEROSIS, V197, P784, DOI 10.1016/j.atherosclerosis.2007.07.026; Bonauto DK, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.130219; Delinsky SS, 2006, OBESITY, V14, P1244, DOI 10.1038/oby.2006.141; Fujino Takehiko, 1999, Fukuoka Acta Medica, V90, P353; Grave R. D., 2010, DIABETES METAB SYNDR, V3, P373; Guize L, 2007, DIABETES CARE, V30, P2381, DOI 10.2337/dc07-0186; Haruyama Y, 2013, J OCCUP HEALTH, V55, P74; Hoshuyama T, 2009, SAN EI SHI S, V51, P55; Jans MP, 2007, J OCCUP ENVIRON MED, V49, P975, DOI 10.1097/JOM.0b013e31814b2eb7; Lallukka T, 2005, INT J OBESITY, V29, P909, DOI 10.1038/sj.ijo.0802962; Liese AD, 1998, EPIDEMIOL REV, V20, P157; Ministry of Health Labour and Welfare Japan, 1993, VIT STAT JAP; Munakata Masanori, 2008, Vasc Health Risk Manag, V4, P415; Nishikitani M, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000958; REN AG, 1994, J EPIDEMIOL COMMUN H, V48, P476, DOI 10.1136/jech.48.5.476; Saito I, 2009, CIRC J, V73, P878; Sekine M, 2011, SOC SCI MED, V73, P593; Silva MN, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-234; Suka Machi, 2013, Sangyo Eiseigaku Zasshi, V55, P1; Umanodan R, 2009, J OCCUP HEALTH, V51, P294	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1076-2752	1536-5948		J OCCUP ENVIRON MED	J. Occup. Environ. Med.	MAR	2015	57	3					246	250		10.1097/JOM.0000000000000399		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CD0XM	WOS:000350797500009		
J	Shigeishi, H; Biddle, A; Gammon, L; Rodini, CO; Yamasaki, M; Seino, S; Sugiyama, M; Takechi, M; Mackenzie, IC				Shigeishi, Hideo; Biddle, Adrian; Gammon, Luke; Rodini, Camila O.; Yamasaki, Miho; Seino, Sayaka; Sugiyama, Masaru; Takechi, Masaaki; Mackenzie, Ian C.			Elevation in 5-FU-induced apoptosis in Head and Neck Cancer Stem Cells by a combination of CDHP and GSK3 beta inhibitors	JOURNAL OF ORAL PATHOLOGY & MEDICINE			English	Article						5-FU; cancer stem cell; GSK3; head and neck squamous cell carcinoma	TUMOR-INITIATING CELLS; CARCINOMA; 5-FLUOROURACIL; CHEMOTHERAPY; RESISTANCE; PHARMACOLOGY; LINES	BackgroundCancer stem cells (CSCs) are involved in both tumourigenesis and in tumour recurrence after therapy. In head and neck squamous cell carcinoma (HNSCC), there are two biologically different CSC phenotypes both of which express high levels of CD44 but differ in their expression levels of epithelial-specific antigen (ESA). One phenotype is CD44(high)/ESA(high) and has epithelial features (Epi-CSCs), while the other is CD44(high)/ESA(low), has undergone epithelial to mesenchymal transition (EMT-CSCs), has mesenchymal features and is migratory (Biddle etal., 2011). CSCs are resistant to therapeutically induced apoptosis but the molecular mechanisms by which they develop apoptotic resistance remains unclear. However, glycogen synthase kinase 3 (GSK3) contributes to regulation of both the self-renewal and switching of these two CSC phenotypes (Shigeishi etal., 2013). MethodsCD44(high)/ESA(low), CD44(high)/ESA(high) and CD44(low) cells were FACS sorted from the HNSCC cell line LUC4, and 5-FU-induced apoptosis was analysed by Annexin V staining followed by flow cytometry analysis. ResultsCD44(high)/ESA(low) cells exhibited marked resistance to 5-FU-induced apoptosis and had high expression of dihydropyrimidine dehydrogenase (DPD). The DPD inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) significantly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. Inhibition of GSK3 induced CD44(high)/ESA(low) cells to undergo mesenchymal-to-epithelial transition (MET) to CD44(high)/ESA(high) cells and pre-existing CD44(high)/ESA(high) cells to differentiate. Apoptosis induced by 5-FU was thus facilitated. Combination of both CDHP and GSK3 inhibitors markedly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. ConclusionsOur results suggest potentially new approaches for the elimination of the therapy resistant HNSCC CSC population.	[Shigeishi, Hideo; Biddle, Adrian; Gammon, Luke; Rodini, Camila O.; Mackenzie, Ian C.] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England; [Shigeishi, Hideo; Yamasaki, Miho; Seino, Sayaka; Takechi, Masaaki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Oral & Maxillofacial Surg, Hiroshima, Japan; [Sugiyama, Masaru] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Publ Oral Hlth, Hiroshima, Japan	Mackenzie, IC (reprint author), Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, 4 Newark St, London E1 2AT, England.	i.c.mackenzie@qmul.ac.uk	Rodini, Camila/C-4437-2012	Rodini, Camila/0000-0002-8763-4967	Scientific Research Fund of Sugiyama Chemical and Industrial Laboratory; Satake Fund for Scientific Research from Hiroshima University Supporters' Association; Japanese Ministry of Education, Culture, Sports, and Technology [11008667]; NC3Rs; Barts and The London Charitable Foundation	This work was supported by grants to Dr. Shigeishi from the Scientific Research Fund of Sugiyama Chemical and Industrial Laboratory (2011), the Satake Fund for Scientific Research from Hiroshima University Supporters' Association (2011) and a Grant-in-aid for Scientific Research (C) (No. 11008667) from the Japanese Ministry of Education, Culture, Sports, and Technology. It was also supported by grants from the NC3Rs and from Barts and The London Charitable Foundation.	Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931; Shigeishi H, 2013, STEM CELLS, V31, P2073, DOI 10.1002/stem.1418; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Ginestier C, 2009, CELL CYCLE, V8, P3297; Petersen PE, 2009, ORAL ONCOL, V45, P454, DOI 10.1016/j.oraloncology.2008.05.023; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Loebinger MR, 2008, BRIT J CANCER, V98, P380, DOI 10.1038/sj.bjc.6604185; Chikamatsu K, 2012, HEAD NECK-J SCI SPEC, V34, P336, DOI 10.1002/hed.21732; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Grem J. L., 1996, CANC CHEMOTHERAPY BI, P149; Harper LJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-166; Harper LJ, 2007, J ORAL PATHOL MED, V36, P594, DOI 10.1111/j.1600-0714.2007.00617.x; Hoque MO, 2001, INT J ONCOL, V19, P953; MILANO G, 1994, ANTICANCER RES, V14, P2295; Ola MS, 2011, MOL CELL BIOCHEM, V35, P41; Omura Kenji, 2003, Int J Clin Oncol, V8, P132, DOI 10.1007/s10147-003-0330-z; SANTI DV, 1980, J MED CHEM, V23, P103, DOI 10.1021/jm00176a001; Sell S, 2007, STEM CELL REV, V3, P1; Shintani Y, 2011, ANTICANCER RES, V31, P4665; Shirasaka T, 1996, ANTI-CANCER DRUG, V7, P548, DOI 10.1097/00001813-199607000-00010; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0904-2512	1600-0714		J ORAL PATHOL MED	J. Oral Pathol. Med.	MAR	2015	44	3					201	207		10.1111/jop.12230		7	Dentistry, Oral Surgery & Medicine; Pathology	Dentistry, Oral Surgery & Medicine; Pathology	CD4JS	WOS:000351049200005		
J	Hiramatsu, T; Itoh, A; Kawashima, H; Ohno, E; Itoh, Y; Sugimoto, H; Sumi, H; Funasaka, K; Nakamura, M; Miyahara, R; Katano, Y; Ishigami, M; Ohmiya, N; Kaneko, K; Ando, H; Goto, H; Hirooka, Y				Hiramatsu, Takeshi; Itoh, Akihiro; Kawashima, Hiroki; Ohno, Eizaburo; Itoh, Yuya; Sugimoto, Hiroyuki; Sumi, Hajime; Funasaka, Kohei; Nakamura, Masanao; Miyahara, Ryoji; Katano, Yoshiaki; Ishigami, Masatoshi; Ohmiya, Naoki; Kaneko, Kenitiro; Ando, Hisami; Goto, Hidemi; Hirooka, Yoshiki			Usefulness and safety of endoscopic retrograde cholangiopancreatography in children with pancreaticobiliary maljunction	JOURNAL OF PEDIATRIC SURGERY			English	Article						Pancreaticobiliary maljunction; Endoscopic retrograde cholangiopancreatography; Magnetic resonance cholangiopancreatography; Children	MAGNETIC-RESONANCE CHOLANGIOPANCREATOGRAPHY; CHOLEDOCHAL CYSTS; STENOSIS	Background: To assess the diagnostic ability and safety of endoscopic retrograde cholangiopancreatography (ERCP) in in-depth preoperative examination of children patients with pancreaticobiliary maljunction (PBM). Methods: In 63 patients with a definite diagnosis of PBM, the ability to visualize the bile and main pancreatic ducts was compared between ERCP, which was performed in 63 patients with a definite diagnosis of PBM, and magnetic resonance cholangiopancreatography (MRCP), which was performed before ERCP in 29 patients. For ERCP, its complications were also evaluated. Results: The intrahepatic bile ducts could be visualized using ERCP in 44 patients (69.8%) and using MRCP in 18 (62.1%). The extrahepatic bile ducts could be visualized using ERCP in 59 patients (93.7%) and using MRCP in 29 (100%). The rates of the visualization of the main pancreatic duct and pancreaticobiliary ductal union were significantly higher in using ERCP than in using MRCP (96.8 vs. 41.4% and 90.5 vs. 37.9%, respectively; P < 0.0001). As complications, hyperamylasemia developed in 12 patients (19%), but no other severe complications such as pancreatitis were observed. Conclusions: ERCP as part of an in-depth preoperative examination of children with PBM is useful and safe. (C) 2015 Elsevier Inc. All rights reserved.	[Hiramatsu, Takeshi; Itoh, Akihiro; Kawashima, Hiroki; Itoh, Yuya; Sugimoto, Hiroyuki; Sumi, Hajime; Nakamura, Masanao; Miyahara, Ryoji; Katano, Yoshiaki; Ishigami, Masatoshi; Ohmiya, Naoki; Goto, Hidemi] Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Nagoya, Aichi 4648601, Japan; [Ohno, Eizaburo; Funasaka, Kohei; Goto, Hidemi; Hirooka, Yoshiki] Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi 4668550, Japan; [Kaneko, Kenitiro; Ando, Hisami] Nagoya Univ, Dept Pediat Surg, Grad Sch Med, Nagoya, Aichi 4648601, Japan	Hirooka, Y (reprint author), Nagoya Univ Hosp, Dept Endoscopy, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.	hirooka@med.nagoya-u.ac.jp	KAWASHIMA, Hiroki/I-7285-2014				ANDO H, 1995, J AM COLL SURGEONS, V181, P125; ANDO H, 1995, J AM COLL SURGEONS, V181, P426; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; Koshinaga T, 2011, J HEPATO-BIL-PAN SCI, V18, P47, DOI 10.1007/s00534-010-0294-0; Matos C, 1998, RADIOLOGY, V209, P443; Otto AK, 2011, SURG ENDOSC, V25, P2536, DOI 10.1007/s00464-011-1582-8; Sugiyama M, 1998, SURGERY, V123, P391, DOI 10.1067/msy.1998.86581; Fumino S, 2011, J PEDIATR SURG, V46, P1373, DOI 10.1016/j.jpedsurg.2011.01.026; Kamisawa T, 2007, ABDOM IMAGING, V32, P129, DOI 10.1007/s00261-006-9005-3; Kamisawa T, 2012, J GASTROENTEROL, V47, P731, DOI 10.1007/s00535-012-0611-2; Kaneko K, 1997, AM J GASTROENTEROL, V92, P1018; Tashiro Seiki, 2003, J Hepatobiliary Pancreat Surg, V10, P345, DOI 10.1007/s00534-002-0741-7	12	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	MAR	2015	50	3					377	381		10.1016/j.jpedsurg.2014.08.024		5	Pediatrics; Surgery	Pediatrics; Surgery	CD1HI	WOS:000350825200003		
J	Pandya, KA; Koga, H; Okawada, M; Coran, AG; Yamataka, A; Teitelbaum, DH				Pandya, Kartikey A.; Koga, Hiroyuki; Okawada, Manabu; Coran, Arnold G.; Yamataka, Atsuyuki; Teitelbaum, Daniel H.			Vaginal anomalies and atresia associated with imperforate anus: Diagnosis and surgical management	JOURNAL OF PEDIATRIC SURGERY			English	Article						Mayer-Rokitansky-Kuster-Hauser Syndrome; Imperforate anus; Vaginal atresia; Colovaginoplasty	ENDORECTAL PULL-THROUGH; KUSTER-HAUSER SYNDROME; RECTOVESTIBULAR FISTULA; ANORECTAL-MALFORMATIONS; HIRSCHSPRUNGS-DISEASE; ABSENT VAGINA; TERM; AGENESIS; GIRL	Background: The association of vaginal atresia (or Mayer-Rokitansky-Kuster-Hauser Syndrome) with imperforate anus is rare and can present significant diagnostic and therapeutic challenges. This study describes clinical characteristics, surgical treatment and outcomes in this group of complex children. Methods: Records of 20 patients were retrospectively analyzed from two pediatric surgical centers. Results: Five patients were excluded from the long-term analysis due to inadequate information, leaving long-term follow-up in 15 patients. Mean follow-up was 10 years (range 1-31.1 years). The diagnosis of vaginal atresia was made pre-operatively in 12 out of 15 patients, and in three patients it was identified during the anoplasty. The anorectal malformations were rectoperineal (N = 2), rectovestibular (N = 6), recto-bladder neck (N = 1) and imperforate anus without fistula (N = 6). Satisfactory surgical repair was performed in 13 patients, while one continues to stool through a low perineal fistula awaiting definitive surgery and another underwent a colostomy and mucous fistula. Delayed vaginal reconstruction was due to a failure to identify the problemprior to anoplasty (N = 3). Long-term results demonstrated that anorectal continence was much worse than initially appreciated, and many had associated urinary incontinence. Overall stooling score was far lower than in a separate group of children with imperforate anus without vaginal atresia (Levitt and Pena, 2007). Conclusions: Vaginal atresia with imperforate anus is a rare and an extensive pre-operative workup of females with imperforate anus must include assessment of vagina patency. Vaginal reconstruction and anorectal continuity can be performed in a variety of approaches, but long-term continence is often not optimal. We propose a pathway for management of this difficult genito-anorectal disorder. (C) 2015 Elsevier Inc. All rights reserved.	[Pandya, Kartikey A.; Coran, Arnold G.; Teitelbaum, Daniel H.] Univ Michigan, Dept Surg, Pediat Surg Sect, Ann Arbor, MI 48109 USA; [Koga, Hiroyuki; Okawada, Manabu; Yamataka, Atsuyuki] Juntendo Univ, Juntendo Hosp, Dept Pediat Surg, Tokyo, Japan	Teitelbaum, DH (reprint author), Univ Michigan, Mott Childrens Hosp, Pediat Surg Sect, 1540 E Hosp Dr,SPC 4211, Ann Arbor, MI 48109 USA.	dttlbm@umich.edu					Acien P, 2008, HUM REPROD, V23, P548, DOI 10.1093/humrep/dem420; Adejuyigbe O, 2002, J PEDIATR SURG, V37, P1479, DOI 10.1053/jpsu.2002.35419; Ishihara M, 2005, PEDIATR SURG INT, V21, P878, DOI 10.1007/s00383-005-1506-6; [Anonymous], 2002, OBSTET GYNECOL, V100, P213; Levitt MA, 2009, J PEDIATR SURG, V44, P1261, DOI 10.1016/j.jpedsurg.2009.02.046; Kim AC, 2010, J PEDIATR SURG, V45, P1213, DOI 10.1016/j.jpedsurg.2010.02.087; BRYAN AL, 1949, SURG GYNECOL OBSTET, V88, P79; EIN SH, 1971, J PEDIATR SURG, V6, P435, DOI 10.1016/S0022-3468(71)80004-0; Hashish MS, 2010, J PEDIATR SURG, V45, P224, DOI 10.1016/j.jpedsurg.2009.10.041; Jarboe MD, 2012, PEDIATR SURG INT, V28, P757, DOI 10.1007/s00383-012-3122-6; Khen-Dunlop N, 2007, J UROLOGY, V177, P1107, DOI 10.1016/j.juro.2006.11.003; Levitt MA, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-33; Levitt MA, 1998, J PEDIATR SURG, V33, P986, DOI 10.1016/S0022-3468(98)90519-X; Marsh CA, 2013, J PEDIATR ADOL GYNEC, V26, P199, DOI 10.1016/j.jpag.2012.11.014; Oppelt PG, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-57; Patankar Shreeprasad P., 2004, Indian Journal of Pediatrics, V71, P1133, DOI 10.1007/BF02829831; Sarin YK, 2002, J PEDIATR SURG, V37, P1217, DOI 10.1053/jpsu.2002.34480; TOLETEVELCEK F, 1989, J PEDIATR SURG, V24, P736, DOI 10.1016/S0022-3468(89)80527-5; Wester T, 2012, J PEDIATR SURG, V47, P571, DOI 10.1016/j.jpedsurg.2011.09.040	19	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	MAR	2015	50	3					431	437		10.1016/j.jpedsurg.2014.07.010		7	Pediatrics; Surgery	Pediatrics; Surgery	CD1HI	WOS:000350825200014		
J	Pooh, RK; Kurjak, A				Pooh, Ritsuko Kimata; Kurjak, Asim			Novel application of three-dimensional HDlive imaging in prenatal diagnosis from the first trimester	JOURNAL OF PERINATAL MEDICINE			English	Article						Fetus; HDlive; prenatal; sonoembryology; three-dimensional; ultrasound	4-DIMENSIONAL SONOGRAPHY	Recent development of three-dimensional (3D) high definition (HD) ultrasound has resulted in remarkable progress in visualization of early embryos and fetuses in sonoembryology. The new technology of HDlive assesses both structural and functional developments in the first trimester with greater reliably than two-dimensional (2D) ultrasound. The ability to visualize not only fetal face, hands, fingers, feet, and toes, but also amniotic membranes, is better with volumetric ultrasound than 2D ultrasound. In this article, detailed and comprehensive structures of normal and abnormal fetuses depicted by 3D HDlive are presented, including various faces of Down's syndrome and holoprosencephaly, as well as low-set ear and finger/toe abnormalities from the first trimester. Three-dimensional HDlive further "humanizes" the fetus, enables detailed observation of the fetal face in the first trimester as shown in this article, and reveals that a small fetus is not more a fetus but a "person" from the first trimester. There has been an immense acceleration in understanding of early human development. The anatomy and physiology of embryonic development is a field where medicine exerts greatest impact on early pregnancy at present, and it opens fascinating aspects of embryonic differentiation. Clinical assessment of those stages of growth relies heavily on 3D/four-dimensional (4D) HDlive, one of the most promising forms of noninvasive diagnostics and embryological phenomena, once matters for textbooks are now routinely recorded with outstanding clarity. New advances deserve the adjective "breathtaking", including 4D parallel study of the structural and functional early human development.	[Pooh, Ritsuko Kimata] Dubrovnik Int Univ, Acad Teaching Ctr, CRIFM Clin Res Inst Fetal Med PMC, Osaka 5430001, Japan; [Kurjak, Asim] Dubrovnik Int Univ, Dept Med Sci, Dubrovnik, Croatia	Pooh, RK (reprint author), Dubrovnik Int Univ, Acad Teaching Ctr, CRIFM Clin Res Inst Fetal Med PMC, 7-1-24 Uehommachi Tennoji Osaka, Osaka 5430001, Japan.	rkpooh@me.com					Pooh RK, 2012, J MATERN-FETAL NEO M, V25, P433, DOI 10.3109/14767058.2011.636107; Kagan KO, 2011, ULTRASOUND OBST GYN, V38, P607, DOI 10.1002/uog.10112; Hata T, 2012, ARCH GYNECOL OBSTET, V286, P1431, DOI 10.1007/s00404-012-2505-1; Bonilla-Musoles F, 2014, DSJUOG IN PRESS; Bonilla-Musoles F, 2013, DONALD SCH J ULTRASO, V7, P1; Grigore M, 2014, DSJUOG IN PRESS; Kurjak A, 2009, FETAL NEUROLOGY, P221; Kurjak A, 2007, AM J OBSTET GYNECOL, V196, P16, DOI 10.1016/j.ajog.2006.06.090; Kurjak A, 2008, J PERINAT MED, V36, P73, DOI 10.1515/JPM.2008.007; Kurjak A, 2005, FERTIL STERIL, V84, P1285, DOI 10.1016/j.fertnstert.2005.03.084; Pooh RK, 2013, DSJUOG, V7, P46; Pooh RK., 2011, DSJUOG, V5, P7; Pooh RK, 2011, AM J OBSTET GYNECOL, V204, p77e1	13	1	1	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0300-5577	1619-3997		J PERINAT MED	J. Perinat. Med.	MAR	2015	43	2					147	158		10.1515/jpm-2014-0157		12	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CC4QM	WOS:000350338000004		
J	Kobayashi, Y; Morioka, I; Koda, T; Nakamachi, Y; Okazaki, Y; Noguchi, Y; Ogi, M; Chikahira, M; Tanimura, K; Ebina, Y; Funakoshi, T; Ohashi, M; Iijima, K; Inoue, N; Kawano, S; Yamada, H				Kobayashi, Yoko; Morioka, Ichiro; Koda, Tsubasa; Nakamachi, Yuji; Okazaki, Yoko; Noguchi, Yoriko; Ogi, Miki; Chikahira, Masatsugu; Tanimura, Kenji; Ebina, Yasuhiko; Funakoshi, Toru; Ohashi, Masanobu; Iijima, Kazumoto; Inoue, Naoki; Kawano, Seiji; Yamada, Hideto			Low total IgM values and high cytomegalovirus loads in the blood of newborns with symptomatic congenital cytomegalovirus infection	JOURNAL OF PERINATAL MEDICINE			English	Article						Antigenemia; immunoglobulin; laboratory markers; serology; viral load	ANTIBODY; DISEASE; TRANSPLANTATION; ANTIGENEMIA; INFANTS; SERUM; ASSAY	Aims: Neurological outcomes differ considerably between symptomatic and asymptomatic infants with congenital cytomegalovirus (CMV) infection. Our objective was to characterize laboratory markers in symptomatic newborns in comparison with asymptomatic newborns with congenital CMV infection. Methods: Ten newborns with symptomatic and 13 newborns with asymptomatic congenital CMV infection were included in this 3-year prospective cohort study. Total immunoglobulin M (IgM), CMV-IgM, CMV antigenemia, and CMV-DNA in blood and urine were measured and their positive rates and quantitative values compared between the symptomatic and asymptomatic groups. Results: Fifty percent of newborns in the symptomatic group were positive based on total IgM; this was significantly lower than in the asymptomatic group (100%). Quantitative total IgM values were significantly lower, and there were significantly more copies of CMV-DNA in the blood of symptomatic newborns than in -asymptomatic newborns (median values for total IgM: 14 vs. 43 mg/dL and blood CMV-DNA: 3.2 x 10(2) vs. 3.5 x 10(1) copies/10(6) white blood cells). CMV-IgM, CMV antigenemia, and urine CMV-DNA did not differ significantly between groups. Conclusion: Low total IgM values and high blood CMV loads were associated with the presence of symptoms in newborns with congenital CMV infection.	[Morioka, Ichiro] Kobe Univ Hosp, Dept Pediat, Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kobayashi, Yoko; Nakamachi, Yuji; Okazaki, Yoko; Noguchi, Yoriko; Kawano, Seiji] Kobe Univ Hosp, Dept Clin Lab, Kobe, Hyogo 6500017, Japan; [Koda, Tsubasa; Iijima, Kazumoto] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Ogi, Miki; Chikahira, Masatsugu] Hyogo Prefectural Inst Publ Hlth & Consumer Sci, Infect Dis Res Div, Kobe, Hyogo, Japan; [Tanimura, Kenji; Ebina, Yasuhiko; Yamada, Hideto] Kobe Univ Hosp, Dept Obstet & Gynecol, Kobe, Hyogo 6500017, Japan; [Funakoshi, Toru] Kobe Childrens Hosp, Dept Obstet, Kobe, Hyogo, Japan; [Ohashi, Masanobu] Nadeshiko Ladies Hosp, Kobe, Hyogo, Japan; [Inoue, Naoki] Natl Inst Infect Dis, Dept Virol 1, Tokyo, Japan; [Inoue, Naoki] Gifu Pharmaceut Univ, Dept Microbiol & Immunol, Gifu, Japan	Morioka, I (reprint author), Kobe Univ Hosp, Dept Pediat, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ichim@med.kobe-u.ac.jp			Ministry of Health, Labor, and Welfare of Japan [H23-Jisedai-Ippan-001]; Japan Association of Obstetricians and Gynecologists [H22, 23, 24-Ogyah-Kenkin]	This work was supported in part by Grants-in-Aid from the Ministry of Health, Labor, and Welfare of Japan (H23-Jisedai-Ippan-001) and the Japan Association of Obstetricians and Gynecologists (H22, 23, 24-Ogyah-Kenkin). We thank Drs. A. Shibata, A. Miwa, T. Yokota, K. Matsuo, M. Nagasaka, D. Kurokawa, and K. Fujita for their clinical examinations of newborns with congenital CMV infection at the Kobe University Hospital.	Lanari M, 2006, PEDIATRICS, V117, pE76, DOI 10.1542/peds.2005-0629; Pass RF, 2006, J CLIN VIROL, V35, P216, DOI 10.1016/j.jcv.2005.09.015; Kimberlin DW, 2003, J PEDIATR-US, V143, P16, DOI 10.1016/S0022-3476(03)00192-6; Metz CE, 1998, MED DECIS MAKING, V18, P110, DOI 10.1177/0272989X9801800118; MASUHO Y, 1987, J GEN VIROL, V68, P1457, DOI 10.1099/0022-1317-68-5-1457; Nelson CT, 1997, CLIN PERINATOL, V24, P151; Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004; Wong V, 2006, J CHILD NEUROL, V21, P309, DOI 10.2310/7010.2006.00058; Tanaka N, 2000, J MED VIROL, V60, P455, DOI 10.1002/(SICI)1096-9071(200004)60:4<455::AID-JMV14>3.0.CO;2-Q; Coenraad S, 2011, LARYNGOSCOPE, V121, P2245, DOI 10.1002/lary.22140; Crumpacker CS, 2010, PRINCIPLES PRACTICE, P1971; DYLEWSKI J, 1983, NEW ENGL J MED, V309, P493; GONDO H, 1994, BRIT J HAEMATOL, V86, P130, DOI 10.1111/j.1365-2141.1994.tb03263.x; GRIFFITHS PD, 1982, PEDIATRICS, V69, P544; Inoue N, 2008, PEDIATR INFECT DIS J, V27, P182, DOI 10.1097/INF.0b013e318161a2d5; KANGRO HO, 1982, J MED VIROL, V10, P203, DOI 10.1002/jmv.1890100306; Kawai T, 1996, JPN J CLIN PATHOL, V44, P429; Koyano S, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000118; Lazzarotto T, 2011, EXPERT REV ANTI-INFE, V9, P841, DOI [10.1586/eri.11.109, 10.1586/ERI.11.109]; Matsuo K, 2014, BRAIN DEV-JPN, V36, P10, DOI 10.1016/j.braindev.2012.12.009; Minematsu T, 1994, J INFECT DIS, V68, P1278; NELSON CT, 1995, J CLIN MICROBIOL, V33, P3317; Noyola DE, 2001, J PEDIATR-US, V138, P325, DOI 10.1067/mpd.2001.112061; RASMUSSEN L, 1982, J INFECT DIS, V145, P191; Revello MG, 1999, J CLIN VIROL, V14, P57, DOI 10.1016/S1386-6532(99)00016-5; Schlesinger Y, 2003, ARCH DIS CHILD, V88, pF371, DOI 10.1136/fn.88.5.F371; Sonoyama A, 2012, J MED VIROL, V84, P1928, DOI 10.1002/jmv.23387; Tanaka Y, 2002, BONE MARROW TRANSPL, V30, P315, DOI 10.1038/sj.bmt.1703661; Yagi M, 2011, RES REPORTS NEONATOL, V1, P5; YOLKEN RH, 1981, J CLIN MICROBIOL, V14, P427	30	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0300-5577	1619-3997		J PERINAT MED	J. Perinat. Med.	MAR	2015	43	2					239	243		10.1515/jpm-2014-0071		5	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CC4QM	WOS:000350338000016		
J	Hidaka, N; Ishii, K; Mabuchi, A; Yamashita, A; Ota, S; Sasahara, J; Murata, M; Mitsuda, N				Hidaka, Nobuhiro; Ishii, Keisuke; Mabuchi, Aki; Yamashita, Akiko; Ota, Shiyo; Sasahara, Jun; Murata, Masaharu; Mitsuda, Nobuaki			Associated anomalies in congenital diaphragmatic hernia: perinatal characteristics and impact on postnatal survival	JOURNAL OF PERINATAL MEDICINE			English	Article						Associated anomalies; congenital diaphragmatic hernia; liver herniation; lung to thorax transverse area ratio; postnatal outcome	TRANSVERSE AREA RATIO; PRENATAL-DIAGNOSIS; BRONCHOPULMONARY SEQUESTRATION; MALFORMATIONS; PROGNOSIS; PREDICTION; FETUSES; PARAMETERS; MORTALITY; POSITION	Objective: We aimed to investigate the clinical characteristics and postnatal outcomes of fetuses with congenital diaphragmatic hernia (CDH) and additional anomalies. Materials and methods: We reviewed the charts of fetuses with CDH managed between 2005 and 2013. Patients were divided into complex and isolated groups based on the presence of additional anomalies. We analyzed the respective polyhydramnios, liver herniation, stomach position, lung to thorax transverse area ratio (LTR), and prognoses of the two groups. The survival rates of both groups were assessed based on the LTR as well as on stomach and liver positions. Results: CDH was diagnosed in 65 fetuses, and additional anomalies were found in 23. The incidences of liver herniation, polyhydramnios, and death were significantly higher, and LTR was significantly lower, in the complex group. The mortality rate of fetuses with a LTR < 0.08 was lower than that of fetuses with a LTR of >= 0.08 in the complex group. Further, the survival rate of fetuses with intrathoracic liver was lower than those without liver herniation. Conclusions: The prognosis of complex CDH is poor. This may result from both the associated anomalies and the severity of CDH itself. Even in complex CDHs, intrathoracic liver and LTR values are useful in estimating postnatal outcome.	[Hidaka, Nobuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, Fukuoka 8128582, Japan; [Hidaka, Nobuhiro] Osaka Med Ctr, Izumi, Japan; [Hidaka, Nobuhiro; Ishii, Keisuke; Mabuchi, Aki; Yamashita, Akiko; Ota, Shiyo; Sasahara, Jun; Murata, Masaharu; Mitsuda, Nobuaki] Res Inst Maternal & Child Hlth, Izumi, Japan; [Ishii, Keisuke; Mabuchi, Aki; Yamashita, Akiko; Ota, Shiyo; Sasahara, Jun; Murata, Masaharu; Mitsuda, Nobuaki] Osaka Med Ctr, Dept Maternal Fetal Med, Izumi, Japan	Hidaka, N (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hidaka.nobuhiro.484@m.kyushu-u.ac.jp					Adatia I., 2004, CONGENITAL DIAPHRAGM; ADZICK NS, 1985, J PEDIATR SURG, V20, P357, DOI 10.1016/S0022-3468(85)80219-0; Albanese CT, 1998, PRENATAL DIAG, V18, P1138, DOI 10.1002/(SICI)1097-0223(199811)18:11<1138::AID-PD416>3.0.CO;2-A; Cohen MS, 2002, J PEDIATR-US, V141, P25, DOI 10.1067/mpd.2002.125004; Victoria T, 2012, PRENATAL DIAG, V32, P715, DOI 10.1002/pd.3890; Witters I, 2001, AM J MED GENET, V103, P278; Allan LD, 1996, CLIN PERINATOL, V23, P795; HARRISON MR, 1994, JAMA-J AM MED ASSOC, V271, P382, DOI 10.1001/jama.271.5.382; Laudy JAM, 2003, PRENATAL DIAG, V23, P634, DOI 10.1002/pd.654; Ruano R, 2012, ULTRASOUND OBST GYN, V39, P42, DOI 10.1002/uog.10095; Jani J, 2007, ULTRASOUND OBST GYN, V30, P67, DOI 10.1002/uog.4052; FAUZA DO, 1994, J PEDIATR SURG, V29, P1113, DOI 10.1016/0022-3468(94)90290-9; HARRISON MR, 1978, J PEDIATR SURG, V13, P227, DOI 10.1016/S0022-3468(78)80391-1; Bedoyan JK, 2004, PEDIATR SURG INT, V20, P170, DOI 10.1007/s00383-004-1138-2; Bulfamante G, 2011, PRENATAL DIAG, V31, P910, DOI 10.1002/pd.2788; Enns GM, 1998, AM J MED GENET, V79, P215, DOI 10.1002/(SICI)1096-8628(19980923)79:3<215::AID-AJMG13>3.3.CO;2-L; Flake A W, 1996, Semin Pediatr Surg, V5, P266; Graziano JN, 2005, J PEDIATR SURG, V40, P1045, DOI 10.1016/j.jpedsurg.2005.03.025; Grethel EJ, 2008, FETAL DIAGN THER, V23, P250, DOI 10.1159/000123609; HASEGAWA T, 1990, J CLIN ULTRASOUND, V18, P705; HATCH EI, 1992, J PEDIATR SURG, V27, P778, DOI 10.1016/S0022-3468(05)80116-2; Hedrick HL, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.07.001; Jani J, 2008, ULTRASOUND OBST GYN, V31, P37, DOI 10.1002/uog.5198; Kitano Y, 2011, ULTRASOUND OBST GYN, V37, P277, DOI 10.1002/uog.8892; LUETIC T, 1995, J ULTRAS MED, V14, P533; MANNI M, 1994, PRENATAL DIAG, V14, P187, DOI 10.1002/pd.1970140308; Menon SC, 2013, J PEDIATR-US, V162, P114, DOI 10.1016/j.jpeds.2012.06.048; Nagata K, 2013, J PEDIATR SURG, V48, P738, DOI 10.1016/j.jpedsurg.2012.12.017; Ryan CA, 1995, J PEDIATR SURG, P883; Skari H, 2000, J PEDIATR SURG, V35, P1187, DOI 10.1053/jpsu.2000.8725; Tonks A, 2004, PRENATAL DIAG, V24, P596, DOI 10.1002/pd.908; Tsukimori K, 2008, J ULTRAS MED, V27, P707; Usui N, 2011, PEDIATR SURG INT, V27, P39, DOI 10.1007/s00383-010-2725-z; Witters I, 2000, PRENATAL DIAG, V20, P404, DOI 10.1002/(SICI)1097-0223(200005)20:5<404::AID-PD813>3.3.CO;2-S; Zaiss I, 2011, AM J PERINAT, V28, P211, DOI 10.1055/s-0030-1268235	35	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0300-5577	1619-3997		J PERINAT MED	J. Perinat. Med.	MAR	2015	43	2					245	252		10.1515/jpm-2014-0110		8	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	CC4QM	WOS:000350338000017		
J	Yorifuji, E; Ishikawa, N; Okada, H; Tsukaya, H				Yorifuji, Eri; Ishikawa, Naoko; Okada, Hiroshi; Tsukaya, Hirokazu			Arundina graminifolia var. revoluta (Arethuseae, Orchidaceae) has fern-type rheophyte characteristics in the leaves	JOURNAL OF PLANT RESEARCH			English	Article						Anatomy; Arundina graminifolia; Arundina graminifolia var. revoluta; Leaf structure; matK; Rheophyte; Taxonomy	LEAF; EXPANSION	Morphological and molecular variation between Arundina graminifolia var. graminifolia and the dwarf variety, A. graminifolia var. revoluta, was examined to assess the validity of their taxonomic characteristics and genetic background for identification. Morphological analysis in combination with field observations indicated that A. graminifolia var. revoluta is a rheophyte form of A. graminifolia characterized by narrow leaves, whereas the other morphological characteristics described for A. graminifolia var. revoluta, such as smaller flowers and short stems, were not always accompanied by the narrower leaf phenotype. Molecular analysis based on matK sequences indicated that only partial differentiation has occurred between A. graminifolia var. graminifolia and A. graminifolia var. revoluta. Therefore, we should consider the rheophyte form an ecotype rather than a variety. Anatomical observations of the leaves revealed that the rheophyte form of A. graminifolia possessed characteristics of the rheophytes of both ferns and angiosperms, such as narrower palisade tissue cells and thinner spongy tissue cells, as well as fewer cells in the leaf-width direction and fewer mesophyll cell layers.	[Yorifuji, Eri; Tsukaya, Hirokazu] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Ishikawa, Naoko] Univ Tokyo, Grad Sch Arts & Sci, Dept Gen Syst Studies, Meguro Ku, Tokyo 1538902, Japan; [Okada, Hiroshi] Hyogo Prefectural Univ, Inst Nat Environm Sci, Sanda, Hyogo 6691546, Japan; [Okada, Hiroshi] Osaka City Univ, Grad Sch Sci, Sumiyoshi Ku, Osaka 5588585, Japan	Tsukaya, H (reprint author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	tsukaya@bs.s.u-tokyo.ac.jp	Tsukaya, Hirokazu/A-2614-2013	Tsukaya, Hirokazu/0000-0002-4430-4538	Mitsubishi Foundation	The authors thank the Secretariat of Permission for Foreign Research, the Ministry of Research and Technology, Republic of Indonesia (RISTEK), Maliau Basin Management Committee and Sabah Biodiversity Council, for permission to conduct the field research in West Kalimantan and Sabah. We thank the Indonesian Institute of Science (LIPI) and the Betung-Kerihun N. P. office for kindly allowing this study to take place in Betung-Kerihun N. P., West Kalimantan. We also thank Dr. Dedy Daernadi of LIPI, Dr. Marlina Ardiyani and Mr. Ujang Hapid of Herbarium Bogoriense (BO), and Mr. Mustarrudin, Suherman, Jon, Anong, Mazid, and Eddy for helping to conduct the botanical surveys during the expedition in West Kalimantan. We thank Dr. Monica Sleiman and Ms. Palasiah Jofan of Universiti Malaysia Sabah, and Mr. Wittona Raili, Rohit Kakoh and Johnlee Paul of Maliau Basin Conservation Area for their assistance with our botanical surveys in Maliau Basin, Sabah. Mr. Arief Hidayat of Herbarium Bogoriense kindly guided us through the complex procedure of obtaining research permission. Ms. T. Shimabukuro of Kinjo Ryokan kindly sent us samples grown in her garden, via an introduction from Prof. Masatsugu Yokota of Ryukyu University. Dr. Keiko Sakakibara of Hiroshima University also sent us samples cultivated at the University. Curators of the Botanical Gardens, the University of Tokyo permitted us to analyze samples cultivated in the greenhouse. A part of the research budget was supported by Mitsubishi Foundation.	Tsuge T, 1996, DEVELOPMENT, V122, P1589; Kocyan A, 2004, PLANT SYST EVOL, V247, P203, DOI 10.1007/s00606-004-0133-3; Hooker JD, 1890, FL BRIT IND, V5, P858; KATO M, 1992, INT J PLANT SCI, V153, P212, DOI 10.1086/297024; KATO M, 1992, CAN J BOT, V70, P165; Lamb A, 2010, MALESIAN ORCHID J, V5, P7; Lamb A, 1994, ORCHIDS OF BORNEO, V1, P64; Okada H, 2013, ACTA PHYTOTAX GEOBOT, V63, P71; Okada Hiroshi, 2010, APG Acta Phytotaxonomica et Geobotanica, V61, P87; Seidenfaden G, 1992, ORCHIDS PENINSULAR M, P146; Tsukaya H, 2002, PLANT CELL PHYSIOL, V43, P372, DOI 10.1093/pcp/pcf051; Tsukaya H, 2005, J PLANT RES, V118, P57, DOI 10.1007/s10265-005-0196-4; USUKURA M, 1994, J PLANT RES, V107, P263, DOI 10.1007/BF02344253; van Steenis CGGJ, 1981, RHEOPHYTES WORLD; Vermeulen JJ, 2011, PLANT SYST EVOL, V293, P71, DOI 10.1007/s00606-011-0420-8	15	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0918-9440	1618-0860		J PLANT RES	J. Plant Res.	MAR	2015	128	2					239	247		10.1007/s10265-014-0689-0		9	Plant Sciences	Plant Sciences	CD1HP	WOS:000350826000002		
J	Nakayama, T; Nakamura, A; Yokoyama, A; Shiratori, T; Inouye, I; Ishida, K				Nakayama, Takeshi; Nakamura, Atsushi; Yokoyama, Akiko; Shiratori, Takashi; Inouye, Isao; Ishida, Ken-ichiro			Taxonomic study of a new eustigmatophycean alga, Vacuoliviride crystalliferum gen. et sp nov.	JOURNAL OF PLANT RESEARCH			English	Article						Eustigmatophyceae; Phylogeny; Taxonomy; Vacuoliviride crystalliferum gen. et sp nov.	PIGMENT COMPOSITION; TRACHYDISCUS MINUTUS; BIODIESEL PRODUCTION; NANNOCHLOROPSIS; ULTRASTRUCTURE; MICROALGAE; TEMPERATURE; SEQUENCE; POSITION; OCULATA	This study investigated the taxonomic affiliation of the algal strain nak-9, which has been reported to absorb radioactive cesium with high efficiency, using light and electron microscopy, and molecular phylogenetic analysis based on 18S ribosomal RNA gene (rDNA) sequences. This alga is spherical and coccoid, with a smooth cell wall, large vacuole, crystalline structure, reddish globule, and refractile granules (lamellate vesicles). The cells possess one to several greenish parietal chloroplasts with a bulging pyrenoid surrounded by lamellate vesicles. The chloroplasts include orderly thylakoid lamellae but no girdle lamella. Molecular phylogenetic analysis suggests that strain nak-9 is a member of the eustigmatophycean clade, which includes Goniochloris, Pseudostaurastrum, and Trachydiscus. On the basis of these results, we propose that strain nak-9 (NIES-2860) comprises a new species and new genus of the Eustigmatophyceae, Vacuoliviride crystalliferum gen. et sp. nov.	[Nakayama, Takeshi; Yokoyama, Akiko; Inouye, Isao; Ishida, Ken-ichiro] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Nakamura, Atsushi; Shiratori, Takashi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	Nakayama, T (reprint author), Univ Tsukuba, Fac Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.	algae@biol.tsukuba.ac.jp					Fawley KP, 2014, J APPL PHYCOL, V26, P1773, DOI 10.1007/s10811-013-0216-z; Moazami N, 2012, BIOMASS BIOENERG, V39, P449, DOI 10.1016/j.biombioe.2012.01.046; Fukuda S, 2014, J PLANT RES, V127, P79, DOI 10.1007/s10265-013-0596-9; Karlson B, 1996, PHYCOLOGIA, V35, P253, DOI 10.2216/i0031-8884-35-3-253.1; Converti A, 2009, CHEM ENG PROCESS, V48, P1146, DOI 10.1016/j.cep.2009.03.006; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; HIBBERD DJ, 1981, BOT J LINN SOC, V82, P93, DOI 10.1111/j.1095-8339.1981.tb00954.x; Gouveia L, 2009, J IND MICROBIOL BIOT, V36, P269, DOI 10.1007/s10295-008-0495-6; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Hegewald E, 2007, HYDROBIOLOGIA, V586, P107, DOI 10.1007/s10750-006-0566-5; Van Wagenen J, 2012, ENERGIES, V5, P731, DOI 10.3390/en5030731; Suda S, 2002, PHYCOLOGIA, V41, P273, DOI 10.2216/i0031-8884-41-3-273.1; Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029; Krienitz L, 2000, PHYCOLOGIA, V39, P219, DOI 10.2216/i0031-8884-39-3-219.1; Nakayama T, 1998, PROTIST, V149, P367, DOI 10.1016/S1434-4610(98)70043-4; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; ANTIA NJ, 1975, J PHYCOL, V11, P339, DOI 10.1111/j.0022-3646.1975.00339.x; Dashiell C, 2009, J PHYCOL, V45, P8; Ettl H, 1978, SUESSWASSERFLORA MIT, V3/1, P1; HIBBERD D J, 1971, Taxon, V20, P523, DOI 10.2307/1218254; HIBBERD DJ, 1972, ANN BOT-LONDON, V36, P49; Hibberd DJ, 1990, HDB PROTOCTISTA, P326; HIBBERD DJ, 1970, NATURE, V225, P758, DOI 10.1038/225758b0; HONDA D, 1995, PHYCOLOGIA, V34, P215, DOI 10.2216/i0031-8884-34-3-215.1; Kasai F., 2009, JPN J PHYCOL S, V57, P1; Komarek J., 1983, BINNENGEWASSER, V16, P1; Neustupa J, 2001, NOVA HEDWIGIA, V123, P373; PASCHER A., 1939, RABENHORST KRYPTOGAM, VXI, P1; PREISIG HR, 1989, PHYCOLOGIA, V28, P61, DOI 10.2216/i0031-8884-28-1-61.1; Pribyl P, 2012, J PHYCOL, V48, P231, DOI 10.1111/j.1529-8817.2011.01109.x; Prior SE, 2010, J ARK ACAD SCI, V63, P139; Rezanka T, 2010, FOLIA MICROBIOL, V55, P265, DOI 10.1007/s12223-010-0039-0; Santos L.M.A., 1996, Nova Hedwigia Beiheft, V112, P391; Schnepf E, 1996, ARCH PROTISTENKD, V146, P237	34	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0918-9440	1618-0860		J PLANT RES	J. Plant Res.	MAR	2015	128	2					249	257		10.1007/s10265-014-0686-3		9	Plant Sciences	Plant Sciences	CD1HP	WOS:000350826000003		
J	Sasabe, M; Ishibashi, N; Haruta, T; Minami, A; Kurihara, D; Higashiyama, T; Nishihama, R; Ito, M; Machida, Y				Sasabe, Michiko; Ishibashi, Nanako; Haruta, Tsuyoshi; Minami, Aki; Kurihara, Daisuke; Higashiyama, Tetsuya; Nishihama, Ryuichi; Ito, Masaki; Machida, Yasunori			The carboxyl-terminal tail of the stalk of Arabidopsis NACK1/HINKEL kinesin is required for its localization to the cell plate formation site	JOURNAL OF PLANT RESEARCH			English	Article						Arabidopsis; Cytokinesis; Cell plates; Kinesin; Microtubules	KINASE KINASE KINASE; PLANT CYTOKINESIS; TOBACCO CELLS; PROTEIN; PHRAGMOPLAST; THALIANA; GENE; MECHANISM; EXPANSION; PATHWAY	Plant cytokinesis is achieved by formation of cell plates in the phragmoplast, a plant-specific cytokinetic apparatus, which consists of microtubules (MTs) and microfilaments. During cytokinesis, the cell plate is expanded centrifugally outward from the inside of cells in a process that is supported by dynamic turnover of MTs. M-phase-specific kinesin NACK1, which comprises the motor domain at the amino-terminal half to move on MT bundles and the stalk region in the carboxyl-terminal half, is a key player in the process of MT turnover. That is, the specific region in the stalk binds the MAP kinase kinase kinase to activate the whole MAP kinase cascade, which stimulates depolymerization of MTs for the MT turnover. The stalk is also responsible for recruiting the activated kinase cascade to the mid-zone of the phragmoplast, which corresponds to the cell-plate formation site. It should be crucial to uncover roles of the NACK1 kinesin stalk as well as the motor domain in the formation of cell plates in order to understand the mechanisms of cell plate formation. Using dissected Arabidopsis NACK1 (AtNACK1/HINKEL) molecules and AtNACK1-fused GFP, we showed that the C-terminal tail of the stalk in addition to the motor domain is critical for its proper localization to the site of cell plate formation in the phragmoplast, probably by affecting its motility activity.	[Sasabe, Michiko; Ishibashi, Nanako; Haruta, Tsuyoshi; Minami, Aki; Kurihara, Daisuke; Higashiyama, Tetsuya; Machida, Yasunori] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Sasabe, Michiko] Hirosaki Univ, Fac Agr & Life Sci, Dept Biol, Hirosaki, Aomori 0368561, Japan; [Kurihara, Daisuke; Higashiyama, Tetsuya] Nagoya Univ, JST ERATO Higashiyama Live Holon Project, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Higashiyama, Tetsuya] Nagoya Univ, Inst Transformat Biomol WPI ITbM, Nagoya, Aichi 4648602, Japan; [Nishihama, Ryuichi] Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; [Ito, Masaki] Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Machida, Y (reprint author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	msasabe@cc.hirosaki-u.ac.jp; yas@bio.nagoya-u.ac.jp	kurihara, daisuke/I-7206-2014	kurihara, daisuke/0000-0003-2703-0405	JSPS [25114504]; Ministry of Education, Culture, Sports, Science and Technology of Japan [19060003, 21770040, 26840086, 23370021]; Hirosaki University; Sumitomo Foundation; Hirosaki University Institutional Research Grant for Young Scientists	This work was supported, in part, by a Grant-in-Aid for Scientific Research on Innovative Areas (No. 25114504) from JSPS to M.S., by a Grant-in-Aid for Scientific Research on Priority Areas (No. 19060003) to Y.M., by a Grant-in-Aid for Young Scientists (B; No. 21770040 and No. 26840086) to M.S. and by a Grant-in-Aid for Scientific Research (B; No. 23370021) to Y.M. and M.I. from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also supported, in part, by a Hirosaki University Grant for Exploratory Research by Young Scientists to M.S., by Grant for Basic Science Research Projects from The Sumitomo Foundation to M.S. and by a Hirosaki University Institutional Research Grant for Young Scientists. Microscopy was conducted using LSM780 at the Institute of Transformative Bio-Molecules at Nagoya University and supported by the Japan Advanced Plant Science Research Network.	Kosetsu K, 2010, PLANT CELL, V22, P3778, DOI 10.1105/tpc.110.077164; Fendrych M, 2010, PLANT CELL, V22, P3053, DOI 10.1105/tpc.110.074351; Jurgens G, 2005, TRENDS CELL BIOL, V15, P277, DOI 10.1016/j.tcb.2005.03.005; Normand G, 2010, ADV EXP MED BIOL, V676, P27; Miki T, 2014, P NATL ACAD SCI USA, V111, pE1053, DOI 10.1073/pnas.1311243111; Takahashi Y, 2010, PLANT CELL PHYSIOL, V51, P1766, DOI 10.1093/pcp/pcq135; Hammond JW, 2010, J CELL BIOL, V189, P1013, DOI 10.1083/jcb.201001057; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; Verhey KJ, 2011, ANNU REV BIOPHYS, V40, P267, DOI 10.1146/annurev-biophys-042910-155310; Twell D, 2002, NAT CELL BIOL, V4, P711, DOI 10.1038/ncb844; Chow CM, 2008, PLANT CELL, V20, P101, DOI 10.1105/tpc.107.052001; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; McMichael CM, 2013, NEW PHYTOL, V197, P1039, DOI 10.1111/nph.12122; Woollard AAD, 2008, CURR OPIN PLANT BIOL, V11, P610, DOI 10.1016/j.pbi.2008.09.010; Krupnova T, 2009, CURR BIOL, V19, P518, DOI 10.1016/j.cub.2009.02.021; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Verhey KJ, 2009, NAT REV MOL CELL BIO, V10, P765, DOI 10.1038/nrm2782; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Araki S, 2004, J BIOL CHEM, V279, P32979, DOI 10.1074/jbc.M403171200; Sasabe M, 2006, GENE DEV, V20, P1004, DOI 10.1101/gad.1408106; Strompen G, 2002, CURR BIOL, V12, P153, DOI 10.1016/S0960-9822(01)00655-8; Nishihama R, 2001, CURR OPIN PLANT BIOL, V4, P507, DOI 10.1016/S1369-5266(00)00208-9; Nishihama R, 2002, CELL, V109, P87, DOI 10.1016/S0092-8674(02)00691-8; Nishihama R, 2001, GENE DEV, V15, P352, DOI 10.1101/gad.863701; Nakaoka Y, 2012, PLANT CELL, V24, P1478, DOI 10.1105/tpc.112.098509; Sasabe M, 2011, P NATL ACAD SCI USA, V108, P17844, DOI 10.1073/pnas.1110174108; Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103; Muller S, 2004, CURR BIOL, V14, P412, DOI 10.1016/j.cub.2004.02.032; Blasius TL, 2007, J CELL BIOL, V176, P11, DOI 10.1083/jcb.200605099; Horiuchi D, 2007, CURR BIOL, V17, P1313, DOI 10.1016/j.cub.2007.06.062; Ishikawa M, 2002, PLANT J, V32, P789, DOI 10.1046/j.1365-313X.2002.01469.x; Ishikawa T, 2003, PLANT J, V33, P235, DOI 10.1046/j.1365-313X.2003.01621.x; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; Kaan HYK, 2011, SCIENCE, V333, P883, DOI 10.1126/science.1204824; Krupnova T, 2013, PLANT J, V74, P781, DOI 10.1111/tpj.12160; Muller S, 2009, TRENDS CELL BIOL, V19, P180, DOI 10.1016/j.tcb.2009.02.002; Murata T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2967; Otegui MS, 2005, TRENDS CELL BIOL, V15, P404, DOI 10.1016/j.tcb.2005.06.003; Peterman TK, 2004, PLANT PHYSIOL, V136, P3080, DOI 10.1104/pp.104.045369; Sablin EP, 2000, CURR OPIN CELL BIOL, V12, P35, DOI 10.1016/S0955-0674(99)00054-X; Sasabe Michiko, 2011, Plant Signal Behav, V6, P743; Sazuka T, 2005, PLANT CELL PHYSIOL, V46, P1934, DOI 10.1093/pcp/pci206; Seeger MA, 2010, J BIOL CHEM, V285, P8155, DOI 10.1074/jbc.M109.068247; Smertenko AP, 2011, CURR BIOL, V21, P1924, DOI 10.1016/j.cub.2011.10.012; Tanaka H, 2004, GENES CELLS, V9, P1199, DOI 10.1111/j.1365-2443.2004.00798.x; Van Damme D, 2008, CELL BIOL INT, V32, P178, DOI 10.1016/j.cellbi.2007.10.010; Waizenegger I, 2000, CURR BIOL, V10, P1371, DOI 10.1016/S0960-9822(00)00775-2; YASUHARA H, 1993, PLANT CELL PHYSIOL, V34, P21	50	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0918-9440	1618-0860		J PLANT RES	J. Plant Res.	MAR	2015	128	2					327	336		10.1007/s10265-014-0687-2		10	Plant Sciences	Plant Sciences	CD1HP	WOS:000350826000010		
J	Tsuboyama-Tanaka, S; Kodama, Y				Tsuboyama-Tanaka, Shoko; Kodama, Yutaka			AgarTrap-mediated genetic transformation using intact gemmae/gemmalings of the liverwort Marchantia polymorpha L.	JOURNAL OF PLANT RESEARCH			English	Article						Agrobacterium; AgarTrap; Bryophytes; Gemma; Marchantia; Transformation	REAL-TIME PCR; COMPLETE SEQUENCE; COPY NUMBER; PLANTS; ORGANIZATION; DNA; REGENERATION; THALLI; GENOME	The dioecious liverwort, Marchantia polymorpha L., is an emerging model plant. Various molecular biological techniques have been optimized for M. polymorpha for the past several years, and recently we reported a simplified Agrobacterium-mediated transformation method using sporelings (immature thalli from spores) of M. polymorpha. This method, termed AgarTrap (Agar-utilized Transformation with Pouring Solutions), completed by exchanging appropriate solutions on a single Petri dish to produce a sufficient number of independent transgenic sporelings. However, because spores are produced by crosses between males and females, the genetic backgrounds of resulting transgenic sporelings are not uniform. To easily produce transgenic liverworts with a uniform genetic background using AgarTrap, we developed an AgarTrap-mediated transformation method using intact gemmae/gemmalings produced by asexual reproduction. Using AgarTrap with male and female gemmae/gemmalings produced a sufficient number of independent transgenic gemmalings with uniform genetic backgrounds. The optimized transformation efficiencies were approximately 30 and 50 % in males and females, respectively. As with AgarTrap using sporelings, AgarTrap using intact gemmae/gemmalings will be useful in promoting studies of the molecular biology of M. polymorpha.	[Tsuboyama-Tanaka, Shoko; Kodama, Yutaka] Utsunomiya Univ, Ctr Biosci Res & Educ, Utsunomiya, Tochigi 3218505, Japan	Kodama, Y (reprint author), Utsunomiya Univ, Ctr Biosci Res & Educ, 350 Mine Machi, Utsunomiya, Tochigi 3218505, Japan.	kodama@cc.utsunomiya-u.ac.jp			Plant Transgenic Design Initiative of University of Tsukuba; Japan Society for the Promotion of Science Research (JSPS) KAKENHI [26840088]; Utsunomiya University	The authors thank Dr. Christopher Suarez (University of Notre Dame) for critical reading of the manuscript. The authors also thank Dr. Takayuki Kohchi (Kyoto University) for providing Tak-1 and BC3-38 lines. This work was supported by the Plant Transgenic Design Initiative of University of Tsukuba (Y. K.), the Japan Society for the Promotion of Science Research (JSPS) KAKENHI (No. 26840088) (Y. K.) and research Projects [CORE Adopted, CDI-F, UU-COE and UU-COE-next] of Utsunomiya University (Y. K).	Kubota A, 2013, BIOSCI BIOTECH BIOCH, V77, P167, DOI 10.1271/bbb.120700; Ingham DJ, 2001, BIOTECHNIQUES, V31, P132; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Qiu YL, 2006, P NATL ACAD SCI USA, V103, P15511, DOI 10.1073/pnas.0603335103; Yamato KT, 2007, P NATL ACAD SCI USA, V104, P6472, DOI 10.1073/pnas.0609054104; Ishizaki K, 2008, PLANT CELL PHYSIOL, V49, P1084, DOI 10.1093/pcp/pcn085; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Chiyoda S, 2008, PLANT CELL REP, V27, P1467, DOI 10.1007/s00299-008-0570-5; Ishizaki K, 2012, J PLANT RES, V125, P643, DOI 10.1007/s10265-012-0477-7; Yang LT, 2005, PLANT CELL REP, V23, P759, DOI 10.1007/s00299-004-0881-0; Ogasawara Y, 2013, PLANT CELL ENVIRON, V36, P1520, DOI 10.1111/pce.12085; Barnes CR, 1908, BOT GAZ, V46, P401, DOI 10.1086/329782; Bubner B, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-14; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; Mason Giovanna, 2002, BMC Biotechnol, V2, P20, DOI 10.1186/1472-6750-2-20; Nasu M, 1997, J FERMENT BIOENG, V84, P519, DOI 10.1016/S0922-338X(97)81904-6; ONO K, 1979, PLANT SCI LETT, V14, P225, DOI 10.1016/0304-4211(79)90074-9; Takenaka M, 2000, TRANSGENIC RES, V9, P179, DOI 10.1023/A:1008963410465; Tsuboyama S, 2014, PLANT CELL PHYSIOL, V55, P229, DOI 10.1093/pcp/pct168	21	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0918-9440	1618-0860		J PLANT RES	J. Plant Res.	MAR	2015	128	2					337	344		10.1007/s10265-014-0695-2		8	Plant Sciences	Plant Sciences	CD1HP	WOS:000350826000011		
J	Misawa, T; Date, Y; Kikuchi, J				Misawa, Takuma; Date, Yasuhiro; Kikuchi, Jun			Human Metabolic, Mineral, and Microbiota Fluctuations Across Daily Nutritional Intake Visualized by a Data-Driven Approach	JOURNAL OF PROTEOME RESEARCH			English	Article						noninvasive human sampling; metabonomics; dietary intake variations; nutrient digitalization; comprehensive significant test; data-driven approach	NMR METABOLOMICS; H-1-NMR SPECTROSCOPY; SUBMERGENCE STRESS; METABONOMICS; IDENTIFICATION; PHENOTYPES; MUTUALISM; STRATEGY; MIXTURES; EXPOSURE	Daily intake information is important for an understanding of the metabolic fluctuation of humans exposed to environmental stimuli. However, little investigation has been performed on the variations in dietary intake as an input and the relationship with human fecal, urinary, and salivary metabolic fluctuations as output information triggered by daily dietary intake. In the present study, we describe a data-driven approach for visualizing the daily intake information on a nutritional scale and for evaluating input-output responses under uncontrolled diets in a human study. For the input evaluation of nutritional intake, we collected information about daily dietary intake and converted this information to numeric data of nutritional elements. Furthermore, for the evaluation of output metabolic, mineral, and microbiota responses, we characterized the metabolic, mineral, and microbiota variations of noninvasive human samples of feces, urine, and saliva. The data-driven approach captured significant differences in the fluctuation of intestinal microbiota and some metabolites caused by a high-protein and a high-fat diet in daily life. This approach should contribute to the metabolic assessment of humans affected by environmental and nutritional factors under unlimited and uncontrolled diets.	[Misawa, Takuma; Date, Yasuhiro; Kikuchi, Jun] Yokohama City Univ, Grad Sch Med Life Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; [Misawa, Takuma; Date, Yasuhiro; Kikuchi, Jun] RIKEN Ctr Sustainable Resource Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; [Kikuchi, Jun] Nagoya Univ, Grad Sch Bioagr l Sci, Nagoya, Aichi 4640810, Japan; [Kikuchi, Jun] RIKEN Res Cluster Innovat, Biomass Engn Program, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Kikuchi, J (reprint author), Yokohama City Univ, Grad Sch Med Life Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	jun.kikuchi@riken.jp	Kikuchi, Jun/M-5512-2015	Kikuchi, Jun/0000-0002-6809-394X	Japan Society for the Promotion of Science (JSPS) [25513012]; Council for Science, Technology and Innovation (CSTI); Cross-ministerial Strategic Innovation Promotion Program (SIP); Bio-oriented Technology Research Advancement Institution (NARO)	We thank Yuuri Tsuboi, Amiu Shino, Makiko Akama, Kenji Sakata, Koyuru Nakayama (RIKEN), Kengo Ito, Tatsuki Ogura, and Yuka Shiokawa (Yokohama City University) for stimulating discussions, technical assistance, and useful advice on NMR measurements, processing, and statistical analysis. We thank Enago (www.enago.jp) for the English language review. This research was supported in part by a Grant-in-Aid for Scientific Research (grant no. 25513012) (to J.K.) from Japan Society for the Promotion of Science (JSPS) and also partially supported by Council for Science, Technology and Innovation (CSTI), Cross-ministerial Strategic Innovation Promotion Program (SIP), and "Technologies for creating next-generation agriculture, forestry and fisheries" funded from Bio-oriented Technology Research Advancement Institution (NARO).	Lewis IA, 2009, P NATL ACAD SCI USA, V106, P18515, DOI 10.1073/pnas.0905999106; Lloyd AJ, 2013, AM J CLIN NUTR, V97, P377, DOI 10.3945/ajcn.112.048033; Ito K, 2014, ANAL CHEM, V86, P1098, DOI 10.1021/ac402869b; Sekiyama Y, 2011, ANAL CHEM, V83, P719, DOI 10.1021/ac102097u; Fan TWM, 2010, METABOLOMICS, V6, P165, DOI 10.1007/s11306-010-0208-9; Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Halouska S, 2012, ACS CHEM BIOL, V7, P166, DOI 10.1021/cb200348m; Fan TWM, 2011, METABOLOMICS, V7, P257, DOI 10.1007/s11306-010-0249-0; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Worley B, 2014, ACS CHEM BIOL, V9, P1138, DOI 10.1021/cb4008937; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Jacobs DM, 2008, NMR BIOMED, V21, P615, DOI 10.1002/nbm.1233; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Garrod S, 1999, MAGNET RESON MED, V41, P1108, DOI 10.1002/(SICI)1522-2594(199906)41:6<1108::AID-MRM6>3.0.CO;2-M; Li JA, 2011, J PROTEOME RES, V10, P1073, DOI 10.1021/pr100862t; Barding GA, 2013, J PROTEOME RES, V12, P898, DOI 10.1021/pr300953k; Bertram HC, 2009, ANAL CHEM, V81, P9188, DOI 10.1021/ac9020598; Heinzmann SS, 2012, J PROTEOME RES, V11, P643, DOI 10.1021/pr2005764; Barding GA, 2012, J PROTEOME RES, V11, P320, DOI 10.1021/pr200919b; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Saric J, 2008, J PROTEOME RES, V7, P352, DOI 10.1021/pr070340k; Date Y, 2014, FOOD CHEM, V152, P251, DOI 10.1016/j.foodchem.2013.11.126; Schlipalius DI, 2012, SCIENCE, V338, P807, DOI 10.1126/science.1224951; Sekiyama Y, 2010, ANAL CHEM, V82, P1643, DOI 10.1021/ac9019076; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Akiyama Kenji, 2008, In Silico Biology, V8, P339; Bae EA, 2002, BIOL PHARM BULL, V25, P743, DOI 10.1248/bpb.25.743; Duarte IF, 2009, MOL BIOSYST, V5, P180, DOI 10.1039/b814426e; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Izrayelit Y, 2012, ACS CHEM BIOL, V7, P1321, DOI 10.1021/cb300169c; An YJ, 2012, ACS CHEM BIOL, V7, P2012, DOI 10.1021/cb3004226; Chikayama E, 2010, ANAL CHEM, V82, P1653, DOI 10.1021/ac9022023; Asakura T, 2014, ANAL CHEM, V86, P5425, DOI 10.1021/ac5005037; Bouatra S, 2013, PLOS ONE, V4, P8, DOI DOI 10.1371/JOURNAL.PONE.0073076; Chang H, 2012, ARCH BIOCHEM BIOPHYS, V520, P51, DOI 10.1016/j.abb.2012.02.002; Chikayama E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003805; Date Y, 2012, POLYM J, V44, P888, DOI 10.1038/pj.2012.105; Ellis JK, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-61; Goodacre R., 2007, J NUTR, V137, p259S; Ishigaki Tohru, 2005, Journal of Physiological Anthropology and Applied Human Science, V24, P573, DOI 10.2114/jpa.24.573; Kato T, 2014, DNA RES, V21, P469, DOI 10.1093/dnares/dsu013; Lauridsen M, 2007, ANAL CHEM, V79, P1181, DOI 10.1021/ac061354x; Ogura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066919; Orfi L, 1998, ANAL CHEM, V70, P1339, DOI 10.1021/ac971011m; Robinette SL, 2008, ANAL CHEM, V80, P3606, DOI 10.1021/ac702530t; Schirra HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002764; Sone H, 2010, DIABETOLOGIA, V53, P419, DOI 10.1007/s00125-009-1622-2; Tumbaugh PJ, 2006, NATURE, V444, P1027	53	4	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	MAR	2015	14	3					1526	1534		10.1021/pr501194k		9	Biochemical Research Methods	Biochemistry & Molecular Biology	CD1NF	WOS:000350840900018		
J	Kagawa, T				Kagawa, Toshinao			The Hermite function expansions of the Heaviside function	JOURNAL OF PSEUDO-DIFFERENTIAL OPERATORS AND APPLICATIONS			English	Article								We calculate the coefficients of Hermite function expansions of the Heaviside functions, x(+)(p) with p is an element of N, 1/x +/- i0, the signum sgn(x) and the principal value p.v.1/x, explicitly.	Tokyo City Univ, Tokyo, Japan	Kagawa, T (reprint author), Tokyo City Univ, Tokyo, Japan.	kagawa_toshinao@ma.noda.tus.ac.jp					SIMON B, 1971, J MATH PHYS, V12, P140, DOI 10.1063/1.1665472; Folland G.B., 1989, HARMONIC ANAL PHASE; Friedlander G., 1982, INTRO THEORY DISTRIB; Oka Y., 2002, THESIS SOPHIA U; Reed M., 1980, METHODS MODERN MATH; Sadlok Z., 1977, ANN POL MATH, V34, P63; Sadlok Z., 1980, ANN POL MATH, V38, P159; Thangavelu S., 1993, LECT HERMITE LAGUERR, V42; Wong M. W., 2014, PARTIAL DIFFERENTIAL	9	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1662-9981	1662-999X		J PSEUDO-DIFFER OPER	J. Pseudo-Differ. Oper. Appl.	MAR	2015	6	1					21	32		10.1007/s11868-015-0109-9		12	Mathematics, Applied; Mathematics	Mathematics	CC5AH	WOS:000350368100003		
J	Kohzaki, M; Ootsuyama, A; Moritake, T; Abe, T; Kubo, T; Okazaki, R				Kohzaki, Masaoki; Ootsuyama, Akira; Moritake, Takashi; Abe, Toshiaki; Kubo, Tatsuhiko; Okazaki, Ryuji			What have we learned from a questionnaire survey of citizens and doctors both inside and outside Fukushima?: survey comparison between 2011 and 2013	JOURNAL OF RADIOLOGICAL PROTECTION			English	Article						Fukushima Daiichi Nuclear Power Plant; questionnaire survey; Tokyo Electric Power Company and Japanese Government	IONIZING-RADIATION; NUCLEAR ACCIDENT; CANCER-RISKS; CHERNOBYL; CHILDREN	The disaster at the Fukushima Daiichi Nuclear Power Plant (FDNPP) remains unresolved because the estimated time to decommission a nuclear reactor appears to be approximately 40 years. The number of workers exposed to radiation doses ranging from 1 to 100 mSv continues to increase. To understand the accident progression at Fukushima and to anticipate what we should do in the future for occupational and environmental health, we performed a survey of citizens and doctors who lived inside and outside Fukushima in 2011 and 2013. In a comparison of these 2 years, the citizens inside Fukushima continue to suffer anxiety, although those living outside Fukushima tended to feel less anxious. Medical students who had recently studied radiation biology showed much less ongoing anxiety compared with other groups, suggesting that learning about the effects of radiation is essential to understanding one's own circumstances objectively and correctly. The lack of trust in the government and in the Tokyo Electric Power Company (TEPCO) in 2013 remains high in all groups. Therefore, long-term forthright explanations from the government, TEPCO, and radiation experts are indispensable not only to establish trust with people but also to alleviate psychological stress.	[Kohzaki, Masaoki; Moritake, Takashi] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Radiol Hlth Sci, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Ootsuyama, Akira] Univ Occupat & Environm Hlth, Sch Med, Dept Radiat Biol & Hlth, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Abe, Toshiaki] Univ Occupat & Environm Hlth, Radioisotope Res Ctr, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; [Kubo, Tatsuhiko] Univ Occupat & Environm Hlth, Sch Med, Dept Publ Hlth, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan	Okazaki, R (reprint author), Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Radiol Hlth Sci, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	ryuji-o@med.uoeh-u.ac.jp					Pierce DA, 2000, RADIAT RES, V154, P178, DOI 10.1667/0033-7587(2000)154[0178:RRCRAL]2.0.CO;2; NEEL JV, 1990, AM J HUM GENET, V46, P1053; Yasunari TJ, 2011, P NATL ACAD SCI USA, V108, P19530, DOI 10.1073/pnas.1112058108; Wakeford R, 2011, J RADIOL PROT, V31, P1, DOI 10.1088/0952-4746/31/1/E02; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Steinhauser G, 2014, SCI TOTAL ENVIRON, V470, P800, DOI 10.1016/j.scitotenv.2013.10.029; Akiba S, 2012, J RADIOL PROT, V32, P1, DOI 10.1088/0952-4746/32/1/1; Grubich AO, 2012, J ENVIRON RADIOACTIV, V107, P51, DOI 10.1016/j.jenvrad.2011.12.013; ICRP (International Commission on Radiological Protection), 2009, ANN ICRP, V109, P23; ICRP (International Commission on Radiological Protection), 2009, ANN ICRP, V111, P39; INPO (Institute of Nuclear Power Operations), 2011, INPO11005; Murayama T, 2012, C P 32 ANN M INT ASS; NEA/OECD (Nuclear Energy Agency/ Organization for Economic Co-operation and Development), 2002, CHERN ASS RAD HLTH I; Okazaki Ryuji, 2012, Journal of UOEH, V34, P91; OTAKE M, 1991, J RADIAT RES, V32, P249, DOI 10.1269/jrr.32.SUPPLEMENT_249; Sakai K., 2012, Annals of the ICRP, V41, P282, DOI 10.1016/j.icrp.2012.08.001; Taniguchi N, 2013, J MED ULTRASON, V40, P219, DOI 10.1007/s10396-013-0456-1; Tokonami S, 2012, SCI REP-UK, V2, DOI 10.1038/srep00507; Tsuji M, 2013, EISEIGAKU ZASSHI, V55, P53; UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation), 2011, EFF ION RAD ANN D HL, VII; UNSCEAR (United Nations Scientific Committee on the Effects of Atomic Radiation), 2014, SCI ANN X LEV EFF RA, V1; Wakeford R, 2011, J RADIOL PROT, V31, P167, DOI 10.1088/0952-4746/31/2/E02	22	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0952-4746	1361-6498		J RADIOL PROT	J. Radiol. Prot.	MAR	2015	35	1					N1	N17		10.1088/0952-4746/35/1/N1		17	Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	CC8SQ	WOS:000350638900002		
J	Nishimura, K; Omori, M; Katsumata, Y; Sato, E; Gono, T; Kawaguchi, Y; Harigai, M; Mimura, M; Yamanaka, H; Ishigooka, J				Nishimura, Katsuji; Omori, Masako; Katsumata, Yasuhiro; Sato, Eri; Gono, Takahisa; Kawaguchi, Yasushi; Harigai, Masayoshi; Mimura, Masaru; Yamanaka, Hisashi; Ishigooka, Jun			Neurocognitive Impairment in Corticosteroid-naive Patients with Active Systemic Lupus Erythematosus: A Prospective Study	JOURNAL OF RHEUMATOLOGY			English	Article						SYSTEMIC LUPUS ERYTHEMATOSUS; NEUROCOGNITIVE IMPAIRMENT; CORTICOSTEROIDS	COGNITIVE DYSFUNCTION; RECEPTOR ANTIBODIES; MEMORY; DISEASE; MOOD; GLUCOCORTICOIDS; AUTOANTIBODIES; ASSOCIATION; PREDICTORS; CRITERIA	Objective. Neurocognitive impairment (NCI) has been intensively studied in patients with systemic lupus erythematosus (SLE). However, those studies have mostly included patients who were treated with corticosteroids, which may itself induce NCI. We investigated NCI in corticosteroid-naive people with SLE who did not exhibit any overt neuropsychiatric manifestations. Methods. Forty-three inpatients with SLE who had no current or past neuropsychiatric history participated in the study. Patients and 30 healthy control subjects with similar demographic characteristics were given a 1-h battery of neuropsychological tests. NCI was defined as scores at least 2 SD below the mean of the healthy control group on at least 2 of the 7 neurocognitive domains. Results of clinical, laboratory, and neurologic tests were compared regarding the presence of NCI. Results. NCI was identified in 12 patients (27.9%) with SLE and in 2 control subjects (6.7%). Patients with SLE showed a significant impairment compared with controls on tasks assessing immediate recall, complex attention/executive function, and psychomotor speed. We identified psychomotor speed (Digit Symbol Substitution Test) as the factor that best differentiated the 2 groups. Further, we identified the score of the SLE Disease Activity Index 2000 as an independent risk factor for NCI in patients with SLE. Conclusion. We conclude that reduced psychomotor speed is an SLE-specific pattern of NCI. Verbal-memory deficits that have been reported in patients with SLE were not evident among patients who were corticosteroid-naive. Our results indicate that impaired psychomotor speed may be added to the symptoms of early SLE.	[Nishimura, Katsuji; Ishigooka, Jun] Tokyo Womens Med Univ, Sch Med, Dept Psychiat, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Sch Med, Inst Rheumatol, Tokyo 1628666, Japan; [Omori, Masako] Kanagawa Psychiat Ctr, Yokohama, Kanagawa, Japan; [Harigai, Masayoshi] Tokyo Med & Dent Univ, Grad Sch, Dept Pharmacovigilance, Tokyo, Japan; [Mimura, Masaru] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan	Nishimura, K (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Psychiat, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	nishimura.katsuji@twmu.ac.jp					Abe Mitsuyo, 2004, No To Shinkei, V56, P567; Liang MH, 1999, ARTHRITIS RHEUM-US, V42, P599; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Menon S, 1999, ARTHRITIS RHEUM-US, V42, P735, DOI 10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L; Naber D, 1996, PSYCHONEUROENDOCRINO, V21, P25, DOI 10.1016/0306-4530(95)00031-3; McLaurin EY, 2005, NEUROLOGY, V64, P297; CARBOTTE RM, 1995, J RHEUMATOL, V22, P863; Afeltra A, 2003, NEUROLOGY, V61, P108; HAY EM, 1992, ARTHRITIS RHEUM, V35, P411, DOI 10.1002/art.1780350409; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Loukkola J, 2003, J CLIN EXP NEUROPSYC, V25, P145, DOI 10.1076/jcen.25.1.145.13621; HANLY JG, 1992, J RHEUMATOL, V19, P562; VARNEY NR, 1984, AM J PSYCHIAT, V141, P369; Tomietto P, 2007, ARTHRIT RHEUM-ARTHR, V57, P1461, DOI 10.1002/art.23098; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Hanly JG, 1999, ARTHRITIS RHEUM, V42, P728, DOI 10.1002/1529-0131(199904)42:4<728::AID-ANR16>3.0.CO;2-O; Brown ES, 2007, J AFFECT DISORDERS, V99, P279, DOI 10.1016/j.jad.2006.09.004; Unterman A, 2011, SEMIN ARTHRITIS RHEU, V41, P1, DOI 10.1016/j.semarthrit.2010.08.001; Appenzeller S, 2006, ANN RHEUM DIS, V65, P1585, DOI 10.1136/ard.2005.049486; Petri M, 2008, J RHEUMATOL, V35, P1776; Omdal R, 2005, EUR J NEUROL, V12, P392, DOI 10.1111/j.1468-1331.2004.00976.x; Lapteva L, 2006, ARTHRITIS RHEUM, V54, P2505, DOI 10.1002/art.22031; Abdel-Nasser AM, 2008, CLIN RHEUMATOL, V27, P1377, DOI 10.1007/s10067-008-0921-1; Brown ES, 2009, ANN NY ACAD SCI, V1179, P41, DOI 10.1111/j.1749-6632.2009.04981.x; Kowal C, 2004, IMMUNITY, V21, P179, DOI 10.1016/j.immuni.2004.07.011; Kozora E, 2008, ARTHRITIS RHEUM, V58, P3286, DOI 10.1002/art.23991; Wolkowitz OM, 2009, ANN NY ACAD SCI, V1179, P19, DOI 10.1111/j.1749-6632.2009.04980.x; Hanly JG, 2006, J RHEUMATOL, V33, P1553; Newcomer JW, 1999, ARCH GEN PSYCHIAT, V56, P527, DOI 10.1001/archpsyc.56.6.527; Mikdashi J, 2007, LUPUS, V16, P418, DOI 10.1177/0961203307079044; Gladman DD, 2002, J RHEUMATOL, V29, P288; Conti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033824; First M. B., 2002, STRUCTURED CLIN INTE; GINSBURG KS, 1992, ARTHRITIS RHEUM, V35, P776, DOI 10.1002/art.1780350711; Gladman DD, 2000, J RHEUMATOL, V27, P2367; Glanz BI, 1997, NEUROPSY NEUROPSY BE, V10, P232; Glanz BI, 2005, LUPUS, V14, P896, DOI 10.1191/0961203305lu2244oa; HANLY JG, 1993, BRIT J RHEUMATOL, V32, P291; Kashima H, 1985, RINSHO SEISHIN IGAKU, V14, P1479; Kivity S, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-90; Kozora E, 2004, ARTHRIT RHEUM-ARTHR, V51, P810, DOI 10.1002/art.20692; Kozora E, 1996, ARTHRITIS RHEUM, V39, P2035, DOI 10.1002/art.1780391213; Lauvsnes MB, 2014, ARTHRITIS R IN PRESS; Lezak MD, 1995, NEUROPSYCHOLOGICAL A, pXVIII; McNair D. M., 1992, MANUAL PROFILE MOOD; Mikdashi J, 2004, RHEUMATOLOGY, V43, P1555, DOI 10.1093/rheumatology/keh384; Mitrushina M., 2005, HDB NORMATIVE DATA N; Watson P, 2012, NEUROPSYCHOL REV, V22, P252, DOI 10.1007/s11065-012-9213-2; Wechsler D, 1981, WECHSLER ADULT INTEL; Whitelaw DA, 1999, LUPUS, V8, P444, DOI 10.1177/096120339900800606	50	1	1	J RHEUMATOL PUBL CO	TORONTO	365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA	0315-162X	1499-2752		J RHEUMATOL	J. Rheumatol.	MAR	2015	42	3					441	448		10.3899/jrheum.140659		8	Rheumatology	Rheumatology	CD0FM	WOS:000350746000018		
J	Katayama, T; Chikamatsu, A; Hirose, Y; Fukumura, T; Hasegawa, T				Katayama, Tsukasa; Chikamatsu, Akira; Hirose, Yasushi; Fukumura, Tomoteru; Hasegawa, Tetsuya			Topotactic reductive fluorination of strontium cobalt oxide epitaxial thin films	JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY			English	Article; Proceedings Paper	European Materials Research Society (EMRS) Spring Meeting / Symposium I on Solution Processing and Properties of Functional Oxide Thin Films and Nanostructures	MAY 26-30, 2014	Lille, FRANCE	European Mat Res Soc		Topotactic reaction; Epitaxial thin film; Oxyfluorides; Transition-metal compounds; Pulsed-laser deposition	OXYFLUORIDES; LA1-XSRXCOO3	Since the discovery of oxyfluoride cuprate superconductors, many efforts have been made to search for new transition-metal oxyfluoride compounds. Recently, the topotactic fluorination reaction using polyvinylidene fluoride (PVDF) has gained attention because of the low-temperature synthesis of oxyfluorides. In this study, we report the fabrication of SrCoO (x) F (y) epitaxial thin films via topotactic fluorination of SrCoO2.5 precursor films with PVDF. X-ray diffraction analysis showed that the SrCoO (x) F (y) film, with an anion-vacant perovskite structure, was obtained by fluorination at 150 A degrees C and that the in-plane lattice constant was completely dependent on the substrate. Energy dispersive X-ray spectrometry revealed that the chemical composition of the fluorinated film was SrCoO1.9 +/- 0.4F0.5 +/- 0.1 and X-ray photoemission spectroscopy showed that the Co ions had a mixed valence state of 2+ and 3+. This valence state was smaller than that in the SrCoO2.5 precursor film, indicating that PVDF acted as a reductive fluorinating agent for the SrCoO2.5 film. Moreover, the SrCoO1.9 +/- 0.4F0.5 +/- 0.1 film did not exhibit ferromagnetism even at 10 K, suggesting the presence of an antiferromagnetic interaction between the Co ions.	[Katayama, Tsukasa; Chikamatsu, Akira; Hirose, Yasushi; Fukumura, Tomoteru; Hasegawa, Tetsuya] Univ Tokyo, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; [Chikamatsu, Akira; Hirose, Yasushi; Fukumura, Tomoteru; Hasegawa, Tetsuya] Japan Sci & Technol Agcy JST, CREST, Bunkyo Ku, Tokyo 1130033, Japan; [Hirose, Yasushi; Hasegawa, Tetsuya] Kanagawa Acad Sci & Technol KAST, Kawasaki, Kanagawa 2130012, Japan	Chikamatsu, A (reprint author), Japan Sci & Technol Agcy JST, CREST, Bunkyo Ku, Tokyo 1130033, Japan.	chikamatsu@chem.s.u-tokyo.ac.jp	Fukumura, Tomoteru/C-2081-2009; CHIKAMATSU, AKIRA/G-4964-2014; Hirose, Yasushi/A-7771-2013	Fukumura, Tomoteru/0000-0002-8957-3520; CHIKAMATSU, AKIRA/0000-0003-0484-6356; Hirose, Yasushi/0000-0002-0792-4631			Ai-Mamouri M., 1994, NATURE, V369, P382, DOI 10.1038/369382a0; ITOH M, 1994, J PHYS SOC JPN, V63, P1486, DOI 10.1143/JPSJ.63.1486; Munakata F, 1997, PHYS REV B, V56, P979, DOI 10.1103/PhysRevB.56.979; Sullivan E, 2012, MATER RES BULL, V47, P2541, DOI 10.1016/j.materresbull.2012.05.002; Kobayashi Y, 2009, J AM CHEM SOC, V131, P9849, DOI 10.1021/ja9040829; BROWN ID, 1985, ACTA CRYSTALLOGR B, V41, P244, DOI 10.1107/S0108768185002063; Katayama T, 2014, J MATER CHEM C, V2, P5350, DOI 10.1039/c4tc00558a; Biesinger MC, 2011, APPL SURF SCI, V257, P2717, DOI 10.1016/j.apsusc.2010.10.051; CHAINANI A, 1992, PHYS REV B, V46, P9976, DOI 10.1103/PhysRevB.46.9976; Ehora G, 2007, CHEM MATER, V19, P2924, DOI 10.1021/cm070576o; Berry FJ, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/21/215207; Fuchs D, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.014466; Jeen H, 2013, NAT MATER, V12, P1057, DOI [10.1038/nmat3736, 10.1038/NMAT3736]; Luo K, 2013, INORG CHEM, V52, P13762, DOI 10.1021/ic402349r; Mentre O, 2010, J AM CHEM SOC, V132, P4865, DOI 10.1021/ja100170m; Moon EJ, 2014, J AM CHEM SOC, V136, P2224, DOI 10.1021/ja410954z; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; Shinawi HE, 2010, J MATER CHEM, V20, P3253; Slater PR, 2002, J FLUORINE CHEM, V117, P43, DOI 10.1016/S0022-1139(02)00166-5; Tsujimoto Y, 2012, INORG CHEM, V51, P4802, DOI 10.1021/ic300116h; Tsujimoto Y, 2011, CHEM COMMUN, V47, P3263, DOI 10.1039/c0cc05482h	21	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0928-0707	1573-4846		J SOL-GEL SCI TECHN	J. Sol-Gel Sci. Technol.	MAR	2015	73	3			SI		527	530		10.1007/s10971-014-3499-x		4	Materials Science, Ceramics	Materials Science	CC9JD	WOS:000350684600003		
J	Carretero-Genevrier, A; Frontera, C; Hassini, A; Oro-Sole, J; Moreno, C; Obradors, X; Puig, T; Mestres, N				Carretero-Genevrier, A.; Frontera, C.; Hassini, A.; Oro-Sole, J.; Moreno, C.; Obradors, X.; Puig, T.; Mestres, N.			Chemical solution growth of La0.7Sr0.3MnO3 nanotubes in confined geometries	JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY			English	Article; Proceedings Paper	European Materials Research Society (EMRS) Spring Meeting / Symposium I on Solution Processing and Properties of Functional Oxide Thin Films and Nanostructures	MAY 26-30, 2014	Lille, FRANCE	European Mat Res Soc		Nanotubes; Functional oxides; Chemical solution deposition; Ferromagnetism; Templating; La0.7Sr0.3MnO3	NANOWIRES; NANOPARTICLES; TRANSITION; NANORODS	Self-standing La0.7Sr0.3MnO3 nanotubes with outer diameter ranging from 100 to 200 nm have been successfully synthesized by template assisted chemical solution deposition using nanoporous anodized alumina membranes of varying pore size. This template synthetic strategy provides rather monodisperse size distributed nanotubes. A sol-gel based polymer precursor route was used to fill the porous membranes and a subsequent heat treatment (700-1,000 A degrees C) enabled the phase formation and crystallization of the nanotubes. A good control over viscosity, stoichiometry and stability of the precursor solution were identified as crucial parameters for the template aided synthesis. The synthesized La0.7Sr0.3MnO3 nanotubes are polycrystalline and ferromagnetic with a Curie temperature of 350 K. Control over the nanowall thickness is attained by varying template filling time which is corroborated by magnetic moment results.	[Carretero-Genevrier, A.; Frontera, C.; Hassini, A.; Oro-Sole, J.; Moreno, C.; Obradors, X.; Puig, T.; Mestres, N.] Inst Ciencia Mat Barcelona ICMAB, CSIC, Bellaterra 08193, Catalonia, Spain; [Carretero-Genevrier, A.] Ecole Cent Lyon, CNRS, INL, F-69134 Ecully, France; [Moreno, C.] Natl Inst Mat Sci, Int Ctr Young Scientists, Tsukuba, Ibaraki 3050047, Japan	Carretero-Genevrier, A (reprint author), Inst Ciencia Mat Barcelona ICMAB, CSIC, Campus UAB, Bellaterra 08193, Catalonia, Spain.	adrien.carretero-genevrier@ec-lyon.fr; narcis.mestres@icmab.es	Frontera, Carlos/B-4910-2008; Mestres, Narcis/B-5305-2013; Moreno, Cesar/G-5011-2012; Obradors, Xavier/A-8146-2012	Frontera, Carlos/0000-0002-0091-4756; Moreno, Cesar/0000-0003-2682-211X; 			Jun YW, 2008, ACCOUNTS CHEM RES, V41, P179, DOI 10.1021/ar700121f; Zhang MF, 2006, NANO LETT, V6, P1075, DOI 10.1021/nl060407n; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Kuang D, 2008, ACS NANO, V2, P1113, DOI 10.1021/nn800174y; Steinhart M, 2004, ANGEW CHEM INT EDIT, V43, P1334, DOI 10.1002/anie.200300614; Curiale J, 2007, APPL SURF SCI, V254, P368, DOI 10.1016/j.apsusc.2007.07.074; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Roy P, 2010, NANOSCALE, V2, P45, DOI 10.1039/b9nr00131j; Curiale J, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.1999842; Batlle X, 2002, J PHYS D APPL PHYS, V35, pR15, DOI 10.1088/0022-3727/35/6/201; Carretero-Genevrier A, 2014, CHEM MATER, V26, P1019, DOI 10.1021/cm403064u; Carretero-Genevrier A, 2008, ADV MATER, V20, P3672, DOI 10.1002/adma.200800487; Carretero-Genevrier A, 2014, CHEM SOC REV, V43, P2042, DOI 10.1039/c3cs60288e; Carretero-Genevrier A, 2010, ADV FUNCT MATER, V20, P892, DOI 10.1002/adfm.200901971; Hernandez BA, 2002, CHEM MATER, V14, P480, DOI 10.1021/cm010998c; Hueso L, 2004, NATURE, V427, P301, DOI 10.1038/427301a; Jim S, 1994, SCIENCE, V264, P413; Martinez B, 1998, PHYS REV LETT, V80, P181, DOI 10.1103/PhysRevLett.80.181; Morrison F., 2003, REV ADV MATER SCI, V4, P114; Pan CS, 2008, EUR J INORG CHEM, P2429, DOI 10.1002/ejic.200800047; Rao CNR, 2001, COLOSSAL MAGNETORESI; Rodriguez-Carvajal J., 1990, SAT M POWD DIFFR 15, P127; Shankar KS, 2004, NANOTECHNOLOGY, V15, P1312, DOI 10.1088/0957-4484/15/9/034; Shick AB, 1999, PHYS REV B, V60, P6254, DOI 10.1103/PhysRevB.60.6254; Xiao LZ, 2002, NANO LETT, V2, P1293; Xu SY, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/8/085301	26	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0928-0707	1573-4846		J SOL-GEL SCI TECHN	J. Sol-Gel Sci. Technol.	MAR	2015	73	3			SI		620	627		10.1007/s10971-014-3570-7		8	Materials Science, Ceramics	Materials Science	CC9JD	WOS:000350684600016		
J	Ahmad, MK; Mohan, VM; Murakami, K				Ahmad, M. K.; Mohan, V. M.; Murakami, K.			Hydrothermal growth of bilayered rutile-phased TiO2 nanorods/micro-size TiO2 flower in highly acidic solution for dye-sensitized solar cell	JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY			English	Article; Proceedings Paper	European Materials Research Society (EMRS) Spring Meeting / Symposium I on Solution Processing and Properties of Functional Oxide Thin Films and Nanostructures	MAY 26-30, 2014	Lille, FRANCE	European Mat Res Soc		Titanium dioxide; Nanorods; TiO2 flower; Rutile; Power conversion efficiency; Hydrothermal	CHEMICAL-VAPOR-DEPOSITION; GEL TEMPLATE SYNTHESIS; NANOTUBE ARRAYS; FILMS	Aligned rutile-phased TiO2 (r-TNRs) nanorods and micro-size rutile-phased TiO2 flowers (r-TFs) films were prepared on fluorine-doped tin oxide (FTO) substrate using highly acidic solution by two steps of hydrothermal process. The hydrothermal process was done at 150 A degrees C in 5 h for the first step and 2 h for the second step. These films were used as a photoelectrode in dye-sensitized solar cell (DSC) application. Aligned r-TNRs and r-TFs were prepared using one-step and two-step hydrothermal processes, respectively. At the end of second step hydrothermal process, micro-size rutile-phased TiO2 flowers (r-TFs) were observed on top of r-TNRs (FTO/r-TNRs/r-TFs). Power conversion efficiencies for both aligned r-TNRs and r-TNRs/r-TFs were compared. From the results, DSC made of r-TNRs only produced energy conversion efficiency of 1.52 % and DSC made of r-TNRs/r-TFs gave excellent energy conversion efficiency (eta) of 4.27 %.	[Ahmad, M. K.] Univ Tun Hussein Onn Malaysia, Microelect & Nanotechnol Shamsuddin Res Ctr MiNT, Batu Pahat 86400, Johor, Malaysia; [Mohan, V. M.; Murakami, K.] Shizuoka Univ, Elect Res Inst, Hamamatsu, Shizuoka 4328011, Japan	Ahmad, MK (reprint author), Univ Tun Hussein Onn Malaysia, Microelect & Nanotechnol Shamsuddin Res Ctr MiNT, Batu Pahat 86400, Johor, Malaysia.	akhairul@uthm.edu.my					Ahmad MK, 2012, ADV RES PHYS, V3, P21208; Ahmad MK, 2011, ADV MAT RES, V222, P24; Attar AS, 2009, MATER CHEM PHYS, V113, P856, DOI 10.1016/j.matchemphys.2008.08.040; Feng XJ, 2005, ANGEW CHEM INT EDIT, V44, P5115, DOI 10.1002/anie.200501337; Huang CM, 2006, CHEM PHYS LETT, V432, P468, DOI 10.1016/j.cplett.2006.10.010; Paulose M, 2006, J PHYS CHEM B, V110, P16179, DOI 10.1021/jp064020k; Francis L, 2011, ENERGY, V36, P627, DOI 10.1016/j.energy.2010.09.054; Li G, 2009, CHINESE J CATAL, V30, P37; Pradhan SK, 2003, J CRYST GROWTH, V256, P83, DOI 10.1016/S0022-0248(03)01339-3; Gratzel M, 2003, J PHOTOCH PHOTOBIO C, V4, P145, DOI 10.1016/S1389-5567(03)00026-1; Liu B, 2009, J AM CHEM SOC, V131, P3985, DOI 10.1021/ja8078972; Kakiuchi K, 2006, J CRYST GROWTH, V293, P541, DOI 10.1016/j.jcrysgro.2006.06.004; Hao Pan, 2011, Applied Surface Science, V257, DOI 10.1016/j.apsusc.2011.01.021; Hong Zhu, 2011, Applied Surface Science, V257, DOI 10.1016/j.apsusc.2011.07.020; Maekawa T, 2008, SURF COAT TECH, V202, P3067, DOI 10.1016/j.surfcoat.2007.11.017; Mohan VM, 2011, ADV RES PHYS, V2, P21112; Peng X, 2005, APPL PHYS A-MATER, V80, P473, DOI 10.1007/s00339-004-3052-9; Regan B. O., 1991, NATURE, V35, P737, DOI DOI 10.1038/353737A0; Yang Y, 2008, MATER SCI ENG B-ADV, V149, P58, DOI 10.1016/j.mseb.2007.12.006; Yun H, 2008, APPL SURF SCI, V255, P2113, DOI 10.1016/j.apsusc.2008.06.194	20	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0928-0707	1573-4846		J SOL-GEL SCI TECHN	J. Sol-Gel Sci. Technol.	MAR	2015	73	3			SI		655	659		10.1007/s10971-015-3615-6		5	Materials Science, Ceramics	Materials Science	CC9JD	WOS:000350684600021		
J	Zhang, J; Xu, L; Zhou, SM; Ye, XC				Zhang, Jing; Xu, Li; Zhou, Shuming; Ye, Xiucai			A novel sleep scheduling scheme in green wireless sensor networks	JOURNAL OF SUPERCOMPUTING			English	Article						Wireless sensor networks; Sleep scheduling; Dec-POMDP; Quasi-Monte Carlo; Upper bound	ALGORITHM; LIFETIME; CONNECTIVITY; COVERAGE	Reduction of unnecessary energy consumption is becoming a major concern in green wireless sensor networks. Sleep scheduling is one of the efficient strategies to achieve energy saving. In this paper, we propose a novel scheme for the sleep scheduling, which is based on Decentralized Partially Observable Markov Decision Process (Dec-POMDP). A sleep scheduling algorithm with online planning (Dec-POP-SSA) with respect to Dec-POMDP is also presented. In Dec-POMDP, due to the hardness of obtaining the state spaces and the reward with mold-free environment, quasi-Monte Carlo is applied to collect state spaces such that the real-time acquisition of beliefs state is achieved, and the reward is evaluated in tracking reward and coverage connectivity intensity. Instead of producing the entire plan, Dec-POP-SSA need only find actions for the current step. We also give the theoretical analysis on the upper bound for Dec-POP-SSA. The numerical experiments show that Dec-POP-SSA may receive the highest reward.	[Zhang, Jing; Xu, Li; Zhou, Shuming] Fujian Normal Univ, Sch Math & Comp Sci, Fuzhou, Peoples R China; [Zhang, Jing] Fujian Univ Technol, Sch Informat Sci & Engn, Fuzhou, Peoples R China; [Xu, Li] Fujian Normal Univ, Fujian Prov Key Lab Network Secur & Cryptol, Fuzhou, Peoples R China; [Ye, Xiucai] Univ Tsukuba, Dept Comp Sci, Tsukuba, Ibaraki, Japan	Xu, L (reprint author), Fujian Normal Univ, Fujian Prov Key Lab Network Secur & Cryptol, Fuzhou, Peoples R China.	jing165455@126.com; xuli@fjnu.edu.cn; zhoushuming@fjnu.edu.cn; yexiucai2013@gmail.com			National Natural Science Foundation of China [61072080, U1405255]; Fujian Normal University Innovative Research Team [IRTL1207]; Natural Science Foundation of Fujian Province [2013J01222, J01223, 2013J01221]; Education Department of Fujian Province science and technology project [JA13215]	The authors wish to thank National Natural Science Foundation of China (Grant No: 61072080, No. U1405255). Fujian Normal University Innovative Research Team (No. IRTL1207). The Natural Science Foundation of Fujian Province (No: 2013J01222, J01223, 2013J01221). The Education Department of Fujian Province science and technology project (JA13215).	Ding Y, 2009, IEEE T PARALL DISTR, V20, P1352, DOI 10.1109/TPDS.2008.230; Shi ZF, 2009, PERFORM EVALUATION, V66, P469, DOI 10.1016/j.peva.2009.02.002; Shi ZF, 2011, PE-WASUN 11: PROCEEDINGS OF THE EIGHTH ACM SYMPOSIUM ON PERFORMANCE EVALUATION OF WIRELESS AD HOC, SENSOR, AND UBIQUITOUS NETWORKS, P117; Kim YH, 2013, J SUPERCOMPUT, V65, P365, DOI 10.1007/s11227-011-0646-9; Bianzino AP, 2012, IEEE COMMUN SURV TUT, V14, P3, DOI 10.1109/SURV.2011.113010.00106; Jiang B, 2013, IEEE T MOBILE COMPUT, V12, P735, DOI 10.1109/TMC.2012.44; Zhao YX, 2012, IEEE T PARALL DISTR, V23, P1528, DOI 10.1109/TPDS.2011.305; Chen Y, 2011, IEEE COMMUN MAG, V49, P30; Liu C, 2006, IEEE T PARALL DISTR, V17, P562, DOI 10.1109/TPDS.2006.77; Morreale P, 2011, INT J SENS NETW, V10, P73, DOI 10.1504/IJSNET.2011.040905; HOEFFDING W, 1963, J AM STAT ASSOC, V58, P13, DOI 10.2307/2282952; Shi ZF, 2013, WIREL NETW, V19, P393, DOI 10.1007/s11276-012-0474-8; BHANDARKAR SM, 1995, PARALLEL COMPUT, V21, P1783, DOI 10.1016/0167-8191(95)00032-9; Fuemmeler JA, 2010, IEEE T SIGNAL PROCES, V58, P3742, DOI 10.1109/TSP.2010.2046896; Arabnia HR, 1993, P 7 ANN INT HIGH PER, P349; ARABNIA HR, 1990, J PARALLEL DISTR COM, V10, P188, DOI 10.1016/0743-7315(90)90028-N; Arabnia HR, 1989, INT J EUROGRAPH ASS, V8, P3, DOI DOI 10.1111/J.1467-8659.1989.TB00448.X; Atia GK, 2011, IEEE T SIGNAL PROCES, V59, P4923, DOI 10.1109/TSP.2011.2160055; Censor-Hillel K, 2014, P SODA, V2014, P546; Demchik V, 2011, COMPUT PHYS COMMUN, V182, P692, DOI 10.1016/j.cpc.2010.12.008; Fuemmeler J. A., 2008, NETWORKED SENSING IN, P267, DOI 10.1007/978-0-387-68845-9_11; Fuemmeler JA, 2011, IEEE T SIGNAL PROCES, V59, P4354, DOI 10.1109/TSP.2011.2159496; Gmez-Prez D, 2013, UNIF DISTRIB THEORY, V8, P31; Halton J. H., 1960, NUMER MATH, V2, P84, DOI DOI 10.1007/BF01386213; Jabbar S, 2014, J SUPERCOMPUT, V70, P104, DOI 10.1007/s11227-014-1108-y; Levy B. C., 2008, PRINCIPLES SIGNAL DE; Mihaylov M, 2013, AGENTS ARTIFICIAL IN, P382; Nan G, 2012, EURASIP J WIREL COMM, V1, P1; Ragi S, 2013, INT CONF UNMAN AIRCR, P260; Shi Z, 2008, P 14 EL LAUNCH TECHN, P1; Shi Z, 2013, INT J SOFT COMPUT MA, V2, P1; Shi ZF, 2007, IEEE WCNC, P355, DOI 10.1109/WCNC.2007.71; Wang L, 2012, SCI CHINA INFORM SCI, V55, P755, DOI 10.1007/s11432-011-4336-2; Wang WN, 2012, CHINA COMMUN, V9, P22; Wei Q, 2012, CHINA COMMUN, V9, P10; Wu F, 2011, ARTIF INTELL, V175, P487, DOI 10.1016/j.artint.2010.09.008; Yu JG, 2014, J NETW COMPUT APPL, V37, P186, DOI 10.1016/j.jnca.2013.02.025; Zeng YY, 2010, J SUPERCOMPUT, V52, P23, DOI 10.1007/s11227-009-0268-7; Zhang DQ, 2014, ADV MATER RES-SWITZ, V846-847, P446, DOI 10.4028/www.scientific.net/AMR.846-847.446	39	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0920-8542	1573-0484		J SUPERCOMPUT	J. Supercomput.	MAR	2015	71	3					1067	1094		10.1007/s11227-014-1354-z		28	Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CD1XR	WOS:000350868400015		
J	Ghimire, MP; Wu, LH; Hu, X				Ghimire, Madhav P.; Wu, Long-Hua; Hu, Xiao			Half Metallic Ferrimagnetism in Hole-Doped Lanthanide Iridates	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						Half metals; Ferrimagnetism; Spintronics; Spin-orbit coupling; First-principles calculations	MAGNETIC-PROPERTIES; ANTIFERROMAGNET; SPINTRONICS	Electronic and magnetic properties of a material of double perovskite [Pr (2-x) Sr (x) MgIrO (6)] (2) had been studied by first-principles density functional approach. Under the cooperative effect of spin-orbit coupling (SOC) and Coulomb interactions of Ir-5d and Pr-4f electrons, our calculations reveal half metallic ferrimagnetism (HMFiM) with the total angular moment mu (t o t) = +/- 3 mu (B) per unit cell for x = 0.5 and 1.5, desirable for spintronic applications. HMFiM is fully retained in presence of SOC due to the large exchange splitting between spin-up and spin-down bands at the Fermi level.	[Ghimire, Madhav P.; Wu, Long-Hua; Hu, Xiao] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Tsukuba, Ibaraki 3050054, Japan	Ghimire, MP (reprint author), Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Tsukuba, Ibaraki 3050054, Japan.	GHIMIRE.Madhavprasad@nims.go.jp			WPI Initiative on Materials Nanoarchitectonics, MEXT, Japan	This work was supported by WPI Initiative on Materials Nanoarchitectonics, MEXT, Japan.	Wan XG, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.205101; Tokura Y, 2006, REP PROG PHYS, V69, P797, DOI 10.1088/0034-4885/69/3/R06; Kim BJ, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.076402; Kunes J, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.153102; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; DEGROOT RA, 1983, PHYS REV LETT, V50, P2024, DOI 10.1103/PhysRevLett.50.2024; Pickett WE, 1998, PHYS REV B, V57, P10613, DOI 10.1103/PhysRevB.57.10613; Galanakis I, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3619844; Hu SJ, 2010, J PHYS CHEM C, V114, P11614, DOI 10.1021/jp103328g; Kandpal HC, 2007, J PHYS D APPL PHYS, V40, P1507, DOI 10.1088/0022-3727/40/6/S01; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389; Lee KW, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.115101; Anisimov VI, 1997, J PHYS-CONDENS MAT, V9, P767, DOI 10.1088/0953-8984/9/4/002; Hu X, 2012, ADV MATER, V24, P294, DOI 10.1002/adma.201102555; Liang QF, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/6/063031; Ghimire MP, 2011, J ALLOY COMPD, V509, P9742, DOI 10.1016/j.jallcom.2011.08.017; Pesin D, 2010, NAT PHYS, V6, P376, DOI 10.1038/NPHYS1606; Wan XG, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.087205; Blaha P, 2001, WIEN2K AUGMENTED PLA; Ghimire M.P., 2014, ARXIV14073408; Mugavero SJ, 2010, J SOLID STATE CHEM, V183, P465, DOI 10.1016/j.jssc.2009.11.025; Nie YM, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.117203; Park JH, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.174401	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		917	919		10.1007/s10948-014-2669-y		3	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800032		
J	Mikuriya, M; Tanaka, Y; Yoshioka, D; Handa, M				Mikuriya, Masahiro; Tanaka, Yusuke; Yoshioka, Daisuke; Handa, Makoto			Molecule-Based Magnetic Compounds Made Up from Dinuclear Ruthenium(II,III) Carboxylate and Dicyanidoargentate(I)	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						Magnetic susceptibility; Antiferromagnetic interaction; Dinuclear ruthenium(II,III) carboxylate; Dicyanido argentate(I)	BUILDING-BLOCKS; DIRUTHENIUM; TETRACARBOXYLATES; MONOCATION; COMPLEXES; PIVALATE	Mixed-metal complexes constructed from mixed-valent dinuclear ruthenium(II,III) carboxylate and dicyanidoargentate(I), K[Ru-2(O2CCH3)(4)Ag(CN)(2)]a <...4H(2)O (1) and K-2.5[Ru-2{O2CC(CH3)(3)}(4)(Ag(CN)(2))(3.5)]a <...3H(2)O (2), were synthesized and characterized by elemental analysis and IR and UV-visible-NIR spectroscopies. These data supported the formulation of mixed-metal adduct of Ru-2(O2CCH3)(4) (+) with two Ag(CN)(2) (-) for 1 and mixed-metal dimer of Ru-2{O2CC(CH3)(3)}(4) (+) with aggregated {Ag(CN)(2) (-)}(2or3) through argentophilic Ag a <...a <...a <... Ag interaction for 2, respectively. A broadband (delta(Ru-2) -> delta (au)(Ru-2)) at near-IR and two bands(delta (au)/pi (au) (Ru-2) -> sigma (au)a-u-O and pi(Ru-O, Ru-2) -> pi (au)(Ru-2)) at visible region were observed in the diffused reflectance spectra (920sh, 634, and 444 nm for 1 and 930sh, 638, and 478 nm for 2, respectively). Temperature dependence of magnetic susceptibility measurement (4.5-300 K) showed that the former is paramagnetic (S = 3/2) with D (zero-field splitting parameter) = 78 cm(-1) and the latter weakly antiferromagnetic with g = 2.07, zJ (the exchange integral multiplied by the number of interacting neighbors) =-0.5 cm(-1), and D = 90 cm(-1).	[Mikuriya, Masahiro; Tanaka, Yusuke; Yoshioka, Daisuke] Kwansei Gakuin Univ, Sch Sci & Technol, Dept Chem, Sanda 6691337, Japan; [Mikuriya, Masahiro; Tanaka, Yusuke; Yoshioka, Daisuke] Kwansei Gakuin Univ, Sch Sci & Technol, Res Ctr Coordinat Mol Based Devices, Sanda 6691337, Japan; [Handa, Makoto] Shimane Univ, Interdisciplinary Grad Sch Sci & Engn, Dept Chem, Matsue, Shimane 6908504, Japan	Mikuriya, M (reprint author), Kwansei Gakuin Univ, Sch Sci & Technol, Dept Chem, 2-1 Gakuen, Sanda 6691337, Japan.	junpei@kwansei.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan) [26410080]; MEXT	The present work was partially supported by Grant-in-Aid for Scientific Research No. 26410080 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT, Japan) and the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2010-2014.	Dong W, 2003, INORG CHEM COMMUN, V6, P873, DOI 10.1016/S1387-7003(03)00133-3; Vos TE, 2004, J AM CHEM SOC, V126, P11630, DOI 10.1021/ja0481351; Mikuriya M, 2006, COORDIN CHEM REV, V250, P2194, DOI 10.1016/j.ccr.2006.01.011; Vos TE, 2005, ANGEW CHEM INT EDIT, V44, P2416, DOI 10.1002/anie.200462546; Aquino MAS, 1998, COORDIN CHEM REV, V170, P141, DOI 10.1016/S0010-8545(97)00079-9; Aquino MAS, 2004, COORDIN CHEM REV, V248, P1025, DOI 10.1016/j.ccr.2004.06.016; Cernak J, 2000, INORG CHIM ACTA, V311, P126, DOI 10.1016/S0020-1693(00)00327-3; Cotton F. A., 2005, MULTIPLE BONDS METAL; Ishida H, 2013, CHEM PAP, V67, P743, DOI 10.2478/s11696-013-0366-0; Matoga D, 2005, CHEM LETT, V34, P1550, DOI 10.1246/cl.2005.1550; Mikuriya M, 2011, NEW J CHEM, V35, P1226, DOI 10.1039/c0nj00855a; Mikuriya M., 2008, B JPN SOC COORD CHEM, V52, P17; Pham DM, 2005, INORG CHIM ACTA, V358, P4261, DOI 10.1016/j.ica.2005.06.033; Sayama Y, 2000, B CHEM SOC JPN, V73, P2499, DOI 10.1246/bcsj.73.2499; Yoshioka D, 2002, CHEM LETT, P1044, DOI 10.1246/cl.2002.1044	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		1013	1016		10.1007/s10948-014-2646-5		4	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800049		
J	Kajitani, J; Hiroi, T; Omachi, A; Miura, O; Mizuguchi, Y				Kajitani, Joe; Hiroi, Takafumi; Omachi, Atsushi; Miura, Osuke; Mizuguchi, Yoshikazu			Increase in T (c) and Change of Crystal Structure by High-Pressure Annealing in BiS2-Based Superconductor CeO0.3F0.7BiS2	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						BiS2-based superconductor; CeO1-xFxBiS2; Crystal structure; High-pressure annealing		Recently, several types of BiS2-based superconductor such as Bi4O4S3, REO1-x F (x) BiS2 (RE: rare earth) and Sr1-x La (x) FBiS2 have been discovered. In this study, we have investigated the crystal structure and the superconducting properties for two kinds of polycrystalline samples (as-grown and high-pressure-annealed samples) of the BiS2-based superconductor CeO0.3F0.7BiS2. We found that both the as-grown and the high-pressure-annealed CeO0.3F0.7BiS2 samples show bulk superconductivity. A higher T (c) was observed in the high-pressure-annealed sample. The T (c) of CeO0.3F0.7BiS2 increased from 2.7 K to 3.7 K by high-pressure annealing. The lattice constant of a and c axes did not show remarkable differences between the as-grown and the high-pressure-annealed samples. Nevertheless, the peak symmetry of the (200) peak seemed to become more symmetric while the (004) peak did not show such a difference, indicating that the crystal structure within the ab-plane changed to a higher-symmetric phase, a perfect tetragonal, by high-pressure annealing in CeO0.3F0.7BiS2.	[Kajitani, Joe; Hiroi, Takafumi; Omachi, Atsushi; Miura, Osuke; Mizuguchi, Yoshikazu] Tokyo Metropolitan Univ, Dept Elect & Elect Engn, Hachioji, Tokyo 1920397, Japan	Mizuguchi, Y (reprint author), Tokyo Metropolitan Univ, Dept Elect & Elect Engn, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	mizugu@tmu.ac.jp			JSPS KAKENHI [25707031, 26600077]	This work was partly supported by JSPS KAKENHI Grant Numbers 25707031, 26600077.	Takahashi H, 2008, NATURE, V453, P376, DOI 10.1038/nature06972; Mizuguchi Y, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.220510; Medvedev S, 2009, NAT MATER, V8, P630, DOI [10.1038/nmat2491, 10.1038/NMAT2491]; Jha R, 2013, J SUPERCOND NOV MAGN, V26, P499, DOI 10.1007/s10948-012-2097-9; Usui H, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.220501; Margadonna S, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.064506; Deguchi K, 2013, EPL-EUROPHYS LETT, V101, DOI 10.1209/0295-5075/101/17004; Demura S., 2013, J PHYS SOC JPN, V82; Demura S., ARXIV13114267; Kajitani J, 2014, SOLID STATE COMMUN, V181, P1, DOI 10.1016/j.ssc.2013.11.027; Kajitani J., 2014, J PHYS SOC JPN, V83; Kotegawa H., 2012, J PHYS SOC JPN, V81; Lin X, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.020504; Mizuguchi Y., 2012, J PHYS SOC JPN, V81; Mizuguchi Y., 2008, APPL PHYS LETT, V93; Sakai H, 2014, J PHYS SOC JPN, V83, DOI 10.7566/JPSJ.83.014709; Tomita T., 2014, J PHYS SOC JPN, V83; Wolowiec C.T., 2013, J PHYS CONDENS MATT, V25; Xing J, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.214518	19	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		1129	1133		10.1007/s10948-014-2689-7		5	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800070		
J	Hiroi, T; Kajitani, J; Omachi, A; Miura, O; Mizuguchi, Y				Hiroi, Takafumi; Kajitani, Joe; Omachi, Atsushi; Miura, Osuke; Mizuguchi, Yoshikazu			Element Substitution Effect on Superconductivity in BiS (2)-Based NdO1-x F-x BiS (2)	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						BiS2-based superconductor; NdO1-xFxBiS2; Element substitution; Metal-insulator transition		Recently, new layered superconductors having a BiS2-type conduction layer have been discovered. NdO1-x F (x) BiS2 is a typical BiS2-based superconductor with a maximum T (c) of 5.4 K. In this study, the effect of element substitution within the superconducting layer of BiS2-based NdO0.5 F 0.5BiS2 was investigated. We systematically synthesized two kinds of polycrystalline samples of NdO0.5 F Bi-0.5(S1-x Se (x) )(2)and NdO0.5 F Bi-0.5(1-y) Sb (y) S (2) by a two-step solid-state reaction method. The phase purity and the changes in lattice constants were investigated by X-ray diffraction. The superconducting properties were investigated by magnetic susceptibility and electrical resistivity measurements. It was found that the partial substitution of S by Se resulted in the uniaxial lattice expansion along the a-axis. The superconducting transition temperature were gradually degraded with increasing Se concentration in NdO0.5 F Bi-0.5(S1-x Se (x) )(2). When Bi was partially substituted by Sb, the uniaxial lattice contraction along the c-axis was observed in NdO0.5 F Bi-0.5(1-y) Sb (y) S (2). In the Sb-substituted system, a metal-insulator transition was observed with increasing Sb concentration.	[Hiroi, Takafumi; Kajitani, Joe; Omachi, Atsushi; Miura, Osuke; Mizuguchi, Yoshikazu] Tokyo Metropolitan Univ, Dept Elect & Elect Engn, Hachioji, Tokyo 1920397, Japan	Mizuguchi, Y (reprint author), Tokyo Metropolitan Univ, Dept Elect & Elect Engn, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	mizugu@tmu.ac.jp			JSPS KAKENHI [25707031, 26600077]	The authors would like to thank Prof. K. Kuroki of Osaka University for the fruitful discussion. This work was partly supported by JSPS KAKENHI Grant Numbers 25707031 and 26600077.	Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; Mizuguchi Y, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.220510; Jha R, 2014, PHYSICA C, V498, P45, DOI 10.1016/j.physc.2014.01.003; Suzuki K, 2013, PHYSCS PROC, V45, P21, DOI 10.1016/j.phpro.2013.04.042; Yazici D, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.174512; Martins GB, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.081102; Jha R, 2013, J SUPERCOND NOV MAGN, V26, P499, DOI 10.1007/s10948-012-2097-9; Usui H, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.220501; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Deguchi K., 2013, EPL, V101; Demura S., 2013, J PHYS SOC JPN, V82; Demura S., ARXIV13114267; Jha R., 2013, J APPL PHYS, V113; Kajitani J, 2014, SOLID STATE COMMUN, V181, P1, DOI 10.1016/j.ssc.2013.11.027; Kajitani J., 2014, J PHYS SOC JPN, V83; Kotegawa H., 2012, J PHYS SOC JPN, V81; Li B., ARXIV12101743; Lin X, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.020504; Mizuguchi Y., 2014, J PHYS SOC JPN, V83; Mizuguchi Y., 2012, J PHYS SOC JPN, V81; Morice C., ARXIV13122615; Sakai H, 2014, J PHYS SOC JPN, V83, DOI 10.7566/JPSJ.83.014709; Shein I.R., 2012, J EXPT THEOR PHYS LE, V96, P859; Tomita T., 2014, J PHYS SOC JPN, V83; Wolowiec C.T., 2013, J PHYS CONDENS MATT, V25; Xing J, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.214518; Yazici D., 2012, PHILOS MAG, V93, P673; Yildirim T, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.020506	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		1149	1153		10.1007/s10948-014-2686-x		5	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800074		
J	Maehata, K; Iyomoto, N; Yamanaka, Y; Ito, T; Hara, T; Mitsuda, K; Yamasaki, NY; Tanaka, K				Maehata, K.; Iyomoto, N.; Yamanaka, Y.; Ito, T.; Hara, T.; Mitsuda, K.; Yamasaki, N. Y.; Tanaka, K.			Development of Compact Dry He-3-He-4 Dilution Refrigerator for Transition Edge Sensor Microcalorimeter X-ray Detector Operation on Electron Microscopes	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						Microcalorimeter; He-3-He-4 dilution refrigerator; Gifford-McMahon cryocooler; Remote helium cooling loop	SPECTROMETER	A compact dry He-3- He-4 dilution refrigerator (DR) was developed for operation of a superconducting transition edge sensor (TES) microcalorimeter x-ray detector mounted on a transmission electron microscope. A Gifford-McMahon (GM)-type mechanical cryocooler was used as a DR pre-cooler to operate the TES microcalorimeter without consuming liquid helium. To reduce the noise and vibrations generated by the GM cryocooler, the DR was separated from the cryocooler in a split system that allows a remote helium cooling loop to pre-cool the DR. In the DR unit, the dilution components of the still, the heat exchangers, and the cascade pair of mixing chambers were assembled into a compact cylinder. A snout made from an oxygen-free copper rod was attached to the DR mixing chamber for placement of the TES microcalorimeter x-ray detector. The lowest temperature and the cooling power in the mixing chamber were measured to be 87 mK and 20 mu W at 100 mK, respectively. The DR unit was shown to maintain the temperature on top of the snout such that it was below the temperature required for multi-pixel-array TES microcalorimeter x-ray detector operation.	[Maehata, K.; Iyomoto, N.] Kyushu Univ, Dept Appl Quantum Phys & Nucl Engn, Nishi Ku, Fukuoka 8190395, Japan; [Yamanaka, Y.; Ito, T.] Taiyo Nippon Sanso Corp, Tsukuba, Ibaraki 3002611, Japan; [Hara, T.] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050044, Japan; [Mitsuda, K.; Yamasaki, N. Y.] Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Sagamihara, Kanagawa 2298510, Japan; [Tanaka, K.] Hitachi High Tech Sci Corp, Shizuoka 4101393, Japan	Maehata, K (reprint author), Kyushu Univ, Dept Appl Quantum Phys & Nucl Engn, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.	maehata@kune2a.nucl.kyushu-u.ac.jp	Yamasaki, Noriko/C-2252-2008		SEN-TAN, Japan Science and Technology Agency (JST)	This work was financially supported by SEN-TAN, Japan Science and Technology Agency (JST).	Angloher G., 2003, NUCL INSTRU METH A, V512; COOPS GM, 1979, CRYOGENICS, V19, P659, DOI 10.1016/0011-2275(79)90068-7; Goldstein J., 2003, SCANNING ELECT MICRO, P314; Hara T, 2010, J ELECTRON MICROSC, V59, P17, DOI 10.1093/jmicro/dfp043; Maehata K, 2014, CRYOGENICS, V61, P86, DOI 10.1016/j.cryogenics.2014.03.002; Nagayoshi K., IEICE T UNPUB	6	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		1161	1165		10.1007/s10948-014-2699-5		5	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800076		
J	Tatsumoto, H; Shirai, Y; Shiotsu, M; Naruo, Y; Kobayashi, H; Inatani, Y				Tatsumoto, Hideki; Shirai, Yasuyuki; Shiotsu, Masahiro; Naruo, Yoshihiro; Kobayashi, Hiroaki; Inatani, Yoshifumi			Heat Transfer Characteristics of a Horizontal Wire in Pools of Liquid and Supercritical Hydrogen	JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM			English	Article						Heat transfer; Pool boiling; Liquid hydrogen; Supercritical pressure		Heat transfer from a horizontal wire immersed in both liquid and supercritical hydrogen was measured with a quasi-steady increase of the heat generation rate for a wide range of bath temperatures and pressures. The nucleate boiling heat transfer coefficient is higher for higher pressures. The critical heat flux (CHF) is highest in the vicinity of 0.4 MPa and is expressed by Kutateladze's equation. The CHFs become higher for higher degrees of subcooling. The heat transfer under supercritical pressures is the same as natural convection heat transfer in liquid hydrogen, but it deteriorates for heated surface temperautres higher than the pseudocritical temperature. The heat transfer correlation was derived based on the experimental data.	[Tatsumoto, Hideki] Japan Atom Energy Agcy, J PARC Ctr, Tokai, Ibaraki 3191195, Japan; [Shirai, Yasuyuki; Shiotsu, Masahiro] Kyoto Univ, Dept Energy Sci & Technol, Kyoto 6068501, Japan; [Naruo, Yoshihiro; Kobayashi, Hiroaki; Inatani, Yoshifumi] Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Sagamihara, Kanagawa 2298510, Japan	Tatsumoto, H (reprint author), Japan Atom Energy Agcy, J PARC Ctr, Tokai, Ibaraki 3191195, Japan.	tatumoto@post.j-parc.jp			JST, ALCA	This research was partly supported by JST, ALCA.	Class C.R., 1960, ADV CRYOGEN ENG, V5, P54; COELING KJ, 1969, J ENG IND, V91, P513; Kutateladze S.S., 1953, AECTR3405, P85; Kutateladze S.S., 1948, KOTLOTURBOSTROENIE, V3, P10; McAdams W H, 1954, HEAT TRANSMISSION; Shiotsu M, 2014, AIP CONF PROC, V1573, P36, DOI 10.1063/1.4860680; Shirai Y, 2010, CRYOGENICS, V50, P410, DOI 10.1016/j.cryogenics.2010.04.001; Steward W G, 1990, ADV CRYOGEN ENG, V35, P403; Tatsumoto H, 2010, J PHYS CONF SER, V234, DOI 10.1088/1742-6596/234/3/032056	9	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1939	1557-1947		J SUPERCOND NOV MAGN	J. Supercond. Nov. Magn	MAR	2015	28	3			SI		1185	1188		10.1007/s10948-014-2706-x		4	Physics, Applied; Physics, Condensed Matter	Physics	CC4XZ	WOS:000350360800080		
J	Oberta, P; Kittler, M; Ac, V; Hrdy, J; Iragashi, N; Scheinost, AC; Uchida, Y				Oberta, P.; Kittler, M.; Ac, V.; Hrdy, J.; Iragashi, N.; Scheinost, A. C.; Uchida, Y.			The influence of metallic brazing materials on the strain formation of internally water-cooled X-ray optics	JOURNAL OF SYNCHROTRON RADIATION			English	Article						X-ray optics; high heat load; internal cooling; crystal brazing	HIGH HEAT LOAD; CRYSTAL MONOCHROMATOR; SYNCHROTRON-RADIATION; SILICON-CRYSTALS; FINITE-ELEMENT; GLASS WAFER; SHAPE; COMPONENTS; CHANNELS; DESIGN	A study of metallic brazing material for internally cooled optics is presented. The study shows the influence of the different material properties on the final quality of the bond in terms of diffracted wavefront distortion, i.e. enlargement of the rocking curve. By choosing the proper brazing material and applying the proper brazing conditions, the influence of the brazing material can be fully eliminated. Furthermore the degradation of some brazing material due to the extreme working conditions of the optics is presented. Measurement results from ESRF and KEK confirm the importance of the proper brazing material choice.	[Oberta, P.; Kittler, M.; Hrdy, J.] Acad Sci Czech Republic, Inst Phys, CZ-18221 Prague 8, Czech Republic; [Oberta, P.] Rigaku Innovat Technol Europe, CZ-14221 Prague 4, Czech Republic; [Ac, V.] Alexander Dubcek Univ Trencin, Dept Phys, SK-91150 Trencin, Slovakia; [Iragashi, N.; Uchida, Y.] High Energy Accelerator Res Org KEK, Photon Factory, Tsukuba, Ibaraki 3050801, Japan; [Scheinost, A. C.] ESRF, Rossendorf Beamline, F-38043 Grenoble 9, France	Oberta, P (reprint author), Acad Sci Czech Republic, Inst Phys, Slovance 6, CZ-18221 Prague 8, Czech Republic.	oberta@fzu.cz	Scheinost, Andreas/D-2275-2010; The Rossendorf Beamline at ESRF, ROBL/A-2586-2011				Schmidt MA, 1998, P IEEE, V86, P1575, DOI 10.1109/5.704262; Zhang L, 2013, J SYNCHROTRON RADIAT, V20, P567, DOI 10.1107/S0909049513009436; BILDERBACK DH, 1989, REV SCI INSTRUM, V60, P1977, DOI 10.1063/1.1140852; Brida S, 2005, MICROSYST TECHNOL, V12, P59, DOI 10.1007/s00542-005-0004-z; CACIUFFO R, 1987, PHYS REP, V152, P1, DOI 10.1016/0370-1573(87)90080-9; Chumakov AI, 2014, J SYNCHROTRON RADIAT, V21, P315, DOI 10.1107/S1600577513033158; DIGENNARO R, 1990, NUCL INSTRUM METH A, V291, P305, DOI 10.1016/0168-9002(90)90077-J; HRDY J, 1992, REV SCI INSTRUM, V63, P459; Hrdy J, 1998, J SYNCHROTRON RADIAT, V5, P667, DOI 10.1107/S0909049597019092; KHOUNSARY AM, 1992, REV SCI INSTRUM, V63, P461, DOI 10.1063/1.1142732; Kim HS, 2004, APPL PHYS LETT, V85, P2370, DOI 10.1063/1.1794855; Knapp G. S., 1996, REV SCI INSTRUM, V67, P3352, DOI 10.1063/1.1147459; Kuroda M, 1998, J SYNCHROTRON RADIAT, V5, P1211, DOI 10.1107/S0909049598000399; Micha JS, 2013, NUCL INSTRUM METH A, V710, P155, DOI 10.1016/j.nima.2012.11.041; Oberta P, 2008, J SYNCHROTRON RADIAT, V15, P8, DOI 10.1107/S0909049507044858; Oberta P, 2008, J SYNCHROTRON RADIAT, V15, P543, DOI 10.1107/S0909049508027374; Raley NF, 1995, P SOC PHOTO-OPT INS, V2639, P40, DOI 10.1117/12.221298; SHU D, 1995, REV SCI INSTRUM, V66, P1783, DOI 10.1063/1.1145849; Shu DM, 2002, REV SCI INSTRUM, V73, P1584, DOI 10.1063/1.1435818; Xiao ZX, 1999, SENSOR ACTUAT A-PHYS, V72, P46, DOI 10.1016/S0924-4247(98)00197-6; Xu ZM, 2012, J SYNCHROTRON RADIAT, V19, P428, DOI 10.1107/S0909049512004050	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-0495	1600-5775		J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	MAR	2015	22		2		SI		342	347		10.1107/S1600577515000764		6	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CC8TM	WOS:000350641100015		
J	Deak, L; Bottyan, L; Callens, R; Coussement, R; Major, M; Nasu, S; Serdons, I; Spiering, H; Yoda, Y				Deak, L.; Bottyan, L.; Callens, R.; Coussement, R.; Major, M.; Nasu, S.; Serdons, I.; Spiering, H.; Yoda, Y.			Stroboscopic detection of nuclear resonance in an arbitrary scattering channel	JOURNAL OF SYNCHROTRON RADIATION			English	Article						nuclear resonant scattering; stroboscopic detection; multilayer	INCIDENCE MOSSBAUER-SPECTROSCOPY; INCIDENCE ANTIREFLECTION FILMS; SYNCHROTRON-RADIATION; X-RAYS; MULTILAYER; DIFFRACTION; POLARIZER; ANALYZER; SPECTRA; OPTICS	The theory of heterodyne/stroboscopic detection of nuclear resonance scattering is developed, starting from the total scattering matrix as a product of the matrix of the reference sample and the sample under study. This general approach holds for all dynamical scattering channels. In the forward channel, which has been discussed in detail in the literature, the electronic scattering manifests itself only in an energy-independent diminution of the scattered intensity. In all other channels, complex resonance line shapes of the heterodyne/stroboscopic spectra are encountered, as a result of the interference of electronic and nuclear scattering. The grazing-incidence case will be evaluated and described in detail. Experimental data of classical X-ray reflectivity and their stroboscopically detected resonant counterpart spectra on the [Fe-nat/Fe-57](10) isotope periodic multilayer and antiferromagnetic [Fe-57/Cr](20) superlattice are fitted simultaneously.	[Deak, L.; Bottyan, L.] RMKI, Wigner RCP, H-1525 Budapest, Hungary; [Callens, R.; Coussement, R.; Serdons, I.] Katholieke Univ Leuven, Inst Kern Stralingsfys, B-3001 Leuven, Belgium; [Major, M.] Tech Univ Darmstadt, Inst Mat Sci, D-64287 Darmstadt, Germany; [Nasu, S.] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan; [Spiering, H.] Johannes Gutenberg Univ Mainz, Inst Anorgan & Analyt Chem, D-55099 Mainz, Germany; [Yoda, Y.] SPring 8 JASRI, Mikazuki, Hyogo 6795198, Japan	Deak, L (reprint author), RMKI, Wigner RCP, POB 49, H-1525 Budapest, Hungary.	deak.laszlo@wigner.mta.hu	Major, Marton/A-8208-2013; Deak, Laszlo/B-2503-2013	Deak, Laszlo/0000-0002-1558-2109	Deutscher Akademischer Austauschdienst (DAAD); FWO-Flanders	The authors gratefully acknowledge the beam time supplied free of charge by the Japan Synchrotron Radiation Institute (JASRI) for experiment No. 2002B239-ND3-np. Our gratitude goes to Dr A. Q. Baron (SPring-8, JASRI) for kindly supplying the fast Hammamatsu APD detectors and Dr Johan Dekoster (IKS Leuven) for preparing the multilayer samples for the experiment. L. Deak and R. Callens thank the Deutscher Akademischer Austauschdienst (DAAD) and the FWO-Flanders, respectively, for financial support.	AFANASEV AM, 1964, SOV PHYS JETP-USSR, V18, P1139; STURHAHN W, 1994, PHYS REV B, V49, P9285, DOI 10.1103/PhysRevB.49.9285; IRKAEV SM, 1993, NUCL INSTRUM METH B, V74, P554, DOI 10.1016/0168-583X(93)95955-5; Chumakov AI, 1999, HYPERFINE INTERACT, V123, P427, DOI 10.1023/A:1017028024642; Rohlsberger R, 2012, NATURE, V482, P199, DOI 10.1038/nature10741; Rohlsberger R, 2010, SCIENCE, V328, P1248, DOI 10.1126/science.1187770; Gerdau E, 1999, HYPERFINE INTERACT, V123, P1; LAX M, 1951, REV MOD PHYS, V23, P287, DOI 10.1103/RevModPhys.23.287; Yoda Y, 2001, NUCL INSTRUM METH A, V467, P715, DOI 10.1016/S0168-9002(01)00474-0; Smirnov GV, 1997, PHYS REV B, V55, P5811, DOI 10.1103/PhysRevB.55.5811; BARON AQR, 1994, PHYS REV B, V50, P10354, DOI 10.1103/PhysRevB.50.10354; BLUME M, 1968, PHYS REV, V171, P417, DOI 10.1103/PhysRev.171.417; Bottyan L, 2002, J MAGN MAGN MATER, V240, P514, DOI 10.1016/S0304-8853(01)00894-0; Callens R, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.104423; Callens R, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.180404; CHUMAKOV AI, 1993, PHYS REV LETT, V71, P2489, DOI 10.1103/PhysRevLett.71.2489; CHUMAKOV AI, 1991, JETP LETT+, V53, P271; Coussement R, 1996, PHYS REV B, V54, P16003, DOI 10.1103/PhysRevB.54.16003; Deak L, 2001, PHYSICA B, V297, P113, DOI 10.1016/S0921-4526(00)00817-6; Deak L, 1999, J APPL PHYS, V85, P1, DOI 10.1063/1.369470; Deak L, 1996, PHYS REV B, V53, P6158, DOI 10.1103/PhysRevB.53.6158; DEAK L, 1994, HYPERFINE INTERACT, V92, P1083, DOI 10.1007/BF02065737; Deak L., 1999, CONDENSED MATTER STU, P151; Deak L, 2002, HYPERFINE INTERACT, V144, P45, DOI 10.1023/A:1025433117295; HANNON JP, 1985, PHYS REV B, V32, P6363, DOI 10.1103/PhysRevB.32.6363; HANNON JP, 1968, PHYS REV, V169, P315, DOI 10.1103/PhysRev.169.315; HANNON JP, 1969, PHYS REV, V186, P306, DOI 10.1103/PhysRev.186.306; HANNON JP, 1985, PHYS REV B, V32, P5068, DOI 10.1103/PhysRevB.32.5068; Kagan Y., 1964, ZH EKSP TEOR FIZ, V47, P1108; L'abbe C, 2000, PHYS REV B, V61, P4181, DOI 10.1103/PhysRevB.61.4181; Nagy D. L., 1999, NATO ASI SER, P323; Nagy DL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.157202; Rohlsberger R., 2005, SPRINGER TRACTS MODE, V208, P1; Rohlsberger R, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.245412; Rohlsberger R, 1999, HYPERFINE INTERACT, V123, P455, DOI 10.1023/A:1017075907804; Serdons I, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.014109; Sladecek M, 2002, SURF SCI, V507, P124, DOI 10.1016/S0039-6028(02)01187-1; Spiering H, 2000, HYPERFINE INTERACT, V125, P197, DOI 10.1023/A:1012637721433; Tancziko F, 2004, NUCL INSTRUM METH B, V226, P461, DOI 10.1016/j.nimb.2004.06.035; TOELLNER TS, 1995, APPL PHYS LETT, V67, P1993, DOI 10.1063/1.114764	40	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-0495	1600-5775		J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	MAR	2015	22		2		SI		385	392		10.1107/S1600577514026344		8	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CC8TM	WOS:000350641100020		
J	Mitsui, T; Imai, Y; Masuda, R; Seto, M; Mibu, K				Mitsui, Takaya; Imai, Yasuhiko; Masuda, Ryo; Seto, Makoto; Mibu, Ko			Fe-57 polarization-dependent synchrotron Mossbauer spectroscopy using a diamond phase plate and an iron borate nuclear Bragg monochromator	JOURNAL OF SYNCHROTRON RADIATION			English	Article						Mossbauer spectroscopy; diamond phase plate; nuclear Bragg reflection; nuclearmonochromator; polarization analysis; circular dichroism; grazing incidence	INCIDENCE ANTIREFLECTION FILMS; (FEBO3)-FE-57 SINGLE-CRYSTAL; TOTAL EXTERNAL REFLECTION; X-RAY; RESONANT SCATTERING; THIN-FILMS; GAMMA-RADIATION; DIFFRACTION; MULTILAYER; REFLECTOMETRY	Energy-domain Fe-57 polarization-dependent synchrotron radiation Mossbauer spectroscopy was developed by using a diamond X-ray phase plate and an iron borate nuclear Bragg monochromator. The former controls the polarization of the incident synchrotron radiation X-rays and the latter filters the Fe-57-Mossbauer radiation with a narrow bandwidth of approximate to 3.4 (0) ((0)similar or equal to 4.7neV: natural linewidth of the Fe-57 nucleus) from the broadband synchrotron radiation. The developed nuclear diffraction optics allowed Fe-57-Mossbauer studies to be performed with various polarization states, i.e. linear polarization, circular polarization and non-polarization. In this paper, the spectrometer system, beam characterization, performance-test experiments and a grazing-incidence Mossbauer measurement of an isotope-enriched (Fe-57: 95%) iron thin film are described.	[Mitsui, Takaya; Seto, Makoto] Japan Atom Energy Agcy, Sayo, Hyogo 6795148, Japan; [Imai, Yasuhiko] Japan Synchrotron Radiat Res Inst, Sayo, Hyogo 6795198, Japan; [Masuda, Ryo; Seto, Makoto] Kyoto Univ, Inst Res Reactor, Kumatori, Osaka 5900494, Japan; [Mibu, Ko] Nagoya Inst Technol, Showa Ku, Nagoya, Aichi 4668555, Japan	Mitsui, T (reprint author), Japan Atom Energy Agcy, 1-1-1 Kouto, Sayo, Hyogo 6795148, Japan.	taka@spring8.or.jp	Mibu, Ko/E-2277-2014	Mibu, Ko/0000-0002-6416-1028	Japan Society for the Promotion of Science (JSPS)	This work was supported by the Grants-in-Aid for Scientific Research (S) from Japan Society for the Promotion of Science (JSPS). TM and KM were partially supported by the Grants-in-Aid for Scientific Research (B) from JSPS. SR-Mossbauer studies were performed at BL11XU, SPring-8 (proposal numbers 2012A3501, 2012B3501, 2013A3501, 2013B3501, 2013B3512 and 2014A3501). The authors would like to thank Dr M. Suzuki for help with the X-ray polarization monitor.	Andreeva M. A., 1994, Journal of Experimental and Theoretical Physics, V78; ANDREEVA MA, 1991, PHYS STATUS SOLIDI A, V127, P455, DOI 10.1002/pssa.2211270221; MOSSBAUER RL, 1958, Z PHYS, V151, P124, DOI 10.1007/BF01344210; Shvydko YV, 1996, PHYS REV B, V54, P14942, DOI 10.1103/PhysRevB.54.14942; GILES C, 1994, J APPL CRYSTALLOGR, V27, P232, DOI 10.1107/S0021889893007976; Potapkin V, 2012, J SYNCHROTRON RADIAT, V19, P559, DOI 10.1107/S0909049512015579; Chumakov AI, 1999, HYPERFINE INTERACT, V123, P427, DOI 10.1023/A:1017028024642; Mitsui T, 2009, J SYNCHROTRON RADIAT, V16, P723, DOI 10.1107/S0909049509033615; HASTINGS JB, 1991, PHYS REV LETT, V66, P770, DOI 10.1103/PhysRevLett.66.770; BATTERMAN BW, 1964, REV MOD PHYS, V36, P681, DOI 10.1103/RevModPhys.36.681; L'abbe C, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.037201; Zhan QF, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/6/063003; Smirnov GV, 1997, PHYS REV B, V55, P5811, DOI 10.1103/PhysRevB.55.5811; Seto M, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.217602; Belyakov V. A., 1976, Soviet Physics - Uspekhi, V18, DOI 10.1070/PU1975v018n04ABEH004870; Belyakov V. A., 1987, SOV PHYS USP, V30, P331, DOI 10.1070/PU1987v030n04ABEH002835; BELYAEV VA, 1968, JETP LETT-USSR, V7, P368; BELYAKOV VA, 1969, JETP LETT-USSR, V9, P393; BELYAKOV VA, 1987, USP FIZ NAUK+, V151, P699, DOI 10.3367/UFNr.0151.198704e.0699; BERNSTEIN S, 1963, PHYS REV, V132, P1625, DOI 10.1103/PhysRev.132.1625; Bottyan L., 2003, SPRING 8 RES FRONTIE, P58; Bouchenoire L, 2003, J SYNCHROTRON RADIAT, V10, P172, DOI 10.1107/S0909049502018654; Burck U., 1980, J PHYS C SOLID STATE, V13, P4511, DOI 10.1088/0022-3719/13/24/014; Callens R, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.180404; Callens R, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.081402; Callens R, 2007, J SYNCHROTRON RADIAT, V14, P366, DOI 10.1107/S0909049507023229; CHUMAKOV AI, 1990, PHYS REV B, V41, P9545, DOI 10.1103/PhysRevB.41.9545; CHUMAKOV AI, 1993, PHYS REV LETT, V71, P2489, DOI 10.1103/PhysRevLett.71.2489; Deak L, 2006, HYPERFINE INTERACT, V167, P709, DOI 10.1007/s10751-006-9479-y; FINKELSTEIN KD, 1994, NUCL INSTRUM METH A, V347, P124, DOI 10.1016/0168-9002(94)91867-8; FRAUENFELDER H, 1962, PHYS REV, V126, P1065, DOI 10.1103/PhysRev.126.1065; FROST JC, 1985, APPL PHYS LETT, V47, P581, DOI 10.1063/1.96078; GERDAU E, 1986, HYPERFINE INTERACT, V27, P59, DOI 10.1007/BF02354744; GERDAU E, 1985, PHYS REV LETT, V54, P835, DOI 10.1103/PhysRevLett.54.835; Gerdau E., 1994, RESONANT ANOMALOUS X, P589; GERDAU E, 1990, HYPERFINE INTERACT, V58, P2433, DOI 10.1007/BF02398356; Gonser U., 1981, MOSSBAUER SPECTROSCO; GONSER U, 1985, HYPERFINE INTERACT, V26, P845, DOI 10.1007/BF02354641; HANNON JP, 1985, PHYS REV B, V32, P6374, DOI 10.1103/PhysRevB.32.6374; HANNON JP, 1979, PHYS REV LETT, V43, P636, DOI 10.1103/PhysRevLett.43.636; HANNON JP, 1985, PHYS REV B, V32, P6363, DOI 10.1103/PhysRevB.32.6363; HANNON JP, 1985, PHYS REV B, V32, P5068, DOI 10.1103/PhysRevB.32.5068; HANNON JP, 1985, PHYS REV B, V32, P5081, DOI 10.1103/PhysRevB.32.5081; Hayakawa S., 1998, ADV XRAY CHE ANAL JP, V29, P233; HIRANO K, 1991, JPN J APPL PHYS 2, V30, pL407, DOI 10.1143/JJAP.30.L407; HIRANO K, 1995, REV SCI INSTRUM, V66, P1604, DOI 10.1063/1.1145921; IRKAEV SM, 1993, NUCL INSTRUM METH B, V74, P545, DOI 10.1016/0168-583X(93)95954-4; ISAENKO SA, 1994, PHYS LETT A, V186, P274, DOI 10.1016/0375-9601(94)90353-0; Jaschke J, 1999, NUCL INSTRUM METH B, V155, P189, DOI 10.1016/S0168-583X(99)00242-6; L'abbe C, 2000, PHYS REV B, V61, P4181, DOI 10.1103/PhysRevB.61.4181; L'Abbe C, 2001, HYPERFINE INTERACT, V135, P275, DOI 10.1023/A:1013938803115; Masuda R, 2008, JPN J APPL PHYS, V47, P8087, DOI 10.1143/JJAP.47.8087; Mibu K, 2013, HYPERFINE INTERACT, V217, P127, DOI 10.1007/s10751-012-0734-0; MIRZABAB.RM, 1971, PHYS LETT A, VA 37, P441, DOI 10.1016/0375-9601(71)90625-6; Mitsui T, 2007, JPN J APPL PHYS 2, V46, pL930, DOI 10.1143/JJAP.46.L930; Mitsui T, 2007, JPN J APPL PHYS 1, V46, P821, DOI 10.1143/JJAP.46.821; Mitsui T, 2012, HYPERFINE INTERACT, V204, P97, DOI 10.1007/s10751-011-0488-0; Mitsui T, 2012, J SYNCHROTRON RADIAT, V19, P198, DOI 10.1107/S0909049511049958; Mitsui T, 2001, NUCL INSTRUM METH A, V467, P1105, DOI 10.1016/S0168-9002(01)00587-3; Nagy D. L., 1999, P MOSSB SPECTR MAT S, P323; Nagy DL, 2000, HYPERFINE INTERACT, V126, P353, DOI 10.1023/A:1012622712772; NASU S, 1994, HYPERFINE INTERACT, V90, P59, DOI 10.1007/BF02069118; Niesen B., 1998, PHYS REV B, V58, P8590; Odeurs J, 1998, HYPERFINE INTERACT, V113, P455, DOI 10.1023/A:1012637514028; Pankhurst QA, 2001, J NON-CRYST SOLIDS, V287, P81, DOI 10.1016/S0022-3093(01)00545-2; PFANNES HD, 1974, NUCL INSTRUM METHODS, V114, P297, DOI 10.1016/0029-554X(74)90547-3; Planckaert N, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3147185; ROHLSBERGER R, 1993, Z PHYS B CON MAT, V92, P489, DOI 10.1007/BF01320512; Rohlsberger R, 2001, PHYS REV LETT, V86, P5597, DOI 10.1103/PhysRevLett.86.5597; Rohlsberger R, 1999, HYPERFINE INTERACT, V123, P455, DOI 10.1023/A:1017075907804; Ruby S. L., 1974, J PHYS, V35, pC6; SHEN Q, 1995, REV SCI INSTRUM, V66, P2374, DOI 10.1063/1.1145625; SHEN Q, 1995, REV SCI INSTRUM, V66, P1610, DOI 10.1063/1.1145857; Shen Q, 1996, P SOC PHOTO-OPT INS, V2856, P82, DOI 10.1117/12.259852; Shen Q., 2000, HDB OPTICS; Shiwaku H, 2004, AIP CONF PROC, V705, P659; SHTRIKMA.S, 1969, REV SCI INSTRUM, V40, P1151, DOI 10.1063/1.1684184; SHTRIKMA.S, 1967, SOLID STATE COMMUN, V5, P701, DOI 10.1016/0038-1098(67)90353-5; SIDDONS DP, 1989, PHYS REV LETT, V62, P1384, DOI 10.1103/PhysRevLett.62.1384; Siddons DP, 1999, HYPERFINE INTERACT, V123, P681, DOI 10.1023/A:1017096512347; SIDDONS DP, 1990, PHYS REV LETT, V64, P1967, DOI 10.1103/PhysRevLett.64.1967; SMIRNOV GV, 1986, JETP LETT+, V43, P352; Smirnov GV, 2000, HYPERFINE INTERACT, V125, P91, DOI 10.1023/A:1012677402777; Smirnov GV, 2011, PHYS REV A, V84, DOI 10.1103/PhysRevA.84.053851; SMIRNOV GV, 1969, JETP LETT-USSR, V9, P70; Smirnov GV, 1996, HYPERFINE INTERACT, V97-8, P551, DOI 10.1007/BF02150198; Sturhahn W, 2004, EUROPHYS LETT, V66, P506, DOI 10.1209/epl/i2003-10235-7; Suzuki M., 2004, THESIS U TOKYO JAPAN; Szymanski K, 2006, PHYS REP, V423, P295, DOI 10.1016/j.physrep.2005.10.010; Szymanski K, 1996, NUCL INSTRUM METH B, V119, P438, DOI 10.1016/0168-583X(96)00336-9; TOELLNER TS, 1995, PHYS REV LETT, V74, P3475, DOI 10.1103/PhysRevLett.74.3475; Trammell G. T., 1961, P INT AT ENERG AGENC, V1, P75; Ueji Y., 2005, ACTA CRYSTALLOGR A, V61, pC433; WAGNER FE, 1968, Z PHYS, V210, P361, DOI 10.1007/BF01449003	94	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-0495	1600-5775		J SYNCHROTRON RADIAT	J. Synchrot. Radiat.	MAR	2015	22		2		SI		427	435		10.1107/S1600577514028306		9	Instruments & Instrumentation; Optics; Physics, Applied	Instruments & Instrumentation; Optics; Physics	CC8TM	WOS:000350641100024		
J	Miyashita, T; Mizuno, Y; Sugawara, Y; Nagamine, Y; Koyama, Y; Miyazaki, T; Uchimoto, K; Iketani, Y; Tojo, K; Goto, T				Miyashita, Tetsuya; Mizuno, Yusuke; Sugawara, Yo; Nagamine, Yusuka; Koyama, Yukihide; Miyazaki, Tomoyuki; Uchimoto, Kazuhiro; Iketani, Yasuhiro; Tojo, Kentaro; Goto, Takahisa			A pilot study of tele-anaesthesia by virtual private network between an island hospital and a mainland hospital in Japan	JOURNAL OF TELEMEDICINE AND TELECARE			English	Article							VASOPRESSOR AUTOMATED-SYSTEM; TREAT HYPOTENSION; SPINAL-ANESTHESIA; CESAREAN-SECTION; TELEMEDICINE; GUIDELINES; MANAGEMENT	We studied the use of tele-anaesthesia between Sado General Hospital (SGH) located on Sado Island and Yokohama City University Hospital (YCUH) located in mainland Japan. The two sites were connected via a virtual private network (VPN). We investigated the relationship between the bandwidth of the VPN and both the frame rate and the delay time of the tele-anaesthesia monitoring system. The tool used for communication between the two hospitals was free videoconferencing software (FaceTime), which can be used over Wi-Fi connections. We also investigated the accuracy of the commands given during teleanaesthesia: any commands from the anaesthetist at the YCUH that were not carried out for any reason, were recorded in the anaesthetic records at the SGH. The original frame rate and data rate at the SGH were 5fps and approximately 18 Mbit/s, respectively. The frame rate at the transmission speeds of 1, 5 and 20 Mbit/s was 0.6, 1.6 and 5.0fps, respectively. The corresponding delay time was 12.2, 4.9 and 0.7s. Twenty-five adult patients were enrolled in the study and tele-anaesthesia was performed. The total duration of anaesthesia was 37 hours. All 888 anaesthetic commands were completed. There were 7 FaceTime disconnections, which lasted for 10min altogether. Because no commands needed to be given during the FaceTime disconnection, the telephone was not used. The anaesthesia assistance system might form part of the solution to medical resource shortages.	[Miyashita, Tetsuya; Mizuno, Yusuke; Sugawara, Yo; Nagamine, Yusuka; Koyama, Yukihide; Miyazaki, Tomoyuki; Uchimoto, Kazuhiro; Iketani, Yasuhiro; Tojo, Kentaro; Goto, Takahisa] Yokohama City Univ Med, Dept Anesthesiol, Yokohama, Kanagawa, Japan	Miyashita, T (reprint author), Yokohama City Univ Med, Dept Anesthesiol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	yushukyo@gmail.com			Sado General Hospital	The work was funded by the Sado General Hospital.	Biswas I, 2013, PEDIATR ANESTH, V23, P1145, DOI 10.1111/pan.12265; Sia ATH, 2012, ANAESTHESIA, V67, P1348, DOI 10.1111/anae.12000; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; Cone SW, 2006, ANESTH ANALG, V102, P1463, DOI 10.1213/01.ane.0000204303.21165.a4; Fiadjoe J, 2009, ANESTH ANALG, V108, P1212, DOI 10.1213/ane.0b013e318198f786; Galvez JA, 2011, CURR OPIN ANESTHESIO, V24, P459, DOI 10.1097/ACO.0b013e328348717b; Hemmerling TM, 2013, BRIT J ANAESTH, V110, P758, DOI 10.1093/bja/aes498; Japanese Society of Anesthesiologists, HIST AN; Kozek-Langenecker SA, 2013, EUR J ANAESTH, V30, P270, DOI 10.1097/EJA.0b013e32835f4d5b; Miyashita T, 2014, J CLIN MONIT COMPUT, V28, P211, DOI 10.1007/s10877-013-9514-x; OECD, PRACT PHYS DOCT; Sng BL, 2014, ANAESTHESIA, V69, P37, DOI 10.1111/anae.12460	12	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1357-633X	1758-1109		J TELEMED TELECARE	J. Telemed. Telecare	MAR	2015	21	2					73	79		10.1177/1357633X14562735		7	Health Care Sciences & Services	Health Care Sciences & Services	CD5RN	WOS:000351145600003		
J	Hayes, CN; Chayama, K				Hayes, C. Nelson; Chayama, Kazuaki			Emerging treatments for chronic hepatitis C	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION			English	Review						clinical trials; direct-acting antiviral; interferon-free therapy; NS3/4A protease inhibitor; NS5A inhibitor; NS5B RNA-dependent RNA polymerase	GENOTYPE 1 INFECTION; TREATMENT-NAIVE PATIENTS; DACLATASVIR PLUS ASUNAPREVIR; INTERFERON-ALPHA 2A; CHRONIC HCV; PEGYLATED INTERFERON; PROTEASE INHIBITOR; VIRUS-INFECTION; DOUBLE-BLIND; PEGINTERFERON ALPHA-2A	Advances in understanding the hepatitis C virus (HCV) life cycle and the urgent need to find complementary direct-acting antiviral (DAA) therapies has led to substantial advancements in treating chronic hepatitis C. The introduction of telaprevir and boceprevir in 2011 increased the sustained virological response (SVR) rate from approximately 50% to > 70%, but this therapy further restricted patient eligibility and is only approved for treating HCV genotype 1 infection. Interferon has long remained the backbone of HCV therapy and helps prevent viral breakthrough. However, interferon has limited effectiveness and is associated with severe adverse effects and toxicity, especially among cirrhotic patients. Moving to interferon-free therapies should greatly improve SVR rates and offer new treatments for other HCV genotypes and for ineligible patients or patients failing to respond to prior therapies. However, without the relative safety of interferon to suppress viral escape, vigilance will be required to select appropriate therapies and monitor resistance. Several DAAs are currently undergoing clinical trials and will soon undergo the approval process. Goals of future HCV clinical research will be to identify combinations of DAAs with high genetic barriers, investigate optimal treatment doses and durations, and determine the role of ribavirin in DAA therapies. Copyright (C) 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.	[Hayes, C. Nelson; Chayama, Kazuaki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Div Frontier Med Sci,Programs Biomed Res, Hiroshima 7348551, Japan; [Hayes, C. Nelson; Chayama, Kazuaki] Hiroshima Univ, Liver Res Project Ctr, Hiroshima 7348551, Japan; [Chayama, Kazuaki] RIKEN, Inst Phys & Chem Res, Lab Digest Dis, Ctr Genom Med, Hiroshima, Japan	Chayama, K (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab,Appl Life Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	chayama@hiroshima-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare, Government of Japan	The authors thank Asumi Nakasaki for assistance in preparation of the manuscript. This work was performed at the Research Center for Molecular Medicine, Faculty of Medicine, Hiroshima University and the Analysis Center of Life Science, Hiroshima University (Hiroshima, Japan). This work was supported in part by Grants-in-Aid for scientific research and development from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare, Government of Japan.	Lawitz E, 2013, LANCET INFECT DIS, V13, P401, DOI 10.1016/S1473-3099(13)70033-1; Perni RB, 2006, ANTIMICROB AGENTS CH, V50, P899, DOI 10.1128/AAC.50.3.899-909.2006; Chayama K, 2012, HEPATOLOGY, V55, P742, DOI 10.1002/hep.24724; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; Rosenquist A, 2014, J MED CHEM, V57, P1673, DOI 10.1021/jm401507s; Ozeki I, 2011, J GASTROENTEROL, V46, P929, DOI 10.1007/s00535-011-0411-0; Moradpour D, 2007, NAT REV MICROBIOL, V5, P453, DOI 10.1038/nrmicro1645; Forns X, 2014, GASTROENTEROLOGY, V146, P1669, DOI 10.1053/j.gastro.2014.02.051; Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494; Kwo PY, 2010, LANCET, V376, P705, DOI 10.1016/S0140-6736(10)60934-8; Okanoue T, 1996, J HEPATOL, V25, P283, DOI 10.1016/S0168-8278(96)80113-9; Poordad F, 2013, NEW ENGL J MED, V368, P45, DOI 10.1056/NEJMoa1208809; Hayashi N, 2014, J HEPATOL, V61, P219, DOI 10.1016/j.jhep.2014.04.004; Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Izumi N, 2014, J GASTROENTEROL, V49, P941, DOI 10.1007/s00535-014-0949-8; Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Butt AA, 2012, CLIN INFECT DIS, V54, P96, DOI 10.1093/cid/cir774; Gerber L, 2013, LIVER INT, V33, P85, DOI 10.1111/liv.12068; Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013; Jacobson IM, 2013, NEW ENGL J MED, V368, P1867, DOI 10.1056/NEJMoa1214854; Lok AS, 2012, NEW ENGL J MED, V366, P216, DOI 10.1056/NEJMoa1104430; Chou R, 2013, ANN INTERN MED, V158, P114, DOI 10.7326/0003-4819-158-2-201301150-00576; Sherman KE, 2011, NEW ENGL J MED, V365, P1014, DOI 10.1056/NEJMoa1014463; Soriano V, 2013, EXPERT OPIN PHARMACO, V14, P1161, DOI 10.1517/14656566.2013.795543; Lawitz E, 2013, J HEPATOL, V59, P18, DOI 10.1016/j.jhep.2013.02.009; Jacobson IM, 2014, LANCET, V384, P403, DOI 10.1016/S0140-6736(14)60494-3; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Hiraga N, 2011, HEPATOLOGY, V54, P781, DOI 10.1002/hep.24460; Lok AS, 2014, J HEPATOL, V60, P490, DOI 10.1016/j.jhep.2013.10.019; Lawitz E, 2013, NEW ENGL J MED, V368, P1878, DOI 10.1056/NEJMoa1214853; Lee C, 2011, ARCH PHARM RES, V34, P1403, DOI 10.1007/s12272-011-0921-6; Hezode C, 2014, GASTROENTEROLOGY, V147, P132, DOI 10.1053/j.gastro.2014.03.051; Manns M, 2014, LANCET, V384, P414, DOI 10.1016/S0140-6736(14)60538-9; Chayama K, 2010, HEPATOL RES, V40, P1155, DOI 10.1111/j.1872-034X.2010.00726.x; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086; Kowdley KV, 2014, NEW ENGL J MED, V370, P1879, DOI 10.1056/NEJMoa1402355; Schinazi R, 2014, LIVER INT, V34, P69, DOI 10.1111/liv.12423; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Manns M, 2014, LANCET, V384, P1597, DOI 10.1016/S0140-6736(14)61059-X; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037; Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912; Hayashi N, 2012, J VIRAL HEPATITIS, V19, pE134, DOI 10.1111/j.1365-2893.2011.01528.x; Kumada H, 2012, J HEPATOL, V56, P78, DOI 10.1016/j.jhep.2011.07.016; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346; Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482; Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454; Kumada H, 2014, HEPATOLOGY, V59, P2083, DOI 10.1002/hep.27113; Pawlotsky JM, 2013, J HEPATOL, V59, P375, DOI 10.1016/j.jhep.2013.03.030; Ascher DB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04765; Everson GT, 2014, GASTROENTEROLOGY, V146, P420, DOI 10.1053/j.gastro.2013.10.057; Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722; Gane EJ, 2014, LIVER INT; Hezode C, 2014, 49 ANN M EUR ASS STU, V60, pS55; Kowdley KV, 2012, J HEPATOL, V56, pS1; Lawitz E, 2014, LANCET, V384, P1756, DOI 10.1016/S0140-6736(14)61036-9; Lawitz E, 2014, 49 ANN M EUR ASS STU, V60, pS25; Liu J, 2012, HEPATOLOGY, V57, P897; Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141; Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869; Quezada Elizabeth M, 2009, Open Biochem J, V3, P39, DOI 10.2174/1874091X00903010039; Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218; Wendt Astrid, 2014, Clin Pharmacol, V6, P1, DOI 10.2147/CPAA.S30338; Wyles David L, 2012, Top Antivir Med, V20, P139; Yang WL, 2013, J FORMOS MED ASSOC, V112, P728, DOI 10.1016/j.jfma.2013.08.013; Zeuzem S, 2014, GASTROENTEROLOGY, V146, p[430, e436]; Zeuzem S, 2014, NEW ENGL J MED, V370, P1993, DOI 10.1056/NEJMoa1316145; Zeuzem S, 2013, NEW ENGL J MED, V369, P630, DOI 10.1056/NEJMoa1213557; Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561	71	5	5	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	0929-6646	1876-0821		J FORMOS MED ASSOC	J. Formos. Med. Assoc.	MAR	2015	114	3					204	215		10.1016/j.jfma.2014.09.001		12	Medicine, General & Internal	General & Internal Medicine	CD4TM	WOS:000351077000002		
J	Irie, D; Kawahito, H; Wakana, N; Kato, T; Kishida, S; Kikai, M; Ogata, T; Ikeda, K; Ueyama, T; Matoba, S; Yamada, H				Irie, Daisuke; Kawahito, Hiroyuki; Wakana, Noriyuki; Kato, Taku; Kishida, Sou; Kikai, Masakazu; Ogata, Takehiro; Ikeda, Koji; Ueyama, Tomomi; Matoba, Satoaki; Yamada, Hiroyuki			Transplantation of periaortic adipose tissue from angiotensin receptor blocker-treated mice markedly ameliorates atherosclerosis development in apoE(-/-) mice	JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM			English	Article						Thoracic periaortic adipose tissue; atherosclerosis; renin angiotensin system; macrophage; adipokines	E-DEFICIENT MICE; CARDIOVASCULAR-DISEASE; INFLAMMATION; ADIPONECTIN; ADIPOCYTES; CYTOKINES; OBESITY; CONTRIBUTES; ADIPOKINES; RESISTANCE	Background: Perivascular adipose tissue is implicated in vasoreactivity; however, its effect on atherosclerosis remains undefined. Methods and results: We examined the effect of a high-cholesterol diet (HCD) on phenotypic alterations of the thoracic periaortic adipose tissue (tPAT) in apoE-deficient (apoE(-/-)) mice. Gene expression of the components of the renin angiotensin system and that of macrophage markers were significantly higher in apoE(-/-) mice fed an HCD than in those fed a chow diet (CD). These changes were absent both in angiotensin II (AngII) receptor blocker (ARB)-treated apoE(-/-) mice and in Ang II type 1 (AT(1)) receptor-deficient apoE(-/-) (Agtr1(-/-)/apoE(-/-)) mice. To evaluate their effect on atherosclerosis, we transplanted tPAT into apoE(-/-) mice alongside the distal abdominal aorta. Transplanted tPAT was harvested from apoE(-/-) and Agtr1(-/-)/apoE(-/-) mice fed a CD (tPAT-CD/apoE(-/-), tPAT-CD/Agtr1(-/-)/apoE(-/-)), HCD (tPAT-HCD/apoE(-/-), tPAT-HCD/Agtr1(-/-)/apoE(-/-)), or HCD in combination with ARB treatment (tPAT-HCD/ARB/apoE(-/-)). Four weeks after transplantation, a significantly increased oil red O-positive area was observed in the aorta of tPAT-HCD/apoE(-/-) mice than in tPAT-CD/apoE(-/-) mice. Such a change was absent in tPAT-HCD/ARB/apoE(-/-) and tPAT-HCD/Agtr1(-/-)/apoE(-/-) mice. Conclusions: Our findings demonstrated that AT(1) receptor plays a crucial role in HCD-induced phenotypic alterations of tPAT, modulation of which could exert beneficial effects on atherosclerosis.	[Irie, Daisuke; Kawahito, Hiroyuki; Wakana, Noriyuki; Kato, Taku; Kishida, Sou; Kikai, Masakazu; Ogata, Takehiro; Ikeda, Koji; Ueyama, Tomomi; Matoba, Satoaki; Yamada, Hiroyuki] Kyoto Prefectural Univ Med, Dept Cardiovasc Med, Kyoto 6028566, Japan	Yamada, H (reprint author), Kyoto Prefectural Univ Med, Dept Cardiovasc Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	hiyamada@koto.kpu-m.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [C: KAKENHI-24591120]	This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (C: KAKENHI-24591120).	Hopkins PN, 2013, PHYSIOL REV, V93, P1317, DOI 10.1152/physrev.00004.2012; Kawahito H, 2013, AM J PHYSIOL-HEART C, V305, pH667, DOI 10.1152/ajpheart.00053.2013; Olson NC, 2012, J CLIN ENDOCR METAB, V97, P1032, DOI 10.1210/jc.2011-2155; Daugherty A, 2000, J CLIN INVEST, V105, P1605, DOI 10.1172/JCI7818; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajprendo.00110.2003; Henrichot E, 2005, ARTERIOSCL THROM VAS, V25, P2594, DOI 10.1161/01.ATV.0000188508.40052.35; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Petrovic N, 2008, AM J PHYSIOL-ENDOC M, V295, pE287, DOI 10.1152/ajpendo.00035.2008; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Chang L, 2012, CIRCULATION, V126, P1067, DOI 10.1161/CIRCULATIONAHA.112.104489; Fasshauer M, 2003, BIOCHEM BIOPH RES CO, V301, P1045, DOI 10.1016/S0006-291X(03)00090-1; Margaritis M, 2013, CIRCULATION, V127, P2209, DOI 10.1161/CIRCULATIONAHA.112.001133; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI2000319246; Ohman MK, 2008, CIRCULATION, V117, P798, DOI 10.1161/CIRCULATIONAHA.107.717595; Tsubakimoto Y, 2009, ARTERIOSCL THROM VAS, V29, P1529, DOI 10.1161/ATVBAHA.109.187732; Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Owen MK, 2013, CIRCULATION, V128, P9, DOI 10.1161/CIRCULATIONAHA.112.001238; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Wassmann S, 2004, CIRCULATION, V110, P3062, DOI 10.1161/01.CIR.000137970.47771.AF; Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Mattu HS, 2013, J ENDOCRINOL, V216, pT17, DOI 10.1530/JOE-12-0232; Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031; Marchesi C, 2009, HYPERTENSION, V54, P1384, DOI 10.1161/HYPERTENSIONAHA.109.138305; Chatterjee TK, 2009, CIRC RES, V104, P541, DOI 10.1161/CIRCRESAHA.108.182998; Thatcher S, 2009, MOL CELL ENDOCRINOL, V302, P111, DOI 10.1016/j.mce.2009.01.019; Takaoka M, 2009, CIRC RES, V105, P906, DOI 10.1161/CIRCRESAHA.109.199653; Britton KA, 2012, J AM HEART ASS, V1; Daugherty A, 2004, CIRCULATION, V110, P3849, DOI 10.1161/01.CIR.0000150540.54220.C4; Fitzgibbons TP, 2011, AM J PHYSIOL-HEART C, V301, pH1425, DOI 10.1152/ajpheart.00376.2011; Fox CS, 2010, CIRC-CARDIOVASC IMAG, V3, P515, DOI 10.1161/CIRCIMAGING.110.958884; Putnam K, 2012, ENDOCRINOLOGY, V153, P4677, DOI 10.1210/en.2012-1352; Rajsheker S, 2009, CURR OPIN PHARMACOL, V10, P1	34	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1470-3203	1752-8976		J RENIN-ANGIO-ALDO S	J. Renin-Angiotensin-Aldosterone Syst.	MAR	2015	16	1					67	78		10.1177/1470320314552434		12	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CD2AC	WOS:000350874800008		
J	Kurisu, S; Iwasaki, T; Mitsuba, N; Ishibashi, K; Dohi, Y; Kihara, Y				Kurisu, Satoshi; Iwasaki, Toshitaka; Mitsuba, Naoya; Ishibashi, Ken; Dohi, Yoshihiro; Kihara, Yasuki			Impact of electrocardiographic findings for diagnosis of left ventricular hypertrophy in patients with primary aldosteronism	JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM			English	Article						Aldosteronism; electrocardiogram; left ventricular hypertrophy; hypertension; diagnosis	MORTALITY; MASS; ADRENALECTOMY; HYPERTENSION; HYPOKALEMIA; VALIDATION; CRITERIA; RISK	Background:Compared to patients with similar levels of hypertension, patients with primary aldosteronism have a greater left ventricular hypertrophy (LVH). The presence of LVH should be detected as early as possible to prevent cardiovascular complications associated with the condition. We evaluated comparative diagnostic value of electrocardiographic (ECG) indexes for LVH in patients with primary aldosteronism. Methods:ECG and echocardiographic data were obtained in 88 patients with primary aldosteronism. We analyzed the four most commonly used ECG indexes, including Sokolow-Lyon index, Cornell voltage index, Cornell product index, and Gubner index. Results:Echocardiographic LVH was found in 35 patients (40%). Sensitivity ranged from 0% for Gubner index to 49% for Cornell product index. Specificity ranged from 81% for Sokolow-Lyon index to 100% for Gubner index. Sokolow-Lyon index (r=0.43, p<0.001), Cornell voltage index (r=0.55, p<0.001) and Cornell product index (r=0.52, p<0.001) correlated significantly with left ventricular mass (LVM) index. No significant correlation was found between Gubner index and LVM index. Conclusions:ECG indexes had a reasonably high specificity, but a low sensitivity for LVH in patients with primary aldosteronism. Cornell voltage index and Cornell product index had a better diagnostic value of LVH, and had a better correlation with LVM index in these patients.	[Kurisu, Satoshi; Iwasaki, Toshitaka; Mitsuba, Naoya; Ishibashi, Ken; Dohi, Yoshihiro; Kihara, Yasuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima, Japan	Kurisu, S (reprint author), 1-2-3 Kasumi Cho,Minami Ku, Hiroshima 7348551, Japan.	skurisu@nifty.com					Verdecchia P, 1998, J AM COLL CARDIOL, V31, P383, DOI 10.1016/S0735-1097(97)00493-2; Haider AW, 1998, J AM COLL CARDIOL, V32, P1454, DOI 10.1016/S0735-1097(98)00407-0; Sundstrom J, 2001, CIRCULATION, V103, P2346; Rocha R, 2001, TRENDS ENDOCRIN MET, V12, P308, DOI 10.1016/S1043-2760(01)00432-5; Rocha R, 2002, ANN NY ACAD SCI, V970, P89; DEVEREUX RB, 1977, CIRCULATION, V55, P613; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015; Catena C, 2007, HYPERTENSION, V50, P911, DOI 10.1161/HYPERTENSIONAHA.107.095448; Born-Frontsberg E, 2009, J CLIN ENDOCR METAB, V94, P1125, DOI 10.1210/jc.2008-2116; KANNEL WB, 1969, ANN INTERN MED, V71, P89; Nadar S, 2003, ANN CLIN BIOCHEM, V40, P439, DOI 10.1258/000456303322326362; Pewsner D, 2007, BRIT MED J, V335, P711, DOI 10.1136/bmj.39276.636354.AE; CASALE PN, 1987, CIRCULATION, V75, P565; Conn JW, 1955, J LAB CLIN MED, V45, P6; Foppa Murilo, 2005, Cardiovasc Ultrasound, V3, P17, DOI 10.1186/1476-7120-3-17; Granguly A, 1998, NEW ENGL J MED, V339, P1828; Gubner R, 1943, ARCH INTERN MED, V72, P196; Hanna Elias B, 2011, Cleve Clin J Med, V78, P404, DOI 10.3949/ccjm.78a.10077; Kato Y, 2011, INT J CARDIOL, V152, P380, DOI 10.1016/j.ijcard.2011.08.012; Lin YH, 2011, J RENIN-ANGIO-ALDO S, V12, P48, DOI 10.1177/1470320310376424; MURATANI H, 1984, JPN CIRC J, V48, P994; Okin PM, 2004, HYPERTENSION, V43, P769, DOI 10.1161/01.HYP.0000118585.73688.c6; Rossi GP, 2005, TRENDS ENDOCRIN MET, V16, P104, DOI 10.1016/j.tem.2005.02.010; SCHILLACI G, 1994, AM J CARDIOL, V74, P714, DOI 10.1016/0002-9149(94)90316-6; Schmidt BMW, 2003, AM J HYPERTENS, V16, P80, DOI 10.1016/S0895-7061(02)03199-0; Tanabe A, 1997, Hypertens Res, V20, P85, DOI 10.1291/hypres.20.85	28	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1470-3203	1752-8976		J RENIN-ANGIO-ALDO S	J. Renin-Angiotensin-Aldosterone Syst.	MAR	2015	16	1					131	136		10.1177/1470320313482604		6	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CD2AC	WOS:000350874800015		
J	Yokota, H; Nagaoka, T; Sato, E; Takahashi, A; Shimouchi, A; Yoshida, A				Yokota, Harumasa; Nagaoka, Taiji; Sato, Eiichi; Takahashi, Atsushi; Shimouchi, Akito; Yoshida, Akitoshi			Serum prorenin levels are not associated with ocular diseases in non-diabetic subjects	JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM			English	Article						Biomarkers; diabetic retinopathy; diastolic blood pressure; eye; immunoassay; human subjects; non-diabetic population; ocular disease; prorenin; prorenin receptor; retina; retinopathy; serological assay	RENIN-ANGIOTENSIN SYSTEM; DIABETIC-RETINOPATHY; NONPROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; KINETIC ASSAY; RECEPTOR; NEOVASCULARIZATION; INFLAMMATION	Introduction: To determine if the serum prorenin level is useful for detecting ocular disease in a non-diabetic population. Materials and methods: We enrolled non-diabetic men (n = 402) and women (n = 349) in our study. We used the antibody-activating direct enzyme kinetic assay of human prorenin to determine serum prorenin levels. We performed multiple regression analysis to determine the factors that affect serum prorenin levels, such as: age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, fasting blood sugar, and HbA1c or estimated glomerular filtration rate. Our study subjects were divided into groups by their ophthalmologic diagnosis. One-way analysis of variance (ANOVA) was performed to detect a significant difference in the serum prorenin levels among the groups. Results: There were no significant differences in serum prorenin levels among the ocular diseases and disorders. The DBP was negatively correlated with serum prorenin levels in men (r = - 0.1992; p = 0.021) and in women (r = - 0.2067; p = 0.031). Conclusion: Considering the current results and those of previous studies together, we found that the prorenin value is useful solely for predicting development of diabetic retinopathy in adults.	[Yokota, Harumasa; Nagaoka, Taiji; Sato, Eiichi; Takahashi, Atsushi; Shimouchi, Akito; Yoshida, Akitoshi] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido 0788510, Japan	Yokota, H (reprint author), Asahikawa Med Univ, Dept Ophthalmol, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	atokoy18@asahikawa-med.ac.jp			Japanese Ministry of Education, Science and Culture in Tokyo [23791955]	This work was supported by the Japanese Ministry of Education, Science and Culture in Tokyo (Grant-in-aid for Young Scientists (B) number 23791955 (to author HY)).	Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Suzuki F, 2003, J BIOL CHEM, V278, P22217, DOI 10.1074/jbc.M302579200; Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457; Veniant M, 1996, J CLIN INVEST, V98, P1966, DOI 10.1172/JCI119000; Satofuka S, 2009, DIABETES, V58, P1625, DOI 10.2337/db08-0254; Kordonouri O, 2000, DIABETES CARE, V23, P1025, DOI 10.2337/diacare.23.7.1025; Danser AHJ, 1998, J HYPERTENS, V16, P853; Wilkinson-Berka JL, 2010, HYPERTENSION, V55, P1454, DOI 10.1161/HYPERTENSIONAHA.109.148221; Ichihara A, 2009, J PHARMACOL SCI, V109, P20, DOI 10.1254/jphs.08R07FM; Kanda A, 2012, DIABETOLOGIA, V55, P3104, DOI 10.1007/s00125-012-2702-2; Kanda A, 2013, BRIT J OPHTHALMOL, V97, P666, DOI 10.1136/bjophthalmol-2012-302680; Kawazu S, 2004, J DIABETES COMPLICAT, V18, P275, DOI 10.1016/j.jdiacomp.2004.03.001; Prescott G, 2002, AM J HYPERTENS, V15, P280, DOI 10.1016/S0895-7061(01)02284-1; Satofuka S, 2007, INVEST OPHTH VIS SCI, V48, P422, DOI 10.1167/iovs.06-0534; Satofuka S, 2006, INVEST OPHTH VIS SCI, V47, P2686, DOI 10.1167/iovs.05-1458; Sealey J E, 1977, Circ Res, V41, P17; Yokota H, 2011, J RENIN-ANGIO-ALDO S, V12, P290, DOI 10.1177/1470320310391327; Yokota H, 2005, BRIT J OPHTHALMOL, V89, P871, DOI 10.1136/bjo.2004.056580	18	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1470-3203	1752-8976		J RENIN-ANGIO-ALDO S	J. Renin-Angiotensin-Aldosterone Syst.	MAR	2015	16	1					153	158		10.1177/1470320314551442		6	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CD2AC	WOS:000350874800018		
J	Abe, M; Oikawa, O; Okada, K; Soma, M				Abe, Masanori; Oikawa, Osamu; Okada, Kazuyoshi; Soma, Masayoshi			Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan	JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM			English	Article						Angiotensin-converting enzyme 2; angiotensin II type 1 receptor blocker; chronic kidney disease; diabetic nephropathy; olmesartan	ACID-BINDING PROTEIN; CHRONIC KIDNEY-DISEASE; HYPERTENSIVE PATIENTS; ALDOSTERONE SYSTEM; GLOMERULAR INJURY; ACE2; MICE; EXPRESSION; ALBUMINURIA; OVEREXPRESSION	Introduction: Angiotensin-converting enzyme 2 (ACE2) is a member of the renin-angiotensin system that degrades angiotensin (Ang) II to the seven-amino acid peptide fragment Ang-(1-7). We evaluated the changes in urinary ACE2 levels in response to treatment with the angiotensin II type 1 receptor blocker olmesartan in diabetes patients with nephropathy. Materials and methods: This prospective, open-label, interventional study was conducted with 31 type 2 diabetes patients with nephropathy. After initial evaluation, patients received 20 mg/day olmesartan, which was increased to 40 mg/day over a 24-week period. Results: In diabetes patients with chronic kidney disease, olmesartan significantly increased urinary ACE2 levels independently of blood pressure and plasma aldosterone levels and reduced albuminuria, urinary liver-type fatty acid binding protein (L-FABP), and plasma aldosterone levels. Multivariable regression analysis revealed that the change in urinary L-FABP levels was an independent predictor of increased urinary ACE2 levels. Conclusion: Olmesartan may have the unique effect of increasing urinary ACE2 levels. However, whether this contributes to olmesartan's renoprotective effect must be examined further.	[Abe, Masanori; Oikawa, Osamu; Okada, Kazuyoshi; Soma, Masayoshi] Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol, Tokyo 1738610, Japan; [Soma, Masayoshi] Nihon Univ, Sch Med, Dept Internal Med, Div Gen Med, Tokyo 1738610, Japan	Abe, M (reprint author), Nihon Univ, Sch Med, Dept Internal Med, Div Nephrol Hypertens & Endocrinol,Itabashi Ku, 30-1 Oyaguchi Kami Chou, Tokyo 1738610, Japan.	abe.masanori@nihon-u.ac.jp					Abe M, 2011, J ATHEROSCLER THROMB, V18, P1018; Abe M, 2011, HYPERTENS RES, V34, P935, DOI 10.1038/hr.2011.67; Abe M, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-135; Abe M, 2013, HEART VESSELS, V28, P480, DOI 10.1007/s00380-012-0274-1; Alghamri MS, 2013, J CARDIOVASC PHARM T, V18, P138, DOI 10.1177/1074248412460124; Wysocki J, 2006, DIABETES, V55, P2132, DOI 10.2337/db06-0033; Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420; Oudit GY, 2006, AM J PATHOL, V168, P1808, DOI 10.2353/ajpath.2006.051091; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Soler MJ, 2007, KIDNEY INT, V72, P614, DOI 10.1038/sj.ki.5002373; Mizuiri S, 2008, AM J KIDNEY DIS, V51, P613, DOI 10.1053/j.ajkd.2007.11.022; Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579; Zhong JC, 2010, CIRCULATION, V122, P717, DOI 10.1161/CIRCULATIONAHA.110.955369; Liu CX, 2011, MOL MED, V17, P59, DOI 10.2119/molmed.2010.00111; Nadarajah R, 2012, KIDNEY INT, V82, P292, DOI 10.1038/ki.2012.83; Thomas MC, 2005, ADV CHRONIC KIDNEY D, V12, P177, DOI 10.1053/j.ackd.2005.01.008; Tikellis C, 2003, HYPERTENSION, V41, P392, DOI 10.1161/01.HYP.0000060689.38912.CB; Oudit GY, 2010, DIABETES, V59, P529, DOI 10.2337/db09-1218; Iwai M, 2012, HYPERTENSION, V60, P137, DOI 10.1161/HYPERTENSIONAHA.112.191452; Park SE, 2013, EUR J ENDOCRINOL, V168, P203, DOI 10.1530/EJE-12-0782; Grobe JL, 2007, AM J PHYSIOL-HEART C, V292, pH736, DOI 10.1152/ajpheart.00937.2006; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Verma A, 2012, MOL THER, V20, P28, DOI 10.1038/mt.2011.155; Ye MH, 2006, J AM SOC NEPHROL, V17, P3067, DOI 10.1681/ASN.2006050423; Ye MH, 2004, HYPERTENSION, V43, P1120, DOI 10.1161/01.HYP.0000126192.27644.76; Ferrario CM, 2010, AM J PHYSIOL-RENAL, V298, pF1297, DOI 10.1152/ajprenal.00110.2010; Mizuiri S, 2011, NEPHROLOGY, V16, P567, DOI 10.1111/j.1440-1797.2011.01467.x; Kobori H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3; Wysocki J, 2013, AM J PHYSIOL-RENAL, V305, pF600, DOI 10.1152/ajprenal.00600.2012; Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100; Wong DW, 2007, AM J PATHOL, V171, P438, DOI 10.2353/ajpath.2007.060977; Senador D, 2009, EXP PHYSIOL, V94, P648, DOI 10.1113/expphysiol.2008.046474; Reich HN, 2008, KIDNEY INT, V74, P1610, DOI 10.1038/ki.2008.497; Bauer I H, 1995, J Hum Hypertens, V9, P237; Chodavarapu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062833; Donoghue M, 2000, CIRC RES, V87, P1; Furuhashi M, AM J HYPERTENS, DOI [10.1093/aih/hpu086, DOI 10.1093/AIH/HPU086]; Gavras I, 1999, CURR MED RES OPIN, V15, P15, DOI 10.1185/03007999909115169; Ichikawa S, 2001, HYPERTENS RES, V24, P641, DOI 10.1291/hypres.24.641; Japanese Society of Hypertension, 2009, HYPERTENS RES, V32, P4; Kamijo A, 2004, J LAB CLIN MED, V143, P23, DOI 10.1016/j.lab.2003.08.001; Kurtz TW, 2008, AM J HYPERTENS, V21, P852, DOI 10.1038/ajh.2008.202; Nakamura T, 2005, DIABETES CARE, V28, P2728, DOI 10.2337/diacare.28.11.2728; Ribeiro-Oliveira Antônio Jr, 2008, Vasc Health Risk Manag, V4, P787; Shaltout HA, 2007, AM J PHYSIOL-RENAL, V292, pF82, DOI 10.1152/ajprenal.00139.2006; Xiao FX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037649	46	1	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1470-3203	1752-8976		J RENIN-ANGIO-ALDO S	J. Renin-Angiotensin-Aldosterone Syst.	MAR	2015	16	1					159	164		10.1177/1470320314551443		6	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CD2AC	WOS:000350874800019		
J	Matsui, Y; Hiraki, T; Gobara, H; Iguchi, T; Fujiwara, H; Nagasaka, T; Toyooka, S; Kanazawa, S				Matsui, Yusuke; Hiraki, Takao; Gobara, Hideo; Iguchi, Toshihiro; Fujiwara, Hiroyasu; Nagasaka, Takeshi; Toyooka, Shinichi; Kanazawa, Susumu			Long-Term Survival following Percutaneous Radiofrequency Ablation of Colorectal Lung Metastases	JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY			English	Article							PULMONARY METASTASES; PROGNOSTIC-FACTORS; RISK-FACTORS; PORCINE MODEL; CANCER; RESECTION; RECURRENCE; MULTICENTER; POPULATION; EXPERIENCE	Purpose: To retrospectively evaluate long-term survival outcomes of radiofrequency (RF) ablation of colorectal lung metastases and evaluate factors associated with improved survival. Materials and Methods: Eighty-four patients (46 male and 38 female; median age, 65 y) with 172 colorectal lung metastases (median size, 1.2 cm) underwent 113 RF ablation sessions. Thirteen patients had viable extrapulmonary recurrences at the time of RF ablation. The primary endpoint was patient survival. Prognostic factors associated with survival were determined by univariate and multivariate analyses. Secondary endpoints were local tumor progression and adverse events (per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0). Results: During follow-up (median duration, 37.5 mo), 36 patients (42.9%) died. The estimated overall survival (OS) rates were 95.2%, 65.0%, and 51.6% at 1, 3, and 5 years, respectively (median OS time, 67.0 mo). Multivariate analysis revealed that a carcinoembryonic antigen (CEA) level of at least 5 ng/mL before RE ablation (P = .03) and the presence of viable extrapulmonary recurrences at the time of RF ablation (P = .001) were independent negative prognostic factors. The local tumor progression rate was 14.0% (24 of 172 tumors). Grade 3 adverse events were observed after two sessions (1.8%), and grade 415 adverse events were not observed. Conclusions: RF ablation of colorectal lung metastases provided favorable long-term survival With a low incidence of severe adverse events. Independent prognostic factors were a high CEA level before RF ablation and the presence of viable extrapulmonary recurrences at the time of RF ablation.	[Matsui, Yusuke; Hiraki, Takao; Gobara, Hideo; Iguchi, Toshihiro; Fujiwara, Hiroyasu; Kanazawa, Susumu] Okayama Univ, Sch Med, Dept Radiol, Kita Ku, Okayama 7008558, Japan; [Nagasaka, Takeshi] Okayama Univ, Sch Med, Dept Surg Gastroenterol, Kita Ku, Okayama 7008558, Japan; [Toyooka, Shinichi] Okayama Univ, Sch Med, Dept Gen Thorac Surg, Kita Ku, Okayama 7008558, Japan	Hiraki, T (reprint author), Okayama Univ, Sch Med, Dept Radiol, Kita Ku, 2-5-1 Shikatacho, Okayama 7008558, Japan.	takaoh@tc4.so-net.ne.jp					Mitry E, 2010, GUT, V59, P1383, DOI 10.1136/gut.2010.211557; Iida T, 2013, ANN SURG, V257, P1059, DOI 10.1097/SLA.0b013e31826eda3b; Kobayashi H, 2007, SURGERY, V141, P67, DOI 10.1016/j.surg.2006.07.020; Manfredi S, 2006, BRIT J SURG, V93, P1115, DOI 10.1002/bjs.5349; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Matsui Y, 2012, J VASC INTERV RADIOL, V23, P780, DOI 10.1016/j.jvir.2012.02.014; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Hiraki T, 2011, ACTA MED OKAYAMA, V65, P287; Gonzalez M, 2013, ANN SURG ONCOL, V20, P572, DOI 10.1245/s10434-012-2726-3; Yedibela S, 2006, ANN SURG ONCOL, V13, P1538, DOI 10.1245/s10434-006-9100-2; Yamakado K, 2009, ONCOL REP, V22, P885, DOI 10.3892/or_00000513; Hiraki T, 2007, J VASC INTERV RADIOL, V18, P1264, DOI 10.1016/j.jvir.2007.06.027; Welter S, 2007, EUR J CARDIO-THORAC, V31, P167, DOI 10.1016/j.ejcts.2006.11.004; Yamakado K, 2007, J VASC INTERV RADIOL, V18, P393, DOI 10.1016/j.jvir.2006.11.003; Gillams A, 2013, CARDIOVASC INTER RAD, V36, P724, DOI 10.1007/s00270-012-0500-3; Landreneau RJ, 2000, EUR J CARDIO-THORAC, V18, P671, DOI 10.1016/S1010-7940(00)00580-7; Hiraki T, 2014, WORLD J GASTROENTERO, V20, P988, DOI 10.3748/wjg.v20.i4.988; Petre EN, 2013, CLIN COLORECTAL CANC, V12, P37, DOI [10.1016/j.clcc.2012.07.003, 10.1016/clcc.2012.07.003]; Kanemitsu Y, 2004, BRIT J SURG, V91, P112, DOI 10.1002/bjs.4370; Blackmon SH, 2012, ANN THORAC SURG, V94, P1802, DOI 10.1016/j.athoracsur.2012.07.014; Dupuy DE, 2006, CHEST, V129, P738, DOI 10.1378/chest.129.3.738; Hiraki T, 2010, J VASC INTERV RADIOL, V21, P1129, DOI 10.1016/j.jvir.2010.03.007; Onaitis MW, 2009, ANN THORAC SURG, V87, P1684, DOI 10.1016/j.athoracsur.2009.03.034; Yan TD, 2007, ANN SURG ONCOL, V14, P1718, DOI 10.1245/s10434-006-9271-x; van der Pool AEM, 2012, COLORECTAL DIS, V14, P56, DOI 10.1111/j.1463-1318.2010.02539.x; Bolukbas S, 2014, ANN THORAC SURG, V97, P1926, DOI 10.1016/j.athoracsur.2014.02.026; Hiraki T, 2013, SEMIN INTERVENT RAD, V30, P169, DOI 10.1055/s-0033-1342958; Hiraki T, 2006, J VASC INTERV RADIOL, V17, P1991, DOI 10.1097/01.RVI.0000251152.12254.AC; Hirosawa T, 2013, SURG TODAY, V43, P494, DOI 10.1007/s00595-012-0373-8; Iishi T, 2009, ACTA MED OKAYAMA, V63, P137; National Cancer Institute, 2009, COMM TERM CRIT ADV E; NCCN, 2014, NCCN CLIN PRACT GUID; Shiono S, 2005, ANN THORAC SURG, V80, P1040, DOI 10.1016/j.athoracsur.2004.12.033	33	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1051-0443	1535-7732		J VASC INTERV RADIOL	J. Vasc. Interv. Radiol.	MAR	2015	26	3					303	310		10.1016/j.jvir.2014.11.013		8	Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease	Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology	CD1KO	WOS:000350834000001		
J	Cao, SY; Tamura, Y; Kikuchi, N; Saito, M; Nakayama, I; Matsuzaki, Y				Cao, Shuyang; Tamura, Yukio; Kikuchi, Naoshi; Saito, Mamoru; Nakayama, Ikuo; Matsuzaki, Yutaka			A case study of gust factor of a strong typhoon	JOURNAL OF WIND ENGINEERING AND INDUSTRIAL AERODYNAMICS			English	Article						Gust factor; Gust averaging time; Sample duration; Typhoon	WIND-SPEED; HURRICANE; LANDFALL	This paper studied the gust factor associated with a very strong typhoon (Typhoon Maemi 2003), whose maximum 10 min mean wind speed was greater than 60 m/s. The wind speed was recorded by multiple sonic and vane anemometers near the seashore of an island. Only stationary wind speed samples are analyzed to obtain the gust factor. The study focuses on the dependences of gust factor on gust averaging time, sample duration, and mean wind speed during the typhoon's passage. The results suggest that typhoon gust factors have no significant difference from those associated with non-typhoon winds, and can be described using models developed for standard neutral boundary layer flow conditions. (C) 2014 Elsevier Ltd. All rights reserved.	[Cao, Shuyang] Tongji Univ, State Key Lab Disaster Reduct Civil Engn, Shanghai 200092, Peoples R China; [Tamura, Yukio] Tokyo Polytech Univ, Wind Engn Res Ctr, Atsugi, Kanagawa 2430297, Japan; [Kikuchi, Naoshi; Saito, Mamoru; Nakayama, Ikuo; Matsuzaki, Yutaka] Furukawa Elect Corp Ltd, Chiyoda Ku, Tokyo 1008322, Japan	Cao, SY (reprint author), Tongji Univ, State Key Lab Disaster Reduct Civil Engn, Siping Rd 1239, Shanghai 200092, Peoples R China.	shuyang@tongji.edu.cn			National Natural Science Foundation of China [51278366, 51478358]; Joint Usage/Research Center of Wind Engineering, Wind Engineering Research Center, Tokyo Polytechnic University	The authors wish to acknowledge the financial support from the National Natural Science Foundation of China (Project nos: 51278366 and 51478358) and the Joint Usage/Research Center of Wind Engineering, Wind Engineering Research Center, Tokyo Polytechnic University. The authors are also grateful to Mr. Koji Kuroiwa of WMO who suggested the analysis focusing on wind averaging conversion factor.	KRAYER WR, 1992, B AM METEOROL SOC, V73, P613, DOI 10.1175/1520-0477(1992)073<0613:GFATHW>2.0.CO;2; POWELL MD, 1982, MON WEATHER REV, V110, P1912, DOI 10.1175/1520-0493(1982)110<1912:TTOTHF>2.0.CO;2; Cao S, 2009, J WIND ENG IND AEROD, V97, P11, DOI 10.1016/j.jweia.2008.10.002; [Anonymous], 2010, 1555 WMOTD; Vickery PJ, 2005, J STRUCT ENG-ASCE, V131, P825, DOI 10.1061/(ASCE)0733-9445(2005)131:5(825); [Anonymous], 1993, TCP31 WMO; ASHCROFT J, 1994, J WIND ENG IND AEROD, V53, P331, DOI 10.1016/0167-6105(94)90090-6; Balderrama JA, 2012, J WIND ENG IND AEROD, V102, P1, DOI 10.1016/j.jweia.2011.12.003; Bendat J.S., 1986, RANDOM DATA ANAL MEA, P566; Brook R.R., 1968, J APPL METEOROL, V7, P567, DOI 10.1175/1520-0450(1968)007<0567:TEOATA>2.0.CO;2; Durst C. S., 1960, METEOROLOGICAL M JUL, V89, P181; Engineering Data Science Unit (ESDU), 1983, STRONG WINDS ATM B 2; POWELL MD, 1987, MON WEATHER REV, V115, P75, DOI 10.1175/1520-0493(1987)115<0075:CITLLK>2.0.CO;2; Wang LJ, 2013, J WIND ENG IND AEROD, V123, P171, DOI 10.1016/j.jweia.2013.08.010; Wieringa J., 1973, Boundary-Layer Meteorology, V3, DOI 10.1007/BF01034986; Xu YL, 2004, J STRUCT ENG-ASCE, V130, P912, DOI 10.1061/(ASCE)0733-9445(2004)130:6(912)	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6105	1872-8197		J WIND ENG IND AEROD	J. Wind Eng. Ind. Aerodyn.	MAR	2015	138						52	60		10.1016/j.jweia.2014.12.012		9	Engineering, Civil; Mechanics	Engineering; Mechanics	CD2SC	WOS:000350928300005		
J	Uernatsu, Y; Yasunaga, J; Koo, C				Uernatsu, Yasushi; Yasunaga, Jumpei; Koo, Choongmo			Design wind loads for open-topped storage tanks in various arrangements	JOURNAL OF WIND ENGINEERING AND INDUSTRIAL AERODYNAMICS			English	Article						Wind load; Storage tank; Open-top; Grouping effect; Wind tunnel experiment; Wind pressure distribution; Buckling; Finite element analysis	CIRCULAR CYLINDRICAL-SHELLS; BUCKLING BEHAVIOR; STEEL TANKS; PRESSURE; SILOS; BINS; THIN; DEFLECTION; CYLINDERS; STABILITY	The present article proposes a model of wind force coefficient for designing open-topped storage tanks in various arrangements; main focus is on oil storage tanks. In our previous paper, we discussed the design wind force coefficients for isolated tanks, based on wind tunnel experiments of wind pressure distributions and buckling as well as on a finite element analysis of buckling under static wind loading. In practice, however, more than two tanks are constructed in various arrangements in a site. In such cases, the wind force distribution and the resultant buckling behavior of tanks may be affected by the arrangement significantly. Therefore, the present article focuses on the grouping effect on the wind force distribution and the buckling behavior. First, the wind pressures are measured simultaneously at many points both on the external and internal surfaces of a rigid model for various arrangements of two to four tanks in a turbulent boundary layer. The effects of arrangement pattern and gap spacing of tanks on the pressure distributions are discussed. Then, the buckling of tanks under static wind loading for various arrangements is analyzed by using a non-linear finite element method. The results indicate that the distribution of positive wind force coefficient in the windward area affects the buckling behavior significantly. Finally, based on the results obtained, we propose a model of wind force coefficient on tanks in various arrangements by modifying the model for isolated tanks that we proposed in our previous paper. For evaluating the design wind loads a gust effect factor approach is employed. The wind load evaluation is based on the quasi-steady principle and therefore the resonant effect is not taken into account. (C) 2015 Elsevier Ltd. All rights reserved.	[Uernatsu, Yasushi] Tohoku Univ, Dept Architecture & Bldg Sci, Sendai, Miyagi 980, Japan; [Yasunaga, Jumpei] JFE Steel Corp, Steel Res Lab, Kawasaki, Kanagawa, Japan; [Koo, Choongmo] MIDAS IT Japan, Tokyo, Japan	Uernatsu, Y (reprint author), Tohoku Univ, Dept Architecture & Bldg Sci, Sendai, Miyagi 980, Japan.	yu@archi.tohoku.ac.jp			Japan Iron and Steel Federation Grant	The wind tunnel experiments on the pressure distributions were carried out at Kajima Technical Research Institute. The authors would like to thank Dr. K. Kondo for arranging the wind tunnel experiments. Acknowledgment also is due to Dr. M. Yamamoto for help with the experiments. The present study is financially supported by The Japan Iron and Steel Federation Grant (2012).	Uematsu Y, 2014, J WIND ENG IND AEROD, V130, P16, DOI 10.1016/j.jweia.2014.03.015; Portela G, 2005, J CONSTR STEEL RES, V61, P786, DOI 10.1016/j.jcsr.2004.11.002; UEMATSU Y, 1985, J WIND ENG IND AEROD, V18, P245, DOI 10.1016/0167-6105(85)90084-4; Portela G, 2005, J CONSTR STEEL RES, V61, P808, DOI 10.1016/j.jcsr.2004.11.001; BRENDEL B, 1981, J STRUCT MECH, V9, P91; Cook N.J., 1980, N10380 BUILD RES EST; HOLROYD RJ, 1985, J WIND ENG IND AEROD, V18, P53, DOI 10.1016/0167-6105(85)90074-1; HOLROYD RJ, 1983, J WIND ENG IND AEROD, V12, P329, DOI 10.1016/0167-6105(83)90054-5; Iamandi C., 2003, P 11 INT C WIND ENG, P1243; JERATH S, 1985, J ENG MECH-ASCE, V111, P610; KUNDURPI PS, 1975, J ENG MECH DIV-ASCE, V101, P517; MACDONALD PA, 1988, J WIND ENG IND AEROD, V31, P165, DOI 10.1016/0167-6105(88)90003-7; MACDONALD PA, 1990, J WIND ENG IND AEROD, V34, P319, DOI 10.1016/0167-6105(90)90160-E; MACDONALD PA, 1990, J WIND ENG IND AEROD, V34, P77, DOI 10.1016/0167-6105(90)90150-B; Resinger F., 1982, BUCKLING SHELLS, P305; SABRANSKY IJ, 1987, J WIND ENG IND AEROD, V26, P65, DOI 10.1016/0167-6105(87)90036-5; UCHIYAMA K, 1987, J WIND ENG IND AEROD, V26, P195, DOI 10.1016/0167-6105(87)90044-4; UEMATSU Y, 1994, J WIND ENG IND AEROD, V51, P249, DOI 10.1016/0167-6105(94)90007-8; UEMATSU Y, 1986, J WIND ENG IND AEROD, V22, P23, DOI 10.1016/0167-6105(86)90009-7; WANG Y, 1974, J ENG MECH DIV-ASCE, V100, P1005; Yamaguchi T., 2014, P 23 NAT S WIND ENG, P409; YAMAKI N, 1984, ELASTIC STABILITY CI; Yasunaga J., 2013, THESIS TOHOKU U	23	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6105	1872-8197		J WIND ENG IND AEROD	J. Wind Eng. Ind. Aerodyn.	MAR	2015	138						77	86		10.1016/j.jweia.2014.12.013		10	Engineering, Civil; Mechanics	Engineering; Mechanics	CD2SC	WOS:000350928300008		
J	Furukawa, H				Furukawa, Hiroshi			Surgical Management of Extensive Peristomal Pyoderma Gangrenosum Associated With Colon Cancer (vol 42, pg 102, 2015)	JOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING			English	Correction									Hokkaido Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sapporo, Hokkaido, Japan	Furukawa, H (reprint author), Hokkaido Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sapporo, Hokkaido, Japan.						Ishikawa K, 2015, J WOUND OSTOMY CONT, V42, P102, DOI 10.1097/WON.0000000000000098	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1071-5754	1528-3976		J WOUND OSTOMY CONT	J. Wound Ostomy Cont. Nurs.	MAR-APR	2015	42	2					192	192				1	Nursing	Nursing	CD1DN	WOS:000350814400014		
J	Salehi, S; Selamat, A; Mashinchi, MR; Fujita, H				Salehi, Saber; Selamat, Ali; Mashinchi, M. Reza; Fujita, Hamido			The synergistic combination of particle swarm optimization and fuzzy sets to design granular classifier	KNOWLEDGE-BASED SYSTEMS			English	Article						Hyperbox geometry of classifiers; Granular classifier; Membership functions; Particle swarm optimization; DBSCAN clustering algorithm	MAX NEURAL-NETWORK; INFORMATION GRANULES; TIME-SERIES; CLUSTERING-ALGORITHM; DYNAMIC MAINTENANCE; FEATURE-SELECTION; ROUGH SETS; MODEL; SYSTEMS; APPROXIMATIONS	Granulation extracts a bundle of similar patterns by decomposing universe. Hyperboxes are granular classifiers to confront the uncertainties in granular computing. This paper proposes a granular classifier to discover hyperboxes in three phases. The first phase of the proposed model uses the set calculus to build the hyperboxes; where, the means of the DBSCAN clustering algorithm constructs the structure. The second phase develops the geometry of hyperboxes to improve the classification rate. It uses the Particle Swarm Optimization (PSO) algorithm to optimize the seed_points and expand the hyperboxes. Finally, the third phase identifies the noise points; where, the patterns in the second phase did not belong to any hyperboxes. We have used the capability of membership function of a fuzzy set to improve the geometry of classifier. The performance of a proposed model is carried out in terms of coverage, mis-classification error and accuracy. Experimental results reveal that the proposed model can adaptively choose an appropriate granularity. (C) 2014 Elsevier B.V. All rights reserved.	[Salehi, Saber; Selamat, Ali] Univ Teknol Malaysia, Fac Comp, Skudai 81310, Johor, Malaysia; [Selamat, Ali; Mashinchi, M. Reza] Univ Teknol Malaysia, IRDA Digital Media Ctr, Johor Baharu 81310, Johor, Malaysia; [Fujita, Hamido] Iwate Prefectural Univ, Takizawa, Iwate 0200193, Japan	Selamat, A (reprint author), Univ Teknol Malaysia, Fac Comp, Utm Johor Bahru 81310, Johor, Malaysia.	aselamat@utm.my			Ministry of Education Malaysia [00M19, 01G72]	The Universiti Teknologi Malaysia (UTM) and Ministry of Education Malaysia under research university grants 00M19 and 01G72 are hereby acknowledged for some of the facilities that were utilized during the course of this research work.	ABE S, 1995, IEEE T FUZZY SYST, V3, P18, DOI 10.1109/91.366565; Pedrycz W, 2012, IEEE T SYST MAN CY B, V42, P582, DOI 10.1109/TSMCB.2011.2170067; Rizzi A, 2002, IEEE T NEURAL NETWOR, V13, P402, DOI 10.1109/72.991426; Wang LZ, 2013, EXPERT SYST APPL, V40, P5673, DOI 10.1016/j.eswa.2013.04.026; Zhang XY, 2013, INT J APPROX REASON, V54, P1130, DOI 10.1016/j.ijar.2013.02.005; Faraone MF, 2012, EXPERT SYST APPL, V39, P8439, DOI 10.1016/j.eswa.2012.01.174; Massanet S, 2014, INFORM SCIENCES, V258, P277, DOI 10.1016/j.ins.2013.06.055; Bhatt HS, 2013, IEEE T INF FOREN SEC, V8, P89, DOI 10.1109/TIFS.2012.2223684; Kang XP, 2012, FUZZY SET SYST, V203, P33, DOI 10.1016/j.fss.2012.03.003; Dick S, 2013, INT J APPROX REASON, V54, P1149, DOI [10.1016/j.ijar.2013.01.012, 10.1016/j.jar.2013.01.012]; Utkin LV, 2014, KNOWL-BASED SYST, V61, P59, DOI 10.1016/j.knosys.2014.02.007; SIMPSON PK, 1992, IEEE T NEURAL NETWOR, V3, P776, DOI 10.1109/72.159066; He KM, 2011, IEEE T PATTERN ANAL, V33, P2341, DOI 10.1109/TPAMI.2010.168; Pal SK, 2013, APPL SOFT COMPUT, V13, P3944, DOI 10.1016/j.asoc.2013.06.026; Sanchez MA, 2014, INFORM SCIENCES, V279, P498, DOI 10.1016/j.ins.2014.04.005; Berlanga FJ, 2010, INFORM SCIENCES, V180, P1183, DOI 10.1016/j.ins.2009.12.020; Wang LZ, 2014, EXPERT SYST APPL, V41, P3134, DOI 10.1016/j.eswa.2013.10.046; Nandedkar AV, 2007, IEEE T NEURAL NETWOR, V18, P42, DOI 10.1109/TNN.2006.882811; Yao YY, 2012, INFORM SCIENCES, V213, P1, DOI 10.1016/j.ins.2012.05.021; Hu QH, 2008, KNOWL-BASED SYST, V21, P294, DOI 10.1016/j.knoys.2007.07.001; Graves D, 2010, FUZZY SET SYST, V161, P522, DOI 10.1016/j.fss.2009.10.021; Maali Y, 2013, KNOWL-BASED SYST, V52, P214, DOI 10.1016/j.knosys.2013.08.009; Pedrycz W, 2014, KNOWL-BASED SYST, V58, P3, DOI 10.1016/j.knosys.2013.07.022; Pedrycz A, 2012, FUZZY SET SYST, V203, P17, DOI 10.1016/j.fss.2012.03.009; Luo C, 2014, INFORM SCIENCES, V257, P210, DOI 10.1016/j.ins.2013.09.035; Tsang ECC, 2013, IEEE T FUZZY SYST, V21, P527, DOI 10.1109/TFUZZ.2012.2218658; Derrac J, 2012, INFORM SCIENCES, V186, P73, DOI 10.1016/j.ins.2011.09.027; Li M, 2014, KNOWL-BASED SYST, V65, P60, DOI 10.1016/j.knosys.2014.04.008; Lin GP, 2012, INT J APPROX REASON, V53, P1080, DOI 10.1016/j.ijar.2012.05.004; Saberi M, 2013, NEUROCOMPUTING, V122, P100, DOI 10.1016/j.neucom.2013.05.020; Pedrycz W, 2008, PATTERN RECOGN, V41, P3720, DOI 10.1016/j.patcog.2008.06.004; Chen HM, 2013, IEEE T KNOWL DATA EN, V25, P274, DOI 10.1109/TKDE.2011.220; Asuncion D.N.A., 2007, UCI MACHINE LEARNING; Baralis E, 2014, KNOWL-BASED SYST, V71, P366, DOI 10.1016/j.knosys.2014.08.015; Chen MY, 2013, INFORM SCIENCES, V220, P180, DOI 10.1016/j.ins.2011.09.013; Ester M, 1996, KDD, V96, P226; Gabrys B, 2000, IEEE T NEURAL NETWOR, V11, P769, DOI 10.1109/72.846747; Hu H, 2014, EXPERT SYST APPL, V41, P2729, DOI 10.1016/j.eswa.2013.11.006; Huang XH, 2014, KNOWL-BASED SYST, V70, P293, DOI 10.1016/j.knosys.2014.07.009; Huttenlocher D P, 1993, PATTERN ANAL MACHINE, V15, P850, DOI DOI 10.1109/34.232073; Li YJ, 2014, KNOWL-BASED SYST, V65, P12, DOI 10.1016/j.knosys.2014.03.024; Lu W, 2014, EXPERT SYST APPL, V41, P3799, DOI 10.1016/j.eswa.2013.12.005; Olson CF, 1998, PROC CVPR IEEE, P150, DOI 10.1109/CVPR.1998.698602; Pedrycz W, 2012, APPL SOFT COMPUT, V12, P2801, DOI 10.1016/j.asoc.2012.03.055; Pedrycz W, 2005, J SYST SOFTWARE, V76, P277, DOI 10.1016/j.jss.2004.06.018; Quteishat A, 2009, NEUROCOMPUTING, V72, P1639, DOI 10.1016/j.neucom.2008.08.012; Quteishat A, 2008, APPL SOFT COMPUT, V8, P985, DOI 10.1016/j.asoc.2007.07.013; Salehi S., 2011, IEEE 2 INT C SOFTW E, P594; Tsipouras MG, 2008, FUZZY SET SYST, V159, P3201, DOI 10.1016/j.fss.2008.04.004; Wang Z, 2014, KNOWL-BASED SYST, V70, P376, DOI 10.1016/j.knosys.2014.07.019	50	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0950-7051	1872-7409		KNOWL-BASED SYST	Knowledge-Based Syst.	MAR	2015	76						200	218		10.1016/j.knosys.2014.12.017		19	Computer Science, Artificial Intelligence	Computer Science	CC2OV	WOS:000350185400016		
J	Hashimoto, K; Kyoda, Y; Tanaka, T; Maeda, T; Kobayashi, K; Uchida, K; Kitamura, H; Hirata, K; Tsukamoto, T; Masumori, N				Hashimoto, Kohei; Kyoda, Yuki; Tanaka, Toshiaki; Maeda, Toshihiro; Kobayashi, Ko; Uchida, Kohsuke; Kitamura, Hiroshi; Hirata, Koichi; Tsukamoto, Taiji; Masumori, Naoya			The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells	LABORATORY INVESTIGATION			English	Article							ANDROGEN-DEPRIVATION THERAPY; COLONIC EPITHELIAL-CELLS; FOCAL ADHESION KINASE; TRANSGENIC MOUSE LINE; CANCER CELLS; MOLECULAR CHARACTERIZATION; PROGNOSTIC-FACTOR; ALLOGRAFT MODEL; BREAST-CANCER; CARCINOMA	Neuroendocrine (NE) cells in prostate cancer have been shown to be associated with the progression of prostate cancer. However, little is known about the molecular basis of this association. We have previously demonstrated that NE cells promote metastasis of a human prostate cancer cell line (LNCaP) with overexpression of the gelsolin gene. The purpose of this study was to investigate the interactions between NE cells and LNCaP cells and the involvement of gelsolin in contributing to the invasive potential of LNCaP cells. In addition, we examined whether neurotensin induced gelsolin-mediated invasion. We used the NE cell line NE-CS that was established from the prostate of the LPB-Tag 12T-10 transgenic mouse. Small interfering RNA (siRNA) targeting gelsolin or not targeting it was transfected into LNCaP cells. Cell invasion was assessed by Matrigel invasion assay. The supernatant of NE-CS cells and neurotensin induced the transformation of LNCaP cells. Neurotensin was observed in the supernatant of NE-CS cells but not in LNCaP cells. The siRNA targeting of gelsolin resulted in inhibition of invasion of LNCaP cells in the culture medium with neurotensin added, and in the supernatant of NE-CS cells with epidermal growth factor. The invasive potential of LNCaP cells enhanced by neurotensin or the supernatant of NE-CS cells through neurotensin receptor 1 (NTSR1) was blocked by a phospholipase Cg inhibitor and an intracellular calcium chelator, with concomitant gelsolin suppression. This study indicates that NE cells and neurotensin induce gelsolin-mediated invasion of LNCaP cells through NTSR1 activation.	[Hashimoto, Kohei; Kyoda, Yuki; Tanaka, Toshiaki; Maeda, Toshihiro; Kobayashi, Ko; Kitamura, Hiroshi; Tsukamoto, Taiji; Masumori, Naoya] Sapporo Med Univ, Sch Med, Dept Urol, Sapporo, Hokkaido 0608543, Japan; [Uchida, Kohsuke] Sanjukai Hosp, Dept Urol, Sapporo, Hokkaido, Japan; [Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Surg 1, Sapporo, Hokkaido 0608543, Japan	Masumori, N (reprint author), Sapporo Med Univ, Sch Med, Dept Urol, Chuo Ku, S1,W16, Sapporo, Hokkaido 0608543, Japan.	masumori@sapmed.ac.jp					Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; McGough AM, 2003, FEBS LETT, V552, P75, DOI 10.1016/S0014-5793(03)00932-3; Shieh DB, 1999, CANCER, V85, P47, DOI 10.1002/(SICI)1097-0142(19990101)85:1<47::AID-CNCR7>3.0.CO;2-L; Masumori N, 2001, CANCER RES, V61, P2239; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Leyton J, 2002, EUR J PHARMACOL, V442, P179, DOI 10.1016/S0014-2999(02)01539-X; Zhao DZ, 2003, AM J PHYSIOL-CELL PH, V284, pC1397, DOI 10.1152/ajpcell.00328.2002; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee HK, 1999, PROSTATE, V40, P14, DOI 10.1002/(SICI)1097-0045(19990615)40:1<14::AID-PROS2>3.0.CO;2-6; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Liao CJ, 2011, GYNECOL ONCOL, V120, P135, DOI 10.1016/j.ygyno.2010.10.005; LEMBACH KJ, 1976, P NATL ACAD SCI USA, V73, P183, DOI 10.1073/pnas.73.1.183; Souaze F, 2006, CANCER RES, V66, P6243, DOI 10.1158/0008-5472.CAN-06-0450; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Lader AS, 2005, EXP CELL RES, V307, P153, DOI 10.1016/j.yexcr.2005.03.001; Noske A, 2005, EUR J CANCER, V41, P461, DOI 10.1016/j.ejca.2004.10.025; Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259; Bok RA, 2002, NAT REV CANCER, V2, P918, DOI 10.1038/nrc951; REINECKE M, 1985, PROG HISTOCHEM CYTOC, V16, P1; Amorino GP, 2007, ONCOGENE, V26, P745, DOI 10.1038/sj.onc.1209814; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Lipianskaya J, 2014, ASIAN J ANDROL, V16, P541, DOI 10.4103/1008-682X.123669; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Nadal R, 2014, NAT REV UROL, V11, P213, DOI 10.1038/nrurol.2014.21; Thor AD, 2001, CLIN CANCER RES, V7, P2415; Rao JY, 2002, CANCER, V95, P1247, DOI 10.1002/cncr.10823; Clegg N, 2003, PROSTATE, V55, P55, DOI 10.1002/pros.10217; Antonarakis ES, 2011, PROSTATE CANCER P D, V14, P206, DOI 10.1038/pcan.2011.24; Barrocas AM, 1999, IMMUNOPHARMACOLOGY, V41, P131, DOI 10.1016/S0162-3109(98)00064-2; di Sant'Agnese PA, 1998, PROSTATE, P74; Dupouy S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004223; Ehlers RA, 2000, BIOCHEM BIOPH RES CO, V269, P704, DOI 10.1006/bbrc.2000.2335; Gay F, 2008, HUM PATHOL, V39, P1420, DOI 10.1016/j.humpath.2008.02.020; Hashimoto K, 2013, PROSTATE, V73, P500, DOI 10.1002/pros.22590; Jiborn T, 1998, UROLOGY, V51, P585, DOI 10.1016/S0090-4295(97)00684-5; Kim JT, 2015, INT J CANCER, V136, P1475, DOI 10.1002/ijc.29123; Masumori N, 2004, J UROLOGY, V171, P439, DOI 10.1097/01.ju.0000099826.63103.94; Morinville A, 2004, INT J BIOCHEM CELL B, V36, P2153, DOI 10.1016/j.biocel.2004.04.013; Paul Indranil, 2013, Genes Cancer, V4, P427, DOI 10.1177/1947601913503341; TANAKA M, 1995, CANCER RES, V55, P3228; Terry Stéphane, 2014, Front Oncol, V4, P60, DOI 10.3389/fonc.2014.00060; Thomas RP, 2003, ENDOCR REV, V24, P571, DOI 10.1210/er.2002-0028; Uchida K, 2005, PROSTATE, V62, P40, DOI 10.1002/pros.20111; Uchida K, 2006, PROSTATE, V66, P536, DOI 10.1002/pros.20369; Vias M, 2007, PROSTATE, V67, P190, DOI 10.1002/pros.20518; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Zhao DZ, 2007, INT J CANCER, V120, P1652, DOI 10.1002/ijc.22407	50	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	MAR	2015	95	3					283	295		10.1038/labinvest.2014.165		13	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CC4EL	WOS:000350303500004		
J	Masugi, Y; Yamazaki, K; Emoto, K; Effendi, K; Tsujikawa, H; Kitago, M; Itano, O; Kitagawa, Y; Sakamoto, M				Masugi, Y.; Yamazaki, K.; Emoto, K.; Effendi, K.; Tsujikawa, H.; Kitago, M.; Itano, O.; Kitagawa, Y.; Sakamoto, M.			Upregulation of integrin beta 4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma	LABORATORY INVESTIGATION			English	Article							ALPHA-6-BETA-4 INTEGRIN; CELL MIGRATION; POOR-PROGNOSIS; TUMOR-CELLS; CANCER; EXPRESSION; CARCINOMA; METASTASIS; GROWTH; MOTILITY	Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and often lethal malignant tumor. Several studies have shown that epithelial-mesenchymal transition (EMT) is frequently observed in clinical samples of PDA and is related to high metastatic rates and poor outcomes. To identify candidate molecules regulating EMT in PDA, we previously used cDNA microarray analysis and identified integrin beta 4 (ITGB4) as one of the genes upregulated in high-EMT xenografts derived from PDA patients. The aim of the current study was to clarify the clinicopathological and functional significance of ITGB4 overexpression in PDA. ITGB4 upregulation in high-EMT xenografts was confirmed by immunohistochemistry. Immunohistochemical analyses of 134 surgically resected PDA cases revealed intratumoral heterogeneity with respect to ITGB4 expression and showed that cancer cells undergoing EMT often display strong diffuse ITGB4 expression. High levels of ITGB4 expression were significantly correlated with the hallmarks of EMT (solitary cell infiltration, reduced E-cadherin expression, and increased vimentin expression), with high tumor grade, and with the presence of lymph node metastasis, and showed an independent prognostic effect. Immunocytochemical analyses of PDA cell lines revealed that localization of ITGB4 changed from regions of cell-cell contact to diffuse cytoplasm and cell edges with occasional localization in filopodia during EMT. Knockdown of ITGB4 reduced the migratory and invasive ability of PDA cells. Overexpression of ITGB4 promoted cell scattering and cell motility in combination with downregulation of E-cadherin and upregulation of vimentin expression. In conclusion, we elucidated the prognostic and clinicopathological significance of ITGB4 overexpression in PDA and also the potential role for ITGB4 in the regulation of cancer invasion and EMT.	[Masugi, Y.; Yamazaki, K.; Emoto, K.; Effendi, K.; Tsujikawa, H.; Sakamoto, M.] Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan; [Kitago, M.; Itano, O.; Kitagawa, Y.] Keio Univ, Sch Med, Dept Surg, Tokyo 1608582, Japan	Sakamoto, M (reprint author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	msakamot@z5.keio.jp	Sakamoto, Michiie/N-2917-2015				Grossman HB, 2000, ONCOL REP, V7, P13; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Cruz-Monserrate Z, 2007, MODERN PATHOL, V20, P656, DOI 10.1038/modpathol.3800782; FURUKAWA T, 1995, AM J PATHOL, V147, P889; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; Yamazaki K, 2009, LAB INVEST, V89, P425, DOI 10.1038/labinvest.2009.5; Mamiya T, 2010, LAB INVEST, V90, P1339, DOI 10.1038/labinvest.2010.105; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; Kitajiri S, 2002, PATHOL INT, V52, P438, DOI 10.1046/j.1440-1827.2002.01379.x; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Adsay NV, 2005, AM J SURG PATHOL, V29, P724, DOI 10.1097/01.pas.0000163360.40357.f1; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Kurahara H, 2012, J SURG ONCOL, V105, P655, DOI 10.1002/jso.23020; Diaz LK, 2005, MODERN PATHOL, V18, P1165, DOI 10.1038/modpathol.3800411; He AR, 2008, EXPERT REV ANTICANC, V8, P1331, DOI 10.1586/14737140.8.8.1331; Hruban RH, 2010, WHO CLASSIFICATION T, P281; Hruban RH, 2007, TUMORS PANCREAS FASC, P120; Kurokawa A, 2008, CANCER, V112, P1272, DOI [10.1002/cncr.23295, 10.1002/cncr23295]; Sobin LH, 2009, TNM CLASSIFICATION M, P132; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tani T, 1997, AM J PATHOL, V151, P1289; Underwood RA, 2009, J HISTOCHEM CYTOCHEM, V57, P123, DOI 10.1369/jhc.2008.952176; Yamazaki K, 2014, LAB INVEST, V94, P683, DOI 10.1038/labinvest.2014.53	35	2	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	MAR	2015	95	3					308	319		10.1038/labinvest.2014.166		12	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CC4EL	WOS:000350303500006		
J	Luo, HM; Sawashita, J; Tian, G; Liu, YY; Li, L; Ding, X; Xu, Z; Yang, M; Miyahara, H; Mori, M; Qian, JZ; Wang, YY; Higuchi, K				Luo, Hongmin; Sawashita, Jinko; Tian, Geng; Liu, Yingye; Li, Lin; Ding, Xin; Xu, Zhe; Yang, Mu; Miyahara, Hiroki; Mori, Masayuki; Qian, Jinze; Wang, Yaoyong; Higuchi, Keiichi			Extracellular deposition of mouse senile AApoAII amyloid fibrils induced different unfolded protein responses in the liver, kidney, and heart	LABORATORY INVESTIGATION			English	Article							ENDOPLASMIC-RETICULUM STRESS; APOLIPOPROTEIN-A-II; ALZHEIMERS-DISEASE; APOA-II; TRANSCRIPTION FACTOR; INBRED STRAINS; BETA PEPTIDES; MICE; APOPTOSIS; AUTOPHAGY	Mouse senile amyloidosis is a disorder in which apolipoprotein A-II deposits extracellularly in many organs as amyloid fibrils (AApoAII). In this study, we intravenously injected 1 mu g of isolated AApoAII fibrils into R1.P1-Apoa2(c) mice, to induce AApoAII amyloidosis. We observed that the unfolded protein response was induced by deposition of AApoAII amyloid. We found that the mRNA and the protein expression levels of heat shock protein A5 (HSPA5; also known as glucose-regulated protein 78) were increased in the liver with AApoAII amyloid deposits. Immunohistochemistry showed that HSPA5 was only detected in hepatocytes close to AApoAII amyloid deposits. Furthermore, gene transcription of several endoplasmic reticulum (ER) stress-related proteins increased, including eukaryotic translation initiation factor 2 alpha kinase 3 (Eif2ak3), activating transcription factor 6 (Atf6), activating transcription factor 4 (Atf4), X-box-binding protein 1 splicing (Xbp1s), DNA-damage inducible transcript 3 (Ddit3), and autophagy protein 5 (Atg5). Moreover, apoptosis-positive cells were increased in the liver. Similar results were seen in the kidney but not in the heart. Our study indicates that ER stress responses differed among tissues with extracellular AApoAII amyloid fibril deposition. Although upregulated HSPA5 and the activated unfolded protein response might have roles in protecting tissues against aggregated extracellular AApoAII amyloid deposition, prolonged ER stress induced apoptosis in the liver and the kidney.	[Luo, Hongmin; Sawashita, Jinko; Tian, Geng; Liu, Yingye; Li, Lin; Ding, Xin; Xu, Zhe; Yang, Mu; Miyahara, Hiroki; Mori, Masayuki; Qian, Jinze; Wang, Yaoyong; Higuchi, Keiichi] Shinshu Univ, Grad Sch Med, Inst Pathogenesis & Dis Prevent, Dept Aging Biol, Matsumoto, Nagano 3908621, Japan; [Luo, Hongmin] Hebei Med Univ, Hosp 3, Shijiazhuang, Peoples R China; [Sawashita, Jinko; Higuchi, Keiichi] Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Biol Sci Intractable Neurol Dis, Matsumoto, Nagano 3908621, Japan; [Tian, Geng] Shijiazhuang Obstet & Gynecol Hosp, Shijiazhuang, Peoples R China; [Mori, Masayuki] Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Adv Med Hlth Promot, Matsumoto, Nagano 3908621, Japan; [Qian, Jinze] Hebei Med Univ, Dept Pathol, Shijiazhuang, Peoples R China	Higuchi, K (reprint author), Shinshu Univ, Grad Sch Med, Inst Pathogenesis & Dis Prevent, Dept Aging Biol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	keiichih@shinshu-u.ac.jp					Casas S, 2007, DIABETES, V56, P2284, DOI 10.2337/db07-0178; Groenendyk J, 2010, CIRC RES, V107, P1185, DOI 10.1161/CIRCRESAHA.110.227033; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Viana RJS, 2012, MOL NEUROBIOL, V46, P522, DOI 10.1007/s12035-012-8301-x; Nijholt DAT, 2011, CELL DEATH DIFFER, V18, P1071, DOI 10.1038/cdd.2010.176; Pereira C, 2004, J MOL NEUROSCI, V23, P97, DOI 10.1385/JMN:23:1-2:097; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Ferreiro E, 2006, NEUROBIOL DIS, V23, P669, DOI 10.1016/j.nbd.2006.05.011; Delpino A, 2002, BIOSCIENCE REP, V22, P407, DOI 10.1023/A:1020966008615; Kampinga HH, 2009, CELL STRESS CHAPERON, V14, P105, DOI 10.1007/s12192-008-0068-7; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Nilsson P, 2013, CELL REP, V5, P61, DOI 10.1016/j.celrep.2013.08.042; Sipe JD, 2012, AMYLOID, V19, P167, DOI 10.3109/13506129.2012.734345; PRAS M, 1968, J CLIN INVEST, V47, P924; Back SH, 2012, ANNU REV BIOCHEM, V81, P767, DOI 10.1146/annurev-biochem-072909-095555; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Haze K, 1999, MOL BIOL CELL, V10, P3787; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hoozemans JJM, 2005, ACTA NEUROPATHOL, V110, P165, DOI 10.1007/s00401-005-1038-0; Xing YM, 2001, LAB INVEST, V81, P493; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Takeda T, 1997, EXP GERONTOL, V32, P117, DOI 10.1016/S0531-5565(96)00068-X; Inagi R, 2014, NAT REV NEPHROL, V10, P369, DOI 10.1038/nrneph.2014.67; Naidoo N, 2008, J NEUROSCI, V28, P6539, DOI 10.1523/JNEUROSCI.5685-07.2008; Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Benson MD, 2008, KIDNEY INT, V74, P218, DOI 10.1038/ki.2008.152; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; Ferreira N, 2012, PLOS ONE, V7, P232, DOI 10.1371/journal.pone.0029933; Flamment M, 2013, M S-MED SCI, V29, P756, DOI 10.1051/medsci/2013298015; Gavilan MP, 2006, NEUROBIOL AGING, V27, P973, DOI 10.1016/j.neurobiolaging.2005.05.010; Gorbatyuk MS, 2013, J GENET SYNDR GENE T, V4, P128, DOI DOI 10.4172/2157-7412; HIGUCHI K, 1993, FEBS LETT, V317, P207, DOI 10.1016/0014-5793(93)81277-7; HIGUCHI K, 1991, BIOCHEM J, V279, P427; HIGUCHI K, 1986, J BIOL CHEM, V261, P2834; HIGUCHI K, 1995, LAB INVEST, V72, P75; HIGUCHI K, 1983, LAB INVEST, V48, P231; Higuchi K, 1996, J GERONTOL A-BIOL, V51, pB295; Higuchi K, 1998, LAB INVEST, V78, P1535; Inoue K, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-48; Kitagawa K, 2003, AMYLOID, V10, P207, DOI 10.3109/13506120309041737; KITAGAWA K, 1994, LAB INVEST, V70, P565; Korenaga T, 2006, AM J PATHOL, V168, P898, DOI 10.2353/ajpath.2006.050350; Lee do Y, 2010, PLOS ONE, V5; Mishra S, 2013, AM J PHYSIOL-HEART C, V305, P95; PRAS M, 1969, J EXP MED, V130, P777, DOI 10.1084/jem.130.4.777; Teixeira PF, 2006, J BIOL CHEM, V281, P21998, DOI 10.1074/jbc.M602302200; Xing YM, 2002, J BIOL CHEM, V277, P33164, DOI 10.1074/jbc.M111570200; YONEZU T, 1986, FEBS LETT, V203, P149, DOI 10.1016/0014-5793(86)80732-3	62	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	MAR	2015	95	3					320	333		10.1038/labinvest.2014.158		14	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	CC4EL	WOS:000350303500007		
J	Fujiwara, Y; Yonemori, K; Shibata, T; Okita, N; Ushirozawa, N				Fujiwara, Yasuhiro; Yonemori, Kan; Shibata, Taro; Okita, Natsuko; Ushirozawa, Nobuko			Japanese universal health care faces a crisis in cancer treatment	LANCET ONCOLOGY			English	Editorial Material									[Fujiwara, Yasuhiro; Yonemori, Kan; Shibata, Taro; Okita, Natsuko; Ushirozawa, Nobuko] Natl Canc Ctr, Off Adv Med Care Evaluat, Tokyo 104, Japan; [Fujiwara, Yasuhiro; Shibata, Taro; Ushirozawa, Nobuko] Natl Canc Ctr, Strateg Planning Bur, Tokyo 104, Japan; [Fujiwara, Yasuhiro; Yonemori, Kan] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan; [Shibata, Taro] Natl Canc Ctr, Biostat Div, Ctr Res Adm & Support, Tokyo 104, Japan; [Okita, Natsuko] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan	Fujiwara, Y (reprint author), Natl Canc Ctr, Off Adv Med Care Evaluat, Tokyo 104, Japan.	yfujiwar@ncc.go.jp					Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Howard DH, 2014, NEW ENGL J MED, V371, P97, DOI 10.1056/NEJMp1401658; [Anonymous], 2010, LANCET, V376, P389; Yonemori K, 2011, INVEST NEW DRUG, V29, P706, DOI 10.1007/s10637-011-9638-0; Cabinet Office Government of Japan, 2014, JAP REV STRAT REV CA; Japanese Council of Regulatory Reform, 2014, OP PAT REQ CUR SYST; Pharmaceuticals and Medical Devices Agency, 2014, UN DRUG DAT PHARM ME; UK Department of Health, 2013, PAT ACC SCHEM GUID C	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAR	2015	16	3					251	252				2	Oncology	Oncology	CC7WA	WOS:000350577900041		
J	Ko, JJ; Xie, WL; Kroeger, N; Lee, JL; Rini, BI; Knox, JJ; Bjarnason, GA; Srinivas, S; Pal, SK; Yuasa, T; Smoragiewicz, M; Donskov, F; Kanesvaran, R; Wood, L; Ernst, DS; Agarwal, N; Vaishampayan, UN; Rha, SY; Choueiri, TK; Heng, DYC				Ko, Jenny J.; Xie, Wanling; Kroeger, Nils; Lee, Jae-Lyun; Rini, Brian I.; Knox, Jennifer J.; Bjarnason, Georg A.; Srinivas, Sandy; Pal, Sumanta K.; Yuasa, Takeshi; Smoragiewicz, Martin; Donskov, Frede; Kanesvaran, Ravindran; Wood, Lori; Ernst, D. Scott; Agarwal, Neeraj; Vaishampayan, Ulka N.; Rha, Sun-young; Choueiri, Toni K.; Heng, Daniel Y. C.			International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study	LANCET ONCOLOGY			English	Article							RANDOMIZED PHASE-3 TRIAL; DOUBLE-BLIND; III TRIAL; SURVIVAL; SORAFENIB; CANCER; SUNITINIB; PROGRESSION; EVEROLIMUS; PAZOPANIB	Background Previous prognostic models for second-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We sought to validate the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targeted therapy after progression on first-line targeted therapy. Methods In this population-based study, we analysed patients who received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada, USA, Greece, Japan, Singapore, South Korea, and Denmark. The primary endpoint was overall survival since the initiation of second-line therapy. We compared the prognostic performance of the IMDC model with the three-factor MSKCC model used for previously treated patients for overall survival since the start of second-line targeted therapy. Findings Between Jan 1, 2005, and Nov 30, 2012, we included 1021 patients treated with second-line targeted therapy. Median overall survival since the start of second-line targeted therapy was 12.5 months (95% CI 11.3-14.3). Five of six predefined factors in the IMDC model (anaemia, thrombocytosis, neutrophilia, Karnofsky performance status [KPS] <80, and <1 year from diagnosis to first-line targeted therapy) were independent predictors of poor overall survival on multivariable analysis. The concordance index using all six prognostic factors (ie, also including hypercalcaemia) was 0.70 (95% CI 0.67-0.72) with the IMDC model and was 0.66 (95% CI 0.64-0.68) with the three-factor MSKCC model. When patients were divided into three risk categories using IMDC criteria, median overall survival was 35.3 months (95% CI 28.3-47.8) in the favourable risk group (n=76), 16.6 months (14.9-17.9) in the intermediate risk group (n=529), and 5.4 months (4.7-6.8) in the poor risk group (n=261). Interpretation The IMDC prognostic model can be applied to patients previously treated with targeted therapy, in addition to previously validated populations in fi rst-line targeted therapy. The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model.	[Ko, Jenny J.; Heng, Daniel Y. C.] Univ Calgary, Tom Baker Canc Ctr, Dept Med Oncol, Calgary, AB T2N 4N2, Canada; [Xie, Wanling; Choueiri, Toni K.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kroeger, Nils] Ernst Moritz Arndt Univ Greifswald, Dept Urol, Univ Hosp Greifswald, Greifswald, Germany; [Lee, Jae-Lyun] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea; [Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Knox, Jennifer J.] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol, Univ Hlth Network, Toronto, ON, Canada; [Bjarnason, Georg A.] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada; [Srinivas, Sandy] Stanford Med Ctr, Div Oncol, Stanford, CA USA; [Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Med Oncol & Expt Therapeut, Duarte, CA USA; [Yuasa, Takeshi] Japanese Fdn Canc Res, Dept Urol, Canc Inst Hosp, Tokyo, Japan; [Smoragiewicz, Martin] Univ British Columbia, British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 1M9, Canada; [Donskov, Frede] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark; [Kanesvaran, Ravindran] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore; [Wood, Lori] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; [Ernst, D. Scott] London Reg Canc Ctr, London, ON N6A 4L6, Canada; [Agarwal, Neeraj] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Vaishampayan, Ulka N.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA; [Rha, Sun-young] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea	Heng, DYC (reprint author), Univ Calgary, Tom Baker Canc Ctr, Alberta Hlth Serv Canc Care, Calgary, AB T2N 4N2, Canada.	daniel.heng@albertahealthservices.ca			DF/HCC Kidney Cancer SPORE [P50 CA101942-01]; Kidney Cancer Research Network of Canada; Canadian Institute for Health Research; Trust Family	DF/HCC Kidney Cancer SPORE P50 CA101942-01, Kidney Cancer Research Network of Canada, Canadian Institute for Health Research, Trust Family, Loker Pinard, Michael Brigham, and Gerald DeWulf.	HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Kroeger N, 2013, CANCER-AM CANCER SOC, V119, P2999, DOI 10.1002/cncr.28151; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Al-Marrawi MY, 2013, TARGET ONCOL, V8, P203, DOI 10.1007/s11523-012-0252-7; Soerensen AV, 2014, EUR J CANCER, V50, P553, DOI 10.1016/j.ejca.2013.10.010; Mckay RR, 2014, EUR UROL, V65, P577, DOI 10.1016/j.eururo.2013.08.012; Choueiri TK, 2007, CANCER, V110, P543, DOI 10.1002/cncr.22827; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Wahlgren T, 2013, BRIT J CANCER, V108, P1541, DOI 10.1038/bjc.2013.119; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Hutson TE, 2014, J CLIN ONCOL, V32, P760, DOI 10.1200/JCO.2013.50.3961; Schofield P, 2006, PALLIATIVE MED, V20, P397, DOI 10.1191/0269216306pm1156oa; Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7; Negrier S, 2002, ANN ONCOL, V13, P1460, DOI 10.1093/annonc/mdf257; Manola J, 2011, CLIN CANCER RES, V17, P5443, DOI 10.1158/1078-0432.CCR-11-0553; Heng DYC, 2013, LANCET ONCOL, V14, P141, DOI 10.1016/S1470-2045(12)70559-4; Iacovelli R, 2012, BJU INT, V110, P1747, DOI [10.1111/j.1464-410X.2012.11518.x, 10.1111/j.1464-410X.2012.11518.11525.x]; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Sternberg CN, 2013, EUR J CANCER, V49, P1287, DOI 10.1016/j.ejca.2012.12.010; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289; Motzer RJ, 2004, J CLIN ONCOL, V22, P454; Cook NR, 2009, ANN INTERN MED, V150, P795; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Dirican A, 2013, ASIAN PAC J CANCER P, V14, P2101, DOI 10.7314/APJCP.2013.14.3.2101; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Procopio G, 2011, EXPERT REV ANTICANC, V11, P1631, DOI [10.1586/era.11.154, 10.1586/ERA.11.154]; Seidel C, 2012, EUR J CANCER, V48, P1023, DOI 10.1016/j.ejca.2012.02.048; Vickers MM, 2010, UROLOGY, V76, P430, DOI 10.1016/j.urology.2009.12.031; Zhang HL, 2011, INT J UROL, V18, P422, DOI 10.1111/j.1442-2042.2011.02761.x	31	6	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAR	2015	16	3					293	300		10.1016/S1470-2045(14)71222-7		8	Oncology	Oncology	CC7WA	WOS:000350577900050		
J	Saad, F; Fizazi, K; Jinga, V; Efstathiou, E; Fong, PC; Hart, LL; Jones, R; McDermott, R; Wirth, M; Suzuki, K; MacLean, DB; Wang, L; Akaza, H; Nelson, J; Scher, HI; Dreicer, R; Webb, IJ; de Wit, R				Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C.; Hart, Lowell L.; Jones, Robert; McDermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; MacLean, David B.; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I.; Dreicer, Robert; Webb, Iain J.; de Wit, Ronald		ELM-PC 4 Investigators	Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial	LANCET ONCOLOGY			English	Article							END-POINTS; ABIRATERONE ACETATE; INCREASED SURVIVAL; DOCETAXEL; MITOXANTRONE; ENZALUTAMIDE; MEN	Background Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Methods In this phase 3, double-blind, placebo-controlled trial, we recruited patients with progressive metastatic castration-resistant prostate cancer and no previous chemotherapy from 324 study centres (ie, hospitals or large urologic or group outpatient offices) in 43 countries. Eligible patients were randomly assigned in a 1: 1 ratio to receive either 400 mg orteronel plus 5 mg prednisone twice daily or placebo plus 5 mg prednisone twice daily. Randomisation was done centrally with an interactive voice response system and patients were stratified by region (Europe, North America, and not Europe or North America) and the presence or absence of radiographic disease progression at baseline. The two primary endpoints were radiographic progression-free survival and overall survival, determined in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01193244. Findings From Oct 31, 2010, to June 29, 2012, 2353 patients were assessed for eligibility. Of those, 1560 were randomly assigned to receive either orteronel plus prednisone (n=781) or placebo plus prednisone (n=779). The clinical cutoff date for the final analysis was Jan 15, 2014 (with 611 deaths). Median follow-up for radiographic progression-free survival was 8.4 months (IQR 3.7-16.6). Median radiographic progression-free survival was 13.8 months (95% CI 13.1-14.9) with orteronel plus prednisone and 8.7 months (8.3-10.9) with placebo plus prednisone (hazard ratio [HR] 0.71, 95% CI 0.63-0.80; p<0.0001). After a median follow-up of 20.7 months (IQR 14.2-25.4), median overall survival was 31.4 months (95% CI 28.6-not estimable) with orteronel plus prednisone and 29.5 months (27.0-not estimable) with placebo plus prednisone (HR 0.92, 95% CI 0.79-1.08; p=0.31). The most common grade 3 or worse adverse events were increased lipase (137 [17%] of 784 patients in the orteronel plus prednisone group vs 14 [2%] of 770 patients in the placebo plus prednisone group), increased amylase (77 [10%] vs nine [1%]), fatigue (50 [6%] vs 14 [2%]), and pulmonary embolism (40 [5%] vs 27 [4%]). Serious adverse events were reported in 358 [46%] patients receiving orteronel plus prednisone and in 292 [38%] patients receiving placebo plus prednisone. Interpretation In chemotherapy-naive patients with metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone. However, no improvement was noted in the other primary endpoint, overall survival. Orteronel plus prednisone was associated with increased toxic effects compared with placebo plus prednisone. On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer.	[Saad, Fred] CRCHUM, Ctr Hosp Univ Montreal, Montreal, PQ H2X 0A9, Canada; [Fizazi, Karim] Univ Paris 11, Inst Gustave Roussy, Villejuif, France; [Jinga, Viorel] Univ Med & Farm, Bucharest, Romania; [Efstathiou, Eleni] Univ Athens, Sch Med, GR-11527 Athens, Greece; [Fong, Peter C.] Auckland City Hosp, Auckland, New Zealand; [Hart, Lowell L.] Florida Canc Specialists, Ft Myers, FL USA; [Jones, Robert] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [McDermott, Raymond] Inc Natl Childrens Hosp, Adelaide & Meath Hosp, Dublin, Ireland; [Wirth, Manfred] Univ Hosp Carl Gustav Carus Dresden, Dresden, Germany; [Suzuki, Kazuhiro] Gunma Univ, Grad Sch Med, Gunma, Japan; [MacLean, David B.; Wang, Ling] Millennium Pharmaceut Inc, Cambridge, MA USA; [Akaza, Hideyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan; [Nelson, Joel] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Dreicer, Robert] Cleveland Clin, Cleveland, OH 44106 USA; [Webb, Iain J.] Millennium Pharmaceut Inc, Cambridge, MA USA; [de Wit, Ronald] Erasmus Univ, Med Ctr, Rotterdam, Netherlands	Saad, F (reprint author), CRCHUM, Ctr Hosp Univ Montreal, Pavilion R,900,Rue St Denis, Montreal, PQ H2X 0A9, Canada.	fred.saad@umontreal.ca		McDermott, Ray/0000-0002-8952-4315	Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited	Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.	Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Wiens BL, 2003, PHARM STAT, V2, P211, DOI 10.1002/pst.064; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fizazi K, 2014, LANCET ONCOL, V15, P975, DOI 10.1016/S1470-2045(14)70240-2; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Lissbrant IF, 2013, ACTA ONCOL, V52, P1593, DOI 10.3109/0284186X.2013.770164; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Rathkopf DE, 2013, J CLIN ONCOL, V31, P3525, DOI 10.1200/JCO.2013.50.1684; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Small EJ, 1997, J CLIN ONCOL, V15, P382; Wilson MK, 2015, LANCET ONCOL, V16, pE32, DOI 10.1016/S1470-2045(14)70375-4; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Italiano A, 2009, EUR UROL, V55, P1368, DOI 10.1016/j.eururo.2008.07.078; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Clark MJ, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0104-5; Dreicer R, 2014, CLIN CANCER RES, V20, P1335, DOI 10.1158/1078-0432.CCR-13-2436; Fizazi K, 2015, J CLIN ONCOL, V33, DOI 10.1200/JCO.2014.56.5119; Horwich A, 2013, ANN ONCOL, V24, P1141, DOI 10.1093/annonc/mds624; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Rathkopf DE, 2014, EUR UROL, V66, P815, DOI 10.1016/j.eururo.2014.02.056; Suzuki K, 2015, CANCER CHEMOTH PHARM, V75, P373, DOI 10.1007/s00280-014-2654-y	27	9	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAR	2015	16	3					338	348		10.1016/S1470-2045(15)70027-6		11	Oncology	Oncology	CC7WA	WOS:000350577900055		
J	Nagai, S; Yanagihara, R; Kishioka, Y				Nagai, Sumimasa; Yanagihara, Reiko; Kishioka, Yasuhiro			Japanese regulatory authority's perspective on biosimilars	LANCET ONCOLOGY			English	Letter							FOLLOW-ON BIOLOGICS		[Nagai, Sumimasa] Pharmaceut & Med Devices Agcy, Off New Drug 5, Tokyo, Japan; [Nagai, Sumimasa] Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Genet Therapeut, Tokyo 1088639, Japan; [Yanagihara, Reiko] Pharmaceut & Med Devices Agcy, Off Stand & Guidelines Dev, Tokyo, Japan; [Kishioka, Yasuhiro] Pharmaceut & Med Devices Agcy, Off Cellular & Tissue Based Prod, Tokyo, Japan	Nagai, S (reprint author), Pharmaceut & Med Devices Agcy, Off New Drug 5, Tokyo, Japan.	sunagai-tky@umin.ac.jp					Arato T, 2011, BIOLOGICALS, V39, P289, DOI 10.1016/j.biologicals.2011.08.006; Bennett CL, 2014, LANCET ONCOL, V15, pE594, DOI 10.1016/S1470-2045(14)70365-1; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1998, ICH HARM TRIP GUID E; Nagasaki M, 2014, J BIOPHARM STAT; Yamaguchi T, 2011, BIOLOGICALS, V39, P328, DOI 10.1016/j.biologicals.2011.06.015	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1470-2045	1474-5488		LANCET ONCOL	Lancet Oncol.	MAR	2015	16	3					E101	E101				1	Oncology	Oncology	CC7WA	WOS:000350577900001		
J	Kawahara, S				Kawahara, Shigeto			Comparing a forced-choice wug test and a naturalness rating test: an exploration using rendaku	LANGUAGE SCIENCES			English	Article						Japanese; Phonology; Rendaku; Lyman's Law; Phonological experiment	LYMANS LAW; GRAMMATICALITY; ACCEPTABILITY; INTUITIONS; LINGUISTICS; LANGUAGE; SYNTAX	A growing body of linguistic studies is now deploying judgment experiments to probe both syntactic and phonological knowledge. Thus a research question arises as to what kind of judgment format is useful for probing our linguistic knowledge. Against this theoretical background, this study compares two types of phonological judgment experimentation: a scale-based naturalness judgment task and a forced-choice wug test. The current analysis uses the data from two previously published studies on rendaku, a famous voicing phenomenon found in Japanese compound formation, and Lyman's Law, which is known to inhibit rendaku. Although the two tasks at first sight show a close correlation with each other, a detailed examination of the data shows that the forced-choice wug-test reveals the influence of Lyman's Law on rendaku more clearly than the naturalness judgment experiment. To the extent that the effect of Lyman's Law is real, the current comparison shows that a forced-choice wug experiment is better than a naturalness judgment experiment. While the impact of the current results is limited and modest, this study provides a first step toward understanding how different tasks in phonological experimentation may compare to one another. It is hoped that the current study will plant a seed for a research program which addresses which kind of phonological judgment experimentation is best-suited to reveal our phonological knowledge. (C) 2014 Elsevier Ltd. All rights reserved.	Keio Univ, Inst Cultural & Linguist Studies, Tokyo 1088345, Japan	Kawahara, S (reprint author), Keio Univ, Inst Cultural & Linguist Studies, 2-15-45 Minatoku, Tokyo 1088345, Japan.	kawahara@id.keio.ac.jp			JSPS [26770147]	This project is supported by JSPS Grant #26770147. I am grateful to Haruka Fukazawa, Hinako Masuda, Mayuki Matsui, Shin-ichiro Sano, Yoko Sugioka, Yuko Sugiyama, and two anonymous reviewers for careful comments on the previous version of the paper and/or suggestions on this general project. Thanks to Helen Stickney for her careful proofreading of the pre-final draft. All remaining errors are mine.	Almeida Diogo, 2012, THESIS U CALIFORNIA; Sprouse J, 2012, J LINGUIST, V48, P609, DOI 10.1017/S0022226712000011; Kawahara S, 2011, J EAST ASIAN LINGUIS, V20, P169, DOI 10.1007/s10831-011-9074-3; Bard EG, 1996, LANGUAGE, V72, P32, DOI 10.2307/416793; Kawahara S, 2011, NAT LANG LINGUIST TH, V29, P705, DOI 10.1007/s11049-011-9131-7; Kawahara S, 2013, LINGUISTICS, V51, P1271, DOI 10.1515/ling-2013-0050; BERKO J, 1958, WORD, V14, P150; Marantz A, 2005, LINGUIST REV, V22, P429, DOI 10.1515/tlir.2005.22.2-4.429; LASNIK H, 1984, LINGUIST INQ, V15, P235; Dabrowska E, 2010, LINGUIST REV, V27, P1, DOI 10.1515/tlir.2010.001; Gibson E, 2010, TRENDS COGN SCI, V14, P233, DOI 10.1016/j.tics.2010.03.005; Riemer N, 2009, LANG SCI, V31, P612, DOI 10.1016/j.langsci.2008.04.001; Wasow T, 2005, LINGUA, V115, P1481, DOI 10.1016/j.lingua.2004.07.001; Daland R, 2011, PHONOLOGY, V28, P197, DOI 10.1017/S0952675711000145; Schutze CT, 2011, WIRES COGN SCI, V2, P206, DOI 10.1002/wcs.102; SPENCER NJ, 1973, J PSYCHOLINGUIST RES, V2, P83, DOI 10.1007/BF01067203; Berent I, 2008, J EXP PSYCHOL HUMAN, V34, P1288, DOI 10.1037/0096-1523.34.5.1288; Coetzee AW, 2009, PHONOLOGY, V26, P1, DOI 10.1017/S0952675709001699; Cowart Wayne, 1997, EXPT SYNTAX APPL OBJ; Edelman S, 2003, TRENDS COGN SCI, V7, P60, DOI 10.1016/S1364-6613(02)00045-1; Ferreira F, 2005, LINGUIST REV, V22, P365, DOI 10.1515/tlir.2005.22.2-4.365; Goldrick Matthew, 2011, HDB PHONOLOGICAL THE, P631; Gouskova M, 2013, LAB PHONOL, V4, P383, DOI 10.1515/lp-2013-0013; HILL AA, 1961, WORD, V17, P1; Ihara Mutsuko, 2009, CURRENT ISSUES UNITY, P1007; Kawahara S, 2012, LINGUA, V122, P1193, DOI 10.1016/j.lingua.2012.05.008; Kawahara Shigeto, 2015, LINGUIST VANGUARD; Kawahara S, 2014, LINGUA, V150, P71, DOI 10.1016/j.lingua.2014.07.007; Kawahara Shigeto, 2014, PERSPECTIVE IN PRESS; Kawahara Shigeto, 2011, BLACKWELL COMPANION, P2283; Lyman Benjamin S., 1894, ORIENT STUD ORIENT C, P1; Macmillan N. A., 2005, DETECTION THEORY USE; Myers J., 2009, LANGUAGE LINGUISTICS, V3, P406; Ohala John J., 1986, PHONOLOGY YB, V3, P3, DOI 10.1017/S0952675700000555; Perkins Jeremy, 2014, THESIS RUTGERS U; Phillips Colin, 2009, JAPANESE KOREAN LING, V17, P49; Pullum GK, 2013, MIND LANG, V28, P492, DOI 10.1111/mila.12029; Schutze C.T., 1996, EMPIRICAL BASE LINGU; Shibatani Masayoshi, 2007, CURRENT ISSUES HIST, P153; Ueyama Ayumi, 2010, JAPANESE KOREAN LING, V17, P27; Vance Timothy, 2014, MOUTON IN PRESS; Vance Timothy, 2015, HDB JAPANESE LANGUAG; VANCE TJ, 1980, LINGUISTICS, V18, P245, DOI 10.1515/ling.1980.18.3-4.245; Yu ACL, 2014, J ACOUST SOC AM, V136, P382, DOI 10.1121/1.4883380	44	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0388-0001	1873-5746		LANG SCI	Lang. Sci.	MAR	2015	48						42	47		10.1016/j.langsci.2014.12.001		6	Linguistics; Language & Linguistics	Linguistics	CD0RW	WOS:000350782600004		
J	Sun, XH; Yan, LH; Chen, T; Yu, Y; Matsuo, S				Sun, Xuehui; Yan, Lihe; Chen, Tao; Yu, Yang; Matsuo, Shigeki			Effect of solvent surface tension on optical limiting properties of graphene dispersions	LASER PHYSICS			English	Article						graphene; optical limiting; nonlinear scattering; surface tension	CARBON NANOTUBE DISPERSIONS; NANOPARTICLES; SUSPENSIONS	The optical limiting (OL) properties and the mechanisms of graphene dispersions in alcohol aqueous solutions with different concentrations were investigated using a nanosecond pulse laser. With increasing the incident laser influence, optical transmittance of graphene dispersions decreased and the nonlinear scattering (NLS) light intensity increased synchronously, indicating that the NLS effect was mainly responsible for the OL process of graphene dispersions. By changing the alcohol concentration in the solvent and analyzing the relations between the solvent surface tensions and the OL properties of different dispersions, we demonstrated that solvent surface tension played a significant role in the OL performance of graphene dispersions, and a lower surface tension would induce a stronger NLS effect and a lower OL threshold.	[Sun, Xuehui; Yan, Lihe; Chen, Tao; Yu, Yang] Xi An Jiao Tong Univ, Minist Educ, Key Lab Phys Elect & Devices, Xian 710049, Peoples R China; [Sun, Xuehui; Yan, Lihe; Chen, Tao; Yu, Yang] Xi An Jiao Tong Univ, Shaanxi Key Lab Informat Photon Tech, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Sch Elect & Informat Engn, Xian 710049, Peoples R China; [Sun, Xuehui; Matsuo, Shigeki] Univ Tokushima, Dept Opt Sci & Technol, Tokushima 7708506, Japan	Sun, XH (reprint author), Xi An Jiao Tong Univ, Minist Educ, Key Lab Phys Elect & Devices, Xianing Xilu 28, Xian 710049, Peoples R China.	liheyan@mail.xjtu.edu.cn			National Natural Science Foundation of China (NSFC) [61235003, 1130424, 11474078]; Research Fund for the Doctoral Program of Higher Education [20130201120025]; Collaborative Innovation Center of Suzhou Nano Ncience and Technology	This work was supported the by the National Natural Science Foundation of China (NSFC) under Grant Nos. 61235003, 1130424 and 11474078 and the Research Fund for the Doctoral Program of Higher Education under Grant No. 20130201120025. This work was also supported by the Collaborative Innovation Center of Suzhou Nano Ncience and Technology. The TEM work was done at the International Center for Dielectric Research (ICDR), Xi'an Jiaotong University, Xi'an, China. In addition, the authors thank Mr Ma and Ms Lu for their help in using TEM.	Liu H, 2008, OPT EXPRESS, V16, P13486, DOI 10.1364/OE.16.013486; Feng M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3279148; Belousova IM, 2003, OPT SPECTROSC+, V94, P86, DOI 10.1134/1.1540206; Bludov YV, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.035406; Vivien L, 2002, CARBON, V40, P1789, DOI 10.1016/S0008-6223(02)00046-5; Wang J, 2009, ADV MATER, V21, P2430, DOI 10.1002/adma.200803616; Wang J, 2010, J PHYS CHEM C, V114, P6148, DOI 10.1021/jp9117248; Wang J, 2008, J PHYS CHEM C, V112, P2298, DOI 10.1021/jp709926r; Belousova IM, 2004, OPT COMMUN, V235, P445, DOI 10.1016/j.optcom.2004.02.053; Krishna MBM, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3553500; Mansour K, 1992, J OPT SOC AM B, V9, P1101; Peres N M R, 2013, J OPT, V15; Sun YP, 1999, INT REV PHYS CHEM, V18, P43, DOI 10.1080/014423599230008; Tan WJ, 2010, J APPL PHYS, V107, DOI 10.1063/1.3310492; Tan WJ, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2968202; Wang J, 2010, OPT COMMUN, V283, P464, DOI 10.1016/j.optcom.2009.10.020; Yang JY, 2012, J PHYS CHEM B, V116, P1221, DOI 10.1021/jp2078665	17	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1054-660X	1555-6611		LASER PHYS	Laser Phys.	MAR	2015	25	3							035901	10.1088/1054-660X/25/3/035901		4	Optics; Physics, Applied	Optics; Physics	CC3UW	WOS:000350277000018		
J	Hyodoh, H; Shimizu, J; Mizuo, K; Okazaki, S; Watanabe, S; Inoue, H				Hyodoh, Hideki; Shimizu, Jyunya; Mizuo, Keisuke; Okazaki, Shunichiro; Watanabe, Satoshi; Inoue, Hiromasa			CT-guided percutaneous needle placement in forensic medicine	LEGAL MEDICINE			English	Article						Postmortem CT; Burning; CO-Hb; Needle placement; CT-guided	POSTMORTEM COMPUTED-TOMOGRAPHY; PROSTATE BIOPSY; BREAST-LESIONS; DEVICE; AUTOPSY	We have developed a technique of CT-guided needle placement in the destructed human body in forensic practice. A sixty-year-old male was found in a burned car and he was also destructed severely. Although blood was needed for the external examination, it was difficult to approach the vessels because of the severely burned condition of the cadaver. Thus, we attempted to obtain a blood sample from a vessel using a CF-guided technique. Postmortem CT demonstrated the presence of blood-containing vessels in the pelvis. Indeed, CT-guided needle placement had no difficulty with surface markers, table location, or depth measurement from the surface. CT-guide needle placement is a feasible and reliable technique, so that when the tissue/blood sample is at risk of being spoiled, CF-guided needle placement could be a substitute for conventional sampling techniques. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Hyodoh, Hideki; Shimizu, Jyunya; Mizuo, Keisuke; Okazaki, Shunichiro; Watanabe, Satoshi; Inoue, Hiromasa] Sapporo Med Univ, Sch Med, Dept Legal Med, Sapporo, Hokkaido, Japan	Hyodoh, H (reprint author), S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan.	hyodoh@sapmed.ac.jp					Aghayev E, 2007, FORENSIC SCI INT, V166, P199, DOI 10.1016/j.forsciint.2006.05.035; Beyersdorff D, 2005, RADIOLOGY, V234, P576, DOI 10.1148/radiol.2342031887; Tsukada H, 2000, AM J ROENTGENOL, V175, P239; OREL SG, 1994, RADIOLOGY, V193, P97; Kanazawa A, 2014, LEGAL MED-TOKYO, V16, P297, DOI 10.1016/j.legalmed.2014.05.004; OREL SG, 1995, RADIOLOGY, V196, P115; Omura MC, 2011, AM J ROENTGENOL, V197, P457, DOI 10.2214/AJR.10.6145; Charlier P, 2012, AM J FOREN MED PATH, V33, pE2, DOI 10.1097/PAF.0b013e31823a8c55; Charlier P, 2013, MED SCI LAW, V53, P227, DOI 10.1177/0025802413479946; Ebert LC, 2014, FORENSIC SCI MED PAT, V10, P179, DOI 10.1007/s12024-013-9520-9; Farina J, 2002, VIRCHOWS ARCH, V440, P635, DOI 10.1007/s00428-002-0607-z; FISCHER U, 1994, RADIOLOGY, V192, P272; Hata N, 2001, RADIOLOGY, V220, P263; Hyodoh H, 2012, JPN J RADIOL, V30, P840, DOI 10.1007/s11604-012-0134-z; Hyodoh H, 2013, FORENSIC SCI INT, V231, P190, DOI 10.1016/j.forsciint.2013.05.011; Uchigasaki S, 2004, FORENSIC SCI INT, V140, P33, DOI 10.1016/j.forsciint.2003.11.029	16	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					79	81		10.1016/j.legalmed.2014.10.002		3	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400002		
J	Watanabe, K; Takahashi, Y; Sano, R; Nakajima, T; Kominato, Y; Kobayashi, S; Shimada, T; Takei, H; Awata, S; Hirasawa, S				Watanabe, Kaho; Takahashi, Yoichiro; Sano, Rie; Nakajima, Tamiko; Kominato, Yoshihiko; Kobayashi, Susumu; Shimada, Takehiro; Takei, Hiroyuki; Awata, Sachiko; Hirasawa, Satoshi			Brain fragility can be estimated by its putrefactive signs on postmortem computed tomography	LEGAL MEDICINE			English	Article						Postmortem computed tomography; Postmortem changes; Brain	REVEAL; BODY	Along with time after death, postmortem computed tomography (PMCT) of the brain can reveal sequential changes. In the present study, we investigated the relationship between brain rigidity and advanced postmortem changes such as intravascular gas production, cerebral settling or cerebral liquefaction on PMCT. We then examined the findings of PMCT as an indicator of successful macroscopic examination of arbitrary brain slices at classical autopsy. The association between these advanced postmortem changes and the validity of macroscopic brain examination was investigated in 149 cases that were examined by PMCT at our department prior to autopsy in the period from September 2011 to December 2013. We found that the postmortem changes, classified into four stages, generally reflected the fragility of the brain. Thus, it is likely that PMCT findings of advanced postmortem changes are able to indicate decreased brain rigidity ahead of autopsy. These findings support the idea that PMCT could be used as a guide by forensic pathologists for suitable handling of a fragile brain, thus enhancing the quality of autopsy. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Watanabe, Kaho; Takahashi, Yoichiro; Sano, Rie; Nakajima, Tamiko; Kominato, Yoshihiko] Gunma Univ, Grad Sch Med, Dept Legal Med, Maebashi, Gumma 3718511, Japan; [Kobayashi, Susumu; Shimada, Takehiro; Awata, Sachiko; Hirasawa, Satoshi] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol & Nucl Med, Maebashi, Gumma 3718511, Japan; [Takei, Hiroyuki] Gunma Univ Hosp, Dept Radiol, Maebashi, Gumma 3718511, Japan	Takahashi, Y (reprint author), Gunma Univ, Grad Sch Med, Dept Legal Med, Maebashi, Gumma 3718511, Japan.	m12702043@gunma-u.ac.jp			Japan Society for the Promotion of Science [25860486, 25460861, 26293161]	This work was supported in part by Grant-in-Aid from the Japan Society for the Promotion of Science (25860486 to Y.T., 25460861 to T.N., 26293161 to Y.K.).	Thali MJ, 2003, J FORENSIC SCI, V48, P386; Levy AD, 2010, AM J FOREN MED PATH, V31, P12, DOI 10.1097/PAF.0b013e3181c65e1a; Christe A, 2010, LEGAL MED, V12, P215, DOI 10.1016/j.legalmed.2010.05.005; Gotsmy WF, 2011, LEGAL MED, V13, P95, DOI 10.1016/j.legalmed.2010.11.006; Sano R, 2011, LEGAL MED-TOKYO, V13, P286, DOI 10.1016/j.legalmed.2011.07.004; Sano R, 2013, LEGAL MED-TOKYO, V15, P32, DOI 10.1016/j.legalmed.2012.05.005; Takahashi Y, 2013, J FORENSIC RADIOL IM, V1, P212	7	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					98	101		10.1016/j.legalmed.2014.10.008		4	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400005		
J	Idota, N; Kobayashi, M; Miyamori, D; Kakiuchi, Y; Ikegaya, H				Idota, Nozomi; Kobayashi, Masaki; Miyamori, Daisuke; Kakiuchi, Yasuhiro; Ikegaya, Hiroshi			Drospirenone detected in postmortem blood of a young woman with pulmonary thromboembolism: A case report and review of the literature	LEGAL MEDICINE			English	Article						Drospirenone; Ethinylestradiol; Oral contraceptive; Pulmonary thromboembolism; Ultra-performance liquid chromatography-mass spectrometry; YAZ	PREMENSTRUAL DYSPHORIC DISORDER; NONFATAL VENOUS THROMBOEMBOLISM; MODERATE ACNE-VULGARIS; ORAL-CONTRACEPTIVES; ETHINYL-ESTRADIOL; ONLY CONTRACEPTION; RISK; WOMEN; ETHINYLESTRADIOL; LEVONORGESTREL	Progestin/estrogen oral contraceptives have some side effects, including venous thromboembolism. To alleviate side effects, improvements have been made to low-dose oral contraceptives, including reductions in the amount of estrogen and/or changes the type of progestin. A compound drug containing 3 mg drospirenone and 20 mu g ethinylestradiol (DRSP/EE20, YAZ (R)) was released in overseas markets in 2006, and in Japan in 2010 as a newly developed low-dose medicines. This drug is expected to have lower side effects. We received a medicolegal autopsy case of a young woman who had been prescribed YAZ for dysmenorrhea for 17 months. The autopsy revealed a blood clot in her pulmonary artery bifurcation. Blood screening by ultra-performance liquid chromatography-mass spectrometry analysis did not detect any medicinal toxicants. However, from police investigations, it is strongly believed that she had been taking YAZ. Therefore we performed a single ion resolution mode assay and detected DRSP. A quantitative analysis revealed 32.3 ng/mL of DRSP. As no other cause of the pulmonary thromboembolism was evident, we consider YAZ as the likely cause of the pulmonary thromboembolism. Recent reports from the past few years suggest a higher risk of venous thromboembolism with DRSP/ EE20 than earlier progestin/estrogen oral contraceptives. Comparing the risk associated with DRSP/EE20 and DRSP/EE30, one report found no differences and another report showed DRSP/EE20 was associated with a higher risk than DRSP/EE30. No cases of thrombosis caused by progestin alone have been reported. But comparing the risk between DRSP/EE20 and other progestins/EE20, two studies reported DRSP/EE20 had a higher risk than other progestins/EE20. The incidence of venous thromboembolism is highest in the first year of use and decreases thereafter. Because DRSP/EE20 has been on the market for only a couple of years, it is necessary for clinicians to use the drug carefully and accumulate more side-effect data. It is important for forensic scientists to confirm all of the prescribed drugs in autopsy cases, search the risks of identified drugs, particularly new drugs, and provide relevant case information in a timely manner. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Idota, Nozomi; Kobayashi, Masaki; Miyamori, Daisuke; Kakiuchi, Yasuhiro; Ikegaya, Hiroshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Forens Med, Kamigyo Ku, Kyoto 6028566, Japan	Idota, N (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Forens Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	idotan@koto.kpu-m.ac.jp; miyamori@koto.kpu-m.ac.jp; kakiuchi@koto.kpu-m.ac.jp; ikegaya@koto.kpu-m.ac.jp					Pearlstein TB, 2005, CONTRACEPTION, V72, P414, DOI 10.1016/j.contraception.2005.08.021; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; VESSEY MP, 1969, BRIT MED J, V2, P651; Yonkers KA, 2005, OBSTET GYNECOL, V106, P492, DOI 10.1097/01.AOG.0000175834.77215.2e; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Rott H, 2013, MINERVA MED, V104, P161; Reif S, 2013, J FAM PLAN REPROD H, V39, DOI 10.1136/jfprhc-2012-100397; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365; Koltun W, 2011, EUR J OBSTET GYN R B, V155, P171, DOI 10.1016/j.ejogrb.2010.12.027; Dinger J, 2010, J FAM PLAN REPROD H, V36, P123, DOI 10.1783/147118910791749416; Suissa S, 1997, CONTRACEPTION, V56, P141, DOI 10.1016/S0010-7824(97)00119-4; Barsoum MK, 2010, THROMB RES, V126, P373, DOI 10.1016/j.thromres.2010.08.010; Bayer in Japan, APPR PRESCR TAK YAZ; Bird ST, 2013, J THROMB HAEMOST, V11, P1059, DOI 10.1111/jth.12224; Blanco-Molina M A, 2012, THROMB RES, V129, P257; Caruso S, 2013, EUR J OBSTET GYN R B, V171, P307, DOI 10.1016/j.ejogrb.2013.09.039; Conard J, 2004, CONTRACEPTION, V70, P437, DOI 10.1016/j.contraception.2004.07.009; Drill VA, 1972, JAMA-J AM MED ASSOC, V21, P593; DRILL VA, 1972, J AMER MED ASSOC, V219, P583, DOI 10.1001/jama.219.5.583; Fenton C, 2007, DRUGS, V67, P1749, DOI 10.2165/00003495-200767120-00007; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32; Ando M, 2011, CIRC J, V75, P1258, DOI 10.1253/circj.CJ-88-0010; Jick SS, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2151; Jordan W.M., 1961, LANCET, V278, P1146; Kluft C, 2006, CONTRACEPTION, V73, P336, DOI 10.1016/j.contraception.2005.09.015; Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890; Lidegaard O, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6423; Lucky AW, 2008, CUTIS, V82, P143; Mantha S, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4944; Ministry of Health Labour and Welfare, DRUG SAF FLASH THROM; Ministry of Health Labour and Welfare, AL THROMB PAT PRESCR; Momoeda M, 2010, SANKA TO FUJINKA, V8, P977; Oslakovic S, 2012, CLIN APPL THROMB HEM; Parkin L, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d2139; Short M, 2009, CLIN DRUG INVEST, V29, P153, DOI 10.2165/00044011-200929030-00002; Stegeman BH, 2013, BMJ-BRIT MED J, V347, pf5298; Stocco B, 2012, CONTRACEPTION, V86, P506, DOI 10.1016/j.contraception.2012.03.013; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197; Vasilakis C, 1999, LANCET, V354, P1610, DOI 10.1016/S0140-6736(99)04394-9; Wichianpitaya J, 2013, OBSTET GYNECOL INT	41	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					109	115		10.1016/j.legalmed.2014.10.001		7	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400007		
J	Inoue, H; Hyodoh, H; Watanabe, S; Okazaki, S; Mizuo, K				Inoue, Hiromasa; Hyodoh, Hideki; Watanabe, Satoshi; Okazaki, Shunichiro; Mizuo, Keisuke			Acute enlargement of subdural hygroma due to subdural hemorrhage in a victim of child abuse	LEGAL MEDICINE			English	Article						Subdural hygroma; Subdural hemorrhage; Bridging vein; Skull fracture; Child abuse; Postmortem CT	HOUNSFIELD-UNIT; HEAD-INJURIES; INFANTS	An 11-month-old female baby was found dead by her mother. Cranial postmortem CT prior to the forensic autopsy showed dilatation of bilateral extra-axial spaces and ventricles. The autopsy revealed a new linear fracture of the left parietal bone and occipital bone, and a healed linear fracture of the right parietal bone and occipital bone like a mirror image of the left one as well. Intracranially, 230 ml of subdural fluid were collected, which was mixed with blood. There was a fresh hemorrhage around a bridging vein of the left parietal lobe and the dura mater. Moreover, the outer side of the cerebrum and the inner side of the dura mater were covered by a thin membrane, which mater might have been previously formed because of being positive for Fe-staining and anti-CD68 antibody. A subdural hematoma might have been developed when the right side of the skull was previously fractured, which was transformed into a subdural hygroma. Subsequently, it is likely that, after the left side fracture of the skull occurred, the subdural hygroma rapidly enlarged due to hemorrhaging from the bridging vein, which resulted in intracranial hypertension, because microbleeding was detected in the brain stem. Accordingly, we diagnosed the cause and manner of death as intracranial hypertension due to subdural hemorrhage in subdural hygroma, and homicide, including child abuse, respectively. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Inoue, Hiromasa; Hyodoh, Hideki; Watanabe, Satoshi; Okazaki, Shunichiro; Mizuo, Keisuke] Sapporo Med Univ, Dept Legal Med, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Inoue, H (reprint author), Sapporo Med Univ, Dept Legal Med, Sch Med, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	inoue-h@sapmed.ac.jp					Zanini MA, 2008, J TRAUMA, V64, P705, DOI 10.1097/TA.0b013e3180485cfc; Jeon SW, 2011, J KOREAN NEUROSURG S, V49, P355, DOI 10.3340/jkns.2011.49.6.355; Blumenthal I, 2002, POSTGRAD MED J, V78, P732, DOI 10.1136/pmj.78.926.732; Case Mary E., 2007, Legal Medicine, V9, P83, DOI 10.1016/j.legalmed.2006.11.017; Ruder TD, 2012, FORENSIC SCI INT, V220, P219, DOI 10.1016/j.forsciint.2012.03.004; John SM, 2013, AM J FOREN MED PATH, V34, P277, DOI 10.1097/PAF.0b013e3182a187e9; John SM, 2013, J TRAUMA ACUTE CARE, V74, P276, DOI 10.1097/TA.0b013e318270d82e; Rooks VJ, 2008, AM J NEURORADIOL, V29, P1082, DOI 10.3174/ajnr.A1004; Caldarelli M, 2002, ACTA NEUROCHIR, V144, P581, DOI 10.1007/s00701-002-0947-0; Gabaeff SC, 2013, LEGAL MED-TOKYO, V15, P177, DOI 10.1016/j.legalmed.2012.12.003; Herold TJS, 2004, J EMERG MED, V27, P361, DOI 10.1016/j.jemermed.2004.03.018; Liu YG, 2009, INJURY, V40, P968, DOI 10.1016/j.injury.2009.01.006; Squier W, 2009, FORENSIC SCI INT, V187, P6, DOI 10.1016/j.forsciint.2009.02.005; Walter Till, 2009, Leg Med (Tokyo), V11 Suppl 1, pS56, DOI 10.1016/j.legalmed.2009.01.112; Zech WD, 2014, INT J LEGAL MED, V128, P795, DOI 10.1007/s00414-014-1030-0	15	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					116	119		10.1016/j.legalmed.2014.10.006		4	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400008		
J	Watanabe, M; Unuma, K; Fujii, Y; Noritake, K; Uemura, K				Watanabe, Mayumi; Unuma, Kana; Fujii, Yusuke; Noritake, Kanako; Uemura, Koichi			An autopsy case of vagus nerve stimulation following acupuncture	LEGAL MEDICINE			English	Article						Acupuncture; Vagus nerve; Vagal stimulation; Autopsy; Forensic pathology		Acupuncture is one of the most popular oriental medical techniques in China, Korea and Japan. This technique is also popular as alternative therapy in the Western World. Serious adverse events are rare following acupuncture, and fatal cases have been rarely reported. A male in his late forties died right after acupuncture treatment. A medico-legal autopsy disclosed severe haemorrhaging around the right vagus nerve in the neck. Other organs and laboratory data showed no significant findings. Thus, it was determined that the man could have died from severe vagal bradycardia and/or arrhythmia resulting from vagus nerve stimulation following acupuncture. To the best of our knowledge, this is the first report of a death due to vagus nerve injury after acupuncture. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Watanabe, Mayumi; Unuma, Kana; Fujii, Yusuke; Noritake, Kanako; Uemura, Koichi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Forens Med, Bunkyo Ku, Tokyo 1138519, Japan	Uemura, K (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Forens Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	kuemura.legm@tmd.ac.jp					Xu SF, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/581203; Chang SA, 2005, INT J CARDIOL, V104, P241, DOI 10.1016/j.ijcard.2004.12.035; Iwadate Kimiharu, 2003, Leg Med (Tokyo), V5, P170, DOI 10.1016/S1344-6223(03)00052-X; Kasuda S, 2004, J NARA MED ASS, V55, P331; Onizuka T, 1998, Kansenshogaku Zasshi, V72, P776; Saukko P, 2004, KNIGHTS FORENSIC PAT; Simmons Roger, 2006, Acupunct Med, V24, P37; White Adrian, 2004, Acupunct Med, V22, P122	8	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					120	122		10.1016/j.legalmed.2014.11.001		3	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400009		
J	Takada, N; Mori, C; Takai, R; Takayama, T; Watanabe, Y; Nakamura, K; Takamizawa, K				Takada, Naoki; Mori, Chikahiro; Takai, Rie; Takayama, Tomohiro; Watanabe, Yoshihisa; Nakamura, Kohei; Takamizawa, Kazuhiro			Involvement of soil bacteria in ABO blood mistyping	LEGAL MEDICINE			English	Article						ABO blood mistyping; ABO antigen		The current study investigated whether ABO blood mistyping of human biological samples is induced by soil bacteria. A total of 380 bacterial strains were isolated from 50 discrete soil samples using human blood agar, and glycosidase activity evaluated for all strains using 4-nitropheny glycosides (4-nitrophenyl n-acetyl-alpha-D-galactosaminide, 4-nitrophenyl-alpha-D-galactopyranoside, 4-nitrophenyl-alpha-L-fucopyranoside) as substrates. Thirteen strains possessed alpha-galactosidase activity, and 16S rRNA sequence analysis revealed a close relatedness to the genus Bacillus. An indirect competitive enzyme-linked immunosorbent assay confirmed seven strains exhibited type B antigen degradation activity. These results demonstrated that 1.8% of the bacteria isolated from soil, were Bacillus sp., possessed galactosidase activity, and had the potential to cause ABO blood mistyping. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Takada, Naoki] Gifu Univ, United Grad Sch Agr Sci, Sci Biol Resources, Gifu 5011193, Japan; [Takada, Naoki; Mori, Chikahiro; Takai, Rie; Takayama, Tomohiro; Watanabe, Yoshihisa] Gifu Prefectural Police Headquarters, Forens Sci Lab, Gifu 5008501, Japan; [Nakamura, Kohei; Takamizawa, Kazuhiro] Gifu Univ, Fac Appl Biol Sci, Gifu 5011193, Japan	Takada, N (reprint author), Gifu Prefectural Police Headquarters, Forens Sci Lab, Gifu 5008501, Japan.	naokiutd_1977@ybb.ne.jp					Anderson KM, 2005, J BIOL CHEM, V280, P7720, DOI 10.1074/jbc.M414099200; Liu QYP, 2007, NAT BIOTECHNOL, V25, P454, DOI 10.1038/nbt1298; Doi Yusuke, 2004, Leg Med (Tokyo), V6, P213, DOI 10.1016/j.legalmed.2004.05.005; Huang J, 2014, APPL ENVIRON MICROB, V80, P29, DOI 10.1128/AEM.02335-13; Inuyama R, 1979, REPORTS NATL RES I P, V32, P1; Iseki S, 1951, P JAPAN ACAD, V27, P455; Iseki S, 1952, P JAPAN ACAD, V28, P370; Iseki S, 1956, P JAPAN ACAD, V32, P201; Lansing CH, 1976, J CLIN INVEST, P74; LEE HC, 1989, J FORENSIC SCI, V34, P7; Michino Junko, 2005, Legal Medicine, V7, P194, DOI 10.1016/j.legalmed.2004.11.005; Nishi E, 2002, RES PRACT FORENSIC M, V45, P27; Ohmori T, 1999, Nihon Hoigaku Zasshi, V53, P338; Rae R, 2010, ENVIRON MICROBIOL, V12, P3007, DOI 10.1111/j.1462-2920.2010.02278.x; Russell FM, 2006, J CLIN MICROBIOL, V44, P3346, DOI 10.1128/JCM.02631-05; Simpson EK, 2008, FORENSIC PATHOLOGY R, V5, P187; Storry J R, 2009, Immunohematology, V25, P48; Takada N, 2014, LEG MED, P139; Vendan RT, 2010, J MICROBIOL, V48, P559, DOI 10.1007/s12275-010-0082-1; Watanabe K, 2010, J FORENSIC SCI, V56, P183; Yuasa I, 1977, REPORTS NATL RES I P, V30, P28; Zhang J, 2012, J MICROBIOL, V50, P191, DOI 10.1007/s12275-012-1472-3	22	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1344-6223			LEGAL MED-TOKYO	Leg. Med.	MAR	2015	17	2					128	133		10.1016/j.legalmed.2014.10.007		6	Medicine, Legal; Social Sciences, Biomedical	Legal Medicine; Biomedical Social Sciences	CD2SD	WOS:000350928400011		
J	Yu, P; Petrus, MN; Ju, W; Zhang, M; Conlon, KC; Nakagawa, M; Maeda, M; Bamford, RN; Waldmann, TA				Yu, P.; Petrus, M. N.; Ju, W.; Zhang, M.; Conlon, K. C.; Nakagawa, M.; Maeda, M.; Bamford, R. N.; Waldmann, T. A.			Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model	LEUKEMIA			English	Article							NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; HISTONE DEACETYLASES; CANCER DEVELOPMENT; MULTIPLE-MYELOMA; ACTIVATION; LYMPHOMA; PROLIFERATION; RESISTANCE; APOPTOSIS	Adult T-cell leukemia (ATL) is an aggressive malignancy caused by human T-cell lymphotropic virus-1. There is no accepted curative therapy for ATL. We have reported that certain ATL patients have increased Notch-1 signaling along with constitutive activation of the nuclear factor-kappa B pathway. Physical and functional interaction between these two pathways provides the rationale to combine the gamma-secretase inhibitor compound E with the proteasome inhibitor bortezomib. Moreover, romidepsin, a histone deacetylase inhibitor, has demonstrated major antitumor action in leukemia/lymphoma. In this study, we investigated the therapeutic efficacy of the single agents and the combination of these agents in a murine model of human ATL, the MT-1 model. Single and double agents inhibited tumor growth as monitored by tumor size (P < 0.05), and prolonged survival of leukemia-bearing mice (P < 0.05) compared with the control group. The combination of three agents significantly enhanced the antitumor efficacy as assessed by tumor size, tumor markers in the serum (human soluble interleukin-2 receptor-alpha and beta(2)-microglobulin) and survival of the MT-1 tumor-bearing mice, compared with all other treatment groups (P < 0.05). Improved therapeutic efficacy obtained by combining compound E, bortezomib and romidepsin supports a clinical trial of this combination in the treatment of ATL.	[Yu, P.; Petrus, M. N.; Ju, W.; Zhang, M.; Conlon, K. C.; Nakagawa, M.; Waldmann, T. A.] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Zhang, M.] NCI, Lab Anim Sci Program, SAIC Frederick Inc, Frederick, MD 21701 USA; [Maeda, M.] Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 606, Japan; [Bamford, R. N.] Transponics, Jacobus, PA USA	Waldmann, TA (reprint author), NCI, Lymphoid Malignancies Branch, Ctr Canc Res, Bldg 10,Room 4N115,10 Ctr Dr, Bethesda, MD 20892 USA.	tawald@mail.nih.gov			Intramural Research Program of Center for Cancer Research, NCI, NIH	This work was supported by the Intramural Research Program of Center for Cancer Research, NCI, NIH.	Agnusdei V, 2014, LEUKEMIA, V28, P278, DOI 10.1038/leu.2013.183; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Parks AL, 2000, DEVELOPMENT, V127, P1373; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Kamdje AHN, 2011, BLOOD, V118, P380, DOI 10.1182/blood-2010-12-326694; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182/blood-2010-10-312603; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Marks PA, 2000, J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Harrison SJ, 2011, BLOOD, V118, P6274, DOI 10.1182/blood-2011-03-339879; Schwarzer R, 2012, LEUKEMIA, V26, P806, DOI 10.1038/leu.2011.265; Chen F, 2011, CELL ONCOL, V34, P545, DOI 10.1007/s13402-011-0060-6; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Paoluzzi L, 2010, CLIN CANCER RES, V16, P554, DOI 10.1158/1078-0432.CCR-09-1937; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Oswald F, 1998, MOL CELL BIOL, V18, P2077; Kikuchi J, 2010, BLOOD, V116, P406, DOI 10.1182/blood-2009-07-235663; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bland CE, 2003, J BIOL CHEM, V278, P13607, DOI 10.1074/jbc.C300016200; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Horie R, 2007, INT REV IMMUNOL, V26, P269, DOI 10.1080/08830180701703364; Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004; Pancewicz J, 2010, P NATL ACAD SCI USA, V107, P16619, DOI 10.1073/pnas.1010722107; Peloponese JM, 2006, IMMUNOL RES, V34, P1, DOI 10.1385/IR:34:1:1; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Sanda T, 2010, BLOOD, V115, P1735, DOI 10.1182/blood-2009-07-235143; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Yuan Y, 2013, ONCOL LETT, V6, P1000, DOI 10.3892/ol.2013.1523; Zuurbier L, 2010, LEUKEMIA, V24, P2014, DOI 10.1038/leu.2010.204	46	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	MAR	2015	29	3					556	566		10.1038/leu.2014.241		11	Oncology; Hematology	Oncology; Hematology	CD0BE	WOS:000350734300005		
J	Kato, T; Sakata-Yanagimoto, M; Nishikii, H; Ueno, M; Miyake, Y; Yokoyama, Y; Asabe, Y; Komada, Y; Muto, H; Obara, N; Suzukawa, K; Hasegawa, Y; Kitabayashi, I; Uchida, K; Hirao, A; Yagita, H; Kageyama, R; Chiba, S				Kato, T.; Sakata-Yanagimoto, M.; Nishikii, H.; Ueno, M.; Miyake, Y.; Yokoyama, Y.; Asabe, Y.; Komada, Y.; Muto, H.; Obara, N.; Suzukawa, K.; Hasegawa, Y.; Kitabayashi, I.; Uchida, K.; Hirao, A.; Yagita, H.; Kageyama, R.; Chiba, S.			Hes1 suppresses acute myeloid leukemia development through FLT3 repression	LEUKEMIA			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE-EXPRESSION PROFILES; HEMATOPOIETIC STEM-CELLS; ZONE B-CELLS; NEUROENDOCRINE DIFFERENTIATION; REGULATES DIFFERENTIATION; TRANSCRIPT LEVEL; TUMOR-SUPPRESSOR; NOTCH PATHWAY; MUTATIONS	In leukemogenesis, Notch signaling can be up and downregulated in a context-dependent manner. The transcription factor hairy and enhancer of split-1 (Hes1) is well-characterized as a downstream target of Notch signaling. Hes1 encodes a basic helix-loop-helix-type protein, and represses target gene expression. Here, we report that deletion of the Hes1 gene in mice promotes acute myeloid leukemia (AML) development induced by the MLL-AF9 fusion protein. We then found that Hes1 directly bound to the promoter region of the FMS-like tyrosine kinase 3 (FLT3) gene and downregulated the promoter activity. FLT3 was consequently upregulated in MLL-AF9-expressing immortalized and leukemia cells with a Hes1- or RBPJ-null background. MLL-AF9-expressing Hes1-null AML cells showed enhanced proliferation and ERK phosphorylation following FLT3 ligand stimulation. FLT3 inhibition efficiently abrogated proliferation of MLL-AF9-induced Hes1-null AML cells. Furthermore, an agonistic anti-Notch2 antibody induced apoptosis of MLL-AF9-induced AML cells in a Hes1-wild type but not a Hes1-null background. We also accessed two independent databases containing messenger RNA (mRNA) expression profiles and found that the expression level of FLT3 mRNA was negatively correlated with those of HES1 in patient AML samples. These observations demonstrate that Hes1 mediates tumor suppressive roles of Notch signaling in AML development, probably by downregulating FLT3 expression.	[Kato, T.; Sakata-Yanagimoto, M.; Nishikii, H.; Yokoyama, Y.; Muto, H.; Obara, N.; Suzukawa, K.; Hasegawa, Y.; Chiba, S.] Univ Tsukuba, Fac Med, Dept Hematol, Tsukuba, Ibaraki 3058575, Japan; [Kato, T.; Chiba, S.] Univ Tsukuba, Tsukuba Adv Res Alliance, Life Sci Ctr, Tsukuba, Ibaraki 3058575, Japan; [Kato, T.; Sakata-Yanagimoto, M.; Miyake, Y.; Asabe, Y.; Komada, Y.; Muto, H.; Obara, N.; Hasegawa, Y.; Chiba, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Hematol, Tsukuba, Ibaraki 3058575, Japan; [Ueno, M.; Hirao, A.] Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Div Mol Genet, Kanazawa, Ishikawa 920, Japan; [Kitabayashi, I.] Natl Canc Ctr, Res Inst, Div Mol Oncol, Tokyo 104, Japan; [Uchida, K.] Univ Tsukuba, Fac Med, Dept Mol Biol Oncol, Tsukuba, Ibaraki 3058575, Japan; [Yagita, H.] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; [Kageyama, R.] Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; [Kageyama, R.] Kyoto Univ, World Premier Int Res Initiat, Inst Integrated Cell Mat Sci WPI iCeMS, Kyoto, Japan	Chiba, S (reprint author), Univ Tsukuba, Fac Med, Dept Hematol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	schiba-t@md.tsukuba.ac.jp		Suzukawa, Kazumi/0000-0001-9904-3905	Ministry of Education, Culture, Sports, Science and Technology of Japan [25860778, 25461407, 25112703, 24390241, 23118503, 22130002]; Sagawa Cancer Foundation; Naito Foundation; Kato Memorial Bioscience Foundation; YASUDA Medical Foundation	We thank Drs T Machino and T Enami (University of Tsukuba) for discussion; Drs A Yokoyama (Kyoto University), H Nakauchi (University of Tokyo/Stanford University), and, M Onodera (National Research Institute for Child Health and Development) for vectors. We also thank T Takahashi for mouse experiments. We are also grateful to Kyowa Hakko Kirin Co., Ltd. for KRN383. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (25860778 to TK; 25461407 to MS-Y; and 25112703, 24390241, 23118503 and 22130002 to SC) and supported by the Sagawa Cancer Foundation, the Naito Foundation, the Kato Memorial Bioscience Foundation and the YASUDA Medical Foundation to MS-Y.	Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Kuchenbauer F, 2005, HAEMATOL-HEMATOL J, V90, P1617; Guiu J, 2013, J EXP MED, V210, P71, DOI 10.1084/jem.20120993; Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171; Kannan S, 2011, BLOOD, V117, P2891, DOI 10.1182/blood-2009-12-253419; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Lobry C, 2013, J EXP MED, V210, P301, DOI 10.1084/jem.20121484; Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699; Wendorff AA, 2010, IMMUNITY, V33, P671, DOI 10.1016/j.immuni.2010.11.014; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Samon JB, 2012, MOL CANCER THER, V11, P1565, DOI 10.1158/1535-7163.MCT-11-0938; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Paganin M, 2011, BLOOD REV, V25, P83, DOI 10.1016/j.blre.2010.09.004; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Sang LY, 2008, SCIENCE, V321, P1095, DOI 10.1126/science.1155998; Kridel R, 2012, BLOOD, V119, P1963, DOI 10.1182/blood-2011-11-391474; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ito T, 2003, ENDOCR PATHOL, V14, P133, DOI 10.1385/EP:14:2:133; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Kannan S, 2013, J EXP MED, V210, P321, DOI 10.1084/jem.20121527; Kindler T, 2010, BLOOD, V116, P5089, DOI 10.1182/blood-2010-04-261867; Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910; Ito T, 2000, DEVELOPMENT, V127, P3913; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Bigas A, 2012, BLOOD, V119, P3226, DOI 10.1182/blood-2011-10-355826; Ozeki K, 2004, BLOOD, V103, P1901, DOI 10.1182/blood-2003-06-1845; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Moriyama Y, 2008, INT IMMUNOL, V20, P763, DOI 10.1093/intimm/dxn034; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Kang HJ, 2010, J KOREAN MED SCI, V25, P841, DOI 10.3346/jkms.2010.25.6.841; Komeno Y, 2005, LEUKEMIA, V19, P930, DOI 10.1038/sj.leu.2403736; McLarren Keith W., 2001, Journal of Biological Chemistry, V276, P1578, DOI 10.1074/jbc.M007629200; Nakahara F, 2010, BLOOD, V115, P2872, DOI 10.1182/blood-2009-05-222836; Pigazzi M, 2011, LEUKEMIA, V25, P560, DOI 10.1038/leu.2010.316; Riccioni R, 2011, BRIT J HAEMATOL, V153, P33, DOI 10.1111/j.1365-2141.2011.08577.x; Suzuki T, 2005, INT J HEMATOL, V82, P285, DOI 10.1532/IJH97.05115; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793	49	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	MAR	2015	29	3					576	585		10.1038/leu.2014.281		10	Oncology; Hematology	Oncology; Hematology	CD0BE	WOS:000350734300007		
J	Sakashita, K; Kato, I; Daifu, T; Saida, S; Hiramatsu, H; Nishinaka, Y; Ebihara, Y; Ma, F; Matsuda, K; Saito, S; Hirabayashi, K; Kurata, T; Uyeni, LTN; Nakazawa, Y; Tsuji, K; Heike, T; Nakahata, T; Koike, K				Sakashita, K.; Kato, I.; Daifu, T.; Saida, S.; Hiramatsu, H.; Nishinaka, Y.; Ebihara, Y.; Ma, F.; Matsuda, K.; Saito, S.; Hirabayashi, K.; Kurata, T.; Uyeni, L. T. N.; Nakazawa, Y.; Tsuji, K.; Heike, T.; Nakahata, T.; Koike, K.			In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia	LEUKEMIA			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELLS; RAS MUTATIONS; SCID MICE; THROMBOPOIETIN; REPOPULATION; PATHOGENESIS; IMPROVEMENT; MOUSE; MODEL	Using serum-containing culture, we examined whether AGM-S3 stromal cells, alone or in combination with hematopoietic growth factor(s), stimulated the proliferation of CD34(+) cells from patients with juvenile myelomonocytic leukemia (JMML). AGM-S3 cells in concert with stem cell factor plus thrombopoietin increased the numbers of peripheral blood CD34(+) cells to approximately 20-fold of the input value after 2 weeks in nine JMML patients with either PTPN11 mutations or RAS mutations, who received allogeneic hematopoietic transplantation. Granulocyte-macrophage colony-stimulating factor (GM-CSF) also augmented the proliferation of JMML CD34(+) cells on AGM-S3 cells. The expansion potential of CD34(+) cells was markedly low in four patients who achieved spontaneous hematological improvement. A large proportion of day-14-cultured CD34(+) cells were negative for CD38 and cryopreservable. Cultured JMML CD34(+)CD38(-) cells expressed CD117, CD116, c-mpl, CD123, CD90, but not CXCR4, and formed GM and erythroid colonies. Day-7-cultured CD34(+) cells from two of three JMML patients injected intrafemorally into immunodeficient mice stimulated with human GM-CSF after transplantation displayed significant hematopoietic reconstitution. The abilities of OP9 cells and MS-5 cells were one-third and one-tenth, respectively, of the value obtained with AGM-S3 cells. Our culture system may provide a useful tool for elucidating leukemogenesis and for therapeutic approaches in JMML.	[Sakashita, K.; Saito, S.; Hirabayashi, K.; Kurata, T.; Uyeni, L. T. N.; Nakazawa, Y.; Koike, K.] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 3908621, Japan; [Kato, I.; Daifu, T.; Saida, S.; Hiramatsu, H.] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Nishinaka, Y.; Nakahata, T.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan; [Ebihara, Y.; Tsuji, K.] Univ Tokyo, Inst Med Sci, Dept Pediat Hematol Oncol, Res Hosp,Minato Ku, Tokyo, Japan; [Ebihara, Y.; Ma, F.; Tsuji, K.] Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Div Stem Cell Proc,Minato Ku, Tokyo, Japan; [Ma, F.] Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China; [Ma, F.] Peking Union Med Coll, Chengdu, Peoples R China; [Matsuda, K.] Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano, Japan; [Tsuji, K.] Shinshu Ueda Med Ctr, Dept Pediat, Natl Hosp Org, Ueda, Nagano, Japan	Koike, K (reprint author), Shinshu Univ, Sch Med, Dept Pediat, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	koikeken@shinshu-u.ac.jp			Ministry of Education of Japan [24390260, 22591154]; Preventive Medical Center of Shinshu University Hospital	This work was supported by Grants-in-Aid for Scientific Research (No. 24390260 and No. 22591154) from the Ministry of Education of Japan and grant from the Preventive Medical Center of Shinshu University Hospital.	Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Yoshida N, 2009, PEDIATR RES, V65, P334, DOI 10.1203/PDR.0b013e3181961d2a; Matsuda K, 2010, BRIT J HAEMATOL, V148, P593, DOI 10.1111/j.1365-2141.2009.07968.x; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Sakaguchi H, 2013, NAT GENET, V45, P937, DOI 10.1038/ng.2698; Loh ML, 2011, BRIT J HAEMATOL, V152, P677, DOI 10.1111/j.1365-2141.2010.08525.x; Matsuda K, 2007, BLOOD, V109, P5477, DOI 10.1182/blood-2006-09-046649; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; Koike K, 2008, BRIT J HAEMATOL, V141, P567, DOI 10.1111/j.1365-2141.2008.07104.x; Lapidot T, 2002, LEUKEMIA, V16, P1992, DOI 10.1038/sj.leu.2402684; Lapidot T, 1996, BLOOD, V88, P2655; Ma F, 2008, STEM CELLS, V26, P706, DOI 10.1634/stemcells.2007-0348; Matsuda K, 2012, BRIT J HAEMATOL, V157, P647, DOI 10.1111/j.1365-2141.2012.09063.x; Sakashita K, 2001, J CLIN INVEST, V108, P1195, DOI 10.1172/JCI13030; Sawai N, 1999, BLOOD, V93, P509; Sawai N, 1998, BLOOD, V91, P4065; Xu MJ, 1998, BLOOD, V92, P2032	17	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	MAR	2015	29	3					606	614		10.1038/leu.2014.239		9	Oncology; Hematology	Oncology; Hematology	CD0BE	WOS:000350734300010		
J	Wang, CQ; Chin, DWL; Chooi, JY; Chng, WJ; Taniuchi, I; Tergaonkar, V; Osato, M				Wang, C. Q.; Chin, D. W. L.; Chooi, J. Y.; Chng, W. J.; Taniuchi, I.; Tergaonkar, V.; Osato, M.			Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis	LEUKEMIA			English	Letter							ACUTE MYELOID-LEUKEMIA; RUNX1; REPRESSION; CBFB-MYH11; GENE		[Wang, C. Q.; Chin, D. W. L.; Chooi, J. Y.; Chng, W. J.; Osato, M.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Wang, C. Q.; Tergaonkar, V.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Taniuchi, I.] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Osato, M.] Inst Bioengn & Nanotechnol, Singapore, Singapore; [Osato, M.] Natl Univ Singapore, Dept Paediat, Singapore 117548, Singapore; [Osato, M.] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan	Wang, CQ (reprint author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.	vinayt@imcb.a-star.edu.sg; csimo@nus.edu.sg	Osato, Motomi/N-5056-2014; ASTAR, IMCB/E-2320-2012	Osato, Motomi/0000-0003-3982-9054; 			Wang CQ, 2013, BLOOD, V122, P562, DOI 10.1182/blood-2012-10-460618; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Hyde RK, 2010, BLOOD, V115, P1433, DOI 10.1182/blood-2009-06-227413; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Mrozek K, 2012, J CLIN ONCOL, V30, P4515, DOI 10.1200/JCO.2012.43.4738; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; de Pater E, 2013, J EXP MED, V210, P2843, DOI 10.1084/jem.20130751	15	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0887-6924	1476-5551		LEUKEMIA	Leukemia	MAR	2015	29	3					753	757		10.1038/leu.2014.316		6	Oncology; Hematology	Oncology; Hematology	CD0BE	WOS:000350734300030		
J	Fujiwara, T; Masaki, Y; Yamamoto, F				Fujiwara, Toshiya; Masaki, Yuka; Yamamoto, Fujio			Evaluation of spatial resolution and estimation error of seafloor displacement observation from vessel-based bathymetric survey by use of AUV-based bathymetric data	MARINE GEOPHYSICAL RESEARCH			English	Article						Repeated bathymetric survey; Seafloor displacement; Spatial resolution; Estimation error; Iheya-north knoll; AUV Urashima	TOHOKU-OKI EARTHQUAKE; TRENCH AXIS	A repeated bathymetric survey reveals seafloor displacement between before and after geodynamic events. We evaluated the less-known spatial resolution and estimation error of the seafloor displacement observation from a vessel-based multi-narrow beam bathymetric survey. In this evaluation, bathymetric data from vessel-based and near-seafloor high-resolution autonomous underwater vehicle (AUV)-based surveys in the same area were used. Simulated vessel-based bathymetric "before and after" data of the seafloor displacement were made using AUV-based bathymetric data. The displacement was verified by comparing these simulated data using the analysis conditions that no locational errors of beam sounding points exist, a footprint effect is uniform, depth accuracy is constant in the analysis area, and there are no depth offset between two data. As a result, we found that the smallest vertical seafloor displacement that can be detected occurs when the horizontal extent of the deformation is larger than several times the size of the footprint (area of the narrow sounding beam projected onto the seafloor) of the used vessel's multi-narrow beam echo sounder, and in the situation that the amplitude of the depth difference is greater than the accuracy of the vessel-based depth measurement (standard deviation of measuring error). When local slopes of the bathymetry are gentler than those of the artificial variation appeared in the depth differences between two data, the horizontal seafloor displacement seems to be difficult to resolve accurately. The local slope of the artificial depth variation is derived from the wavelength and the amplitude which are equivalent to similar to 1-3 times of the footprint size and the accuracy of the depth measurement, respectively.	[Fujiwara, Toshiya] Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Yokosuka, Kanagawa 2370061, Japan; [Masaki, Yuka] Japan Agcy Marine Earth Sci & Technol, Submarine Resources Res Project, Yokosuka, Kanagawa 2370061, Japan; [Yamamoto, Fujio] Japan Agcy Marine Earth Sci & Technol, Marine Technol & Engn Ctr, Yokosuka, Kanagawa 2370061, Japan	Fujiwara, T (reprint author), Japan Agcy Marine Earth Sci & Technol, Inst Res Earth Evolut, Natsushima Cho 2-15, Yokosuka, Kanagawa 2370061, Japan.	toshi@jamstec.go.jp			Kochi University	We thank the officers and crew of R/V Yokosuka and marine technicians of Nippon Marine Enterprises for their outstanding professionalism and dedication. We thank anonymous reviewers for their helpful comments in improving the manuscript. T. Fujiwara's contributions to this research were supported by the grant of Kochi University for the JAMSTEC/Kochi University joint program. The bathymetric data used in this paper are available at JAMSTEC home page (http://www.godac.jamstec.go.jp/darwin/e) or accessible at JAMSTEC Data Management Group (dmo@jamstec.go.jp).	Fujiwara T, 2011, SCIENCE, V334, P1240, DOI 10.1126/science.1211554; Kodaira S, 2012, NAT GEOSCI, V5, P646, DOI [10.1038/ngeo1547, 10.1038/NGEO1547]; Strasser M, 2013, GEOLOGY, V41, P935, DOI 10.1130/G34477.1; Arai K, 2013, GEOLOGY, V41, P1195, DOI 10.1130/G34777.1; FOX CG, 1992, J GEOPHYS RES-SOL EA, V97, P11149, DOI 10.1029/92JB00601; International Hydrographic Organization, 2005, MAN HYDR PUBL, P119; Lurton X, 2010, INTRO UNDERWATER ACO; Masaki Y., 2011, JAMSTEC REP RES DEV, V12, P1; Momma H., 1996, JAMSTEC J DEEP SEA R, V12, P195; Takai K, 2011, P INT OC DRILL PROGR, V331, DOI [10.2204/iodp.proc.331.2011, DOI 10.2204/IODP.PROC.331.2011]; Watts AB, 2012, NAT GEOSCI, V5, P510, DOI 10.1038/ngeo1473; Wessel P., 1995, EOS T AM GEOPHYS UN, V76, P329, DOI DOI 10.1029/95EO00198; Yamamoto F, 2009, 21 M JAP SOC MAR SUR	13	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0025-3235	1573-0581		MAR GEOPHYS RES	Mar. Geophys. Res.	MAR	2015	36	1					45	60		10.1007/s11001-014-9242-8		16	Geochemistry & Geophysics; Oceanography	Geochemistry & Geophysics; Oceanography	CC4YT	WOS:000350363500003		
J	Zhang, SG; Dokko, K; Watanabe, M				Zhang, Shiguo; Dokko, Kaoru; Watanabe, Masayoshi			Carbon materialization of ionic liquids: from solvents to materials	MATERIALS HORIZONS			English	Review							NITROGEN-DOPED CARBON; DEEP-EUTECTIC SOLVENTS; OXYGEN REDUCTION REACTION; HIGH ELECTROCATALYTIC ACTIVITY; HIERARCHICALLY POROUS CARBONS; METAL-FREE ELECTROCATALYSTS; ORDERED MESOPOROUS CARBONS; MEMBRANE FUEL-CELL; ONE-POT SYNTHESIS; LITHIUM-ION	Carbon materials have been extensively used in diverse areas, especially in energy-related applications. Traditionally, these materials have been synthesized by carbonization of low-vapor-pressure natural or synthetic polymers. However, the polymer-related procedures are multistep and time consuming because of the limited solubility and complicated synthesis of polymers. Recently, ionic liquids (ILs), composed of entirely cations and anions, have emerged as a new family of carbon precursors. The carbon-rich nature of ILs, coupled with their attractive properties such as diverse cation-anion combinations, low volatilities, and high thermal stabilities, not only greatly simplifies the entire carbonization process, but also gives rise to carbons with attractive features, which are distinct from those of carbons obtained using conventional polymer precursors, such as very high nitrogen contents and conductivities. In this review, we highlight recent approaches to the preparation of carbon materials using ILs as versatile precursors. We begin with a brief introduction to these novel precursors, discussing the key structures and properties of ILs that enable successful carbonization, and then address synthetic techniques for the fabrication of advanced porous carbons from ILs by either self-or external-template methods, followed by a review of the potential applications of ionic-liquid-derived carbons such as electrocatalysis, Li-ion batteries, supercapacitors, CO2 capture and chemical catalysis. The review concludes with an overview of possible directions for future research in this field.	[Zhang, Shiguo; Dokko, Kaoru; Watanabe, Masayoshi] Yokohama Natl Univ, Dept Chem & Biotechnol, Hodogaya Ku, Yokohama, Kanagawa 2408501, Japan	Watanabe, M (reprint author), Yokohama Natl Univ, Dept Chem & Biotechnol, Hodogaya Ku, 79-5 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	mwatanab@ynu.ac.jp	WATANABE, Masayoshi/M-4816-2014; Dokko, Kaoru/A-4005-2013; Zhang, Shiguo/G-1524-2015	WATANABE, Masayoshi/0000-0003-4092-6150; Dokko, Kaoru/0000-0002-9622-4345; 	Japan Science and Technology Agency (JST) - Advanced Low Carbon Technology Research and Development Program (ALCA) of Japan	This work was supported by the Japan Science and Technology Agency (JST) - Advanced Low Carbon Technology Research and Development Program (ALCA) of Japan.	Men YJ, 2013, J MATER CHEM A, V1, P11887, DOI 10.1039/c3ta12302b; Yan Y, 2012, CHEM COMMUN, V48, P10663, DOI 10.1039/c2cc36234a; Yuan JY, 2011, POLYMER, V52, P1469, DOI 10.1016/j.polymer.2011.01.043; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Hafner JH, 1998, CHEM PHYS LETT, V296, P195, DOI 10.1016/S0009-2614(98)01024-0; Fulvio PF, 2011, PHYS CHEM CHEM PHYS, V13, P13486, DOI 10.1039/c1cp20631a; Vishnyakov A, 1999, LANGMUIR, V15, P8736, DOI 10.1021/la990726c; Mysyk R, 2010, ELECTROCHEM COMMUN, V12, P414, DOI 10.1016/j.elecom.2010.01.007; Gong KP, 2009, SCIENCE, V323, P760, DOI 10.1126/science.1168049; Liu B, 2008, J AM CHEM SOC, V130, P5390, DOI 10.1021/ja7106146; Kaskhedikar NA, 2009, ADV MATER, V21, P2664, DOI 10.1002/adma.200901079; Zhang SG, 2014, J AM CHEM SOC, V136, P1690, DOI 10.1021/ja411981c; Zarbin AJG, 2002, CARBON, V40, P2413, DOI 10.1016/S0008-6223(02)00130-6; Fechler N, 2012, CHEM MATER, V24, P713, DOI 10.1021/cm203667g; Frackowiak E, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1906320; Safavi A, 2012, RSC ADV, V2, P7367; Qiu B, 2013, J MATER CHEM A, V1, P6373, DOI 10.1039/c3ta10774d; Wagle DV, 2014, ACCOUNTS CHEM RES, V47, P2299, DOI 10.1021/ar5000488; Chen LF, 2012, ACS NANO, V6, P7092, DOI 10.1021/nn302147s; Zhang J, 2008, SCIENCE, V322, P73, DOI 10.1126/science.1161916; Jun S, 2000, J AM CHEM SOC, V122, P10712, DOI 10.1021/ja002261e; Peppel T, 2010, ANGEW CHEM INT EDIT, V49, P7116, DOI 10.1002/anie.201000709; Torimoto T, 2010, ADV MATER, V22, P1196, DOI 10.1002/adma.200902184; Zhang XF, 2014, CHEMSUSCHEM, V7, P1710, DOI 10.1002/cssc.201301331; Qie L, 2012, ADV MATER, V24, P2047, DOI 10.1002/adma.201104634; Ma Y, 2012, J MATER CHEM, V22, P7845, DOI 10.1039/c2jm30422h; Su DS, 2013, CHEM REV, V113, P5782, DOI 10.1021/cr300367d; Ding ZJ, 2011, PHYS CHEM CHEM PHYS, V13, P15127, DOI 10.1039/c1cp21513b; Lu JM, 2009, PROG POLYM SCI, V34, P431, DOI 10.1016/j.progpolymsci.2008.12.001; Puziy AM, 2002, CARBON, V40, P1493, DOI 10.1016/S0008-6223(01)00317-7; Chen ZW, 2007, ANGEW CHEM INT EDIT, V46, P4060, DOI 10.1002/anie.200700894; Zhou Y, 2004, NANO LETT, V4, P477, DOI 10.1021/nl025861f; Abbott AP, 2007, CHEM-EUR J, V13, P6495, DOI 10.1002/chem.200601738; Ryu MH, 2013, J PHYS CHEM C, V117, P8092, DOI 10.1021/jp400757s; Kuhn P, 2008, J AM CHEM SOC, V130, P13333, DOI 10.1021/ja803708s; Song HW, 2014, NANO ENERGY, V4, P81, DOI 10.1016/j.nanoen.2013.12.017; Mallick B, 2008, ANGEW CHEM INT EDIT, V47, P7635, DOI 10.1002/anie.200802390; Wooster TJ, 2006, GREEN CHEM, V8, P691, DOI 10.1039/b606395k; Titirici MM, 2010, CHEM SOC REV, V39, P103, DOI 10.1039/b819318p; Paraknowitsch JP, 2010, J MATER CHEM, V20, P6746, DOI 10.1039/c0jm00869a; Yu KMK, 2008, CHEMSUSCHEM, V1, P893, DOI 10.1002/cssc.200800169; MacFarlane DR, 2014, ENERG ENVIRON SCI, V7, P232, DOI 10.1039/c3ee42099j; Zhu X, 2013, ADV MATER, V25, P4152, DOI 10.1002/adma.201300793; Fechler N, 2013, ADV MATER, V25, P75, DOI 10.1002/adma.201203422; Karimi B, 2014, CHEMCATCHEM, V6, P745, DOI 10.1002/cctc.201300893; Ryoo R, 2001, ADV MATER, V13, P677, DOI 10.1002/1521-4095(200105)13:9<677::AID-ADMA677>3.0.CO;2-C; Gutierrez MC, 2011, ENERG ENVIRON SCI, V4, P3535, DOI 10.1039/c1ee01463c; Lee JS, 2009, J AM CHEM SOC, V131, P4596, DOI 10.1021/ja900686d; Jariwala D, 2013, CHEM SOC REV, V42, P2824, DOI 10.1039/c2cs35335k; Bo XJ, 2011, J POWER SOURCES, V196, P8360, DOI 10.1016/j.jpowsour.2011.06.068; Hao GP, 2011, J AM CHEM SOC, V133, P11378, DOI 10.1021/ja203857g; Stein A, 2014, CHEM MATER, V26, P259, DOI 10.1021/cm402184h; Wang Y, 2010, ANGEW CHEM INT EDIT, V49, P3356, DOI 10.1002/anie.201000120; Lee JS, 2010, ADV MATER, V22, P1004, DOI 10.1002/adma.200903403; Yoon S, 2012, J MATER CHEM, V22, P4611, DOI 10.1039/c2jm15325d; Green O, 2009, POLYM REV, V49, P339, DOI 10.1080/15583720903291116; Li Z, 2013, ACS CATAL, V3, P839, DOI 10.1021/cs400077r; Shao YY, 2008, APPL CATAL B-ENVIRON, V79, P89, DOI 10.1016/j.apcatb.2007.09.047; Hallett JP, 2011, CHEM REV, V111, P3508, DOI 10.1021/cr1003248; Zhang QH, 2012, CHEM SOC REV, V41, P7108, DOI 10.1039/c2cs35178a; Carriazo D, 2012, CHEM SOC REV, V41, P4996, DOI 10.1039/c2cs15353j; Wang YJ, 2011, CHEM REV, V111, P7625, DOI 10.1021/cr100060r; Lee SY, 2010, J AM CHEM SOC, V132, P9764, DOI 10.1021/ja102367x; Smiglak M, 2007, ACCOUNTS CHEM RES, V40, P1182, DOI 10.1021/ar7001304; Paraknowitsch JP, 2013, CHEM COMMUN, V49, P1208, DOI 10.1039/c2cc37398j; Balach J, 2013, RSC ADV, V3, P7979, DOI 10.1039/c3ra41229f; Chen AB, 2013, J MATER CHEM A, V1, P1045, DOI 10.1039/c2ta01013e; Kyotani T, 2000, CARBON, V38, P269, DOI 10.1016/S0008-6223(99)00142-6; Im J, 2012, CHEM COMMUN, V48, P2015, DOI 10.1039/c2cc16367e; Lim KH, 2014, APPL CATAL B-ENVIRON, V158, P355, DOI 10.1016/j.apcatb.2014.04.038; Fechler N, 2013, J MATER CHEM A, V1, P14097, DOI 10.1039/c3ta13435k; Chandra V, 2012, CHEM COMMUN, V48, P735, DOI 10.1039/c1cc15599g; Fellinger TP, 2012, J AM CHEM SOC, V134, P4072, DOI 10.1021/ja300038p; Zhang ZY, 2014, CHEM COMMUN, V50, P1469, DOI 10.1039/c3cc48942f; Forsyth SA, 2004, AUST J CHEM, V57, P121, DOI 10.1071/CH03245; Fellinger TP, 2012, J MATER CHEM, V22, P23996, DOI 10.1039/c2jm34486f; Zhao Q, 2013, J MATER CHEM A, V1, P5113, DOI 10.1039/c3ta10291b; Guo BK, 2013, ADV ENERGY MATER, V3, P708, DOI 10.1002/aenm.201200925; Cui ZT, 2014, J POWER SOURCES, V259, P138, DOI 10.1016/j.jpowsour.2014.02.084; Paraknowitsch JP, 2012, CHEM-EUR J, V18, P15416, DOI 10.1002/chem.201202445; Abbott AP, 2003, CHEM COMMUN, P70, DOI 10.1039/b210714g; Palkovits R, 2009, ANGEW CHEM INT EDIT, V48, P6909, DOI 10.1002/anie.200902009; Fellinger TP, 2013, ADV MATER, V25, P5838, DOI 10.1002/adma.201301975; Zhang PF, 2013, ANGEW CHEM INT EDIT, V52, P6028, DOI 10.1002/anie.201301069; Wang XQ, 2010, ANGEW CHEM INT EDIT, V49, P6664, DOI 10.1002/anie.201003163; Chen SM, 2007, J AM CHEM SOC, V129, P2416, DOI 10.1021/ja067972c; Gogotsi Y, 2003, NAT MATER, V2, P591, DOI 10.1038/nmat957; Aijaz A, 2014, CHEM COMMUN, V50, P6498, DOI 10.1039/c4cc02459a; Antonietti M, 2004, ANGEW CHEM INT EDIT, V43, P4988, DOI 10.1002/anie.200460091; Sahraie NR, 2014, J AM CHEM SOC, V136, P14486, DOI 10.1021/ja506553r; Nakashima T, 2003, J AM CHEM SOC, V125, P6386, DOI 10.1021/ja034954b; Xu X, 2012, J AM CHEM SOC, V134, P16987, DOI 10.1021/ja308139s; Yuan JY, 2011, J AM CHEM SOC, V133, P17556, DOI 10.1021/ja207080j; Kuhn P, 2008, ANGEW CHEM INT EDIT, V47, P3450, DOI 10.1002/anie.200705710; Gobel R, 2012, CRYSTENGCOMM, V14, P4946, DOI 10.1039/c2ce25064k; Wu BH, 2012, J MATER CHEM, V22, P13085, DOI 10.1039/c2jm30547j; CazorlaAmoros D, 1996, LANGMUIR, V12, P2820, DOI 10.1021/la960022s; Yuan JY, 2010, CHEM MATER, V22, P5003, DOI 10.1021/cm1012729; Bing YH, 2010, CHEM SOC REV, V39, P2184, DOI 10.1039/b912552c; Liu XF, 2013, CHEM SOC REV, V42, P8237, DOI 10.1039/c3cs60159e; Fechler N, 2014, RSC ADV, V4, P26981, DOI 10.1039/c4ra03461a; Soll S, 2013, SMALL, V9, P4135, DOI 10.1002/smll.201300680; Zhang PF, 2013, RSC ADV, V3, P1890, DOI 10.1039/c2ra22559j; D'Alessandro DM, 2010, ANGEW CHEM INT EDIT, V49, P6058, DOI 10.1002/anie.201000431; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i; Wiggins-Camacho JD, 2009, J PHYS CHEM C, V113, P19082, DOI 10.1021/jp907160v; Xing HB, 2014, ANGEW CHEM INT EDIT, V53, P2099, DOI 10.1002/anie.201309539; Zhang SG, 2014, CHEM MATER, V26, P2915, DOI 10.1021/cm5006168; Paraknowitsch JP, 2012, MACROMOL CHEM PHYS, V213, P1132, DOI 10.1002/macp.201100573; Yuan JY, 2011, MACROMOLECULES, V44, P744, DOI 10.1021/ma102858b; Liu C, 2013, MATER LETT, V108, P285, DOI 10.1016/j.matlet.2013.07.022; Yang SB, 2010, ADV MATER, V22, P838, DOI 10.1002/adma.200902795; Jin ZY, 2014, ADV MATER, V26, P3700, DOI 10.1002/adma.201306273; Zhai YP, 2008, J POROUS MAT, V15, P601, DOI 10.1007/s10934-007-9139-x; Liang CD, 2008, ANGEW CHEM INT EDIT, V47, P3696, DOI 10.1002/anie.200702046; Zhao AD, 2014, ANAL CHIM ACTA, V809, P128, DOI 10.1016/j.aca.2013.10.046; Liang HW, 2013, J AM CHEM SOC, V135, P16002, DOI 10.1021/ja407552k; Ding W, 2013, ANGEW CHEM INT EDIT, V52, P11755, DOI 10.1002/anie.201303924; Carriazo D, 2010, CHEM MATER, V22, P6146, DOI 10.1021/cm1019684; Fulvio PF, 2013, J MATER CHEM A, V1, P59, DOI 10.1039/c2ta00634k; Zhou Y, 2003, J AM CHEM SOC, V125, P14960, DOI 10.1021/ja0380998; Boydston AJ, 2007, J AM CHEM SOC, V129, P14550, DOI 10.1021/ja075963d; Xiao DL, 2013, J LUMIN, V140, P120, DOI 10.1016/j.jlumin.2013.02.032; Kruk M, 2001, CHEM MATER, V13, P3169, DOI 10.1021/cm0101069; Xing W, 2012, ENERG ENVIRON SCI, V5, P7323, DOI 10.1039/c2ee21653a; Hao GP, 2010, ADV MATER, V22, P853, DOI 10.1002/adma.200903765; Zhang LL, 2009, CHEM SOC REV, V38, P2520, DOI 10.1039/b813846j; Schneider S, 2008, ENERG FUEL, V22, P2871, DOI 10.1021/ef800286b; Choi H, 2011, J AM CHEM SOC, V133, P2084, DOI 10.1021/ja1101807; Yuan JY, 2011, EUR POLYM J, V47, P772, DOI 10.1016/j.eurpolymj.2010.09.030; Miran MS, 2012, PHYS CHEM CHEM PHYS, V14, P5178, DOI 10.1039/c2cp00007e; Zhu X, 2012, CHEMSUSCHEM, V5, P1912, DOI 10.1002/cssc.201200355; Han CL, 2014, J MATER CHEM A, V2, P605, DOI 10.1039/c3ta13757k; Wang G, 2013, ELECTROCHEM COMMUN, V31, P31, DOI 10.1016/j.elecom.2013.02.022; Liang J, 2012, ANGEW CHEM INT EDIT, V51, P11496, DOI 10.1002/anie.201206720; Zhao L, 2011, ADV MATER, V23, P1385, DOI 10.1002/adma.201003294; Pan CT, 2012, J MATER CHEM, V22, P13578, DOI 10.1039/c2jm31973j; Lu AH, 2004, CHEM MATER, V16, P100, DOI 10.1021/cm031095h; Gutierrez MC, 2010, CHEM MATER, V22, P2711, DOI 10.1021/cm9023502; Xie ZL, 2011, J MATER CHEM, V21, P7434, DOI 10.1039/c1jm00013f; Karimi B, 2012, CHEM-EUR J, V18, P8634, DOI 10.1002/chem.201200373; Ma Z, 2010, ADV MATER, V22, P261, DOI 10.1002/adma.200900603; Nandi M, 2012, CHEM COMMUN, V48, P10283, DOI 10.1039/c2cc35334b; Liu XF, 2014, CARBON, V69, P460, DOI 10.1016/j.carbon.2013.12.049; Paraknowitsch JP, 2010, ADV MATER, V22, P87, DOI 10.1002/adma.200900965; Lee JS, 2010, CARBON, V48, P3364, DOI 10.1016/j.carbon.2010.05.027; Yang W, 2011, J AM CHEM SOC, V133, P206, DOI 10.1021/ja108039j; Zhao L, 2010, ADV MATER, V22, P5202, DOI 10.1002/adma.201002647; Kuzmicz D, 2014, POLYMER, V55, P3423, DOI 10.1016/j.polymer.2014.04.032; Zhou F, 2009, CHEM SOC REV, V38, P2590, DOI 10.1039/b817899m; Guo DC, 2013, ENERG ENVIRON SCI, V6, P652, DOI 10.1039/c2ee23127a; Yuan JY, 2011, POLYM CHEM-UK, V2, P1654, DOI 10.1039/c1py00196e; Czerw R, 2001, NANO LETT, V1, P457, DOI 10.1021/nl015549q; Yuan JY, 2013, PROG POLYM SCI, V38, P1009, DOI 10.1016/j.progpolymsci.2013.04.002; Ma TY, 2013, CHEM SOC REV, V42, P3977, DOI 10.1039/c2cs35301f; Sevilla M, 2011, ADV FUNCT MATER, V21, P2781, DOI 10.1002/adfm.201100291; Arico AS, 2005, NAT MATER, V4, P366, DOI 10.1038/nmat1368; Cao J, 2014, MATER CHEM PHYS, V144, P17, DOI 10.1016/j.matchemphys.2013.12.001; Karimi B, 2012, CHEM COMMUN, V48, P2776, DOI 10.1039/c2cc16727a; Lu AH, 2013, ANNU REP PROG CHEM A, V109, P484, DOI 10.1039/c3ic90003g; Jian KQ, 2003, ADV MATER, V15, P164, DOI 10.1002/adma.200390036; Arrays N.-D. O. M. G., 2010, ANGEW CHEM INT EDIT, V49, P2565; Byun H, 2012, CARBON LETT, V13, P94, DOI 10.5714/CL.2012.13.2.094; Carriazo D, 2012, CHEMSUSCHEM, V5, P1405, DOI 10.1002/cssc.201200136; Carriazo D, 2013, PART PART SYST CHAR, V30, P316, DOI 10.1002/ppsc.201200157; Cui XJ, 2012, CHEMCATCHEM, V4, P333, DOI 10.1002/cctc.201100410; Dommele S., 2006, CHEM COMMUN, P4859; DucaTruong Q., 2013, J MATER CHEM C, V1, P1713; Elumeeva K, 2014, MATER HORIZONS, V1, P588, DOI 10.1039/c4mh00123k; Fulvio PF, 2013, CHEM COMMUN, V49, P7289, DOI 10.1039/c3cc44175j; Gutierrez MC, 2011, CHEM-EUR J, V17, P10533, DOI 10.1002/chem.201101679; Hulicova-Jurcakova D, 2009, J AM CHEM SOC, V131, P5026, DOI 10.1021/ja809265m; Irran E, 2001, CHEM-EUR J, V7, P5372, DOI 10.1002/1521-3765(20011217)7:24<5372::AID-CHEM5372>3.0.CO;2-#; Jeon JH, 2014, J MATER CHEM A, V2, P624, DOI 10.1039/c3ta14039c; Kan-Nari N, 2010, ADV SYNTH CATAL, V352, P1476, DOI 10.1002/adsc.201000029; Kazemi S. H., 2014, J SOLID STATE ELECTR, P1; Leadbeater NE, 2002, J ORG CHEM, V67, P3145, DOI 10.1021/jo016297g; Lee JS, 2009, CHEM MATER, V21, P4756, DOI 10.1021/cm902522b; Lopez-Salas N, 2014, J MATER CHEM A, V2, P17387, DOI 10.1039/c4ta03266g; Mahurin SM, 2014, CHEMSUSCHEM, V7, P3284, DOI 10.1002/cssc.201402338; MARTINMARTINEZ JM, 1995, FUEL, V74, P111, DOI 10.1016/0016-2361(94)P4340-8; Meng Y., 2005, ANGEW CHEM, V117, P7215, DOI DOI 10.1002/ANGE.200501561; Ni YM, 2014, ACS APPL MATER INTER, V6, P7346, DOI 10.1021/am500737w; Hasche F, 2012, CHEMCATCHEM, V4, P479, DOI 10.1002/cctc.201100408; Paraknowitsch JP, 2011, J MATER CHEM, V21, P15537, DOI 10.1039/c1jm11633a; Parnham ER, 2006, ANGEW CHEM, V118, P5084, DOI 10.1002/ange.200600290; Patino J, 2014, J MATER CHEM A, V2, P8719, DOI 10.1039/c4ta00562g; Patino J, 2012, ENERG ENVIRON SCI, V5, P8699, DOI 10.1039/c2ee22029f; Peng YJ, 2013, J MATER CHEM A, V1, P9257, DOI 10.1039/c3ta11676j; PeteraParaknowitsch J., 2012, PHYS CHEM CHEM PHYS, V14, P6444; Puziy AM, 2002, CARBON, V40, P1507, DOI 10.1016/S0008-6223(01)00318-9; Puziy AM, 2003, CARBON, V41, P1181, DOI 10.1016/S0008-6223(03)00031-9; Tabata S, 2008, J ELECTROCHEM SOC, V155, pK42, DOI 10.1149/1.2826266; Xu X., 2014, CHEMCATCHEM, DOI [10.1002/cctc.201402561R1, DOI 10.1002/CCTC.201402561R1]; Yang HM, 2012, J MATER CHEM, V22, P21852, DOI 10.1039/c2jm35258c; Yao YY, 2013, CARBON, V58, P249, DOI 10.1016/j.carbon.2013.02.060; Zhang DS, 2011, MICROPOR MESOPOR MAT, V141, P110, DOI 10.1016/j.micromeso.2010.10.045; Zhao Q, 2012, MACROMOL RAPID COMM, V33, P1149, DOI 10.1002/marc.201200020; Zheng F, 2012, MATER LETT, V68, P453, DOI 10.1016/j.matlet.2011.11.035; Zhou M, 2012, INT J ELECTROCHEM SC, V7, P9984	200	12	12	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2051-6347	2051-6355		MATER HORIZ	Mater. Horizons	MAR 1	2015	2	2					168	197		10.1039/c4mh00141a		30	Chemistry, Multidisciplinary; Materials Science, Multidisciplinary	Chemistry; Materials Science	CC9CF	WOS:000350664500003		
J	Tsukihara, M; Noto, Y; Sasamoto, R; Hayakawa, T; Saito, M				Tsukihara, Masayoshi; Noto, Yoshiyuki; Sasamoto, Ryuta; Hayakawa, Takahide; Saito, Masatoshi			Initial implementation of the conversion from the energy-subtracted CT number to electron density in tissue inhomogeneity corrections: An anthropomorphic phantom study of radiotherapy treatment planning	MEDICAL PHYSICS			English	Article						dual-energy CT; electron density; CT number; radiotherapy treatment planning; inhomogeneity correction	SINGLE LINEAR RELATIONSHIP; DUAL-SOURCE CT; X-RAY CT; EXPERIMENTAL-VERIFICATION; COMPUTERIZED-TOMOGRAPHY; DOSE DISTRIBUTIONS; RADIATION-THERAPY; CALIBRATION; ACCURACY; SCANNER	Purpose: To achieve accurate tissue inhomogeneity corrections in radiotherapy treatment planning, the authors had previously proposed a novel conversion of the energy-subtracted computed tomography (CT) number to an electron density (Delta HU-rho(e) conversion), which provides a single linear relationship between Delta HU and rho(e) over a wide range of rho(e). The purpose of this study is to present an initial implementation of the Delta HU-rho(e) conversion method for a treatment planning system (TPS). In this paper, two example radiotherapy plans are used to evaluate the reliability of dose calculations in the Delta HU-rho(e) conversion method. Methods: CT images were acquired using a clinical dual-source CT (DSCT) scanner operated in the dual-energy mode with two tube potential pairs and an additional tin (Sn) filter for the high-kV tube (80-140 kV/Sn and 100-140 kV/Sn). Single-energy CT using the same DSCT scanner was also performed at 120 kV to compare the Delta HU-rho(e) conversion method with a conventional conversion from a CT number to rho(e) (Hounsfield units, HU-rho(e) conversion). Lookup tables for.e calibration were obtained from the CT image acquisitions for tissue substitutes in an electron density phantom (EDP). To investigate the beam-hardening effect on dosimetric uncertainties, two EDPs with different sizes (a body EDP and a head EDP) were used for the rho(e) calibration. Each acquired lookup table was applied to two radiotherapy plans designed using the XiO TPS with the superposition algorithm for an anthropomorphic phantom. The first radiotherapy plan was for an oral cavity tumor and the second was for a lung tumor. Results: In both treatment plans, the performance of the Delta HU-rho(e) conversion was superior to that of the conventional HU-rho(e) conversion in terms of the reliability of dose calculations. Especially, for the oral tumor plan, which dealt with dentition and bony structures, treatment planning with the HU-rho(e) conversion exhibited apparent discrepancies between the dose distributions and dose-volume histograms (DVHs) of the body-EDP and head-EDP calibrations. In contrast, the dose distributions and DVHs of the body-EDP and head-EDP calibrations coincided with each other almost perfectly in the Delta HU-rho(e) conversion for 100-140 kV/Sn. The difference between the V100' s (the mean planning target volume receiving 100% of the prescribed dose; a DVH parameter) of the body-EDP and head-EDP calibrations could be reduced to less than 1% using the H Delta U-rho(e) conversion, but exceeded 11% for the HU-rho(e) conversion. Conclusions: The Delta HU-rho(e) conversion can be implemented for currently available TPS's without any modifications or extensions. The Delta HU-rho(e) conversion appears to be a promising method for providing an accurate and reliable inhomogeneity correction in treatment planning for any ill-conditioned scans that include (i) the use of a calibration EDP that is nonequivalent to the patient's body tissues, (ii) a mismatch between the size of the patient and the calibration EDP, or (iii) a large quantity of high-density and high-atomic-number tissue structures. (C) 2015 American Association of Physicists in Medicine.	[Tsukihara, Masayoshi] Niigata Univ, Grad Sch Hlth Sci, Div Radiol Technol, Niigata 9518518, Japan; [Noto, Yoshiyuki] Niigata Univ, Med & Dent Hosp, Dept Radiol, Niigata 9518520, Japan; [Sasamoto, Ryuta; Hayakawa, Takahide; Saito, Masatoshi] Niigata Univ, Fac Med, Sch Hlth Sci, Dept Radiol Technol, Niigata 9518518, Japan	Saito, M (reprint author), Niigata Univ, Fac Med, Sch Hlth Sci, Dept Radiol Technol, Niigata 9518518, Japan.	masaito@clg.niigata-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [25461908]	This work was partially supported by a Grant-in-Aid for Scientific Research (C) (25461908) from the Japan Society for the Promotion of Science (JSPS).	Hunemohr N, 2014, PHYS MED BIOL, V59, P83, DOI 10.1088/0031-9155/59/1/83; Schneider U, 1996, PHYS MED BIOL, V41, P111, DOI 10.1088/0031-9155/41/1/009; Landry G, 2011, RADIOTHER ONCOL, V100, P375, DOI 10.1016/j.radonc.2011.08.029; Schneider W, 2000, PHYS MED BIOL, V45, P459, DOI 10.1088/0031-9155/45/2/314; Kilby W, 2002, PHYS MED BIOL, V47, P1485, DOI 10.1088/0031-9155/47/9/304; Seco J, 2006, MED PHYS, V33, P540, DOI 10.1118/1.2161407; Saito M, 2012, MED PHYS, V39, P2021, DOI 10.1118/1.3694111; CONSTANTINOU C, 1992, MED PHYS, V19, P325, DOI 10.1118/1.596862; PARKER RP, 1979, PHYS MED BIOL, V24, P802, DOI 10.1088/0031-9155/24/4/011; ALVAREZ RE, 1976, PHYS MED BIOL, V21, P733, DOI 10.1088/0031-9155/21/5/002; Primak AN, 2009, MED PHYS, V36, P1359, DOI 10.1118/1.3083567; Bazalova M, 2008, PHYS MED BIOL, V53, P2439, DOI 10.1088/0031-9155/53/9/015; du Plessis FCP, 1998, MED PHYS, V25, P1195, DOI 10.1118/1.598297; Hatton J, 2009, PHYS MED BIOL, V54, pN329, DOI 10.1088/0031-9155/54/15/N01; Landry G, 2013, PHYS MED BIOL, V58, DOI 10.1088/0031-9155/58/15/5029; MCCULLOUGH EC, 1985, MED PHYS, V12, P237, DOI 10.1118/1.595713; Saito M, 2014, MED PHYS, V41, DOI 10.1118/1.4881327; Torikoshi M, 2003, PHYS MED BIOL, V48, P673, DOI 10.1088/0031-9155/48/5/308; Tsukihara M, 2013, PHYS MED BIOL, V58, pN135, DOI 10.1088/0031-9155/58/9/N135; Tsunoo T, 2008, MED PHYS, V35, P4924, DOI 10.1118/1.2987738; Verhaegen F, 2005, PHYS MED BIOL, V50, P937, DOI 10.1088/0031-9155/505/5/016	21	1	1	AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS	MELVILLE	STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA	0094-2405			MED PHYS	Med. Phys.	MAR	2015	42	3					1378	1388		10.1118/1.4908207		11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CC9BC	WOS:000350661500023		
J	Sonohara, F; Nomoto, S; Inokawa, Y; Kanda, M; Yamada, S; Fujii, T; Sugimoto, H; Kodera, Y				Sonohara, Fuminori; Nomoto, Shuji; Inokawa, Yoshikuni; Kanda, Mitsuro; Yamada, Suguru; Fujii, Tsutomu; Sugimoto, Hiroyuki; Kodera, Yasuhiro			Serosal Invasion Strongly Associated With Recurrence After Curative Hepatic Resection of Hepatocellular Carcinoma A Retrospective Study of 214 Consecutive Cases	MEDICINE			English	Article							INTRAHEPATIC RECURRENCE; PROGNOSTIC-FACTORS; RISK-FACTORS; LIVER; SURVIVAL; CLASSIFICATION; CANCER; PERSPECTIVES; HEPATECTOMY; UNIVARIATE	The purpose of this study was to clarify the individual prognostic factors after curative and primary resection of hepatocellular carcinoma (HCC). Reliable prognostic factors and tumor staging for HCC have been required to predict an appropriate prognosis. However, in BCC, no staging system has received universal acceptance, and several tumor factors seem to relate to HCC prognosis, but they are not definitive. At present, few studies have mentioned the importance of scrotal invasion as a prognostic factor. A retrospective search of our database identified 214 consecutive patients who underwent primary and curative hepatectomy for HCC at our department between January 1998 and December 2011. Risk factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed with Cox proportional hazard model, Kaplan-Meier method, and log-rank tests. Multivariate analyses showed that serosal invasion (hazard ratio [FIR], 2.75; P = 0.0005) and vascular invasion (HR, 1.71; P = 0.0331) were independently correlated with RFS. Scrotal invasion was significantly correlated with HCC recurrence (P = 0.0230). The Kaplan Meier method and log-rank tests revealed that the patients with serosal invasion showed significantly worse prognosis both in RFS (P <0.0001) and OS (P = 0.0016). Serosal invasion should be regarded as a strong independent predictor for recurrence in curatively resected HCC cases.	[Sonohara, Fuminori; Nomoto, Shuji; Inokawa, Yoshikuni; Kanda, Mitsuro; Yamada, Suguru; Fujii, Tsutomu; Sugimoto, Hiroyuki; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Surg Gastroenterol, Nagoya, Aichi 4648601, Japan; [Sonohara, Fuminori; Nomoto, Shuji; Inokawa, Yoshikuni] Aichi Gakuin Univ, Sch Dent, Dept Surg, Nagoya, Aichi 4648651, Japan	Nomoto, S (reprint author), Aichi Gakuin Univ, Sch Dent, Dept Surg, Chikusa Ku, 2-11 Suemori Dori, Nagoya, Aichi 4648651, Japan.	snomoto@dpc.agu.ac.jp					Leung TWT, 2002, CANCER, V94, P1760, DOI 10.1002/cncr.10384; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; TRUTMANN M, 1994, ANAT EMBRYOL, V190, P201; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; ADACHI E, 1995, GASTROENTEROLOGY, V108, P768, DOI 10.1016/0016-5085(95)90450-6; Taura K, 2006, ANN SURG, V244, P265, DOI 10.1097/01.sla.0000217921.28563.55; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1; IKEDA K, 1993, CANCER, V71, P19, DOI 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I; Adachi E, 1996, CANCER, V77, P2022, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2022::AID-CNCR9>3.0.CO;2-S; Rahbari NN, 2011, ANN SURG, V253, P453, DOI 10.1097/SLA.0b013e31820d944f; IZUMI R, 1994, GASTROENTEROLOGY, V106, P720; Hanazaki K, 2001, AM J GASTROENTEROL, V96, P1243; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Belghiti J, 2001, J AM COLL SURGEONS, V193, P109, DOI 10.1016/S1072-7515(01)00909-7; Ohtani O, 2008, ANAT REC, V291, P643, DOI 10.1002/ar.20681; KOSUGE T, 1993, HEPATO-GASTROENTEROL, V40, P328; Chen MS, 2006, ANN SURG, V243, P321, DOI 10.1097/01.sla.0000201480.65519.b8; Nzeako UC, 1996, AM J CLIN PATHOL, V105, P65; Burt AD, 2011, MACSWEENS PATHOLOGY; Manghisi G, 1998, HEPATOLOGY, V28, P751; ElAssal ON, 1997, SURGERY, V122, P571, DOI 10.1016/S0039-6060(97)90130-6; Faria SC, 2014, ABDOM IMAGING, V39, P1070, DOI 10.1007/s00261-014-0130-0; Ha TY, 2014, TRANSPL P, V46, P774, DOI 10.1016/j.transproceed.2013.10.053; Japan lcsgo, 2010, GEN RULES CLIN PATHO; Kobayashi A, 2006, HEPATO-GASTROENTEROL, V53, P736; NAGASUE N, 1993, GASTROENTEROLOGY, V105, P488; NG IOL, 1992, CANCER, V70, P45, DOI 10.1002/1097-0142(19920701)70:1<45::AID-CNCR2820700108>3.0.CO;2-7; Shirabe K, 1995, HEPATO-GASTROENTEROL, V42, P923; SZABO G, 1975, RES EXP MED, V166, P193, DOI 10.1007/BF01851185; Takasaki K, 1998, J Hepatobiliary Pancreat Surg, V5, P286, DOI 10.1007/s005340050047; Uenishi T, 2005, J HEPATO-BILIARY-PAN, V12, P479, DOI 10.1007/s00534-005-1026-8; VAUTHEY JN, 1995, AM J SURG, V169, P28, DOI 10.1016/S0002-9610(99)80106-8; Yamamoto J, 1996, BRIT J SURG, V83, P1219; Young B, 2013, WHEATERS FUNCTIONAL	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAR	2015	94	9								10.1097/MD.0000000000000602		6	Medicine, General & Internal	General & Internal Medicine	CD0JD	WOS:000350756800016		
J	Takeuchi, T; Miyasaka, N; Kawai, S; Sugiyama, N; Yuasa, H; Yamashita, N; Sugiyama, N; Wagerle, LC; Vlahos, B; Wajdulas, J				Takeuchi, Tsutomu; Miyasaka, Nobuyuki; Kawai, Shinichi; Sugiyama, Naonobu; Yuasa, Hirotoshi; Yamashita, Noriaki; Sugiyama, Noriko; Wagerle, Lorin Craig; Vlahos, Bonnie; Wajdulas, Joseph			Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials	MODERN RHEUMATOLOGY			English	Review						Clinical trial; Etanercept; Monotherapy; Review; Rheumatoid arthritis	MODIFYING ANTIRHEUMATIC DRUGS; HEALTH-ASSESSMENT QUESTIONNAIRE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; POSTMARKETING SURVEILLANCE; RADIOGRAPHIC OUTCOMES; RISK-FACTORS; METHOTREXATE; DISEASE; COMBINATION	Conventional synthetic disease-modifying anti-rheumatic drugs, including methotrexate, may not be tolerated by all patients with rheumatoid arthritis (RA), and limited international data for etanercept (ETN) monotherapy are available. The aim of this review was to summarize the clinical program for ETN monotherapy in Japanese patients with RA, which has included a pharmacokinetic study, clinical trials for registration, long-term studies, and once-weekly dosing studies. Pharmacokinetic results showed that serum concentrations of ETN were linear with dose levels and were similar to other international studies. Across interventional studies, 652 Japanese patients with active RA were treated with ETN. In the registration studies, ETN treatment led to consistent improvement in American College of Rheumatology 20/50/70 scores, European League Against Rheumatism Good Response, Disease Activity Score 28 erythrocyte sedimentation rate remission, and Health Assessment Questionnaire disability index. In the long-term studies, efficacy was maintained for up to 180 weeks. Similar results were seen in the once-weekly studies. Across the studies, more than 870 patient-years of exposure to ETN were recorded. Discontinuations owing to lack of efficacy or adverse events were modest and no new safety signals were recorded. These studies demonstrated that ETN monotherapy is efficacious and well-tolerated in Japanese patients with RA.	[Takeuchi, Tsutomu] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo 1608582, Japan; [Miyasaka, Nobuyuki] Tokyo Med & Dent Univ, Tokyo, Japan; [Kawai, Shinichi] Toho Univ, Sch Med, Dept Internal Med, Div Rheumatol, Tokyo, Japan; [Sugiyama, Naonobu; Yuasa, Hirotoshi; Yamashita, Noriaki; Sugiyama, Noriko] Pfizer Japan Inc, Tokyo 1518589, Japan; [Wagerle, Lorin Craig; Vlahos, Bonnie; Wajdulas, Joseph] Pfizer Inc, Collegeville, PA USA	Takeuchi, T (reprint author), Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol,Shinju Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	tsutake@z5.keio.jp; naonobu.sugiyama@pfizer.com	Takeuchi, Tsutomu/L-2327-2013	Takeuchi, Tsutomu/0000-0003-1111-8218	Wyeth; Pfizer Inc.	The studies described herein were designed and funded by Wyeth which was acquired by Pfizer Inc in October 2009. The authors would like to thank the investigators and participants in these studies. Medical writing was provided by Patricia McChesney, PhD, CMPP, and Samantha Forester, PhD, CMPP, of the Engage Scientific Solutions (part of the Envision Pharma Group) and was funded by Pfizer Inc.	Kameda H, 2011, INTERNAL MED, V50, P305, DOI 10.2169/internalmedicine.50.4508; Takeuchi T, 2008, ANN RHEUM DIS, V67, P189, DOI 10.1136/ard.2007.072967; Takeuchi T, 2010, NAT REV RHEUMATOL, V6, P644, DOI 10.1038/nrrheum.2010.154; Miyasaka N, 2008, MOD RHEUMATOL, V18, P252, DOI 10.1007/s10165-008-0045-0; Herrinton LJ, 2013, PHARMACOEPIDEM DR S, V22, P394, DOI 10.1002/pds.3409; Tanaka Y, 2012, ANN RHEUM DIS, V71, P817, DOI 10.1136/ard.2011.200317; Takeuchi T, 2013, ANN RHEUM DIS, V72, P1488, DOI 10.1136/annrheumdis-2012-201796; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059; Sakai R, 2012, ARTHRIT CARE RES, V64, P1125, DOI 10.1002/acr.21666; Emery P, 2008, LANCET, V372, P375, DOI 10.1016/S0140-6736(08)61000-4; Koike T, 2012, MOD RHEUMATOL, V22, P498, DOI 10.1007/s10165-011-0541-5; Bruce B, 2003, J RHEUMATOL, V30, P167; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140-6736(04)15640-7; Kameda H, 2011, J RHEUMATOL, V38, P1585, DOI 10.3899/jrheum.110014; Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646; Komano Y, 2011, J RHEUMATOL, V38, P1258, DOI 10.3899/jrheum.101009; Takeuchi T, 2013, MOD RHEUMATOL, V23, P226, DOI 10.1007/s10165-012-0668-z; Takeuchi T, 2013, MOD RHEUMATOL, V23, P623, DOI 10.1007/s10165-012-0742-6; Mori S, 2012, RHEUMATOLOGY, V51, P2120, DOI 10.1093/rheumatology/kes244; Koike T, 2011, MOD RHEUMATOL, V21, P343, DOI 10.1007/s10165-010-0406-3; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; Koike T, 2009, J RHEUMATOL, V36, P898, DOI 10.3899/jrheum.080791; Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14; Gottlieb AB, 2011, J DRUGS DERMATOL, V10, P289; Kawai S, 2006, J CLIN PHARMACOL, V46, P418, DOI 10.1177/0091270006286435; Koike Ryuji, 2007, Mod Rheumatol, V17, P451, DOI 10.1007/s10165-007-0626-3; Koike T, 2012, RHEUMATOL INT, V32, P1617, DOI 10.1007/s00296-011-1807-0; Koike T, 2012, RHEUMATOL INT, V32, P1511, DOI 10.1007/s00296-010-1784-8; Koike T, 2013, J RHEUMATOL, V40, P1658, DOI 10.3899/jrheum.120490; Miyasaka Nobuyuki, 2006, Mod Rheumatol, V16, P63, DOI 10.1007/s10165-006-0457-7; Sakai R, 2012, ANN RHEUM DIS, V71, P1820, DOI 10.1136/annrheumdis-2011-200838; Smolen JS, 2006, CLIN EXP RHEUMATOL, V24, pS7; Takamura A, 2013, MOD RHEUMATOL, V23, P297, DOI 10.1007/s10165-012-0658-1; Takeuchi T, 2012, MOD RHEUMATOL, V22, P327, DOI 10.1007/s10165-011-0516-6	36	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					173	186		10.3109/14397595.2014.914014		14	Rheumatology	Rheumatology	CC7KH	WOS:000350545700001		
J	Tsuboi, H; Matsumoto, I; Hagiwara, S; Hirota, T; Takahashi, H; Ebe, H; Yokosawa, M; Hagiya, C; Asashima, H; Takai, C; Miki, H; Umeda, N; Kondo, Y; Ogishima, H; Suzuki, T; Hirata, S; Saito, K; Tanaka, Y; Horai, Y; Nakamura, H; Kawakami, A; Sumida, T				Tsuboi, Hiroto; Matsumoto, Isao; Hagiwara, Shinya; Hirota, Tomoya; Takahashi, Hiroyuki; Ebe, Hiroshi; Yokosawa, Masahiro; Hagiya, Chihiro; Asashima, Hiromitsu; Takai, Chinatsu; Miki, Haruka; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Hirata, Shintaro; Saito, Kazuyoshi; Tanaka, Yoshiya; Horai, Yoshiro; Nakamura, Hideki; Kawakami, Atsushi; Sumida, Takayuki			Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks	MODERN RHEUMATOLOGY			English	Article						Sjogren's syndrome; Rheumatoid arthritis; Abatacept	CLASSIFICATION CRITERIA; DOUBLE-BLIND; T-CELL; RITUXIMAB; INHIBITION	Objective. To assess the efficacy and safety of abatacept for secondary SjOgren's syndrome (SS) Methods. The primary endpoint of this 1-year, open-labeled, prospective, observational multicenter study of RA-associated secondary SS was the rate of SDAI remission at 52 weeks after initiation of abatacept therapy. The secondary endpoints included that of Saxson's test and Schirmer's test. Adverse events during the study period were also analyzed. Results. Thirty-two patients (all females) were enrolled in this study. Interim analysis at 24 weeks included assessment of efficacy (n = 31) and safety (n = 32). The mean SDAI decreased from 19.8 +/- 11.0 (+/- SD) at baseline to 9.9 +/- 9.9 at 24 weeks (P < 0.05). Patients with clinical remission, as assessed by SDAI, increased from 0 patient (0 week) to 8 patients (25.8%) at 24 weeks. Saliva volume (assessed by Saxson's test) increased slightly from 2232 +/- 1908 (0 week) to 2424 +/- 2004 (24 weeks) mg/2 min (n = 29). In 11 patients with Greenspan grading 1/2 of labial salivary glands biopsy, saliva volume increased from 2945 +/- 2090 (0 week) to 3419 +/- 2121 (24 weeks) mg/2 min (P < 0.05). Schirmer's test for tear volume showed increase from 3.6 +/- 4.6 (0 week) to 5.5 +/- 7.1 (24 weeks) mm/5 min (n 25; P < 0.05). Five adverse events occurred in five of 32 patients (15.6%), and three of these events were infections. Conclusion. Abatacept seems to be effective for both RA and RA-related secondary SS.	[Tsuboi, Hiroto; Matsumoto, Isao; Hagiwara, Shinya; Hirota, Tomoya; Takahashi, Hiroyuki; Ebe, Hiroshi; Yokosawa, Masahiro; Hagiya, Chihiro; Asashima, Hiromitsu; Takai, Chinatsu; Miki, Haruka; Umeda, Naoto; Kondo, Yuya; Ogishima, Hiroshi; Suzuki, Takeshi; Sumida, Takayuki] Univ Tsukuba, Dept Internal Med, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Hirata, Shintaro; Saito, Kazuyoshi; Tanaka, Yoshiya] Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 807, Japan; [Horai, Yoshiro; Nakamura, Hideki; Kawakami, Atsushi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, Nagasaki 852, Japan	Sumida, T (reprint author), Univ Tsukuba, Dept Internal Med, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	tsumida@md.tsukuba.ac.jp			Ministry of Health, Labour and Welfare of Japan	We thank Dr F. G. Issa for the critical reading of the manuscript. This work was supported by Health and Labour Sciences Research Grants for research on intractable diseases (The Research Team for Autoimmune Diseases) from the Ministry of Health, Labour and Welfare of Japan.	Kremer JM, 2006, ANN INTERN MED, V144, P865; Singh N, 2012, J AUTOIMMUN, V39, P229, DOI 10.1016/j.jaut.2012.05.019; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Ramos-Casals M, 2012, NAT REV RHEUMATOL, V8, P399, DOI 10.1038/nrrheum.2012.53; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Iaccarino L, 2013, AUTOIMMUN REV, V12, P363, DOI 10.1016/j.autrev.2012.06.004; Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Sumida T, 2014, J AUTOIMMUN, V51, P44, DOI 10.1016/j.jaut.2013.12.012; Gottenberg JE, 2013, ANN RHEUM DIS, V72, P1026, DOI 10.1136/annrheumdis-2012-202293; Adler S, 2013, ARTHRIT CARE RES, V65, P1862, DOI 10.1002/acr.22052; Emery P, 2010, ANN RHEUM DIS, V69, P510, DOI 10.1136/ard.2009.119016; He J, 2013, RHEUMATOLOGY, V52, P1084, DOI 10.1093/rheumatology/kes374; Dass S, 2008, ANN RHEUM DIS, V67, P1541, DOI 10.1136/ard.2007.083865; Matsudaira R, 2011, J RHEUMATOL, V38, P2346, DOI 10.3899/jrheum.101295; Meijer JM, 2010, ARTHRITIS RHEUM-US, V62, P960, DOI 10.1002/art.27314; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Fujibayashi T, 2004, MOD RHEUMATOL, V14, P425; Kow NY, 2013, CLIN DEV IMMUNOL, V2013; Tobon GJ, 2013, AUTOIMMUNE DIS, V2013, DOI DOI 10.1155/2013/827254; Tsuboi H, 2014, MOD RHEUMATOL, V24, P464, DOI 10.3109/14397595.2013.843765; Westhovens R, 2009, ANN RHEUM DIS, V68, P1870, DOI 10.1136/ard.2008.101121; Yin HE, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3753	23	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					187	193		10.3109/14397595.2014.951144		7	Rheumatology	Rheumatology	CC7KH	WOS:000350545700002		
J	Yamamoto, M; Yajima, H; Takahashi, H; Yokoyama, Y; Ishigami, K; Shimizu, Y; Tabeya, T; Suzuki, C; Naishiro, Y; Takano, K; Yamashita, K; Hashimoto, M; Keira, Y; Honda, S; Abe, T; Suzuki, Y; Mukai, M; Himi, T; Hasegawa, T; Imai, K; Shinomura, Y				Yamamoto, Motohisa; Yajima, Hidetaka; Takahashi, Hiroki; Yokoyama, Yoshihiro; Ishigami, Keisuke; Shimizu, Yui; Tabeya, Tetsuya; Suzuki, Chisako; Naishiro, Yasuyoshi; Takano, Ken-ichi; Yamashita, Ken; Hashimoto, Masato; Keira, Yoshiko; Honda, Saho; Abe, Takashi; Suzuki, Yasuo; Mukai, Masaya; Himi, Tetsuo; Hasegawa, Tadashi; Imai, Kohzoh; Shinomura, Yasuhisa			Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: Results from the SMART database	MODERN RHEUMATOLOGY			English	Article						Autoimmune pancreatitis; Cancer; IgG4-related disease; Mikulicz's disease; rituximab	MIKULICZS-DISEASE; AUTOIMMUNE PANCREATITIS; MALIGNANCIES; MECHANISMS; RISK	Objective. Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a new disease entity that has only been identified this century. Clinical information is thus lacking. We established the Sapporo Medical University and Related Institutes Database for Investigation and Best Treatments of IgG4-related Disease (SMART) to clarify the clinical features of IgG4-RD and provide useful information for clinicians. Methods. Participants comprised 122 patients with IgG4-related dacryoadenitis and/or sialadenitis (IgG4-DS), representing lacrimal and/or salivary lesions of IgG4-RD, followed-up in December 2013. We analyzed the sex ratio, mean age at onset, organ dysfunction, history or complications of malignancy, treatments, rate of clinical remission, and relapse. Results. The sex ratio was roughly equal. Mean age at diagnosis was 59.0 years. Positron emission tomography revealed that the ratio of other organ involvements was 61.4%. Complications of malignancy were observed in 7.4% of cases. Glucocorticoid was used to treat 92.1% of cases, and the mean maintenance dose of prednisolone was 4.8 mg/day. Rituximab was added in three cases, and showed good steroid-sparing effect. The clinical remission rate was 73.8%, and the annual relapse rate was 11.5%. Half of the cases experienced relapses within 7 years of initial treatment. Conclusion. We analyzed the clinical features and treatments of IgG4-DS using SMART, providing useful information for everyday clinical practice.	[Yamamoto, Motohisa; Yajima, Hidetaka; Takahashi, Hiroki; Yokoyama, Yoshihiro; Ishigami, Keisuke; Shimizu, Yui; Tabeya, Tetsuya; Suzuki, Chisako; Naishiro, Yasuyoshi; Shinomura, Yasuhisa] Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sch Med, Sapporo, Hokkaido 0608543, Japan; [Takano, Ken-ichi; Himi, Tetsuo] Sapporo Med Univ, Dept Otolaryngol, Sch Med, Sapporo, Hokkaido 0608543, Japan; [Yamashita, Ken] Sapporo Med Univ, Dept Plast & Reconstruct Surg, Sch Med, Sapporo, Hokkaido 0608543, Japan; [Hashimoto, Masato] Sapporo Med Univ, Dept Ophthalmol, Sch Med, Sapporo, Hokkaido 0608543, Japan; [Keira, Yoshiko; Hasegawa, Tadashi] Sapporo Med Univ, Dept Surg Pathol, Sch Med, Sapporo, Hokkaido 0608543, Japan; [Honda, Saho] JR Sapporo Hosp, Dept Internal Med Gastroenterol & Rheumatol, Sapporo, Hokkaido, Japan; [Abe, Takashi] Kushiro City Gen Hosp, Dept Gastroenterol & Rheumatol, Kushiro, Japan; [Suzuki, Yasuo] Teine Keijinkai Hosp, Dept Ophthalmol, Sapporo, Hokkaido, Japan; [Mukai, Masaya] Sapporo City Gen Hosp, Dept Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan; [Imai, Kohzoh] Univ Tokyo, Inst Med Sci, Ctr Antibody & Vaccine Therapy, Tokyo, Japan	Yamamoto, M (reprint author), Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sch Med, Chuo Ku, South 1 West 16, Sapporo, Hokkaido 0608543, Japan.	mocha@cocoa.plala.or.jp			Ministry of Health, Labour and Welfare, Japan	This work was supported by the Research on Measures for Intractable Diseases Project matching fund subsidy from Ministry of Health, Labour and Welfare, Japan.	Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Tabata T, 2011, INTERNAL MED, V50, P69, DOI 10.2169/internalmedicine.50.4321; Khosroshahi A, 2012, MEDICINE, V91, P57, DOI 10.1097/MD.0b013e3182431ef6; Umehara H, 2012, MOD RHEUMATOL, V22, P21, DOI 10.1007/s10165-011-0571-z; Ebbo M, 2014, ARTHRIT CARE RES, V66, P86, DOI 10.1002/acr.22058; Yamamoto M, 2014, NAT REV RHEUMATOL, V10, P148, DOI 10.1038/nrrheum.2013.183; Stone JH, 2012, ARTHRITIS RHEUM-US, V64, P3061, DOI 10.1002/art.34593; Abu-Shakra M, 2003, CLIN REV ALLERG IMMU, V25, P13, DOI 10.1385/CRIAI:25:1:13; Taniguchi Y, 2013, RHEUMATOLOGY, V52, P1508, DOI 10.1093/rheumatology/ket182; Shiokawa M, 2013, AM J GASTROENTEROL, V108, P610, DOI 10.1038/ajg.2012.465; Yamamoto M, 2006, SCAND J RHEUMATOL, V35, P410; MORGAN WS, 1953, AM J PATHOL, V29, P471; Yamamoto M, 2012, MOD RHEUMATOL, V22, P414, DOI 10.1007/s10165-011-0520-x; Kanno A, 2012, PANCREAS, V41, P835, DOI 10.1097/MPA.0b013e3182480c99; Hirano K, 2014, INTERNAL MED, V53, P171, DOI 10.2169/internalmedicine.53.1342; Okazaki S, 2013, RHEUMATOL INT, V33, P51, DOI 10.1007/s00296-011-2295-y; Uchida K, 2012, INT J RHEUMATOL, V2012; Yamamoto Motohisa, 2006, Mod Rheumatol, V16, P335, DOI 10.1007/s10165-006-0518-Y; Yamamoto Motohisa, 2011, Current Immunology Reviews, V7, P162; Yamamoto M, 2014, RHEUMATOLOGY OXFORD; Yamamoto M, 2012, INT J RHEUMATOL, V2012; Yamamoto M, 2012, ANN RHEUM DIS, V71, P1755, DOI 10.1136/annrheumdis-2012-201694; Yamamoto M, 2005, RHEUMATOLOGY, V44, P1322, DOI 10.1093/rheumatology/kei026	23	4	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					199	204		10.3109/14397595.2014.950036		6	Rheumatology	Rheumatology	CC7KH	WOS:000350545700004		
J	Watanabe, H; Sugimoto, M; Asano, T; Sato, S; Suzuki, E; Takahashi, A; Katakura, K; Kobayashi, H; Ohira, H				Watanabe, Hiroshi; Sugimoto, Mitsuru; Asano, Tomoyuki; Sato, Shuzo; Suzuki, Eiji; Takahashi, Atsushi; Katakura, Kyoko; Kobayashi, Hiroko; Ohira, Hiromasa			Relationship of complement activation route with clinical manifestations in Japanese patients with systemic lupus erythematosus: A retrospective observational study	MODERN RHEUMATOLOGY			English	Article						Antiphospholipid syndrome; Complement; Systemic lupus erythematosus	DEFINITE ANTIPHOSPHOLIPID SYNDROME; INTERNATIONAL CONSENSUS STATEMENT; INDUCED PREGNANCY LOSS; DENSE DEPOSIT DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY; CLASSIFICATION CRITERIA; IMMUNE-RESPONSE; MICE DEFICIENT; 2 PARTS	Objectives. To assess the relationship between the complement activation route and clinical manifestations in systemic lupus erythematosus (SLE). Methods. Patients with SLE in whom complement activation occurred were divided into two groups: those in whom the complement system was mainly activated through the classical pathway (low serum C3 and C4 levels; CP group); and those in whom the complement system was solely activated through the alternative pathway (low serum C3 with normal C4 levels; AP group). Clinical manifestations were compared between the groups. Results. The CP group had higher frequencies of arthritis, serositis, and nephritis, and a higher prevalence of anti-DNA antibodies compared to the AP group (arthritis: 50.0% vs. 13.0%, p = 0.0014; serositis: 37.5% vs. 13.0%, p = 0.0257; nephritis: 63.6% vs. 21.7%, p = 0.0003; anti-DNA antibodies: 73.9% vs. 30.4%, p = 0.0001). In contrast, the AP group had a higher frequency of antiphospholipid (anti-PL) antibodies and a higher prevalence of antiphospholipid syndrome (APS) (anti-PL antibodies: 70.6% vs. 37.3%, p = 0.0136; APS: 39.1% vs. 5.7%, p < 0.0001). Conclusions. Our results suggest that a different complement system mechanism may act in the pathogenesis of APS in patients with SLE.	[Watanabe, Hiroshi; Sugimoto, Mitsuru; Asano, Tomoyuki; Sato, Shuzo; Suzuki, Eiji; Takahashi, Atsushi; Katakura, Kyoko; Kobayashi, Hiroko; Ohira, Hiromasa] Fukushima Med Univ, Sch Med, Dept Gastroenterol & Rheumatol, Fukushima 9601295, Japan	Watanabe, H (reprint author), Fukushima Med Univ, Sch Med, Dept Gastroenterol & Rheumatol, 1 Hikarigaoka, Fukushima 9601295, Japan.	chiehiro@fmu.ac.jp					Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939; Thurman JM, 2003, J IMMUNOL, V170, P1517; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Yang Y, 2004, CURR DIRECT AUTOIMMU, V7, P98; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; Kaya Z, 2001, NAT IMMUNOL, V2, P739, DOI 10.1038/90686; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Pierangeli SS, 2005, ARTHRITIS RHEUM, V52, P2120, DOI 10.1002/art.21157; Man B, 2005, LUPUS, V14, P822, DOI 10.1191/0961203305lu2187oa; Balbir-Gurman A, 2006, SEMIN ARTHRITIS RHEU, V35, P368, DOI 10.1016/j.semarthrit.2006.03.002; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078; INAI S, 1989, INT ARCH ALLER A IMM, V90, P274; Naves M, 1998, EUR J IMMUNOGENET, V25, P317, DOI 10.1046/j.1365-2370.1998.00110.x; Navratil JS, 2006, ARTHRITIS RHEUM, V54, P670, DOI 10.1002/art.21627; Holers VM, 2002, J EXP MED, V195, P211, DOI 10.1084/jem.200116116; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498; Thurman JM, 2006, J IMMUNOL, V176, P1305; Oku K, 2009, ANN RHEUM DIS, V68, P1030, DOI 10.1136/ard.2008.090670; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI18817; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Salmon JE, 2002, ANN RHEUM DIS, V61, P46; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; Peerschke EIB, 2006, J THROMB HAEMOST, V4, P2035, DOI 10.1111/j.1538-7836.2006.02065.x; Peerschke EI, 2010, MOL IMMUNOL, V47, P2170, DOI 10.1016/j.molimm.2010.05.009; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Carroll M C, 2000, Adv Immunol, V74, P61; DAVIS WD, 1992, CLIN EXP RHEUMATOL, V10, P455; Du Y, 2011, SYSTEMIC LUPUS ERYTHEMATOSUS, 5TH EDITION, P453; Fleming SD, 2002, J IMMUNOL, V169, P2126; HARRIS EN, 1990, BRIT J HAEMATOL, V74, P1, DOI 10.1111/j.1365-2141.1990.tb02530.x; HUGHES GRV, 1986, J RHEUMATOL, V13, P486; Humbles AA, 2000, NATURE, V406, P998; Jokiranta TS, 2007, MOL IMMUNOL, V44, P3889, DOI 10.1016/j.molimm.2007.06.003; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841; Liu CC, 2007, DUBOIS LUPUS ERYTHEM, P216; Mao DL, 2003, IMMUNITY, V19, P813, DOI 10.1016/S1074-7613(03)00321-2; Nishizaka H, 2012, INTRO COMPELEMTN, P130; Schwertz R, 2001, PEDIATR ALLERGY IMMU, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TICHENOR JR, 1995, GYNECOL OBSTET INVES, V39, P79; Walker PD, 2007, CURR OPIN NEPHROL HY, V16, P204, DOI 10.1097/MNH.0b013e3280bdc0f4; Walport MJ, 2001, NEW ENGL J MED, V344, P1140; Walport MJ, 2001, NEW ENGL J MED, V344, P1058	50	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					205	209		10.3109/14397595.2014.933998		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700005		
J	Kizawa, T; Nozawa, T; Kikuchi, M; Nagahama, K; Okudela, K; Miyamae, T; Imagawa, T; Nakamura, T; Mori, M; Yokota, S; Tsutsumi, H				Kizawa, Toshitaka; Nozawa, Tomo; Kikuchi, Masako; Nagahama, Kiyotaka; Okudela, Koji; Miyamae, Takako; Imagawa, Tomoyuki; Nakamura, Tomoko; Mori, Masaaki; Yokota, Shumpei; Tsutsumi, Hiroyuki			Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis	MODERN RHEUMATOLOGY			English	Article						Childhood-onset systemic lupus erythematosus; Lupus nephritis; Mycophenolate mofetil; Intravenous cyclophosphamide	LONG-TERM; INTRAVENOUS CYCLOPHOSPHAMIDE; CORTICOSTEROIDS; CLASSIFICATION; AZATHIOPRINE; INDUCTION; CHILDREN	Objectives. We evaluated histological changes occurring in renal biopsy specimens, between the time before initial induction therapy and after 12 months' maintenance therapy, as well as changes in laboratory parameters, SLE disease activity (SLEDAI), and dosage of corticosteroid (CS) in childhood-onset systemic lupus erythematosus (SLE) patients treated with mycophenolate mofetil (MMF). Methods. A retrospective analysis was performed on nine patients diagnosed with childhood-onset SLE and lupus nephritis. They were treated with pulsed mPSL and intravenous cyclophosphamide as induction therapy and MMF (500-1500 mg/day) plus CS as maintenance therapy. Renal biopsy was performed before the initial induction therapy and after 12 months' maintenance therapy. Results. Pathological findings at second biopsy were improved in eight of nine patients (89%). The findings of SLEDAI, urinalysis, and blood tests also showed improvement. CS doses could be tapered satisfactorily. Adverse events were observed in two patients. No patients treated with MMF experienced any disease flares during maintenance therapy. Conclusions. MMF as maintenance therapy might be useful in that not only the histological findings of lupus nephritis were improved, but also CS doses could be beneficially tapered. Nonetheless, this is a retrospective report of only nine cases and further prospective multicenter studies are necessary.	[Kizawa, Toshitaka; Nozawa, Tomo; Kikuchi, Masako; Miyamae, Takako; Imagawa, Tomoyuki; Yokota, Shumpei] Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa 232, Japan; [Nagahama, Kiyotaka] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo 113, Japan; [Okudela, Koji] Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 232, Japan; [Nakamura, Tomoko] Odawara City Hosp, Dept Pediat, Odawara, Kanagawa, Japan; [Mori, Masaaki] Yokohama City Univ, Med Ctr, Dept Pediat, Yokohama, Kanagawa 232, Japan; [Tsutsumi, Hiroyuki] Sapporo Med Univ, Sch Med, Dept Pediat, Sapporo, Hokkaido 0608543, Japan	Kizawa, T (reprint author), Sapporo Med Univ, Sch Med, Dept Pediat, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	kiza871@yahoo.co.jp					Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D; Wu LH, 2013, KIDNEY INT, V83, P715, DOI 10.1038/ki.2012.409; STEINBERG AD, 1991, ARTHRITIS RHEUM, V34, P945, DOI 10.1002/art.1780340803; Pereira T, 2011, CLIN J AM SOC NEPHRO, V6, P2192, DOI 10.2215/CJN.00910111; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hiraki LT, 2012, ARTHRITIS RHEUM-US, V64, P2669, DOI 10.1002/art.34472; Dooley MA, 2011, NEW ENGL J MED, V365, P1886, DOI 10.1056/NEJMoa1014460; Chan TM, 2005, J AM SOC NEPHROL, V16, P1076, DOI 10.1681/ASN.2004080686; Houssiau FA, 2010, ANN RHEUM DIS, V69, P2083, DOI 10.1136/ard.2010.131995; Appel GB, 2009, J AM SOC NEPHROL, V20, P1103, DOI 10.1681/ASN.2008101028; Ginzler EM, 2005, NEW ENGL J MED, V353, P2219, DOI 10.1056/NEJMoa043731; Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P85, DOI 10.1016/S0162-3109(00)00188-0; Contreras G, 2004, NEW ENGL J MED, V350, P971, DOI 10.1056/NEJMoa031855; Zonana-Nacach A, 2000, ARTHRITIS RHEUM, V43, P1801, DOI 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O; Cassidy TJ, 2010, TXB PEDIAT RHEUMATOL, P314; Hafeez F, 2008, JCPSP-J COLL PHYSICI, V18, P17, DOI 01.2008/JCPSP.1721; Klippel JH, 1998, BAILLIERE CLIN RHEUM, V12, P511, DOI 10.1016/S0950-3579(98)80033-2; Kurosawa R, 2006, J JPN PEDIAT SOC, V110, P398; LEHMAN TJA, 1989, J PEDIATR-US, V114, P1055, DOI 10.1016/S0022-3476(89)80463-9; Miyamae T, 2000, JAP J RHEUMATOL, V39, P829; Pillkington C, 1999, ADOLESCENT RHEUMATOL, P71; Yap DYH, 2013, RHEUMATOLOGY, V52, P480, DOI 10.1093/rheumatology/kes293; Yokota S, 1998, JAP J PEDIAT MED, V30, P1666	23	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					210	214		10.3109/14397595.2014.950810		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700006		
J	Matsuki, Y; Atsumi, T; Yamaguchi, K; Hisano, M; Arata, N; Oku, K; Watanabe, N; Sago, H; Takasaki, Y; Murashima, A				Matsuki, Yuko; Atsumi, Tatsuya; Yamaguchi, Koushi; Hisano, Michi; Arata, Naoko; Oku, Kenji; Watanabe, Noriyoshi; Sago, Haruhiko; Takasaki, Yoshinari; Murashima, Atsuko			Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications	MODERN RHEUMATOLOGY			English	Article						Antiphospholpid syndrome; Lupus anticoagulant; Phosphatidylserine-dependent anti-prothrombin antibody; Pregnancy	INTERNATIONAL CONSENSUS STATEMENT; CLASSIFICATION CRITERIA; LUPUS ANTICOAGULANT; ANTIBODIES; WORKSHOP; UPDATE	Objective. To clarify the clinical significance of antiphospholipid antibody (aPL) profile in patients with obstetric antiphospholipid syndrome (APS). Methods. Clinical records of 13 pregnant patients (15 pregnancies) with obstetrical APS were reviewed over 10 years. Patients who met the Sapporo Criteria fully were studied, whereas those with only early pregnancy loss were excluded. In addition to classical aPL: lupus anticoagulant (LA), anticardiolipin antibody (aCL), and anti-beta(2)-glycoprotein I (a beta 2GPI); phosphatidylserine-dependent anti-prothrombin antibody (aPS/PT) and kininogen-dependent anti-phosphatidylethanolamine antibody (aPE) were also examined in each case. Results. Cases were divided into two groups according to patient response to standard treatment: good and poor outcome groups. All cases with poor outcome presented LA, with IgG a beta 2GPI and IgG aPS/PT were also frequently observed. IgG aPE did not correlate with pregnancy outcome. Conclusion. aPL profile may predict pregnancy outcome in patients with this subset of obstetric APS.	[Matsuki, Yuko; Yamaguchi, Koushi; Hisano, Michi; Arata, Naoko; Watanabe, Noriyoshi; Sago, Haruhiko; Murashima, Atsuko] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan; [Matsuki, Yuko; Takasaki, Yoshinari] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Tokyo 1138421, Japan; [Atsumi, Tatsuya; Oku, Kenji] Hokkaido Univ, Grad Sch Med, Dept Med 2, Sapporo, Hokkaido, Japan	Matsuki, Y (reprint author), Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ymatsuki@juntendo.ac.jp					Amengual O, 1996, BRIT J RHEUMATOL, V35, P1239; American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, 2011, OBSTET GYNECOL, V117, P192; Ruiz-Irastorza G, 2010, LANCET, V376, P1498, DOI 10.1016/S0140-6736(10)60709-X; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Pengo V, 2009, J THROMB HAEMOST, V7, P1737, DOI 10.1111/j.1538-7836.2009.03555.x; Sugi T, 1999, FERTIL STERIL, V71, P1060, DOI 10.1016/S0015-0282(99)00119-3; Yamada H, 2009, J REPROD IMMUNOL, V79, P188, DOI 10.1016/j.jri.2008.11.001; Mak A, 2010, RHEUMATOLOGY, V49, P281, DOI 10.1093/rheumatology/kep373; Atsumi T, 2000, ARTHRITIS RHEUM, V43, P1982, DOI 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; Gladman DD, 2002, J RHEUMATOL, V29, P288; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; Oshiro BT, 1996, OBSTET GYNECOL, V87, P489, DOI 10.1016/0029-7844(95)00498-X; Roque H, 2004, THROMB HAEMOSTASIS, V91, P290, DOI 10.1160/TH03-09-0596	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					215	218		10.3109/14397595.2014.942503		4	Rheumatology	Rheumatology	CC7KH	WOS:000350545700007		
J	Tsuchida, Y; Shibuya, M; Shoda, H; Sumitomo, S; Kubo, K; Setoguchi, K; Fujio, K; Yamamoto, K				Tsuchida, Yumi; Shibuya, Mihoko; Shoda, Hirofumi; Sumitomo, Shuji; Kubo, Kanae; Setoguchi, Keigo; Fujio, Keishi; Yamamoto, Kazuhiko			Characteristics of granulomatosis with polyangiitis patients in Japan	MODERN RHEUMATOLOGY			English	Article						Anti-neutrophil cytoplasmic antibodies; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Wegener granulomatosis	ANTIBODY-ASSOCIATED VASCULITIS; ANCA-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; CLASSIFICATION; MYELOPEROXIDASE; METHOTREXATE; EPIDEMIOLOGY; PREVALENCE	Objectives. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease with significant ethnic differences. Reports on characteristics of Japanese granulomatosis with polyangiitis (GPA) patients are limited, and this study was undertaken to determine the characteristics of Japanese GPA patients. Methods. This was a retrospective chart study of 24 Japanese GPA patients. GPA was defined according to the European Medicines Agency algorithm. Results. The percentage of MPO-ANCA-positive patients was 33.3%, higher than the percentages reported in studies from Western countries. MPO-ANCA-positive GPA patients differed from PR3-ANCA-positive GPA patients in organs involved at diagnosis with MPO-ANCA-positive patients having nose and sinus involvement less frequently compared to PR3-ANCA-positive patients. Interstitial lung infiltrates were more common among MPO-ANCA-positive GPA patients compared to PR3-ANCA-positive GPA patients. Conclusion. Among Japanese GPA patients, the proportion of MPO-ANCA-positive patients is higher compared to reports from Western countries, and those patients are often different from the classical picture of GPA.	[Tsuchida, Yumi; Shibuya, Mihoko; Shoda, Hirofumi; Sumitomo, Shuji; Kubo, Kanae; Fujio, Keishi; Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo 1138655, Japan; [Setoguchi, Keigo] Tokyo Metropolitan Komagome Hosp, Dept Allergy & Immunol Dis, Bunkyo Ku, Tokyo, Japan	Tsuchida, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	terai-tky@umin.ac.jp					Abdulkader R, 2013, ANN RHEUM DIS, V72, P1888, DOI 10.1136/annrheumdis-2013-203511; Akahoshi Mitsuteru, 2004, Mod Rheumatol, V14, P179; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P310, DOI 10.1136/ard.2008.088096; Chen M, 2005, KIDNEY INT, V68, P2225, DOI 10.1111/j.1523-1755.2005.00679.x; Reinhold-Keller E, 2000, ARTHRITIS RHEUM, V43, P1021, DOI 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J; Fujimoto S, 2011, RHEUMATOLOGY, V50, P1916, DOI 10.1093/rheumatology/ker205; Liu LJ, 2008, RHEUMATOLOGY, V47, P708, DOI 10.1093/rheumatology/ken079; Schonermarck U, 2001, RHEUMATOLOGY, V40, P178, DOI 10.1093/rheumatology/40.2.178; Kobayashi S, 2013, CLIN EXP NEPHROL, V17, P611, DOI 10.1007/s10157-013-0813-9; Stone JH, 2001, ARTHRITIS RHEUM, V44, P912, DOI 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5; Watts RA, 2008, NEPHROL DIAL TRANSPL, V23, P3928, DOI 10.1093/ndt/gfn354; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; Holle JU, 2011, ARTHRITIS RHEUM-US, V63, P257, DOI 10.1002/art.27763; Pagnoux C, 2008, NEW ENGL J MED, V359, P2790, DOI 10.1056/NEJMoa0802311; Lyons PA, 2012, NEW ENGL J MED, V367, P214, DOI 10.1056/NEJMoa1108735; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101; Watts Richard, 2007, Ann Rheum Dis, V66, P222, DOI 10.1136/ard.2006.054593; Mohammad AJ, 2007, RHEUMATOLOGY, V46, P1329, DOI 10.1093/rheumatology/kem107; Lionaki S, 2012, ARTHRITIS RHEUM-US, V64, P3452, DOI 10.1002/art.34562; Mahr A, 2013, ANN RHEUM DIS, V72, P1003, DOI 10.1136/annrheumdis-2012-201750; JENNETTE JC, 1994, ARTHRITIS RHEUM, V37, P187, DOI 10.1002/art.1780370206; Bligny D, 2004, ARTHRIT RHEUM-ARTHR, V51, P83, DOI 10.1002/art.20082; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488; Jeanette JC, 2013, ARTHRITIS RHEUM, V65, P1, DOI DOI 10.1002/ART.37715; Kamali S, 2013, CLIN RHEUMATOL, V31, P325; Ono N, 2013, MOD RHEUMATOL, V23, P554, DOI 10.1007/s10165-012-0682-1; Hopkins J, 2003, ARTHRITIS RHEUM, V48, P2299, DOI 10.1002/art.11075	27	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					219	223		10.3109/14397595.2014.937475		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700008		
J	Hirose, O; Itabashi, M; Takei, T; Nitta, K				Hirose, Orie; Itabashi, Mitsuyo; Takei, Takashi; Nitta, Kosaku			Comparison of a novel chemiluminescence enzyme immunoassay (CLEIA) with enzyme-linked immunosorbent assay (ELISA) for the determination of MPO-ANCA in patients with ANCA-associated vasculitis	MODERN RHEUMATOLOGY			English	Article						CLEIA; ELISA; MPO-ANCA; ANCA-associated vasculitis; BVAS	ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; CAPTURE-ELISA; WEGENERS-GRANULOMATOSIS; FOLLOW-UP; PROTEINASE-3; DIAGNOSIS; PR3-ANCA; DISEASE; JAPAN; PR3	Background. Myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibody (ANCA) represents the serological hallmark of ANCA-associated vasculitis (AAV). We evaluated the analytical and diagnostic accuracy of chemiluminescence enzyme immunoassay (CLEIA) versus enzyme-linked immunosorbent assay (ELISA) for the detection of MPO-ANCA. Methods. A total of 242 sera obtained from 51 patients with AAV and 103 patients without AAV were tested for MPO-ANCA by ELISA (NephroScholor MPOANC II) and CLEIA (the STACIA MEBLux test). Disease activity in the patients with AAV was determined based on the Birmingham Vasculitis Activity Score. We analyzed the correlations between the MPO-ANCA titers determined by the CLEIA and those determined by the ELISA, and also between the MPO-ANCA titers and the disease activity. Results. The MPO-ANCA titers determined by the CLEIA (x) were strongly correlated with those determined by the ELISA (y). The correlation could be expressed by the following equation in this study: y = 1.8x + 7.7 (r = 0.96; p < 0.0001). At the cutoff value of 3.5 U/ml, the CLEIA yielded positive test results for MPO-ANCA in 73 of the 242 sera (30.2%), while at the cutoff value of 20 U/ml, ELISA yielded positive test results in 57 of the 242 sera (23.6%). The CLEIA yielded false-positive test results in 4 of the 120 sera obtained from the non-AAV patients (3.3%), whereas the ELISA yielded a false-positive result in only 1 of the 120 sera obtained from the non-AAV patients (0.8%). The sensitivity and specificity of the CLEIA for the diagnosis of AAV were 100% and 96.7%, respectively, while those of the ELISA were 94.3% and 99.2%, respectively. The sensitivity and specifi city of the CLEIA for the prediction of active disease were 100% and 64.4%, respectively, while those of the ELISA were 94.3% and 73.6%, respectively. Conclusion. The false positivity rate of the CLEIA for MPO-ANCA tended to be high as compared with that of the ELISA. Also, according to the correlation coefficient between the results of the CLEIA and the ELISA calculated in this study, it is necessary to pay attention to the differences in the sensitivity and specifi city between CLEIA and ELISA.	[Hirose, Orie; Itabashi, Mitsuyo; Takei, Takashi; Nitta, Kosaku] Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Tokyo 1628666, Japan	Itabashi, M (reprint author), Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	m-itaba@fb-4.so-net.ne.jp			Research Group on Progressive Glomerular Disease of the Ministry of Health, Labour, and Welfare of Japan	This study was supported by a grant from the Research Group on Progressive Glomerular Disease of the Ministry of Health, Labour, and Welfare of Japan.	Csernok E, 2004, RHEUMATOLOGY, V43, P174, DOI 10.1093/rheumatology.keh028; Savige J, 1999, AM J CLIN PATHOL, V111, P507; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P1827, DOI 10.1136/ard.2008.101279; Watts RA, 2008, NEPHROL DIAL TRANSPL, V23, P3928, DOI 10.1093/ndt/gfn354; [Anonymous], 1990, INTRO ARTHRITIS RHEU; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Ito-Ihara T, 2008, CLIN EXP RHEUMATOL, V26, P1027; JENNETTE JC, 1994, ARTHRITIS RHEUM, V37, P187, DOI 10.1002/art.1780370206; Arranz O, 2001, CLIN NEPHROL, V56, P295; Damoiseaux J, 2009, ANN RHEUM DIS, V68, P228, DOI 10.1136/ard.2007.086579; Damoiseaux J, 2007, ANN NY ACAD SCI, V1109, P454, DOI 10.1196/annals.1398.051; Falk RJ, 2011, ARTHRITIS RHEUM-US, V63, P863, DOI 10.1002/art.30286; Fujimoto S, 2006, CLIN J AM SOC NEPHRO, V1, P1016, DOI 10.2215/CJN.01461005; Holle JU, 2010, ANN RHEUM DIS, V69, P468, DOI 10.1136/ard.2009.109868; Kaul R, 2009, AUTOIMMUN REV, V8, P224, DOI 10.1016/j.autrev.2008.07.033; Lee AS, 2005, J IMMUNOL METHODS, V307, P62, DOI 10.1016/j.jim.2005.09.004; O'Donnell JL, 2007, PATHOLOGY, V39, P258, DOI 10.1080/00313020701230641; Roggenbuck D, 2009, ANN NY ACAD SCI, V1173, P41, DOI 10.1111/j.1749-6632.2009.04649.x; Russell KA, 2002, CLIN IMMUNOL, V103, P196, DOI 10.1006/clim.2001.5200; Rutgers A, 2004, J CLIN IMMUNOL, V24, P435, DOI 10.1023/B:JOCI.0000029115.79266.ae; Sun JY, 1998, J IMMUNOL METHODS, V211, P111, DOI 10.1016/S0022-1759(97)00203-2; Tanaka R, 2010, CLIN CHIM ACTA, V411, P22, DOI 10.1016/j.cca.2009.09.032; Trevisin M, 2008, J IMMUNOL METHODS, V336, P104, DOI 10.1016/j.jim.2008.03.012; Vermeersch P, 2008, CLIN CHIM ACTA, V397, P77, DOI 10.1016/j.cca.2008.07.026; Wiik A, 2000, ARTHRITIS RES, V2, P252, DOI 10.1186/ar96	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					230	234		10.3109/14397595.2014.951113		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700010		
J	Okamura, K; Yonemoto, Y; Okura, C; Kobayashi, T; Takagishi, K				Okamura, Koichi; Yonemoto, Yukio; Okura, Chisa; Kobayashi, Tsutomu; Takagishi, Kenji			Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						Cytokine; Disease modifying antirheumatic drugs; Iguratimod; Rheumatoid arthritis; T-614	ANTIINFLAMMATORY AGENT 3-FORMYLAMINO-7-METHYLSULFONYLAMINO-6-PHENOXY-4H-1-BENZOPYRAN-4-ONE; MODIFYING ANTIRHEUMATIC DRUG; COLLAGEN-INDUCED ARTHRITIS; PLACEBO-CONTROLLED TRIAL; KAPPA-B ACTIVATION; DOUBLE-BLIND; CYTOKINE PRODUCTION; SYNOVIAL-CELLS; IN-VITRO; T-614	Objective. Iguratimod (IGU) is a new synthetic disease-modifying antirheumatic drug intended to treat patients with rheumatoid arthritis (RA). We conducted a 24-week study on the efficacy of IGU in RA patients with daily clinical use. Methods. Forty-one patients were enrolled in this study, and the improvement in RA was evaluated every 4 weeks during the 24 weeks. Results. The patient's global assessment of the disease activity with a scale (Pt VAS) was significantly decreased beginning at week 4. The disease activity score (DAS) 28-erythrocyte sedimentation rate, DAS28-C-reactive protein (CRP), simplified disease activity index and clinical disease activity index all significantly decreased at week 24. The matrix metalloproteinase-3 level was signifi cantly decreased by the combination treatment with methotrexate at week 24. According to a logistic regression analysis, the factor which was most associated with the achievement of low disease activity (DAS28-CRP < 2.7) at week 24 was the DAS28-CRP at week 0. Conclusions. IGU had signifi cant clinical effects on the RA patients within 24 weeks. IGU might therefore represent a new practical choice to treat RA patients.	[Okamura, Koichi; Yonemoto, Yukio; Okura, Chisa; Kobayashi, Tsutomu; Takagishi, Kenji] Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, Maebashi, Gumma 3718511, Japan; [Kobayashi, Tsutomu] Takasaki Univ Hlth & Welf, Dept Phys Therapy, Takasaki, Gumma, Japan	Okamura, K (reprint author), Gunma Univ, Grad Sch Med, Dept Orthopaed Surg, 3-39-22 Showamachi, Maebashi, Gumma 3718511, Japan.	kokamura@gunma-u.ac.jp					Tanaka K, 2003, RHEUMATOLOGY, V42, P1365, DOI 10.1093/rheumatology/keg381; Kawakami A, 1999, J LAB CLIN MED, V133, P566, DOI 10.1016/S0022-2143(99)90186-5; Mallinckrodt CH, 2003, BIOL PSYCHIAT, V53, P754, DOI 10.1016/S0006-3223(03)01867-X; Mucke HAM, 2012, DRUG TODAY, V48, P577, DOI 10.1358/dot.2012.48.9.1855758; Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291; TANAKA K, 1992, ARZNEIMITTEL-FORSCH, V42-2, P935; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; TANAKA K, 1993, INT J IMMUNOTHER, V9, P69; Inoue E, 2007, ANN RHEUM DIS, V66, P407, DOI 10.1136/ard.2006.054205; Li JT, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/310628; Arnett FC, 1998, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Du F, 2012, INT IMMUNOPHARMACOL, V13, P54, DOI 10.1016/j.intimp.2012.03.003; Du F, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2554; Hara M, 2014, MOD RHEUMATOL, V24, P410, DOI 10.3109/14397595.2013.843756; Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y; Hara Masako, 2007, Mod Rheumatol, V17, P10, DOI 10.1007/s10165-006-0543-x; Ishiguro N, 2013, MOD RHEUMATOL, V23, P430, DOI 10.1007/s10165-012-0724-8; Kohno M, 2001, J RHEUMATOL, V28, P2591; Kuriyama K, 2002, BIOCHEM BIOPH RES CO, V299, P903, DOI 10.1016/S0006-291X(02)02754-7; Lu LJ, 2008, ARTHRITIS RHEUM, V61, P979; Lu LJ, 2008, CHINESE MED J-PEKING, V121, P615; Luo Q, 2013, J IMMUNOL, V191, P4969, DOI 10.4049/jimmunol.1300832; TANAKA K, 1995, JPN J PHARMACOL, V67, P305, DOI 10.1254/jjp.67.305; TANAKA K, 1992, J PHARMACOBIO-DYNAM, V15, P641; TANAKA K, 1992, J PHARMACOBIO-DYNAM, V15, P649; TANAKA K, 1992, ARZNEIMITTEL-FORSCH, V42-2, P945	26	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					235	240		10.3109/14397595.2014.938401		6	Rheumatology	Rheumatology	CC7KH	WOS:000350545700011		
J	Ochi, K; Iwamoto, T; Saito, A; Ikari, K; Toyama, Y; Taniguchi, A; Yamanaka, H; Momohara, S				Ochi, Kensuke; Iwamoto, Takuji; Saito, Asami; Ikari, Katsunori; Toyama, Yoshiaki; Taniguchi, Atsuo; Yamanaka, Hisashi; Momohara, Shigeki			Construct validity, reliability, response rate, and association with disease activity of the quick disabilities of the arm, shoulder and hand questionnaire in the assessment of rheumatoid arthritis	MODERN RHEUMATOLOGY			English	Article						Disabilities of the arm, shoulder and hand; Functional impairment; Health Assessment Questionnaire; Quick disabilities of the arm, shoulder and hand; Rheumatoid arthritis	LARGE OBSERVATIONAL COHORT; FUNCTIONAL DISABILITY; JAPANESE PATIENTS; OUTCOME MEASURE; VALIDATION; PATIENT; VERSION; IORRA; FRACTURES; MORTALITY	Objective. First objective is to validate the Disabilities of the Arm, Shoulder and Hand (DASH) and Quick DASH (QuickDASH) questionnaire in rheumatoid arthritis (RA) patients with functional upper extremity impairment. Next is to clarify which clinical factor is associating with QuickDASH using a large cohort of RA. Methods. The QuickDASH and DASH were applied to our 94 RA patients who underwent surgery for functional upper extremity impairment. Next, the QuickDASH was applied to our cohort of 5191 Japanese patients with RA. Results. In the first cohort of 94 RA patients, both QuickDASH and DASH displayed excellent reliability and validity. The response rate of patients < 65 and >= 65 years of age showed significant difference in the DASH but not in the QuickDASH. In the second cohort with 5191 RA patients, QuickDASH showed a high response rate (93%) and good to moderate correlation with Japanese version of the Health Assessment Questionnaire (r = 0.88) and disease activity score of 28 (DAS28, r = 0.53). Change in QuickDASH score and DAS28-based European League Against Rheumatism response showed significant correlation. Conclusion. QuickDASH seems suitable for evaluating upper extremity impairment, disability index, and disease control in a large cohort of RA patients including elderly patients.	[Ochi, Kensuke; Iwamoto, Takuji; Saito, Asami; Ikari, Katsunori; Momohara, Shigeki] Tokyo Womens Med Univ, Inst Rheumatol, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1620054, Japan; [Taniguchi, Atsuo; Yamanaka, Hisashi] Tokyo Womens Med Univ, Inst Rheumatol, Dept Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan; [Ochi, Kensuke; Iwamoto, Takuji; Toyama, Yoshiaki] Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo, Japan	Ochi, K (reprint author), Tokyo Womens Med Univ, Inst Rheumatol, Dept Orthopaed Surg, Shinjuku Ku, 10-22 Kawada Cyo, Tokyo 1620054, Japan.	ochi@1998.jukuin.keio.ac.jp			Japan Society for the Promotion of Science; the Japanese Society for Surgery of the Hand; Nakatomi Foundation; the Japan Orthopaedics and Traumatology Foundation, Inc [277]; Japanese Osteoporosis Foundation	We would like to thank to all other members in the Institute of Rheumatology, Tokyo Women's Medical University. We also thank Prof. Y. Toyama and other members of the Department of Orthopedic Surgery, Keio University School of Medicine for their support. This work was supported in part by the Japan Society for the Promotion of Science; the Japanese Society for Surgery of the Hand; the Nakatomi Foundation; the Japan Orthopaedics and Traumatology Foundation, Inc. No. 277; and the Japanese Osteoporosis Foundation to K.O.	Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Sato E, 2013, MOD RHEUMATOL, V23, P237, DOI 10.1007/s10165-012-0643-8; Nakajima A, 2010, SCAND J RHEUMATOL, V39, P360, DOI 10.3109/03009741003604542; Raven EEJ, 2008, J RHEUMATOL, V35, P2334, DOI 10.3899/jrheum.080067; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Momohara S, 2011, MOD RHEUMATOL, V21, P476, DOI 10.1007/s10165-011-0432-9; van Gestel AM, 1998, ARTHRITIS RHEUM, V41, P1845, DOI 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Imaeda T, 2005, J ORTHOP SCI, V10, P353, DOI 10.1007/s00776-005-0917-5; Beaton DE, 2005, J BONE JOINT SURG AM, V87A, P1038, DOI 10.2106/JBJS.D.02060; Imaeda T, 2006, J ORTHOP SCI, V11, P248, DOI 10.1007/s00776-006-1013-1; Seto Y, 2013, MOD RHEUMATOL, V23, P1179, DOI 10.1007/s10165-012-0816-5; Momohara S, 2010, ANN RHEUM DIS, V69, P312, DOI 10.1136/ard.2009.107599; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Dias JJ, 2008, J HAND SURG-EUR VOL, V33E, P9, DOI 10.1177/1753193407087121; Furuya T, 2007, J RHEUMATOL, V34, P303; Furuya T, 2013, OSTEOPOROSIS INT, V24, P1257, DOI 10.1007/s00198-012-2080-0; Henmi Shunichi, 2006, Mod Rheumatol, V16, P289, DOI 10.1007/s10165-006-0499-x; Hoshi D, 2013, MOD RHEUMATOL, V23, P1205, DOI 10.1007/s10165-012-0825-4; Ishikawa H, 2008, CLIN RHEUMATOL, V27, P967, DOI 10.1007/s10067-007-0830-8; Ishikawa H, 2010, SKELETAL RADIOL, V39, P467, DOI 10.1007/s00256-009-0867-7; Mackin IA, 2011, RHEUMATOL INT, V31, P823; McMillan Catherine R, 2009, Hand (N Y), V4, P311, DOI 10.1007/s11552-009-9167-x; Momohara S, 2012, MOD RHEUMATOL, V22, P209, DOI 10.1007/s10165-011-0495-7; Momohara Shigeki, 2007, Mod Rheumatol, V17, P476, DOI 10.1007/s10165-007-0629-0; Nakagawa N, 2011, MOD RHEUMATOL, V21, P598, DOI 10.1007/s10165-011-0447-2; Nakajima A, 2013, MOD RHEUMATOL, V23, P945, DOI 10.1007/s10165-012-0773-z; Nakajima Ayako, 2006, Mod Rheumatol, V16, P151, DOI 10.1007/s10165-006-0475-5; Nishida K, 2014, J ORTHOP SCI, V19, P55, DOI 10.1007/s00776-013-0492-0; Ochi K, 2012, MOD RHEUMATOL, V22, P290, DOI 10.1007/s10165-011-0494-8; Ochi K, 2014, CLIN RHEUMATOL, V33, P477, DOI 10.1007/s10067-013-2415-z; Ochi Kensuke, 2013, Arch Osteoporos, V8, P130, DOI 10.1007/s11657-013-0130-7; Seto Y, 2011, MOD RHEUMATOL, V21, P579, DOI 10.1007/s10165-011-0445-4; Tanaka E, 2008, ANN RHEUM DIS, V67, P1153, DOI 10.1136/ard.2007.072751; Tanaka Eiichi, 2006, Mod Rheumatol, V16, P214, DOI 10.1007/s10165-006-0487-1; Tanaka E, 2010, MOD RHEUMATOL, V20, P46, DOI 10.1007/s10165-009-0236-3; Tanaka E, 2013, MOD RHEUMATOL, V23, P742, DOI 10.1007/s10165-012-0729-3; Yamanaka Hisashi, 2007, Mod Rheumatol, V17, P283, DOI 10.1007/s10165-007-0587-6; Yamanaka H, 2012, MOD RHEUMATOL, V23, P1	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					241	245		10.3109/14397595.2014.939420		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700012		
J	Matsumoto, Y; Sugioka, Y; Tada, M; Okano, T; Mamoto, K; Inui, K; Habu, D; Koike, T				Matsumoto, Yoshinari; Sugioka, Yuko; Tada, Masahiro; Okano, Tadashi; Mamoto, Kenji; Inui, Kentaro; Habu, Daiki; Koike, Tatsuya			Relationships between serum 25-hydroxycalciferol, vitamin D intake and disease activity in patients with rheumatoid arthritis - TOMORROW study	MODERN RHEUMATOLOGY			English	Article						Rheumatoid arthritis; Age; 25-hydroxycalciferol; Menopause	D DEFICIENCY; ASSOCIATION; HEALTH; DETERMINANTS; PREVALENCE; DISABILITY; CRITERIA; THERAPY; ASTHMA; RISK	Objectives. The effect of serum 25-hydroxycalciferol [25(OH)D] on rheumatoid arthritis (RA) activity remains controversial. This study was undertaken with an aim to clarify the relationship between serum 25(OH) D and RA activity, and to determine the effects of dietary vitamin D intake and age on serum 25(OH) D level. Methods. A total of 208 outpatients with RA were matched according to age and sex with 205 individuals without RA (controls) from the TOMORROW study (UMIN000003876). We excluded 27 patients with RA and 19 control subjects who had been prescribed vitamin D medication or were taking vitamin D supplements. Vitamin D intake was assessed in the remaining 181 patients and 186 controls using the brief-type dietary history questionnaire. Serum 25(OH) D levels were measured using a radioimmunoassay. Results. Serum 25(OH) D levels were significantly lower in patients with RA than in the controls (p < 0.001). There was a significant and positive correlation between age and 25(OH) D in the patients (r = 0.283, p < 0.001), as with vitamin D intake and 25(OH) D, even after adjusting for age (r = 0.313, p < 0.001). Disease activity and 25(OH) D did not significantly correlate. Conclusions. Patients with RA were observed to have serum 25(OH) D levels which correlated with vitamin D intake and age but not disease activity.	[Matsumoto, Yoshinari; Habu, Daiki] Osaka City Univ, Grad Sch Human Life Sci, Dept Med Nutr, Osaka 558, Japan; [Sugioka, Yuko; Koike, Tatsuya] Osaka City Univ, Sch Med, CSDD, Osaka 545, Japan; [Tada, Masahiro; Okano, Tadashi; Mamoto, Kenji; Inui, Kentaro] Osaka City Univ, Sch Med, Dept Orthopaed Surg, Osaka 545, Japan; [Koike, Tatsuya] Shirahama Fdn Hlth & Welf, Search Inst Bone & Arthrit Dis SINBAD, Wakayama 6492211, Japan	Koike, T (reprint author), Shirahama Fdn Hlth & Welf, Search Inst Bone & Arthrit Dis, 1447 Shirahama Cho, Wakayama 6492211, Japan.	tatsuya@med.osaka-cu.ac.jp			Abbvie; Chugai Pharmaceutical; Eisai; Mitsubishi Tanabe Pharma Corporation; MSD; Ono Pharmaceutical; Takeda Pharmaceutical; Teijin Pharma	Research grants and/or lecture fees have been provided to Tatsuya Koike from Abbvie, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Takeda Pharmaceutical and Teijin Pharma. All other authors have declared no conflicts of interest.	ABUAMER Y, 1994, J CELL BIOCHEM, V55, P435, DOI 10.1002/jcb.240550404; Merlino LA, 2004, ARTHRITIS RHEUM, V50, P72, DOI 10.1002/art.11434; Patel S, 2007, ARTHRITIS RHEUM, V56, P2143, DOI 10.1002/art.22722; Haque UJ, 2010, CLIN EXP RHEUMATOL, V28, P745; Baker JF, 2012, CLIN EXP RHEUMATOL, V30, P658; Ross A Catharine, 2011, J Clin Endocrinol Metab, V96, P53, DOI 10.1210/jc.2010-2704; VANDERHEIJDE DMFM, 1990, ANN RHEUM DIS, V49, P916, DOI 10.1136/ard.49.11.916; Turhanoglu AD, 2011, RHEUMATOL INT, V31, P911, DOI 10.1007/s00296-010-1393-6; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI [10.2188/jeaJE20110075, 10.2188/jea.JE20110075]; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baykal T, 2012, BRATISL MED J, V113, P610, DOI 10.4149/BLL_2012_137; Bosse Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-98; Ceglia L, 2013, J CLIN ENDOCR METAB, V98, pE1927, DOI 10.1210/jc.2013-2820; Chen J, 2014, INT J RHEUM DIS, V17, P66, DOI 10.1111/1756-185X.12160; Furuya T, 2013, CLIN RHEUMATOL, V32, P1081, DOI 10.1007/s10067-013-2216-4; Haga HJ, 2013, CLIN RHEUMATOL, V32, P629; Huang H, 2013, DRUG DES DEV THER, V7, P1003, DOI 10.2147/DDDT.S50599; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; Moghimi J, 2012, Endocr Regul, V46, P61; Murakami K, 2006, AM J CLIN NUTR, V83, P1161; Quraishi MK, 2013, INT J RHEUM DIS, DOI [10.1111/1756-185X.12209, DOI 10.1111/1756-185X.12209, 10.1111/1756-185X.12209.]; Ross AC, 2011, Dietary Reference Intakes for Calcium and Vitamin D, P1; Rossini M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3195; Sabbagh Z, 2013, NUTRIENTS, V5, P2268, DOI 10.3390/nu5072268; Salesi M, 2012, RHEUMATOL INT, V32, P2129, DOI 10.1007/s00296-011-1944-5; Shirazi L, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472-6874-13-33; Song GG, 2012, CLIN RHEUMATOL, V31, P1733, DOI 10.1007/s10067-012-2080-7; Theodoratou E, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2035; vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105; Yazmalar L, 2013, AFR HEALTH SCI, V13, P47, DOI 10.4314/ahs.v13i1.7; Zakeri Z, 2013, INT J RHEUM DIS, DOI [10.1111/1756-185X.12181., DOI 10.1111/1756-185X.12181]	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					246	250		10.3109/14397595.2014.952487		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700013		
J	Kobayakawa, T; Kojima, T; Takahashi, N; Hayashi, M; Yabe, Y; Kaneko, A; Shioura, T; Saito, K; Hirano, Y; Kanayama, Y; Miyake, H; Asai, N; Funahashi, K; Hirabara, S; Hanabayashi, M; Asai, S; Ishiguro, N				Kobayakawa, Tomonori; Kojima, Toshihisa; Takahashi, Nobunori; Hayashi, Masatoshi; Yabe, Yuichiro; Kaneko, Atsushi; Shioura, Tomone; Saito, Kiwamu; Hirano, Yuji; Kanayama, Yasuhide; Miyake, Hiroyuki; Asai, Nobuyuki; Funahashi, Koji; Hirabara, Shinya; Hanabayashi, Masahiro; Asai, Shuji; Ishiguro, Naoki			Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate	MODERN RHEUMATOLOGY			English	Article						Rheumatoid arthritis; Methotrexate; TNF inhibitor; Tocilizumab; Second-line drug	MODIFYING ANTIRHEUMATIC DRUGS; ANTI-ADALIMUMAB ANTIBODIES; CLINICAL-PRACTICE; AMERICAN-COLLEGE; RHEUMATOLOGY/EUROPEAN LEAGUE; CLASSIFICATION CRITERIA; TOCILIZUMAB MONOTHERAPY; EULAR RECOMMENDATIONS; INFLIXIMAB; ETANERCEPT	Objectives. The purpose of this study was to explore drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors (TNFi) in clinical practice in patients with rheumatoid arthritis (RA) on low-dose methotrexate (MTX) or without MTX. Methods. A total of 169 RA patients who had been withdrawn from first-course TNFi therapy and received a different TNFi or tocilizumab (TCZ) as a second biologic agent were selected from the Tsurumai Biologics Communication Registry, an observational cohort database. Retention rates of second biologic treatment were compared by the type of first TNFi and second biologic agents. Results. Eighty-six patients received first-course infliximab (IFX) or adalimumab (ADA) therapy, and 83 patients received first-course etanercept (ETN) therapy. The former group had a significantly higher retention rate (IFX, 81.1%; ADA, 83.3%) of the second biologic therapy compared to the latter (56.6%, p < 0.001, log-rank test). Drug retention rates of the second biologic agent after switching from IFX/ADA were significantly higher with ETN (90.0%) and TCZ (94.7%) than with ADA/IFX (59.3%). Drug retention rates of the second biologic agent after switching from ETN were significantly higher with TCZ (75.9%) than with ADA/IFX (46.3%). The differences were significant even after adjusting for baseline clinical variables using the Cox proportional hazards model. Conclusions. Drug retention rates of IFX and ADA after switching from the first TNFi were significantly lower compared to those of ETN and TCZ in patients on low-dose MTX or without MTX.	[Kobayakawa, Tomonori; Kojima, Toshihisa; Takahashi, Nobunori; Asai, Nobuyuki; Funahashi, Koji; Asai, Shuji; Ishiguro, Naoki] Nagoya Univ Hosp, Dept Orthoped Surg & Rheumatol, Nagoya, Aichi 4668550, Japan; [Hayashi, Masatoshi] Nagano Red Cross Hosp, Dept Rheumatol, Nagano, Japan; [Yabe, Yuichiro] JCHO Tokyo Shinjyuku Med Ctr, Dept Rheumatol, Tokyo, Japan; [Kaneko, Atsushi] Nagoya Med Ctr, Dept Orthoped Surg & Rheumatol, Nagoya, Aichi, Japan; [Shioura, Tomone] Shizuoka Kosei Hosp, Dept Rheumatol, Shizuoka, Japan; [Saito, Kiwamu] SAITO CLIN Orthoped & Rheumatol, Nagoya, Aichi, Japan; [Hirano, Yuji; Hirabara, Shinya] Toyohashi Municipal Hosp, Dept Rheumatol, Toyohashi, Aichi, Japan; [Kanayama, Yasuhide] Toyota Kosei Hosp, Dept Rheumatol, Toyota, Japan; [Miyake, Hiroyuki; Hanabayashi, Masahiro] Ichinomiya Municipal Hosp, Dept Orthoped Surg, Ichinomiya, Japan	Kojima, T (reprint author), Nagoya Univ Hosp, Dept Orthoped Surg & Rheumatol, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	toshik@med.nagoya-u.ac.jp			Daiichi Sankyo Company, Ltd.; Takeda Pharmaceutical Co., Ltd.; Hisamitsu Pharmaceutical Co., Inc.; Otsuka Pharmaceutical Co., Ltd.; Taisho Toyama Pharmaceutical Co., Ltd.; Kaken Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Janssen Pharmaceutical K.K.; Bristol-Myers Squibb; Abbvie Inc.; Chugai Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharmaceutical; Astellas Pharma, Inc.; Pfizer Japan, Inc.; Eisai Pharmaceutical Co.; UCB Co., Ltd.	N. Ishiguro received grants and lecture fees from Daiichi Sankyo Company, Ltd., Takeda Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Otsuka Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Abbvie Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharmaceutical, Astellas Pharma, Inc., and Pfizer Japan, Inc.; T. Kojima received lecture fees from Mitsubishi Tanabe Pharmaceutical, Takeda Pharmaceutical Co., Ltd., Eisai Pharmaceutical Co., Abbvie Inc., Bristol-Myers Squibb, Pfizer Japan, Inc., and Chugai Pharmaceutical Co., Ltd., and research grants from Takeda Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Astellas Pharma, Inc.; A. Kaneko and Y. Hirano received lecture fees from Abbvie Inc., Eisai Pharmaceutical Co., Mitsubishi Tanabe Pharmaceutical, Takeda Pharmaceutical Co., Ltd., Pfizer Japan, Inc., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., UCB Co., Ltd., and Bristol-Myers Squibb.	Alivernini S, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2848; Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532; Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584; Lee SS, 2009, SCAND J RHEUMATOL, V38, P11, DOI 10.1080/03009740802360632; Miyasaka N, 2008, MOD RHEUMATOL, V18, P252, DOI 10.1007/s10165-008-0045-0; Leffers HC, 2011, ANN RHEUM DIS, V70, P1216, DOI 10.1136/ard.2010.140129; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461; Bartelds GM, 2010, ANN RHEUM DIS, V69, P817, DOI 10.1136/ard.2009.112847; Scallon B, 2002, J PHARMACOL EXP THER, V301, P418, DOI 10.1124/jpet.301.2.418; Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059; Salliot C, 2009, ANN RHEUM DIS, V68, P1100, DOI 10.1136/ard.2008.093690; Bendtzen K, 2006, ARTHRITIS RHEUM, V54, P3782, DOI 10.1002/art.22214; Dougados M, 2013, ANN RHEUM DIS, V72, P43, DOI 10.1136/annrheumdis-2011-201282; Bartelds GM, 2007, ANN RHEUM DIS, V66, P921, DOI 10.1136/ard.2006.065615; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Haraoui B, 2004, J RHEUMATOL, V31, P2356; Kojima T, 2012, MOD RHEUMATOL, V22, P339, DOI 10.1007/s10165-011-0518-4; Bombardieri S, 2007, RHEUMATOLOGY, V46, P1191, DOI 10.1093/rheumatology/kem091; Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932; Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573; Soliman MM, 2011, ANN RHEUM DIS, V70, P583, DOI 10.1136/ard.2010.139774; Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Flendrie M, 2003, ANN RHEUM DIS, V62, P30; Greenberg JD, 2012, ANN RHEUM DIS, V71, P1134, DOI 10.1136/annrheumdis-2011-150573; Jamnitski A, 2011, ANN RHEUM DIS, V70, P284, DOI 10.1136/ard.2010.135111; Koike R, 2009, MOD RHEUMATOL, V19, P351, DOI 10.1007/s10165-009-0197-6; Kristensen LE, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2084; Listing J, 2006, ARTHRITIS RES THER, V8, pE66; Marchesoni A, 2009, ANN NY ACAD SCI, V1173, P837, DOI 10.1111/j.1749-6632.2009.04621.x; Markenson JA, 2011, J RHEUMATOL, V38, P1273, DOI 10.3899/jrheum.101142; Ostergaard M, 2007, Scand J Rheumatol, V36, P151; Wakabayashi H, 2012, MOD RHEUMATOL, V22, P116, DOI 10.1007/s10165-011-0485-9	33	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					251	256		10.3109/14397595.2014.953668		6	Rheumatology	Rheumatology	CC7KH	WOS:000350545700014		
J	Hosono, O; Yoshikawa, N; Shimizu, N; Kiryu, S; Uehara, M; Kobayashi, H; Matsumiya, R; Kuribara, A; Maruyama, T; Tanaka, H				Hosono, Osamu; Yoshikawa, Noritada; Shimizu, Noriaki; Kiryu, Shigeru; Uehara, Masaaki; Kobayashi, Hiroshi; Matsumiya, Ryo; Kuribara, Akiko; Maruyama, Takako; Tanaka, Hirotoshi			Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy - Comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging	MODERN RHEUMATOLOGY			English	Article						Bioelectrical impedance analysis; Computed tomography; Glucocorticoid; Magnetic resonance imaging; Muscle atrophy	BODY-COMPOSITION; ATROPHY; RECEPTOR; VOLUME; MEN	Objectives. To determine the availability of bioelectrical impedance analysis (BIA), computed tomography (CT), and magnetic resonance imaging (MRI) for measurement of skeletal muscle mass in patients with rheumatic diseases and quantitatively assess skeletal muscle loss after glucocorticoid (GC) treatment. Methods. The data from 22 patients with rheumatic diseases were retrospectively obtained. The muscle mass of body segments was measured with a BIA device in terms of skeletal muscle mass index (SMI). Cross-sectional area (CSA) was obtained from CT and MRI scans at the mid-thigh level using the image analysis program. We further assessed the data of three different measurements before and after GC treatment in 7 patients with rheumatic diseases. Results. SMI of whole body was significantly correlated with estimated muscle volume and mid-thigh muscle CSA with CT and MRI (p < 0.01). Significant correlations between SMI and mid-thigh muscle CSA of each leg were also found (p < 0.01). All the three measurements were negatively correlated with GC dosage (p < 0.01). Signifi cant decline in mid-thigh muscle CSA with CT and MRI was found after GC treatment in 7 patients (p < 0.02). Those patients showed significant decline in SMI of whole body after GC treatment, but not in SMI of each leg. On the other hand, significant correlations between mid-thigh muscle CSA with CT and MRI were found before and after GC treatment (p < 0.01). Conclusions. GC-related skeletal muscle loss could be quantitatively assessed with BIA, CT, or MRI in patients with rheumatic diseases, and CT and MRI appeared to be more accurate than BIA.	[Hosono, Osamu; Yoshikawa, Noritada; Shimizu, Noriaki; Uehara, Masaaki; Kobayashi, Hiroshi; Matsumiya, Ryo; Kuribara, Akiko; Maruyama, Takako; Tanaka, Hirotoshi] Univ Tokyo, Inst Med Sci, IMSUT Hosp, Dept Rheumatol & Allergy,Minato Ku, Tokyo 1088639, Japan; [Kiryu, Shigeru] Univ Tokyo, Inst Med Sci, IMSUT Hosp, Dept Radiol,Minato Ku, Tokyo 1088639, Japan; [Tanaka, Hirotoshi] Univ Tokyo, Inst Med Sci, IMSUT Hosp, Ctr Antibody & Vaccine Therapy,Minato Ku, Tokyo 1088639, Japan	Tanaka, H (reprint author), Univ Tokyo, Inst Med Sci, IMSUT Hosp, Dept Rheumatol & Allergy,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hirotnk@ims.u-tokyo.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Health, Labor and Welfare, Japan	The authors wish to thank Ms. Tomoka Uchiyama (TANITA Body Weight Scientific Institute) for technical advice and Ms. Tomoe Masuda for her clerical works. This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS) (H.T., N.S., N.Y., H.K. and O.H.), and by a grant-in-aid from the Ministry of Health, Labor and Welfare, Japan (H.T.).	Kuo TY, 2012, P NATL ACAD SCI USA, V109, P11160, DOI 10.1073/pnas.1111334109; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Giraldi FP, 2003, J CLIN ENDOCR METAB, V88, P1554, DOI 10.1210/jc.2002-021518; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Cesari M, 2012, J CACHEXIA SARCOPENI, V3, P181, DOI 10.1007/s13539-012-0078-2; Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253; Menconi M, 2007, CRIT CARE MED, V35, pS602, DOI 10.1097/01.CCM.0000279194.11328.77; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Wang W, 1999, J APPL PHYSIOL, V87, P1163; Schakman O, 2013, INT J BIOCHEM CELL B, V45, P2163, DOI 10.1016/j.biocel.2013.05.036; Kramer HR, 2012, ARTHRITIS RHEUM-US, V64, P2438, DOI 10.1002/art.34464; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Ragnarsson O, 2013, EUR J ENDOCRINOL, V168, P243, DOI 10.1530/EJE-12-0873; Maden-Wilkinson TM, 2014, AGE, V36, P383, DOI 10.1007/s11357-013-9571-6; Barbosa-Silva MCG, 2005, CURR OPIN CLIN NUTR, V8, P311, DOI 10.1097/01.mco.0000165011.69943.39; Hu ZY, 2009, J CLIN INVEST, V119, P3059, DOI 10.1172/JCI38770; CHOWDHURY B, 1994, INT J OBESITY, V18, P219; di Prampero PE, 2003, J BIOMECH, V36, P403, DOI 10.1016/S0021-9290(02)00418-9; Hoffman EP, 2004, NAT MED, V10, P584, DOI 10.1038/nm0604-584; Mattsson S, 2006, PHYS MED BIOL, V51, pR203, DOI 10.1088/0031-9155/51/13/R13; Ogawa M, 2012, CLIN PHYSIOL FUNCT I, V32, P89, DOI 10.1111/j.1475-097X.2011.01057.x; Owczarek J, 2005, PHARMACOL REP, V57, P23; Strandberg Sören, 2010, BMC Med Imaging, V10, P18, DOI 10.1186/1471-2342-10-18; Yamada Y, 2014, J APPL PHYSIOL, V116, P176, DOI 10.1152/japplphysiol.00772.2013	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					257	263		10.3109/14397595.2014.935078		7	Rheumatology	Rheumatology	CC7KH	WOS:000350545700015		
J	Yokogawa, N; Kaneko, T; Nagai, Y; Nunokawa, T; Sawaki, T; Shiroto, K; Shimada, K; Sugii, S				Yokogawa, Naoto; Kaneko, Tetsuji; Nagai, Yoshiki; Nunokawa, Takahiro; Sawaki, Toshioki; Shiroto, Katsuaki; Shimada, Kota; Sugii, Shoji			Validation of RAPID3 using a Japanese version of Multidimensional Health Assessment Questionnaire with Japanese rheumatoid arthritis patients: Characteristics of RAPID3 compared to DAS28 and CDAI	MODERN RHEUMATOLOGY			English	Article						RAPID3; MDHAQ; Japanese; Rheumatoid arthritis; Validation	DISEASE-ACTIVITY INDEX; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ROUTINE ASSESSMENT; CLINICAL-TRIALS; ACTIVITY SCORE; AMERICAN-COLLEGE; SEVERITY CATEGORIES; CARE; RECOMMENDATIONS; REMISSION	Objectives. To validate Routine Assessment of Patient Index Data 3 (RAPID3) using a Japanese version of Multidimensional Health Assessment Questionnaire (MDHAQ) with Japanese rheumatoid arthritis (RA) patients and to describe the characteristics of RAPID3 by comparison with Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI). Methods. The original MDHAQ was translated into Japanese with minor cultural modifications and was translated back in English. Test-retest reliability was evaluated in 50 Japanese RA patients and further validation was performed in 350 Japanese RA patients recruited by seven rheumatologists. RAPID3, CDAI, and DAS28 were assessed on two consecutive visits. Results. The test-retest reliability and the internal reliability of RAPID3 were excellent. Spearman's correlation coefficients between RAPID3 score versus CDAI score and DAS28 score were 0.761 and 0.555. However, the agreement measured by kappa (weighted) for RAPID3 category versus CDAI category and for RAPID3 category versus DA28 category were 0.225 (0.382) and 0.187 (0.336). The sensitivity and specificity of "RAPID3 <= 3 and swollen joint <= 1 "for predicting Boolean remission were 90.0% and 93.4%, respectively. Conclusions. RAPID3 obtained by Japanese MDHAQ was validated with Japanese RA patients and the remission criteria were found to have excellent clinical utility in usual care.	[Yokogawa, Naoto; Nagai, Yoshiki; Nunokawa, Takahiro; Sawaki, Toshioki; Shiroto, Katsuaki; Shimada, Kota; Sugii, Shoji] Tokyo Metropolitan Tama Med Ctr, Dept Rheumat Dis, Fuchu, Tokyo, Japan; [Kaneko, Tetsuji] Tokyo Metropolitan Childrens Med Ctr, Dept Clin Res, Tokyo, Japan	Yokogawa, N (reprint author), Tokyo Metropolitan Tama Med Ctr, Dept Rheumat Dis, Fuchu, Tokyo, Japan.	yokogawan@aol.com					Aletaha D, 2005, ARTHRITIS RES THER, V7, pR796, DOI 10.1186/ar1740; Pincus T, 2011, ARTHRIT CARE RES, V63, P1142, DOI 10.1002/acr.20481; Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Anderson J, 2012, ARTHRIT CARE RES, V64, P640, DOI 10.1002/acr.21649; Pincus T, 1999, ARTHRITIS RHEUM, V42, P2220, DOI 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5; Matsuda Y, 2003, ARTHRIT RHEUM-ARTHR, V49, P784, DOI 10.1002/art.11465; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; FELSON DT, 1993, ARTHRITIS RHEUM, V36, P729, DOI 10.1002/art.1780360601; Smolen JS, 2010, ANN RHEUM DIS, V69, P1058, DOI 10.1136/ard.2009.114652; Castrejon I, 2013, JCR-J CLIN RHEUMATOL, V19, P169, DOI 10.1097/RHU.0b013e3182936b98; Wolfe F, 2004, ARTHRITIS RHEUM, V50, P3296, DOI 10.1002/art.20549; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659; Pincus T, 2008, J RHEUMATOL, V35, P2136, DOI 10.3899/jrheum.080182; Askanase AD, 2011, J RHEUMATOL, V38, P1309, DOI 10.3899/jrheum.101091; Castrejon I, 2013, J RHEUMATOL, V40, P386, DOI 10.3899/jrheum.121059; Felson DT, 2011, ARTHRITIS RHEUM-US, V63, P573, DOI 10.1002/art.30129; Pincus T, 2009, RHEUM DIS CLIN N AM, V35, P819, DOI 10.1016/j.rdc.2009.10.017; Pincus T, 2008, RHEUMATOLOGY, V47, P345, DOI 10.1093/rheumatology/kem364; Pincus T, 2008, J RHEUMATOL, V35, P1550; Smolen JS, 2013, ANN RHEUM DIS; Wolfe F, 2005, J RHEUMATOL, V32, P2410	22	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					264	269		10.3109/14397595.2014.948587		6	Rheumatology	Rheumatology	CC7KH	WOS:000350545700016		
J	Ohtsuji, M; Lin, QS; Nishikawa, K; Ohtsuji, N; Okazaki, H; Tsurui, H; Amano, H; Shirai, T; Nishimoto, N; Nishimura, H; Hirose, S				Ohtsuji, Mareki; Lin, Qingshun; Nishikawa, Keiko; Ohtsuji, Naomi; Okazaki, Hideki; Tsurui, Hiromichi; Amano, Hirofumi; Shirai, Toshikazu; Nishimoto, Norihiro; Nishimura, Hiroyuki; Hirose, Sachiko			IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel Fc gamma RIIB-deficient rheumatoid arthritis mouse model	MODERN RHEUMATOLOGY			English	Article						Interleukin-6; MCP-1; OPG; Osteoclastogenesis; RANKL	TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; ANTIBODY-INDUCED ARTHRITIS; INTERLEUKIN-6 RECEPTOR; AUTOIMMUNE ARTHRITIS; IMMUNE-SYSTEM; TNF RECEPTOR; MICE; CELLS; OSTEOPROTEGERIN	Objective. We earlier found that TNF alpha but not interleukin (IL)-17 is indispensable in the pathogenesis of spontaneously occurring rheumatoid arthritis (RA)-like disease in our newly established Fc gamma RIIB-deficient C57BL/6 (B6) mouse model, designated KO1. Here, we examined the role of IL-6 in the pathogenesis of RA features in KO1, with particular reference to cartilage and bone destruction in arthritic joints. Methods. To evaluate the preventive effect of MR16-1, a rat anti-mouse IL-6 receptor (IL-6R) mAb, 4-month-old preclinical KO1 mice were divided into three groups: the first treated with MR16-1 for 6 months, the second treated with normal rat IgG, as a control, and the third left untreated. The incidence and severity of arthritis, immunological abnormalities, and transcription levels of receptor activator of NF-kappa B ligand (RANKL), osteoprotegerin (OPG), and inflammatory cytokines/chemokines in ankle joint tissues were compared among the three groups. The therapeutic effect of MR16-1 was examined by treating 7-month-old KO1 mice in the early stages of arthritis for 2 months. Results. Compared with the findings in the KO1 mice left untreated or treated with normal rat IgG, the development of arthritis was markedly suppressed in mice with MR16-1 treatment started from preclinical stages. The suppression was associated with the decrease in production of autoantibodies, rheumatoid factors (RF), and anti-cyclic citrullinated peptide (CCP). Histologically, marked synovitis, pannus formation, and cartilage and bone destruction associated with the increase in tartrate-resistant acid phosphatase (TRAP)-positive osteoclast generation were evident in the two control groups; however, these findings were virtually absent in MR16-1-treated mice. Real-time PCR analysis revealed that the up-regulated expression levels of MCP-1, IL-6, and TNF alpha, and the aberrantly high RANKL/OPG expression ratio in synovial joint tissues from the two control groups of mice with overt arthritis were significantly suppressed in MR16-1-treated mice. In mice with therapeutic MR16-1 treatment, there was no progression in arthritis score and the RANKL/OPG ratio in joint tissues was significantly suppressed. Conclusions. Administration of an anti-IL-6R mAb ameliorated spontaneously occurring RA-like disease features, indicating that IL-6, as well as TNF alpha, plays a pivotal role in the pathogenesis of RA in KO1 mice. Current studies showed that, in addition to the role in enhancing autoantibody production, IL-6 promotes synovial tissue inflammation and osteoclastogenesis, leading to the severe synovitis with pannus formation and the progressive cartilage and bone destruction in multiple joints.	[Ohtsuji, Mareki; Nishimura, Hiroyuki] Toin Univ Yokohama, Toin Human Sci & Technol Ctr, Dept Biomed Engn, Yokohama, Kanagawa, Japan; [Ohtsuji, Mareki; Lin, Qingshun; Nishikawa, Keiko; Ohtsuji, Naomi; Okazaki, Hideki; Tsurui, Hiromichi; Shirai, Toshikazu; Hirose, Sachiko] Juntendo Univ, Sch Med, Dept Pathol, Tokyo 1138421, Japan; [Okazaki, Hideki] Musashigaoka Jr Coll, Hlth & Life Sci, Saitama, Japan; [Amano, Hirofumi] Juntendo Univ, Sch Med, Dept Rheumatol & Internal Med, Tokyo 1138421, Japan; [Nishimoto, Norihiro] Osaka Rheumatol Clin, Osaka, Japan	Hirose, S (reprint author), Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	sacchi@juntendo.ac.jp			Ministry of Education, Science, Technology, Sports and Culture of Japan [24590491]; Ministry of Health, Labour and Welfare of Japan	This work was supported in part by a Grant-in-Aid (24590491) from the Ministry of Education, Science, Technology, Sports and Culture of Japan and a grant for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan.	Dayer JM, 2010, RHEUMATOLOGY, V49, P15, DOI 10.1093/rheumatology/kep329; KISHIMOTO T, 1995, BLOOD, V86, P1243; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Yun TJ, 1998, J IMMUNOL, V161, P6113; Liu XH, 2006, ANN NY ACAD SCI, V1068, P225, DOI 10.1196/annals.1346.047; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439; Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; van den Berg WB, 2013, SEMIN ARTHRITIS RHEU, V43, P158, DOI 10.1016/j.semarthrit.2013.04.006; [Anonymous], 2013, ANN RHEUM DIS, V72(, P43; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Abe Y, 2009, MOD RHEUMATOL, V19, P316, DOI 10.1007/s10165-009-0166-0; Atsumi T, 2002, J EXP MED, V196, P979, DOI 10.1084/jem.20020619; Mima T, 2009, CURR OPIN RHEUMATOL, V21, P224, DOI 10.1097/BOR.0b013e3283295fec; Ducreux J, 2014, ARTHRITIS RHEUMATOL, V66, P15, DOI 10.1002/art.38202; Iwamoto T, 2008, FEBS J, V275, P4448, DOI 10.1111/j.1742-4658.2008.06580.x; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Kagari T, 2002, J IMMUNOL, V169, P1459; Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363; Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P; Fleischmann RM, 2003, ARTHRITIS RHEUM, V48, P927, DOI 10.1002/art.10870; Nakae S, 2003, J IMMUNOL, V171, P6173; Sato-Hayashizaki A, 2011, ARTHRITIS RHEUM-US, V63, P2930, DOI 10.1002/art.30485; Zannettino ACW, 2005, J CELL PHYSIOL, V204, P714, DOI 10.1002/jcp.20354; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Palmqvist P, 2002, J IMMUNOL, V169, P3353; Hirota K, 2007, J EXP MED, V204, P41, DOI 10.1084/jem.20062259; Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217; Breedveld FC, 2004, ANN RHEUM DIS, V63, P149, DOI 10.1136/ard.2003.013961; Campbell IK, 2001, J CLIN INVEST, V107, P1519, DOI 10.1172/JCI12724; Catrina AI, 2006, ARTHRITIS RHEUM, V54, P76, DOI 10.1002/art.21528; Doodes PD, 2008, J IMMUNOL, V181, P329; Kikuchi S, 2006, J IMMUNOL, V176, P3240; Mclnnes JB, 2007, NAT REV IMMUNOL, V7, P429; Okazaki H, 2014, MOD RHEUMATOL, V24, P931, DOI 10.3109/14397595.2014.886351; PIGUET PF, 1992, IMMUNOLOGY, V77, P510; Steinman L, 2007, NAT MED, V13, P139; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; Voll RE, 2005, ANN NY ACAD SCI, V1051, P799, DOI 10.1196/annals.1361.123; Yu RYL, 2005, BLOOD, V105, P1777, DOI 10.1182/blood-2004-08-3171	45	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					270	277		10.3109/14397595.2014.950035		8	Rheumatology	Rheumatology	CC7KH	WOS:000350545700017		
J	Ikeuchi, K; Hasegawa, Y; Seki, T; Takegami, Y; Amano, T; Ishiguro, N				Ikeuchi, Kazunna K; Hasegawa, Yukiharu; Seki, Taisuke; Takegami, Yasuhiko; Amano, Takafumi; Ishiguro, Naoki			Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan	MODERN RHEUMATOLOGY			English	Article						Epidemiology; Femoral head; Incidence rate; Nontraumatic osteonecrosis	SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUBCHONDRAL INSUFFICIENCY FRACTURE; AVASCULAR NECROSIS; ROTATIONAL OSTEOTOMY; IDIOPATHIC OSTEONECROSIS; NATURAL-HISTORY; FOLLOW-UP; MRI; DIAGNOSIS; THERAPY	Objectives. To elucidate the epidemiology of nontraumatic osteonecrosis of the femoral head (ONFH), and to estimate the annual incidence rate in Japan. Methods. We examined, over the course of 3 years, personal records and radiographic images from the national registry of documents used for the study of nontraumatic ONFH in patients in Aichi Prefecture, Japan (population: 7.4 million). Those patients not meeting the diagnostic criteria according to the Japanese Investigation Committee for nontraumatic ONFH were excluded from this study. Results. A total of 285 out of the 327 patients who applied for the national registration of nontraumatic ONFH during the 3-year study met the diagnostic criteria for personal records, radiographic images, and magnetic resonance images. Forty-two patients (12.8%) were not considered to have nontraumatic ONFH. The mean age of patients was 50.4 years, and the male-female ratio was 2.1:1. Nontraumatic ONFH was steroid-induced in 135 cases (47.4%), alcohol-associated in 87 cases (30.5%), steroid-induced and alcohol-associated in 14 cases (4.9%), and idiopathic in 49 cases (17.2%). Conclusions. The age-adjusted annual incidence of nontraumatic ONFH in Aichi Prefecture was estimated at 138.5 patients. Thus the annual incidence rate in Japan (population 128 million) was 1.91/100,000.	[Ikeuchi, Kazunna K; Hasegawa, Yukiharu; Seki, Taisuke; Takegami, Yasuhiko; Amano, Takafumi; Ishiguro, Naoki] Nagoya Univ, Grad Sch Med, Nagoya Univ Hosp, Nagoya, Aichi 4648601, Japan	Ikeuchi, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Orthoped, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648601, Japan.	k.ikeuchi@med.nagoya-u.ac.jp			Ministry of Health, Labor and Welfare of Japan	The senior authors (Y. Hasegawa and T. Seki) have received funding from a research grant for the Research on Idiopathic Osteonecrosis of the Femoral Head and the Research on Epidemiology of Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan.	Fukushima W, 2010, CLIN ORTHOP RELAT R, V468, P2715, DOI 10.1007/s11999-010-1292-x; Yamamoto T, 1999, ARTHRITIS RHEUM, V42, P2719, DOI 10.1002/1529-0131(199912)42:12<2719::AID-ANR31>3.0.CO;2-X; Takahashi S, 2012, J ORTHOP SCI, V17, P730, DOI 10.1007/s00776-012-0293-x; Torii Y, 2001, CLIN ORTHOP RELAT R, P124; Ito H, 2003, J BONE JOINT SURG BR, V85B, P796, DOI 10.1302/0301-620X.85B6.13794; Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041; MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459; Kubo T, 1997, MAGN RESON IMAGING, V15, P1017, DOI 10.1016/S0730-725X(97)00159-8; Oinuma K, 2001, ANN RHEUM DIS, V60, P1145, DOI 10.1136/ard.60.12.1145; Kang JS, 2009, J ARTHROPLASTY, V24, P1178, DOI 10.1016/j.arth.2009.05.022; Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007; Hasegawa Y, 2003, J BONE JOINT SURG BR, V85B, P191, DOI 10.1302/0301-620X.85B2.13190; OHZONO K, 1991, J BONE JOINT SURG BR, V73, P68; HIROTA Y, 1993, AM J EPIDEMIOL, V137, P530; Malizos KN, 2007, EUR J RADIOL, V63, P16, DOI 10.1016/j.ejrad.2007.03.019; Jergesen HE, 1997, J BONE JOINT SURG AM, V79A, P359; Nagasawa K, 2005, LUPUS, V14, P385, DOI 10.1191/0961203305lu2103oa; Shigemura T, 2011, RHEUMATOLOGY, V50, P2023, DOI 10.1093/rheumatology/ker277; Yamaguchi R, 2011, ARTHRITIS RHEUM-US, V63, P3169, DOI 10.1002/art.30484; Gangji V, 2011, BONE, V49, P1005, DOI 10.1016/j.bone.2011.07.032; Sugano N, 1999, J BONE JOINT SURG BR, V81B, P590, DOI 10.1302/0301-620X.81B4.9393; Atsumi T, 1999, ARCH ORTHOP TRAUM SU, V119, P388, DOI 10.1007/s004020050435; Gladman DD, 2001, J RHEUMATOL, V28, P2226; Glueck CJ, 1997, CLIN ORTHOP RELAT R, P43; Hasegawa Y, 1997, ARCH ORTHOP TRAUM SU, V116, P251; HUNGERFORD DS, 1978, CLIN ORTHOP RELAT R, P144; Lee JH, 2003, CHEM COMMUN, P270, DOI 10.1097/01.blo.0000092972.12414.a5; Lee SB, 2004, CLIN ORTHOP RELAT R, P161, DOI 10.1097/01.blo.0000128217.18356.87; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; Ministry of Health Labour and Welfare. Japan Intractable Diseases Information Center, HLTH ADM REP CAS; MITCHELL MD, 1986, AM J ROENTGENOL, V147, P67; Mont MA, 1996, CLIN ORTHOP RELAT R, P169; Sakamoto M, 1997, J BONE JOINT SURG BR, V79B, P213, DOI 10.1302/0301-620X.79B2.7179; Sakano S, 2004, J BONE JOINT SURG BR, V86B, P359, DOI 10.1302/0301-620X.86B3.14383; Solarino Giuseppe, 2012, J Orthop Traumatol, V13, P21, DOI 10.1007/s10195-011-0174-7; Sugano Nobuhiko, 2002, J Orthop Sci, V7, P601, DOI 10.1007/s007760200108; SUGIOKA Y, 1992, CLIN ORTHOP RELAT R, P111; Yamamoto T, 2008, ANN RHEUM DIS, V67, P150, DOI 10.1136/ard.2006.066878; Yildurm ZK, 2008, J PEDIAT HEMATOL ONC, V30, P749, DOI 10.1097/MPH.0b013e318180bbc9	39	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					278	281		10.3109/14397595.2014.932038		4	Rheumatology	Rheumatology	CC7KH	WOS:000350545700018		
J	Takatori, Y; Moro, T; Ishihara, K; Kamogawa, M; Oda, H; Umeyama, T; Kim, YT; Ito, H; Kyomoto, M; Tanaka, T; Kawaguchi, H; Tanaka, S				Takatori, Yoshio; Moro, Toru; Ishihara, Kazuhiko; Kamogawa, Morihide; Oda, Hiromi; Umeyama, Takashige; Kim, Yoon Taek; Ito, Hideya; Kyomoto, Masayuki; Tanaka, Takeyuki; Kawaguchi, Hiroshi; Tanaka, Sakae			Clinical and radiographic outcomes of total hip replacement with poly(2-methacryloyloxyethyl phosphorylcholine)-grafted highly cross-linked polyethylene liners: Three-year results of a prospective consecutive series	MODERN RHEUMATOLOGY			English	Article						Arthroplasty; Hip prosthesis; Joint replacement; Polyethylene (UHMWPE); Wear	BIOCOMPATIBLE POLYMER; WEAR PARTICLES; FOLLOW-UP; ARTHROPLASTY; JOINTS; LUBRICATION; OSTEOLYSIS	Objectives. This study aimed to evaluate the clinical safety and wear-resistance of the novel highly cross-linked polyethylene (HXLPE) acetabular liner with surface grafting of poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) at 3 years after total hip replacement (THR). Methods. Eighty consecutive patients underwent cementless THR using a 26-mm diameter cobalt-chromium-molybdenum alloy femoral head and a PMPC-grafted HXLPE liner for the bearing couplings. We evaluated the clinical and radiographic outcomes of 76 patients at 3 years after the index surgery. Results. The clinical results at 3 years were equivalent to a Harris hip score of 95.6 points. No adverse events were associated with the implanted PMPC-grafted HXLPE liner, and no periprosthetic osteolysis was detected. The mean femoral head penetration rate was 0.002 mm/year, representing marked reduction compared with other HXLPE liners. Conclusions. A PMPC-grafted HXLPE liner is a safe option in THR and probably reduces the generation of wear particles.	[Takatori, Yoshio; Moro, Toru; Kyomoto, Masayuki] Univ Tokyo, Grad Sch Med, Div Sci Joint Reconstruct, Tokyo 1138655, Japan; [Moro, Toru; Ito, Hideya; Tanaka, Takeyuki; Kawaguchi, Hiroshi; Tanaka, Sakae] Univ Tokyo, Grad Sch Med, Orthopaed Surg Sensory & Motor Syst Med, Surg Sci, Tokyo 1138655, Japan; [Ishihara, Kazuhiko; Kyomoto, Masayuki] Univ Tokyo, Sch Engn, Dept Mat Engn, Tokyo 1138655, Japan; [Kamogawa, Morihide] JR Tokyo Gen Hosp, Dept Orthopaed Surg, Tokyo, Japan; [Oda, Hiromi; Kim, Yoon Taek] Saitama Med Univ, Dept Orthopaed Surg, Sch Med, Saitama, Japan; [Umeyama, Takashige] NTT Med Ctr Tokyo, Dept Orthopaed Surg, Tokyo, Japan; [Ito, Hideya] Japan Red Cross Med Ctr, Dept Orthopaed Surg, Tokyo, Japan; [Kyomoto, Masayuki] KYOCERA Med Corp, Res Dept, Osaka, Japan	Moro, T (reprint author), Univ Tokyo, Grad Sch Med, Div Sci Joint Reconstruct, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	moro-ort@h.u-tokyo.ac.jp			KYOCERA Medical Corporation	One or more of the authors or institutions received outside funding or grants from KYOCERA Medical Corporation. One of the authors (K.M.) is employed by KYOCERA Medical Corporation.	Udomkiat P, 2001, J BONE JOINT SURG AM, V83A, P1865; Medel FJ, 2007, J BIOMED MATER RES B, V83B, P380, DOI 10.1002/jbm.b.30807; Selan L, 2009, AM J OPHTHALMOL, V147, P134, DOI 10.1016/j.ajo.2008.07.032; Takatori Y, 2013, J ARTIF ORGANS, V16, P170, DOI 10.1007/s10047-012-0681-1; Hills BA, 2000, P I MECH ENG H, V214, P83, DOI 10.1243/0954411001535264; Moro T, 2014, J ORTHOP RES, V32, P369, DOI 10.1002/jor.22526; Moro T, 2009, BIOMATERIALS, V30, P2995, DOI 10.1016/j.biomaterials.2009.02.020; Hui AJ, 2003, J BONE JOINT SURG AM, V85A, P505; Collier JP, 2003, CLIN ORTHOP RELAT R, P289, DOI 10.1097/01.blo.0000073343.50837.03; Lachiewicz PF, 2009, CLIN ORTHOP RELAT R, V467, P3290, DOI 10.1007/s11999-009-1038-9; Glyn-Jones S, 2008, J BONE JOINT SURG BR, V90B, P556, DOI 10.1302/0301-620X.90B5.20545; Calvert GT, 2009, J ARTHROPLASTY, V24, P505, DOI 10.1016/j.arth.2008.02.011; KIRK TB, 1993, J ORTHOP RHEUMATOL, V6, P21; Snyder TA, 2007, J BIOMED MATER RES A, V81A, P85, DOI 10.1002/jbm.a.31006; Kurtz SM, 2014, J MECH BEHAV BIOMED, V31, P107, DOI 10.1016/j.jmbbm.2013.03.022; Engh CA, 2006, J ARTHROPLASTY, V21, P17, DOI 10.1016/j.arth.2006.05.002; Whittaker JP, 2010, J ARTHROPLASTY, V25, P680, DOI 10.1016/j.arth.2009.05.006; Kyomoto M, 2012, BIOMATERIALS, V33, P4451, DOI 10.1016/j.biomaterials.2012.03.028; Kyomoto M, 2007, J MATER SCI-MATER M, V18, P1809, DOI 10.1007/s10856-007-3063-0; Moro T, 2004, NAT MATER, V3, P829, DOI 10.1038/nmat1233; Kuiper KKJ, 2000, AM J CARDIOL, V85, P698, DOI 10.1016/S0002-9149(99)00843-7; SUTHERLAND CJ, 1982, J BONE JOINT SURG AM, V64, P970; Capello WN, 2011, CLIN ORTHOP RELAT R, V469, P825, DOI 10.1007/s11999-010-1556-5; CHARNLEY J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P61; Fujisawa M, 2001, SEIKEIGEKA, V52, P628; Imura S., 1995, J JPN ORTHOP ASSOC, V69, P860; Karrholm J, 1997, CLIN ORTHOP RELAT R, P94; Moro T, 2014, J MECH BEHAV BIOMED, V31, P100, DOI 10.1016/j.jmbbm.2013.03.011; Moro T, 2006, CLIN ORTHOP RELAT R, P58, DOI 10.1097/01.blo.0000246553.33434.5f; Myers Gerard J, 2003, J Extra Corpor Technol, V35, P6; Nagai Ichiro, 2002, J Orthop Sci, V7, P74, DOI 10.1007/s776-002-8422-8; Stilling M, 2010, ACTA ORTHOP, V81, P570, DOI 10.3109/17453674.2010.506632; WILLERT HG, 1990, CLIN ORTHOP RELAT R, P95	33	7	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					286	291		10.3109/14397595.2014.941438		6	Rheumatology	Rheumatology	CC7KH	WOS:000350545700020		
J	Onuma, K; Fujimaki, H; Kenmoku, T; Sukegawa, K; Takano, S; Uchida, K; Takahira, N; Takaso, M				Onuma, Kenji; Fujimaki, Hisako; Kenmoku, Tomonori; Sukegawa, Koji; Takano, Shotaro; Uchida, Kentaro; Takahira, Naonobu; Takaso, Masashi			Bilateral carpal tunnel syndrome due to gouty tophi: conservative and surgical treatment in different hands of the same patient	MODERN RHEUMATOLOGY			English	Article						Carpal tunnel syndrome; Conservative treatment; Flexor tendon; Gouty tophus; Hyperuricemia	TOPHACEOUS GOUT; FEATURES	Gouty tophi are an uncommon cause of carpal tunnel syndrome. We describe a case of bilateral carpal tunnel syndrome due to gouty tophi. Gouty tophi in the right wrist developed slowly, but developed acutely in flexor tendons in the left wrist. Symptoms were numbness and finger movement dysfunction in both hands. The right hand was treated surgically, while the left hand was treated by medication. Both hands improved under a well-controlled serum uremic acid level.	[Onuma, Kenji; Fujimaki, Hisako; Kenmoku, Tomonori; Sukegawa, Koji; Takano, Shotaro; Uchida, Kentaro; Takaso, Masashi] Kitasato Univ, Sch Med, Dept Orthopaed Surg, Sagamihara, Kanagawa 2520374, Japan; [Takahira, Naonobu] Kitasato Univ, Sch Allied Hlth Sci, Dept Rehabil, Sagamihara, Kanagawa 2520374, Japan	Onuma, K (reprint author), Kitasato Univ, Sch Med, Dept Orthopaed Surg, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	onuma@med.kitasato-u.ac.jp					Rich JT, 2004, ORTHOPEDICS, V27, P862; Lin YC, 2009, KAOHSIUNG J MED SCI, V25, P34, DOI 10.1016/S1607-551X(09)70038-5; OHARA LJ, 1967, ARCH INTERN MED, V120, P180, DOI 10.1001/archinte.120.2.180; Chen CKH, 2000, AM J ROENTGENOL, V175, P655; PAI CH, 1993, J HAND SURG-AM, V18A, P667, DOI 10.1016/0363-5023(93)90315-T; Champion D., 1969, MED J AUSTRALIA, V17, P1030; FUJIMOTO WY, 1968, ARTHRITIS RHEUM, V11, P99; Hernandez-Cortes P, 2011, ORTHOPEDICS, V34, pE797, DOI 10.3928/01477447-20110922-36; Iwamoto T, 2010, MOD RHEUMATOL, V20, P210, DOI 10.1007/s10165-009-0258-x; MOORE JR, 1985, J HAND SURG-AM, V10A, P291; OGILVIE C, 1988, J HAND SURG-BRIT EUR, V13B, P42, DOI 10.1016/0266-7681(88)90049-6; PHALEN GS, 1966, J BONE JOINT SURG AM, VA 48, P211; STRAUB LR, 1961, J BONE JOINT SURG AM, V43, P731; Therimadasamy A, 2011, J CLIN ULTRASOUND, V39, P463, DOI 10.1002/jcu.20799	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					298	302		10.3109/14397595.2013.874753		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700022		
J	Kaieda, S; Zaizen, Y; Nomura, Y; Okabe, K; Honda, S; Kage, M; Ida, H; Hoshino, T; Fukuda, T				Kaieda, Shinjiro; Zaizen, Yoshiaki; Nomura, Yoriko; Okabe, Koki; Honda, Seiyo; Kage, Masayoshi; Ida, Hiroaki; Hoshino, Tomoaki; Fukuda, Takaaki			An autopsy case of refractory vasculo-Behcet's disease	MODERN RHEUMATOLOGY			English	Article						Immunosuppressive therapy; Pulmonary artery aneurysm; Vasculitis; Vasculo-Behcet disease	PULMONARY-ARTERY ANEURYSMS; DAGGER-ET DISEASE; VEIN-THROMBOSIS; INFLIXIMAB; INVOLVEMENT; PATIENT	Pulmonary vascular involvement in Behcet's disease is a rare complication with a poor prognosis. We present an autopsy case of vasculo-Behcet's disease complicated by pulmonary hemorrhage, possibly caused by rupture of pulmonary artery aneurysms. The patient was treated with a combination of high-dose steroids and pulse cyclophosphamide, but he died from massive hemoptysis. This case highlights the need for potent new therapies for patients with vasculo-Behcet's disease refractory to conventional immunosuppressive therapy, such as a combination of steroids and cyclophosphamide.	[Kaieda, Shinjiro; Zaizen, Yoshiaki; Okabe, Koki; Honda, Seiyo; Ida, Hiroaki; Hoshino, Tomoaki] Kurume Univ, Sch Med, Dept Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka 8300011, Japan; [Nomura, Yoriko; Kage, Masayoshi] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan; [Fukuda, Takaaki] Kurume Univ, Med Ctr, Ctr Rheumat Dis, Kurume, Fukuoka 8300011, Japan	Kaieda, S (reprint author), Kurume Univ, Sch Med, Dept Med, Div Respirol Neurol & Rheumatol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	shinkaieda@gmail.com					Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; Mehta P, 2010, RHEUMATOLOGY, V49, P2003, DOI 10.1093/rheumatology/keq090; Ideguchi H, 2011, CLIN EXP RHEUMATOL, V29, pS47; HAMURYUDAN V, 1994, BRIT J RHEUMATOL, V33, P48; Uzun O, 2005, CHEST, V127, P2243, DOI 10.1378/chest.127.6.2243; Meguro A, 2010, ANN RHEUM DIS, V69, P747, DOI 10.1136/ard.2009.108571; Hatemi G, 2008, ANN RHEUM DIS, V67, P1656, DOI 10.1136/ard.2007.080432; Leiba M, 2001, ANN RHEUM DIS, V60, P1081, DOI 10.1136/ard.60.12.1081; Hamuryudan V, 2004, AM J MED, V117, P867, DOI 10.1016/j.amjmed.2004.05.027; Seyahi E, 2012, MEDICINE, V91, P35, DOI 10.1097/MD.0b013e318242ff37; Kural-Seyahi E, 2003, MEDICINE, V82, P60, DOI 10.1097/00005792-200301000-00006; Baki K, 2006, ANN RHEUM DIS, V65, P1531, DOI 10.1136/ard.2005.045195; Hamuryudan V, 2004, CLIN EXP RHEUMATOL, V22, pS1; Hirohata S, 2009, CLIN EXP RHEUMATOL, V27, pS91; Lee SW, 2010, CLIN RHEUMATOL, V29, P91, DOI 10.1007/s10067-009-1272-2; Puli SR, 2003, AM J GASTROENTEROL, V98, P939; Rokutanda R, 2013, MOD RHEUMATOL, V23, P412, DOI 10.1007/s10165-012-0721-y; Seyahi E, 2007, RHEUMATOLOGY, V46, P1213, DOI 10.1093/rheumatology/kem103; Tunaci M, 1999, AM J ROENTGENOL, V172, P729; Yoshida S, 2012, MOD RHEUMATOL, V22, P791, DOI 10.1007/s10165-011-0585-6	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					307	311		10.3109/14397595.2013.874755		5	Rheumatology	Rheumatology	CC7KH	WOS:000350545700024		
J	Choe, H; Inaba, Y; Kobayashi, N; Miyamae, Y; Ike, H; Yukizawa, Y; Saito, T				Choe, Hyonmin; Inaba, Yutaka; Kobayashi, Naomi; Miyamae, Yushi; Ike, Hiroyuki; Yukizawa, Yohei; Saito, Tomoyuki			F-18-fluorodeoxy glucose and F-18 fluoride PET for detection of inflammation focus in periprosthetic hip joint infection cases	MODERN RHEUMATOLOGY			English	Article						F-18-fluorodeoxygIucose; F-18-fluoride; positron emission tomography; periprosthetic joint infection	POSITRON-EMISSION-TOMOGRAPHY; ARTHROPLASTY		[Choe, Hyonmin; Inaba, Yutaka; Kobayashi, Naomi; Miyamae, Yushi; Ike, Hiroyuki; Yukizawa, Yohei; Saito, Tomoyuki] Yokohama City Univ, Dept Orthopaed Surg, Yokohama, Kanagawa 232, Japan	Inaba, Y (reprint author), Yokohama City Univ, Dept Orthopaed Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 232, Japan.	yute0131@med.yokohama-cu.ac.jp					Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200; Shi SF, 2012, EXP THER MED, V3, P367, DOI 10.3892/etm.2011.423; Chryssikos T, 2008, CLIN ORTHOP RELAT R, V466, P1338, DOI 10.1007/s11999-008-0237-0; Tsaras G, 2012, J BONE JOINT SURG AM, V94A, P1700, DOI 10.2106/JBJSJ.00756; Parvizi J, 2011, J ARTHROPLASTY, V26, P1136, DOI 10.1016/j.arth.2011.09.026; Basu S, 2009, SEMIN NUCL MED, V39, P36, DOI 10.1053/j.semnuclmed.2008.08.004; Chin B, 2009, MOL IMAGING BIOL, V11, P118, DOI 10.1007/s11307-008-0177-9; Choe H, 2011, ACTA ORTHOP, V82, P427, DOI 10.3109/17453674.2011.594232; Glaudemans AW, 2013, CLIN DEV IMMUNOL, V2013, DOI DOI 10.1155/2013/623036; Jiang YL, 2002, INFECT IMMUN, V70, P3143, DOI 10.1128/IAI.70.6.3143-3148.2002; Kisielinski K, 2003, J ARTHROPLASTY, V18, P528, DOI 10.1016/S0883-5403(03)00058-5; Kobayashi N, 2011, CLIN NUCL MED, V36, pE156, DOI 10.1097/RLU.0b013e3182291ae7	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					322	324		10.3109/14397595.2014.931505		3	Rheumatology	Rheumatology	CC7KH	WOS:000350545700027		
J	Tsuchiya, H; Tsuno, H; Kaneko, S; Yamashita, H; Takahashi, Y; Kano, T; Mimori, A				Tsuchiya, Haruka; Tsuno, Hirotaka; Kaneko, Syunta; Yamashita, Hiroyuki; Takahashi, Yuko; Kano, Toshikazu; Mimori, Akio			Complete atrioventricular block and aseptic meningitis in a patient with adult-onset Still's disease and concurrent hemophagocytic syndrome	MODERN RHEUMATOLOGY			English	Letter						Complete atrioventricular block; Aseptic meningitis; Adult-onset Still's disease; Hemophagocytic syndrome			[Tsuchiya, Haruka; Tsuno, Hirotaka; Kaneko, Syunta; Yamashita, Hiroyuki; Takahashi, Yuko; Kano, Toshikazu; Mimori, Akio] Natl Ctr Global Hlth & Med, Div Rheumat Dis, Tokyo 1628655, Japan	Tsuchiya, H (reprint author), Natl Ctr Global Hlth & Med, Div Rheumat Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	elephantscale@yahoo.co.jp					Arlet JB, 2006, ANN RHEUM DIS, V65, P1596, DOI 10.1136/ard.2005.046904; YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424; El-Sayed ZA, 2009, RHEUMATOLOGY, V48, P843, DOI 10.1093/rheumatology/kep134; POUCHOT J, 1991, MEDICINE, V70, P118; JANKA GE, 1983, EUR J PEDIATR, V140, P221, DOI 10.1007/BF00443367; Blockmans DE, 2000, NEUROLOGY, V54, P1203; Kuek A, 2007, RHEUMATOLOGY, V46, P1043, DOI 10.1093/rheumatology/kem066; OHTA A, 1987, J RHEUMATOL, V14, P1139	8	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-7595	1439-7609		MOD RHEUMATOL	Mod. Rheumatol.	MAR	2015	25	2					332	333		10.3109/14397595.2014.882220		2	Rheumatology	Rheumatology	CC7KH	WOS:000350545700030		
J	Chinzei, N; Hayashi, S; Hashimoto, S; Kanzaki, N; Iwasa, K; Sakata, S; Kihara, S; Fujishiro, T; Kuroda, R; Kurosaka, M				Chinzei, Nobuaki; Hayashi, Shinya; Hashimoto, Shingo; Kanzaki, Noriyuki; Iwasa, Kenjiro; Sakata, Shuhei; Kihara, Shinsuke; Fujishiro, Takaaki; Kuroda, Ryosuke; Kurosaka, Masahiro			Cyclin-dependent kinase inhibitor p21 does not impact embryonic endochondral ossification in mice	MOLECULAR MEDICINE REPORTS			English	Article						endochondral ossification; cell cycle; p21; p27; mouse embryo	CDK INHIBITORS; GROWTH-PLATE; DNA-DAMAGE; CHONDROGENIC DIFFERENTIATION; ATDC5 CELLS; EXPRESSION; P21(CIP1/WAF1); PROGRESSION; PATHWAY; REPLICATION	Endochondral ossification at the growth plate is regulated by a number of factors and hormones. The cyclin-dependent kinase inhibitor p21 has been identified as a cell cycle regulator and its expression has been reported to be essential for endochondral ossification in vitro. However, to the best of our knowledge, the function of p21 in endochondral ossification has not been evaluated in vivo. Therefore, the aim of this study was to investigate the function of p21 in embryonic endochondral ossification in vivo. Wild-type (WT) and p21 knockout (KO) pregnant heterozygous mice were sacrificed on embryonic days E13.5, E15.5 and E18.5. Sagittal histological sections of the forearms of the embryos were collected and stained with Safranin 0 and 5-bromo-2'-deoxyuridine (BrdU). Additionally, the expression levels of cyclin D1, type II collagen, type X collagen, Sox9, and p16 were examined using immunohistochemistry, and the expression levels of p27 were examined using immunofluorescence. Safranin 0 staining revealed no structural change between the cartilage tissues of the WT and p21KO mice at any time point. Type II collagen was expressed ubiquitously, while type X collagen was only expressed in the hypertrophic zone of the cartilage tissues. No differences in the levels of Sox9 expression were observed between the two groups at any time point. The levels of cyclin D1 expression and BrdU uptake were higher in the E13.5 cartilage tissue compared with those observed in the embryonic cartilage tissue at subsequent time points. Expression of p16 and p27 was ubiquitous throughout the tissue sections. These results indicate that p21 may not be essential for embryonic endochondral ossification in articular cartilage of mice and that other signaling networks may compensate for p21 deletion.	[Chinzei, Nobuaki; Hayashi, Shinya; Hashimoto, Shingo; Kanzaki, Noriyuki; Iwasa, Kenjiro; Sakata, Shuhei; Kihara, Shinsuke; Fujishiro, Takaaki; Kuroda, Ryosuke; Kurosaka, Masahiro] Kobe Univ, Dept Orthoped Surg, Grad Sch Med, Kobe, Hyogo 6500017, Japan	Hayashi, S (reprint author), Kobe Univ, Dept Orthoped Surg, Grad Sch Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	shayashi@med.kobe-u.ac.jp					Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Bedelbaeva K, 2010, P NATL ACAD SCI USA, V107, P5845, DOI 10.1073/pnas.1000830107; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Olive M, 2008, J CLIN INVEST, V118, P2050, DOI 10.1172/JCI31244; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Bi WM, 1999, NAT GENET, V22, P85; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; Negishi Y, 2001, J BIOL CHEM, V276, P33249, DOI 10.1074/jbc.M010127200; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; HARPER JW, 1993, CELL, V75, P805; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Canepa ET, 2007, IUBMB LIFE, V59, P419, DOI 10.1080/15216540701488358; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Niculescu AB, 1998, MOL CELL BIOL, V18, P629; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Emons J, 2011, HORM RES PAEDIAT, V75, P383, DOI 10.1159/000327788; Emons JAM, 2006, PEDIATR RES, V60, P288, DOI 10.1203/01.pdr.0000232790.53527.c6; Nakajima M, 2004, BIOCHEM BIOPH RES CO, V320, P1069, DOI 10.1016/j.bbrc.2004.06.057; Stewart MC, 1997, CALCIFIED TISSUE INT, V61, P199, DOI 10.1007/s002239900323	32	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2015	11	3					1601	1608		10.3892/mmr.2014.2889		8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CD2OA	WOS:000350917700007		
J	Douhara, A; Moriya, K; Yoshiji, H; Noguchi, R; Namisaki, T; Kitade, M; Kaji, K; Aihara, Y; Nishimura, N; Takeda, K; Okura, Y; Kawaratani, H; Fukui, H				Douhara, Akitoshi; Moriya, Kei; Yoshiji, Hitoshi; Noguchi, Ryuichi; Namisaki, Tadashi; Kitade, Mitsuteru; Kaji, Kosuke; Aihara, Yosuke; Nishimura, Norihisa; Takeda, Kosuke; Okura, Yasushi; Kawaratani, Hideto; Fukui, Hiroshi			Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model	MOLECULAR MEDICINE REPORTS			English	Article						endotoxin; toll-like receptor 4; hepatic stellate cell; liver fibrosis; intestinal permeability; non-alcoholic steatohepatitis	TIGHT JUNCTION PERMEABILITY; ZINC-DEFICIENCY; PATHOGENESIS; EXPRESSION; CIRRHOSIS; DISEASE; GUT; PROLIFERATION; MECHANISMS; MICROBIOTA	Previous clinical studies have demonstrated that endotoxin/toll-like receptor 4 (TLR4) signaling is critical in the inflammatory pathways associated with non-alcoholic steatohepatitis (NASH). In human and animal studies, NASH was associated with portal lipopolysaccharide (LPS) and the plasma LPS level was hypothesized to be associated with small intestinal bacterial overgrowth, change in composition of the microbiota and increased intestinal permeability. The aim of the present study was to investigate the roles of endogenous endotoxin and TLR4 in the pathogenesis of NASH. The effects of antibiotics were assessed in vivo using a choline deficiency amino acid (CDAA)-induced experimental liver fibrosis model. Antibiotics, including polymyxins and neomycins, were orally administered in drinking water. Antibiotics attenuated hepatic stellate cell (HSC) activation and liver fibrosis via TGF-beta and collagen in an experimental hepatic fibrosis model. The mechanism by which antibiotics attenuated LPS-TLR4 signaling and liver fibrosis was assessed. Notably, TLR4 mRNA level in the liver was elevated in the CDAA group and the CDAA-induced increase was significantly reduced by antibiotics. However, no significant differences were observed in the intestine among all groups. Elevated mRNA levels of LPS binding protein, which was correlated with serum endotoxin levels, were recognized in the CDAA group and the CDAA-induced increase was significantly reduced by antibiotics. The intestinal permeability of the CDAA group was increased compared with the choline-supplemented amino acid group. The tight junction protein (TJP) in the intestine, determined by immunohistochemical analysis was inversely associated with intestinal permeability. Antibiotics improved the intestinal permeability and enhanced TJP expression. Inhibition of LPS-TLR4 signaling with antibiotics attenuated liver fibrosis development associated with NASH via the inhibition of HSC activation. These results indicated that reduction of LPS and restoration of intestinal TJP may be a novel therapeutic strategy for treatment of liver fibrosis development in NASH.	[Douhara, Akitoshi; Moriya, Kei; Yoshiji, Hitoshi; Noguchi, Ryuichi; Namisaki, Tadashi; Kitade, Mitsuteru; Kaji, Kosuke; Aihara, Yosuke; Nishimura, Norihisa; Takeda, Kosuke; Okura, Yasushi; Kawaratani, Hideto; Fukui, Hiroshi] Nara Med Univ, Dept Internal Med 3, Kashihara, Nara 6348521, Japan	Yoshiji, H (reprint author), Nara Med Univ, Dept Internal Med 3, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	yoshijih@naramed-u.ac.jp					Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Seki E, 2012, J PHYSIOL-LONDON, V590, P447, DOI 10.1113/jphysiol.2011.219691; Schumann RR, 2011, BIOCHEM SOC T, V39, P989, DOI 10.1042/BST0390989; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Guo SH, 2013, AM J PATHOL, V182, P375, DOI 10.1016/j.ajpath.2012.10.014; Kaji K, 2014, J GASTROENTEROL, V49, P481, DOI 10.1007/s00535-013-0783-4; Ruiz AG, 2007, OBES SURG, V17, P1374; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Finamore A, 2008, J NUTR, V138, P1664; Musso G, 2010, CURR OPIN LIPIDOL, V21, P76, DOI 10.1097/MOL.0b013e3283347ebb; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Ulluwishewa D, 2011, J NUTR, V141, P769, DOI 10.3945/jn.110.135657; Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Du Plessis J, 2013, J HEPATOL, V58, P1125, DOI 10.1016/j.jhep.2013.01.038; DeMinicis S, 2014, HEPATOLOGY, V59, P1738, DOI 10.1002/hep.26695; Roh YS, 2013, J GASTROEN HEPATOL, V28, P38, DOI 10.1111/jgh.12019; Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848; Jagavelu K, 2010, HEPATOLOGY, V52, P590, DOI 10.1002/hep.23739; Yoshiji H, 2001, HEPATOLOGY, V34, P745, DOI 10.1053/jhep.20001.28231; Szabo G, 2010, DIGEST DIS, V28, P737, DOI 10.1159/000324281; Assimakopoulos SF, 2013, ANN HEPATOL, V12, P301; Assimakopoulos SF, 2011, EUR J CLIN INVEST, V41, P117, DOI 10.1111/j.1365-2362.2010.02379.x; Chiba M, 2013, HEPATOL RES, V43, P365, DOI 10.1111/j.1872-034X.2012.01093.x; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063388; Mohammad Mohammad K, 2012, Nutr Clin Pract, V27, P8, DOI 10.1177/0884533611433534; Nguyen AT, 2014, DIABETES, V63, P471, DOI 10.2337/db13-0903; Ruberto Franco, 2013, Infectious Disorders - Drug Targets, V13, P128	30	2	2	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2015	11	3					1693	1700		10.3892/mmr.2014.2995		8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CD2OA	WOS:000350917700019		
J	Yamamoto, J; Ogura, SI; Shimajiri, S; Nakano, Y; Akiba, D; Kitagawa, T; Ueta, K; Tanaka, T; Nishizawa, S				Yamamoto, Junkoh; Ogura, Shun-Ichiro; Shimajiri, Shohei; Nakano, Yoshiteru; Akiba, Daisuke; Kitagawa, Takehiro; Ueta, Kunihiro; Tanaka, Tohru; Nishizawa, Shigeru			5-Aminolevulinic acid-induced protoporphyrin IX with multi-dose ionizing irradiation enhances host antitumor response and strongly inhibits tumor growth in experimental glioma in vivo	MOLECULAR MEDICINE REPORTS			English	Article						glioblastoma; radiosensitizer; macrophage; ionized calcium-binding adapter molecule 1; microdensitometry; phagocytosis	MEDIATED PHOTODYNAMIC THERAPY; AMELANOTIC MELANOMA; MALIGNANT GLIOMA; PHOTOFRIN-II; RADIATION; CANCER; PORPHYRINS; MICROGLIA; CELLS; MODEL	Ionizing irradiation is a well-established therapeutic modality for malignant gliomas. Due to its high cellular uptake, 5-aminolevulinic acid (ALA) is used for fluorescence-guided resection of malignant gliomas. We have previously shown that 5-ALA sensitizes glioma cells to irradiation in vitro. The aim of the present study was to assess whether 5-ALA acts as a radiosensitizer in experimental glioma in vivo. Rats were subcutaneously injected with 9L gliosarcoma cells and administered 5-ALA. The accumulation of 5-ALA-induced protoporphyrin IX was confirmed by high-performance liquid chromatography (HPLC) analysis. Subcutaneous (s.c.) tumors were subsequently irradiated with 2 Gy/day for five consecutive days. In the experimental glioma model, high-performance liquid chromatography analysis revealed a high level of accumulation of 5-ALA-induced protoporphyrin IX in s.c. tumors 3 h after 5-ALA administration. Multi-dose ionizing irradiation induced greater inhibition of tumor growth in rats that were administered 5-ALA than in the non-5-ALA-treated animals. Immunohistochemical analysis of the s.c. tumors revealed that numerous ionized calcium-binding adapter molecule 1 (Iba1)-positive macrophages gathered at the surface of and within the s.c. tumors following multi-dose ionizing irradiation in combination with 5-ALA administration. By contrast, the s.c. tumors in the control group scarcely showed aggregation of Iba1-positive macrophages. These results suggested that multi-dose ionizing irradiation with 5-ALA induced not only a direct cytotoxic effect but also enhanced the host antitumor immune response and thus caused high inhibition of tumor growth in experimental glioma.	[Yamamoto, Junkoh; Nakano, Yoshiteru; Akiba, Daisuke; Kitagawa, Takehiro; Ueta, Kunihiro; Nishizawa, Shigeru] Univ Occupat & Environm Hlth, Dept Neurosurg, Kitakyushu, Fukuoka 8078556, Japan; [Ogura, Shun-Ichiro] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Bioengn, Yokohama, Kanagawa 2268501, Japan; [Shimajiri, Shohei] Univ Occupat & Environm Hlth, Dept Surg Pathol, Kitakyushu, Fukuoka 8078556, Japan; [Tanaka, Tohru] SBI Pharmaceut Co Ltd, Minato Ku, Tokyo 1066020, Japan	Yamamoto, J (reprint author), Univ Occupat & Environm Hlth, Dept Neurosurg, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078556, Japan.	yama9218@med.uoeh-u.ac.jp			JSPS KAKENHI [25462282]	This study was supported by JSPS KAKENHI (grant no. 25462282).	ABELS C, 1994, BRIT J CANCER, V70, P826, DOI 10.1038/bjc.1994.406; Filipazzi P, 2012, CANCER IMMUNOL IMMUN, V61, P255, DOI 10.1007/s00262-011-1161-9; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Abels C, 1997, J PHOTOCH PHOTOBIO B, V40, P76, DOI 10.1016/S1011-1344(97)00027-4; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Higashikawa F, 2013, NUTRITION, V29, P1030, DOI 10.1016/j.nut.2013.02.008; Niclou SP, 2008, FASEB J, V22, P3120, DOI 10.1096/fj.08-109611; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Hagiya Y, 2013, PHOTODIAGN PHOTODYN, V10, P288, DOI 10.1016/j.pdpdt.2013.02.001; Ito E, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001922; Ishizuka M, 2011, INT IMMUNOPHARMACOL, V11, P358, DOI 10.1016/j.intimp.2010.11.029; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Starke RM, 2012, J NEUROSURG, V116, P588, DOI 10.3171/2011.11.JNS11530; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Bozzini G, 2013, PHOTODIAGN PHOTODYN, V10, P296, DOI 10.1016/j.pdpdt.2013.01.003; Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; BENDA P, 1971, J NEUROSURG, V34, P310, DOI 10.3171/jns.1971.34.3.0310; BERG K, 1995, RADIAT RES, V142, P340, DOI 10.2307/3579143; Cerniglia GJ, 1997, J APPL PHYSIOL, V82, P1939; Ishizuka M, 2011, PHOTODIAGN PHOTODYN, V8, P328, DOI 10.1016/j.pdpdt.2011.04.004; KOSTRON H, 1986, CANCER, V57, P964, DOI 10.1002/1097-0142(19860301)57:5<964::AID-CNCR2820570515>3.0.CO;2-S; Luksiene Z, 2006, CANCER LETT, V235, P40, DOI 10.1016/j.canlet.2005.03.041; Mimura S, 1996, LASER SURG MED, V19, P168; Mlkvy P, 1996, BRIT J CANCER, V73, P1473, DOI 10.1038/bjc.1996.279; Muller P J, 1996, J Clin Laser Med Surg, V14, P263; Prall F, 2012, HISTOPATHOLOGY, V61, P823, DOI 10.1111/j.1365-2559.2012.04285.x; Schaffer M, 2006, ONKOLOGIE, V29, P514, DOI 10.1159/000095979; Schaffer M, 2002, TUMORI, V88, P407; SCHMIDEK HH, 1971, J NEUROSURG, V34, P335, DOI 10.3171/jns.1971.34.3.0335; Skivka LM, 2004, EXP ONCOL, V26, P312; Takahashi J, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-602; Torres Rodrigo Couto, 2003, Neurosurg Focus, V14, pe5; Yamamoto J, 2006, CLIN CANCER RES, V12, P7132, DOI 10.1158/1078-0432.CCR-06-0786; Yamamoto J, 2005, INT J ONCOL, V27, P1207; Yamamoto J, 2012, ONCOL REP, V27, P1748, DOI 10.3892/or.2012.1699	37	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2015	11	3					1813	1819		10.3892/mmr.2014.2991		7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CD2OA	WOS:000350917700035		
J	Kawaguchi, T; Nagao, Y; Abe, K; Imazeki, F; Honda, K; Yamasaki, K; Miyanishi, K; Taniguchi, E; Kakuma, T; Kato, J; Seike, M; Yokosuka, O; Ohira, H; Sata, M				Kawaguchi, Takumi; Nagao, Yumiko; Abe, Kazumichi; Imazeki, Fumio; Honda, Koichi; Yamasaki, Kazumi; Miyanishi, Koji; Taniguchi, Eitaro; Kakuma, Tatsuyuki; Kato, Junji; Seike, Masataka; Yokosuka, Osamu; Ohira, Hiromasa; Sata, Michio			Effects of branched-chain amino acids and zinc-enriched nutrients on prognosticators in HCV-infected patients: A multicenter randomized controlled trial	MOLECULAR MEDICINE REPORTS			English	Article						chronic hepatitis C; prognosticator; tumor marker; nutritional therapy; valine; leucine; isoleucine	CHRONIC LIVER-DISEASE; CHRONIC HEPATITIS-C; INSULIN-RESISTANCE; ALPHA-FETOPROTEIN; FINGER PROTEIN; MUSCLE CRAMPS; ORAL ZINC; SUPPLEMENTATION; CIRRHOSIS; VIRUS	Branched-chain amino acids (BCAAs) and trace element deficiencies are associated with poor prognosis in hepatitis C virus (HCV)-infected patients. The aim of this study was to investigate the effects of BCAA and zinc-enriched supplementation on prognostic factors in HCV-infected patients. Fifty-three HCV-infected patients were enrolled in this multicenter randomized controlled trial. The patients were assigned to either the placebo (n=27) or supplement group (n=26; 6,400 mg/day BCAAs and 10 mg/day zinc) and were followed up for 60 days. Primary outcomes were prognostic factors for chronic liver disease, including the serum BCAA-to-tyrosine ratio (BTR), zinc levels and a-fetoprotein (AFP) levels. There, were no significant differences in any of the prognostic factors between the placebo and supplement groups at baseline. In the supplement group, the BTR and zinc levels were significantly increased compared with the placebo group (BTR: 5.14 1.59 vs. 4.23 1.14, P=0.0290; zinc: 76 +/- 11 vs. 68 +/- 11 mu g/d1, P=0.0497). No significant differences were observed in AFP levels between the groups in the whole analysis. However, a stratification analysis showed a significant reduction in Delta AFP levels in the supplement group, with elevated AFP levels compared with the other groups (-2.72 +/- 3.45 ng/ml, P=0.0079). It was demonstrated that BCAA and zinc-enriched supplementation increased the BTR and zinc levels in the HCV-infected patients. Furthermore, the supplementation reduced the serum AFP levels in patients who had elevated serum AFP levels at baseline. Thus, BCAA and zinc-enriched supplementation may prolong the survival of HCV-infected patients by improving amino acid imbalance and zinc deficiency, and by partly downregulating AFP.	[Kawaguchi, Takumi; Taniguchi, Eitaro; Sata, Michio] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 8300011, Japan; [Kawaguchi, Takumi; Nagao, Yumiko; Sata, Michio] Kurume Univ, Sch Med, Dept Digest Dis & Informat, Kurume, Fukuoka 8300011, Japan; [Abe, Kazumichi; Ohira, Hiromasa] Fukushima Med Univ, Dept Gastroenterol & Rheumatol, Fukushima 9601295, Japan; [Imazeki, Fumio; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba 2608670, Japan; [Honda, Koichi; Seike, Masataka] Oita Univ, Yuhu 879 5593, Fac Med, Dept Gastroenterol, Yuhu 8795593, Japan; [Yamasaki, Kazumi] Narao Med Ctr, Shinkamigoto 8533101, Japan; [Yamasaki, Kazumi] Nagasaki Med Ctr, Natl Hosp Org, Clin Res Ctr, Omura 8568562, Japan; [Miyanishi, Koji; Kato, Junji] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido 0608543, Japan; [Kakuma, Tatsuyuki] Kurume Univ, Ctr Biostat, Kurume, Fukuoka 8300011, Japan	Kawaguchi, T (reprint author), Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	takumi@med.kurume-u.ac.jp					Ikehara O, 2008, BIOL PHARM BULL, V31, P469, DOI 10.1248/bpb.31.469; Zhang YY, 2007, DIABETES, V56, P1647, DOI 10.2337/db07-0123; Hagiwara A, 2012, J CELL PHYSIOL, V227, P2097, DOI 10.1002/jcp.22941; Kawaguchi T, 2004, AM J PATHOL, V165, P1499, DOI 10.1016/S0002-9440(10)63408-6; Kawaguchi T, 2011, HEPATOLOGY, V54, P1063, DOI 10.1002/hep.24412; Xie Z, 2008, P NATL ACAD SCI USA, V105, P10859, DOI 10.1073/pnas.0800647105; Muto Y, 2006, HEPATOL RES, V35, P204, DOI 10.1016/j.hepres.2006.04.007; Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1053/S1542-3565(05)00017-0; Kawaguchi T, 2013, NUTR CLIN PRACT, V28, P580, DOI 10.1177/0884533613496432; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; AULD DS, 1974, P NATL ACAD SCI USA, V71, P2091, DOI 10.1073/pnas.71.5.2091; Chavez-Tapia NC, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-74; Ishida H, 2013, BIOCHEM BIOPH RES CO, V437, P127, DOI 10.1016/j.bbrc.2013.06.051; Ishikawa T, 2013, HEPATOGASTROENTEROLO, V60, P2013; Katayama K, 2011, OPEN J GASTROENTEROL, V1, P22; Kawaguchi T, 2014, CLIN GASTRO IN PRESS; Kawaguchi T, 2008, INT J MOL MED, V22, P105; Kawaguchi T, 2007, LIVER INT, V27, P1287, DOI 10.1111/j.1478-3231.2007.01559.x; Kugelmas M, 2000, J AM COLL NUTR, V19, P13; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; Matsumura H, 2012, J CLIN BIOCHEM NUTR, V51, P178, DOI 10.3164/jcbn.12-11; Moriyama M, 2006, DIGEST DIS SCI, V51, P1967, DOI 10.1007/s10620-005-9051-7; Nagao Y, 2011, J NEW REM CLIN, V60, P198; Nagao Y, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-282; Nagao Y, 2010, MED SCI MONIT, V16, pP17; Nakanishi C, 2010, TOHOKU J EXP MED, V221, P151, DOI 10.1620/tjem.221.151; Nakao K, 2013, HEPATOL RES, V43, P820, DOI 10.1111/hepr.12052; RIGGIO O, 1992, HEPATOLOGY, V16, P785, DOI 10.1002/hep.1840160326; Sako K, 2003, HEPATOL RES, V26, P327, DOI 10.1016/S1386-6346(03)00152-9; Suzuki K, 2008, HEPATOL RES, V38, P267, DOI 10.1111/j.1872-034X.2007.00268.x	30	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR	2015	11	3					2159	2166		10.3892/mmr.2014.2943		8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	CD2OA	WOS:000350917700087		
J	Lee, JW; Asai, M; Jeon, SK; Iimura, T; Yonezawa, T; Cha, BY; Woo, JT; Yamaguchi, A				Lee, Ji-Won; Asai, Midori; Jeon, Sang-Kyung; Iimura, Tadahiro; Yonezawa, Takayuki; Cha, Byung-Yoon; Woo, Je-Tae; Yamaguchi, Akira			Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation	MOLECULAR NUTRITION & FOOD RESEARCH			English	Article						beta-Catenin; Osteoblast; Osteoclast; Rosmarinic acid; Wnt	ACTIVATED PROTEIN-KINASE; KAPPA-B LIGAND; IN-VITRO; OSTEOGENIC DIFFERENTIATION; CELL-PROLIFERATION; RECEPTOR ACTIVATOR; SIGNALING PATHWAY; GREEN TEA; OSTEOPOROSIS; MICE	Scope: Bone homeostasis is ensured by the balance between bone formation and resorption. Thus, control of the recruitment, proliferation, and differentiation of bone cells is essential to maintain bone mass. The aim of this study was to elucidate the effects of rosmarinic acid as a potential therapeutic agent on bone metabolism using bone cells and a mouse model. Methods and results: Rosmarinic acid increased alkaline phosphatase activity and induced mineralization in osteoblasts. Addition of rosmarinic acid to cultures of calvarial osteoblastic cells prepared from T-cell factor/beta-catenin TOP-GAL mutant mice strongly induced the expression of LacZ and promoted stabilization of beta-catenin in the cytoplasm of ST2 cells, suggesting that rosmarinic acid affects the canonical Wnt signaling pathway. Moreover, rosmarinic acid inhibited not only osteoclast formation in cocultures of mouse bone marrow cells and osteoblasts, but also receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastic differentiation in bone marrow-derived macrophages. RANKL-induced p38 mitogen-activated protein kinase and the expression of nuclear factor of activated T cell, c-Jun, and c-Fos were inhibited by rosmarinic acid in bone marrow macrophages. Finally, we confirmed that rosmarinic acid improved bone mass in a soluble RANKL-induced bone loss mouse model. Conclusion: Rosmarinic acid has dual regulatory effects on bone metabolism and may control the bone functions by controlling osteoblastic and osteoclastic differentiation.	[Lee, Ji-Won; Iimura, Tadahiro] Ehime Univ, Proteosci Ctr PROS, Div Bioimaging, Matsuyama, Ehime 790, Japan; [Lee, Ji-Won; Yamaguchi, Akira] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Oral Pathol, Tokyo, Japan; [Lee, Ji-Won; Asai, Midori; Yonezawa, Takayuki; Cha, Byung-Yoon; Woo, Je-Tae] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 4878501, Japan; [Jeon, Sang-Kyung] Keimyung Univ, Food Sci & Technol, Daegu, South Korea; [Iimura, Tadahiro] Ehime Univ Hosp, Translat Res Ctr, Matsuyama, Ehime, Japan	Woo, JT (reprint author), Chubu Univ, Res Inst Biol Funct, 1200 Matsumoto, Kasugai, Aichi 4878501, Japan.	jwoo@isc.chubu.ac.jp			Erina Co. Inc.; MEXT; Japan Society for the Promotion of Science	We thank Dr. Hisataka Yasuda (Oriental Yeast) for generously providing the sRANKL. The authors also thank Dr. Ota Masato (Tokyo Medical and Dental University) for kindly supplying the transgenic TOP-GAL mice. This work was performed at a laboratory supported by an endowment from Erina Co. Inc. and the MEXT-supported Program for the Strategic Research Foundation at Private Universities (Japan). This work was carried out with the support of the Japan Society for the Promotion of Science Post-Doc fellowship received by Dr. J.-W Lee for carrying out research activities at Prof. Yamaguchi's Laboratory at the Tokyo Medical and Dental University, Tokyo, Japan.	Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124; ANDERSON JJB, 1990, BONE MINER, V11, P43, DOI 10.1016/0169-6009(90)90014-7; Petersen M, 2003, PHYTOCHEMISTRY, V62, P121, DOI 10.1016/S0031-9422(02)00513-7; Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009-2677; Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Muhlbauer RC, 2003, BONE, V32, P372, DOI 10.1016/S8756-3282(03)00027-9; Dehority W, 1999, AM J PHYSIOL-ENDOC M, V276, pE62; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022; Ku SK, 2013, FOOD CHEM TOXICOL, V59, P311, DOI 10.1016/j.fct.2013.06.003; Chu X, 2012, MOLECULES, V17, P3586, DOI 10.3390/molecules17033586; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Iuvone T, 2006, J PHARMACOL EXP THER, V317, P1143, DOI 10.1124/jpet.105.099317; Shekarchi M, 2012, PHARMACOGN MAG, V8, P37, DOI 10.4103/0973-1296.93316; Yang MD, 2012, HEPATOLOGY, V55, P1271, DOI 10.1002/hep.24792; Lee H, 2010, BIOCHEM BIOPH RES CO, V398, P741, DOI 10.1016/j.bbrc.2010.07.015; Hsu YC, 2011, J RHEUMATOL, V38, P1844, DOI 10.3899/jrheum.101223; Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003; Baba S, 2004, LIFE SCI, V75, P165, DOI 10.1016/j.lfs.2003.11.028; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; De Oliveira NCD, 2012, FOOD CHEM TOXICOL, V50, P1208, DOI 10.1016/j.fct.2012.01.028; Amado NG, 2009, ANTI-CANCER DRUG, V20, P543, DOI 10.1097/CAD.0b013e32832d1149; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Miyahara T, 2000, J BIOL CHEM, V275, P35715, DOI 10.1074/jbc.M006577200; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502165200; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Xu YC, 2010, PLANTA MED, V76, P956, DOI 10.1055/s-0029-1240893; Fujii M, 1999, MOL BIOL CELL, V10, P3801; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Lucarini R, 2013, PHARM BIOL, V51, P1087, DOI 10.3109/13880209.2013.776613; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Chambers TJ, 2000, J PATHOL, V192, P4; Syed DN, 2011, J INVEST DERMATOL, V131, P1291, DOI 10.1038/jid.2011.6; Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/jbmr.090217, 10.1359/JBMR.090217]; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003-0166; Li JJ, 2011, BONE, V48, P321, DOI 10.1016/j.bone.2010.09.033; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Kelm MA, 2000, PHYTOMEDICINE, V7, P7; Dashwood WM, 2002, BIOCHEM BIOPH RES CO, V296, P584, DOI 10.1016/S0006-291X(02)00914-2; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; GRUBER HE, 1984, METABOLISM, V33, P295, DOI 10.1016/0026-0495(84)90187-2; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; SESSIONS ND, 1989, AM J PHYSIOL, V257, pE606; Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842; Jang AH, 2011, INT IMMUNOPHARMACOL, V11, P1271, DOI 10.1016/j.intimp.2011.04.007; KALU DN, 1989, ENDOCRINOLOGY, V124, P7; Kwan TS, 2004, CYTOKINE GROWTH F R, V15, P49; Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014; PHILLIPSON JD, 1989, J ETHNOPHARMACOL, V25, P61, DOI 10.1016/0378-8741(89)90045-7; TURNER CH, 1991, OSTEOPOROSIS INT, V2, P12, DOI 10.1007/BF01627073; Yang E. J., 2012, J CELL PHYSL, V228, P975; Yun SY, 2003, TRANSPLANTATION, V75, P1758, DOI 10.1097/01.TP.0000063933.12440.50	62	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1613-4125	1613-4133		MOL NUTR FOOD RES	Mol. Nutr. Food Res.	MAR	2015	59	3					386	400		10.1002/mnfr.201400164		15	Food Science & Technology	Food Science & Technology	CD0LF	WOS:000350763500002		
J	Ishii, Y; Matsushita, K; Kuroda, K; Yokoo, Y; Kijima, A; Takasu, S; Kodama, Y; Nishikawa, A; Umemura, T				Ishii, Yuji; Matsushita, Kohei; Kuroda, Ken; Yokoo, Yuh; Kijima, Aki; Takasu, Shinji; Kodama, Yukio; Nishikawa, Akiyoshi; Umemura, Takashi			Acrylamide induces specific DNA adduct formation and gene mutations in a carcinogenic target site, the mouse lung	MUTAGENESIS			English	Article							MAILLARD REACTION; DIETARY EXPOSURE; DRINKING-WATER; GLYCIDAMIDE; RATS; MICE; GENOTOXICITY; ONCOGENICITY; DELETIONS; TOXICITY	Acrylamide (AA) is a contaminant in heated foods and is carcinogenic in multiple organs of rodents. There have been many reports regarding AA-induced DNA modification and genotoxicity. However, the data are insufficient to understand fully the relationship between the two events. A recent report demonstrated carcinogenicity in the mouse lung. The lung is advantageous for investigation of AA-induced genotoxicity because DNA adduct levels are relatively high in this organ. In the present study, reporter gene mutation assays and quantitative analyses of specific DNA adducts were performed in the lungs of mature gpt delta mice treated with AA at doses of 100, 200 and 400 p.p.m. in drinking water for 4 weeks. N7-GA-Gua was detected in all AA-treated mice in a dose-dependent manner. gpt mutant frequencies (MFs) were significantly increased in the middle- and high-dose groups. In the analysis of mutation spectra, significant increases in GC-TA transversions and single base deletion mutations were observed in the high-dose group. Spi(-) MFs were significantly increased in the high-dose group. Analysis of Spi(-) mutants revealed significant increases in the frequencies of single base deletion mutation in runs of G/C and A/T. Analyses of immature mice under the same experimental conditions showed that there were no differences of susceptibility to AA-induced genotoxicity in the two age classes. The overall data clearly show the causal relationship between AA-induced DNA adducts and the gene mutations at carcinogenic target sites.	[Ishii, Yuji; Matsushita, Kohei; Kuroda, Ken; Yokoo, Yuh; Kijima, Aki; Takasu, Shinji; Umemura, Takashi] Natl Inst Hlth Sci, Div Pathol, Setagaya Ku, Tokyo 1588501, Japan; [Kodama, Yukio; Nishikawa, Akiyoshi] Natl Inst Hlth Sci, Biol Safety Res Ctr, Setagaya Ku, Tokyo 1588501, Japan	Umemura, T (reprint author), Natl Inst Hlth Sci, Div Pathol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	umemura@nihs.go.jp			Ministry of Health, Labour and Welfare, Japan [H21-syokuhin-ippan-012]	This work was supported by a grant-in-aid from the Ministry of Health, Labour and Welfare, Japan (H21-syokuhin-ippan-012).	Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Boon PE, 2005, MUTAT RES-GEN TOX EN, V580, P143, DOI 10.1016/j.mrgentox.2004.10.014; Koskinen M, 2000, CHEM-BIOL INTERACT, V129, P209, DOI 10.1016/S0009-2797(00)00206-4; Stadler RH, 2002, NATURE, V419, P449, DOI 10.1038/419449a; Ghanayem BI, 2005, TOXICOL SCI, V88, P311, DOI 10.1093/toxsci/kfi307; Doerge DR, 2005, TOXICOL APPL PHARM, V202, P258, DOI 10.1016/j.taap.2004.07.001; FRIEDMAN MA, 1995, FUND APPL TOXICOL, V27, P95, DOI 10.1006/faat.1995.1112; Tareke E, 2002, J AGR FOOD CHEM, V50, P4998, DOI 10.1021/jf020302f; Mottram DS, 2002, NATURE, V419, P448, DOI 10.1038/419448a; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Friedman M, 2003, J AGR FOOD CHEM, V51, P4504, DOI 10.1021/jf030204+; JOHNSON KA, 1986, TOXICOL APPL PHARM, V85, P154, DOI 10.1016/0041-008X(86)90109-2; Dybing E, 2005, FOOD CHEM TOXICOL, V43, P365, DOI 10.1016/j.fct.2004.11.004; Bull PJ, 2005, ANN OCCUP HYG, V49, P683, DOI 10.1093/annhyg/mei028; Doerge DR, 2008, J AGR FOOD CHEM, V56, P6031, DOI 10.1021/jf073042g; Rosen J, 2002, ANALYST, V127, P880, DOI 10.1039/b204938d; da Costa GG, 2003, CHEM RES TOXICOL, V16, P1328, DOI 10.1021/tx034108e; Hilbig A, 2004, INT J HYG ENVIR HEAL, V207, P463, DOI 10.1078/1438-4639-00317; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V60, P389; Kotova N, 2011, TOXICOL LETT, V207, P18, DOI 10.1016/j.toxlet.2011.08.007; Koyama N, 2011, MUTAGENESIS, V26, P545, DOI 10.1093/mutage/ger014; Manjanatha MG, 2006, ENVIRON MOL MUTAGEN, V47, P6, DOI 10.1002/em.20157; Masumura K, 2011, ENVIRON MOL MUTAGEN, V52, DOI 10.1002/em.20610; Mei N, 2010, TOXICOL SCI, V115, P412, DOI 10.1093/toxsci/kfq069; Nohmi T, 2005, ENVIRON MOL MUTAGEN, V45, P150, DOI 10.1002/em.20110; Nohmi T, 2000, MUTAT RES-FUND MOL M, V455, P191, DOI 10.1016/S0027-5107(00)00077-4; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SEGERBACK D, 1995, CARCINOGENESIS, V16, P1161, DOI 10.1093/carcin/16.5.1161; Spivey A, 2010, ENVIRON HEALTH PERSP, V118, pA160, DOI 10.1289/ehp.118-a160; World Health Organization (WHO), 2006, ENV HLTH CRIT, V233	30	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357	1464-3804		MUTAGENESIS	Mutagenesis	MAR	2015	30	2					227	235		10.1093/mutage/geu062		9	Genetics & Heredity; Toxicology	Genetics & Heredity; Toxicology	CD2ZG	WOS:000350946900008		
J	Saito, T; Mitomi, H; Imamhasan, A; Hayashi, T; Kurisaki-Arakawa, A; Mitani, K; Takahashi, M; Kajiyama, Y; Yao, T				Saito, Tsuyoshi; Mitomi, Hiroyuki; Imamhasan, Abdukadir; Hayashi, Takuo; Kurisaki-Arakawa, Aiko; Mitani, Keiko; Takahashi, Michiko; Kajiyama, Yoshiaki; Yao, Takashi			PTCH1 mutation is a frequent event in oesophageal basaloid squamous cell carcinoma	MUTAGENESIS			English	Article							HEDGEHOG SIGNALING PATHWAY; ACTIVATING MUTATION; CANCER; WNT; DIFFERENTIATION; PREVALENCE; MECHANISMS; DROSOPHILA; ADENOMAS; THERAPY	Basaloid squamous cell carcinoma (BSCC) is a rare and poorly differentiated variant of typical squamous cell carcinoma, and is characterised in part by activation of the Wnt signalling pathway. We previously demonstrated that constitutive activation of the Wnt signalling pathway by epigenetic silencing of secreted frizzled-related protein 4 (SFRP4) is observed in this tumour. Increasing evidence shows that the Wnt signalling pathway cross-talks with other developmental pathways, including the Hedgehog (HH) pathway. The HH pathway is stimulated by inactivating mutations of PTCH1, which have a well-described oncogenic role in basal cell carcinoma (BCC) of the skin. We employed polymerase chain reaction followed by direct sequencing to detect inactivating mutations of PTCH1 using archival tissue samples of 30 oesophageal BSCCs. The frequency of PTCH1 mutation was compared to that of Wnt component genes that we reported previously. We found PTCH1 mutations in 53.3% (16/30) of cases, revealing T1195S as a hotspot mutation. This frequency is quite high for cancers other than BCC of the skin, and PTCH1 mutations were almost mutually exclusive with mutations in APC, Axin1 and Axin2. Considering the fact that activation of Wnt signalling via down-regulation of APC and SFRP5 due to promoter methylation is observed in BCC of the skin, Wnt signalling activation in oesophageal BSCC might be a secondary effect of the PTCH1-inactivating mutations. These findings suggest that the HH and Wnt pathways coordinately contribute to tumourigenesis in oesophageal BSCC. Furthermore, this study provides a potential therapeutic application for HH pathway inhibitors in oesophageal BSCC with highly malignant potential.	[Saito, Tsuyoshi; Mitomi, Hiroyuki; Imamhasan, Abdukadir; Hayashi, Takuo; Kurisaki-Arakawa, Aiko; Mitani, Keiko; Takahashi, Michiko; Yao, Takashi] Juntendo Univ, Dept Human Pathol, Sch Med, Bunkyo Ku, Tokyo 1138421, Japan; [Mitomi, Hiroyuki] Dokkyo Univ, Dept Surg & Mol Pathol, Sch Med, Mibu, Tochigi 3210293, Japan; [Kajiyama, Yoshiaki] Juntendo Univ, Dept Surg, Sch Med, Bunkyo Ku, Tokyo 1138421, Japan	Saito, T (reprint author), Juntendo Univ, Dept Human Pathol, Sch Med, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	tysaitou@juntendo.ac.jp			Ministry of Education, Science, Sports, and Culture, Tokyo, Japan [23590434, 24590429]	This work was supported in part by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture (#23590434 to T.S. and #24590429 to H.M.), Tokyo, Japan.	Xie JW, 2013, ONCOTARGETS THER, V6, P1425, DOI 10.2147/OTT.S34678; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Alvarez-Medina R, 2008, DEVELOPMENT, V135, P237, DOI 10.1242/dev.012054; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Raffel C, 1997, CANCER RES, V57, P842; Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287; Palos-Paz F, 2008, EUR J ENDOCRINOL, V159, P623, DOI 10.1530/EJE-08-0313; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Wilkinson SE, 2013, PROSTATE, V73, P1810, DOI 10.1002/pros.22720; Saito T, 2014, VIRCHOWS ARCH, V464, P135, DOI 10.1007/s00428-014-1538-1; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Kim JH, 2010, CANCER SCI, V101, P328, DOI 10.1111/j.1349-7006.2009.01395.x; Imamhasan A, 2012, HUM PATHOL, V43, P2012, DOI 10.1016/j.humpath.2012.02.010; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Boutet N, 2003, J INVEST DERMATOL, V121, P478, DOI 10.1046/j.1523-1747.2003.12423.x; Bermudez O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063226; Brinkhuizen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051710; Chidambaram A, 1996, CANCER RES, V56, P4599; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074; Geissler K, 2012, ANN HEMATOL, V91, P645, DOI 10.1007/s00277-012-1435-0; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Hui M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3401; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Makinodan E, 2012, EXP DERMATOL, V21, P847, DOI 10.1111/exd.12016; Taboada GF, 2009, PITUITARY, V12, P165, DOI 10.1007/s11102-008-0136-0; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Watt FM, 2004, TRENDS MOL MED, V10, P577, DOI 10.1016/j.molmed.2004.10.008; Weiss GJ, 2012, CANCER-AM CANCER SOC, V118, P5310, DOI 10.1002/cncr.27532; Wilson CH, 2010, ONCOGENE, V29, P4567, DOI 10.1038/onc.2010.202	33	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0267-8357	1464-3804		MUTAGENESIS	Mutagenesis	MAR	2015	30	2					297	301		10.1093/mutage/geu072		5	Genetics & Heredity; Toxicology	Genetics & Heredity; Toxicology	CD2ZG	WOS:000350946900015		
J	Susaki, J				Susaki, Junichi			Region-based automatic mapping of tsunami-damaged buildings using multi-temporal aerial images	NATURAL HAZARDS			English	Article						Remote sensing; Mapping; Extraction; Change detection; Damaged building; Aerial image	SAR DATA; JAPAN EARTHQUAKE; STEREO IMAGERY; URBAN AREAS; 2011 TOHOKU; CLASSIFICATION; EXTRACTION	After a disaster, prompt distribution of information is critical for national or local governments to plan the disaster response and recovery measures. In case of a tsunami, information about buildings destroyed by the waves is required. Here, we present a method that identifies individual damaged buildings by using aerial images obtained pre- and post-tsunami. The method utilizes significant height changes in building regions to assess the damage. Stereo aerial images are used to generate a digital surface model (DSM) of the area. We assume two cases: if geographic information system (GIS) data (building region data) are available, we use them and if GIS data are unavailable, we instead use segmented results and a filtered DSM. In each case, regions corresponding to buildings are identified in the pre-tsunami image. Damaged regions are then extracted by considering the height change within a building region between the pre- and post-disaster images. Horizontal shifts resulting from land deformation caused by the earthquake are automatically estimated by an existing algorithm such as scale-invariant feature transform (Lowe in Int J Comput Vis, 60(2):91-110, 2004). Validation showed that the proposed method extracted damaged buildings with high accuracy (94-96 % in number and 96-98 % in area) when GIS data are available and with lower accuracy (69-79 % in area) when GIS data are unavailable. In addition, we found that horizontal shifts between pre-and post-disaster should be considered to extract the damaged buildings. We conclude that our method can automatically generate effective maps of buildings damaged not only by tsunamis but also by other disasters.	Kyoto Univ, Grad Sch Engn, Dept Civil & Earth Resources Engn, Nishikyo Ku, Kyoto 6158540, Japan	Susaki, J (reprint author), Kyoto Univ, Grad Sch Engn, Dept Civil & Earth Resources Engn, Nishikyo Ku, Kyoto 6158540, Japan.	susaki.junichi.3r@kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [24760412]	This research was supported by a Grant-in-Aid for Scientific Research (KAKENHI) for Young Scientists (B) (24760412) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Brunner D, 2010, IEEE T GEOSCI REMOTE, V48, P2403, DOI 10.1109/TGRS.2009.2038274; Tsutsui K, 2007, IEEE T GEOSCI REMOTE, V45, P1681, DOI 10.1109/TGRS.2007.895209; Sato M, 2012, P IEEE, V100, P2861, DOI 10.1109/JPROC.2012.2200649; Yamaguchi Y, 2012, P IEEE, V100, P2851, DOI 10.1109/JPROC.2012.2195469; Mongus D, 2012, ISPRS J PHOTOGRAMM, V67, P1, DOI 10.1016/j.isprsjprs.2011.10.002; Tuia D, 2009, IEEE T GEOSCI REMOTE, V47, P3866, DOI 10.1109/TGRS.2009.2027895; Gamba P, 2007, IEEE T GEOSCI REMOTE, V45, P1582, DOI 10.1109/TGRS.2006.885392; Yonezawa C, 2001, INT J REMOTE SENS, V22, P1585, DOI 10.1080/01431160118187; Tian J, 2013, ISPRS J PHOTOGRAMM, V79, P226, DOI 10.1016/j.isprsjprs.2013.02.017; Susaki J, 2012, REMOTE SENS-BASEL, V4, P1804, DOI 10.3390/rs4061804; Chini M, 2012, IEEE GEOSCI REMOTE S, V9, P467, DOI 10.1109/LGRS.2011.2182495; Chini M, 2013, IEEE GEOSCI REMOTE S, V10, P347, DOI 10.1109/LGRS.2012.2205661; Novack T, 2011, REMOTE SENS-BASEL, V3, P2263, DOI 10.3390/rs3102263; Susaki J, 2012, REMOTE SENS-BASEL, V4, P911, DOI 10.3390/rs4040911; Chen SW, 2013, IEEE T GEOSCI REMOTE, V51, P1985, DOI 10.1109/TGRS.2012.2210050; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Dekker RJ, 2011, IEEE J-STARS, V4, P960, DOI 10.1109/JSTARS.2011.2164516; ENVI EX, 2009, ENVI EX US GUID; ENVI Feature Extraction Module User's Guide, 2009, ITT Visual Information Solutions, Patent No. [20090123070, 20,090,123,070]; Geospatial Information Authority of Japan, 2013, CRUST MOV GPS BAS ST; Geospatial Information Authority of Japan, 2013, 50 M DEM; Headquarters for Earthquake Research Promotion, 2013, PROB EARTHQ OCC LONG; Inpho, 2013, MATCH T DSM; Inpho, 2013, MATCH AT DSM; Khoshelham K, 2013, IEEE GEOSCI REMOTE S, V10, P1258, DOI 10.1109/LGRS.2013.2257676; Li XW, 2012, IEEE GEOSCI REMOTE S, V9, P677, DOI 10.1109/LGRS.2011.2178392; Liu W, 2012, INT GEOSCI REMOTE SE, P4038, DOI 10.1109/IGARSS.2012.6350523; Liu W, 2011, INT GEOSCI REMOTE SE, P2133; Matsuoka M, 2004, EARTHQ SPECTRA, V20, P975, DOI 10.1193/1.1774182; Pesci A, 2013, ISPRS J PHOTOGRAMM, V79, P185, DOI 10.1016/j.isprsjprs.2013.02.021; Sithole G, 2005, INT ARCH PHOTOGRAM 3, V36, P66; Susaki J, 2013, IEEE J SEL IN PRESS; Wang TL, 2012, IEEE GEOSCI REMOTE S, V9, P452, DOI 10.1109/LGRS.2011.2170657; Watanabe M, 2012, IEEE GEOSCI REMOTE S, V9, P472, DOI 10.1109/LGRS.2011.2182030; Yamaguchi Y, 2011, IEEE T GEOSCI REMOTE, V49, P2251, DOI 10.1109/TGRS.2010.2099124	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0921-030X	1573-0840		NAT HAZARDS	Nat. Hazards	MAR	2015	76	1					397	420		10.1007/s11069-014-1498-4		24	Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences; Water Resources	Geology; Meteorology & Atmospheric Sciences; Water Resources	CC4LZ	WOS:000350326200022		
J	Moignard, V; Woodhouse, S; Haghverdi, L; Lilly, AJ; Tanaka, Y; Wilkinson, AC; Buettner, F; Macaulay, IC; Jawaid, W; Diamanti, E; Nishikawa, SI; Piterman, N; Kouskoff, V; Theis, FJ; Fisher, J; Gottgens, B				Moignard, Victoria; Woodhouse, Steven; Haghverdi, Laleh; Lilly, Andrew J.; Tanaka, Yosuke; Wilkinson, Adam C.; Buettner, Florian; Macaulay, Iain C.; Jawaid, Wajid; Diamanti, Evangelia; Nishikawa, Shin-Ichi; Piterman, Nir; Kouskoff, Valerie; Theis, Fabian J.; Fisher, Jasmin; Goettgens, Berthold			Decoding the regulatory network of early blood development from single-cell gene expression measurements	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELL; YOLK-SAC; HEMATOPOIETIC DEVELOPMENT; DEFINITIVE HEMATOPOIESIS; RNA-SEQ; ADULT HEMATOPOIESIS; FATE DECISIONS; MOUSE EMBRYOS; LEUKEMIA; MICE	Reconstruction of the molecular pathways controlling organ development has been hampered by a lack of methods to resolve embryonic progenitor cells. Here we describe a strategy to address this problem that combines gene expression profiling of large numbers of single cells with data analysis based on diffusion maps for dimensionality reduction and network synthesis from state transition graphs. Applying the approach to hematopoietic development in the mouse embryo, we map the progression of mesoderm toward blood using single-cell gene expression analysis of 3,934 cells with blood-forming potential captured at four time points between E7.0 and E8.5. Transitions between individual cellular states are then used as input to develop a single-cell network synthesis toolkit to generate a computationally executable transcriptional regulatory network model of blood development. Several model predictions concerning the roles of Sox and Hox factors are validated experimentally. Our results demonstrate that single-cell analysis of a developing organ coupled with computational approaches can reveal the transcriptional programs that underpin organogenesis.	[Moignard, Victoria; Woodhouse, Steven; Tanaka, Yosuke; Wilkinson, Adam C.; Jawaid, Wajid; Diamanti, Evangelia; Goettgens, Berthold] Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge, England; [Moignard, Victoria; Woodhouse, Steven; Tanaka, Yosuke; Wilkinson, Adam C.; Diamanti, Evangelia; Goettgens, Berthold] Univ Cambridge, Cambridge Stem Cell Inst, Wellcome Trust Med Res Council, Cambridge, England; [Haghverdi, Laleh; Buettner, Florian; Theis, Fabian J.] Helmholtz Zentrum Munchen, Inst Computat Biol, Neuherberg, Germany; [Haghverdi, Laleh; Theis, Fabian J.] Tech Univ Munich, Dept Math, Garching, Germany; [Lilly, Andrew J.; Kouskoff, Valerie] Univ Manchester, Paterson Inst Canc Res, Canc Res UK Stem Cell Haematopoiesis Grp, Manchester, Lancs, England; [Tanaka, Yosuke; Nishikawa, Shin-Ichi] RIKEN Ctr Dev Biol, Lab Stem Cell Biol, Chuo Ku, Kobe, Hyogo, Japan; [Macaulay, Iain C.] Wellcome Trust Sanger Inst, EBI Single Cell Genom Ctr, Sanger Inst, Cambridge, England; [Piterman, Nir] Univ Leicester, Dept Comp Sci, Leicester, Leics, England; [Fisher, Jasmin] Microsoft Res Cambridge, Cambridge, England; [Fisher, Jasmin] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Gottgens, B (reprint author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge, England.	jasmin.fisher@microsoft.com; bg200@cam.ac.uk			Medical Research Council; Biotechnology and Biological Sciences Research Council; Leukaemia and Lymphoma Research; Leukemia and Lymphoma Society; Wellcome Trust; Medical Research Council Studentship and Centenary Award; Microsoft Research PhD Scholarship	We thank J. Downing (St. Jude Children's Research Hospital, Memphis, TN, USA) for the Runx1-ires-GFP mouse. Research in the authors' laboratory is supported by the Medical Research Council, Biotechnology and Biological Sciences Research Council, Leukaemia and Lymphoma Research, the Leukemia and Lymphoma Society, Microsoft Research and core support grants by the Wellcome Trust to the Cambridge Institute for Medical Research and Wellcome Trust - MRC Cambridge Stem Cell Institute. V.M. is supported by a Medical Research Council Studentship and Centenary Award and S.W. by a Microsoft Research PhD Scholarship.	Moignard V, 2013, NAT CELL BIOL, V15, P363, DOI 10.1038/ncb2709; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yan LY, 2013, NAT STRUCT MOL BIOL, V20, P1131, DOI 10.1038/nsmb.2660; Tanaka Y, 2012, P NATL ACAD SCI USA, V109, P4515, DOI 10.1073/pnas.1115828109; Xue ZG, 2013, NATURE, V500, P593, DOI 10.1038/nature12364; Moignard V, 2013, BLOOD CELL MOL DIS, V51, P239, DOI 10.1016/j.bcmd.2013.07.007; Kataoka H, 2011, BLOOD, V118, P6975, DOI 10.1182/blood-2011-05-352658; Sanchez-Castillo M, 2015, NUCLEIC ACIDS RES, V43, pD1117, DOI 10.1093/nar/gku895; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Wareing S, 2012, STEM CELLS, V30, P1521, DOI 10.1002/stem.1115; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Sacilotto N, 2013, P NATL ACAD SCI USA, V110, P11893, DOI 10.1073/pnas.1300805110; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Lux CT, 2008, BLOOD, V111, P3435, DOI 10.1182/blood-2007-08-107086; Bonzanni N, 2013, BIOINFORMATICS, V29, P80, DOI 10.1093/bioinformatics/btt243; Fan R, 2012, BLOOD, V119, pE139, DOI 10.1182/blood-2011-12-396754; Mikkola HKA, 2003, BLOOD, V101, P508, DOI 10.1182/blood-2002-06-1699; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Tischler J, 2013, CURR OPIN BIOTECH, V24, P69, DOI 10.1016/j.copbio.2012.09.013; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Tang FC, 2011, NAT METHODS, V8, pS6, DOI [10.1038/nmeth.1557, 10.1038/NMETH.1557]; Samokhvalov IM, 2007, NATURE, V446, P1056, DOI 10.1038/nature05725; Costa G, 2012, TRENDS IMMUNOL, V33, P215, DOI 10.1016/j.it.2012.01.012; Garg A, 2008, BIOINFORMATICS, V24, P1917, DOI 10.1093/bioinformatics/btn336; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Sumanas S, 2008, BLOOD, V111, P4500, DOI 10.1182/blood-2007-09-110569; Schlaeger TM, 2005, BLOOD, V105, P3871, DOI 10.1182/blood-2004-11-4467; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Pina C, 2012, NAT CELL BIOL, V14, P287, DOI 10.1038/ncb2442; Wilson NK, 2009, BLOOD, V113, P5456, DOI 10.1182/blood-2009-01-200048; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Pimanda JE, 2007, P NATL ACAD SCI USA, V104, P17692, DOI 10.1073/pnas.0707045104; North T, 1999, DEVELOPMENT, V126, P2563; Taoudi S, 2011, GENE DEV, V25, P251, DOI 10.1101/gad.2009211; Guo GJ, 2013, CELL STEM CELL, V13, P492, DOI 10.1016/j.stem.2013.07.017; Guo GJ, 2010, DEV CELL, V18, P675, DOI 10.1016/j.devcel.2010.02.012; Coifman RR, 2005, P NATL ACAD SCI USA, V102, P7426, DOI 10.1073/pnas.0500334102; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Gandillet A, 2009, BLOOD, V114, P4813, DOI 10.1182/blood-2009-06-226290; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Ding G, 2013, DEV DYNAM, V242, P254, DOI 10.1002/dvdy.23923; Bailey N.T.J., 1995, STAT METHODS BIOL, V1995, P255; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Koksal AS, 2013, ACM SIGPLAN NOTICES, V48, P469, DOI 10.1145/2480359.2429125; Krumsiek J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022649; Mitjavila-Garcia MT, 2002, DEVELOPMENT, V129, P2003; Sachs K, 2005, SCIENCE, V308, P523, DOI 10.1126/science.1105809; Stahlberg A, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1182; Swiers G, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3924; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Wilkinson AC, 2013, BIOL OPEN, V2, P1229, DOI 10.1242/bio.20136296; Xu HL, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003777	58	13	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2015	33	3					269	+		10.1038/nbt.3154		11	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CD0ME	WOS:000350766900023		
J	Ushijima, I; Takamoto, M; Das, M; Ohkubo, T; Katori, H				Ushijima, Ichiro; Takamoto, Masao; Das, Manoj; Ohkubo, Takuya; Katori, Hidetoshi			Cryogenic optical lattice clocks	NATURE PHOTONICS			English	Article							SHIFT; METROLOGY	The accuracy of atomic clocks relies on the superb reproducibility of atomic spectroscopy, which is accomplished by careful control and the elimination of environmental perturbations on atoms. To date, individual atomic clocks have achieved a 10(-18) level of total uncertainties(1,2), but a two-clock comparison at the 10(-18) level has yet to be demonstrated. Here, we demonstrate optical lattice clocks with Sr-87 atoms interrogated in a cryogenic environment to address the blackbody radiation-induced frequency shift(3), which remains the primary source of systematic uncertainty(2,4-6) and has initiated vigorous theoretical(7,8) and experimental(9,10) investigations. The systematic uncertainty for the cryogenic clock is evaluated to be 7.2 x 10(-18), which is expedited by operating two such cryo-clocks synchronously(11,12). After 11 measurements performed over a month, statistical agreement between the two cryo-clocks reached 2.0 x 10(-18). Such clocks' reproducibility is a major step towards developing accurate clocks at the low 10(-18) level, and is directly applicable as a means for relativistic geodesy(13).	[Ushijima, Ichiro; Takamoto, Masao; Das, Manoj; Ohkubo, Takuya; Katori, Hidetoshi] RIKEN, Quantum Metrol Lab, Wako, Saitama 3510198, Japan; [Ushijima, Ichiro; Takamoto, Masao; Das, Manoj; Ohkubo, Takuya; Katori, Hidetoshi] Japan Sci & Technol Agcy, ERATO, Innovat Space Time Project, Bunkyo Ku, Tokyo 1138656, Japan; [Ushijima, Ichiro; Ohkubo, Takuya; Katori, Hidetoshi] Univ Tokyo, Grad Sch Engn, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan; [Takamoto, Masao; Das, Manoj; Katori, Hidetoshi] RIKEN, Ctr Adv Photon, Wako, Saitama 3510198, Japan	Katori, H (reprint author), RIKEN, Quantum Metrol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hkatori@riken.jp			Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST); Photon Frontier Network Program of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	This work received partial support from the Japan Society for the Promotion of Science (JSPS) through its Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) and from the Photon Frontier Network Program of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. The authors thank H. Kubo for his contribution in the initial stage of the experiments, and N. Nemitz, T. Takano, A. Yamaguchi and N. Ohmae for useful comments and conversations.	Akatsuka T, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.032801; Nicholson TL, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.230801; Chou CW, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.070802; Porsev SG, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.020502; Hinkley N, 2013, SCIENCE, V341, P1215, DOI 10.1126/science.1240420; Middelmann T, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.263004; Lodewyck J, 2012, IEEE T ULTRASON FERR, V59, P411, DOI 10.1109/TUFFC.2012.2209; Bloom BJ, 2014, NATURE, V506, P71, DOI 10.1038/nature12941; Chou CW, 2010, SCIENCE, V329, P1630, DOI 10.1126/science.1192720; Takamoto M, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.104302; Derevianko A, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.180801; Huntemann N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.090801; Yamaguchi A, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.082203; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83; Takamoto M, 2011, NAT PHOTONICS, V5, P288, DOI [10.1038/nphoton.2011.34, 10.1038/NPHOTON.2011.34]; Middelmann T, 2011, IEEE T INSTRUM MEAS, V60, P2550, DOI 10.1109/TIM.2010.2088470; Katori H, 2011, NAT PHOTONICS, V5, P203, DOI [10.1038/nphoton.2011.45, 10.1038/NPHOTON.2011.45]; Safronova MS, 2013, PHYS REV A, V87, DOI 10.1103/PhysRevA.87.012509; Westergaard PG, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.210801; ITANO WM, 1993, PHYS REV A, V47, P3554, DOI 10.1103/PhysRevA.47.3554; Sherman JA, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.153002; Mukaiyama T, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.113002; ITANO WM, 1982, PHYS REV A, V25, P1233, DOI 10.1103/PhysRevA.25.1233; Falke S, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/7/073023; Hachisu H, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.053001; Katori H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.153004; Katori H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.173005; Le Targat R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3109; McFerran JJ, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.183004; Rosenband T, 2008, SCIENCE, V319, P1808, DOI 10.1126/science.1154622; Takamoto M, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.013301	31	47	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-4885	1749-4893		NAT PHOTONICS	Nat. Photonics	MAR	2015	9	3					185	189		10.1038/NPHOTON.2015.5		5	Optics; Physics, Applied	Optics; Physics	CD0NQ	WOS:000350771500011		
J	Furukawa, T; Miyagawa, K; Taniguchi, H; Kato, R; Kanoda, K				Furukawa, Tetsuya; Miyagawa, Kazuya; Taniguchi, Hiromi; Kato, Reizo; Kanoda, Kazushi			Quantum criticality of Mott transition in organic materials	NATURE PHYSICS			English	Article							PHASE-TRANSITIONS; INSULATOR; METAL; SUPERCONDUCTIVITY; SYSTEMS	A many-body quantum system on the verge of instability between two competing ground states may exhibit quantum-critical phenomena(1,2), as has been intensively studied for magnetic systems. The Mott metal-insulator transition(3), a phenomenon that is central to many investigations of strongly correlated electrons, is also supposed to be quantum critical, although this has so far not been demonstrated experimentally. Here, we report experimental evidence for the quantum-critical nature of the Mott instability, obtained by investigating the electron transport of three organic systems with different ground states under continuously controlled pressure. The resistivity obeys the material-independent quantum-critical scaling relation bifurcating into a Fermi liquid or Mott insulator, irrespective of the ground states. Electrons on the verge of becoming delocalized behave like a strange quantum-critical fluid before becoming a Fermi liquid.	[Furukawa, Tetsuya; Miyagawa, Kazuya; Kanoda, Kazushi] Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan; [Taniguchi, Hiromi] Saitama Univ, Dept Phys, Sakura Ku, Saitama 3388570, Japan; [Kato, Reizo] RIKEN, Wako, Saitama 3510198, Japan	Furukawa, T (reprint author), Univ Tokyo, Dept Appl Phys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	furukawa@ap.t.u-tokyo.ac.jp; kanoda@ap.t.u-tokyo.ac.jp	Kato, Reizo/I-1073-2014		JSPS KAKENHI [20110002, 25220709, 24654101]; US National Science Foundation [PHYS-1066293]	We would like to thank V. Dobrosavljevic, N. Nagaosa, H. Oike and T. Itou for fruitful discussions. This work was supported in part by JSPS KAKENHI under Grant Nos 20110002, 25220709 and 24654101, and the US National Science Foundation under Grant No. PHYS-1066293 and the hospitality of the Aspen Center for Physics.	Amaricci A, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.155102; Lefebvre S, 2000, PHYS REV LETT, V85, P5420, DOI 10.1103/PhysRevLett.85.5420; Yao X, 1996, PHYS REV B, V54, P17469, DOI 10.1103/PhysRevB.54.17469; Limelette P, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.016401; Kanoda K, 2011, ANNU REV CONDEN MA P, V2, P167, DOI 10.1146/annurev-conmatphys-062910-140521; Misawa T, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.115121; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; Komatsu T, 1996, J PHYS SOC JPN, V65, P1340, DOI 10.1143/JPSJ.65.1340; Kagawa F, 2005, NATURE, V436, P534, DOI 10.1038/nature038O6; Powell BJ, 2011, REP PROG PHYS, V74, DOI 10.1088/0034-4885/74/5/056501; Senthil T, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.045109; Terletska H, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.026401; Sachdev S, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.151602; Senthil T, 2005, PHYSICA B, V359, P9, DOI 10.1016/j.physb.2004.12.041; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; Kurosaki Y, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.177001; KRAVCHENKO SV, 1995, PHYS REV B, V51, P7038, DOI 10.1103/PhysRevB.51.7038; Shimizu Y, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.107001; MCWHAN DB, 1973, PHYS REV B, V7, P1920, DOI 10.1103/PhysRevB.7.1920; Itou T, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.104413; Davison RA, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.245116; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; Kato R, 2012, CRYSTALS, V2, P861, DOI 10.3390/cryst2030861; Kato R., 2007, MULTIFUNCTIONAL COND, P32; Kato R, 2014, B CHEM SOC JPN, V87, P355, DOI 10.1246/bcsj.20130290; Kobashi K., 2007, THESIS U TOKYO; KOSTERLITZ JM, 1974, J PHYS C SOLID STATE, V7, P1046, DOI 10.1088/0022-3719/7/6/005; Mott N.F., 1990, METAL INSULATOR TRAN; Sachdev S., 2011, QUANTUM PHASE TRANSI; Simonian D., 1997, PHYS REV B, V55; Vucicevic J, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.075143; Witczak-Krempa W, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.245102	32	5	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-2473	1745-2481		NAT PHYS	Nat. Phys.	MAR	2015	11	3					221	224		10.1038/NPHYS3235		4	Physics, Multidisciplinary	Physics	CC9FW	WOS:000350674700011		
J	Umegaki, H				Umegaki, Hiroyuki			Type 2 diabetes has a slow and insidious effect on cognition	NATURE REVIEWS NEUROLOGY			English	Editorial Material							ALZHEIMER-DISEASE; DECLINE	Type 2 diabetes mellitus (T2DM) has been linked with cognitive impairment and dementia. A new cross-sectional study reports that T2DM is also associated with dementia in Parkinson disease, and another study describes the long-term clinical course of diabetes-associated cognitive dysfunction; however, the mechanisms through which T2DM affects the brain are not completely understood.	Dept Community Healthcare & Geriatr, Showa Ku, Nagoya, Aichi 4668550, Japan	Umegaki, H (reprint author), Dept Community Healthcare & Geriatr, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.	umegaki@med.nagoya-u.ac.jp					Matsuzaki T, 2010, NEUROLOGY, V75, P764, DOI 10.1212/WNL.0b013e3181eee25f; Thambisetty M, 2013, JAMA NEUROL, V70, P1167, DOI 10.1001/jamaneurol.2013.284; Launer LJ, 2011, LANCET NEUROL, V10, P969, DOI 10.1016/S1474-4422(11)70188-0; Rawlings AM, 2014, ANN INTERN MED, V161, P785, DOI 10.7326/M14-0737; Schubert M, 2003, J NEUROSCI, V23, P7084; Schrijvers EMC, 2010, NEUROLOGY, V75, P1982, DOI 10.1212/WNL.0b013e3181ffe4f6; Cukierman T, 2005, DIABETOLOGIA, V48, P2460, DOI 10.1007/s00125-005-0023-4; Luchsinger JA, 2011, J NUTR HEALTH AGING, V15, P445, DOI 10.1007/s12603-011-0057-x; Bohnen NI, 2014, PARKINSONISM RELAT D, V20, P1394, DOI 10.1016/j.parkreldis.2014.10.008; Umegaki H, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.04.017	10	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4758	1759-4766		NAT REV NEUROL	Nat. Rev. Neurol.	MAR	2015	11	3								10.1038/nrneurol.2015.17		2	Clinical Neurology	Neurosciences & Neurology	CD0NM	WOS:000350771000001		
J	Kitago, Y; Nagae, M; Nakata, Z; Yagi-Utsumi, M; Takagi-Niidome, S; Mihara, E; Nogi, T; Kato, K; Takagi, J				Kitago, Yu; Nagae, Masamichi; Nakata, Zenzaburo; Yagi-Utsumi, Maho; Takagi-Niidome, Shizuka; Mihara, Emiko; Nogi, Terukazu; Kato, Koichi; Takagi, Junichi			Structural basis for amyloidogenic peptide recognition by sorLA	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							ONSET ALZHEIMER-DISEASE; RECEPTOR FAMILY-MEMBER; SORTING RECEPTOR; HEAD-ACTIVATOR; LDL RECEPTOR; PROTEIN; LIGAND; BETA; LR11; BINDING	SorLA is a neuronal sorting receptor considered to be a major risk factor for Alzheimer's disease. We have recently reported that it directs lysosomal targeting of nascent neurotoxic amyloid-beta (All) peptides by directly binding A beta. Here, we determined the crystal structure of the human sorLA domain responsible for A beta capture, Vps10p, in an unbound state and in complex with two ligands. Vps10p assumes a ten-bladed beta-propeller fold with a large tunnel at the center. An internal ligand derived from the sorLA propeptide bound inside the tunnel to extend the beta-sheet of one of the propeller blades. The structure of the sorLA Vps10p-A beta complex revealed that the same site is used. Peptides are recognized by sorLA Vps10p in redundant modes without strict dependence on a particular amino acid sequence, thus suggesting a broad specificity toward peptides with a propensity for beta-sheet formation.	[Kitago, Yu; Nagae, Masamichi; Nakata, Zenzaburo; Takagi-Niidome, Shizuka; Mihara, Emiko; Takagi, Junichi] Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan; [Yagi-Utsumi, Maho; Kato, Koichi] Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi, Japan; [Yagi-Utsumi, Maho; Kato, Koichi] Nagoya City Univ, Grad Sch Pharmaceut Sci, Nagoya, Aichi, Japan; [Nogi, Terukazu] Yokohama City Univ, Grad Sch Med Life Sci, Yokohama, Kanagawa 232, Japan	Takagi, J (reprint author), Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan.	takagi@protein.osaka-u.ac.jp			Scientific Research on Innovative Areas 'Analysis and Synthesis of Multidimensional Immune Organ Network' [24111006]; Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [25102008]; MEXT [12736015, 12004060, S-14-MS-1039]; Okazaki ORION project; National Center for Geriatrics and Gerontology of Japan [25-19]	We would like to thank the staff of the beamlines at Photon Factory and SPring-8 for their help with X-ray data collection, K. Yamashita for help in the setup of MD simulations and for discussions on data analysis, S. Thompson for critical reading and editing of the manuscript, K. Tamura-Kawakami for excellent technical assistance and M. Sakai for preparation of the manuscript. This work was supported by the Grant-in-Aid for Scientific Research on Innovative Areas 'Analysis and Synthesis of Multidimensional Immune Organ Network' (no. 24111006 to J.T.) and 'Dynamic Ordering of Biomolecular Systems for Creation of Integrated Functions' (no. 25102008 to K.K.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), by the 'Platform for Drug Discovery, Informatics, and Structural Life Science' grant from the MEXT (no. 12736015 to J.T.), by the 'X-ray Free Electron Laser Priority Strategy Program' grant from the MEXT (no. 12004060 to J.T.), by the Nanotechnology Platform Project (no. S-14-MS-1039 to J.T.) from the MEXT, by the Okazaki ORION project (to K.K.) and by the Research Funding for Longevity Sciences from the National Center for Geriatrics and Gerontology of Japan (no. 25-19 to K.K.).	MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Trovato A, 2007, PROTEIN ENG DES SEL, V20, P521, DOI 10.1093/protein/gzm042; Chiti F, 2009, NAT CHEM BIOL, V5, P15, DOI 10.1038/nchembio.131; Dodson SE, 2008, J NEUROSCI, V28, P12877, DOI 10.1523/JNEUROSCI.4582-08.2008; Beglova N, 2005, TRENDS BIOCHEM SCI, V30, P309, DOI 10.1016/j.tibs.2005.03.007; Tycko R, 2013, ACCOUNTS CHEM RES, V46, P1487, DOI 10.1021/ar300282r; Caglayan S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007747; Jacobsen L, 1996, J BIOL CHEM, V271, P31379; Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Yamazaki H, 1996, J BIOL CHEM, V271, P24761; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Taira K, 2001, ARTERIOSCL THROM VAS, V21, P1501, DOI 10.1161/hq0901.094500; Willnow TE, 2008, NAT REV NEUROSCI, V9, P899, DOI 10.1038/nrn2516; Nakata Z, 2011, ACTA CRYSTALLOGR F, V67, P129, DOI 10.1107/S1744309110048153; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Bettens K, 2008, HUM MUTAT, V29, P769, DOI 10.1002/humu.20725; Pottier C, 2012, MOL PSYCHIATR, V17, P875, DOI 10.1038/mp.2012.15; Mittag T, 2008, P NATL ACAD SCI USA, V105, P17772, DOI 10.1073/pnas.0809222105; Quistgaard EM, 2009, NAT STRUCT MOL BIOL, V16, P96, DOI 10.1038/nsmb.1543; Scherzer CR, 2004, ARCH NEUROL-CHICAGO, V61, P1200, DOI 10.1001/archneur.61.8.1200; Hampe W, 1999, DEVELOPMENT, V126, P4077; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Libich DS, 2013, P NATL ACAD SCI USA, V110, P11361, DOI 10.1073/pnas.1305715110; Rezgaoui M, 2006, J CELL SCI, V119, P542, DOI 10.1242/jcs.02766; Rossi AM, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2011.305; Schaller HC, 1996, INT J DEV BIOL, V40, P339; Yagi-Utsumi M, 2013, FEBS LETT, V587, P1605, DOI 10.1016/j.febslet.2013.04.007	27	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	MAR	2015	22	3					199	206		10.1038/nsmb.2954		8	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CC7ER	WOS:000350531000008		
J	Fishbain, S; Inobe, T; Israeli, E; Chavali, S; Yu, HQ; Kago, G; Babu, MM; Matouschek, A				Fishbain, Susan; Inobe, Tomonao; Israeli, Eitan; Chavali, Sreenivas; Yu, Houqing; Kago, Grace; Babu, M. Madan; Matouschek, Andreas			Sequence composition of disordered regions fine-tunes protein half-life	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							EPSTEIN-BARR-VIRUS; UBIQUITIN-CONJUGATING ENZYME; SHORT-LIVED PROTEIN; PROTEASOMAL DEGRADATION; HUNTINGTONS-DISEASE; MULTIUBIQUITIN CHAIN; NUCLEAR ANTIGEN-1; DNA-REPAIR; KAPPA-B; AGGREGATION	The proteasome controls the concentrations of most proteins in eukaryotic cells. It recognizes its protein substrates through ubiquitin tags and initiates degradation at disordered regions within the substrate. Here we show that the proteasome has pronounced preferences for the amino acid sequence of the regions at which it initiates degradation. Specifically, proteins in which the initiation regions have biased amino acid compositions show longer half-lives in yeast than proteins with unbiased sequences in the regions. The relationship is also observed on a genomic scale in mouse cells. These preferences affect the degradation rates of proteins in vitro, can explain the unexpected stability of natural proteins in yeast and may affect the accumulation of toxic proteins in disease. We propose that the proteasome's sequence preferences provide a second component to the degradation code and may fine-tune protein half-life in cells.	[Fishbain, Susan; Yu, Houqing; Kago, Grace; Matouschek, Andreas] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Fishbain, Susan; Inobe, Tomonao; Israeli, Eitan; Yu, Houqing; Matouschek, Andreas] Northwestern Univ, Dept Mol Biosci, Evanston, IL USA; [Inobe, Tomonao] Toyama Univ, Frontier Res Core Life Sci, Toyama 930, Japan; [Chavali, Sreenivas; Babu, M. Madan] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Matouschek, A (reprint author), Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.	matouschek@austin.utexas.edu			US National Institutes of Health [R01GM063004, U54GM105816, U54CA143869]; Welch Foundation [F-1817]; Ministry of Education, Culture, Sports, Science and Technology Japan; UK Medical Research Council [MC_U105185859]; European Molecular Biology Organization	We thank J. Brickner and R.A. Lamb (Northwestern University), M. Glickman (Technion), R.V. Pappu (Washington University) and Y. Saeki (Tokyo Metropolitan Institute of Medical Science) for advice and reagents, as well as A. Zokarkar for early experiments on this project. We are also grateful to K. Brown, A. Gnanam and E.J. Cho for help with the CD experiments. This work was supported by the US National Institutes of Health (R01GM063004, U54GM105816 and U54CA143869 (A.M.)); the Welch Foundation (F-1817 (A.M.)); the Program to Disseminate Tenure Track System from the Ministry of Education, Culture, Sports, Science and Technology Japan (T.I.); the UK Medical Research Council (MC_U105185859 (S.C. and M.M.B.); and the European Molecular Biology Organization (Long-Term Fellowship (S.C.) and Young Investigator Program (M.M.B.)).	Akopian TN, 1997, J BIOL CHEM, V272, P1791; Das RK, 2013, P NATL ACAD SCI USA, V110, P13392, DOI 10.1073/pnas.1304749110; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.0.CO;2-H; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; IQBAL K, 1991, MOL NEUROBIOL, V5, P399, DOI 10.1007/BF02935561; Inobe T, 2011, NAT CHEM BIOL, V7, P161, DOI [10.1038/nchembio.521, 10.1038/NCHEMBIO.521]; Mao AH, 2010, P NATL ACAD SCI USA, V107, P8183, DOI 10.1073/pnas.0911107107; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Moesa HA, 2012, MOL BIOSYST, V8, P3262, DOI 10.1039/c2mb25202c; Zuccato C, 2010, PHYSIOL REV, V90, P905, DOI 10.1152/physrev.00041.2009; Schrader EK, 2009, NAT CHEM BIOL, V5, P815, DOI 10.1038/nchembio.250; Babu MM, 2012, SCIENCE, V337, P1460, DOI 10.1126/science.1228775; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Nathan JA, 2013, EMBO J, V32, P552, DOI 10.1038/emboj.2012.354; Waelter S, 2001, MOL BIOL CELL, V12, P1393; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Stack JH, 2000, NAT BIOTECHNOL, V18, P1298, DOI 10.1038/82422; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; Brown CJ, 2011, CURR OPIN STRUC BIOL, V21, P441, DOI 10.1016/j.sbi.2011.02.005; Kalchman MA, 1996, J BIOL CHEM, V271, P19385; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Muller-Spath S, 2010, P NATL ACAD SCI USA, V107, P14609, DOI 10.1073/pnas.1001743107; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Fiumara F, 2010, CELL, V143, P1121, DOI 10.1016/j.cell.2010.11.042; Tian L, 2005, NAT STRUCT MOL BIOL, V12, P1045, DOI 10.1038/nsmb1018; Schauber C, 1998, NATURE, V391, P715; Douglas PM, 2010, J CELL BIOL, V190, P719, DOI 10.1083/jcb.201005144; Daskalogianni C, 2008, J BIOL CHEM, V283, P30090, DOI 10.1074/jbc.M803290200; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Hipp MS, 2012, J CELL BIOL, V196, P573, DOI 10.1083/jcb.201110093; Beskow A, 2009, J MOL BIOL, V394, P732, DOI 10.1016/j.jmb.2009.09.050; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; BANCHER C, 1989, J NEUROPATH EXP NEUR, V48, P81, DOI 10.1097/00005072-198901000-00007; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Fishbain S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1194; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022; Hagal T., 2010, P NATL ACAD SCI USA, V107, P2001; Heessen S, 2005, MOL CELL, V18, P225, DOI 10.1016/j.molcel.2005.03.015; Heinen C, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1179; Hoyt MA, 2006, EMBO J, V25, P1720, DOI 10.1038/sj.emboj.7601058; Juenemann K, 2013, J BIOL CHEM, V288, P27068, DOI 10.1074/jbc.M113.486076; Kraut DA, 2011, ACS CHEM BIOL, V6, P1087, DOI 10.1021/cb2002285; Kraut DA, 2012, ACS CHEM BIOL, V7, P1444, DOI 10.1021/cb3001155; Kruegel U, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002253; Pratt G, 2008, J BIOL CHEM, V283, P12919, DOI 10.1074/jbc.M709347200; Punta M, 2012, NUCLEIC ACIDS RES, V40, pD290, DOI 10.1093/nar/gkr1065; Raman M, 2011, MOL CELL, V44, P72, DOI 10.1016/j.molcel.2011.06.036; Tompa P., 2010, STRUCTURE FUNCTION I; UDENFRIE.S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; van der Lee R, 2014, CELL REP, V8, P1832, DOI 10.1016/j.celrep.2014.07.055; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757; Zhang MS, 2004, J BIOL CHEM, V279, P8635, DOI 10.1074/jbc.M310449200	65	6	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	MAR	2015	22	3					214	221		10.1038/nsmb.2958		8	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CC7ER	WOS:000350531000010		
J	Sato, Y; Goto, E; Shibata, Y; Kubota, Y; Yamagata, A; Goto-Ito, S; Kubota, K; Inoue, J; Takekawa, M; Tokunaga, F; Fukai, S				Sato, Yusuke; Goto, Eiji; Shibata, Yuri; Kubota, Yuji; Yamagata, Atsushi; Goto-Ito, Sakurako; Kubota, Keiko; Inoue, Jun-ichiro; Takekawa, Mutsuhiro; Tokunaga, Fuminori; Fukai, Shuya			Structures of CYLD USP with Met1-or Lys63-linked diubiquitin reveal mechanisms for dual specificity	NATURE STRUCTURAL & MOLECULAR BIOLOGY			English	Article							NF-KAPPA-B; LINEAR UBIQUITIN CHAINS; FAMILIAL CYLINDROMATOSIS; DEUBIQUITINATING ENZYME; POLYUBIQUITIN CHAINS; RECOGNITION; ACTIVATION; DOMAIN; IDENTIFICATION; MUTATIONS	The tumor suppressor CYLD belongs to a ubiquitin (Ub)-specific protease (USP) family and specifically cleaves Met1- and Lys63-linked polyubiquitin chains to suppress inflammatory signaling pathways. Here, we report crystal structures representing the catalytic states of zebrafish CYLD for Met1- and Lys63-linked Ub chains and two distinct precatalytic states for Met1-linked chains. In both catalytic states, the distal Ub is bound to CYLD in a similar manner, and the scissile bond is located close to the catalytic residue, whereas the proximal Ub is bound in a manner specific to Met1- or Lys63-linked chains. Further structure-based mutagenesis experiments support the mechanism by which CYLD specifically cleaves both Met1- and Lys63-linked chains and provide insight into tumor-associated mutations of CYLD. This study provides new structural insight into the mechanisms by which USP family deubiquitinating enzymes recognize and cleave Ub chains with specific linkage types.	[Sato, Yusuke; Yamagata, Atsushi; Goto-Ito, Sakurako; Kubota, Keiko; Fukai, Shuya] Univ Tokyo, Div Life Sci, Synchrotron Radiat Res Org, Tokyo, Japan; [Sato, Yusuke; Yamagata, Atsushi; Goto-Ito, Sakurako; Kubota, Keiko; Fukai, Shuya] Univ Tokyo, Inst Mol & Cellular Biosci, Ctr Struct Biol Challenging Prot, Tokyo, Japan; [Sato, Yusuke; Yamagata, Atsushi; Goto-Ito, Sakurako; Kubota, Keiko; Fukai, Shuya] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba, Japan; [Goto, Eiji; Tokunaga, Fuminori] Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 371, Japan; [Shibata, Yuri; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Div Cellular & Mol Biol, Tokyo, Japan; [Kubota, Yuji; Takekawa, Mutsuhiro] Univ Tokyo, Inst Med Sci, Div Cell Signaling & Mol Med, Tokyo, Japan; [Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Med Prote Lab, Tokyo, Japan; [Fukai, Shuya] Japan Sci & Technol Agcy JST, Core Res Evolutionary Sci & Technol, Tokyo, Japan	Fukai, S (reprint author), Univ Tokyo, Div Life Sci, Synchrotron Radiat Res Org, Tokyo, Japan.	fukai@iam.u-tokyo.ac.jp			CREST, JST;  [22121003];  [22117002];  [22117003];  [22117006];  [25117711];  [25112505];  [24687012];  [24247014]	We thank S. Kaiser for critically reading and improving this manuscript. We also thank the beamline staff at NW12A, BL-1A, BL-5A and BL17A of the Photon Factory (Tsukuba, Japan) and BL32XU and BL41XU of SPring-8 (Hyogo, Japan) for technical help during data collection. This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas 22121003 (S.F.), 22117002 (J.I.), 22117003 (M.T.), 22117006 (F.T.), 25117711 (Y. Sato) and 25112505 (Y. Sato), Grant-in-Aid for Young Scientists (A) 24687012 (Y. Sato), Grant-in-Aid for Scientific Research (A) 24247014 (S.F.) and CREST, JST (S.F.).	Almeida S, 2008, J INVEST DERMATOL, V128, P587, DOI 10.1038/sj.jid.5701045; Bremm A, 2010, NAT STRUCT MOL BIOL, V17, P939, DOI 10.1038/nsmb.1873; Ye Y, 2011, EMBO REP, V12, P350, DOI 10.1038/embor.2011.17; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Blake PW, 2009, HUM MUTAT, V30, P1025, DOI 10.1002/humu.21024; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Bignell GR, 2000, NAT GENET, V25, P160; Trang VH, 2012, ANGEW CHEM INT EDIT, V51, P13085, DOI 10.1002/anie.201207171; Sato Y, 2011, P NATL ACAD SCI USA, V108, P20520, DOI 10.1073/pnas.1109088108; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Licchesi JDF, 2012, NAT STRUCT MOL BIOL, V19, P62, DOI 10.1038/nsmb.2169; Iwai K, 2012, TRENDS CELL BIOL, V22, P355, DOI 10.1016/j.tcb.2012.04.001; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Juang YC, 2012, MOL CELL, V45, P384, DOI 10.1016/j.molcel.2012.01.011; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911; Virdee S, 2010, NAT CHEM BIOL, V6, P750, DOI [10.1038/nchembio.426, 10.1038/NCHEMBIO.426]; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Numan S.M., 2005, CELL, V123, P773; Takiuchi T, 2014, GENES CELLS, V19, P254, DOI 10.1111/gtc.12128; van den Ouweland AMW, 2011, FAM CANCER, V10, P127, DOI 10.1007/s10689-010-9393-y	31	4	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1545-9993	1545-9985		NAT STRUCT MOL BIOL	Nat. Struct. Mol. Biol.	MAR	2015	22	3					222	229		10.1038/nsmb.2970		8	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Biochemistry & Molecular Biology; Biophysics; Cell Biology	CC7ER	WOS:000350531000011		
J	Rowley, S; Liang, LP; Fulton, R; Shimizu, T; Day, B; Patel, M				Rowley, Shane; Liang, Li-Ping; Fulton, Ruth; Shimizu, Takahiko; Day, Brian; Patel, Manisha			Mitochondrial respiration deficits driven by reactive oxygen species in experimental temporal lobe epilepsy	NEUROBIOLOGY OF DISEASE			English	Article						Oxidative stress; Mitochondrial dysfunction; Temporal lobe epilepsy; Seizures; Kainic acid	INDUCED HIPPOCAMPAL DAMAGE; OXIDATIVE STRESS; SUPEROXIDE PRODUCTION; CELL-DEATH; COMPLEX I; ANTICONVULSANT; MICE; EPILEPTOGENESIS; DYSFUNCTION; ACTIVATION	Metabolic alterations have been implicated in the etiology of temporal lobe epilepsy (TLE), but whether or not they have a functional impact on cellular energy producing pathways (glycolysis and/or oxidative phosphorylation) is unknown. The goal of this study was to determine if alterations in cellular bioenergetics occur using real-time analysis of mitochondrial oxygen consumption and glycolytic rates in an animal model of TLE. We hypothesized that increased steady-state levels of reactive oxygen species (ROS) initiated by epileptogenic injury result in impaired mitochondrial respiration. We established methodology for assessment of bioenergetic parameters in isolated synaptosomes from the hippocampus of Sprague Dawley rats at various times in the kainate (I(A) model of TLE. Deficits in indices of mitochondrial respiration were observed at time points corresponding with the acute and chronic phases of epileptogenesis. We asked if mitochondrial bioenergetic dysfunction occurred as a result of increased mitochondrial ROS and if it could be attenuated in the KA model by pharmacologically scavenging ROS. Increased steady-state ROS in mice with forebrain-specific conditional deletion of manganese superoxide dismutase (Sod2(fl/fl)NEX(Cre/Cre) in mice resulted in profound deficits in mitochondrial oxygen consumption. Pharmacological scavenging of ROS with a catalytic antioxidant restored mitochondrial respiration deficits in the KA model of TLE. Together, these results demonstrate that mitochondria( respiration deficits occur in experimental TLE and ROS mechanistically contribute to these deficits. Furthermore, this study provides novel methodology for assessing cellular metabolism during the entire time course of disease development. (C) 2015 Elsevier Inc All rights reserved.	[Rowley, Shane; Patel, Manisha] Univ Colorado, Neurosci Training Program, Aurora, CO 80045 USA; [Liang, Li-Ping; Fulton, Ruth; Patel, Manisha] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO 80045 USA; [Shimizu, Takahiko] Chiba Univ, Grad Sch Med, Dept Adv Aging Med, Chiba 2630022, Japan; [Day, Brian] Natl Jewish Hlth, Denver, CO 80206 USA	Patel, M (reprint author), Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus,12850 E Montview Blvd, Aurora, CO 80045 USA.	manisha.patel@ucdenver.edu			NIH [RO1NS039587, UO1NS083422, 5 F31 NS077739-03]	This work is supported by NIH RO1NS039587(M.P.), NIH UO1NS083422 (M.P.), NIH 5 F31 NS077739-03 (S.R.). The authors wish to thank Drs. Yogendra Raol, Andrew White and the UCAMC In Vivo Neurophysiology and Pathology Core Facilities.	Kann O, 2005, BRAIN, V128, P2396, DOI 10.1093/brain/awh568; Friedman A, 2011, EPILEPSIA, V52, P33, DOI 10.1111/j.1528-1167.2011.03034.x; Rowley S, 2013, FREE RADICAL BIO MED, V62, P121, DOI 10.1016/j.freeradbiomed.2013.02.002; Kovac S, 2012, J CELL SCI, V125, P1796, DOI 10.1242/jcs.099176; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Dunkley PR, 2008, NAT PROTOC, V3, P1718, DOI 10.1038/nprot.2008.171; Ryan K, 2012, J NEUROSCI, V32, P11250, DOI 10.1523/JNEUROSCI.0907-12.2012; Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033; Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029; O'Neill HC, 2010, FREE RADICAL BIO MED, V48, P1188, DOI 10.1016/j.freeradbiomed.2010.01.039; Goebbels S, 2006, GENESIS, V44, P611, DOI 10.1002/dvg.20256; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6; Kudin AP, 2002, EUR J NEUROSCI, V15, P1105, DOI 10.1046/j.1460-9568.2002.01947.x; Kunz WS, 2000, ANN NEUROL, V48, P766, DOI 10.1002/1531-8249(200011)48:5<766::AID-ANA10>3.0.CO;2-M; Liang LP, 2012, NEUROBIOL DIS, V45, P1068, DOI 10.1016/j.nbd.2011.12.025; Castello PR, 2008, J PHARMACOL EXP THER, V324, P970, DOI 10.1124/jpet.107.132134; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; Vielhaber S, 2008, EPILEPSIA, V49, P40, DOI 10.1111/j.1528-1167.2007.01280.x; Stafstrom CE, 2009, ANN NEUROL, V65, P435, DOI 10.1002/ana.21603; Dranka BP, 2010, FREE RADICAL BIO MED, V48, P905, DOI 10.1016/j.freeradbiomed.2010.01.015; Patel M, 2005, J NEUROCHEM, V92, P123, DOI 10.1111/j.1471-4159.2004.02838.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Jarrett SG, 2008, NEUROBIOL DIS, V30, P130, DOI 10.1016/j.nbd.2007.12.009; Lee EM, 2012, EPILEPSIA, V53, P860, DOI 10.1111/j.1528-1167.2012.03432.x; Gasior M, 2010, EPILEPSIA, V51, P1385, DOI 10.1111/j.1528-1167.2010.02593.x; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x; Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x; Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92; Waldbaum S, 2010, J NEUROCHEM, V115, P1172, DOI 10.1111/j.1471-4159.2010.07013.x; Christen Y., 2000, AM J CLIN NUTR, V71, p621S; CHUGANI HT, 1994, EPILEPSIA, V35, P813, DOI 10.1111/j.1528-1157.1994.tb02517.x; Day BJ, 2004, DRUG DISCOV TODAY, V9, P557, DOI 10.1016/S1359-6446(04)03139-3; Delgado-Escueta A V, 1999, Adv Neurol, V79, P3; Galella G, 1983, J Neurosurg Sci, V27, P69; Garda-Cabrero A.M., 2013, NEUROBIOL DIS, V58, P200; GRISAR T, 1984, ANN NEUROL, V16, pS128, DOI 10.1002/ana.410160719; Kovac S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.390; Lian XY, 2007, J NEUROSCI, V27, P12007, DOI 10.1523/JNEUROSCI.3163-07.2007; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Ryan K., 2013, NEUROBIOL DIS, V64, P8; Schmeisser Sebastian, 2013, Mol Metab, V2, P92, DOI 10.1016/j.molmet.2013.02.002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; van Rijckevorsel K, 2006, SEIZURE-EUR J EPILEP, V15, P227, DOI 10.1016/j.seizure.2006.02.019; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; Yuyun Xiong, 2013, Dose Response, V11, P270, DOI 10.2203/dose-response.12-005.Gao	47	3	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2015	75						151	158		10.1016/j.nbd.2014.12.025		8	Neurosciences	Neurosciences & Neurology	CD3ZN	WOS:000351022500013		
J	Terayama, R; Kishimoto, N; Yamamoto, Y; Maruhama, K; Tsuchiya, H; Mizutani, M; Iida, S; Sugimoto, T				Terayama, Ryuji; Kishimoto, Noriko; Yamamoto, Yuya; Maruhama, Kotaro; Tsuchiya, Hiroki; Mizutani, Masahide; Iida, Seiji; Sugimoto, Tomosada			Convergent Nociceptive Input to Spinal Dorsal Horn Neurons After Peripheral Nerve Injury	NEUROCHEMICAL RESEARCH			English	Article						Nerve injury; c-Fos; ERK; Spinal dorsal horn; Immunohistochemistry	C-FOS EXPRESSION; SIGNAL-REGULATED KINASE; GRACILE NUCLEUS NEURONS; INDUCED ERK ACTIVATION; CORD NEURONS; PROTEIN-KINASE; SOMATOTOPIC ORGANIZATION; MECHANICAL STIMULATION; PAIN HYPERSENSITIVITY; CENTRAL SENSITIZATION	The number of c-Fos protein-like immunoreactive (c-Fos-IR) neurons in the spinal dorsal horn evoked by noxious stimulation was previously shown to be increased following peripheral nerve injury, and this increase was proposed to reflect the neuropathic pain state. The aim of this study was to investigate whether anomalous convergent primary afferent input to spinal dorsal horn neurons contributed to nerve injury-induced c-Fos hyperinducibility. Double immunofluorescence labeling for c-Fos and phosphorylated extracellular signal-regulated kinase (p-ERK) was performed to detect convergent synaptic input from different branches of the sciatic nerve after injury to the tibial nerve. c-Fos expression and the phosphorylation of ERK were induced by noxious heat stimulation of the hindpaw and also by electrical stimulation (ES) of the injured tibial nerve, respectively. The number of c-Fos-IR neurons was significantly decreased 3 days after the injury. However, the number of c-Fos-IR neurons returned to the control level 14 days after the injury. P-ERK immunoreactive (p-ERK-IR) neurons were induced in the central terminal field of the tibial nerve by ES of the tibial nerve. The topographic distribution pattern and number of such p-ERK-IR neurons remained unchanged after the nerve injury. The time course of changes in the number of double-labeled neurons, that presumably received convergent primary afferent input, showed a pattern similar to that of c-Fos-IR neurons after the injury. These results indicate that convergent primary nociceptive input through neighboring intact nerves may contribute to c-Fos hyperinducibility in the spinal dorsal horn.	[Terayama, Ryuji; Kishimoto, Noriko; Yamamoto, Yuya; Maruhama, Kotaro; Tsuchiya, Hiroki; Sugimoto, Tomosada] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Funct & Anat, Kita Ku, Okayama 7008525, Japan; [Terayama, Ryuji; Maruhama, Kotaro; Mizutani, Masahide; Iida, Seiji; Sugimoto, Tomosada] Okayama Univ, Adv Res Ctr Oral & Craniofacial Sci, Sch Dent, Okayama 7008525, Japan; [Kishimoto, Noriko; Yamamoto, Yuya; Mizutani, Masahide; Iida, Seiji] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Reconstruct Surg, Okayama 7008525, Japan; [Tsuchiya, Hiroki] ASAHI Med Coll Okayama, Okayama 7000028, Japan	Terayama, R (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Funct & Anat, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	ryujit@md.okayama-u.ac.jp			Japan Society for the Promotion of Science [24592764]	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (24592764).	Noma N, 2008, J COMP NEUROL, V507, P1428, DOI 10.1002/cne.21620; Ji RR, 2002, J NEUROSCI, V22, P478; Kawasaki Y, 2004, J NEUROSCI, V24, P8310, DOI 10.1523/JNEUROSCI.2396-04.2004; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; DEVOR M, 1983, PAIN, V16, P73, DOI 10.1016/0304-3959(83)90087-8; Nomura H, 2002, PAIN, V95, P225, DOI 10.1016/S0304-3959(01)00403-1; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; DEVOR M, 1978, NATURE, V276, P75, DOI 10.1038/276075a0; Dai Y, 2002, J NEUROSCI, V22, P7737; BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402; Fujisawa N, 2012, EXP BRAIN RES, V219, P191, DOI 10.1007/s00221-012-3078-8; Hughes AS, 2008, NEUROSCIENCE, V153, P507, DOI 10.1016/j.neuroscience.2008.01.082; HYLDEN JLK, 1987, BRAIN RES, V411, P341, DOI 10.1016/0006-8993(87)91086-9; LISNEY SJW, 1983, BRAIN RES, V259, P31, DOI 10.1016/0006-8993(83)91064-8; Liu Y, 2004, PAIN, V109, P64, DOI 10.1016/j.pain.2004.01.010; MARKUS H, 1984, BRAIN RES, V296, P27, DOI 10.1016/0006-8993(84)90508-0; MOLANDER C, 1992, NEUROSCIENCE, V50, P223, DOI 10.1016/0306-4522(92)90394-H; Shimizu K, 2006, BRAIN RES, V1072, P99, DOI 10.1016/j.brainres.2005.12.040; Shortland P, 1998, BRAIN RES, V810, P288, DOI 10.1016/S0006-8993(98)00940-8; STRASSMAN AM, 1993, J COMP NEUROL, V331, P495, DOI 10.1002/cne.903310406; STRASSMAN AM, 1993, J NEUROPHYSIOL, V70, P1811; SUGIMOTO T, 1994, EXP NEUROL, V129, P251, DOI 10.1006/exnr.1994.1167; SUGIMOTO T, 1993, BRAIN RES, V621, P161, DOI 10.1016/0006-8993(93)90314-D; SWETT JE, 1985, J COMP NEUROL, V231, P66, DOI 10.1002/cne.902310106; Terayama R, 1997, BRAIN RES, V768, P135, DOI 10.1016/S0006-8993(97)00633-1; Tokunaga A, 1999, BRAIN RES, V847, P321, DOI 10.1016/S0006-8993(99)02074-0; Wang H, 2004, EUR J NEUROSCI, V19, P884, DOI 10.1111/j.1460-9568.2004.03203.x; Yamaguchi D, 2014, INT J NEUROSCI, V124, P213, DOI 10.3109/00207454.2013.842566	30	1	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAR	2015	40	3					438	445		10.1007/s11064-014-1484-y		8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CC9MD	WOS:000350693700003		
J	Chen, A; Akinyemi, RO; Washida, K; Foster, V; Firbank, MJ; Oakley, AE; Okamoto, Y; O'Brien, JT; Allan, LM; Ihara, M; Kalaria, RN				Chen, A.; Akinyemi, R. O.; Washida, K.; Foster, V.; Firbank, M. J.; Oakley, A. E.; Okamoto, Y.; O'Brien, J. T.; Allan, L. M.; Ihara, M.; Kalaria, R. N.			Frontal white matter clasmatodendrosis and cognitive dysfunction in the elderly	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Meeting Abstract	116th Meeting of the British-Neuropathological-Society	MAR 04-06, 2015	Inst Child Hlth, London, ENGLAND	British Neuropathol Soc	Inst Child Hlth				[Chen, A.; Akinyemi, R. O.; Foster, V.; Firbank, M. J.; Oakley, A. E.; O'Brien, J. T.; Allan, L. M.; Kalaria, R. N.] Newcastle Univ, Neurovasc Res Grp, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Washida, K.; Okamoto, Y.; Ihara, M.; Kalaria, R. N.] Natl Cerebral & Cardiovasc Ctr, Dept Stroke & Cerebrovasc Dis, Osaka, Japan		r.n.kalaria@ncl.ac.uk						0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	MAR	2015	41			1	SI	O28	24	25				2	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CD4MJ	WOS:000351056600029		
J	Ogawa, M; Uchino, R; Kawai, A; Kosugi, M; Magata, Y				Ogawa, Mikako; Uchino, Ryuji; Kawai, Ayumi; Kosugi, Mutsumi; Magata, Yasuhiro			PEG modification on In-111-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Atherosclerosis; Liposome; PEG; Macrophage	MACROPHAGES; INFLAMMATION; REMOVAL	Introduction: Previously, we reported a probe for imaging of atherosclerotic plaques: In-111-labeled liposomes. Liposomes were modified with phosphatidylserine (PS) because macrophages recognize PS and phagocytize apoptotic cells in plaques. PS modification was successful and we could visualize atherosclerotic plaques by single-photon emission computed tomography (SPECT). However, too-rapid blood clearance reduced accumulation of PS-liposomes in plaques in vivo. Therefore, in the present study, PS-liposomes were modified with polyethylene glycol (PEG) to retard the rate of blood clearance. Methods: PS-liposomes (size, 100 nm or 200 nm) were PEGylated with PEG2000 or PEG5000 at 1 or 5 mol%, and radiolabeled with In-111. For the study of uptake in vitro, liposomes were incubated with mouse peritoneal macrophages. Biodistribution studies in vivo were carried out in ddY mice. Enlace autoradiograms were obtained with apoE(-/-) mice upon intravenous injection of In-111-liposomes. Results: Uptake was decreased significantly at 5 mol%PEGylation in 100-nm PS-liposomes (*P < 0.05 vs. 0 mol%). All the PEGylated liposomes tested showed significantly lower uptake than the non-PEGylated control in 200-nm liposomes. In vivo results showed slower blood clearance in PEGylated liposomes. Autoradiograms in apoE(-/-) mice were well matched with Oil Red O staining. Additionally, 200-nm PS-liposomes modified with 5% PEG2000 (In-[111]5PEG2000PS200) showed the highest uptake to the region in vivo. Conclusions: As expected, PEGylation retarded the rate of blood clearance. In addition, it affected liposome uptake by macrophages in vitro. These results suggest that the balance between the rate of blood clearance and macrophage recognition is important, and [In-111]5%PEG2000PS200 showed the best results in our investigation. (C) 2014 Elsevier Inc. All rights reserved.	[Ogawa, Mikako; Uchino, Ryuji; Kawai, Ayumi; Kosugi, Mutsumi; Magata, Yasuhiro] Hamamatsu Univ Sch Med, Med Photon Res Ctr, Hamamatsu, Shizuoka 4313192, Japan	Ogawa, M (reprint author), Hamamatsu Univ Sch Med, Med Photon Res Ctr, Dept Mol Imaging, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	mogawa@hama-med.ac.jp			Japan Science and Technology Agency; Japan Society for the Promotion of Science; Japanese Ministry of Health, Labour and Welfare	This research was mainly supported by Japan Science and Technology Agency under collaborative research based on industrial demand ("In vivo Molecular Imaging: Towards Biophotonics Innovations in Medicine"), and partly by the Japan Society for the Promotion of Science, and Japanese Ministry of Health, Labour and Welfare. The authors thank Dr. Jun Furuya for useful assistance with the statistical analysis.	Sanz J, 2013, J AM COLL CARDIOL, V62, P1131, DOI 10.1016/j.jacc.2013.06.045; Tavakoli S, 2014, J NUCL CARDIOL, V21, P1112, DOI 10.1007/s12350-014-9959-4; Ogawa M, 2014, J NUCL MED, V55, P115, DOI 10.2967/jnumed.113.123158; Ogawa M, 2004, J NUCL MED, V45, P1245; Eijgelaar WJ, 2010, PHYSIOL GENOMICS, V41, P212, DOI 10.1152/physiolgenomics.00193.2009; Cocker MS, 2012, J NUCL CARDIOL, V19, P1211, DOI 10.1007/s12350-012-9631-9; FADOK VA, 1992, J IMMUNOL, V148, P2207; Osborn EA, 2013, JACC-CARDIOVASC IMAG, V6, P1327, DOI 10.1016/j.jcmg.2013.09.014; Mauldin JP, 2006, J BIOL CHEM, V281, P21216, DOI 10.1074/jbc.M510952200; Fifer KM, 2011, J AM COLL CARDIOL, V57, P971, DOI 10.1016/j.jacc.2010.09.056; OKU N, 1994, CRIT REV THER DRUG, V11, P231; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323; Ishino S, 2014, EUR J NUCL MED MOL I, V41, P624, DOI 10.1007/s00259-013-2635-0; Libby P, 2001, AM J CARDIOL, V88, p3J; PAPAHADJOPOULOS D, 1990, PROG CLIN BIOL RES, V343, P85; Rosenbaum D, 2012, CURR ATHEROSCLER REP, V14, P429, DOI 10.1007/s11883-012-0264-x; Tait JF, 1999, J BIOL CHEM, V274, P3048, DOI 10.1074/jbc.274.5.3048	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051	1872-9614		NUCL MED BIOL	Nucl. Med. Biol.	MAR	2015	42	3					299	304		10.1016/j.nucmedbio.2014.12.004		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CD0RS	WOS:000350782200014		
J	Inui, A; Chen, CY; Meguid, M				Inui, Akio; Chen, Chih-Yen; Meguid, Michael			Microbiome, peptide autoantibodies, and eating disorders: A missing link between gut and brain	NUTRITION			English	Editorial Material							ANOREXIA-NERVOSA; ALPHA-MSH; GHRELIN; IMMUNOGLOBULINS; BEHAVIOR		[Inui, Akio] Kagoshima Univ, Dept Psychosomat Internal Med, Grad Sch Med & Dent Sci, Kagoshima 890, Japan; [Chen, Chih-Yen] Natl Yang Ming Univ, Sch Med, Taipei Vet Gen Hosp, Dept Med,Fac Med,Div Gastroenterol, Taipei 112, Taiwan; [Meguid, Michael] SUNY Upstate Med Univ, Univ Hosp, Nutr Dept Surg, Syracuse, NY 13210 USA	Inui, A (reprint author), Kagoshima Univ, Dept Psychosomat Internal Med, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.	inui@m.kufm.kagoshima-u-ac.jp					David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Fetissov SO, 2002, P NATL ACAD SCI USA, V99, P17155, DOI 10.1073/pnas.222658699; Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014; Million M, 2013, INT J OBESITY, V37, P1460, DOI 10.1038/ijo.2013.20; Lucas N, 2014, NEUROPEPTIDES, V48, P21, DOI 10.1016/j.npep.2013.10.017; Borre YE, 2014, ADV EXP MED BIOL, V817, P373, DOI 10.1007/978-1-4939-0897-4_17; Fetissov SO, 2008, NUTRITION, V24, P854, DOI 10.1016/j.nut.2008.06.021; Inui A, 2003, NAT REV DRUG DISCOV, V2, P986, DOI 10.1038/nrd1252; Inui A, 2001, MOL PSYCHIATR, V6, P620, DOI 10.1038/sj.mp.4000944; Ogiso K, 2011, NUTRITION, V27, P988, DOI 10.1016/j.nut.2011.05.005; Sandoval DA, 2010, SCIENCE, V328, P179, DOI 10.1126/science.1188876; Takagi K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3685; Tennoune N, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.98; Tennoune N, 2015, NUTRITION, V31, P498, DOI 10.1016/j.nut.2014.11.003; Terashi M, 2011, NUTRITION, V27, P407, DOI 10.1016/j.nut.2011.01.002	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0899-9007	1873-1244		NUTRITION	Nutrition	MAR	2015	31	3					544	545		10.1016/j.nut.2015.01.007		2	Nutrition & Dietetics	Nutrition & Dietetics	CC3RT	WOS:000350267800021		
J	Wakabayashi, H				Wakabayashi, Hidetaka			Comment on "Early nutritional support and physiotherapy improved long-term self-sufficiency in acutely ill older patients"	NUTRITION			English	Editorial Material									Yokohama City Univ, Med Ctr, Dept Rehabil Med, Yokohama, Kanagawa 232, Japan	Wakabayashi, H (reprint author), Yokohama City Univ, Med Ctr, Dept Rehabil Med, Yokohama, Kanagawa 232, Japan.			Wakabayashi, HIdetaka/0000-0002-0364-0818			Covinsky KE, 2011, JAMA-J AM MED ASSOC, V306, P1782, DOI 10.1001/jama.2011.1556; Hegerova P., 2014, NUTRITION, V31, P166; Wakabayashi H, 2014, J REHABIL MED, V46, P277, DOI 10.2340/16501977-1258	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0899-9007	1873-1244		NUTRITION	Nutrition	MAR	2015	31	3					546	546		10.1016/j.nut.2014.09.014		1	Nutrition & Dietetics	Nutrition & Dietetics	CC3RT	WOS:000350267800022		
J	Ikeya, Y; Fukuyama, N; Mori, H				Ikeya, Yoshimori; Fukuyama, Naoto; Mori, Hidezo			Low plasma eicosapentaenoic acid concentration as a possible risk factor for intracerebral hemorrhage	NUTRITION RESEARCH			English	Article						N-3 fatty acids; Eicosapentaenoic acid; Intracerebral hemorrhage; High-density lipoprotein cholesterol; Stroke	POLYUNSATURATED FATTY-ACIDS; BLOOD-PRESSURE; FISH CONSUMPTION; HYPERCHOLESTEROLEMIC PATIENTS; CEREBRAL-HEMORRHAGE; INTERVENTION TRIAL; SERUM-CHOLESTEROL; STROKE; METAANALYSIS; ATHEROSCLEROSIS	N-3 fatty acids, including eicosapentaenoic acid (EPA), prevent ischemic stroke. The preventive effect has been attributed to an antithrombic effect induced by elevated EPA and reduced arachidonic acid (AA) levels. However, the relationship between intracranial hemorrhage and N-3 fatty acids has not yet been elucidated. In this cross-sectional study, we compared common clinical and lifestyle parameters between 70 patients with intracranial hemorrhages and 66 control subjects. The parameters included blood chemistry data, smoking, alcohol intake, fish consumption, and the incidences of underlying diseases. The comparisons were performed using the Mann-Whitney U test followed by multiple logistic regression analysis. Nonparametric tests revealed that the 70 patients with intracerebral hemorrhages exhibited significantly higher diastolic blood pressures and alcohol intakes and lower body mass indices, high-density lipoprotein (HDL) cholesterol levels, EPA concentrations, EPA/AA ratios, and vegetable consumption compared with the 66 control subjects. A multiple logistic regression analysis revealed that higher diastolic blood pressure and alcohol intake and lower body mass index, HDL cholesterol, EPA/AA ratio, and vegetable consumption were relative risk factors for intracerebral hemorrhage. High HDL cholesterol was a common risk factor in both of the sex-segregated subgroups and the <65-year-old subgroup. However, neither EPA nor the EPA/AA ratio was a risk factor in these subgroups. Eicosapentaenoic acid was relative risk factor only in the >= 65-year-old subgroup. Rather than higher EPA levels, lower EPA concentrations and EPA/AA ratios were found to be risk factors for intracerebral hemorrhage in addition to previously known risk factors such as blood pressure, alcohol consumption, and lifestyle. (C) 2015 Elsevier Inc. All rights reserved.	[Ikeya, Yoshimori; Fukuyama, Naoto; Mori, Hidezo] Tokai Univ, Sch Med, Dept Physiol, Isehara, Kanagawa 2591193, Japan; [Ikeya, Yoshimori] Fureai Machida Hosp, Machida, Tokyo, Japan	Ikeya, Y (reprint author), Tokai Univ, Sch Med, Div Physiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	y.ikey@river.ocn.ne.jp					BURR ML, 1989, LANCET, V2, P757; FISHER CM, 1971, J NEUROPATH EXP NEUR, V30, P536, DOI 10.1097/00005072-197107000-00015; He K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47; Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3; Sauvaget C, 2003, INT J EPIDEMIOL, V32, P536, DOI 10.1093/ije/dyg151; Bays HE, 2011, AM J CARDIOL, V108, P682, DOI 10.1016/j.amjcard.2011.04.015; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; DYERBERG J, 1979, LANCET, V2, P433; Itakura H, 2011, J ATHEROSCLER THROMB, V18, P99; Reynolds K, 2003, JAMA-J AM MED ASSOC, V289, P579, DOI 10.1001/jama.289.5.579; Cawood AL, 2010, ATHEROSCLEROSIS, V212, P252, DOI 10.1016/j.atherosclerosis.2010.05.022; Tanaka K, 2008, STROKE, V39, P2052, DOI 10.1161/STROKEAHA.107.509455; YANO K, 1989, STROKE, V20, P1460; SACKS FM, 1995, J AM COLL CARDIOL, V25, P1492, DOI 10.1016/0735-1097(95)00095-L; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Kim HC, 2005, HYPERTENSION, V46, P393, DOI 10.1161/01.HYP.0000177118.46049.e6; Lavie CJ, 2009, J AM COLL CARDIOL, V54, P585, DOI 10.1016/j.jacc.2009.02.084; Zia E, 2007, STROKE, V38, P2681, DOI 10.1161/STROKEAHA.106.479725; BONAA KH, 1990, NEW ENGL J MED, V322, P795, DOI 10.1056/NEJM199003223221202; Charcot J. M., 1868, ARCH PHYSL NORM PATH, V1, P643; COLE FM, 1967, J NEUROL NEUROSUR PS, V30, P61, DOI 10.1136/jnnp.30.1.61; DYERBERG J, 1978, LANCET, V2, P117; Gillum RF, 1996, ARCH INTERN MED, V156, P537, DOI 10.1001/archinte.156.5.537; Valagussa F, 1999, LANCET, V354, P447; Ikeya Y, 2013, NUTRITION, V29, P127, DOI 10.1016/j.nut.2012.05.003; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KELI SO, 1994, STROKE, V25, P328; Osamu E, 2013, J NUTR SCI VITAMINOL, V59, pS44; Pedersen HS, 1999, LANCET, V353, P812, DOI 10.1016/S0140-6736(98)05918-2; Song YM, 2004, STROKE, V35, P831, DOI 10.1161/01.STR.0000119386.22691.1C; TAKEBAYASHI S, 1983, STROKE, V14, P28; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Thrift AG, 1996, STROKE, V27, P2020; Yutaka K, 1995, HISAYAMA STUDY STROK, V26, P368; Zhang HF, 2006, HYPERTENSION, V48, P187, DOI 10.1161/01.HYP.0000231939.40959.60	35	4	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0271-5317			NUTR RES	Nutr. Res.	MAR	2015	35	3					214	220		10.1016/j.nutres.2015.01.003		7	Nutrition & Dietetics	Nutrition & Dietetics	CD6HO	WOS:000351190400004		
J	Ohashi, K; Ando, Y; Munetsuna, E; Yamada, H; Yamazaki, M; Nagura, A; Taromaru, N; Ishikawa, H; Suzuki, K; Teradaira, R				Ohashi, Koji; Ando, Yoshitaka; Munetsuna, Eiji; Yamada, Hiroya; Yamazaki, Mirai; Nagura, Ayuri; Taromaru, Nao; Ishikawa, Hiroaki; Suzuki, Koji; Teradaira, Ryouji			Maternal fructose consumption alters messenger RNA expression of hippocampal StAR, PBR, P450 (11 beta) 11 beta-HSD, and 17 Nu beta-HSD in rat offspring	NUTRITION RESEARCH			English	Article						Maternal fructose consumption; Rat offspring; Hippocampus; Neurosteroid; StAR; PBR	ESTROGEN SYNTHESIS; ESTRADIOL; CELLS; BRAIN; PROLIFERATION; TRIBUTYLTIN; METABOLISM; MECHANISMS; LACTATION; PREGNANCY	Hippocampal functions such as neuronal protection and synapse formation are positively modulated by neurosteroids, which are synthesized de novo within the brain. However, the mechanisms regulating neurosteroidogenesis remain unclear. Fructose, which is used as a sweetener, affects steroid hormone synthesis in peripheral endocrine organs. This monosaccharide can penetrate the blood-brain barrier and impair hippocampal function. Also, fructose is secreted into milk and is thus delivered to the fetus. Based on these observations, we hypothesized that the hippocampal neurosteroidogenesis in the offspring may be affected by maternal fructose consumption. Female rats were fed with normal water or 20% fructose solution during gestation and lactation. Maternal calorie intake did not change significantly, and no significant change in body weight was observed. The levels of messenger RNAs (mRNAs) for steroidogenic enzymes and proteins in the hippocampus of the offspring were analyzed by real-time reverse transcriptase polymerase chain reaction. Maternal fructose consumption during gestation and lactation increased mRNA levels of P450(11 beta)-2, 11 beta-HSD-2, and 17 beta-HSD-1 in the offspring hippocampus, and reduced levels of mRNAs for StAR, PBR, and 17 beta-HSD-3. Maternal fructose consumption might influence hippocampal neurosteroidogenesis in offspring. (C) 2015 Elsevier Inc. All rights reserved.	[Ohashi, Koji; Yamazaki, Mirai; Nagura, Ayuri; Taromaru, Nao; Ishikawa, Hiroaki; Teradaira, Ryouji] Fujita Hlth Univ, Sch Hlth Sci, Dept Clin Biochem, Toyoake, Aichi 4701192, Japan; [Ando, Yoshitaka] Fujita Hlth Univ, Sch Med, Dept Joint Res Lab Clin Med, Toyoake, Aichi 4701192, Japan; [Munetsuna, Eiji] Fujita Hlth Univ, Sch Med, Dept Biochem, Toyoake, Aichi 4701192, Japan; [Yamada, Hiroya] Fujita Hlth Univ, Sch Med, Dept Hyg, Toyoake, Aichi 4701192, Japan; [Suzuki, Koji] Fujita Hlth Univ, Sch Hlth Sci, Dept Publ Hlth, Toyoake, Aichi 4701192, Japan	Munetsuna, E (reprint author), Fujita Hlth Univ, Sch Med, Dept Biotechnol, Toyoake, Aichi 4701192, Japan.	mntneiji@fujita-hu.ac.jp			JSPS KAKENHI [26450169]	This work was supported by JSPS KAKENHI (Grant No. 26450169).	van der Borght K, 2011, REGUL PEPTIDES, V167, P26, DOI 10.1016/j.regpep.2010.11.002; Theys N, 2011, J NUTR BIOCHEM, V22, P985, DOI 10.1016/j.jnutbio.2010.08.015; Hojo Y, 2009, ENDOCRINOLOGY, V150, P5106, DOI 10.1210/en.2009-0305; Rutledge AC, 2007, NUTR REV, V65, pS13, DOI 10.1301/nr.2007.jun.S13-S23; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; JEN KLC, 1991, J NUTR, V121, P1999; Zhou LP, 2007, EXP NEUROL, V203, P72, DOI 10.1016/j.expneurol.2006.07.020; Kinote A, 2012, ENDOCRINOLOGY, V153, P3633, DOI 10.1210/en.2012-1341; Segovia SA, 2014, BIOMED RES INT, DOI 10.1155/2014/418975; Legeza B, 2014, FEBS LETT, V588, P490, DOI 10.1016/j.febslet.2013.12.014; Marriott BP, 2009, J NUTR, V139, pS1228, DOI 10.3945/jn.108.098277; Mortensen OH, 2014, J CEREBR BLOOD F MET, V34, P1205, DOI 10.1038/jcbfm.2014.72; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Hojo Y, 2008, MOL CELL ENDOCRINOL, V290, P31, DOI 10.1016/j.mce.2008.04.017; Stephan BCM, 2010, J GERONTOL A-BIOL, V65, P809, DOI 10.1093/gerona/glq079; Mccarthy MM, 2008, PHYSIOL REV, V88, P91, DOI 10.1152/physrev.00010.2007; Fester L, 2006, J NEUROCHEM, V97, P1136, DOI 10.1111/j.1471-4159.2006.03809.x; Vickers MH, 2011, ENDOCRINOLOGY, V152, P1378, DOI 10.1210/en.2010-1093; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; Vierk R, 2014, NEUROSCIENCE, V274, P24, DOI 10.1016/j.neuroscience.2014.05.003; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Hojo Y, 2004, P NATL ACAD SCI USA, V101, P865, DOI 10.1073/pnas.2630225100; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; Rafati A, 2013, FOLIA NEUROPATHOL, V51, P214, DOI 10.5114/fn.2013.37705; Higo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021631; Jeckel KM, 2014, NUTR RES, V34, P694, DOI 10.1016/j.nutres.2014.07.011; Munetsuna E, 2011, J MOL ENDOCRINOL, V47, P209, DOI 10.1530/JME-11-0008; Munetsuna E, 2009, BIOCHEM BIOPH RES CO, V379, P480, DOI 10.1016/j.bbrc.2008.12.076; Munetsuna E, 2014, ENDOCRINOLOGY, V150, P4260; Munetsuna E, 2014, ENDOCR RES, V39, P168, DOI 10.3109/07435800.2013.875563; Munetsuna E, 2011, GEN COMP ENDOCR, V171, P28, DOI 10.1016/j.ygcen.2010.12.007; Zou M, 2012, NUTR RES, V32, P588, DOI 10.1016/j.nutres.2012.06.012	32	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0271-5317			NUTR RES	Nutr. Res.	MAR	2015	35	3					259	264		10.1016/j.nutres.2014.11.001		6	Nutrition & Dietetics	Nutrition & Dietetics	CD6HO	WOS:000351190400009		
J	Hashimoto, K; Seki, Y; Kasama, K				Hashimoto, Kenkichi; Seki, Yosuke; Kasama, Kazunori			Laparoscopic Intragastric Surgery and Laparoscopic Roux-Y Gastric Bypass Were Performed Simultaneously on a Morbidly Obese Patient with a Gastric Submucosal Tumor: a Report of a Case and Review	OBESITY SURGERY			English	Article						Laparoscopic intragastric surgery; Gastric submucosal tumor; Roux-Y gastric bypass; Morbid obesity; Simultaneous operation	GIST	Background Obesity patients sometimes have gastric submucosal tumors (SMTs). Surgical excision is recommended in cases of SMTs with suspected malignancy or other reasons making follow-up difficult. Laparoscopic intragastric surgery (LIGS) has recently achieved good results in the treatment of gastric SMTs, especially near the esophagogastric junction (EGJ). This procedure has enabled either preservation of the stomach or minimization of the extent of partial resection. Methods The patient is a 43-year-old female with BMI of 48.2 kg/m(2) who is a candidate for LRYGB. A small SMT was found just below the EGJ. A follow-up with an endoscopy would be needed but difficult because the pouch was too small to observe the lesion. We decided to resect the tumor with LIGS and perform LRYGB simultaneously. Results We put the trocars as is our usual LRYGB practice. Observing with laparoscopy and endoscopy, three trocars were inserted into the stomach. After marking the margin of the tumor and injecting normal saline to the submucosal layer, resection of the tumor was performed. Suturing of the defects of the mucosa and the holes of the trocars on the stomach was performed. Then, we performed LRYGB as usual. The patient was discharged uneventfully. The pathological findings showed that the tumor was resected completely. Weight loss has succeeded as her BMI is 32.7 at 1 year after the surgery. Conclusions We performed LIGS and LRYGB simultaneously and safely fora morbidly obese patient with a gastric SMT, and our case is the first case of LIGS during a bariatric procedure.	[Hashimoto, Kenkichi; Seki, Yosuke; Kasama, Kazunori] Yotsuya Med Cube, Weight Loss & Metab Surg Ctr, Tokyo, Japan	Hashimoto, K (reprint author), Yotsuya Med Cube, Weight Loss & Metab Surg Ctr, Tokyo, Japan.	k-hashimoto@mcube.jp; seki@mcube.jp; kasama@mcube.jp					Lau S, 2004, CLIN RADIOL, V59, P487, DOI 10.1016/j.crad.2003.10.018; Zeni TM, 2006, OBES SURG, V16, P142, DOI 10.1381/096089206775565177; Sanchez BR, 2005, OBES SURG, V15, P1384, DOI 10.1381/096089205774859326; Buchwald H, 2013, OBES SURG, V23, P427, DOI 10.1007/s11695-012-0864-0; Beltran MA, 2010, OBES SURG, V20, P393, DOI 10.1007/s11695-009-0009-2; Hara J, 2012, SURG LAPARO ENDO PER, V22, P251, DOI 10.1097/SLE.0b013e3182508083; Raghavendra RS, 2012, JSLS-J SOC LAPAROEND, V16, P360, DOI 10.4293/108680812X13462882736457; Taniguchi E, 1997, SURG ENDOSC-ULTRAS, V11, P287, DOI 10.1007/s004649900347; Wang Y, 2009, BMJ CASE REP	9	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0960-8923	1708-0428		OBES SURG	Obes. Surg.	MAR	2015	25	3					564	567		10.1007/s11695-014-1550-1		4	Surgery	Surgery	CD2GF	WOS:000350892500030		
J	Saville, R; Hatanaka, K; Sano, M; Wada, M				Saville, Ramadhona; Hatanaka, Katsumori; Sano, Minoru; Wada, Masaaki			Application of information and communication technology and data sharing management scheme for the coastal fishery using real-time fishery information	OCEAN & COASTAL MANAGEMENT			English	Article						Catchable stock index; Self-management support; Real-time data sharing; Cloud computing; ICT; Swept area method; Sea cucumber	COMANAGEMENT	In this paper, we propose an automatic computation and data sharing scheme to support management system in coastal fishery using real-time fishery information through information and communication technology (ICT). In Japan, several species of fisheries commodity have not been specified in Total Allowable Catch policy, causing a lot of confusion on fishery cooperatives and fishermen on how to set the catch limit. To deal with the problem, in the previous study, we developed catchable stock index, a method to estimate a certain extent of resource via the swept area method. However, as the calculation of the index was computed on a GIS software manually, it was very time consuming, costly and unable to give an immediate evaluation of the fishing operation. This study aims to support management system in a coastal fishery through the development of automatic catchable stock index algorithm. In this study, ICT was utilized to obtain and transmit the real-time data sharing of fishery information as well as to distribute the computation results to the fishermen and fishery cooperative. The data used were vessels' trajectories and catch records, which included the start/end time and catch amount of each fishing operation. The catchable stock index was automatically computed in an originally developed cloud computing service. We have conducted the test run of the present method in sea cucumber dredge-net fishery on the coast of Rumoi City, Hokkaido, Japan. Data were collected from the entire vessels in Rumoi (16 vessels) during the 2012 and 2013 fishing seasons. The results were returned to the fishermen via the Internet each day during the fishing season, therefore, fishermen were able to immediately evaluate their catch. The estimated catchable stock index for the 2012 and 2013 seasons was 85.5 tons and 923 tons, respectively. By referring to the present system, fishermen voluntarily stopped the 2012 and 2013 fishing season several weeks earlier than their initial schedule to avoid overfishing. Moreover, in the previous study, the spacing of the grid has been decided empirically, but in this study, the adequate grid size could be evaluated due to the fast computation through ratio of the area of a grid cell to the total dredged area. In light of the evidence, the present automatic algorithm provided useful information for supporting the self-management of this coastal fishery. 2015 Elsevier Ltd. All rights reserved.	[Saville, Ramadhona; Hatanaka, Katsumori] Tokyo Univ Agr, Int Biobusiness Studies, Setagaya Ku, Tokyo, Japan; [Sano, Minoru] Hokkaido Res Org, Wakkanai Fisheries Res Inst, Wakkanai, Hokkaido, Japan; [Wada, Masaaki] Future Univ Hakodate, Sch Syst Informat Sci, Hakodate, Hokkaido, Japan	Saville, R (reprint author), Tokyo Univ Agr, Int Biobusiness Studies, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo, Japan.	46713004@nodai.ac.jp			research and development projects for science and technology research promotion program for agriculture, forestry, fisheries and food industry (Ministry of Agriculture, Forestry and Fisheries of japan)	We would like to thank the Shinsei Marine fishery cooperative and fishermen in Rumoi City, Hokkaido, Japan for their understanding of this research and their kind cooperation. This study was conducted using a fund of research and development projects for science and technology research promotion program for agriculture, forestry, fisheries and food industry (Ministry of Agriculture, Forestry and Fisheries of japan).	Akaike S., 2012, 2012 SEIK FISH RES M, P1; Akamine J., 2008, Transborder environmental and natural resource management, P81; Akamine J., 2005, ADV SEA CUCUMBER AQU, P39; SEBER GAF, 1967, J ANIM ECOL, V36, P631, DOI 10.2307/2818; Holmes SJ, 2011, ICES J MAR SCI, V68, P1679, DOI 10.1093/icesjms/fsr101; Makino M, 2005, MAR POLICY, V29, P441, DOI 10.1016/j.marpol.2004.07.005; DELURY DB, 1947, BIOMETRICS, V3, P145, DOI 10.2307/3001390; Choo P.-S., 2008, SEA CUCUMBERS GLOBAL, P81; ENGAS A, 1986, Journal of Northwest Atlantic Fishery Science, V7, P35; Gulland J. A., 1969, MANUAL METHODS FIS 1; Gunderson DR, 1993, SURVEYS FISHERIES RE; Halls A. S., 2005, 4941 FAO; Hokkaido Government, 2013, STAT DAT FISH IND HO; Hokkaido Research Organization (HRO), 2014, SEA CUC RES MAN GUID; KOELLER P A, 1991, Journal of Northwest Atlantic Fishery Science, V11, P51; Makino M., 2011, FISHERIES MANAGEMENT; Ministry of Agriculture Forestry and Fisheries (MAFF) Hokkaido Region, 2010, HOKK FISH CHART; Pope J., 1972, INT COMM NW ATL FISH, V9, P65; Purcell SW, 2010, MANAGING SEA CUCUMBE; Sano M, 2011, NIPPON SUISAN GAKK, V77, P999, DOI 10.2331/suisan.77.999; Shibuya C., 2011, B FAC AGR LIFE SCI H, V13, P39; Shirakihara K., 1994, RES J FOOD AGR, V17, P6; Valencia M.J., 1998, ESENA WORKSH EN REL; Wada M., 2012, OCEANS 2012, DOI 10.1109/OCEANS.2012.6404939; Wada M., 2010, JPN I NAVIG, V122, P53; Wada M., 2008, INFORM PROCESS SOC J, V40, P33; Wada M., 2011, JPN I NAVIG, V124, P355; Wallace JR, 2006, FISH RES, V77, P285, DOI 10.1016/j.fishres.2005.10.014; Yamamoto T., 1995, MAR RES EC, V10, P21; ZHANG CI, 1988, T AM FISH SOC, V117, P180, DOI 10.1577/1548-8659(1988)117<0180:BBCATI>2.3.CO;2; ZIPPIN CALVIN, 1958, JOUR WILDLIFE MANAGEMENT, V22, P82, DOI 10.2307/3797301	31	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0964-5691	1873-524X		OCEAN COAST MANAGE	Ocean Coastal Manage.	MAR	2015	106						77	86		10.1016/j.ocecoaman.2015.01.019		10	Oceanography; Water Resources	Oceanography; Water Resources	CC7FT	WOS:000350533800008		
J	Hashimoto, R; Kanda, M; Takami, H; Shimizu, D; Oya, H; Hibino, S; Okamura, Y; Yamada, S; Fujii, T; Nakayama, G; Sugimoto, H; Koike, M; Nomoto, S; Fujiwara, M; Kodera, Y				Hashimoto, Ryoji; Kanda, Mitsuro; Takami, Hideki; Shimizu, Dai; Oya, Hisaharu; Hibino, Soki; Okamura, Yukiyasu; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Nomoto, Shuji; Fujiwara, Michitaka; Kodera, Yasuhiro			Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy	ONCOLOGY LETTERS			English	Article						hepatocellular carcinoma; expression; prognosis; melanoma-associated antigen-D2	PROMOTER HYPERMETHYLATION; IDENTIFICATION; PROGRESSION; MECHANISMS; NEOPLASIA; APOPTOSIS; MAGE-D2; CANCER; MAGED2; GENES	Hepatocellular carcinoma (HCC) is the most common cause of cancer-related mortality globally. Since the prognosis of advanced HCC patients is extremely poor, the development of novel molecular targets for diagnosis and therapy is urgently required. In the present study, the expression of the melanoma-associated antigen-D2 (MAGE-D2) gene was investigated to determine whether it affects the malignant phenotype of HCC and thus, may serve as a marker of prognosis. Therefore, the expression of MAGE-D2 mRNA and MAGE-D2 protein in nine HCC cell lines and 151 pairs of surgical tissues was analyzed. mRNA expression levels were analyzed using reverse transcription-quantitative polymerase chain reaction and immunohistochemistry was used to compare the clinicopathological parameters of the tumors. A significant difference in the level of MAGE-D2 expression was observed between the normal liver and chronic hepatitis tissues, however, no significant differences were identified among the levels of the chronic hepatitis, cirrhosis and HCC tissues. The expression patterns of the MAGE-D2 protein were consistent with those of its mRNA. The expression levels of MAGE-D2 mRNA in 66 of 151 (44%) patients were higher in the HCC tissues compared with the corresponding non-cancerous tissues. In addition, the disease-specific survival time was significantly shorter for patients with higher levels of MAGE-D2 mRNA expression. Multivariate analysis identified increased expression of MAGE-D2 mRNA as an independent prognostic factor for disease-specific survival (hazard ratio, 2.65; 95% confidence interval, 1.43-4.98; P=0.002). However, increased expression levels of MAGE-D2 mRNA were not significantly associated with other clinicopathological parameters, including extrahepatic recurrence. These results indicated that MAGE-D2 mRNA affects tumor progression and may serve as a prognostic indicator following curative resection. In addition, MAGE-D2 may provide a target for the therapy of HCC.	[Hashimoto, Ryoji; Kanda, Mitsuro; Takami, Hideki; Shimizu, Dai; Oya, Hisaharu; Hibino, Soki; Okamura, Yukiyasu; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Nomoto, Shuji; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4668550, Japan	Kanda, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	m-kanda@med.nagoya-u.ac.jp					Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Minguez B, 2011, DIS MARKERS, V31, P181, DOI 10.3233/DMA-2011-0841; Xiao J, 2004, WORLD J GASTROENTERO, V10, P1849; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Miki D, 2012, CANCER SCI, V103, P846, DOI 10.1111/j.1349-7006.2012.02242.x; Shiraha H, 2013, INT J ONCOL, V42, P1133, DOI 10.3892/ijo.2013.1829; Kanda M, 2009, INT J ONCOL, V35, P477, DOI 10.3892/ijo_00000359; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Kanda M, 2014, INT J ONCOL, V44, P44, DOI 10.3892/ijo.2013.2165; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Kanda M, 2008, J SURG ONCOL, V98, P190, DOI 10.1002/jso.21095; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Sang MX, 2011, CANCER LETT, V302, P85, DOI 10.1016/j.canlet.2010.10.021; Khare S, 2013, WORLD J GASTROENTERO, V19, P5439, DOI 10.3748/wjg.v19.i33.5439; Bertrand M, 2004, DEV DYNAM, V230, P325, DOI 10.1002/dvdy.20026; Chang CC, 2004, ANN NY ACAD SCI, V1028, P340, DOI 10.1196/annals.1322.040; Harper R, 2004, BIOCHEM BIOPH RES CO, V324, P199, DOI 10.1016/j.bbrc.2004.09.037; Kidd M, 2006, CANCER, V106, P1480, DOI 10.1002/cncr.21758; Kidd M, 2006, ANN SURG ONCOL, V13, P253, DOI 10.1245/ASO.2006.12.011; Langnaese K, 2001, CYTOGENET CELL GENET, V94, P233, DOI 10.1159/000048822; Li MH, 2004, INT J ONCOL, V24, P305; Oya H, 2013, DIS ESOPHAGUS; Papageorgio C, 2007, INT J ONCOL, V31, P1205; Sobin LH, 2009, TNM CLASSIFICATION M; Takami H, 2013, J SURG ONCOL, V108, P557, DOI 10.1002/jso.23440; Tseng HY, 2012, CARCINOGENESIS, V33, P1871, DOI 10.1093/carcin/bgs236	32	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAR	2015	9	3					1201	1206		10.3892/ol.2014.2823		6	Oncology	Oncology	CD2OE	WOS:000350918100032		
J	Hoshi, M; Oebisu, N; Takada, J; Iwai, T; Nakamura, H				Hoshi, Manabu; Oebisu, Naoto; Takada, Jun; Iwai, Tdashi; Nakamura, Hiroaki			Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma	ONCOLOGY LETTERS			English	Article						renal cell cancer; sorafenib; bone metastasis; lung metastasis	CANCER; SURVIVAL; TRIAL; INTERLEUKIN-2; COMPLICATIONS; INTERFERON; SURGERY	The current study presents the case of a 59-year-old male with advanced-stage renal cell carcinoma and bone metastases in the proximal femur and ilium (cT3aN3M1; stage IV). Resection of the primary renal cell cancer and palliative surgery with a gamma-nail for an impending fracture of the right proximal femur were performed, followed by radiotherapy. Sorafenib, a multi-kinase inhibitor that blocks the raf and tyrosine kinases of the vascular endothelial and platelet-derived growth factor receptors, was administered for 9 months, resulting in a marked improvement in the metastatic ilium and a reduction in the extent of the lung metastases. The patient suffered minor adverse effects, including a skin rash and mild diarrhea, but remained alive at the time of follow-up at 36 months post-surgery. Sorafenib demonstrated efficacy against the bone metastasis of metastatic renal cell carcinoma.	[Hoshi, Manabu; Oebisu, Naoto; Takada, Jun; Iwai, Tdashi; Nakamura, Hiroaki] Osaka City Univ, Grad Sch Med, Dept Orthoped Surg, Osaka 5458585, Japan	Hoshi, M (reprint author), Osaka City Univ, Grad Sch Med, Dept Orthoped Surg, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	hoshi@med.osaka-cu.ac.jp					Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Lin PP, 2007, J BONE JOINT SURG AM, V89A, P1794, DOI 10.2106/JBJS.F.00603; Weiss RJ, 2013, J SURG ONCOL, V107, P498, DOI 10.1002/jso.23277; Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008; Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Zekri J, 2001, INT J ONCOL, V19, P379; Normanno N, 2006, ENDOCR-RELAT CANCER, V13, P3, DOI 10.1677/erc.1.01185; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999-007-0051-0; Kyoda Y, 2014, INT J CLIN ONCOL, V19, P146, DOI 10.1007/s10147-013-0533-x; Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Negrier S, 2007, CANCER, V110, P2468, DOI 10.1002/cncr.23056	14	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-1074	1792-1082		ONCOL LETT	Oncol. Lett.	MAR	2015	9	3					1409	1411		10.3892/ol.2015.2844		3	Oncology	Oncology	CD2OE	WOS:000350918100073		
J	Alombert-Goget, G; Guyot, Y; Guzik, M; Boulon, G; Ito, A; Goto, T; Yoshikawa, A; Kikuchi, M				Alombert-Goget, G.; Guyot, Y.; Guzik, M.; Boulon, G.; Ito, A.; Goto, T.; Yoshikawa, A.; Kikuchi, M.			Nd3+-doped Lu2O3 transparent sesquioxide ceramics elaborated by the Spark Plasma Sintering (SPS) method. Part 1: Structural, thermal conductivity and spectroscopic characterization	OPTICAL MATERIALS			English	Article						Laser ceramics; SPS method; Lu2O3 sesquioxide; Nd3+ ions; Thermal conductivity; Spectroscopic properties	LASER MATERIALS; OPTICAL-PROPERTIES; LUTETIUM OXIDE; FLASH METHOD; IONS; FABRICATION; CRYSTALS; POLYCRYSTALLINE; DIFFUSIVITY; Y3AL5O12	We report the detailed analysis of both structural characterization by SEM, thermal conductivity of high value and high resolution spectroscopic properties of Nd3+-doped Lu2O3 transparent ceramics fabricated by the non-conventional SPS method. The emission spectra of the main C-2 site shows two close F-4(3/2) -> I-4(11/2) laser lines at 1076.3 and 1080.5 nm, respectively. The optical properties of the two C-2 and C-3i sites and of C-2-C-3i; and C-2-C-2 Nd3+ pairs have especially been analyzed. (C) 2014 Elsevier B.V. All rights reserved.	[Alombert-Goget, G.; Guyot, Y.; Guzik, M.; Boulon, G.] Univ Lyon 1, CNRS, ILM, UMR5306, F-69622 Villeurbanne, France; [Guzik, M.] Univ Wroclaw, Fac Chem, PL-50383 Wroclaw, Poland; [Ito, A.; Goto, T.; Yoshikawa, A.; Kikuchi, M.] Tohoku Univ, IMR, Sendai, Miyagi 9808577, Japan	Boulon, G (reprint author), Univ Lyon 1, CNRS, ILM, UMR5306, F-69622 Villeurbanne, France.	georges.boulon@univ-lyon1.fr	Yoshikawa, Akira/B-9986-2011; Ito, Akihiko/C-2848-2011; Guyot, Yannick/B-5847-2014	Ito, Akihiko/0000-0002-6116-1700; 	University of Lyon (France) [M12 LASMAT]; Tohoku University in Sendai (Japan) [M12 LASMAT]	This work is supported by the ELyT (Engineering and Science Lyon Tohoku Laboratory) LIA (CNRS Associated International Laboratory) Program, Project M12 LASMAT, between the University of Lyon (France) and the Tohoku University in Sendai (Japan).	An Liqiong, 2014, OPT MAT EXP, P1420; PARKER WJ, 1961, J APPL PHYS, V32, P1679, DOI 10.1063/1.1728417; Lupei A, 2003, OPT MATER, V24, P181, DOI 10.1016/S0925-3467(03)00123-X; Guzik M, 2014, CRYST GROWTH DES, V14, P3327, DOI 10.1021/cg500225v; Sanghera J, 2011, OPT MATER, V33, P670, DOI 10.1016/j.optmat.2010.09.012; An LQ, 2011, J AM CERAM SOC, V94, P695, DOI 10.1111/j.1551-2916.2010.04145.x; Lu J, 2002, APPL PHYS LETT, V81, P4324, DOI 10.1063/1.1527234; Boulon G, 2012, OPT MATER, V34, P499, DOI 10.1016/j.optmat.2011.04.018; Zhao W, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.022602; Zhao W, 2011, OPT MATER, V33, P684, DOI 10.1016/j.optmat.2010.10.007; Lupei V, 2009, OPT MATER, V31, P701, DOI 10.1016/j.optmat.2008.04.007; CAPE JA, 1963, J APPL PHYS, V34, P1909, DOI 10.1063/1.1729711; Chani VI, 1999, J CRYST GROWTH, V204, P155, DOI 10.1016/S0022-0248(99)00170-0; Legendziewicz J, 2008, J ALLOY COMPD, V451, P600, DOI 10.1016/j.jallcom.2007.04.135; IKESUE A, 1995, J AM CERAM SOC, V78, P225, DOI 10.1111/j.1151-2916.1995.tb08389.x; BUIJS M, 1987, J LUMIN, V37, P9, DOI 10.1016/0022-2313(87)90177-3; Gaume R, 2003, APPL PHYS LETT, V83, P1355, DOI 10.1063/1.1601676; Sanghera J, 2012, MATERIALS, V5, P258, DOI 10.3390/ma5020258; Petermann K, 2000, J LUMIN, V87-9, P973, DOI 10.1016/S0022-2313(99)00497-4; Peters R, 2007, OPT EXPRESS, V15, P7075, DOI 10.1364/OE.15.007075; Sanghera J, 2013, OPT MATER, V35, P693, DOI 10.1016/j.optmat.2012.04.021; Boulesteix R, 2014, SCRIPTA MATER, V75, P54, DOI 10.1016/j.scriptamat.2013.11.016; An LQ, 2011, J EUR CERAM SOC, V31, P1597, DOI 10.1016/j.jeurceramsoc.2011.03.014; Zych E, 2002, J ALLOY COMPD, V341, P381, DOI 10.1016/S0925-8388(02)00042-7; Lupei A, 2013, OPT MATER, V36, P419, DOI 10.1016/j.optmat.2013.10.004; Bishop B., 2009, GLOBE NEWSWIRE  0318; Chani VI, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.075601; Daldosso M, 2007, J LUMIN, V122, P858, DOI 10.1016/j.jlumin.2006.01.309; Epicier T, 2012, J MATER CHEM, V22, P18221, DOI 10.1039/c2jm32995f; Foci G., 2014, OPT MAT; Fornasiero L, 1999, CRYST RES TECHNOL, V34, P255, DOI 10.1002/(SICI)1521-4079(199902)34:2<255::AID-CRAT255>3.0.CO;2-U; Guzik M., J LUMIN UNPUB; Hao LZ, 2011, OPT EXPRESS, V19, P17774, DOI 10.1364/OE.19.017774; Kaminskii AA, 2008, LASER PHYS LETT, V5, P300, DOI 10.1002/lapl.200710128; Lu JR, 2001, JPN J APPL PHYS 2, V40, pL1277, DOI 10.1143/JJAP.40.L1277; Petermann K, 2002, OPT MATER, V19, P67, DOI 10.1016/S0925-3467(01)00202-6; Ramirez MO, 2008, OPT EXPRESS, V16, P5965, DOI 10.1364/OE.16.005965; Zhou D, 2009, J AM CERAM SOC, V92, P2182, DOI 10.1111/j.1551-2916.2009.03190.x	38	4	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		3	11		10.1016/j.optmat.2014.10.014		9	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000002		
J	Toci, G; Vannini, M; Ciofini, M; Lapucci, A; Pirri, A; Ito, A; Goto, T; Yoshikawa, A; Ikesue, A; Alombert-Goget, G; Guyot, Y; Boulon, G				Toci, G.; Vannini, M.; Ciofini, M.; Lapucci, A.; Pirri, A.; Ito, A.; Goto, T.; Yoshikawa, A.; Ikesue, A.; Alombert-Goget, G.; Guyot, Y.; Boulon, G.			Nd3+-doped Lu2O3 transparent sesquioxide ceramics elaborated by the Spark Plasma Sintering (SPS) method. Part 2: First laser output results and comparison with Nd3+-doped Lu2O3 and Nd3+-Y2O3 ceramics elaborated by a conventional method	OPTICAL MATERIALS			English	Article						Laser ceramics; Lu2O3 sesquioxide; SPS method; Nd3+ ions	CRYSTAL; FABRICATION; PERFORMANCE	We report the first demonstration of laser oscillation of two 1080.5 nm using a 1% Nd3+-doped Lu2O3 transparent ceramics Plasma Sintering (SPS) method. A comparison is made with ceramics elaborated by HIP conventional method. close IR emission lines at 10763 nm and fabricated by the non-conventional Spark Nd3+-doped Lu2O3 and Nd3+-doped Y2O3 (C) 2014 Elsevier B.V. All rights reserved.	[Toci, G.; Vannini, M.] CNR, INO, I-50019 Sesto Fiorentino, Italy; [Ciofini, M.; Lapucci, A.] CNR, INO, I-50125 Florence, Italy; [Pirri, A.] CNR, Ist Fis Applicata Nello Carrara, IFAC, F-69622 Villeurbanne, France; [Ito, A.; Goto, T.; Yoshikawa, A.] Tohoku Univ, IMR, Sendai, Miyagi 9808577, Japan; [Ikesue, A.] World Lab Co Ltd, Atsuta Ku, Nagoya, Aichi 4568587, Japan; [Alombert-Goget, G.; Guyot, Y.; Boulon, G.] Univ Lyon 1, CNRS, ILM, UMR5306, F-69622 Villeurbanne, France	Boulon, G (reprint author), Univ Lyon 1, CNRS, ILM, UMR5306, F-69622 Villeurbanne, France.	georges.boulon@univ-lyon1.fr	Yoshikawa, Akira/B-9986-2011; Ito, Akihiko/C-2848-2011; Guyot, Yannick/B-5847-2014; 	Ito, Akihiko/0000-0002-6116-1700; PIRRI, ANGELA/0000-0002-0302-7773	University of Lyon (France) [M12 LASMAT]; Tohoku University in Sendai (Japan) [M12 LASMAT]	This work is supported by the ELyT (Engineering and Science Lyon Tohoku Laboratory) LIA (CNRS Associated International Laboratory) Program, Project M12 LASMAT, between the University of Lyon (France) and the Tohoku University in Sendai (Japan) who want to express their gratitude to the Firenze's team for laser measurements.	Lu J, 2002, APPL PHYS LETT, V81, P4324, DOI 10.1063/1.1527234; Alombert-Goget G, 2015, OPT MATER, V41, P3, DOI 10.1016/j.optmat.2014.10.014; Ikesue A, 2007, OPT MATER, V29, P1289, DOI 10.1016/j.optmat.2005.12.013; Boulesteix R, 2014, SCRIPTA MATER, V75, P54, DOI 10.1016/j.scriptamat.2013.11.016; Hao LZ, 2011, OPT EXPRESS, V19, P17774, DOI 10.1364/OE.19.017774; Li JH, 2012, LASER PHYS LETT, V9, P195, DOI 10.1002/lapl.201110114; Zhou D, 2009, J AM CERAM SOC, V92, P2182, DOI 10.1111/j.1551-2916.2009.03190.x	7	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		12	16		10.1016/j.optmat.2014.09.033		5	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000003		
J	Kamada, K; Kurosawa, S; Yamaji, A; Shoji, Y; Pejchal, J; Ohashi, Y; Yokota, Y; Yoshikawa, A				Kamada, Kei; Kurosawa, Shunsuke; Yamaji, Akihiro; Shoji, Yasuhiro; Pejchal, Jan; Ohashi, Yuji; Yokota, Yuui; Yoshikawa, Akira			Growth of Nd doped (Lu, Gd)(3)(Ga, Al)(5)O-12 single crystal by the micro pulling down method and their scintillation properties	OPTICAL MATERIALS			English	Article						Single crystal growth; Scintillator; Garnet; Neodymium	LSO-CE; DETECTORS; EFFICIENT; LUAG	Nd 1 mol% doped (Lu, Gd)(3)(Ga, Al)(5)O-12 (LGGAG) single crystals were grown by the micro-pulling down (mu-PD) method. Luminescence and scintillation properties such as absorption, excitation and emission spectra, light yield and decay time were evaluated. Nd1%:Lu3Al5O12 showed the highest light output of around 8200 photons/MeV among the grown crystals. Scintillation decay time of Nd:Y3Al5O12 was 1.32 mu s (36%) 2.02 mu s (64%). Nd:Lu3Ga3Al2O12 was relatively high dense scintillator of 7.38 g/cm(3) with good light yield of 6800 photons/MeV and scintillation decay time of 0.20 mu s (5%) 2.60 mu s (95%). (C) 2014 Elsevier B.V. All rights reserved.	[Kamada, Kei; Kurosawa, Shunsuke; Pejchal, Jan; Yokota, Yuui; Yoshikawa, Akira] Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Kamada, Kei; Shoji, Yasuhiro; Yoshikawa, Akira] C&A Corp, T Biz, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Kurosawa, Shunsuke; Yamaji, Akihiro; Shoji, Yasuhiro; Ohashi, Yuji; Yoshikawa, Akira] Tohoku Univ, Inst Mat Reseach, Aoba Ku, Sendai, Miyagi 9808577, Japan; [Pejchal, Jan] Acad Sci Czech Republic, Inst Phys, Prague 16253, Czech Republic	Kamada, K (reprint author), Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, 6-6-10 Aoba, Sendai, Miyagi 9808579, Japan.		Yoshikawa, Akira/B-9986-2011; Ohashi, Yuji/F-8470-2014		Japan Society for the Promotion of Science (JSPS); Japan Science and Technology Agency (JST); JST; JSPS; JSPS Research Fellowships for Young Scientists; Ministry of Health Labour and Welfare; Czech MEYS KONTAKT Cz-jp collaboration [LH14266]; Crystal Clear Collaboration in CERN; EC Marie Curie Initial Training Network LUMINET [316906]	This work is partially supported by (i) the funding program for next generation world-leading researchers, Japan Society for the Promotion of Science (JSPS), (ii) Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST) (iii) Adaptable & Seamless Technology Transfer Program through Target-driven R&D (A-STEP), JST (iv) JSPS Grant-in-Aid for Exploratory Research, (v) JSPS Research Fellowships for Young Scientists, (vi) the Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare and (vii) Czech MEYS KONTAKT Cz-jp collaboration LH14266 project, Crystal Clear Collaboration in CERN, and EC Marie Curie Initial Training Network LUMINET, No. 316906. In addition, we would like to thank following persons for their support: Mr. Yoshihiro Nakamura in Institute of Multidisciplinary Research for Advanced Materials (IMRAM), and Mr. Hiroshi Uemura, Ms. Keiko Toguchi, Ms. Megumi Sasaki and Ms. Yuka Takeda in IMR, Tohoku University.	Conti M, 2009, PHYS MEDICA, V25, P1, DOI 10.1016/j.ejmp.2008.10.001; Nikl M, 2006, MEAS SCI TECHNOL, V17, pR37, DOI 10.1088/0957-0233/17/4/R01; MELCHER CL, 1992, IEEE T NUCL SCI, V39, P502, DOI 10.1109/23.159655; Weber S, 2003, IEEE T NUCL SCI, V50, P1370, DOI 10.1109/TNS.2003.817952; LEMPICKI A, 1995, IEEE T NUCL SCI, V42, P280, DOI 10.1109/23.467836; Yoshikawa A, 1999, J CRYST GROWTH, V205, P305, DOI 10.1016/S0022-0248(99)00265-1; Kamada K, 2012, J CRYST GROWTH, V352, P88, DOI 10.1016/j.jcrysgro.2011.11.085; Alekhin MS, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4803440; Shah KS, 2003, IEEE T NUCL SCI, V50, P2410, DOI 10.1109/TNS.2003.820614; Wisniewski D, 2002, NUCL INSTRUM METH A, V486, P239, DOI 10.1016/S0168-9002(02)00709-X; Nikl M, 2013, PROG CRYST GROWTH CH, V59, P47, DOI 10.1016/j.pcrysgrow.2013.02.001; Mares JA, 2004, RADIAT MEAS, V38, P353, DOI 10.1016/j.radmeas.2004.04.004; Blazek K, 2004, PHYS STATUS SOLIDI B, V241, P1134, DOI 10.1002/pssb.200301986; Spurrier MA, 2008, IEEE T NUCL SCI, V55, P1178, DOI 10.1109/TNS.2007.913486; Kramer KW, 2006, J MATER CHEM, V16, P2773, DOI 10.1039/b602762h; Danevich FA, 2005, NUCL INSTRUM METH A, V541, P583, DOI 10.1016/j.nima.2004.12.014; Kapusta M, 2005, IEEE T NUCL SCI, V52, P1098, DOI [10.1109/TNS.2005.852731, 10.1106/TNS.2005.0852731]; Moszynski M, 1997, NUCL INSTRUM METH A, V385, P123, DOI 10.1016/S0168-9002(96)00875-3; Kamada K, 2014, OPT MATER, V36, P1942, DOI 10.1016/j.optmat.2014.04.001; Cherepy N.J., 2010, P SOC PHOTO-OPT INS, V7805; Lecoq P, 2002, IEEE T NUCL SCI, V49, P1651, DOI 10.1109/TNS.2002.801487; Nikl M, 2000, PHYS STATUS SOLIDI A, V181, pR10, DOI 10.1002/1521-396X(200009)181:1<R10::AID-PSSA999910>3.0.CO;2-9; Kamada K, 2011, CRYST GROWTH DES, V11, P4484, DOI 10.1021/cg200694a	23	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		32	35		10.1016/j.optmat.2014.10.007		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000006		
J	Yanagida, T; Fujimoto, Y; Ishizu, S; Fukuda, K				Yanagida, Takayuki; Fujimoto, Yutaka; Ishizu, Sumito; Fukuda, Kentaro			Optical and scintillation properties of Nd differently doped YLiF4 from VUV to NIR wavelengths	OPTICAL MATERIALS			English	Article						Crystal; Scintillation detector; Nd3+; Scintillator	CRYSTAL-GROWTH; CHAMBER	Nd 0.1, 0.5, 1, and 3 mol% doped YLiF4 crystalline scintillators were prepared by Tokuyama Corp. and their optical and scintillation properties from vacuum ultraviolet (VUV) to near infrared (NIR) wavelengths were investigated. 4f-5d absorption bands appeared in VUV and several absorption bands due to 4f-4f transition were observed in visible-NIR wavelengths. Nd3+ 5d-4f emission was observed around 180 nm under 160 nm excitation and intense line due to F-4(3/2) -> I-4(11/2) at 1064 nm appeared under 500 nm excitation. In X-ray induced radioluminescence, both VUV and NIR emissions were observed. Scintillation decay times of VUV emission was 40-80 ns while that of 4f-4f ones at visible wavelength were around 12-15 mu s. When Cf-252 neutron was irradiated, VUV scintillation light yield resulted around 90 ph/n. (C) 2014 Elsevier B.V. All rights reserved.	[Yanagida, Takayuki; Fujimoto, Yutaka] Kyushu Inst Technol, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan; [Ishizu, Sumito; Fukuda, Kentaro] Tokuyama Corp, Yamaguchi 7458648, Japan	Yanagida, T (reprint author), Kyushu Inst Technol, Wakamatsu Ku, 2-4 Hibikino, Kitakyushu, Fukuoka 8080196, Japan.	yanagida@lsse.kyutech.ac.jp	Yanagida, Takayuki/F-1814-2014	Yanagida, Takayuki/0000-0002-4298-5886	Ministry of Education, Culture, Sports, Science and Technology of the Japanese government (MEXT) [26249147]; JST A-step	This work was mainly supported by a Grant in Aid for Scientific Research (A)-26249147 from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government (MEXT) and partially by JST A-step. Partial assistance from Nippon Sheet Glass Foundation for Materials Science and Engineering, Tokuyama Science foundation, Iketani Science and Technology Foundation, Hitachi Metals Materials Science Foundation, Mazda Foundation, JFE 21st century Foundation, and The Asahi Glass Foundation, the Cooperative Research Project of Research Institute of Electronics, Shizuoka University and Collaborative Research Program of Institute for Chemical Research, Kyoto University (2014-31) are also gratefully acknowledged.	Abe N, 2010, IEEE T NUCL SCI, V57, P1278, DOI 10.1109/TNS.2009.2036915; Totsuka D, 2011, NUCL INSTRUM METH A, V659, P399, DOI 10.1016/j.nima.2011.08.014; Chechik R, 2008, NUCL INSTRUM METH A, V595, P116, DOI 10.1016/j.nima.2008.07.035; Yanagida T, 2014, OPT MATER, V36, P1044, DOI 10.1016/j.optmat.2014.01.022; Khaidukov NM, 2000, OPT COMMUN, V184, P183, DOI 10.1016/S0030-4018(00)00954-8; Yanagida T, 2013, OPT MATER, V35, P1987, DOI 10.1016/j.optmat.2012.11.002; Yanagida T, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.062401; Yanagida T, 2010, IEEE T NUCL SCI, V57, P1492, DOI 10.1109/TNS.2009.2032265; Yanagida T, 2013, NUCL INSTRUM METH A, V729, P58, DOI 10.1016/j.nima.2013.07.010; Yanagida T, 2010, IEEE T NUCL SCI, V57, P1312, DOI 10.1109/TNS.2010.2042965; Moses WW, 1998, IEEE T NUCL SCI, V45, P462, DOI 10.1109/23.682427; Amiot CL, 2008, SENSORS-BASEL, V8, P3082, DOI 10.3390/s8053082; Belsky AN, 1997, J LUMIN, V72-4, P146, DOI 10.1016/S0022-2313(96)00160-3; Dooley PW, 2000, OPT COMMUN, V183, P451, DOI 10.1016/S0030-4018(00)00898-1; Ito T., 2006, IEEE T NUCL SCI, V53, P2983; Moriyama S., 2002, WORLD SCI, V2002, P123; Rodnyi PA, 2002, NUCL INSTRUM METH A, V486, P244, DOI 10.1016/S0168-9002(02)00710-6; SCHOTANUS P, 1988, NUCL INSTRUM METH A, V272, P913, DOI 10.1016/0168-9002(88)90780-2; Sekiya H, 2011, NUCL INSTRUM METH A, V633, pS36, DOI 10.1016/j.nima.2010.06.114; vanderMarel J, 1997, NUCL INSTRUM METH A, V392, P310, DOI 10.1016/S0168-9002(97)00237-4; Wetter NU, 2013, WOODH PUB SER ELECT, P323, DOI 10.1533/9780857097507.2.323; Yamaji A, 2013, OPT MATER, V35, P1890, DOI 10.1016/j.optmat.2013.02.010; Yamaoka K, 2005, IEEE T NUCL SCI, V52, P2765, DOI 10.1109/TNS.2005.862778; Yanagida T., 2013, J CERAM SOC JPN, V121, P989; Yanagida T, 2013, JPN J APPL PHYS, V52, DOI 10.7567/JJAP.52.076401	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		36	40		10.1016/j.optmat.2014.10.043		5	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000007		
J	Kamada, K; Kurosawa, S; Shoji, Y; Pejchal, J; Ohashi, Y; Yokota, Y; Yoshikawa, A				Kamada, Kei; Kurosawa, Shunsuke; Shoji, Yasuhiro; Pejchal, Jan; Ohashi, Yuji; Yokota, Yuui; Yoshikawa, Akira			Luminescence and scintillation properties of Ce dope SrHfO3 based eutectics	OPTICAL MATERIALS			English	Article						Scintillator; Eutectic; Micro pulling down method; Ce3+	MICROSTRUCTURES	Ce doped SrHfO3/SrAl12O19 eutectics were grown by the micro pulling down (mu-PD) method and their directionally solidified eutectic system has been investigated. Investigations of obtained eutectic structure, luminescence and scintillation performances were also performed. Eutectics were grown at the speed of 0.60-0.90 mm/min. In the eutectics, Ce3+ 4f-5d emission was observed at 410 nm. The eutectics showed light yield of around 300 photon/5.5 meV alpha-ray by Am-241 excitation. Scintillation decay time was 26.4 ns (45%) with slower decay component of 263 ns (55%). (C) 2014 Elsevier B.V. All rights reserved.	[Kamada, Kei; Shoji, Yasuhiro; Yokota, Yuui; Yoshikawa, Akira] C&A Corp, T Biz, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Kamada, Kei; Kurosawa, Shunsuke; Pejchal, Jan; Yoshikawa, Akira] Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Kurosawa, Shunsuke; Shoji, Yasuhiro; Ohashi, Yuji; Yoshikawa, Akira] Tohoku Univ, Inst Mat Reseach, Sendai, Miyagi 9808577, Japan; [Pejchal, Jan] Acad Sci Czech Republic, Inst Phys, Prague 16253, Czech Republic	Kamada, K (reprint author), Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, 6-6-10 Aoba, Sendai, Miyagi 9808579, Japan.		Yoshikawa, Akira/B-9986-2011; Ohashi, Yuji/F-8470-2014		JSPS; Japan Science and Technology Agency (JST); JST; Japan Society for the Promotion of Science (JSPS); JSPS Research Fellowships for Young Scientists; Health Labour Sciences Research Grant; Ministry of Health Labour and Welfare; Czech MEYS KONTAKT Cz-jp collaboration [LH14266]; Crystal Clear Collaboration in CERN; EC Marie Curie Initial Training Network LUMINET [316906]	This work is partially supported by (i) the funding program for next generation world-leading researchers, JSPS, (ii) Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST) (iii) Adaptable & Seamless Technology Transfer Program through Target-driven R&D (A-STEP), JST (iv) Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Exploratory Research (AN.), (v) JSPS Research Fellowships for Young Scientists (S. Kurosawa), (vi) the Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare and (vii) Czech MEYS KONTAKT Cz-jp collaboration LH14266 project, Crystal Clear Collaboration in CERN, and EC Marie Curie Initial Training Network LUMINET, No. 316906. In addition, we would like to thank following persons for their support: Mr. Yoshihiro Nakamura in Institute of Multidisciplinary Research for Advanced Materials (IMRAM), and Mr. Hiroshi Uemura, Ms. Keiko Toguchi, Ms. Megumi Sasaki and Ms. Yuka Takeda in IMR, Tohoku University.	Nikl M, 2006, MEAS SCI TECHNOL, V17, pR37, DOI 10.1088/0957-0233/17/4/R01; MELCHER CL, 1992, IEEE T NUCL SCI, V39, P502, DOI 10.1109/23.159655; Yoshikawa A, 1999, J CRYST GROWTH, V205, P305, DOI 10.1016/S0022-0248(99)00265-1; Pawlak DA, 2006, CHEM MATER, V18, P2450, DOI 10.1021/cm060136h; Yanagida T, 2012, OPT MATER, V34, P868, DOI 10.1016/j.optmat.2011.11.022; Bei H, 2005, ACTA MATER, V53, P69, DOI 10.1016/j.actamat.2004.09.003; Llorca J, 2006, PROG MATER SCI, V51, P711, DOI 10.1016/j.pmatsci.2005.10.002; Choi JS, 1999, MATER RES BULL, V34, P551, DOI 10.1016/S0025-5408(99)00042-2; de Haas JTM, 2005, NUCL INSTRUM METH A, V537, P97, DOI 10.1016/j.nima.2004.07.243; Den T., 2013, IEEE T NUCL SCI, V60; Ji YM, 2005, J CRYST GROWTH, V280, P93, DOI 10.1016/j.jcrysgro.2005.02.048; Kurosawa S., 2013, RADIAT MEAS, P155; Mel'nik M.T., 1988, PHYS STATUS SOLIDI, V29, P611; Mihakova E., 2012, RAPID RES LETT, P1; Misevicius M, 2013, MATER SCI-MEDZG, V19, P438, DOI 10.5755/j01.ms.19.4.2670; Nikl M, 2011, OPT MATER, V34, P433, DOI 10.1016/j.optmat.2011.04.040; Ohashi Y., 2013, APPL PHYS LETT, V102; van Loef EV, 2007, IEEE T NUCL SCI, V54, P741, DOI 10.1109/TNS.2007.896343	18	4	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		41	44		10.1016/j.optmat.2014.10.010		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000008		
J	Kitaura, M; Sato, A; Kamada, K; Kurosawa, S; Ohnishi, A; Sasaki, M; Hara, K				Kitaura, M.; Sato, A.; Kamada, K.; Kurosawa, S.; Ohnishi, A.; Sasaki, M.; Hara, K.			Photoluminescence studies on energy transfer processes in cerium-doped Gd3Al2Ga3O12 crystals	OPTICAL MATERIALS			English	Article						Energy transfer; Host sensitization; Photoluminescence; Scintillator; Ce:GAGG; Synchrotron radiation	GD PHOSPHATE-GLASSES; SCINTILLATION PROPERTIES; GROWTH	We have measured photoluminescence properties of cerium-doped Gd3Al2Ga3O12 (Ce:GAGG) crystals at low temperatures with use of synchrotron radiation. Excitation spectra for the Ce3+ 5d-4f emission exhibit prominent peaks at Gd3+ intra-4f absorption bands. The Gd3+ intra-4f emission band is observed at 3.91 eV, but is not in resonance with the lowest energy Gd3+ intra-4f absorption band at 3.95 eV. The temperature dependence of the Gd3+ emission intensity is not correlated with that of the Ce3+ emission intensity. Decay curves of the Ce3+ emission were also measured at 9 K under excitation at various photon energies. The decay curve is remarkably changed, depending on the excitation photon energies. The present results give us hints to understand the whole of energy transfer processes in Ce:GAGG crystals. (C) 2015 Elsevier B.V. All rights reserved.	[Kitaura, M.; Sato, A.; Ohnishi, A.; Sasaki, M.] Yamagata Univ, Fac Sci, Dept Phys, Yamagata 9908560, Japan; [Kamada, K.; Kurosawa, S.] Tohoku Univ, New Ind Creat Hatchery Ctr, Sendai, Miyagi 9808579, Japan; [Kurosawa, S.] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808679, Japan; [Hara, K.] Shizuoka Univ, Elect Res Inst, Hamamatsu, Shizuoka 4328011, Japan	Kitaura, M (reprint author), Yamagata Univ, Fac Sci, Dept Phys, Yamagata 9908560, Japan.	kitaura@sci.kj.yamagata-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [26420673]; Cooperative Research Project of Research Institute of Electronics, Shizuoka University [p-23]; Inter-University Cooperative Research Program of the Institute for Materials Research, Tohoku University [14K0085]	The present study was supported by a KAKNHI Grant (No. 26420673) from the Japan Society for the Promotion of Science (JSPS), Cooperative Research Project of Research Institute of Electronics, Shizuoka University (No. p-23), and the Inter-University Cooperative Research Program of the Institute for Materials Research, Tohoku University (No. 14K0085). This work was performed at the UVSOR facility under the Joint Studies Program of the Institute for Molecular Science.	DONG J, 1991, PHYS REV B, V43, P8808, DOI 10.1103/PhysRevB.43.8808; Kamada K, 2012, J CRYST GROWTH, V352, P88, DOI 10.1016/j.jcrysgro.2011.11.085; Fukui K, 2014, J SYNCHROTRON RADIAT, V21, P452, DOI 10.1107/S1600577513032931; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; Nikl M, 2000, APPL PHYS LETT, V77, P2159, DOI 10.1063/1.1315337; Sakthong O, 2013, OPT MATER, V36, P568, DOI 10.1016/j.optmat.2013.10.033; Mares JA, 2001, J LUMIN, V94, P321, DOI 10.1016/S0022-2313(01)00293-9; Kondo H, 2003, J LUMIN, V102, P727, DOI 10.1016/S0022-2313(02)00633-6; Deozdowski W., 2014, OPT MATER, V36, P1665; Ferii A., 2014, PHYS MED BIOL, V59, P869; Henderson B., 1989, OPTICAL SPECTROSCOPY; Kamada K, 2012, IEEE T NUCL SCI, V59, P2112, DOI 10.1109/TNS.2012.2197024; KANHO K, 1990, PHYS SCRIPTA, V41, P120, DOI 10.1088/0031-8949/41/1/029; Kato T., 2013, J INSTRUM, V8; Kitaura M., 2014, J APPL PHYS, V115; Mori K, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.165206; Nikl M., 2010, J PHYS C SER, V249; Satoh A., 2014, JPN J APPL PHYS, V53; Selim F.A., 2007, APPL PHYS LETT, V91; Kamada K, 2011, CRYST GROWTH DES, V11, P4484, DOI 10.1021/cg200694a	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		45	48		10.1016/j.optmat.2014.12.040		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000009		
J	Fujimoto, Y; Yanagida, T; Koshimizu, M; Asai, K				Fujimoto, Yutaka; Yanagida, Takayuki; Koshimizu, Masanori; Asai, Keisuke			Photoluminescence, photo-stimulated luminescence and thermoluminescence properties of CaB2O4 crystals activated with Ce3+	OPTICAL MATERIALS			English	Article						Photo-stimulated luminescence; Thermoluminescence; Ce3+ 5d-4f transition	SCINTILLATOR; METABORATE; SRB2O4	Photoluminescence (PL), photo-stimulated luminescence (PSL), and thermoluminescence (TL) properties of a Ce-doped CaB2O4 crystal were studied. The Ce-doped crystal was prepared by the simple solidification method using a Pt crucible under nitrogen atmosphere. A PL emission band in the 350-370 nm wavelength range was obtained under excitation at 325 nm owing to the 5d (t(2g))-4f (F-2(5/2), F-2(7/2))-allowed transition of the Ce3+ emission center. The fluorescence quantum efficiency and the decay time of Ce3+ were estimated to be about 70% and 29 ns, respectively. The 5d-4f emission band of Ce3+ also appeared in the 350-370 nm wavelength range in the TL. and PSL spectra. Good linear TL and PSL responses were observed in the 1-1000 mGy and 1-10,000 mGy X-ray dose range, respectively. (C) 2014 Elsevier B.V. All rights reserved.	[Fujimoto, Yutaka; Koshimizu, Masanori; Asai, Keisuke] Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Yanagida, Takayuki] Kyushu Inst Technol, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan	Fujimoto, Y (reprint author), Tohoku Univ, Aoba Ku, 6-6-04 Aramaki Aza Aoba, Sendai, Miyagi 9808579, Japan.	fuji-you@qpc.che.tohoku.ac.jp	Koshimizu, Masanori/B-9491-2008; Yanagida, Takayuki/F-1814-2014	Koshimizu, Masanori/0000-0002-0905-2144; Yanagida, Takayuki/0000-0002-4298-5886			Furetta C, 2000, APPL RADIAT ISOTOPES, V52, P243, DOI 10.1016/S0969-8043(99)00124-4; Dorenbos P, 2000, J LUMIN, V91, P91, DOI 10.1016/S0022-2313(00)00197-6; Fujimoto Y, 2012, CRYST GROWTH DES, V12, P142, DOI 10.1021/cg200885h; Yavetskiy RP, 2007, J ALLOY COMPD, V441, P202, DOI 10.1016/j.jallcom.2006.09.077; Seo HJ, 1999, J PHYS-CONDENS MAT, V11, P7635, DOI 10.1088/0953-8984/11/39/318; Yanagida T, 2013, OPT MATER, V35, P2480, DOI 10.1016/j.optmat.2013.07.002; TAKAHASHI K, 1984, J LUMIN, V31-2, P266, DOI 10.1016/0022-2313(84)90268-0; Ueda J, 2013, OPT MATER, V35, P1952, DOI 10.1016/j.optmat.2012.11.016; Berezovskaya IV, 2007, RADIAT MEAS, V42, P878, DOI 10.1016/j.radmeas.2007.02.029; PROKIC M, 1980, NUCL INSTRUM METHODS, V175, P83, DOI 10.1016/0029-554X(80)90262-1; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; Santiago M, 2001, PHYS STATUS SOLIDI A, V185, P285, DOI 10.1002/1521-396X(200106)185:2<285::AID-PSSA285>3.0.CO;2-9; Yanagida T, 2005, IEEE T NUCL SCI, V52, P1836, DOI 10.1109/TNS.2005.856757; McKeever SWS, 1996, RADIAT PROT DOSIM, V65, P267; DRISCOLL CMH, 1986, RADIAT PROT DOSIM, V17, P367; Fujimoto Y., 2010, J CRYST GROWTH, V318, P784; Fujimoto Y., 2010, PHYS STATUS SOLIDI B, V248, P444; Haghiri ME, 2013, J LUMIN, V141, P177, DOI 10.1016/j.jlumin.2013.03.039; Kim JB, 1996, ACTA CRYSTALLOGR C, V52, P498, DOI 10.1107/S0108270195010341; MARKEY BG, 1995, RADIAT MEAS, V24, P457, DOI 10.1016/1350-4487(94)00119-L; Shoushan W., 1986, RADIAT PROT DOSIM, V14, P223; Tekin E, 2010, RADIAT MEAS, V45, P764, DOI 10.1016/j.radmeas.2010.04.009; Yukihara EG, 2010, J LUMIN, V130, P2309, DOI 10.1016/j.jlumin.2010.07.010; Zachariasen WH, 1931, P NATL ACAD SCI USA, V17, P617, DOI 10.1073/pnas.17.11.617	24	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		49	52		10.1016/j.optmat.2014.11.049		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000010		
J	Sugawara, K; Koshimizu, M; Yanagida, T; Fujimoto, Y; Haruki, R; Nishikido, F; Kishimoto, S; Asai, K				Sugawara, K.; Koshimizu, M.; Yanagida, T.; Fujimoto, Y.; Haruki, R.; Nishikido, F.; Kishimoto, S.; Asai, K.			Luminescence and scintillation properties of Ce-doped Cs2ZnCl4 crystals	OPTICAL MATERIALS			English	Article						Scintillation; Auger-free luminescence; Cross luminescence; Core-valence luminescence; Relaxed excited state	CHLORIDE	In this study, we have synthesized scintillation materials based on Ce-doped Cs2ZnCl4 crystals. The light yield was enhanced by up to 20% by doping Cs2ZnCl4 with Ce3+ ions. In the scintillation time profiles, fast components exhibited decay time constants on the order of nanoseconds, which was ascribed to Auger-free luminescence (AFL). The light yield of the AFL component decreased at 10 mol% Ce3+ concentration, which is mainly attributed to the reabsorption of AFL photons inside the crystals by Ce3+ ions, as seen in the scintillation spectra. Long components had decay time constants of approximately 30 ns. In addition, at 10 mol% Ce3+ concentration, a prominent band appeared at approximately 500 nm in the scintillation spectrum, which was not observed in the photoluminescence spectra. The long components in the scintillation time profiles and the 500 nm band in the scintillation spectra were tentatively attributed to self-trapped excitons perturbed by Ce3+ ions. (C) 2014 Elsevier B.V. All rights reserved.	[Sugawara, K.; Koshimizu, M.; Fujimoto, Y.; Asai, K.] Tohoku Univ, Grad Sch Engn, Dept Appl Chem, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Yanagida, T.] Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan; [Haruki, R.; Kishimoto, S.] High Energy Accelerator Res Org, Inst Mat Struct Sci, Tsukuba, Ibaraki 3050801, Japan; [Nishikido, F.] Natl Inst Radiol Sci, Mol Imaging Ctr, Inage Ku, Chiba 2638555, Japan	Koshimizu, M (reprint author), Tohoku Univ, Grad Sch Engn, Dept Appl Chem, Aoba Ku, 6-6-07 Aoba, Sendai, Miyagi 9808579, Japan.	koshi@qpc.che.tohoku.ac.jp	Koshimizu, Masanori/B-9491-2008; Yanagida, Takayuki/F-1814-2014	Koshimizu, Masanori/0000-0002-0905-2144; Yanagida, Takayuki/0000-0002-4298-5886	A-STEP program from the Japan Science and Technology Agency; Amano Institute of Technology; Cooperative Research Project of Research Institute of Electronics, Shizuoka University	This research was partially supported by A-STEP program from the Japan Science and Technology Agency. This study was performed with the approval of the Photon Factory Advisory Committee (Proposal No. 2008G104, 2010G179, and 2012G062). Part of this research is also supported by Grant from Amano Institute of Technology and the Cooperative Research Project of Research Institute of Electronics, Shizuoka University.	Yahaba N, 2014, APPL PHYS EXPRESS, V7, DOI 10.7567/APEX.7.062602; Koshimizu M, 2014, OPT MATER, V36, P1930, DOI 10.1016/j.optmat.2014.04.004; MELCHER CL, 1992, NUCL INSTRUM METH A, V314, P212, DOI 10.1016/0168-9002(92)90517-8; Ohnishi A, 2012, J LUMIN, V132, P2639, DOI 10.1016/j.jlumin.2012.05.009; LAVAL M, 1983, NUCL INSTRUM METHODS, V206, P169, DOI 10.1016/0167-5087(83)91254-1; Combes CM, 1999, J LUMIN, V82, P299, DOI 10.1016/S0022-2313(99)00047-2; Gundiah G, 2014, J LUMIN, V149, P374, DOI 10.1016/j.jlumin.2013.09.057; Ishibashi H, 1998, IEEE T NUCL SCI, V45, P518, DOI 10.1109/23.682439; KUBOTA S, 1990, NUCL INSTRUM METH A, V289, P253, DOI 10.1016/0168-9002(90)90267-A; Kunkely H, 2006, INORG CHEM COMMUN, V9, P1, DOI 10.1016/j.inoche.2005.08.017; Li WM, 1996, MATER LETT, V28, P491, DOI 10.1016/0167-577X(96)00104-8; MCGINNET.JA, 1974, INORG CHEM, V13, P1057, DOI 10.1021/ic50135a009; Mihokova E, 1996, J PHYS-CONDENS MAT, V8, P4301, DOI 10.1088/0953-8984/8/23/020; NAGIRNYI V, 1994, CHEM PHYS LETT, V227, P533, DOI 10.1016/0009-2614(94)00857-4; Ohnishi A, 2012, J PHYS SOC JPN, V81, DOI 10.1143/JPSJ.81.114704; Rodnyi PA, 2004, RADIAT MEAS, V38, P343, DOI 10.1016/j.radmeas.2003.11.003; Selling J, 2005, J PHYS-CONDENS MAT, V17, P8069, DOI 10.1088/0953-8984/17/50/024; SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220; vantSpijker JC, 1997, J LUMIN, V72-4, P786, DOI 10.1016/S0022-2313(96)00430-9; van't Spijker JC, 1999, J LUMIN, V85, P1, DOI 10.1016/S0022-2313(99)00170-2; Yokota Y, 2010, RADIAT MEAS, V45, P472, DOI 10.1016/j.radmeas.2009.11.036	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		53	57		10.1016/j.optmat.2014.10.053		5	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000011		
J	Pejchal, J; Fukuda, K; Kurosawa, S; Yokota, Y; Yoshikawa, A				Pejchal, Jan; Fukuda, Kentaro; Kurosawa, Shunsuke; Yokota, Yuui; Yoshikawa, Akira			Luminescence and scintillation properties of rare-earth-doped LuF3 scintillation crystals	OPTICAL MATERIALS			English	Article						Lutetium fluoride; Scintillator; VUV luminescence	PULLING-DOWN METHOD; SINGLE-CRYSTALS; GROWTH; ND3+	The Nd-doped and Er-doped LuF3 single crystals were grown by the micro-pulling-down method to study their scintillation properties in the vacuum-ultraviolet (VUV) region. The doubly Nd-Er codoped single crystal was grown to study possibility of scintillation performance improvement by energy transfer from Er3+ to Nd3+ ions. The LiF flux was to avoid phase transition below melting temperature. The 1%Nd-doped sample showed the highest overall scintillation efficiency under X-ray excitation which was 7 times as high as that of the LaF3:Nd 8% standard. The leading Nd3+ 5d-4f emission was situated at 176 nm, while the Er3+ 5d-4f emission for Er-doped samples was observed at 163 nm, which better matches the sensitivity of some VUV-sensitive photodetectors. The optimum Er concentration was determined to be around 1-3 mol%. No Er3+ 5d-4f emission was observed for the doubly Er,Nd-codoped sample due to energy transfer from the Er3+ to Nd3+ ions. Slight improvement of the light yield was observed in the doubly-doped sample with respect to the Nd-only doped one. (C) 2014 Elsevier B.V. All rights reserved.	[Pejchal, Jan; Kurosawa, Shunsuke; Yokota, Yuui; Yoshikawa, Akira] Tohoku Univ, NICHe, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Pejchal, Jan] Inst Phys AS CR, Prague 16200 6, Czech Republic; [Fukuda, Kentaro] Tokuyama Corp, Shunan, Yamaguchi 7458648, Japan; [Kurosawa, Shunsuke; Yoshikawa, Akira] Inst Mat Res, Aoba Ku, Sendai, Miyagi 9808577, Japan	Pejchal, J (reprint author), Tohoku Univ, NICHe, Aoba Ku, 6-6-10 Aoba, Sendai, Miyagi 9808579, Japan.	pejchalj@imr.tohoku.ac.jp	Yoshikawa, Akira/B-9986-2011		Japan Society for the Promotion of Science (JSPS); Development of Systems and Technology for Advanced Measurement and Analysis (SENTAN), Japan Science and Technology Agency (JST); Adaptable and Seamless Technology Transfer Program through Target-driven RD (A-STEP), JST; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare; New Energy and Industrial Technology Development Organization (NEDO); Supporting Industry program, Ministry of Economy, Trade and Industry (METI); Association for the Progress of New Chemical Technology	This work is partially supported by; (i) Japan Society for the Promotion of Science (JSPS).; (ii) Development of Systems and Technology for Advanced Measurement and Analysis (SENTAN), Japan Science and Technology Agency (JST).; (iii) Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP), JST.; (iv) Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare.; (v) The New Energy and Industrial Technology Development Organization (NEDO).; (vi) Supporting Industry program, Ministry of Economy, Trade and Industry (METI).; (vii) The Association for the Progress of New Chemical Technology.	Fukuda K, 2011, OPT MATER, V33, P1143, DOI 10.1016/j.optmat.2010.10.054; Kurosawa S, 2013, RADIAT MEAS, V55, P108, DOI 10.1016/j.radmeas.2013.01.011; Pejchal J, 2010, IEEE T NUCL SCI, V57, P1196, DOI 10.1109/TNS.2009.2031322; Pejchal J, 2012, PHYS STATUS SOLIDI C, V9, P2243, DOI 10.1002/pssc.201200301; Pejchal J, 2012, IEEE T NUCL SCI, V59, P2177, DOI 10.1109/TNS.2012.2197418; Chechik R, 2008, NUCL INSTRUM METH A, V595, P116, DOI 10.1016/j.nima.2008.07.035; SCHOTANUS P, 1989, IEEE T NUCL SCI, V36, P132, DOI 10.1109/23.34419; Yoshikawa A, 2004, J CRYST GROWTH, V270, P427, DOI 10.1016/j.jcrysgro.2004.06.038; Wegh RT, 1999, PHYS REV B, V60, P10820, DOI 10.1103/PhysRevB.60.10820; VANEIJK CWE, 1994, IEEE T NUCL SCI, V41, P738, DOI 10.1109/23.322798; Pejchal J, 2010, RADIAT MEAS, V45, P265, DOI 10.1016/j.radmeas.2009.10.017; Dorenbos P., 1993, IEEE T NUCL SCI, V37, P119; Grahmaier R., 1994, LUMINESCENT MAT; Kurosawa S., 2012, J I, V7; Sekiya H., 2009, J I, V4; Yanagida T, 2011, NUCL INSTRUM METH A, V659, P258, DOI 10.1016/j.nima.2011.08.056	16	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		58	62		10.1016/j.optmat.2014.10.009		5	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000012		
J	Kamada, K; Nikl, M; Kurosawa, S; Beitlerova, A; Nagura, A; Shoji, Y; Pejchal, J; Ohashi, Y; Yokota, Y; Yoshikawa, A				Kamada, Kei; Nikl, Martin; Kurosawa, Shunsuke; Beitlerova, Alena; Nagura, Aya; Shoji, Yasuhiro; Pejchal, Jan; Ohashi, Yuji; Yokota, Yuui; Yoshikawa, Akira			Alkali earth co-doping effects on luminescence and scintillation properties of Ce doped Gd3Al2Ga3O12 scintillator	OPTICAL MATERIALS			English	Article						Scintillator; Garnet; Single crystal growth	SINGLE-CRYSTAL; LSO-CE; RESOLUTION; DETECTORS; EFFICIENT	The Mg and Ca co-doped Ce:Gd3Al2Ga3O12 single crystals were prepared by micro pulling down method with a wide concentration range 0-1000 ppm of the codopants. Absorption and luminescence spectra were measured together with several other scintillation characteristics, namely the scintillation decay and light yield to reveal the effect of Mg and Ca co-doping. The scintillation decays were accelerated by both Mg and Ca codopants. Comparing to Ca co-doping, the Mg co-doped samples showed much faster decay and comparatively smaller light output decrease with increasing Mg dopant concentration. (C) 2014 Elsevier B.V. All rights reserved.	[Kamada, Kei; Kurosawa, Shunsuke; Pejchal, Jan; Yokota, Yuui; Yoshikawa, Akira] Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Kamada, Kei; Shoji, Yasuhiro; Yoshikawa, Akira] C&A Corp, T Biz, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Nikl, Martin; Beitlerova, Alena; Pejchal, Jan] Inst Phys AS CR, Prague 16253, Czech Republic; [Kurosawa, Shunsuke; Nagura, Aya; Shoji, Yasuhiro; Ohashi, Yuji; Yoshikawa, Akira] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	Kamada, K (reprint author), Tohoku Univ, New Ind Creat Hatchery Ctr, Aoba Ku, 6-6-10 Aoba, Sendai, Miyagi 9808579, Japan.		Yoshikawa, Akira/B-9986-2011; Ohashi, Yuji/F-8470-2014		funding program for next generation world-leading researchers, Japan Society for the Promotion of Science (JSPS); Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST); Adaptable & Seamless Technology Transfer Program through Target-driven RD (A-STEP), JST; JSPS; Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare; Czech MEYS KONTAKT Cz-jp collaboration LH14266 project, Crystal Clear Collaboration in CERN; EC Marie Curie Initial Training Network LUMINET [316906]	This work is partially supported by (i) the funding program for next generation world-leading researchers, Japan Society for the Promotion of Science (JSPS), (ii) Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST) (iii) Adaptable & Seamless Technology Transfer Program through Target-driven R&D (A-STEP), JST (iv) JSPS Grant-in-Aid for Exploratory Research (A.Y), (v) JSPS Research Fellowships for Young Scientists (S.Kurosawa), (vi) the Health Labour Sciences Research Grant, The Ministry of Health Labour and Welfare and (vii) Czech MEYS KONTAKT Cz-jp collaboration LH14266 project, Crystal Clear Collaboration in CERN, and EC Marie Curie Initial Training Network LUMINET, no. 316906. In addition, we would like to thank following persons for their support: Mr. Yoshihiro Nakamura in Institute of Multidisciplinary Research for Advanced Materials (IMRAM), and Mr. Hiroshi Uemura, Ms. Keiko Toguchi, Ms. Megumi Sasaki and Ms. Yuka Takeda in IMR, Tohoku University.	Conti M, 2009, PHYS MEDICA, V25, P1, DOI 10.1016/j.ejmp.2008.10.001; Nikl M, 2006, MEAS SCI TECHNOL, V17, pR37, DOI 10.1088/0957-0233/17/4/R01; MELCHER CL, 1992, IEEE T NUCL SCI, V39, P502, DOI 10.1109/23.159655; Weber S, 2003, IEEE T NUCL SCI, V50, P1370, DOI 10.1109/TNS.2003.817952; Blahuta S, 2013, IEEE T NUCL SCI, V60, P3134, DOI 10.1109/TNS.2013.2269700; Yoshikawa A, 1999, J CRYST GROWTH, V205, P305, DOI 10.1016/S0022-0248(99)00265-1; Kamada K, 2012, J CRYST GROWTH, V352, P88, DOI 10.1016/j.jcrysgro.2011.11.085; Alekhin MS, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4803440; Shah KS, 2003, IEEE T NUCL SCI, V50, P2410, DOI 10.1109/TNS.2003.820614; Liu SP, 2014, PHYS STATUS SOLIDI-R, V8, P105, DOI 10.1002/pssr.201308199; Nikl M, 2013, PROG CRYST GROWTH CH, V59, P47, DOI 10.1016/j.pcrysgrow.2013.02.001; Spurrier MA, 2008, IEEE T NUCL SCI, V55, P1178, DOI 10.1109/TNS.2007.913486; Kramer KW, 2006, J MATER CHEM, V16, P2773, DOI 10.1039/b602762h; Kapusta M, 2005, IEEE T NUCL SCI, V52, P1098, DOI [10.1109/TNS.2005.852731, 10.1106/TNS.2005.0852731]; Moszynski M, 1997, NUCL INSTRUM METH A, V385, P123, DOI 10.1016/S0168-9002(96)00875-3; Kamada K, 2014, OPT MATER, V36, P1942, DOI 10.1016/j.optmat.2014.04.001; Cherepy N.J., 2010, P SOC PHOTO-OPT INS, V7805; Donnald SB, 2013, IEEE T NUCL SCI, V60, P4002, DOI 10.1109/TNS.2013.2277862; Lecoq P, 2002, IEEE T NUCL SCI, V49, P1651, DOI 10.1109/TNS.2002.801487; Nikl M, 2010, Journal of Physics: Conference Series, V249, DOI 10.1088/1742-6596/249/1/012018; Kamada K, 2011, CRYST GROWTH DES, V11, P4484, DOI 10.1021/cg200694a	21	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		63	66		10.1016/j.optmat.2014.10.008		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000013		
J	Koizumi, A; Kawabata, K; Lee, D; Nishikawa, A; Terai, Y; Ofuchi, H; Honma, T; Fujiwara, Y				Koizumi, Atsushi; Kawabata, Kosuke; Lee, Dong-gun; Nishikawa, Atsushi; Terai, Yoshikazu; Ofuchi, Hironori; Honma, Tetsuo; Fujiwara, Yasufumi			In situ Eu doping into AlxGa1-xN grown by organometallic vapor phase epitaxy to improve luminescence properties	OPTICAL MATERIALS			English	Article						Europium; AlGaN; OMVPE; XANES	EARTH-DOPED GAN; ELECTROLUMINESCENCE; PHOTOLUMINESCENCE; TEMPERATURE; ALGAN	We have succeeded in situ Eu doping into AlxGa1-xN grown by organometallic vapor phase epitaxy and investigated the effects of the growth pressure and Al composition on the photoluminescence (PL) properties of Eu3+ ions. The intensity of red emission due to the D-5(0)-F-7(2) transition of Eu3+ ions decreased with increasing Al content in the case of growth at atmospheric pressure. The effect of the reactor pressure on the Eu concentration and Eu3+ PL properties showed that low-pressure growth is effective in increasing the Eu doping concentration and luminescence efficiency. The PL intensity increased with the Al composition and reached a maximum intensity at approximately x = 0.24. At Al compositions of higher than 0.24, X-ray absorption near-edge structure analysis revealed that the concentration of Eu2+ ions increased with increasing Al composition, leading to a reduction in the concentration of optically active Eu3+ ions. (C) 2014 Elsevier B.V. All rights reserved.	[Koizumi, Atsushi; Kawabata, Kosuke; Lee, Dong-gun; Nishikawa, Atsushi; Terai, Yoshikazu; Fujiwara, Yasufumi] Osaka Univ, Grad Sch Engn, Div Mat & Mfg Sci, Suita, Osaka 5650871, Japan; [Ofuchi, Hironori; Honma, Tetsuo] Japan Synchrotron Radiat Res Inst JASRI SPring 8, Sayo, Hyogo 6795198, Japan	Koizumi, A (reprint author), Osaka Univ, Grad Sch Engn, Div Mat & Mfg Sci, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	koizumi@mat.eng.osaka-u.ac.jp	Fujiwara, Yasufumi/D-9052-2012		Ministry of Education, Culture, Sports, Science and Technology of Japan; JSPS KAKENHI [24226009, 26820113]	Part of this research was carried out at the Frontier Research Base for Global Young Researchers, Osaka University, through the program Promotion of Environmental Improvement to Enhance Young Researchers' Independence, with Special Coordination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science and Technology of Japan. This work was also partly supported by JSPS KAKENHI Grant Numbers 24226009 and 26820113. The synchrotron radiation experiments were performed at the BL14B2 beamline of SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (Proposal No. 2012A1311). We also thank Sumitomo Seika Chemicals Co., Ltd. for supplying NH<INF>3</INF>.	FAVENNEC PN, 1989, ELECTRON LETT, V25, P718, DOI 10.1049/el:19890486; Nakamura F, 1998, J CRYST GROWTH, V195, P280, DOI 10.1016/S0022-0248(98)00668-X; Heikenfeld J, 1999, APPL PHYS LETT, V75, P1189, DOI 10.1063/1.124686; Steckl AJ, 2007, MATER TODAY, V10, P20, DOI 10.1016/S1369-7021(07)70176-1; Chen CH, 1996, J ELECTRON MATER, V25, P1004, DOI 10.1007/BF02666736; Nyein EE, 2003, APPL PHYS LETT, V82, P1655, DOI 10.1063/1.1560557; Thon A, 1996, APPL PHYS LETT, V69, P55, DOI 10.1063/1.118117; Nishikawa A, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3478011; Steckl AJ, 2002, IEEE J SEL TOP QUANT, V8, P749, DOI 10.1109/JSTQE.2002.801690; Honma T, 2010, AIP CONF PROC, V1234, P13, DOI 10.1063/1.3463160; Park JH, 2004, APPL PHYS LETT, V85, P4588, DOI 10.1063/1.1821630; Nishikawa A, 2009, APPL PHYS EXPRESS, V2, DOI 10.1143/APEX.2.071004; DUCHEMIN JP, 1981, J CRYST GROWTH, V55, P64, DOI 10.1016/0022-0248(81)90272-4; Fujiwara Y, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.05FA13; Lozykowski HJ, 2000, APPL PHYS LETT, V77, P767, DOI 10.1063/1.1306645; Morishima S, 1999, PHYS STATUS SOLIDI A, V176, P113; Nakanishi Y., 2002, Physica Status Solidi C; Nishikawa A, 2010, PHYS STATUS SOLIDI A, V207, P1397, DOI 10.1002/pssa.200983467; Nishikawa A., 2011, MRS P, Vv02-08, P1342; Uchida K, 1997, MATER RES SOC SYMP P, V449, P129; Wakahara A, 2006, OPT MATER, V28, P731, DOI 10.1016/j.optmat.2005.09.011; Wang K, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.125206	22	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		75	79		10.1016/j.optmat.2014.11.005		5	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000016		
J	Kurosawa, S; Shishido, T; Sugawara, T; Nomura, A; Yubuta, K; Pejchal, J; Murakami, R; Yokota, Y; Shoji, Y; Ohashi, Y; Kamada, K; Yoshikawa, A				Kurosawa, Shunsuke; Shishido, Toetsu; Sugawara, Takamasa; Nomura, Akiko; Yubuta, Kunio; Pejchal, Jan; Murakami, Rikito; Yokota, Yuui; Shoji, Yasuhiro; Ohashi, Yuji; Kamada, Kei; Yoshikawa, Akira			Luminescence study on Eu or Tb doped lanthanum-gadolinium pyrosilicate crystal	OPTICAL MATERIALS			English	Article						Scintillator; Gadolinium pyrosilicate	SCINTILLATION PROPERTIES; INORGANIC SCINTILLATORS; GROWTH	(Eu-0.01, Gd-0.90, La-0.09)(2)Si2O7 (Eu:La-GPS) and (Tb-0.01, Gd-0.90, La-0.09)(2)Si2O7 (Tb:La-GPS) crystals were grown by the floating zone method, and their optical and scintillation properties were investigated. Gd3+-to-Tb3+ or -Eu3+ energy transfer processes were found, and photo-luminescence and radio-luminescence emission spectra showed D-5(0)-F-7(i) (i = 1-4) Eu3+ transitions in Eu:La-GPS, and D-5(3)-F-7(i) (i = 3-6) and D-5(4)-F-7(i) (i = 3-6) transitions in Tb:La-GPS. Using these scintillators, alpha-ray imaging was possible with a CMOS camera. These materials can be used for X-ray detection as well. (C) 2014 Elsevier B.V. All rights reserved.	[Kurosawa, Shunsuke; Shishido, Toetsu; Sugawara, Takamasa; Nomura, Akiko; Yubuta, Kunio; Murakami, Rikito; Shoji, Yasuhiro; Ohashi, Yuji; Yoshikawa, Akira] Tohoku Univ, Inst Mat Res, Aoba Ku, Sendai, Miyagi 9808577, Japan; [Kurosawa, Shunsuke; Pejchal, Jan; Yokota, Yuui; Kamada, Kei; Yoshikawa, Akira] Tohoku Univ, NICHe, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Pejchal, Jan] Inst Phys AS CR, Prague 16200 6, Czech Republic; [Shoji, Yasuhiro; Kamada, Kei; Yoshikawa, Akira] C&A Corp, Aoba Ku, Sendai, Miyagi 9808579, Japan	Kurosawa, S (reprint author), Tohoku Univ, Inst Mat Res, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	kurosawa@imr.tohoku.ac.jp	Yoshikawa, Akira/B-9986-2011; Ohashi, Yuji/F-8470-2014		Japan Society for the Promotion of Science (JSPS) Research Fellowships; JSPS; Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST); Adaptable & Seamless Technology Transfer Program through Target-driven RD (A-STEP), JST; Association for the Progress of New Chemical Technology; Murata Science Foundation; Nippon Sheet Glass Foundation for Materials Science and Engineering; Tonen General Sekiyu Foundation	This work is partially supported by (i) Japan Society for the Promotion of Science (JSPS) Research Fellowships for Young Scientists (S. Kurosawa), (ii) the funding program for next generation world-leading researchers, JSPS, (iii) Development of Systems and Technology for Advanced Measurement and Analysis, Japan Science and Technology Agency (JST) (iv) Adaptable & Seamless Technology Transfer Program through Target-driven R&D (A-STEP), JST, (v) the Association for the Progress of New Chemical Technology, (vi) The Murata Science Foundation, (vii) Nippon Sheet Glass Foundation for Materials Science and Engineering and (vii) Tonen General Sekiyu Foundation. In addition, we would like to thank following persons for their support: Mr. Yoshihiro Nakamura of Institute of Multidisciplinary Research for Advanced Materials (IMRAM), Tohoku University and Yoshihiro Murakami, Mr. Hiroshi Uemura, Ms. Keiko Toguchi, Ms. Megumi Sasaki, Ms. Yuka Takeda and Ms. Kuniko Kawaguchi of IMR/Tohoku University.	Sidletskiy O, 2010, RADIAT MEAS, V45, P365, DOI 10.1016/j.radmeas.2009.12.022; HOLL I, 1988, IEEE T NUCL SCI, V35, P105, DOI 10.1109/23.12684; Gerasymov I, 2011, J CRYST GROWTH, V318, P805, DOI 10.1016/j.jcrysgro.2010.11.047; Chen YH, 2005, J PHYS-CONDENS MAT, V17, P1217, DOI 10.1088/0953-8984/17/7/014; Kurosawa S, 2014, NUCL INSTRUM METH A, V744, P30, DOI 10.1016/j.nima.2014.01.018; Baumer V, 2011, J ALLOY COMPD, V509, P8478, DOI 10.1016/j.jallcom.2011.06.016; Haas J.T.M. d., 2008, IEEE T NUCL SCI, V55, P1086; HE DB, 2011, J RARE EARTH, V29, P48; Kaneko JH, 2004, NUCL INSTRUM METH A, V529, P307, DOI 10.1016/j.nima.2004.04.169; Kawamura S, 2006, IEEE NUCL SCI CONF R, P1160, DOI 10.1109/NSSMIC.2006.356049; Kawamura S, 2007, NUCL INSTRUM METH A, V583, P356, DOI 10.1016/j.nima.2007.09.021; Kurosawa S, 2015, NUCL INSTRUM METH A, V772, P72, DOI 10.1016/j.nima.2014.10.008; Kurosawa S, 2014, J INSTRUM, V9, DOI 10.1088/1748-0221/9/07/C07015; Murakami Rikito, JPN J APPL PHY UNPUB; Pidol L, 2004, IEEE T NUCL SCI, V51, P1084, DOI 10.1109/TNS.2004.829542; ROZSA C, 1990, IEEE T NUCL SCI, V37, P966, DOI 10.1109/23.106744; SAKAI E, 1987, IEEE T NUCL SCI, V34, P418, DOI 10.1109/TNS.1987.4337375; Shannon A. D., 1976, ACTA CRYSTALLOGR A, V32, P751; Suzuki A, 2012, APPL PHYS EXPRESS, V5, DOI 10.1143/APEX.5.102601; Toropov N. A., 1961, RUSS CHEM B, V10, P497; Tsubota Y, 2014, OPT MATER, V36, P665, DOI 10.1016/j.optmat.2013.11.007; Tsubota Youichi, 2011, PROG NUCL SCI TECHNO, P288; van Eijk CWE, 2002, PHYS MED BIOL, V47, pR85, DOI 10.1088/0031-9155/47/8/201; Zhou LY, 2006, MATER CHEM PHYS, V100, P372, DOI 10.1016/j.matchemphys.2006.01.007; Zhou YH, 2002, OPT MATER, V20, P13, DOI 10.1016/S0925-3467(02)00020-4	25	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		80	83		10.1016/j.optmat.2014.12.006		4	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000017		
J	Ueda, J; Shinoda, T; Tanabe, S				Ueda, Jumpei; Shinoda, Tatsuaki; Tanabe, Setsuhisa			Evidence of three different Eu2+ sites and their luminescence quenching processes in CaAl2O4:Eu2+	OPTICAL MATERIALS			English	Article						Eu2+; Phosphors; Temperature quenching; Photoconductivity; Impurity trapped exciton	PERSISTENT LUMINESCENCE; INORGANIC-COMPOUNDS; PHOSPHOR; MECHANISM; DY3+; THERMOLUMINESCENCE; SPECTROSCOPY; ALUMINATE; ENERGIES; SRAL2O4	We report the 5d-4f luminescence of Eu2+ and europium trapped exciton (ETE) luminescence in the different three crystallographic Ca sites in the Eu2+-doped CaAl2O4 and those quenching processes based on the results of the temperature dependence of photoluminescence and photoconductivity. The CaAl2O4:Eu2+ shows the 5d-4f luminescence peaked at 440 nm, 540 nm and the ETE luminescence peaked at 650 rim by UV and blue light excitation at low temperatures. The quenching temperature, at which the luminescence intensity is 50% of the intensity at low temperatures, of 440 nm, 540 nm and 650 nm bands are >300 K, 195 K and 69K, respectively. The strong quenching for the 650 nm band is caused by the thermal ionization process, which was proved by the photoconductivity measurement. We also construct the vacuum referred binding energy diagram in each Ca site and discuss optical properties from the relative energy location between the 5d state, ETE state and conduction band. (C) 2014 Elsevier B.V. All rights reserved.	[Ueda, Jumpei; Shinoda, Tatsuaki; Tanabe, Setsuhisa] Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan; [Ueda, Jumpei] Kyoto Univ, Grad Sch Global Environm Studies, Kyoto 6068501, Japan	Ueda, J (reprint author), Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan.				JSPS KAKENHI [25810136, 23350099]	We would like to acknowledge fruitful discussions on the energy diagram with Professor Pieter Dorenbos of Delft University of Technology. This work was supported by JSPS KAKENHI Grant Numbers 25810136 and 23350099.	ABBRUSCA.V, 1971, J ELECTROCHEM SOC, V118, P930, DOI 10.1149/1.2408226; Aitasallo T, 2006, J PHYS CHEM B, V110, P4589, DOI 10.1021/jp057185m; Ueda J, 2012, PHYS STATUS SOLIDI C, V9, P2322, DOI 10.1002/pssc.201200299; Dorenbos P, 2003, J PHYS-CONDENS MAT, V15, P2645, DOI 10.1088/0953-8984/15/17/318; BLASSE G, 1972, J SOLID STATE CHEM, V4, P52, DOI 10.1016/0022-4596(72)90131-4; Grinberg M, 2008, J NON-CRYST SOLIDS, V354, P4163, DOI 10.1016/j.jnoncrysol.2008.06.025; Dorenbos P, 2003, J PHYS-CONDENS MAT, V15, P8417, DOI 10.1088/0953-8984/15/49/018; Takasaki H, 1996, J CERAM SOC JPN, V104, P322, DOI 10.2109/jcersj.104.322; Dutczak D, 2014, J PHYS CHEM A, V118, P1617, DOI 10.1021/jp500947q; Matsuzawa T, 1996, J ELECTROCHEM SOC, V143, P2670, DOI 10.1149/1.1837067; Dorenbos P, 2003, J LUMIN, V104, P239, DOI 10.1016/S0022-2313(03)00078-4; Bos AJJ, 2011, J LUMIN, V131, P1465, DOI 10.1016/j.jlumin.2011.03.033; Grinberg M, 2011, J LUMIN, V131, P433, DOI 10.1016/j.jlumin.2010.10.043; Dorenbos P, 2013, J LUMIN, V135, P93, DOI 10.1016/j.jlumin.2012.09.034; Clabau F, 2005, CHEM MATER, V17, P3904, DOI 10.1021/cm050763r; Jubera V, 2003, J LUMIN, V101, P1, DOI 10.1016/S0022-2313(02)00335-6; Aitasalo T, 2003, J SOLID STATE CHEM, V171, P114, DOI 10.1016/S0022-4596(02)00194-9; PALILLA FC, 1968, J ELECTROCHEM SOC, V115, P642, DOI 10.1149/1.2411379; Dorenbos P, 2005, J ELECTROCHEM SOC, V152, pH107, DOI 10.1149/1.1926652; POORT SHM, 1995, CHEM MATER, V7, P1547, DOI 10.1021/cm00056a022; Lizzo S, 1997, J PHYS CHEM SOLIDS, V58, P963, DOI 10.1016/S0022-3697(96)00199-0; Dorenbos P, 2005, J LUMIN, V111, P89, DOI 10.1016/j.jlumin.2004.07.003; Blasse G., 1968, PHILIPS RES REP, V23; Dorenbos P, 2005, J PHYS-CONDENS MAT, V17, P8103, DOI 10.1088/0953-8984/17/50/027; Dorenbos P, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.035118; Gatch DB, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.195117; Grinberg M, 2013, OPT MATER, V35, P2006, DOI 10.1016/j.optmat.2012.10.025; Holsa J, 2009, RADIAT PHYS CHEM, V78, pS11, DOI 10.1016/j.radphyschem.2009.02.012; Holsa J, 2004, J ALLOY COMPD, V374, P56, DOI 10.1016/j.jallcom.2003.11.064; HORKNER W, 1976, J INORG NUCL CHEM, V38, P983, DOI 10.1016/0022-1902(76)80011-5; Jia D, 2003, J ELECTROCHEM SOC, V150, pH61, DOI 10.1149/1.1553792; Kunimoto T, 2001, JPN J APPL PHYS 2, V40, pL1126, DOI 10.1143/JJAP.40.L1126; Lange H., 1966, US Patents, Patent No. [3.294.699, 3294699]; Mahlik S, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/24/245601; Murayama Y., 1995, US Patents, Patent No. [5. 242. 006, 5242006]; Nakamura T, 1998, J CHEM SOC FARADAY T, V94, P3009, DOI 10.1039/a804494e; Smet PF, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.035207; Ueda J, 2013, OPT MATER EXPRESS, V3, P787, DOI 10.1364/OME.3.000787; Wiglusz RJ, 2013, J LUMIN, V133, P102, DOI 10.1016/j.jlumin.2011.12.039; Yamamoto H, 1997, J LUMIN, V72-4, P287, DOI 10.1016/S0022-2313(97)00012-4	40	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-3467	1873-1252		OPT MATER	Opt. Mater.	MAR	2015	41				SI		84	89		10.1016/j.optmat.2014.12.010		6	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CD0QM	WOS:000350779000018		
J	Wang, J; Aihara, Y; Kinoshita, M; Shishido, A				Wang, Jing; Aihara, Yosuke; Kinoshita, Motoi; Shishido, Atsushi			Effect of polymer concentration on self-focusing effect in oligothiophene-doped polymer-stabilized liquid crystals	OPTICAL MATERIALS EXPRESS			English	Article							ORIENTATIONAL OPTICAL NONLINEARITY; BLUE PHASES; PHOTOINDUCED REORIENTATION; DYE; DISPLAYS; RANGE; HOST; FILM	Nonlinear optics (NLO) has attracted much attention for its immense potential in applications. However, it typically requires very high light intensities. Recently, we reported that polymer stabilization efficiently enhances the self-focusing effect for dye-doped liquid crystals (LCs). Here we studied the effect of polymer concentration on self-focusing in the dyedoped polymer-stabilized LC (PSLC). Oligothiophene (TR5)-doped PSLCs with different polymer concentrations were prepared, and self-diffraction ring measurement was performed. As polymer concentration increased, the threshold light intensity for self-focusing effect first decreased then slightly increased. The lowest threshold light intensity of 3.4 W/cm(2) was obtained at 10 mol%. Polymer stabilization of the LCs decreased the threshold intensity by a factor of 7. We also discussed the possible mechanism for the polymer concentration dependence of NLO response in the TR5-doped PSLC. (C) 2015 Optical Society of America	[Wang, Jing; Aihara, Yosuke; Kinoshita, Motoi; Shishido, Atsushi] Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; [Shishido, Atsushi] JST, PRESTO, Kawaguchi, Saitama 3320012, Japan	Wang, J (reprint author), Tokyo Inst Technol, Chem Resources Lab, Midori Ku, R1-12,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	ashishid@res.titech.ac.jp	Shishido, Atsushi/E-5176-2014	Shishido, Atsushi/0000-0002-0396-5874	Japan Science and Technology Agency (JST); Precursory Research for Embryonic Science and Technology (PRESTO), "Molecular Technology and Creation of New Functions"	This work was supported by Precursory Research for Embryonic Science and Technology (PRESTO), "Molecular Technology and Creation of New Functions", Japan Science and Technology Agency (JST).	Matharu AS, 2007, CHEM SOC REV, V36, P1868, DOI 10.1039/b706242g; Khoo IC, 1998, OPT LETT, V23, P253, DOI 10.1364/OL.23.000253; Kondo M, 2010, J MATER CHEM, V20, P117, DOI 10.1039/b917342k; Yu YL, 2003, NATURE, V425, P145, DOI 10.1038/425145a; Woltman SJ, 2007, NAT MATER, V6, P929, DOI 10.1038/nmat2010; Khoo IC, 2009, PHYS REP, V471, P221, DOI 10.1016/j.physrep.2009.01.001; Kikuchi H, 2002, NAT MATER, V1, P64, DOI 10.1038/nmat712; Coles HJ, 2005, NATURE, V436, P997, DOI 10.1038/nature003932; Priimagi A, 2014, J MATER CHEM C, V2, P7155, DOI 10.1039/c4tc01236d; Lucchetti L, 2004, OPT COMMUN, V233, P417, DOI 10.1016/j.optcom.2004.01.057; Aihara Y, 2013, ADV OPT MATER, V1, P787, DOI 10.1002/adom.201300326; DURBIN SD, 1981, OPT LETT, V6, P411; Simoni F, 2001, OPT EXPRESS, V9, P85; Hisakado Y, 2005, ADV MATER, V17, P96, DOI 10.1002/adma.200400639; JANOSSY I, 1990, MOL CRYST LIQ CRYST, V179, P1, DOI 10.1080/00268949008055354; Kim KH, 2009, NPG ASIA MATER, V1, P29, DOI 10.1038/asiamat.2009.3; TABIRYAN NV, 1986, MOL CRYST LIQ CRYST, V136, P1, DOI 10.1080/00268948608074569; JANOSSY I, 1992, OPT LETT, V17, P1183, DOI 10.1364/OL.17.001183; White TJ, 2009, SOFT MATTER, V5, P3623, DOI 10.1039/b906758b; Zhang HC, 2000, ADV MATER, V12, P1336, DOI 10.1002/1521-4095(200009)12:18<1336::AID-ADMA1336>3.0.CO;2-A; Schadt M, 1997, ANNU REV MATER SCI, V27, P305, DOI 10.1146/annurev.matsci.27.1.305; Deniset-Besseau A, 2010, OPT EXPRESS, V18, P1113, DOI 10.1364/OE.18.001113; Dierking I, 2000, ADV MATER, V12, P167, DOI 10.1002/(SICI)1521-4095(200002)12:3<167::AID-ADMA167>3.0.CO;2-I; Jamil M, 2011, CURR SCI INDIA, V101, P1544; JANOSSY I, 1994, PHYS REV E, V49, P2957, DOI 10.1103/PhysRevE.49.2957; Kosa T, 2004, MOL CRYST LIQ CRYST, V421, P107, DOI 10.1080/15421400490501581; Lee JH, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.051701; Marrucci L., 2002, LIQ CRYST TODAY, V11, P1; Marrucci L, 1997, J CHEM PHYS, V107, P9783, DOI 10.1063/1.475276; Shen Y. R, 1984, PRINCIPLE NONLINEAR; SHIBAEV VP, 1982, EUR POLYM J, V18, P651, DOI 10.1016/0014-3057(82)90093-3; Sio L. D., 2014, J MATER CHEM C, V2, P3532; Wagner E, 2007, EXP THERM FLUID SCI, V31, P687, DOI 10.1016/j.expthermflusci.2006.07.003; Yaegashi M, 2005, CHEM MATER, V17, P4304, DOI 10.1021/cm0503580	34	1	1	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2159-3930			OPT MATER EXPRESS	Opt. Mater. Express	MAR 1	2015	5	3					538	548		10.1364/OME.5.000538		11	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CC9CI	WOS:000350664800009		
J	Masai, H; Hino, Y; Yanagida, T; Fujimoto, Y; Tokuda, Y				Masai, Hirokazu; Hino, Yusuke; Yanagida, Takayuki; Fujimoto, Yutaka; Tokuda, Yomei			High energy-transfer rate from Sn2+ to Mn2+ in phosphate glasses	OPTICAL MATERIALS EXPRESS			English	Article							PHOTOLUMINESCENCE PROPERTIES; LUMINESCENCE; RELAXATION; EMISSION; CE3+; SM3+	High energy-transfer rates from Sn2+ to Mn2+ centers are demonstrated in ZnO-P2O5 glass. Emission decay curves of Sn2+ suggest an energy exchange interaction between Sn2+ and Mn2+. It is notable that the high energy-transfer rates are attained for random phosphate glass and that the transfer rate becomes slower with increasing amounts of Mn2+. Because these glasses possess high internal quantum efficiencies independent of the Sn2+ or Mn2+ concentration, we emphasize that effective energy-transfer paths are generated in the transparent glass phosphor, which leads to the development of a transparent inorganic light-emitting material different from conventional rare-earth-containing powdered phosphors. (C) 2015 Optical Society of America	[Masai, Hirokazu; Hino, Yusuke; Tokuda, Yomei] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; [Yanagida, Takayuki; Fujimoto, Yutaka] Kyushu Inst Technol, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan	Masai, H (reprint author), Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.	masai_h@scl.kyoto-u.ac.jp	Yanagida, Takayuki/F-1814-2014	Yanagida, Takayuki/0000-0002-4298-5886	JSPS KAKENHI [26709048]; Kyoto Technoscience Center, Collaborative Research Program of I.C.R., Kyoto University [2014-31]; SPRITS program, Kyoto University	This work was partially supported by a JSPS KAKENHI Grant-in-Aid for Young Scientists (A) number 26709048, the Kyoto Technoscience Center, Collaborative Research Program of I.C.R., Kyoto University (grant #2014-31), and the SPRITS program, Kyoto University. H.M. gratefully acknowledges the support of Prof. Yasuhiro Yamada (I.C.R. Kyoto University) for his fruitful discussion.	ACEVES R, 1995, J LUMIN, V65, P113, DOI 10.1016/0022-2313(95)00069-3; REISFELD R, 1975, J SOLID STATE CHEM, V15, P140, DOI 10.1016/0022-4596(75)90237-6; Dorenbos P, 2003, J PHYS-CONDENS MAT, V15, P8417, DOI 10.1088/0953-8984/15/49/018; Masai H, 2012, J NON-CRYST SOLIDS, V358, P265, DOI 10.1016/j.jnoncrysol.2011.09.025; Liu YY, 2010, J AM CERAM SOC, V93, P1891, DOI 10.1111/j.1551-2916.2010.03659.x; Paulose PI, 2003, J PHYS CHEM SOLIDS, V64, P841, DOI 10.1016/S0022-3697(02)00416-X; REISFELD R, 1979, J SOLID STATE CHEM, V28, P391, DOI 10.1016/0022-4596(79)90090-2; ROPP RC, 1960, J ELECTROCHEM SOC, V107, P15, DOI 10.1149/1.2427594; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; Masai H, 2011, OPT LETT, V36, P2868, DOI 10.1364/OL.36.002868; Masai H, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4766340; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; BLASSE G, 1967, J CHEM PHYS, V47, P5139, DOI 10.1063/1.1701771; Masai H, 2010, APPL PHYS EXPRESS, V3, DOI 10.1143/APEX.3.082102; Masai H, 2014, J MATER CHEM C, V2, P2137, DOI 10.1039/c3tc32259a; Segawa H, 2012, J NON-CRYST SOLIDS, V358, P1333, DOI 10.1016/j.jnoncrysol.2012.03.001; Caldino U, 2005, J PHYS-CONDENS MAT, V17, P7297, DOI 10.1088/0953-8984/17/46/013; BLASSE G, 1967, J CHEM PHYS, V47, P1920, DOI 10.1063/1.1712219; Kim JS, 2004, APPL PHYS LETT, V84, P2931, DOI 10.1063/1.1695441; Wegh RT, 1999, SCIENCE, V283, P663, DOI 10.1126/science.283.5402.663; CLAPP RH, 1947, J OPT SOC AM, V37, P355, DOI 10.1364/JOSA.37.000355; Auzel F., CHEM REV, V104, P139; BUTLER KH, 1950, J ELECTROCHEM SOC, V97, P265, DOI 10.1149/1.2778007; Davis T. S., 1971, Journal of Luminescence, V4, DOI 10.1016/0022-2313(71)90008-1; Jimenez J, 2014, J ELECTRON MATER, V43, P3588, DOI 10.1007/s11664-014-3240-0; LESKELA M, 1985, J SOLID STATE CHEM, V59, P272, DOI 10.1016/0022-4596(85)90294-4; Masai H, 2014, B CHEM SOC JPN, V87, P556, DOI 10.1246/bcsj.20130281; Masai H., OPT EXPRESS, V20, P27319; Mendez A, 1998, J LUMIN, V79, P269, DOI 10.1016/S0022-2313(98)00040-4; Munoz A. F, 1988, PHYS REV B, V38, P9980; SKUJA L, 1992, J NON-CRYST SOLIDS, V149, P77, DOI 10.1016/0022-3093(92)90056-P; Wachtel A., 1966, J ELECTROCHEM SOC, V103, P160; WEBER MJ, 1971, PHYS REV B, V4, P2932, DOI 10.1103/PhysRevB.4.2932; Yen W.M., 2007, PHOSPHOR HDB	34	2	2	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2159-3930			OPT MATER EXPRESS	Opt. Mater. Express	MAR 1	2015	5	3					617	622		10.1364/OME.5.000617		6	Materials Science, Multidisciplinary; Optics	Materials Science; Optics	CC9CI	WOS:000350664800018		
J	Suzuki, M; Ganeev, RA; Yoneya, S; Kuroda, H				Suzuki, Masayuki; Ganeev, Rashid A.; Yoneya, Shin; Kuroda, Hiroto			Generation of broadband noise-like pulse from Yb-doped fiber laser ring cavity	OPTICS LETTERS			English	Article							MHZ REPETITION RATE; DISPERSION; COHERENCE	We have demonstrated a generation of the noise-like pulse (NLP) with broadband spectrum in a nonlinear polarized evolution-based passive mode-locked Yb-doped fiber (YDF) ring laser. At the cavity dispersion of near zero, the NLP with spectrum bandwidth up to 131 nm (FWHM) was obtained at a central wavelength of 1070 nm with output power of 136 mW and 80 MHz repetition rate. To our best knowledge, this spectrum bandwidth of NLP is the broadest among the reported YDF lasers. The autocorrelation function of pulse contained the short (30 fs) and long (4.6 ps) components. This short coherence light source is well suited for the optical coherent tomography used for ophthalmology at a wavelength of similar to 1000 nm. (C) 2015 Optical Society of America	[Suzuki, Masayuki; Ganeev, Rashid A.; Yoneya, Shin; Kuroda, Hiroto] Saitama Med Univ, Fac Med, Ophthalmol & Adv Laser Med Ctr, Iruma, Saitama 3500495, Japan	Suzuki, M (reprint author), Saitama Med Univ, Fac Med, Ophthalmol & Adv Laser Med Ctr, 38 Morohongo Moroyama Machi, Iruma, Saitama 3500495, Japan.	mksuzuki@saitama-med.ac.jp			Takeda Science Foundation; Naito Foundation	This work was supported by the Takeda Science Foundation, and the Naito Foundation. One of author (M.S.) thanks Dr. Hajime Okada of Japan Atomic Energy Agency for helpful discussions in the early stage of this study, and Mr. Michihiro Kaneda of Sparking Photon Inc. for technical support.	Kobtsev S, 2009, OPT EXPRESS, V17, P20707, DOI 10.1364/OE.17.020707; Ma D, 2010, OPT LETT, V35, P2858, DOI 10.1364/OL.35.002858; Wise FW, 2008, LASER PHOTONICS REV, V2, P58, DOI 10.1002/lpor.200710041; Lan Y, 2013, OPT LETT, V38, P1292, DOI 10.1364/OL.38.001292; KELLER U, 1992, OPT LETT, V17, P505, DOI 10.1364/OL.17.000505; Zhao LM, 2008, OPT COMMUN, V281, P157, DOI 10.1016/j.optcom.2007.09.006; Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252; Runge AFJ, 2013, OPT LETT, V38, P4327, DOI 10.1364/OL.38.004327; Tong YC, 1997, ELECTRON LETT, V33, P983, DOI 10.1049/el:19970663; Lecaplain C, 2014, PHYS REV A, V90, DOI 10.1103/PhysRevA.90.013805; Horowitz M, 1997, OPT LETT, V22, P799, DOI 10.1364/OL.22.000799; Vazquez-Zuniga LA, 2012, IEEE PHOTONIC TECH L, V24, P1549, DOI 10.1109/LPT.2012.2208451; Ilday FO, 2005, OPT EXPRESS, V13, P2716, DOI 10.1364/OPEX.13.002716; Kurita T, 2012, OPT LETT, V37, P3972, DOI 10.1364/OL.37.003972; Marschall S, 2012, BIOMED OPT EXPRESS, V3, P1620, DOI 10.1364/BOE.3.001620; Zaytsev AK, 2013, LASER PHYS LETT, V10, DOI 10.1088/1612-2011/10/4/045104; Zhang L., 2014, INT J OPT, V2014	17	4	4	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0146-9592	1539-4794		OPT LETT	Opt. Lett.	MAR 1	2015	40	5					804	807		10.1364/OL.40.000804		4	Optics	Optics	CD0YW	WOS:000350801500032		
J	Suzuki, Y; Kajitani, K; Ohde, H				Suzuki, Yoshimasa; Kajitani, Kazuo; Ohde, Hisashi			Method for observing phase objects without halos or directional shadows	OPTICS LETTERS			English	Article							PLURIPOTENT STEM-CELLS; CONTRAST MICROSCOPY	A new microscopy method for observing phase objects without halos or directional shadows is proposed. The method is based on transformation of the surface profile of phase objects into a light intensity pattern. The key optical element is an annular aperture at the front focal plane of a condenser. The light flux passing through the annular aperture is changed by the specimen's surface profile and then passes through an objective and contributes to image formation. Theory and experimental results are presented. Phase images of induced pluripotent stem (iPS) cells with clear outlines were obtained with this method. (C) 2015 Optical Society of America	[Suzuki, Yoshimasa; Kajitani, Kazuo; Ohde, Hisashi] Olympus Corp, Opt Technol R&D Dept, Hachioji, Tokyo 1928512, Japan	Suzuki, Y (reprint author), Olympus Corp, Opt Technol R&D Dept, Hachioji, Tokyo 1928512, Japan.	yo_suzuki@ot.olympus.co.jp					Otaki T, 2000, OPT REV, V7, P119, DOI 10.1007/s10043-000-0119-5; Vainrub A, 2006, OPT LETT, V31, P2855, DOI 10.1364/OL.31.002855; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Berkovitz A, 2005, HUM REPROD, V20, P185, DOI 10.1093/humrep/deh545; Chamot E., 1961, HDB CHEM MICROSCOPY; HOFFMAN R, 1977, J MICROSC-OXFORD, V110, P205; Ross K. F. A., 1967, PHASE CONTRAST INTER; Vartiainen I, 2014, OPT LETT, V39, P1601, DOI 10.1364/OL.39.001601; YAMAMOTO K, 1983, J MICROSC-OXFORD, V129, P49	10	0	0	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	0146-9592	1539-4794		OPT LETT	Opt. Lett.	MAR 1	2015	40	5					812	815		10.1364/OL.40.000812		4	Optics	Optics	CD0YW	WOS:000350801500034		
J	Capannelli, G				Capannelli, Giovanni			REGIONAL INTEGRATION IN EAST ASIA: Theoretical and Historical Perspectives.	PACIFIC AFFAIRS			English	Book Review									[Capannelli, Giovanni] Asian Dev Bank Inst, Tokyo, Japan	Capannelli, G (reprint author), Asian Dev Bank Inst, Tokyo, Japan.						AMAKO S, 2013, REGIONAL INTEGRATION	1	0	0	PACIFIC AFFAIRS UNIV BRITISH COLUMBIA	VANCOUVER	#164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA	0030-851X	1715-3379		PAC AFF	Pac. Aff.	MAR	2015	88	1					151	154				4	Area Studies	Area Studies	CC9QP	WOS:000350706000011		
J	Kajiya, K				Kajiya, Kenji			MONEY, TRAINS, AND GUILLOTINES: Art and Revolution in 1960s Japan. Asia-Pacific.	PACIFIC AFFAIRS			English	Book Review									[Kajiya, Kenji] Kyoto City Univ Arts, Kyoto, Japan	Kajiya, K (reprint author), Kyoto City Univ Arts, Kyoto, Japan.						Marotti William, 2013, MONEY TRAINS GUILLOT	1	0	0	PACIFIC AFFAIRS UNIV BRITISH COLUMBIA	VANCOUVER	#164-1855 WEST MALL, VANCOUVER, BC V6T 1Z2, CANADA	0030-851X	1715-3379		PAC AFF	Pac. Aff.	MAR	2015	88	1					198	200				3	Area Studies	Area Studies	CC9QP	WOS:000350706000033		
J	Taguchi, T; Katanosaka, K; Yasui, M; Hayashi, K; Yamashita, M; Wakatsuki, K; Kiyama, H; Yamanaka, A; Mizumura, K				Taguchi, Toru; Katanosaka, Kimiaki; Yasui, Masaya; Hayashi, Koei; Yamashita, Mai; Wakatsuki, Koji; Kiyama, Hiroshi; Yamanaka, Akihiro; Mizumura, Kazue			Peripheral and spinal mechanisms of nociception in a rat reserpine-induced pain model	PAIN			English	Article						Nociceptors; Dorsal root ganglion; Pain-related ion channels; Spinal microglia; Reserpine; Rat	SENSING ION CHANNELS; IN-VITRO; ECCENTRIC CONTRACTION; SENSORY NEUROPATHY; INDUCED MYALGIA; MUSCLE PAIN; AGED RATS; HYPERALGESIA; ASIC3; RECEPTORS	Chronic widespread pain is a serious medical problem, yet the mechanisms of nociception and pain are poorly understood. Using a reserpine-induced pain model originally reported as a putative animal model for fibromyalgia, this study was undertaken to eXamine the following: (1) expression of several ion channels responsible for pain, mechanotransduction, and generation/propagation of action potentials in the dorsal root ganglion (DRG), (2) activities of peripheral nociceptive afferents, and (3) alterations in spinal microglial cells. A significant increase in mRNA expression of the acid-sensing ion channel (ASIC)-3 was detected in the DRG, and the behavioral mechanical hyperalgesia was significantly reversed by subcutaneous injection of APETx2, a selective blocker of ASIC3. Single-fiber recordings in vitro revealed facilitated mechanical responses of mechanoresponsive C-fibers both in the skin and muscle although the proportion of mechanoresponsive C-nociceptors was paradoxically decreased. In the spinal dorsal horn, microglial cells labeled with lba1 immunoreactivity was activated, especially in laminae L-ll Where the nociceptive input is mainly processed compared with the other laminae. The activated microglia and behavioral hyperalgesia were significantly.tranquilized by intraperitoneal injection of minocycline. These results suggest that the increase in ASIC3 in the DRG facilitated mechanical response of the remaining C-nociceptors and that activated spinal microglia may direct to intensify pain in this model. Pain may be further amplified by reserpine-induced dysfunction of the descending pain inhibitory system and by the decrease in. peripheral drive to this system resulting torn a reduced proportion of mechanoresponsive C-nociceptors.	[Taguchi, Toru; Katanosaka, Kimiaki; Hayashi, Koei; Yamashita, Mai; Wakatsuki, Koji; Yamanaka, Akihiro] Nagoya Univ, Environm Med Res Inst, Dept Neurosci 2, Nagoya, Aichi 4648601, Japan; [Yasui, Masaya; Kiyama, Hiroshi] Nagoya Univ, Grad Sch Med, Dept Funct Anat & Neurosci, Nagoya, Aichi 4648601, Japan; [Mizumura, Kazue] Chubu Univ, Coll Life & Hlth Sci, Dept Phys Therapy, Kasugai, Aichi 487, Japan; [Katanosaka, Kimiaki] Chubu Univ, Coll Life & Hlth Sci, Dept Biomed Sci, Kasugai, Aichi 487, Japan	Taguchi, T (reprint author), Nagoya Univ, Environm Med Res Inst, Dept Neurosci 2, Div Stress Recognit & Response,Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	tagu@riem.nagoya-u.ac.jp	Kiyama, Hiroshi/M-8867-2014		Kanzawa Medical Research Foundation; Akaeda Medical Research Foundation; Japan Society for the Promotion of Science [25282160, 23300142]	This work was funded by the Kanzawa Medical Research Foundation, the Akaeda Medical Research Foundation, and Grant-in-Aid for Scientific Research (B) (No. 25282160 to T. Taguchi and No. 23300142 to A. Yamanaka) from the Japan Society for the Promotion of Science.	ALMGREN O, 1976, N-S ARCH PHARMACOL, V292, P133, DOI 10.1007/BF00498583; Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010; Jones RCW, 2005, J NEUROSCI, V25, P10981, DOI 10.1523/JNEUROSCI.0703-05.2005; Taguchi T, 2010, PAIN, V151, P771, DOI 10.1016/j.pain.2010.09.011; DeSantana JM, 2008, CURR PAIN HEADACHE R, V12, P338, DOI 10.1007/s11916-008-0057-7; Radhakrishnan R, 2003, PAIN, V104, P567, DOI 10.1016/S0304-3959(03)00114-3; Bardin L, 2009, BEHAV BRAIN RES, V205, P360, DOI 10.1016/j.bbr.2009.07.005; Orstavik K, 2006, J NEUROSCI, V26, P11287, DOI 10.1523/JNEUROSCI.2659-06.2006; Nasu T, 2010, EUR J PAIN, V14, P236, DOI 10.1016/j.ejpain.2009.05.009; Graven-Nielsen T, 2010, NAT REV RHEUMATOL, V6, P599, DOI 10.1038/nrrheum.2010.107; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Oe T, 2010, NEUROSCIENCE, V169, P1860, DOI 10.1016/j.neuroscience.2010.06.061; Karczewski J, 2010, BRIT J PHARMACOL, V161, P950, DOI 10.1111/j.1476-5381.2010.00918.x; Nakayama H, 1998, J AUTONOM NERV SYST, V69, P148, DOI 10.1016/S0165-1838(98)00013-7; Cummins TR, 2007, PAIN, V131, P243, DOI 10.1016/j.pain.2007.07.026; Ro JY, 2009, PAIN, V144, P270, DOI 10.1016/j.pain.2009.04.021; Shinoda M, 2008, J PAIN, V9, P687, DOI 10.1016/j.jpain.2008.02.007; Yunus MB, 2008, SEMIN ARTHRITIS RHEU, V37, P339, DOI 10.1016/j.semarthrit.2007.09.003; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022; Sluka KA, 2001, MUSCLE NERVE, V24, P37, DOI 10.1002/1097-4598(200101)24:1<37::AID-MUS4>3.0.CO;2-8; Zimmermann K, 2009, NAT PROTOC, V4, P174, DOI 10.1038/nprot.2008.223; Fujii Y, 2008, PAIN, V140, P292, DOI 10.1016/j.pain.2008.08.013; Polydefkis M, 2000, NEUROLOGY, V55, P1115; Namer B, 2009, J PHYSIOL-LONDON, V587, P419, DOI 10.1113/jphysiol.2008.162941; Oaklander AL, 2013, PAIN, V154, P2310, DOI 10.1016/j.pain.2013.06.001; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; Page AJ, 2005, GUT, V54, P1408, DOI 10.1136/gut.2005.071084; Raghavendra V, 2004, EUR J NEUROSCI, V20, P467, DOI 10.1111/j.1460-9568.2004.03514.x; Khasar SG, 2009, J PAIN, V10, P1073, DOI 10.1016/j.jpain.2009.04.005; REEH PW, 1986, NEUROSCI LETT, V66, P141, DOI 10.1016/0304-3940(86)90180-1; Taguchi T, 2005, J PHYSIOL-LONDON, V564, P259, DOI 10.1113/jphysiol.2004.079483; Nagakura Y, 2009, PAIN, V146, P26, DOI 10.1016/j.pain.2009.05.024; Taguchi T, 2005, J NEUROPHYSIOL, V94, P2822, DOI 10.1152/jn.00470.2005; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Hori K, 2010, PAIN, V149, P393, DOI 10.1016/j.pain.2010.03.005; Staud R, 2011, BEST PRACT RES CL RH, V25, P155, DOI 10.1016/j.berh.2010.01.010; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Nagakura Y, 2012, BEHAV BRAIN RES, V226, P242, DOI 10.1016/j.bbr.2011.09.023; De Col R, 2008, J PHYSIOL-LONDON, V586, P1089, DOI 10.1113/jphysiol.2007.145383; Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; Bergman E, 1996, J COMP NEUROL, V375, P303; Campero M, 2004, ACTA PHYSIOL SCAND, V182, P305, DOI 10.1111/j.1365-201X.2004.01357.x; Furuta S, 2009, NEUROSCIENCE, V164, P1252, DOI 10.1016/j.neuroscience.2009.09.021; GOLD MS, 1994, NEUROSCI LETT, V175, P166, DOI 10.1016/0304-3940(94)91105-3; Green PG, 2011, PAIN, V152, P2549, DOI 10.1016/j.pain.2011.07.021; Kamiya H, 2005, DIABETES-METAB RES, V21, P448, DOI 10.1002/dmrr.541; Khasar SG, 2003, J PAIN, V4, P278, DOI 10.1016/S1526-5900(03)00631-X; KITA T, 1979, JPN J PHARMACOL, V29, P479, DOI 10.1254/jjp.29.479; Loyd DR, 2013, SEMIN CELL DEV BIOL, V24, P51, DOI 10.1016/j.semcdb.2012.09.002; MIZUMURA K, 1987, PFLUG ARCH EUR J PHY, V408, P565, DOI 10.1007/BF00581157; Nishiyori M, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-52; Obreja O, 2010, PAIN, V148, P59, DOI 10.1016/j.pain.2009.10.006; Ogino S, 2013, PHARMACOL BIOCHEM BE, V108, P8, DOI 10.1016/j.pbb.2013.04.007; Suarez-Roca H, 2006, PHYSIOL BEHAV, V88, P82, DOI 10.1016/j.physbeh.2006.03.010; Taguchi T, 2012, J PHYSIOL SCI, V62, pS184; Taguchi T, 2011, EUR J PAIN, V15, P351, DOI 10.1016/j.ejpain.2010.08.007; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	61	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959	1872-6623		PAIN	Pain	MAR	2015	156	3					415	427		10.1097/01.j.pain.0000460334.49525.5e		13	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	CC7CW	WOS:000350526300011		
J	Kosugi, S; Shiotani, M; Otsuka, Y; Suzuki, T; Katori, N; Hashiguchi, S; Morisaki, H				Kosugi, Shizuko; Shiotani, Masahiro; Otsuka, Yasuhisa; Suzuki, Takeshi; Katori, Nobuyuki; Hashiguchi, Saori; Morisaki, Hiroshi			Long-Term Outcomes of Percutaneous Radiofrequency Thermocoagulation of Gasserian Ganglion for 2nd-and Multiple-Division Trigeminal Neuralgia	PAIN PRACTICE			English	Article						trigeminal neuralgia; trigeminal neuralgia; idiopathic; radiofrequency ablation; Gasserian ganglion; outcomes	RETROGASSERIAN GLYCEROL RHIZOTOMY; BALLOON COMPRESSION; FOLLOW-UP; PAIN	ObjectivesThe objective of this study was to examine the long-term outcome of percutaneous radiofrequency thermocoagulation (PRT) of the Gasserian ganglion for the 2nd division and multiple division trigeminal neuralgia (TN), compared to the isolated 3rd division TN. MethodsOne hundred and forty-eight procedures performed in 89 patients with typical TN between April 2004 and September 2011 in a single pain center were retrospectively analyzed. Baseline characteristics of these patients, immediate outcome, duration pain-free, and complications were obtained from their medical records and questionnaires sent in June 2012. Duration pain-free was assessed by Kaplan-Meier analysis. ResultsOf the 148 PRT of the Gasserian ganglion, 37 procedures were performed for isolated 2nd-division TN (V2 TN), 67 procedures were for both 2nd- and 3rd-division TN (V2+V3 TN), and 38 procedures were for isolated 3rd-division TN (V3 TN). The remaining 6 procedures were performed for V1+V2 TN and V1+V2+V3 TN. Immediate success rates of PRT for V2 TN, V2+V3 TN, and V3 TN were 100%, 86.6%, and 100%, respectively, whereas the durations pain-free for V2 TN and V2+V3 TN were significantly shorter than that for V3 TN (9, 12, and 36months, respectively: P=0.012). ConclusionFor 2nd-division TN and multiple-division TN, less long-term pain relief after PRT of the Gasserian ganglion can be expected compared with that for isolated trigeminal 3rd-division neuralgia, even if immediate pain relief is achieved.	[Kosugi, Shizuko; Shiotani, Masahiro; Otsuka, Yasuhisa] Shiotani Pain Clin, Tokyo, Japan; [Kosugi, Shizuko; Suzuki, Takeshi; Katori, Nobuyuki; Hashiguchi, Saori; Morisaki, Hiroshi] Keio Univ, Sch Med, Dept Anesthesiol, Tokyo 1608582, Japan	Kosugi, S (reprint author), Keio Univ, Sch Med, Dept Anesthesiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	shizuko.kosugi@gmail.com					Taha JM, 1996, NEUROSURGERY, V38, P865, DOI 10.1097/00006123-199605000-00001; Omeis I, 2008, STEREOT FUNCT NEUROS, V86, P259, DOI 10.1159/000138770; ONOFRIO BM, 1975, J NEUROSURG, V42, P132, DOI 10.3171/jns.1975.42.2.0132; Kouzounias K, 2010, NEUROSURGERY, V67, P925, DOI 10.1227/NEU.0b013e3181eb5230; TAHA JM, 1995, J NEUROSURG, V83, P989, DOI 10.3171/jns.1995.83.6.0989; LICHTOR T, 1990, J NEUROSURG, V72, P49, DOI 10.3171/jns.1990.72.1.0049; Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3; Zakrzewska JM, 1999, PAIN, V79, P51, DOI 10.1016/S0304-3959(98)00145-6; Yoon KB, 1999, ANAESTHESIA, V54, P803, DOI 10.1046/j.1365-2044.1999.00905.x; Fraioli MF, 2009, SURG NEUROL, V71, P180, DOI 10.1016/j.surneu.2007.09.024; Kanpolat Y, 2001, NEUROSURGERY, V48, P524, DOI 10.1097/00006123-200103000-00013; NUGENT GR, 1974, J NEUROSURG, V40, P517, DOI 10.3171/jns.1974.40.4.0517; Pollock BE, 2005, J NEUROSURG, V102, P223, DOI 10.3171/jns.2005.102.2.0223; Chroni E, 2011, CLIN NEUROPHYSIOL, V122, P410, DOI 10.1016/j.clinph.2010.07.002; CRUCCU G, 1987, NEUROLOGY, V37, P631; Kouzounias K, 2010, J NEUROSURG, V113, P486, DOI 10.3171/2010.1.JNS091106; TOBLER WD, 1983, NEUROSURGERY, V12, P313; BERGENHEIM AT, 1995, NEUROSURGERY, V36, P303; Bergenheim AT, 1995, NEUROSURGERY, V36, P309; Bergenheim AT, 2013, WORLD NEUROSURG, V79, P359, DOI 10.1016/j.wneu.2012.03.014; Brown J A, 2000, Clin Neurosurg, V46, P455; FRAIOLI B, 1989, NEUROSURGERY, V24, P239; Koopman JS, 2001, PAIN, V5, P507; NORTH RB, 1990, J NEUROSURG, V72, P851, DOI 10.3171/jns.1990.72.6.0851; SANDERS M, 1992, CLIN J PAIN, V8, P23, DOI 10.1097/00002508-199203000-00005; Udupi BP, 2012, NEUROSURGERY, V70, P407, DOI 10.1227/NEU.0b013e318233a85f	26	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	MAR	2015	15	3					223	228		10.1111/papr.12163		6	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	CD3MI	WOS:000350982300005		
J	Chaudhuri, KR; Sauerbier, A; Rojo, JM; Sethi, K; Schapira, AHV; Brown, RG; Antonini, A; Stocchi, F; Odin, P; Bhattacharya, K; Tsuboi, Y; Abe, K; Rizos, A; Rodriguez-Blazquez, C; Martinez-Martin, P				Chaudhuri, K. Ray; Sauerbier, A.; Rojo, J. M.; Sethi, K.; Schapira, A. H. V.; Brown, R. G.; Antonini, A.; Stocchi, F.; Odin, P.; Bhattacharya, K.; Tsuboi, Y.; Abe, K.; Rizos, A.; Rodriguez-Blazquez, Carmen; Martinez-Martin, P.			The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system	PARKINSONISM & RELATED DISORDERS			English	Article						Parkinson's disease; Non-motor symptoms; NMS Questionnaire; Classification; Grading; Prevalence	QUALITY-OF-LIFE; PATIENTS PERSPECTIVE; RATING-SCALES; RECOMMENDATIONS; CRITIQUE; PROGRESSION; ANXIETY	Background: Non-motor symptoms (NMS) of Parkinson's disease (PD) affect virtually every patient, yet they are under-recognized and under-treated. The NMS Questionnaire (NMSQuest) is a validated 30-item self-assessment instrument useful for NMS screening in clinic. Objective: Development of a straight forward grading classification of the burden of non-motor symptoms in PD based on the number of NMS as assessed by the NMS Questionnaire. Methods: In an observational, cross-sectional, international study of 383 consecutive patients distribution of the declared NMS as per NMSQuest was analyzed according to previously published levels based on the Non-Motor Symptoms Scale and also the median and interquartile range (IR, percentiles 25 and 75) of the total NMSQuest scores. After post hoc checking, these values were proposed as cut-off points for estimating NMS burden based only on the accumulation of symptoms. Results: Burden and number of NMS correlate closely (r >= 0.80). On the basis of this finding, five levels (0 = No NMS to 4 = Very severe) of NMSQuest grading were proposed after identification of their cut-offs by ordinal logistic regression and median and interquartile range distribution. These values coincided almost completely with those obtained by median and interquartile range in an independent sample. Concordance between this classification and HY staging was weak (weighted kappa = 0.30), but was substantial (weighted kappa = 0.68) with the Non-Motor Symptoms Scale grading. Conclusion: Completion of NMSQuest and subsequent grading of the burden could allow the health care professional to approach the severity of NMS burden using the self completed NMSQuest in a primary care setting. (C) 2015 Elsevier Ltd. All rights reserved.	[Chaudhuri, K. Ray; Sauerbier, A.; Rizos, A.] Kings Coll London, Natl Parkinson Fdn, Int Ctr Excellence, London WC2R 2LS, England; [Chaudhuri, K. Ray; Brown, R. G.] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Mental Hlth Biomed Res Ctr, London, England; [Chaudhuri, K. Ray; Brown, R. G.] South London & Maudsley NHS Fdn Trust, Dementia Unit, London, England; [Chaudhuri, K. Ray; Brown, R. G.] Kings Coll London, London WC2R 2LS, England; [Chaudhuri, K. Ray] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London WC2R 2LS, England; [Rojo, J. M.] Spanish Council Sci Res, Dept Stat, Ctr Human & Social Sci, Madrid, Spain; [Sethi, K.] Med Coll Georgia, Movement Disorders Program, Augusta, GA 30912 USA; [Schapira, A. H. V.] UCL Inst Neurol, Dept Clin Neurosci London, London, England; [Brown, R. G.] Kings Coll London, Dept Psychol, Inst Psychiat, London WC2R 2LS, England; [Antonini, A.] IRCCS San Camillo, Dept Parkinsons Dis, Venice, Italy; [Stocchi, F.] IRCCS San Raffaele, Dept Neurol, Rome, Italy; [Odin, P.] Lund Univ, Lund, Sweden; [Bhattacharya, K.] Bangur Inst Neurol, Kolkata, India; [Tsuboi, Y.] Fukuoka Univ, Fac Med, Dept Neurol, Fukuoka 81401, Japan; [Abe, K.] Hyogo Coll Med Hosp, Div Neurol, Hyogo Coll Med, Dept Community Hlth Med, Nishinomiya, Hyogo, Japan; [Rodriguez-Blazquez, Carmen; Martinez-Martin, P.] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid 28029, Spain; [Rodriguez-Blazquez, Carmen; Martinez-Martin, P.] Carlos III Inst Hlth, Ctr Networked Biomed Res Neurodegenerat Dis CIBER, Madrid 28029, Spain	Martinez-Martin, P (reprint author), Carlos III Inst Hlth, Natl Ctr Epidemiol, Avda Monforte de Lemos 5, Madrid 28029, Spain.	pmartinez@isciii.es	Schapira, Anthony/A-1245-2010; Rodriguez-Blazquez, Carmen/K-6447-2012; Brown, Richard/A-9599-2010	Schapira, Anthony/0000-0002-3018-3966; Rodriguez-Blazquez, Carmen/0000-0003-3829-0675; 	Parkinson's disease non-motor group	Parkinson's disease non-motor group.	HOEHN MM, 1967, NEUROLOGY, V17, P427; Marinus J, 2004, J NEUROL NEUROSUR PS, V75, P388, DOI 10.1136/jnnp.2003.017509; Politis M, 2010, MOVEMENT DISORD, V25, P1646, DOI 10.1002/mds.23135; Martinez-Martin P, 2007, MOVEMENT DISORD, V22, P1623, DOI 10.1002/mds.21586; Jenkinson C, 1997, PSYCHOL HEALTH, V12, P805, DOI 10.1080/08870449708406741; Sauerbier A, 2014, BRIT J HOSP MED, V75, P18; Leentjens AFG, 2008, MOVEMENT DISORD, V23, P2015, DOI 10.1002/mds.22233; Martinez-Martin P, 2005, J CLIN EPIDEMIOL, V58, P674, DOI 10.1016/j.jclinepi.2004.09.014; Schrag A, 2007, MOVEMENT DISORD, V22, P1077, DOI 10.1002/mds.21333; Zis P, 2014, J PARKINSON DIS, V4, P541, DOI 10.3233/JPD-140372; Chaudhuri KR, 2007, MOVEMENT DISORD, V22, P1901, DOI 10.1002/mds.21596; Chaudhuri KR, 2010, MOVEMENT DISORD, V25, P704, DOI 10.1002/mds.22868; Antonini A, 2012, J NEUROL, V259, P2621, DOI 10.1007/s00415-012-6557-8; Chaudhuri KR, 2006, MOVEMENT DISORD, V21, P916, DOI 10.1002/mds.20844; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834; Martinez-Martin P, 2009, NEUROLOGY, V73, P1584, DOI 10.1212/WNL.0b013e3181c0d416; Breen KC, 2013, J NEURAL TRANSM, V120, P531, DOI 10.1007/s00702-012-0928-2; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P399, DOI 10.1002/mds.23462; Khoo TK, 2013, NEUROLOGY, V80, P276, DOI 10.1212/WNL.0b013e31827deb74; Hinnell C, 2012, MOVEMENT DISORD, V27, P236, DOI 10.1002/mds.23961; Chaudhuri KR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057221; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; Fisk JD, 2005, J NEUROL NEUROSUR PS, V76, P58, DOI 10.1136/jnnp.2003.017897; Lee MA, 2007, PARKINSONISM RELAT D, V13, P284, DOI 10.1016/j.parkreldis.2006.11.009; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Martinez-Martin P, 2014, GUIDE ASSESSMENT SCA; Martinez-Martin P, 2014, MOVEMENT DISORD, V29, P166, DOI 10.1002/mds.25799; Mollenhauer B, 2013, NEUROLOGY, V81, P1226, DOI 10.1212/WNL.0b013e3182a6cbd5; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8020	1873-5126		PARKINSONISM RELAT D	Parkinsonism Relat. Disord.	MAR	2015	21	3					287	291		10.1016/j.parkreldis.2014.12.031		5	Clinical Neurology	Neurosciences & Neurology	CD2SU	WOS:000350930100022		
J	Fujioka, S; Strongosky, AJ; Hassan, A; Rademakers, R; Dickson, DW; Wszolek, ZK				Fujioka, Shinsuke; Strongosky, Audrey J.; Hassan, Anhar; Rademakers, Rosa; Dickson, Dennis W.; Wszolek, Zbigniew K.			Clinical presentation of a patient with SLC20A2 and THAP1 deletions: Differential diagnosis of oromandibular dystonia	PARKINSONISM & RELATED DISORDERS			English	Letter						SLC20A2; THAP1; Oromandibular dystonia; Basal ganglia calcification; IBGC3; Genetic testing	BASAL GANGLIA CALCIFICATION		[Fujioka, Shinsuke; Strongosky, Audrey J.; Wszolek, Zbigniew K.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA; [Fujioka, Shinsuke] Fukuoka Univ, Dept Neurol, Fukuoka 81401, Japan; [Hassan, Anhar] Mayo Clin, Dept Neurol, Rochester, MN USA; [Rademakers, Rosa; Dickson, Dennis W.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA	Wszolek, ZK (reprint author), Mayo Clin, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	Wszolek.zbigniew@mayo.edu					Wider C, 2009, J NEUROL, V256, P839, DOI 10.1007/s00415-009-5025-6; Wang C, 2012, NAT GENET, V44, P254, DOI 10.1038/ng.1077; Baker M, 2014, NEUROGENETICS, V15, P23, DOI 10.1007/s10048-013-0378-5; Bonazza S, 2011, NEUROL SCI, V32, P537, DOI 10.1007/s10072-011-0514-7; LeDoux MS, 2012, PARKINSONISM RELAT D, V18S1, pS162; Wszolek ZK, 2006, NEUROLOGY, V67, P620, DOI 10.1212/01.wnl.0000230141.40784.09	6	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8020	1873-5126		PARKINSONISM RELAT D	Parkinsonism Relat. Disord.	MAR	2015	21	3					329	331		10.1016/j.parkreldis.2014.12.024		3	Clinical Neurology	Neurosciences & Neurology	CD2SU	WOS:000350930100034		
J	Saigoh, K; Mitsui, J; Hirano, M; Shioyama, M; Samukawa, M; Ichikawa, Y; Goto, J; Tsuji, S; Kusunoki, S				Saigoh, Kazumasa; Mitsui, Jun; Hirano, Makito; Shioyama, Mitsuaki; Samukawa, Makoto; Ichikawa, Yaeko; Goto, Jun; Tsuji, Shoji; Kusunoki, Susumu			The first Japanese familial case of spinocerebellar ataxia 23 with a novel mutation in the PDYN gene	PARKINSONISM & RELATED DISORDERS			English	Letter						Spinocerebellar ataxia 23; Head tremor; Hot cross bun (HCB) sign; Parkinsonism; Multiple system atrophy, Prodynorphin (PDYN)	MULTIPLE SYSTEM ATROPHY		[Saigoh, Kazumasa; Hirano, Makito; Shioyama, Mitsuaki; Samukawa, Makoto; Kusunoki, Susumu] Kinki Univ, Fac Med, Dept Neurol, Osaka 5898511, Japan; [Mitsui, Jun; Ichikawa, Yaeko; Goto, Jun; Tsuji, Shoji] Univ Tokyo, Grad Sch Med, Dept Neurol, Tokyo 1138654, Japan	Saigoh, K (reprint author), Kinki Univ, Fac Med, Dept Neurol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	saigoh@k.email.ne.jp; kusunoki-tky@umin.ac.jp					Watanabe H, 2010, MOVEMENT DISORD, V25, P1916, DOI 10.1002/mds.23196; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Bakalkin G, 2010, AM J HUM GENET, V87, P593, DOI 10.1016/j.ajhg.2010.10.001; Watanabe H, 2002, BRAIN, V125, P1070, DOI 10.1093/brain/awf117; Jezierska J, 2013, J NEUROL, V260, P1807, DOI 10.1007/s00415-013-6882-6	5	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8020	1873-5126		PARKINSONISM RELAT D	Parkinsonism Relat. Disord.	MAR	2015	21	3					332	334		10.1016/j.parkreldis.2014.12.028		3	Clinical Neurology	Neurosciences & Neurology	CD2SU	WOS:000350930100035		
J	Sakai, T; Nishimura, S; Ogiya, A; Tanabe, M; Kimura, K; Morizono, H; Iijima, K; Miyagi, Y; Makita, M; Ito, Y; Oguchi, M; Horii, R; Akiyama, F; Iwase, T				Sakai, Takehiko; Nishimura, Seiichiro; Ogiya, Akiko; Tanabe, Masahiko; Kimura, Kiyomi; Morizono, Hidetomo; Iijima, Kotaro; Miyagi, Yumi; Makita, Masujiro; Ito, Yoshinori; Oguchi, Masahiko; Horii, Rie; Akiyama, Futoshi; Iwase, Takuji			Four types of Ipsilateral Breast Tumor Recurrence (IBTR) after breast-conserving surgery: Classification of IBTR based on precise pathological examination	PATHOLOGY INTERNATIONAL			English	Article						breast cancer; breast-conserving surgery; ipsilateral breast tumor recurrence; new primary tumor; true recurrence	TRUE RECURRENCES; THERAPY; RELAPSE	We classified ipsilateral breast tumor recurrences (IBTRs) based on strict pathological rules. Ninety-six women who were surgically treated for IBTR were included. IBTRs were classified according to their origins and were distinguished based on strict pathological rules: relationship between the IBTR and the primary lumpectomy scar, surgical margin status of the primary cancer, and the presence of in situ lesions of IBTR. The prognosis of these subgroups were compared to that of new primary tumors (NP) in the narrow sense (NPn) that occurred far from the scar. Distant-disease free survival of IBTR that occurred close to the scar with in situ lesions and a negative surgical margin of the primary cancer (NP occurred close to the scar, NPcs) was similar to that of NPn. In contrast, IBTR that occurred close to the scar without in situ lesions (true recurrence (TR) that arose from residual invasive carcinoma foci, TRinv) had significantly poorer prognosis than NPn. IBTR that occurred close to the scar with in situ lesions and a positive surgical margin of the primary cancer (TR arising from a residual in situ lesion, TRis) had more late recurrences than NPcs. Precise pathological examinations indicated four distinct IBTR subtypes with different characteristics.	[Sakai, Takehiko; Nishimura, Seiichiro; Ogiya, Akiko; Tanabe, Masahiko; Kimura, Kiyomi; Morizono, Hidetomo; Iijima, Kotaro; Miyagi, Yumi; Makita, Masujiro; Iwase, Takuji] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Oncol, Breast Oncol Ctr, Tokyo 1358550, Japan; [Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Breast Oncol Ctr, Tokyo 1358550, Japan; [Oguchi, Masahiko] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Breast Oncol Ctr, Tokyo 1358550, Japan; [Horii, Rie] Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Tokyo 1358550, Japan; [Akiyama, Futoshi] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 1358550, Japan	Sakai, T (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Oncol, Breast Oncol Ctr,Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	takehiko.sakai@jfcr.or.jp					Bollet MA, 2008, J NATL CANCER I, V100, P48, DOI 10.1093/jnci/djm266; Smith TE, 2000, INT J RADIAT ONCOL, V48, P1281, DOI 10.1016/S0360-3016(00)01378-X; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; Vicini FA, 2007, CANCER, V109, P1264, DOI 10.1002/cncr.22529; HAFFTY BG, 1993, INT J RADIAT ONCOL, V27, P575; Huang E, 2002, CANCER, V95, P2059, DOI 10.1002/cncr.10952; Komoike Yoshifumi, 2005, Breast Cancer, V12, P104, DOI 10.2325/jbcs.12.104; Nishimura Seiichiro, 2005, Breast Cancer, V12, P112, DOI 10.2325/jbcs.12.112; The Japanese Breast Cancer Society, 2012, GEN RUL CLIN PATH RE; Yi M, 2011, ANN SURG, V253, P572, DOI 10.1097/SLA.0b013e318208fc2a; Yoshida T, 2010, BREAST J, V16, P127, DOI 10.1111/j.1524-4741.2009.00884.x	11	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					113	118		10.1111/pin.12253		6	Pathology	Pathology	CC8UZ	WOS:000350645300003		
J	Ohta, M; Ookoshi, T; Naiki, H; Imamura, Y				Ohta, Makoto; Ookoshi, Tadakazu; Naiki, Hironobu; Imamura, Yoshiaki			HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma	PATHOLOGY INTERNATIONAL			English	Article						CD15; cytology; HBME-1; immunocytochemistry; papillary carcinoma; thyroid cancer	FINE-NEEDLE-ASPIRATION; CYTOKERATIN 19; DIAGNOSIS; LESIONS; EXPRESSION; NEOPLASMS; BENIGN; LEU-M1; TUMORS; MESOTHELIOMA	Papillary carcinoma is the most common thyroid malignancy. As the cytological diagnosis of papillary carcinoma is not difficult in patients with the usual type of lesion, fine-needle aspiration (FNA) cytology is an effective method for preoperative evaluation. However, this modality is often ineffective in identifying the follicular variant of papillary thyroid carcinoma (FVPTC) due to its similarity to other follicular lesions and the incompleteness of typical nuclear features. Therefore, we investigated the expression of immunocytochemical markers of papillary carcinoma in cytological specimens of FVPTC and evaluated their utilities. The immunoreactivity of HBME-1 and CD15 was investigated using 50 imprint smear cytological specimens obtained from thyroid lesions, including 13 FVPTC. The sensitivity and specificity of HBME-1 for FVPTC were 92% and 89%, respectively, while those of CD15 were 23% and 100%, respectively. In conclusion, HBME-1 is a sensitive marker of papillary carcinoma, including both usual type and FVPTC, in cytological specimens. Therefore, using HBME-1 immunocytochemistry in FNA cytology will lead to reduction of the incidence of false-negative diagnoses of FVPTC. Although CD15 is apparently inferior in terms of sensitivity for FVPTC, its excellent specificity will support the definitive diagnosis of thyroid malignancies, including FVPTC, after screening with HBME-1.	[Ohta, Makoto] Fukui Red Cross Hosp, Dept Pathol, Fukui, Japan; [Ohta, Makoto; Ookoshi, Tadakazu; Naiki, Hironobu] Univ Fukui, Fac Med Sci, Dept Pathol Sci, Div Mol Pathol, Fukui 910, Japan; [Imamura, Yoshiaki] Univ Fukui Hosp, Div Surg Pathol, Fukui 9101193, Japan	Imamura, Y (reprint author), Univ Fukui Hosp, Div Surg Pathol, 23-3 Matsuoka Shimoaizuki, Fukui 9101193, Japan.	suki@u-fukui.ac.jp	Naiki, Hironobu/G-5599-2014				Schmitt AC, 2010, CANCER CYTOPATHOL, V118, P196, DOI 10.1002/cncy.20082; Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Cochand-Priollet B, 2011, THYROID, V21, P1067, DOI 10.1089/thy.2011.0014; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Kakudo K, 2012, PATHOL INT, V62, P155, DOI 10.1111/j.1440-1827.2011.02773.x; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Zidan J, 2003, CANCER, V97, P1181, DOI 10.1002/cncr.11175; Ko HM, 2003, ACTA CYTOL, V47, P727, DOI 10.1159/000326596; Miettinen M, 1996, VIRCHOWS ARCH, V429, P213; Chhieng DC, 1997, CANCER CYTOPATHOL, V81, P157, DOI 10.1002/(SICI)1097-0142(19970625)81:3<157::AID-CNCR5>3.0.CO;2-O; DeLellis RA, 2004, WHO CLASSIFICATION T; HANJAN SNS, 1982, CLIN IMMUNOL IMMUNOP, V23, P172, DOI 10.1016/0090-1229(82)90106-4; Hirokawa M, 2000, DIAGN CYTOPATHOL, V22, P197, DOI 10.1002/(SICI)1097-0339(20000301)22:3<197::AID-DC13>3.0.CO;2-F; HSU SM, 1984, AM J CLIN PATHOL, V82, P29; Imamura Y, 1998, APPL IMMUNOHISTOCHEM, V6, P181, DOI 10.1097/00022744-199812000-00002; Kim JY, 2002, ACTA CYTOL, V46, P679, DOI 10.1159/000326975; Mai KT, 1999, PATHOL INT, V49, P601, DOI 10.1046/j.1440-1827.1999.00908.x; MIETTINEN M, 1995, APPL IMMUNOHISTOCHEM, V3, P115; Nga ME, 2008, DIAGN CYTOPATHOL, V36, P550, DOI 10.1002/dc.20841; Pazaitou-Panayiotou K, 2010, J ONCOL, V2010; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rossi ED, 2005, CANCER CYTOPATHOL, V105, P87, DOI 10.1002/cncr.21026; Sack MT, 1997, MODERN PATHOL, V10, P668; Saleh HA, 2009, CYTOJOURNAL, V6, DOI 10.4103/1742-6413.55894; SCHRODER S, 1987, VIRCHOWS ARCH A, V411, P435, DOI 10.1007/BF00735224; SCOPA CD, 1993, MODERN PATHOL, V6, P691; SHEIBANI K, 1992, HUM PATHOL, V23, P107, DOI 10.1016/0046-8177(92)90231-Q; SHEIBANI K, 1986, AM J SURG PATHOL, V10, P227, DOI 10.1097/00000478-198604000-00001; UCHIDA H, 1989, ACTA PATHOL JAPON, V39, P169; vansHoeven KH, 1998, DIAGN CYTOPATHOL, V18, P93; Wallander M, 2010, APPL IMMUNOHISTO M M, V18, P231, DOI 10.1097/PAI.0b013e3181c61cdd	32	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					119	125		10.1111/pin.12252		7	Pathology	Pathology	CC8UZ	WOS:000350645300004		
J	Iribe, Y; Kuroda, N; Nagashima, Y; Yao, M; Tanaka, R; Gotoda, H; Kawakami, F; Imamura, Y; Nakamura, Y; Ando, M; Araki, A; Matsushima, J; Nakatani, Y; Furuya, M				Iribe, Yasuhiro; Kuroda, Naoto; Nagashima, Yoji; Yao, Masahiro; Tanaka, Reiko; Gotoda, Hiroko; Kawakami, Fumi; Imamura, Yoshiaki; Nakamura, Yasushi; Ando, Midori; Araki, Akinobu; Matsushima, Jun; Nakatani, Yukio; Furuya, Mitsuko			Immunohistochemical characterization of renal tumors in patients with Birt-Hogg-Dube Syndrome	PATHOLOGY INTERNATIONAL			English	Article						Birt-Hogg-Dube Syndrome (BHD); folliculin (FLCN); hybrid oncocytic; chromophobe tumor (HOCT); immunohistochemistry; renal tumor	FAMILIES; CANCER; FLCN	Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant disorder associated with a germline mutation of folliculin (FLCN). The affected families are at a high risk for developing multiple renal cell carcinomas (RCC). Little is known about the immunostaining patterns of mutant FLCN-associated RCCs. We investigated 32 RCCs obtained from 17 BHD patients. The studied tumors included chromophobe RCCs (n = 15), hybrid oncocytic/chromophobe tumors (HOCT) (n = 14) and clear cell RCCs (n = 3). Almost all chromophobe RCCs and HOCTs revealed positive staining for S100A1, Ksp-cadherin and CD82. They stained either focally or diffusely for CK7, and were negative for CA-IX. All clear cell RCCs were positively stained for CA-IX and negative for CK7. These data confirmed that mutant FLCN-associated oncocytic and clear cell RCCs exhibited generally similar immunostaining patterns compared to their sporadic counterparts. Frequent positive staining for S100A1, Ksp-cadherin and CD82 in chromophobe RCCs and HOCTs indicated that these two types were relatively similar rather than distinctively different in their patterns of immunoreactivity. Characteristic peri-nuclear halos and polygonal cells with clear cytoplasm, which often misleads pathologists into the diagnosis of clear cell RCC, should be carefully examined using an immunohistochemical panel including CA-IX, Ksp-cadherin, CD82 and CK7.	[Iribe, Yasuhiro; Furuya, Mitsuko] Yokohama City Univ, Grad Sch Med, Dept Mol Pathol, Yokohama, Kanagawa 2360004, Japan; [Yao, Masahiro] Yokohama City Univ, Grad Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan; [Kuroda, Naoto] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Japan; [Nagashima, Yoji] Tokyo Womens Med Univ, Dept Surg Pathol, Kochi, Japan; [Tanaka, Reiko] Chiba Univ, Med Mycol Res Ctr, Chiba, Japan; [Araki, Akinobu] Chiba Canc Ctr, Dept Pathol, Chiba 2608717, Japan; [Matsushima, Jun; Nakatani, Yukio] Chiba Univ, Grad Sch Med, Dept Diagnost Pathol, Chiba, Japan; [Gotoda, Hiroko] Sapporo Kosei Hosp, Dept Pathol, Sapporo, Hokkaido, Japan; [Kawakami, Fumi] Kobe Univ Hosp, Dept Pathol, Kobe, Hyogo, Japan; [Imamura, Yoshiaki] Fukui Univ Hosp, Div Surg Pathol, Fukui, Japan; [Nakamura, Yasushi] Wakayama Med Univ, Dept Clin Lab Med, Wakayama, Japan; [Ando, Midori] Okayama Univ Hosp, Dept Pathol, Okayama, Japan	Furuya, M (reprint author), Yokohama City Univ, Grad Sch Med, Dept Mol Pathol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	mfuruya@yokohama-cu.ac.jp			JSPS KAKENHI [23590406, 26460456, 24590408]; Ministry of Health, Labor and Welfare; Yokohama Foundation for Advancement of Medical Science; Mitsubishi Foundation; Project for Development of Innovative Research on Cancer Therapeutics	The authors thank Drs. Toshiharu Sakuma, Shin Sasaki, Tomohiro Hasaka, Keisuke Sugimoto, and Akinori Iba for providing clinical information and renal tissues and Ms. Hiromi Soeda and Ms. Yuka Imanishi for excellent assistance. This work was supported by JSPS KAKENHI Grant Number 23590406 (M.F.), 26460456 (Y. Nagashima) and 24590408 (Y. Nakatani), and the Ministry of Health, Labor and Welfare (Y. Nakatani), Yokohama Foundation for Advancement of Medical Science (M.F.), The Mitsubishi Foundation (M.F.), and Project for Development of Innovative Research on Cancer Therapeutics (M.Y.).	Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Furuya M, 2012, AM J SURG PATHOL, V36, P589, DOI 10.1097/PAS.0b013e3182475240; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Hasumi H, 2012, J NATL CANCER I, V104, P1750, DOI 10.1093/jnci/djs418; Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47; Adley BP, 2006, ARCH PATHOL LAB MED, V130, P1865; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; HORNSTEIN OP, 1975, ARCH DERMATOL FORSCH, V253, P161, DOI 10.1007/BF00582068; Houweling AC, 2011, BRIT J CANCER, V105, P1912, DOI 10.1038/bjc.2011.463; Klomp JA, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-59; Kuroda N, 2014, ANN DIAGN PATHOL, V18, P171, DOI 10.1016/j.anndiagpath.2014.03.002; Ohe C, 2012, MED MOL MORPHOL, V45, P98, DOI 10.1007/s00795-011-0546-3; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					126	132		10.1111/pin.12254		7	Pathology	Pathology	CC8UZ	WOS:000350645300005		
J	Kameda, K; Shono, T; Takagishi, S; Kono, S; Aoki, T; Ito, Y; Kamimura, T; Sugita, Y; Ohshima, K				Kameda, Katsuharu; Shono, Tadahisa; Takagishi, Soh; Kono, Shinji; Aoki, Takatoshi; Ito, Yoshikiyo; Kamimura, Tomohiko; Sugita, Yasuo; Ohshima, Koichi			Epstein-Barr virus-positive diffuse large B-cell primary central nervous system lymphoma associated with organized chronic subdural hematoma: A case report and review of the literature	PATHOLOGY INTERNATIONAL			English	Review						B-cell lymphoma; chronic inflammation; chronic subdural hematoma; Epstein-Barr virus; primary central nervous system lymphoma; pseudocyst	LYMPHOPROLIFERATIVE DISORDERS; CHRONIC INFLAMMATION	We here report on a rare case of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) detected in both brain parenchyma and in an organized chronic subdural hematoma (OCSH). A 96-year-old man diagnosed with asymptomatic OCSH in the left frontal convexity was referred to our hospital because of a de novo mass lesion just beneath the OCSH on contrast-enhanced magnetic resonance imaging. The size of the OCSH remained stable. We diagnosed the lesion as a malignant tumor. At surgery, the organized hematoma and the soft fragile tumor were removed. Histological examinations revealed pleomorphic lymphoid cells not only in the brain tissue but also in the OCSH component with tumor necrosis, and these were immunopositive for B-cell markers. In situ hybridization revealed positive signals for EBV-encoded small RNAs, consistent with EBV-positive DLBCL. Since the membranes of the subdural hematoma were fibrous and the tumor progression resulted in necrosis of the tumor, the DLBCL may have originally developed in the OCSH and infiltrated into the brain parenchyma. We believe that this rare case provides crucial information for the understanding of DLBCLs associated with OCSH.	[Kameda, Katsuharu; Shono, Tadahisa; Takagishi, Soh] Harasanshin Hosp, Dept Neurosurg, Fukuoka 8120033, Japan; [Kono, Shinji] Harasanshin Hosp, Dept Pathol, Fukuoka 8120033, Japan; [Aoki, Takatoshi; Ito, Yoshikiyo; Kamimura, Tomohiko] Harasanshin Hosp, Dept Hematol, Fukuoka 8120033, Japan; [Sugita, Yasuo; Ohshima, Koichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 830, Japan	Kameda, K (reprint author), Harasanshin Hosp, Dept Neurosurg, Hakata Ku, 1-8 Taihaku Machi, Fukuoka 8120033, Japan.	kkameda55@gmail.com					Alimehmeti R, 2002, SURG NEUROL, V57, P179, DOI 10.1016/S0090-3019(01)00694-2; Oyama T, 2007, CLIN CANCER RES, V13, P5124, DOI 10.1158/1078-0432.CCR-06-2823; Fujimoto M, 2008, PATHOL INT, V58, P668, DOI 10.1111/j.1440-1827.2008.02288.x; HAINES DE, 1993, NEUROSURGERY, V32, P111; Valli R, 2011, INT J SURG PATHOL, V19, P117, DOI 10.1177/1066896910391253; Miller DV, 2010, AM J SURG PATHOL, V34, P377, DOI 10.1097/PAS.0b013e3181ce9128; Loong F, 2010, MODERN PATHOL, V23, P493, DOI 10.1038/modpathol.2009.168; Shono T, 2001, J CLIN NEUROSCI, V8, P411, DOI 10.1054/jocn.2000.0951; Boroumand N, 2012, AM J SURG PATHOL, V36, P1074, DOI 10.1097/PAS.0b013e3182515fb5; Oyama T, 2003, AM J SURG PATHOL, V27, P16, DOI 10.1097/00000478-200301000-00003; Chan J, 2008, WHO CLASSIFICATION T, P243; Deckert M, 2007, WHO CLASSIFICATION T; Gotoh M, 2001, NEUROL SURG TOKYO, V29, P259; Nakamura S, 2008, CLASSIFICATION OF TU, V94, P243; REYES MG, 1990, SURG NEUROL, V33, P35, DOI 10.1016/0090-3019(90)90222-B; Rocchi G, 2007, SURG NEUROL, V67, P374, DOI 10.1016/j.surneu.2006.08.066; ROSENBLUTH PR, 1962, JAMA-J AM MED ASSOC, V179, P759; Sugita Y, 2012, PATHOL INT, V62, P412, DOI 10.1111/j.1440-1827.2012.02824.x; Sugita Y, 2010, J NEURO-ONCOL, V100, P271, DOI 10.1007/s11060-010-0191-z; Utsuki S, 2011, BRAIN TUMOR PATHOL, V28, P145, DOI 10.1007/s10014-011-0020-x	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					138	143		10.1111/pin.12242		6	Pathology	Pathology	CC8UZ	WOS:000350645300007		
J	Uehara, K; Usami, Y; Imai, Y; Shimizu, M				Uehara, Keiichiro; Usami, Yu; Imai, Yukihiro; Shimizu, Michio			Melanotic oncocytic metaplasia of the nasopharynx	PATHOLOGY INTERNATIONAL			English	Article						melanin; melanotic oncocytic metaplasia; nasopharynx; oncocytic metaplasia	OF-THE-LITERATURE	We present three cases of melanotic oncocytic metaplasia of the nasopharynx. Case 1 and Case 2 were a 70- and a 61-year-old woman, and Case 3 was a 74-year-old man. Although Case 1 was asymptomatic, Cases 2 and 3 had hoarseness. All cases were Japanese and their nasopharyngeal examination revealed single or multiple black nodules measuring a few millimeters in diameter. In each case, biopsies were performed to rule out malignancy. Histological examination showed respiratory mucosa with oncocytic metaplasia and melanin pigments. Immunohistochemically, S-100 protein and melan-A positive dendritic melanocytes were observed in the basal layer of the oncocytes. Melanotic oncocytic metaplasia is extremely rare, and so far only 21 cases have been reported in the English literature to our knowledge. It has been reported in only older Asians, predominantly in males; there have been only three female patients including our two cases. All of our cases were long-time smokers, which supports the previously described hypothesis that smoking may be a predisposing factor for melanin pigmentation. Since melanotic oncocytic metaplasia may clinically mimic a malignant tumor, it is important to be aware of this lesion.	[Uehara, Keiichiro; Shimizu, Michio] Saitama Med Univ, Saitama Int Med Ctr, Dept Pathol, Hidaka City, Saitama 3501298, Japan; [Uehara, Keiichiro; Usami, Yu; Imai, Yukihiro] Kobe City Med Ctr Gen Hosp, Dept Clin Pathol, Kobe, Hyogo, Japan; [Usami, Yu] Osaka Univ, Dent Hosp, Div Clin Lab, Osaka, Japan	Shimizu, M (reprint author), Saitama Med Univ, Saitama Int Med Ctr, Dept Pathol, 1397-1 Yamane, Hidaka City, Saitama 3501298, Japan.	shimizu@saitama-med.ac.jp					Chang IW, 2014, POL J PATHOL, V65, P162, DOI 10.5114/PJP.2014.43969; Hirakawa E, 1999, VIRCHOWS ARCH, V434, P455, DOI 10.1007/s004280050366; Kondo T, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-5; Kurihara K, 1997, PATHOL INT, V47, P315, DOI 10.1111/j.1440-1827.1997.tb04499.x; Li Y, 2010, CHINESE MED J-PEKING, V123, P1230, DOI 10.3760/cma.j.issn.0366-6999.2010.09.026; Liao CT, 2005, INT J SURG PATHOL, V13, P279, DOI 10.1177/106689690501300308; Lui PCW, 2004, PATHOLOGY, V36, P504, DOI 10.1080/00313020412331283860; Mills SE, 2012, HISTOLOGY PATHOLOGIS, P461; Na JY, 2012, KOREAN J PATHOL, V46, P201, DOI 10.4132/KoreanJPathol.2012.46.2.201; Sakaki M, 2004, VIRCHOWS ARCH, V444, P345, DOI 10.1007/s00428-003-0970-4; SHEK TWH, 1995, HISTOPATHOLOGY, V26, P273, DOI 10.1111/j.1365-2559.1995.tb01442.x; Takano K, 2004, AURIS NASUS LARYNX, V31, P161, DOI 10.1016/j.anl.2004.01.003; Xue WC, 1999, HISTOPATHOLOGY, V35, P481	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					144	147		10.1111/pin.12247		4	Pathology	Pathology	CC8UZ	WOS:000350645300008		
J	Mochizuki, K; Kondo, T; Tahara, I; Inoue, T; Kasai, K; Oishi, N; Nakazawa, T; Komiyama, A; Katoh, R				Mochizuki, Kunio; Kondo, Tetsuo; Tahara, Ippei; Inoue, Tomohiro; Kasai, Kazunari; Oishi, Naoki; Nakazawa, Tadao; Komiyama, Akira; Katoh, Ryohei			Gastric adenocarcinoma of pyloric gland type with high-grade malignancy	PATHOLOGY INTERNATIONAL			English	Letter							PHENOTYPIC-EXPRESSION; STOMACH; ADENOMA		[Mochizuki, Kunio; Kondo, Tetsuo; Tahara, Ippei; Inoue, Tomohiro; Kasai, Kazunari; Oishi, Naoki; Nakazawa, Tadao; Katoh, Ryohei] Univ Yamanashi, Dept Pathol, Chuo, Japan; [Komiyama, Akira] Fujinomiya City Gen Hosp, Fujinomiya, Japan	Mochizuki, K (reprint author), Univ Yamanashi, Dept Pathol, Chuo, Japan.						Vieth M, 2003, VIRCHOWS ARCH, V442, P317, DOI 10.1007/s00428-002-0750-6; Matsubara A, 2013, J PATHOL, V229, P579, DOI 10.1002/path.4153; Vieth M, 2010, VIRCHOWS ARCH, V457, P529, DOI 10.1007/s00428-010-0968-7; Ueyama H, 2010, AM J SURG PATHOL, V34, P609, DOI 10.1097/PAS.0b013e3181d94d53; Coyne JD, 2012, INT J SURG PATHOL, V20, P71, DOI 10.1177/1066896911416114; Kabashima A, 2002, HUM PATHOL, V33, P80, DOI 10.1053/hupa.2002.30182; Kushima Ryoji, 2006, Gastric Cancer, V9, P177, DOI 10.1007/s10120-006-0381-8; Lauwers GY, 2010, WHO CLASSIFICATION T, V98, P48; TATEMATSU M, 1990, ACTA PATHOL JAPON, V40, P494; Tsukamoto T, 2007, PATHOL INT, V57, P517, DOI 10.1111/j.1440-1827.2007.02134.x	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	MAR	2015	65	3					148	150		10.1111/pin.12241		3	Pathology	Pathology	CC8UZ	WOS:000350645300009		
J	Hayashi, M; Takane, Y; Ebisawa, H				Hayashi, Masahiko; Takane, Yositake; Ebisawa, Hiromichi			Time-dependent Ginzburg-Landau equation of charge-density-waves and numerical simulation of the sliding	PHYSICA B-CONDENSED MATTER			English	Article						Charge density wave; Time-dependent Ginzburg-Landau equation; Dynamics; Sliding	PHASE-SLIP; CURRENT CONVERSION; CONDUCTION NOISE; LONG-RANGE; SYSTEMS; GENERATION; DYNAMICS; NUCLEATION; CRYSTALS; NBSE3	Time-dependent Ginzburg-Landau equation (TDGL) for charge-density-wave (CDW) conductors is discussed. At first, we study a purely one-dimensional case, where the current electrodes are attached from the sides. One of the characteristics of our TDGL is that the non-equilibrium chemical potential for right-moving and left-moving electrons are taken into account as dynamical variables. Then the dynamical interaction between the condensate and the quasiparticles is demonstrated in an apparent form. We present some results of the numerical simulation of the sliding of CDW based on our TDGL. Possible extension to quasi-one dimensional (three-dimensional) systems is also discussed. (C) 2014 Elsevier B.V. All rights reserved.	[Hayashi, Masahiko] Akita Univ, Fac Educ & Human Studies, Akita 0108502, Japan; [Takane, Yositake] Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Quantum Matter, Higashihiroshima 7398530, Japan; [Ebisawa, Hiromichi] Tohoku Univ, Inst Liberal Arts & Sci, Sendai, Miyagi 9808576, Japan	Hayashi, M (reprint author), Akita Univ, Fac Educ & Human Studies, Akita 0108502, Japan.	m-hayashi@ed.akita-u.ac.jp			JSPS [24540392]	This work was supported by JSPS KAKENHI Grant No. 24540392.	Adelman TL, 1996, PHYS REV B, V53, P1833, DOI 10.1103/PhysRevB.53.1833; Brazovskii S, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.096801; Monceau P, 2012, ADV PHYS, V61, P325, DOI 10.1080/00018732.2012.719674; Matsuura T, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.014304; Matsuura T, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.165118; FUKUYAMA H, 1978, PHYS REV B, V17, P535, DOI 10.1103/PhysRevB.17.535; Artemenko SN, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.125420; Artemenko SN, 2000, PHYS REV LETT, V84, P5184, DOI 10.1103/PhysRevLett.84.5184; ARTEMENKO SN, 1995, PHYS REV LETT, V75, P497, DOI 10.1103/PhysRevLett.75.497; Ayari A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.235119; BATISTIC I, 1984, J PHYS-PARIS, V45, P1049, DOI 10.1051/jphys:019840045060104900; BRAZOVSKII S, 1991, J PHYS I, V1, P1173; BRAZOVSKII S, 1992, J PHYS I, V2, P409; Brazovskii S, 2000, PHYS REV B, V61, P10640, DOI 10.1103/PhysRevB.61.10640; DUAN JM, 1993, PHYS REV B, V48, P4860, DOI 10.1103/PhysRevB.48.4860; FEINBERG D, 1988, J PHYS-PARIS, V49, P485, DOI 10.1051/jphys:01988004903048500; FUKUYAMA H, 1976, J PHYS SOC JPN, V41, P513, DOI 10.1143/JPSJ.41.513; GORKOV LP, 1968, SOV PHYS JETP-USSR, V27, P328; Gor'kov L. P., 1984, Soviet Physics - JETP, V59; GORKOV LP, 1983, JETP LETT+, V38, P87; Hatakenaka N., 1998, PHYS REV B, V57, P2003; Hayashi M, 2010, PHYSICA C, V470, pS962, DOI 10.1016/j.physc.2009.12.054; Hayashi M., UNPUB; Hayashi M, 2012, J PHYS CONF SER, V400, DOI 10.1088/1742-6596/400/1/012015; Kirova N, 2009, J SUPERCOND NOV MAGN, V22, P559, DOI 10.1007/s10948-009-0467-8; Mantel OC, 2000, PHYS REV LETT, V84, P538, DOI 10.1103/PhysRevLett.84.538; Markovic N, 2000, PHYS REV LETT, V84, P534, DOI 10.1103/PhysRevLett.84.534; O'Neill K, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.066601; ONG NP, 1985, PHYS REV B, V32, P6582, DOI 10.1103/PhysRevB.32.6582; ONG NP, 1984, PHYS REV LETT, V52, P663, DOI 10.1103/PhysRevLett.52.663; RAMAKRISHNA S, 1992, PHYS REV LETT, V68, P2066, DOI 10.1103/PhysRevLett.68.2066; Sinchenko AA, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.046402; Takane Y, 2001, J PHYS SOC JPN, V70, P1869, DOI 10.1143/JPSJ.70.1869; Takane Y, 2003, J PHYS SOC JPN, V72, P1835, DOI 10.1143/JPSJ.72.1835; Takane Y, 2005, J PHYS SOC JPN, V74, P847, DOI 10.1143/JPSJ.74.847; Takane Y, 2002, J PHYS SOC JPN, V71, P1824, DOI 10.1143/JPSJ.71.1824; Takane Y, 2002, J PHYS SOC JPN, V71, P1019, DOI 10.1143/JPSJ.71.1019; Tinkham M., 1966, SUPERCONDUCTIVITY; Yi T, 2012, PHYSICA B, V407, P1839, DOI 10.1016/j.physb.2012.01.044; Yi TY, 2012, J SUPERCOND NOV MAGN, V25, P1323, DOI 10.1007/s10948-012-1603-4; Zhang H, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.125134	41	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		6	10		10.1016/j.physb.2014.11.029		5	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300003		
J	Matsuura, T; Hara, J; Inagaki, K; Tsubota, M; Hosokawa, T; Tanda, S				Matsuura, T.; Hara, J.; Inagaki, K.; Tsubota, M.; Hosokawa, T.; Tanda, S.			Melted discommensuration of charge density waves	PHYSICA B-CONDENSED MATTER			English	Article						Charge density wave; soliton; Shapiro step	SHAPIRO STEPS; TAS3; INTERFERENCE; TRANSITION; TRANSPORT; CRYSTALS; NBSE3	We investigate the charge density wave transport on the quasi one-dimensional system, orthorhombic tantalum trisulfide (o-TaS3), by applying a radio-frequency ac voltage. New ac-dc interference spectrum is observed in the differential conductance, which appears at both sides of the zero-bias peak. The frequency and amplitude dependences of the new spectrum do not correspond to those orally conventional ac-dc interference spectrum, namely integer and fractional Shapiro steps. The results suggest that there are unconventional internal degrees of freedom in the CDW. We propose that randomly distributed 2 pi phase solitons contribute electrical conduction when both ac and dc voltages are applied. Our results provide a new insight for a general understanding of CDW dynamics. (C) 2014 Elsevier B.V. All rights reserved.	[Matsuura, T.; Hara, J.; Hosokawa, T.; Tanda, S.] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan; [Matsuura, T.; Tanda, S.] Hokkaido Univ, Ctr Educ & Res Topol Sci & Technol, Sapporo, Hokkaido 0608628, Japan; [Inagaki, K.] Asahikawa Med Univ, Dept Phys, Asahikawa, Hokkaido 0788510, Japan; [Tsubota, M.] Hokkaido Univ, Div Quantum Sci & Engn, Sapporo, Hokkaido 0608628, Japan	Matsuura, T (reprint author), Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan.	toru@eng.hokudai.ac.jp					Sivakov AG, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.267001; SHAPIRO S, 1963, PHYS REV LETT, V11, P80, DOI 10.1103/PhysRevLett.11.80; Monceau P, 2012, ADV PHYS, V61, P325, DOI 10.1080/00018732.2012.719674; MCMILLAN WL, 1976, PHYS REV B, V14, P1496, DOI 10.1103/PhysRevB.14.1496; Matsuura T, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.014304; Tsubota M, 2009, PHYSICA B, V404, P416, DOI 10.1016/j.physb.2008.11.066; THOMPSON AH, 1981, PHYS REV LETT, V47, P64, DOI 10.1103/PhysRevLett.47.64; Bikiakovic K., 1989, SYNTHETIC MET, V29, pF289; BROWN SE, 1984, PHYS REV LETT, V52, P2277, DOI 10.1103/PhysRevLett.52.2277; Inagaki K, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.093708; Latyshev Yu. I., 1987, JETP LETT, V46; MAHER MP, 1991, PHYS REV B, V43, P9968, DOI 10.1103/PhysRevB.43.9968; MONCEAU P, 1980, PHYS REV LETT, V45, P43, DOI 10.1103/PhysRevLett.45.43; OKWAMOTO Y, 1979, J PHYS SOC JPN, V46, P1420, DOI 10.1143/JPSJ.46.1420; Ringland KL, 2000, PHYS REV B, V61, P4405, DOI 10.1103/PhysRevB.61.4405; SAMBONGI T, 1977, SOLID STATE COMMUN, V22, P729, DOI 10.1016/0038-1098(77)90055-2; Simmonds RW, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.035301; Tsubota M, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/57011; TSUTSUMI K, 1978, J PHYS SOC JPN, V44, P1735, DOI 10.1143/JPSJ.44.1735; Van Look L, 1999, PHYS REV B, V60, pR6998, DOI 10.1103/PhysRevB.60.R6998; Zaitsev-Zotov SV, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.266404	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		30	33		10.1016/j.physb.2014.11.034		4	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300008		
J	Nomura, K; Yamamoto, M; Matsunaga, N; Hirose, S; Shimohara, N; Satoh, T; Isome, T; Liu, Y; Kawamoto, A				Nomura, K.; Yamamoto, M.; Matsunaga, N.; Hirose, S.; Shimohara, N.; Satoh, T.; Isome, T.; Liu, Y.; Kawamoto, A.			Coexistence of charge order and antiferromagnetism in (TMTTF)(2)SbF6: NMR study	PHYSICA B-CONDENSED MATTER			English	Article						Charge order; Antiferromagnetism; NMR; Quasi-one-dimensional conductor	CONDUCTORS; H-1-NMR; SALTS; SDW	The electronic state of (TMTTF)(2)SbF6 was investigated by the H-1 and C-13 NMR measurements. The temperature dependence of T-1(-1) in H-1 NMR shows a sharp peak associated with the antiferromagnetic transition at T-AF = 6 K. The temperature dependence of T-1(-1) is described by the power law T-2.4 below T-A. This suggests the nodal gapless spin wave excitation in antiferromagnetic phase. In 13C NMR, two sharp peaks at high temperature region, associated with the inner and the outer carbon sites in TMTTF dimer, split into four peaks below 150 K. It indicates that the charge disproportionation occurs. The degree of charge disproportionation Delta rho is estimated as (025 +/- 0.09)e from the chemical shift difference. This value Delta rho is consistent with that obtained from the infrared spectroscopy. In the antiferromagnetic state (AFI), the observed line shape is well fitted by eight Lorentzian peaks. This suggests that the charge order with the same degree still remains in the AF state. From the line assignment, the AF staggered spin amplitude is obtained as 0.70 mu(B) and 0.24 mu(B) at the charge rich and the poor sites, respectively. These values corresponding to almost 1 mu(B) per (timer are quite different from 0.11 mu(B) of another AF (AFII) state in (TMITF)(2)Br with effective higher pressure. As a result, it is understood that the antiferromagnetic staggered spin order is stabilized on the CO state in the AFI phase of (TMTTF)2(S)bF(6). (C) 2014 Elsevier B.V. All rights reserved	[Nomura, K.; Yamamoto, M.; Matsunaga, N.; Hirose, S.; Shimohara, N.; Satoh, T.; Isome, T.; Liu, Y.; Kawamoto, A.] Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan	Nomura, K (reprint author), Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan.	knmr@phys.sci.hokudai.ac.jp			Ministry of Education, Culture, Sports, Science and Technology [25610083]	We would like to thank Mr. Y. Oka for a valuable discussion. This work was supported in part by a Grant-in-Aid for Science Research (Grant no. 25610083) from the Ministry of Education, Culture, Sports, Science and Technology.	Dumm M, 2004, J PHYS IV, V114, P57, DOI 10.1051/jp4:2004114010; Fujiyama S, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.014705; JEROME D, 1991, SCIENCE, V252, P1509, DOI 10.1126/science.252.5012.1509; TAKAHASHI T, 1986, PHYSICA B & C, V143, P417, DOI 10.1016/0378-4363(86)90155-5; Chow DS, 2000, PHYS REV LETT, V85, P1698, DOI 10.1103/PhysRevLett.85.1698; Matsunaga N, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.144415; Seo H, 1997, J PHYS SOC JPN, V66, P1249, DOI 10.1143/JPSJ.66.1249; Miyagawa K, 2000, PHYS REV B, V62, pR7679, DOI 10.1103/PhysRevB.62.R7679; Yu W, 2004, J PHYS IV, V114, P35, DOI 10.1051/jp4:2004114006; COULON C, 1986, PHYS REV B, V33, P6235, DOI 10.1103/PhysRevB.33.6235; Dressel M, 2012, CRYSTALS, V2, P528, DOI 10.3390/cryst2020528; Hirose S, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.205107; Iwase F., 2011, PHYS REV, VB84; Matsunaga N., 2014, UNPUB; Nomura K, 1999, SYNTHETIC MET, V103, P2147, DOI 10.1016/S0379-6779(98)00617-1; Oka Y., 2014, UNPUB	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		53	57		10.1016/j.physb.2014.11.039		5	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300012		
J	Katono, K; Ichimura, K; Taniguchi, T; Kawashima, Y; Yamaya, K; Tanda, S				Katono, K.; Ichimura, K.; Taniguchi, T.; Kawashima, Y.; Yamaya, K.; Tanda, S.			Charge disproportionation in alpha-(BEDT-T1F)(2)X	PHYSICA B-CONDENSED MATTER			English	Article						Charge ordering; Organic conductors; STM	STATE	We performed scanning tunneling microscopy (STM) at room temperature on a - b surface of alpha-(BETD-TTF)(2)I-3 which undergoes a charge ordering transition at T-CO = 135 K. BEDT-TTF molecular arrangement with a-type was clearly observed. Charge modulation with two fold molecular periodicity was observed along both Columns I and II. The auto correlation of the charge modulation along Column II has extended in the area observed by STM. On the other hand, that along the column I is much weaker than column II although the charge modulation locally develop. The charge modulations along Columns I and II form horizontal stripe structure with some inhomogeneity, whose structure is similar to the charge order below T-CO 135 K. Our result suggests that horizontal charges stripe at room temperature is a precursor of the charge ordered state. (C) 2014 Elsevier B.V. All rights reserved	[Katono, K.; Ichimura, K.; Taniguchi, T.; Kawashima, Y.; Yamaya, K.; Tanda, S.] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan; [Ichimura, K.; Tanda, S.] Hokkaido Univ, Ctr Educ & Res Topol Sci & Technol, Sapporo, Hokkaido 0608628, Japan	Katono, K (reprint author), Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan.	k_katono@eng.hokudai.ac.jp			Japan Society for the Promotion of Science of Japan [24654095]	The authors are grateful to Dr. K. Yamamoto for providing the high quality single crystals. This work was supported by Grants-in-Aid for Challenging Exploratory Research (No. 24654095) from Japan Society for the Promotion of Science of Japan.	Hiraki K, 1998, PHYS REV LETT, V80, P4737, DOI 10.1103/PhysRevLett.80.4737; Yue Y, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.075134; Yamamoto K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.085110; Kakiuchi T, 2007, J PHYS SOC JPN, V76, DOI 10.1143/JPSJ.76.113702; Hanaguri T, 2004, NATURE, V430, P1001, DOI 10.1038/nature02861; COLEMAN RV, 1988, ADV PHYS, V37, P559, DOI 10.1080/00018738800101439; Ichimura K, 2009, PHYSICA B, V404, P570, DOI 10.1016/j.physb.2008.11.033; Kawai T, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.074711; Kawashima Y., SOLID STATE COMMUN, V16710; Mori E, 2012, J PHYS SOC JPN, V81, DOI 10.1143/JPSJ.81.014707; Moroto S, 2004, J PHYS IV, V114, P339, DOI 10.1051/jp4:2004114077; Nogami Y, 1999, SYNTHETIC MET, V102, P1778, DOI 10.1016/S0379-6779(98)00612-2	12	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		64	67		10.1016/j.physb.2014.11.041		4	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300014		
J	Naka, M; Hashimoto, H; Ishihara, S				Naka, Makoto; Hashimoto, Hiroshi; Ishihara, Sumio			Dynamical properties of interacting charge system on frustrated lattices	PHYSICA B-CONDENSED MATTER			English	Article						Charge order; Optical spectra; Photo-excitation	TRANSITION; LUFE2O4	Dynamical properties in interacting fermion systems on geometrically frustrated lattices are introduced. As a minimal model for the electronic charge order phenomena, we adopt the so-called spin-less fermion V-t model where the hoppings and interactions of spin-less fermions are taken into account in frustrated lattices. By analyzing this model, we examine (1) dielectric and optical properties in a double triangular lattice, (2) a collective excitation in a dimer-molecular system on a triangular lattice, and (3) a photoexcited state in a triangular lattice. We demonstrate that frustration effects influence directly dynamical properties in these charge systems, and explain successfully recent some experimental results. (C) 2014 Elsevier B.V. All rights reserved	[Naka, Makoto] RIKEN, Ctr Emergent Matter Sci, Wako, Saitama 3510198, Japan; [Hashimoto, Hiroshi; Ishihara, Sumio] Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan; [Ishihara, Sumio] Core Res Evolut Sci & Technol, Sendai, Miyagi 9808578, Japan	Ishihara, S (reprint author), Tohoku Univ, Dept Phys, Sendai, Miyagi 9808578, Japan.	ishihara@cmpr.phys.tohoku.ac.jp			Ministry of Education, Science and Culture of Japan [26287070]	We thank H. Seo, H. Matsueda, T. Watanabe, J. Nasu, K. lwano, K. Ishii, S. Iwai, N. Ikeda, T. Sasaki, S. Koshihara, and H. Okamoto for their helpful discussions. This work was supported by KAKENHI from the Ministry of Education, Science and Culture of Japan (No. 26287070). Some of the numerical calculations were performed using the supercomputing facilities at ISSP, the University of Tokyo.	Verwey EJW, 1941, PHYSICA, V8, P979, DOI 10.1016/S0031-8914(41)80005-6; ANDERSON PW, 1956, PHYS REV, V102, P1008, DOI 10.1103/PhysRev.102.1008; [Anonymous], 2006, J PHYS SOC JPN, V75; Seo H, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.051009; de Groot J, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.187601; Naka M, 2010, J PHYS SOC JPN, V79, DOI 10.1143/JPSJ.79.063707; Yamada Y, 1997, J PHYS SOC JPN, V66, P3733, DOI 10.1143/JPSJ.66.3733; Dayal S, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.245106; [Anonymous], 2010, J PHYS SOC JPN, V79; Yonemitsu K, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.075105; Ikeda N, 2005, NATURE, V436, P1136, DOI 10.1038/nature04039; Abdel-Jawad M, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.125119; Diep HT, 2005, FRUSTRATED SPIN SYSTEMS, P1, DOI 10.1142/9789812567819; Gomi H, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.035101; Hashimoto H, 2014, J PHYS SOC JPN, V83, DOI 10.7566/JPSJ.83.123703; Hotta C., 2010, PHYS REV B, V82; Hotta C, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.123704; Iwano K, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.106405; KINO H, 1995, J PHYS SOC JPN, V64, P1877, DOI 10.1143/JPSJ.64.1877; Merino J, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.125111; Nagano A., 2007, PHYS REV LETT, V99; Naka M, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.224441; Nasu K., 2004, PHOTOINDUCED PHASE T; Nishimoto S, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.035113; PARK TJ, 1986, J CHEM PHYS, V85, P5870, DOI 10.1063/1.451548; Prelovsek P., ARXIV11115931; Watanabe T, 2010, J PHYS SOC JPN, V79, DOI 10.1143/JPSJ.79.114714; Watanabe T, 2009, J PHYS SOC JPN, V78, DOI 10.1143/JPSJ.78.113702	28	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		68	72		10.1016/j.physb.2014.11.042		5	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300015		
J	Takehara, R; Miyagawa, K; Kanoda, K; Miyamoto, T; Matsuzaki, H; Okamoto, H; Taniguchi, H; Matsubayashi, K; Uwatoko, Y				Takehara, Ryosuke; Miyagawa, Kazuya; Kanoda, Kazushi; Miyamoto, Tatsuya; Matsuzaki, Hiroyuki; Okamoto, Hiroshi; Taniguchi, Hiromi; Matsubayashi, Kazuyuki; Uwatoko, Yoshiya			Electron transport in TTF-CA under High pressures	PHYSICA B-CONDENSED MATTER			English	Article						Neutral-ionic transition; TTF-CA; Resistivity measurements; High pressure	IONIC PHASE-TRANSITION; CHARGE-TRANSFER CRYSTAL; ORGANIC-CRYSTALS; PARA-CHLORANIL	We investigate the electron transport in the neutral-ionic transition material, tetrathialulvalene-p-chloranil (TTF-CA), under extremely high pressures up to 82.5 kbar, using a cubic anvil system. At room temperature, as pressure is applied, the resistivity steeply decreases in the neutral phase and exhibits a minimum followed by an increase, which reproduces the previously reported results. However, resistivity is found to become insensitive to pressure above 20 kbar, where the ionic phase is stabilized. The robust transport characteristics of the ionic phase is in contrast with the pressure-sensitive transport in the neutral phase. The temperature dependence of resistivity is insulating in the whole pressure range up to 82.5 kbar but shows breaks in the activation plot at certain temperatures, suggesting that some phase transition occurs in the ionic phase. (C) 2014 Elsevier B.V. All rights reserved.	[Takehara, Ryosuke; Miyagawa, Kazuya; Kanoda, Kazushi] Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan; [Miyamoto, Tatsuya; Matsuzaki, Hiroyuki; Okamoto, Hiroshi] Univ Tokyo, Dept Adv Mat Sci, Kashiwa, Chiba 2778561, Japan; [Taniguchi, Hiromi] Saitama Univ, Dept Phys, Saitama 3388570, Japan; [Matsubayashi, Kazuyuki; Uwatoko, Yoshiya] Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan	Kanoda, K (reprint author), Univ Tokyo, Dept Appl Phys, Bunkyo Ku, Tokyo 1138656, Japan.	kanoda@ap.t.u-tokyo.ac.jp	Matsubayashi, Kazuyuki/F-7696-2013		JSPS KAKENHI [20110002, 25220709, 24654101]	The authors thank N. Nagaosa, A. Maeda, F. Kagawa, M. Hosoda, T. Nishikawa, and K. Sunami for fruitful discussions, and also thank H. Uemura for preparing samples. This work was supported in part by JSPS KAKENHI under Grant Nos, 20110002, 25220709, and 24654101.	Kobayashi K, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.237601; TORRANCE JB, 1981, PHYS REV LETT, V46, P253, DOI 10.1103/PhysRevLett.46.253; LECOINTE M, 1995, PHYS REV B, V51, P3374, DOI 10.1103/PhysRevB.51.3374; Iwase F., UNPUB; LeCointe M, 1996, J MOL STRUCT, V374, P147, DOI 10.1016/0022-2860(95)08989-6; LemeeCailleau MH, 1997, PHYS REV LETT, V79, P1690, DOI 10.1103/PhysRevLett.79.1690; Matsuzaki H, 2005, J PHYS SOC JPN, V74, P2925, DOI 10.1143/JPSJ.74.2925; MCCONNEL.HM, 1965, P NATL ACAD SCI USA, V53, P46, DOI 10.1073/pnas.53.1.46; MITANI T, 1987, PHYS REV B, V35, P427, DOI 10.1103/PhysRevB.35.427; NAGAOSA N, 1986, J PHYS SOC JPN, V55, P2745, DOI 10.1143/JPSJ.55.2745; NAGAOSA N, 1986, J PHYS SOC JPN, V55, P2754, DOI 10.1143/JPSJ.55.2754; Oison V, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.035120; OKAMOTO H, 1989, PHYS REV B, V39, P10693, DOI 10.1103/PhysRevB.39.10693; Okamoto H., 1988, SYNTHETIC MET, V27, P189, DOI 10.1016/0379-6779(88)90143-9; Soos ZG, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.155119; TOKURA Y, 1986, SOLID STATE COMMUN, V57, P607, DOI 10.1016/0038-1098(86)90332-7	16	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		83	87		10.1016/j.physb.2014.11.045		5	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300018		
J	Oka, Y; Nobukane, H; Matsunaga, N; Nomura, K; Katono, K; Ichimura, K; Kawamoto, A				Oka, Y.; Nobukane, H.; Matsunaga, N.; Nomura, K.; Katono, K.; Ichimura, K.; Kawamoto, A.			STM spectroscopy on deuterated kappa-(ET-d[3,3])(2)Cu[N(Cn)(2)]Br	PHYSICA B-CONDENSED MATTER			English	Article						Organic superconductor; STM/STS; Mechanism of superconductivity		We performed the STM Spectroscopy (STS) measurement on organic superconductor deuterated kappa-(ET-d[3,3])(2)Cu[N(CN)(2)]Br to clarify the mechanism of superconductivity. The mechanism of superconductivity in kappa-ET2X is predicted as the spin fluctuation mechanism where the gap symmetry changes from d(x2-y2) to d(xy) with increasing the electron correlation. In previous STS measurements, we found that d[2,2]-Br, d[0,0]-Br and Cu(NCS)(2) were d-wave superconductors and the symmetry was described by the d(x2-y2). The electron correlation of these salts is still weak in the frame of the spin fluctuation model. So, we investigated the d[3,3]-Br which located at stronger electron correlation region than the previously studied salts by the STS. We also investigated the STS on the cut lateral surfaces by the focused ion beam (FIB) method to measure the in-plane anisotropy of superconducting gap in more detail as well as the asgrown surfaces, It was found from the result that d[3,3]-Br was d-wave superconductor and the gap symmetry was d(x2-y2) as well as the previously studied ET salts. Therefore, d[3,3]-Br is also still weak in spite of stronger electron correlation than other ET salts. On the other hand, we also observed the two-type superconducting gaps which are the nodal and anti-nodal type gaps at the same angle surface. This suggests the coexistence of d(x2-y2) and d(xy). It may be the evidence of the change from d(x2-y2) to d(xy) caused by the locally stronger electron correlation around the anti-ferromagnetic insulating region. (C) 2014 Elsevier B.V. All rights reserved.	[Oka, Y.; Nobukane, H.; Matsunaga, N.; Nomura, K.; Kawamoto, A.] Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 060, Japan; [Katono, K.; Ichimura, K.] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 060, Japan	Oka, Y (reprint author), Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 060, Japan.	okapi0809@mail.sci.hokudai.ac.jp			Ministry of Education, Culture, Sports, Science and Technology [25610083]	This study was supported in part by a Grant-in-Aid for Science Research (Grant no. 25610083) from the Ministry of Education, Culture, Sports, Science and Technology.	Ichimura K, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.114707; Kashiwaya S, 2000, REP PROG PHYS, V63, P1641, DOI 10.1088/0034-4885/63/10/202; Arai T, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.104518; Kuroki K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.100516; ANZAI H, 1995, J CRYST GROWTH, V154, P145, DOI 10.1016/0022-0248(95)00144-1; Ichimura K, 2006, J PHYS SOC JPN, V75, DOI 10.1143/JPSJ.75.051012; Kanoda K, 1997, HYPERFINE INTERACT, V104, P235, DOI 10.1023/A:1012696314318; Kawamoto A, 1998, J AM CHEM SOC, V120, P10984, DOI 10.1021/ja9827292; Oka Y, 2012, J PHYS CONF SER, V400, DOI 10.1088/1742-6596/400/2/022090	9	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		93	95		10.1016/j.physb.2014.11.047		3	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300020		
J	Kanno, T; Matsumoto, T; Ichimura, K; Matsuura, T; Tanda, S				Kanno, T.; Matsumoto, T.; Ichimura, K.; Matsuura, T.; Tanda, S.			Metal-insulator transition in iron doped 2H-TaSe2: Suggestion of chiral unitary localization	PHYSICA B-CONDENSED MATTER			English	Article						Quantum phase transition; Anderson localization; Low-dimensional conductor	WEAK-LOCALIZATION; CONDUCTANCE	We investigated the conduction of electrons in a quasi two-dimensional random magnetic field (RMF) system, namely iron-doped transition metal dichalcogenide 2H-FexTa1-xSe2. We observed a clear metal-insulator transition by increasing the Fe doping rate. The temperature dependence of the resistances is consistent with the unitary class of Anderson localization. However, the observed critical sheet resistance is between 2 and 19 k Omega, which is inconsistent with the unitary class (2h/e(2) = 51.6 k Omega). We propose that chiral symmetry can be present in 2H-FexTa1-xSe2 because the magnetoresistance of the crystals is similar to that of dirty graphites. (C) 2014 Elsevier B.V. All rights reserved.	[Kanno, T.; Matsumoto, T.; Ichimura, K.; Matsuura, T.; Tanda, S.] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan; [Ichimura, K.; Matsuura, T.; Tanda, S.] Hokkaido Univ, Ctr Educ & Res Topol Sci & Technol, Sapporo, Hokkaido 0608628, Japan	Kanno, T (reprint author), Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan.	t_kanno@ec.hokudai.ac.jp					Gusynin VP, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146801; Ostrovsky PM, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.235443; ABRAHAMS E, 1979, PHYS REV LETT, V42, P673, DOI 10.1103/PhysRevLett.42.673; GADE R, 1993, NUCL PHYS B, V398, P499, DOI 10.1016/0550-3213(93)90601-K; HIKAMI S, 1980, PROG THEOR PHYS, V63, P707, DOI 10.1143/PTP.63.707; Castro Neto AH, 2001, PHYS REV LETT, V86, P4382, DOI 10.1103/PhysRevLett.86.4382; BERGMANN G, 1984, PHYS REP, V107, P1, DOI 10.1016/0370-1573(84)90103-0; KOIKE Y, 1985, J PHYS SOC JPN, V54, P713, DOI 10.1143/JPSJ.54.713; Konig EJ, 2012, PHYS REV B, V85, DOI 10.1103/PhysRevB.85.195130; Kordyuk A.A., 2010, ARXIV10031976; LEE DH, 1992, PHYS REV LETT, V68, P2386, DOI 10.1103/PhysRevLett.68.2386; Markos P, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.115318; Markos P, 2006, J PHYS A-MATH GEN, V39, P3221, DOI 10.1088/0305-4470/39/13/003; Schweitzer L, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.205419	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		165	167		10.1016/j.physb.2014.11.061		3	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300034		
J	Nobukane, H; Matsuyama, T; Tanda, S				Nobukane, Hiroyoshi; Matsuyama, Toyoki; Tanda, Satoshi			Topological electromagnetic response in the chiral superconductor Sr2RuO4	PHYSICA B-CONDENSED MATTER			English	Article						Chiral superconductivity; Topological magneto-electric effect; Chern structure; Fractionalization	SPIN; STATISTICS; PARITY	We report the observation of a fractional topological magneto-electric effect in Sr2RuO4 single crystal thin films by measuring the electric transport properties. In the absence of an external magnetic held, the surface transport in Sr2RuO4 thin films exhibited a fractional quantum Hall conductance in the superconducting state. The fractional magnetic-held-induced electric polarization was observed under zero bias current. We can understand the fractional quantum Hall conductance as a consequence of the observation of the (2 + 1)-dimensional topological surface state in the (3 + 1)-dimensional fractional topological magneto-electric effect in Sr2RuO4 thin films. (C) 2014 Elsevier B.V. All rights reserved.	[Nobukane, Hiroyoshi] Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan; [Matsuyama, Toyoki] Nara Univ Educ, Dept Phys, Nara 6308528, Japan; [Tanda, Satoshi] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 060S628, Japan; [Nobukane, Hiroyoshi; Matsuyama, Toyoki; Tanda, Satoshi] Hokkaido Univ, Ctr Educ & Res Topol Sci & Technol, Sapporo, Hokkaido 060862S, Japan	Nobukane, H (reprint author), Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan.	nobukane@sci.hokudai.ac.jp			JSPS KAKENHI [25800183]; Takayanagi Memorial Foundation	We thank Y. Asano, K. Inagaki, T. Honma, K. lchimura, S. Takayanagi, K. Yamaya, N. Matsunaga, K. Nomura for experimental help and useful discussions. This work was supported by JSPS KAKENHI (No. 25800183) and Takayanagi Memorial Foundation.	Lutchyn RM, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.104508; Ivanov DA, 2001, PHYS REV LETT, V86, P268, DOI 10.1103/PhysRevLett.86.268; Qi XL, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.195424; Read N, 2000, PHYS REV B, V61, P10267, DOI 10.1103/PhysRevB.61.10267; Qi XL, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.134519; Jang J, 2011, SCIENCE, V331, P186, DOI 10.1126/science.1193839; Goryo J, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.060501; Goryo J, 1999, PHYS LETT A, V260, P294, DOI 10.1016/S0375-9601(99)00538-1; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; MATSUYAMA T, 1987, PROG THEOR PHYS, V77, P711, DOI 10.1143/PTP.77.711; Mineev VP, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.212501; Nobukane H, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.144502; Nobukane H, 2009, SOLID STATE COMMUN, V149, P1212, DOI 10.1016/j.ssc.2009.04.022; Nobukane H, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.020209; TSUI DC, 1982, PHYS REV LETT, V48, P1559, DOI 10.1103/PhysRevLett.48.1559; Volovik G. E., 1988, Soviet Physics - JETP, V67; Volovik G. E., 2003, UNIVERSE HELIUM DROP; VOLOVIK GE, 1989, J PHYS-CONDENS MAT, V1, P5263, DOI 10.1088/0953-8984/1/31/025; Wilczek F., 1990, FRACTIONAL STAT ANYO; Yakovenko VM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.087003	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		168	170		10.1016/j.physb.2014.11.062		3	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300035		
J	Hosokawa, T; Matsuura, T; Tsubota, M; Tanda, S				Hosokawa, T.; Matsuura, T.; Tsubota, M.; Tanda, S.			Hysteretic current switching phenomena in TaS3 ring crystals	PHYSICA B-CONDENSED MATTER			English	Article						Ring crystal; CDW; TaS3	CHARGE-DENSITY	We have investigated the time fluctuation of the charge density wave current in TaS3 ring crystals. The CDW current fluctuates between two discrete current values when a constant dc voltage is applied. We measured dc voltage dependence of the current switching. We discovered that the CDW current has the high current dominant regime and the low current dominant regime, and a hysteresis between the two regimes as a function of dc voltage. (C) 2014 Elsevier B.V. All rights reserved.	[Hosokawa, T.; Matsuura, T.; Tanda, S.] Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan; [Matsuura, T.; Tanda, S.] Hokkaido Univ, Ctr Educ & Res Topol Sci & Technol, Sapporo, Hokkaido 0608628, Japan; [Tsubota, M.] Hokkaido Univ, Div Quantum Sci & Engn, Sapporo, Hokkaido 0608628, Japan	Hosokawa, T (reprint author), Hokkaido Univ, Dept Appl Phys, Sapporo, Hokkaido 0608628, Japan.	thosokcawa@ec.hokudai.ac.jp					BARDEEN J, 1980, PHYS REV LETT, V45, P1978, DOI 10.1103/PhysRevLett.45.1978; AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; Shpyrko OG, 2007, NATURE, V447, P68, DOI 10.1038/nature05776; Miller JH, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.036404; THOMPSON AH, 1981, PHYS REV LETT, V47, P64, DOI 10.1103/PhysRevLett.47.64; MAKI K, 1977, PHYS REV LETT, V39, P46, DOI 10.1103/PhysRevLett.39.46; SAMBONGI T, 1977, SOLID STATE COMMUN, V22, P729, DOI 10.1016/0038-1098(77)90055-2; Tsubota M, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/57011; TSUTSUMI K, 1978, J PHYS SOC JPN, V44, P1735, DOI 10.1143/JPSJ.44.1735	9	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		171	173		10.1016/j.physb.2014.11.063		3	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300036		
J	Murata, K; Fukumoto, Y; Yokogawa, K; Kang, W; Takaoka, R; Tada, R; Hirayama, H; Brooks, JS; Graf, D; Yoshino, H; Sasaki, T; Kato, R				Murata, Keizo; Fukumoto, Yuhei; Yokogawa, Keiichi; Kang, Woun; Takaoka, Ryo; Tada, Ryota; Hirayama, H.; Brooks, James S.; Graf, David; Yoshino, Harukazu; Sasaki, Takahiko; Kato, Reizo			Possible quantum Hall effect in a magnetic-field-induced phase transition in the quasi-one-dimensional CDW organic conductor, HMTSF-TCNQ	PHYSICA B-CONDENSED MATTER			English	Article						Charge density wave (CDW); Magnetic-field-induced-CDW; HMTSF-TCNQ		We have studied the angular dependence of magnetoresistance and Hall effect of the CDW organic conductor, HMTSF-TCNQ in order to see whether a magnetic-field-induced phase exists in the charge density wave (CDW) system, similarly to the magnetic-field-induced SDW phases in (TMTSF)(2)X. The anomaly in magnetoresistance was observed only around the pressure where the CDW is almost suppressed, i.e. around 0.8-1.1 GPa, but neither at low pressures (0 and 0.5 GPa) nor at high pressure above 2 GPa. This behavior is quite similar to that of (TMTSF)(2)X. At 1.1 GPa anomalies were found at fields of 0.2 T and 10 T. We speculate that at 1.1 GPa the field-induced phase is located between 0.2 T and 10 T, where 1D Fermi surface sheet and 20 Fermi-surface pocket are present. The R-xy shows plateau structure and R-xx was very small in the same region, suggestive of quantum Hall effect. (C) 2014 Elsevier B.V. All rights reserved.	[Murata, Keizo; Fukumoto, Yuhei; Yokogawa, Keiichi; Takaoka, Ryo; Tada, Ryota; Hirayama, H.; Yoshino, Harukazu] Osaka City Univ, Grad Sch Sci, Sumiyoshi Ku, Osaka 5588585, Japan; [Kang, Woun] Ewha Womans Univ, Seoul 120750, South Korea; [Sasaki, Takahiko] Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32306 USA; [Sasaki, Takahiko] Tohoku Univ, Inst Mat Res, Aoba Ku, Sendai, Miyagi 9808577, Japan; [Kato, Reizo] RIKEN, Wako, Saitama 3510198, Japan	Murata, K (reprint author), Osaka City Univ, Grad Sch Sci, Sumiyoshi Ku, Osaka 5588585, Japan.	muratak@sci.osaka-cu.ac.jp	Sasaki, Takahiko/F-1231-2010; Kato, Reizo/I-1073-2014	Sasaki, Takahiko/0000-0002-0767-5428; 	JSPS Inst. Prog. for Young Researcher Overseas Visits "Promoting International Young Researchers in Mathematics and Math. Sci. by OCAMI"; M. Education [23110722]; NSF DMR [1005293, 0654118]; National Research Foundation of Korea (NRF) - Korean Government (MSIP) [2011-0030902, 2010-00453, 2008-0061893]; State of Florida;  [09H0072];  [10H0005];  [11H0046]	This work was carried out at the National High Magnetic Field Laboratory at Tallahassee, USA, starting from the preliminary work performed at High Field Laboratory for Superconducting Materials, Institute for Materials Research, Tohoku University (Project nos, 09H0072, 10H0005, and 11H0046).; This work is partially supported JSPS Inst. Prog. for Young Researcher Overseas Visits "Promoting International Young Researchers in Mathematics and Math. Sci. by OCAMI" and Grant-in-Aid Sci. Res, on Innovative Areas #23110722 from M. Education and NSF DMR#1005293 (FSU), W.K. was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Korean Government (MSIP) (Nos. 2011-0030902, 2010-00453 and 2008-0061893). Work at the NHMFL is supported by the NSF DMR#0654118, and by the State of Florida. To achieve this experiment, the assistance of A. Kiswandhi, S. Benjamin, L. Winter of the Brooks group was indispensable. We appreciate Prof. H. Fujiwara of Osaka Prefecture University for the X-ray examination for selecting high quality crystals.	Andres D, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.201101; Chaikin P., 1996, J PHYS, V16, P187; Jerome D, 2002, ADV PHYS, V51, P293, DOI 10.1080/00018730110116362; Jerome D., 1980, J PHYS LETT, V41, P95, DOI DOI 10.1051/JPHYSLET:0198000410409500; Lebed AG, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.046401; Murata K, 2014, LOW TEMP PHYS+, V40, P371, DOI 10.1063/1.4869591; Murata K, 1997, REV SCI INSTRUM, V68, P2490, DOI 10.1063/1.1148145; Murata K., 2014, J MOD PHYS, V5, P673; PHILLIPS TE, 1976, J CHEM SOC CHEM COMM, P334, DOI 10.1039/c39760000334; WEGER M, 1976, SOLID STATE COMMUN, V19, P1149, DOI 10.1016/0038-1098(76)90120-4; WEYL C, 1976, SOLID STATE COMMUN, V19, P925, DOI 10.1016/0038-1098(76)90688-8	11	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0921-4526	1873-2135		PHYSICA B	Physica B	MAR 1	2015	460				SI		241	244		10.1016/j.physb.2014.11.080		4	Physics, Condensed Matter	Physics	CD1BI	WOS:000350808300052		
J	Zhang, L; Tatsuno, T; Hasegawa, I; Tadano, T; Ohta, T				Zhang, Li; Tatsuno, Takanori; Hasegawa, Isao; Tadano, Takeshi; Ohta, Tomihisa			Furanonaphthoquinones from Tabebuia avellanedae induce cell cycle arrest and apoptosis in the human non-small cell lung cancer cell line A549	PHYTOCHEMISTRY LETTERS			English	Article						Tabebuia avellanedae; Furanonaphthoquinone; Anti-cancer; Apoptosis; Cell cycle	BETA-LAPACHONE; ANTICANCER AGENTS; GROWTH-INHIBITION; DOWN-REGULATION; BCL-2 FAMILY; NAPHTHOQUINONES; ACTIVATION; THERAPY; PROTEIN; DEATH	A series of furanonaphthoquinones based on the naphtho[2,3-b]furan-4,9-dione skeleton were obtained from water extract of the inner bark of Tabebuia avellanedae Lorentz ex Griseb. The chemical structure of the new compound (3) was determined by spectroscopic techniques. Compounds 2 and 3 produced cytotoxicity in A549, SiHa and MCF-7 cells at micromolar concentrations. In addition, results indicated that the position of the phenolic group is of great importance for increasing cytotoxic effect. Furthermore, cell cycle analysis was evaluated by PI staining and apoptosis was determined by annnexin-V FITC/PI staining using flow cytometry analysis. The results showed that compounds 2 and 3 induced the cell cycle arrest and apoptosis at G2/M phase in A549 cells. Investigation of the cyclin protein family members by Western blotting showed that cyclin A and cyclin B protein levels were strongly decreased with the increasing time of incubation with compounds 2 and 3, which may be the major factor that caused G2/M phase arrest. Reverse transcription polymerase chain reaction (RT-PCR) analysis demonstrated that following the exposure of A549 cells to compounds 2 and 3, the level of mRNA expressions of tumor suppressor P53 and apoptotic protein BAX was down-regulated. The caspase-3 enzyme activity was also higher in compounds 2 and 3 exposed A549 cells. Therefore, these furanonaphthoquinones isolated from T. avellanedae are promising leads for potential anticancer drugs. (C) 2014 Published by Elsevier B.V. on behalf of Phytochemical Society of Europe.	[Zhang, Li; Hasegawa, Isao; Tadano, Takeshi; Ohta, Tomihisa] Kanazawa Univ, Coll Med Pharmaceut Hlth Sci, Lab Environm & Hlth Sci, Kanazawa, Ishikawa 9201192, Japan; [Tatsuno, Takanori] Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan	Ohta, T (reprint author), Kanazawa Univ, Coll Med Pharmaceut Hlth Sci, Lab Environm & Hlth Sci, Kanazawa, Ishikawa 9201192, Japan.	ohta@p.kanazawa-u.ac.jp					Alonso J.R., 2004, CORPUS; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Subramanian S, 1998, STRUCT CHEM, V9, P47, DOI 10.1023/A:1022487632133; Kawabe T, 2004, MOL CANCER THER, V3, P513; UEDA S, 1994, PHYTOCHEMISTRY, V36, P323, DOI 10.1016/S0031-9422(00)97069-9; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Castellanos JRG, 2009, J ETHNOPHARMACOL, V121, P1, DOI 10.1016/j.jep.2008.10.004; Yamashita M, 2009, BIOORGAN MED CHEM, V17, P6286, DOI 10.1016/j.bmc.2009.07.039; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; DEOLIVEIRA AB, 1993, PHYTOCHEMISTRY, V34, P1409; BLOCK JB, 1974, CANCER CHEMOTH REP 2, V4, P27; Choi YH, 2003, J BIOCHEM MOL BIOL, V36, P223; de Miranda F G, 2001, BMC Pharmacol, V1, P6; de Santana C F, 1968, Rev Inst Antibiot (Recife), V8, P89; Foster I, 2008, RADIOGRAPHY, V14, P144, DOI 10.1016/j.radi.2006.12.001; GOSALVEZ M, 1976, CANCER TREAT REP, V60, P1; Lee JH, 2005, PHARMACOL RES, V51, P553, DOI 10.1016/j.phrs.2005.02.004; Lee J. I., 2006, Experimental Oncology, V28, P30; CONSOLACAO MD, 1975, J MED CHEM, V18, P1159; Lubeck W., 1998, HEALING POWER PAU AR; Maximov GK, 2008, BIOTECHNOL BIOTEC EQ, V22, P664; Mukherjee B, 2009, INT J MOL MED, V24, P253, DOI 10.3892/ijmm_00000228; Pereira Eliezer Menezes, 2006, Ann Clin Microbiol Antimicrob, V5, P5, DOI 10.1186/1476-0711-5-5; Queiroz MLS, 2008, J ETHNOPHARMACOL, V117, P228, DOI 10.1016/j.jep.2008.01.034; RAO MM, 1982, J NAT PROD, V45, P600, DOI 10.1021/np50023a014; Williams RB, 2006, PLANTA MED, V72, P564, DOI 10.1055/s-2006-931554; Woo HJ, 2006, J MED FOOD, V9, P161, DOI 10.1089/jmf.2006.9.161; Yamashita M, 2007, BIOORG MED CHEM LETT, V17, P6417, DOI 10.1016/j.bmcl.2007.10.005; Zhang Man, 2009, Pathophysiology, V16, P305, DOI 10.1016/j.pathophys.2009.02.004	35	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1874-3900	1876-7486		PHYTOCHEM LETT	Phytochem. Lett.	MAR	2015	11						9	17		10.1016/j.phytol.2014.09.013		9	Biochemistry & Molecular Biology; Plant Sciences	Biochemistry & Molecular Biology; Plant Sciences	CC7SQ	WOS:000350569100003		
J	Tanaka, H; Takaya, Y; Toyoda, J; Yasuda, T; Sato, M; Murata, J; Murata, H; Kaburagi, K; Iida, O; Sugimura, K; Sakai, E				Tanaka, Hitoshi; Takaya, Yoshiaki; Toyoda, Junya; Yasuda, Tadashi; Sato, Masaru; Murata, Jin; Murata, Hiroko; Kaburagi, Koichi; Iida, Osamu; Sugimura, Koji; Sakai, Eiji			Two new butanolides from the roots of Litsea acuminata	PHYTOCHEMISTRY LETTERS			English	Article						Litsea acuminata; Lauraceae; Butanolides; Licunolide A; Licunolide B; Cytotoxicity	ACTINODAPHNE-LONGIFOLIA; LACTONIC COMPOUNDS; LANCIFOLIA; ASSAY	Two new butanolides, licunolides A (1) and B (2), were isolated from the roots of Litsea acuminata, together with three known compounds: isolancifolide (3), longifolin (4), and sesquirose furan (5). The structures of compounds 1 and 2 were determined by spectroscopic studies (IR, MS, 1D and 2D NMR) and chemical evidence. This is the first report of 4-hydroxy-5-methylbutanolides with a C-10-side chain from a natural source. Longifolin (4) and sesquirose furan (5) showed a significant cytotoxicity against HeLa cell lines in vitro. (C) 2014 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.	[Tanaka, Hitoshi; Takaya, Yoshiaki; Toyoda, Junya] Meijo Univ, Fac Pharm, Tempaku Ku, Nagoya, Aichi 4688503, Japan; [Yasuda, Tadashi; Sato, Masaru] Asahi Univ, Sch Dent, Dept Oral Biol, Gifu 5010296, Japan; [Murata, Jin] Univ Tokyo, Bot Gardens, Grad Sch Sci, Bunkyo Ku, Tokyo 1120001, Japan; [Murata, Hiroko] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan; [Kaburagi, Koichi; Iida, Osamu; Sugimura, Koji] Natl Inst Biomed Innovat, Res Ctr Med Plant Resources, Tanegashima Div, Nakatate, Kagoshima 8913604, Japan; [Sakai, Eiji] Gifu Pharmaceut Univ, Gifu 5028585, Japan	Tanaka, H (reprint author), Meijo Univ, Fac Pharm, Tempaku Ku, Nagoya, Aichi 4688503, Japan.	hitoshi@meijo-u.ac.jp					Agrawal N, 2013, CHEM BIODIVERS, V10, P394, DOI 10.1002/cbdv.201100300; Agrawal N, 2011, CHEM BIODIVERS, V8, P223, DOI 10.1002/cbdv.200900408; Tominaga H, 1999, ANAL COMMUN, V36, P47, DOI 10.1039/a809656b; Miyamoto T, 2002, AVIAN DIS, V46, P10, DOI 10.1637/0005-2086(2002)046[0010:LPRDET]2.0.CO;2; KOMAE H, 1972, PHYTOCHEMISTRY, V11, P1181, DOI 10.1016/S0031-9422(00)88484-8; Gangwal M. L., 2012, International Journal of Chemical Sciences, V10, P519; HAYASHI N, 1972, CHEM IND-LONDON, P572; Liu R, 2013, BIOCHEM SYST ECOL, V50, P293, DOI 10.1016/j.bse.2013.04.008; Pupo MT, 1998, PHYTOCHEMISTRY, V48, P307, DOI 10.1016/S0031-9422(97)01089-3; Su YC, 2013, REC NAT PROD, V7, P27; Sulaiman SN, 2011, MOLECULES, V16, P3119, DOI 10.3390/molecules16043119; TAKEDA K, 1972, TETRAHEDRON, V28, P3757, DOI 10.1016/S0040-4020(01)93822-0; TANAKA H, 1989, PHYTOCHEMISTRY, V28, P952, DOI 10.1016/0031-9422(89)80155-4; TANAKA H, 1989, PHYTOCHEMISTRY, V28, P2516, DOI 10.1016/S0031-9422(00)98022-1; Tanaka H, 2009, J NAT MED, V63, P331, DOI 10.1007/s11418-009-0323-y; TANAKA H, 1989, PHYTOCHEMISTRY, V28, P1905, DOI 10.1016/S0031-9422(00)97884-1; TANAKA H, 1989, PHYTOCHEMISTRY, V28, P626, DOI 10.1016/0031-9422(89)80066-4; Tsai Ian-Lih, 2001, Planta Medica, V67, P865, DOI 10.1055/s-2001-18840	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1874-3900	1876-7486		PHYTOCHEM LETT	Phytochem. Lett.	MAR	2015	11						32	36		10.1016/j.phytol.2014.11.001		5	Biochemistry & Molecular Biology; Plant Sciences	Biochemistry & Molecular Biology; Plant Sciences	CC7SQ	WOS:000350569100007		
J	Tabata, A; Taniguchi, M; Shibano, M				Tabata, Akinori; Taniguchi, Masahiko; Shibano, Makio			Ecliptamines A-D, four new guanidine alkaloids from Eclipta prostrata L.	PHYTOCHEMISTRY LETTERS			English	Article						Guanidine alkaloid; Eclipta prostrata L.; Asteraceae; Cyclooxygenase	CARBOXYLIC-ACIDS; EXTRACTS; ALCOHOLS; ALBA	Four structurally unique guanidine alkaloids ecliptamines A-D (1-4) and one known analog (5) were isolated from the aerial parts of Eclipta prostrata (Asteraceae). Their structures were elucidated on the basis of spectroscopic analyses and chemical methods. The inhibitory activities of 1, 2 and 5 were assayed with respect to cyclooxygenase-1 (COX-1) and -2 (COX-2). Compound 5 showed moderate inhibitory activities against COX-1 and -2 with IC50 values of 3.0 x 10(-3) M and 8.3 x 10(-4) M, respectively, whereas aspirin as a positive control displayed the IC50 values of 4.2 x 10(-4) M (against COX-1) and 7.1 x 10(-4) M (against COX-2). (C) 2015 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.	[Tabata, Akinori; Taniguchi, Masahiko; Shibano, Makio] Osaka Univ Pharmaceut Sci, Takatsuki, Osaka 5691094, Japan	Shibano, M (reprint author), Osaka Univ Pharmaceut Sci, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.	shibano@gly.oups.ac.jp					Abdel-Kader MS, 1998, J NAT PROD, V61, P1202, DOI 10.1021/np970561c; Cong HJ, 2013, J NAT PROD, V76, P1351, DOI 10.1021/np400235s; Tewtrakul S, 2011, PHYTOTHER RES, V25, P1313, DOI 10.1002/ptr.3383; Goda Y, 2009, J NAT MED-TOKYO, V63, P58, DOI 10.1007/s11418-008-0275-7; Liu QM, 2012, FOOD CHEM TOXICOL, V50, P4016, DOI 10.1016/j.fct.2012.08.007; Diogo LC, 2009, BASIC CLIN PHARMACOL, V104, P293, DOI 10.1111/j.1742-7843.2008.00350.x; MORS WB, 1989, TOXICON, V27, P1003, DOI 10.1016/0041-0101(89)90151-7; Wiart C, 2004, FITOTERAPIA, V75, P68, DOI 10.1016/j.fitote.2003.07.013; Kunishima M, 2001, TETRAHEDRON, V57, P1551, DOI 10.1016/S0040-4020(00)01137-6; Arumachalam G., 2009, AFR J PHARM PHARMACO, V3, P97; Kusumi T, 2005, J SYN ORG CHEM JPN, V63, P1102; Raveesha K.A., 2013, INT J CHEM ANAL SCI, V4, P136; Ryu S, 2013, PLANTA MED, V79, P1031, DOI 10.1055/s-0032-1328767; Wagner H., 1986, PLANTA MED, V52, P370, DOI 10.1055/s-2007-969188	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1874-3900	1876-7486		PHYTOCHEM LETT	Phytochem. Lett.	MAR	2015	11						224	228		10.1016/j.phytol.2015.01.001		5	Biochemistry & Molecular Biology; Plant Sciences	Biochemistry & Molecular Biology; Plant Sciences	CC7SQ	WOS:000350569100041		
J	Fuentes, RG; Toume, K; Arai, MA; Sadhu, SK; Ahmed, F; Ishibashi, M				Fuentes, Rolly G.; Toume, Kazufumi; Arai, Midori A.; Sadhu, Samir K.; Ahmed, Firoj; Ishibashi, Masami			Limonoids with Wnt signal inhibitory activity isolated from the fruits of Azadirachta excelsa	PHYTOCHEMISTRY LETTERS			English	Article						beta-Catenin; Limonoids; Adenomatous polyposis coli; Colorectal cancer	CHINESE MELIA-AZEDARACH; COLON-CANCER CELLS; BETA-CATENIN; PATHWAY; APC; TARGET; ANTIFEEDANTS; ACTIVATION	The Wnt signal regulates various biological processes, and its aberrant activation is associated with the development of diseases. Thus, inhibiting the Wnt signal provides a promising strategy to treat these diseases. Our cell-based luciferase assay system, which targets the Wnt signal (TOP assay), revealed that Azadirachta excelsa inhibited the Wnt signal. The activity-guided isolation of the MeOH fruit extract of A. excelsa provided one new (1) and seven known (2-8) limonoids. Their structures were elucidated based on their spectroscopic data, and their NMR data were compared with those in the literature. Compounds 3-6 potently inhibited the Wnt signal with IC50 values of 127 nM, 300 nM, 252 nM, and 121 nM, respectively. Compound 4 exhibited selective cytotoxicity against AGS and HCT116. Western blot analysis showed that 4 did not affect the level or localization of beta-catenin, but downregulated the level of c-myc. Our results suggested that 4 may have inhibited the Wnt signal by affecting the components downstream of beta-catenin. (C) 2015 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved.	[Fuentes, Rolly G.; Toume, Kazufumi; Arai, Midori A.; Ishibashi, Masami] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; [Sadhu, Samir K.] Khulna Univ, Sch Life Sci, Pharm Discipline, Khulna 9208, Bangladesh; [Ahmed, Firoj] Univ Dhaka, Dept Pharmaceut Chem, Dhaka 1000, Bangladesh; [Fuentes, Rolly G.] Univ Philippines, Visayas Tacloban Coll, Tacloban City 6500, Philippines	Ishibashi, M (reprint author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	mish@chiba-u.jp	Ahmed, Firoj/D-9276-2015; Ishibashi, Masami /E-5328-2015; Arai, Midori/O-4613-2015; Toume, Kazufumi/A-2632-2012	Ahmed, Firoj/0000-0003-0690-1451; Ishibashi, Masami /0000-0002-2839-1045; Toume, Kazufumi/0000-0002-3315-145X	Japan Society for the Promotion of Science (JSPS) [23102008, 26305001, 25870128]	This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (Grant Numbers, 23102008, 26305001 and 25870128). We are grateful to Prof. J. Nathans (John Hopkins University School of Medicine) for providing us with STF/293 cells and Prof. R.T. Moon (University of Washington) for the SuperFOPflash plasmid.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213; Zhang Y, 2012, PHYTOCHEMISTRY, V73, P106, DOI 10.1016/j.phytochem.2011.10.001; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; NAKATANI M, 1994, PHYTOCHEMISTRY, V36, P39, DOI 10.1016/S0031-9422(00)97008-0; Tan QG, 2011, CHEM REV, V111, P7437, DOI 10.1021/cr9004023; Ryu MJ, 2008, BIOCHEM BIOPH RES CO, V377, P1304, DOI 10.1016/j.bbrc.2008.10.171; Choi H, 2010, BIOCHEM BIOPH RES CO, V391, P915, DOI 10.1016/j.bbrc.2009.11.164; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Toume K, 2013, ORG LETT, V15, P6106, DOI 10.1021/ol4029995; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; ITOKAWA H, 1995, CHEM PHARM BULL, V43, P1171; Lindhagen E, 2008, NAT PROTOC, V3, P1364, DOI 10.1038/nprot.2008.114; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Park HY, 2014, CHEMBIOCHEM, V15, P872, DOI 10.1002/cbic.201300786; Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151; Li XF, 2009, CHEM-ASIAN J, V4, P540, DOI 10.1002/asia.200800354; HUANG RC, 1994, B CHEM SOC JPN, V67, P2468, DOI 10.1246/bcsj.67.2468; MACLEOD JK, 1990, J CHEM ECOL, V16, P2511, DOI 10.1007/BF01017474; OELRICHS PB, 1983, PHYTOCHEMISTRY, V22, P531, DOI 10.1016/0031-9422(83)83039-8	24	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1874-3900	1876-7486		PHYTOCHEM LETT	Phytochem. Lett.	MAR	2015	11						280	285		10.1016/j.phytol.2015.01.015		6	Biochemistry & Molecular Biology; Plant Sciences	Biochemistry & Molecular Biology; Plant Sciences	CC7SQ	WOS:000350569100052		
J	Suzuki, H; Oshita, E; Fujimori, N; Nakajima, Y; Kawagoe, Y; Suzuki, S				Suzuki, Hikaru; Oshita, Eri; Fujimori, Nozomi; Nakajima, Yuko; Kawagoe, Yumi; Suzuki, Shunji			Grape expansins, VvEXPA14 and VvEXPA18 promote cell expansion in transgenic Arabidopsis plant	PLANT CELL TISSUE AND ORGAN CULTURE			English	Article						Cell expansion; Expansin; Grape; VvEXPA14; VvEXPA18	BERRY SIZE; SEEDLESS GRAPEVINES; GENE-EXPRESSION; VITIS-VINIFERA; GROWTH; THALIANA; SUPERFAMILY; MATURATION; PROTEINS; BINDING	We herein report the molecular characterization of grape expansins, VvEXPA14 and VvEXPA18. VvEXPA14 and VvEXPA18 transcription was detected in grape berries at 2 weeks post flowering and their expression was upregulated during growth phase I, the period of rapid berry expansion. Experiments using VvEXPA14:GFP or VvEXPA18: GFP fusion proteins demonstrated that both expansins were localized at cell wall, suggesting that both expansins may function on cell wall. Transgenic tobacco cells overexpressing VvEXPA14 or VvEXPA18 exhibited cell expansion. In addition, VvEXPA14- or VvEXPA18-overexpressing Arabidopsis plants showed primary root elongation associated with cell expansion. VvEXPA14 overexpression enlarged rosette leaves in Arabidopsis transgenic plants, although the height of the plants remained unchanged. Since plant expansin play role in cell wall loosing and softening, these results underscore the possibility that VvEXPA14 and VvEXPA18 are involved in cell expansion and plant growth.	[Suzuki, Hikaru; Oshita, Eri; Fujimori, Nozomi; Nakajima, Yuko; Kawagoe, Yumi; Suzuki, Shunji] Univ Yamanashi, Inst Enol & Viticulture, Lab Fruit Genet Engn, Kofu, Yamanashi 4000005, Japan	Suzuki, S (reprint author), Univ Yamanashi, Inst Enol & Viticulture, Lab Fruit Genet Engn, Kofu, Yamanashi 4000005, Japan.	suzukis@yamanashi.ac.jp					Lee DK, 2003, PLANT PHYSIOL, V131, P985, DOI 10.1104/pp.009902; Houel C, 2013, AUST J GRAPE WINE R, V19, P208, DOI 10.1111/ajgw.12021; MCQUEENMASON SJ, 1995, PLANT PHYSIOL, V107, P87; SHCHERBAN TY, 1995, P NATL ACAD SCI USA, V92, P9245, DOI 10.1073/pnas.92.20.9245; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; NAGATA T, 1992, INT REV CYTOL, V132, P1; Choi DS, 2003, PLANT CELL, V15, P1386, DOI 10.1105/tpc.011965; Fasoli M, 2012, PLANT CELL, V24, P3489, DOI 10.1105/tpc.112.100230; Wieczorek K, 2006, PLANT J, V48, P98, DOI 10.1111/j.1365-313X.2006.02856.x; Roby G, 2004, AUST J GRAPE WINE R, V10, P100, DOI 10.1111/j.1755-0238.2004.tb00012.x; Schlosser J, 2008, PROTOPLASMA, V232, P255, DOI 10.1007/s00709-008-0280-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Kende H, 2004, PLANT MOL BIOL, V55, P311, DOI 10.1007/s11103-004-0158-6; Cho HT, 2000, P NATL ACAD SCI USA, V97, P9783, DOI 10.1073/pnas.160276997; Kobayashi H, 2009, PLANT BIOTECHNOL REP, V3, P225, DOI 10.1007/s11816-009-0095-6; Kohno M, 2012, MOL BIOL REP, V39, P911, DOI 10.1007/s11033-011-0816-0; Chervin C, 2008, PHYSIOL PLANTARUM, V134, P534, DOI 10.1111/j.1399-3054.2008.01158.x; Cho HT, 1997, PLANT PHYSIOL, V113, P1137, DOI 10.1104/pp.113.4.1137; Dal Santo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062206; Ezzahouani A, 1995, AM J ENOL VITICULT, V46, P559; Grimplet Jérôme, 2012, BMC Res Notes, V5, P213, DOI 10.1186/1756-0500-5-213; Ishimaru M, 2007, J PLANT PHYSIOL, V164, P1675, DOI 10.1016/j.jplph.2006.07.017; Lee HW, 2013, PLANT J, V73, P212, DOI 10.1111/tpj.12013; Platt C, 1971, AM J ENOL VITICULT, V22, P92; Sampedro J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-242; STAUDT G, 1986, ANN BOT-LONDON, V58, P789; Takato H, 2013, J PLANT PHYSIOL, V170, P591, DOI 10.1016/j.jplph.2012.11.011; Walker RR, 2005, AUST J GRAPE WINE R, V11, P2, DOI 10.1111/j.1755-0238.2005.tb00273.x; Williams LE, 2005, AGR FOREST METEOROL, V129, P85, DOI 10.1016/j.agrformet.2004.11.007	29	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0167-6857	1573-5044		PLANT CELL TISS ORG	Plant Cell Tissue Organ Cult.	MAR	2015	120	3					1077	1085		10.1007/s11240-014-0662-6		9	Biotechnology & Applied Microbiology; Plant Sciences	Biotechnology & Applied Microbiology; Plant Sciences	CC4CM	WOS:000350298400021		
J	Ogawa, R; Akaishi, S; Dohi, T; Kuribayashi, S; Miyashita, T; Hyakusoku, H				Ogawa, Rei; Akaishi, Satoshi; Dohi, Teruyuki; Kuribayashi, Shigehiko; Miyashita, Tsuguhiro; Hyakusoku, Hiko			Analysis of the Surgical Treatments of 63 Keloids on the Cartilaginous Part of the Auricle: Effectiveness of the Core Excision Method	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							HYPERTROPHIC SCARS; RADIATION-THERAPY; IRRADIATION; RECONSTRUCTION; BRACHYTHERAPY; RADIOTHERAPY; PREVENTION; PROTOCOL; RISK; FLAP	Background: Treatments for keloids on the cartilaginous part of the auricle (i.e., the upper part of the ear excluding the earlobe) include surgical excision, cryosurgery, postoperative radiation therapy, steroid injection, taping stabilization, and pressure therapy. However, to date, there is no universally accepted treatment strategy for auricle keloids. Methods: In this retrospective cohort study, the 63 primary auricle keloids in all 57 patients who underwent surgery from 2006 to 2012 were included. Mild scars such as hypertrophic scars were excluded. All 63 scars were treated with surgery, namely, total excision or intralesional excision (core excision method), and postoperative adjuvant radiation therapy and self-managed scar stabilization with surgical tape. The postsurgical radiation therapy consisted of 15 Gy administered in three fractions over 3 days. The recurrence rates associated with the two surgical methods over 18 months of follow-up were recorded. Results: Of the 57 patients, 91.2 percent were women. Of the 63 lesions, 95.2 percent and 4.8 percent were caused by piercing and trauma, respectively. All were primary keloids. Before 2009, all lesions (n = 37) were treated by total excision. After 2009, all lesions (n = 26) were treated by core excision. These methods were associated with recurrence rates of 8.1 percent and 0 percent, respectively, although this difference did not achieve statistical significance (p > 0.05). The overall recurrence rate was 4.8 percent. Complications such as wound dehiscence and pigmentation during the 18-month follow-up period were not observed. Conclusion: Auricle keloids can be treated by customized plans consisting of appropriate surgical modalities, postoperative radiotherapy, and self-management.	Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Tokyo 1138603, Japan; Nippon Med Coll Hosp, Dept Radiat Oncol, Tokyo, Japan	Ogawa, R (reprint author), Nippon Med Sch, Dept Plast Reconstruct & Aesthet Surg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	r.ogawa@nms.ac.jp					Ogawa R, 2010, PLAST RECONSTR SURG, V125, P557, DOI 10.1097/PRS.0b013e3181c82dd5; Har-Shai Y, 2003, PLAST RECONSTR SURG, V111, P1841, DOI 10.1097/01.PRS.0000056868.42679.05; Ogawa R, 2007, ANN PLAS SURG, V59, P688, DOI 10.1097/SAP.0b013c3180423b32; Ragoowansi R, 2001, BRIT J PLAST SURG, V54, P504, DOI 10.1054/bjps.2001.3656; Ogawa R, 2003, PLAST RECONSTR SURG, V111, P547, DOI 10.1097/01.PRS.0000040466.55214.35; Veen RE, 2007, INT J RADIAT ONCOL, V69, P1205, DOI 10.1016/j.ijrobp.2007.04.032; Ogawa R, 2009, PLAST RECONSTR SURG, V124, P1196, DOI 10.1097/PRS.0b013e3181b5a3ae; BILBEY JH, 1988, CHEST, V94, P1291, DOI 10.1378/chest.94.6.1291; Lee Y, 2001, ANN PLAS SURG, V46, P135, DOI 10.1097/00000637-200102000-00008; Gurtner GC, 2011, ANN SURG, V254, P217, DOI 10.1097/SLA.0b013e318220b159; Park TH, 2011, PLAST RECONSTR SURG, V128, P431, DOI 10.1097/PRS.0b013e31821e7006; Kim DY, 2004, PLAST RECONSTR SURG, V113, P1668, DOI 10.1097/01.PRS.0000117199.47891.4F; Collin E, 1929, ACTA RADIOL, V10, P186; DeBeurmann R, 1906, ANN DERMATOL SYPHIL, V7, P151; Dohi T, 2010, SCAR MANAGEMENT, V4, P75; Dooranbas FJ, 1990, RAD ONCOL BIOL PHYS, V18, P833; Fraunholz IB, 2005, STRAHLENTHER ONKOL, V181, P724, DOI 10.1007/s00066-005-1411-x; Har-Shai Y, 2010, PLAST RECONSTR SURG, V126, P1798, DOI 10.1097/PRS.0b013e3181ef823d; HOFFMAN S, 1982, ANN PLAS SURG, V9, P265, DOI 10.1097/00000637-198209000-00020; HORTON CE, 1953, PLAST RECONSTR SURG, V12, P86; Huang Chenyu, 2013, Plast Reconstr Surg Glob Open, V1, pe25, DOI 10.1097/GOX.0b013e31829c4597; Huang CY, 2012, ARCH DERMATOL RES, V304, P589, DOI 10.1007/s00403-012-1278-5; Kuribayashi S, 2011, J RADIAT RES, V52, P365, DOI 10.1269/jrr.10159; MAGUIRE HC, 1965, J AMER MED ASSOC, V192, P325; Malaker K, 2004, ANN PLAS SURG, V52, P602, DOI 10.1097/01.sap.0000095408.74866.fl; Ogawa R, 2012, WOUND REPAIR REGEN, V20, P149, DOI 10.1111/j.1524-475X.2012.00766.x; Ogawa R, 2003, PLAST RECONSTR SURG, V111, P554; Ogawa R, 2012, J WOUND TECHNOL, V15, P28; Ogawa R, 2013, PLAST RECONSTR SURG, V132, p818E, DOI 10.1097/PRS.0b013e3182a4c35e; Rustad KC, 2013, DIFFERENTIATION, V86, P87, DOI 10.1016/j.diff.2013.02.003; Simplot TC, 1998, AM J OTOLARYNG, V19, P305, DOI 10.1016/S0196-0709(98)90003-5; Sleilati F, 2006, J PLAST RECONSTR AES, V59, P1003, DOI 10.1016/j.bjps.2006.03.003; Sunohara M, 2012, AESTHET PLAST SURG, V36, P628, DOI 10.1007/s00266-011-9858-x; Tannir D, 2000, DERMATOL SURG, V26, P687, DOI 10.1046/j.1524-4725.2000.00047.x; VALENTA LJ, 1982, CLIN ENDOCRINOL, V17, P123, DOI 10.1111/j.1365-2265.1982.tb01572.x; Vivante H, 2007, INDIAN J DERMATOL VE, V73, P336	36	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	MAR	2015	135	3					868	875		10.1097/PRS.0000000000000962		8	Surgery	Surgery	CD0IO	WOS:000350754700065		
J	Kanao, M; Zhao, DP; Wiens, DA; Stutzmann, E				Kanao, Masaki; Zhao, Dapeng; Wiens, Douglas A.; Stutzmann, Eleonore			Recent advance in polar seismology: Global impact of the International Polar Year	POLAR SCIENCE			English	Article						International polar year; Polar seismology; Global impact; Arctic and Antarctic		The most exciting initiative for the recent polar studies was the International Polar Year (IPY) in 2007-2008. The IPY has witnessed a growing community of seismologists who have made considerable efforts to acquire high-quality data in polar regions. It also provided an excellent opportunity to make significant advances in seismic instrumentation of the polar regions to achieve scientific targets involving global issues. Taking these aspects into account, we organize and publish a special issue in Polar Science on the recent advance in polar seismology and cryoseismology as fruitful achievements of the IPY. (C) 2015 Elsevier B.V. and NIPR. All rights reserved.	[Kanao, Masaki] Grad Univ Adv Studies SOKENDAI, Natl Inst Polar Res, Res Org Informat & Syst, Tachikawa, Tokyo 1908518, Japan; [Zhao, Dapeng] Tohoku Univ, Dept Geophys, Sendai, Miyagi 9808578, Japan; [Wiens, Douglas A.] Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; [Stutzmann, Eleonore] Inst Phys Globe Paris, F-75238 Paris 05, France	Kanao, M (reprint author), Grad Univ Adv Studies SOKENDAI, Natl Inst Polar Res, Res Org Informat & Syst, 10-3 Midori Cho, Tachikawa, Tokyo 1908518, Japan.	kanao@nipr.ac.jp					Antonovskaya G, 2015, POLAR SCI, V9, P158, DOI 10.1016/j.polar.2014.08.003; Chiu K, 2015, POLAR SCI, V9, P130, DOI 10.1016/j.polar.2014.09.001; Eisen O, 2015, POLAR SCI, V9, P51, DOI 10.1016/j.polar.2014.10.003; Grad M, 2015, POLAR SCI, V9, P168, DOI 10.1016/j.polar.2014.11.001; Iwata T, 2015, POLAR SCI, V9, P26, DOI 10.1016/j.polar.2014.10.002; Krupnik I., 2011, UNDERSTANDING EARTH, P695; Melnik EA, 2015, POLAR SCI, V9, P119, DOI 10.1016/j.polar.2014.09.002; Murayama T, 2015, POLAR SCI, V9, P35, DOI 10.1016/j.polar.2014.07.005; Olivieri M, 2015, POLAR SCI, V9, P94, DOI 10.1016/j.polar.2014.09.004; Rapley C., 2004, FRAMEWORK INT POLAR, P57; Schlindwein V, 2015, POLAR SCI, V9, P146, DOI 10.1016/j.polar.2014.10.001; Shimizu H, 2015, POLAR SCI, V9, P17, DOI 10.1016/j.polar.2014.07.002; Shulgin A, 2015, POLAR SCI, V9, P107, DOI 10.1016/j.polar.2014.11.002; Storchak DA, 2015, POLAR SCI, V9, P5, DOI 10.1016/j.polar.2014.08.002; Toyokuni G, 2015, POLAR SCI, V9, P80, DOI 10.1016/j.polar.2014.12.001; Wilson T., 2011, UNDERSTANDING EARTHS, V2007-2008, P273; Wittlinger G, 2015, POLAR SCI, V9, P66, DOI 10.1016/j.polar.2014.07.006	17	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					1	4		10.1016/j.polar.2014.12.003		4	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700001		
J	Storchak, DA; Kanao, M; Delahaye, E; Harris, J				Storchak, Dmitry A.; Kanao, Masaki; Delahaye, Emily; Harris, James			Long-term accumulation and improvements in seismic event data for the polar regions by the International Seismological Centre	POLAR SCIENCE			English	Article						International Seismological Centre; Teleseismic events; Earthquake detectability; Polar regions; Global earthquake catalogue	EARTHQUAKE; ANTARCTICA; LOCATION; PLATE	The International Seismological Centre (ISC) is a non-governmental non-profit making organization funded by 62 research and operational institutions around the world and charged with the production of the ISC Bulletin - the definitive summary of the global seismicity based on reports from over 130 agencies worldwide, including those active in Polar regions. Jointly with the National Earthquake Information Center (NEIC) of the United States Geological Survey (USGS), the ISC runs the International Seismic Station Registry. The ISC is also charged with maintaining the International Association of Seismology and Physics of the Earth Interior (IASPEI) Reference event List. The new ISC product, the ISC Event Bibliography allows users to obtain references to scientific articles describing specific seismic events, natural and anthropogenic. In this paper we demonstrate how these products and services are applicable to seismic events both in Arctic and Antarctic regions. We also give a summary of the ISC data in polar regions and provide credit to Institutions that report these data to the ISC. (C) 2014 Elsevier B.V. and NIPR. All rights reserved.	[Storchak, Dmitry A.; Delahaye, Emily; Harris, James] Int Seismol Ctr, Thatcham RG19 4NS, Berks, England; [Kanao, Masaki] Res Org Informat & Syst, Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan; [Kanao, Masaki] Grad Univ Adv Studies SOKENDAI, Dept Polar Sci, Tachikawa, Tokyo 1908518, Japan	Kanao, M (reprint author), Res Org Informat & Syst, Natl Inst Polar Res, 10-3 Midori Cho, Tachikawa, Tokyo 1908518, Japan.	dmitry@isc.ac.uk; kanao@nipr.ac.jp; emily@isc.ac.uk; james@isc.ac.uk			ISC; Syowa Station; JSPS KAKENHI [26241010]	The authors express their sincere appreciation to all Members of ISC, the data contributors, funding agencies and sponsors for supporting the long term operations by the ISC. The authors are also grateful to all members of the NIPR, led by Prof. K. Shiraishi, Director-General. In particular, they acknowledge Profs. K. Kaminuma, K. Shibuya and Y. Nogi for their support of the operation of Syowa Station. We would like to show our special appreciation to Ms. A. Ibaraki of the Polar Data Centre, of NIPR, for her great efforts in interpretation of Syowa data for many years. The authors also express their sincere appreciation to Dr I. Bondar for providing figures on relocated seismicity and to Mrs M. Aspinwall of the ISC, for her careful proof reading and improvement of this manuscript. We would like to express our sincere appreciation to Dr. A. Reading of Tasmania University and one anonymous referee, for their critical reading and giving useful comments. Finally, the authors are grateful to Prof. K. Shibuya of NIPR as the Editor-in-Chief, and Prof. D. Zhao of Tohoku University as the guest-managing-editor of this special issue, for their great editorial endeavors in publishing this article in Polar Science. This work was partially supported by JSPS KAKENHI Grand Number 26241010 (P.I. by Dr. Masaki Kanao).	Adams R.D., 1982, ANTARCT GEOSCI, P955; ADAMS RD, 1985, GEOPHYS J ROY ASTR S, V81, P489, DOI 10.1111/j.1365-246X.1985.tb06416.x; Adams R.D., 1972, ANTARCTIC GEOLOGY GE, P495; Boger SD, 2011, GONDWANA RES, V19, P335, DOI 10.1016/j.gr.2010.09.003; Bondar I, 2011, GEOPHYS J INT, V186, P1220, DOI 10.1111/j.1365-246X.2011.05107.x; Di Giacomo D, 2014, SEISMOL RES LETT, V85, P354, DOI 10.1785/0220130143; Grob M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047525; Gutenberg B, 1945, B SEISMOL SOC AM, V35, P57; Himeno T, 2011, POLAR SCI, V5, P421, DOI 10.1016/j.polar.2011.08.002; JOHNSTON AC, 1987, NATURE, V330, P467, DOI 10.1038/330467a0; Kaminuma K., 2001, P JOINT INT SEM REC, P23; Kaminuma K., 2000, POLAR GEOSCI, V13, P145; Kaminuma K., 1994, TERR AANTARTICA, V1, P423; Kaminuma K., 1971, ANTARCT REC, V42, P53; Kanao M., 2006, POLAR GEOSCI, V19, P202; Kanao Masaki, 2010, Antarctic Record, V54, P11; Kanao M., 2012, SEISMIC WAVES RES AN, P1; Reading AM, 2007, GEOL SOC AM SPEC PAP, V425, P285, DOI 10.1130/2007.2425(18); Reading A.M., 2002, ROYAL SOC NZ B, V35, P479; Reading AM, 2006, ANTARCTICA: CONTRIBUTIONS TO GLOBAL EARTH SCIENCES, P351, DOI 10.1007/3-540-32934-X_43; RINGDAL F, 1986, B SEISMOL SOC AM, V76, P1641; Rouland D, 2003, TECTONOPHYSICS, V376, P1, DOI 10.1016/j.tecto.2003.08.006; Rouland G., 1992, B SEISMOL SOC AM, V82, P2448; Tsuboi S, 2000, EARTH PLANETS SPACE, V52, P133	24	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					5	16		10.1016/j.polar.2014.08.002		12	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700002		
J	Shimizu, H; Hiramatsu, Y; Kawasaki, I				Shimizu, Hironobu; Hiramatsu, Yoshihiro; Kawasaki, Ichiro			Search for latitudinal variation of spectral peak frequencies of low-frequency eigenmodes excited by great earthquakes	POLAR SCIENCE			English	Article						Free oscillation; D '' layer; Eigenfrequency; Latitudinal variation; Degree-two heterogeneity	FREE OSCILLATIONS; NORMAL-MODES; OUTER CORE; EARTH; LAYER	Continuous waveform records of STS-1 seismometers of the Incorporated Research Institutions for Seismology (IRIS) and superconducting gravimeters of the Global Geodynamics Project (GGP) obtained during the 2004 Sumatra-Andaman, the 2010 Chile, and the 2011 off the Pacific coast of Tohoku earthquakes are examined to search for latitudinal variations of the spectral peak frequencies of S-0(0), S-1(0), and S-0(2). No latitudinal variation is determined. The observed spectral peak frequencies are identical to those of the Preliminary Reference Earth Model (PREM). (C) 2014 Elsevier B.V. and NIPR. All rights reserved.	[Shimizu, Hironobu] Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan; [Hiramatsu, Yoshihiro] Kanazawa Univ, Dept Earth Sci, Coll Sci & Engn, Kanazawa, Ishikawa 9201192, Japan; [Kawasaki, Ichiro] Tono Res Inst Earthquake Sci, Gifu 5096132, Japan	Hiramatsu, Y (reprint author), Kanazawa Univ, Dept Earth Sci, Coll Sci & Engn, Kanazawa, Ishikawa 9201192, Japan.	yoshizo@staff.kanazawa-u.ac.jp					WOODHOUSE JH, 1978, GEOPHYS J ROY ASTR S, V53, P335, DOI 10.1111/j.1365-246X.1978.tb03746.x; TAMURA Y, 1991, GEOPHYS J INT, V104, P507, DOI 10.1111/j.1365-246X.1991.tb05697.x; WOODHOUSE JH, 1986, GEOPHYS RES LETT, V13, P1549, DOI 10.1029/GL013i013p01549; STEVENSON DJ, 1987, GEOPHYS J INT, V88, P311, DOI 10.1111/j.1365-246X.1987.tb01383.x; MORI J, 1995, J GEOPHYS RES-SOL EA, V100, P20359, DOI 10.1029/95JB02243; Cauchy A.-L., 1822, EX MATH, V3, P160; Dahlen F.A., 1998, THEORETICAL GLOBAL S, P619; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Garnero EJ, 2000, SCIENCE, V289, P70, DOI 10.1126/science.289.5476.70; Ishiguro M., 1981, P 9 INT S EARTH TID, P283; Kawasaki I., 2011, LATITUDE DEPENDENT F, P147; LI XD, 1991, J GEOPHYS RES-SOLID, V96, P551, DOI 10.1029/90JB02009; MASTERS G, 1981, GEOPHYS RES LETT, V8, P569, DOI 10.1029/GL008i006p00569; Romanowicz B., 2000, J GEOPHYS RES, V105, p[559, 578]; Roult G, 2010, PHYS EARTH PLANET IN, V179, P45; Tsuboi S, 2002, EARTH PLANETS SPACE, V54, P167; WESSEL P, 1998, EOS T AGU, V0079; WIDMER R, 1992, GEOPHYS J INT, V111, P559, DOI 10.1111/j.1365-246X.1992.tb02112.x	18	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					17	25		10.1016/j.polar.2014.07.002		9	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700003		
J	Iwata, T; Kanao, M				Iwata, Takaki; Kanao, Masaki			A quantitative evaluation of the annual variation in teleseismic detection capability at Syowa Station, Antarctica	POLAR SCIENCE			English	Article						Earthquake detection capability; Annual variation; Syowa Station; Bayesian statistics; Statistical seismology	EARTHQUAKE DETECTION CAPABILITY; MAGNITUDE; COMPLETENESS; DENSITIES; CATALOGS	In this study, we evaluate the annual variation in teleseismic detection capability at Syowa Station (69.0 degrees S, 39.6 degrees E) located in East Antarctica, a variation that has been noted in previous studies. For the quantitative evaluation of the annual variation, we introduced a statistical model of a magnitude-frequency distribution of earthquakes covering the entire magnitude range. The annual variation in the model parameter that quantifies the detection capability was then estimated by using Bayesian analysis. In the estimation, we incorporated the annual variation in air temperature at the station and succeeded in clarifying the significant effect that the variation in temperature has on the teleseismic detection capability. (C) 2014 Elsevier B.V. and NIPR. All rights reserved.	[Iwata, Takaki] Inst Stat Math, Tachikawa, Tokyo 1908562, Japan; [Kanao, Masaki] Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan	Iwata, T (reprint author), Tokiwa Univ, 1-430-1 Miwa, Mito, Ibaraki 3108585, Japan.	tiwata@tokiwa.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [23240039, 25330053]	This study was partially supported by the Grants-in-Aid 23240039 for Scientific Research (A), and 25330053 for Scientific Research (C), by the Ministry of Education, Culture, Sports, Science and Technology, Japan The supercomputer system of the Institute of Statistical Mathematics was used for this study. Figures were drawn using the Generic Mapping Tools (Wessel and Smith, 1998).	Akaike H., 1980, BAYESIAN STAT, P143; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; OGATA Y, 1993, GEOPHYS J INT, V113, P727, DOI 10.1111/j.1365-246X.1993.tb04663.x; Woessner J, 2005, B SEISMOL SOC AM, V95, P684, DOI 10.1785/0120040007; GOOD IJ, 1971, BIOMETRIKA, V58, P255, DOI 10.2307/2334515; Hillers G, 2011, GEOPHYS J INT, V184, P860, DOI 10.1111/j.1365-246X.2010.04886.x; Eggermon P.P.B., 2001, DENSITY ESTIMATION, VI; Good IJ, 1965, ESTIMATION PROBABILI; Grob M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047525; Gutenberg B., 1944, B SEISMOL SOC AM, V34, P185; Iwata T, 2014, AUST NZ J STAT, V56, P201, DOI 10.1111/anzs.12079; Iwata T., 2013, EARTHQUAKE RES ANAL, P167; Iwata T, 2008, GEOPHYS J INT, V174, P849, DOI 10.1111/j.1365-246X.2008.03864.x; Iwata T, 2013, GEOPHYS J INT, V194, P1909, DOI 10.1093/gji/ggt208; Iwata T., 2012, RES GEOPHYS, V2, P24; Kanao M., 2012, SEISMIC WAVES RES AN; Kanao M., 2012, INT J GEOSCI, V3, P809; Kanao M., 1999, ANTARCTIC REC, p[43, 16]; Powell M. J. D., 1981, APPROXIMATION THEORY; RINGDAL F, 1975, B SEISMOL SOC AM, V65, P1631; Shearer P.M., 2009, INTRO SEISMOLOGY; TIERNEY L, 1986, J AM STAT ASSOC, V81, P82, DOI 10.2307/2287970; Ushio Shuki, 2003, Antarctic Record, V47, P338; Utsu T., 1971, J FAC SCI HOKKAIDO 7, V3, P379; Utsu T, 2002, INT HDB EARTHQUAKE E, P733, DOI DOI 10.1016/S0074-6142(02)80247-9; Utsu T., 1974, Journal of Physics of the Earth, V22; WESSEL P, 1998, EOS T AGU, V0079	27	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					26	34		10.1016/j.polar.2014.10.002		9	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700004		
J	Murayama, T; Kanao, M; Yamamoto, MY; Ishihara, Y; Matsushima, T; Kakinami, Y				Murayama, Takahiko; Kanao, Masaki; Yamamoto, Masa-Yuki; Ishihara, Yoshiaki; Matsushima, Takeshi; Kakinami, Yoshihiro			Infrasound array observations in the Lutzow-Holm Bay region, East Antarctica	POLAR SCIENCE			English	Article						Infrasound; Array observations; Lutzow-Holm Bay; East Antarctica; Microbaroms; Surface environment	LARGE BOLIDES; WAVES; REENTRY; EARTH	The characteristic features of infrasound waves observed in Antarctica reveal a physical interaction involving surface environmental variations in the continent and the surrounding Southern Ocean. A single infrasound sensor has been making continuous recordings since 2008 at Syowa Station (SYO; 69.0S, 39.6E) in the Lutzow-Holm Bay (LHB) of East Antarctica. The continuously recorded data clearly show the contamination of background oceanic signals (microbaroms) throughout all seasons. In austral summer 2013, several field stations with infrasound sensors were established along the coast of the LHB. Two infrasound arrays of different diameters were set up: one at SYO (with a 100-m spacing triangle) and one in the S16 area on the continental ice sheet (with a 1000-m spacing triangle). In addition to these arrays, isolated single stations were deployed at two outcrops in the LHB. These newly established arrays clearly detected the propagation direction and frequency content of microbaroms from the Southern Ocean. Microbarom measurements are a useful tool for characterizing ocean wave climates, complementing other oceanographic and geophysical data from the Antarctic. In addition to the microbaroms, several other remarkable infrasound signals were detected, including regional earthquakes, and airburst shock waves emanating from a meteoroid entering the atmosphere over the Russian Republic on 15 February 2013. Detailed and continuous measurements of infrasound waves in Antarctica could prove to be a new proxy for monitoring regional environmental change as well as temporal climate variations in high southern latitudes. (C) 2014 Elsevier B.V. and NIPR. All rights reserved.	[Murayama, Takahiko] Japan Weather Assoc, Toshima Ku, Tokyo 1706055, Japan; [Kanao, Masaki] Res Org Informat & Syst, Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan; [Yamamoto, Masa-Yuki; Kakinami, Yoshihiro] Kochi Univ Technol, Kami, Kochi 7828502, Japan; [Ishihara, Yoshiaki] Japan Aerosp Explorat Agcy, Lunar & Planetary Explorat Program Grp, Chuo Ku, Sagamihara, Kanagawa 2525210, Japan; [Matsushima, Takeshi] Kyushu Univ, Fac Sci, Shimabara, Nagasaki 8550843, Japan	Kanao, M (reprint author), Res Org Informat & Syst, Natl Inst Polar Res, 10-3 Midori Cho, Tachikawa, Tokyo 1908518, Japan.	murayama@jwa.or.jp; kanao@nipr.ac.jp; yamamoto.masa-yuki@kochi-tech.ac.jp; ishihara.yoshiaki@jaxa.jp; mat@sevo.kyushu-u.ac.jp; kakinami.yoshihiro@kochi-tech.ac.jp		Kakinami, Yoshihiro/0000-0001-7806-5734	Ministry of Education, Science, Sports and Culture [19740265]; JSPS KAKENHI [26241010]	We would like to express our sincere appreciation to many people who collaborated in the infrasound observations at SYO, in LHB, as well as members of the Japanese Antarctic Research Expeditions (JARE; Prof. Kazuyuki Shiraishi, director general of NIPR; Prof. Kentaro Watanabe of NIPR, the leader of JARE-54, and many other expedition members). Infrasound observation at SYO was partially supported by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Young Scientists (B) 19740265, 2007 (P.I. by Dr. Yoshiaki Ishihara). Part of the data retrieval from SYO to Japan and initial processing was performed by Mr. Toshifumi Suzuki and Mr. Takayasu Komatsu, Kochi University of Technology. This work was also supported by JSPS KAKENHI Grand Number 26241010 (P.I. by Dr. Masaki Kanao). We would also like to express our sincere appreciation to two anonymous referees, Prof. Kazuo Shibuya of NIPR as the Editor-in-Chief, and Prof. Dapeng Zhao of Tohoku University as the guest-managing-editor of this special issue, for their great editorial endeavors in publishing this article in Polar Science.	Wiens DA, 2008, NATURE, V453, P770, DOI 10.1038/nature06990; Iyemori T, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024083; Brown PG, 2013, NATURE, V503, P238, DOI 10.1038/nature12741; Stutzmann E, 2009, GEOCHEM GEOPHY GEOSY, V10, DOI 10.1029/2009GC002619; de Groot-Hedlin C, 2011, GEOPHYS J INT, V185, P305, DOI 10.1111/j.1365-246X.2010.04925.x; CANSI Y, 1995, GEOPHYS RES LETT, V22, P1021, DOI 10.1029/95GL00468; Nishida K, 2000, SCIENCE, V287, P2244, DOI 10.1126/science.287.5461.2244; Arai N, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL049146; Arrowsmith SJ, 2008, EARTH MOON PLANETS, V102, P357, DOI 10.1007/s11038-007-9205-z; Bromirski PD, 2009, SCIENCE, V324, P1026, DOI 10.1126/science.1171839; Butler R., 2008, GLOBAL SEISMOGRAPHIC, P6; Cansi Y., 1997, NEWS LETT, V11, P1021; Garces M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018614; Grob M, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047525; Hanson J, 2001, PURE APPL GEOPHYS, V158, P425, DOI 10.1007/PL00001190; Hedlin M., 2002, EOS T AGU, V83, P557; Hedlin MAH, 2005, J ACOUST SOC AM, V117, P1880, DOI 10.1121/1.1760778; Ishihara Y, 2012, EARTH PLANETS SPACE, V64, P655, DOI 10.5047/eps.2012.01.003; Ishihara Y, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020287; Kanao M., 2012, SEISMIC WAVES RES AN; Kanao Masaki, 2010, Antarctic Record, V54, P11; Kanao M., 2011, INTER J GEOPHYS, V2011, P1, DOI [10.1155/2011/272646, DOI 10.1155/2011/272646]; Le Pichon A, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006020; Le Pichon A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023893; MacAyeal DR, 2009, J GLACIOL, V55, P193; Matoza RS, 2007, J VOLCANOL GEOTH RES, V160, P249, DOI 10.1016/j.jvolgeores.2006.10.006; Ostrashev V.E., 2005, J ACOUST SOC AM, V117, P503; POSMENTI.ES, 1967, GEOPHYS J ROY ASTR S, V13, P487, DOI 10.1111/j.1365-246X.1967.tb02301.x; Uehira Kenji, 2009, Earth, Planets and Space, V61; WILSON CR, 1969, J GEOPHYS RES, V74, P1812, DOI 10.1029/JA074i007p01812; Yamamoto M, 2011, PUBL ASTRON SOC JPN, V63, P971; Yamamoto M.-Y., 2013, INT J GEOSCI, V4, P797	32	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					35	50		10.1016/j.polar.2014.07.005		16	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700005		
J	Toyokuni, G; Takenaka, H; Kanao, M; Tsuboi, S; Tono, Y				Toyokuni, Genti; Takenaka, Hiroshi; Kanao, Masaki; Tsuboi, Seiji; Tono, Yoko			Numerical modeling of seismic waves for estimating the influence of the Greenland ice sheet on observed seismograms	POLAR SCIENCE			English	Article						Greenland ice sheet; seismic waveform; guided wave; finite-difference method (FDM); GLISN project	FINITE-DIFFERENCE METHODS; GLACIAL EARTHQUAKES; PROPAGATION; NETWORK; GLISN; AREA	We calculate regional synthetic seismograms for a realistic structure model beneath Greenland, including surface topography and ice sheet thickness, for observations of the multinational GreenLand Ice Sheet monitoring Network (GLISN). The thick and heterogeneous Greenland ice sheet can cause distortion of the seismic waveforms observed at the GLISN stations on ice. We developed a numerical technique that calculates accurate regional seismic wavefields with low computational requirements. Here, we calculate the elastic wave propagation up to 2 Hz for four structural models of the Greenland ice sheet from a seismic source at various depths and with different mechanisms. Our computations for a realistic ice sheet model, the near-surface seismic source produced a very characteristic wave train with a group velocity smaller than the S-wavespeed in the ice, considered to be an ice-sheet guided S wave, developed by the superposition of post-critical reflections between the free surface and the ice bed. We named this wave "Le", analogous to the Lg wave, a crustally guided S wave. Furthermore, computation for a deeper seismic source resulted in reinforcement of the crustal Sg-coda wave with a group velocity range of similar to 3.1-2.6 km/s, which agrees with the characteristic waveform observed on the Greenland ice sheet. (C) 2014 Elsevier B.V. and NIPR. All rights reserved.	[Toyokuni, Genti] Tohoku Univ, Res Ctr Predict Earthquakes & Volcan Erupt, Grad Sch Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; [Takenaka, Hiroshi] Okayama Univ, Dept Earth Sci, Kita Ku, Okayama 7008530, Japan; [Kanao, Masaki] Natl Inst Polar Res, Tachikawa, Tokyo 1908518, Japan; [Tsuboi, Seiji; Tono, Yoko] Japan Agcy Marine Earth Sci & Technol, Kanazawa Ku, Yokohama, Kanagawa 2360001, Japan	Toyokuni, G (reprint author), Tohoku Univ, Res Ctr Predict Earthquakes & Volcan Erupt, Grad Sch Sci, Aoba Ku, 6-6 Aza Aoba, Sendai, Miyagi 9808578, Japan.	toyokuni@aob.gp.tohoku.ac.jp			JSPS KAKENHI [24403006]	The authors are grateful to Mr. Dean Childs, Dr. Tetsuto Himeno, and all the other GLISN members for their contribution to the field operations at Greenland. Discussions with Prof. Mare Yamamoto were very helpful in improving the manuscript. The Japanese GLISN team has been supported by JSPS KAKENHI 24403006. We thank the editor, Prof. Kazuo Shibuya, and the two anonymous referees who provided constructive review comments that have improved this paper. Most figures were generated using the Generic Mapping Tools freeware package (Wessel and Smith, 1998).	ALTERMAN Z, 1968, B SEISMOL SOC AM, V58, P367; Nakamura T, 2014, PURE APPL GEOPHYS, V171, P1153, DOI 10.1007/s00024-013-0717-3; KENNETT BLN, 1986, B SEISMOL SOC AM, V76, P1133; Ekstrom G, 2003, SCIENCE, V302, P622, DOI 10.1126/science.1088057; Igel H, 1996, GEOPHYS J INT, V124, P363, DOI 10.1111/j.1365-246X.1996.tb07026.x; Ekstrom G, 2006, SCIENCE, V311, P1756, DOI 10.1126/science.1122112; Bamber JL, 2001, J GEOPHYS RES-ATMOS, V106, P33773, DOI 10.1029/2001JD900054; Nakamura T, 2012, B SEISMOL SOC AM, V102, P2420, DOI 10.1785/0120110356; Kennett BLN, 2001, GEOPHYS J INT, V146, P562, DOI 10.1046/j.1365-246x.2001.01467.x; Dahl-Jensen T, 2010, GEOL SURV DEN GREENL, P55; Bamber J., 2001, GREENLAND 5 KM DEM I; Bamber JL, 2001, J GEOPHYS RES-SOL EA, V106, P6733, DOI 10.1029/2000JB900365; Clinton John F., 2014, Eos, Transactions American Geophysical Union, V95, DOI 10.1002/2014EO020001; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Furumura T, 2001, B SEISMOL SOC AM, V91, P667, DOI 10.1785/0120000270; Furumura T., 2014, PORGR EARTH PLANET S, V1, P10, DOI DOI 10.1186/2197-4284-1-10; Ishizawa K., 1981, ANTARCT REC, V73, P147; Kennett B.L.N., 2002, SEISMIC WAVEFIELD, P534; Livingston C.W, 1960, 75 US ARM SNOW IC PE, P100; Nettles M, 2010, ANNU REV EARTH PL SC, V38, P467, DOI 10.1146/annurev-earth-040809-152414; ROBINSON ES, 1968, J GEOPHYS RES, V73, P739, DOI 10.1029/JB073i002p00739; STEPHEN RA, 1983, GEOPHYS J ROY ASTR S, V72, P39, DOI 10.1111/j.1365-246X.1983.tb02803.x; STEPHEN RA, 1988, REV GEOPHYS, V26, P445, DOI 10.1029/RG026i003p00445; Takenaka H., 2009, P 9 SEGJ INT S SAPP; Takenaka H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018068; Toyokuni Genti, 2014, Antarctic Record, V58, P1; Toyokuni G., 2015, QUASICYLINDRIC UNPUB; Toyokuni G., 2012, SEISMIC WAVES RES AN, P85, DOI DOI 10.5772/32422; WESSEL P, 1998, EOS T AGU, V0079	29	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-9652	1876-4428		POLAR SCI	Polar Sci.	MAR	2015	9	1					80	93		10.1016/j.polar.2014.12.001		14	Ecology; Geosciences, Multidisciplinary	Environmental Sciences & Ecology; Geology	CD3QG	WOS:000350993700008		
J	Randrianantoandro, TN; Kono, H; Kubota, S				Randrianantoandro, Tiana N.; Kono, Hiroichi; Kubota, Satoko			Knowledge and behavior in an animal disease outbreak - Evidence from the item count technique in a case of African swine fever in Madagascar	PREVENTIVE VETERINARY MEDICINE			English	Article						African swine fever; Item count technique; Madagascar	BASE RATES; BUSHPIGS; TICKS	Pig production in Madagascar is not sufficient for domestic consumption. Unfortunately, African swine fever (ASF), which is a severe disease, is endemic in Madagascar and constitutes a constant threat for farmers. Therefore, ASF must be eradicated in order to guarantee the development of pig production. One of the main, strategies in controlling ASF is stamping out which requires the farmers' collaboration in reporting cases or suspected cases. The objective of this study was to estimate the proportion of farmers who knowingly sell ASF-infected meat without reporting. Since selling ASF-infected meat is prohibited by the government, we used the item count technique (ICT), an indirect questioning technique appropriate for measuring the proportion of people engaged in sensitive behavior, for one subsample, while another subsample was asked directly whether they sell ASF-infected meat. Based on the ICT, approximately 73.2% of farmers who have experienced ASF sell the ASF-infected meat. This estimate was not statistically different from that obtained by direct questioning. In the 28% of interviewed farmers who believe ASF can affect humans, the ICT yielded a higher estimate than did direct questioning, indicating that pig farmers who sell ASF-infected meat hide that fact because of their belief that infected meat might harm human consumers, not because of the law. The ICT was thus a suitable technique to address the problem of sensitive behavior. In the case of ASF outbreaks, the Malagasy government should enforce the law more strictly and provide compensation as incentive for reporting cases. (C) 2014 Elsevier B.V. All rights reserved.	[Randrianantoandro, Tiana N.; Kono, Hiroichi; Kubota, Satoko] Obihiro Univ Agr & Vet Med, Lab Hyg Econ, Obihiro, Hokkaido 0808555, Japan	Kono, H (reprint author), Obihiro Univ Agr & Vet Med, Lab Hyg Econ, E2206-1,Bldg 1,2-11 Inada, Obihiro, Hokkaido 0808555, Japan.	kono@obihiro.ac.jp			Obihiro University of Agriculture and Veterinary Medicine	The authors would like to thank Mr. Andriamiaramiantraferana for leading the team for the field work in Madagascar. We are also grateful to Obihiro University of Agriculture and Veterinary Medicine for funding this research.	DALTON DR, 1994, PERS PSYCHOL, V47, P817, DOI 10.1111/j.1744-6570.1994.tb01578.x; Glynn AN, 2013, PUBLIC OPIN QUART, V77, P159, DOI 10.1093/poq/nfs070; LaBrie JW, 2000, J SEX RES, V37, P321; Arguilaguet J. M., 2012, PLOS ONE, V7; Costard S., 2009, 12 S INT SOC VET EP; DROITCOUR J, 1991, WILEY S PRO, P185; FAOSTAT, 2012, IMP QUANT MEAT SWIN; Ministry of Agriculture, 2007, REC AGR CAMP AGR 200; Ministry of Agriculture, 2007, PROT SURV PEST PORC; OIE, 2013, MONTHL AN DIS STAT L; Penrith M. -L., 2004, INFECT DIS LIVESTOCK, V1, P171; Penrith M. -L., 2013, VIRUS RES, V173, P191; Ravaomanana J, 2011, TRANSBOUND EMERG DIS, V58, P247, DOI 10.1111/j.1865-1682.2011.01207.x; Rayburn N. R., 2003, J AGGRESSION MALTREA, V6, P137, DOI 10.1300/J146v06n02_07; Roger F, 2001, EXP APPL ACAROL, V25, P263, DOI 10.1023/A:1010687502145; Rousset D., 2001, Archives de l'Institut Pasteur de Madagascar, V67, P31	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-5877	1873-1716		PREV VET MED	Prev. Vet. Med.	MAR 1	2015	118	4					483	487		10.1016/j.prevetmed.2014.12.016		5	Veterinary Sciences	Veterinary Sciences	CC7GM	WOS:000350535700024		
J	Hoshi, A				Hoshi, Akinari			On Noether's problem for cyclic groups of prime order	PROCEEDINGS OF THE JAPAN ACADEMY SERIES A-MATHEMATICAL SCIENCES			English	Article						Noether's problem; rationality problem; algebraic tori; class number; cyclotomic field	UNRAMIFIED BRAUER GROUPS; CLASS NUMBER PROBLEM; RETRACT RATIONALITY; INVARIANT; FINITE; FIELDS	Let k be a field and G be a finite group acting on the rational function field k(x(g) vertical bar g is an element of G) by k-automorphisms h(x(g)) = x(hg) for any g, h is an element of G. Noether's problem asks whether the invariant field k(G) = k(x(g) vertical bar g is an element of G)(G) is rational (i.e. purely transcendental) over k. In 1974, Lenstra gave a necessary and sufficient condition to this problem for abelian groups G. However, even for the cyclic group C-p of prime order p, it is unknown whether there exist infinitely many primes p such that Q(C-p) is rational over Q. Only known 17 primes p for which Q(C-p) is rational over Q are p <= 43 and p = 61,67,71. We show that for primes p < 20000, Q(C-p) is not (stably) rational over Q except for affirmative 17 primes and undetermined 46 primes. Under the GRH, the generalized Riemann hypothesis, we also confirm that Q(C-p) is not (stably) rational over Q for undetermined 28 primes p out of 46.	Niigata Univ, Dept Math, Nishi Ku, Niigata 9502181, Japan	Hoshi, A (reprint author), Niigata Univ, Dept Math, Nishi Ku, 8050 Ikarashi 2 No Cho, Niigata 9502181, Japan.				JSPS KAKENHI Grant [25400027]	The author thanks Profs. Shizuo Endo and Ming-chang Kang for valuable discussions. He also thanks Profs. Keiichi Komatsu, Takashi Fukuda and John C. Miller for helpful comments. This work was supported by JSPS KAKENHI Grant Number 25400027.	Hoshi A, 2013, ASIAN J MATH, V17, P689; LENSTRA HW, 1974, INVENT MATH, V25, P299, DOI 10.1007/BF01389732; Kang MC, 2009, P AM MATH SOC, V137, P1867; SALTMAN DJ, 1984, INVENT MATH, V77, P71, DOI 10.1007/BF01389135; Moravec P, 2012, AM J MATH, V134, P1679; Kang MC, 2012, J ALGEBRA, V349, P22, DOI 10.1016/j.jalgebra.2011.10.024; SWAN RG, 1969, INVENT MATH, V7, P148, DOI 10.1007/BF01389798; MASUDA K, 1968, J MATH SOC JPN, V20, P223; Kang MC, 2014, J ALGEBRA, V397, P407, DOI 10.1016/j.jalgebra.2013.08.039; Chu H, 2010, INT MATH RES NOTICES, P2329, DOI 10.1093/imrn/rnp217; Bogomolov F. A., 1988, MATH USSR IZV, V30, P455, DOI 10.1070/IM1988v030n03ABEH001024; Bogomolov F.A., 2013, BIRATIONAL GEOMETRY, P57; ENDO S, 1973, J MATH SOC JPN, V25, P7; Fischer E., 1915, NACHR KONIGL GES WIS, P77; Fukuda T, 2009, EXP MATH, V18, P213, DOI 10.1080/10586458.2009.10128896; Fukuda T., 2010, J THEOR NOMBR BORDX, V22, P359; Fukuda T, 2011, INT J NUMBER THEORY, V7, P1627, DOI 10.1142/S1793042111004782; Hoshi A., ARXIV14023678V2; Hoshi A., 2005, THESIS WASEDA U; Kang MC, 2013, ADV MATH, V245, P34, DOI 10.1016/j.aim.2013.06.009; Kuniyoshi H., 1955, NAGOYA MATH J, V8, P65; Kuniyoshi H., 1954, TOHOKU MATH J, V6, P101, DOI 10.2748/tmj/1178245169; Kuniyoshi H., 1956, P INT S ALG NUMB THE, P241; Lenstra H. W., 1980, QUEENS PAPERS PURE A, V54, P91; MASLEY JM, 1976, J REINE ANGEW MATH, V287, P248; Masuda K., 1955, NAGOYA MATH J, V8, P59; Miller JC, 2014, ACTA ARITH, V164, P381, DOI 10.4064/aa164-4-4; Miller J. C., MATH COMP IN PRESS; Noether E., 1913, JAHRESBER DTSCH MATH, V22, P316; Noether E, 1918, MATH ANN, V78, P221; Swan R. G., 1981, MONOGRAPHS TXB PURE, V69; Swan R.G., 1983, E NOETHER BRYN MAWR, P21; Voskresenskii V., 1998, TRANSLATIONS MATH MO, V179; Voskresenskii V. E., 1970, MATH USSR IZV, V34, p[366, 371], DOI 10.1070/IM1970v004n02ABEH000910; Voskresenskii V. E., 1973, RUSS MATH SURV, V28, p[77, 79], DOI 10.1070/RM1973v028n04ABEH001594; Voskresenskii V. E., 1971, MATH USSR IZV, V35, p[1037, 1049], DOI 10.1070/IM1971v005n05ABEH001200; Washington L. C., 1997, GRADUATE TEXTS MATH, V83	37	1	1	JAPAN ACAD	TOKYO	7-32, UENO PARK, TAITO-KU, TOKYO, 110-0007, JAPAN	0386-2194			P JPN ACAD A-MATH	Proc. Jpn. Acad. Ser. A-Math. Sci.	MAR	2015	91	3					39	44		10.3792/pjaa.91.39		6	Mathematics	Mathematics	CD6IZ	WOS:000351194100002		
J	Heidarzadeh, M; Satake, K				Heidarzadeh, Mohammad; Satake, Kenji			New Insights into the Source of the Makran Tsunami of 27 November 1945 from Tsunami Waveforms and Coastal Deformation Data	PURE AND APPLIED GEOPHYSICS			English	Article						Makran earthquake of 27 November 1945; tsunami; Makran Subduction Zone; spectral analysis; Fourier analysis; wavelet analysis; tsunami waveform inversion; coseismic deformation	NORTHWESTERN INDIAN-OCEAN; SUBDUCTION ZONE; ARABIAN SEA; EARTHQUAKE; PAKISTAN; HAZARD; IRAN; GENERATION; SPACE; FAULT	We constrain the source of the 27 November 1945 tsunami in the Makran Subduction Zone (MSZ) using available tsunami waveforms recorded on tide gauges at Mumbai (India) and Karachi (Pakistan), and that inferred at Port Victoria (Seychelles), and coseismic deformation data along the Makran coast. Spectral analysis of the tsunami waveforms shows that the tsunami governing period was 40-50 min at Karachi whereas it was around 22 min at Mumbai. The inferred tsunami waveform at Port Victoria also indicated a period of around 21 min for the tsunami. Tsunami numerical simulations from the previously proposed source models failed in reproducing the observed tsunami waveforms and coseismic deformation data. Sensitivity analysis showed that the source fault needs to be extended offshore into deep water in order to reproduce the first 22-min signal at Mumbai. Based on the inversion of the observed tsunami waveforms, we propose a four-segment fault with varying slip amounts as the final source. This source includes a slip of 4.3 m onshore near Ormara (Pakistan) and a slip of 10 m offshore at water depth of around 3,000 m. The total fault length is 220 km, and the average slip is 6.1 m. This source, first, reproduces fairly well the observed tide gauge records at Mumbai and Karachi, second, produces similar to 1 m of uplift at Ormara and similar to 1 m of subsidence at Pasni, and third, gives a moment magnitude of 8.3 for the earthquake, which is in the acceptable range of seismic data. The computed 1 m uplift at Ormara is in the uplift range of 1-3 m reported in the literature. As the tide gauge stations were located in the far field, our proposed source explains mainly the tectonic source of the tsunami.	[Heidarzadeh, Mohammad; Satake, Kenji] Univ Tokyo, ERI, Bunkyo Ku, Tokyo 1130032, Japan	Heidarzadeh, M (reprint author), Univ Tokyo, ERI, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	mheidar@eri.u-tokyo.ac.jp	Satake, Kenji/E-2312-2011; Heidarzadeh, Mohammad/A-1354-2016	Heidarzadeh, Mohammad/0000-0002-1112-1276	Japan Society for the Promotion of Science (JSPS)	The tide gauge records of the Makran tsunami of November 1945 at Karachi and Mumbai were first retrieved by NEETU et al. (2011) and were digitized here for this study. We thank two anonymous reviewers for their constructive comments. We are grateful to Dr. Hermann M. Fritz (the editor) and Dr. Takeo Ishibe for their critical reviews of the manuscript. This study was supported by the Japan Society for the Promotion of Science (JSPS).	Rabinovich AB, 2007, PURE APPL GEOPHYS, V164, P261, DOI 10.1007/s00024-006-0164-5; SATAKE K, 1987, J PHYS EARTH, V35, P241; Satake K, 2003, PURE APPL GEOPHYS, V160, P2087, DOI 10.1007/s00024-003-2421-1; Heidarzadeh M, 2008, OCEAN ENG, V35, P774, DOI 10.1016/j.oceaneng.2008.01.017; Donato SV, 2009, MAR GEOL, V257, P54, DOI 10.1016/j.margeo.2008.10.012; Fujii Y, 2011, EARTH PLANETS SPACE, V63, P815, DOI 10.5047/eps.2011.06.010; Rajendran CP, 2013, NAT HAZARDS, V65, P219, DOI 10.1007/s11069-012-0355-6; Fritz HM, 2010, ESTUAR COAST SHELF S, V86, P102, DOI 10.1016/j.ecss.2009.10.019; Pilarczyk JE, 2012, MAR GEOL, V295, P128, DOI 10.1016/j.margeo.2011.12.002; Borrero JC, 2013, PURE APPL GEOPHYS, V170, P1249, DOI 10.1007/s00024-012-0559-4; Heidarzadeh M, 2014, GEOPHYS J INT, V199, P752, DOI 10.1093/gji/ggu297; Satake K, 2013, B SEISMOL SOC AM, V103, P1473, DOI 10.1785/0120120122; BEER A, 1946, NATURE, V158, P63, DOI 10.1038/158063b0; [Anonymous], 1945, NATURE, V156, P712; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Heidarzadeh M, 2011, NAT HAZARDS, V56, P577, DOI 10.1007/s11069-010-9574-x; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; QUITTMEYER RC, 1979, B SEISMOL SOC AM, V69, P773; Shah-hosseini M, 2011, MAR GEOL, V290, P17, DOI 10.1016/j.margeo.2011.10.003; Neetu S, 2011, NAT HAZARDS, V59, P1609, DOI 10.1007/s11069-011-9854-0; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P861, DOI 10.1029/96GL00736; Bell C., 2000, POL PSMSL TIDAL ANAL; BYRNE DE, 1992, J GEOPHYS RES-SOL EA, V97, P449, DOI 10.1029/91JB02165; DUDA SJ, 1965, TECTONOPHYSICS, V2, P409, DOI 10.1016/0040-1951(65)90035-1; Gutenberg B., 1954, SEISMICITY EARTH ASS; Heck NH, 1947, B SEISMOL SOC AM, V37, P269; Heidarzadeh M, 2009, NAT HAZARDS, V48, P229, DOI 10.1007/s11069-008-9259-x; Heidarzadeh M, 2009, OCEAN ENG, V36, P368, DOI 10.1016/j.oceaneng.2009.01.004; Heidarzadeh M, 2013, PURE APPL GEOPHYS, V170, P1449, DOI 10.1007/s00024-012-0509-1; Heidarzadeh M, 2008, PURE APPL GEOPHYS, V165, P2045, DOI 10.1007/s00024-008-0415-8; Heidarzadeh M, 2013, PURE APPL GEOPHYS, V170, P1275, DOI 10.1007/s00024-012-0558-5; Hoffmann G, 2013, Z GEOMORPHOL, V57, P257, DOI 10.1127/0372-8854/2013/S-00134; IOC IHO BODC, 2003, CENT ED GEBCO DIG AT; Jaiswal RK, 2009, NAT HAZARDS, V48, P245, DOI 10.1007/s11069-008-9261-3; Kreyszig E., 2010, ADV ENG MATH; MATHWORKS, 2014, MATLAB US MAN; Mokhtari M, 2015, ARAB J GEOSCI, V8, P4291, DOI 10.1007/s12517-014-1375-1; Okal EA, 2006, EARTHQ SPECTRA, V22, pS203, DOI 10.1193/1.2202647; PAGE WD, 1979, TECTONOPHYSICS, V52, P533, DOI 10.1016/0040-1951(79)90269-5; Pendse C.G., 1946, INDIA METEOROL DEP S, V10, P141; Rabinovich A.B., 1997, J GEOPHYS RES, V102, P663; Richter C.F., 1958, ELEMENTARY SEISMOLOG; Smith GL, 2013, GEOPHYS RES LETT, V40, P1528, DOI 10.1002/grl.50374; TAKAHASHI T, 1995, PURE APPL GEOPHYS, V144, P747, DOI 10.1007/BF00874393; Tinti S, 1999, PHYS CHEM EARTH PT B, V24, P417, DOI 10.1016/S1464-1909(99)00022-2; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Yalciner A, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC002113	47	2	2	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	0033-4553	1420-9136		PURE APPL GEOPHYS	Pure Appl. Geophys.	MAR	2015	172	3-4					621	640		10.1007/s00024-014-0948-y		20	Geochemistry & Geophysics	Geochemistry & Geophysics	CD2HG	WOS:000350895700002		
J	Murotani, S; Iwai, M; Satake, K; Shevchenko, G; Loskutov, A				Murotani, Satoko; Iwai, Maki; Satake, Kenji; Shevchenko, Georgy; Loskutov, Artem			Tsunami Forerunner of the 2011 Tohoku Earthquake Observed in the Sea of Japan	PURE AND APPLIED GEOPHYSICS			English	Article						The 2011 Tohoku earthquake; tsunami forerunner; the Sea of Japan; seafloor deformation; tide gauge; tsunami simulation	SPACE; GENERATION; SURFACE	During the March 11, 2011 Tohoku tsunami, some Japanese and Russian tide gauges in the Sea of Japan recorded sea level disturbances with periods of several to 10 min and amplitudes of several to a few tens of centimeters starting immediately after the earthquake. Tsunami travel times computed from the 2011 source in the Pacific Ocean to these stations are 1-2 h. To examine the cause of the observed tsunami forerunners and to reproduce them, we carried out tsunami numerical computations from three kinds of coseismic seafloor deformation: the vertical displacement in the tsunami source area in the Pacific Ocean, the vertical displacement extending in the Sea of Japan, and the vertical displacement including the effects of the horizontal displacement and the seafloor slope in both the Pacific Ocean and the Sea of Japan. Only the last source reproduced the observed tsunami forerunners. This indicates that the tsunami forerunners were produced by the horizontal displacement of fault motion and the seafloor slope in the Sea of Japan. For the tide gauge records in Japan, the forerunners with periods longer than 2 min were well reproduced by the tsunami simulation. The shorter-period components may be induced by seismic ground shakings. For the tide gauge records in Russia, the agreement between the observed and computed waveforms was less satisfactory, probably because of less accurate and coarser bathymetry data.	[Murotani, Satoko; Satake, Kenji] Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan; [Iwai, Maki] Univ Tokyo, Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; [Shevchenko, Georgy; Loskutov, Artem] Russian Acad Sci, Inst Marine Geol & Geophys, Far Eastern Branch, Yuzhno Sakhalinsk 693022, Russia	Murotani, S (reprint author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	s-mur-o@eri.u-tokyo.ac.jp; satake@eri.u-tokyo.ac.jp; shevchenko@imgg.ru; loskutov-imgg@yandex.ru	Satake, Kenji/E-2312-2011		Special Project "Integrated Research Project on Seismic and Tsunami Hazards around the Sea of Japan'' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan	We thank Mohammad Heidarzadeh, who read the manuscript and provided valuable comments. We are grateful to Alexander Rabinovich, the editor, and two anonymous reviewers for comments that improved this article. We are grateful to JMA, JCG, and GSI, who provided us with the tide gauge records. Figures were produced using GMT (WESSEL and SMITH 1998). This study was supported by the Special Project "Integrated Research Project on Seismic and Tsunami Hazards around the Sea of Japan'' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Fujii Y, 2011, EARTH PLANETS SPACE, V63, P815, DOI 10.5047/eps.2011.06.010; SATAKE K, 1995, PURE APPL GEOPHYS, V144, P455, DOI 10.1007/BF00874378; Yoshida Y, 2011, EARTH PLANETS SPACE, V63, P565, DOI 10.5047/eps.2011.05.011; Satake K, 2013, B SEISMOL SOC AM, V103, P1473, DOI 10.1785/0120120122; Sun WK, 2009, GEOPHYS J INT, V177, P817, DOI 10.1111/j.1365-246X.2009.04113.x; Iinuma T, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2012JB009186; Rabinovich AB, 2013, GEOPHYS RES LETT, V40, P3157, DOI 10.1002/grl.50625; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Tanioka Y, 1996, GEOPHYS RES LETT, V23, P861, DOI 10.1029/96GL00736; Bondevik S, 2013, GEOPHYS RES LETT, V40, P3374, DOI 10.1002/grl.50639; Heidarzadeh M, 2014, PURE APPL GEOPHYS, V171, P3405, DOI 10.1007/s00024-013-0731-5; JAPAN METEOROLOGICAL AGENCY, 2012, REP 2011 PAC COAST T, V133; Shevchenko G, 2014, PURE APPL GEOPHYS, V171, P3329, DOI 10.1007/s00024-013-0727-1; Tanioka Y, 2000, PURE APPL GEOPHYS, V157, P977, DOI 10.1007/s000240050013; WESSEL P, 1998, EOS T AGU, V0079; YOKOTA Y, 2011, GEOPHYS RES LETT, V38, DOI DOI 10.1029/2011GL050	16	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	0033-4553	1420-9136		PURE APPL GEOPHYS	Pure Appl. Geophys.	MAR	2015	172	3-4					683	697		10.1007/s00024-014-1006-5		15	Geochemistry & Geophysics	Geochemistry & Geophysics	CD2HG	WOS:000350895700005		
J	Heidarzadeh, M; Satake, K; Murotani, S; Gusman, AR; Watada, S				Heidarzadeh, Mohammad; Satake, Kenji; Murotani, Satoko; Gusman, Aditya Riadi; Watada, Shingo			Deep-Water Characteristics of the Trans-Pacific Tsunami from the 1 April 2014 M (w) 8.2 Iquique, Chile Earthquake	PURE AND APPLIED GEOPHYSICS			English	Article						Pacific Ocean; tsunami; Iquique earthquake of 1 April 2014; chilean tsunami; DART buoy; deep-water waves; fourier analysis; wavelet analysis; numerical modeling	2004 SUMATRA-TSUNAMI; FAR-FIELD; OCEAN	We studied the tsunami generated by the 1 April 2014 M (w) 8.2 Iquique (Chile) earthquake using 20 Deep-ocean Assessment and Reporting of Tsunamis (DART) records and applying Fourier and wavelet analyses as well as performing numerical simulations. Deep-water tsunami wave heights were in the range of 0.8-35.0 cm. For the stations located more than 2,200 km from the source, the average wave height was 1.7 +/- A 1.1 cm. The observed tsunami arrivals were delayed by 1-17 min relative to the simulated ones based on the linear long wave equations, and the delays were proportional to the tsunami travel distances. A small initial depression was observed at DART stations located at distances > 10,000 km from the source whereas, traditionally, an initial elevation is expected at stations located seaward of subduction zones. Fourier analyses showed tsunami governing periods of 21.1 +/- A 1.7 and 14.7 +/- A 0.7 min, corresponding to a fault length of 60-70 km and a fault width of 40-45 km. While the two 21-min and 15-min signals appeared in most DART stations during similar to 0.5 h following the conventional arrival times, the 15-min signal was delayed at some far-field stations. Distribution of maximum DART wave heights across the Pacific Ocean did not show a meaningful relation between maximum DART wave heights and directivity or distance from the source.	[Heidarzadeh, Mohammad; Satake, Kenji; Murotani, Satoko; Gusman, Aditya Riadi; Watada, Shingo] Univ Tokyo, ERI, Bunkyo Ku, Tokyo 1130032, Japan	Heidarzadeh, M (reprint author), Univ Tokyo, ERI, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	mheidar@eri.u-tokyo.ac.jp	Satake, Kenji/E-2312-2011; watada, shingo/M-7237-2015; Heidarzadeh, Mohammad/A-1354-2016	watada, shingo/0000-0001-9924-968X; Heidarzadeh, Mohammad/0000-0002-1112-1276	Japan Society for the Promotion of Science (JSPS)	The sea level data used in this study were provided through the USA National Oceanographic and Atmospheric Administration (NOAA). We thank Hiroshi Tsuruoka and Takeo Ishibe at the Earthquake Research Institute (ERI) for assisting in preparation of some figures. Several figures were drafted using the GMT software (WESSEL and SMITH 1991). We are sincerely grateful to Prof. Alexander Rabinovich, the editor, and two anonymous reviewers for comments that improved this article. This study is supported by the Japan Society for the Promotion of Science (JSPS).	Rabinovich AB, 2007, PURE APPL GEOPHYS, V164, P261, DOI 10.1007/s00024-006-0164-5; Borrero JC, 2013, PURE APPL GEOPHYS, V170, P1249, DOI 10.1007/s00024-012-0559-4; Okal EA, 2011, PURE APPL GEOPHYS, V168, P969, DOI 10.1007/s00024-010-0215-9; Titov V, 2005, SCIENCE, V309, P2045, DOI 10.1126/science.1114576; Watada S, 2014, J GEOPHYS RES-SOL EA, V119, P4287, DOI 10.1002/2013JB010841; Rabinovich AB, 2013, PURE APPL GEOPHYS, V170, P1529, DOI 10.1007/s00024-012-0541-1; An C, 2014, GEOPHYS RES LETT, V41, P3988, DOI 10.1002/2014GL060567; Rabinovich AB, 2013, GEOPHYS RES LETT, V40, P3157, DOI 10.1002/grl.50625; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; BENMENAH.A, 1972, J GEOPHYS RES, V77, P3097, DOI 10.1029/JB077i017p03097; GUSMAN A.R., 2014, AGU FALL M 2014 DEC; Heidarzadeh M, 2014, PURE APPL GEOPHYS, V171, P3405, DOI 10.1007/s00024-013-0731-5; Heidarzadeh M, 2013, PURE APPL GEOPHYS, V170, P1449, DOI 10.1007/s00024-012-0509-1; Heidarzadeh M, 2013, PURE APPL GEOPHYS, V170, P1275, DOI 10.1007/s00024-012-0558-5; IOC IHO BODC, 2003, CENT ED GEBCO DIG AT; IOC-ITIC, 2014, 01 APR 2014 UTC MW 8; Liu P. L.-F., 1998, TECHNICAL REPORT; MATHWORKS, 2014, MATLAB US MAN; Mofjeld HO, 2001, GEOPHYS RES LETT, V28, P335, DOI 10.1029/2000GL011710; NOAA, 2014, NAT DAT BUOY CTR NAT; Okal EA, 2014, GEOPHYS J INT, V196, P340, DOI 10.1093/gji/ggt328; PTWC, 2014, SEA LEV OBS 01 APR 2; SATAKE K, 1988, PURE APPL GEOPHYS, V126, P27, DOI 10.1007/BF00876912; USGS, 2014, US GEOL SURV EARTHQ; Wessel P., 1991, EOS T AM GEOPHYS UN, V72, P441, DOI DOI 10.1029/90EO00319	25	2	2	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	0033-4553	1420-9136		PURE APPL GEOPHYS	Pure Appl. Geophys.	MAR	2015	172	3-4					719	730		10.1007/s00024-014-0983-8		12	Geochemistry & Geophysics	Geochemistry & Geophysics	CD2HG	WOS:000350895700007		
J	Tolkova, E; Tanaka, H; Roh, M				Tolkova, Elena; Tanaka, Hitoshi; Roh, Min			Tsunami Observations in Rivers from a Perspective of Tsunami Interaction with Tide and Riverine Flow	PURE AND APPLIED GEOPHYSICS			English	Article						Tsunami; river; water level measurements; tide-tsunami interaction; wave-current interaction; numerical modeling	2011 TOHOKU TSUNAMI; SET-UP; WAVE; MODEL; RUNUP	The observations of the 2011 Tohoku tsunami and the 2010 Chilean tsunami in several rivers in Japan and in the Columbia River in the USA are analyzed for patterns of tsunami behavior in river environments. Tsunamis in rivers exhibit actions very different from those observed on an open coast, but very similar among different rivers, though the action scale in different rivers varies greatly. We describe two tsunami effects in rivers as observed in field data. First, the river tide modulates the tsunami wave in a very specific way common to all rivers. Second, a strong near-field tsunami can cause significant prolonged water accumulation in lower river reaches. Both effects are inherent in tidal river environments, and have been reproduced numerically in a simplified 1-D river using a non-linear, shallow-water model with bottom friction. The numerical experiments highlight the indispensable role of a tsunami's interaction with tide and riverine flow.	[Tolkova, Elena] NorthWest Res Associates, Bellevue, WA 98009 USA; [Tanaka, Hitoshi; Roh, Min] Tohoku Univ, Dept Civil Engn, Sendai, Miyagi 9808579, Japan	Tolkova, E (reprint author), NorthWest Res Associates, Bellevue, WA 98009 USA.	e.tolkova@gmail.com; tanaka@tsu-nami2.civil.tohoku.ac.jp; rohmin@kasen.civil.tohoku.ac.jp					Abe K, 1986, CONT SHELF RES, V5, P655; Adityawan MB, 2012, J EARTHQ TSUNAMI, V6, DOI 10.1142/S1793431112500339; Fritz HM, 2011, PURE APPL GEOPHYS, V168, P1989, DOI 10.1007/s00024-011-0283-5; Zhang YLJ, 2011, OCEAN MODEL, V40, P246, DOI 10.1016/j.ocemod.2011.09.005; GUZA RT, 1981, J GEOPHYS RES-OC ATM, V86, P4133, DOI 10.1029/JC086iC05p04133; BOWEN AJ, 1968, J GEOPHYS RES, V73, P2569, DOI 10.1029/JB073i008p02569; Liu HJ, 2013, PURE APPL GEOPHYS, V170, P1033, DOI 10.1007/s00024-012-0496-2; Tolkova E, 2013, PURE APPL GEOPHYS, V170, P1115, DOI 10.1007/s00024-012-0518-0; Titov VV, 1998, J WATERW PORT C-ASCE, V124, P157, DOI 10.1061/(ASCE)0733-950X(1998)124:4(157); Kowalik Z, 2010, CONT SHELF RES, V30, P633, DOI 10.1016/j.csr.2009.10.004; HOREL JD, 1984, J CLIM APPL METEOROL, V23, P1660, DOI 10.1175/1520-0450(1984)023<1660:CPCATA>2.0.CO;2; Burwell D, 2007, OCEAN MODEL, V19, P10, DOI 10.1016/i.ocemod.2007.05.003; CHEN C.-N., 2013, MANAGEMENT, DOI [10.1111/jfr3.12088, DOI 10.1111/JFR3.12088]; Horrevoets AC, 2004, J HYDROL, V294, P213, DOI 10.1016/j.jhydrol.2004.02.012; KAYANE K., 2011, J JSCE B, VB2-67, pI_246; KONISHI T., 1983, STUDIES RIVER INVASI, V31, P67; Kowalik Z, 2006, SCI TSUNAMI HAZARDS, V24, P242; LANDER J. F., 1993, TSUNAMIS AFFECTING W; Le T. V. H., 2007, ESTUARINE COASTAL SH, V71, P110, DOI [10.1016/j.ecss.2006.08.21, DOI 10.1016/J.ECSS.2006.08.21]; Mom N., 2011, GEOPHYS RES LETT, V38, DOI DOI 10.1029/2011GL049210; Shimozono T, 2014, PURE APPL GEOPHYS, V171, P3217, DOI 10.1007/s00024-014-0803-1; Stoker J. J., 1957, WATER WAVES; Tanaka H., 2008, J HYDROSCI HYDRAULIC, V66, P91; Tanaka H, 2012, P 33 INT C COAST ENG; TANAKA H., 2013, P 7 INT C COAST DYN, P1601; Tanaka H, 2014, OCEAN DYNAM, V64, P1319, DOI 10.1007/s10236-014-0749-y; TINH N. X., 2007, P INT C VIOL FLOWS V; Tolkova E, 2014, PURE APPL GEOPHYS, V171, P2289, DOI 10.1007/s00024-014-0825-8; Tsuji Y, 1991, NAT HAZARDS, V4, P257, DOI 10.1007/BF00162791; WILSON B. W., 1972, GREAT ALASKA EARTHQU, P158; WILSON B. W., 1972, GREAT ALASKA EARTHQU, P361; Yasuda H, 2010, J HYDRAUL ENG-ASCE, V136, P93, DOI 10.1061/(ASCE)HY.1943-7900.0000150; Yeh H., 2012, Journal of Disaster Research, V7, P604	33	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	0033-4553	1420-9136		PURE APPL GEOPHYS	Pure Appl. Geophys.	MAR	2015	172	3-4					953	968		10.1007/s00024-014-1017-2		16	Geochemistry & Geophysics	Geochemistry & Geophysics	CD2HG	WOS:000350895700021		
J	Nakamura, T; Iwase, A; Bayasula, B; Nagatomo, Y; Kondo, M; Nakahara, T; Takikawa, S; Goto, M; Kotani, T; Kiyono, T; Kikkawa, F				Nakamura, Tomoko; Iwase, Akira; Bayasula, B.; Nagatomo, Yoshinari; Kondo, Mika; Nakahara, Tatsuo; Takikawa, Sachiko; Goto, Maki; Kotani, Tomomi; Kiyono, Tohru; Kikkawa, Fumitaka			CYP51A1 Induced by Growth Differentiation Factor 9 and Follicle-Stimulating Hormone in Granulosa Cells Is a Possible Predictor for Unfertilization	REPRODUCTIVE SCIENCES			English	Article						cholesterol synthesis pathway; CYP51A1; fertilization; GDF9; granulosa cell	MEIOSIS-ACTIVATING STEROL; LANOSTEROL 14-ALPHA-DEMETHYLASE; MOUSE OOCYTES; IN-VITRO; MATURATION; OVARIES; FOLLICULOGENESIS; FERTILIZATION; RESUMPTION; PATHWAY	Growth differentiation factor 9 (GDF9), an oocyte-secreted factor, whose receptors exist in granulosa cells, is involved in follicle progression. Therefore, GDF9 is considered to potentially mediate signals necessary for follicular growth. However, the effect of GDF9 on human granulosa cells is not fully understood. Human immortalized nonluteinized granulosa cell line (HGrC1) which we have previously reported was stimulated with GDF9 and/or follicle-stimulating hormone (FSH). Granulosa cells obtained from in vitro fertilization (IVF) patients were also evaluated with quantitative reverse transcription polymerase chain reaction (RT-PCR). Real-time RT-PCR showed that GDF9 increased messenger RNA (mRNA) levels of enzymes required for cholesterol biosynthesis, such as 3-hydroxy-3-methylglutanyl-CoA synthase 1 (HMGCS1), farnesyl-diphosphate farnesyltransferase 1, squalene epoxidase, lanosterol synthase, and cytochrome P450, family 51, subfamily A, polypeptide 1 (CYP51A1). A greater increase in mRNA levels of HMGCS1 and CYP51A1 was observed by combined treatment with GDF9 and FSH. Clinical samples showed a significant increase in CYP51A1 mRNA in the group of granulosa cells connected with unfertilized oocytes. Our results suggest that GDF9, possibly with FSH, may play significant roles in the regulation of cholesterol biosynthesis and the expression of CYP51A1 which might be a predictor for unfertilization.	[Nakamura, Tomoko; Iwase, Akira; Bayasula, B.; Nagatomo, Yoshinari; Kondo, Mika; Nakahara, Tatsuo; Takikawa, Sachiko; Goto, Maki; Kotani, Tomomi; Kikkawa, Fumitaka] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Iwase, Akira; Goto, Maki] Nagoya Univ Hosp, Dept Maternal & Perinatal Med, Showa Ku, Nagoya, Aichi, Japan; [Kiyono, Tohru] Natl Canc Ctr, Res Inst, Div Virol, Tyuo Ku, Tokyo 104, Japan	Iwase, A (reprint author), Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	akiwase@med.nagoya-u.ac.jp			Japan Society for the Promotion of Science, Japan [24592468]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Grant-in-Aid for Scientific Research 24592468 to Akira Iwase from Japan Society for the Promotion of Science, Japan.	Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Iwase A, 2009, J CLIN ENDOCR METAB, V94, P2184, DOI 10.1210/jc.2008-1948; Sato Y, 2011, LIFE SCI, V88, P43, DOI 10.1016/j.lfs.2010.10.019; Su YQ, 2009, SEMIN REPROD MED, V27, P32, DOI 10.1055/s-0028-1108008; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; Su YQ, 2008, DEVELOPMENT, V135, P111, DOI 10.1242/dev.009068; Tamura H, 2008, J PINEAL RES, V44, P280, DOI [10.1111/j.1600-079X.2007.00524.x, 10.1111/j.1600-079X.2007.00524.X]; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Baltsen M, 2001, BIOL REPROD, V65, P1743, DOI 10.1095/biolreprod65.6.1743; Bayasula Iwase A, 2013, J ASSIST REPROD GEN, V30, P1231, DOI DOI 10.1007/S10815-013-0004-323888310; Bayasula Iwase A, 2012, ENDOCRINOLOGY, V153, P2851; Cavilla JL, 2001, HUM REPROD, V16, P547, DOI 10.1093/humrep/16.3.547; Downs SM, 2001, BIOL REPROD, V64, P80, DOI 10.1095/biolreprod64.1.80; Grondahl C, 1998, BIOL REPROD, V58, P1297, DOI 10.1095/biolreprod58.5.1297; HILLIER SG, 1988, HUM REPROD, V3, P507; Ito Y, 2003, ZOOL SCI, V20, P717, DOI 10.2108/zsj.20.717; Jin SY, 2006, MOL CELL ENDOCRINOL, V249, P64, DOI 10.1016/j.mce.2006.01.008; Monaco ME, 2007, ZYGOTE, V15, P149, DOI 10.1017/S0967199407004133; Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004; Quinn MCJ, 2006, REPROD FERT DEVELOP, V18, P501, DOI 10.1071/RD05051; Rozman D, 2002, MOL CELL ENDOCRINOL, V187, P179, DOI 10.1016/S0303-7207(01)00693-1; Ruan BF, 1998, J LIPID RES, V39, P2005; Tsafriri A, 1998, MOL HUM REPROD, V4, P483, DOI 10.1093/molehr/4.5.483; Vaknin KM, 2001, BIOL REPROD, V64, P299, DOI 10.1095/biolreprod64.1.299; VEECK LL, 1988, ANN NY ACAD SCI, V541, P259, DOI 10.1111/j.1749-6632.1988.tb22263.x; Waksmonski SL, 2002, J INSECT PHYSIOL, V48, P667, DOI 10.1016/S0022-1910(02)00095-1; Wang C, 2009, J LIPID RES, V50, P2164, DOI 10.1194/jlr.M800533-JLR200	28	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1933-7191	1933-7205		REPROD SCI	Reprod. Sci.	MAR	2015	22	3					377	384		10.1177/1933719114529375		8	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CD4KY	WOS:000351052500015		
J	Strom, RG; Malhotra, R; Xiao, ZY; Ito, T; Yoshida, F; Ostrach, LR				Strom, Robert G.; Malhotra, Renu; Xiao, Zhi-Yong; Ito, Takashi; Yoshida, Fumi; Ostrach, Lillian R.			The inner solar system cratering record and the evolution of impactor populations	RESEARCH IN ASTRONOMY AND ASTROPHYSICS			English	Article						solar system: formation; minor planets, asteroids; Earth; Moon	MAIN-BELT ASTEROIDS; LUNAR CATACLYSM IMPACTORS; LATE HEAVY BOMBARDMENT; NEAR-EARTH ASTEROIDS; COLLISIONAL EVOLUTION; TERRESTRIAL PLANETS; GLOBAL DISTRIBUTION; SIZE DISTRIBUTION; MELT BRECCIAS; MARE BASALTS	We review previously published and newly obtained crater size-frequency distributions in the inner solar system. These data indicate that the Moon and the terrestrial planets have been bombarded by two populations of objects. Population 1, dominating at early times, had nearly the same size distribution as the present-day asteroid belt, and produced heavily cratered surfaces with a complex, multi-sloped crater size-frequency distribution. Population 2, dominating since about 3.8-3.7 Gyr, had the same size distribution as near-Earth objects (NEOs) and a much lower impact flux, and produced a crater size distribution characterized by a differential -3 single-slope power law in the crater diameter range 0.02 km to 100 km. Taken together with the results from a large body of work on age-dating of lunar and meteorite samples and theoretical work in solar system dynamics, a plausible interpretation of these data is as follows. The NEO population is the source of Population 2 and it has been in near-steady state over the past similar to 3.7-3.8 Gyr; these objects are derived from the main asteroid belt by size-dependent non-gravitational effects that favor the ejection of smaller asteroids. However, Population 1 was composed of main belt asteroids ejected from their source region in a size-independent manner, possibly by means of gravitational resonance sweeping during orbit migration of giant planets; this caused the so-called Late Heavy Bombardment (LHB). The LHB began some time before similar to 3.9 Gyr, peaked and declined rapidly over the next similar to 100 to 300 Myr, and possibly more slowly from about 3.8-3.7 Gyr to similar to 2 Gyr. A third crater population (Population S) consisted of secondary impact craters that can dominate the cratering record at small diameters.	[Strom, Robert G.; Malhotra, Renu] Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; [Xiao, Zhi-Yong] China Univ Geosci, Planetary Sci Inst, Wuhan 430074, Peoples R China; [Ito, Takashi; Yoshida, Fumi] Natl Astron Observ, Tokyo 1818588, Japan; [Ostrach, Lillian R.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Strom, RG (reprint author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.	rstrom@lpl.arizona.edu			NSF [AST-1312498]	We thank Z. Ivezic and J. S. Stuart for providing us with digital versions of their published data. RM acknowledges research support from NSF grant #AST-1312498. We also thank the anonymous referee for their comments which improved the quality of this paper.	Agnor CB, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/2/143; Cuk M, 2012, ICARUS, V218, P69, DOI 10.1016/j.icarus.2011.11.031; Minton DA, 2010, ICARUS, V207, P744, DOI 10.1016/j.icarus.2009.12.008; Tsiganis K, 2005, NATURE, V435, P459, DOI 10.1038/nature03539; McEwen AS, 2006, ANNU REV EARTH PL SC, V34, P535, DOI 10.1146/annurev.earth.34.031405.125018; MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0; Xiao ZY, 2014, ICARUS, V228, P260, DOI 10.1016/j.icarus.2013.10.002; Head JW, 2011, SCIENCE, V333, P1853, DOI 10.1126/science.1211997; Robbins SJ, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046450; Willbold M, 2011, NATURE, V477, P195, DOI 10.1038/nature10399; Hiesinger H, 2000, J GEOPHYS RES-PLANET, V105, P29239, DOI 10.1029/2000JE001244; Strom RG, 2011, PLANET SPACE SCI, V59, P1960, DOI 10.1016/j.pss.2011.03.018; Stoffler D, 2006, REV MINERAL GEOCHEM, V60, P519, DOI 10.2138/rmg.2006.60.05; Zappala V, 1998, ICARUS, V134, P176, DOI 10.1006/icar.1998.5946; Hiesinger H, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001985; Hartmann WK, 2005, ICARUS, V174, P294, DOI 10.1016/j.icarus.2004.11.023; Cuk M, 2011, ICARUS, V216, P363, DOI 10.1016/j.icarus.2011.08.011; Strom RG, 2005, SCIENCE, V309, P1847, DOI 10.1126/science.1113544; Dones L, 2009, SATURN FROM CASSINI-HUYGENS, P613, DOI 10.1007/978-1-4020-9217-6_19; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Marchi S, 2009, ASTRON J, V137, P4936, DOI 10.1088/0004-6256/137/6/4936; Le Feuvre M, 2011, ICARUS, V214, P1, DOI 10.1016/j.icarus.2011.03.010; Cuk M, 2010, ICARUS, V207, P590, DOI 10.1016/j.icarus.2009.12.013; Liou JC, 1997, SCIENCE, V275, P375, DOI 10.1126/science.275.5298.375; Bottke WF, 2006, ANNU REV EARTH PL SC, V34, P157, DOI 10.1146/annurev.earth.34.031405.125154; Bottke WF, 2012, NATURE, V485, P78, DOI 10.1038/nature10967; STROM RG, 1977, PHYS EARTH PLANET IN, V15, P156, DOI 10.1016/0031-9201(77)90028-0; Malhotra R, 2011, ICARUS, V216, P359, DOI 10.1016/j.icarus.2010.11.037; Fassett CI, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047294; HARTMANN WK, 1966, ICARUS, V5, P406, DOI 10.1016/0019-1035(66)90054-6; Strom RG, 2008, SCIENCE, V321, P79, DOI 10.1126/science.1159317; Bottke WF, 2005, ICARUS, V175, P111, DOI 10.1016/j.icarus.2004.10.026; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; Collins GS, 2005, METEORIT PLANET SCI, V40, P817; Minton DA, 2009, NATURE, V457, P1109, DOI 10.1038/nature07778; Johnson BC, 2012, NATURE, V485, P75, DOI 10.1038/nature10982; Michael GG, 2010, EARTH PLANET SC LETT, V294, P223, DOI 10.1016/j.epsl.2009.12.041; Joy KH, 2012, SCIENCE, V336, P1426, DOI 10.1126/science.1219633; Gomes R, 2005, NATURE, V435, P466, DOI 10.1038/nature03676; Robinson MS, 2010, SPACE SCI REV, V150, P81, DOI 10.1007/s11214-010-9634-2; Haskin LA, 1998, METEORIT PLANET SCI, V33, P959; Kring DA, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001529; Chapman CR, 2007, ICARUS, V189, P233, DOI 10.1016/j.icarus.2006.12.020; Trail D, 2007, GEOCHIM COSMOCHIM AC, V71, P4044, DOI 10.1016/j.gca.2007.06.003; Dundas CM, 2007, ICARUS, V186, P31, DOI 10.1016/j.icarus.2006.08.011; RUBINCAM DP, 1988, J GEOPHYS RES-SOLID, V93, P13805, DOI 10.1029/JB093iB11p13805; Neukum G, 2001, SPACE SCI REV, V96, P55, DOI 10.1023/A:1011989004263; Jedicke R, 1998, ICARUS, V131, P245, DOI 10.1006/icar.1997.5876; Frey H, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL033515; Yoshida F, 2003, PUBL ASTRON SOC JPN, V55, P701; TERA F, 1974, EARTH PLANET SC LETT, V22, P1, DOI 10.1016/0012-821X(74)90059-4; Norman MD, 2014, EARTH PLANET SC LETT, V388, P387, DOI 10.1016/j.epsl.2013.11.040; Feldman WC, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001506; Xiao ZY, 2012, ICARUS, V220, P254, DOI 10.1016/j.icarus.2012.05.012; Morbidelli A, 2009, ASTRON ASTROPHYS, V507, P1041, DOI 10.1051/0004-6361/200912876; Stuart JS, 2004, ICARUS, V170, P295, DOI [10.1016/j.icarus.2004.03.018, 10.1016/j.icarcus.2004.03.018]; Arvidson R.E., 1979, ICARUS, V37, P467, DOI DOI 10.1016/0019-1035(79)90009-5; Benavidez PG, 2012, ICARUS, V219, P57, DOI 10.1016/j.icarus.2012.01.015; Binzel R. P., 2002, ASTEROIDS, VIII, P409; Chapman C.R., 1986, SATELLITES, P492; Cheng AF, 2004, ICARUS, V169, P357, DOI 10.1016/j.icarus.2004.02.002; Croft S.K., 1985, J GEOPHYS RES, V90, P828; Dawson RI, 2012, ASTROPHYS J, V750, DOI 10.1088/0004-637X/750/1/43; Farinella P, 1999, SCIENCE, V283, P1507, DOI 10.1126/science.283.5407.1507; French B.M., 1998, TRACES CATASTROPHE; Gallant J, 2009, ICARUS, V202, P371, DOI 10.1016/j.icarus.2009.03.025; Greenberg R., 1991, MIRANDA URANUS, V1, P693; Grieve Richard A., 1994, HAZARDS DUE COMETS A, P417; HARTMANN WK, 1995, METEORITICS, V30, P451; Hartmann WK, 2007, ICARUS, V186, P11, DOI 10.1016/j.icarus.2006.09.009; Head JW, 2010, SCIENCE, V329, P1504, DOI 10.1126/science.1195050; Ito T, 2010, ASTRON ASTROPHYS, V519, DOI 10.1051/0004-6361/200912901; Ito T., 2006, ADV SPACE RES, V38, P817; Ivanov B. A., 2002, ASTEROIDS, P89; Ivezic Z, 2001, ASTRON J, V122, P2749, DOI 10.1086/323452; JeongAhn Y., 2010, B AM ASTRONOMICAL SO, V42, P1053; Kirchoff MR, 2013, ICARUS, V225, P325, DOI 10.1016/j.icarus.2013.03.018; Kirkwood D., 1882, OBSERVATORY, V5, P194; Liu DY, 2012, EARTH PLANET SC LETT, V319, P277, DOI 10.1016/j.epsl.2011.12.014; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; Marchi S, 2013, NATURE, V499, P59, DOI 10.1038/nature12280; Masiero JR, 2011, ASTROPHYS J, V741, DOI 10.1088/0004-637X/741/2/68; McEwen AS, 2005, ICARUS, V176, P351, DOI 10.1016/j.icarus.2005.02.009; McKinnon W.B., 1991, CRATERING URANIAN ST, V1, P629; Melosh H. J., 1999, COMPUTING PROJECTILE; Melosh H.J., 1989, IMPACT CRATERING GEO; Michael GG, 2013, ICARUS, V226, P885, DOI 10.1016/j.icarus.2013.07.004; Minton DA, 2011, ASTROPHYS J, V732, DOI 10.1088/0004-637X/732/1/53; Morbidelli A, 2003, ICARUS, V163, P120, DOI 10.1016/S0019-1035(03)00047-2; Morota T, 2003, EARTH PLANET SC LETT, V206, P315, DOI 10.1016/S0012-821X(02)01111-1; Neukum G., 1994, SPACE SCI SERIES, P359; Ostrach LR, 2015, ICARUS, V250, P602, DOI 10.1016/j.icarus.2014.11.010; Ryder G, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001583; Schmidt R.M., 1987, INT J IMPACT ENG, V5, P543, DOI DOI 10.1016/0734-743X(87)90069-8; Shoemaker E. M., 1965, NATURE LUNAR SURFACE, P23; Stern SA, 2000, ICARUS, V143, P360, DOI 10.1006/icar.1999.6263; Strom R. G., 1988, MERCURY, P336; Strom R.G., 1992, MARS, P383, DOI DOI 10.1016/S0032-0633(99)00016-1; STROM RG, 1981, J GEOPHYS RES-SPACE, V86, P8659, DOI 10.1029/JA086iA10p08659; STROM RG, 1979, SPACE SCI REV, V24, P3; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; STROM RG, 1990, SCIENCE, V250, P437, DOI 10.1126/science.250.4979.437; Tera F., 1973, LUNAR PLANET SCI, VIV, P723; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Turner G., 1973, LUN SCI C 4, V4; Usui F, 2013, ASTROPHYS J, V762, DOI 10.1088/0004-637X/762/1/56; Wilhelms D. E., 1978, LUNAR PLANET SCI, V9, P3735; Wood C, 1978, LUNAR PLANET SCI, V9, P3669; ZAHNLE KJ, 1992, J GEOPHYS RES-PLANET, V97, P10243	109	2	2	NATL ASTRONOMICAL OBSERVATORIES, CHIN ACAD SCIENCES	BEIJING	20A DATUN RD, CHAOYANG, BEIJING, 100012, PEOPLES R CHINA	1674-4527			RES ASTRON ASTROPHYS	Res. Astron. Astrophys.	MAR	2015	15	3					407	434		10.1088/1674-4527/15/3/009		28	Astronomy & Astrophysics	Astronomy & Astrophysics	CC9HY	WOS:000350680800009		
J	Itagaki, T; Nakano, Y; Okuda, N; Izawa, M; Onodera, M; Imanaka, H; Nishimura, M				Itagaki, Taiga; Nakano, Yuuki; Okuda, Nao; Izawa, Masayo; Onodera, Mutsuo; Imanaka, Hideaki; Nishimura, Masaji			Hyperoxemia in Mechanically Ventilated, Critically Ill Subjects: Incidence and Related Factors	RESPIRATORY CARE			English	Article						oxygenation; hyperoxemia; mechanical ventilation; oxygen toxicity; acute lung injury; critical care	ACUTE LUNG INJURY; OBSERVATIONAL COHORT; CARDIAC-ARREST; OXYGEN; RESUSCITATION; ASSOCIATION; MORTALITY; PRESSURE	BACKGROUND: Excessive supplemental oxygen causes injurious hyperoxemia. Before establishing the best P-aO2 targets for mechanically ventilated patients, it is important to understand the incidence of hyperoxemia and related factors. We investigated oxygenation in mechanically ventilated subjects in our ICU and evaluated factors related to hyperoxemia (P-aO2 > 120 mm Hg) at 48 h after initiation of mechanical ventilation. METHODS: We retrospectively reviewed the medical records of patients admitted to our ICU from January 2010 to May 2013. Inclusion criteria were 15 y of age or older and administration of mechanical ventilation for > 48 h. Patients at risk of imminent death on admission or who had received noninvasive ventilation were excluded. We collected subject demographics, reasons for mechanical ventilation, and during mechanical ventilation, we collected arterial blood gas data and ventilator settings on the first day of intubation (T1), 48 h after initiation of mechanical ventilation (T2), and on the day of extubation (T3). Multivariable logistic regression analysis was performed to clarify independent variables related to hyperoxemia at T2. RESULTS: For the study period, data for 328 subjects were analyzed. P-aO2 statistically significantly increased over time to 90 (interquartile range of 74-109) mm Hg at Ti, 105 (89-120) mm Hg at T2, and 103 (91-119) mm Hg at T3 (P < .001), coincident with decreases in F-IO2 of 0.4 (0.3-0.5) at T1, 0.3 (0.3-0.4) at T2, and 0.3 (0.3-0.35) at T3 (P < .001). Hyperoxemia occurred in 15.6% (T1), 25.3% (T2), and 22.4% (T3) of subjects. Multivariable logistic regression analysis revealed that hyperoxemia was independently associated with age of < 40 y (odds ratio 2.6, 95% CI 1.1-6.0), Acute Physiology and Chronic Health Evaluation II scores of >= 30 (odds ratio 0.53, 95% Cl 0.3-1.0), and decompensated heart failure (odds ratio 1.9, 95% CI 1.1 to 3.5). CONCLUSIONS: During mechanical ventilation of critically ill subjects, P-aO2 increased, and F-IO2 decreased. One in 4 subjects were hyperoxemic at T2, and hyperoxemia persisted until T3.	[Itagaki, Taiga; Okuda, Nao; Izawa, Masayo; Onodera, Mutsuo; Nishimura, Masaji] Univ Tokushima, Dept Emergency & Crit Care Med, Grad Sch, Tokushima 7708503, Japan; [Nakano, Yuuki] Univ Tokushima, Sch Med, Tokushima 7708503, Japan; [Imanaka, Hideaki] Tokushima Univ Hosp, Dept Emergency & Disaster Med, Tokushima, Japan	Nishimura, M (reprint author), Univ Tokushima, Dept Emergency & Crit Care Med, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	nmasaji@tokushima-u.ac.jp					Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Martin DS, 2013, CRIT CARE MED, V41, P423, DOI 10.1097/CCM.0b013e31826a44f6; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Schmidt B, 2013, JAMA-J AM MED ASSOC, V309, P2111, DOI 10.1001/jama.2013.5555; Wijesinghe M, 2009, HEART, V95, P198, DOI 10.1136/hrt.2008.148742; Antonelli M, 2001, INTENS CARE MED, V27, P1718; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; ZWEMER CF, 1994, RESUSCITATION, V27, P159, DOI 10.1016/0300-9572(94)90009-4; Maniatis NA, 2008, VASC PHARMACOL, V49, P119, DOI 10.1016/j.vph.2008.06.009; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010; Panwar R, 2013, ANAESTH INTENS CARE, V41, P505; DAVIS WB, 1983, NEW ENGL J MED, V309, P878, DOI 10.1056/NEJM198310133091502; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Kavanagh BP., 1998, CURR OPIN CRIT CARE, V4, P16, DOI 10.1097/00075198-199802000-00003	15	0	0	DAEDALUS ENTERPRISES INC	IRVING	9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA	0020-1324	1943-3654		RESP CARE	Respir. Care	MAR	2015	60	3					335	340		10.4187/respcare.03451		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	CD2IB	WOS:000350898700005		
J	Chikata, Y; Okuda, N; Izawa, M; Onodera, M; Nishimura, M				Chikata, Yusuke; Okuda, Nao; Izawa, Masayo; Onodera, Mutsuo; Nishimura, Masaji			Performance of Ventilators Compatible With Magnetic Resonance Imaging: A Bench Study	RESPIRATORY CARE			English	Article						magnetic resonance imaging; MRI; MRI-compatible ventilator	TRANSPORT; ANESTHETIST	BACKGROUND: Magnetic resonance imaging (MRI) is indispensable for diagnosing brain and spinal cord abnormalities. Magnetic components cannot be used during MRI procedures; therefore, patient support equipment must use MRI-compatible materials. However, little is known of the performance of MRI-compatible ventilators. METHODS: At commonly used settings, we tested the delivered tidal volume (V-T), F-IO2, PEEP, and operation of the high-inspiratory-pressure-relief valves of 4 portable MRI-compatible ventilators (Pneupac VR1, ParaPAC 200DMRI, CAREvent MRI, iVent201) and one ICU ventilator (Servo-i). Each ventilator was set in volume control/continuous mandatory ventilation mode. Breathing frequency and V-T were tested at 10 breaths/min and 300, 500, and 700 mL, respectively. The Pneupac VR1 has fixed V-T and frequency combinations, so it was tested at V-T = 300 mL and 20 breaths/min, V-T = 500 mL and 12 breaths/min, and V-T = 800 mL and 10 breaths/min. F-IO2, was 0.6 and 1.0. At the air-mix setting, F-IO2 was fixed at 0.5 with the Pneupac VR1, 0.45 with the ParaPAC 200DMRI, and 0.6 with the CAREvent MRI. PEEP was set at 5 and 10 cm H2O, and pressure relief was set at 30 and 40 cm H2O. RESULTS: V-T error varied widely among ventilators (-28.1 to 25.5%). As V-T increased, error decreased with the Pneupac VR1, ParaPAC 200DMRI, and CAREvent MRI (P < .05). F-IO2 error ranged from 13.3 to 25.3% at 0.6 (or air mix). PEEP error varied among ventilators (-29.2 to 42.5%). Only the Servo-i maintained V-T, F-IO2 and PEEP at set levels. The pressure-relief valves worked in all ventilators. CONCLUSIONS: None of the MRI-compatible ventilators maintained V-T, F-IO2, and PEEP at set levels. Vital signs of patients with unstable respiratory mechanics should be monitored during transport and MRI.	[Chikata, Yusuke] Tokushima Univ Hosp, Med Equipment Ctr, Tokushima, Japan; [Okuda, Nao; Izawa, Masayo; Onodera, Mutsuo; Nishimura, Masaji] Univ Tokushima, Emergency & Crit Care Med, Grad Sch, Tokushima 7708503, Japan	Nishimura, M (reprint author), Univ Tokushima, Emergency & Crit Care Med, Grad Sch, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	nmasaji@tokushima-u.ac.jp					Blakeman TC, 2011, RESP CARE, V56, P1791, DOI 10.4187/respcare.01176; Blakeman TC, 2013, RESP CARE, V58, P264, DOI 10.4187/respcare.01994; Boussen S, 2013, RESP CARE, V58, P1911, DOI 10.4187/respcare.02144; Chipman DW, 2007, RESP CARE, V52, P740; Lyazidi A, 2010, INTENS CARE MED, V36, P2074, DOI 10.1007/s00134-010-2044-9; MENON DK, 1992, ANAESTHESIA, V47, P240, DOI 10.1111/j.1365-2044.1992.tb02130.x; PEDEN CJ, 1992, ANAESTHESIA, V47, P508, DOI 10.1111/j.1365-2044.1992.tb02278.x; Williams EJ, 1999, ANAESTHESIA, V54, P969, DOI 10.1046/j.1365-2044.1999.01009.x; Zanetta G, 2002, INTENS CARE MED, V28, P443, DOI 10.1007/s00134-002-1242-5	9	0	0	DAEDALUS ENTERPRISES INC	IRVING	9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA	0020-1324	1943-3654		RESP CARE	Respir. Care	MAR	2015	60	3					341	346		10.4187/respcare.03528		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	CD2IB	WOS:000350898700006		
J	Goto, S; Sayanagi, K; Ikuno, Y; Jo, Y; Gomi, F; Nishida, K				Goto, So; Sayanagi, Kaori; Ikuno, Yasushi; Jo, Yukari; Gomi, Fumi; Nishida, Kohji			COMPARISON OF VISUAL PROGNOSES BETWEEN NATURAL COURSE OF SIMPLE HEMORRHAGE AND CHOROIDAL NEOVASCULARIZATION TREATED WITH INTRAVITREAL BEVACIZUMAB IN HIGHLY MYOPIC EYES A 1-Year Follow-up	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						high myopia; subretinal hemorrhage; simple hemorrhage; choroidal neovascularization; bevacizumab	INDOCYANINE GREEN ANGIOGRAPHY; LACQUER CRACK FORMATION; PATHOLOGICAL MYOPIA; SUBRETINAL HEMORRHAGES; INJECTION; OUTCOMES; DEGENERATION; PROGRESSION; ATROPHY; ACUITY	Purpose: To compare the long-term outcomes of simple hemorrhage (SH) without any treatments and myopic choroidal neovascularization (mCNV) treated with intravitreal bevacizumab in highly myopic eyes. Methods: Twenty eyes (17 patients) with SH and 28 eyes (27 patients) with mCNV were included. We retrospectively evaluated the refractive error, axial length, age, best-corrected visual acuity, and the integrity of photoreceptor inner segment/outer segment junction and compared the two groups. Results: The mean patient age was 41.6 +/- 11.2 years, the mean refractive error -12.7 +/- 3.57 diopters, and the mean axial length was 29.64 +/- 1.42 mm. Patients in the SH group were significantly (P < 0.001) younger than those in the mCNV group (34.8 vs. 46.5 years, respectively). There were no significant differences in other parameters between the groups. Compared with baseline, the best-corrected visual acuity improved significantly (P < 0.01) at 12 months in both groups. The change in vision at 12 months in the SH group was significantly (P < 0.05) better than that in the mCNV group, although there were no significant differences at 3 months or 6 months. The final integrity of photoreceptor inner segment/outer segment junction was significantly associated with the final best-corrected visual acuity (P, 0.05). Conclusion: Eyes with SH had a more favorable visual prognosis compared with eyes with mCNV treated with intravitreal bevacizumab. The differential diagnosis of these pathologies is important.	[Goto, So; Sayanagi, Kaori; Ikuno, Yasushi; Jo, Yukari; Gomi, Fumi; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan	Sayanagi, K (reprint author), Osaka Univ, Sch Med, Dept Ophthalmol, E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaori.sayanagi@ophthal.med.osaka-u.ac.jp					AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573; Reichel E, 1995, OPHTHALMOLOGY, V102, P1871; Baba T, 2010, BRIT J OPHTHALMOL, V94, P864, DOI 10.1136/bjo.2009.166025; Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P1, DOI 10.1007/s00417-012-2022-8; Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570; Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003; HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177; Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8; Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5; Hayashi K, 2012, RETINA-J RET VIT DIS, V32, P687, DOI 10.1097/IAE.0b013e3182278bae; Quaranta M, 1996, AM J OPHTHALMOL, V122, P663; Ikuno Y, 2010, AM J OPHTHALMOL, V149, P140, DOI 10.1016/j.ajo.2009.08.008; Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887; HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923; Asai T, 2014, INVEST OPHTH VIS SCI, V55, P226, DOI 10.1167/iovs.13-12658; Axer-Siegez R, 2004, OPHTHAL SURG LAS IM, V35, P139; HAYASAKA S, 1990, GRAEF ARCH CLIN EXP, V228, P277, DOI 10.1007/BF00920048; Ikuno Y, 2008, RETINA-J RET VIT DIS, V28, P1124, DOI 10.1097/IAE.0b013e318174417a; Kim YM, 2011, EYE, V25, P936, DOI 10.1038/eye.2011.94; KLEIN RM, 1988, AM J OPHTHALMOL, V106, P282, DOI 10.1016/0002-9394(88)90362-5; Li Haitao, 2004, Yan Ke Xue Bao, V20, P57; Moriyama M, 2011, RETINA-J RET VIT DIS, V31, P74, DOI 10.1097/IAE.0b013e3181e91148; Nagaoka N, 2011, AM J OPHTHALMOL, V152, P420, DOI 10.1016/j.ajo.2011.03.002; OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P29; OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003; Shih YF, 2006, BRIT J OPHTHALMOL, V90, P546, DOI 10.1136/bjo.2005.081992; Tabandeh H, 1999, OPHTHALMOLOGY, V106, P2063, DOI 10.1016/S0161-6420(99)90484-0; Yoon JU, 2012, RETINA-J RET VIT DIS, V32, P949, DOI [10.1097/IAE.0b013e318227a9ef, 10.1097/IAE.0b013e318227aa09]	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	MAR	2015	35	3					429	434				6	Ophthalmology	Ophthalmology	CC4AO	WOS:000350293100019		
J	Mukai, R; Sato, T; Kishi, S				Mukai, Ryo; Sato, Taku; Kishi, Shoji			REPAIR MECHANISM OF RETINAL PIGMENT EPITHELIAL TEARS IN AGE-RELATED MACULAR DEGENERATION	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article						age-related macular degeneration; Bruch membrane; retinal pigment epithelial tears; spectral domain optical coherence tomography; subretinal fluid; swept-source optical coherence tomography	POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; GOOD VISUAL-ACUITY; CLINICOPATHOLOGICAL CORRELATION; PHOTODYNAMIC THERAPY; PRESERVATION; VERTEPORFIN; FOVEA	Purpose: To investigate repair mechanisms of retinal pigment epithelial (RPE) tears in age-related macular degeneration. Methods: The authors retrospectively studied 10 eyes with age-related macular degeneration that developed RPE tears during follow-up or after treatment with an antivascular endothelial growth factor drug or photodynamic therapy combined with ranibizumab. After development of the RPE tears, all follow-ups exceeded 13 months. Spectral domain or swept-source optical coherence tomography have been used to examine consecutive retinal changes where the RPE tears developed and attempted to determine the repair mechanisms. Results: Retinal pigment epithelial tears developed during the natural course (n = 4) after ranibizumab treatment (n = 2) and after photodynamic therapy and ranibizumab (n = 4). Subretinal fluid persisted for more than 6 months after the RPE tears developed (n = 4), with the area where the RPE was lost found to be covered with thickened proliferative tissue. In 6 eyes where the subretinal fluid was absorbed within 2 months, optical coherence tomography showed the outer retina appeared to be directly attached to Bruch membrane, and there was attenuation of the normal hyperreflective band attributable to normal RPE during follow-up. Conclusion: Results suggest that two repair processes may be present in the area where RPE tears developed. Persistent subretinal fluid may lead to repair with thick proliferative tissue, while the outer retina appears to attach to Bruch membrane when there is early subretinal fluid resolution after RPE tear development.	[Mukai, Ryo; Sato, Taku; Kishi, Shoji] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan	Mukai, R (reprint author), Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gunma 3718511, Japan.	ryohmukai@gmail.com					YEO JH, 1988, OPHTHALMOLOGY, V95, P8; HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417; Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb; Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024; Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366; TOTH CA, 1995, OPHTHALMOLOGY, V102, P272; Lee MY, 2011, RETINA-J RET VIT DIS, V31, P65, DOI 10.1097/IAE.0b013e3181e586e3; Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234; Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db; Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198; BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694; CHUANG EL, 1988, EYE, V2, P106; Coscas G, 1990, REV INT TRACH PATHOL, V67, P17; Coscas G, 1990, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V67, P13; DECKER WL, 1983, OPHTHALMOLOGY, V90, P507; GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513; Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007; HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769; MACHEMER R, 1991, ARCH OPHTHALMOL-CHIC, V109, P1492; NEGI A, 1984, OPHTHALMOLOGY, V91, P1678; Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832; West S, 2001, B WORLD HEALTH ORGAN, V79, P244	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	MAR	2015	35	3					473	480				8	Ophthalmology	Ophthalmology	CC4AO	WOS:000350293100026		
J	Hori, S; Yamamoto, K				Hori, Sadao; Yamamoto, Kaori			Optic Coherence Tomography of Foveal Hemorrhage Associated With Chronic Myelogenous Leukemia	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Editorial Material						optic coherence tomography; foveal hemorrhage; chronic myelogenous leukemia			[Hori, Sadao] Nishi Kasai Inouye Eye Hosp, Tokyo 1340088, Japan; [Yamamoto, Kaori] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan	Hori, S (reprint author), Nishi Kasai Inouye Eye Hosp, Edogawa Ku, 5-4-9 Nishi Kasai, Tokyo 1340088, Japan.	hori-s@inouye-eye.or.jp					Chankiewitz E, 2010, OPHTHALMOLOGE, V107, P359, DOI 10.1007/s00347-009-2081-3; LEONARDY NJ, 1990, AM J OPHTHALMOL, V109, P436; Ortiz JM, 2010, INT J OPHTHALMOL-CHI, V3, P281, DOI 10.3980/j.issn.2222-3959.2010.03.24	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	MAR	2015	35	3					597	599				3	Ophthalmology	Ophthalmology	CC4AO	WOS:000350293100043		
J	Oribe, N; Hirano, Y; Kanba, S; del Re, E; Seidman, L; Mesholam-Gately, R; Goldstein, JM; Shenton, M; Spencer, KM; McCarley, RW; Niznikiewicz, M				Oribe, Naoya; Hirano, Yoji; Kanba, Shigenobu; del Re, Elisabetta; Seidman, Larry; Mesholam-Gately, Raquelle; Goldstein, Jill M.; Shenton, Martha; Spencer, Kevin M.; McCarley, Robert W.; Niznikiewicz, Margaret			Progressive Reduction of Visual P300 Amplitude in Patients With First-Episode Schizophrenia: An ERP Study	SCHIZOPHRENIA BULLETIN			English	Article						EEG; first-episode schizophrenia; P300; longitudinal; progression of schizophrenia	EVENT-RELATED POTENTIALS; GRAY-MATTER VOLUME; SUPERIOR TEMPORAL GYRUS; MISMATCH NEGATIVITY; PROCESSING DEFICITS; ONSET SCHIZOPHRENIA; LONGITUDINAL MRI; BRAIN; ATTENTION; ABNORMALITIES	Objective: To understand the underlying dynamic neurophysiological changes over the course of schizophrenia, it is important to study subjects longitudinally from the early stage of the illness. We previously reported that visual P300 was already impaired in patients with first-episode schizophrenia (FESZ). This study demonstrates how the visual P300, as well as earlier components P1, N1, and N200, changed at the 1-year follow-up after their initial measurement. Methods: Visual ERPs were recorded with the same experimental paradigm and acquisition protocol at both time points in FESZ (n = 18) and healthy comparison subjects (n = 24). Participants silently counted infrequent target stimuli ("x") amid standard stimuli ("y") presented on the screen while the 64-channel electroencephalogram was recorded. Results: FESZ showed smaller visual P300, N200, P1 (trend level) amplitude and delayed P300 and N1 latency at both time points; however, only P300 showed progressive amplitude reduction over the course of the illness at 1-year follow-up. P300 latency did not change over time in either group. FESZ showed significantly reduced Spatial Span total score at both time points, and there was a significant negative correlation between P300 peak amplitude and the Brief Psychiatric Rating Scale positive symptom score at baseline. Conclusion: These data show progressive P300 amplitude reduction in response to visual stimuli in the early stage of schizophrenia. These visual P300 findings support the concept of progression of schizophrenia, suggesting the usefulness of the visual P300 as a biological marker of progression.	[Oribe, Naoya; Hirano, Yoji; del Re, Elisabetta; McCarley, Robert W.; Niznikiewicz, Margaret] Harvard Univ, Sch Med, Clin Neurosci Div,Dept Psychiat, Lab Neurosci,VA Boston Healthcare Syst Brockton D, Brockton, MA 02301 USA; [Oribe, Naoya; Hirano, Yoji; Spencer, Kevin M.] Harvard Univ, Sch Med, Dept Psychiat,Boston Div, Neural Dynam Lab,Boston Vet Affairs Healthcare Sy, Boston, MA 02115 USA; [Oribe, Naoya; Hirano, Yoji; Kanba, Shigenobu] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan; [Seidman, Larry; Mesholam-Gately, Raquelle] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Mental Hlth Ctr,Publ Psychiat Div,B, Boston, MA 02115 USA; [Goldstein, Jill M.] Harvard Univ, Sch Med, Dept Psychiat, Brigham & Womens Hosp,Connors Ctr Womens Hlth & G, Boston, MA 02115 USA; [Goldstein, Jill M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA; [Shenton, Martha] Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Shenton, Martha] Brigham & Womens Hosp, Dept Radiol, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Shenton, Martha] Harvard Univ, Sch Med, Boston Div, Res & Dev,Boston Vet Affairs Healthcare Syst, Boston, MA USA	Niznikiewicz, M (reprint author), Harvard Univ, Sch Med, Dept Psychiat 116A, VA Boston Healthcare Syst,Brockton Div, 940 Belmont St, Brockton, MA 02301 USA.	Margaret_Niznikiewicz@hms.harvard.edu			Department of Veterans Affairs Medical Research Awards (Schizophrenia Center, Merit Awards); National Institute of Mental Health [K05MH070047, R01MH50747, R01MH40799, R01MH052807, CIDAR P50MH080272]; Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation [S2208]; Japan Society for the Promotion of Science [B 22791129]; Fund for Pharmacopsychiatry Research from SENSHIN Medical Research Foundation	Department of Veterans Affairs Medical Research Awards (Schizophrenia Center, Merit Awards to R.W.M. and M.E.S.); National Institute of Mental Health (K05MH070047 and R01MH50747 to M.E.S., R01MH40799 and R01MH052807 to R.W.M., CIDAR P50MH080272 to R.W.M. and M.E.S.); Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (S2208 to S.K.) and Grant-in-Aid for Young Scientists (B 22791129 to Y.H.) from Japan Society for the Promotion of Science; Fund for Pharmacopsychiatry Research (to Y.H.) from SENSHIN Medical Research Foundation.	Mesholam-Gately RI, 2009, NEUROPSYCHOLOGY, V23, P315, DOI 10.1037/a0014708; Dichter GS, 2006, J NERV MENT DIS, V194, P179, DOI 10.1097/01.nmd.0000202490.97425.de; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Lieberman JA, 2005, ARCH GEN PSYCHIAT, V62, P361, DOI 10.1001/archpsyc.62.4.361; Sun D, 2009, MOL PSYCHIATR, V14, P976, DOI 10.1038/mp.2008.34; FORD JM, 1994, BIOL PSYCHIAT, V36, P153, DOI 10.1016/0006-3223(94)91221-1; FORD JM, 1994, BIOL PSYCHIAT, V35, P96, DOI 10.1016/0006-3223(94)91198-3; Mathalon DH, 2001, ARCH GEN PSYCHIAT, V58, P148, DOI 10.1001/archpsyc.58.2.148; Bledowski C, 2004, J NEUROSCI, V24, P9353, DOI 10.1523/JNEUROSCI.1897-04.2004; Light GA, 2005, AM J PSYCHIAT, V162, P1741, DOI 10.1176/appi.ajp.162.9.1741; Nakamura M, 2007, BIOL PSYCHIAT, V62, P773, DOI 10.1016/j.biopsych.2007.03.030; Carpenter DM, 2008, NEUROREPORT, V19, P1369, DOI 10.1097/WNR.0b013e32830abc35; Butler PD, 2007, BRAIN, V130, P417, DOI 10.1093/brain/awl233; Dias EC, 2011, ARCH GEN PSYCHIAT, V68, P654, DOI 10.1001/archgenpsychiatry.2011.17; Mathalon DH, 2000, BIOL PSYCHIAT, V47, P434, DOI 10.1016/S0006-3223(99)00277-2; Friedman JI, 2008, AM J PSYCHIAT, V165, P1024, DOI 10.1176/appi.ajp.2008.07101640; ANNETT M, 1970, BRIT J PSYCHOL, V61, P303; Salisbury DF, 2007, ARCH GEN PSYCHIAT, V64, P521, DOI 10.1001/archpsyc.64.5.521; Jaaro-Peled H, 2009, TRENDS NEUROSCI, V32, P485, DOI 10.1016/j.tins.2009.05.007; Ruggeri M, 2005, SCHIZOPHR RES, V75, P107, DOI 10.1016/j.schres.2004.05.017; Rosenberger G, 2008, SCHIZOPHR RES, V102, P181, DOI 10.1016/j.schres.2008.04.019; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Lewis DA, 2008, NEUROPSYCHOPHARMACOL, V33, P141, DOI 10.1038/sj.npp.1301563; Doniger GM, 2002, ARCH GEN PSYCHIAT, V59, P1011, DOI 10.1001/archpsyc.59.11.1011; SIMSON R, 1977, ELECTROEN CLIN NEURO, V42, P528, DOI 10.1016/0013-4694(77)90216-4; Gur RE, 1998, ARCH GEN PSYCHIAT, V55, P145, DOI 10.1001/archpsyc.55.2.145; Kasai K, 2003, AM J PSYCHIAT, V160, P156, DOI 10.1176/appi.ajp.160.1.156; van Haren NEM, 2007, NEUROPSYCHOPHARMACOL, V32, P2057, DOI 10.1038/sj.npp.1301347; Bestelmeyer PEG, 2012, PSYCHIAT RES, V197, P140, DOI 10.1016/j.psychres.2011.09.030; Umbricht D, 2005, SCHIZOPHR RES, V76, P1, DOI 10.1016/j.schres.2004.12.002; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Horan WP, 2012, SCHIZOPHR RES, V135, P95, DOI 10.1016/j.schres.2011.11.005; Stige S, 2007, DEV NEUROPSYCHOL, V32, P563; Luck SJ, 2009, PSYCHOPHYSIOLOGY, V46, P776, DOI 10.1111/j.1469-8986.2009.00817.x; Schechter I, 2005, CLIN NEUROPHYSIOL, V116, P2204, DOI 10.1016/j.clinph.2005.06.013; Jeon YW, 2003, PSYCHOPHYSIOLOGY, V40, P684, DOI 10.1111/1469-8986.00070; Kasai K, 2003, ARCH GEN PSYCHIAT, V60, P766, DOI 10.1001/archpsyc.60.8.766; Keshavan MS, 1998, J PSYCHIAT RES, V32, P161, DOI 10.1016/S0022-3956(97)00038-1; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; Rapoport JL, 1999, ARCH GEN PSYCHIAT, V56, P649, DOI 10.1001/archpsyc.56.7.649; Bender S, 1999, PSYCHIAT RES-NEUROIM, V90, P41, DOI 10.1016/S0925-4927(98)00053-5; Bruder G, 1998, J ABNORM PSYCHOL, V107, P399, DOI 10.1037/0021-843X.107.3.399; Catts VS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00060; Donkers Franc C L, 2011, Front Psychiatry, V2, P51, DOI 10.3389/fpsyt.2011.00051; Douaud G, 2009, BRAIN, V132, P2437, DOI 10.1093/brain/awp126; DUNCAN CC, 1988, SCHIZOPHRENIA BULL, V14, P199; EGAN MF, 1994, SCHIZOPHR RES, V11, P259, DOI 10.1016/0920-9964(94)90020-5; Ergen M, 2008, NEUROSCI LETT, V440, P304, DOI 10.1016/j.neulet.2008.05.054; First M. B., 2002, STRUCTURED CLIN INTE; Foxe JJ, 2001, NEUROREPORT, V12, P3815, DOI 10.1097/00001756-200112040-00043; GALDERISI S, 1988, INT J PSYCHOPHYSIOL, V6, P167, DOI 10.1016/0167-8760(88)90002-5; Gallinat J, 2001, PSYCHOPHARMACOLOGY, V158, P55, DOI 10.1007/s002130100835; Gratton G., 1983, CLIN NEUROPHYSIOL, V55, P468, DOI DOI 10.1016/0013-4694(83)90135-9; Higashima M, 2003, SCHIZOPHR RES, V59, P147, DOI 10.1016/S0920-9964(01)00397-8; Hollingshead A. B., 1965, 2 FACTOR INDEX SOCIA; Mathalon DH, 2000, BIOL PSYCHIAT, V47, P413, DOI 10.1016/S0006-3223(99)00151-1; Molina V, 2004, NEUROPSYCHOBIOLOGY, V50, P182, DOI 10.1159/000079112; Neuhaus AH, 2013, EUR ARCH PSY CLIN N, V263, P241, DOI 10.1007/s00406-012-0326-7; ODONNELL BF, 1995, ARCH GEN PSYCHIAT, V52, P544; Oranje B, 2012, SCHIZOPHR B; Oribe N, 2013, SCHIZOPHR RES, V146, P95, DOI 10.1016/j.schres.2013.01.015; PFEFFERBAUM A, 1989, ARCH GEN PSYCHIAT, V46, P1035; Potts GF, 2002, ARCH GEN PSYCHIAT, V59, P418, DOI 10.1001/archpsyc.59.5.418; Soltani Maryam, 2000, Critical Reviews in Neurobiology, V14, P199; Sponheim SR, 2006, BIOL PSYCHIAT, V60, P242, DOI 10.1016/j.biopsych.2005.11.017; Stoll AL., 2001, PSYCHOPHARMACOLOGY R; van der Stelt O, 2004, ARCH GEN PSYCHIAT, V61, P237, DOI 10.1001/archpsyc.61.3.237; Vita A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.116; Vohs JL, 2008, J ABNORM PSYCHOL, V117, P119, DOI 10.1037/0021-843X.117.1.119; Wechsler D, 1999, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER MEMORY SCAL; Wilkinson G. S., 2006, WIDE RANGE ACHIEVEME; Wood SM, 2006, INT J PSYCHOPHYSIOL, V60, P67, DOI 10.1016/j.ijpsycho.2005.05.005	74	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	MAR	2015	41	2					460	470		10.1093/schbul/sbu083		11	Psychiatry	Psychiatry	CD3LI	WOS:000350979500021		
J	Sun, Q; Mu, L; Zeng, X; Zhao, JL; Yamato, T; Zhang, JX				Sun, Qiang; Mu, Lan; Zeng, Xi; Zhao, Jianglin; Yamato, Takehiko; Zhang, Jianxin			Synthesis and fluorescence properties of a 1,3-disubstituted thiacalix[4]arene crown-5 armed with phenothiazine moieties	SCIENCE CHINA-CHEMISTRY			English	Article						thiacalix[4]crown; phenothiazine; Fe3+ and Cr3+; hydrolysis reaction	1,3-ALTERNATE CONFORMATION; METAL-ION; RECOGNITION; COMPLEXATION; CALIXARENES; CHEMOSENSOR; MOLECULE; SENSORS; BINDING; PROBE	A new thiacalix[4]arene phenothiazine derivative (2) based on a thiacalix[4]crown with a 1,3-alternate conformation has been synthesized and characterized. In THF-water mixture, Compound 2 exhibits a strong fluorescence emission, with a large Stokes shift (lambda(ex/em) = 357 nm/505 nm, Delta lambda = 148 nm), which helps to avoid interference in excitation and emission. For the metal ions tested, the fluorescence of Compound 2 was quenched only by Fe3+ and Cr3+ ions. Evidence for the hydrolysis reaction promoted by the metal ions is given by X-ray crystallography, mass spectra (MS), infrared (IR) spectra, and fluorescence spectroscopy data.	[Sun, Qiang; Mu, Lan; Zeng, Xi] Guizhou Univ, Key Lab Macrocycl & Supramol Chem Guizhou Prov, Guiyang 550025, Peoples R China; [Zhao, Jianglin; Yamato, Takehiko] Saga Univ, Fac Sci & Engn, Dept Appl Chem, Saga, Saga 8408502, Japan; [Zhang, Jianxin] Key Lab Chem Nat Prod Guizhou Prov, Guiyang 550002, Peoples R China; [Zhang, Jianxin] Chinese Acad Sci, Guiyang 550002, Peoples R China	Zeng, X (reprint author), Guizhou Univ, Key Lab Macrocycl & Supramol Chem Guizhou Prov, Guiyang 550025, Peoples R China.	zengxi1962@163.com; yamatot@cc.saga-u.ac.jp			National Natural Science Foundation of China [21165006]; Fund of the International Cooperation Projects of Guizhou Province [20137002]; "Chun-Hui" Fund of Chinese Ministry of Education [Z2011033, Z2012053]	This work was supported by the National Natural Science Foundation of China (21165006), the Fund of the International Cooperation Projects of Guizhou Province (20137002) and the "Chun-Hui" Fund of Chinese Ministry of Education (Z2011033 and Z2012053).	Kim SK, 2004, J AM CHEM SOC, V126, P16499, DOI 10.1021/ja045689c; Lai RY, 2003, J AM CHEM SOC, V125, P12631, DOI 10.1021/ja036600q; Ikeda A, 1997, CHEM REV, V97, P1713, DOI 10.1021/cr960385x; Li N, 2010, CHEM COMMUN, V46, P3363, DOI 10.1039/c001408g; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; Song PS, 2011, J MATER CHEM, V21, P13470, DOI 10.1039/c1jm12098k; Lee SH, 2004, J ORG CHEM, V69, P2902, DOI 10.1021/jo049954o; McDonagh C, 2008, CHEM REV, V108, P400, DOI 10.1021/cr068102g; Morohashi N, 2006, CHEM REV, V106, P5291, DOI 10.1021/cr050565j; Kumar M, 2012, SENSOR ACTUAT B-CHEM, V161, P311, DOI 10.1016/j.snb.2011.10.037; BOHMER V, 1995, ANGEW CHEM INT EDIT, V34, P713, DOI 10.1002/anie.199507131; Kumar M, 2009, TETRAHEDRON, V65, P7510, DOI 10.1016/j.tet.2009.07.014; Kumar M, 2009, ORG LETT, V11, P2567, DOI 10.1021/ol900845g; Chang KC, 2008, TETRAHEDRON LETT, V49, P5013, DOI 10.1016/j.tetlet.2008.06.060; Dondoni A, 2010, CHEM REV, V110, P4949, DOI 10.1021/cr100027b; Kim JS, 2007, CHEM REV, V107, P3780, DOI 10.1021/cr068046j; Zheng XY, 2010, J INCL PHENOM MACRO, V68, P139, DOI 10.1007/s10847-010-9759-7; Fu Y, 2013, DALTON T, V42, P3552, DOI 10.1039/c2dt32115g; GUTSCHE CD, 1988, TETRAHEDRON, V44, P4689, DOI 10.1016/S0040-4020(01)86171-8; Bhalla V, 2007, TETRAHEDRON LETT, V48, P1581, DOI 10.1016/j.tetlet.2006.12.142; Casas CP, 2008, J INCL PHENOM MACRO, V60, P173; Chen GZ, 1990, ANAL APPL SPECTROFLU, P120; Eichhorn LG, 1954, J AM CHEM SOC, V76, P5183; Haverlock TJ, 2003, J AM CHEM SOC, V125, P1126, DOI 10.1021/ja0255251; Kumar M, 2012, DALTON T, V41, P408, DOI 10.1039/c1dt11169h; Kumar M, 2009, EUR J ORG CHEM, P4534, DOI 10.1002/ejoc.200900506; Kundrat O, 2009, ORG LETT, V11, P4188, DOI 10.1021/ol901812m; Lee JY, 2007, ORG LETT, V9, P493, DOI 10.1021/ol062863o; Ma QL, 2001, ANAL CHIM ACTA, V439, P73, DOI 10.1016/S0003-2670(01)01009-1; TAKESHITA M, 1995, B CHEM SOC JPN, V68, P1088, DOI 10.1246/bcsj.68.1088; Valeur B, 2000, COORDIN CHEM REV, V205, P3, DOI 10.1016/S0010-8545(00)00246-0; Yang L, 2005, J ORG CHEM, V70, P5987, DOI 10.1021/jo050665p; Zabulica A, 2013, DYES PIGMENTS, V96, P686, DOI 10.1016/j.dyepig.2012.11.001	33	1	1	SCIENCE PRESS	BEIJING	16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA	1674-7291	1869-1870		SCI CHINA CHEM	Sci. China-Chem.	MAR	2015	58	3					539	544		10.1007/s11426-014-5202-z		6	Chemistry, Multidisciplinary	Chemistry	CC4PY	WOS:000350336500027		
J	Shao, YY; Zhang, Y; He, WQ; Liu, C; Minari, T; Wu, SJ; Zeng, M; Zhang, Z; Gao, XS; Lu, XB; Liu, JM				Shao, Yayun; Zhang, Yang; He, Wenqiang; Liu, Chuan; Minari, Takeo; Wu, Sujuan; Zeng, Min; Zhang, Zhang; Gao, Xingsen; Lu, Xubing; Liu, J-M			Role of growth temperature on the frequency response characteristics of pentacene-based organic devices	SEMICONDUCTOR SCIENCE AND TECHNOLOGY			English	Article						organic thin film transistor; frequency response; pentacene	THIN-FILM TRANSISTORS; ELECTRONICS; MORPHOLOGY	The ac frequency response characteristics (FRC) of organic thin film transistors and metalinsulator semiconductor diodes were highly improved by controlling the morphology and electrical characteristics of semiconducting pentacene films. The devices with films grown at 50 degrees C show much higher cutoff frequency and better frequency stability of flat-band voltage, as compared to those with films grown at other temperatures below or above. The improvement mainly originates from the maximum field effect carrier mobility of 0.78 cm(2) V-1 s(-1) and a small metal/organic contact resistance (R-c) obtained in the optimum thin film transistors. Our results indicate growth temperature precisely tunes the film microstructure and metal/semiconductor interface, which together determine the FRC of pentacene-based organic devices.	[Shao, Yayun; Zhang, Yang; He, Wenqiang; Wu, Sujuan; Zeng, Min; Zhang, Zhang; Gao, Xingsen; Lu, Xubing; Liu, J-M] S China Normal Univ, Inst Adv Mat, Guangzhou 510006, Guangdong, Peoples R China; [Shao, Yayun; Zhang, Yang; He, Wenqiang; Wu, Sujuan; Zeng, Min; Zhang, Zhang; Gao, Xingsen; Lu, Xubing; Liu, J-M] S China Normal Univ, Lab Quantum Engn & Quantum Mat, Guangzhou 510006, Guangdong, Peoples R China; [Liu, Chuan] Sun Yat Sen Univ, Sch Phys & Engn, State Key Lab Optoelect Mat & Technol, Guangzhou 510274, Guangdong, Peoples R China; [Minari, Takeo] Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton, Tsukuba, Ibaraki 3050044, Japan; [Liu, J-M] Nanjing Univ, Solid State Microstruct Lab, Nanjing 210093, Jiangsu, Peoples R China; [Liu, J-M] Nanjing Univ, Innovat Ctr Adv Microstruct, Nanjing 210093, Jiangsu, Peoples R China	Shao, YY (reprint author), S China Normal Univ, Inst Adv Mat, Guangzhou 510006, Guangdong, Peoples R China.	luxubing@scnu.edu.cn; liujm@nju.edu.cn			National Natural Science Foundation of China [61271127, 51472093, 51431006]; program for Changjiang Scholars and Innovative Research Team in University [IRT1243]; Program for International Innovation Cooperation Platform of Guangzhou [2014J4500016]	This work was supported by the National Natural Science Foundation of China (Contract Nos. 61271127, 51472093, 51431006) and the program for Changjiang Scholars and Innovative Research Team in University (Grant No. IRT1243). The Program for International Innovation Cooperation Platform of Guangzhou (No. 2014J4500016).	Katz HE, 2004, CHEM MATER, V16, P4748, DOI 10.1021/cm049781j; Dimitrakopoulos CD, 1996, J APPL PHYS, V80, P2501, DOI 10.1063/1.363032; Wang A, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2349299; Scheinert S, 2004, PHYS STATUS SOLIDI A, V201, P1263, DOI 10.1002/pssa.200404335; Dimitrakopoulos CD, 2002, ADV MATER, V14, P99, DOI 10.1002/1521-4095(20020116)14:2<99::AID-ADMA99>3.0.CO;2-9; Liu C, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4860958; Shtein M, 2002, APPL PHYS LETT, V81, P268, DOI 10.1063/1.1491009; Rotzoll R, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2186384; Meijer EJ, 2004, SYNTHETIC MET, V142, P53, DOI 10.1016/j.synthmet.2003.07.006; Lu XB, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4711211; Wang SD, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2967193; Knipp D, 2003, J APPL PHYS, V93, P347, DOI 10.1063/1.1525068; Chou WY, 2006, ORG ELECTRON, V7, P445, DOI 10.1016/j.orgel.2006.05.007; Dunn L, 2009, APPL PHYS A-MATER, V95, P153, DOI 10.1007/s00339-008-5059-0; Hamadani BH, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2917523; Jaiswal M, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2186989; Kitamura M, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/18/184011; Lenski DR, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3153159; Lindner T, 2007, J APPL PHYS, V102, DOI 10.1063/1.2776235; Lu XB, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3599056; Miyadera T, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2754350; Scheinert S, 2003, SYNTHETIC MET, V139, P501, DOI 10.1016/S0379-6779(03)00205-4; Schroder D. K., 2006, SEMICONDUCTOR MAT DE; Suzuki S, 2008, JPN J APPL PHYS, V47, P3167, DOI 10.1143/JJAP.47.3167; Yang Y, 2009, ADV MATER, V21, P1401, DOI 10.1002/adma.200900844	25	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0268-1242	1361-6641		SEMICOND SCI TECH	Semicond. Sci. Technol.	MAR	2015	30	3							035005	10.1088/0268-1242/30/3/035005		7	Engineering, Electrical & Electronic; Materials Science, Multidisciplinary; Physics, Condensed Matter	Engineering; Materials Science; Physics	CC8PU	WOS:000350631400006		
J	Nath, TK; Aziz, N; Inoue, M				Nath, Tapan Kumar; Aziz, Nasim; Inoue, Makoto			Contribution of Homestead Forests to Rural Economy and Climate Change Mitigation: A Study from the Ecologically Critical Area of Cox's Bazar-Teknaf Peninsula, Bangladesh	SMALL-SCALE FORESTRY			English	Article						Plant diversity and structure; Carbon sequestration; Household income; Biodiversity conservation	SMALLHOLDER FARMING SYSTEMS; TREE SPECIES-DIVERSITY; CARBON SEQUESTRATION; BIODIVERSITY CONSERVATION; AGROFORESTRY SYSTEMS; HOMEGARDENS; BIOMASS; INDIA; INDONESIA; ECOSYSTEM	Homestead forests in the Teknaf Peninsula ecologically critical area of Cox's Bazar in Bangladesh have not been widely studied. This paper explores floristic diversity of homestead forests together with their contribution to the household economy and climate change mitigation. Data were collected from a survey of 140 households and a vegetation survey of 70 homesteads in three sites. Villagers allocated 70 % of their homestead area for homestead forestry and altogether 73 plant species were recorded from the study sites. The average density was 4,000 plants/ha. The above-ground biomass was estimated 235.45 Mg/ha, equivalent to 117.73 Mg C/ha. Villagers maintain sustainability of homestead forests by planting seedlings every year and thus ensure several diameter and height classes. Homestead forests contribute substantially to household income, provide fuelwood and timber for own consumption and sale, and protect villagers during cyclones. Homestead forests thus meet the conditions to be a clean development mechanism forestry project which would provide a win-win strategy for involving small-scale farmers in climate change mitigation and adaptation initiatives, and biodiversity conservation.	[Nath, Tapan Kumar] Univ Nottingham, Sch Biosci, Semenyih, Selangor, Malaysia; [Aziz, Nasim] Int Union Conservat Nat, Dhaka, Bangladesh; [Inoue, Makoto] Univ Tokyo, Dept Global Agr Sci, Tokyo, Japan	Nath, TK (reprint author), Univ Nottingham, Sch Biosci, Malaysia Campus, Semenyih, Selangor, Malaysia.	Tapan.Nath@nottingham.edu.my					Alam M, 2010, TECHNICAL SERIES, V52, P120; Alam M, 2011, J SUSTAIN FOR, V30, P584; Alam M, 2010, SMALL-SCALE FOR, V9, P213, DOI 10.1007/s11842-010-9111-5; Ali AMS, 2005, HUM ECOL, V33, P245, DOI 10.1007/s10745-005-2434-8; Bardhan S, 2012, AGROFOREST SYST, V85, P29, DOI 10.1007/s10457-012-9515-7; Kumar BM, 2004, AGROFOREST SYST, V61-2, P135, DOI 10.1023/B:AGFO.0000028995.13227.ca; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Chandrashekara UM, 2010, TROP ECOL, V51, P221; Montagnini F, 2004, AGROFOREST SYST, V61-2, P281, DOI 10.1023/B:AGFO.0000029005.92691.79; Kaya M, 2002, AGROFOREST SYST, V54, P225, DOI 10.1023/A:1016060808831; Nair PKR, 2009, J PLANT NUTR SOIL SC, V172, P10, DOI 10.1002/jpln.200800030; Das T, 2005, CURR SCI INDIA, V89, P155; Thomas S, 2010, LAND USE POLICY, V27, P880, DOI 10.1016/j.landusepol.2009.12.002; Henry M, 2009, AGR ECOSYST ENVIRON, V129, P238, DOI 10.1016/j.agee.2008.09.006; FRANGI JL, 1985, ECOL MONOGR, V55, P351, DOI 10.2307/1942582; Shin MY, 2007, J ENVIRON MANAGE, V82, P260, DOI 10.1016/j.jenvman.2005.12.025; Brown S., 1997, 134 FAO; CWBMP (Coastal & Wetland Biodiversity Management Project), 2006, DOEGOBUNDPGEFBGD99G3; FMP, 1992, ADBTA1355BANUNDPFAOB; Hammermaster ET, 1981, PROJECT REPORT INVEN; Haq MZ, 2012, NAT HAZARDS, V64, P1305, DOI 10.1007/s11069-012-0299-x; JENSEN M, 1993, AGROFOREST SYST, V24, P171, DOI 10.1007/BF00706890; Kabir ME, 2008, BIOTROPICA, V40, P95, DOI 10.1111/j.1744-7429.2007.00346.x; Kabir ME, 2009, AGROFOREST SYST, V75, P129, DOI 10.1007/s10457-008-9142-5; Kehlenbeck K, 2004, AGROFOREST SYST, V63, P53, DOI DOI 10.1007/S10531-010-9813-1; Kohli RK, 1996, J FOR RES, V1, P205, DOI 10.1007/BF02348326; Kumar BM, 2011, AGR ECOSYST ENVIRON, V140, P430, DOI 10.1016/j.agee.2011.01.006; Kumar BM, 2006, ADV AGROFORESTRY, V3, P185; LEUSCHNER WA, 1987, AGROFOREST SYST, V5, P139, DOI 10.1007/BF00047518; FERNANDES ECM, 1986, AGR SYST, V21, P279, DOI 10.1016/0308-521X(86)90104-6; Margalef R., 1957, GEN SYST, V3, P36, DOI DOI 10.1016/S0097-8485(01)0073-0; Mattsson E, 2013, AMBIO, V42, P892, DOI 10.1007/s13280-013-0390-x; Millate-E- Mustafa M. D., 1996, AGROFOREST SYST, V33, P263; MoEF, 2005, NAT AD PROG ACT NAPA; Montagnini F, 2006, ADV AGROFORESTRY, V3, P61; Muhammed Nur, 2011, International Journal of Biodiversity Science Ecosystem Services & Management, V7, P247, DOI 10.1080/21513732.2011.629211; Mustafa MM, 2000, INT TREE CROP J, V10, P215; Panwar NL, 2009, MITIG ADAPT STRAT GL, V14, P569, DOI 10.1007/s11027-009-9184-7; Rahman MM, 2005, SMALL SCALE FOREST E, V4, P359; Roshetko M, 2002, AM J ALTERNATIVE AGR, V17, P125; Saikia P, 2012, TROP ECOL, V53, P105; Salam MA, 2000, AGROFOREST SYST, V50, P77, DOI 10.1023/A:1006403101782; Shannon CE, 1963, MATH THEORY COMMUNIC; Shastri CM, 2002, CURR SCI INDIA, V82, P1080; van Noordwijk M, 2002, SCI CHINA SER C, V45, P75; Verchot L. V., 2007, Mitigation and Adaptation Strategies for Global Change, V12, P901, DOI 10.1007/s11027-007-9105-6	46	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1873-7617	1873-7854		SMALL-SCALE FOR	Small-Scale For.	MAR	2015	14	1					1	18		10.1007/s11842-014-9270-x		18	Forestry	Forestry	CD2HO	WOS:000350896900001		
J	Yoshizawa, T; Kadekawa, K; Tyagi, P; Yoshikawa, S; Takahashi, R; Takahashi, S; Yoshimura, N				Yoshizawa, T.; Kadekawa, K.; Tyagi, P.; Yoshikawa, S.; Takahashi, R.; Takahashi, S.; Yoshimura, N.			Mechanisms inducing autonomic dysreflexia during urinary bladder distention in rats with spinal cord injury	SPINAL CORD			English	Article							NERVE GROWTH-FACTOR; DETRUSOR OVERACTIVITY; FACTOR EXPRESSION; AFFERENT NEURONS; RESINIFERATOXIN; HYPEREXCITABILITY; HYPERREFLEXIA; MANAGEMENT; CAPSAICIN; BLOCKS	Objectives: This study investigated the mechanisms inducing autonomic dysreflexia due to enhanced bladder-to-vascular reflexes in rats with spinal cord injury (SCI). Methods: SCI was produced by the transection of the Th4-5 spinal cord in female Sprague-Dawley rats. At 4 weeks after SCI, changes in blood pressure during graded increases in intravesical pressure (20-60 cm H2O) were measured in spinal-intact (SI) and SCI rats under urethane anesthesia. In five animals, effects of C-fiber desensitization induced by intravesical application of resiniferatoxin (RTX), a TRPV1 agonist, on the bladder-to-vascular reflex were also examined. Nerve growth factor (NGF) levels of mucosa and detrusor muscle layers of the bladder were measured by enzyme-linked immunosorbent assay. The expression levels of TRPV1 and TRPA1 channels were also examined in laser captured bladder afferent neurons obtained from L6 DRG, which were labeled by Dil injected into the bladder wall. Results: In SI and SCI rats, systemic arterial blood pressure was increased in a pressure-dependent manner during increases in the intravesical pressure, with significantly higher blood pressure elevation at the intravesical pressure of 20 cm H2O in SCI rats vs SI rats. The arterial blood pressure responses to bladder distention were significantly reduced by RTX-induced desensitization of C-fiber bladder afferent pathways. SCI rats had higher NGF protein levels in the bladder and higher TRPV1 and TRPA1 mRNA levels in bladder afferent neurons compared with SI rats. Conclusions: The bladder-to-vascular reflex induced by TRPV1-expressing C-fiber afferents during bladder distention is enhanced after SCI in association with increased expression of NGF in the bladder and TRP channels in bladder afferent neurons.	[Yoshizawa, T.; Kadekawa, K.; Tyagi, P.; Yoshikawa, S.; Takahashi, R.; Yoshimura, N.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15213 USA; [Yoshizawa, T.; Takahashi, S.] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Yoshimura, N.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Yoshimura, N (reprint author), Univ Pittsburgh, Sch Med, Dept Urol, Suite 700 Kaufmann Med Bldg,3471 Fifth Ave, Pittsburgh, PA 15213 USA.	nyos@pitt.edu			Department of Defense [W81XWH-11-10763]; Paralyzed Veterans of America [2793]; National Institutes of Health [DK088836, P01 DK093424]	This work was supported by the Department of Defense (W81XWH-11-10763), Paralyzed Veterans of America (2793) and National Institutes of Health (DK088836 and P01 DK093424).	Andrade EL, 2011, AM J PHYSIOL-RENAL, V300, pF1223, DOI 10.1152/ajprenal.00535.2010; Chuang YC, 2001, AM J PHYSIOL-REG I, V281, pR1302; Brady CM, 2004, BJU INT, V93, P770, DOI 10.1111/j.1464-410X.2004.04722.x; Julius D, 2013, ANNU REV CELL DEV BI, V29, P355, DOI 10.1146/annurev-cellbio-101011-155833; Seki S, 2002, J UROLOGY, V168, P2269, DOI 10.1097/01.ju.0000025338.65642.09; Lamb K, 2004, J PAIN, V5, P150, DOI 10.1016/j.jpain.2004.01.001; Elkelini MS, 2012, BJU INT, V109, P402, DOI 10.1111/j.1464-410X.2011.010362.x; Santos-Silva A, 2012, AUTON NEUROSCI-BASIC, V166, P35, DOI 10.1016/j.autneu.2011.09.005; Kashyap M, 2013, J UROLOGY, V190, P757, DOI 10.1016/j.juro.2013.02.090; Giannantoni A, 2002, J UROLOGY, V167, P1710, DOI 10.1016/S0022-5347(05)65183-X; Krassioukov A, 2009, ARCH PHYS MED REHAB, V90, P682, DOI 10.1016/j.apmr.2008.10.017; Marsh DR, 2002, J NEUROTRAUM, V19, P1531, DOI 10.1089/089771502762300201; Yoshimura N, 2006, J NEUROSCI, V26, P10847, DOI 10.1523/JNEUROSCI.3023-06.2006; de Groat WC, 2010, NEUROUROL URODYNAM, V29, P63, DOI 10.1002/nau.20761; Krenz NR, 1999, J NEUROSCI, V19, P7405; Khastgir J, 2007, EXPERT OPIN PHARMACO, V8, P945, DOI 10.1517/14656566.8.7.945; Ramer LM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00257; Takahashi R, 2013, J UROLOGY, V190, P2296, DOI 10.1016/j.juro.2013.07.058; WEAVER LC, 1985, AM J PHYSIOL, V248, pR236; Zvara Peter, 2007, BMC Physiology, V7, P9, DOI 10.1186/1472-6793-7-9	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAR	2015	53	3					190	194		10.1038/sc.2014.233		5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CD0XQ	WOS:000350797900005		
J	Toyone, T; Ozawa, T; Inada, K; Orita, S; Inoue, G; Ohtori, S; Takahashi, K				Toyone, Tomoaki; Ozawa, Tomoyuki; Inada, Kunimasa; Orita, Sumihisa; Inoue, Gen; Ohtori, Seiji; Takahashi, Kazuhisa			Horizontal Fixation of the L3 Vertebra With a Tilt of Less Than 5 degrees Can Prevent the Long-Term Curve Progression of Unfused Adult Scoliosis	SPINE			English	Article						adult scoliosis; disc wedging; lateral spondylolisthesis; degenerative lumbar scoliosis; PLIF; vertebral tilt; fusion; surgery; long-term follow-up; interbody fusion; spinal deformity	PAIN	Study Design. Prospective consecutive series. Objective. The objective of this 10-year follow-up study was to assess the efficacy of concave PLIF for lumbosacral hemicurve in treating patients with adult scoliosis. Summary of Background Data. Long-term results and clinical significance of PLIF for allowing L3 vertebra to become horizontal in adult scoliosis have not yet been reported. Methods. Fourteen patients (53-72 yr) were operatively treated and prospectively studied. The surgical procedure was, after decompression of the affected nerve root, to correct the wedged disc below the caudal end vertebra, L3 or L4, which allowed for the end vertebra to become horizontal by way of concave PLIF. The followup period was 10 years. Results. Mean visual analogue scale (100 mm) score was 78 before surgery, 20 at 2 years after surgery, and 17 at the final follow-up in leg pain, 67, 25, and 28, respectively, in low back pain, and 13, 7, and 7, respectively, in the disability score (Rolland-Morris). The mean Cobb angles were 24 degrees, 16 degrees, and 17 degrees, respectively, in scoliosis, 17 degrees, 9 degrees, and 10 degrees, respectively, in L3 vertebral tilt, and 21 degrees, 28 degrees, and 26 degrees, respectively, in lumbar lordosis. In 7 patients with postoperative L3 vertebral tilt of less than 5 degrees, the Cobb angle of the unfused main curve improved over time. Conclusion. The results of this study suggest that horizontal fixation of the L3 vertebra can prevent the long-term development of unfused adult scoliosis.	[Toyone, Tomoaki; Ozawa, Tomoyuki; Inada, Kunimasa; Orita, Sumihisa; Inoue, Gen; Ohtori, Seiji; Takahashi, Kazuhisa] Teikyo Univ, Chiba Med Ctr, Dept Orthopaed Surg, Ichihara, Chiba 2990111, Japan	Toyone, T (reprint author), Teikyo Univ, Chiba Med Ctr, Dept Orthopaed Surg, 3426-3 Anesaki, Ichihara, Chiba 2990111, Japan.	tomotomot2001@gmail.com					Aebi M, 2005, EUR SPINE J, V14, P925, DOI 10.1007/s00586-005-1053-9; Bradford DS, 1999, SPINE, V24, P2617, DOI 10.1097/00007632-199912150-00009; Watanuki A, 2012, J ORTHOP SCI, V17, P526, DOI 10.1007/s00776-012-0253-5; Schwab FJ, 2002, SPINE, V27, P387, DOI 10.1097/00007632-200202150-00012; Cho KJ, 2008, EUR SPINE J, V17, P650, DOI 10.1007/s00586-008-0615-z; Chin Kingsley R, 2009, Am J Orthop (Belle Mead NJ), V38, P404; Cobb JR, AM ACAD ORTHOPAEDIC, P261; Daubs Michael D, 2012, Evid Based Spine Care J, V3, P27, DOI 10.1055/s-0032-1328140; HUSKISSO.EC, 1974, LANCET, V2, P1127; Hwang Dae-Woo, 2009, Asian Spine J, V3, P58, DOI 10.4184/asj.2009.3.2.58; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Seo JY, 2011, J NEUROSURG-SPINE, V15, P558, DOI 10.3171/2011.6.SPINE10929; Simmons ED, 2001, CLIN ORTHOP RELAT R, P45	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAR 1	2015	40	5					312	315		10.1097/BRS.0000000000000242		4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CD0HO	WOS:000350751600017		
J	Yoshioka, K; Murakami, H; Demura, S; Kato, S; Tsuchiya, H				Yoshioka, Katsuhito; Murakami, Hideki; Demura, Satoru; Kato, Satoshi; Tsuchiya, Hiroyuki			Prevalence and Risk Factors for Development of Venous Thromboembolism After Degenerative Spinal Surgery	SPINE			English	Article						degenerative spinal surgery; prophylaxis; pulmonary thromboembolism; deep venous thrombosis; venous thromboembolism; risk factors	DEEP-VEIN THROMBOSIS; SILENT PULMONARY-EMBOLISM; TOTAL KNEE ARTHROPLASTY; TOTAL HIP; COST-EFFECTIVENESS; HEPARIN-THERAPY; PROPHYLAXIS; COMPLICATIONS; METAANALYSIS; FUSION	Study Design. Prospective clinical study. Objective. To identify the incidence and risk factors for venous thromboembolism (VTE) associated with degenerative spinal surgery procedures at the different spinal levels for various pathologies. Summary of Background Data. Spinal surgery includes procedures for treatment of various pathologies at different spinal levels. There have been no studies on VTE after degenerative spinal surgery with respect to screening patients for both deep venous thrombosis and pulmonary thromboembolism (PE). Methods. We prospectively investigated the occurrence of VTE after degenerative spinal surgery in 459 patients who were divided into 5 groups: group 1, patients with cervical degenerative disease treated with posterior decompression; group 2, patients with cervical degenerative disease treated with instrumentation for spinal fusion; group 3, patients with thoracolumbar degenerative disease treated with instrumentation for spinal fusion; group 4, patients with lumbar spinal stenosis treated with posterior decompression; and group 5, patients with lumbar spondylolisthesis treated with 1-level posterior lumbar interbody fusion. A deep venous thrombosis and PE screening was performed for all patients. Binomial logistic regression analysis was used to assess the association of risk factors. Results. The incidence of VTE was 2.8%, 3.4%, 10.8%, 12.5%, and 10.1% in groups 1, 2, 3, 4, and 5, respectively. Female sex, advanced age, spinal level, and neurological deficits, were all risk factors. Cervical spinal surgery in particular had an associated low risk. In patients with PE, 3 of the 4 had no deep venous thrombosis, indicating that screening for PE is also needed in high-risk patients. Conclusion. The prevalence of VTE after elective spinal surgery was different in each group.	[Yoshioka, Katsuhito; Murakami, Hideki; Demura, Satoru; Kato, Satoshi; Tsuchiya, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Kanazawa, Ishikawa 9208641, Japan	Yoshioka, K (reprint author), Kanazawa Univ, Dept Orthopaed Surg, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	ortho0825yoshy@yahoo.co.jp			Japan cardiovascular research foundation	The Japan cardiovascular research foundation funds were received in support of this work.	ANDERSON FA, 1992, ARCH INTERN MED, V152, P1660, DOI 10.1001/archinte.152.8.1660; Cheng JS, 2010, SPINE, V35, pS117, DOI 10.1097/BRS.0b013e3181d833d4; CAIN JE, 1995, SPINE, V20, P1600, DOI 10.1097/00007632-199507150-00008; Yoshioka K, 2010, J NEUROSURG-SPINE, V13, P594, DOI 10.3171/2010.5.SPINE09883; Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P929; Awad JN, 2005, J BONE JOINT SURG BR, V87B, P1248, DOI 10.1302/0301-620X.87B9.16518; Goldhaber SZ, 2010, J AM COLL CARDIOL, V56, P1, DOI 10.1016/j.jacc.2010.01.057; Brambilla S, 2004, EUR SPINE J, V13, P1, DOI 10.1007/s00586-003-0538-7; Oglesby M, 2013, SPINE, V38, pE521, DOI 10.1097/BRS.0b013e3182897839; Pateder DB, 2008, SPINE, V33, P301, DOI 10.1097/BRS.0b013e31816245e1; Masuda EM, 2012, J VASC SURG, V55, P550, DOI 10.1016/j.jvs.2011.05.092; Gephart MGH, 2012, WORLD NEUROSURG, V78, P545, DOI 10.1016/j.wneu.2011.12.089; Rokito SE, 1996, SPINE, V21, P853, DOI 10.1097/00007632-199604010-00016; Glotzbecker MP, 2009, SPINE, V34, P291, DOI 10.1097/BRS.0b013e318195601d; PAIEMENT GD, 1991, AM J SURG, V161, P519, DOI 10.1016/0002-9610(91)91124-2; Tzoran I, 2012, J THROMB HAEMOST, V10, P564, DOI 10.1111/j.1538-7836.2012.04648.x; Wen DY, 1998, SURG NEUROL, V50, P521, DOI 10.1016/S0090-3019(98)00083-4; Abdollahi M, 2003, THROMB HAEMOSTASIS, V89, P493; Le Gal G, 2004, J THROMB HAEMOST, V2, P1244, DOI 10.1111/j.1538-7836.2004.00795.x; [Anonymous], 2003, CIRCULATION; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; MAYNARD MJ, 1991, CLIN ORTHOP RELAT R, P125; Oda T, 2000, SPINE, V25, P2962, DOI 10.1097/00007632-200011150-00019; Epstein NE, 2005, SPINE, V30, P2538, DOI 10.1097/01.brs.0000186318.80139.40; Xing KH, 2008, THROMB RES, V123, P24, DOI 10.1016/j.thromres.2008.05.005; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; Cho KJ, 2007, SPINE, V32, P2232; SMITH MD, 1994, J BONE JOINT SURG AM, V76A, P980; Lee HM, 2000, SPINE, V25, P1827; Shepherd A, 2006, HIP INT, V16, P53; Dearborn JT, 1999, SPINE, V24, P1471, DOI 10.1097/00007632-199907150-00013; Stein PD, 2010, AM J MED, V123, P426, DOI 10.1016/j.amjmed.2009.09.037; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Sansone JM, 2010, J BONE JOINT SURG AM, V92A, P304, DOI 10.2106/JBJS.H.01815; De Martino RR, 2012, J VASC SURG, V56, P228, DOI 10.1016/j.jvs.2011.09.087; Righini M, 2008, CURR OPIN PULM MED, V14, P408, DOI 10.1097/MCP.0b013e32830460ea; Zhou XD, 2013, THROMB RES, V132, P531, DOI 10.1016/j.thromres.2013.09.005; LIEBERMAN JR, 1994, J BONE JOINT SURG AM, V76A, P1239; GRADYBENSON JC, 1994, J BONE JOINT SURG AM, V76A, P1649; FERREE BA, 1993, SPINE, V18, P1079, DOI 10.1097/00007632-199306150-00019; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Hohl JB, 2015, J SPINAL DISORD TECH, V28, pE310, DOI 10.1097/BSD.0b013e31828b7d82; Jameson SS, 2011, J SHOULDER ELB SURG, V20, P764, DOI 10.1016/j.jse.2010.11.034; Kearon C, 2003, CIRCULATION, V107, P122; Maung AA, 2011, J TRAUMA, V71, P1241, DOI 10.1097/TA.0b013e318235ded0; Smith JS, 2010, SPINE, V35, P2140, DOI 10.1097/BRS.0b013e3181cbc8e7; Strom RG, 2013, SPINE, V38, pE1498, DOI 10.1097/BRS.0b013e3182a4408d; *THRIFT CONS GROUP, 1992, BRIT MED J, V305, P567; Watson N, 1968, Paraplegia, V6, P113; West JL, 1992, SPINE, V17, P254	52	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAR 1	2015	40	5					E301	E306		10.1097/BRS.0000000000000727		6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CD0HO	WOS:000350751600007		
J	Isozaki, Y				Isozaki, Yasuki			First hitting time of the integer lattice by symmetric stable processes	STATISTICS & PROBABILITY LETTERS			English	Article						Symmetric stable processes; Hitting time; Poisson summation formula		For one-dimensional Brownian motion, the first hitting time of a point has infinite mean while the exit time from an interval has finite exponential moments. In this note we establish its counterparts for symmetric stable processes. The Laplace transform of the first hitting time of the integer lattice is obtained. (C) 2014 Elsevier B.V. All rights reserved.	Kyoto Inst Technol, Dept Math & Phys Sci, Sakyo Ku, Kyoto 6068585, Japan	Isozaki, Y (reprint author), Kyoto Inst Technol, Dept Math & Phys Sci, Sakyo Ku, Kyoto 6068585, Japan.	isozaki@kit.ac.jp					Bertoin J, 1996, LEVY PROCESSES; BORODIN A. N., 1996, HDB BROWNIAN MOTION; CHUI CK, 1992, INTRO WAVELETS; Lukacs E., 1952, PAC J MATH, V2, P615; PORT SC, 1967, J ANAL MATH, V20, P371, DOI 10.1007/BF02786681; Yano K, 2009, LECT NOTES MATH, V1979, P187, DOI 10.1007/978-3-642-01763-6_8	6	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-7152	1879-2103		STAT PROBABIL LETT	Stat. Probab. Lett.	MAR	2015	98						50	53		10.1016/j.spl.2014.12.013		4	Statistics & Probability	Mathematics	CC6ZF	WOS:000350516800008		
J	Chang, YT; Strawderman, WE				Chang, Yuan-Tsung; Strawderman, William E.			A note on stochastic domination for discrete exponential families	STATISTICS & PROBABILITY LETTERS			English	Article						Discrete exponential families; Stochastic domination; Universal domination; Pitman closeness	PARAMETERS; CRITERION	We show that, for discrete exponential families, the sample mean of n observations does not stochastically dominate a single observation when estimating the population mean. This is in stark contrast to the case of a normal distribution. (C) 2014 Elsevier B.V. All rights reserved.	[Chang, Yuan-Tsung] Mejiro Univ, Fac Studies Contemporary Soc, Dept Social Informat, Tokyo, Japan; [Strawderman, William E.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ 08855 USA	Strawderman, WE (reprint author), Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ 08855 USA.	straw@stat.rutgers.edu			Simons Foundation [209035];  [22500263];  [26330067]	The authors thank an anonymous referee for his/her careful reading of the paper and for suggestions which improved the presentation. In particular, the Remark in Section 4 was a direct result of the referee's comments. This work is supported by Grant-in-Aid for Scientific Research (C) No. 22500263 and No. 26330067, Japan. This work was partially supported by a grant from the Simons Foundation (#209035 to William Strawderman).	Pitman EJG, 1937, P CAMB PHILOS SOC, V33, P212; Casella G., 1988, THEORY POINT ESTIMAT; Chang Y.T., 2012, J MATH SYST SCI, V2, P1; Chang YT, 2014, J MULTIVARIATE ANAL, V128, P1, DOI 10.1016/j.jmva.2014.02.014; Chang Y.T., 2014, ANN I STAT IN PRESS; Chang YT, 2012, J STAT PLAN INFER, V142, P2619, DOI 10.1016/j.jspi.2012.03.006; HWANG JT, 1985, ANN STAT, V13, P295, DOI 10.1214/aos/1176346594; NAYAK TK, 1990, J STAT PLAN INFER, V24, P259, DOI 10.1016/0378-3758(90)90046-W; Rao C. R., 1981, STAT RELATED TOPICS, P123; ROBERT CP, 1993, J AM STAT ASSOC, V88, P57, DOI 10.2307/2290692	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-7152	1879-2103		STAT PROBABIL LETT	Stat. Probab. Lett.	MAR	2015	98						131	135		10.1016/j.spl.2014.12.020		5	Statistics & Probability	Mathematics	CC6ZF	WOS:000350516800019		
J	Ono, H; Nakajima, K; Agawa, S; Ibuta, T; Maruo, R; Usui, T				Ono, Hideki; Nakajima, Keiji; Agawa, Shingo; Ibuta, Toshio; Maruo, Ryota; Usui, Tateo			Formation Conditions of Ti2O3, MgTi2O4, Mg2TiO4, and MgAl2O4 in Ti-Mg-Al Complex Deoxidation of Molten Iron	STEEL RESEARCH INTERNATIONAL			English	Article						inclusion; deoxidation; equilibrium; oxide; iron; steelmaking	LIQUID-IRON; NONMETALLIC INCLUSION; EQUILIBRIA; THERMODYNAMICS; TITANIUM; STEEL	The relationships of the compounds in the Mg-Ti-Al-O system in equilibrium with molten iron are investigated at temperatures ranging from 1873 to 1973 K, and the thermodynamic calculations are conducted in avoiding Al2O3 or spinel MgAl2O4 formation and for inclusion control. The equilibrium relations between the compounds (Mg2TiO4, MgTi2O4, or MgAl2O4) and the composition of solutes in steel are clarified. The conditions are shown that the transformation of the stable compound from Mg-Ti spinel to Mg-Al spinel occurs at Mg contents ranging from 1 to 10 ppm by mass. It is also found, on the Mg-Ti spinel, the stable compound is transformed from inverse-spinel Mg2TiO4 to normal-spinel MgTi2O4 at Ti = about 60 ppm by mass. In addition, the stable compound is transformed from MgTi2O4 to Ti2O3 at Ti about 1000 ppm by mass.	[Ono, Hideki; Usui, Tateo] Osaka Univ, Div Mat & Mfg Sci, Grad Sch Engn, Suita, Osaka 5650871, Japan; [Nakajima, Keiji] Royal Inst Technol KTH, Dept Mat Sci & Engn, Div Appl Proc Met, SE-10044 Stockholm, Sweden; [Agawa, Shingo] JFE Steel Corp, Tokyo, Japan; [Ibuta, Toshio; Maruo, Ryota] Nippon Steel & Sumitomo Met, Tokyo, Japan; Osaka Univ, Grad Sch Engn, Suita, Osaka 565, Japan	Ono, H (reprint author), Osaka Univ, Div Mat & Mfg Sci, Grad Sch Engn, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	ono@mat.eng.osaka-u.ac.jp					Kikuchi N, 2007, ISIJ INT, V47, P1255, DOI 10.2355/isijinternational.47.1255; [Anonymous], 1985, J PHYS CHEM REF DATA, V14; [Anonymous], 1996, PHYS CHEM METALS, P209; Cha WY, 2008, ISIJ INT, V48, P729, DOI 10.2355/isijinternational.48.729; Chase M. W., JANAF THERMOCHEMICAL; Engh T. A., 1992, PRINCIPLES METAL REF, P417; Fujii K, 2000, ISIJ INT, V40, P1059, DOI 10.2355/isijinternational.40.1059; Han Q., 1990, ISIJ INT, V1, P166; Itoh H, 1998, TETSU TO HAGANE, V84, P85; JANKE D, 1976, ARCH EISENHUTTENWES, V47, P195; Ohta H, 1997, METALL MATER TRANS B, V28, P1131, DOI 10.1007/s11663-997-0069-4; Pak JJ, 2007, ISIJ INT, V47, P16, DOI 10.2355/isijinternational.47.16; Pelton AD, 1998, Z PHYS CHEM, V207, P163; Satoh N, 2009, TETSU TO HAGANE, V95, P827; Takamura J.I., 1990, P 6 INT IR STEEL C I, V1, P591; The Japan Society for the Promotion of Science, 1988, 19 COMM STEELM, P275; Yanchang G., 1990, METALL T B, V21B, P543	17	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1611-3683	1869-344X		STEEL RES INT	Steel Res. Int.	MAR	2015	86	3					241	251		10.1002/srin.201400034		11	Metallurgy & Metallurgical Engineering	Metallurgy & Metallurgical Engineering	CD0GY	WOS:000350749900006		
J	Yamashita, S; Aoki, T; Inoue, Y; Kaneko, J; Sakamoto, Y; Sugawara, Y; Hasegawa, K; Kokudo, N				Yamashita, Suguru; Aoki, Taku; Inoue, Yosuke; Kaneko, Junichi; Sakamoto, Yoshihiro; Sugawara, Yasuhiko; Hasegawa, Kiyoshi; Kokudo, Norihiro			Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy	SURGERY			English	Article							RANDOMIZED CONTROLLED-TRIAL; PROGNOSTIC-FACTORS; ETHANOL INJECTION; THERMAL ABLATION; CIRRHOSIS; COHORT; TUMORS; RISK	Background. Although radiofrequency ablation (RFA) is an effective local ablative technique for the treatment of hepatocellular carcinoma (HCC), the optimal treatment for recurrence after RFA has not been established. Methods. Between September 2002 and December 2011, 46 hepatectomies (salvage group) were performed for intrahepatic (local or multifocal) recurrent HCC after RFA. The difference between the imaging findings before RFA and at the time of salvage resection, especially in the Local recurrent group, and the short-term and long-term, outcomes after salvage surgery were analyzed retrospectively by comparing them with those for a matched control group (n = 46) and with those of patients who underwent a second hepatic resection for HCC recurrence after an initial hepatic resection during the same period (n = 155). Results. The tumor-occupying region was more distributed widely before the salvage resection compared with that before RFA, and a more extensive operation would have been required (rather than the RFA) in the local group. An evaluation of the short-term outcomes revealed that salvage resection required a longer operative time and was associated with a greater frequency of morbidity. The long-term outcomes of the salvage group were poorer than those of patients who underwent repeat hepatic resection for HCC recurrence after an initial hepatic resection. Conclusion. The indications for RFA should be determined carefully, because recurrence after RFA may be associated with a more aggressive pattern of recurrence, and the long-term results after salvage resection are unsatisfactory.	[Yamashita, Suguru; Aoki, Taku; Inoue, Yosuke; Kaneko, Junichi; Sakamoto, Yoshihiro; Sugawara, Yasuhiko; Hasegawa, Kiyoshi; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div,Bunkyo Ku, Tokyo 1138655, Japan	Kokudo, N (reprint author), Univ Tokyo, Grad Sch Med, Dept Surg, Hepatobiliary Pancreat Surg Div,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	KOKUDO-2SU@h.u-tokyo.ac.jp					Buscarini L, 2001, EUR RADIOL, V11, P914, DOI 10.1007/s003300000659; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Lau WY, 2009, ANN SURG, V249, P20, DOI 10.1097/SLA.0b013e31818eec29; Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; Nicoli N, 2004, AM J SURG, V188, P165, DOI 10.1016/j.amjsurg.2003.12.061; Livraghi T, 2005, BRIT J SURG, V92, P856, DOI 10.1002/bjs.4986; Cho YK, 2009, HEPATOLOGY, V49, P453, DOI 10.1002/hep.22648; Rossi S, 1998, AM J ROENTGENOL, V170, P1015; Poon RTP, 2002, ANN SURG, V235, P466, DOI 10.1097/00000658-200204000-00004; Hasegawa K, 2005, ANN SURG, V242, P252, DOI 10.1097/01.sla.0000171307.37401.db; N'Kontchou G, 2009, HEPATOLOGY, V50, P1475, DOI 10.1002/hep.23181; Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003; Fernandes ML, 2009, BRIT J SURG, V96, P756, DOI 10.1002/bjs.6645; Shiina S, 2012, AM J GASTROENTEROL, V107, P569, DOI 10.1038/ajg.2011.425; MAKUUCHI M, 1993, SEMIN SURG ONCOL, V9, P298, DOI 10.1002/ssu.2980090404; Brunello F, 2008, SCAND J GASTROENTERO, V43, P727, DOI 10.1080/00365520701885481; Choi D, 2007, EUR RADIOL, V17, P684, DOI 10.1007/s00330-006-0461-5; Ijichi M, 2000, ARCH SURG-CHICAGO, V135, P1395, DOI 10.1001/archsurg.135.12.1395; Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009; Minagawa M, 2003, ANN SURG, V238, P703, DOI 10.1097/01.sla.0000094549.11754.e6; Harrison LE, 2003, J AM COLL SURGEONS, V197, P759, DOI 10.1016/S1072-7515(03)00750-6; Inoue Y, 2009, SURGERY, V145, P9, DOI 10.1016/j.surg.2008.09.005; Kawamura Y, 2011, AM J ROENTGENOL, V197, pW665, DOI 10.2214/AJR.11.6843; Koda M, 2003, HEPATOL RES, V27, P163, DOI 10.1016/S1386-6346(03)00207-9; Leniconi R, 2005, RADIOLOGY, V23, P961; Makuuchi M, 2002, ONCOLOGY-BASEL, V62, P74, DOI 10.1159/000048280; Makuuchi M, 1998, HEPATO-GASTROENTEROL, V45, P1267; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Minagawa M, 2007, ANN SURG, V245, P909, DOI 10.1097/01.sla.0000254368.65878.da; Noda I, 2010, J GASTROENTEROL, V45, P105, DOI 10.1007/s00535-009-0131-x; Rossi Sandro, 2002, Int J Clin Oncol, V7, P225, DOI 10.1007/s101470200034; Sugo H, 2012, ANN SURG ONCOL, V19, P2238, DOI 10.1245/s10434-012-2220-y; Takada Yasutsugu, 2003, Int J Clin Oncol, V8, P332, DOI 10.1007/s10147-003-0328-6; Torzilli G, 1999, ARCH SURG-CHICAGO, V134, P984, DOI 10.1001/archsurg.134.9.984; Torzilli G, 2007, BRIT J SURG, V94, P208, DOI 10.1002/bjs.5603; Yan K, 2008, EUR J RADIOL, V67, P336, DOI 10.1016/j.ejrad.2007.07.007	37	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	MAR	2015	157	3					463	472		10.1016/j.surg.2014.10.019		10	Surgery	Surgery	CD1MN	WOS:000350839100008		
J	Takahashi, H; Akita, H; Gotoh, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Sugimura, K; Motoori, M; Kishi, K; Noura, S; Fujiwara, Y; Ohue, M; Ohigashi, H; Yano, M; Sakon, M; Ishikawa, O				Takahashi, Hidenori; Akita, Hirofumi; Gotoh, Kunihito; Kobayashi, Shogo; Marubashi, Shigeru; Miyoshi, Norikatsu; Sugimura, Keijiro; Motoori, Masaald; Kishi, Kentaro; Noura, Shingo; Fujiwara, Yoshiyuki; Ohue, Masayuki; Ohigashi, Hiroald; Yano, Masahiko; Sakon, Masato; Ishikawa, Osamu			Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: Impact of splenic vessels involvement on operative outcome and pattern of recurrence	SURGERY			English	Article							SINGLE-INSTITUTION EXPERIENCE; INTERNATIONAL STUDY-GROUP; CELIAC AXIS RESECTION; FULL-DOSE GEMCITABINE; DISTAL PANCREATECTOMY; 1423 PANCREATICODUODENECTOMIES; RESECTABLE ADENOCARCINOMA; CANCER; CARCINOMA; SURVIVAL	Background. Among the various multimodal treatment strategies for pancreatic ductal adenocarcinoma (PDA), preoperative chemoradiation therapy (CRT) and subsequent operation is a promising strategy. The aim of this study is to evaluate the outcome of preoperative gemcitabine-based CRT for FDA of the body and tail, focusing on the associations among splenic vessel involvement, surgical outcomes, and pattern of recurrence. Methods. A total of 99 patients with FDA of the body and tail received preoperative CRT The status of tumor involvement of the splenic artery (SA) and vein (SV) were evaluated based on radiographical findings obtained before the initiation of preoperative CRT We assessed the following in association with the status of SA and SV involvement: (1) resection rate, (2) survival, and (3) pattern of recurrence. Results. The resection rate of SA-positive cases (71%) was significantly lesser than that of SA-negative cases (94%; P = .004), whereas SV involvement was not associated with the resection rate. The 5-year survival rates of the resected SA-negative and SA-positive cases were 76% and 20%, respectively < .001). The 5-year cumulative incidence of distant recurrence was significantly higher in the SA-positive patients than in the SA-negative patients (74% vs 17%; P < .001). Conclusion. In preoperative CRT for FDA of the body and tail, positive SA involvement was associated with a lesser resection rate, and the survival rate for the patients with SA-positive tumors was lesser than that for patients with SA-negative tumors because of the greater incidence of distant recurrence in SA-positive patients.	[Takahashi, Hidenori; Akita, Hirofumi; Gotoh, Kunihito; Kobayashi, Shogo; Marubashi, Shigeru; Miyoshi, Norikatsu; Sugimura, Keijiro; Motoori, Masaald; Kishi, Kentaro; Noura, Shingo; Fujiwara, Yoshiyuki; Ohue, Masayuki; Ohigashi, Hiroald; Yano, Masahiko; Sakon, Masato; Ishikawa, Osamu] Osaka Med Ctr Canc & Cardiovascr Dis, Dept Surg, Osaka 5378511, Japan	Takahashi, H (reprint author), Osaka Med Ctr Canc & Cardiovascr Dis, Dept Surg, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.	takahasi-hi@mc.pref.osaka.jp			Osaka Foundation for the Prevention of Cancer and Cardiovascular Diseases	This work was partly supported by a grant from the Osaka Foundation for the Prevention of Cancer and Cardiovascular Diseases.	Winter JM, 2006, J GASTROINTEST SURG, V10, P1199, DOI 10.1016/j.gassur.2006.08.018; Kanda M, 2010, ANN SURG, V251, P483, DOI 10.1097/SLA.0b013e3181cf9171; Assifi MM, 2011, SURGERY, V150, P466, DOI 10.1016/j.surg.2011.07.006; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; White RR, 2005, ANN SURG ONCOL, V12, P214, DOI 10.1245/ASO.2005.03.105; Sperti C, 2010, PANCREATOLOGY, V10, P491, DOI 10.1159/000276984; Christein JD, 2005, J GASTROINTEST SURG, V9, P922, DOI 10.1016/j.gassur.2005.04.008; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Takahashi H, 2011, SURGERY, V150, P547, DOI 10.1016/j.surg.2011.03.001; Slidell MB, 2008, ANN SURG ONCOL, V15, P165, DOI 10.1245/s10434-007-9587-1; Lu DSK, 1997, AM J ROENTGENOL, V168, P1439; Kitami C, 2013, SURG TODAY, V43, P33, DOI 10.1007/s00595-012-0179-8; Hirano S, 2007, ANN SURG, V246, P46, DOI 10.1097/01.sla.0000258608.52615.5a; Takahashi H, 2012, ANN SURG, V255, P95, DOI 10.1097/SLA.0b013e31823d813c; Shoup M, 2003, J GASTROINTEST SURG, V7, P946, DOI 10.1016/j.gassur.08.004; Shimada K, 2006, SURGERY, V139, P288, DOI 10.1016/j.surg.2005.08.004; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Ohigashi H, 2009, ANN SURG, V250, P88, DOI 10.1097/SLA.0b013e3181ad65cc; Brennan MF, 1996, ANN SURG, V223, P506, DOI 10.1097/00000658-199605000-00006; Kayahara M, 2007, PANCREAS, V35, P218; Takahashi H, 2010, ANN SURG, V251, P461, DOI 10.1097/SLA.0b013e3181cc90a3; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Takahashi H, 2013, ANN SURG, V258, P1040, DOI 10.1097/SLA.0b013e31829b3ce4; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Wente MN, 2007, SURGERY, V142, P761, DOI 10.1016/j.surg.2007.05.005; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Talamonti MS, 2006, ANN SURG ONCOL, V13, P150, DOI 10.1245/ASO.2006.03.039; Warshaw AL, 1996, ANN SURG, V223, P511; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; JOHNSON CD, 1993, BRIT J SURG, V80, P1177, DOI 10.1002/bjs.1800800937; Lillemoe KD, 1999, ANN SURG, V229, P693, DOI 10.1097/00000658-199905000-00012; Partelli S, 2011, ANN SURG ONCOL, V18, P3608, DOI 10.1245/s10434-011-1769-1; Sobin LH, 2009, TNM CLASSIFICATION M; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	MAR	2015	157	3					484	495		10.1016/j.surg.2014.09.022		12	Surgery	Surgery	CD1MN	WOS:000350839100010		
J	Kurokawa, Y; Hiki, N; Yoshikawa, T; Kishi, K; Ito, Y; Ohi, M; Wada, N; Takiguchi, S; Mine, S; Hasegawa, S; Matsuda, T; Takeuchi, H				Kurokawa, Yukinori; Hiki, Naoki; Yoshikawa, Takaki; Kishi, Kentaro; Ito, Yuichi; Ohi, Masaki; Wada, Noriko; Takiguchi, Shuji; Mine, Shinji; Hasegawa, Shinichi; Matsuda, Tatsuo; Takeuchi, Hiroya			Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction	SURGERY			English	Article							LIMITED TRANSHIATAL RESECTION; RANDOMIZED CONTROLLED-TRIAL; GASTRIC-CANCER; ESOPHAGEAL; CLASSIFICATION; CHEMOTHERAPY; DISSECTION	Background. Whether thorough mediastinal dissection is indicated in patients with Siewert type II adenocarcinoma of the esophagogastric junction (EGJ) remains controversial. We conducted a multicenter study to find a preoperative indicator of mediastinal node metastasis. Methods. We retrospectively collected data on 315 patients with pT2-T4 Siewert type II tumors who underwent R0 or R1 resection. The rates of metastasis or recurrence were investigated for the upper, middle, and lower mediastinal lymph nodes. Multivariate logistic analysis was used to identify significant indicators of metastasis or recurrence in the mediastinal nodes. Results. The overall rates of metastasis or recurrence in the upper, middle, and lower mediastinal lymph nodes were 4 %, 7%, and 11%, respectively. Rates were significantly higher when the distance from the EGJ to the proximal edge of primary tumor was >3 cm for the upper and middle mediastinal nodes and >2 cm for the lower mediastinal nodes. Multivariate analysis revealed that this distance was the only factor significantly associated with metastasis or recurrence in any mediastinal region. The 5-year overall survival rate in the 12 patients with metastasis in the upper or middle mediastinal lymph nodes was 17%. Conclusion. The distance from the EGJ to the proximal edge of primary tumor may be a significant indicator of metastasis or recurrence in the mediastinal lymph nodes in patients with Siewert type II tumors. Thorough mediastinal lymph node dissection via a transthoracic approach may provide a therapeutic benefit when the distance is >3 cm.	[Kurokawa, Yukinori; Wada, Noriko; Takiguchi, Shuji] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan; [Hiki, Naoki; Mine, Shinji] Canc Inst Hosp, Dept Surg Gastroenterol, Gastroenterol Ctr, Tokyo, Japan; [Yoshikawa, Takaki; Hasegawa, Shinichi] Kanagawa Canc Ctr, Dept Surg, Yokohama, Kanagawa 2410815, Japan; [Kishi, Kentaro] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka, Japan; [Ito, Yuichi] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan; [Ohi, Masaki] Mie Univ, Grad Sch Med, Dept Innovat Surg, Tsu, Mie, Japan; [Matsuda, Tatsuo; Takeuchi, Hiroya] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan	Yoshikawa, T (reprint author), Kanagawa Canc Ctr, Dept Surg, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 2410815, Japan.	yoshikawat@kcch.jp; htakeuchi@a6.keio.jp					Omloo JMT, 2007, ANN SURG, V246, P992, DOI 10.1097/SLA.0b013e31815c4037; Sasako M, 2006, LANCET ONCOL, V7, P644, DOI 10.1016/S1470-2045(06)70766-5; Mine S, 2013, BRIT J SURG, V100, P261, DOI 10.1002/bjs.8967; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Hasegawa S, 2013, ANN SURG ONCOL, V20, P4252, DOI 10.1245/s10434-013-3036-0; Siewert JR, 1998, BRIT J SURG, V85, P1457; Bollschweiler E, 2001, CANCER, V92, P549, DOI 10.1002/1097-0142(20010801)92:3<549::AID-CNCR1354>3.0.CO;2-L; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO;2-U; Hulscher JBF, 2002, NEW ENGL J MED, V347, P1662, DOI 10.1056/NEJMoa022343; Crew KD, 2004, SEMIN ONCOL, V31, P450, DOI 10.1053/j.seminoncol.2004.04.021; Nunobe S, 2008, J SURG ONCOL, V97, P392, DOI 10.1002/jso.20987; Bancewicz J, 2002, LANCET, V359, P1727; Grbski V, 2007, LANCET ONCOL, V8, P226; Matsumoto S, 2012, AM SURGEON, V78, P1285; Siewert JR, 2000, ANN SURG, V232, P353; Sobin LH, 2009, TNM CLASSIFICATION M	16	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	MAR	2015	157	3					551	555		10.1016/j.surg.2014.08.099		5	Surgery	Surgery	CD1MN	WOS:000350839100018		
J	Nakano, T; Endo, K; Ukaji, Y				Nakano, Takeo; Endo, Kohei; Ukaji, Yutaka			Copper(I)-Catalyzed Carbometalation of Nonfunctionalized Cyclopropenes Using Organozinc and Grignard Reagents	SYNLETT			English	Article						alkenes; catalysis; copper; magnesium; metalation; nucleophilic additions; organometallic reagents; zinc	IRON-CATALYZED CARBOMETALATION; CONTAINING NATURAL-PRODUCTS; ALPHA-AMINO-ACIDS; ASYMMETRIC CYCLOPROPANATION; STEREOSELECTIVE-SYNTHESIS; CARBOZINCATION; ALLYLZINCATION; DERIVATIVES; CHEMISTRY; ALKENES	A highly efficient method was developed for the copper(I)-catalyzed carbometalation of various nonfunctionalized and functionalized cyclopropenes. Electrophilic trapping of the cyclopropylmetal intermediates gave multifunctionalized cyclopropanes.	[Nakano, Takeo; Endo, Kohei; Ukaji, Yutaka] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan; [Endo, Kohei] Japan Sci & Technol Agcy JST, PRESTO, Kawaguchi, Saitama 3320012, Japan	Endo, K (reprint author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Mat Sci, Kanazawa, Ishikawa 9201192, Japan.	kendo@se.kanazawa-u.ac.jp			JST PRESTO program	This work was supported by the JST PRESTO program and a Grant-in-Aid for Scientific Research (B).	Wurz RP, 2002, ORG LETT, V4, P4531, DOI 10.1021/ol0270879; Brackmann F, 2007, CHEM REV, V107, P4493, DOI 10.1021/cr078376j; Long J, 2003, J AM CHEM SOC, V125, P13632, DOI 10.1021/ja030488e; Chanthamath S, 2013, ORG LETT, V15, P772, DOI 10.1021/ol303404c; Lorenz JC, 2004, J ORG CHEM, V69, P327, DOI 10.1021/jo030312v; Kramer K, 2011, ORG LETT, V13, P819, DOI 10.1021/ol1029904; Thompson JL, 2007, J AM CHEM SOC, V129, P6090, DOI 10.1021/ja069314y; Gregg TM, 2009, ORG LETT, V11, P4434, DOI 10.1021/ol9017968; SIMMONS HE, 1959, J AM CHEM SOC, V81, P4256, DOI 10.1021/ja01525a036; Donaldson WA, 2001, TETRAHEDRON, V57, P8589, DOI 10.1016/S0040-4020(01)00777-3; Delaye PO, 2013, ANGEW CHEM INT EDIT, V52, P5333, DOI 10.1002/anie.201300664; Akagawa K, 2013, ORG LETT, V15, P4964, DOI 10.1021/ol402227y; Didier D, 2014, CHEM-EUR J, V20, P1038, DOI 10.1002/chem.201303569; Pietruszka J, 2003, CHEM REV, V103, P1051, DOI 10.1021/cr010027g; Negishi E, 2007, B CHEM SOC JPN, V80, P233, DOI 10.1246/bcsj.80.233; Hamaker CG, 2001, ORGANOMETALLICS, V20, P5171, DOI 10.1021/om010513u; Rubin M, 2007, CHEM REV, V107, P3117, DOI 10.1021/cr050988l; Lindsay VNG, 2009, J AM CHEM SOC, V131, P16383, DOI 10.1021/ja9044955; NAKAMURA E, 1988, J AM CHEM SOC, V110, P1297, DOI 10.1021/ja00212a051; Tarwade V, 2009, J AM CHEM SOC, V131, P5382, DOI 10.1021/ja900949n; Yan N, 2008, J ORG CHEM, V73, P563, DOI 10.1021/jo702176x; Tarwade V, 2012, J ORG CHEM, V77, P9900, DOI 10.1021/jo3019076; Shirakawa E, 2012, J AM CHEM SOC, V134, P272, DOI 10.1021/ja206745w; Nakamura M, 2000, J AM CHEM SOC, V122, P978, DOI 10.1021/ja983066r; Nakamura M, 2003, CHEM REV, V103, P1295, DOI 10.1021/cr0100244; Zhu ZB, 2011, CHEM SOC REV, V40, P5534, DOI 10.1039/c1cs15074j; Endo K, 2013, EUR J ORG CHEM, V2013, P6514, DOI 10.1002/ejoc.201301026; Fantauzzi S, 2008, ORGANOMETALLICS, V27, P6143, DOI 10.1021/om800556v; ISAKA M, 1990, J AM CHEM SOC, V112, P7428, DOI 10.1021/ja00176a072; KUBOTA K, 1993, J AM CHEM SOC, V115, P5867, DOI 10.1021/ja00066a082; Kubota K, 1996, HETEROCYCLES, V42, P565; Long J, 2009, ORG LETT, V11, P5226, DOI 10.1021/ol902150j; Nakamura E, 1997, J ORG CHEM, V62, P792, DOI 10.1021/jo962140q; NAKAMURA M, 1995, J AM CHEM SOC, V117, P1179, DOI 10.1021/ja00108a055; Nakano T, 2014, ORG LETT, V16, P1418, DOI 10.1021/ol500208r; Panne P, 2008, ORG LETT, V10, P2987, DOI 10.1021/ol800983y; RICHEY HG, 1981, TETRAHEDRON LETT, V22, P3471, DOI 10.1016/S0040-4039(01)81934-1; Simaan S, 2007, ORG LETT, V9, P2569, DOI 10.1021/ol070974x; Simmons H. E., 1958, J AM CHEM SOC, V80, P5323, DOI 10.1021/ja01552a080; Smith MA, 2007, ORGANOMETALLICS, V26, P609, DOI 10.1021/om060766t; Tang Y, 1997, J ORG CHEM, V62, P954, DOI 10.1021/jo9610218; WAKAMIYA T, 1986, TETRAHEDRON LETT, V27, P2143, DOI 10.1016/S0040-4039(00)84470-6; Wang Y, 2008, ANGEW CHEM INT EDIT, V47, P7350, DOI 10.1002/anie.200802391; Wurz RP, 2004, J ORG CHEM, V69, P1262, DOI 10.1021/jo035596y; Zhang DH, 2006, J AM CHEM SOC, V128, P15050, DOI 10.1021/ja0647708	45	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	MAR	2015	26	5					671	675		10.1055/s-0034-1379959		5	Chemistry, Organic	Chemistry	CD0IL	WOS:000350754400018		
J	Monguchi, Y; Wakayama, F; Takada, H; Sawama, Y; Sajiki, H				Monguchi, Yasunari; Wakayama, Fumika; Takada, Hitoshi; Sawama, Yoshinari; Sajiki, Hironao			Osmium on Chelate Resin: Nonvolatile Catalyst for the Synthesis of Diols from Alkenes	SYNLETT			English	Article						chelate resin; diols; osmium; oxidation; supported catalyst	NANOCRYSTALLINE MAGNESIUM-OXIDE; ONE-POT SYNTHESIS; ASYMMETRIC DIHYDROXYLATION; ION-EXCHANGERS; CHIRAL DIOLS; OLEFINS; TETROXIDE; TETRAOXIDE	Osmium tetraoxide (OsO4) was immobilized on a commercially available chelate resin DIAION CR11 (CR11) just by simply immersing it in a methanol solution of OsO4 at room temperature. The resulting purple solid, 5% Os/CR11, indicated no volatility, and effectively catalyzed the oxidation of various alkenes to the corresponding diols.	[Monguchi, Yasunari; Wakayama, Fumika; Sawama, Yoshinari; Sajiki, Hironao] Gifu Pharmaceut Univ, Organ Chem Lab, Gifu 5011196, Japan; [Takada, Hitoshi] Organo Corp, Minami Ku, Sagamihara, Kanagawa 2520332, Japan	Monguchi, Y (reprint author), Gifu Pharmaceut Univ, Organ Chem Lab, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	monguchi@gifu-pu.ac.jp; sajiki@gifu-pu.ac.jp					Akiyama R, 2012, RSC ADV, V2, P7456, DOI 10.1039/c2ra21123h; Kobayashi S, 2001, ORG LETT, V3, P2649, DOI 10.1021/ol01616965; Cavaco SA, 2009, J HAZARD MATER, V169, P516, DOI 10.1016/j.jhazmat.2009.03.129; DeClue MS, 2004, ORG BIOMOL CHEM, V2, P2287, DOI 10.1039/b406341d; Choudary BM, 2002, J AM CHEM SOC, V124, P5341, DOI 10.1021/ja017889j; KOLB HC, 1994, CHEM REV, V94, P2483, DOI 10.1021/cr00032a009; Motorina I, 2001, ORG LETT, V3, P2325, DOI 10.1021/ol010096h; Kobayashi S, 1999, J AM CHEM SOC, V121, P11229, DOI 10.1021/ja993099m; Choudary BM, 2002, CHEM COMMUN, P586, DOI 10.1039/b110681n; Choudary BM, 2004, ADV SYNTH CATAL, V346, P45, DOI 10.1002/adsc.200303133; Choudary BM, 2001, J AM CHEM SOC, V123, P9220, DOI 10.1021/ja016101u; Choudary BM, 2006, ADV SYNTH CATAL, V348, P1734, DOI 10.1002/adsc.200606077; Metin O, 2012, GREEN CHEM, V14, P1488, DOI 10.1039/c2gc16616j; Nagayama S, 1998, J ORG CHEM, V63, P6094, DOI 10.1021/jo981127y; Monguchi Y, 2013, GREEN CHEM, V15, P490, DOI 10.1039/c2gc36584g; Severeyns A, 2001, ANGEW CHEM INT EDIT, V40, P586, DOI 10.1002/1521-3773(20010202)40:3<586::AID-ANIE586>3.0.CO;2-L; Caps V, 2003, APPL CATAL A-GEN, V252, P37, DOI 10.1016/S0926-860X(03)00372-7; Cavaco A., 2007, J HAZARD MATER, V144, P634; Choudary B. M., 2001, ANGEW CHEM INT EDIT, V40, P4620; Choudary BM, 2004, ADV SYNTH CATAL, V346, P1471, DOI 10.1002/adsc.200404112; Choudary BM, 2003, ADV SYNTH CATAL, V345, P1190, DOI 10.1002/adsc.200303114; Choudary BM, 2003, J ORG CHEM, V68, P1736, DOI 10.1021/jo026687i; Fujita K, 2012, CHEM PHARM BULL, V60, P1594; Gando-Ferreira LM, 2011, CHEM ENG J, V172, P277, DOI 10.1016/j.cej.2011.05.105; Jun BH, 2008, SYNLETT, P2313, DOI 10.1055/s-2008-1078274; Koivula R, 2000, HYDROMETALLURGY, V56, P93, DOI 10.1016/S0304-386X(00)00077-3; Lee BS, 2005, TETRAHEDRON LETT, V46, P4491, DOI 10.1016/j.tetlet.2005.04.113; Lohray B. B., 1992, TETRAHEDRON LETT, V37, P5453; Moen AR, 2008, J MOL CATAL B-ENZYM, V50, P74, DOI 10.1016/j.molcatb.2007.09.003; PINI D, 1991, TETRAHEDRON LETT, V32, P5175, DOI 10.1016/S0040-4039(00)93459-2; Reddy SM, 2006, TETRAHEDRON LETT, V47, P5285, DOI 10.1016/j.tetlet.2006.05.138; SCHRODER M, 1980, CHEM REV, V80, P187, DOI 10.1021/cr60324a003; Yang JW, 2002, ORG LETT, V4, P4685, DOI 10.1021/ol027109r	33	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	MAR	2015	26	5					700	704		10.1055/s-0034-1379990		5	Chemistry, Organic	Chemistry	CD0IL	WOS:000350754400023		
J	Tamura, M; Murase, D; Komura, K				Tamura, Mizuki; Murase, Daisuke; Komura, Kenichi			Direct Amide Synthesis from Equimolar Amounts of Carboxylic Acid and Amine Catalyzed by Mesoporous Silica SBA-15	SYNTHESIS-STUTTGART			English	Article						amides; amines; carboxylic acids; heterogeneous catalysis; green chemistry	MULTIVALENT METAL-SALTS; EFFICIENT CATALYST; DIRECT AMIDATION; ESTERIFICATION; ALCOHOLS; CARBOXAMIDES; CONDENSATION	Direct amide synthesis from equimolar amounts of carboxylic acid and amine using mesoporous silica as a versatile heterogeneous catalyst is reported.	[Tamura, Mizuki; Murase, Daisuke; Komura, Kenichi] Gifu Univ, Fac Engn, Dept Mat Sci & Technol, Gifu 5011193, Japan	Komura, K (reprint author), Gifu Univ, Fac Engn, Dept Mat Sci & Technol, Yanagido 1-1, Gifu 5011193, Japan.	kkomura@gifu-u.ac.jp					ALLEN CL, 2012, J CHEM SOC CHEM COMM, V48, P666; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Gu LQ, 2014, CHEM COMMUN, V50, P7017, DOI 10.1039/c4cc01148a; Charville H, 2010, CHEM COMMUN, V46, P1813, DOI 10.1039/b923093a; Komura K, 2011, GREEN CHEM, V13, P828, DOI 10.1039/c0gc00673d; Anunziata OA, 2007, J COLLOID INTERF SCI, V315, P184, DOI 10.1016/j.jcis.2007.06.033; Kawagoe Y, 2013, TETRAHEDRON, V69, P3971, DOI 10.1016/j.tet.2013.03.021; Chaudhari PS, 2010, GREEN CHEM, V12, P1707, DOI 10.1039/c0gc00053a; Constable DJC, 2007, GREEN CHEM, V9, P411, DOI 10.1039/b703488c; Lundberg H, 2014, CHEM SOC REV, V43, P2714, DOI 10.1039/c3cs60345h; Maki T, 2007, TETRAHEDRON, V63, P8645, DOI 10.1016/j.tet.2007.03.157; Ishihara K, 2009, TETRAHEDRON, V65, P1085, DOI 10.1016/j.tet.2008.11.004; Gernigon N, 2012, J ORG CHEM, V77, P8386, DOI 10.1021/jo3013258; Mantri K, 2005, GREEN CHEM, V7, P677, DOI 10.1039/b504369g; Benz G, 1991, COMPREHENSIVE ORGANI, V6, P381; Chung S W, 2011, SYNLETT, P2072; Comerford J. W., 2009, CHEM COMMUN, V2562; Gooen L J, 2009, SYNTHESIS, V160; Ieda N., 2008, IND ENG CHEM RES, V47, P8631; Ishihara K, 1996, ORG CHEM, V61, P4196; Ishihara K, 2000, MACROMOLECULES, V33, P2511; Komura K, 2008, SYNTHESIS, V2407; Latta R, 2001, SYNTHESIS, V1611; Liu S, 2013, EUR J ORG CHEM, P5692; Lundberg H, 2012, SYNLETT, P2201, DOI 10.1055/s-0032-1316993; Mantri K, 2005, SYNTHESIS, P1939; Mantri K, 2005, CHEM LETT, V34, P1502, DOI 10.1246/cl.2005.1502; Mantri K, 2007, MATER SCI FORUM, V475-479, P2317; Nakamura R, 2008, CATAL COMMUN, V9, P511, DOI 10.1016/j.catcom.2007.03.024; Reddy YT, 2008, CHEM LETT, V37, P528, DOI 10.1246/cl.2008.528; Sheldon RA, 2007, GREEN CHEM, V9, P1273, DOI 10.1039/b713736m; Terada Y, 2008, SYNTHESIS, V2318; Tozawa T, 2005, CHEM LETT, V34, P1334, DOI 10.1246/cl.2005.1334; Wakasugi K, 2003, TETRAHEDRON, V59, P5337, DOI 10.1016/S0040-4020(03)00734-8	34	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	MAR	2015	47	6					769	776		10.1055/s-0034-1379966		8	Chemistry, Organic	Chemistry	CC6JH	WOS:000350470700003		
J	Chen, WT; Chan, A; Jovic, V; Sun-Waterhouse, D; Murai, K; Idriss, H; Waterhouse, GIN				Chen, Wan-Ting; Chan, Andrew; Jovic, Vedran; Sun-Waterhouse, Dongxiao; Murai, Kei-ichiro; Idriss, Hicham; Waterhouse, Geoffrey I. N.			Effect of the TiO2 Crystallite Size, TiO2 Polymorph and Test Conditions on the Photo-Oxidation Rate of Aqueous Methylene Blue	TOPICS IN CATALYSIS			English	Article						Photocatalysis; Anatase; Rutile; Brookite; P25; Methylene blue	PHOTOCATALYTIC DEGRADATION; WATER; ANATASE; DYES; DECOMPOSITION; NANOPARTICLES; ADSORPTION; TITANIA	This study systematically re-examines the titania-catalysed photo-oxidation of methylene blue (MB) in aqueous solution at 20 degrees C, placing particular emphasis on the effects of TiO2 crystallite size, TiO2 polymorph (anatase, brookite, rutile and combinations thereof) and experimental test conditions on the rate of MB photo-oxidation. For all TiO2 samples tested, the highest rate of MB photo-oxidation was observed at pH 6, slightly above the isoelectric point of TiO2 (similar to 5.8 for P25 TiO2). Increasing the ionic strength at pH 6 induced MB dimer formation in solution, and lowered the rate of MB photo-oxidation by TiO2. For all TiO2 polymorphs, the surface area normalised rate increased with crystallite size reflecting the corresponding reduction in surface and bulk defects (electron-hole pair recombination sites). The optimum crystallite sizes were similar to 20-25 nm for anatase and similar to 50 nm for brookite. The photocatalytic activity of the different TiO2 powders followed the general order P25 > anatase > brookite >> rutile, with the high activity of P25 TiO2 providing strong evidence that anatase-rutile heterojunctions act as "hotspots" for MB photo-oxidation. Mixed phase anatase-rutile or brookite-rutile powders, each containing similar to 5 wt% rutile, demonstrated superior area normalized photocatalytic activities for MB photo-oxidation compared to pure phase anatase or brookite powders of comparable crystallite size. Finally, deposition of Pd, Pt or Au nanoparticles decreased the activity of P25 TiO2 for MB photo-oxidation. This paper clarifies long-standing confusion in the scientific literature about the photo-oxidation of aqueous MB over TiO2 and M/TiO2 (M = Pd, Pt and Au) photocatalysts.	[Chen, Wan-Ting; Chan, Andrew; Jovic, Vedran; Sun-Waterhouse, Dongxiao; Waterhouse, Geoffrey I. N.] Univ Auckland, Sch Chem Sci, Auckland 1, New Zealand; [Murai, Kei-ichiro] Univ Tokushima, Grad Sch Adv Technol & Sci, Tokushima 770, Japan; [Idriss, Hicham] KAUST, Corp Res & Innovat CRI, SABIC, Thuwal, Saudi Arabia; [Waterhouse, Geoffrey I. N.] MacDiarmid Inst Adv Mat & Nanotechnol, Wellington, New Zealand	Waterhouse, GIN (reprint author), Univ Auckland, Sch Chem Sci, Auckland 1, New Zealand.	g.waterhouse@auckland.ac.nz			Energy Education Trust of New Zealand; MacDiarmid Institute for Advance Materials and Nanotechnology; Australian Institute of Nuclear Science and Engineering [ALN-GRA11126]; Japan Society for the Promotion of Science (JSPS) [S13179]	Wan-Ting Chen acknowledges the Energy Education Trust of New Zealand for the award of a doctoral scholarship. The authors acknowledge funding support the MacDiarmid Institute for Advance Materials and Nanotechnology and the Australian Institute of Nuclear Science and Engineering (ALN-GRA11126). Geoff Waterhouse thanks the Japan Society for the Promotion of Science (JSPS) for award of a JSPS Fellowship to work in Japan (S13179). The authors thank Dr. Peter Swedlund of the University of Auckland for useful insight regarding the competitive adsorption of MB and phosphate on TiO<INF>2</INF> surfaces.	Wu CH, 2006, IND ENG CHEM RES, V45, P6450, DOI 10.1021/ie0602759; Toyoda M, 2004, APPL CATAL B-ENVIRON, V49, P227, DOI 10.1016/j.apcatb.2003.12.012; Baiju KV, 2007, J PHYS CHEM C, V111, P7612, DOI 10.1021/jp070452z; Zanella R, 2002, J PHYS CHEM B, V106, P7634, DOI 10.1021/jp0144810; Houas A, 2001, APPL CATAL B-ENVIRON, V31, P145, DOI 10.1016/S0926-3373(00)00276-9; Chakrabarti S, 2004, J HAZARD MATER, V112, P269, DOI 10.1016/j.jhazmat.2004.05.013; Koyuncu I, 2002, DESALINATION, V143, P243, DOI 10.1016/S0011-9164(02)00263-1; Kobya M, 2003, J HAZARD MATER, V100, P163, DOI 10.1016/S0304-3894(03)00102-X; Ohno T, 2001, J PHYS CHEM B, V105, P2417, DOI 10.1021/jp003211z; WOOD PM, 1988, BIOCHEM J, V253, P287; LAKSHMI S, 1995, J PHOTOCH PHOTOBIO A, V88, P163, DOI 10.1016/1010-6030(94)04030-6; Kuo WS, 2001, CHEMOSPHERE, V45, P77, DOI 10.1016/S0045-6535(01)00008-X; Wang XQ, 2014, J CATAL, V310, P100, DOI 10.1016/j.jcat.2013.04.022; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Kim TH, 2004, J HAZARD MATER, V112, P95, DOI 10.1016/j.jhazmat.2004.04.008; BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126; Bolong N, 2009, DESALINATION, V1-3, P229; Cavigli L, 2009, J APPL PHYS, V106, DOI 10.1063/1.3211291; Chan C-C, 2009, CHEM ENG J, V2-3, P492; Chang H, 2004, MATER TRANS, V45, P3334, DOI 10.2320/matertrans.45.3334; Chen P, 2008, CLEAN, V5-6, P507; Crittenden JC, 1996, WATER ENVIRON RES, V68, P270, DOI 10.2175/106143096X127703; Du P, 2008, J CATAL, V1, P75; Huang C. P., 1993, Waste Management, V13, P361, DOI 10.1016/0956-053X(93)90070-D; Konstantinou I.K., 2004, APPL CATAL, V499, P1; Lachheb H, 2002, APPL CATAL B-ENVIRON, V39, P75, DOI 10.1016/S0926-3373(02)00078-4; Malik P, 2004, J HAZARD MATER, V1, P81; Tauc J., 1972, Journal of Non-Crystalline Solids, V8-10, DOI 10.1016/0022-3093(72)90194-9; Mills A, 2012, APPL CATAL B-ENVIRON, V128, P144, DOI 10.1016/j.apcatb.2012.01.019; Ohtani B, 2010, J PHOTOCH PHOTOBIO A, V2-3, P179; Petrovic M, 2003, TRENDS ANAL CHEM, V10, P685; Reyes-Coronado D, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/14/145605; Sangpour P, 2010, J PHYS CHEM C, V33, P13955; Su R, 2011, J PHYS CHEM C, V49, P24287; Suttiponparnit K, 2011, NANOSCALE RES LETT, V1, P27; Syoufian A, 2008, J COLLOID INTERF SCI, V2, P507; Talebian N, 2010, THIN SOLID FILMS, V8, P2210; Wang X, 2011, CHEMCATCHEM, V11, P1665; Winardi S, 2010, LANGMUIR, V7, P4567	39	3	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1022-5528	1572-9028		TOP CATAL	Top. Catal.	MAR	2015	58	2-3					85	102		10.1007/s11244-014-0348-7		18	Chemistry, Applied; Chemistry, Physical	Chemistry	CC7TT	WOS:000350572000004		
J	Scott, MS; Waterhouse, GIN; Kato, K; Chang, SLY; Idriss, H; Sohnel, T				Scott, M. S.; Waterhouse, G. I. N.; Kato, K.; Chang, S. L. Y.; Idriss, H.; Soehnel, T.			Structural Analysis of Rh-Pd/CeO2 Catalysts Under Reductive Conditions: An X-ray Investigation	TOPICS IN CATALYSIS			English	Article						In-situ CO reduction; Rh and Pd XANES; Rh and Pd XPS; Bimetallic catalysts; Ethanol steam reforming (ESR); CeO2 HRTEM	TEMPERATURE-PROGRAMMED DESORPTION; FIELD-ION MICROSCOPE; GAS-SHIFT REACTION; SITU FT-IR; HYDROGEN-PRODUCTION; TUNGSTEN SURFACES; ETHANOL REACTIONS; SUPPORTED PD; RH; CEO2	X-ray photoelectron spectroscopy (XPS) and X-ray absorption spectroscopy (XAS) were used to probe the electronic and geometric structures of Rh-Pd/CeO2 catalysts before and after ethanol steam reforming (ESR) at 400 degrees C, as well as after heating in CO atmospheres as a function of time and temperatures. The O/Ce ratio determined by XPS for the as-prepared Rh-Pd/CeO2 catalysts (individual metal loadings of 0.5 or 2 wt%) were close to 2, with the Rh and Pd present primarily in oxidized form (as oxide and chloride surface species). After ESR at 400 degrees C the ceria support was heavily reduced to CeO2-x (x = 0.3-0.4), with Rh-0 (64 % of total Rh) and Pd-0 (67 % of total Pd) being the dominant species. Heating the as-prepared Rh-Pd/CeO2 catalysts under a CO atmosphere at 200-400 degrees C while monitoring the Pd and Rh K edges by XAS was also conducted. XAS of the K edge of Pd and Rh indicated, as expected, reduction of Pd before that of Rh from 200 degrees C onward. The FCC order of Pd is however perturbed at 400 degrees C. On the contrary, Rh once reduced maintained a well ordered (FCC) structure. This observation is rationalised by the greater reduction effect of Pd on CeO2 compared to Rh and therefore at the interface Pd structure may be altered at high temperatures.	[Scott, M. S.; Waterhouse, G. I. N.; Soehnel, T.] Univ Auckland, Sch Chem Sci, Auckland 1, New Zealand; [Kato, K.] JASRI, SPring 8, Sayo, Hyogo 6795198, Japan; [Chang, S. L. Y.] Monash Univ, Sch Chem, Melbourne, Vic 3800, Australia; [Chang, S. L. Y.] Forschungszentrum Julich, Peter Grunberg Inst, Ernst Ruska Ctr Microscopy & Spect Electrons, D-52425 Julich, Germany	Sohnel, T (reprint author), Univ Auckland, Sch Chem Sci, Private Bag 92019, Auckland 1, New Zealand.	t.soehnel@auckland.ac.nz			Monash Centre for Electron Microscopy; Monash University, Victoria, Australia; MacDiarmid Institute for Advanced Materials and Nanotechnology, Wellington, New Zealand; University of Auckland	This research was undertaken on the XAS beamline at the Australian Synchrotron, Victoria, Australia and the BL01B1 XAFS beamline at the SPring-8 Synchrotron, Hyogo, Japan. The authors are thankful for the beam time and the financial support and Chris Glover, Bernt Johannessen (AS) and Kiyofumi Nitta and Tomoya Uruga (SPring-8) for technical assistance. We thank the Monash Centre for Electron Microscopy, Monash University, Victoria, Australia and the MacDiarmid Institute for Advanced Materials and Nanotechnology, Wellington, New Zealand for their support. MS and TS thank R. Dronskowski and his group (RWTH Aachen University) for the hospitality during our research stay and for all the efforts to make our visit so enjoyable. We also thank the University of Auckland for support of this work through grants-in-aid and travel support.	Mayrhofer KJJ, 2009, ANGEW CHEM INT EDIT, V48, P3529, DOI 10.1002/anie.200806209; Tao F, 2008, SCIENCE, V322, P932, DOI 10.1126/science.1164170; Ruban AV, 1999, PHYS REV B, V59, P15990, DOI 10.1103/PhysRevB.59.15990; Sheng PY, 2004, APPL CATAL A-GEN, V261, P171, DOI 10.1016/j.apcata.2003.10.046; Cai WJ, 2008, CATAL TODAY, V138, P152, DOI 10.1016/j.cattod.2008.05.019; Bunluesin T, 1998, APPL CATAL B-ENVIRON, V15, P107, DOI 10.1016/S0926-3373(97)00040-4; SHIDO T, 1993, J CATAL, V141, P71, DOI 10.1006/jcat.1993.1119; Idriss H, 2004, PLATIN MET REV, V48, P105, DOI 10.1595/147106704X1603; Ravel B, 2005, J SYNCHROTRON RADIAT, V12, P537, DOI 10.1107/S0909049505012719; Idriss H, 2008, CHEMSUSCHEM, V1, P905, DOI 10.1002/cssc.200800196; Yee A, 2000, J CATAL, V191, P30, DOI 10.1006/jcat.1999.2765; Nahar G, 2014, RENEW SUST ENERG REV, V32, P777, DOI 10.1016/j.rser.2013.12.040; Chen HL, 2006, J PHYS CHEM B, V110, P14816, DOI 10.1021/jp0610259; Wilson EL, 2008, J PHYS CHEM C, V112, P10918, DOI 10.1021/jp8004103; PLUMMER EW, 1968, J CHEM PHYS, V49, P3479, DOI 10.1063/1.1670622; Yee A, 1999, J CATAL, V186, P279, DOI 10.1006/jcat.1999.2563; Diagne C, 2002, CATAL COMMUN, V3, P565, DOI 10.1016/S1566-7367(02)00226-1; Alfredsson M, 2002, PHYS CHEM CHEM PHYS, V4, P6100, DOI 10.1039/b204680f; Mukherjee P, 2002, CHEM MATER, V14, P1678, DOI 10.1021/cm010372m; Sheng PY, 2007, CATAL TODAY, V129, P313, DOI 10.1016/j.cattod.2006.09.040; Craciun R, 2002, APPL CATAL A-GEN, V230, P153, DOI 10.1016/S0926-860X(01)01003-1; Ferencz Z, 2014, ACS CATAL, V4, P1205, DOI 10.1021/cs500045z; Diagne C, 2004, CR CHIM, V7, P617, DOI 10.1016/j.crci.2004.03.004; BASSETT DW, 1978, THIN SOLID FILMS, V48, P237, DOI 10.1016/0040-6090(78)90245-6; Choi Y, 2014, PHYS CHEM CHEM PHYS, V16, P22588, DOI 10.1039/c4cp03366c; Craciun R, 1998, CATAL LETT, V51, P149, DOI 10.1023/A:1019022009310; DHANAK VR, 1990, SURF SCI, V238, P289, DOI 10.1016/0039-6028(90)90087-O; Kraus W, 2000, POWDER CELL 2 4; Li BH, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.125422; Mavrikakis M, 2002, CATAL LETT, V81, P153, DOI 10.1023/A:1016560502889; Newville M, 2001, J SYNCHROTRON RADIAT, V8, P322, DOI 10.1107/S0909049500016964; Rasband WS, 1997, IMAGE J 1997 2014; ROUX H, 1978, SURF SCI, V71, P375, DOI 10.1016/0039-6028(78)90338-2; Scott M, 2008, AM CHEM SOC DIV PETR, V51, P1; Shen WJ, 2000, CATAL LETT, V64, P23, DOI 10.1023/A:1019070516657; Sheng PY, 2004, J VAC SCI TECHNOL A, V22, P1652, DOI 10.1116/1.1705591; Sheng PY, 2002, J CATAL, V208, P393, DOI 10.1006/cat.2002.3576; Yang CW, 2014, PHYS CHEM CHEM PHYS, V16, P24165, DOI 10.1039/c4cp02372b; Yang ZX, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.075421; Yee A, 2000, CATAL TODAY, V63, P325	40	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1022-5528	1572-9028		TOP CATAL	Top. Catal.	MAR	2015	58	2-3					123	133		10.1007/s11244-014-0351-z		11	Chemistry, Applied; Chemistry, Physical	Chemistry	CC7TT	WOS:000350572000007		
J	Shinkawa, S				Shinkawa, Seiji			POSSIBLE PATHWAYS FROM AGREEING TO NON-AGREEING GENITIVE APPOSITIVES AS SEEN IN LA3AMON'S BRUT	TRANSACTIONS OF THE PHILOLOGICAL SOCIETY			English	Article								In Old English, genitive nouns in apposition are both marked for case. King Arthur's men, for example, would be Arthornures cyninges menn, Arthornures menn thornaes cyninges, among a few other possibilities. Non-agreeing genitive appositives such as Arthornur kinges men and Arthornures men (thorne) king began to appear in the Early Middle English period. The analysis in two versions of La?amon's Brut suggests two possible pathways through which they were established. One is the development of the name and the title as a compound-like unit, which marks genitive only at the end of the second element as in Arthornur kinges men, and the other is ambiguous appositive or predicative expressions such as Arthornures men (thorne) king, interpretable as either King Arthur's men' or men of Arthur, (who is) (the) king', which seem to have led post-head constituents of split genitives to appear in the nominative or unmarked case, resulting in genitive marking only on the pre-head components. These new usages are thus originally and essentially independent of the developments of the case-marking system itself.	[Shinkawa, Seiji] Hakuoh Univ, Oyama, Tochigi 3238585, Japan	Shinkawa, S (reprint author), Hakuoh Univ, Fac Business Adm, 1117 Daigyoji, Oyama, Tochigi 3238585, Japan.	shinkawa@fc.hakuoh.ac.jp					Allen CL, 1997, T PHILOL SOC, V95, P111, DOI 10.1111/1467-968X.00015; Allen Cynthia, 2003, ENGL LANG LINGUIST, V7, P1, DOI 10.1017/S1360674303211023; Allen Cynthia, 2008, GENITIVES EARLY ENGL; Allen Cynthia L, 2003, P 2002 C AUSTR LING, P1; Allen Cynthia L, 2002, SYNTACTIC EFFECTS MO, P57; [Anonymous], 2008, LAEM LING ATL EARL M; BROOK GEORGE L., 1963, LAYAMON; CANNON C, 1993, MEDIUM AEVUM, V62, P187; Keith W. J., 1960, MEDIUM AEVUM, V29, P161; Mitchell Bruce, 1985, OLD ENGLISH SYNTAX; Shinkawa S, 2013, NEUPHILOL MITT, V114, P473; SHINKAWA SEIJI, 2012, UNHISTORICAL GENDER; Stanley E. G., 1969, MEDIUM AEVUM, V38, P23; Stanley Eric G., 1968, NOTES QUERIES, V15, P85; Stroud Theodore A., 1952, J ENGLISH GERMANIC P, V51, P42	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0079-1636	1467-968X		T PHILOL SOC	Trans. Philol. Soc.	MAR	2015	113	1					127	136		10.1111/1467-968X.12056		10	Language & Linguistics	Linguistics	CD4XU	WOS:000351090300007		
J	Edo, E; Kuroda, S				Edo, Eric; Kuroda, Shigeru			GENERALISATIONS OF THE TAME AUTOMORPHISMS OVER A DOMAIN OF POSITIVE CHARACTERISTIC	TRANSFORMATION GROUPS			English	Article								In this paper, we introduce two generalizations of the tame subgroup of the automorphism group of a polynomial ring over a domain of positive characteristic. We study detailed structures of these new 'tame subgroups' in the case of two variables.	[Edo, Eric] Univ New Caledonia, ERIM, Noumea, New Caledonia; [Kuroda, Shigeru] Tokyo Metropolitan Univ, Dept Math & Informat Sci, Hachioji, Tokyo 1920397, Japan	Edo, E (reprint author), Univ New Caledonia, ERIM, BP R4-98851, Noumea, New Caledonia.	eric.edo@univ-nc.nc; kuroda@tmu.ac.jp					Shestakov IP, 2004, J AM MATH SOC, V17, P197, DOI 10.1090/S0894-0347-03-00440-5; Edo E., 2001, ANN POL MATH, V76, P67, DOI 10.4064/ap76-1-6; Jung H. W. E., 1942, J REINE ANGEW MATH, V184, P161; Kuroda S., 2012, SAITAMA MATH J, V29, P79; Magnus W., 1976, COMBINATORIAL GROUP; Nagata M., 1972, LECT MATH, V5; TANAKA T, 2008, FOLIA PHARMACOL JPN, V132, P3; van den Essen A., 2000, POLYNOMIAL AUTOMORPH; van der Kulk W., 1953, NIEUW ARCH WISK, V1, P33	9	1	1	SPRINGER BIRKHAUSER	NEW YORK	233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA	1083-4362	1531-586X		TRANSFORM GROUPS	Transform. Groups	MAR	2015	20	1					65	81		10.1007/s00031-014-9288-3		17	Mathematics	Mathematics	CC9OI	WOS:000350699700003		
J	Shigeta, T; Sakamoto, S; Li, XK; Cai, SJ; Liu, C; Kurokawa, R; Nakazawa, A; Kasahara, M; Uemoto, S				Shigeta, Takanobu; Sakamoto, Seisuke; Li, Xiao-Kang; Cai, Songjie; Liu, Chi; Kurokawa, Ryosuke; Nakazawa, Atsuko; Kasahara, Mureo; Uemoto, Shinji			Luminal Injection of Hydrogen-Rich Solution Attenuates Intestinal Ischemia-Reperfusion Injury in Rats	TRANSPLANTATION			English	Article							ISCHEMIA/REPERFUSION INJURY; TRANSPLANTATION; PRESERVATION; SALINE; RADICALS; PROTECTS; STATES; GRAFT	Background. Luminal preservation of the intestine is an attractive method to locally mitigate preservation injury and ischemic-reperfusion injury in small bowel transplantation (SBT) because this method has a potential to maintain the intestinal graft integrity. Hydrogen is noted as an antioxidant material by reducing hydroxyl radicals. We hypothesized that hydrogen-containing solution can be an optimum material for luminal preservation method in SBT. Methods. Ischemic reperfusion was induced in Lewis rats by occlusion of the supramesenteric artery and vein for 90 min. Experimental protocols were divided into four groups: sham operation group, no luminal injection (control) group, luminal injection of 5% glucose saline (GS) solution group, and luminal injection of hydrogen-rich GS (HRGS) group. Two milliliters of experimental solution was locally injected into the lumen of the intestine before declamping of vessels. Oxidative stress markers, proinflammatory cytokines, apoptosis in the crypt cells, and morphologic changes of the intestine were assessed. Results. The production of malondialdehyde and 8-hydroxydeoxyguanosine, as oxidative stress markers, were markedly suppressed in HRGS group. The level of proinflammatory cytokines, such as inducible nitric oxide synthase and interleukin-6, was significantly inhibited in HRGS group. Crypt apoptosis was also significantly suppressed in HRGS group. Histopathologically, integrity of villus in intestine was maintained in HRGS group in comparison to the other groups. Conclusion. Luminal injection of hydrogen-rich solution can reduce oxidative stress and consequently ameliorate ischemic-reperfusion injury. Hydrogen-containing solution can be a novel and promising luminal preservation material in SBT.	[Shigeta, Takanobu; Sakamoto, Seisuke; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Organ Transplant Ctr, Tokyo 1578535, Japan; [Shigeta, Takanobu; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Div Hepatobiliary Pancret Surg & Transplantat, Kyoto, Japan; [Li, Xiao-Kang; Cai, Songjie; Liu, Chi; Kurokawa, Ryosuke] Natl Res Inst Child Hlth & Dev, Div Transplantat Immunol, Tokyo, Japan; [Kurokawa, Ryosuke] MiZ Co Ltd, Yokohama, Kanagawa, Japan; [Nakazawa, Atsuko] Natl Ctr Child Hlth & Dev, Dept Clin Pathol, Tokyo 1578535, Japan	Sakamoto, S (reprint author), Natl Ctr Child Hlth & Dev, Organ Transplantat Ctr, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.	sakamoto-si@ncchd.go.jp			National Center for Child Health and Development [24-08, 25-06]	This study was supported by a grant from the National Center for Child Health and Development (24-08, 25-06).	Chen H, 2011, J SURG RES, V167, P316, DOI 10.1016/j.jss.2009.07.045; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; Roskott AM, 2010, TRANSPLANTATION, V90, P622, DOI 10.1097/TP.0b013e3181ebf796; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Buchholz BM, 2011, TRANSPLANTATION, V92, P985, DOI 10.1097/TP.0b013e318230159d; Lenaerts K, 2013, CURR OPIN ORGAN TRAN, V18, P298, DOI 10.1097/MOT.0b013e32835ef1eb; Heinrich PC, 1998, BIOCHEM J, V334, P297; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Zheng XF, 2009, FREE RADICAL RES, V43, P478, DOI 10.1080/10715760902870603; PARK PO, 1990, SURGERY, V107, P574; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Noda K, 2013, J HEART LUNG TRANSPL, V32, P241, DOI 10.1016/j.healun.2012.11.004; Buchholz BM, 2008, AM J TRANSPLANT, V8, P2015, DOI 10.1111/j.1600-6143.2008.02359.x; Mazariegos GV, 2010, AM J TRANSPLANT, V10, P1020, DOI 10.1111/j.1600-6143.2010.03044.x; Zhao L, 2013, J ZHEJIANG UNIV-SC B, V14, P382, DOI 10.1631/jzus.B1200317; Ohta S, 2011, CURR PHARM DESIGN, V17, P2241; Abe T, 2012, TRANSPLANTATION, V94, P14, DOI 10.1097/TP.0b013e318255f8be; Mallick IH, 2004, DIGEST DIS SCI, V49, P1359, DOI 10.1023/B:DDAS.0000042232.98927.91; Chuai YH, 2012, BIOCHEM J, V442, P49, DOI 10.1042/BJ20111786; Kawamura T, 2010, TRANSPLANTATION, V90, P1344, DOI 10.1097/TP.0b013e3181fe1357; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Eto M, 2011, EUR J CARDIO-THORAC, V39, P465, DOI 10.1016/j.ejcts.2010.08.011; Fujimoto Y, 2002, AM J TRANSPLANT, V2, P229, DOI 10.1034/j.1600-6143.2002.20307.x; Ishibashi Toru, 2012, Med Gas Res, V2, P27, DOI 10.1186/2045-9912-2-27; Oltean M, 2012, AM J TRANSPLANT, V12, P2044, DOI 10.1111/j.1600-6143.2012.04067.x; SCHWEIZER E, 1994, TRANSPLANTATION, V57, P1406, DOI 10.1097/00007890-199405150-00024; Wen SH, 2012, SHOCK, V38, P411, DOI 10.1097/SHK.0b013e3182662266	27	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0041-1337	1534-6080		TRANSPLANTATION	Transplantation	MAR	2015	99	3					500	507		10.1097/TP.0000000000000510		8	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	CD0HX	WOS:000350752500017		
J	Fujioka, M; Okano, H; Edge, ASB				Fujioka, Masato; Okano, Hideyuki; Edge, Albert S. B.			Manipulating cell fate in the cochlea: a feasible therapy for hearing loss	TRENDS IN NEUROSCIENCES			English	Review						sensory systems; cell replacement; hearing loss; hair cells	MAMMALIAN INNER-EAR; HAIR-CELLS; STEM-CELLS; ACOUSTIC TRAUMA; MOUSE COCHLEA; IN-VIVO; REGULATES DEVELOPMENT; SUPPORTING CELLS; REGENERATION; EXPRESSION	Mammalian auditory hair cells do not spontaneously regenerate, unlike hair cells in lower vertebrates, including fish and birds. In mammals, hearing loss due to the loss of hair cells is permanent and intractable. Recent studies in the mouse have demonstrated spontaneous hair cell regeneration during a short postnatal period, but this regenerative capacity is lost in the adult cochlea. Reduced regeneration coincides with a transition that results in a decreased pool of progenitor cells in the cochlear sensory epithelium. Here, we review the signaling cascades involved in hair cell formation and morphogenesis of the organ of Corti in developing mammals, the changing status of progenitor cells in the cochlea, and the regeneration of auditory hair cells in adult mammals.	[Fujioka, Masato] Keio Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Tokyo, Japan; [Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Tokyo 160, Japan; [Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, Boston, MA 02114 USA; [Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA	Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	albert_edge@meei.harvard.edu	Okano, Hideyuki/J-5973-2013		MEXT [24592560]; MHLW (Comprehensive Research on Disability Health and Welfare); Takeda Science Foundation; NIH [RO1 DC007174, R21 DC010440, P30 DC05209]	We are grateful to T. Nagai for his excellent technical assistance in the electron microscopy. This work was supported by MEXT. KAKENHI (Grant-in-Aid for Scientific Research (C), 24592560), by MHLW (Comprehensive Research on Disability Health and Welfare), by Takeda Science Foundation to M.F, and by NIH grants RO1 DC007174, R21 DC010440, and P30 DC05209.	Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193; Jacques BE, 2007, DEVELOPMENT, V134, P3021, DOI 10.1242/dev.02874; Kelly MC, 2012, J NEUROSCI, V32, P6699, DOI 10.1523/JNEUROSCI.5420-11.2012; Ku YC, 2014, J NEUROSCI, V34, P3523, DOI 10.1523/JNEUROSCI.2606-13.2014; Liu ZY, 2012, J NEUROSCI, V32, P6600, DOI 10.1523/JNEUROSCI.0818-12.2012; Oshima K, 2007, JARO-J ASSOC RES OTO, V8, P18, DOI 10.1007/s10162-006-0058-3; Shi FX, 2012, J NEUROSCI, V32, P9639, DOI 10.1523/JNEUROSCI.1064-12.2012; Kelley MW, 2006, NAT REV NEUROSCI, V7, P837, DOI 10.1038/nrn1987; Woods C, 2004, NAT NEUROSCI, V7, P1310, DOI 10.1038/nn1349; Jeon SJ, 2011, J NEUROSCI, V31, P8351, DOI 10.1523/JNEUROSCI.6366-10.2011; Radde-Gallwitz K, 2004, J COMP NEUROL, V477, P412, DOI 10.1002/cne.20257; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; Cox BC, 2014, DEVELOPMENT, V141, P816, DOI 10.1242/dev.103036; White PM, 2006, NATURE, V441, P984, DOI 10.1038/nature04849; Lanford PJ, 1999, NAT GENET, V21, P289; Yamamoto N, 2011, DEV BIOL, V353, P367, DOI 10.1016/j.ydbio.2011.03.016; Hayashi T, 2007, DEV DYNAM, V236, P525, DOI 10.1002/dvdy.21026; Ahlfeld J, 2013, CANCER RES, V73, P3796, DOI 10.1158/0008-5472.CAN-13-0238; Oesterle EC, 2008, JARO-J ASSOC RES OTO, V9, P65, DOI 10.1007/s10162-007-0106-7; Hartman BH, 2009, JARO-J ASSOC RES OTO, V10, P321, DOI 10.1007/s10162-009-0162-2; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Shi FX, 2013, P NATL ACAD SCI USA, V110, P13851, DOI 10.1073/pnas.1219952110; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Zine A, 2001, J NEUROSCI, V21, P4712; Yamamoto N, 2006, J MOL MED-JMM, V84, P37, DOI 10.1007/s00109-005-0706-9; Chai RJ, 2012, P NATL ACAD SCI USA, V109, P8167, DOI 10.1073/pnas.1202774109; Bramhall NF, 2014, STEM CELL REP, V2, P311, DOI 10.1016/j.stemcr.2014.01.008; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Mizutari K, 2013, NEURON, V77, P58, DOI 10.1016/j.neuron.2012.10.032; Bermingham-McDonogh O, 2006, J COMP NEUROL, V496, P172, DOI 10.1002/cne.20944; Burns J, 2008, J COMP NEUROL, V511, P396, DOI 10.1002/cne.21849; Chen P, 1999, DEVELOPMENT, V126, P1581; Korrapati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073276; Kuwahara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094408; Martone T, 2014, EUR J NEUROSCI, V39, P1729, DOI 10.1111/ejn.12576; Tona Y, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-66; Watanabe R, 2012, MOL CELL NEUROSCI, V49, P104, DOI 10.1016/j.mcn.2011.11.001	39	0	0	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0166-2236			TRENDS NEUROSCI	Trends Neurosci.	MAR	2015	38	3					139	144		10.1016/j.tins.2014.12.004		6	Neurosciences	Neurosciences & Neurology	CD2UA	WOS:000350933300003		
J	Araki, M; Ishii, T				Araki, Motoko; Ishii, Tetsuya			Towards social acceptance of plant breeding by genome editing	TRENDS IN PLANT SCIENCE			English	Editorial Material						genome editing; crops; breeding; GMO; regulations; society	ZINC-FINGER NUCLEASES; CRISPR-CAS SYSTEM; TARGETED MUTAGENESIS; EFFECTOR NUCLEASES; RICE; CROPS; FOODS; DEHYDROGENASE; FRAGRANCE; SAFETY	Although genome-editing technologies facilitate efficient plant breeding without introducing a transgene, it is creating indistinct boundaries in the regulation of genetically modified organisms (GMOs). Rapid advances in plant breeding by genome-editing require the establishment of a new global policy for the new biotechnology, while filling the gap between process-based and product-based GMO regulations. In this Opinion article we review recent developments in producing major crops using genome-editing, and we propose a regulatory model that takes into account the various methodologies to achieve genetic modifications as well as the resulting types of mutation. Moreover, we discuss the future integration of genome-editing crops into society, specifically a possible response to the 'Right to Know' movement which demands labeling of food that contains genetically engineered ingredients.	[Araki, Motoko; Ishii, Tetsuya] Hokkaido Univ, Off Hlth & Safety, Sapporo, Hokkaido 0600808, Japan	Ishii, T (reprint author), Hokkaido Univ, Off Hlth & Safety, Sapporo, Hokkaido 0600808, Japan.	tishii@general.hokudai.ac.jp		Ishii, Tetsuya/0000-0002-7085-7750			Ahmed FE, 2002, TRENDS BIOTECHNOL, V20, P215, DOI 10.1016/S0167-7799(01)01920-5; Wang YP, 2014, NAT BIOTECHNOL, V32, P947, DOI 10.1038/nbt.2969; Shan QW, 2013, NAT BIOTECHNOL, V31, P686, DOI 10.1038/nbt.2650; Britt AB, 2003, TRENDS PLANT SCI, V8, P90, DOI 10.1016/S1360-1385(03)00002-5; Curtin SJ, 2011, PLANT PHYSIOL, V156, P466, DOI 10.1104/pp.111.172981; Charles C, 2014, MUTAT RES-GEN TOX EN, V768, P33, DOI 10.1016/j.mrgentox.2014.04.014; Chen SH, 2008, PLANT CELL, V20, P1850, DOI 10.1105/tpc.108.058917; Ray A, 2002, TRENDS PLANT SCI, V7, P435, DOI 10.1016/S1360-1385(02)02327-0; Holme IB, 2013, PLANT BIOTECHNOL J, V11, P395, DOI 10.1111/pbi.12055; Haun W, 2014, PLANT BIOTECHNOL J, V12, P934, DOI 10.1111/pbi.12201; Wendt T, 2013, PLANT MOL BIOL, V83, P279, DOI 10.1007/s11103-013-0078-4; Shukla VK, 2009, NATURE, V459, P437, DOI 10.1038/nature07992; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; Joung JK, 2013, NAT REV MOL CELL BIO, V14, P49, DOI 10.1038/nrm3486; Bawa AS, 2013, J FOOD SCI TECH MYS, V50, P1035, DOI 10.1007/s13197-012-0899-1; Durai S, 2005, NUCLEIC ACIDS RES, V33, P5978, DOI 10.1093/nar/gki912; Goodman RE, 2011, CURR ALLERGY ASTHM R, V11, P317, DOI 10.1007/s11882-011-0195-6; Mannion AM, 2012, PROG PHYS GEOG, V36, P747, DOI 10.1177/0309133312457109; Li T, 2012, NAT BIOTECHNOL, V30, P390, DOI 10.1038/nbt.2199; Bradbury LMT, 2008, PLANT MOL BIOL, V68, P439, DOI 10.1007/s11103-008-9381-x; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Shan QW, 2013, MOL PLANT, V6, P1365, DOI 10.1093/mp/sss162; Lor VS, 2014, PLANT PHYSIOL, V166, P1288, DOI 10.1104/pp.114.247593; Hartung F, 2014, PLANT J, V78, P742, DOI 10.1111/tpj.12413; Liang Z, 2014, J GENET GENOMICS, V41, P63, DOI 10.1016/j.jgg.2013.12.001; Araki M, 2014, TRENDS BIOTECHNOL, V32, P234, DOI 10.1016/j.tibtech.2014.03.005; Bevan MW, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-6-206; Camachol A, 2014, NAT BIOTECHNOL, V32, P1087, DOI 10.1038/nbt.3057; Davison J, 2010, PLANT SCI, V178, P94, DOI 10.1016/j.plantsci.2009.12.005; EFSA Panel on Genetically Modified Organisms, 2012, EFSA J, V10, P2943; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Jia HG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093806; Jiang WZ, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt780; Kanchiswamy CN, 2015, TRENDS BIOTECHNOL, V33, P62, DOI 10.1016/j.tibtech.2014.07.003; Ramessar K, 2008, NAT BIOTECHNOL, V26, P975, DOI 10.1038/nbt0908-975; Schouten Henk J, 2007, J Biomed Biotechnol, V2007, P82612, DOI 10.1155/2007/82612; Tsukaya H, 2013, EMBO REP, V14, P3, DOI 10.1038/embor.2012.202; Voytas DF, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001877; Xu RF, 2014, RICE, V7, DOI 10.1186/s12284-014-0005-6	39	5	5	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1360-1385			TRENDS PLANT SCI	Trends Plant Sci.	MAR	2015	20	3					145	149		10.1016/j.tplants.2015.01.010		5	Plant Sciences	Plant Sciences	CD2TY	WOS:000350933100003		
J	Choi, H; Ma, S				Choi, Heesup; Ma, Sangjoon			An optimal lightweight foamed mortar mix suitable for tunnel drainage carried out using the composite lining method	TUNNELLING AND UNDERGROUND SPACE TECHNOLOGY			English	Article						Drainage material; Clogging; Lightweight foamed mortar; In-plane flow; Transmissivity; Back space; Open-cell	GEOTEXTILES; CONCRETE	In this paper, an optimal lightweight foamed mortar mix suitable is proposed for facilitating tunnel drainage carried out using the composite lining method. A physical performance evaluation and pore structure analysis is provided in order to assess the performance of different lightweight foamed mortar mix proportions with various void fractions and foam solution concentrations. Furthermore, on the basis of an in-plane permeability test that simulated the permeation of fines of soil leaking with underground water, the formation and distribution of open-cell foams by measuring the outflow characteristics and outflow volume for each mix of the nonwoven geotextile and lightweight foamed mortar, which are the existing tunnel drainage materials was examined. Consequently, a mix employing a foaming agent with a dilution rate of 2% (#1) showed a better drain performance than all the other mixes, because it had the most appropriately formed and distributed open-cell foams, the key component for tunnel drainage. In other words, the mix of dilution rate of 2% was thought to have achieved stable closed-cell foams because of the decline in the surface tension of the foams, as well as the optimal formation and distribution of open-cell foams that possess excellent permeability because of the cohesiveness between the foams. Moreover, the thickness (drainage space) of it was approximately 17 times that of the nonwoven geotextile, and because the closed-cell and open-cell foams were connected like a spider web, it could be expected to reduce the blocking of drainage caused by the fines of soil. (C) 2014 Elsevier Ltd. All rights reserved.	[Choi, Heesup] Kitami Inst Technol, Dept Civil Engn, Kitami, Hokkaido, Japan; [Ma, Sangjoon] Korea Inst Construct Technol, Dept Geoinfra, Goyang, South Korea	Ma, S (reprint author), Korea Inst Construct Technol, Dept Geoinfra, Goyang, South Korea.	sjma@kictre.kr					[Anonymous], D471603 ASTM; Kearsley EP, 2001, CEMENT CONCRETE RES, V31, P805, DOI 10.1016/S0008-8846(01)00490-2; [Anonymous], 1995, D35 ASTM COMM, P53; Tikalsky PJ, 2004, CEMENT CONCRETE RES, V34, P889, DOI 10.1016/j.cemconres.2003.11.005; Choi M.C., 2005, KOR CONCR I SPRING C, V2005, P241; Giroud J.P., 1981, MAT CONST PAR, V14, P257, DOI 10.1007/BF02473945; Hoff G. C., 1972, CEMENT CONCRETE RES, V2, P91, DOI 10.1016/0008-8846(72)90026-9; Jeon H.Y., 2003, POLYM TEST, V22, P118; KICT, 2008, DEV NEW NATM COMP LI; KOERNER RM, 1984, GEOTEXT GEOMEMBRANES, V1, P57, DOI 10.1016/0266-1144(84)90005-0; Korea Concrete Institute, 1996, CONCR ENG KCI, P112; Korea Concrete Institute, 2001, CONCR ADM MAT KCI, P112; Korean Tunneling Association, 2004, THEOR BUS TUNN KTA, P441; Ku H.S, 1998, J KOREA ARCH I, V13, P321; Lee I.M., 1997, KOREA GEOTECH SOC, V13, P155; Lee S.H, 2002, J KOREA CONCR I, V14, P742; Lee S.H, 1992, J KOREA GEOTECH SOC, V8, P61; Ma S.J., 2006, KGS FALL C 2006 DAEG, P774; Ma S.J., 2006, KGS SPRING C 2006 SE, P77; Matsuo S., 1968, SOILS FOUND, V8, P10; Mindess S., 2003, CONCRETE; Miura N., 1979, SOILS FOUND, V19, P1; Mok M.S., 2008, P 4 AS REG C GEOS JU, P17; Monteiro P. J. M., 2006, CONCRETE MICROSTRUCT; Murata H., 1987, P JSCE, V382, P131; Oh S.C., 2001, J KOREA CONCR I, V13, P285; Palmeira EM, 2002, GEOTEXT GEOMEMBRANES, V20, P97, DOI 10.1016/S0266-1144(02)00004-3; Park B.K., 1999, J KOREAN GEOTECHNICA, V15, P127; Power T.C., 1954, P AM CONCR I, V51, P285; Rumann G., 1982, P 2 INT C GEOT, V1, P55; Yamada S., 1994, LIGHTWEIGHT BANKING, V22, P22	31	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0886-7798			TUNN UNDERGR SP TECH	Tunn. Undergr. Space Technol.	MAR	2015	47						93	105		10.1016/j.tust.2014.12.002		13	Construction & Building Technology; Engineering, Civil	Construction & Building Technology; Engineering	CC6ZY	WOS:000350518700010		
J	Yuki, M; Nitta, M; Omachi, T				Yuki, Masashi; Nitta, Makiko; Omachi, Tetsuo			Parathyroid hormone-related protein-induced hypercalcemia due to osteosarcoma in a cat	VETERINARY CLINICAL PATHOLOGY			English	Article						Endocrine; feline; HHM; malignant mesenchymal tumor; paraneoplastic syndrome	HUMORAL HYPERCALCEMIA; MALIGNANCY	A 15-year-old castrated male mixed-breed cat was presented with a history of sarcoma of the distal right hind limb. Biochemical analysis revealed increased concentrations of blood urea, creatinine, total calcium, ionized calcium, and parathyroid hormone-related protein (PTHrP). The mass was removed surgically by amputation of the hind limb. Osteosarcoma was diagnosed based on histopathologic examination. All abnormal serum analyte concentrations improved immediately after surgery, including azotemia, total calcium, ionized calcium, and PTHrP. The biochemical results were attributed to osteosarcoma causing PTHrP-induced hypercalcemia.	[Yuki, Masashi; Nitta, Makiko] Yuki Anim Hosp, Nagoya, Aichi, Japan; [Omachi, Tetsuo] Patho Labo Co Ltd, Shizuoka, Kanagawa, Japan	Yuki, M (reprint author), Yuki Anim Hosp, Minato Ku, 2-99 Kiba Cho, Nagoya, Aichi 4550021, Japan.	yuki-masashi@mvf.biglobe.ne.jp					Sheafor SE, 1996, J AM ANIM HOSP ASSOC, V32, P503; Vasilopulos RJ, 2003, COMP CONT EDUC PRACT, V25, P122; Savary KCM, 2000, J VET INTERN MED, V14, P184, DOI 10.1892/0891-6640(2000)014<0184:HICARS>2.3.CO;2; KLAUSNER JS, 1990, J AM VET MED ASSOC, V196, P103; Anderson TE, 2000, J AM ANIM HOSP ASSOC, V36, P52; Bolliger AP, 2002, VET CLIN PATH, V31, P3, DOI 10.1111/j.1939-165X.2002.tb00268.x; Cole DEC, 2007, CLIN BIOCHEM, V40, P585, DOI 10.1016/j.clinbiochem.2007.03.019; ENGELMAN RW, 1985, CANCER, V56, P777, DOI 10.1002/1097-0142(19850815)56:4<777::AID-CNCR2820560413>3.0.CO;2-V; Gone A, 1994, VET PATHOL, V31, P308; Gordon J, 2000, NEW ENGL J MED, V342, P177; Ichizuka K, 1999, ENDOCR J, V46, P479, DOI 10.1507/endocrj.46.479; Martin CK, 2011, VET PATHOL, V48, P302, DOI 10.1177/0300985810384414	12	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-6382	1939-165X		VET CLIN PATH	Vet. Clin. Pathol.	MAR	2015	44	1					141	144		10.1111/vcp.12224		4	Veterinary Sciences	Veterinary Sciences	CD0MH	WOS:000350767400016		
J	Kanemaki, N; Fukiage, C; Ichikawa, Y; Shearer, TR; Azuma, M				Kanemaki, Nobuyuki; Fukiage, Chiho; Ichikawa, Yoichiro; Shearer, Thomas R.; Azuma, Mitsuyoshi			Serum antibodies against beta H-crystallins in the American Cocker Spaniel	VETERINARY OPHTHALMOLOGY			English	Article						American Cocker Spaniels; cataracts; dog; immunoblotting; serum antibodies; beta H-crystallins	DEAMIDATION ALTERS; CATARACT FORMATION; LENS; DOGS; AUTOANTIBODIES; EXPRESSION; CONTRIBUTE; CALPAIN; MOUSE	ObjectiveTo detect antibodies for lens H-crystallins in the serum from the American Cocker Spaniel (ACS) presenting with and without cataracts and with and without uveitis. Animal StudiedSeventy-three American Cocker Spaniels and six normal Beagles. ProceduresSera were collected from 73 ACSs, including those with normal lenses and those with cataracts, or uveitis. Fractionated, normal Beagle lens H-crystallins were separated by one- or two-dimensional electrophoresis. The separated lens H-crystallins were used on immunoblots as sentinel substrates against which the ACS sera were tested for the presence of antibodies against H-crystallins. ResultsSera from approximately two-thirds of study animals contained antibodies to some H-crystallin polypeptides, but reactivity varied among patients. Contrary to some hypotheses, serum antibodies to groups of H-crystallins did not relate to the stages of cataract. However, detailed analysis by two-dimensional immunoblotting and mass spectrometry showed that three spots originating from A1-crystallin were detected only in sera from cataract patients. ConclusionSerum antibodies to A1-crystallin may be associated with the development of cataract.	[Kanemaki, Nobuyuki; Ichikawa, Yoichiro] Azabu Univ, Vet Teaching Hosp, Chuo Ku, Sagamihara, Kanagawa 2525201, Japan; [Fukiage, Chiho; Azuma, Mitsuyoshi] Senju Pharmaceut Co Ltd, Senju Lab Ocular Sci, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Shearer, Thomas R.; Azuma, Mitsuyoshi] Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA	Kanemaki, N (reprint author), Azabu Univ, Vet Teaching Hosp, Chuo Ku, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 2525201, Japan.	kanemaki@azabu-u.ac.jp			Senju Pharmaceutical Co. Ltd.	Dr. Shearer is a paid consultant for Senju Pharmaceutical Co. Ltd., a company that may have a commercial interest in the results of this research and technology. Dr. Azuma is an employee of Senju Pharmaceutical Co., Ltd. These potential conflicts of interest were reviewed, and management plans approved by the OHSU Conflict of Interest in Research Committee were implemented.	Takata T, 2007, BIOCHEMISTRY-US, V46, P8861, DOI 10.1021/bi700487q; Xi JH, 2003, MOL VIS, V9, P410; Ranjan M, 2008, MOL VIS, V14, P2056; Gelatt KN, 2005, VET OPHTHALMOL, V8, P101, DOI 10.1111/j.1463-5224.2005.00352.x; Leasure J, 2001, VET OPHTHALMOL, V4, P273, DOI 10.1046/j.1463-5216.2001.00199.x; Chan MP, 2008, BIOCHEMISTRY-US, V47, P11062, DOI 10.1021/bi8012438; Adkins EA, 2005, J AM ANIM HOSP ASSOC, V41, P235; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Rhodes JD, 2009, EXP EYE RES, V88, P226, DOI 10.1016/j.exer.2008.10.025; Takata T, 2009, MOL VIS, V15, P241; Wilmarth PA, 2006, J PROTEOME RES, V5, P2554, DOI 10.1021/pr050473a; DUNCAN G, 1984, CIBA F SYMP, V106, P132; BARNETT KC, 1985, J SMALL ANIM PRACT, V26, P305, DOI 10.1111/j.1748-5827.1985.tb02204.x; Barros Paulo S. M., 1999, Veterinary Ophthalmology, V2, P83; Baumworcel N, 2009, VET OPHTHALMOL, V12, P299, DOI 10.1111/j.1463-5224.2009.00715.x; COBB BF, 1969, COMP BIOCHEM PHYSIOL, V28, P841, DOI 10.1016/0010-406X(69)92118-5; DANIEL WJ, 1984, CURR EYE RES, V3, P911, DOI 10.3109/02713688409167208; DAVID LL, 1993, FEBS LETT, V324, P265, DOI 10.1016/0014-5793(93)80131-D; Davidson MG, 2007, VET OPHTHALMOLOGY, P859; Denis HM, 2003, VET OPHTHALMOL, V6, P321, DOI 10.1111/j.1463-5224.2003.00314.x; Dirks RPH, 1998, EXP EYE RES, V66, P267, DOI 10.1006/exer.1997.0439; Donaldson P, 2001, NEWS PHYSIOL SCI, V16, P118; Feng JH, 2000, J BIOL CHEM, V275, P11585, DOI 10.1074/jbc.275.16.11585; Ibaraki N, 1997, EXP EYE RES, V64, P229, DOI 10.1006/exer.1996.0203; MERCK KB, 1993, MOL BIOL REP, V17, P93, DOI 10.1007/BF00996216; Muller C, 2008, ANIM GENET, V39, P87, DOI 10.1111/j.1365-2052.2007.01680.x; Park SA, 2009, VET OPHTHALMOL, V12, P205, DOI 10.1111/j.1463-5224.2009.00697.x; Robertson LJG, 2005, INVEST OPHTH VIS SCI, V46, P4634, DOI 10.1167/iovs.04-1291; Wang L, 2011, MOL VIS, V17, P3423; Williams DL, 2006, VET OPHTHALMOL, V9, P292, DOI 10.1111/j.1463-5224.2006.00498.x	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1463-5216	1463-5224		VET OPHTHALMOL	Vet. Ophthalmol.	MAR	2015	18	2					109	115		10.1111/vop.12113		7	Veterinary Sciences	Veterinary Sciences	CD0IG	WOS:000350753800004		
J	Keira, Y; Takasawa, A; Murata, M; Nojima, M; Takasawa, K; Ogino, J; Higashiura, Y; Sasaki, A; Kimura, Y; Mizuguchi, T; Tanaka, S; Hirata, K; Sawada, N; Hasegawa, T				Keira, Yoshiko; Takasawa, Akira; Murata, Masaki; Nojima, Masanori; Takasawa, Kumi; Ogino, Jiro; Higashiura, Yukimura; Sasaki, Ayaka; Kimura, Yasutoshi; Mizuguchi, Toru; Tanaka, Satoshi; Hirata, Koichi; Sawada, Norimasa; Hasegawa, Tadashi			An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens	VIRCHOWS ARCHIV			English	Article						Claudin-18; Maspin; p53; Human bile duct cancer; Early diagnosis	BILIARY INTRAEPITHELIAL NEOPLASIA; MICROSATELLITE INSTABILITY; INTEROBSERVER AGREEMENT; CANCER-CELLS; EXPRESSION; TRACT; CHOLANGIOCARCINOMA; GENE; OVEREXPRESSION; ADENOCARCINOMA	Biliary tract cancers have an extremely poor outcome, and specific diagnostic markers and effective treatments are needed urgently. In this study, we assessed the capacity of panel of immunohistochemical markers including claudin-18, maspin, and p53 to distinguish biliary tract carcinoma and biliary intraepithelial neoplasia (BilIN) from non-neoplastic epithelium. We performed a retrospective study of 66 biliary tract cancer specimens and 63 specimens with non-neoplastic lesions. Of the surgical specimens, 96.7 % with adenocarcinoma/BilIN were detected as neoplastic, and all 63 specimens histologically diagnosed as non-neoplastic lesion were detected as non-neoplastic with high sensitivity (91.1 %) and specificity (100 %). Of presurgical endobiliary forceps biopsy specimens, all with adenocarcinoma/BilIN and only 1 of the 19 with a non-neoplastic lesion were distinguished as neoplastic with high sensitivity (100 %) and specificity (94.7 %). Moreover, this panel provided good separation of neoplasm from malignancy-undetermined atypical epithelium (18/21, 85.7 %). This panel achieves a more reliable distinction of biliary tract cancers and BilINs from non-neoplastic epithelia in both surgical and biopsy specimens than immunohistochemical analysis with single antibodies and is useful in supporting a diagnosis of adenocarcinoma and BilIN.	[Keira, Yoshiko; Ogino, Jiro; Hasegawa, Tadashi] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido, Japan; [Takasawa, Akira; Murata, Masaki; Takasawa, Kumi; Higashiura, Yukimura; Sasaki, Ayaka; Tanaka, Satoshi; Sawada, Norimasa] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan; [Nojima, Masanori] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Adv Med Promot, Tokyo, Japan; [Kimura, Yasutoshi; Mizuguchi, Toru; Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Surg, Sapporo, Hokkaido, Japan; [Kimura, Yasutoshi; Mizuguchi, Toru; Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; [Kimura, Yasutoshi; Mizuguchi, Toru; Hirata, Koichi] Sapporo Med Univ, Sch Med, Dept Sci, Sapporo, Hokkaido, Japan	Takasawa, A (reprint author), Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan.	atakasawa@sapmed.ac.jp					Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Matsuda Y, 2007, CANCER SCI, V98, P1014, DOI 10.1111/j.1349-7006.2007.00490.x; Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025; Albores-Saavedra J, 2009, J SURG ONCOL, V100, P598, DOI 10.1002/jso.21374; Sato Y, 2012, AM J PATHOL, V180, P123, DOI 10.1016/j.ajpath.2011.09.010; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962; Sawada N, 2013, PATHOL INT, V63, P1, DOI 10.1111/pin.12021; Everhart JE, 2009, GASTROENTEROLOGY, V136, P1134, DOI 10.1053/j.gastro.2009.02.038; Kawashima H, 2013, J HEPATO-BIL-PAN SCI, V20, P441, DOI 10.1007/s00534-012-0581-z; Cao DF, 2007, MODERN PATHOL, V20, P570, DOI 10.1038/modpathol.3800772; Zen Y, 2007, MODERN PATHOL, V20, P701, DOI 10.1038/modpathol.3800788; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Fujisawa K, 2005, LAB INVEST, V85, P214, DOI 10.1038/labinvest.3700214; Khan SA, 2005, LIVER INT, V25, P704, DOI 10.1111/j.1478-3231.2005.01106.x; Zen Y, 2005, PATHOL INT, V55, P180, DOI 10.1111/j.1440-1827.2005.01816.x; Rashid A, 2002, CLIN CANCER RES, V8, P3156; Bettstetter M, 2005, J PATHOL, V205, P606, DOI 10.1002/path.1732; Hsu M, 2013, CANCER-AM CANCER SOC, V119, P1669, DOI 10.1002/cncr.27955; Ishihara S, 2007, DIGEST SURG, V24, P131, DOI 10.1159/000101901; Ito T, 2011, J CELL BIOCHEM, V112, P1761, DOI 10.1002/jcb.23095; Josse H, 2012, DIAGN CYTOPATHOL, V40, P321; Nagakawa Takukazu, 2002, J Hepatobiliary Pancreat Surg, V9, P569, DOI 10.1007/s005340200076; Kawashima H, 2012, DIGEST ENDOSC, V24, P22, DOI 10.1111/j.1443-1661.2012.01253.x; Khalkhali-Ellis Z, 2006, CLIN CANCER RES, V12, P7279, DOI 10.1158/1078-0432.CCR-06-1589; Mary L, 2010, HUM PATHOL, V41, P1210; Matsuda A, 2013, JPN J CLIN ONCOL, V43, P328, DOI 10.1093/jjco/hys233; Merikallio H, 2011, INT J CLIN EXP PATHO, V4, P667; Nakanuma Y, 2010, WHO CLASSIFICATION T, P217; Niimi T, 2001, MOL CELL BIOL, V21, P7380, DOI 10.1128/MCB.21.21.7380-7390.2001; Riener MO, 2010, HUM PATHOL, V41, P1558, DOI 10.1016/j.humpath.2009.12.016; Shinozaki A, 2011, VIRCHOWS ARCH, V459, P73, DOI 10.1007/s00428-011-1092-z; Singh AB, 2010, J ONCOL, V2010, DOI DOI 10.1155/2010/541957; Soini Y, 2012, J CLIN PATHOL, V65, P431, DOI 10.1136/jclinpath-2011-200400; Tamada K, 2002, GUT, V50, P326, DOI 10.1136/gut.50.3.326; Tretiakova M, 2012, AM J SURG PATHOL, V36, P101, DOI 10.1097/PAS.0b013e31822fbc95	35	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2015	466	3					265	277		10.1007/s00428-014-1705-4		13	Pathology	Pathology	CD5RH	WOS:000351145000004		
J	Sadahira, Y; Sugihara, T; Fujiwara, H; Nishimura, H; Suetsugu, Y; Takeshita, M; Okamura, S; Goto, M				Sadahira, Yoshito; Sugihara, Takashi; Fujiwara, Hideyo; Nishimura, Hirotake; Suetsugu, Yoshimasa; Takeshita, Morishige; Okamura, Seiichi; Goto, Makoto			WRN protein as a novel erythroblast immunohistochemical marker with applications for the diagnosis of Werner syndrome	VIRCHOWS ARCHIV			English	Article						Werner syndrome; Immunohistochemistry; WRN; Erythroblasts	DNA HELICASES; SYNDROME GENE; EXPRESSION; CELLS	Genetic testing for mutations in the WRN gene is critical for the diagnosis of Werner syndrome (WS); however, these tests cannot be performed in a clinical setting. Nearly all of the WRN mutations result in expression of truncated WRN proteins that are missing the C-terminal nuclear localization signal. We evaluated the use of WRN protein immunohistochemistry for diagnosing WS using paraffin-embedded bone marrow sections. Using a well-defined commercially available polyclonal antibody against the C terminus of WRN, we found that of all the cell types tested, bone marrow erythroid precursors showed the strongest nuclear expression of WRN. Immunohistochemical analysis of bone marrow samples from 120 patients with non-WS hematological disorders (age range, 7 days-90 years) revealed WRN staining of the nuclei of CD71-positive early and late erythroid precursors. Erythroblasts negative for WRN immunostaining were only observed in two patients, both of whom were diagnosed with WS: one with concomitant myelodysplastic syndrome and the other with erythroleukemia with overexpression of TP53. Western blot analysis and immunocytochemistry indicated WRN was localized in the nuclei of the four positive control cell lines from non-WS patients but not in the five cell lines from WS patients, who had three different types of WRN mutations. Thus, immunohistochemical detection of WRN in erythroblasts from bone marrow paraffin sections could be useful in screening of WS cases and worthy of further molecular confirmation.	[Sadahira, Yoshito; Fujiwara, Hideyo; Nishimura, Hirotake] Kawasaki Med Univ, Dept Pathol, Kurashiki, Okayama 7010192, Japan; [Sugihara, Takashi] Kawasaki Med Univ, Dept Hematol, Kurashiki, Okayama 7010192, Japan; [Suetsugu, Yoshimasa] Fukuyama City Hosp, Dept Internal Med, Fukuyama, Hiroshima 7218511, Japan; [Takeshita, Morishige] Fukuoka Univ, Dept Pathol, Fac Med, Johnan Ku, Fukuoka 8140180, Japan; [Okamura, Seiichi] Natl Hosp Org Kyushu Med Ctr, Dept Hematol, Minami Ku, Fukuoka 8111395, Japan; [Okamura, Seiichi] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Minami Ku, Fukuoka 8111395, Japan; [Goto, Makoto] Nerima Hikarigaoka Hosp, Div Rheumatol, Nerima Ku, Tokyo 1790072, Japan; [Goto, Makoto] Tokyo Womens Med Univ, East Med Ctr, Dept Rheumatol Orthoped Surg, Arakawa Ku, Tokyo 1168567, Japan	Sadahira, Y (reprint author), Kawasaki Med Univ, Dept Pathol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	sadapath@med.kawasaki-m.ac.jp					Muftuoglu M, 2008, HUM GENET, V124, P369, DOI 10.1007/s00439-008-0562-0; Takemoto M, 2013, GERIATR GERONTOL INT, V13, P475, DOI 10.1111/j.1447-0594.2012.00913.x; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Friedrich K, 2010, HUM GENET, V128, P103, DOI 10.1007/s00439-010-0832-5; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Marsee DK, 2010, AM J CLIN PATHOL, V134, P429, DOI 10.1309/AJCPCRK3MOAOJ6AT; Goto M, 2013, BIOSCI TRENDS, V7, P13, DOI 10.5582/bst.2013.v7.1.13; Singh DK, 2009, BIOGERONTOLOGY, V10, P235, DOI 10.1007/s10522-008-9205-z; Goto M, 1999, HUM GENET, V105, P301, DOI 10.1007/s004390051105; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mikami M, 2005, EXP HEMATOL, V33, P531, DOI 10.1016/j.exphem.2005.01.013; Motonaga K, 2002, J CLIN PATHOL, V55, P195; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Yamabe Y, 1997, BIOCHEM BIOPH RES CO, V236, P151, DOI 10.1006/bbrc.1997.6919	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	MAR	2015	466	3					343	350		10.1007/s00428-014-1703-6		8	Pathology	Pathology	CD5RH	WOS:000351145000011		
J	Hasan, MM; Shafiquzzaman, M; Nakajima, J; Ahmed, AKT; Azam, MS				Hasan, Md. Mahmudul; Shafiquzzaman, Md.; Nakajima, Jun; Ahmed, Abdel Kader T.; Azam, Mohammad Shafiul			Application of a Low Cost Ceramic Filter to a Membrane Bioreactor for Greywater Treatment	WATER ENVIRONMENT RESEARCH			English	Article						ceramic filter; MBR; greywater reclamation and reuse; surfactant; low cost technology; developing countries	WASTE-WATER TREATMENT; GREY WATER; GRAVITATIONAL FILTRATION; MULTISTORY BUILDINGS; REUSE; SYSTEMS; REACTOR; RESOURCES; TOXICITY; LAS	The performance of a low cost and simple ceramic filter to a membrane bioreactor (MBR) process was evaluated for greywater treatment. The ceramic filter was submerged in an acrylic cylindrical column bioreactor. Synthetic greywater (prepared by shampoo, dish cleaner and laundry detergent) was fed continuously into the reactor. The filter effluent was obtained by gravitational pressure. The average flux performance was observed to be 11.5 LMH with an average hydraulic retention time of 1.7 days. Complete biodegradation of surfactant (methylene blue active substance removal: 99-100%) as well as high organic removal performance (biochemical oxygen demand: 97-100% and total organic carbon: >88%) was obtained. The consistency of flux (11.5 LMH) indicated that the filter can be operated for a long time without fouling. The application of this simple ceramic filter would make MBR technology cost-effective in developing countries for greywater reclamation and reuse.	[Hasan, Md. Mahmudul; Nakajima, Jun] Ritsumeikan Univ, Dept Environm Syst Engn, Shiga, Japan; [Shafiquzzaman, Md.] Caledonian Coll Engn, Dept Built & Nat Environm, Seeb, Oman; [Ahmed, Abdel Kader T.] Aswan Univ, Fac Engn, Dept Civil Engn, Aswan, Egypt; [Azam, Mohammad Shafiul] UITS, Dept Civil Engn, Dhaka, Bangladesh	Shafiquzzaman, M (reprint author), Caledonian Coll Engn, Dept Built & Nat Environm, Seeb, Oman.	khokon_k@yahoo.com			Open Research Centre Project for Private Universities Matching Fund from the Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was partly supported by the Open Research Centre Project for Private Universities Matching Fund from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Al-Jayyousi R. O., 2003, DESALINATION, V156, P181; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; KARPISCAK MM, 1990, WATER RESOUR BULL, V26, P939; Paulo PL, 2013, ECOL ENG, V50, P95, DOI 10.1016/j.ecoleng.2012.03.022; Meng FG, 2013, BIOTECHNOL BIOENG, V110, P1903, DOI 10.1002/bit.24866; Revitt DM, 2011, WATER RES, V45, P1549, DOI 10.1016/j.watres.2010.11.027; Verstraete W, 2009, BIORESOURCE TECHNOL, V100, P5537, DOI 10.1016/j.biortech.2009.05.047; Wangkarn S, 2005, TALANTA, V67, P686, DOI 10.1016/j.talanta.2005.03.011; Domene E, 2006, URBAN STUD, V43, P1605, DOI 10.1080/00420980600749969; Li Z, 2003, WATER SCI TECHNOL, V48, P101; Meng FG, 2009, WATER RES, V43, P1489, DOI 10.1016/j.watres.2008.12.044; Massoud MA, 2009, J ENVIRON MANAGE, V90, P652, DOI 10.1016/j.jenvman.2008.07.001; Engelhardt N, 1998, WATER SCI TECHNOL, V38, P429, DOI 10.1016/S0273-1223(98)00542-3; Sirisattha S, 2004, WATER RES, V38, P61, DOI 10.1016/j.watres.2003.08.027; Chin WH, 2009, WATER RES, V43, P3940, DOI 10.1016/j.watres.2009.06.050; Donner E, 2010, SCI TOTAL ENVIRON, V408, P2444, DOI 10.1016/j.scitotenv.2010.02.033; Elmitwalli TA, 2007, WATER RES, V41, P1379, DOI 10.1016/j.watres.2006.12.016; Eriksson E., 2002, URBAN WATER, V4, P85, DOI DOI 10.1016/S1462-0758(01)00064-4; Ernst M, 2007, DESALINATION, V202, P293, DOI 10.1016/j.desal.2005.12.067; Friedler E, 2005, WATER SCI TECHNOL, V51, P187; Friedler E, 2006, DESALINATION, V190, P221, DOI 10.1016/j.desal.2005.10.007; Fujimura Y., 1997, J ENV LAB ASS, V22, P25; Ghisi E, 2007, BUILD ENVIRON, V42, P2512, DOI 10.1016/j.buildenv.2006.07.019; Gross A, 2007, ECOL ENG, V31, P107, DOI 10.1016/j.ecoleng.2007.06.006; Hasan MM, 2011, DESALINATION, V276, P272, DOI 10.1016/j.desal.2011.03.062; Hernández Leal L, 2007, Water Sci Technol, V56, P193, DOI 10.2166/wst.2007.572; IMURA M, 1995, WATER SCI TECHNOL, V31, P163, DOI 10.1016/0273-1223(95)00418-M; Jabornig S, 2013, J MEMBRANE SCI, V446, P277, DOI 10.1016/j.memsci.2013.06.049; Japanese Industrial Standards Committee, 2008, PUBL JIS; Jedidi I, 2011, POWDER TECHNOL, V208, P427, DOI 10.1016/j.powtec.2010.08.039; Jiwakok S., 2012, JPN J WATER TREAT BI, V48, P109; Karabelnik K, 2012, ECOL ENG, V49, P84, DOI 10.1016/j.ecoleng.2012.08.035; Katukiza K., 2014, J ENVIRON MANAGE, V133, P258; Khemakhem S, 2007, DESALINATION, V206, P210, DOI 10.1016/j.desal.2006.03.567; Kujawa-Roeleveld Katarzyna, 2006, Reviews in Environmental Science and Bio/Technology, V5, P115, DOI 10.1007/s11157-005-5789-9; Laine A. T., 2001, THESIS CRANFIELD U U; Lamine M, 2012, DESALIN WATER TREAT, V46, P182, DOI 10.1080/19443994.2012.677553; Li F., 2009, SCI TOTAL ENVIRON, V407, P439; Li FY, 2008, WATER SCI TECHNOL, V57, P1901, DOI 10.2166/wst.2008.601; Little V. L., 2002, GRAYWATER GUIDELINES; Liu Rui, 2005, Process Biochemistry, V40, P125, DOI 10.1016/j.procbio.2003.11.038; Liu S, 2010, WATER RES, V44, P267, DOI 10.1016/j.watres.2009.09.023; Lu W., 2003, CHEMOSPHERE, V52, P1452; Mah DYS, 2009, RESOUR CONSERV RECY, V53, P113, DOI 10.1016/j.resconrec.2008.07.008; Merza C, 2007, DESALINATION, V215, P37, DOI 10.1016/j.desal.2006.10.026; Moreno-Garrido I, 2001, FRESEN J ANAL CHEM, V371, P474; Mourad KA, 2011, J ENVIRON MANAGE, V92, P2447, DOI 10.1016/j.jenvman.2011.05.004; Murat S., 2013, J MEMBRANE SCI, V429, P139; Pidou M., 2007, P I CIVIL ENG-ENG SU, V160, P119; Pidou M, 2008, CHEMOSPHERE, V71, P147, DOI 10.1016/j.chemosphere.2007.10.046; Santasmasas C, 2013, RESOUR CONSERV RECY, V72, P102, DOI 10.1016/j.resconrec.2013.01.004; Shafiquzzaman Md, 2011, Journal of Water and Environment Technology, V9, DOI 10.2965/jwet.2011.333; Smith E, 2012, WATER SCI TECHNOL, V66, P72, DOI 10.2166/wst.2012.167; TERZIC S, 1994, MAR POLLUT BULL, V28, P735, DOI 10.1016/0025-326X(94)90332-8; Thomas H., 2000, MEMBR TECHNOL, V2000, P10; Ueda T, 1996, WATER SCI TECHNOL, V34, P189, DOI 10.1016/S0273-1223(96)00803-7; Ueda T, 1999, WATER RES, V33, P2888, DOI 10.1016/S0043-1354(98)00518-1; U.S. Environmental Protection Agency (EPA), 2004, EPA625R04108; Ushijima K, 2013, ECOL ENG, V50, P62, DOI 10.1016/j.ecoleng.2012.04.028; Venhuis SH, 2004, INT J PHOTOENERGY, V6, P115, DOI 10.1155/S1110662X04000157; Wang YK, 2012, BIORESOURCE TECHNOL, V122, P17, DOI 10.1016/j.biortech.2012.04.020; Wilderer P. A., 2004, Water Science and Technology, V49, P7	62	0	0	WATER ENVIRONMENT FEDERATION	ALEXANDRIA	601 WYTHE ST, ALEXANDRIA, VA 22314-1994 USA	1061-4303	1554-7531		WATER ENVIRON RES	Water Environ. Res.	MAR	2015	87	3					233	241				9	Engineering, Environmental; Environmental Sciences; Limnology; Water Resources	Engineering; Environmental Sciences & Ecology; Marine & Freshwater Biology; Water Resources	CD1YP	WOS:000350870900006		
J	Nishizawa, M				Nishizawa, Masafumi			The regulators of yeast PHO system participate in the transcriptional regulation of G(1) cyclin under alkaline stress conditions	YEAST			English	Article						cyclin; alkali stress; stress response; phosphate regulation; transcription	SACCHAROMYCES-CEREVISIAE GENOME; DEPENDENT KINASE; CELL-CYCLE; GENE-EXPRESSION; CDK INHIBITOR; COMPLEX; PROTEIN; DEGRADATION; PATHWAY; FAMILY	The yeast Pho85 kinase oversees whether environmental conditions are favourable for cell growth and enables yeast cells to express only genes that are appropriate for the conditions. Alkaline stress perturbs transport of molecules across the plasma membrane that is vital for cell survival. Progression through the cell cycle is halted until the cells can adapt to the stress conditions. I found that Pho85 is required for CLN2 expression and that overproduction of the transcription factors Pho4, Rim101 and Crz1, all targets of Pho85, inhibited CLN2 expression. CLN2 expression in the absence of Pho85 could be recovered only when all the three transcription factors were deleted. Whi5, a functional homologue of the mammalian Rb protein, represses CLN2 expression and is inactivated when phosphorylated by either of the CDK-cyclin complexes, Cdc28-Cln3 or Pho85-Pcl9. Under alkaline conditions, the absence of Whi5 caused an increase in CLN2 expression but failed to do so when Pho85 was also absent, or when Pho4 was overproduced. The expression level of CLN2 in a pho85 pho4 rim101 crz1 quadruple mutant was stimulated when the Whi5 activity was repressed by overproduction of Pho85-Pcl9. These results indicate that Whi5 is also under control of alkaline stress. The inhibitory function of Whi5 on CLN2 is dependent on Rpd3 HDAC, and the absence of Rpd3 could also suppress the inhibitory effect of Pho4 overproduction. Based on these findings, a model is presented in which Pho85 and Pho4 functions in CLN2 regulation under alkaline conditions. Copyright (c) 2015 John Wiley & Sons, Ltd.	[Nishizawa, Masafumi] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1608582, Japan	Nishizawa, M (reprint author), Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	mas@z8.keio.jp			Japan Society for the Promotion of Science (JSPS) [KAKENHI 23570214]	I thank N. Morohashi, M. Shimizu and A. Toh-e for help and advice in the experiment, and J. Tkacz for reading the manuscript. This study was supported by the Japan Society for the Promotion of Science (JSPS; Grant No. KAKENHI 23570214).	Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Bai L, 2010, DEV CELL, V18, P544, DOI 10.1016/j.devcel.2010.02.007; Murakami K, 2007, APPL MICROBIOL BIOT, V75, P589, DOI 10.1007/s00253-007-0859-2; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Menoyo S, 2013, MOL CELL BIOL, V33, P1273, DOI 10.1128/MCB.01556-12; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Kaffman A, 1998, NATURE, V396, P482; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; Sopko R, 2006, MOL CELL, V21, P319, DOI 10.1016/j.molcel.2005.12.011; Biswas D, 2008, MOL CELL BIOL, V28, P4445, DOI 10.1128/MCB.00164-08; Wanke V, 2005, EMBO J, V24, P4271, DOI 10.1038/sj.emboj.7600889; Nishizawa M, 2008, PLOS BIOL, V6, P2817, DOI 10.1371/journal.pbio.0060326; Lamb TM, 2001, J BIOL CHEM, V276, P1850; Pramila T, 2006, GENE DEV, V20, P2266, DOI 10.1101/gad.1450606; VANDERREST ME, 1995, MICROBIOL REV, V59, P304; Ashe M, 2008, J BIOL CHEM, V283, P6040, DOI 10.1074/jbc.M708248200; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; Gueldener Ullrich, 1996, Nucleic Acids Research, V24, P2519; Huang DQ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000188; Huang DQ, 2002, MOL CELL BIOL, V22, P5076, DOI 10.1128/MCB.22.14.5076-5088.2002; Measday V, 2000, MOL MICROBIOL, V35, P825, DOI 10.1046/j.1365-2958.2000.01754.x; Meimoun A, 2000, MOL BIOL CELL, V11, P915; Newcomb LL, 2002, MOL CELL BIOL, V22, P1607, DOI 10.1128/MCB.22.5.1607-1614.2002; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393; Nishizawa M, 1999, J BIOL CHEM, V274, P33859, DOI 10.1074/jbc.274.48.33859; Nishizawa M, 2004, YEAST, V21, P903, DOI 10.1002/yea.1138; Nishizawa M, 1999, GENES CELLS, V4, P627, DOI 10.1046/j.1365-2443.1999.00290.x; Nishizawa M, 2010, EUKARYOT CELL, V9, P943, DOI 10.1128/EC.00247-09; Reid Robert J D, 2002, Methods Enzymol, V350, P258; Sambrook J, 2001, MOL CLONING LAB MANU; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; TANAKA K, 1990, MOL CELL BIOL, V10, P4303	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0749-503X	1097-0061		YEAST	Yeast	MAR	2015	32	3					367	378		10.1002/yea.3064		12	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Microbiology; Mycology	CD2IZ	WOS:000350902000003		
J	Sueishi, Y; Kamogawa, E; Nakamura, H; Ukai, M; Kunieda, M; Okada, T; Shimmei, M; Kotake, Y				Sueishi, Yoshimi; Kamogawa, Erisa; Nakamura, Hideo; Ukai, Mitsuko; Kunieda, Michio; Okada, Taiichi; Shimmei, Masashi; Kotake, Yashige			Kinetic Evaluation of Spin Trapping Rate Constants of New CYPMPO-type Spin Traps for Superoxide and Other Free Radicals	ZEITSCHRIFT FUR PHYSIKALISCHE CHEMIE-INTERNATIONAL JOURNAL OF RESEARCH IN PHYSICAL CHEMISTRY & CHEMICAL PHYSICS			English	Article						Spin Trapping; Spin Trapping Rate Constant; CYPMPO Derivatives	SCAVENGING CAPACITY; HYDROXYL; ESR; IDENTIFICATION; ANTIOXIDANTS; ADDUCT	CYPMPO (5-(2,2-dimethyl-1,3-propoxyl cyclophosphoryl)-5-methyl-1-pyrroline N-oxide) is a phosphorus containing spin trap that has been useful in aqueous media. Using a kinetic ESR spin trapping technique, we evaluated free radical trapping rate constants of two newly synthesized CYPMPO-type spin traps, including 2,2-dibutyl-substituted CYPMPO (DBCYP) and 5-phenyl-substituted CYPMPO (PhCYP). We investigated the spin trapping of five free radical species, i.e., superoxide, hydroxyl radical, alkoxyl radical, alkyl peroxyl radical and methyl radical. Other than superoxide, spin trapping rate constants of DBCYP and PhCYP are comparable to CYPMPO, ranging from 43.9% to 101% of CYPMPO's corresponding rate constants. However, PhCYP's spin-trapping rate constant against superoxide was 44% higher than that of CYPMPO. The results indicate that DBCYP and PhCYP may be the spin traps as useful as CYPMPO either in aqueous or non-aqueous medium.	[Sueishi, Yoshimi; Kamogawa, Erisa] Okayama Univ, Fac Sci, Dept Chem, Kita Ku, Okayama 7008530, Japan; [Nakamura, Hideo; Ukai, Mitsuko] Hokkaido Univ, Dept Humanities & Reg Sci, Hakodate, Hokkaido 0408567, Japan; [Kunieda, Michio; Okada, Taiichi] Mikuni Pharmaceut Ind Co Ltd, Toyonaka, Osaka 5610823, Japan; [Shimmei, Masashi; Kotake, Yashige] Rad Res Inc, Hino, Tokyo 1910061, Japan	Sueishi, Y (reprint author), Okayama Univ, Fac Sci, Dept Chem, Kita Ku, Okayama 7008530, Japan.	ysueishi@cc.okayama-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [25450169]	This work was supported in part by a Grant-in-Aid for Science Research (C) (No. 25450169) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	Taniguchi H, 1999, J AM CHEM SOC, V121, P11875, DOI 10.1021/ja993140l; Sueishi Y, 2014, J CLIN BIOCHEM NUTR, V54, P67, DOI 10.3164/jcbn.13-53; Kamogawa E, 2014, BIOORG MED CHEM LETT, V24, P1376, DOI 10.1016/j.bmcl.2014.01.045; Kamibayashi M, 2006, FREE RADICAL RES, V40, P1166, DOI 10.1080/10715760600883254; JANZEN EG, 1969, J AM CHEM SOC, V91, P4481, DOI 10.1021/ja01044a028; Kohri S, 2009, ANAL BIOCHEM, V386, P167, DOI 10.1016/j.ab.2008.12.022; Nakamura K, 2010, B CHEM SOC JPN, V83, P1037, DOI 10.1246/bcsj.20100078; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; Karoui H, 2011, ORG BIOMOL CHEM, V9, P2473, DOI 10.1039/c0ob00876a; BURKITT MJ, 1991, P NATL ACAD SCI USA, V88, P8440, DOI 10.1073/pnas.88.19.8440; DAVIS FA, 1992, CHEM REV, V92, P919, DOI 10.1021/cr00013a008; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; JANZEN EG, 1995, J ORG CHEM, V60, P5441, DOI 10.1021/jo00122a022; KIM H, 1993, PHOTOCHEM PHOTOBIOL, V57, P777, DOI 10.1111/j.1751-1097.1993.tb09210.x; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; Nakamura H., 2013, NAKASHIMA FDN RES RE, P72; Oowada S, 2012, J CLIN BIOCHEM NUTR, V51, P117, DOI 10.3164/jcbn.11-113; POYER JL, 1980, BIOCHEM BIOPH RES CO, V94, P1154, DOI 10.1016/0006-291X(80)90540-9; Sueishi Y, 2002, B CHEM SOC JPN, V75, P2043, DOI 10.1246/bcsj.75.2043	19	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0942-9352			Z PHYS CHEM	Z. Phys. Chemie-Int. J. Res. Phys. Chem. Chem. Phys.	MAR	2015	229	3					317	326		10.1515/zpch-2014-0610		10	Chemistry, Physical	Chemistry	CD3SV	WOS:000351002100001		
J	Miura, S; Ohno, Y; Kimura, H; Kichikawa, K				Miura, Sachiko; Ohno, Yoshiharu; Kimura, Hiroshi; Kichikawa, Kimihiko			Quantitative lung perfused blood volume imaging on dual-energy CT: capability for quantitative assessment of disease severity in patients with acute pulmonary thromboembolism	ACTA RADIOLOGICA			English	Article						Lung; CT; pulmonary thromboembolism; perfusion; dual-energy CT	RIGHT-VENTRICULAR DYSFUNCTION; INITIAL-EXPERIENCE; DEFECT SCORE; SPIRAL CT; EMBOLISM; ANGIOGRAPHY; ECHOCARDIOGRAPHY; OBSTRUCTION; QUANTIFICATION; HYPERTENSION	Background: Regional iodine distribution assessment on dual-energy computed tomography (DECT) has been suggested as useful for management of acute pulmonary thromboembolism (APTE) patients. However, no reported studies have made a direct comparison between quantitatively assessed DECT and right-to-left ventricular (RV/LV) ratio on CT for differentiation of right heart dysfunction (RHD) from non-right heart dysfunction (NRHD) in APTE patients. Purpose: To determine the capability of DECT for differentiation of RHD from NRHD in APTE patients. Material and Methods: Thirteen APTE patients underwent DECT and echocardiography at onset of APTE. Patients were divided into RHD (n=7) and NRHD (n=6) groups based on echocardiography. A normalized lung perfused blood volume map was generated, and two kinds of overall perfusion (OP) index were determined, one placed over each lung field (OP index A) and as the average from six regions of interest (ROIs) placed over each lung field (OP index B). The heterogeneity index was also determined as the standard deviation for the six ROIs. RV/LV ratio evaluations were also performed. To assess differences between the two groups, each index was statistically compared with the Mann-Whitney U test. The receiver-operating curve-based positive test was then performed to determine the feasible threshold value for dividing patients into the two groups. Finally, differentiation capabilities of the indexes were compared using McNemar's test. Results: Significant differences between the two groups were found for both OP indexes and RV/LV ratio (P<0.05). For each of the feasible threshold values, accuracy of each OP index with and without RV/LV ratio was better than that of the RV/LV ratio. Conclusion: Quantitative DECT has good potential for differentiation of APTE patients with and without right heart dysfunction.	[Miura, Sachiko; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Kashihara, Nara 6348521, Japan; [Ohno, Yoshiharu] Kobe Univ, Grad Sch Med, Adv Biomed Imaging Res Ctr, Kobe, Hyogo 657, Japan; [Ohno, Yoshiharu] Kobe Univ, Grad Sch Med, Dept Radiol, Div Funct & Diagnost Imaging Res, Kobe, Hyogo 657, Japan; [Kimura, Hiroshi] Nara Med Univ, Dept Internal Med 2, Kashihara, Nara 6348521, Japan	Miura, S (reprint author), Nara Med Univ, Dept Radiol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	sachimiu@naramed-u.ac.jp					Araoz PA, 2007, RADIOLOGY, V242, P889, DOI 10.1148/radiol.2423051441; Chae EJ, 2010, AM J ROENTGENOL, V194, P604, DOI 10.2214/AJR.09.2681; Ohno Y, 2004, J MAGN RESON IMAGING, V20, P353, DOI 10.1002/jmrt.20137; van der Meer RW, 2005, RADIOLOGY, V235, P798, DOI 10.1148/radiol.2353040893; Bae KT, 2010, RADIOLOGY, V256, P32, DOI 10.1148/radiol.10090908; Mastora I, 2003, EUR RADIOL, V13, P29, DOI 10.1007/s00330-002-1515-y; Kucher N, 2003, CIRCULATION, V108, P2191, DOI 10.1161/01.CIR.0000100687.99687.CE; Ohno Y, 2012, AM J ROENTGENOL, V199, pW477, DOI 10.2214/AJR.11.8275; Johnson TRC, 2007, EUR RADIOL, V17, P1510, DOI 10.1007/s00330-006-0517-6; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Galie N, 2009, EUR HEART J, V30, P2493, DOI 10.1093/eurheartj/ehp297; Ohno Y, 2002, RADIOLOGY, V224, P503, DOI 10.1148/radiol.2242010992; Chae EJ, 2008, RADIOLOGY, V249, P671, DOI 10.1148/radiol.2492071956; Qanadli SD, 2001, AM J ROENTGENOL, V176, P1415; Schoepf UJ, 2004, CIRCULATION, V110, P3276, DOI 10.1161/01.CIR.0000147612.59751.4C; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Bankier AA, 1997, J THORAC IMAG, V12, P150, DOI 10.1097/00005382-199704000-00012; Ceylan N, 2011, ACAD RADIOL, V18, P47, DOI 10.1016/j.acra.2010.08.024; Hoey ETD, 2011, AM J ROENTGENOL, V196, P524, DOI 10.2214/AJR.10.4842; Jerjes-Sanchez C, 1995, J THROMB THROMBOLYS, V2, P227, DOI DOI 10.1007/BF0:062714; Kubo Takeshi, 2008, AJR Am J Roentgenol, V191, P1071, DOI 10.2214/AJR/07.2630; Nural MS, 2009, ACTA RADIOL, V50, P629, DOI 10.1080/02841850902902532; Ohno Y, 2004, AM J ROENTGENOL, V183, P91; Ohno Y, 2010, J MAGN RESON IMAGING, V31, P1081, DOI 10.1002/jmri.22146; Renard B, 2011, EUR J RADIOL, V79, P467, DOI 10.1016/j.ejrad.2010.04.018; Sueyoshi E, 2011, EUR J RADIOL, V80, pE505, DOI 10.1016/j.ejrad.2010.10.011; Thieme SF, 2012, EUR RADIOL, V22, P269, DOI 10.1007/s00330-011-2267-3; Wu AS, 2004, RADIOLOGY, V230, P831, DOI 10.1148/radiol.2303030083	28	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	MAR	2015	56	3					284	293		10.1177/0284185114524953		10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CC3JG	WOS:000350242900005		
J	Qin, Y; Ogawa, T; Fujii, S; Shinohara, Y; Kitao, S; Miyoshi, F; Takasugi, M; Watanabe, T; Kaminou, T				Qin, Ying; Ogawa, Toshihide; Fujii, Shinya; Shinohara, Yuki; Kitao, Shin-ichiro; Miyoshi, Fuminori; Takasugi, Marie; Watanabe, Takashi; Kaminou, Toshio			High incidence of asymptomatic cerebral microbleeds in patients with hemorrhagic onset-type moyamoya disease: a phase-sensitive MRI study and meta-analysis	ACTA RADIOLOGICA			English	Article						Moyamoya disease; cerebral microbleeds; phase-sensitive imaging (PSI); susceptibility-weighted imaging (SWI); T2*-weighted imaging (T2*WI)	AMYLOID ANGIOPATHY; INTRACEREBRAL HEMORRHAGE; FOLLOW-UP; BRAIN; PROGRESS; VESSELS	Background: disease is a relatively rare cerebrovascular occlusive disorder. Several studies have reported cerebral microbleeds (CMBs) in moyamoya disease patients using T2*-weighted imaging (T2*WI) and/or susceptibility-weighted imaging (SWI). Purpose: To investigate the incidence, distribution patterns, and influencing factors of asymptomatic CMBs in patients with moyamoya disease. Material and Methods: Phase-sensitive imaging (PSI) was used to investigate 27 consecutive moyamoya disease patients with a 3-T magnetic resonance imaging system, then a meta-analysis of 245 patients (asymptomatic moyamoya disease, n=23; ischemic moyamoya disease, n=161; hemorrhagic moyamoya disease, n=61) from four previous individual studies and our PSI study was performed. The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Based on the clinical and radiological data, we divided the studies into different model groups to calculate the incidence of CMBs and discuss the distribution patterns of CMBs. Results: Thirty-five asymptomatic CMBs were demonstrated in 14 moyamoya disease patients (51.9%) in our PSI study. Of these, 45.7% were located in the periventricular white matter. In the meta-analysis, the pooled incidence of asymptomatic CMBs in moyamoya disease was 46% (95% confidence interval [CI], 28.2-63.8%) on SWI or PSI and 29.6% (95% CI, 17.4-41.7%) on T2*WI. Statistical analysis showed that PSI or SWI offered better detection of CMBs in moyamoya disease than T2*WI, and 3-T T2*WI offered better detection than 1.5-T T2*WI. Furthermore, hemorrhagic onset-type moyamoya disease correlated with a high incidence of asymptomatic CMBs. Conclusion: PSI or SWI can detect CMBs better than T2*WI, and 3-T T2*WI. Hemorrhagic onset-type moyamoya disease seems to correlate with a high incidence of asymptomatic CMBs. The meta-analysis indicates that asymptomatic CMBs may be an important factor for hemorrhagic stroke risk. Long-term evaluation of CMBs using PSI or SWI may contribute to the management of moyamoya disease.	[Qin, Ying; Ogawa, Toshihide; Fujii, Shinya; Shinohara, Yuki; Kitao, Shin-ichiro; Miyoshi, Fuminori; Takasugi, Marie; Kaminou, Toshio] Tottori Univ, Dept Pathophysiol Therapeut Sci, Div Radiol, Yonago, Tottori 6838504, Japan; [Watanabe, Takashi] Tottori Univ, Fac Med, Dept Neurol Sci, Div Neurosurg, Yonago, Tottori 6838504, Japan	Ogawa, T (reprint author), Tottori Univ, Fac Med, Dept Pathophysiol Therapeut Sci, Div Radiol, 36-1 Nishi Cho, Yonago, Tottori 6838504, Japan.	ogawa@med.tottori-u.ac.jp					Rosand J, 2005, ANN NEUROL, V58, P459, DOI 10.1002/ana.20596; SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288; Fan YH, 2003, STROKE, V34, P2459, DOI 10.1161/01.STR.0000090841.90286.81; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; SUZUKI J, 1983, STROKE, V14, P104; Ikezaki K, 1997, CLIN NEUROL NEUROSUR, V99, pS183; Yoshida Y, 1999, STROKE, V30, P2272; Fujii S, 2010, AM J NEURORADIOL, V31, P55, DOI 10.3174/ajnr.A1752; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Gregoire SM, 2009, NEUROLOGY, V73, P1759, DOI 10.1212/WNL.0b013e3181c34a7d; Takahashi JC, 2010, NEUROL MED-CHIR, V50, P824; Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622; Lee SH, 2004, NEUROLOGY, V62, P72; Morioka M, 2003, STROKE, V34, P90, DOI 10.1161/01.STR.0000047120367507.0D; EZURA M, 1995, CHILD NERV SYST, V11, P591, DOI 10.1007/BF00300998; Kuroda S, 2013, STROKE, V44, P516, DOI 10.1161/STROKEAHA.112.678805; Knudsen KA, 2001, NEUROLOGY, V56, P537; Kobayashi E, 2000, J NEUROSURG, V93, P976, DOI 10.3171/jns.2000.93.6.0976; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Duan L, 2012, STROKE, V43, P56, DOI 10.1161/STROKEAHA.111.621300; Greenberg SM, 1999, NEUROLOGY, V53, P1135; Greenberg SM, 1996, NEUROLOGY, V46, P1751; Kikuta K, 2007, NEUROL MED-CHIR, V47, P564, DOI 10.2176/nmc.47.564; Mori N, 2008, INVEST RADIOL, V43, P574, DOI 10.1097/RLI.0b013e31817fb432; YAMASHITA M, 1983, STROKE, V14, P50; Chabriat Hugues, 2003, Adv Neurol, V92, P147; Ishikawa T, 2005, NEUROL MED-CHIR, V45, P495, DOI 10.2176/nmc.45.495; Kikuta K, 2005, J NEUROSURG, V102, P470, DOI 10.3171/jns.2005.102.3.0470; Kikuta K, 2008, ACT NEUR S, V103, P123; Kikuta KI, 2008, NEUROSURGERY, V62, P104, DOI [10.1227/01.NEU.0000311067.41239.E6, 10.1227/01.NEU.0000297105.57378.3B]; Nishimoto A, 1979, Neurol Med Chir (Tokyo), V19, P221, DOI 10.2176/nmc.19.221; Ryan Robert W J, 2012, Surg Neurol Int, V3, P72, DOI 10.4103/2152-7806.97730; TAKAHASHI M, 1980, RADIOLOGY, V136, P379; Wakai K, 1997, CLIN NEUROL NEUROSUR, V99, P221	34	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	MAR	2015	56	3					329	338		10.1177/0284185114524198		10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CC3JG	WOS:000350242900010		
J	Nakatsuka, T				Nakatsuka, Tomoyuki			ON UNIQUENESS OF SYMMETRIC NAVIER-STOKES FLOWS AROUND A BODY IN THE PLANE	ADVANCES IN DIFFERENTIAL EQUATIONS			English	Article							WEAK SOLUTIONS; EQUATIONS	We investigate the uniqueness of symmetric weak solutions to the stationary Navier-Stokes equation in a two-dimensional exterior domain Omega. It is known that, under suitable symmetry condition on the domain and the data, the problem admits at least one symmetric weak solution tending to zero at infinity. Given two symmetric weak solutions u and v, we show that if u satisfies the energy inequality parallel to del u parallel to(2)(L2(Omega)) <= (f, u) and sup(x is an element of Omega)(vertical bar x vertical bar + 1)vertical bar v(x)vertical bar is sufficiently small, then u = v. The proof relies upon a density property for the solenoidal vector field and the Hardy inequality for symmetric functions.	Nagoya Univ, Grad Sch Math, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nakatsuka, T (reprint author), Nagoya Univ, Grad Sch Math, Chikusa Ku, Furocho, Nagoya, Aichi 4648602, Japan.				 [25002702]	This work was partly supported by Grant-in-Aid for JSPS Fellows Number 25002702. The author would like to thank Professor R. Farwig and Professor M. Yamazaki for useful comments.	AMICK CJ, 1988, ACTA MATH-DJURSHOLM, V161, P71, DOI 10.1007/BF02392295; Abe K, 2013, ACTA MATH-DJURSHOLM, V211, P1, DOI 10.1007/s11511-013-0098-6; Bogovskii M. E., 1979, SOV MATH DOKL, V20, P1094; BORCHERS W., 1990, HOKKAIDO MATH J, V19, P67; CHANG ID, 1961, ARCH RATION MECH AN, V7, P388, DOI 10.1007/BF00250771; Fujita H., 1961, J FS U TOKYO, V9, P59; Galdi G. P., 1994, LINEARIZD STEADY PRO, VI; Galdi G. P., 1994, DIFFERENTIAL INTEGRA, V7, P847; Galdi G. P., 2004, HDB DIFFERENTIAL EQU, VI, P71; Galdi G. P., 1994, NONLINEAR STEADT PRO, VII; GALDI GP, 1990, ARCH RATION MECH AN, V112, P291, DOI 10.1007/BF02384076; Gilbarg D., 1978, ANN SCUOLA NORM SUP, V5, P381; Gilbarg D., 1974, RUSS MATH SURV, V29, P109, DOI 10.1070/RM1974v029n02ABEH003843; Kozono H, 1999, NONLINEAR ANAL-THEOR, V38, P959, DOI 10.1016/S0362-546X(98)00145-X; Kozono H., 1992, ANN SCUOLA NORM SUP, V19, P155; Kozono H., 1992, J MATH SOC JAPAN, V44, P307, DOI 10.2969/jmsj/04420307; Ladyzhenskaya O.A., 1978, J SOVIET MATH, V10, P257, DOI 10.1007/BF01566606; Leray J., 1933, J MATH PURE APPL, V12, P1; MASUDA K, 1984, TOHOKU MATH J, V36, P623, DOI 10.2748/tmj/1178228767; Miyakawa T., 1995, ADV MATH SCI APPL, V5, P411; Pileckas K, 2012, MATH ANN, V352, P643, DOI 10.1007/s00208-011-0653-4; Russo A, 2009, J MATH FLUID MECH, V11, P407, DOI 10.1007/s00021-007-0264-8; Yamazaki M., 2009, ANN U FERRARA, V55, P407; Yamazaki M., 2011, GAKUTO INT SER MATH, V35, P220	24	0	0	KHAYYAM PUBL CO INC	ATHENS	PO BOX 429, ATHENS, OH 45701 USA	1079-9389			ADV DIFFERENTIAL EQU	Adv. Differ. Equat.	MAR-APR	2015	20	3-4					193	212				20	Mathematics, Applied; Mathematics	Mathematics	CC3QT	WOS:000350264800001		
J	Yagura, K				Yagura, Kenjiro			Effect of intergenerational asset transfers on land distribution in rural Cambodia: case studies of three rice-growing villages	AGRICULTURAL ECONOMICS			English	Article						D31; J12; Q15; Landholdings; Inequality; Intergenerational transfers; Marriage; Cambodia	CREDIT CONSTRAINTS; FARM SIZE; PRODUCTIVITY; MARKETS; RISK; DETERMINANTS; IMPACT; SALES; INDIA	After land reallocation in the early 1980s, inequality in landholdings has re-emerged in rural Cambodia. Besides land sales and purchases, intergenerational transfers of assets may foster inequality in landholdings among second generation (2G) couples who, having wed after the 1980s reallocation, received no land from the government. Data analysis of three rice-growing villages reveals that land received directly from parents accounts for 18-41% of inequality in landholdings among sample 2G couples. Although net land gain after marriage, primarily through purchases, is the largest contributor to the inequality, nonland assets received from parents positively affect the net gain. Direct and indirect effects combined, assets received from parents account for 35-57% of inequality in landholdings. The effect of assortative matching of the acreage received from parents has hitherto been small.	Hannan Univ, Fac Econ, Matsubara, Osaka 5808502, Japan	Yagura, K (reprint author), Hannan Univ, Fac Econ, 5-4-33 Amami Higashi, Matsubara, Osaka 5808502, Japan.	k-yagura@hannan-u.ac.jp			KAKENHI [20780168]	This study was supported by KAKENHI [Grant-in-Aid for Young Scientists (B) (20780168)]. I am grateful to anonymous reviewers for their helpful comments on the earlier version of this article. I am deeply indebted to Mr. Dork Vuthy from the Royal University of Phnom Penh and research assistants for preparing and conducting the field survey. Moreover, I extend my heartfelt gratitude to people in the surveyed villages for cooperating with the survey.	Akram-Lodhi A. H., 2005, Journal of Agrarian Change, V5, P73, DOI 10.1111/j.1471-0366.2004.00095.x; Amakawa N., 2001, KAMBOJIA NO FUKKO KA; ESWARAN M, 1990, OXFORD ECON PAP, V42, P473; ROSENZWEIG MR, 1993, ECON J, V103, P56, DOI 10.2307/2234337; Portes A, 1998, ANNU REV SOCIOL, V24, P1, DOI 10.1146/annurev.soc.24.1.1; FEDER G, 1985, J DEV ECON, V18, P297, DOI 10.1016/0304-3878(85)90059-8; Cowell FA, 2011, J ECON INEQUAL, V9, P509, DOI 10.1007/s10888-011-9176-1; Andre C, 1998, J ECON BEHAV ORGAN, V34, P1, DOI 10.1016/S0167-2681(97)00045-0; SHORROCKS AF, 1982, ECONOMETRICA, V50, P193, DOI 10.2307/1912537; Baland JM, 2007, ECON DEV CULT CHANGE, V55, P283, DOI 10.1086/508717; Becker G., 1981, TREATISE FAMILY; CAIN M, 1981, POPUL DEV REV, V7, P435, DOI 10.2307/1972559; CARTER MR, 1984, OXFORD ECON PAP, V36, P131; CARTER MR, 1990, AM J AGR ECON, V72, P1146, DOI 10.2307/1242523; Chan S., 2002, CAMBODIA DEVELOPMENT; Deininger K, 2008, OXFORD B ECON STAT, V70, P67, DOI 10.1111/j.1468-0084.2007.00484.x; Deininger K, 2003, WORLD DEV, V31, P1385, DOI 10.1016/S0305-750X(03)00101-3; Deininger K, 2009, WORLD DEV, V37, P410, DOI 10.1016/j.worlddev.2008.06.004; Ebihara M. M., 1971, THESIS; Engvall A., 2007, STOCKHOLM SCHOOL OF; Engvall A., 2007, COUNTRY ECONOMIC REP; Fafchamps M., 2006, GPRG WPS 039; Fafchamps M, 2005, ECON DEV CULT CHANGE, V53, P347, DOI 10.1086/425373; Fitzgerald I., 2007, TRENDS IN COMMUNITYW; Kobayashi S., 2007, ASIAN AFR AREA STUD, V6, P540; National Institute of Statistics, 2010, GENERAL POPULATION C; National Institute of Statistics, 2009, GENERAL POPULATION C; Quisumbing Agnes R., 2005, Food and Nutrition Bulletin, V26, pS55; Rawal V, 2001, ECON DEV CULT CHANGE, V49, P611, DOI 10.1086/452518; Takahashi M., 2001, KAMBOJIA NO FUKKO KA; Tong K., 2012, CAMBODIA DEVELOPMENT, V66; Yagura K., 2005, DEV CHANGE, V36, P759; Yagura K., 2005, Japanese Journal of Rural Economics, V7, P30; Yu B., 2009, IFPRI DISCUSSION PAP	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0169-5150	1574-0862		AGR ECON-BLACKWELL	Agric. Econ.	MAR	2015	46	2					173	186		10.1111/agec.12149		14	Agricultural Economics & Policy; Economics	Agriculture; Business & Economics	CC6QR	WOS:000350492300004		
J	Stickley, A; Koyanagi, A; Koposov, R; McKee, M; Murphy, A; Ruchkin, V				Stickley, Andrew; Koyanagi, Ai; Koposov, Roman; McKee, Martin; Murphy, Adrianna; Ruchkin, Vladislav			Binge Drinking and Eating Problems in Russian Adolescents	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Adolescent; Binge Drinking; Eating Problems; Russia	HIGH-SCHOOL-STUDENTS; SUBSTANCE USE; ADVERSE OUTCOMES; NORTHERN RUSSIA; NORMAL-WEIGHT; ALCOHOL-USE; BEHAVIORS; DISORDERS; PREVALENCE; RISK	BackgroundBinge drinking may be linked to problematic eating behavior, although as yet, little research has been conducted on this association. The objective of this study was to examine the relationship between binge drinking and eating problems in Russian adolescents. MethodsData were drawn from the Social and Health Assessment, a cross-sectional school-based survey of 6th to 10th grade students (aged 12 to 17years old) carried out in Arkhangelsk, Russia. Information was collected on various eating problems (worries about weight, feeling fat, excessive eating, fasting and excessive exercise, and purging behaviors) and binge drinking (5 or more drinks in a row). Logistic regression analysis was used to examine the relationship between binge drinking and eating problems. ResultsAmong the 2,488 adolescents included in the statistical analysis, nearly 50% of girls expressed worries about their weight, while 35.0 and 41.5% of adolescent boys and girls reported excessive eating, respectively. The prevalence of purging behaviors (vomiting/using laxatives) was, however, much lower among both sexes (females2.6%; males3.3%). In a regression model adjusted for demographic factors and depressive symptoms, among girls, binge drinking was associated with 5 of the 6 eating problems with odds ratios (ORs) ranging from 1.21 (upset about weight gain) to 1.68 (excessive eating). For boys, binge drinking was linked to feeling overweight (OR: 1.47, confidence interval [CI]: 1.20 to 1.81) and vomiting/used laxatives (OR: 4.13, CI: 1.58 to 10.80). ConclusionsMany adolescents in Russia report problematic eating attitudes and behaviors, and eating problems are associated with binge drinking. More research is now needed in this setting to better understand adolescent eating problems and their association with alcohol misuse, so that contextually suitable interventions can be implemented to reduce these behaviors and mitigate their potentially detrimental effects.	[Stickley, Andrew; Koyanagi, Ai] Sodertorn Univ, Stockholm Ctr Hlth Soc Transit SCOHOST, S-14189 Huddinge, Sweden; [Stickley, Andrew] Univ Tokyo, Dept Human Ecol, Tokyo, Japan; [Koposov, Roman] UiT, Reg Ctr Child & Youth Mental Hlth & Child Welf, Tromso, Norway; [McKee, Martin; Murphy, Adrianna] London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1, England; [Ruchkin, Vladislav] Uppsala Univ, Div Neurosci, Dept Child & Adolescent Psychiat, Uppsala, Sweden	Stickley, A (reprint author), Sodertorn Univ, Stockholm Ctr Hlth Soc Transit SCOHOST, S-14189 Huddinge, Sweden.	andrew.stickley@sh.se					Miller JW, 2007, PEDIATRICS, V119, P76, DOI 10.1542/peds.2006-1517; Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040; [Anonymous], 2002, VSER PER NAS 2002 GO; Stickley A, 2007, EUR J PUBLIC HEALTH, V17, P444, DOI 10.1093/eurpub/ckl275; Paljarvi T, 2009, ADDICTION, V104, P1168, DOI 10.1111/j.1360-0443.2009.02577.x; Stickley A, 2009, PUBLIC HEALTH, V123, P20, DOI 10.1016/j.puhe.2008.07.009; Stice E, 2000, PSYCHOL ASSESSMENT, V12, P123, DOI 10.1037//1040-3590.12.2.123; Stolle M, 2009, DTSCH ARZTEBL INT, V106, P323, DOI 10.3238/arztebl.2009.0323; Bekman NM, 2013, ALCOHOL CLIN EXP RES, V37, P1432, DOI 10.1111/acer.12096; Field AE, 2012, PEDIATRICS, V130, pE289, DOI 10.1542/peds.2011-3663; Xing Y, 2006, J ADOLESCENT HEALTH, V39, P495, DOI 10.1016/j.jadohealth.2006.03.014; Stewart SH, 2006, J HEALTH PSYCHOL, V11, P409, DOI 10.1177/1359105306063313; Pisetsky EM, 2008, INT J EAT DISORDER, V41, P464, DOI 10.1002/eat.20520; Sonneville KR, 2013, JAMA PEDIATR, V167, P149, DOI 10.1001/2013.jamapediatrics.12; Ross HE, 1999, INT J EAT DISORDER, V26, P245, DOI 10.1002/(SICI)1098-108X(199911)26:3<245::AID-EAT2>3.0.CO;2-R; Eichen DM, 2012, J YOUTH ADOLESCENCE, V41, P1, DOI 10.1007/s10964-010-9612-8; Boyadjieva S, 1996, INT J EAT DISORDER, V19, P93; Dolan B, 1993, EUROPEAN EATING DISO, V1, P71, DOI 10.1002/erv.2400010202; Ferriter C, 2011, EAT BEHAV, V12, P99, DOI 10.1016/j.eatbeh.2011.01.001; Field AE, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00018; Grunbaum Jo Anne, 2004, Morbidity and Mortality Weekly Report, V53, P1; Hibell B, 2012, 2011 ESPAD REOPRT SU; Hibell B., 2004, ESPAD REPORT 2003 AL; KILLEN JD, 1987, INT J EAT DISORDER, V6, P349, DOI 10.1002/1098-108X(198705)6:3<349::AID-EAT2260060304>3.0.CO;2-5; Koposov RA, 2002, ALCOHOL ALCOHOLISM, V37, P297, DOI 10.1093/alcalc/37.3.297; Lock J, 2001, CHILD PSYCHIAT HUM D, V31, P249, DOI 10.1023/A:1026433506298; O'Keefe P, 1999, EUR EAT DISORD REV, V7, P129, DOI 10.1002/(SICI)1099-0968(199905)7:2<129::AID-ERV234>3.0.CO;2-#; Ortega RO, 2012, SALUD MENT, V35, P83; Page Randy M, 2006, Int Q Community Health Educ, V27, P39, DOI 10.2190/IQ.27.1.d; Patrick ME, 2013, JAMA PEDIATR, V167, P1019, DOI 10.1001/jamapediatrics.2013.2392; Pavlova B, 2010, SOC PSYCH PSYCH EPID, V45, P541, DOI 10.1007/s00127-009-0092-7; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Root TL, 2010, PSYCHOL MED, V40, P105, DOI 10.1017/S0033291709005662; Rosstat, 2003, REG ROSSII SOTS EK P; Ruchkin V., 2004, SOCIAL HLTH ASSESSME; Sarlio-Lähteenkorva S, 2003, Eat Weight Disord, V8, P289; Stevens J, 1997, OBES RES, V5, P227; Stewart SH, 2000, PSYCHOL ADDICT BEHAV, V14, P77, DOI 10.1037/0893-164X.14.1.77; Stickley A, 2013, DRUG ALCOHOL DEPEN, V133, P838, DOI 10.1016/j.drugalcdep.2013.08.028; Stickley A, 2013, ADDICT BEHAV, V38, P1988, DOI 10.1016/j.addbeh.2012.12.009; Sukhodolsky DG, 2004, J ABNORM CHILD PSYCH, V32, P225, DOI 10.1023/B:JACP.0000019773.86910.fe; Unikel C, 2011, SUBST USE MISUSE, V46, P523, DOI 10.3109/10826081003725260; Windle M, 1999, ALCOHOL USE ADOLESCE	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	MAR	2015	39	3					540	547		10.1111/acer.12644		8	Substance Abuse	Substance Abuse	CC8TL	WOS:000350641000019		
J	Ishibashi, M; Kawahara, Y; Chen, KR				Ishibashi, Masafumi; Kawahara, Yoshie; Chen, Ko-Ron			Spectrum of Cutaneous Vasculitis in Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): A Case Series	AMERICAN JOURNAL OF DERMATOPATHOLOGY			English	Article						eosinophilic vasculitis; neutrophilic vasculitis; granulomatous arteritis; phlebitis; leukocytoclastic vasculitis; myeloperoxidase antineutrophil cytoplasmic antibody	TERM-FOLLOW-UP; DISEASE; CLASSIFICATION; INVOLVEMENT; FEATURES; CRITERIA	Background: The diverse histopathologic spectrum of cutaneous vasculitis in eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) has not been well described. Methods: Fifteen skin biopsy specimens from 9 EGPA patients with histopathologically proven necrotizing vasculitis were reviewed clinicopathologically. Results: Among 8 patients with dermal small vessel vasculitis, neutrophilic vasculitis was observed in 2 myeloperoxidase (MPO)-antineutrophil cytoplasmic antibodies (ANCA)-positive patients, whereas the remaining 6 MPO-ANCA-negative patients showed eosinophilic vasculitis in 3 and a mixed infiltrate of neutrophils and eosinophils in another 3 patients. Five patients with muscular vessel vasculitis showed vasculitis at different inflammatory stages in separate or coexisting at the same biopsied skin lesions: acute stage (eosinophilic vasculitis), granulomatous stage (granulomatous vasculitis), and healed stage. Coexistent small vessel and muscular vessel vasculitis was found in 4 patients. Conclusions: The histopathologic spectrum of dermal small vessel vasculitis in EGPA ranges from eosinophilic vasculitis with negative MPO-ANCA at one end to neutrophilic vasculitis with positive MPO-ANCA at the other end. The affected vessels ranging from dermal small vessels to subcutaneous muscular vessels in addition to the MPO-ANCA phenotype may account for the many facets of vasculitis in EGPA.	[Ishibashi, Masafumi; Chen, Ko-Ron] Saiseikai Cent Hosp, Dept Dermatol, Tokyo 1080073, Japan; [Ishibashi, Masafumi] Nippon Kokan Ltd Co Hosp, Dept Dermatol, Kawasaki, Kanagawa, Japan; [Kawahara, Yoshie] Keiyu Hosp, Dept Dermatol, Yokohama, Kanagawa, Japan	Chen, KR (reprint author), Saiseikai Cent Hosp, Dept Dermatol, Minato Ku, 1-4-17 Mita, Tokyo 1080073, Japan.	chenkr54@yahoo.co.jp					Chen KR, 2007, J CUTAN PATHOL, V34, P330, DOI 10.1111/j.1600-0560.2006.00614.x; Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763; Kallenberg CGM, 2005, ARTHRITIS RHEUM, V52, P2589, DOI 10.1002/art.21253; Sinico RA, 2005, ARTHRITIS RHEUM, V52, P2926, DOI 10.1002/art.21250; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Carlson JA, 2005, AM J DERMATOPATH, V27, P504, DOI 10.1097/01.dad.0000181109.54532.c5; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094; Reid AJC, 1998, QJM-MON J ASSOC PHYS, V91, P219, DOI 10.1093/qjmed/91.3.219; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Ishibashi M, 2011, J CUTAN PATHOL, V38, P290, DOI 10.1111/j.1600-0560.2010.01513.x; Comarmond C, 2013, ARTHRITIS RHEUM-US, V65, P270, DOI 10.1002/art.37721; Chen KR, 2013, CLIN EXP NEPHROL, V17, P676, DOI 10.1007/s10157-012-0736-x; Chen KR, 2010, AM J DERMATOPATH, V32, P688, DOI 10.1097/DAD.0b013e3181d7759d; Chen KR, 1992, DERMATOLOGY, V19, P40; Chen KR, 1996, J AM ACAD DERMATOL, V35, P173, DOI 10.1016/S0190-9622(96)90318-7; CHEN KR, 1994, ARCH DERMATOL, V130, P1159; Chen KR, 2011, ADV DIAGNOSIS TREATM, P19; Davis MDP, 1997, J AM ACAD DERMATOL, V37, P199, DOI 10.1016/S0190-9622(97)80125-9; Della Rossa A, 2002, RHEUMATOLOGY, V41, P1286, DOI 10.1093/rheumatology/41.11.1286; Drage LA, 2002, J AM ACAD DERMATOL, V47, P209, DOI 10.1067/mjd.2002.124600; Hellmich B, 2005, ANN NY ACAD SCI, V1051, P121, DOI 10.1196/annals.1361.053; Pagnoux C, 2010, CURR OPIN RHEUMATOL, V22, P21, DOI 10.1097/BOR.0b013e328333390b; Sablé-Fourtassou Régis, 2005, Ann Intern Med, V143, P632	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0193-1091	1533-0311		AM J DERMATOPATH	Am. J. Dermatopathol.	MAR	2015	37	3					214	221				8	Dermatology	Dermatology	CC4AW	WOS:000350294000008		
J	Nakamura, Y; Kashiwagi, K; Nakamura, A; Muto, M				Nakamura, Yoshitaka; Kashiwagi, Keisuke; Nakamura, Akiko; Muto, Masahiko			Verrucous Carcinoma of the Foot Diagnosed Using p53 and Ki-67 Immunostaining in a Patient With Diabetic Neuropathy	AMERICAN JOURNAL OF DERMATOPATHOLOGY			English	Letter							SKIN-LESIONS; FEET		[Nakamura, Yoshitaka; Kashiwagi, Keisuke; Nakamura, Akiko; Muto, Masahiko] Yamaguchi Univ, Grad Sch Med, Dept Dermatol, Ube, Yamaguchi 755, Japan	Nakamura, Y (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Dermatol, Ube, Yamaguchi 755, Japan.						Adegboyega PA, 2005, APPL IMMUNOHISTO M M, V13, P171, DOI 10.1097/01.pai.0000132190.39351.9b; ACKERMAN LV, 1948, SURGERY, V23, P670; Ashida A, 2013, INT J DERMATOL, V52, P378, DOI 10.1111/j.1365-4632.2011.04891.x; Gerbig AW, 1995, BRIT J DERMATOL, V133, P1011, DOI 10.1111/j.1365-2133.1995.tb06946.x; Lee MY, 2004, SPINAL CORD, V42, P431, DOI 10.1038/sj.sc.3101606; Murao K, 2012, EUR J DERMATOL, V22, P274, DOI 10.1684/ejd.2012.1640; Sueki H, 2004, CLIN EXP DERMATOL, V29, P247, DOI 10.1111/j.1365-2230.2004.01479.x	7	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0193-1091	1533-0311		AM J DERMATOPATH	Am. J. Dermatopathol.	MAR	2015	37	3					257	259				3	Dermatology	Dermatology	CC4AW	WOS:000350294000017		
J	Koba, S; Nagase, K; Ikeda, S; Aoki, S; Misago, N; Narisawa, Y				Koba, Shinichi; Nagase, Kotaro; Ikeda, Satoshi; Aoki, Shigehisa; Misago, Noriyuki; Narisawa, Yutaka			Merkel Cell Carcinoma With Glandular Differentiation Admixed With Sweat Gland Carcinoma and Spindle Cell Carcinoma: Histogenesis of Merkel Cell Carcinoma From Hair Follicle Stem Cells	AMERICAN JOURNAL OF DERMATOPATHOLOGY			English	Article						Merkel cell carcinoma; sweat gland carcinoma; glandular differentiation; spindle cell carcinoma	CUTANEOUS NEUROENDOCRINE CARCINOMA; LEIOMYOSARCOMATOUS DIFFERENTIATION; SARCOMATOUS DIFFERENTIATION; SEBACEOUS DIFFERENTIATION; ATYPICAL FIBROXANTHOMA; APOCRINE CARCINOMA; BULGE AREA; T-ANTIGEN; TUMOR; SKIN	We describe a unique case of Merkel cell carcinoma (MCC) with a heterogeneous differentiation exhibiting distinct triphasic phenotypic differentiation features: small cells typical of MCC, sweat gland carcinoma (sweat gland Ca.) with possible decapitation secretion, and spindle cell carcinoma (spindle cell Ca.). The patient was an 84-year-old Japanese woman. We evaluated the present case immunohistochemically with various antibodies. The histological features showed a gradual transition from MCC to sweat gland Ca. and spindle cell Ca. For clarifying the histogenesis, immunophenotypic analysis of the 3 different components of the carcinoma was performed using hair follicle stem cell markers (eg, CK15, CK19, and CD200) that have been identified as biomarkers of human bulge cells. The triphasic components immunohistochemically shared the characteristic feature of CK19 and CD200 expression. We posit that the MCC arose from hair follicle stem cells residing within the bulge area where Merkel cells are preferentially situated. Based on our findings, we recommend adding this rare neoplasm to the expanding morphological spectrum of MCC.	[Koba, Shinichi; Nagase, Kotaro; Misago, Noriyuki; Narisawa, Yutaka] Saga Univ, Div Dermatol, Dept Internal Med, Fac Med, Saga 8498501, Japan; [Ikeda, Satoshi; Aoki, Shigehisa] Saga Univ, Fac Med, Dept Pathol & Microbiol, Saga 8498501, Japan	Koba, S (reprint author), Saga Univ, Div Dermatol, Dept Internal Med, Fac Med, 5-1-1 Nabeshima, Saga 8498501, Japan.	shinichi.koba@gmail.com					Uchugonova A, 2011, J CELL BIOCHEM, V112, P2046, DOI 10.1002/jcb.23122; Kloepper JE, 2008, EXP DERMATOL, V17, P592, DOI 10.1111/j.1600-0625.2008.00720.x; Youker SR, 2005, J CUTAN MED SURG, V9, P6, DOI 10.1007/s10227-005-0024-4; Walsh NMG, 2001, HUM PATHOL, V32, P680, DOI 10.1053/hupa.2001.25904; Martin B, 2013, HISTOPATHOLOGY, V62, P711, DOI 10.1111/his.12091; Adhikari LA, 2012, J CUTAN PATHOL, V39, P47, DOI 10.1111/j.1600-0560.2011.01794.x; Lyle S, 1998, J CELL SCI, V111, P3179; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Pontiggia L, 2009, J INVEST DERMATOL, V129, P480, DOI 10.1038/jid.2008.254; Kuwamoto S, 2011, HUM PATHOL, V42, P1063, DOI 10.1016/j.humpath.2011.01.020; Cheuk W, 2001, ARCH PATHOL LAB MED, V125, P228; Robson A, 2008, AM J SURG PATHOL, V32, P682, DOI 10.1097/PAS.0b013e3181590ba4; Shuda M, 2008, P NATL ACAD SCI USA, V105, P16272, DOI 10.1073/pnas.0806526105; Miyamoto T, 2005, J CLIN PATHOL, V58, P757, DOI 10.1136/jcp.2004.019794; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Yamamoto O, 1999, J CUTAN PATHOL, V26, P232, DOI 10.1111/j.1600-0560.1999.tb01836.x; Boutilier R, 2001, AM J DERMATOPATH, V23, P46, DOI 10.1097/00000372-200102000-00008; Cooper L, 2000, HISTOPATHOLOGY, V36, P540, DOI 10.1046/j.1365-2559.2000.00896.x; Covello R, 2010, EUR J DERMATOL, V20, P529, DOI 10.1684/ejd.2010.0983; Eusebi V, 2000, AM J SURG PATHOL, V24, P223, DOI 10.1097/00000478-200002000-00008; Fernandez-Figueras MT, 2002, J CUTAN PATHOL, V29, P619, DOI 10.1034/j.1600-0560.2002.291010.x; Gho CG, 2004, BRIT J DERMATOL, V150, P860, DOI 10.1111/j.0007-0963.2004.05862.x; Gomez-Moyano E, 2013, INT J DERMATOL, V52, P93, DOI 10.1111/j.1365-4632.2012.05675.x; GOULD E, 1988, AM J SURG PATHOL, V12, P768, DOI 10.1097/00000478-198810000-00005; HEENAN PJ, 1990, AM J DERMATOPATH, V12, P7, DOI 10.1097/00000372-199002000-00002; Hwang JHK, 2008, J CUTAN PATHOL, V35, P955, DOI 10.1111/j.1600-0560.2007.00917.x; ISIMBALDI G, 1993, AM J DERMATOPATH, V15, P260, DOI 10.1097/00000372-199306000-00012; Lau PP, 2011, ANN DIAGN PATHOL; LEONG ASY, 1986, PATHOLOGY, V18, P256; Mc Menamin ME, 2006, AM J SURG PATHOL, V30, P1299, DOI 10.1097/01.pas.0000208900.23483.ba; MEROT Y, 1990, INT J DERMATOL, V29, P102, DOI 10.1111/j.1365-4362.1990.tb04077.x; NARISAWA Y, 1994, J INVEST DERMATOL, V102, P506, DOI 10.1111/1523-1747.ep12373164; NARISAWA Y, 1993, ARCH DERMATOL RES, V285, P261, DOI 10.1007/BF00371594; Ohyama Manabu, 2012, Methods Mol Biol, V879, P389, DOI 10.1007/978-1-61779-815-3_24; REQUENA L, 1992, AM J DERMATOPATH, V14, P186, DOI 10.1097/00000372-199206000-00002; Rios-Martin Juan J., 1998, Journal of Dermatology (Tokyo), V25, P314; Tan KB, 2008, PATHOLOGY, V40, P314, DOI 10.1080/00313020701813685; WARKEL RL, 1978, ARCH DERMATOL, V114, P198, DOI 10.1001/archderm.114.2.198	38	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0193-1091	1533-0311		AM J DERMATOPATH	Am. J. Dermatopathol.	MAR	2015	37	3					E31	E36				6	Dermatology	Dermatology	CC4AW	WOS:000350294000002		
J	Bower, K; Pomer, A; Olszowy, KM; Sun, C; Lee, G; Chan, CW; Silverman, H; Dancause, KN; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, C; Lum, JK; Garruto, RM				Bower, K.; Pomer, A.; Olszowy, K. M.; Sun, C.; Lee, G.; Chan, C. W.; Silverman, H.; Dancause, K. N.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C.; Lum, J. K.; Garruto, R. M.			Maximal voluntary contraction (MVC) and its relationship with muscle and fat composition in Vanuatu	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Bower, K.; Pomer, A.; Olszowy, K. M.; Chan, C. W.; Garruto, R. M.] SUNY Binghamton, Lab Biomed & Neurosci, Binghamton, NY USA; [Bower, K.; Pomer, A.; Olszowy, K. M.; Sun, C.; Lee, G.; Chan, C. W.; Silverman, H.; Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA; [Pomer, A.; Sun, C.; Chan, C. W.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Chan, C. W.; Kaneko, A.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Island Malaria Grp, Stockholm, Sweden; [Silverman, H.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA; [Silverman, H.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Hempstead, NY 11550 USA; [Dancause, K. N.] McGill Univ, Douglas Hosp, Res Ctr, Psychosocial Res Div, Montreal, PQ, Canada; [Tarivonda, L.; Taleo, G.] Minist Hlth, Port Vila, Vanuatu; [Abong, M.] Kaljoral Senta, Port Vila, Vanuatu; [Regenvanu, R.] Minist Justice & Social Affairs, Port Vila, Vanuatu; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA; [Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA					Wenner-Gren Foundation for Anthropological Research [Gr 8301]; Harper College Grants in Support of Research, Scholarship, and Creative Work	Research was funded by the Wenner-Gren Foundation for Anthropological Research (Gr 8301) and the Harper College Grants in Support of Research, Scholarship, and Creative Work.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					262	263				2	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300030		
J	Buffa, G; Olszowy, KM; Sun, C; Silverman, H; Pomer, A; Dancause, KN; Lee, G; Chan, CW; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, CA; Lum, JK; Garruto, RM				Buffa, G.; Olszowy, K. M.; Sun, C.; Silverman, H.; Pomer, A.; Dancause, K. N.; Lee, G.; Chan, C. W.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C. A.; Lum, J. K.; Garruto, R. M.			Changes in adult blood pressure associated with modernization in the Republic of Vanuatu: 2007-2011	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Buffa, G.; Olszowy, K. M.; Pomer, A.; Chan, C. W.; Garruto, R. M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Binghamton, NY USA; [Buffa, G.; Olszowy, K. M.; Sun, C.; Silverman, H.; Pomer, A.; Chan, C. W.; Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA; [Buffa, G.; Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA; [Sun, C.; Silverman, H.; Pomer, A.; Lee, G.; Chan, C. W.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Silverman, H.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA; [Silverman, H.] Hofstra Univ, North Shore LIJ Sch Med, Hempstead, NY 11550 USA; [Dancause, K. N.] McGill Univ, Douglas Hosp, Res Ctr, Psychol Res Div, Montreal, PQ, Canada; [Chan, C. W.; Kaneko, A.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Isl Malaria Grp, Stolkholm, Sweden; [Tarivonda, L.; Taleo, G.] Minist Hlth, Port Vila, Vanuatu; [Abong, M.] Kaljoral Senta, Port Vila, Vanuatu; [Regenvanu, R.] Minist Justice & Social Affairs, Port Vila, Vanuatu; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C. A.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA					Wenner-Gren Foundation for Anthropological Research [Gr 8301]; Binghamton University Laboratory of Evolutionary Anthropology and Health; Harper College Grants in Support of Research, Scholarship, and Creative Work; Binghamton University Undergraduate Research Center Summer Scholars and Artists Program	This research was funded by the Wenner-Gren Foundation for Anthropological Research (Gr 8301), start-up funds from the Binghamton University Laboratory of Evolutionary Anthropology and Health, the Harper College Grants in Support of Research, Scholarship, and Creative Work, and the 2014 Binghamton University Undergraduate Research Center Summer Scholars and Artists Program.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					264	264				1	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300034		
J	Inoue, Y; Yazawa, A; Stickley, A; Li, D; Watanabe, C				Inoue, Y.; Yazawa, A.; Stickley, A.; Li, D.; Watanabe, C.			Activity space expansion and its association with subjective quality of life in the initial stage of economic development in rural Hainan, China.	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Inoue, Y.; Yazawa, A.; Stickley, A.; Watanabe, C.] Univ Tokyo, Dept Human Ecol, Grad Sch Med, Tokyo, Japan; [Li, D.] Hainan Ctr Dis Control & Prevent, Hainan, Peoples R China					Japan Society for the Promotion of Science [20401011, 11J02876]; Institutional Program for Young Researcher Overseas Visits	This research was financially supported by the Japan Society for the Promotion of Science; Grant numbers: 20401011, 11J02876; and Institutional Program for Young Researcher Overseas Visits.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					271	272				2	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300054		
J	Loud, SM; Pomer, A; Olszowy, KM; Sun, C; Dancause, KN; Chan, CW; Silverman, H; Lee, G; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, CA; Garruto, RM; Lum, JK				Loud, S. M.; Pomer, A.; Olszowy, K. M.; Sun, C.; Dancause, K. N.; Chan, C. W.; Silverman, H.; Lee, G.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C. A.; Garruto, R. M.; Lum, J. K.			Comparing diet patterns among student resident subgroups in Aneityum, Vanuatu.	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Loud, S. M.; Pomer, A.; Olszowy, K. M.; Sun, C.; Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA; [Loud, S. M.; Pomer, A.; Sun, C.; Lee, G.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Pomer, A.; Olszowy, K. M.; Garruto, R. M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Binghamton, NY USA; [Dancause, K. N.] McGill Univ, Douglas Hosp, Res Ctr, Psychol Res Div, Montreal, PQ, Canada; [Chan, C. W.; Kaneko, A.] Karolinska Inst, Isl Malaria Grp, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Silverman, H.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA; [Silverman, H.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Hempstead, NY 11550 USA; [Tarivonda, L.; Taleo, G.] Minist Hlth, Port Vila, Vanuatu; [Abong, M.] Kaljoral Senta, Port Vila, Vanuatu; [Regenvanu, R.] Minist Justice & Social Affairs, Port Vila, Vanuatu; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C. A.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA; [Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA					Wenner-Gren Foundation for Anthropological Research [Gr 8301]; Binghamton University Laboratory of Evolutionary Anthropology and Health; Harper College Grants in Support of Research, Scholarship, and Creative Work	This research was funded by the Wenner-Gren Foundation for Anthropological Research (Gr 8301), start-up funds from the Binghamton University Laboratory of Evolutionary Anthropology and Health, and the Harper College Grants in Support of Research, Scholarship, and Creative Work.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					273	274				2	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300059		
J	Mann, H; Li, I; Spathis, R; Olszowy, KM; Sun, C; Silverman, H; Pomer, A; Dancause, KN; Lee, G; Chan, CW; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, CA; Garruto, RM; Lum, JK				Mann, H.; Li, I.; Spathis, R.; Olszowy, K. M.; Sun, C.; Silverman, H.; Pomer, A.; Dancause, K. N.; Lee, G.; Chan, C. W.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C. A.; Garruto, R. M.; Lum, J. K.			Contribution of economic development to central adiposity and elevated C-reactive protein levels in older females from Vanuatu.	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Mann, H.; Li, I.; Spathis, R.; Olszowy, K. M.; Sun, C.; Pomer, A.; Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA; [Mann, H.; Li, I.; Spathis, R.; Sun, C.; Pomer, A.; Lee, G.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Spathis, R.; Olszowy, K. M.; Pomer, A.; Weitz, C. A.; Garruto, R. M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Binghamton, NY USA; [Silverman, H.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA; [Silverman, H.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Hempstead, NY 11550 USA; [Dancause, K. N.] McGill Univ, Douglas Hosp Res Ctr, Psychol Res Div, Montreal, PQ, Canada; [Chan, C. W.; Kaneko, A.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Isl Malaria Grp, Stockholm, Sweden; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C. A.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA; [Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA					Wenner-Gren Foundation for Anthropological Research [Gr 8301]; Binghamton University Laboratory of Evolutionary Anthropology and Health; Harper College Grants in Support of Research, Scholarship, and Creative Work	This research was funded by the Wenner-Gren Foundation for Anthropological Research (Gr 8301), start-up funds from the Binghamton University Laboratory of Evolutionary Anthropology and Health, and the Harper College Grants in Support of Research, Scholarship, and Creative Work.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					275	275				1	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300062		
J	Olszowy, KM; Pomer, A; Dancause, KN; Sun, C; Silverman, H; Lee, G; Chan, CW; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, CA; Lum, JK; Garruto, RM				Olszowy, K. M.; Pomer, A.; Dancause, K. N.; Sun, C.; Silverman, H.; Lee, G.; Chan, C. W.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C. A.; Lum, J. K.; Garruto, R. M.			Secular changes in adult stature across four Melanesian islands of varying economic development in Vanuatu: implications for chronic disease risk.	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Olszowy, K. M.; Pomer, A.; Chan, C. W.; Garruto, R. M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Binghamton, NY USA; [Olszowy, K. M.; Pomer, A.; Sun, C.; Silverman, H.; Chan, C. W.; Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA; [Pomer, A.; Sun, C.; Silverman, H.; Lee, G.; Chan, C. W.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Dancause, K. N.] McGill Univ, Douglas Hosp, Res Ctr, Psychol Res Div, Montreal, PQ, Canada; [Tarivonda, L.] Minist Hlth, Port Vila, Vanuatu; [Taleo, G.] Kaljoral Senta, Port Vila, Vanuatu; [Abong, M.; Regenvanu, R.] Minist Justice & Social Affairs, Port Vila, Vanuatu; [Kaneko, A.] Karolinska Inst, Dept Microbiol, Isl Malaria Grp, Solna, Sweden; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C. A.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA; [Lum, J. K.; Garruto, R. M.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA					Wenner-Gren Foundation for Anthropological Research; Harper College Grants in Support of Research, Scholarship, and Creative Work	Wenner-Gren Foundation for Anthropological Research and Harper College Grants in Support of Research, Scholarship, and Creative Work.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					280	280				1	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300074		
J	Pomer, A; Olszowy, KM; Sun, C; Dancause, KN; Chan, CW; Silverman, H; Lee, G; Tarivonda, L; Taleo, G; Abong, M; Regenvanu, R; Kaneko, A; Weitz, CA; Garruto, RM; Lum, JK				Pomer, A.; Olszowy, K. M.; Sun, C.; Dancause, K. N.; Chan, C. W.; Silverman, H.; Lee, G.; Tarivonda, L.; Taleo, G.; Abong, M.; Regenvanu, R.; Kaneko, A.; Weitz, C. A.; Garruto, R. M.; Lum, J. K.			Height and reproductive success in Ni-Vanuatu women	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Pomer, A.; Olszowy, K. M.; Sun, C.; Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Anthropol, Binghamton, NY 13902 USA; [Pomer, A.; Sun, C.; Lee, G.; Lum, J. K.] SUNY Binghamton, Lab Evolutionary Anthropol & Hlth, Binghamton, NY USA; [Pomer, A.; Olszowy, K. M.; Garruto, R. M.] SUNY Binghamton, Lab Biomed Anthropol & Neurosci, Binghamton, NY USA; [Dancause, K. N.] McGill Univ, Douglas Hosp Res Ctr, Psychol Res Div, Montreal, PQ, Canada; [Chan, C. W.; Kaneko, A.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Isl Malaria Grp, Stockholm, Sweden; [Silverman, H.] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA; [Silverman, H.] Hofstra Univ, Hofstra North Shore LIJ Sch Med, Hempstead, NY 11550 USA; [Tarivonda, L.; Taleo, G.] Minist Hlth, Port Vila, Vanuatu; [Abong, M.] Kaljoral Senta, Port Vila, Vanuatu; [Regenvanu, R.] Minist Justice & Social Affairs, Port Vila, Vanuatu; [Kaneko, A.] Osaka City Univ, Grad Sch Med, Dept Parasitol, Osaka 558, Japan; [Kaneko, A.] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Weitz, C. A.] Temple Univ, Dept Anthropol, Philadelphia, PA 19122 USA; [Garruto, R. M.; Lum, J. K.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA					Wenner-Gren Foundation for Anthropological Research [Gr 8301]; Binghamton University Laboratory of Evolutionary Anthropology and Health; Harper College Grants in Support of Research, Scholarship, and Creative Work	This research was funded by the Wenner-Gren Foundation for Anthropological Research (Gr 8301), start-up funds from the Binghamton University Laboratory of Evolutionary Anthropology and Health, and the Harper College Grants in Support of Research, Scholarship, and Creative Work.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					282	283				2	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300081		
J	Yazawa, A; Inoue, Y; Stickley, A; Li, D; Watanabe, C				Yazawa, A.; Inoue, Y.; Stickley, A.; Li, D.; Watanabe, C.			The interaction of season of birth on the association between QOL and inflammation in China: a cohort effect?	AMERICAN JOURNAL OF HUMAN BIOLOGY			English	Meeting Abstract									[Yazawa, A.; Inoue, Y.; Stickley, A.; Watanabe, C.] Univ Tokyo, Grad Sch Med, Dept Human Ecol, Tokyo, Japan; [Li, D.] Hainan Ctr Dis Control & Prevent, Hainan, Peoples R China					Japan Society for the Promotion of Science [20401011, 11J02876]; Institutional Program for Young Researcher Overseas Visits	This research was supported by the Japan Society for the Promotion of Science; Contract Grant number: 20401011, 11J02876: and Institutional Program for Young Researcher Overseas Visits.		0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1042-0533	1520-6300		AM J HUM BIOL	Am. J. Hum. Biol.	MAR-APR	2015	27	2					292	293				2	Anthropology; Biology	Anthropology; Life Sciences & Biomedicine - Other Topics	CC6KH	WOS:000350473300110		
J	Shiraishi, N; Kitamura, K; Hayata, M; Ogata, T; Tajiri-Okamura, K; Nakayama, Y; Kohda, Y; Tomita, K; Mukoyama, M				Shiraishi, Naoki; Kitamura, Kenichiro; Hayata, Manabu; Ogata, Tomohiro; Tajiri-Okamura, Keiko; Nakayama, Yushi; Kohda, Yukimasa; Tomita, Kimio; Mukoyama, Masashi			Low-Density Lipoprotein Apheresis for Proteinuria in Lupus Nephritis With Intraglomerular Foam Cells Containing Cholesterol Crystals	AMERICAN JOURNAL OF KIDNEY DISEASES			English	Article						Low-density lipoprotein (LDL) apheresis; lupus nephritis; foam cell; cholesterol crystal; nephrotic syndrome; LDL cholesterol; systemic lupus erythematosus (SLE); proteinuria	RESISTANT NEPHROTIC SYNDROME; LDL-APHERESIS; DISEASE	A 28-year-old woman with systemic lupus erythematosus was referred to our hospital due to nephrotic-level proteinuria despite approximately 1 year of treatment with 50 to 60 mg/d of prednisolone and 100 to 150 mg/d of cyclosporine with methylprednisolone pulse therapy. Kidney biopsy showed diffuse global lupus nephritis (World Health Organization class 4-G A/C) with many intraglomerular foam cells containing cholesterol crystals. Surprisingly, proteinuria diminished after only 5 low-density lipoprotein (LDL) cholesterol apheresis sessions. This case demonstrated the potential of LDL apheresis to exhibit a remarkable effect on not only focal segmental glomerulosclerosis, but also other types of nephritis, particularly nephritis with intraglomerular foam cells. (C) 2015 by the National Kidney Foundation, Inc.	[Shiraishi, Naoki] Sakurajyuji Hosp, Kumamoto 8614173, Japan; [Kitamura, Kenichiro; Hayata, Manabu; Ogata, Tomohiro; Tajiri-Okamura, Keiko; Nakayama, Yushi; Kohda, Yukimasa; Mukoyama, Masashi] Kumamoto Univ, Grad Sch Life Sci, Dept Nephrol, Kumamoto, Japan; [Tomita, Kimio] Tomei Atsugi Hosp, Kanagawa, Japan	Shiraishi, N (reprint author), Sakurajyuji Hosp, Minami Ku, 1-1-1 Miyukikibe, Kumamoto 8614173, Japan.	n.shiraishi@sakurajyuji.jp					Abrass CK, 2004, AM J NEPHROL, V24, P46, DOI 10.1159/000075925; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891; Daimon S, 2000, NEPHROL DIAL TRANSPL, V15, P235, DOI 10.1093/ndt/15.2.235; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Adorni MP, 2012, J LIPID RES, V53, P984, DOI 10.1194/jlr.P024810; MUSO E, 1994, NEPHROL DIAL TRANSPL, V9, P257; Kamijo Y, 2002, THER APHER, V6, P459, DOI 10.1046/j.1526-0968.2002.00458.x; Muso E, 2001, NEPHRON, V89, P408, DOI 10.1159/000046112; Clement LC, 2014, NAT MED, V20, P37, DOI 10.1038/nm.3396; Kirschenbaum MA, 1996, MINER ELECTROL METAB, V22, P47; Kobayashi S, 2008, CLIN EXP NEPHROL, V12, P9, DOI 10.1007/s10157-007-0003-8; Magil AB, 1999, MODERN PATHOL, V12, P33; Masutani K, 2005, CLIN TRANSPLANT, V19, P59, DOI 10.1111/j.1399-0012.2005.00397.x; SCHONHOLZER KW, 1992, NEPHRON, V62, P130; Ueda S, 2011, THER APHER DIAL, V15, P499, DOI 10.1111/j.1744-9987.2011.00984.x; Vaziri ND, 2014, AM J KIDNEY DIS, V64, P495, DOI 10.1053/j.ajkd.2014.04.016	17	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0272-6386	1523-6838		AM J KIDNEY DIS	Am. J. Kidney Dis.	MAR	2015	65	3					490	493		10.1053/j.ajkd.2014.09.028		4	Urology & Nephrology	Urology & Nephrology	CC2JD	WOS:000350170400020		
J	Yoshimura-Furuhata, M; Nishimura-Tadaki, A; Amano, Y; Ehara, T; Hamasaki, Y; Muramatsu, M; Shishido, S; Aikawa, A; Hamada, R; Ishikura, K; Hataya, H; Hidaka, Y; Noda, S; Koike, K; Wakui, K; Fukushima, Y; Matsumoto, N; Awazu, M; Miyake, N; Kosho, T				Yoshimura-Furuhata, Megumi; Nishimura-Tadaki, Akira; Amano, Yoshiro; Ehara, Takashi; Hamasaki, Yuko; Muramatsu, Masaki; Shishido, Seiichiro; Aikawa, Atsushi; Hamada, Riku; Ishikura, Kenji; Hataya, Hiroshi; Hidaka, Yoshihiko; Noda, Shunsuke; Koike, Kenichi; Wakui, Keiko; Fukushima, Yoshimitsu; Matsumoto, Naomichi; Awazu, Midori; Miyake, Noriko; Kosho, Tomoki			Renal Complications in 6p Duplication Syndrome: Microarray-Based Investigation of the Candidate Gene(s) for the Development of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) and Focal Segmental Glomerular Sclerosis (FSGS)	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						6p duplication syndrome; congenital anomalies of kidney and urinary tract (CAKUT); focal segmental glomerular sclerosis (FSGS); microarray comparative genomic hybridization; forkhead transcription factor 1 (FOXC1)	PARTIAL TRISOMY 6P; LOW-BIRTH-WEIGHT; FOXC1 GENE; GLOMERULOSCLEROSIS; DISEASE; MUTATIONS; TRANSLOCATION; HYPOPLASIA; PHENOTYPE; GLAUCOMA	6p duplication syndrome is a rare chromosomal disorder that frequently manifests renal complications, including proteinuria, hypoplastic kidney, and hydronephrosis. We report a girl with the syndrome, manifesting left hydronephrosis, proteinuria/hematuria, and focal segmental glomerular sclerosis (FSGS) resulting in chronic end-stage renal failure, successfully treated with renal transplantation. Microarray comparative genomic hybridization showed the derivative chromosome 6 to have a 6.4-Mb duplication at 6p25.3-p25.1 with 32 protein-coding genes and a 220-Kb deletion at 6p25.3 with two genes of no possible relation to the renal pathology. Review of the literature shows that variation of renal complications in the syndrome is compatible with congenital anomalies of the kidney and urinary tract (CAKUT). FSGS, observed in another patient with 6p duplication syndrome, could be a non-coincidental complication. FOXC1, located within the 6.4-Mb duplicated region at 6p25.3-p25.2, could be a candidate gene for CAKUT, but its single gene duplication effect would not be sufficient. FSGS would be a primary defect associated with duplicated gene(s) albeit no candidate could be proposed, or might occur in association with CAKUT. (c) 2015 Wiley Periodicals, Inc.	[Yoshimura-Furuhata, Megumi; Amano, Yoshiro] Nagano Red Cross Hosp, Dept Pediat, Nagano, Japan; [Yoshimura-Furuhata, Megumi; Hidaka, Yoshihiko; Noda, Shunsuke; Koike, Kenichi] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 3908621, Japan; [Nishimura-Tadaki, Akira; Matsumoto, Naomichi; Miyake, Noriko] Yokohama City Grad Sch Med, Dept Human Genet, Yokohama, Kanagawa, Japan; [Ehara, Takashi] Matsumoto Univ, Grad Sch Hlth Sci, Dept Hlth & Sport Sci, Matsumoto, Nagano, Japan; [Hamasaki, Yuko; Shishido, Seiichiro] Toho Univ, Sch Med, Dept Pediat Nephrol, Tokyo, Japan; [Muramatsu, Masaki; Aikawa, Atsushi] Toho Univ, Sch Med, Dept Nephrol, Tokyo, Japan; [Hamada, Riku; Ishikura, Kenji; Hataya, Hiroshi] Tokyo Metropolitan Childrens Med Ctr, Dept Nephrol, Fuchu, Tokyo, Japan; [Wakui, Keiko; Fukushima, Yoshimitsu; Kosho, Tomoki] Shinshu Univ, Sch Med, Dept Med Genet, Matsumoto, Nagano 3908621, Japan; [Awazu, Midori] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan	Kosho, T (reprint author), Shinshu Univ, Sch Med, Dept Med Genet, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	ktomoki@shinshu-u.ac.jp			Research on Intractable Diseases, Ministry of Health, Labour and Welfare, Japan; Strategic Research Program for Brain Sciences; Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science; Takeda Science Foundation; Hayashi Memorial Foundation for Female Natural Scientists	Grant sponsor: Research on Intractable Diseases, Ministry of Health, Labour and Welfare, Japan; Grant sponsor: The Strategic Research Program for Brain Sciences; Grant sponsor: Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant sponsor: A Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science; Grant sponsor: The Takeda Science Foundation; Grant sponsor: The Hayashi Memorial Foundation for Female Natural Scientists.	Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467-011-1939-1; Song RF, 2011, PEDIATR NEPHROL, V26, P353, DOI 10.1007/s00467-010-1629-4; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Lowik MM, 2007, KIDNEY INT, V72, P1198, DOI 10.1038/sj.ki.5002469; Ikezumi Y, 2013, AM J NEPHROL, V38, P149, DOI 10.1159/000353898; Hwang DY, 2014, KIDNEY INT, V85, P1429, DOI 10.1038/ki.2013.508; Brown EJ, 2010, NAT GENET, V42, P72, DOI 10.1038/ng.505; Saisawat P, 2012, KIDNEY INT, V81, P196, DOI 10.1038/ki.2011.315; Hodgin JB, 2009, CLIN J AM SOC NEPHRO, V4, P71, DOI 10.2215/CJN.01700408; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Kopp JB, 2008, NAT GENET, V40, P1175, DOI 10.1038/ng.226; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Mele C, 2011, NEW ENGL J MED, V365, P295, DOI 10.1056/NEJMoa1101273; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Crosson JT, 2007, TRANSPL P, V39, P737, DOI 10.1016/j.transproceed.2007.02.010; Barua M, 2013, KIDNEY INT, V83, P316, DOI 10.1038/ki.2012.349; Batanian JR, 2001, CLIN GENET, V59, P52, DOI 10.1034/j.1399-0004.2001.590109.x; Bates CM, 2014, CLIN J AM SOC NEPHRO, V9, P1141, DOI 10.2215/CJN.00860114; Berner AL, 2012, CYTOGENET GENOME RES, V136, P308, DOI 10.1159/000337019; BERNHEIM A, 1979, HUM GENET, V48, P13, DOI 10.1007/BF00273268; BREUNING MH, 1977, HUM GENET, V38, P7, DOI 10.1007/BF00295802; BURD L, 1988, CLIN GENET, V33, P356; COTE GB, 1978, J MED GENET, V15, P479, DOI 10.1136/jmg.15.6.479; Delahaye A, 2012, AM J MED GENET A, V158A, P2430, DOI 10.1002/ajmg.a.35548; Engelen JJM, 2001, AM J MED GENET, V99, P48, DOI 10.1002/1096-8628(20010215)99:1<48::AID-AJMG1128>3.0.CO;2-T; Giardino D, 2002, AM J MED GENET, V108, P36, DOI 10.1002/ajmg.10225; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Komaki F, 2013, CELLS TISSUES ORGANS, V198, P22, DOI 10.1159/000351291; Kume T, 2000, DEVELOPMENT, V127, P1387; Lehmann OJ, 2000, AM J HUM GENET, V67, P1129; Mirzayans F, 2000, EUR J HUM GENET, V8, P71, DOI 10.1038/sj.ejhg.5200354; Nakano Takako, 2003, Tokai J Exp Clin Med, V28, P121; Pierpont MEM, 2000, AM J MED GENET, V95, P275, DOI 10.1002/1096-8628(20001127)95:3<275::AID-AJMG15>3.0.CO;2-X; SMITH BS, 1985, AM J MED GENET, V20, P649, DOI 10.1002/ajmg.1320200411; Stohler R, 2007, AM J MED GENET A, V143A, P1978, DOI 10.1002/ajmg.a.31678; THERKELS.AJ, 1971, ANN GENET-PARIS, V14, P13; WAUTERS JG, 1993, CLIN GENET, V44, P262; Yosypiv IV, 2012, INT J NEPHROL, V909083, P1	39	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAR	2015	167	3					592	601		10.1002/ajmg.a.36942		10	Genetics & Heredity	Genetics & Heredity	CC3XB	WOS:000350283400015		
J	Fukasawa, T; Kubota, T; Tanaka, M; Asada, H; Matsusawa, K; Hattori, T; Kato, Y; Negoro, T				Fukasawa, Tatsuya; Kubota, Tetsuo; Tanaka, Masaharu; Asada, Hideyuki; Matsusawa, Kaname; Hattori, Tetsuo; Kato, Yuichi; Negoro, Tamiko			Apneas Observed in Trisomy 18 Neonates Should be Differentiated from Epileptic Apneas	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						trisomy 18; newborn; epilepsy; apnea	NATURAL-HISTORY; SEIZURES; CHILDREN	Many children with trisomy 18 have apneas from the neonatal period. It has been reported that some children with trisomy 18 have epilepsy, including epileptic apneas. However, no previous report has described epileptic apneas in trisomy 18 neonates. We retrospectively reviewed the clinical records of neonates with trisomy 18 who were born at Anjo Kosei Hospital between July 2004 and October 2013 and investigated whether they had epileptic apneas during the neonatal period and whether antiepileptic drugs (AEDs) were effective for treating them. We identified 16 patients with trisomy 18. Nine patients who died within 3 days of birth were excluded. Five of the remaining seven patients had apneas. All five patients underwent electroencephalograms (EEGs) to assess whether they suffered epileptic apneas. Three of the five patients had EEG-confirmed seizures. In two patients, the apneas corresponded to ictal discharges. In one patient, ictal discharges were recorded when she was under mechanical ventilation, but no ictal discharges that corresponded to apneas were recorded after she was extubated. AEDs were effective for treating the apneas and stabilizing the SpO(2) in all three patients. Among neonates with trisomy 18 who lived longer than 3 days, three of seven patients had EEG-confirmed seizures. AEDs were useful for treating their epileptic apneas and stabilizing their SpO(2). Physicians should keep epileptic apneas in mind when treating apneas in neonates with trisomy 18. (c) 2015 Wiley Periodicals, Inc.	[Fukasawa, Tatsuya; Kubota, Tetsuo; Tanaka, Masaharu; Asada, Hideyuki; Matsusawa, Kaname; Hattori, Tetsuo; Kato, Yuichi; Negoro, Tamiko] Anjo Kosei Hosp, Dept Pediat, Anjo, Aichi 4468602, Japan; [Negoro, Tamiko] Nihon Fukushi Univ, Fac Child Dev, Dept Clin Psychol, Mihama, Aichi, Japan	Fukasawa, T (reprint author), Anjo Kosei Hosp, Dept Pediat, 28 Higashihirokute Anjo Cho, Anjo, Aichi 4468602, Japan.	fukasawa@kosei.anjo.aichi.jp					Embleton ND, 1996, ARCH DIS CHILD, V75, pF38, DOI 10.1136/fn.75.1.F38; Murray DM, 2008, ARCH DIS CHILD-FETAL, V93, pF187, DOI 10.1136/adc.2005.086314; Kosho T, 2013, AM J MED GENET A, V161A, P1531, DOI 10.1002/ajmg.a.35990; Kumada T, 2013, AM J MED GENET A, V161A, P696, DOI 10.1002/ajmg.a.35763; Kumada T, 2010, PEDIATR NEUROL, V42, P61, DOI [10.1016/j.pediatrneurol.2009.08.004, 10.1016/j.pediatmeurol.2009.08.004]; Kosho T, 2006, AM J MED GENET A, V140A, P937, DOI 10.1002/ajmg.a.31175; Cereda A, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-81; Fogarasi A, 2006, EPILEPSIA, V47, P584, DOI 10.1111/j.1528-1167.2006.00472.x; Scher MS., 2012, AVERYS DIS NEWBORN, P901	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	MAR	2015	167	3					602	606		10.1002/ajmg.a.36929		5	Genetics & Heredity	Genetics & Heredity	CC3XB	WOS:000350283400016		
J	Hayashi, K; Chung, O; Park, S; Lee, SP; Sachdeva, RCL; Mizoguchi, I				Hayashi, Kazuo; Chung, Onejune; Park, Seojung; Lee, Seung-Pyo; Sachdeva, Rohit C. L.; Mizoguchi, Itaru			Influence of standardization on the precision (reproducibility) of dental cast analysis with virtual 3-dimensional models	AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS			English	Article							BEAM COMPUTED-TOMOGRAPHY; ORTHODONTIC TREATMENT; DIGITAL MODELS; PLASTER MODELS; ACCURACY; RELIABILITY; VALIDITY; IMPRESSION	Introduction: Virtual 3-dimensional (3D) models obtained by scanning of physical casts have become an alternative to conventional dental cast analysis in orthodontic treatment. If the precision (reproducibility) of virtual 3D model analysis can be further improved, digital orthodontics could be even more widely accepted. The purpose of this study was to clarify the influence of "standardization" of the target points for dental cast analysis using virtual 3D models. Physical plaster models were also measured to obtain additional information. Methods: Five sets of dental casts were used. The dental casts were scanned with R700 (3Shape, Copenhagen, Denmark) and REXCAN DS2 3D (Solutionix, Seoul, Korea) scanners. In this study, 3 system and software packages were used: SureSmile (OraMetrix, Richardson, Tex), Rapidform (Inus, Seoul, Korea), and IDEAS (SDRC, Milford, Conn). Results: Without standardization, the maximum differences were observed between the SureSmile software and the Rapidform software (0.39 mm +/- 0.07). With standardization, the maximum differences were observed between the SureSmile software and measurements with a digital caliper (0.099 mm +/- 0.01), and this difference was significantly greater (P<0.05) than the 2 other mean difference values. Furthermore, the results of this study showed that the mean differences "WITH" standardization were significantly lower than those "WITHOUT" standardization for all systems, software packages, or methods. Conclusions: The results showed that elimination of the influence of usability or habituation is important for improving the reproducibility of dental cast analysis.	[Hayashi, Kazuo; Chung, Onejune; Mizoguchi, Itaru] Hlth Sci Univ Hokkaido, Sch Dent, Dept Oral Growth & Dev, Div Orthodont & Dentofacial Orthoped, Ishikari, Hokkaido 0610293, Japan; [Lee, Seung-Pyo] Seoul Natl Univ, Sch Dent, Dept Oral Anat, Seoul, South Korea; [Sachdeva, Rohit C. L.] OraMetrix, Richardson, TX USA	Hayashi, K (reprint author), Hlth Sci Univ Hokkaido, Sch Dent, Dept Oral Growth & Dev, Div Orthodont & Dentofacial Orthoped, Kanazawa 1757, Ishikari, Hokkaido 0610293, Japan.	kazu@hoku-iryo-u.ac.jp					Alford TJ, 2011, ANGLE ORTHOD, V81, P383, DOI 10.2319/071810-413.1; Bartlett JW, 2008, ULTRASOUND OBST GYN, V31, P466, DOI 10.1002/uog.5256; Zilberman O, 2003, ANGLE ORTHOD, V73, P301; Santoro M, 2003, AM J ORTHOD DENTOFAC, V124, P101, DOI 10.1016/S0889-5406(03)00152-5; Hayashi K, 2004, EUR J ORTHODONT, V26, P585, DOI 10.1093/ejo/26.6.585; Grunheid T, 2014, AM J ORTHOD DENTOFAC, V145, P157, DOI 10.1016/j.ajodo.2013.10.012; Jang I, 2009, ANGLE ORTHOD, V79, P447, DOI 10.2319/042308-225.1; Sjogren APG, 2010, J DIGIT IMAGING, V23, P482, DOI 10.1007/s10278-009-9211-y; Bootvong K, 2010, EUR J ORTHODONT, V32, P589, DOI 10.1093/ejo/cjp159; Sousa MVS, 2012, AM J ORTHOD DENTOFAC, V142, P269, DOI 10.1016/j.ajodo.2011.12.028; Akyalcin S, 2013, AM J ORTHOD DENTOFAC, V144, P916, DOI 10.1016/j.ajodo.2013.04.024; Larson BE, 2013, ANGLE ORTHOD, V83, P557, DOI 10.2319/080612-635.1; Martorelli M, 2014, J DENT, V42, P460, DOI 10.1016/j.jdent.2013.12.018; Stevens DR, 2006, AM J ORTHOD DENTOFAC, V129, P794, DOI 10.1016/j.ajodo.2004.08.023; Hayashi K, 2013, AM J ORTHOD DENTOFAC, V144, P619, DOI 10.1016/j.ajodo.2013.04.021; Gracco Antonio, 2007, Prog Orthod, V8, P252; Im J, 2014, AM J ORTHOD DENTOFAC, V145, P434, DOI 10.1016/j.ajodo.2013.12.014; Jeon H, 2013, ORTHOD CRANIOFAC RES, V16, P65, DOI 10.1111/ocr.12006; Kang SH, 2014, INT J ORAL MAX SURG, V43, P1293, DOI 10.1016/j.ijom.2014.06.009; Keating Andrew P, 2008, J Orthod, V35, P191, DOI 10.1179/146531207225022626; Leifert MF, 2009, AM J ORTHOD DENTOFAC, V136, P16; Leifert MF, 2009, AM J ORTHOD DENTOFAC, V136, p16e1; Maeda Y, 2001, INSTRUMENTATION ENG; Moles Randall, 2009, J Clin Orthod, V43, P161; Quimby ML, 2004, ANGLE ORTHOD, V74, P298; Rangel FA, 2012, ISRN DENT, V2012; Rangel FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059130; Sachdeva Rohit, 2005, J Clin Orthod, V39, P297	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0889-5406	1097-6752		AM J ORTHOD DENTOFAC	Am. J. Orthod. Dentofac. Orthop.	MAR	2015	147	3					373	380		10.1016/j.ajodo.2014.11.015		8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CC6AP	WOS:000350447200020		
J	Fukase, H; Kondo, O; Ishida, H				Fukase, Hitoshi; Kondo, Osamu; Ishida, Hajime			Brief Communication: Size and Placement of Developing Anterior Teeth in Immature Neanderthal Mandibles From Dederiyeh Cave, Syria: Implications for Emergence of the Modern Human Chin	AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY			English	Article						Neanderthal; mandibular symphysis; CT; ontogeny; chimpanzee	MIDDLE PLEISTOCENE HOMINIDS; MODERN JAPANESE MANDIBLES; CROSS-SECTIONAL GEOMETRY; INFANT GROWTH-PATTERNS; MANDIBULAR SYMPHYSIS; PREHISTORIC JOMON; SEXUAL-DIMORPHISM; MORPHOLOGY; EVOLUTION; DENTITION	Evolutionary and functional significance of the human chin has long been explored from various perspectives including masticatory biomechanics, speech, and anterior tooth size. Recent ontogenetic studies have indicated that the spatial position of internally forming anterior teeth partially constrains adult mandibular symphyseal morphology. The present study therefore preliminarily examined the size and placement of developing anterior teeth in immature Neanderthal mandibles of Dederiyeh 1 and 2, compared with similarly-aged modern humans (N = 16) and chimpanzees (N = 7) whose incisors are comparatively small and large among extant hominids, respectively. The Dederiyeh 1 mandible is described as slightly presenting a mental trigone and attendant mental fossa, whereas Dederiyeh 2 completely lacks such chin-associated configurations. Results showed that, despite symphyseal size being within the modern human range, both Dederiyeh mandibles accommodated overall larger anterior dentition and displayed a remarkably wide bicanine space compared to those of modern humans. Dederiyeh 2 had comparatively thicker deciduous incisor roots and more enlarged permanent incisor crypts than Dederiyeh 1, but both Dederiyeh individuals exhibited a total dental size mostly intermediate between modern humans and chimpanzees. These findings potentially imply that the large deciduous/permanent incisors collectively distended the labial alveolar bone, obscuring an incipient mental trigone. It is therefore hypothesized that the appearance of chin-associated features, particularly of the mental trigone and fossa, can be accounted for partly by developmental relationships between the sizes of the available mandibular space and anterior teeth. This hypothesis must be, however, further addressed with more referential samples in future studies. Am J Phys Anthropol 156:482-488, 2015. (c) 2014 Wiley Periodicals, Inc.	[Fukase, Hitoshi] Hokkaido Univ, Grad Sch Med, Div Human Evolut Studies, Sapporo, Hokkaido 0608638, Japan; [Kondo, Osamu] Univ Tokyo, Grad Sch Sci, Div Anthropol, Dept Biol Sci, Tokyo 1130033, Japan; [Ishida, Hajime] Univ Ryukyus, Grad Sch Med, Dept Human Biol & Anat, Ryukyus, Okinawa 9030215, Japan	Fukase, H (reprint author), Hokkaido Univ, Grad Sch Med, Div Human Evolut Studies, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.	fukase@pop.med.hokudai.ac.jp			Japan Society for the Promotion of Science;  [1201];  [17102002];  [22870025]	Grant sponsor: Grant-in-aid for Scientific Research; Grant number: 1201, 17102002, 22870025; Grant sponsor: Japan Society for the Promotion of Science.	Liversidge HM, 2004, AM J PHYS ANTHROPOL, V123, P172, DOI 10.1002/ajpa.10318; de Leon MSP, 2008, P NATL ACAD SCI USA, V105, P13764, DOI 10.1073/pnas.0803917105; DEAN MC, 1981, FOLIA PRIMATOL, V36, P111, DOI 10.1159/000156011; Duarte C, 1999, P NATL ACAD SCI USA, V96, P7604, DOI 10.1073/pnas.96.13.7604; Le Cabec A, 2013, J HUM EVOL, V64, P169, DOI 10.1016/j.jhevol.2012.08.011; ROSAS A, 1995, J HUM EVOL, V28, P533, DOI 10.1006/jhev.1995.1041; Suwa G, 2011, ANTHROPOL SCI, V119, P159, DOI 10.1537/ase.110617; Dobson SD, 2002, J HUM EVOL, V43, P67, DOI 10.1006/jhev.2002.0563; Schwartz JH, 2000, J HUM EVOL, V38, P367, DOI 10.1006/jhev.1999.0339; ARENSBURG B, 1989, AM J PHYS ANTHROPOL, V78, P431, DOI 10.1002/ajpa.1330780311; ASCENZI A, 1971, NATURE, V233, P280, DOI 10.1038/233280a0; Barber N, 1995, ETHOL SOCIOBIOL, V16, P395, DOI 10.1016/0162-3095(95)00068-2; BERGER H, 1969, AMER J ORTHODONTICS, V56, P516, DOI 10.1016/0002-9416(69)90212-7; CAWOOD JI, 1988, INT J ORAL MAX SURG, V17, P232, DOI 10.1016/S0901-5027(88)80047-X; Cobb SN, 2011, J ANAT, V218, P96, DOI 10.1111/j.1469-7580.2010.01321.x; Coquerelle M, 2013, J ANAT, V222, P178, DOI 10.1111/joa.12008; Coquerelle M, 2010, J ANAT, V217, P507, DOI 10.1111/j.1469-7580.2010.01287.x; Daegling D. J., 1993, EVOL ANTHROPOL, V1, P170, DOI 10.1002/evan.1360010506; Daegling DJ, 2012, J ANTHR, V2012; DAY MH, 1973, AM J PHYS ANTHROPOL, V39, P341, DOI 10.1002/ajpa.1330390303; DEAN M C, 1991, Zeitschrift fuer Morphologie und Anthropologie, V78, P425; de Castro JMB, 2011, J HUM EVOL, V61, P12, DOI 10.1016/j.jhevol.2011.03.005; Dodo Y., 2003, NEANDERTHAL BURIAL E, P93; FAERMAN M, 1994, J HUM EVOL, V27, P405, DOI 10.1006/jhev.1994.1056; Fukase H, 2008, AM J PHYS ANTHROPOL, V136, P441, DOI 10.1002/ajpa.20828; Fukase H, 2011, AM J PHYS ANTHROPOL, V144, P607, DOI 10.1002/ajpa.21449; Fukase H, 2012, AM J PHYS ANTHROPOL, V147, P217, DOI 10.1002/ajpa.21640; Fukase H, 2010, ANTHROPOL SCI, V118, P75, DOI 10.1537/ase.090513; Groning F, 2011, AM J PHYS ANTHROPOL, V144, P593, DOI 10.1002/ajpa.21447; HOWELL FC, 1960, CURR ANTHROPOL, V1, P195, DOI 10.1086/200100; Hublin JJ, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P295; Hublin JJ, 1981, ASPECTS HUMAN EVOLUT, P167, DOI London; Ichim I, 2007, MED HYPOTHESES, V69, P20, DOI 10.1016/j.mehy.2006.11.048; Ishida H, 2003, NEANDERTHAL BURIALS, P271; Kondo O, 2005, CURRENT TRENDS DENT, P243; Lam YM, 1996, AM J PHYS ANTHROPOL, V100, P545; LIEBERMAN DE, 1995, CURR ANTHROPOL, V36, P159, DOI 10.1086/204348; Mallegni F, 1997, J HUM EVOL, V33, P651, DOI 10.1006/jhev.1997.0159; Marshall SD, 2011, AM J ORTHOD DENTOFAC, V139, P456, DOI 10.1016/j.ajodo.2009.05.038; McCown TD, 1980, STONE AGE MOUNT CARM; MOORREES COENRAAD F.A., 1963, JOUR DENT RES, V42, P1490, DOI 10.1177/00220345630420062701; Muhesen T., 2003, NEANDERTHAL BURIALS; RIESENFE.A, 1969, ACTA ANAT, V72, P246; Smith FH, 1989, EMERGENCE MODERN HUM, P181; Smith P, 1977, ERETZ ISRAEL, V13, P164; SMITH P, 1978, J HUM EVOL, V7, P401, DOI 10.1016/S0047-2484(78)80090-6; SOIKKONEN K, 1995, J ORAL REHABIL, V22, P831, DOI 10.1111/j.1365-2842.1995.tb00230.x; Suzuki H, 1970, AMUD MAN HIS CAVE SI; Thayer ZM, 2010, AM J PHYS ANTHROPOL, V143, P417, DOI 10.1002/ajpa.21330; TILLIER A-M, 1982, Zeitschrift fuer Morphologie und Anthropologie, V73, P125; TILLIER AM, 1989, HUMAN REVOLUTION, P286; TILLIER AM, 1981, CR ACAD SCI II, V293, P725; Trinkaus E., 2002, PORTRAIT ARTIST CHIL, P312; Ubelaker D.H., 1989, HUMAN SKELETAL REMAI; Weidenreich F, 1936, PALAEONTOLOGICA SI D, V7, P1; Wolpoff MH., 1975, DETERMINANTS MANDIBU, P1	56	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-9483	1096-8644		AM J PHYS ANTHROPOL	Am. J. Phys. Anthropol.	MAR	2015	156	3					482	488		10.1002/ajpa.22665		7	Anthropology; Evolutionary Biology	Anthropology; Evolutionary Biology	CC3VE	WOS:000350277800014		
J	Nakano, N; Matsumoto, T; Takayama, K; Matsushita, T; Araki, D; Uefuji, A; Nagai, K; Zhang, SR; Inokuchi, T; Nishida, K; Kuroda, R; Kurosaka, M				Nakano, Naoki; Matsumoto, Tomoyuki; Takayama, Koji; Matsushita, Takehiko; Araki, Daisuke; Uefuji, Atsuo; Nagai, Kanto; Zhang, Shurong; Inokuchi, Takao; Nishida, Kyohei; Kuroda, Ryosuke; Kurosaka, Masahiro			Age-Dependent Healing Potential of Anterior Cruciate Ligament Remnant-Derived Cells	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						ACL reconstruction; bone-tendon healing; age-related differences; angiogenesis; osteogenesis	MESENCHYMAL STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; AUTOLOGOUS RUPTURED TISSUE; RABBIT MODEL; TENDON GRAFT; PATELLAR TENDON; STROMAL CELLS; THERAPEUTIC NEOVASCULARIZATION; MYOCARDIAL-ISCHEMIA; VASCULAR WALL	Background: The anterior cruciate ligament (ACL) does not heal spontaneously after injury, and ACL patients of different ages respond differently to treatment. Although ACL-derived CD34-positive cells contribute to bone-tendon healing after ACL reconstruction, the relationship between the healing potential of ACL-derived cells and a patient's age is unknown. Hypothesis: ACL-derived cells from young patients will have a greater effect on the maturation of bone-tendon integration in an immunodeficient rat model of ACL reconstruction compared with cells derived from older patients. Study Design: Controlled laboratory study. Methods: Sixty 10-week-old female immunodeficient rats underwent ACL reconstruction (using the autologous flexor digitorum longus tendon as a graft) followed by intracapsular administration of ACL-derived cells from patients aged 10 to 19 years (younger group) or patients aged 30 to 39 years (older group), or they were given phosphate-buffered saline (PBS; PBS group). Histologic, radiographic, and biomechanical examinations were performed 2 to 8 weeks after surgery. In addition, intrinsic and human cell-derived angiogenesis and osteogenesis were examined by immunohistochemistry. Results: In the younger group, histologic assessment demonstrated early bone-tendon healing, which induced endochondral ossification-like integration. Micro-computed tomography showed a statistically significant reduction in the area of tibial bone tunnel in the younger group (week 4, 20.0% 11.2% reduction; week 8, 25.7% 5.6% reduction) compared with the older group (week 4, 1.8% +/- 3.0% reduction; week 8, 4.0% +/- 5.9% reduction) and the PBS group (week 4, -0.5% +/- 3.2% reduction; week 8, 3.3% +/- 5.2% reduction) (week 4, P < .05; week 8, P < .01). Failure loads during tensile testing demonstrated a significantly higher ultimate load to failure in the younger group (17.52 +/- 4.01 N) compared with the older (8.05 +/- 2.91 N) and PBS (7.01 +/- 3.16 N) groups (P < .05), and isolectin B4 and rat osteocalcin immunostaining indicated enhanced intrinsic angiogenesis and osteogenesis in the younger group. There was no statistically significant difference in the results of radiographic and biomechanical examinations between the older and PBS groups. Double immunohistochemistry for human-specific endothelial cell and osteoblast markers demonstrated a greater ability of differentiation into endothelial cells and osteoblasts in the younger group. Conclusion: ACL-derived cells from younger patients enhanced early bone-tendon healing in an immunodeficient rat model of ACL reconstruction. Clinical Relevance: Surgeons should consider a patient's age when performing ACL reconstruction with remnant preservation or ruptured tissue incorporation, as this can predict healing ability.	[Nakano, Naoki; Matsumoto, Tomoyuki; Takayama, Koji; Matsushita, Takehiko; Araki, Daisuke; Uefuji, Atsuo; Nagai, Kanto; Zhang, Shurong; Inokuchi, Takao; Nishida, Kyohei; Kuroda, Ryosuke; Kurosaka, Masahiro] Kobe Univ, Grad Sch Med, Kobe, Hyogo 6500017, Japan	Matsumoto, T (reprint author), Kobe Univ, Grad Sch Med, Dept Orthopaed Surg, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	matsun@m4.dion.ne.jp					Matsumoto T, 2012, AM J SPORT MED, V40, P1296, DOI 10.1177/0363546512439026; Matsumoto T, 2012, STEM CELLS DEV, V21, P859, DOI 10.1089/scd.2010.0528; Rodeo SA, 1999, AM J SPORT MED, V27, P476; Tomita F, 2001, ARTHROSCOPY, V17, P461, DOI 10.1053/jars.2001.24059; Tavian M, 2005, ANN NY ACAD SCI, V1044, P41, DOI 10.1196/annals.1349.006; Lin CS, 2012, CYTOTHERAPY, V14, P1159, DOI 10.3109/14653249.2012.729817; Petersen W, 2003, ARCH ORTHOP TRAUM SU, V123, P283, DOI 10.1007/s00402-003-0527-7; Mifune Y, 2012, CELL TRANSPLANT, V21, P1651, DOI 10.3727/096368912X647234; Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474-9726.2008.00377.x; Kawamoto A, 2001, CIRCULATION, V103, P634; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Lim JK, 2004, ARTHROSCOPY, V20, P899, DOI 10.1016/j.arthro.2004.06.035; Papageorgiou CD, 2001, AM J SPORT MED, V29, P620; Agung M, 2006, KNEE SURG SPORT TR A, V14, P1307, DOI 10.1007/s00167-006-0124-8; Murray MM, 2000, J BONE JOINT SURG AM, V82A, P1387; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Uefuji A, 2014, AM J SPORT MED, V42, P1478, DOI 10.1177/0363546514529092; Zengin E, 2006, DEVELOPMENT, V133, P1543, DOI 10.1242/dev.02315; Matsumoto T, 2014, ARTHROSCOPY, V30, P468, DOI 10.1016/j.arthro.2013.12.014; BALLOCK RT, 1989, J ORTHOPAED RES, V7, P474, DOI 10.1002/jor.1100070404; Cobellis G, 2010, CELL TRANSPLANT, V19, P1425, DOI 10.3727/096368910X509068; Frank CB, 1997, J BONE JOINT SURG AM, V79A, P1556; GRANA WA, 1994, AM J SPORT MED, V22, P344, DOI 10.1177/036354659402200309; Grassman SRM, 2002, KNEE, V9, P21, DOI 10.1016/S0968-0160(01)00128-4; Hasegawa A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4165; HEFTI FL, 1991, J BONE JOINT SURG AM, V73A, P373; Howson KM, 2005, AM J PHYSIOL-CELL PH, V289, pC1396, DOI 10.1152/ajpcell.00168.2005; Ju YJ, 2006, AM J SPORT MED, V34, P84, DOI 10.1177/0363546505278700; Kohno T, 2007, J ORTHOP SCI, V12, P67, DOI 10.1007/s00776-006-1088-8; Kopf S, 2010, KNEE SURG SPORT TR A, V18, P1445, DOI 10.1007/s00167-009-1041-4; Lee SY, 2007, J CELL PHYSIOL, V210, P561, DOI 10.1002/jcp.20890; Mastrangelo AN, 2010, J ORTHOP RES, V28, P1100, DOI 10.1002/jor.21070; Ouyang HW, 2004, AM J SPORT MED, V32, P321, DOI 10.1177/0095399703258682; Park MJ, 2001, INT ORTHOP, V25, P35, DOI 10.1007/s002640000199; Soon MYH, 2007, AM J SPORT MED, V35, P962, DOI 10.1177/036354650730057; Wen CY, 2009, BONE, V45, P545, DOI 10.1016/j.bone.2008.08.112; Yoshikawa T, 2006, AM J SPORT MED, V34, P1918, DOI 10.1177/0363546506294469	39	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					700	708		10.1177/0363546514561436		9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500025		
J	Chook, JB; Ong, LY; Takebe, Y; Chan, KG; Choo, M; Kamarulzaman, A; Tee, KK				Chook, Jack Bee; Ong, Lai Yee; Takebe, Yutaka; Chan, Kok Gan; Choo, Martin; Kamarulzaman, Adeeba; Tee, Kok Keng			Molecular Detection of HIV-1 Subtype B, CRF01_AE, CRF33_01B, and Newly Emerging Recombinant Lineages in Malaysia	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTIREGION HYBRIDIZATION ASSAY; REAL-TIME PCR; GENOTYPING ASSAY; RISK POPULATIONS; DRUG-RESISTANCE; HIGH-THROUGHPUT; KUALA-LUMPUR; IDENTIFICATION; FORM	A molecular genotyping assay for human immunodeficiency virus type 1 (HIV-1) circulating in Southeast Asia is difficult to design because of the high level of genetic diversity. We developed a multiplex real-time polymerase chain reaction (PCR) assay to detect subtype B, CRF01_AE, CRF33_01B, and three newly described circulating recombinant forms, (CRFs) (CRF53_01B, CRF54_01B, and CRF58_01B). A total of 785 reference genomes were used for subtype-specific primers and TaqMan probes design targeting the gag, poi, and env genes. The performance of this assay was compared and evaluated with direct sequencing and phylogenetic analysis. A total of 180 HIV-infected subjects from Kuala Lumpur, Malaysia were screened and 171 samples were successfully genotyped, in agreement with the phylogenetic data. The HIV-1 genotype distribution was as follows: subtype B (16.7%); CRF01_AE (52.8%); CRF33_01B (24.4%); CRF53_01B (1.1%); CRF54_01B (0.6%); and CRF01_AE/B unique recombinant forms (4.4%). The overall accuracy of the genotyping assay was over 95.0%, in which the sensitivities for subtype B, CRF01_AE, and CRF33_01B detection were 100%, 100%, and 97.7%, respectively. The specificity of genotyping was 100%, inter-subtype specificities were > 95% and the limit of detection of 10(3) copies/mL for plasma. The newly developed real-time PCR assay offers a rapid and cost-effective alternative for large-scale molecular epidemiological surveillance for HIV-1.	[Chook, Jack Bee; Ong, Lai Yee; Choo, Martin; Kamarulzaman, Adeeba; Tee, Kok Keng] Univ Malaya, Fac Med, Dept Med, Ctr Excellence Res AIDS CERiA, Kuala Lumpur 50603, Malaysia; [Takebe, Yutaka] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan; [Chan, Kok Gan] Univ Malaya, Fac Sci, Inst Biol Sci, Div Genet & Mol Biol, Kuala Lumpur 50603, Malaysia	Tee, KK (reprint author), Univ Malaya, Fac Med, Dept Med, Ctr Excellence Res AIDS CERiA, Kuala Lumpur 50603, Malaysia.	jackbee2002@um.edu.my; onglaiyee@um.edu.my; takebe@niid.go.jp; kokgan@um.edu.my; martin.ceria@um.edu.my; adeeba@ummc.edu.my; k2tee@um.edu.my	CHAN, KOK GAN/B-8347-2010; Tee, Kok Keng/A-8148-2008	CHAN, KOK GAN/0000-0002-1883-1115; Tee, Kok Keng/0000-0002-7923-5448	Ministry of Education, Malaysia [E-000001-20001, H-500001-00-A000011-000001, H-500001-00-A000012-000001]	This work was supported by grants from the Ministry of Education, Malaysia: High Impact Research E-000001-20001 to AK, and High Impact Research H-500001-00-A000011-000001 and H-500001-00-A000012-000001 to KKT.	Chow WZ, 2012, J VIROL, V86, P11398, DOI 10.1128/JVI.01932-12; Ng OT, 2012, AIDS RES HUM RETROV, V28, P527, DOI [10.1089/AID.2011.0177, 10.1089/aid.2011.0177]; Jagodzinski LL, 2000, J CLIN MICROBIOL, V38, P1247; Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006; Tovanabutra S, 2007, AIDS RES HUM RETROV, V23, P829, DOI 10.1089/aid.2006.0300; Wei M, 2004, J CLIN MICROBIOL, V42, P4261, DOI 10.1128/JCM.42.9.4261-4267.2004; SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423; Liu YJ, 2012, AIDS RES HUM RETROV, V28, P1357, DOI 10.1089/aid.2011.0376; Sahbandar IN, 2009, AIDS RES HUM RETROV, V25, P637, DOI 10.1089/aid.2008.0266; Tovanabutra S, 2003, AIDS RES HUM RETROV, V19, P561, DOI 10.1089/088922203322230923; Katoh K, 2009, METHODS MOL BIOL, V537, P39, DOI 10.1007/978-1-59745-251-9_3; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Robertson DL, 2000, SCIENCE, V288, P55; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Tee KK, 2006, JAIDS-J ACQ IMM DEF, V43, P523; Li Y, 2010, JAIDS-J ACQ IMM DEF, V54, P129, DOI 10.1097/QAI.0b013e3181d82ce5; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93; Chen JHK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012198; Chow WZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062560; Chow WZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085250; Freitas FB, 2013, AIDS RES HUM RETROV, V29, P318, DOI [10.1089/AID.2012.0025, 10.1089/aid.2012.0025]; Hoelscher M, 2002, AIDS, V16, P2055, DOI 10.1097/00002030-200210180-00011; Kijak GH, 2004, AIDS RES HUM RETROV, V20, P521, DOI 10.1089/088922204323087778; Kijak GH, 2007, VIROLOGY, V358, P178, DOI 10.1016/j.virol.2006.07.055; Lee CC, 2009, HIV MED, V10, P370, DOI 10.1111/j.1468-1293.2009.00698.x; Ng KT, 2012, J VIROL, V86, P11405, DOI 10.1128/JVI.01949-12; Ong LY, 2014, J MED VIROL, V86, P38, DOI 10.1002/jmv.23772; UNAIDS, 2012, GLOBAL REPORT UNAIDS; van Hal SJ, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-12	30	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2015	92	3					507	512		10.4269/ajtmh.14-0681		6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	CC7EB	WOS:000350529400011		
J	Shimasaki, T; Chung, H; Shiiki, S				Shimasaki, Teppei; Chung, Heath; Shiiki, Soichi			Case Report: Five Cases of Recurrent Meningitis Associated with Chronic Strongyloidiasis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							BACTERIAL-MENINGITIS; STERCORALIS INFECTION; HYPERINFECTION; THIABENDAZOLE; DIAGNOSIS; JAPAN	Although meningitis secondary to chronic strongyloidiasis is a rare complication, it is associated with a high mortality rate. Recurrent meningitis can occur if the underlying parasitic infection is left untreated. We report five cases of recurrent meningitis related to chronic strongyloidiasis that were associated with human T-lymphotropic virus type 1 (HTLV-1) infection. Common causative organisms are Escherichia coli, Streptococcus bovis, and Klebsiella pneumonia. One patient died during the second episode of meningitis. Three patients showed significant gastrointestinal and respiratory symptoms before developing headache and fever. In four cases, patients developed multiple recurrences even with the treatment of thiabendazol. Ivermectin seems to be a better agent compared with thiabendazol to achieve eradication of strongyloidiasis.	[Shimasaki, Teppei; Chung, Heath] Univ Hawaii, Dept Med, John A Burns Sch Med, Honolulu, HI 96813 USA; [Shiiki, Soichi] Okinawa Chubli Hosp, Dept Med, Nakagami, Okinawa, Japan	Shimasaki, T (reprint author), Univ Hawaii, Dept Med, John A Burns Sch Med, 1256 Lusitana St,7th Floor, Honolulu, HI 96813 USA.	shimasaki.t@gmail.com; heath.chung@gmail.com; shiiki_soichi@hosp.pref.okinawa.jp					Adriani KS, 2007, CLIN INFECT DIS, V45, pE46, DOI 10.1086/520682; Sasaki Y, 2013, INFECTION, V41, P1189, DOI 10.1007/s15010-013-0483-2; Keiser PB, 2004, CLIN MICROBIOL REV, V17, P208, DOI 10.1128/CMR.17.1.208-217.2004; Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707; Karunajeewa H, 2006, J TRAVEL MED, V13, P84, DOI 10.1111/j.1708-8305.2006.00004x; Link K, 1999, SOUTHERN MED J, V92, P728, DOI 10.1097/00007611-199907000-00016; BERK SL, 1987, ARCH INTERN MED, V147, P1257, DOI 10.1001/archinte.147.7.1257; Hayashi J, 1997, AM J TROP MED HYG, V56, P71; Marra NM, 2010, MEM I OSWALDO CRUZ, V105, P57, DOI 10.1590/S0074-02762010000100008; Mejia R, 2012, CURR OPIN INFECT DIS, V25, P458, DOI 10.1097/QCO.0b013e3283551dbd; Biggs BA, 2009, AM J TROP MED HYG, V80, P788; Bisoffi Z, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001254; GROVE DI, 1982, AM J TROP MED HYG, V31, P469; MAK DBY, 1993, MED J AUSTRALIA, V159, P354; Requena-Mendez A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002002; Satoh M, 2002, CLIN EXP IMMUNOL, V127, P354, DOI 10.1046/j.1365-2249.2002.01733.x; Schar F, 2013, PLOS NEGLECT TROP D, V7, P7, DOI DOI 10.1371/JOURNAL.PNTD.0002288; Somin Marina, 2008, Eur J Intern Med, V19, pe42, DOI 10.1016/j.ejim.2007.07.009; Vadlamudi Raja S, 2006, Clin Mol Allergy, V4, P8, DOI 10.1186/1476-7961-4-8; Vandebosch S, 2008, ACTA GASTRO-ENT BELG, V71, P413	20	1	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2015	92	3					601	604		10.4269/ajtmh.14-0564		4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	CC7EB	WOS:000350529400030		
J	Hayashi, K; Yamada, T; Sawa, T				Hayashi, K.; Yamada, T.; Sawa, T.			Comparative study of Poincare plot analysis using short electroencephalogram signals during anaesthesia with spectral edge frequency 95 and bispectral index	ANAESTHESIA			English	Article							HEART-RATE-VARIABILITY; CEREBRAL STATE; TIME-DELAY; APPROXIMATE ENTROPY; NARCOTREND INDEXES; GENERAL-ANESTHESIA; AWARENESS; EEG; CONSCIOUSNESS; SEVOFLURANE	The return or Poincare plot is a non-linear analytical approach in a two-dimensional plane, where a timed signal is plotted against itself after a time delay. Its scatter pattern reflects the randomness and variability in the signals. Quantification of a Poincare plot of the electroencephalogram has potential to determine anaesthesia depth. We quantified the degree of dispersion (i.e. standard deviation, SD) along the diagonal line of the electroencephalogram-Poincare plot (named as SD1/SD2), and compared SD1/SD2 values with spectral edge frequency 95 (SEF95) and bispectral index values. The regression analysis showed a tight linear regression equation with a coefficient of determination (R-2) value of 0.904 (p<0.0001) between the Poincare index (SD1/SD2) and SEF95, and a moderate linear regression equation between SD1/SD2 and bispectral index (R-2=0.346, p<0.0001). Quantification of the Poincare plot tightly correlates with SEF95, reflecting anaesthesia-dependent changes in electroencephalogram oscillation.	[Hayashi, K.] Nantan Gen Hosp, Kyoto, Japan; [Yamada, T.; Sawa, T.] Kyoto Prefectural Univ Med Sci, Kyoto, Japan	Hayashi, K (reprint author), Nantan Gen Hosp, Kyoto, Japan.	zukko@koto.kpu-m.ac.jp			Japan Society for the Promotion of Science (JSPS), Tokyo, Japan [24592313]	We are grateful to Satoshi Hagihira, M.D., Ph.D. (Associate Professor, Department of Anesthesiology, Osaka University Graduate School of Medicine, Osaka, Japan), for supplying BSA software. This work was supported by Grant-in-Aid for Scientific Research (C) No. 24592313 from Japan Society for the Promotion of Science (JSPS), Tokyo, Japan.	Anier A, 2012, BRIT J ANAESTH, V109, P928, DOI 10.1093/bja/aes312; Sleigh JW, 1999, BRIT J ANAESTH, V82, P666; Avidan MS, 2008, NEW ENGL J MED, V358, P1097, DOI 10.1056/NEJMoa0707361; Revuelta M, 2008, BRIT J ANAESTH, V101, P653, DOI 10.1093/bja/aen245; Russell IF, 2013, ANAESTHESIA, V68, P1010, DOI 10.1111/anae.12357; Morimoto Y, 2004, ANESTH ANALG, V98, P1336, DOI 10.1213/01.ANE.0000105867.17108.B6; Walling PT, 2006, ANESTHESIOLOGY, V105, P927, DOI 10.1097/00000542-200611000-00013; Whitlock EL, 2011, ANESTHESIOLOGY, V115, P1209, DOI 10.1097/ALN.0b013e3182395dcb; Avidan MS, 2011, NEW ENGL J MED, V365, P591, DOI 10.1056/NEJMoa1100403; Pandit JJ, 2013, ANAESTHESIA, V68, P343, DOI 10.1111/anae.12190; Litt B, 2002, LANCET NEUROL, V1, P22, DOI 10.1016/S1474-4422(02)00003-0; Laitio TT, 2000, ANESTHESIOLOGY, V93, P69, DOI 10.1097/00000542-200007000-00015; Pilge S, 2006, ANESTHESIOLOGY, V104, P488, DOI 10.1097/00000542-200603000-00016; Bates D. M., 2014, LME4 LINEAR MIXED EF; Doble M, 2008, INT J BIOL MED SCI, V3, P4; Dressler O, 2004, BRIT J ANAESTH, V93, P806, DOI 10.1093/bja/aeh270; Drongelen W, 2007, SIGNAL PROCESSING NE, P279, DOI 10.1016/B978-012370867-0/50017-6; Hagihira S, USER MANUAL BSA VER; Hayashi K, 2015, CLIN NEUROPHYSIOL, V126, P404, DOI 10.1016/j.clinph.2014.04.019; Kreuzer M, 2012, ANESTH ANALG, V115, P315, DOI [10.1213/ANE.0b013e31825801ea, 10.1213/ANE.0b01301825801ca]; Otzenberger H, 1997, NEUROSCI LETT, V229, P173, DOI 10.1016/S0304-3940(97)00448-5; Pandit JJ, 2014, BRIT J ANAESTH, V112, P385, DOI 10.1093/bja/aet562; Zanner R, 2009, BRIT J ANAESTH, V103, P394, DOI 10.1093/bja/aep198	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2015	70	3					310	317		10.1111/anae.12885		8	Anesthesiology	Anesthesiology	CC1NW	WOS:000350109000012		
J	Tokuwaka, J; Satsumae, T; Mizutani, T; Yamada, K; Inomata, S; Tanaka, M				Tokuwaka, J.; Satsumae, T.; Mizutani, T.; Yamada, K.; Inomata, S.; Tanaka, M.			The relationship between age and minimum alveolar concentration of sevoflurane for maintaining bispectral index below 50 in children	ANAESTHESIA			English	Article							ANESTHESIA; ISOFLURANE; SEDATION; MONITOR; INFANTS; BIS	We evaluated the minimum alveolar concentration of sevoflurane required to maintain the bispectral index below 50 in children. We studied 55 children, divided into 1-year-old, 2- to 4-year-old and 5- to 9-year-old groups and used Dixon's up-and-down method and probit analysis. In the 1-year-old group, the bispectral index values remained above 50, with the end-tidal sevoflurane concentration reaching 4.0% or higher. The minimum alveolar concentration of sevoflurane for maintaining the bispectral index below 50 was significantly higher in the 2- to 4-year-old group (2.33%, 95% CI 2.25-2.57) than in the 5- to 9-year-old group (2.10%, 95% CI 1.94-2.25; p=0.005). We conclude that assessing the depth of anaesthesia using bispectral index is unreliable in children aged <2years anaesthetised with sevoflurane.	[Tokuwaka, J.; Satsumae, T.; Yamada, K.; Inomata, S.; Tanaka, M.] Univ Tsukuba, Dept Anaesthesiol, Tsukuba, Ibaraki, Japan; [Mizutani, T.] Univ Tsukuba, Dept Emergency & Crit Care Med, Tsukuba, Ibaraki, Japan	Satsumae, T (reprint author), Univ Tsukuba, Dept Anaesthesiol, Tsukuba, Ibaraki, Japan.	tsuu@md.tsukuba.ac.jp					McDermott NB, 2003, ANESTH ANALG, V97, P39, DOI 10.1213/01.ANE.0000067402.02136.A2; Denman WT, 2000, ANESTH ANALG, V90, P872; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Davidson AJ, 2005, BRIT J ANAESTH, V95, P674, DOI 10.1093/bja/aei247; Davidson AJ, 2008, PEDIATR ANESTH, V18, P702, DOI 10.1111/j.1460-9592.2008.02664.x; Dixon W, 1967, STAT ENDOCRINOLOGY, P251; Ekman A, 2007, ANESTH ANALG, V105, P688, DOI 10.1213/01.ane.0000278117.31134.34; Gibert S, 2012, ANESTHESIOLOGY, V117, P1253, DOI 10.1097/ALN.0b013e318273e272; Kim HS, 2005, BRIT J ANAESTH, V95, P362, DOI 10.1093/bja/aei196; Matsuura T, 2009, BRIT J ANAESTH, V102, P331, DOI 10.1093/bja/aen382; Scholle S, 1999, SOMNOLOGIE, V3, P163, DOI 10.1007/s11818-999-0029-0; Tsuruta S, 2011, PEDIATR ANESTH, V21, P1124, DOI 10.1111/j.1460-9592.2011.03602.x; Wodey E, 2005, BRIT J ANAESTH, V94, P810, DOI 10.1093/bja/aei140	13	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2015	70	3					318	322		10.1111/anae.12890		5	Anesthesiology	Anesthesiology	CC1NW	WOS:000350109000013		
J	Yasui, GS; Senhorini, JA; Shimoda, E; Pereira-Santos, M; Nakaghi, LSO; Fujimoto, T; Arias-Rodriguez, L; Silva, LA				Yasui, G. S.; Senhorini, J. A.; Shimoda, E.; Pereira-Santos, M.; Nakaghi, L. S. O.; Fujimoto, T.; Arias-Rodriguez, L.; Silva, L. A.			Improvement of gamete quality and its short-term storage: an approach for biotechnology in laboratory fish	ANIMAL			English	Article						cryopreservation; sperm; oocyte; fish; yellowtail tetra	LOACH MISGURNUS-ANGUILLICAUDATUS; PSETTA-MAXIMA; TELEOST FISH; COMMON CARP; STORED OVA; SPERM; FERTILIZATION; EGGS; ZEBRAFISH; CRYOPRESERVATION	In fish, in vitro fertilization is an important reproductive tool used as first step for application of others biotechniques as chromosome and embryo manipulation. In this study, we aimed to optimize gamete quality and their short-term storage from the yellowtail tetra Astyanax altiparanae, for future application in laboratory studies. Working with sperm, we evaluated the effects of spawning inducers (carp pituitary gland and Ovopel (R) [(D-Ala6, Pro9-NEt) - mGnRH+metoclopramide]) and the presence of female on sperm motility. Additionally, we developed new procedures for short-term storage of sperm and oocytes. Briefly, sperm motility was higher when male fish were treated with carp pituitary gland (73.1 +/- 4.0%) or Ovopel (R) (79.5 +/- 5.5%) when compared with the control group treated with 0.9% NaCl (55.6 +/- 27.2%; P=0.1598). Maintenance of male fish with an ovulating female fish also improved sperm motility (74.4 +/- 7.4%) when compared with untreated male fish (42.1 +/- 26.1%; P=0.0018). Storage of sperm was optimized in modified Ringer solution, in which the sperm was kept motile for 18 days at 2.5 degrees C. The addition of antibiotics or oxygen decreased sperm motility, but partial change of supernatant and the combination of those conditions improve storage ability of sperm. Fertilization ability of oocytes decreased significantly after storage for 30, 60 90 and 120 min at 5, 10, 15 and 20 degrees C when compared with fresh oocytes (P=0.0471), but considering only the stored samples, the optimum temperature was 15 degrees C. Those data describe new approaches to improve semen quality and gametes short-term storage in yellowtail tetra A. altiparanae and open new possibilities in vitro fertilization.	[Yasui, G. S.; Silva, L. A.] Univ Sao Paulo, Dept Vet Med FZEA, Lab Theriogenol Dr OJ Ginther, BR-13630080 Pirassununga, SP, Brazil; [Senhorini, J. A.] Natl Ctr Res & Conservat Continental Fish, Chico Mendes Inst Biodivers Conservat, BR-13630970 Pirassununga, SP, Brazil; [Shimoda, E.] Univ Candido Mendes, Dept Pharm, BR-28030335 Campos Dos Goytacazes, RJ, Brazil; [Pereira-Santos, M.; Nakaghi, L. S. O.] Sao Paulo State Univ, Aquaculture Ctr, BR-14884900 Jaboticabal, SP, Brazil; [Fujimoto, T.] Hokkaido Univ, Fac Fisheries Sci, Hakodate, Hokkaido 0418611, Japan; [Arias-Rodriguez, L.] Juarez Autonomous Univ Tabasco, Biol Sci Acad Div, Villahermosa 86150, Tabasco, Mexico	Yasui, GS (reprint author), Univ Sao Paulo, Dept Vet Med FZEA, Lab Theriogenol Dr OJ Ginther, Ave Duque Caxias Norte 225, BR-13630080 Pirassununga, SP, Brazil.	yasui@usp.br	Silva, Luciano/G-6925-2012	Silva, Luciano/0000-0002-9545-179X	Sao Paulo Research Foundation (FAPESP) [2011/11664-1, 2010/17429-1]	The authors are grateful to Sao Paulo Research Foundation (FAPESP) for the financial support of this research (Young Investigators Award Grant #2010/17429-1 and Young Researcher Scholarship #2011/11664-1). They also acknowledge CEPTA-ICMBio for gently provide the facilities and experimental fish.	WITHLER FC, 1968, J FISH RES BOARD CAN, V25, P2695; Sun YH, 2005, BIOL REPROD, V72, P510, DOI 10.1095/biolreprod.104.031302; Bencic DC, 2000, N AM J AQUACULT, V62, P19, DOI 10.1577/1548-8454(2000)062<0019:STSOSS>2.0.CO;2; Fujimoto T, 2008, J APPL ICHTHYOL, V24, P430, DOI 10.1111/j.1439-0426.2008.01131.x; Coward K, 2002, REV FISH BIOL FISHER, V12, P33, DOI 10.1023/A:1022613404123; Fujimoto T, 2006, ZOOL SCI, V23, P977, DOI 10.2108/zsj.23.977; HARVEY B, 1984, AQUACULTURE, V37, P391, DOI 10.1016/0044-8486(84)90304-1; Dietrich MA, 2012, J GREAT LAKES RES, V38, P445, DOI 10.1016/j.jglr.2012.06.009; Piferrer F, 2009, AQUACULTURE, V293, P125, DOI 10.1016/j.aquaculture.2009.04.036; BILLARD R, 1992, J EXP ZOOL, V261, P122, DOI 10.1002/jez.1402610203; Billard R, 2004, AQUACULTURE, V236, P1, DOI 10.1016/j.aquaculture.2003.10.029; KUROKURA H, 1984, AQUACULTURE, V37, P267, DOI 10.1016/0044-8486(84)90159-5; Niksirat H, 2007, AQUACULTURE, V262, P528, DOI 10.1016/j.aquaculture.2006.10.031; Cosson J, 2004, AQUACULT INT, V12, P69, DOI 10.1023/B:AQUI.0000017189.44263.bc; Babiak I, 2003, J EXP ZOOL PART A, V300A, P140, DOI 10.1002/jez.a.10319; Suquet M, 1999, AQUAT LIVING RESOUR, V12, P239, DOI 10.1016/S0990-7440(00)86634-6; Yasui GS, 2009, ANIM REPROD SCI, V116, P335, DOI 10.1016/j.anireprosci.2009.02.021; Rizzo E, 2003, THERIOGENOLOGY, V60, P1059, DOI 10.1016/S0093-691X(03)00108-0; JENSEN JOT, 1984, AQUACULTURE, V37, P251, DOI 10.1016/0044-8486(84)90158-3; Yasui GS, 2008, CRYOLETTERS, V29, P383; Jing RY, 2009, AQUACULTURE, V290, P165, DOI 10.1016/j.aquaculture.2009.02.027; Barrett I., 1951, Journal of the Fisheries Research Board of Canada, V8, P125; Brown CG, 1995, PROGR FISH CULTURIST, V57, P64; Dreanno C, 1998, AQUACULTURE, V169, P247, DOI 10.1016/S0044-8486(98)00262-2; Fauvel C, 2012, J APPL ICHTHYOL, V28, P961, DOI 10.1111/jai.12071; Hagedorn M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021059; He QT, 2012, AQUACULTURE, V324, P319, DOI 10.1016/j.aquaculture.2011.10.034; Lahnsteiner F, 2003, THERIOGENOLOGY, V60, P829, DOI 10.1016/S0093-691X(02)01300-6; Lee KY, 2002, NAT BIOTECHNOL, V20, P795, DOI 10.1038/nbt721; LIN S, 1992, P NATL ACAD SCI USA, V89, P4519, DOI 10.1073/pnas.89.10.4519; Linhart O, 2001, J FISH BIOL, V59, P616; Liu TM, 2002, J EXP ZOOL, V293, P719, DOI 10.1002/jez.10177; Nam YK, 2004, THERIOGENOLOGY, V61, P933, DOI 10.1016/S0093-691X(03)00258-9; Perchec G, 1998, AQUACULTURE, V160, P317, DOI 10.1016/S0044-8486(97)00301-3; Poleo GA, 2001, BIOL REPROD, V65, P961, DOI 10.1095/biolreprod65.3.961; POON DC, 1970, PROG FISH CULT, V32, P81, DOI 10.1577/1548-8640(1970)32[81:TEODFO]2.0.CO;2; Rothbard S., 1996, Aquaculture Research, V27, P175, DOI 10.1111/j.1365-2109.1996.tb00982.x; Sohrabnezhad M, 2006, J APPL ICHTHYOL, V22, P395, DOI 10.1111/j.1439-0426.2007.00993.x; Tanaka D, 2009, J EXP ZOOL PART A, V311A, P11, DOI 10.1002/jez.491; Yasui GS, 2010, AQUACULTURE, V308, pS140, DOI 10.1016/j.aquaculture.2010.05.041; Yasui GS, 2011, J ANIM SCI, V89, P2380, DOI 10.2527/jas.2010-3633	41	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1751-7311	1751-732X		ANIMAL	Animal	MAR	2015	9	3					464	470		10.1017/S1751731114002511		7	Agriculture, Dairy & Animal Science; Veterinary Sciences	Agriculture; Veterinary Sciences	CC0PN	WOS:000350038100011		
J	Piamya, P; Tiantong, A; Chen, SE; Liu, WB; Yu, C; Nagahata, H; Chang, CJ				Piamya, P.; Tiantong, A.; Chen, S. -E.; Liu, W. -B.; Yu, C.; Nagahata, H.; Chang, C. -J.			Fingerprinting of gelatinase subtypes for different topographic regions on non-retaining placenta of Holstein cows	ANIMAL			English	Article						matrix metalloproteinase; gelatin zymography; holstein cow; non-retaining placenta; topographic region	MATRIX METALLOPROTEINASES TIMP-2; RETAINED FETAL MEMBRANES; NEUTROPHIL GELATINASE; TISSUE INHIBITOR-2; LIPOCALIN NGAL; MMP-9 ACTIVITY; EXPRESSION; COMPLEX; GESTATION; ENDOMETRIUM	The contribution of matrix metalloproteinases (MMP) to timely discharge of the placenta from bovine uterus at parturition is yet inconclusive, partly because of the presence of multiple MMP forms in situ. In the current study, the expression of different gelatinase subtypes on non-retaining placentas of Holstein cows was fingerprinted by using gelatin zymography. Different topographic regions on the placenta were measured separately, including the placentome-like structure and the fetal and maternal sides of interplacentomal placenta, all sampled from the central and peripheral areas of the placenta, respectively. The spontaneously ruptured umbilical cords were cross-sectioned as fetus end, middle and placenta end also for separate measurement. Body fluids including blood samples from the parturient cows, their neonatal calves and umbilical cord, as well as fetal fluids and the first colostrum were measured concomitantly. Results showed multiple forms of gelatinases subtypes in the placenta tissues and body fluids, including neutrophil gelatinase-associated lipocalin (NGAL)-MMP-9 complex, both the latent and active forms of MMP-2 and MMP-9; of them, the latent forms were much more abundantly and frequently expressed than the active forms. NGAL-MMP-9 complex was more prevalently present in the body fluids than in the placenta tissues. No distinguishable pattern of the expression of any gelatinase subtype was observed among the placentome-like structure, interplacentomal placenta and umbilical cord, or between fetal and maternal sides. Nonetheless, for interplacentomal placenta, proMMP-9 expression was higher in the central than in the peripheral area. In addition, proMMP-2 expression was higher in the rupture end (fetus end) than the placenta end of the umbilical cord. In conclusion, the current validated gelatin zymography detected a gradient proMMP-9 expression on the non-retaining placenta of cows in reverse to the proximity to the umbilical insertion point, and a gradient proMMP-2 expression on a section of the umbilical cord in reverse to the proximity to the rupture site, suggesting roles played by gelatinases in normal discharge of the placenta at term.	[Piamya, P.; Tiantong, A.; Chen, S. -E.; Liu, W. -B.; Chang, C. -J.] Natl Chung Hsing Univ, Dept Anim Sci, Taichung 402, Taiwan; [Yu, C.] Natl Pingtung Univ Sci & Technol, Dept Anim Sci, Pingtung 912, Taiwan; [Nagahata, H.] RakunoGakuen Univ, Sch Vet Med, Dept Anim Hlth, Ebetsu, Hokkaido 0698501, Japan	Piamya, P (reprint author), Natl Chung Hsing Univ, Dept Anim Sci, Taichung 402, Taiwan.	crchang@mail.nchu.edu.tw					Cross JC, 2006, DIFFERENTIATION, V74, P393, DOI 10.1111/j.1432-0436.2006.00103.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Yu TC, 2012, VET IMMUNOL IMMUNOP, V147, P161, DOI 10.1016/j.vetimm.2012.04.011; Walter I, 2001, PLACENTA, V22, P473, DOI 10.1053/plac.2001.0633; Beceriklisoy HB, 2007, REPROD DOMEST ANIM, V42, P654, DOI 10.1111/j.1439-0531.2006.00838.x; McNaughton AP, 2009, VET REC, V165, P615; Maj JG, 1997, PLACENTA, V18, P683, DOI 10.1016/S0143-4004(97)90010-2; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Takagi M, 2007, MOL REPROD DEV, V74, P801, DOI 10.1002/mrd.20637; WOODING FBP, 1980, J REPROD FERTIL, V59, P425; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Pugin J, 1999, AM J RESP CELL MOL, V20, P458; Dilly M, 2011, THERIOGENOLOGY, V75, P1104, DOI 10.1016/j.theriogenology.2010.11.019; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Peter AT, 2013, THERIOGENOLOGY, V80, P693, DOI 10.1016/j.theriogenology.2013.06.004; Roy R, 2008, CLIN CANCER RES, V14, P6610, DOI 10.1158/1078-0432.CCR-08-1136; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Makowski GS, 2003, CLIN CHIM ACTA, V329, P77, DOI 10.1016/S0009-8981(03)00015-9; Kizaki K, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477-7827-6-66; Klisch K, 1999, PLACENTA, V20, P451, DOI 10.1053/plac.1999.0402; Kolkenbrock H, 1996, BIOL CHEM, V377, P529, DOI 10.1515/bchm3.1996.377.7-8.529; Provatopoulou X, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-390; SAS Institute, 2008, SAS STAT US GUID REL; Thomas K, 2002, HUM REPROD, V17, P63, DOI 10.1093/humrep/17.1.63; Uekita T, 2004, PLACENTA, V25, P810, DOI 10.1016/j.placenta.204.03.007; Vagnoni KE, 1998, PLACENTA, V19, P447, DOI 10.1016/S0143-4004(98)91037-2; Wischral A, 2001, ANIM REPROD SCI, V67, P181, DOI 10.1016/S0378-4320(01)00119-1	27	1	1	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1751-7311	1751-732X		ANIMAL	Animal	MAR	2015	9	3					490	499		10.1017/S1751731114002420		10	Agriculture, Dairy & Animal Science; Veterinary Sciences	Agriculture; Veterinary Sciences	CC0PN	WOS:000350038100014		
J	Kouazounde, JB; Gbenou, JD; Babatounde, S; Srivastava, N; Eggleston, SH; Antwi, C; Baah, J; McAllister, TA				Kouazounde, J. B.; Gbenou, J. D.; Babatounde, S.; Srivastava, N.; Eggleston, S. H.; Antwi, C.; Baah, J.; McAllister, T. A.			Development of methane emission factors for enteric fermentation in cattle from Benin using IPCC Tier 2 methodology	ANIMAL			English	Article						methane; enteric fermentation; emission factor; cattle; Benin; Africa		The objective of this study was to develop emission factors (EF) for methane (CH4) emissions from enteric fermentation in cattle native to Benin. Information on livestock characteristics and diet practices specific to the Benin cattle population were gathered from a variety of sources and used to estimate EF according to Tier 2 methodology of the 2006 Intergovernmental Panel on Climate Change (IPCC) Guidelines for National Greenhouse Gas Inventories. Most cattle from Benin are Bos taurus represented by Borgou, Somba and Lagune breeds. They are mainly multi-purpose, being used for production of meat, milk, hides and draft power and grazed in open pastures and crop lands comprising tropical forages and crops. Estimated enteric CH4 EFs varied among cattle breeds and subcategory owing to differences in proportions of gross energy intake expended to meet maintenance, production and activity. EFs ranged from 15.0 to 43.6, 16.9 to 46.3 and 24.7 to 64.9 kg CH4/head per year for subcategories of Lagune, Somba and Borgou cattle, respectively. Average EFs for cattle breeds were 24.8, 29.5 and 40.2 kg CH4/head per year for Lagune, Somba and Borgou cattle, respectively. The national EF for cattle from Benin was 39.5 kg CH4/head per year. This estimated EF was 27.4% higher than the default EF suggested by IPCC for African cattle with the exception of dairy cattle. The outcome of the study underscores the importance of obtaining country-specific EF to estimate global enteric CH4 emissions.	[Kouazounde, J. B.; Gbenou, J. D.] Univ Abomey Calavi, Fac Sci & Tech, Dept Chem, Cotonou, Benin; [Babatounde, S.] Univ Abomey Calavi, Fac Agron Sci, Dept Anim Prod, Cotonou, Benin; [Srivastava, N.; Eggleston, S. H.] IGES, IPCC Natl Greenhouse Gas Inventory Program, Tech Support Unit, Hayama, Kanagawa 2400115, Japan; [Antwi, C.] Univ Sci & Technol Kumasi, Coll Agr & Nat Resources Kwame Nkrumah, Dept Anim Sci, Kumasi, Ghana; [Baah, J.; McAllister, T. A.] Agr & Agri Food Canada, Lethbridge Res Ctr, Lethbridge, AB T1J 4B1, Canada	Kouazounde, JB (reprint author), Univ Abomey Calavi, Fac Sci & Tech, Dept Chem, POB 526, Cotonou, Benin.	tim.mcAllister@agr.gc.ca			Japanese Government	This research work was carried out at IPCC-TFI Technical Support Unit (TSU). The 'TSU Inventory Internship' programme has been launched by the Institute for Global Environmental Strategies and funded by the Japanese Government. The authors have benefited from the support of all kind from Mr Taka Hiraishi (TFI Co-chair) and all TSU staff. They have also benefited from the advice from or collaboration with Dr Keith R. Lassey (NIWA, New Zealand), Mr Epiphane D. Ahlonsou (ASECNA, Benin), Prof. Nestor Aho (UAC, Benin), Dr Sabin Guendehou (CBRST, Benin), and Ms Eunice DOSSA (Benin).	Achard F., 2001, JACHERE AFRIQUE TROP, V2, P201; Adanléhoussi A., 2003, Tropicultura, V21, P135; Akadiri FA, 1979, THESIS INTERSTATE CO; Kvenvolden KA, 2005, MAR PETROL GEOL, V22, P579, DOI 10.1016/j.marpetgeo.2004.08.004; Storm Ida M L D, 2012, Animals (Basel), V2, P160, DOI 10.3390/ani2020160; Yan T, 2009, ANIMAL, V3, P1455, DOI 10.1017/S175173110900473X; Lassey KR, 2007, AGR FOREST METEOROL, V142, P120, DOI 10.1016/j.agrformet.2006.03.028; Babatounde S., 2009, Rencontres Autour des Recherches sur les Ruminants, V16, P29; Chabi Macco Y, 1992, THESIS NATL U BENIN; Dehoux JP, 1994, ANIMAL GENETIC RES I, V13, P39; Dehoux JP, 1993, REV MONDIALE ZOOTECH, V74/75, P36; Djenontin AJ, 2004, B RECHERCHE AGRONOMI, V43, P30; Faculte des Sciences Agronomiques (FSA), 2006, PROD TRANSF LAIT FRA; Food and Agriculture Organization (FAO), 2009, DOM AN DIV INF SYST; Food and Agriculture Organization (FAO), 2000, GLOB IMP DOM METH EM; Gbangboche AB, 2011, RES J ANIMAL SCI, V5, P17; Gerber PJ, 2013, TACKING CLIMATE CHAN; Goutondji LESA, 2007, THESIS U PRETORIA PR; Hoste CH, 1992, MONOGRAPH ILCA, V2; Intergovernmental Panel for Climate Change (IPCC), 2006, 2006 IPCC GUIDELINES, V4; Pachauri RK, 2007, CLIMATE CHANGE 2007, P35; Kora S, 2005, THESIS NATL U BENIN; Ministere de l'Agriculture et de l'Elevage (MAEP), 2003, ET RESS ZOOG; Ministry of Environment Urban Settlement and Town Planning (MEHU), 2011, DEUX COMM NAT REP BE; NRC - National Research Council, 1996, NUTR REQ BEEF CATTL; Olivier J, 2012, CO2 EMISSIONS FUEL C, pIII1; Sejian V, 2012, ENV STRESS AMELIORAT, P469, DOI [10.1007/978-3-642-29205-7_16, DOI 10.1007/978-3-642-29205-7_16]; Senou M., 2008, Revue d'Élevage et de Médecine Vétérinaire des Pays Tropicaux, V61, P109; Symoens C, 1991, CAP BUILD IMPR QUAL, V44, P487; United Nations Development Programme (UNDP), 2002, CAP BUILD IMPR QUAL; Youssao AKI, 2013, INT J BIOL CHEM SCI, V7, P125	31	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1751-7311	1751-732X		ANIMAL	Animal	MAR	2015	9	3					526	533		10.1017/S1751731114002626		8	Agriculture, Dairy & Animal Science; Veterinary Sciences	Agriculture; Veterinary Sciences	CC0PN	WOS:000350038100018		
J	Yoon, J; Kasai, H				Yoon, Jaewoo; Kasai, Hiroaki			Wenyingzhuangia heitensis sp nov., a new species of the family Flavobacteriaceae within the phylum Bacteroidetes isolated from seawater	ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY			English	Article						Bacteroidetes; Flavobacteriaceae; Wenyingzhuangia heitensis sp nov.; 16S rRNA gene; Polyphasic taxonomy	PERFORMANCE LIQUID-CHROMATOGRAPHY; IN-SITU HYBRIDIZATION; DEOXYRIBONUCLEIC-ACID; BACTERIAL SYSTEMATICS; DIVERSITY; SEA	A Gram-negative, strictly aerobic, beige-pigmented, non-motile, rod-shaped strain designated H-MN17(T) was isolated from seawater in Japan. Phylogenetic analyses based on the 16S rRNA gene sequence revealed that the novel isolate was affiliated with the family Flavobacteriaceae within the phylum Bacteroidetes and that it showed highest sequence similarity (97.5 %) to Wenyingzhuangia marina D1(T). The hybridization values for DNA-DNA relatedness between the strains of H-MN17(T) and W. marina D1(T) were lower than 70 %, which is accepted as the phylogenetic definition of a novel species. The DNA G+C content of strain H-MN17(T) was 31.8 mol%; MK-6 was the major menaquinone; and anteiso-C15:0, anteiso-C17:0 and anteiso-C19:0 were identified as the major (> 10 %) cellular fatty acids. A complex polar lipid profile was present consisting of phosphatidylethanolamine, three unidentified lipids, three unidentified glycolipids and three unidentified aminolipids. From the distinct phylogenetic position and combination of genotypic and phenotypic characteristics, the strain is considered to represent a novel species of the genus Wenyingzhuangia for which the name Wenyingzhuangia heitensis sp. nov. is proposed. The type strain of W. heitensis sp. nov. is H-MN17(T) (=KCTC 42245(T) = NBRC 110601(T)).	[Yoon, Jaewoo] Keimyung Univ, Coll Pharm, Taegu 704701, South Korea; [Kasai, Hiroaki] Kitasato Univ, Marine Biosci Kamaishi Res Lab, Ofunato, Iwate 0220101, Japan	Yoon, J (reprint author), Keimyung Univ, Coll Pharm, 1095 Dalgubeoldaero, Taegu 704701, South Korea.	jwyoon@kmu.ac.kr					AKAGAWAMATSUSHITA M, 1992, INT J SYST BACTERIOL, V42, P621; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Kim OS, 2012, INT J SYST EVOL MICR, V62, P716, DOI 10.1099/ijs.0.038075-0; MARMUR J, 1961, J MOL BIOL, V3, P208; Brettar I, 2004, INT J SYST EVOL MICR, V54, P2335, DOI 10.1099/ijs.0.63255-0; Cottrell MT, 2000, APPL ENVIRON MICROB, V66, P5116, DOI 10.1128/AEM.66.12.5116-5122.2000; Glockner FO, 1999, APPL ENVIRON MICROB, V65, P3721; Bernardet JF, 2002, INT J SYST EVOL MICR, V52, P1049, DOI 10.1099/ijs.0.02136-0; DITTMER JC, 1964, J LIPID RES, V5, P126; O'Sullivan LA, 2002, APPL ENVIRON MICROB, V68, P201, DOI 10.1128/AEM.68.1.201-210.2002; COLLINS MD, 1981, J APPL BACTERIOL, V51, P129, DOI 10.1111/j.1365-2672.1981.tb00916.x; WEISBURG WG, 1991, J BACTERIOL, V173, P697; PERRY LB, 1973, J APPL BACTERIOL, V36, P227, DOI 10.1111/j.1365-2672.1973.tb04095.x; KOMAGATA K, 1987, METHOD MICROBIOL, V19, P161; Bowman JP, 1997, APPL ENVIRON MICROB, V63, P3068; HAYAKAWA M, 1987, J FERMENT BIOENG, V65, P501, DOI 10.1016/0385-6380(87)90108-7; DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Atlas R. M., 1993, HDB MICROBIOLOGICAL; BIANCHI A, 1995, MICROBIAL DIVERSITY AND ECOSYSTEM FUNCTION, P185; Collins C. H., 1984, MICROBIOLOGICAL METH; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.2307/2408678; Giovannoni S.J., 2000, MICROBIAL ECOLOGY OC, P47; HANSEN GH, 1991, J MICROBIOL METH, V13, P231; Kimura M., 1983, NEUTRAL THEORY MOL E; MESBAH M, 1989, INT J SYST BACTERIOL, V39, P159; MINNIKIN DE, 1984, J MICROBIOL METH, V2, P233, DOI 10.1016/0167-7012(84)90018-6; Pinhassi J, 2003, APPL ENVIRON MICROB, V69, P199, DOI 10.1128/AEM.69.1.199-211.2003; Reichenbach H, 1989, BERGEYS MANUAL SYSTE, V3, P2015; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Sasser M., 1990, 101 MIDI; WAYNE LG, 1987, INT J SYST BACTERIOL, V37, P463; Worliczek HL, 2007, SYST APPL MICROBIOL, V30, P355, DOI 10.1016/j.syapm.2007.03.004	34	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0003-6072	1572-9699		ANTON LEEUW INT J G	Antonie Van Leeuwenhoek	MAR	2015	107	3					655	661		10.1007/s10482-014-0360-8		7	Microbiology	Microbiology	CC3HB	WOS:000350236300002		
J	Toda, H; Ohuchi, T; Imae, R; Itoh, N				Toda, Hiroshi; Ohuchi, Takuya; Imae, Ryouta; Itoh, Nobuya			Microbial Production of Aliphatic (S)-Epoxyalkanes by Using Rhodococcus sp Strain ST-10 Styrene Monooxygenase Expressed in Organic-Solvent-Tolerant Kocuria rhizophila DC2201	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							INHIBENS DSM 17395; ASYMMETRIC EPOXIDATION; ENANTIOSELECTIVE EPOXIDATION; ALCOHOL-DEHYDROGENASE; EFFICIENT SYNTHESIS; PSEUDOMONAS; BIOCATALYSIS; OLEFINS; CHLOROPEROXIDASE; ESCHERICHIA	We describe the development of biocatalysis for producing optically pure straight-chain (S)-epoxyalkanes using styrene monooxygenase of Rhodococcus sp. strain ST-10 (RhSMO). RhSMO was expressed in the organic solvent-tolerant microorganism Kocuria rhizophila DC2201, and the bioconversion reaction was performed in an organic solvent-water biphasic reaction system. The biocatalytic process enantioselectively converted linear terminal alkenes to their corresponding (S)-epoxyalkanes using glucose and molecular oxygen. When 1-heptene and 6-chloro-1-hexene were used as substrates (400 mM) under optimized conditions, 88.3 mM (S)-1,2-epoxyheptane and 246.5 mM (S)-1,2-epoxy-6-chlorohexane, respectively, accumulated in the organic phase with good enantiomeric excess (ee; 84.2 and 95.5%). The biocatalysis showed broad substrate specificity toward various aliphatic alkenes, including functionalized and unfunctionalized alkenes, with good to excellent ee. Here, we demonstrate that this biocatalytic system is environmentally friendly and useful for producing various enantiopure (S)-epoxyalkanes.	[Itoh, Nobuya] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan; Toyama Prefectural Univ, Dept Biotechnol, Imizu, Toyama, Japan	Itoh, N (reprint author), Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan.	nbito@pu-toyama.ac.jp					Patel RN, 2008, COORDIN CHEM REV, V252, P659, DOI 10.1016/j.ccr.2007.10.031; Lakner FJ, 1996, J ORG CHEM, V61, P3923, DOI 10.1021/jo960074m; Schaus SE, 2002, J AM CHEM SOC, V124, P1307, DOI 10.1021/ja016737l; Zech H, 2013, PROTEOMICS, V13, P2869, DOI 10.1002/pmic.201200560; Inoue K, 2005, APPL ENVIRON MICROB, V71, P3633, DOI 10.1128/AEM.71.7.3633-3641.2005; Kuhn D, 2012, J IND MICROBIOL BIOT, V39, P1125, DOI 10.1007/s10295-012-1126-9; HANSON RM, 1986, J ORG CHEM, V51, P1922, DOI 10.1021/jo00360a058; IRIE R, 1991, TETRAHEDRON LETT, V32, P1055, DOI 10.1016/S0040-4039(00)74486-8; CHANG SB, 1994, J AM CHEM SOC, V116, P6937, DOI 10.1021/ja00094a059; ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; Tu Y, 1996, J AM CHEM SOC, V118, P9806, DOI 10.1021/ja962345g; Shu LH, 2001, TETRAHEDRON, V57, P5213, DOI 10.1016/S0040-4020(01)00362-3; Zech H, 2013, PROTEOMICS, V13, P2851, DOI 10.1002/pmic.201200513; Farinas ET, 2004, TETRAHEDRON, V60, P525, DOI 10.1016/j.tet.2003.10.099; KATSUKI T, 1980, J AM CHEM SOC, V102, P5974, DOI 10.1021/ja00538a077; Farina V, 2006, CHEM REV, V106, P2734, DOI 10.1021/cr040700c; Volmer J, 2014, APPL ENVIRON MICROB, V80, P6539, DOI 10.1128/AEM.01940-14; Panke S, 1998, APPL ENVIRON MICROB, V64, P2032; Beltrametti F, 1997, APPL ENVIRON MICROB, V63, P2232; Siriphongphaew A, 2012, APPL MICROBIOL BIOT, V95, P357, DOI 10.1007/s00253-012-4039-7; Park JB, 2007, BIOTECHNOL BIOENG, V98, P1219, DOI 10.1002/bit.21496; Itoh N, 2012, APPL MICROBIOL BIOT, V93, P1075, DOI 10.1007/s00253-011-3447-4; Champreda V, 2006, APPL MICROBIOL BIOT, V71, P840, DOI 10.1007/s00253-005-0208-2; Fujita K, 2006, ENZYME MICROB TECH, V39, P511, DOI 10.1016/j.enzmictec.2006.01.033; Gennaro PD, 2007, ARCH MICROBIOL, V188, P117; HASHIMOTO Y, 1992, J GEN MICROBIOL, V138, P1003; Hirasawa K, 2001, BIOSCI BIOTECH BIOCH, V65, P239, DOI 10.1271/bbb.65.239; Hollmann F, 2003, J AM CHEM SOC, V125, P8209, DOI 10.1021/ja034119u; Iida H, 2005, TOSOH RES TECHNOL RE, V49, P3; Itoh N, 2003, APPL MICROBIOL BIOT, V61, P240, DOI 10.1007/s00253-002-1195-1; ITOH N, 1994, BIOSCI BIOTECH BIOCH, V58, P1306; Martinez CA, 2000, CURR ORG CHEM, V4, P263, DOI 10.2174/1385272003376265; Matsumura E, 2012, US patent, Patent No. [20,120,142,050, 20120142050]; Sharma R, 2009, ORG LETT, V11, P3194, DOI 10.1021/ol9010147; Toda H, 2014, ADV SYNTH CATAL, V356, P3443, DOI 10.1002/adsc.201400383; Toda H, 2012, J BIOSCI BIOENG, V113, P12, DOI 10.1016/j.jbiosc.2011.08.028; Toda H, 2012, APPL MICROBIOL BIOT, V96, P407, DOI 10.1007/s00253-011-3849-3; Toda H, 2012, TETRAHEDRON-ASYMMETR, V23, P1542, DOI 10.1016/j.tetasy.2012.09.017; ZHANG W, 1991, J ORG CHEM, V56, P2296, DOI 10.1021/jo00007a012	39	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	MAR	2015	81	6					1919	1925		10.1128/AEM.03405-14		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CC7NM	WOS:000350554800005		
J	Doi, Y				Doi, Yuki			L-Lactate Production from Biodiesel-Derived Crude Glycerol by Metabolically Engineered Enterococcus faecalis: Cytotoxic Evaluation of Biodiesel Waste and Development of a Glycerol-Inducible Gene Expression System	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							L-LACTIC ACID; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; OXIDATIVE STRESS; DEHYDROGENASES; BACTERIAL; TRANSFORMATION; DISSIMILATION; FERMENTATION; REDUCTASE	Biodiesel waste is a by-product of the biodiesel production process that contains a large amount of crude glycerol. To reuse the crude glycerol, a novel bioconversion process using Enterococcus faecalis was developed through physiological studies. The E. faecalis strain W11 could use biodiesel waste as a carbon source, although cell growth was significantly inhibited by the oil component in the biodiesel waste, which decreased the cellular NADH/NAD(+) ratio and then induced oxidative stress to cells. When W11 was cultured with glycerol, the maximum culture density (optical density at 600 nm [OD600]) under anaerobic conditions was decreased 8-fold by the oil component compared with that under aerobic conditions. Furthermore, W11 cultured with dihydroxyacetone (DHA) could show slight or no growth in the presence of the oil component with or without oxygen. These results indicated that the DHA kinase reaction in the glycerol metabolic pathway was sensitive to the oil component as an oxidant. The lactate dehydrogenase (Ldh) activity of W11 during anaerobic glycerol metabolism was 4.1-fold lower than that during aerobic glycerol metabolism, which was one of the causes of low L-lactate productivity. The E. faecalis pflB gene disruptant (Delta pfl mutant) expressing the ldhL1(LP) gene produced 300 mM L-lactate from glycerol/crude glycerol with a yield of > 99% within 48 h and reached a maximum productivity of 18 mM h(-1) (1.6 g liter(-1) h(-1)). Thus, our study demonstrates that metabolically engineered E. faecalis can convert crude glycerol to L-lactate at high conversion efficiency and provides critical information on the recycling process for biodiesel waste.	Okayama Univ Sci, Dept Appl Chem & Biotechnol, Fac Engn, Okayama, Japan	Doi, Y (reprint author), Okayama Univ Sci, Dept Appl Chem & Biotechnol, Fac Engn, Okayama, Japan.	yuki.doi.doct@gmail.com			Japan Soap and Detergent Association; Okayama Foundation for Science and Technology	This study was partly supported by research grants from the Japan Soap and Detergent Association and the Okayama Foundation for Science and Technology.	Abdel-Rahman MA, 2013, BIOTECHNOL ADV, V31, P877, DOI 10.1016/j.biotechadv.2013.04.002; Bizzini A, 2010, J BACTERIOL, V192, P779, DOI 10.1128/JB.00959-09; Dobson R, 2012, J IND MICROBIOL BIOT, V39, P217, DOI 10.1007/s10295-011-1038-0; Datta R, 2006, J CHEM TECHNOL BIOT, V81, P1119, DOI 10.1002/jctb.1486; Yaakob Z, 2014, RENEW SUST ENERG REV, V35, P136, DOI 10.1016/j.rser.2014.03.055; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Ma FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5; Bryk R, 2000, NATURE, V407, P211; DATTA R, 1995, FEMS MICROBIOL REV, V16, P221; Sauvageot N, 2012, MICROBIOL-SGM, V158, P2661, DOI 10.1099/mic.0.061663-0; FARR SB, 1991, MICROBIOL REV, V55, P561; GARVIE EI, 1980, MICROBIOL REV, V44, P106; Anand P, 2012, NEW BIOTECHNOL, V29, P199, DOI 10.1016/j.nbt.2011.05.010; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; La Carbona S, 2007, MOL MICROBIOL, V66, P1148, DOI 10.1111/j.1365-2958.2007.05987.x; Hajek M, 2010, BIORESOURCE TECHNOL, V101, P3242, DOI 10.1016/j.biortech.2009.12.094; Ranganathan SV, 2008, BIORESOURCE TECHNOL, V99, P3975, DOI 10.1016/j.biortech.2007.04.060; Feldman-Salit A, 2013, J BIOL CHEM, V288, P21295, DOI 10.1074/jbc.M113.458265; British Petroleum, 2014, BP STAT REV WORLD EN; Doi Y, 2014, J BACTERIOL, V196, P2472, DOI 10.1128/JB.01512-14; FRIESENEGGER A, 1991, FEMS MICROBIOL LETT, V79, P323, DOI 10.1016/0378-1097(91)90106-K; GANCEDO C, 1968, EUR J BIOCHEM, V5, P165, DOI 10.1111/j.1432-1033.1968.tb00353.x; Van Gerpen J, 2005, FUEL PROCESS TECHNOL, V86, P1097, DOI 10.1016/j.fuproc.2004.11.005; Girotti A W, 1985, J Free Radic Biol Med, V1, P87, DOI 10.1016/0748-5514(85)90011-X; GUNSALUS IC, 1947, J BACTERIOL, V54, P239; HONDMANN DHA, 1991, J GEN MICROBIOL, V137, P629; Huycke MM, 2002, ENTEROCOCCI: PATHOGENESIS, MOLECULAR BIOLOGY, AND ANTIBIOTIC RESISTANCE, P133; Ilmen M, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-53; JACOBS NJ, 1960, J BACTERIOL, V79, P532; LIN ECC, 1976, ANNU REV MICROBIOL, V30, P535, DOI 10.1146/annurev.mi.30.100176.002535; Mazumdar S, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-7; Rehman A, 2008, J CHEM TECHNOL BIOT, V83, P1072; Rivaldi JD, 2013, APPL MICROBIOL BIOT, V97, P1735, DOI 10.1007/s00253-012-4621-z; Uchikoba H, 2002, PROTEINS, V46, P206, DOI 10.1002/prot.1165; Vodnar DC, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-92; WIRTH R, 1986, J BACTERIOL, V165, P831; Wittenberger CL, 1970, J BACTERIOL, V101, P717	37	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	MAR	2015	81	6					2082	2089		10.1128/AEM.03418-14		8	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	CC7NM	WOS:000350554800023		
J	Khumchoo, N; Khaorapapong, N; Ogawa, M				Khumchoo, Nuttapom; Khaorapapong, Nithima; Ogawa, Makoto			Formation of zinc oxide particles in cetyltrimethylammonium-smectites	APPLIED CLAY SCIENCE			English	Article						Zinc oxide; Cetyltrimethylammonium ion; Montmorillonite; Saponite; Optical property	WALLED CARBON NANOTUBES; LAYERED SILICATES; ZNO-NANOPARTICLES; OPTICAL-PROPERTIES; MESOPOROUS SILICA; ALKYLAMMONIUM-MONTMORILLONITES; PHOTOCATALYTIC PROPERTIES; INTERCALATION; COMPLEXES; SURFACE	Zinc oxide was prepared in the interlayer space of cetyltrimethylammonium-smectites (a natural montmorillonite and a synthetic saponite) by the reaction between the aqueous solutions of zinc chloride and sodium hydroxide in the presence of cetyltrimethylammonium-smectites. The products were characterized by X-ray powder diffraction, Fourier transform infrared spectroscopy, as well as scanning electron, transmission electron, and optical microscopies. The formation of zinc oxide nanoparticles in the interlayer space of cetyltrimethylammonium-smectites was indicated by the transmission electron micrograph, diffuse reflectance absorption and the photoluminescence spectra. The photoluminescence of zinc oxide was affected by the interactions with cetyltrimethylammonium cation and silicate layer. The photoluminescence intensities of zinc oxide in cetyltrimethylammonium-saponite were higher than those in cetyltrimethylammonium-montmorillonite due to the quenching impurity in montmorillonite. Thus, the luminescence characteristics (both intensity and the energy) were controlled by the host-guest interactions with selection of host and modification. (C) 2015 Elsevier B.V. All rights reserved.	[Khumchoo, Nuttapom; Khaorapapong, Nithima] Khon Kaen Univ, Fac Sci, Mat Chem Res Ctr, Dept Chem, Khon Kaen 40002, Thailand; [Khumchoo, Nuttapom; Khaorapapong, Nithima] Khon Kaen Univ, Fac Sci, Ctr Excellence Innovat Chem, Khon Kaen 40002, Thailand; [Ogawa, Makoto] Waseda Univ, Dept Earth Sci, Shinjuku Ku, Tokyo 1698050, Japan; [Ogawa, Makoto] Waseda Univ, Grad Sch Creat Sci & Engn, Shinjuku Ku, Tokyo 1698050, Japan; [Ogawa, Makoto] FIT Grp Sci & Technol Inst Project, Bangkok 10900, Thailand	Khaorapapong, N (reprint author), Khon Kaen Univ, Fac Sci, Mat Chem Res Ctr, Dept Chem, Khon Kaen 40002, Thailand.	nithima@kku.ac.th			Higher Education Research Promotion; National Research University Project of Thailand, Office of the Higher Education Commission, through the Advanced Functional Materials Cluster of Khon Kaen University; Kaen University and the Center of Excellence for Innovation in Chemistry (PERCH-CIC), Commission on Higher Education, Ministry of Education, Thailand	This work was supported by the Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, through the Advanced Functional Materials Cluster of Khon Kaen University and the Center of Excellence for Innovation in Chemistry (PERCH-CIC), Commission on Higher Education, Ministry of Education, Thailand.	Al-Kahlout A, 2012, THIN SOLID FILMS, V520, P1814, DOI 10.1016/j.tsf.2011.08.095; Ogawa M, 1997, B CHEM SOC JPN, V70, P2593, DOI 10.1246/bcsj.70.2593; Ni RJ, 2009, J THERM ANAL CALORIM, V96, P943, DOI 10.1007/s10973-009-0046-z; MALLA PB, 1991, NATURE, V351, P555, DOI 10.1038/351555a0; Ruiz-Hitzky E, 2011, CHEM SOC REV, V40, P801, DOI 10.1039/c0cs00052c; Xu WG, 2010, J COLLOID INTERF SCI, V351, P210, DOI 10.1016/j.jcis.2010.07.052; Zhang WH, 2000, CHEM MATER, V12, P1408, DOI 10.1021/cm990740a; Zhu LP, 2009, MATER SCI ENG B-ADV, V163, P194, DOI 10.1016/j.mseb.2009.05.021; DONER HE, 1969, SCIENCE, V166, P1406, DOI 10.1126/science.166.3911.1406; Ogawa M, 2014, DALTON T, V43, P10340, DOI 10.1039/c4dt00147h; Sharma PK, 2009, J LUMIN, V129, P605, DOI 10.1016/j.jlumin.2009.01.004; Nemeth J, 2004, LANGMUIR, V20, P2855, DOI 10.1021/la035097s; Xiong HM, 2010, J MATER CHEM, V20, P4251, DOI 10.1039/b918413a; Jiang Q, 2006, J MATER CHEM, V16, P1536, DOI 10.1039/b516061h; Khaorapapong N, 2011, DALTON T, V40, P5964, DOI 10.1039/c0dt01736a; Fatimah I, 2011, APPL CLAY SCI, V53, P553, DOI 10.1016/j.clay.2011.05.001; Yang LY, 2010, J HAZARD MATER, V179, P438, DOI 10.1016/j.jhazmat.2010.03.023; Bisio C, 2011, LANGMUIR, V27, P7250, DOI 10.1021/la200892d; Sasai R, 2014, APPL CLAY SCI, V93-94, P72, DOI 10.1016/j.clay.2014.02.023; Garcia MA, 2007, NANO LETT, V7, P1489, DOI 10.1021/nl070198m; Kameshima Y, 2009, APPL CLAY SCI, V45, P20, DOI 10.1016/j.clay.2009.03.005; Chen HG, 2004, OPT MATER, V25, P79, DOI 10.1016/S0925-3467(03)00229-5; Okada T, 2012, CHEM-ASIAN J, V7, P1980, DOI 10.1002/asia.201101015; OGAWA M, 1995, CHEM REV, V95, P399, DOI 10.1021/cr00034a005; Yuan SJ, 2009, COLLOID SURFACE A, V348, P76, DOI 10.1016/j.colsurfa.2009.06.040; LAGALY G, 1981, CLAY MINER, V16, P1, DOI 10.1180/claymin.1981.016.1.01; Ontam A, 2012, J MATER CHEM, V22, P20001, DOI 10.1039/c2jm33327a; Pimchan P, 2011, APPL CLAY SCI, V54, P287, DOI 10.1016/j.clay.2011.09.002; Topkaya E, 2014, J COLLOID INTERF SCI, V430, P6, DOI 10.1016/j.jcis.2014.05.022; Djurisic AB, 2012, J MATER CHEM, V22, P6526, DOI 10.1039/c2jm15548f; Pimchan P, 2014, APPL CLAY SCI, V101, P223, DOI 10.1016/j.clay.2014.08.004; Ghosh A, 2009, J ALLOY COMPD, V469, P56, DOI 10.1016/j.jallcom.2008.02.061; Chen CS, 2006, ACTA MATER, V54, P5401, DOI [10.1016/j.actamat.2006.07.003, 10.0116/j.actamat.2006.07.003]; Comini E, 2010, Materials Today, V13, DOI 10.1016/S1369-7021(10)70126-7; Han ZH, 2005, J PHYS CHEM B, V109, P2673, DOI 10.1021/jp046541i; Hur S.G., 2006, J PHYS CHEM B, V110, P1590; Ide Y., 2013, J NANOSCI NANOTECHNO, V13, P1; Khaorapapong N., 2011, Clay Science, V15, P147; Lagaly G, 2006, DEV CLAY SCI, V1, P309, DOI 10.1016/S1572-4352(05)01010-X; Lu QS, 2009, NANOSCALE RES LETT, V4, P646, DOI 10.1007/s11671-009-9294-x; Mihai GD, 2010, J MATER SCI, V45, P5786, DOI 10.1007/s10853-010-4652-8; Mogyorosi K., 2001, PROG COLLOID POLYM S, V117, P88; OGAWA M, 1993, LANGMUIR, V9, P1529, DOI 10.1021/la00030a018; OGAWA M, 1995, LANGMUIR, V11, P4598, DOI 10.1021/la00011a068; Ogawa M., 2004, HDB LAYERED MAT, P191; Ogawa M, 2010, CRYST GROWTH DES, V10, P2068, DOI 10.1021/cg900922v; OGAWA M, 1992, CLAY CLAY MINER, V40, P485, DOI 10.1346/CCMN.1992.0400501; Okada T., 2011, Clay Science, V15, P103; Ontam A, 2012, COLLOID SURFACE A, V411, P27, DOI 10.1016/j.colsurfa.2012.06.038; Ontam A, 2011, J COLLOID INTERF SCI, V357, P554, DOI 10.1016/j.jcis.2011.02.016; Ozawa K, 2009, MATER LETT, V63, P366, DOI 10.1016/j.matlet.2008.10.038; Pimchan P, 2014, APPL CLAY SCI, V95, P310, DOI 10.1016/j.clay.2014.04.033; PINNAVAI.TJ, 1971, J PHYS CHEM-US, V75, P3957, DOI 10.1021/j100695a007; Sasai R, 2003, J PHOTOCH PHOTOBIO A, V155, P223, DOI 10.1016/S1010-6030(02)00372-6; Sasai R, 2008, J CERAM SOC JPN, V116, P205, DOI 10.2109/jcersj2.116.205; VAIA RA, 1994, CHEM MATER, V6, P1017, DOI 10.1021/cm00043a025; Vaishnavi TS, 2008, MATER LETT, V62, P1649, DOI 10.1016/j.matlet.2007.09.051; van Olphen H., 1977, INTRO CLAY COLLOID C; Yadav RS, 2009, STRUCT CHEM, V20, P1093, DOI 10.1007/s11224-009-9514-0	59	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-1317	1872-9053		APPL CLAY SCI	Appl. Clay Sci.	MAR	2015	105						236	242		10.1016/j.clay.2015.01.001		7	Chemistry, Physical; Materials Science, Multidisciplinary; Mineralogy	Chemistry; Materials Science; Mineralogy	CC2PO	WOS:000350187300031		
J	Takano, H; Hagiwara, K; Ueda, K				Takano, Hideaki; Hagiwara, Kenta; Ueda, Kenji			Fundamental role of cobalamin biosynthesis in the developmental growth of Streptomyces coelicolor A3 (2)	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Cobalamin; Streptomyces; Antibiotic production; Cell differentiation; Riboswitch	ANTIBIOTIC BIOSYNTHESIS; GENE-REGULATION; RNA-POLYMERASE; A3(2); VITAMIN-B-12; CINNAMONENSIS; TRANSCRIPTION; CATALYSIS; SUBUNIT; DOMAIN	Cobalamin (Cbl) (synonym, vitamin B12) is the cobalt-containing cofactor produced only by some prokaryotes. Streptomyces is an effective Cbl producer. To study the role of Cbl production in Streptomyces, a knockout mutant for Cbl biosynthesis (cob) was generated in Streptomyces coelicolor A3 (2). The growth of the mutant was similar to that of the wild type in a rich medium, but inhibited in minimal medium, suggesting the involvement of Cbl in some step of primary metabolism. Methionine synthesis catalyzed by MetH, the Cbl-dependent methionine synthase, is a candidate. However, supplementing the minimal medium with methionine did not rescue the growth of the cob mutant, indicating that the availability of Cbl affects another primary function. Transcriptional analysis confirmed that the mutant induced metE encoding an alternative Cbl-independent methionine synthase, probably due to the Cbl-dependent riboswitch mechanism. The cob mutant produced low levels of pigment antibiotics and formed fewer aerial mycelium and spores in a rich medium, suggesting that a Cbl-dependent mechanism controls development. A similar developmental defect was observed for a knockout mutant for SCO4800, encoding the putative Cbl-dependent isobutyryl-CoA mutase (Icm) small subunit. Since the knockout of the Icm large subunit (SCO5415) did not affect the developmental phenotype, SCO4800 likely regulates development independently from SCO5415. Effective Cbl production is fundamental to the diverse functions underlying the complex developmental life cycle of S. coelicolor A3 (2).	[Takano, Hideaki; Hagiwara, Kenta; Ueda, Kenji] Nihon Univ, Coll Bioresource Sci, Life Sci Res Ctr, Fujisawa, Kanagawa 2520880, Japan	Takano, H (reprint author), Nihon Univ, Coll Bioresource Sci, Life Sci Res Ctr, 1866 Kameino, Fujisawa, Kanagawa 2520880, Japan.	takano.hideaki@nihon-u.ac.jp			Strategic Research Foundation; Ministry of Education, Culture, Sports, Science and Technology, Japan [23780093]; Noda Institute for Scientific Research; Institute for Fermentation, Osaka, Japan; Foundation NAGASE Science Technology Development; Charitable Trust of the Araki Medical and Biochemical Research Memorial Fund	We thank Haruo Ikeda for providing pKU463. This study was supported, in part, by a grant of Strategic Research Foundation and a Grant-in-Aid for the encouragement of young scientists (no. 23780093) of the Ministry of Education, Culture, Sports, Science and Technology, Japan, a grant from the Noda Institute for Scientific Research, the Institute for Fermentation, Osaka, Japan, and the Foundation NAGASE Science Technology Development and the Charitable Trust of the Araki Medical and Biochemical Research Memorial Fund.	Takano H, 2011, J BACTERIOL, V193, P2451, DOI 10.1128/JB.01125-10; Klug G, 2014, MOL MICROBIOL, V91, P635, DOI 10.1111/mmi.12490; Kelemen GH, 2001, MOL MICROBIOL, V40, P804, DOI 10.1046/j.1365-2958.2001.02417.x; Ratnatilleke A, 1999, J BIOL CHEM, V274, P31679, DOI 10.1074/jbc.274.44.31679; Bystrykh LV, 1996, J BACTERIOL, V178, P2238; Liu G, 2013, MICROBIOL MOL BIOL R, V77, P112, DOI 10.1128/MMBR.00054-12; Ortiz-Guerrero JM, 2011, P NATL ACAD SCI USA, V108, P7565, DOI 10.1073/pnas.1018972108; BROWN KL, 1992, MOL MICROBIOL, V6, P1133, DOI 10.1111/j.1365-2958.1992.tb01551.x; Hu HF, 2002, J BACTERIOL, V184, P3984, DOI 10.1128/JB.184.14.3984-3991.2002; Takano H, 2005, J BACTERIOL, V187, P1825, DOI 10.1128/JB.187.5.1825-1832.2005; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; Gruber K, 2011, CHEM SOC REV, V40, P4346, DOI 10.1039/c1cs15118e; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Zhang WW, 2001, J BACTERIOL, V183, P2071, DOI 10.1128/JB.183.6.2071-2080.2001; Chater KF, 2010, FEMS MICROBIOL REV, V34, P171, DOI 10.1111/j.1574-6976.2009.00206.x; Kieser T., 2000, PRACTICAL STREPTOMYC; Sambrook J., 2012, MOL CLONING LAB MANU; SAUNDERS AP, 1952, J BACTERIOL, V64, P725; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; Warner DF, 2007, J BACTERIOL, V189, P3655, DOI 10.1128/JB.00040-07	21	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	MAR	2015	99	5					2329	2337		10.1007/s00253-014-6325-z		9	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CC0ME	WOS:000350029000025		
J	Tran, KT; Maeda, T; Sanchez-Torres, V; Wood, TK				Kien Trung Tran; Maeda, Toshinari; Sanchez-Torres, Viviana; Wood, Thomas K.			Beneficial knockouts in Escherichia coli for producing hydrogen from glycerol	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Glycerol; Hydrogen production; Escherichia coli; Transposon mutagenesis	CRUDE GLYCEROL; TRANSPOSON MUTAGENESIS; ANAEROBIC FERMENTATION; FORMATE DEHYDROGENASE; MOLECULAR ANALYSIS; ENTERIC BACTERIA; SHIKIMATE KINASE; INSERTION SITES; METABOLISM; K-12	Glycerol is an inexpensive and abundant source for biofuel production on a large scale. Escherichia coli is a robust bacterium for producing hydrogen; however, its hydrogen productivity from glycerol is low. In this study, we conducted random transposon mutagenesis to identify uncharacterized genes whose inactivation is beneficial for hydrogen production from glycerol. Through screening, four mutant strains were found that are able to have from 1.3- to 1.6-fold higher hydrogen productivity (mu mol H-2/mg protein) than that of their parent strain (p < 0.05). These mutations were identified as aroM, gatZ, ycgR, and yfgI. The hydrogen yield (mol H-2/mol glycerol consumed) of the aroM, gatZ, ycgR, and yfgI strains was 1.7-, 1.4-, 2.4-, and 2.1-fold higher than that of their parent strain, respectively. Moreover, a single disruption in these genes resulted in a faster cell growth and glycerol consumption under anaerobic conditions. In E. coli, AroM is predicted to be involved in the shikimate pathway, GatZ is tagatose-1,6-bisphosphate aldolase 2 which converts dihydroxyacetone phosphate to 1,6-biphosphate, and YcgR acts as a molecular brake limiting the swimming speed and ATP consumption. So far, the function of YfgI in general and in hydrogen production in particular remains unknown.	[Kien Trung Tran; Maeda, Toshinari] Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Dept Biol Funct Engn, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan; [Maeda, Toshinari] Kyushu Inst Technol, Res Ctr Adv Ecofitting Technol, Wakamatsu Ku, Kitakyushu, Fukuoka 8080196, Japan; [Sanchez-Torres, Viviana] Univ Ind Santander, Escuela Ingn Quim, Bucaramanga 678, Santander, Colombia; [Wood, Thomas K.] Penn State Univ, Dept Chem Engn, University Pk, PA 16802 USA	Maeda, T (reprint author), Kyushu Inst Technol, Grad Sch Life Sci & Syst Engn, Dept Biol Funct Engn, Wakamatsu Ku, 2-4 Hibikino, Kitakyushu, Fukuoka 8080196, Japan.	toshi.maeda@life.kyutech.ac.jp		Wood, Thomas/0000-0002-6258-529X	Japan Student Services Organization; JGC-S Scholarship Foundation	The authors would like to thank the Japan Student Services Organization for providing the scholarship of K. T. Tran during this study. This research was supported by the JGC-S Scholarship Foundation. Many thanks to the NBRP-E. coli at the National Institute of Genetics (Japan) for providing Keio mutant strains.	AHMED A, 1985, GENE, V39, P305, DOI 10.1016/0378-1119(85)90328-2; Tran KT, 2014, APPL MICROBIOL BIOT, V98, P4757, DOI 10.1007/s00253-014-5600-3; Bagramyan K, 2002, FEBS LETT, V516, P172, DOI 10.1016/S0014-5793(02)02555-3; Zhang XL, 2010, APPL ENVIRON MICROB, V76, P2397, DOI 10.1128/AEM.02902-09; Trinh CT, 2009, APPL ENVIRON MICROB, V75, P6696, DOI 10.1128/AEM.00670-09; Riley M, 2006, NUCLEIC ACIDS RES, V34, P1, DOI 10.1093/nar/gkj405; Knobloch JKM, 2003, APPL ENVIRON MICROB, V69, P5812, DOI 10.1128/AEM.69.10.5812-5818.2003; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49; Sanchez-Torres V, 2013, INT J HYDROGEN ENERG, V38, P3905, DOI 10.1016/j.ijhydene.2013.01.031; Kim DH, 2011, BIORESOURCE TECHNOL, V102, P8423, DOI 10.1016/j.biortech.2011.02.113; Dobson R, 2012, J IND MICROBIOL BIOT, V39, P217, DOI 10.1007/s10295-011-1038-0; Paul K, 2010, MOL CELL, V38, P128, DOI 10.1016/j.molcel.2010.03.001; Maeda T, 2008, MICROB BIOTECHNOL, V1, P30, DOI 10.1111/j.1751-7915.2007.00003.x; Blankschien MD, 2010, METAB ENG, V12, P409, DOI 10.1016/j.ymben.2010.06.002; Durnin G, 2009, BIOTECHNOL BIOENG, V103, P148, DOI 10.1002/bit.22246; Brinkkotter A, 2002, ARCH MICROBIOL, V177, P410, DOI 10.1007/s00203-002-0406-6; Kim S, 2009, INT J HYDROGEN ENERG, V34, P7417, DOI 10.1016/j.ijhydene.2009.05.053; AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; Zhou JD, 2013, NUCLEIC ACIDS RES, V41, pD613, DOI 10.1093/nar/gks1235; Gonzalez R, 2008, METAB ENG, V10, P234, DOI 10.1016/j.ymben.2008.05.001; Hansen CF, 2009, ANIM PROD SCI, V49, P154, DOI 10.1071/EA08210; Clomburg JM, 2011, BIOTECHNOL BIOENG, V108, P867, DOI 10.1002/bit.22993; Hamer L, 2001, CURR OPIN CHEM BIOL, V5, P67, DOI 10.1016/S1367-5931(00)00162-9; Boehm A, 2010, CELL, V141, P107, DOI 10.1016/j.cell.2010.01.018; Altaras NE, 1999, APPL ENVIRON MICROB, V65, P1180; HERRMANN KM, 1995, PLANT PHYSIOL, V107, P7, DOI 10.1104/pp.107.1.7; Girgis HS, 2007, PLOS GENET, V3, P1644, DOI 10.1371/journal.pgen.0030154; Yazdani SS, 2008, METAB ENG, V10, P340, DOI 10.1016/j.ymben.2008.08.005; Kim DH, 2006, INT J HYDROGEN ENERG, V31, P2158, DOI 10.1016/j.ijhydene.2006.02.012; Cai JL, 2014, BIORESOURCE TECHNOL, V154, P254, DOI 10.1016/j.biortech.2013.12.057; Das D, 2001, INT J HYDROGEN ENERG, V26, P13, DOI 10.1016/S0360-3199(00)00058-6; Anand P, 2012, NEW BIOTECHNOL, V29, P199, DOI 10.1016/j.nbt.2011.05.010; Clomburg JM, 2013, TRENDS BIOTECHNOL, V31, P20, DOI 10.1016/j.tibtech.2012.10.006; Nobelmann B, 1996, J BACTERIOL, V178, P6790; Hu HB, 2010, BIOCHEM BIOPH RES CO, V391, P1033, DOI 10.1016/j.bbrc.2009.12.013; Ma Q, 2012, ISME J, V6, P1356, DOI 10.1038/ismej.2011.210; Murarka A, 2008, APPL ENVIRON MICROB, V74, P1124, DOI 10.1128/AEM.02192-07; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Maeda T, 2007, APPL MICROBIOL BIOT, V77, P879, DOI 10.1007/s00253-007-1217-0; Bongaerts J, 2001, METAB ENG, V3, P289, DOI 10.1006/mben.2001.0196; Liu HY, 2012, INT J HYDROGEN ENERG, V37, P8282, DOI 10.1016/j.ijhydene.2012.02.065; Armitage JP, 2010, CELL, V141, P24, DOI 10.1016/j.cell.2010.03.023; Baba Tomoya, 2006, Mol Syst Biol, V2; CHAO YP, 1993, J BACTERIOL, V175, P6939; Das S, 2005, J MICROBIOL METH, V63, P89, DOI 10.1016/j.mimet.2005.02.011; DEFEYTER RC, 1986, J BACTERIOL, V165, P226; ELY B, 1979, J BACTERIOL, V138, P933; ENOCH HG, 1975, J BIOL CHEM, V250, P6693; Ko M, 2000, J MOL BIOL, V303, P371, DOI 10.1006/jmbi.2000.4147; Ma C, 2012, INT J HYDROGEN ENERG, V37, P12229, DOI 10.1016/j.ijhydene.2012.05.148; Maeda T, 2009, J HAZARD MATER, V168, P656, DOI 10.1016/j.jhazmat.2009.02.067; Maeda T, 2008, APPL MICROBIOL BIOT, V79, P77, DOI 10.1007/s00253-008-1416-3; Mazumdar S, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-7; Nakata PA, 2002, PLANT SCI, V162, P267, DOI 10.1016/S0168-9452(01)00566-0; NOBELMANN B, 1995, BBA-GENE STRUCT EXPR, V1262, P69, DOI 10.1016/0167-4781(95)00053-J; PANNEKOEK H, 1980, GENE, V12, P51, DOI 10.1016/0378-1119(80)90015-3; Poladyan A, 2013, CURR MICROBIOL, V66, P49, DOI 10.1007/s00284-012-0240-2; Reizer J, 1996, MICROBIOL-SGM, V142, P231; SAIKUSA T, 1987, AGR BIOL CHEM TOKYO, V51, P1893; Sanchez-Torres V, 2009, APPL ENVIRON MICROB, V75, P5639, DOI 10.1128/AEM.00638-09; Skunca N, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002852; Tokumoto H, 2012, BIORESOURCE TECHNOL, V107, P327, DOI 10.1016/j.biortech.2011.12.051; Trchounian K, 2011, INT J HYDROGEN ENERG, V36, P4323, DOI 10.1016/j.ijhydene.2010.12.128; TRUNIGER V, 1994, J BACTERIOL, V176, P1796; Wheeler D, 2007, COMP GENOMICS, V1; Yamane Taro, 1967, STAT INTRO ANAL; Yang FX, 2012, BIOTECHNOL BIOFUELS, V5, DOI 10.1186/1754-6834-5-13; Yusoff MZM, 2013, BIOCHEM BIOPH RES CO, V439, P576, DOI 10.1016/j.bbrc.2013.09.016	68	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	MAR	2015	99	6					2573	2581		10.1007/s00253-014-6338-7		9	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CC4YJ	WOS:000350362500009		
J	Ikeda, M; Noguchi, N; Ohshita, M; Senoo, A; Mitsuhashi, S; Takeno, S				Ikeda, Masato; Noguchi, Norio; Ohshita, Masakazu; Senoo, Akihiro; Mitsuhashi, Satoshi; Takeno, Seiki			A third glucose uptake bypass in Corynebacterium glutamicum ATCC 31833	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Corynebacterium glutamicum; Phosphotransferase system; Glucose uptake bypass; beta-Glucoside-PTS; bglF	UNCOUPLED ENZYME-IIGLC; PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; BETA-GLUCOSIDE; SUGAR-TRANSPORT; PHOSPHORYLATION; IDENTIFICATION; OVERPRODUCTION; SPECIFICITY	In Corynebacterium glutamicum, the phosphoenolpyruvate-dependent sugar phosphotransferase system (PTS) has long been the only known glucose uptake system, but we recently found suppressor mutants emerging from a PTS-negative strain of C. glutamicum ATCC 31833 on glucose agar plates, and identified two alternative potential glucose uptake systems, the myo-inositol transporters encoded by iolT1 and iolT2. The expression of either gene renders the PTS-negative strain WT Delta ptsH capable of growing on glucose. In the present study, we found a suppressor strain that still grew on glucose even after the iolT1 and iolT2 genes were both disrupted under the PTS-negative background. Whole-genome sequencing of the suppressor strain SPH1 identified a G-to-T exchange at 134 bp upstream of the bglF gene encoding an EII component of the beta-glucoside-PTS, which is found in limited wild-type strains of C. glutamicum. Introduction of the mutation into strain WT Delta ptsH allowed the PTS-negative strain to grow on glucose. Reverse transcription-quantitative PCR analysis revealed that the mutation upregulates the bglF gene by approximately 11-fold. Overexpression of bglF under the gapA promoter in strain WT Delta ptsH rendered the strain capable of growing on glucose, and deletion of bglF in strain SPH1 abolished the growth again, proving that bglF is responsible for glucose uptake in the suppressor strain. Simultaneous disruption of three glucokinase genes, glk (Cgl2185, NCgl2105), ppgK (Cgl1910, NCgl1835), and Cgl2647 (NCgl2558), in strain SPH1 resulted in no growth on glucose. Plasmid-mediated expression of any of the three genes in the triple-knockout mutant restored the growth on glucose. These results indicate that C. glutamicum ATCC 31833 has an additional non-PTS glucose uptake route consisting of the bglF-specified EII permease and native glucokinases.	[Ikeda, Masato; Noguchi, Norio; Ohshita, Masakazu; Takeno, Seiki] Shinshu Univ, Fac Agr, Dept Biosci & Biotechnol, Nagano 3994598, Japan; [Senoo, Akihiro; Mitsuhashi, Satoshi] Kyowa Hakko Bio Co Ltd, Bioproc Dev Ctr, Tsukuba, Ibaraki 3050841, Japan	Ikeda, M (reprint author), Shinshu Univ, Fac Agr, Dept Biosci & Biotechnol, Nagano 3994598, Japan.	m_ikeda@shinshu-u.ac.jp					Lindner SN, 2010, APPL MICROBIOL BIOT, V87, P703, DOI 10.1007/s00253-010-2568-5; Mitsuhashi S, 2004, APPL MICROBIOL BIOT, V63, P592, DOI 10.1007/s00253-003-1402-8; Moon MW, 2007, J MOL MICROB BIOTECH, V12, P43, DOI 10.1159/000096458; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Takeno S, 2007, APPL MICROBIOL BIOT, V75, P1173, DOI 10.1007/s00253-007-0926-8; Lindner SN, 2011, APPL ENVIRON MICROB, V77, P3571, DOI 10.1128/AEM.02713-10; Flores N, 1996, NAT BIOTECHNOL, V14, P620, DOI 10.1038/nbt0596-620; Gourdon P, 2003, J BIOTECHNOL, V104, P77, DOI 10.1016/S0168-1656(03)00165-2; Ikeda M, 2012, APPL MICROBIOL BIOT, V96, P1191, DOI 10.1007/s00253-012-4488-z; Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1; Tanaka Y, 2011, J BACTERIOL, V193, P349, DOI 10.1128/JB.01123-10; Ikeda M, 2013, APPL ENVIRON MICROB, V79, P4586, DOI 10.1128/AEM.00828-13; Parche S, 2001, J MOL MICROB BIOTECH, V3, P423; Tanaka Y, 2009, MICROBIOL-SGM, V155, P3652, DOI 10.1099/mic.0.029496-0; Ohnishi J, 2002, APPL MICROBIOL BIOT, V58, P217, DOI 10.1007/s00253-001-0883-6; Kind S, 2011, METAB ENG, V13, P617, DOI 10.1016/j.ymben.2011.07.006; Takeno S, 2013, APPL ENVIRON MICROB, V79, P6776, DOI 10.1128/AEM.02003-13; Eggeling L., 2005, HDB CORYNEBACTERIUM; Hayashi M, 2002, BIOSCI BIOTECH BIOCH, V66, P1337, DOI 10.1271/bbb.66.1337; Ikeda M, 2011, APPL MICROBIOL BIOT, V90, P1443, DOI 10.1007/s00253-011-3210-x; Ikeda M, 2013, US Patent, Patent No. 8530203; Ikeda M, 2013, CORYNEBACTERIUM GLUT, V23, P107; Katayama S, 2013, FOOD CHEM, V138, P757, DOI 10.1016/j.foodchem.2012.10.076; Kinoshita S, 1978, PRIMARY PRODUCTS MET, P209; Kotrba P, 2003, MICROBIOL-SGM, V149, P1569, DOI 10.1099/mic.0.26053-0; Lindner Steffen N, 2011, Bioeng Bugs, V2, P291, DOI 10.4161/bbug.2.5.17116; MORI M, 1987, AGR BIOL CHEM TOKYO, V51, P2671; Park SY, 2000, FEMS MICROBIOL LETT, V188, P209, DOI 10.1111/j.1574-6968.2000.tb09195.x; POSTMA PW, 1980, J BACTERIOL, V141, P476; POSTMA PW, 1981, J BACTERIOL, V147, P382; RUIJTER GJG, 1991, ARCH MICROBIOL, V155, P234, DOI 10.1007/BF00252206; RUIJTER GJG, 1990, J BACTERIOL, V172, P4783; RUIJTER GJG, 1992, J BACTERIOL, V174, P2843; Sambrook J, 2001, MOL CLONING LAB MANU; Schilling O, 2006, NUCLEIC ACIDS RES, V34, P6102, DOI 10.1093/nar/gkl733; SCHNETZ K, 1990, J BIOL CHEM, V265, P13464; Steen JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088688	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	MAR	2015	99	6					2741	2750		10.1007/s00253-014-6323-1		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CC4YJ	WOS:000350362500024		
J	Takabatake, A; Kawazoe, N; Izawa, S				Takabatake, Akiko; Kawazoe, Nozomi; Izawa, Shingo			Plasma membrane proteins Yro2 and Mrh1 are required for acetic acid tolerance in Saccharomyces cerevisiae	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Acetic acid stress; Bioethanol; Lignocellulosic biomass; Haa1; Saccharomyces cerevisiae	TRANSCRIPTIONAL ACTIVATOR; OXIDATIVE STRESS; ZYGOSACCHAROMYCES-BAILII; GENE-EXPRESSION; LACTIC-ACID; WEAK ACIDS; GROWTH; FERMENTATION; GENOME; IDENTIFICATION	Yro2 and its paralogous protein Mrh1 of Saccharomyces cerevisiae have seven predicted transmembrane domains and predominantly localize to the plasma membrane. Their physiological functions and regulation of gene expression have not yet been elucidated in detail. We herein demonstrated that MRH1 was constitutively expressed, whereas the expression of YRO2 was induced by acetic acid stress and entering the stationary phase. Fluorescence microscopic analysis revealed that Mrh1 and Yro2 were distributed as small foci in the plasma membrane under acetic acid stress conditions. The null mutants of these genes (mrh1a dagger, yro2a dagger, and mrh1a dagger yro2a dagger) showed delayed growth and a decrease in the productivity of ethanol in the presence of acetic acid, indicating that Yro2 and Mrh1 are involved in tolerance to acetic acid stress.	[Takabatake, Akiko; Kawazoe, Nozomi; Izawa, Shingo] Kyoto Inst Technol, Grad Sch Sci & Technol, Lab Microbial Technol, Kyoto 6068585, Japan	Izawa, S (reprint author), Kyoto Inst Technol, Grad Sch Sci & Technol, Lab Microbial Technol, Kyoto 6068585, Japan.	thioredoxin@kit.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [26292039]	We are grateful to Dr. D. Watanabe (Nara Inst. Sci. Technol.) for valuable discussion. This study was supported by a grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology (No. 26292039).	Graves T, 2006, J IND MICROBIOL BIOT, V33, P469, DOI 10.1007/s10295-006-0091-6; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; van Maris AJA, 2006, ANTON LEEUW INT J G, V90, P391, DOI 10.1007/s10482-006-9085-7; Yoshikawa K, 2011, YEAST, V28, P349, DOI 10.1002/yea.1843; Pampulha ME, 2000, FEMS MICROBIOL LETT, V184, P69, DOI 10.1016/S0378-1097(00)00022-7; Byrne KP, 2005, GENOME RES, V15, P1456, DOI 10.1101/gr.3672305; Mira NP, 2011, NUCLEIC ACIDS RES, V39, P6896, DOI 10.1093/nar/gkr228; MartinezPastor MT, 1996, EMBO J, V15, P2227; SIKORSKI RS, 1989, GENETICS, V122, P19; Stratford M, 2013, INT J FOOD MICROBIOL, V166, P126, DOI 10.1016/j.ijfoodmicro.2013.06.025; Kahana JA, 1998, MOL BIOL CELL, V9, P1741; Tanaka K, 2012, APPL ENVIRON MICROB, V78, P8161, DOI 10.1128/AEM.02356-12; Mira NP, 2014, DNA RES, V21, P299, DOI 10.1093/dnares/dst058; Mira NP, 2010, OMICS, V14, P587, DOI 10.1089/omi.2010.0048; Kamo K, 2012, BIOCHEM BIOPH RES CO, V420, P119, DOI 10.1016/j.bbrc.2012.02.126; Narendranath NV, 2001, J IND MICROBIOL BIOT, V26, P171, DOI 10.1038/sj.jim.7000090; Carmelo V, 1997, BBA-BIOMEMBRANES, V1325, P63, DOI 10.1016/S0005-2736(96)00245-3; CHESSON A, 1983, J SCI FOOD AGR, V34, P1330, DOI 10.1002/jsfa.2740341204; Kato K, 2011, YEAST, V28, P339, DOI 10.1002/yea.1842; Mira NP, 2010, OMICS, V14, P525, DOI 10.1089/omi.2010.0072; Sopko R, 2006, MOL CELL, V21, P319, DOI 10.1016/j.molcel.2005.12.011; Mollapour M, 2007, MOL CELL BIOL, V27, P6446, DOI 10.1128/MCB.02205-06; KUGE S, 1994, EMBO J, V13, P655; MAIORELLA B, 1983, BIOTECHNOL BIOENG, V25, P103, DOI 10.1002/bit.260250109; Palmqvist E, 2000, BIORESOURCE TECHNOL, V74, P17, DOI 10.1016/S0960-8524(99)00160-1; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Fernandes AR, 2005, BIOCHEM BIOPH RES CO, V337, P95, DOI 10.1016/j.bbrc.2005.09.010; Helle S, 2003, ENZYME MICROB TECH, V33, P786, DOI 10.1016/S0141-0229(03)00214-X; Bandhakavi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001598; Costa C, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00170; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; Haitani Y, 2012, J BIOSCI BIOENG, V114, P648, DOI 10.1016/j.jbiosc.2012.07.002; Inaba T, 2013, AMB EXPRESS, V3, DOI 10.1186/2191-0855-3-74; Iwaki A, 2012, BIOCHEM J, V446, P225, DOI 10.1042/BJ20120583; Kataja K, 2006, J MICROBIOL METH, V67, P102, DOI 10.1016/j.mimet.2006.03.013; Keller G, 2001, J BIOL CHEM, V276, P38697, DOI 10.1074/jbc.M107131200; Lee Y. Y., 1999, ADV BIOCHEM ENG BIOT, V65, P93; Mira NP, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475-2859-9-79; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Narendranath NV, 2001, J AM SOC BREW CHEM, V59, P187; Niu W, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000120; PHOWCHINDA O, 1995, BIOTECHNOL LETT, V17, P237, DOI 10.1007/BF00127996; Sugiyama K, 2000, BIOCHEM J, V352, P71, DOI 10.1042/0264-6021:3520071; Takahashi T, 2011, J TOXICOL SCI, V36, P859; Viela-Moura A, 2011, APPL MICROBIOL BIOT, V89, P271; Wu K, 2000, BBA-BIOMEMBRANES, V1463, P477, DOI 10.1016/S0005-2736(99)00255-2; Wu WS, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-439	48	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	MAR	2015	99	6					2805	2814		10.1007/s00253-014-6278-2		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	CC4YJ	WOS:000350362500030		
J	Aoyama, T; Fujita, Y; Madoba, K; Nankaku, M; Yamada, M; Tomita, M; Goto, K; Ikeguchi, R; Kakinoki, R; Matsuda, S; Nakamura, T; Toguchida, J				Aoyama, Tomoki; Fujita, Yasuko; Madoba, Katsuyuki; Nankaku, Manabu; Yamada, Minoru; Tomita, Motoko; Goto, Koji; Ikeguchi, Ryosuke; Kakinoki, Ryosuke; Matsuda, Shuichi; Nakamura, Takashi; Toguchida, Junya			Rehabilitation Program After Mesenchymal Stromal Cell Transplantation Augmented by Vascularized Bone Grafts for Idiopathic Osteonecrosis of the Femoral Head: A Preliminary Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Mesenchymal stromal cells; Osteonecrosis; Rehabilitation	STEM-CELLS; CONTACT PRESSURES; CORE DECOMPRESSION; IMPLANTATION; NECROSIS; INVIVO; HIP; OSTEOCYTES; STRENGTH; EXERCISE	Objective: To determine the feasibility and safety of implementing a 12-week rehabilitation program after mesenchymal stromal cell (MSC) transplantation augmented by vascularized bone grafting for idiopathic osteonecrosis (ION) of the femoral head. Design: A prospective case series. Setting: University clinical research laboratory. Participants: Participants (N=10) with ION who received MSC transplantation augmented by vascularized bone grafting. Intervention: A 12-week exercise program, which included range-of-motion (ROM) exercises, muscle-strengthening exercises, and aerobic training. Main Outcome Measures: Measures of ROM, muscle strength, Timed Up and Go test, and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) were collected before surgery and again at 6 and 12 months after surgery. Results: All participants completed the 12-week program. External rotation ROM as well as extensor and abductor muscle strength significantly improved 6 months after treatment compared with that before treatment (P<05). Significant improvements were also seen in physical function, role physical, and bodily pain subgroup scores of the SF-36 (P<.05). No serious adverse events occurred. Conclusions: This study demonstrates the feasibility and safety of a multiplex rehabilitation program after MSC transplantation and provides support for further study on the benefits of rehabilitation programs in regenerative medicine. (C) 2015 by the American Congress of Rehabilitation Medicine	[Aoyama, Tomoki; Yamada, Minoru] Kyoto Univ, Grad Sch Med, Dept Phys Therapy, Human Hlth Sci, Kyoto 6068507, Japan; [Fujita, Yasuko; Nankaku, Manabu; Kakinoki, Ryosuke; Matsuda, Shuichi; Nakamura, Takashi] Kyoto Univ Hosp, Rehabil Unit, Kyoto 606, Japan; [Madoba, Katsuyuki; Tomita, Motoko] Kyoto Hakuaikai Hosp, Dept Rehabil, Kyoto, Japan; [Goto, Koji; Ikeguchi, Ryosuke; Kakinoki, Ryosuke; Matsuda, Shuichi; Nakamura, Takashi] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto, Japan; [Toguchida, Junya] Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Kyoto, Japan; [Toguchida, Junya] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto, Japan	Aoyama, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Phys Therapy, Human Hlth Sci,Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	blue@hs.med.kyoto-u.ac.jp			Japan Society for the Promotion of Science [23300199, 26282154]	Supported by the Japan Society for the Promotion of Science (grant nos. 23300199 and 26282154).	Ambrosio F, 2010, TISSUE ENG PT A, V16, P839, DOI 10.1089/ten.TEA.2009.0113; Ambrosio F, 2011, PM&R, V3, pS59, DOI 10.1016/j.pmrj.2011.05.001; Steinert AF, 2012, STEM CELL TRANSL MED, V1, P237, DOI 10.5966/sctm.2011-0036; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Johnson AJ, 2014, CLIN ORTHOP RELAT R, V472, P617, DOI 10.1007/s11999-013-3220-3; Gangji V, 2004, J BONE JOINT SURG AM, V86A, P1153; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3; Zhao DW, 2012, BONE, V50, P325, DOI 10.1016/j.bone.2011.11.002; Hasegawa S, 2008, ARCH PHYS MED REHAB, V89, P1187, DOI 10.1016/j.apmr.2007.10.030; Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198; Aoyama T, 2014, TISSUE ENG PART B-RE, V20, P233, DOI [10.1089/ten.TEB.2014.0090, 10.1089/ten.teb.2014.0090]; Garman R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000653; Martin JR, 2013, CROAT MED J, V54, P219, DOI 10.3325/cmj.2013.54.219; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Neumayr LD, 2006, J BONE JOINT SURG AM, V88A, P2573, DOI 10.2106/JBJS.E.01454; Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthes.2004.04.002; Sen B, 2011, J BIOMECH, V44, P593, DOI 10.1016/j.jbiomech.2010.11.022; Kalyani RR, 2013, J AM GERIATR SOC, V61, P769, DOI 10.1111/jgs.12204; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136; STRICKLAND EM, 1992, PHYS THER, V72, P691; Malizos KN, 2007, EUR J RADIOL, V63, P16, DOI 10.1016/j.ejrad.2007.03.019; Mont MA, 2010, J BONE JOINT SURG AM, V92A, P2165, DOI 10.2106/JBJS.I.00575; Burgers TA, 2013, BONE, V54, P244, DOI 10.1016/j.bone.2013.02.022; Gangji V, 2011, BONE, V49, P1005, DOI 10.1016/j.bone.2011.07.032; Klein-Nulend J, 2012, EUR CELLS MATER, V24, P278; Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79; HODGE WA, 1986, P NATL ACAD SCI USA, V83, P2879, DOI 10.1073/pnas.83.9.2879; Ishizaka M, 1997, CLIN ORTHOP RELAT R, P140; Kaushik AP, 2012, WORLD J ORTHOP, V3, P49; KLEINNULEND J, 1995, FASEB J, V9, P441; KREBS DE, 1991, PHYS THER, V71, P301; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; Marti-Carvajal AJ, 2012, COCHRANE DB SYST REV, V5; McKay D, 2013, PEDIATR EXERC SCI, V25, P221; Mont MA, 1996, CLIN ORTHOP RELAT R, P169; Rastogi S, 2013, Musculoskelet Surg, V97, P223, DOI 10.1007/s12306-013-0273-0; Sugano Nobuhiko, 2002, J Orthop Sci, V7, P601, DOI 10.1007/s007760200108; Takao M, 2006, J ORTHOP RES, V24, P1231, DOI 10.1002/jor.20134; Usui T, 2003, Orthod Craniofac Res, V6 Suppl 1, P163, DOI 10.1034/j.1600-0544.2003.250.x; Wang Tao, 2014, Eur J Orthop Surg Traumatol, V24, P197, DOI 10.1007/s00590-012-1161-2	41	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2015	96	3					532	539		10.1016/j.apmr.2014.09.040		8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CC3QZ	WOS:000350265400022		
J	Wakana, N; Irie, D; Kikai, M; Terada, K; Yamamoto, K; Kawahito, H; Kato, T; Ogata, T; Ueyama, T; Matoba, S; Yamada, H				Wakana, Noriyuki; Irie, Daisuke; Kikai, Masakazu; Terada, Kensuke; Yamamoto, Keita; Kawahito, Hiroyuki; Kato, Taku; Ogata, Takehiro; Ueyama, Tomomi; Matoba, Satoaki; Yamada, Hiroyuki			Maternal High-Fat Diet Exaggerates Atherosclerosis in Adult Offspring by Augmenting Periaortic Adipose Tissue-Specific Proinflammatory Response	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						adipose tissue; atherosclerosis; developmental biology; inflammation; macrophage	ACTIVATED-RECEPTOR-GAMMA; CARDIOVASCULAR-DISEASE; MACROPHAGE ACCUMULATION; EPIGENETIC CHANGES; FOLLOW-UP; OBESITY; INFLAMMATION; EXPRESSION; PREGNANCY; MOUSE	Objective Maternal obesity elicits offspring's metabolic disorders via developmental modifications of visceral adipose tissue; however, its effect on atherogenesis remains undefined. Perivascular adipose tissue has recently been implicated in vascular remodeling and vasoreactivity. We hypothesize that developmental modifications of perivascular adipose tissue by maternal high-fat diet (HFD) exposure promotes atherosclerosis in adult offspring. Approach and Results Eight-week-old female apolipoprotein E-deficient mice were fed an HFD or normal diet (ND) during gestation and lactation. Offspring were fed a high-cholesterol diet from 8 weeks of age. Twenty-week-old male offspring of HFD-fed dams (O-HFD) showed a 2.1-fold increase in atherosclerotic lesion of the entire aorta compared with those of ND-fed dams (O-ND). Although mRNA expressions of interleukin-6, tumor necrosis factor, and monocyte chemotactic protein-1 and accumulation of macrophages in epididymal white adipose tissue were less in O-HFD than in O-ND, thoracic periaortic adipose tissue (tPAT) showed an exaggerated inflammatory response in O-HFD. Intra-abdominal transplantation of tPAT from 8-week-old O-HFD alongside the distal abdominal aorta exaggerated atherosclerosis development of the infrarenal aorta in recipient apolipoprotein E-deficient mice compared with tPAT from O-ND (210%, P<0.01). Although macrophage accumulation was rarely detected in tPAT of 8-week-old offspring, mRNA expression and protein levels of macrophage colony-stimulating factor were markedly elevated in O-HFD (2.3-fold, 3.3-fold, respectively, P<0.05), suggesting that increased macrophage colony-stimulating factor expression contributes to the augmented accumulation of macrophages, followed by the enhanced proinflammatory response. Conclusions Our findings demonstrate that maternal HFD exaggerates atherosclerosis development in offspring by augmenting tPAT-specific inflammatory response proceeded by an increased expression of macrophage colony-stimulating factor.	[Wakana, Noriyuki; Irie, Daisuke; Kikai, Masakazu; Terada, Kensuke; Yamamoto, Keita; Kawahito, Hiroyuki; Kato, Taku; Ogata, Takehiro; Ueyama, Tomomi; Matoba, Satoaki; Yamada, Hiroyuki] Kyoto Prefectural Univ Med, Dept Cardiovasc Med, Kyoto 6028566, Japan	Yamada, H (reprint author), Kyoto Prefectural Univ Med, Dept Cardiovasc Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	hiyamada@koto.kpu-m.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [C: KAKENHI-24591120]	This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (C: KAKENHI-24591120).	Gaillard R, 2014, HYPERTENSION, V63, P683, DOI 10.1161/HYPERTENSIONAHA.113.02671; Suganami T, 2010, J LEUKOCYTE BIOL, V88, P33, DOI 10.1189/jlb.0210072; Hopkins PN, 2013, PHYSIOL REV, V93, P1317, DOI 10.1152/physrev.00004.2012; Kawahito H, 2013, AM J PHYSIOL-HEART C, V305, pH667, DOI 10.1152/ajpheart.00053.2013; Olson NC, 2012, J CLIN ENDOCR METAB, V97, P1032, DOI 10.1210/jc.2011-2155; Turunen MP, 2011, CARDIOVASC RES, V90, P441, DOI 10.1093/cvr/cvr109; Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077; Henrichot E, 2005, ARTERIOSCL THROM VAS, V25, P2594, DOI 10.1161/01.ATV.0000188508.40052.35; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Baker SJ, 2007, ONCOGENE, V26, P6724, DOI 10.1038/sj.onc.1210757; Borengasser SJ, 2013, ENDOCRINOLOGY, V154, P4113, DOI 10.1210/en.2012-2255; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Hochner H, 2012, CIRCULATION, V125, P1381, DOI 10.1161/CIRCULATIONAHA.111.070060; Galic S, 2010, MOL CELL ENDOCRINOL, V316, P129, DOI 10.1016/j.mce.2009.08.018; Chang L, 2012, CIRCULATION, V126, P1067, DOI 10.1161/CIRCULATIONAHA.112.104489; Cooper ME, 2010, CIRC RES, V107, P1403, DOI 10.1161/CIRCRESAHA.110.223552; Turunen MP, 2009, BBA-GEN SUBJECTS, V1790, P886, DOI 10.1016/j.bbagen.2009.02.008; Bekkering S, 2014, ARTERIOSCL THROM VAS, V34, P1731, DOI 10.1161/ATVBAHA.114.303887; Dahlhoff M, 2014, BBA-MOL BASIS DIS, V1842, P304, DOI 10.1016/j.bbadis.2013.11.021; Margaritis M, 2013, CIRCULATION, V127, P2209, DOI 10.1161/CIRCULATIONAHA.112.001133; Muhlhausler BS, 2007, ENDOCRINOLOGY, V148, P878, DOI 10.1210/en.2006-1115; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI2000319246; van Kampen E, 2014, J LEUKOCYTE BIOL, V96, P833, DOI 10.1189/jlb.1A0114-017R; Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011; Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4; Lee J, 2013, ARCH PHARM RES, V36, P208, DOI 10.1007/s12272-013-0023-8; Owen MK, 2013, CIRCULATION, V128, P9, DOI 10.1161/CIRCULATIONAHA.112.001238; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Mattu HS, 2013, J ENDOCRINOL, V216, pT17, DOI 10.1530/JOE-12-0232; Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031; Marchesi C, 2009, HYPERTENSION, V54, P1384, DOI 10.1161/HYPERTENSIONAHA.109.138305; Aiken CE, 2013, REPRODUCTION, V145, pR1, DOI 10.1530/REP-11-0489; Chan GC, 2005, J IMMUNOL, V175, P3846; Robbins CS, 2013, NAT MED, V19, P1166, DOI 10.1038/nm.3258; Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839; Chatterjee TK, 2009, CIRC RES, V104, P541, DOI 10.1161/CIRCRESAHA.108.182998; Mingrone G, 2008, DIABETES CARE, V31, P1872, DOI 10.2337/dc08-0432; Takaoka M, 2009, CIRC RES, V105, P906, DOI 10.1161/CIRCRESAHA.109.199653; Elahi MM, 2009, BRIT J NUTR, V102, P514, DOI 10.1017/S000711450820749X; Fox CS, 2010, CIRC-CARDIOVASC IMAG, V3, P515, DOI 10.1161/CIRCIMAGING.110.958884; Gehrke S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082516; Khalil CA, 2014, THER ADV CHRONIC DIS, V5, P178; Masuyama H, 2012, ENDOCRINOLOGY, V153, P2823, DOI 10.1210/en.2011-2161; Rajsheker S, 2009, CURR OPIN PHARMACOL, V10, P1; Reynolds RM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4539; Roth P, 1996, J LEUKOCYTE BIOL, V59, P817; Shaposhnik Z, 2010, J LIPID RES, V51, P1962, DOI 10.1194/jlr.M005215; Singer Kanakadurga, 2014, Mol Metab, V3, P664, DOI 10.1016/j.molmet.2014.06.005; Vieira-Potter VJ, 2014, CELL MICROBIOL, V16, P1484, DOI 10.1111/cmi.12336; Yu ZB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061627	52	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	MAR	2015	35	3					558	569		10.1161/ATVBAHA.114.305122		12	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CC5JV	WOS:000350395800014		
J	Hanawa, T; Tomisaka, K				Hanawa, Tomoyuki; Tomisaka, Kohji			STRUCTURE AND STABILITY OF FILAMENTARY CLOUDS SUPPORTED BY A LATERAL MAGNETIC FIELD	ASTROPHYSICAL JOURNAL			English	Article						ISM: clouds; ISM: magnetic fields; magnetohydrodynamics (MHD); stars: formation	STAR-FORMATION; NONHOMOLOGOUS CONTRACTION; ISOTHERMAL CLOUDS; INTERCLOUD MEDIUM; DARK CLOUD; EQUILIBRIA; TAURUS; FRAGMENTATION; EVOLUTIONS; COLLAPSE	We have constructed two types of analytical models for an isothermal filamentary cloud supported mainly by magnetic tension. The first one describes an isolated cloud while the second considers filamentary clouds spaced periodically. Both models assume that the filamentary clouds are highly flattened. The former is proved to be the asymptotic limit of the latter in which each filamentary cloud is much thinner than the distance to the neighboring filaments. We show that these models reproduce the main features of the 2D equilibrium model of Tomisaka for a filamentary cloud threaded by a perpendicular magnetic field. It is also shown that the critical mass to flux ratio is M/Phi = (2 pi root G)(-1), where M, Phi and G denote the cloud mass, the total magnetic flux of the cloud, and the gravitational constant, respectively. This upper bound coincides with that for an axisymmetric cloud supported by poloidal magnetic fields. We apply the variational principle for studying the Jeans instability of the first model. Our model cloud is unstable against fragmentation as well as the filamentary clouds threaded by a longitudinal magnetic field. The fastest growing mode has a wavelength several times longer than the cloud diameter. The second model describes quasi-static evolution of a filamentary molecular cloud by ambipolar diffusion.	[Hanawa, Tomoyuki] Chiba Univ, Ctr Frontier Sci, Chiba 2638522, Japan; [Tomisaka, Kohji] Natl Astron Observ Japan, Div Theoret Astron, Mitaka, Tokyo 1818588, Japan; [Tomisaka, Kohji] Grad Univ Adv Studies, Sch Phys Sci, Dept Astron Sci, SOKENDAI, Mitaka, Tokyo 1818588, Japan	Hanawa, T (reprint author), Chiba Univ, Ctr Frontier Sci, Chiba 2638522, Japan.	hanawa@faculty.chiba-u.jp; tomisaka@th.nao.ac.jp	Tomisaka, Kohji/E-6508-2013	Tomisaka, Kohji/0000-0003-2726-0892	JSPS KAKENHI [24540226]	This work was supported in part by JSPS KAKENHI Grant Number 24540226.	Abramowicz M., 1965, HDB MATH FUNCTIONS F; MESTEL L, 1956, MON NOT R ASTRON SOC, V116, P503; Pereyra A, 2004, ASTROPHYS J, V603, P584, DOI 10.1086/381702; MONETI A, 1984, ASTROPHYS J, V282, P508, DOI 10.1086/162228; Heitsch F, 2014, MON NOT R ASTRON SOC, V443, P230, DOI 10.1093/mnras/stu1147; Binney J., 2008, GALACTIC DYNAMICS; GOODMAN AA, 1990, ASTROPHYS J, V359, P363, DOI 10.1086/169070; HANAWA T, 1993, ASTROPHYS J, V404, pL83, DOI 10.1086/186749; MESTEL L, 1984, ASTRON ASTROPHYS, V136, P98; MOUSCHOVIAS TC, 1976, ASTROPHYS J, V207, P141, DOI 10.1086/154478; MOUSCHOVIAS TC, 1976, ASTROPHYS J, V206, P753, DOI 10.1086/154436; Nakamura F., 1995, APJ, V444, P700; NAKANO T, 1978, PUBL ASTRON SOC JPN, V30, P671; OSTRIKER J, 1964, ASTROPHYS J, V140, P1056, DOI 10.1086/148005; Palmeirim P, 2013, ASTRON ASTROPHYS, V550, DOI 10.1051/0004-6361/201220500; Shu FH, 1997, ASTROPHYS J, V475, P251, DOI 10.1086/303521; Stodolkiewicz J. S., 1963, ACTA ASTRON, V13, P30; STRITTMA.PA, 1966, MON NOT R ASTRON SOC, V132, P359; TOMISAKA K, 1991, ASTROPHYS J, V376, P190, DOI 10.1086/170267; TOMISAKA K, 1988, ASTROPHYS J, V335, P239, DOI 10.1086/166923; TOMISAKA K, 1995, ASTROPHYS J, V438, P226, DOI 10.1086/175067; Tomisaka K, 2014, ASTROPHYS J, V785, DOI 10.1088/0004-637X/785/1/24	22	1	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							11	10.1088/0004-637X/801/1/11		11	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700011		
J	Susa, H; Doi, K; Omukai, K				Susa, Hajime; Doi, Kentaro; Omukai, Kazuyuki			DISSIPATION OF MAGNETIC FIELDS IN STAR-FORMING CLOUDS WITH DIFFERENT METALLICITIES	ASTROPHYSICAL JOURNAL			English	Article						magnetohydrodynamics (MHD); stars: magnetic field; stars: Population II; stars: Population III	SMALL-SCALE DYNAMO; 1ST STARS; POPULATION-III; PROTOSTELLAR COLLAPSE; INTERSTELLAR GRAINS; FRAGMENTATION; ACCRETION; GENERATION; GALAXIES; DUST	We study the dissipation process of magnetic fields in the metallicity range 0-1Z(circle dot) for contracting prestellar cloud cores. By solving non-equilibrium chemistry for important charged species, including charged grains, we evaluate the drift velocity of the magnetic-field lines with respect to the gas. We find that the magnetic flux dissipates in the density range 10(12) cm(-3) less than or similar to n(H) less than or similar to 10(17) cm(-3) for the solar-metallicity case at the scale of the core, which is assumed to be the Jeans scale. The dissipation density range becomes narrower for lower metallicity. The magnetic field is always frozen to the gas below metallicity less than or similar to 10(-7)-10(-6) Z(circle dot), depending on the ionization rate by cosmic rays and/or radioactivity. With the same metallicity, the dissipation density range becomes wider for lower ionization rates. The presence of such a dissipative regime is expected to cause various dynamical phenomena in protostellar evolution such as the suppression of jet/outflow launching and the fragmentation of circumstellar disks depending on the metallicity.	[Susa, Hajime; Doi, Kentaro] Konan Univ, Dept Phys, Kobe, Hyogo 658, Japan; [Omukai, Kazuyuki] Tohoku Univ, Astron Inst, Sendai, Miyagi 980, Japan	Susa, H (reprint author), Konan Univ, Dept Phys, Kobe, Hyogo 658, Japan.	susa@konan-u.ac.jp			Ministry of Education, Science, Sports, and Culture [C22540295, B25287040]	We appreciate fruitful discussions with Masahiro Machida and the support of the Ministry of Education, Science, Sports, and Culture, Grant-in-Aid for Scientific Research (C22540295:HS, B25287040:KO).	Ahn K, 2012, ASTROPHYS J LETT, V756, DOI 10.1088/2041-8205/756/1/L16; Schneider R, 2012, MON NOT R ASTRON SOC, V419, P1566, DOI 10.1111/j.1365-2966.2011.19818.x; Ando M, 2010, ASTROPHYS J, V716, P1566, DOI 10.1088/0004-637X/716/2/1566; Umebayashi T, 2009, ASTROPHYS J, V690, P69, DOI [10.1088/0004-637X/690/1/69, 10.1088/0004-637x/690/1/69]; UMEBAYASHI T, 1990, MON NOT R ASTRON SOC, V243, P103; Hosokawa T, 2011, SCIENCE, V334, P1250, DOI 10.1126/science.1207433; Brandenburg A, 2005, PHYS REP, V417, P1, DOI 10.1016/j.physrep.2005.06.005; Omukai K, 2003, ASTROPHYS J, V589, P677, DOI 10.1086/374810; PRASAD SS, 1980, ASTROPHYS J SUPPL S, V43, P1, DOI 10.1086/190665; Bromm V, 2001, MON NOT R ASTRON SOC, V328, P969, DOI 10.1046/j.1365-8711.2001.04915.x; Clark PC, 2008, ASTROPHYS J, V672, P757, DOI 10.1086/524187; Umeda H, 2002, ASTROPHYS J, V565, P385, DOI 10.1086/323946; Schneider R, 2003, NATURE, V422, P869, DOI 10.1038/nature01579; Omukai K, 2005, ASTROPHYS J, V626, P627, DOI 10.1086/429955; DRAINE BT, 1987, ASTROPHYS J, V320, P803, DOI 10.1086/165596; WOLFIRE MG, 1995, ASTROPHYS J, V443, P152, DOI 10.1086/175510; Wise JH, 2014, MON NOT R ASTRON SOC, V442, P2560, DOI 10.1093/mnras/stu979; Schneider R, 2006, MON NOT R ASTRON SOC, V369, P1437, DOI [10.1111/j.1365-2966.2006.10391.x, 10.1111/j.1365-2966.10391.x]; Heger A, 2002, ASTROPHYS J, V567, P532, DOI 10.1086/338487; Galli D, 2013, ANNU REV ASTRON ASTR, V51, P163, DOI 10.1146/annurev-astro-082812-141029; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; Bromm V, 2002, ASTROPHYS J, V564, P23, DOI 10.1086/323947; Schneider R, 2002, ASTROPHYS J, V571, P30, DOI 10.1086/339917; MATHIS JS, 1977, ASTROPHYS J, V217, P425, DOI 10.1086/155591; Sur S, 2010, ASTROPHYS J LETT, V721, pL134, DOI [10.1088/2041-8205/721/2/L134, 10.1088/2041-205/721/2/L134]; Bovino S, 2011, ASTROPHYS J, V731, DOI 10.1088/0004-637X/731/2/107; Chen PF, 2014, ASTROPHYS J, V795, DOI 10.1088/0004-637X/795/2/144; Doi K, 2011, ASTROPHYS J, V741, DOI 10.1088/0004-637X/741/2/93; Dopcke G., 2013, APJ, V776, P103; Dopcke G, 2011, ASTROPHYS J LETT, V729, DOI 10.1088/2041-8205/729/1/L3; Federrath C, 2011, ASTROPHYS J, V731, DOI 10.1088/0004-637X/731/1/62; Frebel A, 2007, MON NOT R ASTRON SOC, V380, pL40, DOI 10.1111/j.1745-3933.2007.00344.x; Hirano S, 2014, ASTROPHYS J, V781, DOI 10.1088/0004-637X/781/2/60; Howk JC, 2012, NATURE, V489, P121, DOI 10.1038/nature11407; Ji Alexander P., 2014, Astrophysical Journal, V782, DOI 10.1088/0004-637X/782/2/95; KAZANTSE.AP, 1968, SOV PHYS JETP-USSR, V26, P1031; Lacki B. C., 2014, MNRAS, V440, P373; Latif MA, 2013, ASTROPHYS J LETT, V772, DOI 10.1088/2041-8205/772/1/L3; Machida MN, 2008, ASTROPHYS J LETT, V682, pL1, DOI 10.1086/590109; Machida MN, 2008, ASTROPHYS J, V676, P1088, DOI 10.1086/528364; Maki H, 2004, ASTROPHYS J, V609, P467, DOI 10.1086/421103; Maki H, 2007, PUBL ASTRON SOC JPN, V59, P787; McElroy D, 2013, ASTRON ASTROPHYS, V550, DOI 10.1051/0004-6361/201220465; Mckee CF, 2008, ASTROPHYS J, V681, P771, DOI 10.1086/587434; NAKANO T, 1986, MON NOT R ASTRON SOC, V218, P663; Nakauchi D, 2014, MON NOT R ASTRON SOC, V442, P2667, DOI 10.1093/mnras/stu1042; Omukai K, 2000, ASTROPHYS J, V534, P809, DOI 10.1086/308776; Omukai K, 2010, ASTROPHYS J, V722, P1793, DOI 10.1088/0004-637X/722/2/1793; Omukai K, 2012, PUBL ASTRON SOC JPN, V64; Peters T, 2014, MON NOT R ASTRON SOC, V442, P3112, DOI 10.1093/mnras/stu1097; Pinto C, 2008, ASTRON ASTROPHYS, V484, P17, DOI 10.1051/0004-6361:20078819; Ritter JS, 2012, ASTROPHYS J, V761, DOI 10.1088/0004-637X/761/1/56; Schleicher DRG, 2010, ASTRON ASTROPHYS, V522, DOI 10.1051/0004-6361/201015184; Schneider R, 2010, MON NOT R ASTRON SOC, V402, P429, DOI 10.1111/j.1365-2966.2009.15891.x; Schober J, 2012, ASTROPHYS J, V754, DOI 10.1088/0004-637X/754/2/99; Shiromoto Y, 2014, ASTROPHYS J, V782, DOI 10.1088/0004-637X/782/2/108; Spruit HC, 2002, ASTRON ASTROPHYS, V381, P923, DOI 10.1051/0004-6361:20011465; Stacy A, 2007, MON NOT R ASTRON SOC, V382, P229, DOI 10.1111/j.1365-2966.2007.12247.x; Susa H, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/2/185; Susa H, 2014, ASTROPHYS J, V792, DOI 10.1088/0004-637X/792/1/32; Tomida K, 2013, ASTROPHYS J, V763, DOI 10.1088/0004-637X/763/1/6; Turk MJ, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/2/154; Wise JH, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/1/50	63	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							13	10.1088/0004-637X/801/1/13		12	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700013		
J	Takahashi, T; Asai, A; Shibata, K				Takahashi, Takuya; Asai, Ayumi; Shibata, Kazunari			PROMINENCE ACTIVATION BY CORONAL FAST MODE SHOCK	ASTROPHYSICAL JOURNAL			English	Article						magnetohydrodynamics (MHD); shock waves; Sun: corona; Sun: filaments, prominences; Sun: flares	MORETON WAVES; EIT WAVES; H-ALPHA; LORENTZ FORCE; SOLAR CORONA; SOHO MISSION; FLARE WAVES; FILAMENT; EUV; OSCILLATIONS	An X5.4 class flare occurred in active region NOAA11429 on 2012 March 7. The flare was associated with a very fast coronal mass ejection (CME) with a velocity of over 2500 km s(-1). In the images taken with the Solar Terrestrial Relations Observatory-B/COR1, a dome-like disturbance was seen to detach from an expanding CME bubble and propagated further. A Type-II radio burst was also observed at the same time. On the other hand, in extreme ultraviolet images obtained by the Solar Dynamic Observatory/Atmospheric Imaging Assembly (AIA), the expanding dome-like structure and its footprint propagating to the north were observed. The footprint propagated with an average speed of about 670 km s(-1) and hit a prominence located at the north pole and activated it. During the activation, the prominence was strongly brightened. On the basis of some observational evidence, we concluded that the footprint in AIA images and the ones in COR1 images are the same, that is, the MHD fast mode shock front. With the help of a linear theory, the fast mode Mach number of the coronal shock is estimated to be between 1.11 and 1.29 using the initial velocity of the activated prominence. Also, the plasma compression ratio of the shock is enhanced to be between 1.18 and 2.11 in the prominence material, which we consider to be the reason for the strong brightening of the activated prominence. The applicability of linear theory to the shock problem is tested with a nonlinear MHD simulation.	[Takahashi, Takuya] Kyoto Univ, Dept Astron, Sakyo Ku, Kyoto 6068502, Japan; [Asai, Ayumi] Kyoto Univ, Unit Synerget Studies Space, Yamashina Ku, Kyoto 6078471, Japan; [Takahashi, Takuya; Shibata, Kazunari] Kyoto Univ, Kwasan & Hida Observ, Yamashina Ku, Kyoto 6078471, Japan	Takahashi, T (reprint author), Kyoto Univ, Dept Astron, Sakyo Ku, Kyoto 6068502, Japan.	takahashi@kwasan.kyoto-u.ac.jp			JSPS KAKENHI [24740331, 23340045, 25287039]	The SDO/AIA data are courtesy of the NASA/SDO and AIA science team. The authors thank the SMART team at the Hida observatory of Kyoto University who continuously provide high quality H alpha full disk images of the Sun. The simulation code used in this work was created with the help of the HPCI Strategic Program. This work is financially supported by JSPS KAKENHI grant Nos. 24740331, 23340045, and 25287039. The authors are grateful to Dr. Andrew Hillier (Kyoto University) for helpful comments.	NEWKIRK G, 1961, ASTROPHYS J, V133, P983, DOI 10.1086/147104; Tripathi D, 2009, SPACE SCI REV, V149, P283, DOI 10.1007/s11214-009-9583-9; Lemen James R., 2012, Solar Physics, V275, DOI 10.1007/s11207-011-9776-8; Eto S, 2002, PUBL ASTRON SOC JPN, V54, P481; Thompson BJ, 2000, SOL PHYS, V193, P161, DOI 10.1023/A:1005222123970; Gilbert HR, 2008, ASTROPHYS J, V685, P629, DOI 10.1086/590545; Dedner A, 2002, J COMPUT PHYS, V175, P645, DOI 10.1006/jcph.2001.6961; Mackay DH, 2010, SPACE SCI REV, V151, P333, DOI 10.1007/s11214-010-9628-0; Vrsnak B, 2002, ASTRON ASTROPHYS, V394, P299, DOI 10.1051/0004-6361:20021121; Driesman A, 2008, SPACE SCI REV, V136, P17, DOI 10.1007/s11214-007-9286-z; Tripathi D, 2007, ASTRON ASTROPHYS, V473, P951, DOI 10.1051/0004-6361:20077255; Mann G, 1999, ASTRON ASTROPHYS, V348, P614; Warmuth A, 2001, ASTROPHYS J, V560, pL105, DOI 10.1086/324055; Okamoto TJ, 2004, ASTROPHYS J, V608, P1124, DOI 10.1086/420838; Labrosse N, 2010, SPACE SCI REV, V151, P243, DOI 10.1007/s11214-010-9630-6; Domingo V, 1995, SOL PHYS, V162, P1, DOI 10.1007/BF00733425; Kaiser ML, 2008, SPACE SCI REV, V136, P5, DOI 10.1007/s11214-007-9277-0; Gopalswamy N, 2001, J GEOPHYS RES-SPACE, V106, P25261, DOI 10.1029/2000JA004025; Isobe H, 2007, SOL PHYS, V246, P89, DOI 10.1007/s11207-007-9091-6; Zhang YZ, 2011, PUBL ASTRON SOC JPN, V63, P685; Warmuth A, 2007, LECT NOTES PHYS, V725, P107, DOI [10.1007/978-3-510-71570-2_6, 10.1007/978-3-540-71570-2_6]; Pesnell WD, 2012, SOL PHYS, V275, P3, DOI 10.1007/s11207-011-9841-3; Delaboudiniere JP, 1995, SOL PHYS, V162, P291, DOI 10.1007/BF00733432; Liu W, 2010, ASTROPHYS J LETT, V723, pL53, DOI 10.1088/2041-8205/723/1/L53; Wills-Davey MJ, 2009, SPACE SCI REV, V149, P325, DOI 10.1007/s11214-009-9612-8; MORETON GE, 1960, ASTRON J, V65, P494, DOI 10.1086/108346; Thompson BJ, 1999, ASTROPHYS J, V517, pL151, DOI 10.1086/312030; Miyoshi T, 2005, J COMPUT PHYS, V208, P315, DOI 10.1016/j.jcp.2005.02.017; Asai A., 2011, ASTROPHYS J LETT, V745, pL18; Chen PF, 2011, ASTROPHYS J LETT, V732, DOI 10.1088/2041-8205/732/2/L20; Gallagher P. T., 2010, SPACE SCI REV, V158, P365; KAI K, 1970, SOL PHYS, V11, P310, DOI 10.1007/BF00155230; Kondo T., 1995, Journal of the Communications Research Laboratory, V42; Liu R, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/2/166; Ma SL, 2011, ASTROPHYS J, V738, DOI 10.1088/0004-637X/738/2/160; Petrie GJD, 2012, ASTROPHYS J, V759, DOI 10.1088/0004-637X/759/1/50; Shibata K, 2011, LIVING REV SOL PHYS, V8; Shibata K., 2011, SOLAR ACTIVITY 1992; Smith S. F., 1971, Physics of the solar corona; Terradas J, 2008, ASTROPHYS J LETT, V678, pL153, DOI 10.1086/588728; Title A., 2006, BAAS, V38, P261; Uchida Y., 1968, Solar Physics, V4, DOI 10.1007/BF00146996; Vrsnak B, 2007, ASTRON ASTROPHYS, V471, P295, DOI 10.1051/0004-6361:20077668; Wang S, 2012, ASTROPHYS J LETT, V757, DOI 10.1088/2041-8205/757/1/L5; WILD JP, 1954, AUST J PHYS, V7, P439; Wulser JP, 2004, P SOC PHOTO-OPT INS, V5171, P111, DOI 10.1117/12.506877	46	1	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							37	10.1088/0004-637X/801/1/37		11	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700037		
J	Takeuchi, TM; Ohta, K; Yuma, S; Yabe, K				Takeuchi, T. M.; Ohta, K.; Yuma, S.; Yabe, K.			WHEN DID ROUND DISK GALAXIES FORM?	ASTROPHYSICAL JOURNAL			English	Article						galaxies: evolution; galaxies: formation; galaxies: structure	HUBBLE DEEP FIELD; SIMILAR-TO 2; EXTRAGALACTIC LEGACY SURVEY; MASS-METALLICITY RELATION; LDSS REDSHIFT SURVEYS; LYMAN BREAK GALAXIES; STAR-FORMATION; MORPHOLOGICAL PROPERTIES; LUMINOSITY FUNCTION; SPIRAL GALAXIES	When and how galaxy morphology, such as the disk and bulge seen in the present-day universe, emerged is still not clear. In the universe at z greater than or similar to 2, galaxies with various morphologies are seen, and star-forming galaxies at z similar to 2 show the intrinsic shape of bar-like structures. Then, when did the round disk structure form? Here we take a simple and straightforward approach to see the epoch when a round disk galaxy population emerged by constraining the intrinsic shape statistically based on the apparent axial ratio distribution of galaxies. We derived the distributions of the apparent axial ratios in the rest-frame optical light (similar to 5000 angstrom) of star-forming main-sequence galaxies at 2.5 > z > 1.4, 1.4 > z > 0.85, and 0.85 > z > 0.5, and found that their apparent axial ratios show peaky distributions at z greater than or similar to 0.85, while a rather flat distribution at the lower redshift. By using a tri-axial model (A > B > C) for the intrinsic shape, we found that the best-fit models give the peaks of the B/A distribution of 0.81 +/- 0.04, 0.84 +/- 0.04, and 0.92 +/- 0.05 at 2.5 > z > 1.4, 1.4 > z > 0.85, and 0.85 > z > 0.5, respectively. The last value is close to the local value of 0.95. Thickness (C/A) is similar to 0.25 at all the redshifts and is close to the local value (0.21). The results indicate that the shape of the star-forming galaxies in the main sequence changes gradually, and that the round disk is established at around z similar to 0.9. The establishment of the round disk may be due to the cessation of a violent interaction between galaxies or the growth of a bulge and/or a supermassive black hole residing at the center of a galaxy that dissolves the bar structure.	[Takeuchi, T. M.; Ohta, K.] Kyoto Univ, Dept Astron, Kyoto 6068502, Japan; [Yuma, S.] Univ Tokyo, Inst Cosm Ray Res, Kashiwa, Chiba 2778582, Japan; [Yabe, K.] Natl Astron Observ Japan, Mitaka, Tokyo 1818588, Japan	Takeuchi, TM (reprint author), Kyoto Univ, Dept Astron, Kyoto 6068502, Japan.	ohta@kusastro.kyoto-u.ac.jp			Japan Society for the Promotion of Science [24540230, 24103003]; NASA [NAS5-26555]	We thank the referee for useful comments. K.O.'s efforts are supported by the Grant-in-Aid for Scientific Research (24540230) and the Grant-in-Aid for Scientific Research on Innovative Area (24103003) from the Japan Society for the Promotion of Science. This work is partially based on observations taken by the CANDELS Multi-Cycle Treasury Program with the NASA/ESA HST, which is operated by the Association of Universities for Research in Astronomy, Inc., under NASA contract NAS5-26555. Parts of the observations in GOODS-S have been carried out using the Very Large Telescope at the ESO Paranal Observatory under Program ID 168.A-0485. Based on observations obtained with MegaPrime/MegaCam, a joint project of CFHT and CEA/IRFU, at the Canada-France-Hawaii Telescope (CFHT) which is operated by the National Research Council (NRC) of Canada, the Institut National des Science de l'Univers of the Centre National de la Recherche Scientifique (CNRS) of France, and the University of Hawaii. This work is based in part on data products produced at Terapix available at the Canadian Astronomy Data Centre as part of the Canada-France-Hawaii Telescope Legacy Survey, a collaborative project of NRC and CNRS.	Akiyama M, 2008, ASTROPHYS J SUPPL S, V175, P1, DOI 10.1086/523670; Athanassoula E, 2005, MON NOT R ASTRON SOC, V363, P496, DOI 10.1111/j.1365-2966.2005.09445.x; Ueda Y, 2003, ASTROPHYS J, V598, P886, DOI 10.1086/378940; Ohta K, 2007, ASTROPHYS J SUPPL S, V169, P1, DOI 10.1086/510204; Noeske KG, 2007, ASTROPHYS J, V660, pL43, DOI 10.1086/517926; Giavalisco M, 2004, ASTROPHYS J, V600, pL93, DOI 10.1086/379232; Daddi E, 2007, ASTROPHYS J, V670, P156, DOI 10.1086/521818; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Hasinger G, 2005, ASTRON ASTROPHYS, V441, P417, DOI 10.1051/0004-6361:20042134; Bolzonella M, 2000, ASTRON ASTROPHYS, V363, P476; Padilla ND, 2008, MON NOT R ASTRON SOC, V388, P1321, DOI 10.1111/j.1365-2966.2008.13480.x; Berentzen I, 2004, MON NOT R ASTRON SOC, V347, P220, DOI 10.1111/j.1365-2966.2004.07198.x; Buitrago F, 2013, MON NOT R ASTRON SOC, V428, P1460, DOI 10.1093/mnras/sts124; Melvin T, 2014, MON NOT R ASTRON SOC, V438, P2882, DOI 10.1093/mnras/stt2397; Calzetti D, 2000, ASTROPHYS J, V533, P682, DOI 10.1086/308692; Scarlata C, 2007, ASTROPHYS J SUPPL S, V172, P406, DOI 10.1086/516582; Nonino M, 2009, ASTROPHYS J SUPPL S, V183, P244, DOI 10.1088/0067-0049/183/2/244; Abraham RG, 1996, MON NOT R ASTRON SOC, V279, pL47; Mortlock A, 2013, MON NOT R ASTRON SOC, V433, P1185, DOI 10.1093/mnras/stt793; Steidel CC, 1996, ASTRON J, V112, P352, DOI 10.1086/118019; Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; Lawrence A, 2007, MON NOT R ASTRON SOC, V379, P1599, DOI 10.1111/j.1365-2966.2007.12040.x; Peng CY, 2010, ASTRON J, V139, P2097, DOI 10.1088/0004-6256/139/6/2097; Bruce VA, 2012, MON NOT R ASTRON SOC, V427, P1666, DOI 10.1111/j.1365-2966.2012.22087.x; Ravindranath S, 2006, ASTROPHYS J, V652, P963, DOI 10.1086/507016; OSTRIKER JP, 1973, ASTROPHYS J, V186, P467, DOI 10.1086/152513; Bouche N, 2010, ASTROPHYS J, V718, P1001, DOI 10.1088/0004-637X/718/2/1001; Hayashi M, 2007, ASTROPHYS J, V660, P72, DOI 10.1086/513068; Martin DC, 2005, ASTROPHYS J, V619, pL1, DOI 10.1086/426387; Brinchmann J, 1998, ASTROPHYS J, V499, P112, DOI 10.1086/305621; Sheth K, 2008, ASTROPHYS J, V675, P1141, DOI 10.1086/524980; Barden M, 2005, ASTROPHYS J, V635, P959, DOI 10.1086/497679; Dickinson M, 2003, ESO ASTROPHY SYMP, P324, DOI 10.1007/10899892_78; Cameron E, 2011, ASTROPHYS J, V743, DOI 10.1088/0004-637X/743/2/146; Conselice C. J., 2011, MNRAS, V417, P2270; Schreiber NMF, 2009, ASTROPHYS J, V706, P1364, DOI 10.1088/0004-637X/706/2/1364; Furusawa H, 2008, ASTROPHYS J SUPPL S, V176, P1, DOI 10.1086/527321; GEHRELS N, 1986, ASTROPHYS J, V303, P336, DOI 10.1086/164079; Giavalisco M, 1996, ASTROPHYS J, V470, P189, DOI 10.1086/177859; Grogin NA, 2011, ASTROPHYS J SUPPL S, V197, DOI 10.1088/0067-0049/197/2/35; Hozumi S, 2012, PUBL ASTRON SOC JPN, V64; Koekemoer AM, 2011, ASTROPHYS J SUPPL S, V197, DOI 10.1088/0067-0049/197/2/36; Law DR, 2012, ASTROPHYS J, V745, DOI 10.1088/0004-637X/745/1/85; Lilly S, 1998, ASTROPHYS J, V500, P75, DOI 10.1086/305713; Miller SH, 2011, ASTROPHYS J, V741, DOI 10.1088/0004-637X/741/2/115; NOGUCHI M, 1987, MON NOT R ASTRON SOC, V228, P635; OHTA K, 1990, ASTROPHYS J, V357, P71, DOI 10.1086/168892; Patel SG, 2012, ASTROPHYS J LETT, V748, DOI 10.1088/2041-8205/748/2/L27; Retzlaff J., 2010, ASTRON ASTROPHYS, V511, P50; Ryden BS, 2004, ASTROPHYS J, V601, P214, DOI 10.1086/380437; Sargent MT, 2007, ASTROPHYS J SUPPL S, V172, P434, DOI 10.1086/516584; Sawicki M, 2012, PUBL ASTRON SOC PAC, V124, P1208, DOI 10.1086/668636; SCHADE D, 1995, ASTROPHYS J, V451, pL1, DOI 10.1086/309677; Talia M, 2014, ASTRON ASTROPHYS, V562, DOI 10.1051/0004-6361/201322193; vandenBergh S, 1996, ASTRON J, V112, P359, DOI 10.1086/118020; van der Wel A, 2014, ASTROPHYS J LETT, V792, DOI 10.1088/2041-8205/792/1/L6; van Dokkum PG, 2013, ASTROPHYS J LETT, V771, DOI 10.1088/2041-8205/771/2/L35; Wang T, 2012, ASTROPHYS J, V752, DOI 10.1088/0004-637X/752/2/134; Yabe K, 2012, PUBL ASTRON SOC JPN, V64; Yabe K, 2014, MON NOT R ASTRON SOC, V437, P3647, DOI 10.1093/mnras/stt2185; Yuma S, 2012, ASTROPHYS J, V761, DOI 10.1088/0004-637X/761/1/19; Yuma S, 2011, ASTROPHYS J, V736, DOI 10.1088/0004-637X/736/2/92	62	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							2	10.1088/0004-637X/801/1/2		7	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700002		
J	Tanaka, M				Tanaka, Masayuki			PHOTOMETRIC REDSHIFT WITH BAYESIAN PRIORS ON PHYSICAL PROPERTIES OF GALAXIES	ASTROPHYSICAL JOURNAL			English	Article						galaxies: distances and redshifts; surveys	STELLAR POPULATION SYNTHESIS; STAR-FORMATION RATE; DIGITAL SKY SURVEY; MEDIUM-BAND SURVEY; VLT DEEP SURVEY; SPECTRAL ENERGY-DISTRIBUTION; NEAR-INFRARED SPECTROSCOPY; TELESCOPE LENSING SURVEY; POST-STARBURST GALAXIES; INITIAL MASS FUNCTION	We present a proof-of-concept analysis of photometric redshifts with Bayesian priors on physical properties of galaxies. This concept is particularly suited for upcoming/on-going large imaging surveys, in which only several broadband filters are available and it is hard to break some of the degeneracies in the multi-color space. We construct model templates of galaxies using a stellar population synthesis code and apply Bayesian priors on physical properties such as stellar mass and star formation rate. These priors are a function of redshift and they effectively evolve the templates with time in an observationally motivated way. We demonstrate that the priors help reduce the degeneracy and deliver significantly improved photometric redshifts. Furthermore, we show that a template error function, which corrects for systematic flux errors in the model templates as a function of rest-frame wavelength, delivers further improvements. One great advantage of our technique is that we simultaneously measure redshifts and physical properties of galaxies in a fully self-consistent manner, unlike the two-step measurements with different templates often performed in the literature. One may rightly worry that the physical priors bias the inferred galaxy properties, but we show that the bias is smaller than systematic uncertainties inherent in physical properties inferred from the spectral energy distribution fitting and hence is not a major issue. We will extensively test and tune the priors in the on-going Hyper Suprime-Cam survey and will make the code publicly available in the future.	Natl Astron Observ Japan, Mitaka, Tokyo 1818588, Japan	Tanaka, M (reprint author), Natl Astron Observ Japan, Osawa 2-21-1, Mitaka, Tokyo 1818588, Japan.				CFHT	This work is based on observations obtained with MegaPrime/ MegaCam, a joint project of CFHT and CEA/ IRFU, at the Canada- France- Hawaii Telescope ( CFHT) which is operated by the National Research Council ( NRC) of Canada, the Institut National des Sciences de l'Univers of the Centre National de la Recherche Scientifique ( CNRS) of France, and the University of Hawaii. This research used the facilities of the Canadian Astronomy Data Centre operated by the National Research Council of Canada with the support of the Canadian Space Agency. CFHTLenS data processing was made possible thanks to significant computing support from the NSERC Research Tools and Instruments grant program. This research uses data from the VIMOS VLT Deep Survey, obtained from the VVDS database operated by Cesam, Laboratoire d'Astrophysique de Marseille, France. This study makes use of data from the NEWFIRMMedium- Band Survey, a multiwavelength survey conducted with the NEWFIRM instrument at the KPNO, supported in part by the NSF and NASA.	da Cunha E, 2008, MON NOT R ASTRON SOC, V388, P1595, DOI 10.1111/j.1365-2966.2008.13535.x; Pacifici C, 2012, MON NOT R ASTRON SOC, V421, P2002, DOI 10.1111/j.1365-2966.2012.20431.x; Daddi E, 2007, ASTROPHYS J, V670, P156, DOI 10.1086/521818; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Shirasaki M, 2014, ASTROPHYS J, V786, DOI 10.1088/0004-637X/786/1/43; Connolly AJ, 1995, ASTRON J, V110, P2655, DOI 10.1086/117720; Kriek M, 2009, ASTROPHYS J, V700, P221, DOI 10.1088/0004-637X/700/1/221; Pforr J, 2012, MON NOT R ASTRON SOC, V422, P3285, DOI 10.1111/j.1365-2966.2012.20848.x; Walcher J, 2011, ASTROPHYS SPACE SCI, V331, P1, DOI 10.1007/s10509-010-0458-z; Elbaz D, 2007, ASTRON ASTROPHYS, V468, P33, DOI 10.1051/0004-6361:20077525; Pozzetti L, 2007, ASTRON ASTROPHYS, V474, P443, DOI 10.1051/0004-6361:20077609; Driver SP, 2011, MON NOT R ASTRON SOC, V413, P971, DOI 10.1111/j.1365-2966.2010.18188.x; BEERS TC, 1990, ASTRON J, V100, P32, DOI 10.1086/115487; Hildebrandt H, 2012, MON NOT R ASTRON SOC, V421, P2355, DOI 10.1111/j.1365-2966.2012.20468.x; Garn T, 2010, MON NOT R ASTRON SOC, V409, P421, DOI 10.1111/j.1365-2966.2010.17321.x; Le Fevre O, 2005, ASTRON ASTROPHYS, V439, P845, DOI 10.1051/0004-6361:20041960; Santos JS, 2014, MON NOT R ASTRON SOC, V438, P2565, DOI 10.1093/mnras/stt2376; Calzetti D, 2000, ASTROPHYS J, V533, P682, DOI 10.1086/308692; Maraston C, 2009, MON NOT R ASTRON SOC, V394, pL107, DOI 10.1111/j.1745-3933.2009.00621.x; Henriques BMB, 2012, MON NOT R ASTRON SOC, V421, P2904, DOI 10.1111/j.1365-2966.2012.20521.x; York DG, 2000, ASTRON J, V120, P1579, DOI 10.1086/301513; Ilbert O, 2009, ASTROPHYS J, V690, P1236, DOI 10.1088/0004-637X/690/2/1236; Kriek M, 2010, ASTROPHYS J LETT, V722, pL64, DOI 10.1088/2041-8205/722/1/L64; Feldmann R, 2006, MON NOT R ASTRON SOC, V372, P565, DOI 10.1111/j.1365-2966.2006.10930.x; Sobral D, 2012, MON NOT R ASTRON SOC, V420, P1926, DOI 10.1111/j.1365-2966.2011.19977.x; Heymans C, 2012, MON NOT R ASTRON SOC, V427, P146, DOI 10.1111/j.1365-2966.2012.21952.x; Erben T, 2009, ASTRON ASTROPHYS, V493, P1197, DOI 10.1051/0004-6361:200810426; Gonzalez V, 2010, ASTROPHYS J, V713, P115, DOI 10.1088/0004-637X/713/1/115; Lawrence A, 2007, MON NOT R ASTRON SOC, V379, P1599, DOI 10.1111/j.1365-2966.2007.12040.x; Brammer GB, 2008, ASTROPHYS J, V686, P1503, DOI 10.1086/591786; Arnouts S, 1999, MON NOT R ASTRON SOC, V310, P540, DOI 10.1046/j.1365-8711.1999.02978.x; Erben T, 2013, MON NOT R ASTRON SOC, V433, P2545, DOI 10.1093/mnras/stt928; Schneider M, 2006, ASTROPHYS J, V651, P14, DOI 10.1086/507675; Collister AA, 2004, PUBL ASTRON SOC PAC, V116, P345, DOI 10.1086/383254; Hopkins AM, 2003, ASTROPHYS J, V599, P971, DOI 10.1086/379608; Conroy C, 2010, ASTROPHYS J, V712, P833, DOI 10.1088/0004-637X/712/2/833; Lilly SJ, 2007, ASTROPHYS J SUPPL S, V172, P70, DOI 10.1086/516589; Ilbert O, 2006, ASTRON ASTROPHYS, V457, P841, DOI 10.1051/0004-6361:20065138; Conroy C, 2009, ASTROPHYS J, V699, P486, DOI 10.1088/0004-637X/699/1/486; Maraston C, 2010, MON NOT R ASTRON SOC, V407, P830, DOI 10.1111/j.1365-2966.2010.16973.x; Baum W. A., 1962, IAU S, V15, P390; Benitez N, 2000, ASTROPHYS J, V536, P571, DOI 10.1086/308947; Calzetti D, 1997, AIP CONF PROC, V408, P403; Kind MC, 2013, MON NOT R ASTRON SOC, V432, P1483, DOI 10.1093/mnras/stt574; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; Coil AL, 2011, ASTROPHYS J, V741, DOI 10.1088/0004-637X/741/1/8; Dahlen T, 2013, ASTROPHYS J, V775, DOI 10.1088/0004-637X/775/2/93; Davis M, 2003, P SOC PHOTO-OPT INS, V4834, P161, DOI 10.1117/12.457897; de Putter R, 2014, ASTROPHYS J, V780, DOI 10.1088/0004-637X/780/2/185; Fontana A, 2004, ASTRON ASTROPHYS, V424, P23, DOI 10.1051/0004-6361:20035626; Guzzo L, 2014, ASTRON ASTROPHYS, V566, DOI 10.1051/0004-6361/201321489; Hildebrandt H, 2010, ASTRON ASTROPHYS, V523, DOI 10.1051/0004-6361/201014885; Hsieh BC, 2014, ASTROPHYS J, V792, DOI 10.1088/0004-637X/792/2/102; Ilbert O, 2013, ASTRON ASTROPHYS, V556, DOI 10.1051/0004-6361/201321100; Inoue AK, 2011, MON NOT R ASTRON SOC, V415, P2920, DOI 10.1111/j.1365-2966.2011.18906.x; Ivezic Z., 2008, SERB ASTRON J, V176; Komatsu E, 2011, ASTROPHYS J SUPPL S, V192, DOI 10.1088/0067-0049/192/2/18; Le Fevre O., 2013, ARXIV13076518; MADAU P, 1995, ASTROPHYS J, V441, P18, DOI 10.1086/175332; McQuinn M, 2013, MON NOT R ASTRON SOC, V433, P2857, DOI 10.1093/mnras/stt914; Menard B., 2013, ARXIV13034722; Muzzin A, 2013, ASTROPHYS J SUPPL S, V206, DOI 10.1088/0067-0049/206/1/8; Newman JA, 2008, ASTROPHYS J, V684, P88, DOI 10.1086/589982; Nishizawa AJ, 2010, ASTROPHYS J, V718, P1252, DOI 10.1088/0004-637X/718/2/1252; Rodighiero G, 2011, ASTROPHYS J LETT, V739, DOI 10.1088/2041-8205/739/2/L40; Sanchez C, 2014, MON NOT R ASTRON SOC, V445, P1482, DOI 10.1093/mnras/stu1836; Schrabback T, 2010, ASTRON ASTROPHYS, V516, DOI 10.1051/0004-6361/200913577; Spergel D., 2013, ARXIV13055422; Stabenau HF, 2008, MON NOT R ASTRON SOC, V387, P1215, DOI 10.1111/j.1365-2966.2008.13317.x; Stark DP, 2013, ASTROPHYS J, V763, DOI 10.1088/0004-637X/763/2/129; Tanaka M, 2013, PUBL ASTRON SOC JPN, V65; Tanaka M, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/200913939; Tanaka M, 2013, ASTROPHYS J, V772, DOI 10.1088/0004-637X/772/2/113; The Dark Energy Survey Collaboration, 2005, ARXIVASTROPH0510346; van Dokkum PG, 2014, ASTROPHYS J, V791, DOI 10.1088/0004-637X/791/1/45; van Dokkum PG, 2009, PUBL ASTRON SOC PAC, V121, P2, DOI 10.1086/597138; Whitaker KE, 2012, ASTROPHYS J LETT, V754, DOI 10.1088/2041-8205/754/2/L29; Whitaker KE, 2011, ASTROPHYS J, V735, DOI 10.1088/0004-637X/735/2/86; Wray JJ, 2008, ASTROPHYS J, V678, P144, DOI 10.1086/529127; Wuyts S, 2011, ASTROPHYS J, V738, DOI 10.1088/0004-637X/738/1/106; Wuyts S, 2011, ASTROPHYS J, V742, DOI 10.1088/0004-637X/742/2/96; Zibetti S, 2013, MON NOT R ASTRON SOC, V428, P1479, DOI 10.1093/mnras/sts126	82	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							20	10.1088/0004-637X/801/1/20		19	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700020		
J	Tasker, EJ; Wadsley, J; Pudritz, R				Tasker, Elizabeth J.; Wadsley, James; Pudritz, Ralph			STAR FORMATION IN DISK GALAXIES. III. DOES STELLAR FEEDBACK RESULT IN CLOUD DEATH?	ASTROPHYSICAL JOURNAL			English	Article						galaxies: ISM; ISM: clouds; ISM: structure; local interstellar matter; methods: numerical; stars: formation	GIANT MOLECULAR CLOUDS; LARGE-MAGELLANIC-CLOUD; INTERSTELLAR-MEDIUM; SUPERSONIC TURBULENCE; FORMING GALAXIES; OB ASSOCIATIONS; GAS KINEMATICS; GALACTIC DISKS; BARRED GALAXY; MILKY-WAY	Stellar feedback, star formation, and gravitational interactions are major controlling forces in the evolution of giant molecular clouds (GMCs). To explore their relative roles, we examine the properties and evolution of GMCs forming in an isolated galactic disk simulation that includes both localized thermal feedback and photoelectric heating. The results are compared with the three previous simulations in this series, which consists of a model with no star formation, star formation but no form of feedback, and star formation with photoelectric heating in a set with steadily increasing physical effects. We find that the addition of localized thermal feedback greatly suppresses star formation but does not destroy the surrounding GMC, giving cloud properties closely resembling the run in which no stellar physics is included. The outflows from the feedback reduce the mass of the cloud but do not destroy it, allowing the cloud to survive its stellar children. This suggests that weak thermal feedback such as the lower bound expected for a supernova may play a relatively minor role in the galactic structure of quiescent Milky-Way-type galaxies, compared to gravitational interactions and disk shear.	[Tasker, Elizabeth J.; Wadsley, James; Pudritz, Ralph] McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4M1, Canada; [Tasker, Elizabeth J.] Hokkaido Univ, Dept Cosmosci, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan	Tasker, EJ (reprint author), McMaster Univ, Dept Phys & Astron, 1280 Main St West, Hamilton, ON L8S 4M1, Canada.						Agertz O, 2013, ASTROPHYS J, V770, DOI 10.1088/0004-637X/770/1/25; BLITZ L, 1990, ASTROPHYS J, V352, pL13, DOI 10.1086/185682; McKee CF, 1997, ASTROPHYS J, V476, P144, DOI 10.1086/303587; Brunt CM, 2004, ASTROPHYS J, V604, P196, DOI 10.1086/381648; Renaud F, 2013, MON NOT R ASTRON SOC, V436, P1836, DOI 10.1093/mnras/stt1698; Robertson BE, 2008, ASTROPHYS J LETT, V685, pL27, DOI 10.1086/592329; Hughes A, 2010, MON NOT R ASTRON SOC, V406, P2065, DOI 10.1111/j.1365-2966.2010.16829.x; Truelove JK, 1997, ASTROPHYS J, V489, pL179, DOI 10.1086/310975; Hopkins PF, 2012, MON NOT R ASTRON SOC, V421, P3488, DOI 10.1111/j.1365-2966.2012.20578.x; Fujimoto Y, 2014, MON NOT R ASTRON SOC, V439, P936, DOI 10.1093/mnras/stu014; Heyer MH, 1998, ASTROPHYS J, V502, P265, DOI 10.1088/0004-637X/699/2/1092; Tasker EJ, 2008, MON NOT R ASTRON SOC, V390, P1267, DOI 10.1111/j.1365-2966.2008.13836.x; Mckee CF, 2007, ANNU REV ASTRON ASTR, V45, P565, DOI 10.1146/annurev.astro.45.051806.110602; Federrath C, 2008, ASTROPHYS J LETT, V688, pL79, DOI 10.1086/595280; Krumholz MR, 2007, ASTROPHYS J, V654, P304, DOI 10.1086/509101; Banerjee R, 2007, ASTROPHYS J, V668, P1028, DOI 10.1086/521097; Kawamura A, 2009, ASTROPHYS J SUPPL S, V184, P1, DOI 10.1088/0067-0049/184/1/1; Ossenkopf V, 2002, ASTRON ASTROPHYS, V390, P307, DOI 10.1051/0004-6361:20020629; Dobbs CL, 2013, MON NOT R ASTRON SOC, V432, P653, DOI 10.1093/mnras/stt508; Williams JP, 1997, ASTROPHYS J, V476, P166, DOI 10.1086/303588; Rosolowsky E, 2003, ASTROPHYS J, V599, P258, DOI 10.1086/379166; Joung MKR, 2006, ASTROPHYS J, V653, P1266, DOI 10.1086/508795; Bigiel F, 2008, ASTRON J, V136, P2846, DOI 10.1088/0004-6256/136/6/2846; Heyer MH, 2001, ASTROPHYS J, V551, P852, DOI 10.1086/320218; Wada K, 2007, ASTROPHYS J, V660, P276, DOI 10.1086/513002; SARAZIN CL, 1987, ASTROPHYS J, V320, P32, DOI 10.1086/165522; Tasker EJ, 2009, ASTROPHYS J, V700, P358, DOI 10.1088/0004-637X/700/1/358; Fujimoto Y, 2014, MON NOT R ASTRON SOC, V445, pL65, DOI 10.1093/mnrasl/slu138; Bournaud F, 2010, MON NOT R ASTRON SOC, V409, P1088, DOI 10.1111/j.1365-2966.2010.17370.x; Heyer MH, 2004, ASTROPHYS J, V615, pL45, DOI 10.1086/425978; Dale JE, 2013, MON NOT R ASTRON SOC, V431, P1062, DOI 10.1093/mnras/stt236; ROSEN A, 1995, ASTROPHYS J, V440, P634, DOI 10.1086/175303; Dobbs CL, 2011, MON NOT R ASTRON SOC, V413, P2935, DOI 10.1111/j.1365-2966.2011.18371.x; MACLOW MM, 1988, ASTROPHYS J, V324, P776, DOI 10.1086/165936; Thornton K, 1998, ASTROPHYS J, V500, P95, DOI 10.1086/305704; Kainulainen J, 2009, ASTRON ASTROPHYS, V508, pL35, DOI 10.1051/0004-6361/200913605; Brunt CM, 2009, ASTRON ASTROPHYS, V504, P883, DOI 10.1051/0004-6361/200911797; Wolfire MG, 2003, ASTROPHYS J, V587, P278, DOI 10.1086/368016; Benincasa SM, 2013, ASTROPHYS J, V776, DOI 10.1088/0004-637X/776/1/23; Bryan GL, 2014, ASTROPHYS J SUPPL S, V211, DOI 10.1088/0067-0049/211/2/19; Durier F, 2012, MON NOT R ASTRON SOC, V419, P465, DOI 10.1111/j.1365-2966.2011.19712.x; Fukui Y, 2014, ASTROPHYS J, V780, DOI 10.1088/0004-637X/780/1/36; Fukui Y, 2009, ASTROPHYS J, V705, P144, DOI 10.1088/0004-637X/705/1/144; Hirota A, 2014, PUBL ASTRON SOC JPN, V66, DOI 10.1093/pasj/psu006; Kennicutt RC, 1998, ASTROPHYS J, V498, P541; Lee EJ, 2012, ASTROPHYS J, V752, DOI 10.1088/0004-637X/752/2/146; Mac Low MM, 1999, ASTROPHYS J, V524, P169, DOI 10.1086/307784; Meidt SE, 2013, ASTROPHYS J, V779, DOI 10.1088/0004-637X/779/1/45; Murray N, 2011, ASTROPHYS J, V729, DOI 10.1088/0004-637X/729/2/133; Schaye J., 2012, MNRAS, V426, P140; STONE JM, 1992, ASTROPHYS J SUPPL S, V80, P753, DOI 10.1086/191680; Takahira K, 2014, ASTROPHYS J, V792, DOI 10.1088/0004-637X/792/1/63; Tan JC, 2000, ASTROPHYS J, V536, P173, DOI 10.1086/308905; Tasker EJ, 2011, ASTROPHYS J, V730, DOI 10.1088/0004-637X/730/1/11; Tasker EJ, 2008, ASTROPHYS J, V673, P810, DOI 10.1086/523889; TOOMRE A, 1964, ASTROPHYS J, V139, P1217, DOI 10.1086/147861; VAZQUEZSEMADENI E, 1994, ASTROPHYS J, V423, P681, DOI 10.1086/173847	57	3	3	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							33	10.1088/0004-637X/801/1/33		14	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700033		
J	Whalen, DJ; Smidt, J; Heger, A; Hirschi, R; Yusof, N; Even, W; Fryer, CL; Stiavelli, M; Chen, KJ; Joggerst, CC				Whalen, Daniel J.; Smidt, Joseph; Heger, Alexander; Hirschi, Raphael; Yusof, Norhasliza; Even, Wesley; Fryer, Chris L.; Stiavelli, Massimo; Chen, Ke-Jung; Joggerst, Candace C.			PAIR-INSTABILITY SUPERNOVAE IN THE LOCAL UNIVERSE (vol 9, 797, 2014)	ASTROPHYSICAL JOURNAL			English	Correction									[Whalen, Daniel J.] Heidelberg Univ, Inst Theoret Astrophys, Zentrum Astron, D-69120 Heidelberg, Germany; [Smidt, Joseph] Los Alamos Natl Lab, CCS 2, Los Alamos, NM 87545 USA; [Heger, Alexander] Monash Univ, Monash Ctr Astrophys, Clayton, Vic 3800, Australia; [Heger, Alexander] Univ Minnesota, Sch Phys & Astron, Minneapolis, MN 55455 USA; [Hirschi, Raphael] Keele Univ, Astrophys Grp, Keele ST5 5BG, Staffs, England; [Hirschi, Raphael] Univ Tokyo, Inst Phys & Math Universe WPI, Kashiwa, Chiba 2778583, Japan; [Yusof, Norhasliza] Univ Malaya, Dept Phys, Kuala Lumpur 50603, Malaysia; [Even, Wesley; Fryer, Chris L.] Los Alamos Natl Lab, T 2, Los Alamos, NM 87545 USA; [Stiavelli, Massimo] Space Telescope Sci Inst, Baltimore, MD 21218 USA; [Chen, Ke-Jung] Univ Calif Santa Cruz, Dept Astron & Astrophys, Santa Cruz, CA 95064 USA; [Joggerst, Candace C.] Los Alamos Natl Lab, XTD 3, Los Alamos, NM 87545 USA	Whalen, DJ (reprint author), Heidelberg Univ, Inst Theoret Astrophys, Zentrum Astron, Albert Ueberle Str 2, D-69120 Heidelberg, Germany.	dwhalen1999@gmail.com	YUSOF, NORHASLIZA/B-9363-2010	YUSOF, NORHASLIZA/0000-0002-6883-0874			WHALEN DJ, 2014, APJ, V9	1	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-637X	1538-4357		ASTROPHYS J	Astrophys. J.	MAR 1	2015	801	1							71	10.1088/0004-637X/801/1/71		1	Astronomy & Astrophysics	Astronomy & Astrophysics	CC6PR	WOS:000350488700071		
J	Abramson, LE; Gladders, MD; Dressler, A; Oemler, A; Poggianti, B; Vulcani, B				Abramson, Louis E.; Gladders, Michael D.; Dressler, Alan; Oemler, Augustus, Jr.; Poggianti, Bianca; Vulcani, Benedetta			MATCHING THE EVOLUTION OF THE STELLAR MASS FUNCTION USING LOG-NORMAL STAR FORMATION HISTORIES	ASTROPHYSICAL JOURNAL LETTERS			English	Article						galaxies: evolution; galaxies: luminosity function, mass function; galaxies: star formation	DIGITAL-SKY-SURVEY; DARK-MATTER HALOS; QUIESCENT GALAXIES; FIELD GALAXIES; Z=2; DENSITY; BULGE	We show that a model consisting of individual, log-normal star formation histories for a volume-limited sample of z approximate to 0 galaxies reproduces the evolution of the total and quiescent stellar mass functions at z less than or similar to 2.5 and stellar massesM(*) >= 10(10) M-circle dot. This model has previously been shown to reproduce the star formation rate/stellar mass relation (SFR-M-*) over the same interval, is fully consistent with the observed evolution of the cosmic SFR density at z <= 8, and entails no explicit "quenching" prescription. We interpret these results/features in the context of other models demonstrating a similar ability to reproduce the evolution of (1) the cosmic SFR density, (2) the total/quiescent stellar mass functions, and (3) the SFR-M-* relation, proposing that the key difference between modeling approaches is the extent to which they stress/address diversity in the (star-forming) galaxy population. Finally, we suggest that observations revealing the timescale associated with dispersion in SFR(M-*) will help establish which models are the most relevant to galaxy evolution.	[Abramson, Louis E.; Gladders, Michael D.] Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; [Abramson, Louis E.; Gladders, Michael D.] Univ Chicago, Kavli Inst Cosmol Phys, Chicago, IL 60637 USA; [Dressler, Alan; Oemler, Augustus, Jr.] Observ Carnegie Inst Sci, Pasadena, CA 91101 USA; [Poggianti, Bianca] Osserv Astron Padova, INAF, I-35122 Padua, Italy; [Vulcani, Benedetta] Univ Tokyo, Todai Inst Adv Study, Kavli Inst Phys & Math Universe WPI, Kashiwa, Chiba 2778582, Japan	Abramson, LE (reprint author), Univ Chicago, Dept Astron & Astrophys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	labramson@uchicago.edu			inaugural James Cronin Fellowship	L.E.A. thanks Daniel Kelson for his patience and Doug Watson, Avishai Dekel, Nir Mandelker, and the referee for their thoughtful and helpful responses to our original draft. He also acknowledges generous support from the inaugural James Cronin Fellowship.	Abramson LE, 2014, ASTROPHYS J LETT, V785, DOI 10.1088/2041-8205/785/2/L36; Madau P, 2014, ANNU REV ASTRON ASTR, V52, P415, DOI 10.1146/annurev-astro-081811-125615; Noeske KG, 2007, ASTROPHYS J, V660, pL43, DOI 10.1086/517926; Omand CMB, 2014, MON NOT R ASTRON SOC, V440, P843, DOI 10.1093/mnras/stu331; Williams RJ, 2010, ASTROPHYS J, V713, P738, DOI 10.1088/0004-637X/713/2/738; Martig M, 2009, ASTROPHYS J, V707, P250, DOI 10.1088/0004-637X/707/1/250; York DG, 2000, ASTRON J, V120, P1579, DOI 10.1086/301513; Bluck AFL, 2014, MON NOT R ASTRON SOC, V441, P599, DOI 10.1093/mnras/stu594; Hearin AP, 2013, MON NOT R ASTRON SOC, V435, P1313, DOI 10.1093/mnras/stt1374; Wechsler RH, 2002, ASTROPHYS J, V568, P52, DOI 10.1086/338765; Kauffmann G, 2003, MON NOT R ASTRON SOC, V341, P33, DOI 10.1046/j.1365-8711.2003.06291.x; Moster BP, 2013, MON NOT R ASTRON SOC, V428, P3121, DOI 10.1093/mnras/sts261; Ball NM, 2006, MON NOT R ASTRON SOC, V373, P845, DOI 10.1111/j.1365-2966.2006.11082.x; Behroozi PS, 2013, ASTROPHYS J, V770, DOI 10.1088/0004-637X/770/1/57; Cucciati O, 2012, ASTRON ASTROPHYS, V539, DOI 10.1051/0004-6361/201118010; Gladders MD, 2013, ASTROPHYS J, V770, DOI 10.1088/0004-637X/770/1/64; Guglielmo, 2015, MNRAS UNPUB; Henriques B., 2014, ARXIV14100365; Kelson D. D., 2014, ARXIV14065191; Lang P, 2014, ASTROPHYS J, V788, DOI 10.1088/0004-637X/788/1/11; Lu Z., 2014, ARXIV14065048; Moustakas J, 2013, ASTROPHYS J, V767, DOI 10.1088/0004-637X/767/1/50; Munoz J. A., 2014, ARXIV14041915; Muzzin A, 2013, ASTROPHYS J, V777, DOI 10.1088/0004-637X/777/1/18; Oemler A, 2013, ASTROPHYS J, V770, DOI 10.1088/0004-637X/770/1/63; Salmi F, 2012, ASTROPHYS J LETT, V754, DOI 10.1088/2041-8205/754/1/L14; Salmon B., 2014, ARXIV14076012; Tomczak AR, 2014, ASTROPHYS J, V783, DOI 10.1088/0004-637X/783/2/85; Watson DF, 2013, ASTROPHYS J, V772, DOI 10.1088/0004-637X/772/2/139; Wuyts S, 2011, ASTROPHYS J, V742, DOI 10.1088/0004-637X/742/2/96	30	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	2041-8205	2041-8213		ASTROPHYS J LETT	Astrophys. J. Lett.	MAR 1	2015	801	1							L12	10.1088/2041-8205/801/1/L12		5	Astronomy & Astrophysics	Astronomy & Astrophysics	CC3QB	WOS:000350262900012		
J	Adriani, O; Barbarino, GC; Bazilevskaya, GA; Bellotti, R; Boezio, M; Bogomolov, EA; Bongi, M; Bonvicini, V; Bottai, S; Bravar, U; Bruno, A; Cafagna, F; Campana, D; Carbone, R; Carlson, P; Casolino, M; Castellini, G; Christian, ER; De Donato, C; de Nolfo, GA; De Santis, C; De Simone, N; Di Felice, V; Formato, V; Galper, AM; Karelin, AV; Koldashov, SV; Koldobskiy, S; Krutkov, SY; Kvashnin, AN; Lee, M; Leonov, A; Malakhov, V; Marcelli, L; Martucci, M; Mayorov, AG; Menn, W; Merge, M; Mikhailov, VV; Mocchiutti, E; Monaco, A; Mori, N; Munini, R; Osteria, G; Palma, F; Panico, B; Papini, P; Pearce, M; Picozza, P; Ricci, M; Ricciarini, SB; Ryan, JM; Sarkar, R; Scotti, V; Simon, M; Sparvoli, R; Spillantini, P; Stochaj, S; Stozhkov, YI; Thakur, N; Vacchi, A; Vannuccini, E; Vasilyev, GI; Voronov, SA; Yurkin, YT; Zampa, G; Zampa, N				Adriani, O.; Barbarino, G. C.; Bazilevskaya, G. A.; Bellotti, R.; Boezio, M.; Bogomolov, E. A.; Bongi, M.; Bonvicini, V.; Bottai, S.; Bravar, U.; Bruno, A.; Cafagna, F.; Campana, D.; Carbone, R.; Carlson, P.; Casolino, M.; Castellini, G.; Christian, E. R.; De Donato, C.; de Nolfo, G. A.; De Santis, C.; De Simone, N.; Di Felice, V.; Formato, V.; Galper, A. M.; Karelin, A. V.; Koldashov, S. V.; Koldobskiy, S.; Krutkov, S. Y.; Kvashnin, A. N.; Lee, M.; Leonov, A.; Malakhov, V.; Marcelli, L.; Martucci, M.; Mayorov, A. G.; Menn, W.; Merge, M.; Mikhailov, V. V.; Mocchiutti, E.; Monaco, A.; Mori, N.; Munini, R.; Osteria, G.; Palma, F.; Panico, B.; Papini, P.; Pearce, M.; Picozza, P.; Ricci, M.; Ricciarini, S. B.; Ryan, J. M.; Sarkar, R.; Scotti, V.; Simon, M.; Sparvoli, R.; Spillantini, P.; Stochaj, S.; Stozhkov, Y. I.; Thakur, N.; Vacchi, A.; Vannuccini, E.; Vasilyev, G. I.; Voronov, S. A.; Yurkin, Y. T.; Zampa, G.; Zampa, N.			PAMELA'S MEASUREMENTS OF MAGNETOSPHERIC EFFECTS ON HIGH-ENERGY SOLAR PARTICLES	ASTROPHYSICAL JOURNAL LETTERS			English	Article						Earth; Sun: coronal mass ejections (CMEs); Sun: flares; Sun: heliosphere; Sun: particle emission	GROUND-LEVEL ENHANCEMENT; COSMIC-RAYS; OCTOBER 22; CYCLE 24; EVENT; PROTONS	The nature of particle acceleration at the Sun, whether through flare reconnection processes or through shocks driven by coronal mass ejections, is still under scrutiny despite decades of research. The measured properties of solar energetic particles (SEPs) have long been modeled in different particle-acceleration scenarios. The challenge has been to disentangle the effects of transport from those of acceleration. The Payload for Antimatter Matter Exploration and Light-nuclei Astrophysics (PAMELA) instrument enables unique observations of SEPs including the composition and angular distribution of the particles about the magnetic field, i.e., pitch angle distribution, over a broad energy range (>80 MeV)-bridging a critical gap between space-based and ground-based measurements. We present high-energy SEP data from PAMELA acquired during the 2012 May 17 SEP event. These data exhibit differential anisotropies and thus transport features over the instrument rigidity range. SEP protons exhibit two distinct pitch angle distributions: a low-energy population that extends to 90 degrees and a population that is beamed at high energies (>1 GeV), consistent with neutron monitor measurements. To explain a low-energy SEP population that exhibits significant scattering or redistribution accompanied by a high-energy population that reaches the Earth relatively unaffected by dispersive transport effects, we postulate that the scattering or redistribution takes place locally. We believe that these are the first comprehensive measurements of the effects of solar energetic particle transport in the Earth's magnetosheath.	[Adriani, O.; Bongi, M.; Mori, N.; Spillantini, P.] Univ Florence, Dept Phys & Astron, I-50019 Florence, Italy; [Adriani, O.; Bongi, M.; Bottai, S.; Mori, N.; Papini, P.; Ricciarini, S. B.; Spillantini, P.; Vannuccini, E.] Ist Nazl Fis Nucl, Sez Florence, I-50019 Florence, Italy; [Barbarino, G. C.; Scotti, V.] Univ Naples Federico II, Dept Phys, I-80126 Naples, Italy; [Barbarino, G. C.; Campana, D.; Osteria, G.; Panico, B.; Scotti, V.] Ist Nazl Fis Nucl, Sez Naples, I-80126 Naples, Italy; [Bazilevskaya, G. A.; Kvashnin, A. N.; Stozhkov, Y. I.] PN Lebedev Phys Inst, RU-119991 Moscow, Russia; [Bellotti, R.; Bruno, A.; Monaco, A.] Univ Bari, I-70126 Bari, Italy; [Bellotti, R.; Cafagna, F.; Monaco, A.] Ist Nazl Fis Nucl, Sez Bari, I-70126 Bari, Italy; [Boezio, M.; Bonvicini, V.; Carbone, R.; Formato, V.; Mocchiutti, E.; Munini, R.; Zampa, G.; Zampa, N.] Ist Nazl Fis Nucl, Sez Trieste, I-34149 Trieste, Italy; [Bogomolov, E. A.; Krutkov, S. Y.; Vasilyev, G. I.] AF Ioffe Phys Tech Inst, RU-194021 St Petersburg, Russia; [Bravar, U.; Lee, M.; Ryan, J. M.] Univ New Hampshire, Ctr Space Sci, Durham, NH 03824 USA; [Casolino, M.; De Donato, C.; De Santis, C.; De Simone, N.; Di Felice, V.; Merge, M.; Palma, F.; Picozza, P.; Sparvoli, R.] Ist Nazl Fis Nucl, Sez Rome Tor Vergata, I-00133 Rome, Italy; [De Donato, C.; Marcelli, L.; Martucci, M.; Merge, M.; Palma, F.; Picozza, P.; Sparvoli, R.] Univ Roma Tor Vergata, Dept Phys, I-00133 Rome, Italy; [Galper, A. M.; Karelin, A. V.; Koldashov, S. V.; Koldobskiy, S.; Leonov, A.; Malakhov, V.; Mayorov, A. G.; Mikhailov, V. V.; Voronov, S. A.; Yurkin, Y. T.] Natl Res Nucl Univ MEPhI, RU-115409 Moscow, Russia; [Carlson, P.; Pearce, M.] KTH, Dept Phys, SE-10691 Stockholm, Sweden; [Carlson, P.; Pearce, M.] AlbaNova Univ Ctr, Oskar Klein Ctr Cosmoparticle Phys, SE-10691 Stockholm, Sweden; [Casolino, M.] RIKEN, Adv Sci Inst, Wako, Saitama, Japan; [Castellini, G.; Ricciarini, S. B.] IFAC, I-50019 Florence, Italy; [Christian, E. R.; de Nolfo, G. A.; Thakur, N.] NASA, Goddard Space Flight Ctr, Heliophys Div, Greenbelt, MD 20771 USA; [Formato, V.; Munini, R.] Univ Trieste, Dept Phys, I-34147 Trieste, Italy; [Menn, W.; Simon, M.] Univ Siegen, Dept Phys, D-57068 Siegen, Germany; [Di Felice, V.] ASI, Sci Data Ctr, I-00133 Rome, Italy; [Martucci, M.; Ricci, M.] Ist Nazl Fis Nucl, Lab Nazl Frascati, I-00044 Frascati, Italy; [Sarkar, R.] Indian Ctr Space Phys, Kolkata 700084, W Bengal, India; [Stochaj, S.] New Mexico State Univ, Elect & Comp Engn, Las Cruces, NM 88003 USA; [Vacchi, A.] Udini Univ, Dept Math & Informat, Trieste, Italy; [Vacchi, A.] Ist Nazl Fis Nucl, Trieste, Italy; [Sarkar, R.] Ist Nazl Fis Nucl, Sez Trieste, I-34149 Trieste, Italy	Adriani, O (reprint author), Univ Florence, Dept Phys & Astron, I-50019 Florence, Italy.	georgia.a.denolfo@nasa.gov	Krutkov, Sergey/E-7561-2014; Vasilyev, Gennady/E-4843-2014; De Santis, Cristian/C-1210-2011; De Donato, Cinzia/J-9132-2015; Palma, Francesco/K-3224-2015; Koldobskiy, Sergey/K-6507-2015; Barbarino, Giancarlo/L-2559-2015; Bongi, Massimo/L-9417-2015; Bazilevskaya, Galina/M-6175-2015; Stozhkov, Yuri/M-7433-2015; Kvashnin, Aleksandr/M-8673-2015; Mikhailov, Vladimir/B-5368-2014	Monaco, Alfonso/0000-0002-5968-8642; casolino, marco/0000-0001-6067-5104; Picozza, Piergiorgio/0000-0002-7986-3321; Boezio, Mirko/0000-0002-8015-2981; Bellotti, Roberto/0000-0003-3198-2708; De Santis, Cristian/0000-0002-7280-2446; De Donato, Cinzia/0000-0002-9725-1281; Palma, Francesco/0000-0001-7076-8830; Koldobskiy, Sergey/0000-0001-9187-0383; Barbarino, Giancarlo/0000-0001-9253-3397; Bongi, Massimo/0000-0002-6050-1937; Kvashnin, Aleksandr/0000-0001-7218-6738; 	NASA Heliophysics and Solar Research grant; National Science Foundation (SHINE); Italian Space Agency (ASI); Deutsches Zentrum fur Luft-und Raumfahrt (DLR); Swedish National Space Board; Swedish Research Council; Russian Space Agency (Roscosmos); Russian Science Foundation	The authors acknowledge support from a NASA Heliophysics and Solar Research grant, the National Science Foundation (SHINE), the Italian Space Agency (ASI), Deutsches Zentrum fur Luft-und Raumfahrt (DLR), the Swedish National Space Board, the Swedish Research Council, the Russian Space Agency (Roscosmos), and the Russian Science Foundation. We gratefully thank N. Tsyganenko and Dr. Charlie Farrugia for helpful discussions, and Drs. M. I. Sitnov and G. K. Stephens for support in the use of the TS07D model.	Adriani O, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.051101; Adriani O, 2013, ASTROPHYS J, V765, DOI 10.1088/0004-637X/765/2/91; Ajello M, 2014, ASTROPHYS J, V789, DOI 10.1088/0004-637X/789/1/20; Adriani O, 2009, NATURE, V458, P607, DOI 10.1038/nature07942; Sitnov MI, 2008, J GEOPHYS RES-SPACE, V113, DOI 10.1029/2007JA013003; Tsyganenko NA, 2007, J GEOPHYS RES-SPACE, V112, DOI 10.1029/2007JA012260; Schwartz SJ, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.215002; Bieber JW, 2002, ASTROPHYS J, V567, P622, DOI 10.1086/338246; Papaioannou A, 2014, SOL PHYS, V289, P423, DOI 10.1007/s11207-013-0336-2; Mewaldt RA, 2012, SPACE SCI REV, V171, P97, DOI 10.1007/s11214-012-9884-2; Smart DF, 2000, SPACE SCI REV, V93, P305, DOI 10.1023/A:1026556831199; Bieber JW, 2013, ASTROPHYS J, V771, DOI 10.1088/0004-637X/771/2/92; Bruno A., 2014, ARXIV14121765; Bruno A., 2013, P 33 ICRC UNPUB; Cramp JL, 1997, J GEOPHYS RES-SPACE, V102, P24237, DOI 10.1029/97JA01947; EARL JA, 1976, ASTROPHYS J, V206, P301, DOI 10.1086/154385; Evenson P., 2013, P 33 ICRC UNPUB; Finlay C. C., 2010, GEOJI, V183; Fluckiger E. O., 1993, EOS T AGU S, V74, P487; Gopalswamy N, 2013, ASTROPHYS J LETT, V765, DOI 10.1088/2041-8205/765/2/L30; Gutynska O., 2008, WDS 08 P CONTR PAP 2, P151; Makhmutov VS, 2002, ADV SPACE RES, V29, P2101, DOI 10.1016/S0273-1177(02)00235-1; McCracken KG, 2008, J GEOPHYS RES-SPACE, V113, DOI 10.1029/2007JA012829; Ruffolo D, 2006, ASTROPHYS J, V639, P1186, DOI 10.1086/499419; Smart D. F., 1965, JGR, V70, P4117; Smart D. F., 1997, P 25 ICRC, V1, P129; SOUTHWOOD DJ, 1993, J GEOPHYS RES, V98, P9181, DOI 10.1029/92JA02837; Stormer C., 1950, THE POLAR AURORA; Thakur N., 2012, 2013 SPRING M WASH D; Vashenyuk EV, 2006, GEOMAGN AERONOMY+, V46, P424, DOI 10.1134/S0016793206040037; Vlasova NA, 2011, COSMIC RES+, V49, P485, DOI 10.1134/S0010952511060116	31	1	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	2041-8205	2041-8213		ASTROPHYS J LETT	Astrophys. J. Lett.	MAR 1	2015	801	1							L3	10.1088/2041-8205/801/1/L3		5	Astronomy & Astrophysics	Astronomy & Astrophysics	CC3QB	WOS:000350262900003		
J	Davidson, K; Mehner, A; Humphreys, RM; Martin, JC; Ishibashi, K				Davidson, Kris; Mehner, Andrea; Humphreys, Roberta M.; Martin, John C.; Ishibashi, Kazunori			ETA CARINAE'S 2014.6 SPECTROSCOPIC EVENT: THE EXTRAORDINARY He II AND N II FEATURES	ASTROPHYSICAL JOURNAL LETTERS			English	Article						circumstellar matter; stars: individual (eta Carinae); stars: massive; stars: variables: general; stars: winds, outflows; X-rays: stars	ACCRETION; EMISSION; VARIABILITY; COMPANION; LINES	Eta Carinae's spectroscopic events (periastron passages) in 2003, 2009, and 2014 differed progressively. He II lambda 4687 and nearby N II multiplet 5 have special significance because they respond to very soft X-rays and the ionizing UV radiation field (EUV). Hubble Space Telescope (HST)/STIS observations in 2014 show dramatic increases in both features compared to the previous 2009.1 event. These results appear very consistent with a progressive decline in the primary wind density, proposed years ago on other grounds. If material falls onto the companion star near periastron, the accretion rate may now have become too low to suppress the EUV.	[Davidson, Kris; Humphreys, Roberta M.] Univ Minnesota, Minnesota Inst Astrophys, Minneapolis, MN 55455 USA; [Mehner, Andrea] ESO, Vitacura, Santiago De Chi, Chile; [Martin, John C.] Univ Illinois, Barber Observ, Springfield, IL 62703 USA; [Ishibashi, Kazunori] Nagoya Univ, Grad Sch Sci, Div Elementary Particle Phys & Astrophys, Nagoya, Aichi 4648602, Japan	Davidson, K (reprint author), Univ Minnesota, Minnesota Inst Astrophys, 116 Church St SE, Minneapolis, MN 55455 USA.				NASA [NAS 5-26555]	Based on observations made with the NASA/ESA Hubble Space Telescope, which is operated by the Association of Universities for Research in Astronomy, Inc., under NASA contract NAS 5-26555.	Madura TI, 2013, MON NOT R ASTRON SOC, V436, P3820, DOI 10.1093/mnras/stt1871; Corcoran MF, 2010, ASTROPHYS J, V725, P1528, DOI 10.1088/0004-637X/725/2/1528; Damineli A, 2011, IAU SYMP P SERIES, V272, P604, DOI 10.1017/S1743921311011513; Davidson K, 2005, ASTRON J, V129, P900, DOI 10.1086/427132; Davidson K, 2012, ASTROPHYSICS SPACE S, V384, P43; Davidson K., 2006, HST CALIBRATION WORK, P247; Hamann F., 2012, ASTROPHYSICS SPACE S, V384, P95; Humphreys R. M., 2012, ASTROPHYSICS SPACE S, V384, P1; Humphreys RM, 2008, ASTRON J, V135, P1249, DOI 10.1088/0004-6256/135/4/1249; Kashi A, 2009, NEW ASTRON, V14, P11, DOI 10.1016/j.newast.2008.04.003; Kashi A, 2009, ASTROPHYS J LETT, V701, pL59, DOI 10.1088/0004-637X/701/1/L59; Martin JC, 2010, ASTRON J, V139, P2056, DOI 10.1088/0004-6256/139/5/2056; Martin JC, 2006, ASTRON J, V132, P2717, DOI 10.1086/508933; Martin JC, 2006, ASTROPHYS J, V640, P474, DOI 10.1086/500038; Mehner A, 2010, ASTROPHYS J LETT, V717, pL22, DOI 10.1088/2041-8205/717/1/L22; Mehner A, 2011, ASTROPHYS J, V740, DOI 10.1088/0004-637X/740/2/80; Mehner A, 2010, ASTROPHYS J, V710, P729, DOI 10.1088/0004-637X/710/1/729; Mehner A, 2012, ASTROPHYS J, V751, DOI 10.1088/0004-637X/751/1/73; Remmen G., 2012, APJ, V773, P27; Soker N, 2005, ASTROPHYS J, V635, P540, DOI 10.1086/497389; Soker N, 2007, ASTROPHYS J, V661, P482, DOI 10.1086/514811; Soker N., 2003, APJ, V597, P513; Steiner JE, 2004, ASTROPHYS J, V612, pL133, DOI 10.1086/424831; Teodoro M., 2014, ATEL, P6464; Teodoro M, 2012, ASTROPHYS J, V746, DOI 10.1088/0004-637X/746/1/73; ZANELLA R, 1984, ASTRON ASTROPHYS, V137, P79	26	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	2041-8205	2041-8213		ASTROPHYS J LETT	Astrophys. J. Lett.	MAR 1	2015	801	1							L15	10.1088/2041-8205/801/1/L15		5	Astronomy & Astrophysics	Astronomy & Astrophysics	CC3QB	WOS:000350262900015		
J	Umezaki, Y; Iohara, D; Anraku, M; Ishitsuka, Y; Irie, T; Uekama, K; Hirayama, F				Umezaki, Yoshitaka; Iohara, Daisuke; Anraku, Makoto; Ishitsuka, Yoichi; Irie, Tetsumi; Uekama, Kaneto; Hirayama, Fumitoshi			Preparation of hydrophilic C-60(OH)(10)/2-hydroxypropyl-beta-cyclodextrin nanoparticles for the treatment of a liver injury induced by an overdose of acetaminophen	BIOMATERIALS			English	Article						Polyhydroxylated fullerene; Cyclodextrin; Nanoparticle; Antioxidant; Liver; Acetaminophen	WATER-SOLUBLE FULLERENE; ACETYL-L-CYSTEINE; BIOLOGICAL-ACTIVITY; GAMMA-CYCLODEXTRIN; C-60 NANOPARTICLES; N-ACETYLCYSTEINE; IN-VIVO; HEPATOTOXICITY; MICE; PROTECTION	Stable hydrophilic C-60(OH)(10) nanoparticles were prepared from 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and applied to the treatment of an acetaminophen overdose induced liver Injury. C60(OH)10 nanoparticles were produced by cogrinding alpha-CD, beta-CD, gamma-CD and HP-beta-CD and characterized in terms of solubility, mean particle diameter, zeta-potential and long term dispersibility in water. Hydrophilic C-60(OH)(10) nanoparticles with particle sizes less than 50 nm were effectively produced by cogrinding HP-beta-CD with C-60(OH)(10) at a molar ratio of 1:3 (C-60(OH)(10):CD). The resulting C-60(OH)(10)/HP-beta-CD nanoparticles were stable in water and showed no aggregation over a 1 month period. The C-60(OH)(10)/CDs nanoparticles scavenged not only free radicals (DPPH and ABTS radicals) but also reactive oxygen species (O-2(center dot-) and center dot OH). When C-60(OH)(10)/HP-beta-CD nanoparticles were intraperitoneally administered to mice with a liver injury induced by an overdose of acetaminophen (APAP), the ALT and AST levels were markedly reduced to almost the same level as that for normal mice. Furthermore, the administration of the nanoparticles prolonged the survival rate of liver injured mice, while all of the mice that were treated with APAP died within 40 h. To reveal the mechanism responsible for liver protection by C-60(OH)(10) nanoparticles, GSH level, CYP2E1 expression and peroxynitrite formation in the liver were assessed. C-60(OH)(10)/HP-beta-CD nanoparticles had no effect on CYP2E1 expression and GSH depletion, but suppressed the generation of peroxynitrite in the liver. The findings indicate that the protective effect of C-60(OH)(10)/ HP-beta-CD nanoparticles was due to the suppression of oxidative stress in mitochondria, as the result of scavenging ROS such as O-2(center dot-), NO and peroxynitrite, which act as critical mediators in the liver injuries. (C) 2014 Elsevier Ltd. All rights reserved.	[Umezaki, Yoshitaka; Iohara, Daisuke; Anraku, Makoto; Hirayama, Fumitoshi] Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, Kumamoto 8600082, Japan; [Ishitsuka, Yoichi; Irie, Tetsumi] Kumamoto Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Kumamoto 8620973, Japan; [Uekama, Kaneto] Sojo Univ, DDS Res Inst, Nishi Ku, Kumamoto 8600082, Japan	Hirayama, F (reprint author), Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, 4-22-1 Ikeda, Kumamoto 8600082, Japan.	fhira@ph.sojo-u.ac.jp			JSPS KAKENHI [25860034]	This work was partly supported by JSPS KAKENHI Grant Number 25860034. The authors are grateful to Ms. Fukuzawa and Ms. Fukudome for their technical assistance.	ANDERSSON T, 1992, J CHEM SOC CHEM COMM, P604, DOI 10.1039/c39920000604; Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F; YOSHIDA ZI, 1994, ANGEW CHEM INT EDIT, V33, P1597, DOI 10.1002/anie.199415971; Li CH, 2011, PHARMACOEPIDEM DR S, V20, P810, DOI 10.1002/pds.2103; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; Hinson JA, 1998, CHEM RES TOXICOL, V11, P604, DOI 10.1021/tx9800349; Zakharian TY, 2005, J AM CHEM SOC, V127, P12508, DOI 10.1021/ja0546525; Leelarungrayub N, 2006, NUTRITION, V22, P266, DOI 10.1016/j.nut.2005.05.010; Jaeschke H, 2012, LIVER INT, V32, P8, DOI 10.1111/j.1478-3231.2011.02501.x; Shimizu D, 2014, PHARMACOL RES, V87, P26, DOI 10.1016/j.phrs.2014.06.003; Cover C, 2005, J PHARMACOL EXP THER, V315, P879, DOI 10.1124/jpet.105.088898; Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005; Chen YW, 2004, AM J PHYSIOL-REG I, V287, pR21, DOI 10.1152/ajpregu.00310.2003; RUOFF RS, 1993, J PHYS CHEM-US, V97, P3379, DOI 10.1021/j100115a049; Craig DGN, 2011, BRIT J CLIN PHARMACO, V71, P273, DOI 10.1111/j.1365-2125.2010.03819.x; Nakagawa Y, 2014, ARCH TOXICOL, V88, P115, DOI 10.1007/s00204-013-1096-3; Bakry R, 2007, INT J NANOMED, V2, P639; Jensen AW, 1996, BIOORGAN MED CHEM, V4, P767, DOI 10.1016/0968-0896(96)00081-8; Hanawa N, 2008, J BIOL CHEM, V283, P13565, DOI 10.1074/jbc.M708916200; CORCORAN GB, 1986, J PHARMACOL EXP THER, V238, P54; North TE, 2010, P NATL ACAD SCI USA, V107, P17315, DOI 10.1073/pnas.1008209107; Injac R, 2009, BIOMATERIALS, V30, P1184, DOI 10.1016/j.biomaterials.2008.10.060; Knight TR, 2001, TOXICOL SCI, V62, P212, DOI 10.1093/toxsci/62.2.212; LoGuidice A, 2011, HEPATOLOGY, V54, P969, DOI 10.1002/hep.24464; Nakagawa Y, 2011, ARCH TOXICOL, V85, P1429, DOI 10.1007/s00204-011-0688-z; Eropkin MY, 2013, PHARM CHEM J+, V47, P87, DOI 10.1007/s11094-013-0901-x; Fileti EE, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/36/365703; Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006-291X(02)00445-X; Heymann D, 1996, FULLERENE SCI TECHN, V4, P509, DOI 10.1080/10641229608001567; Iohara D, 2011, MOL PHARMACEUT, V8, P1276, DOI 10.1021/mp200204v; Kogure K, 1999, BBA-GEN SUBJECTS, V1426, P133, DOI 10.1016/S0304-4165(98)00146-9; LAUTERBURG BH, 1983, J CLIN INVEST, V71, P980, DOI 10.1172/JCI110853; Maeda-Mamiya R, 2010, P NATL ACAD SCI USA, V107, P5339, DOI 10.1073/pnas.0909223107; Masubuchi Y, 2009, CHEM-BIOL INTERACT, V179, P273, DOI 10.1016/j.cbi.2008.10.028; MCEWEN CN, 1992, J AM CHEM SOC, V114, P4412, DOI 10.1021/ja00037a064; Mirkov SM, 2004, NITRIC OXIDE-BIOL CH, V11, P201, DOI 10.1016/j.niox.2004.08.003; Misirkic MS, 2009, BIOMATERIALS, V30, P2319, DOI 10.1016/j.biomaterials.2009.01.023; Tomishima Y, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-21	39	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAR	2015	45						115	123		10.1016/j.biomaterials.2014.12.032		9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CC2RD	WOS:000350191400013		
J	Miyake, Y; Tanaka, K; Okubo, H; Sasaki, S; Arakawa, M				Miyake, Y.; Tanaka, K.; Okubo, H.; Sasaki, S.; Arakawa, M.			Re: Intake of dairy products and calcium and prevalence of depressive symptoms during pregnancy in Japan: a cross-sectional study Reply	BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Letter									[Miyake, Y.] Ehime Univ, Grad Sch Med, Dept Publ Hlth, Matsuyama, Ehime 790, Japan; [Tanaka, K.] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka 81401, Japan; [Okubo, H.] Natl Inst Publ Hlth, Dept Hlth Promot, Saitama, Japan; [Sasaki, S.] Univ Tokyo, Grad Sch Med, Dept Social & Prevent Epidemiol, Tokyo, Japan; [Arakawa, M.] Univ Ryukyus, Grad Sch Tourism Sci, Hlth Tourism Res Ctr, Nishihara, Okinawa 90301, Japan	Miyake, Y (reprint author), Ehime Univ, Grad Sch Med, Dept Publ Hlth, Matsuyama, Ehime 790, Japan.						Bergink V, 2013, BIOL PSYCHIAT, V73, P1000, DOI 10.1016/j.biopsych.2012.11.006; Desbonnet L, 2010, NEUROSCIENCE, V170, P1179, DOI 10.1016/j.neuroscience.2010.08.005; Foster JA, 2013, TRENDS NEUROSCI, V36, P305, DOI 10.1016/j.tins.2013.01.005; Christian LM, 2009, BRAIN BEHAV IMMUN, V23, P750, DOI 10.1016/j.bbi.2009.02.012; Miyake Y, 2014, BJOG, V122, P336	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1470-0328	1471-0528		BJOG-INT J OBSTET GY	BJOG	MAR	2015	122	4					586	587		10.1111/1471-0528.13088		2	Obstetrics & Gynecology	Obstetrics & Gynecology	CC1XS	WOS:000350139300034		
J	Shimojima, K; Okumura, A; Ikeno, M; Nishimura, A; Saito, A; Saitsu, H; Matsumoto, N; Yamamoto, T				Shimojima, Keiko; Okumura, Akihisa; Ikeno, Mitsuru; Nishimura, Akira; Saito, Akira; Saitsu, Hirotomo; Matsumoto, Naomichi; Yamamoto, Toshiyuki			A de novo TUBB4A mutation in a patient with hypomyelination mimicking Pelizaeus-Merzbacher disease	BRAIN & DEVELOPMENT			English	Article						Hypomyelinating leukoencephalopathy; TUBB4A; Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC); Pelizaeus Merzbacher disease (PMD); Genetic counseling	BASAL GANGLIA; PLP1 DUPLICATION; ATROPHY; CEREBELLUM; LEUKOENCEPHALOPATHY; POLR3A	Objective: Hypomyelinating leukoencephalopathy is a heterogeneous disorder caused by mutations in several-different genes. Clinical entity of hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) is one of them. Method: A male patient showed pendular nystagmus, infantile hypotonia, an abnormal pattern of brain auditory evoked potential, and hypomyelination on brain magnetic resonance imaging, which suggested Pelizaeus Merzbacher disease (PMD) as the candidate diagnosis; however, no abnormality was found in the proteolipid protein 1 gene (PLP1) that is responsible for PMD. Whole exome sequencing was performed to identify pathogenic mutations in this patient. Results: A de novo mutation was identified in the tubulin 4a gene (TUBB4A), which has been recently reported to be associated with H-ABC. Although the patient did not show any neurological features suggesting H-ABC, such as extrapyramidal or cerebellar signs, radiological findings demonstrated the finding of cerebellar atrophy at the age of 36 months. Conclusion: This study suggested us the difficulty of clinical diagnosis for H-ABC early in the life of the patient, which makes predication of prognosis and genetic counseling difficult. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Shimojima, Keiko] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi, Saitama, Japan; [Shimojima, Keiko; Yamamoto, Toshiyuki] Tokyo Womens Med Univ, Inst Integrated Med Sci, Tokyo 1628666, Japan; [Okumura, Akihisa; Ikeno, Mitsuru] Juntendo Univ, Fac Med, Dept Pediat, Tokyo, Japan; [Okumura, Akihisa] Aichi Med Univ, Dept Pediat, Nagakute, Aichi 48011, Japan; [Nishimura, Akira] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto 602, Japan; [Saito, Akira] StaGen Co Ltd, Stat Genet Anal Div, Tokyo, Japan; [Saitsu, Hirotomo; Matsumoto, Naomichi] Yokohama City Univ, Grad Sch Med, Dept Human Genet, Yokohama, Kanagawa 232, Japan	Yamamoto, T (reprint author), Tokyo Womens Med Univ, Inst Integrated Med Sci, 8-1 Kawada Cho, Tokyo 1628666, Japan.	yamamoto.toshiyuki@twmu.ac.jp			JST PRESTO program; Health Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare, Japan; Japan Society for the Promotion of Science (JSPS)	We would like to express our gratitude to the patient and his family for their cooperation. This work was partially supported by JST PRESTO program and a Grant-in-Aid for Young Scientists (B) from Japan Society for the Promotion of Science (JSPS) (KS), and a Grant-in-Aid for Scientific Research from Health Labor Sciences Research Grants from the Ministry of Health, Labor, and Welfare, Japan (TY).	Lohmann K, 2013, ANN NEUROL, V73, P537, DOI 10.1002/ana.23829; Saitsu H, 2011, AM J HUM GENET, V89, P644, DOI 10.1016/j.ajhg.2011.10.003; Simons C, 2013, AM J HUM GENET, V92, P767, DOI 10.1016/j.ajhg.2013.03.018; Shimojima K, 2012, J HUM GENET, V57, P580, DOI 10.1038/jhg.2012.71; Hersheson J, 2013, ANN NEUROL, V73, P546, DOI 10.1002/ana.23832; Timmons M, 2006, NEUROLOGY, V67, P2066, DOI 10.1212/01.wnl.0000247666.28904.35; Hanefeld FA, 2005, NEUROLOGY, V65, P701, DOI 10.1212/01.wnl.0000174642.32187.20; Hattori Ayako, 2010, No To Hattatsu, V42, P42; Matta APD, 2007, ARQ NEURO-PSIQUIAT, V65, P161, DOI 10.1590/S0004-282X2007000100033; NEZU A, 1995, BRAIN DEV-JPN, V17, P175, DOI 10.1016/0387-7604(95)00028-A; Sasaki M, 2009, BRAIN DEV-JPN, V31, P582, DOI 10.1016/j.braindev.2008.09.003; Shimojima K, 2010, BRAIN DEV-JPN, V32, P171, DOI 10.1016/j.braindev.2009.02.011; Shimojima K, 2014, BRAIN DEV-JPN, V36, P315, DOI 10.1016/j.braindev.2013.04.011; Shimojima K, 2013, J NEUROL SCI, V330, P123, DOI 10.1016/j.jns.2013.04.017; Takanashi J, 2002, NEUROLOGY, V58, P237; van der Knaap MS, 2002, AM J NEURORADIOL, V23, P1466; Wolf NI, 2007, NEUROPEDIATRICS, V38, P64, DOI 10.1055/s-2007-985137; Yamamoto T, 2013, CONGENIT ANOM, V53, P3, DOI 10.1111/cga.12005	18	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					281	285		10.1016/j.braindev.2014.05.004		5	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300002		
J	Katayama, K; Povalko, N; Yatsuga, S; Nishioka, J; Kakuma, T; Matsuishi, T; Koga, Y				Katayama, Koujyu; Povalko, Nataliya; Yatsuga, Shuichi; Nishioka, Junko; Kakuma, Tatsuyuki; Matsuishi, Toyojiro; Koga, Yasutoshi			New TRPM6 mutation and management of hypomagnesaemia with secondary hypocalcaemia	BRAIN & DEVELOPMENT			English	Article						TRPM6; HSH; Genotype phenotype correlation; Magnesium; Mental retardation; Failure to thrive	FAMILIAL HYPOMAGNESEMIA; MAGNESIUM	Background: TRPM6 gene mutation has been reported to cause hypomagnesemia with secondary hypocalcemia (HSH). However, the genotype phenotype correlation for TRPM6 gene mutations has not been clarified. Objective: To elucidate the factors underlying the severe neurological complications in HSH and evaluate the potential association between the location of TRPM6 gene mutations and clinical data of HSH. Methods: A Japanese patient diagnosed with HSH at 10 weeks of age exhibited neurological damage and failed to thrive. Magnesium supplements were therefore started at 12 weeks of age. Mutational analysis of the TRPM6 gene was performed using a direct sequencing method to determine the position and type of mutation. Using the data of 29 HSH patients reported in the literature, linear regression analysis was also performed to examine the association between TRPM6 gene mutation location and HSH onset age, initial serum magnesium and calcium concentrations, and dose of oral magnesium. Results: A novel stop-codon homozygous mutation [c.4190 G > A] W1397X was identified in exon 26 of the patient's TRPM6 gene. No statistical correlation was found between the location of mutations in the TRPM6 gene and the clinical data for 4 clinical indicators of HSH. Conclusions: We identified the first Japanese HSH patient with a novel nonsense mutation in the TRPM6 gene. Regression analysis of mutation locations in the protein-coding region of TRPM6 and the reported clinical data for 4 clinical indicators of HSH in 30 HSH patients did not detect a genotype phenotype correlation. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Katayama, Koujyu; Povalko, Nataliya; Yatsuga, Shuichi; Nishioka, Junko; Matsuishi, Toyojiro; Koga, Yasutoshi] Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; [Kakuma, Tatsuyuki] Kurume Univ, Grad Sch Med, Dept Biostat, Kurume, Fukuoka 830, Japan	Koga, Y (reprint author), Kurume Univ, Sch Med, Dept Pediat & Child Hlth, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	yasukoga@med.kurume-u.ac.jp			Ministry of Culture and Education in Japan [16390308]	This work was supported in part by a grant (#16390308) from the Ministry of Culture and Education in Japan to Y.K.	Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Schlingmann KP, 2007, BBA-MOL BASIS DIS, V1772, P813, DOI 10.1016/j.bbadis.2007.03.009; Esteban-Oliva D, 2009, EUR J PEDIATR, V168, P439, DOI 10.1007/s00431-008-0767-1; Schlingmann KP, 2005, J AM SOC NEPHROL, V16, P3061, DOI 10.1681/ASN.2004110989; Guran T, 2012, NEPHROL DIAL TRANSPL, V27, P667, DOI 10.1093/ndt/gfr300; MODY I, 1987, J NEUROPHYSIOL, V57, P869; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; Walder RY, 2009, HUM MOL GENET, V18, P4367, DOI 10.1093/hmg/ddp392; PAUNIER L, 1968, PEDIATRICS, V41, P385; Apa H, 2008, INDIAN J PEDIATR, V75, P632, DOI 10.1007/s12098-008-0121-7; CHALLA A, 1995, ACTA PAEDIATR, V84, P1075, DOI 10.1111/j.1651-2227.1995.tb13830.x; Cole DEC, 2000, EUR J PEDIATR, V159, P38, DOI 10.1007/s004310050007; Japtap VS, 2012, INDIAN J ENDOCRINOL, V16, P624; Lainez S, 2013, EUR J HUM GENET, P1; LOMBECK I, 1975, Z KINDERHEILKD, V118, P249, DOI 10.1007/BF00492330; MILLA PJ, 1979, GUT, V20, P1028, DOI 10.1136/gut.20.11.1028; Munoz-Hoyos A, 2011, PSYCHIAT RES, V188, P96, DOI 10.1016/j.psychres.2010.10.004; Shalev H, 1998, ARCH DIS CHILD, V78, P127; Skuse D, 1996, LANCET, V348, P353, DOI 10.1016/S0140-6736(96)01358-X	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					292	298		10.1016/j.braindev.2014.06.006		7	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300004		
J	Yamamoto, H; Okumura, A; Natsume, J; Kojima, S; Mizuguchi, M				Yamamoto, Hiroyuki; Okumura, Akihisa; Natsume, Jun; Kojima, Seiji; Mizuguchi, Masashi			A severity score for acute necrotizing encephalopathy	BRAIN & DEVELOPMENT			English	Article						Acute necrotizing encephalopathy; ANE; Severity score; Prognosis; Risk	INFLUENZA; CHILDHOOD; CHILDREN; INCREASE; LESIONS; BRAIN	Objective: To develop a score that predicts the prognosis of children with acute necrotizing encephalopathy (ANE). Method: We retrospectively evaluated clinical variables and neurological outcome in two cohorts of children with ANE. Firstly, we developed the ANE severity score (ANE-SS) according to the clinical variables that correlated with neurological outcome in 41 children who were included in our previous reports in 2009. We then applied the scoring system to a second cohort of 32 patients who were newly collected in 2011. We investigated the correlation between the ANE-SS and neurological outcome in all 73 patients. Results: In the first cohort, brain stem lesions on MRI and state of shock at onset were significantly correlated with outcome. Age over 48 months, elevated CSF protein, and low platelet counts tended to be correlated with outcome. No types of treatment were correlated with outcome. The developed ANE-SS ranged from 0 to 9 points, with 3 points for existence of shock, 2 points for brain stem lesions, 2 points for age over 48 months, 1 point for platelet count below 100,000/mu L, and 1 point for CSF protein above 60 mg/dl. Patients were classed as low risk (ANE-SS 0-1 points), medium risk (ANE-SS 2-4 points), or high risk (ANE-SS 5-9 points). ANE-SS was significantly correlated with outcome in the group of 73 patients. Conclusion: ANE-SS can be used to predict outcome in patients with ANE. More effective treatments need to be developed for high-risk patients. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Yamamoto, Hiroyuki; Natsume, Jun; Kojima, Seiji] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi 4668550, Japan; [Okumura, Akihisa] Juntendo Univ, Fac Med, Dept Pediat, Tokyo, Japan; [Okumura, Akihisa] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan	Yamamoto, H (reprint author), Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	h-yamamoto@med.nagoya-u.ac.jp					Akiyoshi K, 2006, PEDIATR NEUROL, V34, P315, DOI 10.1016/j.pediatrneurol.2005.08.030; Togashi T, 2004, VIRUS RES, V103, P75, DOI 10.1016/j.virusres.2004.02.016; MIZUGUCHI M, 1995, J NEUROL NEUROSUR PS, V58, P555, DOI 10.1136/jnnp.58.5.555; Wong AM, 2006, AM J NEURORADIOL, V27, P1919; Ito Y, 1999, J MED VIROL, V58, P420, DOI 10.1002/(SICI)1096-9071(199908)58:4<420::AID-JMV16>3.0.CO;2-T; Hoshino A, 2012, BRAIN DEV-JPN, V34, P337, DOI 10.1016/j.braindev.2011.07.012; Tsuge M, 2010, MICROBIOL IMMUNOL, V54, P417, DOI 10.1111/j.1348-0421.2010.00226.x; Okumura A, 2009, BRAIN DEV-JPN, V31, P221, DOI 10.1016/j.braindev.2008.03.005; Mizuguchi M, 2007, ACTA NEUROL SCAND, V115, P45, DOI 10.1111/j.1600-0404.2007.00809.x; Bergamino L, 2012, BRAIN DEV-JPN, V34, P384, DOI 10.1016/j.braindev.2011.08.001; Ichiyama T, 2003, PEDIATR INT, V45, P734, DOI 10.1111/j.1442-200X.2003.01822.x; Kansagra SM, 2011, PEDIATR NEUROL, V45, P400, DOI 10.1016/j.pediatrneurol.2011.09.007; Kim JH, 2004, KOREAN J RADIOL, V5, P171; Kubo T, 2006, SCAND J INFECT DIS, V38, P1122, DOI 10.1080/00365540600740520; MIZUGUCHI M, 1989, ACTA NEUROPATHOL, V78, P108; Mizuguchi M, 1997, BRAIN DEV-JPN, V19, P81, DOI 10.1016/S0387-7604(96)00063-0; Okumura A, 2009, BRAIN DEV-JPN, V31, P594, DOI 10.1016/j.braindev.2008.09.002; Okumura A, 2009, MICROBIOL IMMUNOL, V53, P277, DOI 10.1111/j.1348-0421.2009.00124.x; Vargas WS, 2012, PEDIATR NEUROL, V46, P387, DOI 10.1016/j.pediatrneurol.2012.03.001	19	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					322	327		10.1016/j.braindev.2014.05.007		6	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300009		
J	Nishiyama, M; Tanaka, T; Fujita, K; Maruyama, A; Nagase, H				Nishiyama, Masahiro; Tanaka, Tsukasa; Fujita, Kyoko; Maruyama, Azusa; Nagase, Hiroaki			Targeted temperature management of acute encephalopathy without AST elevation	BRAIN & DEVELOPMENT			English	Article						Acute encephalopathy; Febrile seizure; Hypothermia; Refractory status epilepticus; Targeted temperature management	ACUTE NECROTIZING ENCEPHALOPATHY; NEONATAL ENCEPHALOPATHY; HYPOTHERMIA THERAPY; FEBRILE SEIZURES; CARDIAC-ARREST; INFLUENZA; DIFFUSION; CHILDHOOD; OUTCOMES	Background: Acute encephalopathy is a leading cause of mortality and neurological sequelae in children. Although many strategies have been proposed, effective therapies have not yet been established. The objective of this retrospective study was to assess the effectiveness of targeted temperature management in children with acute encephalopathy. Methods: We retrospectively evaluated the clinical courses and outcomes of 57 children who were consecutively admitted at Kobe Children's Hospital between October 2002 and August 2011. These children had acute encephalopathy with serum aspartate aminotransferase (AST) levels below 90 IU/1 within 6 h of onset. We compared the clinical characteristics and neurological outcomes of children treated with targeted temperature management and those who received conventional care. Targeted temperature management was defined as temperature control (34.5-36 degrees C) with intubation, and the continuous use of anticonvulsants and muscle relaxants induced within 24 h of onset. Outcome was measured using the Pediatric Cerebral Performance Category Scale with grade 1 representing a good clinical outcome and grades 2-6 reflecting poor outcomes. Results: Outcomes were good in all children treated with targeted temperature management (n = 23) as well as in 24 out of the 34 children who received conventional care (p = 0.004). The age, gender, refractory status epilepticus rate, prolonged neurological abnormality rate, preceding infection rate, and laboratory results were not significantly different between the two groups. Conclusions: We determined that targeted temperature management could improve outcome in acute encephalopathy without AST elevation. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Nishiyama, Masahiro; Tanaka, Tsukasa; Fujita, Kyoko; Maruyama, Azusa; Nagase, Hiroaki] Hyogo Prefectural Kobe Childrens Hosp, Dept Neurol, Kobe, Hyogo 6540081, Japan	Nagase, H (reprint author), Hyogo Prefectural Kobe Childrens Hosp, Dept Neurol, Suma Ku, 1-1-1 Takakuradai, Kobe, Hyogo 6540081, Japan.	nagasehiroaki@msn.com			Hyogo prefectural medical association	This study was supported by the Hyogo prefectural medical association.	Yokota S, 2000, PEDIATR INT, V42, P197; Munakata M, 2000, BRAIN DEV-JPN, V22, P373, DOI 10.1016/S0387-7604(00)00169-8; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Epstein Y, 2011, SCAND J MED SCI SPOR, V21, P742, DOI 10.1111/j.1600-0838.2011.01333.x; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Kawano G, 2011, ARCH DIS CHILD, V96, P936, DOI 10.1136/adc.2009.180554; Holzer M, 2002, NEW ENGL J MED, V346, P549; Rincon F, 2014, INT J STROKE, V9, P646, DOI 10.1111/ijs.12220; Gunn AJ, 1999, PEDIATR RES, V46, P274, DOI 10.1203/00006450-199909000-00005; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Hoshino A, 2012, BRAIN DEV-JPN, V34, P337, DOI 10.1016/j.braindev.2011.07.012; Takanashi J, 2006, NEUROLOGY, V66, P1304, DOI 10.1212/01.wnl.0000210487.36667.a5; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Okumura A, 2009, BRAIN DEV-JPN, V31, P221, DOI 10.1016/j.braindev.2008.03.005; Mizuguchi M, 2007, ACTA NEUROL SCAND, V115, P45, DOI 10.1111/j.1600-0404.2007.00809.x; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; CHAVESCARBALLO E, 1990, AM J DIS CHILD, V144, P1079; Hayashi N, 2012, BRAIN DEV-JPN, V34, P632, DOI 10.1016/j.braindev.2011.11.007; Iwata O, 2011, BRAIN DEV-JPN, V33, P221, DOI 10.1016/j.braindev.2010.11.008; Kimura Seiji, 2000, No To Hattatsu, V32, P62; Mizuguchi M, 1997, BRAIN DEV-JPN, V19, P81, DOI 10.1016/S0387-7604(96)00063-0; Nagase H, 2013, PEDIATR INT, V55, P310, DOI 10.1111/ped.12046; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Research Committee on the Clarification of Etiology and Establishment of Therapeutic and Preventive Measures of Influenza Encephalopathy, 2005, GUID INFL ENC, P1; Sakuma H, 2009, BRAIN DEV-JPN, V31, P510, DOI 10.1016/j.braindev.2009.02.010; Simbruner G, 2010, PEDIATRICS, V126, pE771, DOI 10.1542/peds.2009-2441	28	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					328	333		10.1016/j.braindev.2014.06.005		6	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300010		
J	Hatanaka, M; Kashiwagi, M; Tanabe, T; Nakahara, H; Ohta, K; Tamai, H				Hatanaka, Mari; Kashiwagi, Mitsuru; Tanabe, Takuya; Nakahara, Hiroshi; Ohta, Kazumi; Tamai, Hiroshi			Overlapping MERS and mild AESD caused by HHV-6 infection	BRAIN & DEVELOPMENT			English	Article						Overlap; Human herpesvirus 6; Clinically mild encephalitis/encephalopathy with a reversible splenial lesion; Acute encephalopathy with biphasic seizures and late reduced diffusion	ENCEPHALOPATHY; CHILDREN	We report the case of an overlapping encephalopathy syndrome consisting of clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) and a mild form of acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) caused by human herpesvirus-6. A previously healthy 17-month-old girl was admitted to our hospital as a precaution because of seizures that had developed more than 25 hours (h) after fever. Brain diffusion-weighted images (DWI) showed high signal intensity in the central splenial region on Day 2. She regained consciousness 16 h after the second seizure. On Day 6, she had a secondary cluster of partial seizures. DWI showed resolution of the splenial lesion and revealed reduced diffusion in the fronto-subcortical white matter. She regained consciousness 36 h after the secondary cluster of seizures without any sequelae. A third DWI performed on Day 15 showed that the fronto-subcortical white matter lesions had completely disappeared. Based on the clinicoradiological findings, we diagnosed the patient with overlapping MERS and mild AESD. Our case, together with previous reports, suggests that patients can develop combined encephalopathy syndromes as a phenotype. Many encephalopathy syndromes have been established and classified; however, some may not present as independent syndromes. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Hatanaka, Mari; Ohta, Kazumi] Rakuwakai Otowa Hosp, Dept Pediat, Kyoto, Japan; [Kashiwagi, Mitsuru] Hirakata City Hosp, Dept Pediat, Hirakata, Osaka 5731013, Japan; [Tanabe, Takuya] Tanabe Childrens Clin, Dept Child Neurol, Nara, Japan; [Nakahara, Hiroshi] Nakahara Hiroshi Kids Clin, Dept Pediat, Sakuma, Japan; [Tamai, Hiroshi] Osaka Med Coll, Dept Pediat, Osaka, Japan	Kashiwagi, M (reprint author), Hirakata City Hosp, Dept Pediat, 2-14-1 Kinnya Honnmachi, Hirakata, Osaka 5731013, Japan.	dbs003@art.osaka-med.ac.jp					Kawamura Y, 2013, BRAIN DEV-JPN, V35, P590, DOI 10.1016/j.braindev.2012.08.005; Kashiwagi M, 2014, BRAIN DEV-JPN, V36, P330, DOI 10.1016/j.braindev.2013.05.007; Shinohara M, 2013, NEUROLOGY, V80, P1571, DOI 10.1212/WNL.0b013e31828f18d8; Yoshikawa T, 2000, BRAIN DEV-JPN, V22, P307, DOI 10.1016/S0387-7604(00)00113-3; Hoshino A, 2012, BRAIN DEV-JPN, V34, P337, DOI 10.1016/j.braindev.2011.07.012; Kobayashi K, 2010, EPILEPSY RES, V91, P143, DOI 10.1016/j.eplepsyres.2010.07.005; Fujiki Youhei, 2011, Rinsho Shinkeigaku, V51, P510; Ministry of Education Culture Sports Science and Technology, 2009, GBT47892 MIN PUBL HL, P1; Takanashi J, 2009, BRAIN DEV-JPN, V31, P521, DOI 10.1016/j.braindev.2009.02.012; Yoshitomi Shinsaku, 2012, No To Hattatsu, V44, P487	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					334	338		10.1016/j.braindev.2014.04.011		5	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300011		
J	Okumura, A; Nakazawa, M; Igarashi, A; Abe, S; Ikeno, M; Nakahara, E; Yamashiro, Y; Shimizu, T; Takahashi, T				Okumura, Akihisa; Nakazawa, Mika; Igarashi, Ayuko; Abe, Shinpei; Ikeno, Mitsuru; Nakahara, Eri; Yamashiro, Yuichiro; Shimizu, Toshiaki; Takahashi, Toshiyuki			Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis	BRAIN & DEVELOPMENT			English	Article						Anti-aquaporin 4 antibody; Acute disseminated encephalomyelitis; Optic neuritis; Steroids; Vaccination	H1N1 INFLUENZA VACCINE; TERM-FOLLOW-UP; NEUROMYELITIS-OPTICA; MULTIPLE-SCLEROSIS; ANTI-AQUAPORIN-4 ANTIBODY; DEMYELINATING DISORDERS; PEDIATRIC-PATIENTS; CRITERIA; FEATURES; MARKER	Objective: To describe the clinical and neuroimaging features of a young female patient with acute disseminated encephalomyelitis associated with anti-aquaporin-4 antibodies. Methods: The patient had mild encephalopathy 14 days after influenza vaccination. Cerebrospinal fluid analysis revealed an increased cell count and a marked increase in myelin basic protein. Magnetic resonance imaging (MRI) demonstrated multiple lesions in the juxtacortical white matter. The patient was diagnosed with acute disseminated encephalomyelitis and treated with methylprednisolone pulse therapy. She recovered in 1 month. However, right retrobulbar optic neuritis appeared 2 months after discharge, and serum anti-aquaporin 4 antibodies were measured with a cell-based assay. Results: Anti-aquaporin 4 antibodies were present in the patient's serum. She was treated with a prolonged course of oral prednisolone. The patient was negative for serum anti-aquaporin 4 antibodies 8 months after the second clinical event, and prednisolone was discontinued 13 months after the second clinical event. Serum anti-aquaporin 4 antibodies remained negative 4 months after the discontinuation of prednisolone. There was no evidence of relapse at 9 months after discontinuation of steroids. Conclusions: This case will expand the spectrum of anti-aquaporin-4 antibody-related central nervous system disorders. The measurement of anti-aquaporin 4 antibody may be considered in patients with a clinical diagnosis of acute disseminated encephalomyelitis and a second clinical event within a short interval. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Okumura, Akihisa; Nakazawa, Mika; Igarashi, Ayuko; Abe, Shinpei; Ikeno, Mitsuru; Nakahara, Eri; Shimizu, Toshiaki] Juntendo Univ, Fac Med, Dept Pediat, Tokyo, Japan; [Okumura, Akihisa] Aichi Med Univ, Dept Pediat, Nagakute, Aichi 4801195, Japan; [Yamashiro, Yuichiro] Juntendo Univ, Grad Sch Med, Probiot Res Lab, Tokyo, Japan; [Takahashi, Toshiyuki] Tohoku Univ, Dept Neurol, Grad Sch Med, Sendai, Miyagi 980, Japan	Okumura, A (reprint author), Aichi Med Univ, Dept Pediat, 1-1 Yazako Karimata, Nagakute, Aichi 4801195, Japan.	okumura.akihisa.479@mail.aichi-med-u.ac.jp			Ministry of Health, Labor, and Welfare of Japan [H24-Shinkou-Ippan-002, H25-Nanji-Ippan-009]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [23591518]	We thank the patient and her families for their cooperation. This study is supported by the Grants from the Ministry of Health, Labor, and Welfare of Japan (H24-Shinkou-Ippan-002 and H25-Nanji-Ippan-009), and the Grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (23591518).	McKeon A, 2008, NEUROLOGY, V71, P93, DOI 10.1212/01.wnl.0000314832.24682.c6; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Lotze TE, 2008, PEDIATRICS, V122, pE1039, DOI 10.1542/peds.2007-2758; Takahashi T, 2007, BRAIN, V130, P1235, DOI 10.1093/brain/awm062; Trebst C, 2014, J NEUROL, V261, P1, DOI 10.1007/s00415-013-7169-7; Saiki S, 2009, J NEUROL SCI, V284, P217, DOI 10.1016/j.jns.2009.05.022; Collongues N, 2010, NEUROLOGY, V75, P1084, DOI 10.1212/WNL.0b013e3181f39a66; Krupp LB, 2013, MULT SCLER J, V19, P1261, DOI 10.1177/1352458513484547; Tenembaum S, 2002, NEUROLOGY, V59, P1224; Leake JAD, 2004, PEDIATR INFECT DIS J, V23, P756, DOI 10.1097/01.inf.0000133048.75452.dd; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Marin SE, 2013, NEUROIMAG CLIN N AM, V23, P245, DOI 10.1016/j.nic.2012.12.005; Fujii K, 2012, PEDIATR INT, V54, P539, DOI 10.1111/j.1442-200X.2011.03501.x; Hino-Fukuyo Naomi, 2011, No To Hattatsu, V43, P359; Janus S, 2010, NAT REV NEUROL, V6, P383; Lapphra K, 2011, PEDIATR INFECT DIS J, V30, P84, DOI 10.1097/INF.0b013e3181f11126; Long YM, 2012, CLIN NEUROL NEUROSUR, V114, P1131, DOI 10.1016/j.clineuro.2012.01.022	18	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					339	343		10.1016/j.braindev.2014.04.013		5	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300012		
J	Suzuki, K; Hiramoto, A; Okumura, T				Suzuki, Keiko; Hiramoto, Azuma; Okumura, Toshikatsu			A case report on reversible Pelger-Huet anomaly depending on serum free fraction of valproic acid	BRAIN & DEVELOPMENT			English	Article						Pelger-Huet anomalies; Valproic acid; Hypoalbuminemia		Pelger-Huet anomalies, which are characterized by an abnormal nuclear shape and chromatin organization in blood granulocytes, and are frequently confused with myelodysplastic syndrome. We herein report a case of Lenox syndrome in a patient treated with VPA for more than 25 years who developed significant Pelger-Huet anomalies. Despite the lack of any changes in the total VPA level throughout the patient's clinical course, the free fraction of VPA potently increased, likely due to a reduction in serum albumin. Following the administration of a smaller dose of VPA that reduced the serum free fraction of VPA to the normal range, the Pelger-Huet anomalies completely disappeared. It is necessary to monitor the free fraction of VPA in order to detect an overdose, which may induce adverse effects under conditions of hypoalbuminemia. The present case showed, for the first time, that VPA-induced Pelger-Huet anomalies occur in a dose-dependent and reversible manner. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Suzuki, Keiko; Okumura, Toshikatsu] Asahikawa Med Univ Hosp, Dept Gen Med, Asahikawa, Hokkaido 0788510, Japan; [Suzuki, Keiko; Hiramoto, Azuma] Inst Children Adults Severe Disabil, Dept Neurol, Asahikawa, Hokkaido, Japan	Suzuki, K (reprint author), Asahikawa Med Univ Hosp, Dept Gen Med, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 0788510, Japan.	kii_suzu@yahoo.co.jp					Wang E, 2011, AM J CLIN PATHOL, V135, P291, DOI 10.1309/AJCPVFY95MAOBKRS; Dusse LMS, 2010, CLIN CHIM ACTA, V411, P1587, DOI 10.1016/j.cca.2010.07.011; Hirano Y, 2012, J BIOL CHEM, V287, P42654, DOI 10.1074/jbc.M112.397950; Polioudaki H, 2001, EMBO REP, V2, P920, DOI 10.1093/embo-reports/kve199; Colella R, 2012, AM J CLIN PATHOL, V137, P358, DOI 10.1309/AJCP3G8MDUXYSCID; GANICK DJ, 1990, AM J PEDIAT HEMATOL, V12, P80; Jansen AJG, 2012, NETH J MED, V70, P329; de Maat Monique M R, 2011, Ann Pharmacother, V45, pe18, DOI 10.1345/aph.1P308; MAY RB, 1993, EPILEPSIA, V34, P1098, DOI 10.1111/j.1528-1157.1993.tb02139.x; Yi JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054792	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					344	346		10.1016/j.braindev.2014.06.004		3	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300013		
J	Kobayashi, Y; Kawashima, H; Magara, S; Akasaka, N; Tohyama, J				Kobayashi, Yu; Kawashima, Hideshi; Magara, Shinichi; Akasaka, Noriyuki; Tohyama, Jun			Gomez-Lopez-Hernandez syndrome in a Japanese patient: A case report	BRAIN & DEVELOPMENT			English	Article						Gomez-Lopez-Hernandez syndrome; Rhombencephalosynapsis; Alopecia; Trigeminal anesthesia	TRIGEMINAL-DERMAL DYSPLASIA; RHOMBENCEPHALOSYNAPSIS	Gomez-Lopez-Hernandez syndrome (GLHS) is a rare neurocutaneous syndrome characterized by the triad of rhombencephalosynapsis, trigeminal anesthesia, and bilateral parieto-occipital alopecia. We herein describe the first Japanese patient with GLHS characterized by the standard triad with typical craniofacial anomaly including hypertelorism, brachyturricephaly and midface retrusion, and a short stature. This female patient had also exhibited fever-induced convulsive seizures and psychomotor developmental delay since infancy. Brain magnetic resonance imaging showed severe rhombencephalosynapsis, supratentorial abnormalities (aplasia of the septum pellucidum, severe ventricular enlargement, and hypoplasia of the corpus callosum), and hippocampus atrophy. Bilateral ectopic cerebellums were also observed. This report describes the long-term clinical outcome of GLHS and a new neuroradiological finding regarding rhombencephalosynapsis. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Kobayashi, Yu; Kawashima, Hideshi; Magara, Shinichi; Akasaka, Noriyuki; Tohyama, Jun] Nishi Niigata Chuo Natl Hosp, Epilepsy Ctr, Dept Child Neurol, Niigata 9502085, Japan	Kobayashi, Y (reprint author), Nishi Niigata Chuo Natl Hosp, Epilepsy Ctr, Dept Child Neurol, Nishi Ku, 1-14-1 Masago, Niigata 9502085, Japan.	u-kb@masa.go.jp					LOPEZHERNANDEZ A, 1982, NEUROPEDIATRICS, V13, P99, DOI 10.1055/s-2008-1059606; Gomy I, 2008, AM J MED GENET A, V146A, P649, DOI 10.1002/ajmg.a.32173; Rush ET, 2013, AM J MED GENET A, V161A, P320, DOI 10.1002/ajmg.a.35817; Ishak GE, 2012, BRAIN, V135, P1370, DOI 10.1093/brain/aws065; Schell-Apacik CC, 2008, EUR J PEDIATR, V167, P123, DOI 10.1007/s00431-007-0478-z; Tully HM, 2012, AM J MED GENET A, V158A, P2393, DOI 10.1002/ajmg.a.35561; Sukhudyan B, 2010, EUR J PEDIATR, V169, P1523, DOI 10.1007/s00431-010-1259-7; Gomez M R, 1979, Brain Dev, V1, P253; Munoz MV, 1997, AM J MED GENET, V72, P34, DOI 10.1002/(SICI)1096-8628(19971003)72:1<34::AID-AJMG7>3.0.CO;2-V; Poretti A, 2008, EUR J MED GENET, V51, P197, DOI 10.1016/j.ejmg.2008.01.004	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					356	358		10.1016/j.braindev.2014.05.002		3	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300016		
J	Nakayama, T; Sato, Y; Uematsu, M; Takagi, M; Hasegawa, S; Kumada, S; Kikuchi, A; Hino-Fukuyo, N; Sasahara, Y; Haginoya, K; Kure, S				Nakayama, Tojo; Sato, Yuko; Uematsu, Mitsugu; Takagi, Masatoshi; Hasegawa, Setsuko; Kumada, Satoko; Kikuchi, Atsuo; Hino-Fukuyo, Naomi; Sasahara, Yoji; Haginoya, Kazuhiro; Kure, Shigeo			Myoclonic axial jerks for diagnosing atypical evolution of ataxia telangiectasia	BRAIN & DEVELOPMENT			English	Article						Ataxia telangiectasia; Myoclonic jerk; AFP; Extrapyramidal sign; ATM gene	DYSTONIA; KINASE; GENE	Background: Ataxia telangiectasia (A-T) is a common inherited cause of early childhood-onset ataxia, distinguished by progressive cerebellum malfunction, capillary vessel extension, and immunodeficiency. The diagnosis of A-T is sometimes difficult to establish in patients with atypical clinical evolution. Case report: We experienced a pediatric 12-years-old female patient, who was finally diagnosed with classic AT, demonstrating progressive dystonic-myoclonic axial jerks with ataxia as a predominant clinical feature. Oculocutaneous telangiectasias and immune status were unremarkable. Her myoclonic jerks were spontaneous or stimulus-sensitive, and partially ameliorated by levodopa treatment, but the ataxia was slowly progressive. A laboratory examination showed moderate atrophy of the vermis and cerebellum on brain magnetic resonance imaging, elevated serum alpha fetoprotein (AFP) levels, and total absence of A-T mutated (ATM) protein activity. We subsequently confirmed compound heterozygous truncating mutations of the ATM gene in this patient. Conclusion: Our findings highlight the importance of recognizing dystonic-myoclonic jerks as one of the extrapyramidal signs of classic A-T. Measurement of AFP levels should be considered in patients with unexplained myoclonic jerk movements with ataxia in whom definitive diagnoses are not identified. Physicians should be aware that there are cases where typical findings of A-T may not be fulfilled. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.	[Nakayama, Tojo; Sato, Yuko; Uematsu, Mitsugu; Kikuchi, Atsuo; Hino-Fukuyo, Naomi; Sasahara, Yoji; Haginoya, Kazuhiro; Kure, Shigeo] Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Takagi, Masatoshi; Hasegawa, Setsuko] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Haginoya, Kazuhiro] Takuto Rehabil Ctr Children, Dept Pediat Neurol, Sendai, Miyagi, Japan; [Kumada, Satoko] Tokyo Metropolitan Neurol Hosp, Dept Neuropediat, Tokyo, Japan	Nakayama, T (reprint author), Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	tojo-nakayama@umin.ac.jp					Ambrose M, 2007, HUM MOL GENET, V16, P2154, DOI 10.1093/hmg/ddm166; Verhagen MMM, 2012, HUM MUTAT, V33, P561, DOI 10.1002/humu.22016; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; BODENSTEINER JB, 1980, ARCH NEUROL-CHICAGO, V37, P464; Eilam R, 2003, NEUROSCIENCE, V121, P83, DOI 10.1016/S0306-4522(03)00322-1; Jafar-Nejad PMS, 2012, SWAIMANS PEDIAT NEUR, P939; KOEPP M, 1994, MOVEMENT DISORD, V9, P455, DOI 10.1002/mds.870090414; MCFARLIN DE, 1972, MEDICINE, V51, P281; Saunders-Pullman R, 2012, NEUROLOGY, V78, P649, DOI 10.1212/WNL.0b013e3182494d51; Takagi M, 2004, BLOOD, V103, P283, DOI 10.1182/blood-2003-01-0094	10	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0387-7604	1872-7131		BRAIN DEV-JPN	Brain Dev.	MAR	2015	37	3					362	365		10.1016/j.braindev.2014.06.001		4	Clinical Neurology	Neurosciences & Neurology	CC1IL	WOS:000350094300018		
J	Ikeda, Y; Inomata, T; Fujita, T; Iida, Y; Nabeta, T; Naruke, T; Koitabashi, T; Takeuchi, I; Kitamura, T; Miyaji, K; Ako, J				Ikeda, Yuki; Inomata, Takayuki; Fujita, Teppei; Iida, Yuichiro; Nabeta, Takeru; Naruke, Takashi; Koitabashi, Toshimi; Takeuchi, Ichiro; Kitamura, Tadashi; Miyaji, Kagami; Ako, Junya			Morphological changes in mitochondria during mechanical unloading observed on electron microscopy: a case report of a bridge to complete recovery in a patient with idiopathic dilated cardiomyopathy	CARDIOVASCULAR PATHOLOGY			English	Article						Left ventricular assist device; Dilated cardiomyopathy; Electron microscopy; Vacuolization; Mitochondria		The recovery of the cardiac function under mechanical support has not been well documented from a histopathological point of view. We herein report a case of idiopathic dilated cardiomyopathy in which the patient showed a complete recovery of the systolic function following treatment with a left ventricular assist device (LVAD) for deteriorated heart failure. A light microscopic observation showed marked regression of hypertrophic myocytes with significant intracellular vacuolization and scarcity at the time of LVAD implantation after the administration of mechanical support. Furthermore, an electron microscopic observation revealed that these findings were regulated primarily by volumetric regression and morphometric improvements in cardiomyocytic mitochondria. (C) 2014 Elsevier Inc. All rights reserved.	[Ikeda, Yuki; Inomata, Takayuki; Fujita, Teppei; Iida, Yuichiro; Nabeta, Takeru; Naruke, Takashi; Koitabashi, Toshimi; Takeuchi, Ichiro; Ako, Junya] Kitasato Univ Sch Med, Dept Cardiovasc Med, Sagamihara, Kanagawa 2520373, Japan; [Kitamura, Tadashi; Miyaji, Kagami] Kitasato Univ Hosp, Dept Cardiovasc Surg, Sagamihara, Kanagawa, Japan	Inomata, T (reprint author), Kitasato Univ Sch Med, Dept Cardiovasc Med, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520373, Japan.	inotaka@med.kitasato-u.ac.jp					Drakos SG, 2012, CIRCULATION, V126, P230, DOI 10.1161/CIRCULATIONAHA.111.040261; Ong SB, 2010, CARDIOVASC RES, V88, P16, DOI 10.1093/cvr/cvq237; Saito S, 2010, J HEART LUNG TRANSPL, V29, P672, DOI 10.1016/j.healun.2010.01.007; de Weger RA, 2011, J HEART LUNG TRANSPL, V30, P497, DOI 10.1016/j.healun.2010.11.011; NODA S, 1980, JPN CIRC J, V44, P95	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-8807	1879-1336		CARDIOVASC PATHOL	Cardiovasc. Pathol.	MAR-APR	2015	24	2					128	131		10.1016/j.carpath.2014.10.003		4	Cardiac & Cardiovascular Systems; Pathology	Cardiovascular System & Cardiology; Pathology	CC3EY	WOS:000350230000010		
J	Murai, T; Lee, T; Yonetsu, T; Isobe, M; Kakuta, T				Murai, Tadashi; Lee, Tetsumin; Yonetsu, Taishi; Isobe, Mitsuaki; Kakuta, Tsunekazu			Influence of Microvascular Resistance on Fractional Flow Reserve after Successful Percutaneous Coronary Intervention	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						coronary physiology; fractional flow reserve; microcirculation; percutaneous coronary intervention; coronary flow	INTRAVASCULAR ULTRASOUND; MICROCIRCULATORY RESISTANCE; MYOCARDIAL-INFARCTION; PRESSURE MEASUREMENT; FUNCTIONAL SEVERITY; BALLOON ANGIOPLASTY; STENOSIS SEVERITY; VELOCITY RESERVE; ARTERY STENOSIS; FOLLOW-UP	Objectives and BackgroundIncreased microvascular resistance may impair hyperemic coronary flow by limiting the maximal and constant vasodilation, resulting in increased fractional flow reserve (FFR) due to the underestimation of the translesional pressure gradient. We examined whether microvascular resistance affects FFR after successful percutaneous coronary intervention (PCI). Methods and Results: We measured FFR and the index of microcirculatory resistance (IMR) in 104 coronary arteries of 98 patients after successful elective stenting. FFR values were compared according to the quartiles of the IMR values. Coronary flow was assessed using the hyperemic mean transit time (T-mn). The IMR values for the interquartile ranges of 8.5-11.3, 13.9-16.3, 20.9-24.5, and 34.2-61.6 were 10.2, 15.1, 22.8, and 38.2, respectively. Both FFR and T-mn values differed significantly across the IMR quartiles (P<0.001). The angiographic and intravascular ultrasound findings and post-PCI cardiac troponin levels showed no significant difference across the IMR quartiles. Multivariate logistic regression analysis revealed that the left anterior descending artery lesion location (odds ratio [OR] 0.17, 95% confidence interval [CI] 0.06-0.49, P=0.001), IMR (OR 1.05, 95% CI 1.01-1.09, P=0.012), and minimal cross-sectional lumen area (OR 1.49, 95% CI 1.03-2.17, P=0.036) were independent predictors of increased FFR. Conclusions: Increased microvascular resistance may reduce coronary flow and increase FFR after successful elective PCI. (c) 2014 Wiley Periodicals, Inc. (c) 2014 Wiley Periodicals, Inc.	[Murai, Tadashi; Lee, Tetsumin; Kakuta, Tsunekazu] Tsuchiura Kyodo Gen Hosp, Dept Cardiol, Tsuchiura, Ibaraki 3000053, Japan; [Yonetsu, Taishi] Kameda Med Ctr, Dept Cardiol, Kamogawa, Japan; [Isobe, Mitsuaki] Tokyo Med & Dent Univ, Dept Cardiovasc Med, Tokyo, Japan	Kakuta, T (reprint author), Tsuchiura Kyodo Gen Hosp, Dept Cardiol, 11-7 Manabeshin Machi, Tsuchiura, Ibaraki 3000053, Japan.	kaz@joy.email.ne.jp					Aarnoudse W, 2004, CATHETER CARDIO INTE, V62, P56, DOI 10.1002/ccd.10793; Bech GJW, 2001, CIRCULATION, V103, P2928; Tonino PAL, 2009, NEW ENGL J MED, V360, P213, DOI 10.1056/NEJMoa0807611; Pijls NHJ, 2007, J AM COLL CARDIOL, V49, P2105, DOI 10.1016/j.jacc.2007.01.087; Pijls NHJ, 1996, NEW ENGL J MED, V334, P1703, DOI 10.1056/NEJM199606273342604; Fearon WF, 2001, CIRCULATION, V104, P1917, DOI 10.1161/hc4101.097539; Claeys MJ, 2001, CATHETER CARDIO INTE, V54, P427, DOI 10.1002/ccd.2005; Hanekamp CEE, 1999, CIRCULATION, V99, P1015; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; Fearon WF, 2003, CIRCULATION, V108, P2198, DOI 10.1161/01.CIR.0000099521.31396.9D; Pijls NHJ, 2002, CIRCULATION, V105, P2950, DOI 10.1161/01.CIR.0000020547.92091.76; Pijls NHJ, 2002, CIRCULATION, V105, P2482, DOI 10.1161/01.CIR.0000017199.09457.3D; Kang SJ, 2011, CIRC-CARDIOVASC INTE, V4, P65, DOI 10.1161/CIRCINTERVENTIONS.110.959148; Fearon WF, 2004, CIRCULATION, V109, P2269, DOI 10.1161/01.CIR.0000128669.99355.CB; Selvanayagam JB, 2007, CIRCULATION, V116, P1458, DOI 10.1161/CIRCULATIONAHA.106.671909; Bech GJW, 1999, CIRCULATION, V99, P883; Aarnoudse W, 2004, CIRCULATION, V110, P2137, DOI 10.1161/01.CIR.0000143893.18451.0E; Kern MJ, 2000, CIRCULATION, V101, P1344; Ng MKC, 2006, CIRCULATION, V113, P2054, DOI 10.1161/CIRCULATIONAHA.105.603522; Fearon WF, 2003, CIRCULATION, V107, P3129, DOI 10.1161/01.CIR.0000080700.98607.D1; Bishop AH, 2004, AM HEART J, V147, P792, DOI 10.1016/j.ahj.2003.12.009; Albertal M, 2002, CIRCULATION, V105, P1573, DOI 10.1161/01.CIR.0000012514.15806.DD; UREN NG, 1994, NEW ENGL J MED, V331, P222, DOI 10.1056/NEJM199407283310402; Blows LJ, 2007, HEART, V93, P419, DOI 10.1136/hrt.2005.066837; DesBruyne B, 2001, CIRCULATION, V104, P2003; Patel B, 2010, PHARMACOL THERAPEUT, V127, P131, DOI 10.1016/j.pharmthera.2010.04.014; Piek JJ, 2001, EUR HEART J, V22, P1725, DOI 10.1053/euhj.2000.2587; Tamita K, 2002, CATHETER CARDIO INTE, V57, P452, DOI 10.1002/ccd.10350; Yanagisawa H, 2004, CIRC J, V68, P993, DOI 10.1253/circj.68.993	29	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	MAR	2015	85	4					585	592		10.1002/ccd.25499		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CC2VN	WOS:000350202900017		
J	Attizzani, GF; Ohno, Y; Capodanno, D; Francaviglia, B; Grasso, C; Sgroi, C; Wang, W; Fujino, Y; Ganocy, SJ; Longo, G; Tamburino, CI; Di Salvo, M; La Manna, A; Capranzano, P; Tamburino, C				Attizzani, Guilherme F.; Ohno, Yohei; Capodanno, Davide; Francaviglia, Bruno; Grasso, Carmelo; Sgroi, Carmelo; Wang, Wei; Fujino, Yusuke; Ganocy, Stephen J.; Longo, Giovanni; Tamburino, Claudia I.; Di Salvo, Marilena; La Manna, Alessio; Capranzano, Piera; Tamburino, Corrado			New Insights on Acute Expansion and Longitudinal Elongation of Bioresorbable Vascular Scaffolds In Vivo and At Bench Test: A Note of Caution on Reliance to Compliance Charts and Nominal Length	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						bioresorbable vascular scaffolds; optical coherence tomography; elongation; expansion	OPTICAL COHERENCE TOMOGRAPHY; CORONARY-ARTERY-DISEASE; ELUTING STENT IMPLANTATION; INTRAVASCULAR ULTRASOUND; SERIAL ASSESSMENT; FREQUENCY; RECOIL; PLAQUE; TRIAL	ObjectivesWe performed systematic optical coherence tomography (OCT) analyses after bioresorbable vascular scaffolds (BVS) implantation in a real world setting aiming at evaluating scaffold expansion and longitudinal integrity. Backgrounda comprehensive elucidation of BVS acute performance in the real-world setting is lacking. Methodsacute BVS expansion compared with compliance chart information and longitudinal integrity were assessed in 29 patients (32 lesions) by OCT. In addition, bench experiments with four scaffolds were performed with different combinations of deployment pressures and tube stiffness. Resultsscaffold underexpansion, using compliance chart information as reference, was observed in 97% of OCT cross-sections in vivo; however, only 8.3% of the cross-section analyzed revealed BVS area <5 mm(2). Calcified plaques were more common in the lowest (9.7%) compared with the mid (8.8%) and highest (6.3%) tertiles of scaffold expansion (P=0.003 and P=0.001 for lowest vs. mid, and lowest vs. highest, respectively). Seventeen (54.8%) scaffolds were elongated during implantation, but no signs of scaffold fracture were revealed. Elongation and impaired expansion were reproduced in the bench testing when the scaffold was deployed with high pressure in a hard tube. Conclusionscompliance chart information should not be used to predict final BVS dimensions in the clinical setting. While BVS expansion could be potentially impaired by calcified plaques, they may elongate during deployment. Bench experiments confirmed the elongation phenomenon when BVS were deployed with high pressure in hard tubes. (c) 2014 Wiley Periodicals, Inc.	[Attizzani, Guilherme F.; Ohno, Yohei; Capodanno, Davide; Francaviglia, Bruno; Grasso, Carmelo; Sgroi, Carmelo; Longo, Giovanni; Tamburino, Claudia I.; Di Salvo, Marilena; La Manna, Alessio; Capranzano, Piera; Tamburino, Corrado] Univ Catania, Ferrarotto Hosp, Dept Cardiol, I-95100 Catania, Italy; [Attizzani, Guilherme F.] Pitangueiras Hosp, Dept Intervent Cardiol, Sao Paulo, Brazil; [Attizzani, Guilherme F.; Capodanno, Davide] Univ Hosp Cleveland, Harrington Heart & Vasc Inst, Case Med Ctr, Cleveland, OH 44106 USA; [Tamburino, Corrado] Excellence Newest Adv ETNA Fdn, Catania, Italy; [Wang, Wei] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA; [Fujino, Yusuke] New Tokyo Hosp, Chiba, Japan; [Ganocy, Stephen J.] Case Western Reserve Univ, Dept Biostat, Cleveland, OH 44106 USA	Capodanno, D (reprint author), Univ Catania, Ferrarotto Hosp, Dept Cardiol, Via Citelli 1, I-95100 Catania, Italy.	dcapodanno@gmail.com			St Jude Medical, Inc.	Conflicts of interest: Dr. Attizzani reports receiving Consultant Fees from St Jude Medical, Inc. The other authors report no conflict of interest.	Gomez-Lara J, 2010, JACC-CARDIOVASC INTE, V3, P1190, DOI 10.1016/j.jcin.2010.07.016; Bezerra HG, 2009, JACC-CARDIOVASC INTE, V2, P1035, DOI 10.1016/j.jcin.2009.06.019; Kume T, 2006, AM J CARDIOL, V97, P1172, DOI 10.1016/j.amjcard.2005.11.035; Onuma Y, 2011, CATHETER CARDIO INTE, V78, P3, DOI 10.1002/ccd.22864; Attizzani GF, 2013, AM J CARDIOL, V112, P1557, DOI 10.1016/j.amjcard.2013.07.013; Ormiston JA, 2014, CIRC-CARDIOVASC INTE, V7, P62, DOI 10.1161/CIRCINTERVENTIONS.113.000621; Gomez-Lara J, 2011, JACC-CARDIOVASC INTE, V4, P992, DOI 10.1016/j.jcin.2011.03.020; Williams PD, 2012, EUROINTERVENTION, V8, P267, DOI 10.4244/EIJV8I2A41; Carrozza JP, 1999, CIRCULATION, V100, P756; Costa JD, 2007, AM HEART J, V153, P297, DOI 10.1016/j.ahj.2006.08.026; Fujii K, 2005, J AM COLL CARDIOL, V45, P995, DOI 10.1016/j.jacc.2004.12.066; Jang IK, 2005, CIRCULATION, V111, P1551, DOI 10.1161/01.CIR.0000159354.43778.69; Mehanna EA, 2011, INT J CARDIOVAS IMAG, V27, P259, DOI 10.1007/s10554-010-9793-y; Jones MR, 2014, JACC-CARDIOVASC INTE, V7, P674, DOI 10.1016/j.jcin.2014.01.163; Fujino Y, 2013, JACC-CARDIOVASC INTE, V6, P1035, DOI 10.1016/j.jcin.2013.05.015; Costa MA, 2008, AM J CARDIOL, V101, P1704, DOI 10.1016/j.amjcard.2008.02.053; Mehanna E, 2013, CIRC J, V77, P2334, DOI 10.1253/circj.CJ-12-1458; Bezerra HG, 2013, JACC-CARDIOVASC INTE, V6, P228, DOI 10.1016/j.jcin.2012.09.017; Dzavik V, 2014, JACC-CARDIOVASC INTE, V7, P81, DOI 10.1016/j.jcin.2013.07.013; Fujino Y, 2013, CATHETER CARDIO INTE, V82, pE173, DOI 10.1002/ccd.24843; Iwamoto Y, 2012, J CARDIOL, V59, P160, DOI 10.1016/j.jjcc.2011.12.003; Ormiston JA, EUROINTERVE IN PRESS; Pitney M, 2011, EUROINTERVENTION, V7, P256, DOI 10.4244/EIJV7I2A41	23	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	MAR	2015	85	4					E99	E107		10.1002/ccd.25645		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CC2VN	WOS:000350202900001		
J	Nakayama, A; Miura, H; Ooki, M; Harada, S				Nakayama, Ayumi; Miura, Hirohito; Ooki, Makoto; Harada, Shuitsu			During development intense Sox2 expression marks not only Prox1-expressing taste bud cell but also perigemmal cell lineages	CELL AND TISSUE RESEARCH			English	Article						Taste bud; Primordia; Circumvallate; Fungiform; Soft palate	SOFT PALATE; PAPILLA DEVELOPMENT; SONIC-HEDGEHOG; MOUSE; TONGUE; RAT; INNERVATION; EPITHELIUM; RENEWAL; PATTERN	Sox2 is proposed to regulate the differentiation of bipotential progenitor cells into taste bud cells. However, detailed expression of Sox2 remains unclear. In this report, Sox2 expression during taste bud development in the fungiform (FF), circumvallate (CV) and soft palate (SP) areas is examined together with Prox1. First, we immunohistochemically checked Prox1 expression in adults and found that almost all taste bud cells are Prox1-positive. During FF development, intense Sox2 expression was restricted to taste bud primordia expressing Prox1 at E12.5. However, at E14.5, Sox2 was intensely expressed outside the developing taste buds resolving to perigemmal Sox2 expression in adults. In the SP, at E14.5, taste bud primordia emerged as Prox1-expressing cell clusters. However, intense Sox2 expression was not restricted to taste bud primordia but was detected widely in the epithelium. During development, Sox2 expression outside developing taste buds was generally down-regulated but was retained in the perigemmal region similarly to that in the FF. In the CV, the initial stage of taste bud development remained unclear because of the lack of taste bud primordia comparable to that in the FF and SP. Here, we show that Prox1-expressing cells appear in the apical epithelium at E12.5, in the inner trench wall at E17.5 and in the outer trench wall at E18.5. Sox2 was again not restricted to developing taste bud cells expressing Prox1 during CV development. The expression patterns support that Sox2 does not serve as a cell fate selector between taste bud cells and surrounding keratinocytes but rather may contribute to them both.	[Nakayama, Ayumi; Miura, Hirohito; Ooki, Makoto; Harada, Shuitsu] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan; [Nakayama, Ayumi] Kagoshima Univ, Med & Dent Hosp, Kagoshima 8908520, Japan	Miura, H (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	hmiura@dent.kagoshima-u.ac.jp			JSPS KAKENHI [23592742, 26462818, 22791793]; Research Grant for Young Scientist in Oral Biology from Kagoshima University	We thank Dr. John Caprio for valuable comments on the manuscript. This work was supported by JSPS KAKENHI to HM (23592742, 26462818) to A. N. (22791793) and a Research Grant for Young Scientist in Oral Biology from Kagoshima University to A.N.	FARBMAN AI, 1980, CELL TISSUE KINET, V13, P349, DOI 10.1111/j.1365-2184.1980.tb00474.x; Elsir T, 2012, CANCER METAST REV, V31, P793, DOI 10.1007/s10555-012-9390-8; Kapsimali M, 2013, SEMIN CELL DEV BIOL, V24, P200, DOI 10.1016/j.semcdb.2012.11.002; BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; Liu F, 2007, NAT GENET, V39, P106, DOI 10.1038/ng1932; Nakayama A, 2008, J COMP NEUROL, V509, P211, DOI 10.1002/cne.21738; Okubo T, 2009, STEM CELLS, V27, P442, DOI 10.1634/stemcells.2008-0611; Calinescu AA, 2009, J COMP NEUROL, V514, P1, DOI 10.1002/cne.21999; Miura H, 2003, GENE EXPR PATTERNS, V3, P427, DOI 10.1016/S1567-133X(03)00081-4; Harada S, 2000, PHYSIOL BEHAV, V68, P333, DOI 10.1016/S0031-9384(99)00184-5; Hall JMH, 2003, DEV BIOL, V255, P263, DOI 10.1016/S0012-1606(02)00048-9; Okubo T, 2006, GENE DEV, V20, P2654, DOI 10.1101/gad.1457106; Mistretta CM, 2003, DEV BIOL, V254, P1, DOI 10.1016/S0012-1606(02)00014-3; BARLOW LA, 1995, DEV BIOL, V169, P273, DOI 10.1006/dbio.1995.1143; Thirumangalathu S, 2009, DEVELOPMENT, V136, P1519, DOI 10.1242/dev.029090; Kapsimali M, 2011, DEVELOPMENT, V138, P3473, DOI 10.1242/dev.058669; Hall JM, 1999, J COMP NEUROL, V406, P143, DOI 10.1002/(SICI)1096-9861(19990405)406:2<143::AID-CNE1>3.0.CO;2-X; Seta Y, 2003, J COMP NEUROL, V464, P49, DOI 10.1002/cne.10787; Ito A, 2010, NEUROSCI LETT, V471, P189, DOI 10.1016/j.neulet.2010.01.039; Kusakabe Y, 2002, CHEM SENSES, V27, P445, DOI 10.1093/chemse/27.5.445; Ota MS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000443; Petersen CI, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002098; STONE LM, 1995, P NATL ACAD SCI USA, V92, P1916, DOI 10.1073/pnas.92.6.1916; Suzuki Y, 2008, CELL TISSUE RES, V332, P393, DOI 10.1007/s00441-008-0600-1; Suzuki Y, 2010, J MOL HISTOL, V41, P205, DOI 10.1007/s10735-010-9280-8	25	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAR	2015	359	3					743	753		10.1007/s00441-014-2076-5		11	Cell Biology	Cell Biology	CC4VE	WOS:000350351400004		
J	Yoshida, S; Kato, T; Higuchi, M; Chen, M; Ueharu, H; Nishimura, N; Kato, Y				Yoshida, Saishu; Kato, Takako; Higuchi, Masashi; Chen, Mo; Ueharu, Hiroki; Nishimura, Naoto; Kato, Yukio			Localization of juxtacrine factor ephrin-B2 in pituitary stem/progenitor cell niches throughout life	CELL AND TISSUE RESEARCH			English	Article						Pituitary; Stem/progenitor cells; Niche; Ephrin-B2; CAR; Rat	FOLLICULO-STELLATE CELLS; EPH RECEPTORS; STEM-CELLS; SIDE POPULATION; ADULT; EXPRESSION; REVERSE; ORGANOGENESIS; PROLIFERATION; MECHANISMS	We have recently reported that Sox2-expressing pituitary stem/progenitor cells contact each other via a tight-junction protein CAR to form stem/progenitor cell niches in the marginal cell layer facing the lumen and in the clusters scattered in the parenchyma of the anterior lobe. However, the microenvironment of the niche for the maintenance of stem cell function in the pituitary remains obscure. In this study of pituitary stem/progenitor cell niches, we have attempted to identify the expression of juxtacrine factor ephrin and its receptor. We have found that ephrin-B2 is expressed in the pituitary throughout development but changes its localization pattern. Notably, in the adult pituitary, ephrin-B2 immuno-signals occur in SOX2-, E-cadherin-, and CAR-triple-positive stem/progenitor cells in the niches. Our data suggest that ephrin-B2 signaling has an important role in the formation of pituitary stem/progenitor cell niches and in pituitary organogenesis.	[Yoshida, Saishu; Ueharu, Hiroki; Nishimura, Naoto; Kato, Yukio] Meiji Univ, Grad Sch Agr, Div Life Sci, Kanagawa 2148571, Japan; [Kato, Takako; Higuchi, Masashi; Chen, Mo; Kato, Yukio] Meiji Univ, Inst Reprod & Endocrinol, Kanagawa 2148571, Japan; [Kato, Yukio] Meiji Univ, Sch Agr, Dept Life Sci, Kanagawa 2148571, Japan	Kato, Y (reprint author), Meiji Univ, Grad Sch Agr, Div Life Sci, Kanagawa 2148571, Japan.	yukato@isc.meiji.ac.jp			JSPS KAKENHI [21380184, 24580435]; Institute of Science and Technology, Meiji University; Meiji University International Institute for BioResource Research (MUIIR)	This work was partially supported by JSPS KAKENHI grant nos. 21380184 to Y.K. and 24580435 to T.K. and by a research grant (A) to Y.K. from the Institute of Science and Technology, Meiji University. The study was also supported by the Meiji University International Institute for BioResource Research (MUIIR).	Chen JH, 2006, MOL ENDOCRINOL, V20, P3293, DOI 10.1210/me.2006-0293; Allaerts W, 2005, EUR J ENDOCRINOL, V153, P1, DOI 10.1530/eje.1.01949; Itakura E, 2007, ENDOCRINOLOGY, V148, P1518, DOI 10.1210/en.2006-1390; Rizzoti K, 2013, CELL STEM CELL, V13, P419, DOI 10.1016/j.stem.2013.07.006; Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625; Chen JH, 2005, ENDOCRINOLOGY, V146, P3985, DOI 10.1210/en.2005-0185; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Genander M, 2010, STEM CELLS, V28, P1196, DOI 10.1002/stem.442; Fu QL, 2012, ENDOCRINOLOGY, V153, P3224, DOI 10.1210/en.2012-1152; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Olert J, 2001, PATHOL RES PRACT, V197, P823, DOI 10.1078/0344-0338-00166; Ashton RS, 2012, NAT NEUROSCI, V15, P1399, DOI 10.1038/nn.3212; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Xi HQ, 2012, J CELL MOL MED, V16, P2894, DOI 10.1111/j.1582-4934.2012.01612.x; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Fauquier T, 2008, P NATL ACAD SCI USA, V105, P2907, DOI 10.1073/pnas.0707886105; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; Mellitzer G, 1999, NATURE, V400, P77; Davis SW, 2010, MOL CELL ENDOCRINOL, V323, P4, DOI 10.1016/j.mce.2009.12.012; Andoniadou CL, 2013, CELL STEM CELL, V13, P433, DOI 10.1016/j.stem.2013.07.004; Pitulescu ME, 2010, GENE DEV, V24, P2480, DOI 10.1101/gad.1973910; Nomura T, 2010, CELL STEM CELL, V7, P730, DOI 10.1016/j.stem.2010.11.009; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Gremeaux L, 2012, STEM CELLS DEV, V21, P801, DOI 10.1089/scd.2011.0496; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Fu QL, 2012, STEM CELLS DEV, V21, P3245, DOI 10.1089/scd.2012.0290; Chen JH, 2009, STEM CELLS, V27, P1182, DOI 10.1002/stem.51; Vankelecom H, 2014, MOL CELL ENDOCRINOL, V385, P2, DOI 10.1016/j.mce.2013.08.018; Daar IO, 2012, SEMIN CELL DEV BIOL, V23, P65, DOI 10.1016/j.semcdb.2011.10.012; Zhu XY, 2007, PHYSIOL REV, V87, P933, DOI 10.1152/physrev.00006.2006; Chen CC, 2012, J DERMATOL SCI, V66, P3, DOI 10.1016/j.jdermsci.2012.02.007; Chen M, 2013, CELL TISSUE RES, V354, P823, DOI 10.1007/s00441-013-1713-8; Dasen JS, 2001, ANNU REV NEUROSCI, V24, P327, DOI 10.1146/annurev.neuro.24.1.327; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Hafner C, 2005, WORLD J GASTROENTERO, V11, P4511; Higuchi M, 2014, CELL TISSUE RES, V357, P323, DOI 10.1007/s00441-014-1861-5; Jensen PL, 2000, STEM CELLS, V18, P63, DOI 10.1634/stemcells.18-1-63; Meyer S, 2005, INT J ONCOL, V27, P1197; Nakada M, 2010, INT J CANCER, V126, P1155, DOI 10.1002/ijc.24849; Taniguchi Y, 2001, ANAT EMBRYOL, V203, P89, DOI 10.1007/s004290000140; Vankelecom H, 2010, EUR J NEUROSCI, V32, P2063, DOI 10.1111/j.1460-9568.2010.07523.x; VILAPORC.E, 1972, Z ZELLFORSCH MIK ANA, V129, P328, DOI 10.1007/BF00307293; Yoshida S, 2011, J NEUROENDOCRINOL, V23, P933, DOI 10.1111/j.1365-2826.2011.02198.x; Yoshida S, 2009, BIOCHEM BIOPH RES CO, V385, P11, DOI 10.1016/j.bbrc.2009.05.027; Zarbalis K, 2000, MECH DEVELOP, V93, P165, DOI 10.1016/S0925-4773(00)00252-5	46	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAR	2015	359	3					755	766		10.1007/s00441-014-2054-y		12	Cell Biology	Cell Biology	CC4VE	WOS:000350351400005		
J	Morita, S; Furube, E; Mannari, T; Okuda, H; Tatsumi, K; Wanaka, A; Miyata, S				Morita, Shoko; Furube, Eriko; Mannari, Tetsuya; Okuda, Hiroaki; Tatsumi, Kouko; Wanaka, Akio; Miyata, Seiji			Vascular endothelial growth factor-dependent angiogenesis and dynamic vascular plasticity in the sensory circumventricular organs of adult mouse brain	CELL AND TISSUE RESEARCH			English	Article						Angiogenesis; VEGF; Blood-brain barrier; Endothelial cell; Vascular permeability	TYROSINE KINASE INHIBITORS; INDUCIBLE FACTOR 1-ALPHA; CENTRAL-NERVOUS-SYSTEM; MEDIAN-EMINENCE; TARGET GENES; RAT-BRAIN; IN-VITRO; HYPOTHALAMONEUROHYPOPHYSEAL SYSTEM; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR	The sensory circumventricular organs (CVOs), which comprise the organum vasculosum of the lamina terminalis (OVLT), the subfornical organ (SFO) and the area postrema (AP), lack a typical blood-brain barrier (BBB) and monitor directly blood-derived information to regulate body fluid homeostasis, inflammation, feeding and vomiting. Until now, almost nothing has been documented about vascular features of the sensory CVOs except fenestration of vascular endothelial cells. We therefore examine whether continuous angiogenesis occurs in the sensory CVOs of adult mouse. The angiogenesis-inducing factor vascular endothelial growth factor-A (VEGF-A) and the VEGF-A-regulating transcription factor hypoxia-inducible factor-1 alpha were highly expressed in neurons of the OVLT and SFO and in both neurons and astrocytes of the AP. Expression of the pericyte-regulating factor platelet-derived growth factor B was high in astrocytes of the sensory CVOs. Immunohistochemistry of bromodeoxyuridine and Ki-67, a nuclear protein that is associated with cellular proliferation, revealed active proliferation of endothelial cells. Moreover, immunohistochemistry of caspase-3 and the basement membrane marker laminin showed the presence of apoptosis and sprouting of endothelial cells, respectively. Treatment with the VEGF receptor-associated tyrosine kinase inhibitor AZD2171 significantly reduced proliferation and filopodia sprouting of endothelial cells, as well as the area and diameter of microvessels. The mitotic inhibitor cytosine-b-D-arabinofuranoside reduced proliferation of endothelial cells and the vascular permeability of blood-derived low-molecular-weight molecules without changing vascular area and microvessel diameter. Thus, our data indicate that continuous angiogenesis is dependent on VEGF signaling and responsible for the dynamic plasticity of vascular structure and permeability.	[Morita, Shoko; Furube, Eriko; Mannari, Tetsuya; Miyata, Seiji] Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan; [Morita, Shoko; Okuda, Hiroaki; Tatsumi, Kouko; Wanaka, Akio] Nara Med Univ, Fac Med, Dept Anat & Neurosci, Kashihara, Nara 6348521, Japan	Miyata, S (reprint author), Kyoto Inst Technol, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.	smiyata@kit.ac.jp			Scientific Research Grants from the Japan Society for the Promotion of Science [24500411, 26830029]; National Institute of Child Health and Human Development	This work was supported in part by Scientific Research Grants from the Japan Society for the Promotion of Science (No. 24500411 to S. Miyata and No. 26830029 to S. Morita). The hybridomas of anti-CD31 (2H8) IgG developed by Dr. Steven Bogen and anti-PV1 (MECA-32) IgG developed by Dr. Eugene C Butcher were obtained from the DSHB, which was developed under the auspices of the National Institute of Child Health and Human Development and is maintained by The University of Iowa, Iowa City, IA 52242.	Miyata S, 2002, MICROSC RES TECHNIQ, V56, P143, DOI 10.1002/jemt.10012; Taniguchi Y, 2011, CELL TISSUE RES, V343, P303, DOI 10.1007/s00441-010-1110-5; Daneman R, 2005, CELL, V123, P9, DOI 10.1016/j.cell.2005.09.017; Feldser D, 1999, CANCER RES, V59, P3915; Hjelmeland AB, 2011, NAT NEUROSCI, V14, P1375, DOI 10.1038/nn.2955; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lee DA, 2012, NAT NEUROSCI, V15, P700, DOI 10.1038/nn.3079; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X; Mannari T, 2013, GLIA, V61, P957, DOI 10.1002/glia.22488; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bennett L, 2009, MOL CELL NEUROSCI, V41, P337, DOI 10.1016/j.mcn.2009.04.007; Masuda N, 1999, NUCLEIC ACIDS RES, V27, P4436, DOI 10.1093/nar/27.22.4436; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Stenzel D, 2011, EMBO REP, V12, P1135, DOI 10.1038/embor.2011.194; Morita S, 2013, EUR J NEUROSCI, V37, P508, DOI 10.1111/ejn.12047; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Ruan J, 2013, BLOOD, V121, P5192, DOI 10.1182/blood-2013-03-490763; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Fry M, 2007, EXP BIOL MED, V232, P14; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Roth J, 2004, FRONT BIOSCI-LANDMRK, V9, P290, DOI 10.2741/1241; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409; Mullier A, 2010, J COMP NEUROL, V518, P943, DOI 10.1002/cne.22273; Shimizu H, 2007, NEURON, V54, P59, DOI 10.1016/j.neuron.2007.03.014; Hartog TE, 2009, J NEUROSCI, V29, P15511, DOI 10.1523/JNEUROSCI.2564-09.2009; Schiera G, 2007, J CELL MOL MED, V11, P1384, DOI 10.1111/j.1582-4934.2007.00100.x; Nadeau S, 2000, J NEUROSCI, V20, P3456; Ciura S, 2011, J NEUROSCI, V31, P14669, DOI 10.1523/JNEUROSCI.1420-11.2011; Morabito A, 2006, ONCOLOGIST, V11, P753, DOI 10.1634/theoncologist.11-7-753; Mackenzie F, 2012, DEVELOPMENT, V139, P1371, DOI 10.1242/dev.072348; Hourai A, 2013, J NEUROSCI RES, V91, P757, DOI 10.1002/jnr.23206; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Furube E, 2014, J ENDOCRINOL, V222, P161, DOI 10.1530/JOE-14-0075; Morita S, 2012, CELL TISSUE RES, V349, P589, DOI 10.1007/s00441-012-1421-9; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434; Zhong H, 2000, CANCER RES, V60, P1541; Morita S, 2013, CELL BIOCHEM FUNCT, V31, P668, DOI 10.1002/cbf.2953; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Rocha Ana, 2007, Angiogenesis, V10, P279, DOI 10.1007/s10456-007-9080-2; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Udo H, 2008, J NEUROSCI, V28, P14522, DOI 10.1523/JNEUROSCI.3673-08.2008; Bauman JE, 2007, CLIN CANCER RES, V13, p4632S, DOI 10.1158/1078-0432.CCR-07-0212; Bruick RK, 2001, GENE DEV, V15, P2497, DOI 10.1101/gad.931601; Ciofi P, 2009, ENDOCRINOLOGY, V150, P5509, DOI 10.1210/en.2009-0584; Ferguson AV, 2014, NEUROBIOLOGY BODY FL; Fry M, 2010, INT J PEPT, V2010; Groothuis DR, 2000, BRAIN RES, V856, P281, DOI 10.1016/S0006-8993(99)02089-2; Hanrahan EO, 2007, CLIN CANCER RES, V13, p4617S, DOI 10.1158/1078-0432.CCR-07-0539; Hornby Pamela J., 2000, American Journal of Medicine, V108, p90S; Imamura Y, 2010, J NEUROSCI RES, V88, P1995, DOI 10.1002/jnr.22370; Jakobsson L, 2008, FASEB J, V22, P1530, DOI 10.1096/fj.07-9617com; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005; KEEP RF, 1995, J PHYSIOL-LONDON, V488, P439; Mancuso Michael R., 2008, Lymphatic Research and Biology, V6, P173, DOI 10.1089/lrb.2008.1014; Mannari T, 2014, J NEUROENDOCRINOL, V26, P497, DOI 10.1111/jne.12172; Mannari T, 2014, CELL TISSUE RES, V358, P43, DOI 10.1007/s00441-014-1933-6; Miyata S, 2011, J NEUROSCI METH, V202, P9, DOI 10.1016/j.jneumeth.2011.08.002; Miyata S, 2001, J COMP NEUROL, V434, P413, DOI 10.1002/cne.1184; Morita S, 2010, NEUROSCIENCE, V166, P1068, DOI 10.1016/j.neuroscience.2010.01.041; MUJUMDAR RB, 1989, CYTOMETRY, V10, P11, DOI 10.1002/cyto.990100104; Namimatsu S, 2005, J HISTOCHEM CYTOCHEM, V53, P3, DOI 10.1369/jhc.4C6466.2005; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Paxinos G., 2007, MOUSE BRAIN STEREOTA; Prevot V, 2002, J NEUROENDOCRINOL, V14, P247, DOI 10.1046/j.0007-1331.2001.00772.x; Robertson P L, 1985, Brain Res, V355, P219; Robins SC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3049; Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863; Siso S, 2010, ACTA NEUROPATHOL, V120, P689, DOI 10.1007/s00401-010-0743-5; TUOR UI, 1992, J NEUROCHEM, V59, P999, DOI 10.1111/j.1471-4159.1992.tb08341.x; Willis CL, 2007, NEUROSCIENCE, V150, P498, DOI 10.1016/j.neuroscience.2007.09.023; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	80	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAR	2015	359	3					865	884		10.1007/s00441-014-2080-9		20	Cell Biology	Cell Biology	CC4VE	WOS:000350351400013		
J	Fujiwara, K; Horiguchi, K; Maliza, R; Tofrizal, A; Batchuluun, K; Ramadhani, D; Syaidah, R; Tsukada, T; Azuma, M; Kikuchi, M; Yashiro, T				Fujiwara, Ken; Horiguchi, Kotaro; Maliza, Rita; Tofrizal, Alimuddin; Batchuluun, Khongorzul; Ramadhani, Dini; Syaidah, Rahimi; Tsukada, Takehiro; Azuma, Morio; Kikuchi, Motoshi; Yashiro, Takashi			Expression of the heparin-binding growth factor midkine and its receptor, Ptprz1, in adult rat pituitary	CELL AND TISSUE RESEARCH			English	Article						Pituitary gland; Midkine; Protein tyrosine phosphatase receptor-type Z; In situ hybridization; Rat	FOLLICULO-STELLATE CELLS; GREEN FLUORESCENT PROTEIN; ANTERIOR-PITUITARY; MOUSE EMBRYOGENESIS; TRANSGENIC RAT; GLAND; CULTURE	Midkine (MK) belongs to a family of secreted heparin-binding growth factors and is highly expressed in various tissues during development. MK has multiple functions, such as regulation of cell proliferation, migration, survival and differentiation. We recently reported that MK mRNA is strongly expressed in the developing rat pituitary gland. In the adult pituitary, however, expression of MK and its receptor and the characteristics of the cells that produce them, have not been determined. Therefore, in this study, we investigate whether MK and its receptor, protein tyrosine phosphatase receptor-type Z (Ptprz1), are present in the adult rat pituitary. In situ hybridization, real-time reverse transcription-PCR and immunoblotting were performed to assess MK and Ptprz1 expression. We also characterize MK- and Ptprz1-expressing cells by double-staining with in situ hybridization and immunohistochemical techniques for each pituitary hormone or S100 protein [a marker of folliculostellate (FS) cells]. MK-expressing cells were located in the anterior and posterior lobes but not in the intermediate lobe. Double-staining and immunoblotting revealed that MK mRNA and protein were only expressed in FS cells in the anterior pituitary. Regarding Ptprz1 expression, Ptprz1 mRNA was detected in adrenocorticotropic hormone (ACTH) cells and growth hormone (GH) cells but not in prolactin cells, thyroid-stimulating hormone cells, luteinizing hormone cells, or FS cells. These findings suggest that MK produced in FS cells acts locally on ACTH cells and GH cells via Ptprz1 in the adult rat anterior pituitary.	[Fujiwara, Ken; Maliza, Rita; Tofrizal, Alimuddin; Batchuluun, Khongorzul; Ramadhani, Dini; Syaidah, Rahimi; Tsukada, Takehiro; Azuma, Morio; Kikuchi, Motoshi; Yashiro, Takashi] Jichi Med Univ, Sch Med, Dept Anat, Div Histol & Cell Biol, Shimotsuke, Tochigi 3290498, Japan; [Horiguchi, Kotaro] Kyorin Univ, Dept Hlth Sci, Lab Anat & Cell Biol, Tokyo, Japan; [Kikuchi, Motoshi] Jichi Med Univ, Sch Med, Lab Nat Hist, Shimotsuke, Tochigi 3290498, Japan	Yashiro, T (reprint author), Jichi Med Univ, Sch Med, Dept Anat, Div Histol & Cell Biol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	ken_fuji@jichi.ac.jp; tyashiro@jichi.ac.jp			JSPS KAKENHI [24790199, 26460281, 23790233, 25860147]; promotional funds for the Keirin Race of the Japan Keirin Association; Jichi Medical University Young Investigator Award from Jichi Medical University School of Medicine	We thank Prof. K. Inoue (Saitama University, Japan) for supplying the transgenic rats. We are also grateful to Prof. Y. Hanazono and Dr. T. Abe (Jichi Medical University) for performing fluorescence-activated cell sorting and to David Kipler, ELS of Supernatant Communications for revising the language of the manuscript. This work was partly supported by JSPS KAKENHI Grant Numbers 24790199, 26460281, 23790233 and 25860147, by promotional funds for the Keirin Race of the Japan Keirin Association and by the Jichi Medical University Young Investigator Award from Jichi Medical University School of Medicine.	MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Itakura E, 2007, ENDOCRINOLOGY, V148, P1518, DOI 10.1210/en.2006-1390; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Inoue K, 1999, ARCH HISTOL CYTOL, V62, P205, DOI 10.1679/aohc.62.205; Chen M, 2013, CELL TISSUE RES, V354, P823, DOI 10.1007/s00441-013-1713-8; Diamond-Stanic MK, 2011, AM J PHYSIOL-RENAL, V300, pF139, DOI 10.1152/ajprenal.00249.2010; Fujiwara K, 2007, CELL TISSUE RES, V329, P321, DOI 10.1007/s00441-007-0423-5; Fujiwara K, 2007, CELL TISSUE RES, V328, P129, DOI 10.1007/s00441-006-0345-7; Fujiwara K, 2014, CELL TISSUE RES, V357, P337, DOI 10.1007/s00441-014-1875-z; Horiguchi K, 2012, ENDOCRINOLOGY, V153, P1717, DOI 10.1210/en.2011-1937; Horiguchi K, 2008, ANAT SCI INT, V83, P256, DOI 10.1111/j.1447-073X.2008.00239.x; Horiguchi K, 2010, J ENDOCRINOL, V204, P115, DOI 10.1677/JOE-09-0333; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P814, DOI 10.1111/bph.12353; Syaidah R, 2013, CELL TISSUE RES, V354, P633, DOI 10.1007/s00441-013-1698-3; Vankelecom H, 2010, EUR J NEUROSCI, V32, P2063, DOI 10.1111/j.1460-9568.2010.07523.x; Yao X, 2010, ACTA PHARMACOL SIN, V31, P629, DOI 10.1038/aps.2010.39; Yoshida S, 2011, J NEUROENDOCRINOL, V23, P933, DOI 10.1111/j.1365-2826.2011.02198.x	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAR	2015	359	3					909	914		10.1007/s00441-014-2073-8		6	Cell Biology	Cell Biology	CC4VE	WOS:000350351400016		
J	Koskimaki, J; Matsui, N; Umemori, J; Rantamaki, T; Castren, E				Koskimaki, Janne; Matsui, Nobuaki; Umemori, Juzoh; Rantamaki, Tomi; Castren, Eero			Nimodipine Activates TrkB Neurotrophin Receptors and Induces Neuroplastic and Neuroprotective Signaling Events in the Mouse Hippocampus and Prefrontal Cortex	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Delayed cortical ischemia; Nimodipine; Antidepressant; Neuronal plasticity; Subarachnoid hemorrhage; TrkB receptor; Vasospasm	CALCIUM-CHANNEL ANTAGONISTS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; RANDOMIZED CLINICAL-TRIAL; DELAYED CEREBRAL-ISCHEMIA; ANTIDEPRESSANT DRUGS; CA2+ CHANNEL; DOUBLE-BLIND; VASCULAR DEPRESSION; NEURONAL INJURY; RAT HIPPOCAMPUS	The L-type calcium channel blocker nimodipine improves clinical outcome produced by delayed cortical ischemia or vasospasm associated with subarachnoid hemorrhage. While vasoactive mechanisms are strongly implicated in these therapeutic actions of nimodipine, we sought to test whether nimodipine might also regulate neurotrophic and neuroplastic signaling events associated with TrkB neurotrophin receptor activation. Adult male mice were acutely treated with vehicle or nimodipine (10 mg/kg, s.c., 1.5 h) after which the phosphorylation states of TrkB, cyclic-AMP response element binding protein (CREB), protein kinase B (Akt), extracellular regulated kinase (ERK), mammalian target of rapamycin (mTor) and p70S6 kinase (p70S6k) from prefrontal cortex and hippocampus were assessed. Nimodipine increased the phosphorylation of the TrkB catalytic domain and the phosphoslipase-C gamma 1 (PLC gamma 1) domain, whereas phosphorylation of the TrkB Shc binding site remained unaltered. Nimodipine-induced TrkB phosphorylation was associated with increased phosphorylation levels of Akt and CREB in the prefrontal cortex and the hippocampus whereas phosphorylation of ERK, mTor and p70S6k remained unaltered. Nimodipine-induced TrkB signaling was not associated with changes in BDNF mRNA or protein levels. These nimodipine-induced changes on TrkB signaling mimic those produced by antidepressant drugs and thus propose common mechanisms and long-term functional consequences for the effects of these medications. This work provides a strong basis for investigating the role of TrkB-associated signaling underlying the neuroprotective and neuroplastic effects of nimodipine in translationally relevant animal models of brain trauma or compromised synaptic plasticity.	[Koskimaki, Janne; Matsui, Nobuaki; Umemori, Juzoh; Rantamaki, Tomi; Castren, Eero] Univ Helsinki, Neurosci Ctr, FIN-00014 Helsinki, Finland; [Koskimaki, Janne] Univ Turku, Fac Med, FIN-20520 Turku, Finland; [Koskimaki, Janne] Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki 00029, Finland; [Matsui, Nobuaki] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan	Castren, E (reprint author), Univ Helsinki, Neurosci Ctr, POB 56 Viikinkaari 4, FIN-00014 Helsinki, Finland.	eero.castren@helsinki.fi			Orion Pharma; Hermo Pharma; Ono Pharmaceuticals; Maire Taponen foundation	E.C. is an advisor and shareholder in Herantis Pharma, Inc. E.C. and T.R. have received research support from Orion Pharma, Hermo Pharma and Ono Pharmaceuticals. J.K. has received funding from Maire Taponen foundation for completing thesis. N.M and J.U. have nothing to declare. All authors declare no financial conflict of interests related to this study.	ALBORCH E, 1995, PHARMACOL THERAPEUT, V68, P1, DOI 10.1016/0163-7258(95)00025-9; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05-.2005; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Castren E, 2013, TRENDS NEUROSCI, V36, P259, DOI 10.1016/j.tins.2012.12.010; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Rantamaki T, 2007, NEUROPSYCHOPHARMACOL, V32, P2152, DOI 10.1038/sj.npp.1301345; Sinnegger-Brauns MJ, 2004, J CLIN INVEST, V113, P1430, DOI 10.1172/JCI200420208; Kobayashi T, 1998, EUR J PHARMACOL, V363, P1, DOI 10.1016/S0014-2999(98)00774-2; Karpova NN, 2010, CELL MOL NEUROBIOL, V30, P1117, DOI 10.1007/s10571-010-9544-6; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003; Frank CA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00040; Calin-Jageman I, 2008, J NEUROCHEM, V105, P573, DOI 10.1111/j.1471-4159.2008.05286.x; Etminan N, 2011, J CEREBR BLOOD F MET, V31, P1443, DOI 10.1038/jcbfm.2011.7; Mattson MP, 2007, AGING CELL, V6, P337, DOI 10.1111/j.1474-9726.2007.00275.x; ZAFRA F, 1990, EMBO J, V9, P3545; Lipscombe D, 2004, J NEUROPHYSIOL, V92, P2633, DOI 10.1152/jn.00486.2004; Taragano FE, 2005, INT PSYCHOGERIATR, V17, P487, DOI 10.1016/S1041610205001493; Castren E, 2010, DEV NEUROBIOL, V70, P289, DOI 10.1002/dneu.20758; Bhat S, 2012, PROG NEUROBIOL, V99, P1, DOI 10.1016/j.pneurobio.2012.06.001; Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; PICKARD JD, 1989, BRIT MED J, V298, P636; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Castren E, 2012, J NEUROSCI, V32, P14074, DOI 10.1523/JNEUROSCI.3287-12.2012; Saarelainen T, 2003, J NEUROSCI, V23, P349; Karpova NN, 2011, SCIENCE, V334, P1731, DOI 10.1126/science.1214592; Winkler T, 2003, ACT NEUR S, V86, P425; Hashioka S, 2012, NEUROPHARMACOLOGY, V63, P685, DOI 10.1016/j.neuropharm.2012.05.033; Poulsen FR, 2004, NEUROSCIENCE, V126, P665, DOI 10.1016/j.neuroscience.2004.04.008; Deak F, 2000, NEUROPHARMACOLOGY, V39, P1029, DOI 10.1016/S0028-3908(99)00206-3; Bading H, 2013, NAT REV NEUROSCI, V14, P593, DOI 10.1038/nrn3531; Minichiello L, 2009, NAT REV NEUROSCI, V10, P850, DOI 10.1038/nrn2738; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169; Zhao H, 2006, MOL NEUROBIOL, V34, P249, DOI 10.1385/MN:34:3:249; Castren E, 2013, JAMA PSYCHIAT, V70, P983, DOI 10.1001/jamapsychiatry.2013.1; CZYRAK A, 1989, NEUROPHARMACOLOGY, V28, P229, DOI 10.1016/0028-3908(89)90097-X; CZYRAK A, 1990, PHARMACOL BIOCHEM BE, V35, P557, DOI 10.1016/0091-3057(90)90289-T; DEJONG GI, 1992, BRAIN RES, V596, P345, DOI 10.1016/0006-8993(92)91570-5; Di Lieto A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032869; Dorhout Mees SM, 2007, COCHRANE DB SYST REV, V18; Dorsch N, 2011, ACTA NEUROCHIR SUPPL, V110, P5, DOI 10.1007/978-3-7091-0353-1_1; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1227/01.NEU.000003638.90415.04; Dubovsky SL, 2001, J ECT, V17, P3, DOI 10.1097/00124509-200103000-00002; Gepdiremen A, 1997, FUNDAM CLIN PHARM, V11, P117; Gómez-Palacio-Schjetnan Andrea, 2013, Curr Top Behav Neurosci, V15, P117, DOI 10.1007/7854_2012_231; Kim HJ, 2013, BRAIN RES, V1490, P23, DOI 10.1016/j.brainres.2012.10.062; LAURSEN J, 1988, CLIN NEUROL NEUROSUR, V90, P329, DOI 10.1016/0303-8467(88)90005-4; LAZAREWICZ JW, 1990, STROKE, V21, P108; Liu Changqin, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P170; Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246; Maya Vetencourt JF, 2008, SCIENCE, V18, P385; MOGILNICKA E, 1987, EUR J PHARMACOL, V138, P413, DOI 10.1016/0014-2999(87)90480-8; NUGLISCH J, 1990, J CEREBR BLOOD F MET, V10, P654; Rantamaki T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020567; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Ricci A, 2002, CLIN EXP HYPERTENS, V24, P715, DOI 10.1081/CEH-120015347; Segal RA, 1996, J BIOL CHEM, V271, P20175; Sheldon S, 2013, J NEUROL SCI, V332, P145, DOI 10.1016/j.jns.2013.06.021; Taragano FE, 2001, INT J GERIATR PSYCH, V16, P254, DOI 10.1002/gps.340.abs; Taya K, 2000, PHYSIOL BEHAV, V70, P19, DOI 10.1016/S0031-9384(00)00221-3; Thomas S, 2008, ACT NEUR S, V102, P377, DOI 10.1007/978-3-211-85578-2_72; Triggle DJ, 2006, CURR PHARM DESIGN, V12, P443, DOI 10.2174/138161206775474503; Uutela M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00150; Zornow M H, 1996, New Horiz, V4, P107	70	1	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2015	35	2					189	196		10.1007/s10571-014-0110-5		8	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CC3HG	WOS:000350236800005		
J	Ishikawa, T; Yasuda, S; Minoda, S; Ibuki, T; Fukuhara, K; Iwanaga, Y; Ariyoshi, T; Sasaki, H				Ishikawa, Toshizo; Yasuda, Seiko; Minoda, Seiji; Ibuki, Takae; Fukuhara, Kayoko; Iwanaga, Yasutake; Ariyoshi, Toru; Sasaki, Hironori			Neurotropin(A (R)) Ameliorates Chronic Pain via Induction of Brain-Derived Neurotrophic Factor	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Chronic pain; Pain-related depression; Neurotropin (R); BDNF; pERK1/2	ANTERIOR CINGULATE CORTEX; DEPRESSION-LIKE BEHAVIOR; SIGNAL-REGULATED KINASE; DESCENDING CONTROL; NEUROPATHIC PAIN; ANTIDEPRESSANT TREATMENT; INHIBITORY SYSTEMS; MAJOR DEPRESSION; SPATIAL MEMORY; FACTOR BDNF	Neurotropin (NTP)(A (R)), a non-protein extract isolated from the inflamed skin of rabbits inoculated with vaccinia virus, is used clinically for the treatment of neuropathic pain. Moreover, NTP may activate the descending pain inhibitory system. Depression-like behavior is often complicated by chronic pain. However, little is known about NTP-mediated prevention of mood disorders in chronic pain and its molecular mechanisms. We aimed to investigate the effects of NTP on brain-derived neurotrophic factor (BDNF)-mediated signaling and gene expression in chronic pain. In addition, these effects of NTP were compared with pregabalin which is an anticonvulsant, anxiolytic analgesic used to treat neuropathic pain and fibromyalgia. A chronic constriction injury model was established in Sprague-Dawley rats. The pain response was assessed using a paw withdrawal latency (PWL) test and depression was assessed by the immobility time in a forced swim test (FST). NTP was orally administered in two doses of 50 NU (Neurotropin Unit) and 100 NU/kg for 7 days from day 7 after injury. To measure the analgesic and anti-depressant effects of NTP, either K252a (a tyrosine kinase inhibitor), or 5,7-dihydroxy tryptamine (5,7-DHT, a selective toxin for 5-HTergic neurons) was administered by intracerebroventricular injection. Changes in pERK1/2 and pCREB (immunohistochemistry), 5-HT, and BDNF protein level (ELISA) and BDNF mRNA (RT-PCR) were measured in the anterior cingulate cortex (ACC) and in the rostral ventromedial medulla (RVM) 14 days after injury. After injury, the rats showed a decrease in PWL associated with the increase in time of immobility in FST. In this injury model, NTP blocked both the decrease in PWL and the increase in the FST, while pregabalin (10 mg/kg, po.) did not affect the increase in the FST. These effects of NTP were reversed by K252a, and 5,7-DHT. The analgesic effects of pregabalin were not reversed by K252a. NTP normalized the injury-induced excessive activation of pERK1/2 associated with decreased pCREB and BDNF mRNA in the ACC and in the RVM, and these changes were reversed by 5,7-DHT. In contrast, pregabalin did not affect either pCREB or BDNF levels in the chronic pain model. NTP ameliorated chronic pain and pain-related depression by normalizing the induction of BDNF associated with the 5-HTergic system. Pregabalin showed the analgesic effects but had no effects on either depression or the BDNF pathway. These results suggest that NTP may represent an additional drug strategy for chronic pain associated with depression.	[Ishikawa, Toshizo; Yasuda, Seiko; Minoda, Seiji; Fukuhara, Kayoko; Iwanaga, Yasutake; Ariyoshi, Toru; Sasaki, Hironori] Yamaguchi Univ, Grad Sch Med, Div Neurosci, Ube, Yamaguchi 7558505, Japan; [Minoda, Seiji] Syuto Gen Hosp, Div Lab Med, Yamaguchi, Japan; [Ibuki, Takae] Kyoto Prefectural Univ Med, Dept Anesthesiol, Kyoto 602, Japan; [Sasaki, Hironori] Yamaguchi Grand Med Ctr, Div Lab Med, Hofu, Yamaguchi, Japan	Ishikawa, T (reprint author), Yamaguchi Univ, Grad Sch Med, Div Neurosci, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	medlibn@yamaguchi-u.ac.jp					Merighi A, 2008, PROG NEUROBIOL, V85, P297, DOI 10.1016/j.pneurobio.2008.04.004; Tripp A, 2012, AM J PSYCHIAT, V169, P1194, DOI 10.1176/appi.ajp.2012.12020248; Bremner JD, 2000, AM J PSYCHIAT, V157, P115; Cao H, 2012, NEUROSCI BULL, V28, P77, DOI 10.1007/s12264-012-1060-x; Seifert F, 2009, CELL MOL LIFE SCI, V66, P375, DOI 10.1007/s00018-008-8428-0; Kafitz KW, 1999, NATURE, V401, P918; Sindrup SH, 2005, BASIC CLIN PHARMACOL, V96, P399, DOI 10.1111/j.1742-7843.2005.pto_96696601.x; Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Fumagalli F, 2005, J NEUROCHEM, V93, P1551, DOI 10.1111/j.1471-4159.2005.03149.x; Suzuki R, 2004, TRENDS PHARMACOL SCI, V25, P613, DOI 10.1016/j.tips.2004.10.002; Blendy JA, 2006, BIOL PSYCHIAT, V59, P1144, DOI 10.1016/j.biopsych.2005.11.003; HANAOKA Y, 1994, J NEUROL SCI, V122, P28, DOI 10.1016/0022-510X(94)90048-5; Duric V, 2005, NEUROSCIENCE, V133, P999, DOI 10.1016/j.neuroscience.2005.04.002; Gustin SM, 2010, PAIN, V148, P438, DOI 10.1016/j.pain.2009.12.001; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; Heldt SA, 2007, MOL PSYCHIATR, V12, P656, DOI 10.1038/sj.mp.4001957; STAMFORD JA, 1995, BRIT J ANAESTH, V75, P217; Zeng Q, 2008, BRAIN RES, V1200, P27, DOI 10.1016/j.brainres.2008.01.038; Alkon DL, 2005, P NATL ACAD SCI USA, V102, P16432, DOI 10.1073/pnas.0508001102; KENSHALO DR, 1980, J NEUROPHYSIOL, V43, P1594; Saita K, 1996, J PHARMACOL EXP THER, V276, P231; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Vanegas H, 2004, BRAIN RES REV, V46, P295, DOI 10.1016/j.brainresrev.2004.07; Cao H, 2009, NEUROSCI BULL, V25, P301, DOI 10.1007/s12264-009-0904-5; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x; Fukuhara K, 2012, CELL MOL NEUROBIOL, V32, P971, DOI 10.1007/s10571-011-9782-2; Moisset X, 2007, NEUROIMAGE, V37, pS80, DOI 10.1016/j.neuroimage.2007.03.054; Gao YJ, 2004, PAIN, V110, P343, DOI 10.1016/j.pain.2004.04.030; Gebhart GF, 2004, NEUROSCI BIOBEHAV R, V27, P729, DOI 10.1016/j.neubiorev.2003.11.008; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689; Cejas PJ, 2000, PAIN, V86, P195, DOI 10.1016/S0304-3959(00)00245-1; Fukumitsu H, 1999, NEUROSCI LETT, V274, P115, DOI 10.1016/S0304-3940(99)00691-6; FURUKAWA Y, 1989, FEBS LETT, V247, P463, DOI 10.1016/0014-5793(89)81391-2; Gao Y.J., 2009, OPEN PAIN J, V2, P11; Ishikawa K, 2014, NEUROREPORT, V25, P226, DOI 10.1097/WNR.0000000000000072; Ishikawa K., 2010, Bulletin of the Yamaguchi Medical School, V57, P49; Kawamura M, 1998, LIFE SCI, V62, P2181, DOI 10.1016/S0024-3205(98)00195-7; LIPP J, 1991, CLIN NEUROPHARMACOL, V14, P131, DOI 10.1097/00002826-199104000-00003; Miura T, 2005, J PHARMACOL SCI, V97, P429, DOI 10.1254/jphs.FPJ04050X; Moisset X, 2010, EUR J PAIN, V14, P142, DOI 10.1016/j.ejpain.2009.04.011; Murphy GM, 2013, PHARMACOGENET GENOM, V23, P301, DOI 10.1097/FPC.0b013e328360b175; Nagata K., 2009, MOL PAIN, V23, P20; Okazaki R, 2008, ANESTH ANALG, V107, P1064, DOI 10.1213/ane.0b013e31817e7a59; Paxinos G, 1998, RAT BRAIN STEREOTAXI; Schwenkreis P, 2009, AM J NEURORADIOL, V30, P1279, DOI 10.3174/ajnr.A1630; Sun MK, 2008, NEUROREPORT, V19, P355, DOI 10.1097/WNR.0b013e3282f519c7; Zhang FE, 2005, PAIN, V57, P545	51	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2015	35	2					231	241		10.1007/s10571-014-0118-x		11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	CC3HG	WOS:000350236800009		
J	Srinivasu, P; Venkanna, D; Kantam, ML; Tang, J; Bhargava, SK; Aldalbahi, A; Wu, KCW; Yamauchi, Y				Srinivasu, Pavuluri; Venkanna, Dupati; Kantam, Mannepalli Lakshmi; Tang, Jing; Bhargava, Suresh K.; Aldalbahi, Ali; Wu, Kevin C. -W.; Yamauchi, Yusuke			Ordered Hexagonal Mesoporous Aluminosilicates and their Application in Ligand-Free Synthesis of Secondary Amines	CHEMCATCHEM			English	Article						ligand-free synthesis; mesoporous aluminosilicate; mesoporous materials; secondary amines	N-ALKYLATION; SILICA NANOPARTICLES; PLATINUM NANOPARTICLES; PRIMARY ALCOHOLS; TERTIARY-AMINES; EFFICIENT; CATALYST; ZEOLITE; ADSORPTION; REDUCTION	A new facile synthesis of ordered mesoporous aluminosilicates has been developed and applied for the efficient catalytic synthesis of N-benzyl secondary amines under ligand and base-free conditions. The MAS(38) catalyst with a well-ordered mesoporous structure and strong acidic sites was used for acid-catalyzed organic transformations and its operational simplicity and ease of its isolation procedure make it an attractive alternative to current methodologies.	[Srinivasu, Pavuluri; Venkanna, Dupati; Kantam, Mannepalli Lakshmi] CSIR Indian Inst Chem Technol, Inorgan & Phys Chem Div, Hyderabad 500007, Andhra Pradesh, India; [Tang, Jing; Yamauchi, Yusuke] Natl Inst Mat Sci, World Premier Int WPI Res Ctr Mat Nanoarchitecton, Tsukuba, Ibaraki 3050044, Japan; [Bhargava, Suresh K.] RMIT Univ, Sch Appl Sci, Adv Mat & Ind Chem Grp, Melbourne, Vic 3001, Australia; [Aldalbahi, Ali; Yamauchi, Yusuke] King Saud Univ, Coll Sci, Dept Chem, Riyadh 11451, Saudi Arabia; [Wu, Kevin C. -W.] Natl Taiwan Univ, Dept Chem Engn, Taipei 10617, Taiwan	Srinivasu, P (reprint author), CSIR Indian Inst Chem Technol, Inorgan & Phys Chem Div, Hyderabad 500007, Andhra Pradesh, India.	pavuluri.srini@iict.res.in; kevinwu@ntu.edu.tw; Yamauchi.Yusuke@nims.go.jp	Yamauchi, Yusuke/D-2780-2015; Bhargava, Suresh/C-5783-2011	Bhargava, Suresh/0000-0002-3127-8166	University Grants Commission (UGC) in India	D. V. thanks the University Grants Commission (UGC) in India for the award of research fellowship.	Hamid MHSA, 2009, J AM CHEM SOC, V131, P1766, DOI 10.1021/ja807323a; Yamauchi Y, 2013, J CERAM SOC JPN, V121, P831, DOI 10.2109/jcersj2.121.831; Wang HJ, 2012, CHEM-ASIAN J, V7, P802, DOI 10.1002/asia.201100949; Blank B, 2008, ADV SYNTH CATAL, V350, P749, DOI 10.1002/adsc.200700596; Wang YH, 2013, J AM CHEM SOC, V135, P1506, DOI 10.1021/ja310498c; Do PTM, 2013, ACS CATAL, V3, P41, DOI 10.1021/cs300673b; Lee YC, 2013, CHEMCATCHEM, V5, P2153, DOI 10.1002/cctc.201300219; [Anonymous], 2010, ANGEW CHEM, V122, P4048; Nandi M, 2011, CHEM COMMUN, V47, P6677, DOI 10.1039/c1cc11007a; Oveisi H, 2010, CHEM-ASIAN J, V5, P1978, DOI 10.1002/asia.201000351; Wang D, 2013, ADV SYNTH CATAL, V355, P1117, DOI 10.1002/adsc.201200732; Wang HJ, 2011, J AM CHEM SOC, V133, P14526, DOI 10.1021/ja2058617; Martinez R, 2009, ORG BIOMOL CHEM, V7, P2176, DOI 10.1039/b901929d; He L, 2010, CHEM-EUR J, V16, P13965, DOI 10.1002/chem.201001848; Zhao YS, 2011, ANGEW CHEM INT EDIT, V50, P3006, DOI 10.1002/anie.201006660; Zhao Q, 2002, J PHYS CHEM B, V106, P4462, DOI 10.1021/jp015574k; Weng W, 2010, ANGEW CHEM INT EDIT, V49, P3956, DOI 10.1002/anie.200907008; Thomson KT, 1998, J CHEM PHYS, V108, P8584, DOI 10.1063/1.476287; Joo SH, 2009, NAT MATER, V8, P126, DOI [10.1038/nmat2329, 10.1038/NMAT2329]; Wu KCW, 2012, J MATER CHEM, V22, P1251, DOI 10.1039/c1jm13811a; Chen HW, 2014, J POWER SOURCES, V245, P411, DOI 10.1016/j.jpowsour.2013.06.142; Wu KCW, 2011, J MATER CHEM, V21, P8934, DOI 10.1039/c1jm10548e; Hanada S, 2007, J ORG CHEM, V72, P7551, DOI 10.1021/jo070591c; [Anonymous], 2011, ANGEW CHEM, V123, P3062; Cami-Kobeci G, 2004, CHEM COMMUN, P1072, DOI 10.1039/b402020k; Cicuendez M, 2012, CHEM MATER, V24, P1100, DOI 10.1021/cm203416x; Derouane EG, 2000, J CATAL, V194, P410, DOI 10.1006/jcat.2000.2933; Du HW, 2002, J PHYS CHEM B, V106, P395, DOI 10.1021/jp013310s; Insaf SS, 1999, SYNTHESIS-STUTTGART, P435; Lee Y. C., 2014, CHEMSUSCHEM, V7, P3421; Liao YT, 2014, INT J NANOMED, V9, P2767, DOI 10.2147/IJN.S60171; Tillack A, 2008, EUR J ORG CHEM, P4745, DOI 10.1002/ejoc.200800671; Turcotte M., 2001, KIRK OTHMER ENCY CHE, V2, P537	33	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	MAR	2015	7	5					747	751		10.1002/cctc.201402916		5	Chemistry, Physical	Chemistry	CC6KJ	WOS:000350473500006		
J	Atanda, L; Mukundan, S; Shrotri, A; Ma, Q; Beltramini, J				Atanda, Luqman; Mukundan, Swathi; Shrotri, Abhijit; Ma, Qing; Beltramini, Jorge			Catalytic Conversion of Glucose to 5-Hydroxymethyl-furfural with a Phosphated TiO2 Catalyst	CHEMCATCHEM			English	Article						carbohydrates; heterogeneous catalysis; HMF; mesoporous materials; titanium	SOLID ACID CATALYSTS; TITANIUM-DIOXIDE NANOPARTICLES; MICROWAVE-ASSISTED CONVERSION; HIGH PHOTOCATALYTIC ACTIVITY; FRUCTOSE DEHYDRATION; HETEROGENEOUS ZIRCONIUM; IONIC LIQUIDS; WATER; BIOMASS; PHASE	Nanosized phosphated TiO2 catalysts with different phosphate contents were synthesized and tested for the conversion of glucose to 5-hydroxymethylfurfural. The resulting materials were characterized by using N-2-adsorption, XRD, inductively coupled plasma atomic emission spectroscopy, X-ray spectroscopy, TEM, temperature-programmed desorption of ammonia, and FTIR spectroscopy of pyridine adsorption techniques to determine their structural, bulk, surface, and acid properties. We found that TiO2 nanoparticles catalyzed this reaction under mild conditions in a water-butanol biphasic system. The incorporation of phosphorus into the TiO2 framework remarkably enhances the target product selectivity, which is ascribed to increased surface area, enhanced acidity, as well as thermal stability resulting from the Ti-O-P bond formation. Under optimal reaction conditions, phosphated TiO2 was found to exhibit excellent catalytic performance, which resulted in 97% glucose conversion and 81% HMF yield after 3 h of reaction at 175 degrees C. More importantly, the catalyst showed good stability and could be reused for several reaction cycles.	[Atanda, Luqman; Mukundan, Swathi; Shrotri, Abhijit; Ma, Qing; Beltramini, Jorge] Univ Queensland, Nanomat Ctr AIBN, Brisbane, Qld 4072, Australia; [Atanda, Luqman; Mukundan, Swathi; Shrotri, Abhijit; Ma, Qing; Beltramini, Jorge] Univ Queensland, Sch Chem Engn, Brisbane, Qld 4072, Australia; [Shrotri, Abhijit] Hokkaido Univ, Catalysis Res Ctr, Kita Ku, Sapporo, Hokkaido 0010021, Japan	Beltramini, J (reprint author), Univ Queensland, Nanomat Ctr AIBN, Brisbane, Qld 4072, Australia.	j.beltramini@uq.edu.au			Nanomaterials Center (NANOMAC) at the University of Queensland, Australia; International Postgraduate Research Scholarship; UQ Centennial Scholarship	We gratefully acknowledge financial support from the Nanomaterials Center (NANOMAC) at the University of Queensland, Australia. We also acknowledge the facilities and the scientific and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the University of Queensland. L.A. acknowledges sponsorship from the International Postgraduate Research Scholarship and UQ Centennial Scholarship).	Kruger JS, 2013, ACS CATAL, V3, P1279, DOI 10.1021/cs4002157; Kimura H, 2013, J PHYS CHEM A, V117, P2102, DOI 10.1021/jp312002h; Shimizu K, 2009, CATAL COMMUN, V10, P1849, DOI 10.1016/j.catcom.2009.06.012; Qi XH, 2009, CATAL COMMUN, V10, P1771, DOI 10.1016/j.catcom.2009.05.029; Albu SP, 2008, ADV MATER, V20, P4135, DOI 10.1002/adma.200801189; Qi XH, 2008, IND ENG CHEM RES, V47, P9234, DOI 10.1021/ie801016s; Dee SJ, 2011, CHEMSUSCHEM, V4, P1166, DOI 10.1002/cssc.201000426; Tao FR, 2010, CHEMSUSCHEM, V3, P1298, DOI 10.1002/cssc.201000184; Chen D, 2006, IND ENG CHEM RES, V45, P4110, DOI 10.1021/ie0600902; Teleki A, 2006, SENSOR ACTUAT B-CHEM, V119, P683, DOI 10.1016/j.snb.2006.01.027; Kamat PV, 2007, J PHYS CHEM C, V111, P2834, DOI 10.1021/jp066952u; Parida KM, 1999, J COLLOID INTERF SCI, V217, P388, DOI 10.1006/jcis.1999.6347; Fan CY, 2011, BIOMASS BIOENERG, V35, P2659, DOI 10.1016/j.biombioe.2011.03.004; Zhao HB, 2007, SCIENCE, V316, P1597, DOI 10.1126/science.1141199; Puddu V, 2010, APPL CATAL B-ENVIRON, V94, P211, DOI 10.1016/j.apcatb.2009.08.003; Benvenuti F, 2000, APPL CATAL A-GEN, V193, P147, DOI 10.1016/S0926-860X(99)00424-X; Peng TY, 2005, J PHYS CHEM B, V109, P4947, DOI 10.1021/jp044771r; Bao SJ, 2008, ADV FUNCT MATER, V18, P591, DOI 10.1002/adfm.200700728; Wang JJ, 2012, GREEN CHEM, V14, P2506, DOI 10.1039/c2gc35699f; KUSTER BFM, 1990, STARCH-STARKE, V42, P314, DOI 10.1002/star.19900420808; van Putten RJ, 2013, CHEM REV, V113, P1499, DOI 10.1021/cr300182k; Kwak ES, 2009, ADV FUNCT MATER, V19, P1093, DOI 10.1002/adfm.200801540; LOURVANIJ K, 1993, IND ENG CHEM RES, V32, P11, DOI 10.1021/ie00013a002; Watanabe M, 2005, APPL CATAL A-GEN, V295, P150, DOI 10.1016/j.apcata.2005.08.007; Roman-Leshkov Y, 2007, NATURE, V447, P982, DOI 10.1038/nature05923; Ordomsky VV, 2012, J CATAL, V287, P68, DOI 10.1016/j.jcat.2011.12.002; Weingarten R, 2012, ENERG ENVIRON SCI, V5, P7559, DOI 10.1039/c2ee21593d; Li CZ, 2009, TETRAHEDRON LETT, V50, P5403, DOI 10.1016/j.tetlet.2009.07.053; Qi XH, 2008, CATAL COMMUN, V9, P2244, DOI 10.1016/j.catcom.2008.04.025; Torres AI, 2010, ENERG ENVIRON SCI, V3, P1560, DOI 10.1039/c0ee00082e; Kuo CH, 2014, GREEN CHEM, V16, P785, DOI 10.1039/c3gc40909k; Paul M, 2010, PHYS CHEM CHEM PHYS, V12, P9389, DOI 10.1039/b925619a; Chandra D, 2008, J PHYS CHEM C, V112, P8668, DOI 10.1021/jp800846v; Mao YB, 2006, J AM CHEM SOC, V128, P8217, DOI 10.1021/ja0607483; Xie MZ, 2010, J HAZARD MATER, V176, P139, DOI 10.1016/j.jhazmat.2009.11.008; Carlini C, 2004, APPL CATAL A-GEN, V275, P111, DOI 10.1016/j.apcata.2004.07.026; Dutta S, 2011, APPL CATAL A-GEN, V409, P133, DOI 10.1016/j.apcata.2011.09.037; Mohamed MM, 2007, MICROPOR MESOPOR MAT, V103, P174, DOI 10.1016/j.micromeso.2007.01.052; Yong G, 2008, ANGEW CHEM INT EDIT, V47, P9345, DOI 10.1002/anie.200803207; Yu JC, 2003, CHEM MATER, V15, P2280, DOI 10.1021/cm0340781; Stahlberg T, 2011, CHEMSUSCHEM, V4, P451, DOI 10.1002/cssc.201000374; Chheda JN, 2007, GREEN CHEM, V9, P342, DOI 10.1039/b611568c; De S, 2011, GREEN CHEM, V13, P2859, DOI 10.1039/c1gc15550d; Nikolla E, 2011, ACS CATAL, V1, P408, DOI 10.1021/cs2000544; Qi XH, 2010, CHEMSUSCHEM, V3, P1071, DOI 10.1002/cssc.201000124; Wang TF, 2014, GREEN CHEM, V16, P548, DOI 10.1039/c3gc41365a; Binder JB, 2009, J AM CHEM SOC, V131, P1979, DOI 10.1021/ja808537j; Korosi L, 2007, CHEM MATER, V19, P4811, DOI 10.1021/cm070692r; Ohara M, 2010, APPL CATAL A-GEN, V383, P149, DOI 10.1016/j.apcata.2010.05.040; Dutta A, 2012, J MATER CHEM, V22, P14094, DOI 10.1039/c2jm30623a; Yan HP, 2009, CATAL COMMUN, V10, P1558, DOI 10.1016/j.catcom.2009.04.020; Roman-Leshkov Y, 2006, SCIENCE, V312, P1933, DOI 10.1126/science.1126337; Zhang J, 2012, ACS CATAL, V2, P1211, DOI 10.1021/cs300045r; Asghari FS, 2006, CARBOHYD RES, V341, P2379, DOI 10.1016/j.carres.2006.06.025; Qi XH, 2009, GREEN CHEM, V11, P1327, DOI 10.1039/b905975j; Das SK, 2011, ACS CATAL, V1, P493, DOI 10.1021/cs200005z; Centi G., 2007, CATALYSIS RENEWABLES; Dalai AK, 1998, IND ENG CHEM RES, V37, P3869, DOI 10.1021/ie980091x; De S, 2011, J MATER CHEM, V21, P17505, DOI 10.1039/c1jm13229f; Fan L. T., 1987, CELLULOSE HYDROLYSIS; Guo SY, 2013, MATER RES BULL, V48, P3032, DOI 10.1016/j.materresbull.2013.04.056; Moreau Y. C., 1994, IND CROP PROD, V3, P85; Nakajima K, 2014, J MOL CATAL A-CHEM, V388, P100, DOI 10.1016/j.molcata.2013.09.012; Raj KJA, 2010, INDIAN J CHEM A, V49, P9; Sethi D, 2014, J PHOTOCH PHOTOBIO B, V130, P310, DOI 10.1016/j.jphotobiol.2013.12.003; Takagaki A, 2009, CHEM COMMUN, P6276, DOI 10.1039/b914087e; Yong G, 2008, ANGEW CHEM, V120, P9485, DOI 10.1002/ange.200803207	67	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	MAR	2015	7	5					781	790		10.1002/cctc.201402794		10	Chemistry, Physical	Chemistry	CC6KJ	WOS:000350473500012		
J	Yang, ZH; Hafez, IH; Berber, MR; Nakashima, N				Yang, Zehui; Hafez, Inas H.; Berber, Mohamed R.; Nakashima, Naotoshi			An Enhanced Anode based on Polymer-Coated Carbon Black for use as a Direct Methanol Fuel Cell Electrocatalyst	CHEMCATCHEM			English	Article						direct methanol fuel cells; durability; methanol oxidation reaction; platinum	START/STOP OPERATING CONDITION; OXYGEN REDUCTION; ELECTROLYTE MEMBRANE; OXIDATION REACTIONS; CO-TOLERANCE; CATALYSTS; PERFORMANCE; DURABILITY; PLATINUM; ELECTROOXIDATION	Sluggish methanol oxidation reaction and low durability are the main obstacles for commercialization of direct methanol fuel cells (DMFCs). In this study, we describe the fabrication of 4 different carbon black (CB)-based electrocatalysts for the DMFC by changing the weight ratio between the Pt feed and polymer wrapped carbon support. In all the fabricated electrocatalysts, CB was coated with poly[2,2'-(2,6-pyridine)-5,5'-bibenzimidazole] on which the Pt nanoparticles were deposited, which were further coated with poly(vinylphosphonic acid). We found that a decrease in the Pt particle size produced higher catalytic activity. The electrochemical surface area (ECSA) of the electrocatalyst with the smallest Pt particle size was 120.8 +/- 12.0 m(2) g(Pt)(-1). The mass activity of the methanol oxidation reaction reached 1860 mA mg(Pt)(-1), which is, to the best of our knowledge, the highest value among the recorded catalytic activities of the CB-based electrocatalysts. Moreover, after 100 000 cycles the electrocatalyst displayed only 38% and 10.7% decrease in ECSA and methanol oxidation activity, respectively. Such an obtained durability was approximate to 10 times higher than that of the commercial CB/Pt electrocatalyst.	[Yang, Zehui; Nakashima, Naotoshi] Kyushu Univ, Grad Sch Engn, Dept Appl Chem, Nishi Ku, Fukuoka 819039, Japan; [Hafez, Inas H.; Berber, Mohamed R.; Nakashima, Naotoshi] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2CNER, Fukuoka 8190395, Japan; [Hafez, Inas H.] Damanhour Univ, Fac Agr, Dept Nat Resources & Agr Engn, Damanhour 22516, Egypt; [Berber, Mohamed R.] Tanta Univ, Fac Sci, Dept Chem, Tanta 31527, Egypt; [Nakashima, Naotoshi] Japan Sci & Technol Agcy JST, CREST, Chiyoda Ku, Tokyo 1020075, Japan	Nakashima, N (reprint author), Kyushu Univ, Grad Sch Engn, Dept Appl Chem, Nishi Ku, 744 Motooka, Fukuoka 819039, Japan.	nakashima-tcm@mail.cstm.kyushu-u.ac.jp	Nakashima, Naotoshi/C-8791-2009		Low-Carbon Research Network (LCnet); Nanotechnology Platform Project (Molecules and Materials Synthesis) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Science and Technology Agency (JST) through its Center of Innovation Science and Technology-based Radical Innovation and Entrepreneurship Program (COI Program); China Scholarship Council (CSC)	This work was supported in part by the Low-Carbon Research Network (LCnet) and the Nanotechnology Platform Project (Molecules and Materials Synthesis) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan and by The Japan Science and Technology Agency (JST) through its Center of Innovation Science and Technology-based Radical Innovation and Entrepreneurship Program (COI Program). Z.H.Y. acknowledges the China Scholarship Council (CSC) for their support.	Franceschini EA, 2011, J POWER SOURCES, V196, P1723, DOI 10.1016/j.jpowsour.2010.10.016; Hyeon T, 2003, ANGEW CHEM INT EDIT, V42, P4352, DOI 10.1002/anie.200250856; Zana A, 2013, ELECTROCHIM ACTA, V114, P455, DOI 10.1016/j.electacta.2013.10.097; Liao SJ, 2006, J AM CHEM SOC, V128, P3504, DOI 10.1021/ja0578653; Lufrano F, 2013, J POWER SOURCES, V243, P519, DOI 10.1016/j.jpowsour.2013.05.180; Zhang WM, 2010, NANOSCALE, V2, P282, DOI 10.1039/b9nr00140a; Okamoto M, 2009, SMALL, V5, P735, DOI 10.1002/smll.200801742; Gu YJ, 2006, LANGMUIR, V22, P11447, DOI 10.1021/la0620531; Kakinuma K, 2013, ELECTROCHIM ACTA, V110, P316, DOI 10.1016/j.electacta.2013.06.127; [Anonymous], 2008, ANGEW CHEM, V120, P1484; Gharibi H, 2013, ELECTROCHIM ACTA, V97, P216, DOI 10.1016/j.electacta.2013.01.121; Xue XZ, 2006, ELECTROCHEM COMMUN, V8, P1280, DOI 10.1016/j.elecom.2006.06.010; Koenigsmann C, 2011, ENERG ENVIRON SCI, V4, P1161, DOI 10.1039/c0ee00197j; Yano H, 2010, PHYS CHEM CHEM PHYS, V12, P3806, DOI 10.1039/b923460h; Stephens IEL, 2012, ENERG ENVIRON SCI, V5, P6744, DOI 10.1039/c2ee03590a; Hara M, 2012, ELECTROCHIM ACTA, V70, P171, DOI 10.1016/j.electacta.2012.03.043; [Anonymous], 2006, ANGEW CHEM, V118, P5441; Sun XL, 2014, J AM CHEM SOC, V136, P5745, DOI 10.1021/ja500590n; Samms SR, 1996, J ELECTROCHEM SOC, V143, P1225, DOI 10.1149/1.1836621; Rhee CH, 2005, CHEM MATER, V17, P1691, DOI 10.1021/cm048058q; Paik Y, 2008, ANGEW CHEM INT EDIT, V47, P94, DOI 10.1002/anie.200703190; Guo SJ, 2010, ACS NANO, V4, P547, DOI 10.1021/nn9014483; Huang HJ, 2014, J MATER CHEM A, V2, P6266, DOI 10.1039/c3ta14754a; Ohma A, 2011, ECS TRANSACTIONS, V41, P775, DOI 10.1149/1.3635611; [Anonymous], 2003, ANGEW CHEM, V115, P4488; Li XL, 2013, J POWER SOURCES, V226, P223, DOI 10.1016/j.jpowsour.2012.10.061; Cao L, 2006, ANGEW CHEM INT EDIT, V45, P5315, DOI 10.1002/anie.200601301; Kakinuma K, 2011, ELECTROCHIM ACTA, V56, P2881, DOI 10.1016/j.electacta.2010.12.077; Yano H, 2013, J ELECTROANAL CHEM, V688, P137, DOI 10.1016/j.jelechem.2012.09.028; Zhao X, 2011, ENERG ENVIRON SCI, V4, P2736, DOI 10.1039/c1ee01307f; [Anonymous], 2008, ANGEW CHEM, V120, P100; Yang MH, 2013, CHEM MATER, V25, P1783, DOI 10.1021/cm400304q; Wang DL, 2013, NAT MATER, V12, P81, DOI [10.1038/nmat3458, 10.1038/NMAT3458]; Joo SH, 2009, ELECTROCHIM ACTA, V54, P5746, DOI 10.1016/j.electacta.2009.05.022; Li WZ, 2003, J PHYS CHEM B, V107, P6292, DOI 10.1021/jp022505c; Matsumoto K, 2011, ADV FUNCT MATER, V21, P1089, DOI 10.1002/adfm.201001806; Xue XZ, 2007, J POWER SOURCES, V172, P560, DOI 10.1016/j.jpowsour.2007.05.091; Liu HS, 2006, J POWER SOURCES, V155, P95, DOI 10.1016/j.jpowsour.2006.01.030; Sun SH, 2011, ANGEW CHEM INT EDIT, V50, P422, DOI 10.1002/anie.201004631; Zhao Y, 2007, ADV FUNCT MATER, V17, P1537, DOI 10.1002/adfm.200600416; Berber MR, 2014, CHEMCATCHEM, V6, P567, DOI 10.1002/cctc.201300884; An K, 2013, J AM CHEM SOC, V135, P16689, DOI 10.1021/ja4088743; Xiao L, 2005, FUEL CELLS, V5, P287, DOI 10.1002/fuce.200400067; Franceschini EA, 2012, ELECTROCHIM ACTA, V71, P173, DOI 10.1016/j.electacta.2012.03.121; Liu Y, 2013, J AM CHEM SOC, V135, P530, DOI 10.1021/ja307635r; [Anonymous], 2011, ANGEW CHEM, V123, P442; Fang B, 2009, J AM CHEM SOC, V131, P15330, DOI 10.1021/ja905749e; Chen L, 2008, ELECTROCHIM ACTA, V53, P4316, DOI 10.1016/j.electacta.2007.12.076; Zhao XJ, 2013, ELECTROCHIM ACTA, V97, P33, DOI 10.1016/j.electacta.2013.02.062; Chu YY, 2010, J POWER SOURCES, V195, P1799, DOI 10.1016/j.jpowsour.2009.10.039; Ding LX, 2012, J AM CHEM SOC, V134, P5730, DOI 10.1021/ja212206m; Bahrami H, 2013, J POWER SOURCES, V230, P303, DOI 10.1016/j.jpowsour.2012.12.009; Berber MR, 2014, J MATER CHEM A, V2, P19053, DOI 10.1039/c4ta03956d; Berber MR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01764; Hafez IH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06295; Hsu CH, 2012, J POWER SOURCES, V198, P83, DOI 10.1016/j.jpowsour.2011.10.012; Lee M, 2011, ELECTROCHEMISTRY, V79, P381; Shao JJ, 2014, J MATER CHEM A, V2, P1940, DOI 10.1039/c3ta14134a; Song SQ, 2011, APPL CATAL B-ENVIRON, V103, P287, DOI 10.1016/j.apcatb.2011.01.012; Sun SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01775; Tomita A, 2008, ANGEW CHEM INT EDIT, V47, P1462, DOI 10.1002/anie.200703928; Yang GX, 2010, ELECTROCHEM COMMUN, V12, P492, DOI 10.1016/j.elecom.2010.01.029; Yang ZH, 2014, J MATER CHEM A, V2, P18875, DOI 10.1039/c4ta03185g; Zhao J, 2006, J MATER SCI, V41, P5514, DOI 10.1007/s10853-006-0276-4	64	7	7	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	MAR	2015	7	5					808	813		10.1002/cctc.201402917		6	Chemistry, Physical	Chemistry	CC6KJ	WOS:000350473500015		
J	Konishi, H; Muto, T; Ueda, T; Yamada, Y; Yamaguchi, M; Manabe, K				Konishi, Hideyuki; Muto, Takashi; Ueda, Tsuyoshi; Yamada, Yayoi; Yamaguchi, Miyuki; Manabe, Kei			Imidazole Derivatives as Accelerators for Ruthenium-Catalyzed Hydroesterification and Hydrocarbamoylation of Alkenes: Extensive Ligand Screening and Mechanistic Study	CHEMCATCHEM			English	Article						alkenes; carbonylation; ligand design; reaction mechanisms; ruthenium	METHYL-FORMATE; CARBON-MONOXIDE; ALKYL FORMATES; CARBONYLATION REACTIONS; EXCHANGE-REACTIONS; OLEFINS; METAL; ETHYLENE; ESTERS; RU	Imidazole derivatives are effective ligands for promoting the [Ru-3(CO)(12)]-catalyzed hydroesterification of alkenes using formates. Extensive ligand screening was performed to identify 2-hydroxymethylated imidazole as the optimal ligand. Neither carbon monoxide gas nor a directing group was required, and the reaction also showed a wide substrate generality. The Ruimidazole catalyst system also promoted intramolecular hydrocarbamoylation to afford lactams. A Ru-imidazole complex was unambiguously analyzed by X-ray crystallography, and it had a trinuclear structure derived from one [Ru-3(CO)(12)] and two ligands. This complex was also successfully used for hydroesterification. The mechanism was examined in detail by using D-and C-13-labeled formates, indicating that the hydroesterification reaction proceeds by a decarbonylation-recarbonylation pathway.	[Konishi, Hideyuki; Muto, Takashi; Ueda, Tsuyoshi; Yamada, Yayoi; Yamaguchi, Miyuki; Manabe, Kei] Univ Shizuoka, Sch Pharmaceut Sci, Suruga Ku, Shizuoka 4228526, Japan; [Ueda, Tsuyoshi] Daiichi Sankyo Co Ltd, Pharmaceut Technol Div, Proc Technol Res Labs, Hiratsuka, Kanagawa 2540014, Japan	Manabe, K (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	manabe@u-shizuoka-ken.ac.jp			Daiichi-Sankyo Co. Ltd.; Uehara Memorial Foundation; JSPS [23790016]; Ministry of Education, Culture, Sports, Science and Technology, Japan	We thank Dr. Yoshinobu Ishikawa (University of Shizuoka) for his assistance with the X-ray crystallographic analysis. This work was partly supported by Daiichi-Sankyo Co. Ltd., the Uehara Memorial Foundation, JSPS Grant-in-Aid for Young Scientists (B, 23790016), and Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Ammar H. B., 2003, EUR J INORG CHEM, P4055; Wu LP, 2014, ANGEW CHEM INT EDIT, V53, P6310, DOI 10.1002/anie.201400793; REPPE W, 1953, LIEBIGS ANN CHEM, V582, P38; Armanino N, 2014, ORG LETT, V16, P572, DOI 10.1021/ol4034463; Kiss G, 2001, CHEM REV, V101, P3435, DOI 10.1021/cr010328q; NAHMED EM, 1990, J MOL CATAL, V59, pL15, DOI 10.1016/0304-5102(90)85097-2; WU Z, 1995, J AM CHEM SOC, V117, P5503, DOI 10.1021/ja00125a010; Fleischer I, 2013, CHEMSUSCHEM, V6, P417, DOI 10.1002/cssc.201200759; Ko S, 2003, ORG LETT, V5, P2687, DOI 10.1021/ol034862r; Armanino N, 2013, J AM CHEM SOC, V135, P6814, DOI 10.1021/ja4026787; SUZUKI Y, 1995, J MOL CATAL A-CHEM, V95, P129, DOI 10.1016/1381-1169(94)00012-3; Kanyiva KS, 2009, TETRAHEDRON LETT, V50, P3463, DOI 10.1016/j.tetlet.2009.02.195; KEIM W, 1989, J MOL CATAL, V54, P95, DOI 10.1016/0304-5102(89)80142-7; Konishi H, 2014, SYNLETT, V25, P1971, DOI 10.1055/s-0033-1339136; ISNARD P, 1983, J ORGANOMET CHEM, V256, P135, DOI 10.1016/S0022-328X(00)99305-7; Sheldon RA, 2012, CHEM SOC REV, V41, P1437, DOI 10.1039/c1cs15219j; KONDO T, 1989, J MOL CATAL, V50, P31, DOI 10.1016/0304-5102(89)80107-5; Fabre S, 1997, ANGEW CHEM INT EDIT, V36, P1092, DOI 10.1002/anie.199710921; Profir I, 2014, ORG BIOMOL CHEM, V12, P6972, DOI 10.1039/c4ob01246a; Donets PA, 2013, J AM CHEM SOC, V135, P11772, DOI 10.1021/ja406730t; Anastas P, 2010, CHEM SOC REV, V39, P301, DOI 10.1039/b918763b; Inoue S, 2006, ORG LETT, V8, P2519, DOI 10.1021/ol060715s; Katafuchi Y, 2011, ADV SYNTH CATAL, V353, P475, DOI 10.1002/adsc.201000750; Ko S, 2002, J AM CHEM SOC, V124, P750, DOI 10.1021/ja017076v; Wang LJ, 2004, ORG LETT, V6, P4207, DOI 10.1021/ol048378f; Tse SKS, 2010, ADV SYNTH CATAL, V352, P1512, DOI 10.1002/adsc.201000037; UEDA W, 1988, J MOL CATAL, V44, P197, DOI 10.1016/0304-5102(88)80030-0; Kondo T, 1999, ORGANOMETALLICS, V18, P4123, DOI 10.1021/om990373c; JENNER G, 1990, J ORGANOMET CHEM, V387, P315, DOI 10.1016/0022-328X(90)87180-L; MLEKUZ M, 1987, ORGANOMETALLICS, V6, P1591, DOI 10.1021/om00150a041; Li B, 2014, J AM CHEM SOC, V136, P1125, DOI 10.1021/ja411913e; Ko S, 2003, J ORG CHEM, V68, P1607, DOI 10.1021/jo026591o; Wang HN, 2014, ORG LETT, V16, P186, DOI 10.1021/ol403171p; Konishi H, 2012, ORG LETT, V14, P4722, DOI 10.1021/ol301850y; Miyazaki Y, 2012, CHEM LETT, V41, P298, DOI 10.1246/cl.2012.298; Morimoto T, 2004, ANGEW CHEM INT EDIT, V43, P5580, DOI 10.1002/anie.200301736; BRYNDZA HE, 1985, ORGANOMETALLICS, V4, P1686, DOI 10.1021/om00128a037; Dallmann K, 2001, J MOL CATAL A-CHEM, V172, P81, DOI 10.1016/S1381-1169(01)00127-3; DARENSBOURG DJ, 1994, INORG CHEM, V33, P3526, DOI 10.1021/ic00094a015; Fabre S., 1997, ANGEW CHEM, V109, P1167, DOI 10.1002/ange.19971091031; Hu YH, 2010, J AM CHEM SOC, V132, P3153, DOI 10.1021/ja909962f; LEGRAND C, 1994, J CHEM SOC CHEM COMM, P1173, DOI 10.1039/c39940001173; Morimoto T., 2004, ANGEW CHEM, V116, P5698, DOI 10.1002/ange.200301736; Mulzer J., 1991, COMPREHENSIVE ORGANI, V6, P323; Nath DCD, 2006, AUST J CHEM, V59, P218, DOI 10.1071/CH06010; Sawama Y, 2012, SYNLETT, P959, DOI 10.1055/s-0031-1289696; TOTH I, 1993, J CHEM SOC CHEM COMM, P529, DOI 10.1039/c39930000529; VANDOORN JA, 1981, J ORGANOMET CHEM, V222, P299, DOI 10.1016/S0022-328X(00)89158-5; Wu L., 2014, ANGEW CHEM, V126, P6426; Yahya R. M., 1998, ENZYME MICROB TECHNO, V23, P438	50	4	4	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	MAR	2015	7	5					836	845		10.1002/cctc.201402986		10	Chemistry, Physical	Chemistry	CC6KJ	WOS:000350473500019		
J	Yamashita, T; Ueda, A; Mitsui, T; Tomonaga, A; Matsumoto, S; Kodama, T; Fujitani, H				Yamashita, Takefumi; Ueda, Akihiko; Mitsui, Takashi; Tomonaga, Atsushi; Matsumoto, Shunji; Kodama, Tatsuhiko; Fujitani, Hideaki			The Feasibility of an Efficient Drug Design Method with High-Performance Computers	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						computational drug design; molecular dynamics; binding free energy; high-performance computing; force field parameter	HIV-1 REVERSE-TRANSCRIPTASE; BINDING FREE-ENERGIES; FORCE-FIELDS; NONNUCLEOSIDE INHIBITORS; LEAD OPTIMIZATION; DYNAMICS; DOCKING; PROTEIN; PREDICTION; DISCOVERY	In this study, we propose a supercomputer-assisted drug design approach involving all-atom molecular dynamics (MD)-based binding free energy prediction after the traditional design/selection step. Because this prediction is more accurate than the empirical binding affinity scoring of the traditional approach, the compounds selected by the MD-based prediction should be better drug candidates. In this study, we discuss the applicability of the new approach using two examples. Although the MD-based binding free energy prediction has a huge computational cost, it is feasible with the latest 10 petaflop-scale computer. The supercomputer-assisted drug design approach also involves two important feedback procedures: The first feedback is generated from the MD-based binding free energy prediction step to the drug design step. While the experimental feedback usually provides binding affinities of tens of compounds at one time, the supercomputer allows us to simultaneously obtain the binding free energies of hundreds of compounds. Because the number of calculated binding free energies is sufficiently large, the compounds can be classified into different categories whose properties will aid in the design of the next generation of drug candidates. The second feedback, which occurs from the experiments to the MD simulations, is important to validate the simulation parameters. To demonstrate this, we compare the binding free energies calculated with various force fields to the experimental ones. The results indicate that the prediction will not be very successful, if we use an inaccurate force field. By improving/validating such simulation parameters, the next prediction can be made more accurate.	[Yamashita, Takefumi; Mitsui, Takashi; Kodama, Tatsuhiko; Fujitani, Hideaki] Univ Tokyo, Res Ctr Adv Sci & Technol, Lab Syst Biol & Med, Meguro Ku, Tokyo 1538904, Japan; [Ueda, Akihiko; Mitsui, Takashi; Tomonaga, Atsushi; Matsumoto, Shunji] Fujitsu Ltd, Next Generat Healthcare Innovat Ctr, BioIT R&D Off, Ota Ku, Tokyo 1448588, Japan	Yamashita, T (reprint author), Univ Tokyo, Res Ctr Adv Sci & Technol, Lab Syst Biol & Med, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	yamashita@lsbm.org			MEXT SPIRE Supercomputational Life Science [hp120297, hp130006, hp140228]; FIRST Kodama project	This research was partly funded by MEXT SPIRE Supercomputational Life Science (hp120297, hp130006, and hp140228) and partly by the FIRST Kodama project. In particular, the huge computational resources of the K computer (RIKEN, Japan) enabled us to perform all the MP-CAFEE calculations.	Bingham RJ, 2004, J AM CHEM SOC, V126, P1675, DOI 10.1021/ja038461i; Rao SN, 2007, J CHEM INF MODEL, V47, P2159, DOI 10.1021/ci6004299; Diller DJ, 2001, PROTEINS, V43, P113, DOI 10.1002/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T; Grdadolnik J, 2011, P NATL ACAD SCI USA, V108, P1794, DOI 10.1073/pnas.1017317108; Schneider G, 2005, NAT REV DRUG DISCOV, V4, P649, DOI 10.1038/nrd1799; Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l; Beauchamp KA, 2012, J CHEM THEORY COMPUT, V8, P1409, DOI 10.1021/ct2007814; Yamashita T, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2434778; Fujitani H, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.021914; Warren GL, 2012, DRUG DISCOV TODAY, V17, P1270, DOI 10.1016/j.drudis.2012.06.011; Enyedy IJ, 2008, J COMPUT AID MOL DES, V22, P161, DOI 10.1007/s10822-007-9165-4; Tzanov AT, 2014, J PHYS CHEM B, V118, P6539, DOI 10.1021/jp500193w; Smith RD, 2011, J CHEM INF MODEL, V51, P2115, DOI 10.1021/ci200269q; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Shoichet BK, 2004, NATURE, V432, P862, DOI 10.1038/nature03197; Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n; Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306; Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e; McInnes C, 2007, CURR OPIN CHEM BIOL, V11, P494, DOI 10.1016/j.cbpa.2007.08.033; Kim JT, 2006, J AM CHEM SOC, V128, P15372, DOI 10.1021/ja066472g; Blaney J, 2012, J COMPUT AID MOL DES, V26, P13, DOI 10.1007/s10822-011-9518-x; Essex JW, 1997, J PHYS CHEM B, V101, P9663, DOI 10.1021/jp971990m; Fujitani H, 2013, J PHYS CONF SER, V454, DOI 10.1088/1742-6596/454/1/012018; Fujitani H, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1999637; Fujitani H, 2009, J CHEM THEORY COMPUT, V5, P1155, DOI 10.1021/ct8005437; Jorgensen WL, 2006, BIOORG MED CHEM LETT, V16, P663, DOI 10.1016/j.bmcl.2005.10.038; Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t; Moore GE, 1998, P IEEE, V86, P82, DOI 10.1109/JPROC.1998.658762; Okada O, 2013, BIOPHYS CHEM, V180, P119, DOI 10.1016/j.bpc.2013.07.005; Pierce AC, 1997, ANGEW CHEM INT EDIT, V36, P1466, DOI 10.1002/anie.199714661; Schneider G, 2009, TRENDS BIOTECHNOL, V27, P18, DOI 10.1016/j.tibtech.2008.09.005; Seabra GD, 2009, J PHYS CHEM A, V113, P11938, DOI 10.1021/jp903474v; TOP500, TOP500 SUP COMP SIT; Yamashita T, 2014, CHEM PHARM BULL, V62, P661; Yamashita T, 2014, CHEM PHYS LETT, V609, P50, DOI 10.1016/j.cplett.2014.06.028; Yamashita T, 2004, J CHEM PHYS, V121, P2105, DOI 10.1063/1.1768158; Yamashita T, 2005, CHEM PHYS LETT, V405, P142, DOI 10.1016/j.cplett.2005.02.012	37	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					147	155				9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200001		
J	Ikematsu, Y; Uchida, S; Namiki, N				Ikematsu, Yasuyuki; Uchida, Shinya; Namiki, Noriyuki			Preparation and Evaluation of Orally Disintegrating Tablets Containing Vitamin E as a Model Fat-Soluble Drug	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						orally disintegrating tablet; fat-soluble drug; vitamin E; disintegration; tensile strength; porosity	REDISPERSIBLE DRY EMULSION; IN-VIVO; TOCOPHEROL ACETATE; PHASE-TRANSITION; OILY MEDICINE; DOSAGE FORM; FORMULATION; NICOTINATE; GRANULES; DESIGN	The purpose of the present study was to develop orally disintegrating tablets (ODTs) containing fat-soluble drugs that disintegrate rapidly while having appropriate tablet strength. We chose vitamin E (YE) as a model drug; d-alpha-tocopheryl acetate, as the oily YE (VE-OI), and d-alpha-tocopheryl acid succinate, as the powder YE (VE-PO), were used. The oily YE was added directly to ODTs (YE-OI ODTs) and also used for the preparation of two types of YE granule, i.e., granules prepared using adsorption to calcium silicate (YE-FL granules) and granules prepared using spray-drying with gelatin (YE-SD granules); each type of granule was added to ODTs (YE-FL ODTs and VE-SD ODTs). Powder YE was added directly to ODTs (YE-PO ODTs). Various YE ODTs were prepared using these four additional methods with varying amounts of YE per tablet and were evaluated with respect to their manufacturability, physicochemical characteristics, and stability. It was demonstrated that a tablet porosity of 30% to 35% and tensile strength of 7kg/cm(2) or greater are required to provide YE ODTs with rapid disintegration and appropriate tablet strength, and that YE-SD granules and powder VE are suitable forms of YE to be added. When stability tests of YE-SD ODTs and VE-PO ODTs were performed, VE-PO ODTs exhibited prolongation of disintegration time and increased tensile strength, whereas YE-SD ODTs showed none of these changes. These changes were thought to be attributable to a decrease in the pore size of YE-PO ODTs resulting from the softening and migration of powder YE under hot storage conditions.	[Ikematsu, Yasuyuki; Uchida, Shinya; Namiki, Noriyuki] Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharm Practice & Sci, Suruga Ku, Shizuoka 4228526, Japan; [Ikematsu, Yasuyuki] Eisai & Co Ltd, Global Formulat Res Japan, Pharmaceut Sci & Technol Core Funct Unit, Eisai Prod Creat Syst, Gifu 5016195, Japan	Namiki, N (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharm Practice & Sci, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	namiki@u-shizuoka-ken.ac.jp					AlHusban F, 2010, EUR J PHARM BIOPHARM, V75, P254, DOI 10.1016/j.ejpb.2010.03.012; Koseki T, 2008, CHEM PHARM BULL, V56, P1384, DOI 10.1248/cpb.56.1384; Abdelbary G, 2004, INT J PHARM, V278, P423, DOI 10.1016/j.ijpharm.2004.03.023; Tapia C, 2007, DRUG DEV IND PHARM, V33, P585, DOI 10.1080/03639040601085359; Kuno Y, 2008, INT J PHARM, V355, P87, DOI 10.1016/j.ijpharm.2007.11.046; Kim JI, 2013, INT J PHARMACEUT, V455, P31, DOI 10.1016/j.ijpharm.2013.07.072; Kuno Y, 2005, J CONTROL RELEASE, V105, P16, DOI 10.1016/j.jconrel.2005.01.018; Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273; Mizumoto T, 2005, INT J PHARM, V306, P83, DOI 10.1016/j.ijpharm.2005.09.009; FELL JT, 1970, J PHARM SCI, V59, P688, DOI 10.1002/jps.2600590523; NYSTROM C, 1993, DRUG DEV IND PHARM, V19, P2143, DOI 10.3109/03639049309047189; Morita Y, 2002, CHEM PHARM BULL, V50, P1181, DOI 10.1248/cpb.50.1181; Jin FY, 2010, INT J PHARMACEUT, V389, P58, DOI 10.1016/j.ijpharm.2010.01.017; Dobetti L, 2001, PHARM TECH, V6; Food and Drug Administration Center for Drug Evaluation and Research (CDER)., 2008, GUID IND OR DIS TABL; Fu YR, 2005, J CONTROL RELEASE, V109, P203, DOI 10.1016/j.jconrel.2005.09.021; Sunada H, 2002, POWDER TECHNOL, V122, P188, DOI 10.1016/S0032-5910(01)00415-6; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009, INT C HARM TECHN REQ; Kawano Y, 2010, YAKUGAKU ZASSHI, V130, P1737, DOI 10.1248/yakushi.130.1737; KIMURA T, 1989, CHEM PHARM BULL, V37, P439; Mallet L, 1996, J AM PHARM ASSOC, V43, P628; Namiki N., 2013, PHARM TECH JPN, V29, P1971; Sakata Y, 2011, DRUG DEV IND PHARM, V37, P1049, DOI 10.3109/03639045.2011.559246; Sheshala R, 2011, ARCH PHARM RES, V34, P1945, DOI 10.1007/s12272-011-1115-y; [Anonymous], 2009, SCI PHARM, DOI DOI 10.3797/scipharm.0811-09-01; Sugimoto M, 2006, CHEM PHARM BULL, V54, P175, DOI 10.1248/cpb.54.175; Takashima Y, 1999, INT J PHARM, V187, P125, DOI 10.1016/S0378-5173(99)00179-9; TAKEUCHI H, 1992, DRUG DEV IND PHARM, V18, P919, DOI 10.3109/03639049209069307; TAKEUCHI H, 1991, CHEM PHARM BULL, V39, P3362; Tsushima Y., 2012, J JPN SOC PHARM MACH, V21, P337; Yamamoto H., 1998, J SOC POWDER TECH JA, V35, P671; YUASA H, 1994, CHEM PHARM BULL, V42, P2327	32	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					156	163				8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200002		
J	Uchiyama, J; Aoki, S; Uemoto, Y				Uchiyama, Jumpei; Aoki, Shigeru; Uemoto, Yoshifumi			New Approach to Evaluate the Lubrication Process in Various Granule Filling Levels and Rotating Mixer Sizes Using a Thermal Effusivity Sensor	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						lubrication process mechanism; process analytical technology; thermal effusivity; monitoring lubrication process; magnesium stearate	NEAR-INFRARED SPECTROSCOPY; POWDER BLEND HOMOGENEITY; FILM COATING PROCESS; BOHLE BIN-BLENDER; MAGNESIUM STEARATE; SCALE-UP; COMPRESSED TABLETS; DISSOLUTION RATE; MIXING TIME; PREDICTION	The principles of thermal effusivity are applied to an understanding of the detailed mechanisms of the lubrication process in a rotating mixer. The relationships and impact of the lubrication process by the pattern of powder flow, the filling level, and the rotating mixer size were investigated. Thermal effusivity profiles of the lubrication process, as obtained, indicate that lubrication is a two-phase process. The intersection point of the first and second phases (IPFS) is influenced by changing the filling level, thus changing the resulting number of avalanche flows created. The slope of the second phase (SSP) is influenced by the relationship between the number and the length of avalanche flows. Understanding this difference between the first and second phases is important to successfully evaluate the impact of proposed changes in the lubrication process. From this knowledge, a predictive model of the lubrication profile can be generated to allow an evaluation of proposed changes to the lubrication process. This model allows estimation of the lubrication profile at different filling levels and in different rotating mixer sizes. In this study, the actual lubrication profile almost coincides with the model predicted lubrication profile. Based on these findings, it is assumed that lubrication profiles at a commercial scale can be predicted from data generated at the laboratory scale. Further, it is assumed that changes in the filling level can also be estimated from the laboratory or current data.	[Uchiyama, Jumpei; Aoki, Shigeru] Eisai & Co Ltd, Japan Technol, Global Demand Chain Technol, New Chem Ent Demand Chain Unit,Eisai Demand Chain, Gifu 5016195, Japan; [Uemoto, Yoshifumi] Eisai & Co Ltd, Global Formulat Japan Pharmaceut Sci Technol, Gifu 5016195, Japan	Uchiyama, J (reprint author), Eisai & Co Ltd, Japan Technol, Global Demand Chain Technol, New Chem Ent Demand Chain Unit,Eisai Demand Chain, 1 Kawashimatakehaya, Gifu 5016195, Japan.	j-uchiyama@hhc.eisai.co.jp					Abe H, 2012, DRUG DEV IND PHARM, V38, P412, DOI 10.3109/03639045.2011.608679; Andersson M., 2000, ANAL CHEM, V72, P2100; Santomaso A, 2004, CHEM ENG SCI, V59, P3269, DOI 10.1016/j.ces.2004.04.026; Vanarase AU, 2010, CHEM ENG SCI, V65, P5728, DOI 10.1016/j.ces.2010.01.036; Arratia PE, 2006, POWDER TECHNOL, V161, P202, DOI 10.1016/j.powtec.2005.10.009; Vanarase AU, 2011, POWDER TECHNOL, V208, P26, DOI 10.1016/j.powtec.2010.11.038; Kirsch JD, 1996, PHARMACEUT RES, V13, P234, DOI 10.1023/A:1016039014090; Sekulic SS, 1996, ANAL CHEM, V68, P509, DOI 10.1021/ac950964m; El-Hagrasy AS, 2001, J PHARM SCI, V90, P1298, DOI 10.1002/jps.1082; ERTEL KD, 1988, J PHARM SCI, V77, P625, DOI 10.1002/jps.2600770715; Nakagawa H, 2013, INT J PHARMACEUT, V441, P402, DOI 10.1016/j.ijpharm.2012.11.014; Andersson M, 1999, J PHARMACEUT BIOMED, V20, P27, DOI 10.1016/S0731-7085(98)00237-4; Mullarney MP, 2003, INT J PHARM, V257, P227, DOI 10.1016/S0378-5173(03)00144-3; Wang J, 2010, EUR J PHARM BIOPHARM, V75, P1, DOI 10.1016/j.ejpb.2010.01.007; ROBLOTTREUPEL L, 1986, INT J PHARM, V31, P131, DOI 10.1016/0378-5173(86)90222-X; Portillo PM, 2008, POWDER TECHNOL, V182, P368, DOI 10.1016/j.powtec.2007.06.024; Radeke CA, 2010, CHEM ENG SCI, V65, P6435, DOI 10.1016/j.ces.2010.09.035; Faure A, 2001, EUR J PHARM BIOPHARM, V52, P269, DOI 10.1016/S0939-6411(01)00184-9; Sudah OS, 2002, INT J PHARM, V247, P57, DOI 10.1016/S0378-5173(02)00377-0; Hailey PA, 1996, J PHARMACEUT BIOMED, V14, P551, DOI 10.1016/0731-7085(95)01674-0; Armstrong N. A., 2002, ENCY PHARM TECHNOLOG, V2002, P2713; BILLANY MR, 1982, DRUG DEV IND PHARM, V8, P497, DOI 10.3109/03639048209022117; Blanco M, 2002, TALANTA, V56, P203, DOI 10.1016/S0039-9140(01)00559-8; Bolhuis G. K., 1987, PHARM TECH JPN, V3, P877; BOLHUIS GK, 1987, DRUG DEV IND PHARM, V13, P1547, DOI 10.3109/03639048709068680; Brone D, 2000, POWDER TECHNOL, V110, P179, DOI 10.1016/S0032-5910(99)00204-1; Donoso M, 2003, PHARM DEV TECHNOL, V8, P357, DOI 10.1081/PDT-120024689; Duong NH, 2003, DRUG DEV IND PHARM, V29, P679, DOI 10.1081/DDC-120021317; El Hagrasy A. S., 2006, J PHARM INNOV    SEP, P37; Fukui E, 2001, INT J PHARM, V216, P137, DOI 10.1016/S0378-5173(01)00580-4; Ghorab M, 2007, AAPS PHARMSCITECH, V8, pE155, DOI 10.1208/pt0801023; Harnby N., 2000, PHARM SCI TECHNOL TO, V3, P303, DOI 10.1016/S1461-5347(00)00283-2; Harris H., 2007, J PYROTECHNICS, V25, P49; HOLM P, 1985, POWDER TECHNOL, V43, P213, DOI 10.1016/0032-5910(85)80002-4; HUSSAIN MSH, 1988, INT J PHARM, V42, P89, DOI 10.1016/0378-5173(88)90164-0; Inoue I., 1970, CHEM ENG, V34, P1323; Iskandarani B, 2001, DRUG DEV IND PHARM, V27, P651, DOI 10.1081/DDC-100107321; JAROSZ PJ, 1984, DRUG DEV IND PHARM, V10, P259, DOI 10.3109/03639048409064649; KIKUTA J, 1994, DRUG DEV IND PHARM, V20, P343, DOI 10.3109/03639049409050187; Kushner J, 2010, INT J PHARMACEUT, V399, P19, DOI 10.1016/j.ijpharm.2010.07.033; Lemieux M, 2007, CHEM ENG SCI, V62, P1783, DOI 10.1016/j.ces.2006.12.012; LEVY G, 1963, J PHARM SCI, V52, P1139, DOI 10.1002/jps.2600521209; LINDBERG NO, 1982, DRUG DEV IND PHARM, V8, P775, DOI 10.3109/03639048209042702; Maeda J, 2012, CHEM PHARM BULL, V60, P1155; Mathews L, 2002, PHARM TECHNOL, V26, P80; Muzzio F. J., 2005, PHARM TECHNOLOGY SCA, ps34; Otsuka M, 2009, J PHARM SCI-US, V98, P4296, DOI 10.1002/jps.21748; Otsuka M, 2006, J PHARM SCI-US, V95, P1425, DOI 10.1002/jps.20514; Rao KP, 2005, PHARM DEV TECHNOL, V10, P423, DOI 10.1081/PDT-200054462; Roy Y., 2004, PHARM TECHNOL, V28, P21; Roy Y, 2005, TABLETS CAPSULES, V3, P38; SHAH AC, 1977, J PHARM SCI, V66, P1377, DOI 10.1002/jps.2600661006; Sirois PJ, 2000, PHARM DEV TECHNOL, V5, P365, DOI 10.1081/PDT-100100552; Tardos GI, 1997, POWDER TECHNOL, V94, P245, DOI 10.1016/S0032-5910(97)03321-4; Terashita K., 2012, PHARM TECH JPN, V28, P2407; Terashita K, 2008, PHARM TECH JAPAN, V24, P613; Terashita K., 2012, PHARM TECH JAPAN, V28, P921; Uchiyama J., DRUG DEV IN IN PRESS; Uchiyama J, 2014, DRUG DEV IND PHARM, V40, P999, DOI 10.3109/03639045.2013.795581; VanderWatt JG, 1997, EUR J PHARM BIOPHARM, V43, P91, DOI 10.1016/S0939-6411(96)00005-7; Van Puyvelde DR, 1999, POWDER TECHNOL, V106, P183, DOI 10.1016/S0032-5910(99)00074-1; Wargo DJ, 1996, J PHARMACEUT BIOMED, V14, P1415, DOI 10.1016/0731-7085(96)01739-6; Yano T., 1974, POWDER TECHNOLOGY JA, V11, P392; Yonemochi Etsuo, 2008, Netsu Sokutei, V35	64	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					164	179				16	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200003		
J	Matsumoto, K; Ueno, M; Nakanishi, I; Anzai, K				Matsumoto, Ken-ichiro; Ueno, Megumi; Nakanishi, Ikuo; Anzai, Kazunori			Density of Hydroxyl Radicals Generated in an Aqueous Solution by Irradiating Carbon-Ion Beam	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						hydroxyl radical; carbon-ion beam; ionizing radiation; EPR spin-trapping; reactive oxygen species; high linear energy transfer	VISUALIZATION	The density of hydroxyl radicals ((OH)-O-center dot) produced in aqueous samples by exposure to X-ray or carbon-ion beams was investigated. The generation of (OH)-O-center dot was detected by the electron paramagnetic resonance (EPR) spin-trapping technique using 5,5-dimethy1-1-pyrroline-N-oxide (DMPO) as the spin-trapping agent. When the concentration of DMPO is in excess of the generated OH, the production of DMPO-OH (spin-trapped (OH)-O-center dot) should be saturated. Reaction mixtures containing several concentrations (0.5-1685 mm) of DMPO were then irradiated by a 32 Gy 290MeV carbon-ion beam (C290-beam) or X-ray. C290-beam irradiation was performed at the Heavy-Ion Medical Accelerator in Chiba (HIMAC, National Institute of Radiological Sciences, Chiba, Japan), applying different linear energy transfers (LET) (20-169 keV/mu m). The amount of DMPO-OH in the irradiated samples was detected by EPR spectroscopy. The generation of DMPO-OH increased with the concentration of initial DMPO, displayed a shoulder around 3.3 mm DMPO, and reached a plateau. This plateau suggests that the generated (OH)-O-center dot were completely trapped. Another linear increase in DMPO-OH measured in solutions with higher DMPO concentrations suggested very dense (OH)-O-center dot generation (>1.7m). Generation of (OH)-O-center dot is expected to be localized on the track of the radiation beam, because the maximum concentration of measured DMPO-OH was 40, mu M. These results suggested that both sparse (approximate to 3.3 mM) and dense (>1.7M) (OH)-O-center dot generation occurred in the irradiated samples. The percentage of dense (OH)-O-center dot generation increased with increasing LET. Different types of dense (OH)-O-center dot generation may be expected for X-ray and C290-beams.	[Matsumoto, Ken-ichiro; Ueno, Megumi; Nakanishi, Ikuo; Anzai, Kazunori] Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Radio Redox Response Res Team, Adv Particle Radiat Biol Res Program,Inage Ku, Chiba 2638555, Japan; [Anzai, Kazunori] Nihon Pharmaceut Univ, Ina, Saitama 3620806, Japan	Matsumoto, K (reprint author), Natl Inst Radiol Sci, Res Ctr Charged Particle Therapy, Radio Redox Response Res Team, Adv Particle Radiat Biol Res Program,Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	matsumok@nirs.go.jp	Nakanishi, Ikuo/E-4430-2012	Nakanishi, Ikuo/0000-0001-9204-0664	JSPS KAKENHI [23591853]	The authors are grateful to the staff of the HIMAC for their help in irradiating samples by the carbon-ion beam. This work was supported by JSPS KAKENHI Grant Number 23591853.	Kamada T, 2012, INT J CLIN ONCOL, V17, P85, DOI 10.1007/s10147-012-0388-6; Furusawa Y, 2000, RADIAT RES, V154, P485, DOI 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2; Matsumoto K, 2009, MAGN RESON MED, V61, P1033, DOI 10.1002/mrm.21958; CARMICHAEL AJ, 1984, RADIAT RES, V100, P222, DOI 10.2307/3576343; Matsumoto A, 2005, MAGNET RESON MED, V54, P1530, DOI 10.1002/mrm.20714; Matsumoto K, 2010, MAGN RESON MED SCI, V9, P131; Moritake T, 2003, RADIAT RES, V159, P670, DOI 10.1667/0033-7587(2003)159[0670:ESTOHR]2.0.CO;2; Muroya Y, 2006, RADIAT RES, V165, P485, DOI 10.1667/RR3540.1; Ueno M, 2013, J CLIN BIOCHEM NUTR, V52, P95, DOI 10.3164/jcbn.12-75	9	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					195	199				5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200006		
J	Uchimoto, H; Tsuji, T; Kawasaki, I; Arimitsu, K; Yasui, H; Yamashita, M; Ohta, S; Nishide, K				Uchimoto, Hitomi; Tsuji, Tomoko; Kawasaki, Ikuo; Arimitsu, Kenji; Yasui, Hiroyuki; Yamashita, Masayuki; Ohta, Shunsaku; Nishide, Kiyoharu			Preparation of Chiral Ligands Connected with Quaternary Ammonium Group for Recyclable Catalytic Asymmetric Transfer Hydrogenation in Ionic Liquid	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						ionic liquid; recyclable catalytic asymmetric hydrogenation; task-specific ligand; imidazolium salt	DENDRITIC CATALYSTS; AROMATIC KETONES; SOLVENTS; WATER	Reuse of chiral ruthenium catalyst in catalytic asymmetric transfer hydrogenation (CATH) has attracted attention from economic and environmental viewpoints, and reactions using ionic liquids (ILs) as solvent are recognized as one of the most useful methods for reuse of the catalyst. We synthesized (1S,2S)-N(p-toluenesulfonyl)-1,2-diphenylethylenediamine (TsDPEN) derivatives with various ionic moieties, and investigated the effect of their structure with respect to catalytic ability and recyclability in CATH with ILs. Ligand 3a having an imidazolium group showed the best results, and significant differences were observed depending on the structure of the ionic moiety or the length of the alkyl chain connecting the ligand site and the ionic moiety. Among various prochiral ketones used as substrates at various cycles, 3a showed a relatively good result.	[Uchimoto, Hitomi; Kawasaki, Ikuo; Arimitsu, Kenji; Nishide, Kiyoharu] Mukogawa Womens Univ, Sch Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan; [Tsuji, Tomoko; Kawasaki, Ikuo; Yamashita, Masayuki; Ohta, Shunsaku] Kyoto Pharmaceut Univ, Dept Pharmaceut Mfg Chem, Yamashina Ku, Kyoto 6078414, Japan; [Yasui, Hiroyuki] Kyoto Pharmaceut Univ, Dept Analyt & Bioinorgan Chem, Div Analyt & Phys Sci, Yamashina Ku, Kyoto 6078414, Japan	Kawasaki, I (reprint author), Mukogawa Womens Univ, Sch Pharmaceut Sci, 11-68 Koshien Kyuban Cho, Nishinomiya, Hyogo 6638179, Japan.	ikuo_k@mukogawa-u.ac.jp; nishide@mukogawa-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [23590031]	A part of this work was financially supported by a Grant-in-Aid for Scientific Research (C) (Research project number: 23590031) from Japan Society for the Promotion of Science (JSPS).	BROWN HC, 1988, J AM CHEM SOC, V110, P1539, DOI 10.1021/ja00213a030; Geldbach TJ, 2004, J AM CHEM SOC, V126, P8114, DOI 10.1021/ja048886k; Wu XF, 2004, ORG BIOMOL CHEM, V2, P1818, DOI 10.1039/b403627a; Baan Z, 2009, GREEN CHEM, V11, P1937, DOI 10.1039/b913305d; Comyns C, 2000, CATAL LETT, V67, P113, DOI 10.1023/A:1019005202912; Baan Z, 2005, TETRAHEDRON LETT, V46, P6203, DOI 10.1016/j.tetlet.2005.07.070; Ni BK, 2010, CHEM-EUR J, V16, P4426, DOI 10.1002/chem.200902747; HASHIGUCHI S, 1995, J AM CHEM SOC, V117, P7562, DOI 10.1021/ja00133a037; Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t; Wasserscheid P, 2000, ANGEW CHEM INT EDIT, V39, P3772, DOI 10.1002/1521-3773(20001103)39:21<3772::AID-ANIE3772>3.0.CO;2-5; Trindade AF, 2009, CHEM REV, V109, P418, DOI 10.1021/cr800200t; Noyori R, 2001, J ORG CHEM, V66, P7931, DOI 10.1021/jo010721w; Matsunaga H, 2005, TETRAHEDRON LETT, V46, P3645, DOI 10.1016/j.tetlet.2005.03.165; Li XG, 2004, ORG LETT, V6, P3321, DOI 10.1021/ol0487175; Huddleston JG, 2001, GREEN CHEM, V3, P156, DOI 10.1039/b103275p; Bayston DJ, 1998, TETRAHEDRON-ASYMMETR, V9, P2015, DOI 10.1016/S0957-4166(98)00214-6; Berthold H, 2002, SYNTHESIS-STUTTGART, P1607; Chen YC, 2002, J ORG CHEM, V67, P5301, DOI 10.1021/jo0257795; Chen YC, 2001, CHEM COMMUN, P1488, DOI 10.1039/b104160f; Chen YC, 2005, J ORG CHEM, V70, P1006, DOI 10.1021/jo048317v; Foowler F. W., 1972, J ORG CHEM, V37, P1321, DOI 10.1021/jo00974a009; Joerger JM, 2006, ARKIVOC, P152; Kawasaki I, 2005, CHEM COMMUN, P2134, DOI 10.1039/b500320b; Li XG, 2004, TETRAHEDRON LETT, V45, P951, DOI 10.1016/j.tetlet.2003.11.104; NARITA K, 1977, CHEM PHARM BULL, V25, P135; Noyori R, 2002, ANGEW CHEM INT EDIT, V41, P2008, DOI 10.1002/1521-3773(20020617)41:12<2008::AID-ANIE2008>3.0.CO;2-4; Ohkuma T., 1999, COMPREHENSIVE ASYMME, P199; Palmer M. J., 1999, TETRAHEDRON-ASYMMETR, V10, P2045; Sheldon R, 2001, CHEM COMMUN, P2399, DOI 10.1039/b107270f; Shinkai S., 1985, J CHEM SOC P2, V1985, P503; terHalle R, 1997, SYNLETT, P1257	31	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					200	209				10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200007		
J	Demizu, Y; Yamashita, H; Misawa, T; Doi, M; Tanaka, M; Kurihara, M				Demizu, Yosuke; Yamashita, Hiroko; Misawa, Takashi; Doi, Mitsunobu; Tanaka, Masakazu; Kurihara, Masaaki			Effects of D-Leu Residues on the Helical Secondary Structures of L-Leu-Based Nonapeptides	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						alpha-aminoisobutyric acid; peptide; conformation; helical structure	CHAIN CHIRAL CENTERS; D-AMINO ACIDS; PEPTIDE HELICES; BETA-PEPTIDES; EQUAL AMOUNTS; SCREW-SENSE; FOLDAMERS; OLIGOPEPTIDES; 3(10)-HELIX; METATHESIS	The influence of D-Leu residues on the helical structures of L-Leu-based-nonapeptides was investigated. Specifically, the preferred conformations of four diastereomeric nonapeptides, Boc-(L-Leu-L-Leu-Aib)(3)-OMe (1); Boc-(L-Leu-L-Leu-Aib)(2)-L-Leu-D-Leu-Aib-OMe (2), which contained one D-Leu residue; Boc-L-Leu-D-Leu-Aib-L-Leu-L-Leu-Aib-L-Leu-D-Leu-Aib-OMe (3), which contained two D-Leu residues; and Boc-(L-Leu-D-Leu-Aib)(3)-OMe (4), were analyzed in solution and in the crystalline state. Peptide 1 formed a right-handed (P) 3(10)-helix in solution. Peptides 2 and 3 both formed (P) 3(10)-helices in solution and (P) alpha-helices in the crystalline state. Peptide 4 formed a (P) alpha-helix both in solution and in the crystalline state.	[Demizu, Yosuke; Yamashita, Hiroko; Misawa, Takashi; Kurihara, Masaaki] Natl Inst Hlth Sci, Div Organ Chem, Setagaya Ku, Tokyo 1588501, Japan; [Yamashita, Hiroko; Kurihara, Masaaki] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; [Doi, Mitsunobu] Osaka Univ Pharmaceut Sci, Osaka 5691094, Japan; [Tanaka, Masakazu] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan	Demizu, Y (reprint author), Natl Inst Hlth Sci, Div Organ Chem, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	demizu@nihs.go.jp; masaaki@nihs.go.jp			JSPS KAKENHI [26460169]; Tokyo Biochemical Research Foundation	This study was supported, in part, by JSPS KAKENHI Grant No. 26460169 (Y.D.) and by a Grant-in-Aid from the Tokyo Biochemical Research Foundation (Y.D.).	Demizu Y, 2012, CHEM-EUR J, V18, P2430, DOI 10.1002/chem.201102902; Crisma M, 2006, BIOPOLYMERS, V84, P3, DOI 10.1002/bip.20357; Kim YW, 2011, NAT PROTOC, V6, P761, DOI 10.1038/nprot.2011.324; Toniolo C, 1996, J AM CHEM SOC, V118, P2744, DOI 10.1021/ja9537383; Goodman CM, 2007, NAT CHEM BIOL, V3, P252, DOI 10.1038/nchembio876; Cheng RP, 2001, CHEM REV, V101, P3219, DOI 10.1021/cr000045i; Demizu Y, 2011, ORG BIOMOL CHEM, V9, P3303, DOI 10.1039/c0ob01146k; Seebach D, 2004, CHEM BIODIVERS, V1, P1111, DOI 10.1002/cbdv.200490087; Royo S, 2005, J AM CHEM SOC, V127, P2036, DOI 10.1021/ja043116u; Blackwell HE, 2001, J ORG CHEM, V66, P5291, DOI 10.1021/jo015533k; Aravinda S, 2003, J AM CHEM SOC, V125, P15065, DOI 10.1021/ja072762; Beurskens P. T., 1994, DIRDIF 99 PROGRAM SY; CRISMA M, 1988, INT J BIOL MACROMOL, V10, P300, DOI 10.1016/0141-8130(88)90008-6; Demizu Y, 2011, CHEM-EUR J, V17, P11107, DOI 10.1002/chem.201101809; Demizu Y, 2007, CHEM PHARM BULL, V55, P840, DOI 10.1248/cpb.55.840; Demizu Y, 2013, J ORG CHEM, V78, P12106, DOI 10.1021/jo402133e; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; Imamura Y, 2013, J MED CHEM, V56, P1443, DOI 10.1021/jm301306c; Schellman C, 1980, PROTEIN FOLDING, P53; Sheldrick G. M., 1997, PROGRAM CRYSTAL STRU	20	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	MAR	2015	63	3					218	224				7	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CC1HQ	WOS:000350092200009		
J	Takeuchi, J; Ohkubo, A; Yuasa, H				Takeuchi, Junji; Ohkubo, Akihiro; Yuasa, Hideya			A Ring-Flippable Sugar as a Stimuli-Responsive Component of Liposomes	CHEMISTRY-AN ASIAN JOURNAL			English	Article						carbohydrates; conformation analysis; molecular devices; liposomes; zinc	DRUG-DELIVERY; MOLECULAR MACHINE; HINGE SUGAR; FLUORESCENCE SENSOR; ELECTRON-MICROSCOPY; METAL-COMPLEXES; VESICLES; NANOPARTICLE; MECHANISM; CARRIERS	For the development of a liposome that takes in and out a drug in response to stimuli, 2,4-diaminoxylose (Xyl), which allows stimuli-responsive conformational switches between C-4(1) and C-1(4), was incorporated into a lipid structure: Xyl derivatives with C8 and C16 methylene chains at the 1,3-positions (C8Xyl and C16Xyl) were synthesized. H-1 NMR spectroscopy indicates that the addition of Zn2+ and then H+ induces conformational switches from the chair (C-4(1)) to the reverse chair (1C4) and C-1(4)-to-C-4(1), respectively, at Xyl; this leads to transformation of the lipids between linear and bent structures. Osmotic pressure and electron microscopy studies demonstrate that C8Xyl in water forms spherical solid aggregates (C8Xyl +/- Zn), which are converted into liposomes (C8Xyl+ Zn) upon the addition of Zn2+, and C16Xyl forms liposomes regardless of the presence of Zn2+. The aggregates of C8Xyl + Zn incorporated a fluorophore and only C8Xyl+ Zn released the content upon the addition of HCl. This study shows that Xyl could be a stimuli-responsive component of a liposome.	[Takeuchi, Junji; Ohkubo, Akihiro; Yuasa, Hideya] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Yuasa, H (reprint author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Life Sci, Midori Ku, 4259J2-10 Nagatsutacho, Yokohama, Kanagawa 2268501, Japan.	hyuasa@bio.titech.ac.jp			"Collaborative Research Based on Industrial Demand" program from Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS) [24550148]; SBI Pharmaceuticals Co., Ltd.	We are thankful to Prof. Hisakazu Mihara and Prof. Shun-Ichiro Ogura at the Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, for their assistance in the DLS analyses and cell experiments, respectively. We would like to thank Keiko Ikeda and Chieko Hara, Technical Department, Tokyo Institute of Technology, for TEM measurements and elemental analyses, respectively. The combustion analysis of compound 3 was carried out in the microanalytical laboratory of the One-Stop Sharing Facility Center for Future Drug Discoveries, Graduate School of Pharmaceutical Sciences, the University of Tokyo. We thank this facility for analysis. This work was supported by a "Collaborative Research Based on Industrial Demand" program from Japan Science and Technology Agency (JST) and a Grant-in-Aid for Scientific Research (no. 24550148) from the Japan Society for the Promotion of Science (JSPS). We are also grateful to SBI Pharmaceuticals Co., Ltd., for the financial support.	Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Beves JE, 2014, J AM CHEM SOC, V136, P2094, DOI 10.1021/ja4123973; von Delius M, 2010, NAT CHEM, V2, P96, DOI [10.1038/nchem.481, 10.1038/NCHEM.481]; Yuasa H, 2004, ORG BIOMOL CHEM, V2, P3548, DOI 10.1039/b411344f; Yuasa H, 1999, J AM CHEM SOC, V121, P5089, DOI 10.1021/ja984062p; Al-Jamal WT, 2011, ACCOUNTS CHEM RES, V44, P1094, DOI 10.1021/ar200105p; Champin B, 2007, CHEM SOC REV, V36, P358, DOI 10.1039/b604484k; Lu TW, 2013, ORG LETT, V15, P5742, DOI 10.1021/ol4027864; Pontier SM, 2012, DEV DYNAM, V241, P92, DOI 10.1002/dvdy.22766; Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Rodnina MV, 2011, BIOCHEM SOC T, V39, P658, DOI 10.1042/BST0390658; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017; Izumi T, 2004, CHEM COMMUN, P94, DOI 10.1039/b311811h; Steichen SD, 2013, EUR J PHARM SCI, V48, P416, DOI 10.1016/j.ejps.2012.12.006; Stano P, 2010, CHEM COMMUN, V46, P3639, DOI 10.1039/b913997d; Maherani B, 2011, CURR NANOSCI, V7, P436; Chiang YT, 2014, BIOMATERIALS, V35, P5414, DOI 10.1016/j.biomaterials.2014.03.046; Yoshizaki Y, 2014, BIOMATERIALS, V35, P8186, DOI 10.1016/j.biomaterials.2014.05.077; Hardouin-Lerouge M, 2011, CHEM SOC REV, V40, P30, DOI 10.1039/b915145c; Lewandowski B, 2013, SCIENCE, V339, P189, DOI 10.1126/science.1229753; GEBICKI JM, 1976, CHEM PHYS LIPIDS, V16, P142, DOI 10.1016/0009-3084(76)90006-2; Dial BE, 2011, ORG LETT, V13, P244, DOI 10.1021/ol102659n; BLOK MC, 1975, BIOCHIM BIOPHYS ACTA, V406, P187, DOI 10.1016/0005-2736(75)90003-6; Yuasa H, 2006, ORG BIOMOL CHEM, V4, P3694, DOI 10.1039/b609115f; Chang LF, 2014, CURR OPIN STRUC BIOL, V29, P1, DOI 10.1016/j.sbi.2014.08.003; Yuasa H, 2004, ORG LETT, V6, P1489, DOI 10.1021/ol049628v; Balamuralidhara V., 2011, AM J DRUG DISCOV DEV, V1, P24, DOI 10.3923/ajdd.2011.24.48; Balzani V., 2003, MOL DEVICES MACHINES, P288; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; Elsayed MMA, 2011, PHARM RES-DORDR, V28, P2204, DOI 10.1007/s11095-011-0448-z; HARRIS JR, 1994, MICRON, V25, P5; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; Idrissi FZ, 2014, CELL MOL LIFE SCI, V71, P641, DOI 10.1007/s00018-013-1452-8; Kohli AG, 2014, J CONTROL RELEASE, V190, P274, DOI 10.1016/j.jconrel.2014.04.047; Laouini A., 2012, J COLLOID SCI BIOTEC, V1, P147; Mitsuhashi N, 2009, EUR J ORG CHEM, P1598, DOI 10.1002/ejoc.200801285; Stewart Alastair G, 2013, Bioarchitecture, V3, P2, DOI 10.4161/bioa.23301; Tian H, 2011, MOLECULAR SWITCHES, VOL 1, 2ND EDITION, P301; Viera LI, 1996, CHEM PHYS LIPIDS, V81, P45, DOI 10.1016/0009-3084(96)02532-7; Yuasa H, 2007, ORG BIOMOL CHEM, V5, P2920, DOI 10.1039/b709115j; Yuasa H, 2005, CHEM-EUR J, V11, P6478, DOI 10.1002/chem.200500096	42	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	MAR	2015	10	3					586	594		10.1002/asia.201403271		9	Chemistry, Multidisciplinary	Chemistry	CB9NW	WOS:000349959500014		
J	Aoki, S; Fukumoto, T; Itoh, T; Kurihara, M; Saito, S; Komabiki, SY				Aoki, Shin; Fukumoto, Taketo; Itoh, Taiki; Kurihara, Masayuki; Saito, Shigeto; Komabiki, Shin-ya			Synthesis of Disaccharide Nucleosides by the O-Glycosylation of Natural Nucleosides with Thioglycoside Donors	CHEMISTRY-AN ASIAN JOURNAL			English	Article						chemical glycosylation; disaccharide nucleosides; nucleosides; O-glycosylation; thioglycoside	STREPTOMYCES SP KO-8119; ADENOPHOSTIN-A; PENICILLIUM-BREVICOMPACTUM; OLIGOSACCHARIDE SYNTHESIS; BIOLOGICAL PROPERTIES; STRUCTURE ELUCIDATION; CYTOSAMINOMYCIN-C; BUILDING-BLOCKS; POTENT AGONISTS; TOPOISOMERASE-I	Disaccharide nucleosides constitute an important group of naturally-occurring sugar derivatives. In this study, we report on the synthesis of disaccharide nucleosides by the direct O-glycosylation of nucleoside acceptors, such as adenosine, guanosine, thymidine, and cytidine, with glycosyl donors. Among the glycosyl donors tested, thioglycosides were found to give the corresponding disaccharide nucleosides in moderate to high chemical yields with the above nucleoside acceptors using p-toluenesulfenyl chloride (TolSCl) and silver triflate (AgOTf) as promoters. The interaction of these promoters with nucleoside acceptors was examined by H-1 NMR spectroscopic experiments.	[Aoki, Shin; Fukumoto, Taketo; Itoh, Taiki; Kurihara, Masayuki; Saito, Shigeto; Komabiki, Shin-ya] Tokyo Univ Sci, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan; [Aoki, Shin] Tokyo Univ Sci, Ctr Technol Canc, Noda, Chiba 2788510, Japan	Aoki, S (reprint author), Tokyo Univ Sci, Fac Pharmaceut Sci, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	shinaoki@rs.noda.tus.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan [223900051, 226590051, 24659011]; High-Tech Research Center Project for Private Universities; NEXT	This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (Nos. 223900051, 226590051, and 24659011 for S.A) and High-Tech Research Center Project for Private Universities (matching fund subside from NEXT). We appreciate the assistance of Mrs. Fukiko Hasegawa (Faculty of Pharmaceutical Sciences, Tokyo University of Science) for collecting and interpreting the mass spectral data and Mrs. Noriko Sawabe for the measurement of <SUP>1</SUP>H NMR at low temperature.	ANDERSSON F, 1986, TETRAHEDRON LETT, V27, P3919, DOI 10.1016/S0040-4039(00)83917-9; SCHMIDT RR, 1980, ANGEW CHEM INT EDIT, V19, P731, DOI 10.1002/anie.198007311; Maity SK, 2012, CARBOHYD RES, V354, P40, DOI 10.1016/j.carres.2012.03.024; Huang XF, 2004, ANGEW CHEM INT EDIT, V43, P5221, DOI 10.1002/anie.200460176; McCormick J, 1999, J AM CHEM SOC, V121, P5661, DOI 10.1021/ja990274q; HANEDA K, 1994, J ANTIBIOT, V47, P774; Codee JDC, 2005, CHEM SOC REV, V34, P769, DOI 10.1039/b417138c; Efimtseva EV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1136, DOI 10.1023/A:1020963207320; YDE M, 1973, CARBOHYD RES, V26, P227, DOI 10.1016/S0008-6215(00)85042-9; Kurosu M, 2006, J CARBOHYD CHEM, V25, P427, DOI 10.1080/07328300600803518; Benito D, 2009, CARBOHYD RES, V344, P2559, DOI 10.1016/j.carres.2009.09.030; SHIOMI K, 1994, J ANTIBIOT, V47, P782; Gao R, 2004, BIOCHEMISTRY-US, V43, P6167, DOI 10.1021/bi040005z; TI GS, 1982, J AM CHEM SOC, V104, P1316, DOI 10.1021/ja00369a029; Wunderlich CH, 2012, J AM CHEM SOC, V134, P7558, DOI 10.1021/ja302148g; Duron SG, 2004, ORG LETT, V6, P839, DOI 10.1021/ol0400084; Angusti A, 2008, CHEM PHARM BULL, V56, P423, DOI 10.1248/cpb.56.423; Sugimura H, 2008, CHEM LETT, V37, P1038, DOI 10.1246/cl.2008.1038; Pogosyan A, 2013, CARBOHYD RES, V380, P9, DOI 10.1016/j.carres.2013.06.019; Knapp S, 2000, ORG LETT, V2, P1391, DOI 10.1021/ol005696f; KANIE O, 1994, J AM CHEM SOC, V116, P12073, DOI 10.1021/ja00105a066; Gu GF, 2003, CARBOHYD RES, V338, P1603, DOI 10.1016/S0008-6215(03)00244-1; Henningfeld KA, 1996, J AM CHEM SOC, V118, P11701, DOI 10.1021/ja961788h; Riley AM, 2002, CARBOHYD RES, V337, P1067, DOI 10.1016/S0008-6215(02)00103-9; KOBAYASHI J, 1994, J ORG CHEM, V59, P255, DOI 10.1021/jo00080a046; KNAPP S, 1995, CHEM REV, V95, P1859, DOI 10.1021/cr00038a006; BINDER WH, 1995, TETRAHEDRON-ASYMMETR, V6, P1703, DOI 10.1016/0957-4166(95)00216-C; Abe H, 2000, TETRAHEDRON LETT, V41, P2391, DOI 10.1016/S0040-4039(00)00171-4; Eisenhuth R, 2009, J ORG CHEM, V74, P26, DOI 10.1021/jo8018889; Somu RV, 2006, J MED CHEM, V49, P7623, DOI 10.1021/jm061068d; Gulyaeva IV, 2004, NUCLEOS NUCLEOT NUCL, V23, P1849, DOI 10.1081/NCN-200040627; HOTODA H, 1995, TETRAHEDRON LETT, V36, P5037, DOI 10.1016/0040-4039(95)00916-Z; Mikhailov SN, 1999, NUCLEOS NUCLEOT NUCL, V18, P691, DOI 10.1080/15257779908041543; SCHMIDT RR, 1982, ANGEW CHEM INT EDIT, V21, P781, DOI 10.1002/anie.198207811; Liao KJ, 2012, CHINESE CHEM LETT, V23, P1371, DOI 10.1016/j.cclet.2012.10.022; SIM MM, 1993, J AM CHEM SOC, V115, P2260, DOI 10.1021/ja00059a023; Septak M, 1996, NUCLEIC ACIDS RES, V24, P3053, DOI 10.1093/nar/24.15.3053; Cui ZY, 2007, HELV CHIM ACTA, V90, P297, DOI 10.1002/hlca.200790034; TAKAHASHI S, 1994, J ANTIBIOT, V47, P95; Behr JB, 2003, BIOORG MED CHEM LETT, V13, P1713, DOI 10.1016/S0960-894X(03)00239-7; Bhat B, 1997, TETRAHEDRON LETT, V38, P8811, DOI 10.1016/S0040-4039(97)10423-3; Chen X., ACS S SERIES, V990; Crich D, 2008, CARBOHYD RES, V343, P1858, DOI 10.1016/j.carres.2008.03.002; Demchenko A. V., 2008, HDB CHEM GLYCOSYLATI; Efimtseva EV, 2004, USP KHIM+, V73, P435; Efimtseva E V, 2009, Mol Biol (Mosk), V43, P327; France RR, 2004, ORG BIOMOL CHEM, V2, P2195, DOI 10.1039/b316728c; FUGEDI P, 1986, CARBOHYD RES, V149, pC9, DOI 10.1016/S0008-6215(00)90385-9; Grundler G., 1984, LIEBIGS ANN CHEM, V2, P1826; Hansen SG, 2007, EUR J ORG CHEM, P3392, DOI 10.1002/ejoc.200700048; HIROTA J, 1995, FEBS LETT, V368, P248, DOI 10.1016/0014-5793(95)00659-W; Huang X., 2004, ANGEW CHEM, V116, P5333, DOI 10.1002/ange.200460176; Itoh Y., 2010, TRENDS GLYCOSCI GLYC, V22, P119; Khan SH, 1996, MODERN METHODS CARBO; KONDO H, 1994, J ORG CHEM, V59, P864, DOI 10.1021/jo00083a032; KONDO H, 1992, J AM CHEM SOC, V114, P8748, DOI 10.1021/ja00048a085; Lin CC, 1996, J AM CHEM SOC, V118, P6826, DOI 10.1021/ja952265x; Lindhorst T. K., 2007, ESSENTIALS CARBOHYDR; Lundt I., 1970, ACTA CHEM SCAND B, V30, P680; MARTIN TJ, 1993, GLYCOCONJUGATE J, V10, P16, DOI 10.1007/BF00731182; MARTIN TJ, 1992, TETRAHEDRON LETT, V33, P6123; Marwood RD, 2000, J CHEM SOC PERK T 1, P1935, DOI 10.1039/b001386m; NAKAMURA M, 1993, CHEM PHARM BULL, V41, P21; OHTSUKA E, 1985, TETRAHEDRON, V41, P5271, DOI 10.1016/S0040-4020(01)96777-8; Schmidt R. R., 1982, ANGEW CHEM, V94, P790; Schmidt R. R., 1980, ANGEW CHEM, V92, P763, DOI 10.1002/ange.19800920933; Sugimura H., 2003, NUCLEIC ACIDS RES, V3, P21; Tai CA, 2003, J ORG CHEM, V68, P8719, DOI 10.1021/jo030073b; TAKAHASHI M, 1993, J ANTIBIOT, V46, P1643; Tocik Z, 2007, TETRAHEDRON, V63, P4516, DOI 10.1016/j.tet.2007.03.059; TOSHIMA K, 1993, CHEM REV, V93, P1503, DOI 10.1021/cr00020a006; Verma VP, 2013, CHEM-EUR J, V19, P846, DOI 10.1002/chem.201203418; WATANABE Y, 1993, SYNLETT, P115; Yasomanee JP, 2013, TRENDS GLYCOSCI GLYC, V25, P13, DOI 10.4052/tigg.25.13; Ye M, 2012, J MOL CATAL B-ENZYM, V79, P35, DOI 10.1016/j.molcatb.2012.03.018	75	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	MAR	2015	10	3					740	751		10.1002/asia.201403319		12	Chemistry, Multidisciplinary	Chemistry	CB9NW	WOS:000349959500035		
J	Mao, J; Kuranaga, T; Hamamoto, H; Sekimizu, K; Inoue, M				Mao, Ji; Kuranaga, Takefumi; Hamamoto, Hiroshi; Sekimizu, Kazuhisa; Inoue, Masayuki			Rational Design, Synthesis, and Biological Evaluation of Lactam-Bridged Gramicidin A Analogues: Discovery of a Low-Hemolytic Antibacterial Peptide	CHEMMEDCHEM			English	Article						antibiotics; ion channels; natural products; peptides; structure-activity relationships	TRANSMEMBRANE ION-CHANNEL; SOLID-STATE NMR; PHOSPHOLIPID-VESICLES; CIRCULAR-DICHROISM; COUPLING REAGENTS; CRYSTAL-STRUCTURE; NATURAL-PRODUCTS; POLYTHEONAMIDE B; SINGLE-CHANNEL; SIDE-CHAIN	A linear peptide, gramicidin A (GA), folds into a beta(6.3)-helix, functions as an ion channel in the cell membrane, and exerts antibacterial activity. Herein we describe the rational design, synthesis, and biological evaluation of lactam-bridged GA analogues. The GA analogue with a 27-membered macrolactam was found to adopt a stable beta(6.3)-helical conformation and exhibits higher ion-exchange activity than GA. Furthermore, this GA analogue retains the potent antibiotic activity of GA, but its hemolytic activity and toxicity toward mammalian cells are significantly lower than those of GA. This study thus dissociates the antibacterial and hemolytic/cytotoxic activities of GA, and charts a rational path forward for the development of new ion-channel-based antibiotics.	[Mao, Ji; Kuranaga, Takefumi; Hamamoto, Hiroshi; Sekimizu, Kazuhisa; Inoue, Masayuki] Univ Tokyo, Grad Sch Phramaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Inoue, M (reprint author), Univ Tokyo, Grad Sch Phramaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	inoue@mol.f.u-tokyo.ac.jp			Funding Program for Next-Generation World-Leading Researchers (JSPS)	This research was supported financially by the Funding Program for Next-Generation World-Leading Researchers (JSPS), a Grant-in-Aid for Scientific Research (A) to M.I., and a Grant-in-Aid for Young Scientists (B) (JSPS) to T.K.	Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Coates A, 2002, NAT REV DRUG DISCOV, V1, P895, DOI 10.1038/nrd940; O'Connell KMG, 2013, ANGEW CHEM INT EDIT, V52, P10706, DOI 10.1002/anie.201209979; Wilson RM, 2010, ANGEW CHEM INT EDIT, V49, P6032, DOI 10.1002/anie.201000775; [Anonymous], 1999, GRAMICIDIN RELATED I; Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a052; WALLACE BA, 1981, BIOCHEMISTRY-US, V20, P5754, DOI 10.1021/bi00523a018; El-Faham A, 2011, CHEM REV, V111, P6557, DOI 10.1021/cr100048w; Brotherhood PR, 2010, CHEM SOC REV, V39, P3633, DOI 10.1039/b926225n; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Macrae MX, 2010, J AM CHEM SOC, V132, P1766, DOI 10.1021/ja909876h; Kelkar DA, 2007, BBA-BIOMEMBRANES, V1768, P2011, DOI 10.1016/j.bbamem.2007.05.011; KETCHEM RR, 1993, SCIENCE, V261, P1457, DOI 10.1126/science.7690158; Butler MS, 2011, J ANTIBIOT, V64, P413, DOI 10.1038/ja.2011.44; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Gokel GW, 2013, ACCOUNTS CHEM RES, V46, P2824, DOI 10.1021/ar400026x; Epand RM, 2009, MOL BIOSYST, V5, P580, DOI 10.1039/b900278m; Matile S, 2011, CHEM SOC REV, V40, P2453, DOI 10.1039/c0cs00209g; Haynes CJE, 2011, CHEM COMMUN, V47, P8203, DOI 10.1039/c1cc12061a; Garner J, 2007, ORG BIOMOL CHEM, V5, P3577, DOI 10.1039/b710425a; Hamada T, 2010, J AM CHEM SOC, V132, P12941, DOI 10.1021/ja104616z; Pfeifer JR, 2006, ANGEW CHEM INT EDIT, V45, P501, DOI 10.1002/anie.200502570; URRY DW, 1971, P NATL ACAD SCI USA, V68, P1907, DOI 10.1073/pnas.68.8.1907; Montenegro J, 2013, ACCOUNTS CHEM RES, V46, P2955, DOI 10.1021/ar400061d; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Davis JT, 2010, CHEM SOC REV, V39, P3843, DOI 10.1039/b926164h; Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X; Taylor JW, 2002, BIOPOLYMERS, V66, P49, DOI 10.1002/bip.10203; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; ARSENIEV AS, 1985, FEBS LETT, V186, P168, DOI 10.1016/0014-5793(85)80702-X; BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; Bunkoczi G., 2005, ANGEW CHEM, V117, P1364, DOI 10.1002/ange.200461933; Bunkoczi G, 2005, ANGEW CHEM INT EDIT, V44, P1340, DOI 10.1002/anie.200461933; Carpino Louis A, 2002, Angew Chem Int Ed Engl, V41, P441, DOI 10.1002/1521-3773(20020201)41:3<441::AID-ANIE441>3.0.CO;2-N; Carpino L. A., 2002, ANGEW CHEM, V114, P457, DOI DOI 10.1002/1521-3757(20020201); CARPINO LA, 1994, TETRAHEDRON LETT, V35, P2279, DOI 10.1016/0040-4039(94)85198-0; Chan W. C., 2000, FMOC SOLID PHASE PEP; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; Connell K. M. G. O I, 2013, ANGEW CHEM, V125, P10904; DAUMAS P, 1989, BIOCHIMIE, V71, P77, DOI 10.1016/0300-9084(89)90135-1; DOURTOGLOU V, 1984, SYNTHESIS-STUTTGART, P572, DOI 10.1055/s-1984-30895; Doyle DA, 1997, J MOL BIOL, V266, P963, DOI 10.1006/jmbi.1996.0837; FONSECA V, 1992, BIOCHEMISTRY-US, V31, P5340, DOI 10.1021/bi00138a014; Fyles TM, 2013, ACCOUNTS CHEM RES, V46, P2847, DOI 10.1021/ar4000295; Greathouse D V, 1999, Methods Enzymol, V294, P525; Herrell WE, 1941, J CLIN INVEST, V20, P583, DOI 10.1172/JCI101251; Hotchkiss RD, 1940, J BIOL CHEM, V132, P791; Inoue M, 2011, ISR J CHEM, V51, P346, DOI 10.1002/ijch.201100002; Itoh H, 2012, J AM CHEM SOC, V134, P14011, DOI 10.1021/ja303831a; Itoh H, 2013, ACCOUNTS CHEM RES, V46, P1567, DOI 10.1021/ar300315p; Jordan JB, 2006, BIOCHEMISTRY-US, V45, P14012, DOI 10.1021/bi061560z; KILLIAN JA, 1988, BIOCHEMISTRY-US, V27, P4848, DOI 10.1021/bi00413a040; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P391; Koeppe RE, 1996, ANNU REV BIOPH BIOM, V25, P231; Kovacs F, 1999, P NATL ACAD SCI USA, V96, P7910, DOI 10.1073/pnas.96.14.7910; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; MATTICE GL, 1995, BIOCHEMISTRY-US, V34, P6827, DOI 10.1021/bi00020a029; Mayer M, 2013, ACCOUNTS CHEM RES, V46, P2998, DOI 10.1021/ar400129t; MORROW JS, 1979, J MOL BIOL, V132, P733, DOI 10.1016/0022-2836(79)90386-3; Otis F, 2013, ACCOUNTS CHEM RES, V46, P2934, DOI 10.1021/ar400044k; Pfeifer J. R., 2006, ANGEW CHEM, V118, P515, DOI 10.1002/ange.200502570; Reiss P, 2008, CHEMBIOCHEM, V9, P377, DOI 10.1002/cbic.200700519; Reiss P, 2013, ACCOUNTS CHEM RES, V46, P2773, DOI 10.1021/ar400007w; RUSSELL EWB, 1986, BIOPHYS J, V49, P673; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; STANKOVIC CJ, 1989, SCIENCE, V244, P813, DOI 10.1126/science.2471263; Sychev SV, 2014, J PEPT SCI, V20, P657, DOI 10.1002/psc.2643; Sychev SV, 1996, J PEPT SCI, V2, P141, DOI 10.1002/psc.59; Wallace BA, 1998, J STRUCT BIOL, V121, P123, DOI 10.1006/jsbi.1997.3948; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; Wang F, 2012, CHEMBIOCHEM, V13, P51, DOI 10.1002/cbic.201100671; Wilson R. M., 2010, ANGEW CHEM, V122, P6168, DOI 10.1002/ange.201000775; WOOLLEY GA, 1995, J AM CHEM SOC, V117, P4448, DOI 10.1021/ja00121a002	74	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1860-7179	1860-7187		CHEMMEDCHEM	ChemMedChem	MAR	2015	10	3					540	545		10.1002/cmdc.201402473		6	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	CC6DX	WOS:000350456200010		
J	Yang, SB; Chen, CL; Chen, Y; Li, JX; Wang, DQ; Wang, XK; Hu, WP				Yang, Shubin; Chen, Changlun; Chen, Yue; Li, Jiaxing; Wang, Dongqi; Wang, Xiangke; Hu, Wenping			Competitive Adsorption of Pb-II, Ni-II, and Sr-II Ions on Graphene Oxides: A Combined Experimental and Theoretical Study	CHEMPLUSCHEM			English	Article						adsorption; density functional calculations; graphene; lead; nickel	SOLID-STATE NMR; GRAPHITE OXIDE; CHEMICAL-REDUCTION; NANOSHEETS; MODEL	The individual and competitive adsorption of Pb-II, Ni-II, and Sr-II on graphene oxides (GOs) was investigated by experimental and density functional theory (DFT) studies. Experimental results indicate that 1)in all the single, binary, and ternary metal-ion adsorption systems, the sequence of maximum adsorption capacities is Pb-II>Ni-II>Sr-II on GOs; 2)the desorption hysteresis of metal ions from GOs shows the adsorption affinity in the same sequence: Pb-II>Ni-II>Sr-II. For the first time, DFT calculations indicate that 1)Pb-II and Ni-II prefer to interact with the COH group, whereas Sr-II interacts with COH and COC comparably, and 2)Pb-II can easily abstract the OH group from the GOs to form the much more stable Pb(OH)-GO complex. These findings are very important and useful for understanding the mechanisms of heavy-metal-ion adsorption on GOs and assessing the adsorption of coexisting heavy-metal ions on GOs.	[Yang, Shubin; Chen, Changlun; Li, Jiaxing; Wang, Xiangke] North China Elect Power Univ, Sch Environm & Chem Engn, Beijing 102206, Peoples R China; [Chen, Yue] Kyoto Univ, Dept Fukui Inst Fundamental Chem, Sakyo Ku, Kyoto 6068103, Japan; [Wang, Dongqi] Chinese Acad Sci, Inst High Energy Phys, Multidiciplinary Initiat Ctr, Beijing 100049, Peoples R China; [Wang, Xiangke] King Abdulaziz Univ, Fac Engn, Jeddah 21589, Saudi Arabia; [Hu, Wenping] Chinese Acad Sci, Beijing Natl Lab Mol Sci, Inst Chem, Key Lab Organ Solids, Beijing 100190, Peoples R China	Chen, CL (reprint author), North China Elect Power Univ, Sch Environm & Chem Engn, Beijing 102206, Peoples R China.	clchen@ipp.ac.cn; xkwang@ipp.ac.cn	li, jiaxing/H-9805-2012	li, jiaxing/0000-0002-7683-2482	NSFC [91126020, 41273134, 21225730, 21272236, 91326202]	This study was financially supported by the NSFC (grant nos. 91126020, 41273134, 21225730, 21272236, and 91326202).	Laus R, 2011, BIORESOURCE TECHNOL, V102, P8769, DOI 10.1016/j.biortech.2011.07.057; Lan JH, 2010, ACS NANO, V4, P4225, DOI 10.1021/nn100962r; Casabianca LB, 2010, J AM CHEM SOC, V132, P5672, DOI 10.1021/ja9030243; Cossi M, 1999, J CHEM PHYS, V111, P5295, DOI 10.1063/1.479788; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Bourlinos AB, 2003, LANGMUIR, V19, P6050, DOI 10.1021/la026525h; Huang X, 2012, CHEM SOC REV, V41, P666, DOI 10.1039/c1cs15078b; Sitko R, 2013, DALTON T, V42, P5682, DOI 10.1039/c3dt33097d; Ramesha GK, 2011, J COLLOID INTERF SCI, V361, P270, DOI 10.1016/j.jcis.2011.05.050; Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034; Zhao GX, 2011, DALTON T, V40, P10945, DOI 10.1039/c1dt11005e; Cai WW, 2008, SCIENCE, V321, P1815, DOI 10.1126/science.1162369; Szabo T, 2006, CHEM MATER, V18, P2740, DOI 10.1021/cm060258; Cossi M, 2003, J COMPUT CHEM, V24, P669, DOI 10.1002/jcc.10189; Zhou XZ, 2009, J PHYS CHEM C, V113, P10842, DOI 10.1021/jp903821n; Huang X, 2011, SMALL, V7, P1876, DOI 10.1002/smll.201002009; Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068; Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g; Barroso-Bujans F, 2010, CARBON, V48, P1079, DOI 10.1016/j.carbon.2009.11.029; Zhao GX, 2011, ENVIRON SCI TECHNOL, V45, P10454, DOI 10.1021/es203439v; Yang ST, 2010, J COLLOID INTERF SCI, V351, P122, DOI 10.1016/j.jcis.2010.07.042; Balabanov NB, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1998907; DIGIANO FA, 1978, CHEM ENG SCI, V33, P1667, DOI 10.1016/0009-2509(78)85143-4; Frisch M. J., 2009, GAUSSIAN 09 REVISION; Jaycock M. J., 1981, CHEM INTERFACES; Markham E.C., 1931, J AM CHEM SOC, V53, P497, DOI DOI 10.1021/JA01353A013; Matsuo Y, 2002, J MATER CHEM, V12, P1592, DOI 10.1039/b107436a	27	11	12	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	2192-6506			CHEMPLUSCHEM	ChemPlusChem	MAR	2015	80	3					480	484		10.1002/cplu.201402284		5	Chemistry, Multidisciplinary	Chemistry	CC6JR	WOS:000350471700004		
J	Sen, R; Saha, D; Koner, S; Mal, D; Brandao, P; Lin, Z				Sen, Rupam; Saha, Debraj; Koner, Subratanath; Mal, Dasarath; Brandao, Paula; Lin, Zhi			pH-Tuned Modulation of 1D Chain to 3D Metal-Organic Framework: Synthesis, Structure and Their Useful Application in the Heterogeneous Claisen-Schmidt Reaction	CHEMPLUSCHEM			English	Article						Claisen-Schmidt reaction; heterogeneous catalysis; hydrothermal synthesis; magnesium; structure elucidation	DIRECT ALDOL REACTIONS; HYDROTHERMAL SYNTHESIS; NANOCRYSTALLINE MGO; GAS-ADSORPTION; LEWIS-ACID; TEMPERATURE; DIMENSIONALITY; CONDENSATION; CARBOXYLATES; CATALYSIS	The role of pH in the formation of metal-organic frameworks (MOFs) has been studied on magnesium-based carboxylate framework systems [Mg(Pdc)(H2O)(3)](n) (1) and [Mg(Pdc)(H2O)](n) (2) (Pdc=pyridine-2,3-dicarboxylate). The investigation reveals the formation of two different compounds of one- or three-dimensions starting from the same reaction mixture that differs only in pH. Isolated compounds have been characterized by IR and elemental analysis; both compounds were also successfully characterized by single-crystal X-ray diffraction. This study shows that the gradual increase in pH helps to construct a higher-dimensional network. Catalytic activity of compounds 1 and 2 was tested for the Claisen-Schmidt reaction. Compound 2 was successfully dehydrated to produce a coordinately unsaturated compound 2a, which shows higher catalytic activity than 1 or 2 in heterogeneous medium.	[Sen, Rupam; Mal, Dasarath; Brandao, Paula; Lin, Zhi] Univ Aveiro, CICECO, Dept Chem, P-3810193 Aveiro, Portugal; [Saha, Debraj; Koner, Subratanath] Jadavpur Univ, Dept Chem, Kolkata 700032, India	Sen, R (reprint author), Kyushu Univ, Inst Mat Chem & Engn, Fukuoka 8168580, Japan.	rupamsen1@yahoo.com; zlin@ua.pt	Lin, Zhi/A-5638-2011; Brandao, Paula/J-3759-2013	Lin, Zhi/0000-0002-5984-7228; Brandao, Paula/0000-0002-4746-6073	Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/71798/2010]; CSIR [09/096(782) 2013-EMR-I]; FEDER through Programa Operacional Factores de Competitividade COMPETE; national funds through the FCT within the CICECO [FCOMP-01-0124-FERDER-037271]	R.S. thanks the Fundacao para a Ciencia e Tecnologia (FCT) for a postdoctoral grant (SFRH/BPD/71798/2010). D.S. thanks the CSIR (ref. no. 09/096(782) 2013-EMR-I) for a Senior Research Fellowship. The Portuguese group is financially supported by FEDER through Programa Operacional Factores de Competitividade COMPETE and national funds through the FCT within the CICECO project FCOMP-01-0124-FERDER-037271 (FCT ref. Pest-C/CTM/LA0011/2013). Financial support from CSIR, New Delhi by a grant (grant no. 01(2542)/11/EMR-II) (to S.K.) is gratefully acknowledged.	Mahata P, 2008, INORG CHEM, V47, P8451, DOI 10.1021/ic800621q; Luo SZ, 2007, TETRAHEDRON, V63, P1923, DOI 10.1016/j.tet.2006.12.079; Luo JH, 2008, J AM CHEM SOC, V130, P9626, DOI 10.1021/ja801411f; Biswas S, 2012, J MATER CHEM, V22, P10200, DOI 10.1039/c2jm15592c; Gandara F, 2009, CHEM MATER, V21, P655, DOI 10.1021/cm8029517; Horike S, 2008, J AM CHEM SOC, V130, P5854, DOI 10.1021/ja800669j; Vermoortele F, 2011, CHEM COMMUN, V47, P1521, DOI 10.1039/c0cc03038d; Saines PJ, 2010, CHEM-EUR J, V16, P7579, DOI 10.1002/chem.201000390; Pathan NB, 2011, CATAL COMMUN, V12, P1170, DOI 10.1016/j.catcom.2011.03.040; Nwe K, 2009, BIOCONJUGATE CHEM, V20, P1375, DOI 10.1021/bc900146z; Saha D, 2012, DALTON T, V41, P7399, DOI 10.1039/c2dt00057a; [Anonymous], 2008, ANGEW CHEM, V120, P5044; Pan YY, 2010, CHEM COMMUN, V46, P2280, DOI 10.1039/b922061e; Eddaoudi M, 2002, P NATL ACAD SCI USA, V99, P4900, DOI 10.1073/pnas.082051899; Yang HX, 2010, INORG CHEM, V49, P736, DOI 10.1021/ic902091p; Platero-Prats AE, 2011, CRYST GROWTH DES, V11, P1750, DOI 10.1021/cg200078j; Ferey G, 2005, SCIENCE, V309, P2040, DOI 10.1126/science.1116275; Morris RE, 2008, ANGEW CHEM INT EDIT, V47, P4966, DOI 10.1002/anie.200703934; Shishido S, 2008, J AM CHEM SOC, V130, P10588, DOI 10.1021/ja800784a; [Anonymous], 2006, ANGEW CHEM, V118, P287; Blatov VA, 2000, J APPL CRYSTALLOGR, V33, P1193, DOI 10.1107/S0021889800007202; Yin PX, 2011, CRYSTENGCOMM, V13, P3536, DOI 10.1039/c0ce00762e; Takashima Y, 2011, CRYSTENGCOMM, V13, P3360, DOI 10.1039/c1ce05201b; Furukawa H, 2008, J AM CHEM SOC, V130, P11650, DOI 10.1021/ja803783c; Hu SQ, 2007, TETRAHEDRON LETT, V48, P5613, DOI 10.1016/j.tetlet.2007.06.051; [Anonymous], 2004, ANGEW CHEM, V116, P1490; Goto Y, 2008, J AM CHEM SOC, V130, P14354, DOI 10.1021/ja7114053; Maspoch D, 2007, CHEM SOC REV, V36, P770, DOI 10.1039/b501600m; Solin N, 2009, CATAL COMMUN, V10, P1386, DOI 10.1016/j.catcom.2009.03.001; Sen R, 2012, CHEM-EUR J, V18, P5979, DOI 10.1002/chem.201102953; Rao CNR, 2004, ANGEW CHEM INT EDIT, V43, P1466, DOI 10.1002/anie.200300588; Jiang D, 2008, J CATAL, V257, P390, DOI 10.1016/j.jcat.2008.05.021; Gu XJ, 2007, INORG CHEM, V46, P3212, DOI 10.1021/ic0623056; [Anonymous], 2004, ANGEW CHEM, V116, P2388; Blatov V.A., 2004, CRYSTENGCOMM, V6, P378, DOI DOI 10.1039/B409722J; Bruker, 2007, APEX 2 SAINT XPREP; Bruker, 2001, SADABS; Choudary BM, 2006, TETRAHEDRON, V62, P9571, DOI 10.1016/j.tet.2006.07.091; Choudary BM, 2004, J AM CHEM SOC, V126, P3396, DOI 10.1021/ja038954n; Dan M, 2006, ANGEW CHEM INT EDIT, V45, P281, DOI 10.1002/anie.200502413; Dey BK, 2009, J MOL CATAL A-CHEM, V303, P137, DOI 10.1016/j.molcata.2009.01.015; Dhakshinamoorthy A, 2010, CHEM COMMUN, V46, P6476, DOI 10.1039/c0cc02210a; Dhakshinamoorthy A, 2013, ADV SYNTH CATAL, V355, P247, DOI 10.1002/adsc.201200618; Dhakshinamoorthy A, 2010, ADV SYNTH CATAL, V352, P3022, DOI 10.1002/adsc.201000537; Dubey M., 2008, APPL CATAL A-GEN, V338, P20; El-Molla SA, 2006, APPL CATAL A-GEN, V298, P103, DOI 10.1016/j.apcata.2005.09.029; Fernandez-Lopez R, 2005, EUR J ORG CHEM, P5268, DOI 10.1002/ejoc.200500352; Forster PM, 2004, CHEM COMMUN, P368, DOI 10.1039/b311156c; Gao Q, 2012, CRYST GROWTH DES, V12, P281, DOI 10.1021/cg201059d; Gurunatha KL, 2008, INORG CHEM, V47, P6578, DOI 10.1021/ic8007377; Huang CH, 2009, INORG CHEM, V48, P7237, DOI 10.1021/ic900696f; Kantam K. L., 2007, ADV SYNTH CATAL, V349, P1887; Kantam ML, 2007, TETRAHEDRON LETT, V48, P6121, DOI 10.1016/j.tetlet.2007.06.141; Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610; Kong XJ, 2009, INORG CHEM, V48, P3268, DOI 10.1021/ic802357m; Lopez J., 2000, STUD SURF SCI CATAL, V130, P491; Mahata P, 2007, CHEM COMMUN, P4471, DOI 10.1039/b708060c; Matsumoto N, 1999, INORG CHEM, V38, P1165, DOI 10.1021/ic981158b; Mobin SM, 2014, CRYST GROWTH DES, V14, P4124, DOI 10.1021/cg5007346; Perrio-Huard C, 2000, J CHEM SOC PERK T 1, P311, DOI 10.1039/a908991h; Prats AEP, 2010, CHEMCATCHEM, V2, P147, DOI 10.1002/cctc.200900228; Saha D, 2013, DALTON T, V42, P13912, DOI 10.1039/c3dt51509e; Saha D, 2014, DALTON T, V43, P13006, DOI 10.1039/c4dt00575a; Satyanarayana M, 2004, BIOORGAN MED CHEM, V12, P883, DOI 10.1016/j.bmc.2003.12.026; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Tong ML, 2004, CHEM COMMUN, P418, DOI 10.1039/b312058a; Yun JW, 1996, INORG CHEM, V35, P7590, DOI 10.1021/ic960894h; Zeidan RK, 2007, J CATAL, V247, P379, DOI 10.1016/j.jcat.2007.02.005; Zhang J, 2008, CHEM COMMUN, P444, DOI 10.1039/b715945e	69	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	2192-6506			CHEMPLUSCHEM	ChemPlusChem	MAR	2015	80	3					591	598		10.1002/cplu.201402340		8	Chemistry, Multidisciplinary	Chemistry	CC6JR	WOS:000350471700020		
J	Hasegawa, Y; Ishikura, T; Hasegawa, T; Watanabe, T; Suzuki, J; Nakayama, M; Okamura, Y; Okazaki, T; Koseki, H; Ohara, O; Ikeno, M; Masumoto, H				Hasegawa, Yoshinori; Ishikura, Tomoyuki; Hasegawa, Takanori; Watanabe, Takashi; Suzuki, Junpei; Nakayama, Manabu; Okamura, Yoshiaki; Okazaki, Tuneko; Koseki, Haruhiko; Ohara, Osamu; Ikeno, Masashi; Masumoto, Hiroshi			Generating a transgenic mouse line stably expressing human MHC surface antigen from a HAC carrying multiple genomic BACs	CHROMOSOMA			English	Article							HUMAN ARTIFICIAL CHROMOSOMES; PRONUCLEAR INJECTION; TARGETED TRANSGENESIS; GENE-EXPRESSION; MICE; CONSTRUCTION; CENTROMERE; DELIVERY; NUMBER; CELLS	The human artificial chromosome (HAC) vector is a promising tool to improve the problematic suppression and position effects of transgene expression frequently seen in transgenic cells and animals produced by conventional plasmid or viral vectors. We generated transgenic mice maintaining a single HAC vector carrying two genomic bacterial artificial chromosomes (BACs) from human HLA-DR loci (DRA and DRB1). Both transgenes on the HAC in transgenic mice exhibited tissue-specific expression in kidney, liver, lung, spleen, lymph node, bone marrow, and thymus cells in RT-PCR analysis. Stable functional expression of a cell surface HLA-DR marker from both transgenes, DRA and DRB1 on the HAC, was detected by flow cytometric analysis of splenocytes and maintained through at least eight filial generations. These results indicate that the de novo HAC system can allow us to manipulate multiple BAC transgenes with coordinated expression as a surface antigen through the generation of transgenic animals.	[Hasegawa, Yoshinori; Okamura, Yoshiaki; Masumoto, Hiroshi] Kazusa DNA Res Inst, Lab Cell Engn, Dept Frontier Res, Kisarazu, Chiba 2920818, Japan; [Hasegawa, Yoshinori; Suzuki, Junpei; Nakayama, Manabu; Ohara, Osamu] Kazusa DNA Res Inst, Dev Technol Dept, Kisarazu, Chiba 2920818, Japan; [Ishikura, Tomoyuki; Hasegawa, Takanori; Watanabe, Takashi; Koseki, Haruhiko; Ohara, Osamu] RIKEN, Ctr Integrat Med Sci IMS RCAI, Yokohama, Kanagawa 2300045, Japan; [Okazaki, Tuneko; Ikeno, Masashi] Chromo Res Inc, Nagoya, Aichi 4580039, Japan	Masumoto, H (reprint author), Kazusa DNA Res Inst, Lab Cell Engn, Dept Frontier Res, 2-6-7 Kazusa Kamatari, Kisarazu, Chiba 2920818, Japan.	masumoto@kazusa.or.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Core Research for Evolutional Science and Technology (CREST) JST; Kazusa DNA Research Institute Foundation	We would like to thank K. Sumi, Y. Hasegawa, and Y. Yamanaka for their technical assistance. This work was supported by a grant-in-aid for the Project for Developing Innovation Systems, Program for Fostering Regional Innovation (O.O.), from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Core Research for Evolutional Science and Technology (CREST) JST (H.M.), and the Kazusa DNA Research Institute Foundation.	Kazuki Y, 2011, MOL THER, V19, P1591, DOI 10.1038/mt.2011.136; Ohtsuka M, 2012, EXP ANIM TOKYO, V61, P489; Chandler KJ, 2007, MAMM GENOME, V18, P693, DOI 10.1007/s00335-007-9056-y; Ikeno M, 2012, NUCLEIC ACIDS RES, V40, P10742, DOI 10.1093/nar/gks874; Doherty AMO, 2003, MAMM GENOME, V14, P583, DOI 10.1007/s00335-003-4002-0; Suzuki M, 2012, INT IMMUNOL, V24, P243, DOI 10.1093/intimm/dxs045; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; FUKUI Y, 1993, IMMUNOGENETICS, V37, P204; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; ALTMANN DM, 1993, HUM IMMUNOL, V37, P149, DOI 10.1016/0198-8859(93)90180-9; Ohzeki J, 2012, EMBO J, V31, P2391, DOI 10.1038/emboj.2012.82; Asami J, 2011, TRANSGENIC RES, V20, P913, DOI 10.1007/s11248-010-9469-3; Iida Y, 2010, DNA RES, V17, P293, DOI 10.1093/dnares/dsq020; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Ikeno M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp058; Jux B, 2013, INT IMMUNOL, V25, P307, DOI 10.1093/intimm/dxs157; Maehara K, 2010, MOL CELL BIOL, V30, P2090, DOI 10.1128/MCB.01318-09; Miyamoto K, 2014, TRANSGENIC RES, V23, P317, DOI 10.1007/s11248-013-9772-x; Moro M, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-24; Nakayama M, 2005, BIOTECHNIQUES, V38, P917, DOI 10.2144/05386RR02; Ohtsuka M, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq860; PINKERT CA, 1985, EMBO J, V4, P2225; Suzuki E, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1280; Suzuki N, 2006, J BIOL CHEM, V281, P26615, DOI 10.1074/jbc.M603053200; Vintersten Kristina, 2008, V415, P83, DOI 10.1007/978-1-59745-570-1_5	26	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-5915	1432-0886		CHROMOSOMA	Chromosoma	MAR	2015	124	1					107	118		10.1007/s00412-014-0488-3		12	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CC4ET	WOS:000350304400009		
J	Matsuo, T; Motohashi, S; Wanaka, K; Walenga, JM				Matsuo, Takefumi; Motohashi, Shinya; Wanaka, Keiko; Walenga, Jeanine M.			Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery	CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS			English	Article						anti-PF4/heparin complex antibodies; cardiovascular surgery; heparin-induced thrombocytopenia; reactive thrombocytosis	HEPARIN-INDUCED THROMBOCYTOPENIA; CORONARY-BYPASS SURGERY; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; INDUCED THROMBOSIS; PLATELET COUNT; IMPACT; RISK	To study the production of anti-platelet factor 4 (anti-PF4)/heparin complex antibodies of Ig (immunoglobulin) G/IgA/IgM using enzyme-linked immunosorbent assay (ELISA; heparin-induced thrombocytopenia [HIT] antibodies) in 79 patients undergoing cardiovascular surgery, we employed Delta optical density (OD) as a marker of HIT-antibody production. The Delta ODs were calculated from the differences in the ODs using ELISA. Patient were classified into 3 Delta OD ranges: Delta OD >= 1.0, Delta OD >= 0.4 to < 1.0, and Delta OD < 0.4. The underlying disease, time course of the postoperative platelet count, D-dimer level, postoperative brain magnetic resonance imaging (MRI), use of cardiopulmonary bypass and postoperative thrombocytosis were not considered for the 3 Delta OD classifications. None of the 6 patients with Delta OD >= 1.0 and a positive functional assay was diagnosed with HIT due to the absence of HIT-derived thrombocytopenia. In conclusion, HIT-antibody production increased until day 7 after heparin cessation and reached a trace level on day 14. It was demonstrated that HIT-antibody production is in remission unless there is any evidence of a further increase during the second week postsurgery.	[Matsuo, Takefumi] Hyogo Prefectural Awaji Hosp, Internal Med, Sumoto 6560013, Japan; [Motohashi, Shinya] Yamanashi Univ Hosp, Cardiovasc Surg, Chuo, Yamanashi, Japan; [Wanaka, Keiko] Kobe Res Projects Thrombosis & Haemostasis, Kobe, Hyogo, Japan; [Walenga, Jeanine M.] Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	Matsuo, T (reprint author), Hyogo Prefectural Awaji Hosp, 1-6-6 Shimogamo, Sumoto 6560013, Japan.	tak-matsuo@deluxe.ocn.ne.jp					Warkentin TE, 2008, J THROMB HAEMOST, V6, P1304, DOI 10.1111/j.1538-7836.2008.03025.x; Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x; SHERIDAN D, 1986, BLOOD, V67, P27; Selleng S, 2010, J THROMB HAEMOST, V8, P30, DOI 10.1111/j.1538-7836.2009.03626.x; Warkentin TE, 2003, ANN THORAC SURG, V76, P2121, DOI 10.1016/S0003-4975(03)00756-2; SCHMUZIGER M, 1995, EUR J CARDIO-THORAC, V9, P393, DOI 10.1016/S1010-7940(05)80172-1; Warkentin TE, 2000, BLOOD, V96, P1703; Kerendi F, 2007, ANN THORAC SURG, V84, P1548, DOI 10.1016/j.athoracsur.2007.05.080; AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95; Bennett-Guerrero E, 2005, J THORAC CARDIOV SUR, V130, P1567, DOI 10.1016/j.jtcvs.2005.07.052; Bigdeli AK, 2009, HEART SURG FORUM, V12, pE368, DOI 10.1532/HSF98.20091057; Gruel Y, 2010, J THROMB HAEMOST, V8, P27, DOI 10.1111/j.1538-7836.2009.03646.x; Matsuo T, 2000, SEMIN THROMB HEMOST, V26, P101, DOI 10.1055/s-2000-9811; Pouplard C, 2005, BRIT J HAEMATOL, V128, P837, DOI 10.1111/j.1365-2141.2005.05381.x; Pouplard C, 2007, ARCH MAL COEUR VAISS, V100, P563; Selleng S, 2008, J THROMB HAEMOST, V6, P428, DOI 10.1111/j.1538-7836.2007.02870.x; Senay S, 2011, HEART SURG FORUM, V14, pE366, DOI 10.1532/HSF98.20111031; Tibayan FA, 2010, J THORAC CARDIOV SUR, V139, pE6, DOI 10.1016/j.jtcvs.2008.07.006; Trossaert M, 1998, BRIT J HAEMATOL, V101, P653, DOI 10.1046/j.1365-2141.1998.00750.x	19	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1076-0296	1938-2723		CLIN APPL THROMB-HEM	Clin. Appl. Thromb.-Hemost.	MAR	2015	21	2					177	180		10.1177/1076029613507334		4	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CC6QP	WOS:000350492000013		
J	Nagai, Y; Shiraishi, D; Tanaka, Y; Nagasawa, Y; Ohwada, S; Shimauchi, H; Aso, H; Endo, Y; Sugawara, S				Nagai, Y.; Shiraishi, D.; Tanaka, Y.; Nagasawa, Y.; Ohwada, S.; Shimauchi, H.; Aso, H.; Endo, Y.; Sugawara, S.			Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						antigen transportation; sublingual ductal system; sublingual immunotherapy	REGULATORY T-CELLS; DENDRITIC CELLS; LANGERHANS CELLS; ORAL-MUCOSA; IMMUNOTHERAPY; TOLERANCE; RHINOCONJUNCTIVITIS; INDUCTION; CHILDREN; EFFICACY	BackgroundSublingual immunotherapy (SLIT) has proven to be safe and efficient for the treatment of type I allergies. However, the mechanisms underlying allergen transportation within the sublingual compartment, the localization of antigens, and the identities of the cells responsible for this immunization remain incompletely understood. ObjectiveIn this study, we focused on the sublingual ductal system and analysed the localization and transportation of antigens after their sublingual application. MethodsIn mice given adjuvant-free antigens sublingually, tissues were removed at 0, 0.5, 1, or 2h after the application and subjected to immunohistochemistry. Cells isolated from the sublingual duct and mucosa were analysed by flow cytometry. ResultsSubstantial immunoreactivity to ovalbumin (OVA) was evident in sublingual ductal epithelial cells at 30min and 1h after sublingual administration of OVA, but it had disappeared at 2h. The ductal epithelial cells incorporated not only OVA, but also particulate antigens such as latex or silica beads and microbes. MHC class II (MHCII)(+) antigen-presenting cells (APCs) were located around the sublingual ductal system, and MHCII+ cells were co-localized with, and around, antigen-incorporated sublingual duct cells. CD11b(+) CD11c(-) cells were present among CD45(+) MHCII+ cells at greater frequency in the sublingual duct than in the sublingual mucosa, and they were the main contributors to the incorporation of OVA in vitro. Conclusions and Clinical RelevanceThis study reveals that sublingual antigens can be transported across sublingual ductal epithelial cells to the ductal APCs. If the system is the same in humans as in mice, the ductal APCs may prove to be important target cells for SLIT.	[Nagai, Y.; Shiraishi, D.; Tanaka, Y.; Endo, Y.; Sugawara, S.] Tohoku Univ, Grad Sch Dent, Dept Oral Biol, Div Oral Immunol, Sendai, Miyagi 9808575, Japan; [Shiraishi, D.; Shimauchi, H.] Tohoku Univ, Grad Sch Dent, Dept Oral Biol, Div Periodontol & Endodontol, Sendai, Miyagi 9808575, Japan; [Tanaka, Y.] Tohoku Univ, Grad Sch Dent, Liaison Ctr Innovat Dent, Sendai, Miyagi 9808575, Japan; [Nagasawa, Y.; Ohwada, S.; Aso, H.] Tohoku Univ, Grad Sch Agr Sci, Cellular Biol Lab, Sendai, Miyagi 9808575, Japan	Sugawara, S (reprint author), Tohoku Univ, Grad Sch Dent, Dept Oral Biol, Div Oral Immunol,Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	s_sugawara@dent.tohoku.ac.jp					Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2008, ALLERGY, V63, P720, DOI 10.1111/j.1398-9995.2007.01611.x; Song JH, 2009, J IMMUNOL, V182, P6851, DOI 10.4049/jimmunol.0803568; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Hovav AH, 2014, MUCOSAL IMMUNOL, V7, P27, DOI 10.1038/mi.2013.42; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Ciprandi G, 2006, ALLERGY, V61, P511, DOI 10.1111/j.1398-9995.2006.01046.x; Allam JP, 2009, CURR OPIN ALLERGY CL, V9, P554, DOI 10.1097/ACI.0b013e32833239a9; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Nagatake T, 2009, J EXP MED, V206, P2351, DOI 10.1084/jem.20091436; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Cuburu N, 2009, J IMMUNOL, V183, P7851, DOI 10.4049/jimmunol.0803740; Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/nmat2784, 10.1038/NMAT2784]; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Sun JB, 2008, J IMMUNOL, V181, P8278; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Brook I, 2009, ORAL MAXIL SURG CLIN, V21, P269, DOI 10.1016/j.coms.2009.05.001; Mascarell L, 2011, MUCOSAL IMMUNOL, V4, P638, DOI 10.1038/mi.2011.28; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2009.02194.x, 10.1111/j.1398-9995.2008.01875.x]; Piconi S, 2010, J IMMUNOL, V185, P7723, DOI 10.4049/jimmunol.1002465; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x	24	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894	1365-2222		CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2015	45	3					677	686		10.1111/cea.12329		10	Allergy; Immunology	Allergy; Immunology	CC6DT	WOS:000350455800013		
J	Katagiri, S; Ohkuma, Y; Hayashi, T; Gekka, T; Tsuneoka, H				Katagiri, Satoshi; Ohkuma, Yasuhiro; Hayashi, Takaaki; Gekka, Tamaki; Tsuneoka, Hiroshi			Fundus autofluorescence findings of acute posterior multifocal placoid pigment epitheliopathy with chronic thyroiditis and splenectomy	CLINICAL AND EXPERIMENTAL OPTOMETRY			English	Article									[Katagiri, Satoshi; Ohkuma, Yasuhiro; Hayashi, Takaaki; Gekka, Tamaki; Tsuneoka, Hiroshi] Jikei Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan	Katagiri, S (reprint author), Jikei Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.	taka@jikei.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25462738]; Vehicle Racing Commemorative Foundation	This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid for Scientific Research [C] 25462738 to TH) and the Vehicle Racing Commemorative Foundation (to TH).	Asherson RA, 2008, J RHEUMATOL, V35, P1224; DEUTMAN AF, 1972, BRIT J OPHTHALMOL, V56, P863, DOI 10.1136/bjo.56.12.863; Framme C, 2002, RETINA-J RET VIT DIS, V22, P653, DOI 10.1097/00006982-200210000-00023; GASS JDM, 1968, ARCH OPHTHALMOL-CHIC, V80, P177; JACKLIN HN, 1977, ARCH OPHTHALMOL-CHIC, V95, P995; Ruiz Vinals AT, 2002, ARCH SOC ESP OFTALMO, V77, P381; Souka AAR, 2006, GRAEF ARCH CLIN EXP, V244, P1219, DOI 10.1007/s00417-006-0343-1; Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P479, DOI 10.1097/00006982-200604000-00020; Steiner Scott, 2012, Int Ophthalmol Clin, V52, P211, DOI 10.1097/IIO.0b013e318265d45a	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0816-4622	1444-0938		CLIN EXP OPTOM	Clin. Exp. Optom.	MAR	2015	98	2					186	189		10.1111/cxo.12208		4	Ophthalmology	Ophthalmology	CC6TI	WOS:000350501000014		
J	Yanagi, T; Mizuochi, T; Homma, K; Ueki, I; Seki, Y; Hasegawa, T; Takei, H; Nittono, H; Kurosawa, T; Matsuishi, T; Kimura, A				Yanagi, Tadahiro; Mizuochi, Tatsuki; Homma, Keiko; Ueki, Isao; Seki, Yoshitaka; Hasegawa, Tomonobu; Takei, Hajime; Nittono, Hiroshi; Kurosawa, Takao; Matsuishi, Toyojiro; Kimura, Akihiko			Distinguishing primary from secondary Delta(4)-3-oxosteroid 5 beta-reductase (SRD5B1, AKR1D1) deficiency by urinary steroid analysis	CLINICAL ENDOCRINOLOGY			English	Article							BILE-ACID METABOLISM; DELTA-4-3-OXOSTEROID 5-BETA-REDUCTASE; NEONATAL HEMOCHROMATOSIS; LIVER-DISEASE; GENE ANALYSIS; FAILURE; MUTATIONS; DIAGNOSIS; HEPATITIS; INFANTS	ObjectiveDeficiency of (4)-3-oxosteroid 5-reductase (5-reductase), a bile acid synthesis disorder, presents findings of neonatal cholestasis and hyper-3-oxo-(4) bile aciduria. The 5-reductase enzyme participates in not only bile acid synthesis but also hepatic steroid metabolism. Deficiency of 5-reductase includes 2 types: primary deficiency, with an SRD5B1 gene mutation; and secondary deficiency, lacking a mutation. Secondary deficiency is caused by fulminant liver failure from various aetiologies including neonatal hemochromatosis (NH). Distinguishing primary from secondary deficiency based on -glutamyltransferase (GGT), serum total bile acids (TBA), and urinary bile acid analysis using gas chromatography-mass spectroscopy (GC-MS) is very difficult. SRD5B1 gene analysis is the only reliable method. We examined urinary steroid analysis as a way to distinguish primary from secondary 5-reductase deficiency. Design, patients and measurementsWe examined 12 patients with cholestatic jaundice, normal or slightly elevated GGT, and hyper-3-oxo-(4) bile aciduria using urinary steroid analysis by GC-MS of both cortisol and cortisone compounds, such as 5-tetrahydrocortisol (5-THF) and 5-tetrahydrocortisone (5-THE). Patients previously were diagnosed with primary 5-reductase deficiency (n=3), deficiency secondary to NH (n=3) and deficiency secondary to other liver disorders (n=6). ResultsUrinary steroid analysis in 3 primary deficiency and 3 NH patients showed low 5-THE and elevated 5/5-THE ratios, making distinction difficult without also considering the clinical course and abdominal magnetic resonance imaging (MRI) findings, such as a very low signal intensity in liver and/or pancreas, especially in T-2-weighted images. In the six patients with other secondary deficiencies, urinary 5-THF and 5/5-THF differed from those in primary deficiency (P<005). ConclusionsUrinary steroid analysis can distinguish primary and NH-related deficiencies from other secondary deficiencies.	[Yanagi, Tadahiro; Mizuochi, Tatsuki; Ueki, Isao; Seki, Yoshitaka; Matsuishi, Toyojiro; Kimura, Akihiko] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Kurume, Fukuoka 8300011, Japan; [Mizuochi, Tatsuki] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [Homma, Keiko] Keio Univ Hosp, Cent Clin Labs, Tokyo, Japan; [Hasegawa, Tomonobu] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Takei, Hajime; Nittono, Hiroshi] Junshin Clin, Inst Bile Acid, Tokyo, Japan; [Kurosawa, Takao] Hlth Sci Univ Hokkaido, Fac Pharmaceut Sci, Sapporo, Hokkaido, Japan	Kimura, A (reprint author), Kurume Univ, Dept Pediat & Child Hlth, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	ashikita-aki@water.ocn.ne.jp			Japan Society for the Promotion of Science [B20368921]; Morinaga Foundation for Health Nutrition	This work was supported by the Japan Society for the Promotion of Science (Grant-in-aid for Young Scientists B20368921) and the Morinaga Foundation for Health & Nutrition to Tatsuki Mizuochi. We thank Dr. Jorge A. Bezerra in Cincinnati Children's Hospital Medical Center for insightful review of this manuscript.	Heubi JE, 2007, SEMIN LIVER DIS, V27, P282, DOI 10.1055/s-2007-985073; SETCHELL KDR, 1988, J CLIN INVEST, V82, P2148, DOI 10.1172/JCI113837; Lemonde HA, 2003, GUT, V52, P1494, DOI 10.1136/gut.52.10.1494; Clayton PT, 2011, J INHERIT METAB DIS, V34, P593, DOI 10.1007/s10545-010-9259-3; Homma K, 2003, ENDOCR J, V50, P783, DOI 10.1507/endocrj.50.783; Ueki I, 2009, J GASTROEN HEPATOL, V24, P776, DOI 10.1111/j.1440-1746.2008.05669.x; Gonzales E, 2004, J HEPATOL, V40, P716, DOI 10.1016/j.jhep.2003.12.024; CLAYTON PT, 1988, LANCET, V1, P1283; Palermo M, 2008, STEROIDS, V73, P417, DOI 10.1016/j.steroids.2007.12.001; Baric I, 2012, J PEDIATR GASTR NUTR, V55, pE126, DOI 10.1097/MPG.0b013e3182347a26; Clayton PT, 1996, GUT, V38, P623, DOI 10.1136/gut.38.4.623; Debray FG, 2012, PEDIATRICS, V129, pE1076, DOI 10.1542/peds.2011-0568; Gonzales E, 2009, GASTROENTEROLOGY, V137, P1310, DOI 10.1053/j.gastro.2009.07.043; Haas D., 2012, WORLD J GASTROENTERO, V18; IIDA T, 1993, CHEM PHARM BULL, V41, P763; Kimura A, 1999, PEDIATR RES, V45, P603, DOI 10.1203/00006450-199904010-00022; KONDO KH, 1994, EUR J BIOCHEM, V219, P357, DOI 10.1111/j.1432-1033.1994.tb19947.x; LEPPIK RA, 1983, STEROIDS, V41, P475, DOI 10.1016/0039-128X(83)90087-9; ONISHI Y, 1991, BIOL CHEM H-S, V372, P1039, DOI 10.1515/bchm3.1991.372.2.1039; Seki Y, 2013, J INHERIT METAB DIS, V36, P565, DOI 10.1007/s10545-012-9526-6; Shanmugan N. P., 2012, EUROPEAN J PEDIAT, V170, P573; SHNEIDER BL, 1994, J PEDIATR-US, V124, P234, DOI 10.1016/S0022-3476(94)70310-8; Siafakas CG, 1997, J PEDIATR GASTR NUTR, V25, P321, DOI 10.1097/00005176-199709000-00015	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAR	2015	82	3					346	351		10.1111/cen.12596		6	Endocrinology & Metabolism	Endocrinology & Metabolism	CC1QE	WOS:000350115600005		
J	Yamada, S; Muragaki, Y; Maruyama, T; Komori, T; Okada, Y				Yamada, Shinobu; Muragaki, Yoshihiro; Maruyama, Takashi; Komori, Takashi; Okada, Yoshikazu			Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Malignant glioma; Surgical resection; Intraoperative MRI; Neurochemical navigation; Photodynamic diagnosis; 5-ALA	ROBOTIC LASER-ABLATION; GROSS TOTAL RESECTION; GLIOBLASTOMA-MULTIFORME; INDUCED FLUORESCENCE; PRECISION NEUROSURGERY; VOLUMETRIC-ANALYSIS; TUMOR FLUORESCENCE; CLINICAL ARTICLE; SURGERY; EXTENT	Objective: To evaluate the role of the neurochemical navigation with 5-aminolevulinic acid (5-ALA) during intraoperative MRI (iMRI)-guided resection of the intracranial malignant gliomas. Methods: The analysis included 99 consecutive surgical cases. Resection of the bulk of the neoplasm was mainly guided by the updated neuronavigation based on the low-field-strength (0.3 T) iMRI, whereas at the periphery of the lesion neurochemical navigation with 5-ALA was additionally used. Results: In total, 286 tissue specimens were obtained during surgeries for histopathological examination. According to iMRI 98 samples with strong (91 cases), weak (6 cases), or absent (1 case) fluorescence corresponded to the bulk of the lesion and all of those ones contained tumor. Out of 188 tissue specimens obtained from the "peritumoral brain," the neoplastic elements were identified in 89%, 81% and 29% of samples with, respectively, strong (107 cases), weak (47 cases) and absent (34 cases) fluorescence. Positive predictive values of the tissue fluorescence for presence of neoplasm within and outside of its boundaries on iMRI were 100% and 86%, respectively. Conclusion: Neurochemical navigation with 5-ALA is useful adjunct during iMRI-guided resection of intracranial malignant gliomas, which allows identification of the tumor extension beyond its radiological borders. (C) 2015 Elsevier B.V. All rights reserved.	[Yamada, Shinobu; Muragaki, Yoshihiro; Maruyama, Takashi] Tokyo Womens Med Univ, Fac Adv Technosurg, Tokyo 1628666, Japan; [Komori, Takashi] Tokyo Womens Med Univ, Inst Adv Biomed Engn & Sci, Tokyo 1628666, Japan; [Muragaki, Yoshihiro; Maruyama, Takashi; Okada, Yoshikazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo 1628666, Japan; [Komori, Takashi] Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; [Komori, Takashi] Tokyo Metropolitan Inst Med Sci, Dept Brain Dev & Regenerat, Lab Brain Tumor Pathol, Tokyo 113, Japan; [Yamada, Shinobu] Nobelpharma Co Ltd, Dept Business Dev, Tokyo, Japan; [Yamada, Shinobu] Nobelpharma Co Ltd, Dept Res & Dev, Tokyo, Japan	Muragaki, Y (reprint author), Tokyo Womens Med Univ, Fac Adv Technosurg, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	ymuragaki@twmu.ac.jp					Valle RD, 2011, J NEURO-ONCOL, V102, P105, DOI 10.1007/s11060-010-0296-4; [Anonymous], 2003, CANC THER EV PROGR C; Ando T, 2011, BRAIN TUMOR PATHOL, V28, P43, DOI 10.1007/s10014-010-0002-4; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Schucht P, 2012, NEUROSURGERY, V71, P927, DOI 10.1227/NEU.0b013e31826d1e6b; Proescholdt MA, 2005, CLIN NEUROL NEUROSUR, V107, P95, DOI 10.1016/j.clineuro.2004.02.025; Stummer W, 2014, NEUROSURGERY, V74, P310, DOI 10.1227/NEU.0000000000000267; Idoate MA, 2011, NEUROPATHOLOGY, V31, P575, DOI 10.1111/j.1440-1789.2011.01202.x; Tsugu A, 2011, WORLD NEUROSURG, V76, P120, DOI 10.1016/j.wneu.2011.02.005; Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6; Stummer W, 2011, J NEUROSURG, V114, P613, DOI 10.3171/2010.3.JNS097; Utsuki S, 2007, NEUROL MED-CHIR, V47, P210, DOI 10.2176/nmc.47.210; Roder C, 2014, EJSO-EUR J SURG ONC, V40, P297, DOI 10.1016/j.ejso.2013.11.022; Pichlmeier U, 2008, NEURO-ONCOLOGY, V10, P1025, DOI 10.1215/15228517-2008-052; Nabavi A, 2009, NEUROSURGERY, V65, P1070, DOI 10.1227/01.NEU.0000360128.03597.C7; Stummer W, 2000, J NEUROSURG, V93, P1003, DOI 10.3171/jns.2000.93.6.1003; Roessler K, 2012, NEUROL RES, V34, P314, DOI 10.1179/1743132811Y.0000000078; Shioyama T, 2013, J NEUROSURG, V118, P1232, DOI 10.3171/2013.1.JNS12681; Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998; Liao HE, 2012, MED IMAGE ANAL, V16, P754, DOI 10.1016/j.media.2010.11.004; Colditz MJ, 2012, J CLIN NEUROSCI, V19, P1611, DOI 10.1016/j.jocn.2012.03.013; Valdes PA, 2011, J NEUROSURG, V115, P11, DOI 10.3171/2011.2.JNS101451; Senft C, 2010, CLIN NEUROL NEUROSUR, V112, P237, DOI 10.1016/j.clineuro.2009.12.003; Colditz MJ, 2012, J CLIN NEUROSCI, V19, P1471, DOI 10.1016/j.jocn.2012.03.009; Roberts DW, 2011, J NEUROSURG, V114, P595, DOI 10.3171/2010.2.JNS091322; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Aldave G, 2013, NEUROSURGERY, V72, P915, DOI 10.1227/NEU.0b013e31828c3974; Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9; Senft C, 2012, J NEURO-ONCOL, V109, P81, DOI 10.1007/s11060-012-0864-x; Barone DG, 2014, COCHRANE DB SYST REV, V1; Della Puppa A, 2013, ACTA NEUROCHIR, V155, P965, DOI 10.1007/s00701-013-1660-x; Valle RD, 2014, NEUROLOGIA, V29, P131, DOI 10.1016/j.nrl.2013.05.004; Eyupoglu IY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044885; Feigl GC, 2010, J NEUROSURG, V113, P352, DOI 10.3171/2009.10.JNS09447; Hervey-Jumper SL, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0284-7; Iseki H, 2008, MINIM INVAS NEUROSUR, V51, P285, DOI 10.1055/s-0028-1082333; Liao HG, 2008, LECT NOTES COMPUT SC, V5242, P373; Louis DN, 2007, WHO CLASSIFICATION T; Maruyama T, 2001, INT CONGR SER, V1230, P270; Miyatake Shin-ichi, 2007, Neurosurgery, V61, pE1101; Muragaki Yoshihiro, 2011, Acta Neurochir Suppl, V109, P67, DOI 10.1007/978-3-211-99651-5_11; Muragaki Y, 2011, DIAGNOSTIC TECHNIQUE, P517; Muragaki Y, 2012, J HEALTHC ENG, V3, P551, DOI 10.1260/2040-2295.3.4.551; Muragaki Y, 2006, ACT NEUR S, V98, P67; Schucht P, 2014, ACTA NEUROCHIR, V156, P305, DOI 10.1007/s00701-013-1906-7; Smith LGF, 2012, WORLD NEUROSURG, V78, P556; Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.neu.0000317304.31579.17, 10.1227/01.NEU.0000297118.47076.5F]; Stummer W, 2011, ACTA NEUROCHIR, V153, P1211, DOI 10.1007/s00701-011-1001-x; Suzuki T, 2013, J NEUROSURG, V119, P1331, DOI 10.3171/2013.7.JNS122340	49	3	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAR	2015	130						134	139		10.1016/j.clineuro.2015.01.005		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CC2PD	WOS:000350186200026		
J	Shiozawa, M; Takahashi, H; Asakawa, Y; Iwasaki, N				Shiozawa, Maho; Takahashi, Hidekazu; Asakawa, Yuya; Iwasaki, Naohiko			Color stability of adhesive resin cements after immersion in coffee	CLINICAL ORAL INVESTIGATIONS			English	Article						Adhesive resin cements; Color stability; Water sorption; Water solubility	STAINING SOLUTIONS; RESTORATIVE MATERIALS; DIFFERENT DRINKS; DENTAL CERAMICS; WATER SORPTION; BOND STRENGTH; IN-VITRO; DISCOLORATION; ACCEPTABILITY; COMPOSITES	Marginal discoloration of luting cement may affect the appearance of esthetic restorations. This study evaluated the color stability of current adhesive resin cements after immersion in coffee. Four dual-cured resin cements (Clearfil SA cement Automix Universal, Maxcem Elite Clear, Maxcem Elite Yellow, and RelyX Unicem2 Automix A2) and two chemical-cured resin cements (Super-Bond C&B Clear and Super-Bond C&B Esthetic) were examined. The CIE L*a*b* of 2.0-mm-thick disc-shaped specimens was measured using a spectrophotometer on a white background (n = 6). The color differences (a dagger E) after 1-day and 1-week immersion in 37 A degrees C water or coffee were analyzed by two-way ANOVA by selecting immersion solution and product as main factors, followed by Tukey's HSD test (alpha = 0.05). Water sorption and solubility were also evaluated. The two-way ANOVA of the a dagger Es suggested that the two main factors and their interaction were significant. The a dagger Es after coffee immersion were significantly greater than those after water immersion, except for Super-Bond C&B Esthetic. The a dagger Es after water immersion were not significantly different among the products; those of Maxcem Elite Clear and Maxcem Elite Yellow after coffee immersion were significantly greater than the others. The water sorption and solubility significantly correlated with the a dagger Es. The a dagger Es of the adhesive resin cements examined after 1-week coffee immersion were significantly different among the products. The product showing greater water sorption and solubility displayed greater color change. Adhesive resin cements should be carefully selected when the marginal appearance of the ceramic restoration is important.	[Shiozawa, Maho] Tokyo Med & Dent Univ, Dept Masticatory Funct Rehabil, Div Oral Hlth Sci, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan; [Takahashi, Hidekazu; Asakawa, Yuya; Iwasaki, Naohiko] Tokyo Med & Dent Univ, Fac Dent, Sch Oral Hlth Care Sci, Course Oral Hlth Engn,Bunkyo Ku, Tokyo 1138549, Japan	Takahashi, H (reprint author), Tokyo Med & Dent Univ, Fac Dent, Sch Oral Hlth Care Sci, Course Oral Hlth Engn,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	takahashi.bmoe@tmd.ac.jp					Alhazali N, 2012, J DENT S1, V40, pe10; Rosenstiel SF, 1998, J PROSTHET DENT, V80, P280, DOI 10.1016/S0022-3913(98)70128-3; Luhrs AK, 2010, CLIN ORAL INVEST, V14, P193, DOI 10.1007/s00784-009-0279-z; Yiu CKY, 2006, BIOMATERIALS, V27, P1695, DOI 10.1016/j.biomaterials.2005.09.037; Falkensammer F, 2013, J PROSTHET DENT, V109, P378, DOI 10.1016/S0022-3913(13)60323-6; Santos MJ, 2013, OPER DENT, V38, P3, DOI 10.2341/12-039-C; Bagheri R, 2005, J DENT, V33, P389, DOI 10.1016/j.jdent.2004.10.018; Wang F, 2013, J PROSTHET DENT, V110, P14, DOI 10.1016/S0022-3913(13)60333-9; Corekci B, 2010, AM J ORTHOD DENTOFAC, V138, P741, DOI 10.1016/j.ajodo.2008.12.029; Douglas RD, 2007, J PROSTHET DENT, V97, P200, DOI 10.1016/j.prosdent.2007.02.012; Shin DH, 2009, DENT MATER, V25, P1030, DOI 10.1016/j.dental.2009.03.004; Aschenbrenner CM, 2012, CLIN ORAL INVEST, V16, P191, DOI 10.1007/s00784-010-0501-z; Borrelli RC, 2002, J AGR FOOD CHEM, V50, P6527, DOI 10.1021/jf025686o; Guler AU, 2005, J PROSTHET DENT, V94, P118, DOI 10.1016/j.prosdent.2005.05.004; Ito S, 2005, BIOMATERIALS, V26, P6449, DOI 10.1016/j.biomaterials.2005.04.052; Lindsey DT, 2007, J DENT, V35, P593, DOI 10.1016/j.jdent.2007.03.006; Sabatini C, 2013, OPER DENT, V38, P186, DOI 10.2341/11-317-L; Hill EE, 2011, AUST DENT J, V56, P67, DOI 10.1111/j.1834-7819.2010.01297.x; Schneider LFJ, 2008, DENT MATER, V24, P1169, DOI 10.1016/j.dental.2008.01.007; Ghinea R, 2010, J DENT, V38, pE57, DOI 10.1016/j.jdent.2010.07.008; Stober T, 2001, DENT MATER, V17, P87, DOI 10.1016/S0109-5641(00)00065-8; Blatz MB, 2003, J PROSTHET DENT, V89, P268, DOI 10.1067/mpr.2003.50; Perez MD, 2011, J DENT, V39, pE37, DOI 10.1016/j.jdent.2011.09.007; Arocha MA, 2013, CLIN ORAL INVEST, V17, P1481, DOI 10.1007/s00784-012-0837-7; Bayindir F, 2012, J DENT, V40, pE41, DOI 10.1016/j.jdent.2012.07.014; Bindl A, 2006, J ORAL REHABIL, V33, P520, DOI 10.1111/j.1365-2842.2005.01588.x; Ertas E, 2006, DENT MATER J, V25, P371; Gonulol N, 2012, J DENT, V40, pE64, DOI 10.1016/j.jdent.2012.07.005; Haddad MF, 2011, J CRANIOFAC SURG, V22, P952, DOI 10.1097/SCS.0b013e31820fe205; Hitz T, 2012, DENT MATER, V28, P83, DOI 10.1016/j.dental.2012.09.006; Ilie N, 2012, CLIN ORAL INVEST, V16, P505, DOI 10.1007/s00784-011-0527-x; Imamura S, 2008, DENT MATER J, V27, P802; JOHNSTON WM, 1989, J DENT RES, V68, P819, DOI 10.1177/00220345890680051301; Ladha Komal, 2010, J Indian Prosthodont Soc, V10, P79, DOI 10.1007/s13191-010-0022-0; Malekipour Mohammad Reza, 2012, Dent Res J (Isfahan), V9, P441; Marghalani HY, 2012, DENT MATER, V28, pE187, DOI 10.1016/j.dental.2012.04.037; Park JK, 2010, AM J DENT, V23, P39; Um C M, 1991, Quintessence Int, V22, P377	38	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-6981	1436-3771		CLIN ORAL INVEST	Clin. Oral Investig.	MAR	2015	19	2					309	317		10.1007/s00784-014-1272-8		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CC4VT	WOS:000350353300017		
J	Kawanabe, N; Fukushima, H; Ishihara, Y; Yanagita, T; Kurosaka, H; Yamashiro, T				Kawanabe, Noriaki; Fukushima, Hiroaki; Ishihara, Yoshihito; Yanagita, Takeshi; Kurosaka, Hiroshi; Yamashiro, Takashi			Isolation and characterization of SSEA-4-positive subpopulation of human deciduous dental pulp cells	CLINICAL ORAL INVESTIGATIONS			English	Article						SSEA-4+human deciduous dental pulp stem cells; Adult stem cells; Multipotent stem cells; Clonal assays; Multilineage differentiation	MESENCHYMAL STEM-CELLS; HUMAN BONE-MARROW; PERIODONTAL-LIGAMENT; STROMAL CELLS; IN-VITRO; IDENTIFICATION; TEETH; DIFFERENTIATE; POPULATION; EXPRESSION	It is well accepted that stage-specific embryonic antigen (SSEA)-4 is an antigen that is useful to isolate adult stem cells analogous to embryonic stem cells. Therefore, in the present study, we investigated whether SSEA-4 can also be used as a marker to identify human deciduous dental pulp (D-DP) stem cells. Intact deciduous teeth were collected from healthy patients who were undergoing orthodontic treatment at Okayama University Hospital. Immunofluorescence analysis, flow cytometric analysis, and multilineage differentiation assay were performed to characterize SSEA-4+ D-DP cells. The D-DP cells had the characteristics of mesenchymal stem cells (MSCs), namely plastic adherence, specific surface antigen expression, and multipotent differentiation potential. SSEA-4 expression was detected in D-DP cells in vitro and ex vivo samples. A flow cytometric analysis demonstrated that 21.2 % of the D-DP cells were positive for SSEA-4. The SSEA-4+ clonal D-DP cells showed multilineage differentiation potential toward adipocytes, osteoblasts, and chondrocytes in vitro. In fact, 26.1 % (6/23) of the SSEA-4+ clonal D-DP cells showed adipogenic potential, 91.3 % (21/23) showed osteogenic potential, 91.3 % (21/23) showed chondrogenic potential, and 87.0 % (20/23) showed both osteogenic and chondrogenic potential. Thus, the majority of SSEA-4+ D-DP cells had the potential for multilineage differentiation. Hence, SSEA-4 appears to be a specific marker that can be used to identify D-DP stem cells. SSEA-4+ D-DP cells appear to be a promising source of stem cells for regenerative therapy.	[Kawanabe, Noriaki; Yanagita, Takeshi] Okayama Univ Hosp, Dept Orthodont, Kita Ku, Okayama 7008525, Japan; [Fukushima, Hiroaki; Ishihara, Yoshihito; Kurosaka, Hiroshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthodont, Okayama 7008530, Japan; [Yamashiro, Takashi] Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Osaka, Japan	Kawanabe, N (reprint author), Okayama Univ Hosp, Dept Orthodont, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	kawanabe@md.okayama-u.ac.jp			Japan Society for the Promotion of Science, Japan [24593091, 24249093]	The present study was supported by Grants-in-Aid for Scientific Research (to N. Kawanabe [24593091] and T. Yamashiro [24249093]) from the Japan Society for the Promotion of Science, Japan.	Jubeli E, 2012, J CONTROL RELEASE, V158, P194, DOI 10.1016/j.jconrel.2011.09.084; Fukushima H, 2012, J DENT RES, V91, P955, DOI 10.1177/0022034512458123; Trubiani O, 2005, INT J IMMUNOPATH PH, V18, P213; Chang H, 2012, STEM CELL TRANSL MED, V1, P480, DOI 10.5966/sctm.2011-0056; Kawanabe N, 2010, DIFFERENTIATION, V79, P74, DOI 10.1016/j.diff.2009.10.005; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Silverio KG, 2010, J PERIODONTOL, V81, P1207, DOI 10.1902/jop.2010.090729; Muraglia A, 2000, J CELL SCI, V113, P1161; Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Brimble SN, 2007, STEM CELLS, V25, P54, DOI 10.1634/stemcells.2006-0232; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Sakai VT, 2010, J DENT RES, V89, P791, DOI 10.1177/0022034510368647; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Yen BL, 2005, STEM CELLS, V23, P3, DOI 10.1634/stemcells.2004-0098; SIMMONS PJ, 1991, BLOOD, V78, P55; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Kawanabe N, 2006, BIOCHEM BIOPH RES CO, V344, P1278, DOI 10.1016/j.bbrc.2006.03.237; Kawanabe N, 2012, EXP CELL RES, V318, P453, DOI 10.1016/j.yexcr.2012.01.008; Kerkis I, 2006, CELLS TISSUES ORGANS, V184, P105, DOI 10.1159/000099617; Maddox JR, 2012, CELLS TISSUES ORGANS, V196, P107, DOI 10.1159/000331332; Miettinen M, 2000, MODERN PATHOL, V13, P536, DOI 10.1038/modpathol.3880093; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; National Institutes of Health, 2001, STEM CELLS SCI PROGR; Telles PD, 2011, J APPL ORAL SCI, V19, P189, DOI 10.1590/S1678-77572011000300002; Yanagisawa M, 2011, NEUROCHEM RES, V36, P1623, DOI 10.1007/s11064-010-0358-1	30	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-6981	1436-3771		CLIN ORAL INVEST	Clin. Oral Investig.	MAR	2015	19	2					363	371		10.1007/s00784-014-1260-z		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CC4VT	WOS:000350353300024		
J	Eichler, HG; Baird, LG; Barker, R; Bloechl-Daum, B; Borlum-Kristensen, F; Brown, J; Chua, R; Del Signore, S; Dugan, U; Ferguson, J; Garner, S; Goettsch, W; Haigh, J; Honig, P; Hoos, A; Huckle, P; Kondo, T; Le Cam, Y; Leufkens, H; Lim, R; Longson, C; Lumpkin, M; Maraganore, J; O'Rourke, B; Oye, K; Pezalla, E; Pignatti, F; Raine, J; Rasi, G; Salmonson, T; Samaha, D; Schneeweiss, S; Siviero, PD; Skinner, M; Teagarden, JR; Tominaga, T; Trusheim, MR; Tunis, S; Unger, TF; Vamvakas, S; Hirsch, G				Eichler, H-G; Baird, L. G.; Barker, R.; Bloechl-Daum, B.; Borlum-Kristensen, F.; Brown, J.; Chua, R.; Del Signore, S.; Dugan, U.; Ferguson, J.; Garner, S.; Goettsch, W.; Haigh, J.; Honig, P.; Hoos, A.; Huckle, P.; Kondo, T.; Le Cam, Y.; Leufkens, H.; Lim, R.; Longson, C.; Lumpkin, M.; Maraganore, J.; O'Rourke, B.; Oye, K.; Pezalla, E.; Pignatti, F.; Raine, J.; Rasi, G.; Salmonson, T.; Samaha, D.; Schneeweiss, S.; Siviero, P. D.; Skinner, M.; Teagarden, J. R.; Tominaga, T.; Trusheim, M. R.; Tunis, S.; Unger, T. F.; Vamvakas, S.; Hirsch, G.			From Adaptive Licensing to Adaptive Pathways: Delivering a Flexible Life-Span Approach to Bring New Drugs to Patients	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article							HEALTH TECHNOLOGY-ASSESSMENT; ALZHEIMERS-DISEASE; CLINICAL-TRIALS; CANCER; ACCESS; INNOVATION; EFFICACY; PROPOSAL; THERAPY; NETWORK	The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life-span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade-off, help de-risk drug development, and lead to better outcomes for patients.	[Eichler, H-G; Bloechl-Daum, B.; Leufkens, H.; Pignatti, F.; Raine, J.; Rasi, G.; Salmonson, T.; Vamvakas, S.] EMA, London, England; [Baird, L. G.; Hirsch, G.] MIT, Ctr Biomed Innovat, Cambridge, MA 02139 USA; [Barker, R.] CASMI, London, England; [Bloechl-Daum, B.] Med Univ Vienna, Vienna, Austria; [Borlum-Kristensen, F.] Danish Hlth & Med Author, European Network Hlth Technol Assessment EUnetHTA, Copenhagen, Denmark; [Brown, J.] Pilgrim Hlth Care Inst, Boston, MA USA; [Brown, J.; Schneeweiss, S.] Harvard Univ, Sch Med, Boston, MA USA; [Chua, R.] HSA, Singapore, Singapore; [Del Signore, S.] Sanofi Aventis, Chilly Mazarin, France; [Dugan, U.] Bristol Myers Squibb Co, Global Clin Res, Wallingford, CT 06492 USA; [Ferguson, J.] Novartis Vaccines & Diagnost Cambridge, Cambridge, MA USA; [Garner, S.; Longson, C.] Natl Inst Hlth & Care Excellence NICE, London, England; [Goettsch, W.] Zorginst Nederland, Diemen, Netherlands; [Haigh, J.] Amgen Ltd, Uxbridge, Middx, England; [Hoos, A.] M4P Med 4 Patients Consulting, London, England; [Huckle, P.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Kondo, T.; Tominaga, T.] PMDA, Tokyo, Japan; [Le Cam, Y.] European Org Rare Dis EURORDIS, Paris, France; [Leufkens, H.] CBG MEB, Utrecht, Netherlands; [Leufkens, H.] Univ Utrecht, Utrecht, Netherlands; [Lim, R.] Hlth Canada, Ottawa, ON K1A 0L2, Canada; [Lumpkin, M.] Bill & Melinda Gates Fdn, Seattle, WA USA; [Maraganore, J.] Alnylam Pharmaceut, Cambridge, MA USA; [Maraganore, J.] Biotechnol Ind Assoc BIO, Washington, DC USA; [O'Rourke, B.] CADTH, Ottawa, ON, Canada; [Oye, K.; Unger, T. F.] MIT, Cambridge, MA 02139 USA; [Pezalla, E.] AETNA, Hartford, CT USA; [Raine, J.] Med & Healthcare Prod Regulatory Agcy MHRA, London, England; [Rasi, G.] Univ Roma Tor Vergata, Rome, Italy; [Salmonson, T.] Lakemedelsverket, Uppsala, Sweden; [Samaha, D.] INESSS, Quebec City, PQ, Canada; [Siviero, P. D.] Agenzia Italiana Farmaco AIFA, Rome, Italy; [Siviero, P. D.] Med Evaluat Comm MEDEV, Rome, Italy; [Teagarden, J. R.] NORD, Danbury, CT USA; [Trusheim, M. R.] MIT, Sloan Sch Management, Cambridge, MA 02139 USA; [Tunis, S.] CMTP, Baltimore, MD USA; [Unger, T. F.] Naia Pharmaceut, Cambridge, MA USA	Eichler, HG (reprint author), EMA, London, England.	Hans-Georg.Eichler@ema.europa.eu					Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Pimplikar SW, 2010, J NEUROSCI, V30, P14946, DOI 10.1523/JNEUROSCI.4305-10.2010; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Henshall C, 2013, INT J TECHNOL ASSESS, V29, P353, DOI 10.1017/S0266462313000378; Psaty BM, 2014, NEW ENGL J MED, V370, P2165, DOI 10.1056/NEJMp1401664; Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238; Eichler HG, 2013, NAT REV DRUG DISCOV, V12, P907, DOI 10.1038/nrd4129; Eichler HG, 2010, NAT REV DRUG DISCOV, V9, P277, DOI 10.1038/nrd3079; [Anonymous], 2007, PRIC REP PHARM 2020; Kozauer N, 2013, NEW ENGL J MED, V368, P1169, DOI 10.1056/NEJMp1302513; Trusheim MR, 2007, NAT REV DRUG DISCOV, V6, P287, DOI 10.1038/nrd2251; Sleijfer S, 2013, J CLIN ONCOL, V31, P1834, DOI 10.1200/JCO.2012.45.3639; Schneeweiss S, 2011, CLIN PHARMACOL THER, V90, P777, DOI 10.1038/clpt.2011.235; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Fleurence RL, 2014, J AM MED INFORM ASSN, V21, P578, DOI 10.1136/amiajnl-2014-002747; Woodcock J, 2012, CLIN PHARMACOL THER, V91, P378, DOI 10.1038/clpt.2011.337; Eichler HG, 2012, CLIN PHARMACOL THER, V91, P426, DOI 10.1038/clpt.2011.345; Schneeweiss S, 2014, NEW ENGL J MED, V370, P2161, DOI 10.1056/NEJMp1401111; Willyard C, 2013, NAT MED, V19, P655, DOI 10.1038/nm0613-655; Bianco P, 2014, NATURE, V510, P336; Arlett P., 2014, PHARMACOEPIDEMIOL DR; ASCO Completes Prototype for CancerLinQ, MARK 1 DEM LEARN HLT; Baird LG, 2014, CLIN PHARMACOL THER, V96, P559, DOI 10.1038/clpt.2014.145; Baird L., 2013, SCRIP REGULATOR 0524; Beyer A., 2014, MED DECIS UNPUB 0613; Burke M., WHY ALZHEIMERS DRUGS; CMTP, 2014, CMTP ISS REC LAT PHA; Coast J., 2013, EXPERT REV PHARM OUT, V14, P473; Durham M. S., 2010, TYSABRI APPROVED FUN; Dyer O, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g4231; EFPIA, EFPIA RIGHT PREV TRE; EMA, 2014, EMA1135892014; EMA, 2014, PAT CONS; EMA Benefit-risk Methodology Project, 2010, WORK PACK 2 REP APPL; European Medicines Agency, EPAR ZIAG; European Medicines Agency (EMA), 2007, REFL PAP METH ISS CO; FDA, 2014, VOIC PAT SER REP FDA; FDA, 2014, GUID IND EXP PROGR S; FDA, 2013, STRUCT APPR BEN RISK; Ferrario A, 2013, MANAGED ENTRY AGREEM; Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2010, GUID IND AD DES CLIN; Genetic Alliance UK, NEW MED SER COND WEI; Husereau D., 2014, INT J TECHNOL ASSESS, V12, P1; Institute of Medicine, 2013, IMPL NAT CANC CLIN T, P36; Johnston JD, 2014, BRIT J CLIN PHARMACO, V77, P939, DOI 10.1111/bcp.12250; KCE, 2010, KCE REP C, V147C; Keane M, 2013, AM J BIOETHICS, V13, P19, DOI 10.1080/15265161.2013.814732; Kenny M. A Q, 2012, A Q A T MULLER; Kocher R, 2014, NEW ENGL J MED, V370, P1473, DOI 10.1056/NEJMp1400868; Kristensen FB, 2009, INT J TECHNOL ASSESS, V25, P1, DOI 10.1017/S0266462309990626; New Governmental Regulatory System for Stem Cell-Based Therapies in Japan, 2014, THERAPEUTIC INN 0328; NICE, 2014, NICE SEEKS VIEWS IT; Rabinowitz J., 2011, 24 C EUR COLL NEUR P; Roth D, 2011, HASTINGS CENT REP, V41, P29; Schlich T, 2013, NEW ENGL J MED, V369, P1978, DOI 10.1056/NEJMp1309194; Selker HP, 2014, CLIN PHARMACOL THER, V95, P147, DOI 10.1038/clpt.2013.177; Spearpoint PA, 2014, VALUE HEALTH, V17, pA100; Sutter S., 2014, PINK SHEET      0602, P10; Tabernero J, 2014, J CLIN ONCOL S, V32, p5s; Tominaga T, 2013, CLIN PHARMACOL THER, V93, P342, DOI 10.1038/clpt.2012.268; Vermeer N. S., CLIN PHARM THER; Woosley RL, 2005, ISSUES SCI TECHNOL, V21, P63; Young S. S., 2011, SIGNIFICANCE, P116	63	7	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	MAR	2015	97	3					234	246		10.1002/cpt.59		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CC3WK	WOS:000350281500025		
J	Naaim-Bouvet, F; Bellot, H; Nishimura, K; Genthon, C; Palerme, C; Guyomarc'h, G; Vionnet, V				Naaim-Bouvet, Florence; Bellot, Herve; Nishimura, Kouichi; Genthon, Christophe; Palerme, Cyril; Guyomarc'h, Gilbert; Vionnet, Vincent			Detection of snowfall occurrence during blowing snow events using photoelectric sensors (vol 106, pg 11, 2014)	COLD REGIONS SCIENCE AND TECHNOLOGY			English	Correction									[Naaim-Bouvet, Florence; Bellot, Herve] Irstea, UR ETNA, F-38402 St Martin Dheres, France; [Naaim-Bouvet, Florence; Bellot, Herve] Univ Grenoble Alpes, F-38041 Grenoble, France; [Nishimura, Kouichi] Nagoya Univ, Nagoya, Aichi 4648601, Japan; [Genthon, Christophe; Palerme, Cyril] CNRS, UJF, LGGE, St Martin Dheres, France; [Guyomarc'h, Gilbert; Vionnet, Vincent] CNRS, Meteo Fmnce, CNRM GAME, URA 1357, F-75700 Paris, France	Naaim-Bouvet, F (reprint author), Irstea, UR ETNA, F-38402 St Martin Dheres, France.	florence.naaim@irstea.fr					Naaim-Bouvet F, 2014, COLD REG SCI TECHNOL, V106, P11, DOI 10.1016/j.coldregions.2014.05.005	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-232X	1872-7441		COLD REG SCI TECHNOL	Cold Reg. Sci. Tech.	MAR	2015	111						49	49		10.1016/j.coldregions.2014.12.007		1	Engineering, Environmental; Engineering, Civil; Geosciences, Multidisciplinary	Engineering; Geology	CC1IO	WOS:000350094600005		
J	Nomura, K; Makino, H; Nakaji-Hirabayashi, T; Kitano, H; Ohno, K				Nomura, Kouji; Makino, Hirokazu; Nakaji-Hirabayashi, Tadashi; Kitano, Hiromi; Ohno, Kohji			Temperature-responsive copolymer brush constructed on a silica microparticle by atom transfer radical polymerization	COLLOID AND POLYMER SCIENCE			English	Article						ATRP; Microparticle; Polymer brush; Protein adsorption; Temperature responsiveness; Zwitterionic copolymer	A BLOCK TELOMERS; GOLD NANOPARTICLES; GLASS SUBSTRATE; NONSPECIFIC ADSORPTION; SENSING CAPABILITIES; GRAFT-COPOLYMERS; SURFACE; IMMOBILIZATION; RESISTANCE; MONOLAYER	A polymer, poly(2-(2-methoxyethoxy)ethyl methacrylate) (PMDM), was accumulated on a silica microparticle by surface-initiated atom transfer radical polymerization (ATRP). The hydrodynamic diameter of the polymer-grafted silica particle (PMDM-SiP) dispersed in water was observed to decrease above 24 degrees C, which could be ascribed to a coil-globule transition of PMDM chains. This is in accordance with the increase in turbidity of an aqueous solution of free PMDM, which was produced parallel in liquid phase at the ATRP, above 23 degrees C. The lower critical solution temperature (LCST), defined as the temperature at which the absorbance reached the optical density of 0.30, was 27.6 degrees C for free PMDM. An introduction of zwitterionic vinyl monomer, carboxymethylbetaine (CMB), into both a polymer brush and a free polymer (P(MDM-r-CMB)) raised the LCST. In addition, the hydrodynamic diameter (D-h) of the polymer-modified particles was not affected by the presence of NaBr nor lysozyme at 15 degrees C, whereas it was largely affected at 35 degrees C due to the decrease in hydrophilicity of the polymer graft chain above the LCST. In contrast, bovine serum albumin did not affect the D-h value of the polymer-modified particles both below and above the LCST. The usefulness of the PMDM brush having CMB as a comonomer in the biomedical field was suggested.	[Nomura, Kouji; Makino, Hirokazu; Kitano, Hiromi] Toyama Univ, Grad Sch Sci & Engn, Dept Appl Chem, Toyama 9308555, Japan; [Nakaji-Hirabayashi, Tadashi] Toyama Univ, Frontier Res Core Life Sci, Toyama 9308555, Japan; [Ohno, Kohji] Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Kitano, H (reprint author), Toyama Univ, Grad Sch Sci & Engn, Dept Appl Chem, Toyama 9308555, Japan.	kitano@eng.u-toyama.ac.jp			Japan Society for the Promotion of Science (JSPS) [22350101, 26188100]; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan [20106007]	This research was supported by a Grant-in-Aid for Scientific Research (22350101 and 26188100) from the Japan Society for the Promotion of Science (JSPS) and a Grant-in-Aid for Innovative Areas (20106007) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan. T. N.-H. is grateful to the Japan Science & Technology Promotion Foundation (JST) for the tenure track program. The authors are indebted to Osaka Organic Chemical Industry for the kind gift of CMB.	Zhang Z, 2006, LANGMUIR, V22, P10072, DOI 10.1021/la062175d; Mignot A, 2013, CHEM-EUR J, V19, P6122, DOI 10.1002/chem.201203003; Ohno K, 2003, ANGEW CHEM INT EDIT, V42, P2751, DOI 10.1002/anie.200250850; Ohno K, 2005, MACROMOLECULES, V38, P2137, DOI 10.1021/ma048011q; Kitano H, 2006, BIOMACROMOLECULES, V7, P1065, DOI 10.1021/bm050782u; Ohno K, 2010, MACROMOLECULES, V43, P8805, DOI 10.1021/ma1018389; Lee CS, 2013, MACROMOL BIOSCI, V13, P321, DOI 10.1002/mabi.201200308; Alli S, 2012, J APPL POLYM SCI, V124, P536, DOI 10.1002/app.34933; Kitano H, 2011, COLLOID SURFACE B, V88, P455, DOI 10.1016/j.colsurfb.2011.07.029; Tsujii Y, 2001, MACROMOLECULES, V34, P8872, DOI 10.1021/ma010733j; Suzuki H, 2011, COLLOID SURFACE B, V84, P111, DOI 10.1016/j.colsurfb.2010.12.023; Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232; Kitano H, 2004, MACROMOL CHEM PHYSIC, V205, P1651, DOI 10.1002/macp.200400135; Matsuura K, 2007, MACROMOL CHEM PHYSIC, V208, P862, DOI 10.1002/macp.200600652; Morokoshi S, 2004, LANGMUIR, V20, P8897, DOI 10.1021/la049201x; Edmondson S, 2004, CHEM SOC REV, V33, P14, DOI 10.1039/b210143m; Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t; Obiweluozor FO, 2014, MACROMOL CHEM PHYS, V215, P1077, DOI 10.1002/macp.201300778; Chang Y, 2006, LANGMUIR, V22, P2222, DOI 10.1021/la052692v; Ye JD, 2009, J PHYS CHEM B, V113, P676, DOI 10.1021/jp808905s; Brandrup J, 2003, POLYM HDB; Cai Y, 2013, MACROMOL CHEM PHYS, V214, P892; Kitano H, 2010, J COLLOID INTERF SCI, V345, P325, DOI 10.1016/j.jcis.2009.10.004; Kitano H, 2009, J COLLOID INTERF SCI, V331, P343, DOI 10.1016/j.jcis.2008.11.058; Kitano H, 2009, COLLOID SURFACE B, V70, P91, DOI 10.1016/j.colsurfb.2008.12.016; Kitano H, 2004, MACROMOL CHEM PHYSIC, V205, P2064, DOI 10.1002/macp.200400134; Kitano H, 2005, J COLLOID INTERF SCI, V282, P340, DOI 10.1016/j.jcis.2004.08.157; Kitano H, 2011, MACROMOL BIOSCI, V11, P557, DOI 10.1002/mabi.201000437; KITANO H, 1991, MAKROMOL CHEM, V192, P2915; Kitano H, 1999, J COLLOID INTERF SCI, V212, P58, DOI 10.1006/jcis.1998.6043; Kitano H, 1997, LANGMUIR, V13, P5041, DOI 10.1021/la970271w; Maeda Y, 2007, LANGMUIR, V23, P11259, DOI 10.1021/la7016006; Ohno K, 2002, MACROMOLECULES, V35, P8989, DOI 10.1021/ma0209491; OHSHIMA H, 1993, J COLLOID INTERF SCI, V159, P512, DOI 10.1006/jcis.1993.1356; Ohshima H, 2010, BIOPHYSICAL CHEM BIO; Okuda Y, 2000, Japan Patent, Patent No. 3032155; TAKEUCHI S, 1993, MAKROMOL CHEM, V194, P1991; Uchiyama Y, 2007, Japan Patent, Patent No. 3878315; von der Ehe C, 2014, MACROMOL CHEM PHYS, V215, P1306, DOI 10.1002/macp.201400099; Yamakawa T, 1979, BIOCH DATA BOOK, VI	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAR	2015	293	3					851	859		10.1007/s00396-014-3476-5		9	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CC5AA	WOS:000350367200018		
J	Yamamoto, T; Kawaguchi, K				Yamamoto, Tetsuya; Kawaguchi, Kan			Effect of electrolyte species on size of particle through soap-free emulsion polymerization of styrene using AIBN and electrolyte	COLLOID AND POLYMER SCIENCE			English	Article						Soap-free emulsion polymerization; Oil-soluble initiator; Counter ion; Ionic radius	AFM; METHACRYLATE; MECHANISM	The addition of electrolyte to a soap-free emulsion polymerization using oil-soluble initiator, 2,2'-azobis(2-methylpropionitrile) (AIBN), was useful for production of the micron-sized polystyrene particle. To investigate the effect of electrolyte species on particle size, we focus on the counter ion and ionic radius of the cation during the synthesis of the particle. As a result, because the order of acid dissociation constant of the acid was HCl < HNO3 < CH3COOH, the suspension using chloride salt has lower pH and included the larger particles due to the coagulation growth process. Cation with a larger ionic radius could promote the particle growth strongly because its hydration was so weaker that it had the ability to reduce the thickness of the electrical double layer of negatively charged polystyrene particle. In summary, the addition of strongly acidic salt with larger cationic radius to the polymerization was efficient for making the size of polystyrene particle larger.	[Yamamoto, Tetsuya; Kawaguchi, Kan] Nagoya Univ, Dept Chem Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Yamamoto, T (reprint author), Nagoya Univ, Dept Chem Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	ytetsuya@nuce.nagoya-u.ac.jp	Yamamoto, Tetsuya/C-9065-2011		Ministry of Education, Culture, Sports, Science and Technology of Japan [25420817]; Tatematsu Foundation; Foundation for the Promotion Ion Engineering	This study was financially supported in part by Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 25420817), Tatematsu Foundation, and The Foundation for the Promotion Ion Engineering.	ARAI M, 1979, J POLYM SCI POL CHEM, V17, P3655, DOI 10.1002/pol.1979.170171121; Nakabayashi H, 2010, LANGMUIR, V26, P7512, DOI 10.1021/la904316f; Yamamoto T, 2013, COLLOID POLYM SCI, V291, P2741, DOI 10.1007/s00396-013-3059-x; GOODALL AR, 1977, J POLYM SCI POL CHEM, V15, P2193, DOI 10.1002/pol.1977.170150912; Yamamoto T, 2012, COLLOID POLYM SCI, V290, P1023, DOI 10.1007/s00396-012-2618-x; Yamamoto T, 2005, J COLLOID INTERF SCI, V292, P392, DOI 10.1016/j.jcis.2005.05.095; Tanrisever T, 1996, J APPL POLYM SCI, V61, P485; Yamamoto T, 2006, J COLLOID INTERF SCI, V297, P112, DOI 10.1016/j.jcis.2005.10.025; Yamamoto T, 2012, COLLOID POLYM SCI, V290, P1833, DOI 10.1007/s00396-012-2807-7; Guven G, 2004, COLLOID POLYM SCI, V282, P708, DOI 10.1007/s00396-003-1001-3; Nagao D, 2000, J CHEM ENG JPN, V33, P468, DOI 10.1252/jcej.33.468; Yamamoto T, 2004, CHEM LETT, V33, P1440, DOI 10.1246/cl.2004.1440; Yamamoto T, 2006, J CHEM ENG JPN, V39, P596, DOI 10.1252/jcej.39.596	13	4	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-402X	1435-1536		COLLOID POLYM SCI	Colloid Polym. Sci.	MAR	2015	293	3					1003	1006		10.1007/s00396-015-3511-1		4	Chemistry, Physical; Polymer Science	Chemistry; Polymer Science	CC5AA	WOS:000350367200032		
J	Schweisfurth, TG; Herstatt, C				Schweisfurth, Tim G.; Herstatt, Cornelius			Embedded (Lead) Users as Catalysts to Product Diffusion	CREATIVITY AND INNOVATION MANAGEMENT			English	Article							CONSUMER INNOVATIVENESS; PERSPECTIVE-TAKING; OPINION LEADERS; PERCEIVED-RISK; COMMUNITIES; ADOPTION; EMPATHY; CONSEQUENCES; ANTECEDENTS; KNOWLEDGE	Firms can harness social user networks not only for ideation, but also to accelerate and facilitate diffusion of new product introductions. They select individuals whose own product adoptions and opinions influence adoption decisions of others. In this paper we transfer this rationale to firm employees. We focus on embedded users' who are employees of a firm, but at the same time users of the firm's products. We aim to find out if their access to user networks, use experience and lead userness impact their opinion leadership and domain-specific innovativeness. We also show how cognitive empathy towards external users is a mechanism to explain these relationships. Drawing on the user innovation and consumer behaviour literature, we derive and test eight hypotheses on a sample of 54 firm employees in gaming hardware firms. We find that lead userness is positively related to domain-specific innovativeness and opinion leadership, but use experience only to the former. Cognitive empathy mediates all relationships in our study. To facilitate embedded users' tendency to act as opinion leaders and to adopt new products, managers should encourage their employees to use the firm's products to build use experience and thus develop cognitive empathy towards external users.	[Schweisfurth, Tim G.] Tech Univ Munich, TUM Sch Management, D-80290 Munich, Germany; [Herstatt, Cornelius] Hamburg Univ Technol, Technol & Innovat Management, Hamburg, Germany; [Herstatt, Cornelius] Swiss Fed Inst Technol ETHZ, Zurich, Switzerland; [Herstatt, Cornelius] Univ Zurich, CH-8006 Zurich, Switzerland; [Herstatt, Cornelius] Univ St Gallen, St Gallen, Switzerland; [Herstatt, Cornelius] Tohoku Univ, Sendai, Miyagi 980, Japan	Schweisfurth, TG (reprint author), Tech Univ Munich, TUM Sch Management, D-80290 Munich, Germany.	tim.schweisfurth@tum.de; c.herstatt@tuhh.de					Dye MWG, 2009, CURR DIR PSYCHOL SCI, V18, P321; Baldwin C, 2011, ORGAN SCI, V22, P1399, DOI 10.1287/orsc.1100.0618; CHAN KK, 1990, J ADVERTISING, V19, P53; Kratzer J, 2009, J CONSUM RES, V36, P646, DOI 10.1086/599324; Citrin AV, 2000, IND MANAGE DATA SYST, V100, P294, DOI 10.1108/02635570010304806; Galinsky AD, 2005, GROUP PROCESS INTERG, V8, P109, DOI 10.1177/1368430205051060; Beatty SE, 1996, J RETAILING, V72, P223, DOI 10.1016/S0022-4359(96)90028-7; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037//0022-3514.44.1.113; FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312; ARMSTRONG JS, 1977, J MARKETING RES, V14, P396, DOI 10.2307/3150783; Franke N, 2003, RES POLICY, V32, P157, DOI 10.1016/S0048-7333(02)00006-9; Hoffmann S, 2010, J BUS RES, V63, P778, DOI 10.1016/j.jbusres.2009.06.007; Franke N, 2006, J PROD INNOVAT MANAG, V23, P301, DOI 10.1111/j.1540-5885.2006.00203.x; Morrison PD, 2004, RES POLICY, V33, P351, DOI 10.1016/j.respol.2003.09.007; Stock RM, 2005, J ACAD MARKET SCI, V33, P536, DOI 10.1177/0092070305276868; Schreier M, 2007, MARKET LETT, V18, P15, DOI 10.1007/s11002-006-9009-3; FLYNN LR, 1993, EDUC PSYCHOL MEAS, V53, P1105, DOI 10.1177/0013164493053004023; Homburg C, 2009, J MARKETING, V73, P64; Conchar MP, 2004, J ACAD MARKET SCI, V32, P418, DOI 10.1177/0092070304267551; BREMS C, 1989, J PSYCHOL, V123, P329; Hyysalo S, 2009, R&D MANAGE, V39, P247, DOI 10.1111/j.1467-9310.2009.00558.x; MYERS JH, 1972, J MARKETING RES, V9, P41, DOI 10.2307/3149604; DiStefano C, 2006, STRUCT EQU MODELING, V13, P440, DOI 10.1207/s15328007sem1303_6; Wadell C, 2013, INT J TECHNOL MANAGE, V61, P293, DOI 10.1504/IJTM.2013.052672; WOOD R, 1989, ACAD MANAGE REV, V14, P361, DOI 10.5465/AMR.1989.4279067; Hirunyawipada T, 2006, J CONSUM MARK, V23, P182, DOI 10.1108/07363760610674310; Parker SK, 2001, ACAD MANAGE J, V44, P1085, DOI 10.2307/3069390; Jeppesen LB, 2006, ORGAN SCI, V17, P45, DOI 10.1287/orsc.1050.0156; Burt RS, 1999, ANN AM ACAD POLIT SS, V566, P37, DOI 10.1177/0002716299566001004; Henseler J, 2009, ADV INT MARKETING, V20, P277, DOI 10.1108/S1474-7979(2009)0000020014; Grewal R, 2000, J ECON PSYCHOL, V21, P233, DOI 10.1016/S0167-4870(00)00003-9; Magnusson PR, 2009, J PROD INNOVAT MANAG, V26, P578; Mitchell VW, 1999, J BUS RES, V46, P167, DOI 10.1016/S0148-2963(98)00020-4; Shoham A, 2008, PSYCHOL MARKET, V25, P280, DOI 10.1002/mar.20209; Chiu CM, 2006, DECIS SUPPORT SYST, V42, P1872, DOI 10.1016/j.dss.2006.04.001; Dahlander L, 2006, RES POLICY, V35, P1243, DOI 10.1016/j.respol.2006.09.011; Jeppesen LB, 2009, RES POLICY, V38, P1582, DOI 10.1016/j.respol.2009.09.002; Schreier M, 2008, J PROD INNOVAT MANAG, V25, P331, DOI 10.1111/j.1540-5885.2008.00305.x; Roehrich G, 2004, J BUS RES, V57, P671, DOI 10.1016/S0148-2963(02)00311-9; Iyengar R, 2011, MARKET SCI, V30, P195, DOI 10.1287/mksc.1100.0566; CHAO GT, 1994, J APPL PSYCHOL, V79, P730, DOI 10.1037//0021-9010.79.5.730; Harrison SH, 2011, ORGAN SCI, V22, P391, DOI 10.1287/orsc.1100.0538; Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373; Santos FA, 2005, ORGAN SCI, V16, P491, DOI 10.1287/orsc.1050.0152; Spann M, 2009, J PROD INNOVAT MANAG, V26, P322; Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9101.88.5.879; Morrison PD, 2000, MANAGE SCI, V46, P1513, DOI 10.1287/mnsc.46.12.1513.12076; Hair JF, 2012, J ACAD MARKET SCI, V40, P414, DOI 10.1007/s11747-011-0261-6; Dahlander L, 2005, RES POLICY, V34, P481, DOI 10.1016/j.respol.2005.02.003; BARRETTLENNARD GT, 1981, J COUNS PSYCHOL, V28, P91, DOI 10.1037//0022-0167.28.2.91; Chin Wynne W., 1998, MODERN METHODS BUSIN, P295; Comer L.B., 1999, J PERSONAL SELLING S, V19, P15; Flynn L. R., 1996, J ACAD MARKET SCI, V24, P137, DOI DOI 10.1177/0092070396242004; GATIGNON H, 1985, J CONSUM RES, V11, P849, DOI 10.1086/209021; Goldsmith R. E., 1991, J ACAD MARKET SCI, V19, P209, DOI DOI 10.1007/BF02726497; Hair J. F., 2011, J MARKETING THEORY P, V19, P139, DOI DOI 10.2753/MTP1069-6679190202; Haldin-Herrgard T., 2000, J INTELLECTUAL CAPIT, V1, P357, DOI 10.1108/14691930010359252; Hennig-Thurau T., 2003, J RELATIONSHIP MARKE, V2, P23, DOI 10.1300/J366v02n01_03; Herche J., 1996, J ACAD MARKET SCI, V24, P366, DOI DOI 10.1177/0092070396244007; Herstatt C., REVOLUTIONIZING INNO; HIRSCHMAN EC, 1980, J CONSUM RES, V7, P283, DOI 10.1086/208816; Im S, 2007, J ACAD MARKET SCI, V35, P63, DOI 10.1007/s11747-006-0007-z; Jacoby J., 1972, ADV CONSUM RES, P382; KATZ E, 1957, PUBLIC OPIN QUART, V21, P61, DOI 10.1086/266687; KRATZER J., 2008, CREATIVITY INNOVATIO, V17, P26, DOI 10.1111/j.1467-8691.2008.00466.x; LEONARDBARTON D, 1992, STRATEGIC MANAGE J, V13, P111, DOI 10.1002/smj.4250131009; Mahr D., 2011, RES POLICY, V41, P167; Nooteboom B., 2000, J MANAGEMENT GOVERNA, V4, P69, DOI 10.1023/A:1009941416749; Ozer M, 1999, J PROD INNOVAT MANAG, V16, P77, DOI 10.1016/S0737-6782(98)00037-X; PETERSON RA, 1994, J CONSUM RES, V21, P381, DOI 10.1086/209405; Rogers E., 2003, DIFFUSION INNOVATION; Schweisfurth TG, 2016, R&D MANAGE, V46, P107, DOI 10.1111/radm.12103; Schweisfurth TG, 2015, RES POLICY, V44, P168, DOI 10.1016/j.respol.2014.09.007; Sharma A, 2001, J BUS RES, V54, P125, DOI 10.1016/S0148-2963(99)00090-9; Simbeck K., 2013, SOCIAL NETWORKING, V2, P9; URBAN GL, 1988, MANAGE SCI, V34, P569, DOI 10.1287/mnsc.34.5.569; VONHIPPEL E, 1994, MANAGE SCI, V40, P429, DOI 10.1287/mnsc.40.4.429	77	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0963-1690	1467-8691		CREAT INNOV MANAG	Creat. Innov. Manag.	MAR	2015	24	1					151	168		10.1111/caim.12106		18	Management	Business & Economics	CC3VL	WOS:000350278600011		
J	Nishimoto, T; Furuta, M; Kataoka, M; Kishida, M				Nishimoto, Takuto; Furuta, Masakazu; Kataoka, Michihiko; Kishida, Masao			Important Role of Catalase in the Cellular Response of the Budding Yeast Saccharomyces cerevisiae Exposed to Ionizing Radiation	CURRENT MICROBIOLOGY			English	Article							OXIDATIVE STRESS; CELLS; OVEREXPRESSION	Ionizing radiation indirectly causes oxidative stress in cells via reactive oxygen species (ROS), such as hydroxyl radicals (OH-) generated by the radiolysis of water. We investigated how the catalase function was affected by ionizing radiation and analyzed the phenotype of mutants with a disrupted catalase gene in Saccharomyces cerevisiae exposed to radiation. The wild-type yeast strain and isogenic mutants with disrupted catalase genes were exposed to various doses of Co-60 gamma-rays. There was no difference between the wild-type strain and the cta1 disruption mutant following exposure to gamma-ray irradiation. In contrast, there was a significant decrease in the ctt1 disruption mutant, suggesting that this strain exhibited decreased survival on gamma-ray exposure compared with other strains. In all three strains, stationary phase cells were more tolerant to the exposure of gamma-rays than exponential phase cells, whereas the catalase activity in the wild-type strain and cta1 disruption mutant was higher in the stationary phase than in the exponential phase. These data suggest a correlation between catalase activity and survival following gamma-ray exposure. However, this correlation was not clear in the ctt1 disruption mutant, suggesting that other factors are involved in the tolerance to ROS induced by irradiation.	[Nishimoto, Takuto; Kataoka, Michihiko; Kishida, Masao] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Div Appl Life Sci, Naka Ku, Sakai, Osaka 5998531, Japan; [Furuta, Masakazu] Osaka Prefecture Univ, Grad Sch Technol, Dept Quantum & Radiat, Naka Ku, Sakai, Osaka 5998531, Japan	Kishida, M (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Div Appl Life Sci, Naka Ku, 1-1 Gakuen Cho, Sakai, Osaka 5998531, Japan.	masyksd@biochem.osakafu-u.ac.jp	Kataoka, Michihiko/E-5847-2011				Amari F, 2008, J AGR FOOD CHEM, V56, P11740, DOI 10.1021/jf802829r; Akada R, 1997, MOL GEN GENET, V254, P267; Herrero E, 2008, BBA-GEN SUBJECTS, V1780, P1217, DOI 10.1016/j.bbagen.2007.12.004; Lu J, 2014, FREE RADICAL BIO MED, V66, P75, DOI 10.1016/j.freeradbiomed.2013.07.036; BEERS RF, 1952, J BIOL CHEM, V195, P133; Abbott DA, 2009, APPL ENVIRON MICROB, V75, P2320, DOI 10.1128/AEM.00009-09; Mate MJ, 1999, J MOL BIOL, V286, P135, DOI 10.1006/jmbi.1998.2453; Rowe LA, 2012, MECH AGEING DEV, V133, P147, DOI 10.1016/j.mad.2012.03.009; ITO H, 1983, J BACTERIOL, V153, P163; Charles JS, 2012, GENETICS, V190, P1267; Lacerda CMD, 2011, MYCOPATHOLOGIA, V171, P395, DOI 10.1007/s11046-011-9395-9; Lee JH, 2001, BBA-GEN SUBJECTS, V1526, P191, DOI 10.1016/S0304-4165(01)00126-X; Lee SM, 1998, BBA-PROTEIN STRUCT M, V1382, P167, DOI 10.1016/S0167-4838(97)00172-6; Petrova VY, 2004, BIOCHEM J, V380, P393, DOI 10.1042/BJ20040042; Ross SJ, 2000, MOL BIOL CELL, V11, P2631; Sasano Y, 2012, J BIOSCI BIOENG, V113, P451, DOI 10.1016/j.jbiosc.2011.11.017; Shingo I, 1996, BIOCHEM J, V320, P61; SPEVAK W, 1983, MOL CELL BIOL, V3, P1545; ZIMNIAK P, 1976, EUR J BIOCHEM, V71, P393, DOI 10.1111/j.1432-1033.1976.tb11126.x	19	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0343-8651	1432-0991		CURR MICROBIOL	Curr. Microbiol.	MAR	2015	70	3					404	407		10.1007/s00284-014-0733-2		4	Microbiology	Microbiology	CC3IO	WOS:000350240600014		
J	Suzuki, K; Miyamoto, M; Miyamoto, T; Hirata, K				Suzuki, Keisuke; Miyamoto, Masayuki; Miyamoto, Tomoyuki; Hirata, Koichi			Parkinson's Disease and Sleep/Wake Disturbances	CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS			English	Review						Parkinson's disease; Insomnia; Excessive daytime sleepiness; Restless legs syndrome; Rapid eye movement sleep behavior disorder; Sleep apnea syndrome	EYE-MOVEMENT SLEEP; RESTLESS LEGS SYNDROME; EXCESSIVE DAYTIME SLEEPINESS; QUALITY-OF-LIFE; DISORDER SCREENING QUESTIONNAIRE; BEHAVIOR DISORDER; REM-SLEEP; NEURODEGENERATIVE DISEASE; NONMOTOR SYMPTOMS; JAPANESE PATIENTS	Sleep disturbances are a common non-motor feature in patients with Parkinson's disease (PD). Early diagnosis and appropriate management are imperative for enhancing patient quality of life. Sleep disturbances can be caused by multiple factors in addition to age-related changes in sleep, such as nocturnal motor symptoms (rigidity, resting tremor, akinesia, tardive dyskinesia, and the "wearing off" phenomenon), non-motor symptoms (pain, hallucination, and psychosis), nocturia, and medication. Disease-related pathology involving the brainstem and changes in the neurotransmitter systems (norepinephrine, serotonin, and acetylcholine) responsible for regulating sleep structure and the sleep/wake cycle play a role in emerging excessive daytime sleepiness and sleep disturbances. Additionally, screening for sleep apnea syndrome, rapid eye movement sleep behavior disorder, and restless legs syndrome is clinically important. Questionnaire-based assessment utilizing the PD Sleep Scale-2 is useful for screening PD-related nocturnal symptoms. In this review, we focus on the current understanding and management of sleep disturbances in PD.	[Suzuki, Keisuke; Miyamoto, Masayuki; Hirata, Koichi] Dokkyo Med Univ, Dept Neurol, Shimotsuga, Tochigi 3210293, Japan; [Miyamoto, Masayuki] Dokkyo Med Univ, Sch Nursing, Shimotsuga, Tochigi 3210293, Japan; [Miyamoto, Tomoyuki] Dokkyo Med Univ, Koshigaya Hosp, Dept Neurol, Saitama, Japan	Suzuki, K (reprint author), Dokkyo Med Univ, Dept Neurol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan.	keisuke@dokkyomed.ac.jp					American Academy of Sleep Medicine, 2014, AASM MAN SCOR SLEEP; American Academy of Sleep Medicine, 2014, INT CLASS SLEEP DIS; Trenkwalder C, 2011, MOVEMENT DISORD, V26, P90, DOI 10.1002/mds.23441; Chaudhuri KR, 2002, J NEUROL NEUROSUR PS, V73, P629, DOI 10.1136/jnnp.73.6.629; Thannickal TC, 2007, BRAIN, V130, P1586, DOI 10.1093/brain/awm097; Miyamoto T, 2009, SLEEP MED, V10, P1151, DOI 10.1016/j.sleep.2009.05.007; Maria B, 2003, RESP MED, V97, P1151, DOI 10.1016/S0954-6111(03)00188-4; Ondo WG, 2002, ARCH NEUROL-CHICAGO, V59, P421, DOI 10.1001/archneur.59.3.421; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; Ondo WG, 2001, NEUROLOGY, V57, P1392; Boeve BF, 2011, SLEEP MED, V12, P445, DOI 10.1016/j.sleep.2010.12.009; Neikrug AB, 2014, SLEEP MED, V15, P959, DOI 10.1016/j.sleep.2014.04.009; Avidan A, 2013, J NEUROPSYCH CLIN N, V25, P319, DOI 10.1176/appi.neuropsych.12070175; Stiasny-Kolster K, 2007, MOVEMENT DISORD, V22, P2386, DOI 10.1002/mds.21740; Postuma RB, 2012, NEUROLOGY, V79, P428, DOI 10.1212/WNL.0b013e31825dd383; Dhawan V, 2006, J NEUROL SCI, V248, P158, DOI 10.1016/j.jns.2006.05.004; Murray ME, 2013, NEUROLOGY, V81, P1681, DOI 10.1212/01.wnl.0000435299.57153.f0; Diederich NJ, 2005, MOVEMENT DISORD, V20, P1413, DOI 10.1002/mds.20624; Schenck CH, 1996, NEUROLOGY, V46, P388; Trenkwalder C, 2011, MOVEMENT DISORD, V26, P644, DOI 10.1002/mds.23476; Postuma RB, 2010, MOVEMENT DISORD, V25, P2304, DOI 10.1002/mds.23347; Miyamoto T, 2006, NEUROLOGY, V67, P2236, DOI 10.1212/01.wnl.0000249313.25627.2e; Schmidauer C, 2005, ANN NEUROL, V58, P630, DOI 10.1002/ana.20572; da Silva FP, 2014, SLEEP MED REV, V18, P173, DOI 10.1016/j.smrv.2013.04.005; Postuma RB, 2012, MOVEMENT DISORD, V27, P720, DOI 10.1002/mds.24939; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Boeve BF, 2013, SLEEP MED, V14, P754, DOI 10.1016/j.sleep.2012.10.015; Sixel-Doring F, 2011, NEUROLOGY, V77, P1048, DOI 10.1212/WNL.0b013e31822e560e; Garcia-Lorenzo D, 2013, BRAIN, V136, P2120, DOI 10.1093/brain/awt152; Krishnan PR, 2003, MOVEMENT DISORD, V18, P181, DOI 10.1002/mds.10307; Wong JC, 2014, SLEEP, V37, P369, DOI 10.5665/sleep.3416; Trotti LM, 2010, MOVEMENT DISORD, V25, P2246, DOI 10.1002/mds.23231; Rolinski M, 2014, J NEUROL NEUROSUR PS, V85, P560, DOI 10.1136/jnnp-2013-306104; Plomhause L, 2013, SLEEP MED, V14, P1035, DOI 10.1016/j.sleep.2013.04.018; Postuma RB, 2008, J NEUROL NEUROSUR PS, V79, P1117, DOI 10.1136/jnnp.2008.149195; Postuma RB, 2009, BRAIN, V132, P3298, DOI 10.1093/brain/awp244; Arnulf I, 2002, NEUROLOGY, V58, P1019; Lee JE, 2009, MOVEMENT DISORD, V24, P579, DOI 10.1002/mds.22410; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Iranzo A, 2010, LANCET NEUROL, V9, P1070, DOI 10.1016/S1474-4422(10)70216-7; Valko PO, 2012, PARKINSONISM RELAT D, V18, P525, DOI 10.1016/j.parkreldis.2012.01.023; Nomura T, 2006, MOVEMENT DISORD, V21, P380, DOI 10.1002/mds.20734; Buskova J, 2011, J NEUROL, V258, P2254, DOI 10.1007/s00415-011-6109-7; Shin HY, 2013, PARKINSONISM RELAT D, V19, P355, DOI 10.1016/j.parkreldis.2012.09.009; Nomura T, 2013, J NEUROL SCI, V327, P22, DOI 10.1016/j.jns.2013.01.036; Kumar S, 2002, MOVEMENT DISORD, V17, P775, DOI 10.1002/mds.10167; SCHENCK CH, 1986, SLEEP, V9, P293; De Cock VC, 2010, SLEEP MED, V11, P247, DOI 10.1016/j.sleep.2009.05.008; Braga-Neto P, 2004, J NEUROL SCI, V217, P41, DOI 10.1016/j.jns.2003.08.010; Gagnon JF, 2009, ANN NEUROL, V66, P39, DOI 10.1002/ana.21680; Boeve BF, 2010, ANN NY ACAD SCI, V1184, P15, DOI 10.1111/j.1749-6632.2009.05115.x; Fronczek R, 2007, BRAIN, V130, P1577, DOI 10.1093/brain/awm090; Tandberg E, 1998, MOVEMENT DISORD, V13, P895, DOI 10.1002/mds.870130606; Moller JC, 2010, J NEUROL SCI, V289, P135, DOI 10.1016/j.jns.2009.08.035; Arnulf I, 2012, MOVEMENT DISORD, V27, P677, DOI 10.1002/mds.24957; Frauscher B, 2014, NEUROLOGY, V82, P1076, DOI 10.1212/WNL.0000000000000247; Gjerstad MD, 2011, NEUROLOGY, V77, P1941, DOI 10.1212/WNL.0b013e31823a0cc8; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Overeem S, 2002, CURR OPIN NEUROL, V15, P739, DOI 10.1097/01.wco.0000044800.53746.5a; Postuma RB, 2012, BRAIN, V135, P1860, DOI 10.1093/brain/aws093; Chaudhuri KR, 2010, MOVEMENT DISORD, V25, P704, DOI 10.1002/mds.22868; Schenck CH, 2013, SLEEP MED, V14, P744, DOI 10.1016/j.sleep.2012.10.009; Postuma RB, 2010, NEUROLOGY, V74, P239, DOI 10.1212/WNL.0b013e3181ca0166; Angelini M, 2011, J NEUROL SCI, V310, P286, DOI 10.1016/j.jns.2011.08.012; Peeraully T, 2012, MOVEMENT DISORD, V27, P1729, DOI 10.1002/mds.25197; Kim YE, 2014, J PARKINSON DIS, V4, P237, DOI 10.3233/JPD-130293; Tandberg E, 1999, MOVEMENT DISORD, V14, P922, DOI 10.1002/1531-8257(199911)14:6<922::AID-MDS1003>3.0.CO;2-7; Mahale R, 2014, SLEEP MED, V15, P642, DOI 10.1016/j.sleep.2014.01.022; Gjerstad MD, 2006, NEUROLOGY, V67, P853, DOI 10.1212/01.wnl.0000233980.25978.9d; Diederich NJ, 2012, J NEUROL SCI, V314, P12, DOI 10.1016/j.jns.2011.10.025; Duncan GW, 2014, MOVEMENT DISORD, V29, P195, DOI 10.1002/mds.25664; Hobson DE, 2002, JAMA-J AM MED ASSOC, V287, P455, DOI 10.1001/jama.287.4.455; Peralta CM, 2009, MOVEMENT DISORD, V24, P2076, DOI 10.1002/mds.22694; Iranzo A, 2005, SLEEP, V28, P203; Iranzo A, 2007, MOVEMENT DISORD, V22, pS424, DOI 10.1002/mds.21600; Arnulf Isabelle, 2009, Parkinsonism Relat Disord, V15 Suppl 3, pS101, DOI 10.1016/S1353-8020(09)70792-8; Bliwise DL, 2012, MOVEMENT DISORD, V27, P1118, DOI 10.1002/mds.25082; Bolitho SJ, 2014, MOVEMENT DISORD, V29, P736, DOI 10.1002/mds.25832; Bugalho P, 2013, PARKINSONISM RELAT D, V19, P1084, DOI 10.1016/j.parkreldis.2013.07.017; Ohayon MM, 1997, J CLIN PSYCHIAT, V58, P369; Chaudhuri K Ray, 2009, Parkinsonism Relat Disord, V15 Suppl 4, pS101, DOI 10.1016/S1353-8020(09)70845-4; Compta Y, 2009, BRAIN, V132, P3308, DOI 10.1093/brain/awp263; Dauvilliers Y, 2013, NEUROLOGY, V80, P2233, DOI 10.1212/WNL.0b013e318296e967; De Cock VC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107278; Diederich NJ, 2003, SLEEP MOVEMENT DISOR, P478; Erro R, 2012, J NEUROL, V259, P1808, DOI 10.1007/s00415-011-6407-0; Frauscher B, 2012, MOVEMENT DISORD, V27, P1673, DOI 10.1002/mds.25223; Gagnon Jean-François, 2012, Front Neurol, V3, P82, DOI 10.3389/fneur.2012.00082; Gong Y, 2014, SLEEP MED, V15, P647, DOI 10.1016/j.sleep.2013.12.021; Hogl B, 2011, MOVEMENT DISORD, V25, P2704, DOI DOI 10.1002/MDS.23190; Iranzo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089741; Iwanami M, 2010, SLEEP MED, V11, P361, DOI 10.1016/j.sleep.2009.12.006; Kaynak D, 2005, EUR J NEUROL, V12, P199, DOI 10.1111/j.1468-1331.2004.00971.x; LEES AJ, 1988, CLIN NEUROPHARMACOL, V11, P512, DOI 10.1097/00002826-198812000-00004; Li SX, 2010, SLEEP MED, V11, P43, DOI 10.1016/j.sleep.2009.06.008; McDade EM, 2013, MOVEMENT DISORD, V28, P1847, DOI 10.1002/mds.25653; Miyamoto T, 2011, PARKINSONISM RELAT D, V17, P219, DOI 10.1016/j.parkreldis.2010.11.020; Miyamoto T, 2010, SLEEP MED, V11, P100, DOI 10.1016/j.sleep.2009.05.006; Neikrug AB, 2013, J CLIN SLEEP MED, V9, P1119, DOI 10.5664/jcsm.3148; Neikrug AB, 2014, SLEEP, V37, P177, DOI 10.5665/sleep.3332; Nihei Y, 2012, J NEUROL, V259, P1606, DOI 10.1007/s00415-011-6386-1; Nomura T, 2010, PARKINSONISM RELAT D, V16, P683, DOI 10.1016/j.parkreldis.2010.08.011; Ohayon MM, 1997, J CLIN PSYCHIAT, V58, P77; Ondo WG, 2014, J NEURAL TRANSM, V121, pS3, DOI 10.1007/s00702-014-1239-6; Postuma RB, 2008, MOVEMENT DISORD, V23, P1665, DOI 10.1002/mds.22099; Rissling I, 2006, SLEEP, V29, P108; Sixel-Doring F, 2011, J CLIN SLEEP MED, V7, P75; Suzuki K, 2013, INTERNAL MED, V52, P863, DOI 10.2169/internalmedicine.52.9083; Suzuki K, 2014, SLEEP DISTURBANCES P, DOI [10.5772/57320, DOI 10.5772/57320]; Suzuki K, 2008, J NEUROL SCI, V271, P47, DOI 10.1016/j.jns.2008.03.008; Suzuki K, 2007, MOVEMENT DISORD, V22, P1245, DOI 10.1002/mds.21257; Suzuki K, 2012, J NEUROL SCI, V318, P76, DOI 10.1016/j.jns.2012.03.022; Suzuki K, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-18; Tan EK, 2002, NEUROLOGY, V58, P465; Trenkwalder C, 2010, PARKINSONISM, P980; TROTTI LM, 2014, J AM SOC EXP NEUROTH, V11, P68, DOI DOI 10.1007/S13311-013-0236-Z; van Guist MM, 2013, PARKINSONISM RELAT D, V19, P654, DOI 10.1016/j.parkreldis.2013.03.014; Yasui K, 2006, J NEUROL SCI, V250, P120, DOI 10.1016/j.jns.2006.08.004; Yong MH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022511	119	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1528-4042	1534-6293		CURR NEUROL NEUROSCI	Curr. Neurol. Neurosci. Rep.	MAR	2015	15	3							8	10.1007/s11910-015-0525-5		11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CC3GL	WOS:000350234600007		
J	Miao, GX; Hayashi, S				Miao, Guangxia; Hayashi, Shigeo			Manipulation of Gene Expression by Infrared Laser Heat Shock and Its Application to the Study of Tracheal Development in Drosophila	DEVELOPMENTAL DYNAMICS			English	Article						Drosophila; heat shock promoter; infrared laser; FGF signaling; trachea	TARGETED SINGLE CELLS; LONG-RANGE ACTION; MORPHOGEN GRADIENT; GLIAL-CELLS; FGF; SYSTEM; INDUCTION; BREATHLESS; PHENOTYPES; ZEBRAFISH	Background:Induction of gene expression in a specific cell and a defined time window is desirable to investigate gene function at the cellular level during morphogenesis. To achieve this, we attempted to introduce the infrared laser-evoked gene operator system (IR-LEGO, Kamei et al., 2009) in the Drosophila embryo. In this technique, infrared laser light illumination induces genes to be expressed under the control of heat shock promoters at the single cell level. Results: We applied IR-LEGO to a transgenic fly stock, HS-eGFP, in which the enhanced green fluorescent protein (eGFP) gene is placed under the control of heat shock protein 70 promoter, and showed that eGFP expression can be induced in single cells within 1-2 hr after IR illumination. Furthermore, induction of HS-Branchless transgene encoding the Drosophila fibroblast growth factor (FGF) effectively altered the migration and branching patterns of the tracheal system. Conclusions: Our results indicated that IR-LEGO is a promising choice for the timely control of gene expression in a small group of cells in the Drosophila embryo. By using IR-LEGO, we further demonstrated that the tracheal terminal branching program is sensitive to localized expression of exogenous FGF. Developmental Dynamics 244:479-487, 2015. (c) 2014 Wiley Periodicals, Inc.	[Miao, Guangxia; Hayashi, Shigeo] RIKEN Ctr Dev Biol, Lab Morphogenet Signaling, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Miao, Guangxia; Hayashi, Shigeo] Kobe Univ, Grad Sch Sci, Dept Biol, Nada Ku, Kobe, Hyogo 657, Japan	Hayashi, S (reprint author), RIKEN Ctr Dev Biol, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	shayashi@cdb.riken.jp			RIKEN International Program Associate Program; MEXT Japan	We thank Shin Takagi (Nagoya University) for introducing the technique of IR-LEGO; Yasuhiro Kamei (National Institute of Basic Biology) and members of Hayashi lab for critical comments on the manuscript; Makoto Sato (University of Kanazawa), Markus Affolter (University of Basel), and Bloomington Stock Center for generously providing reagents and fly stocks. G.M. is supported by the RIKEN International Program Associate Program. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas from MEXT Japan to S.H.	McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; BRAND AH, 1993, DEVELOPMENT, V118, P401; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Kamei Y, 2009, NAT METHODS, V6, P79, DOI [10.1038/nmeth.1278, 10.1038/NMETH.1278]; Sato M, 2002, DEV CELL, V3, P195, DOI 10.1016/S1534-5807(02)00202-2; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Deisseroth K, 2006, J NEUROSCI, V26, P10380, DOI 10.1523/JNEUROSCI.3863-06.2006; Deguchi T, 2009, DEV GROWTH DIFFER, V51, P769, DOI 10.1111/j.1440-169X.2009.01135.x; Ito K, 1997, DEVELOPMENT, V124, P761; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Guillemin K, 1996, DEVELOPMENT, V122, P1353; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Kimura E, 2013, ARTERIOSCL THROM VAS, V33, P1264, DOI 10.1161/ATVBAHA.112.300602; Oshima K, 2006, CURR BIOL, V16, P1531, DOI 10.1016/j.cub.2006.06.032; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Ohshiro T, 2002, MECH DEVELOP, V114, P3, DOI 10.1016/S0925-4773(02)00042-4; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Dong B, 2014, DEVELOPMENT IN PRESS; Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Kato K, 2004, DEVELOPMENT, V131, P5253, DOI 10.1242/dev.01404; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; Suzuki M, 2013, DEV GROWTH DIFFER, V55, P454, DOI 10.1111/dgd.12061; Thummel CS, 1992, DROS INF SERV, V71, P150	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	MAR	2015	244	3			SI		479	487		10.1002/dvdy.24192		9	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	CC6MR	WOS:000350479700021		
J	Islam, MN; Itoh, S; Yanagita, T; Sumiyoshi, K; Hayano, S; Kuremoto, KI; Kurosaka, H; Honjo, T; Kawanabe, N; Kamioka, H; Sakai, T; Ishimaru, N; Taniuchi, I; Yamashiro, T				Islam, Md. Nurul; Itoh, Shinsuke; Yanagita, Takeshi; Sumiyoshi, Kumi; Hayano, Satoru; Kuremoto, Koh-Ichi; Kurosaka, Hiroshi; Honjo, Tadashi; Kawanabe, Noriaki; Kamioka, Hiroshi; Sakai, Takayoshi; Ishimaru, Naozumi; Taniuchi, Ichiro; Yamashiro, Takashi			Runx/Cbfb Signaling Regulates Postnatal Development of Granular Convoluted Tubule in the Mouse Submandibular Gland	DEVELOPMENTAL DYNAMICS			English	Article						Cbfb; organogenesis; gland; craniofacial	BINDING-FACTOR BETA; SUBMAXILLARY-GLAND; SECRETORY ACTIVITY; SALIVARY-GLAND; LACRIMAL GLAND; RUNX3; DIFFERENTIATION; EXPRESSION; CELLS; ORGAN	Background:The rodent salivary gland is not fully developed at birth and the cellular definitive differentiation takes place postnatally. However, little is known about its molecular mechanism. Results:Here we provide the loss-of-function genetic evidence that Runx signaling affects postnatal development of the submandibular gland (SMG). Core binding factor (Cbfb) is a cotranscription factor which forms a heterodimer with Runx proteins. Cbfb was specifically expressed in the duct epithelium, specifically in the SMG. Epithelial Cbfb deficiency resulted in decrease in the size of the SMG and in the saliva secretion on postnatal day 35. The Cbfb mutant SMG specifically exhibited involution of the granular convoluted tubules (GCT), with a down-regulated expression of its marker genes, such as Klk1, Ngf, and Egf. The induction of GCT is under the control of androgens, and the Cbfb mutant SMG demonstrated down-regulated expression of Crisp3, an androgen-dependent transcript. Because the circulating testosterone or tissue dihydrotestosterone levels were not affected in the Cbfb mutants, it appears that Runx/Cbfb signaling regulate androgen receptor pathway, but does not affect the circulating testosterone levels or the enzymatic conversion to DHT. Conclusions:Runx signaling is important in the postnatal development of androgen-dependent GCT in the SMG. Developmental Dynamics 244:488-496, 2015. (c) 2014 Wiley Periodicals, Inc.	[Islam, Md. Nurul; Itoh, Shinsuke; Hayano, Satoru; Kurosaka, Hiroshi; Honjo, Tadashi; Kawanabe, Noriaki; Kamioka, Hiroshi; Yamashiro, Takashi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Orthodont Sci Funct Recovery & Reconstruct, Okayama 7008530, Japan; [Itoh, Shinsuke; Kurosaka, Hiroshi; Yamashiro, Takashi] Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Suita, Osaka 5650871, Japan; [Yanagita, Takeshi; Sumiyoshi, Kumi] Okayama Univ Hosp, Dept Orthodont, Okayama, Japan; [Kuremoto, Koh-Ichi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Adv Prosthodont, Hiroshima, Japan; [Sakai, Takayoshi] Osaka Univ, Grad Sch Dent, Dept Oral Facial Disorders, Osaka, Japan; [Ishimaru, Naozumi] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Oral Mol Pathol, Tokushima 770, Japan; [Taniuchi, Ichiro] RIKEN Res Ctr Allergy & Immunol, Lab Transcript Regulat, Yokohama, Kanagawa, Japan	Yamashiro, T (reprint author), Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, 1-8 Yamada Oka, Suita, Osaka 5650871, Japan.	yamashiro@dent.osaka-u.ac.jp			Japan Society for the Promotion of Science [24249093]	Grant sponsor: Japan Society for the Promotion of Science; Grant number: 24249093.	Rothova M, 2012, DEV DYNAM, V241, P1183, DOI 10.1002/dvdy.23804; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Sabbadini E, 1995, NEUROIMMUNOMODULAT, V2, P184, DOI 10.1159/000097197; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Voronov D, 2013, INVEST OPHTH VIS SCI, V54, P3115, DOI 10.1167/iovs.13-11791; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Tucker AS, 2007, SEMIN CELL DEV BIOL, V18, P237, DOI 10.1016/j.semcdb.2007.01.006; CARAMIA F, 1966, J ULTRA MOL STRUCT R, V16, P524, DOI 10.1016/S0022-5320(66)80004-7; CHABOT JG, 1987, CELL TISSUE RES, V248, P351; Chrétien M, 1977, Int Rev Cytol, V50, P333; GRESIK EW, 1994, MICROSC RES TECHNIQ, V27, P1, DOI 10.1002/jemt.1070270102; HAENDLER B, 1993, ENDOCRINOLOGY, V133, P192, DOI 10.1210/en.133.1.192; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Konttinen YT, 2010, ORAL DIS, V16, P577, DOI 10.1111/j.1601-0825.2010.01669.x; Kurosaka H, 2011, STEM CELLS, V29, P1792, DOI 10.1002/stem.722; MINETTI CASA, 1985, J BIOL BUCCALE, V13, P205; MIZUKI N, 1992, MOL CELL ENDOCRINOL, V89, P25, DOI 10.1016/0303-7207(92)90207-M; MUDD BD, 1975, J DENT RES, V54, P193, DOI 10.1177/00220345750540012601; Osorio KM, 2008, DEVELOPMENT, V135, P1059, DOI 10.1242/dev.012799; SCHWIDETZKY U, 1995, BIOCHEM J, V309, P831; Sullivan DA, 1996, ACTA OPHTHALMOL SCAN, V74, P421; Yamashiro T, 2002, MECH DEVELOP, V119, pS107, DOI 10.1016/S0925-4773(03)00101-1	31	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	MAR	2015	244	3			SI		488	496		10.1002/dvdy.24231		9	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	CC6MR	WOS:000350479700022		
J	Mimura, Y				Mimura, Yoshifumi			A PRIORI BOUNDS OF STATIONARY SOLUTIONS OF TWO DIMENSIONAL KELLER-SEGEL SYSTEM ON POLYGONAL DOMAINS	DIFFERENTIAL AND INTEGRAL EQUATIONS			English	Article							MODELING CHEMOTAXIS; BLOW-UP; BEHAVIOR	We consider a Neumann boundary problem like Ge Hand's problem on polygonal domains and prove that a priori bounds of solutions fail for specific parameters. The same results are already proved by Senba-Suzuki in 2000 when domains are open sets in R-2 with smooth boundaries. The novelty is that the foregoing specific parameters depend on angles of polygonal domains.	Tohoku Univ, Math Inst, Sendai, Miyagi 9808578, Japan	Mimura, Y (reprint author), Tohoku Univ, Math Inst, Sendai, Miyagi 9808578, Japan.						Horstmann D, 2001, EUR J APPL MATH, V12, P159; KELLER EF, 1970, J THEOR BIOL, V26, P399, DOI 10.1016/0022-5193(70)90092-5; BREZIS H, 1991, COMMUN PART DIFF EQ, V16, P1223, DOI 10.1080/03605309108820797; CHANG SYA, 1988, J DIFFER GEOM, V27, P259; Gajewski H, 1998, MATH NACHR, V195, P77, DOI 10.1002/mana.19981950106; BILER P., 1998, ADV MATH SCI APPL, V8, P715; BREZIS H, 1973, J MATH SOC JPN, V25, P565; Grisvard Pierre, 1985, ELLIPTIC PROBLEMS NO; Herrero MA, 1996, J MATH BIOL, V35, P177, DOI 10.1007/s002850050049; Horstmann D, 2001, NODEA-NONLINEAR DIFF, V8, P399, DOI 10.1007/PL00001455; Kabeya Y., 1998, RIMS KOKYUROKU, V1025, P44; LI YY, 1994, INDIANA U MATH J, V43, P1255, DOI 10.1512/iumj.1994.43.43054; Nagai T, 1997, FUNKC EKVACIOJ-SER I, V40, P411; Senba T., 2000, ADV MATH SCI APPL, V10, P191; Suzuki T., 2005, FREE ENERGY SELF INT; Wang G, 2002, MATH NACHR, V233, P221, DOI 10.1002/1522-2616(200201)233:1<221::AID-MANA221>3.3.CO;2-D	16	0	0	KHAYYAM PUBL CO INC	ATHENS	PO BOX 429, ATHENS, OH 45701 USA	0893-4983			DIFFER INTEGRAL EQU	Differ. Integral Equ.	MAR-APR	2015	28	3-4					347	360				14	Mathematics, Applied; Mathematics	Mathematics	CC3QS	WOS:000350264700009		
J	Herbst, S; Shah, A; Moya, MM; Marzola, V; Jensen, B; Reed, A; Birrell, MA; Saijo, S; Mostowy, S; Shaunak, S; Armstrong-James, D				Herbst, Susanne; Shah, Anand; Moya, Maria Mazon; Marzola, Vanessa; Jensen, Barbara; Reed, Anna; Birrell, Mark A.; Saijo, Shinobu; Mostowy, Serge; Shaunak, Sunil; Armstrong-James, Darius			Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus	EMBO MOLECULAR MEDICINE			English	Article						aspergillus; calcineurin; phagocytosis; TLR9; transplant	SURVEILLANCE NETWORK TRANSNET; INVASIVE FUNGAL-INFECTIONS; BETA-GLUCAN RECEPTOR; TOLL-LIKE RECEPTORS; CANDIDA-ALBICANS; HOST-DEFENSE; TNF-ALPHA; TRANSPLANT RECIPIENTS; MURINE MACROPHAGES; HUMAN NEUTROPHILS	Transplant recipients on calcineurin inhibitors are at high risk of invasive fungal infection. Understanding how calcineurin inhibitors impair fungal immunity is a key priority for defining risk of infection. Here, we show that the calcineurin inhibitor tacrolimusimpairs clearance of the major mould pathogen Aspergillus fumigatus from the airway, by inhibiting macrophage inflammatory responses. This leads to defective early neutrophil recruitment and fungal clearance. We confirm these findings in zebrafish, showing an evolutionarily conserved role for calcineurin signalling in neutrophil recruitment during inflammation. We find that calcineurin-NFAT activation is phagocytosis dependent and collaborates with NF-B for TNF- production. For yeast zymosan particles, activation of macrophage calcineurin-NFAT occurs via the phagocytic Dectin-1-spleen tyrosine kinase pathway, but for A.fumigatus, activation occurs via a phagosomal TLR9-dependent and Bruton's tyrosine kinase-dependent signalling pathway that is independent of MyD88. We confirm the collaboration between NFAT and NF-B for TNF- production in primary alveolar macrophages. These observations identify inhibition of a newly discovered macrophage TLR9-BTK-calcineurin-NFAT signalling pathway as a key immune defect that leads to organ transplant-related invasive aspergillosis.	[Herbst, Susanne; Shah, Anand; Marzola, Vanessa; Jensen, Barbara; Shaunak, Sunil; Armstrong-James, Darius] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London, England; [Moya, Maria Mazon; Mostowy, Serge] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Mol Bacteriol & Infect, London, England; [Reed, Anna] Royal Brompton & Harefield Hosp, Lung Transplant Unit, London, England; [Birrell, Mark A.; Armstrong-James, Darius] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Saijo, Shinobu] Chiba Univ, Med Mycol Res Ctr, Chiba, Japan	Armstrong-James, D (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Immun, London, England.	d.armstrong@imperial.ac.uk			Medical Research Council (UK) [G0902260/1, MR/K002708/1]; Wellcome Trust Research Career Development Fellowship [WT097411MA]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College Academic Health Science Centre for Infectious Diseases	This work was supported by a Medical Research Council (UK) Clinician Scientist Fellowship to DAJ [G0902260/1]. AS is supported by a Medical Research Council (UK) Clinical Research Fellowship [MR/K002708/1]. Work in the SM laboratory is supported by a Wellcome Trust Research Career Development Fellowship [WT097411MA]. We are grateful to the patients of Harefield Hospital UK for kind consent to participate in this study. This project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and the Imperial College Academic Health Science Centre for Infectious Diseases. The views expressed in this publication are those of the authors and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health. We are indebted to David Gray (University of Edinburgh) for TLR9<SUP>-/-</SUP> knockout mice. We are also grateful for Myd88<SUP>-/-</SUP> mice from the Swiss Immunological Mouse Repository (SwImMR), Dectin-1<SUP>-/-</SUP> mice from Professor Yoichiro Iwakura from the University of Tokyo and Rag<SUP>-/-</SUP> mice from Professor Marina Botto at Imperial College London. I am grateful to David Holden for helpful scientific discussions.	Fung JJ, 2004, TRANSPLANTATION, V77, pS41, DOI 10.1097/01.TP.0000126926.61434.A5; Kubo T, 2009, J EXP MED, V206, P1971, DOI 10.1084/jem.20082392; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Schelenz S, 1999, MED MYCOL, V37, P183, DOI 10.1046/j.1365-280X.1999.00219.x; Liu XG, 2011, NAT IMMUNOL, V12, P416, DOI 10.1038/ni.2015; Stockhammer OW, 2009, J IMMUNOL, V182, P5641, DOI 10.4049/jimmunol.0900082; Yarilina A, 2011, P NATL ACAD SCI USA, V108, P1573, DOI 10.1073/pnas.1010030108; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Moalli F, 2010, BLOOD, V116, P5170, DOI 10.1182/blood-2009-12-258376; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Im SH, 2004, MOL CELLS, V18, P1; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Zanoni I, 2009, NATURE, V460, P264, DOI 10.1038/nature08118; Baddley JW, 2010, CLIN INFECT DIS, V50, P1559, DOI 10.1086/652768; Penninga L, 2010, EUR J CLIN PHARMACOL, V66, P1177, DOI 10.1007/s00228-010-0902-6; Werner JL, 2009, J IMMUNOL, V182, P4938, DOI 10.4049/jimmunol.0804250; Armstrong-James D, 2014, TRENDS MICROBIOL, V22, P120, DOI 10.1016/j.tim.2014.01.001; Yissachar N, 2013, MOL CELL, V49, P322, DOI 10.1016/j.molcel.2012.11.003; Wu ZL, 2013, J IMMUNOL, V191, P5885, DOI 10.4049/jimmunol.1301271; Carrion SD, 2013, J IMMUNOL, V191, P2581, DOI 10.4049/jimmunol.1300748; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Schelenz S, 2013, IMMUNOBIOLOGY, V218, P477, DOI 10.1016/j.imbio.2012.06.006; Kasperkovitz PV, 2010, J IMMUNOL, V185, P7614, DOI 10.4049/jimmunol.1002760; Luther K, 2007, CELL MICROBIOL, V9, P368, DOI 10.1111/j.1462-5822.2006.00796.x; Hemmi H, 2000, NATURE, V408, P740; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; Dennehy KM, 2008, EUR J IMMUNOL, V38, P500, DOI 10.1002/eji.200737741; Armstrong-James D, 2012, AM J TRANSPLANT, V12, P3437, DOI 10.1111/j.1600-6143.2012.04254.x; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; Serrano-Gomez D, 2005, IMMUNOBIOLOGY, V210, P175, DOI 10.1016/j.imbio.2005.05.011; Greenblatt MB, 2010, J EXP MED, V207, P923, DOI 10.1084/jem.20092531; Zaslavsky A, 2013, BLOOD, V121, P3205, DOI 10.1182/blood-2012-04-421172; Pappas PG, 2010, CLIN INFECT DIS, V50, P1101, DOI 10.1086/651262; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Lee YH, 2010, SCAND J RHEUMATOL, V39, P271, DOI 10.3109/03009740903501642; Madan T, 1997, INFECT IMMUN, V65, P3171; Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P1037, DOI 10.1167/iovs.07-1279; Rosas M, 2008, J IMMUNOL, V181, P3549; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Kontoyiannis DP, 2010, CLIN INFECT DIS, V50, P1091, DOI 10.1086/651263; Lee BL, 2014, TRENDS CELL BIOL, V24, P360, DOI 10.1016/j.tcb.2013.12.002; Oum JH, 2002, MOL CELLS, V13, P77; Henry KM, 2013, J LEUKOCYTE BIOL, V94, P633, DOI 10.1189/jlb.1112594; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Herbst S, 2013, DIS MODEL MECH, V6, P643, DOI 10.1242/dmm.010330; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Fisher MC, 2012, NATURE, V484, P186, DOI 10.1038/nature10947; Goodridge HS, 2007, J IMMUNOL, V178, P3107; Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965; Renshaw SA, 2006, BLOOD, V108, P3976, DOI 10.1182/blood-2006-05-024075; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Mehrad B, 1999, J IMMUNOL, V162, P1633; Ramirez-Ortiz ZG, 2008, INFECT IMMUN, V76, P2123, DOI 10.1128/IAI.00047-08; Ifrim DC, 2013, J IMMUNOL, V190, P4129, DOI 10.4049/jimmunol.1202611; Antony P, 2004, BIOCHEM SOC T, V32, P113, DOI 10.1042/BST0320113; Armstrong-James D, 2012, CURR OPIN MICROBIOL, V15, P434, DOI 10.1016/j.mib.2012.06.001; Eltom S, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0087-0; Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-42; Hasenberg M, 2011, INT J MED MICROBIOL, V301, P436, DOI 10.1016/j.ijmm.2011.04.012; Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030; Lougaris V, 2014, J ALLERGY CLIN IMMUN, V133, P1644, DOI 10.1016/j.jaci.2013.12.1085; Mostowy S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003588; Palha N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003619; Panther Franziska, 2009, Recent Pat Cardiovasc Drug Discov, V4, P180; Ramaprakash H, 2009, INFECT IMMUN, V77, P108, DOI 10.1128/IAI.00998-08; RICHARDSON MD, 1991, MYCOSES, V34, P141; Slesiona S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031223; Strijbis K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003446; Svensson A, 2011, CURR MED RES OPIN, V27, P1395, DOI 10.1185/03007995.2011.582483; Tourneur E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003152; Wagener J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004050; Zanoni I, 2012, J CLIN INVEST, V122, P1747, DOI 10.1172/JCI60688; Zeini M, 2009, DEVELOPMENT, V136, P3335, DOI 10.1242/dev.037903	76	7	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1757-4676	1757-4684		EMBO MOL MED	EMBO Mol. Med.	MAR	2015	7	3					240	258				19	Medicine, Research & Experimental	Research & Experimental Medicine	CD0MJ	WOS:000350767600002		
J	Saito, T; Fukushima, K; Umeki, K; Nakajima, K				Saito, Tomoya; Fukushima, Kazuko; Umeki, Kazunori; Nakajima, Kensuke			Severe Fever with Thrombocytopenia Syndrome in Japan and Public Health Communication	EMERGING INFECTIOUS DISEASES			English	Article								A fatal case of severe fever with thrombocytopenia syndrome was reported in Japan in 2013. The ensuing process of public communication offers lessons on how to balance public health needs with patient privacy and highlights the importance of multilateral collaborations between scientific and political communities.	[Saito, Tomoya; Fukushima, Kazuko; Umeki, Kazunori; Nakajima, Kensuke] Minist Hlth Labour & Welf, Hlth Serv Bur, Tokyo, Japan; [Saito, Tomoya] Natl Inst Publ Hlth, Saitama, Japan	Saito, T (reprint author), Natl Inst Publ Hlth, Dept Hlth Crisis Management, 2-3-6 Minami, Wako, Saitama 3510197, Japan.	tsaito@niph.go.jp		Saito, Tomoya/0000-0001-6250-4464			Takahashi T, 2014, J INFECT DIS, V209, P816, DOI 10.1093/infdis/jit603; Yu XJ, 2011, NEW ENGL J MED, V364, P1523, DOI 10.1056/NEJMoa1010095; Fukushi S, 2014, INFECT AGENTS SURVEI, V35, P40; Honma Y, 2013, INFECT AGENTS SURVEI, V34, P312; Inter-ministerial Pandemic and Avian Influenza Committee, 2013, GUID PAND NEW INF DI; Iuchi A, 2013, INFECT AGENTS SURVEI, V34, P207; Maeda K., 2014, KAGAKURYOUHOU NO RYO, V30, P291; Morikawa S, 2014, INFECT AGENTS SURVEI, V35, P75; Morikawa S, 2013, INFECT AGENTS SURVEI, V34, P303; National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division Ministry of Health Labour and Welfare, 2014, INFECT AGENTS SURVEI, V35, P31; Saijo M, 2013, INFECT AGENTS SURVEI, V34, P40; Saijo M, 2013, INFECT AGENTS SURVEI, V34, P108; Saijo M, 2013, INFECT AGENTS SURVEI, V34, P110; Takahashi T, 2013, INFECT AGENTS SURVEI, V34, P269; Tuberculosis and Infectious Disease Control Division Health Service Bureau Ministry of Health Labour and Welfare, 2004, SMALLP PREP GUID	15	1	2	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	MAR	2015	21	3					487	489		10.3201/eid2103.140831		3	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CC3SI	WOS:000350269300019		
J	Isozumi, R; Uemura, H; Kimata, I; Ichinose, Y; Logedi, J; Omar, AH; Kaneko, A				Isozumi, Rie; Uemura, Haruki; Kimata, Isao; Ichinose, Yoshio; Logedi, John; Omar, Ahmeddin H.; Kaneko, Akira			Novel Mutations in K13 Propeller Gene of Artemisinin-Resistant Plasmodium falciparum	EMERGING INFECTIOUS DISEASES			English	Article							MALARIA; CAMBODIA; KENYA	We looked for mutations in the Plasmodium falciparum K13 propeller gene of an artemisinin-resistant parasite on islands in Lake Victoria, Kenya, where transmission in 2012-2013 was high. The 4 new types of nonsynonymous, and 5 of synonymous, mutations we detected among 539 samples analyzed provide clues to understanding artemisinin-resistant parasites.	[Isozumi, Rie; Kimata, Isao; Kaneko, Akira] Osaka City Univ, Osaka 558, Japan; [Uemura, Haruki; Ichinose, Yoshio] Nagasaki Univ, Inst Trop Med, Nagasaki 852, Japan; [Logedi, John; Omar, Ahmeddin H.] Minist Publ Hlth & Sanitat, Nairobi, Kenya; [Kaneko, Akira] Karolinska Inst, Stockholm, Sweden	Isozumi, R (reprint author), Osaka City Univ, Dept Med, Osaka Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	wushiqilihui@hotmail.co.jp			Institute of Tropical Medicine [2013-A-7, 2014-A-18]; Japan Society for Promotion of Science [24390141, 26257504]; Health Labour Science Research Grant; Japanese Society for the Promotion of Science Core-to-Core Program B, Asia-Africa Science Platforms	This research was funded by the cooperative research grants (2013-A-7 and 2014-A-18) of the Institute of Tropical Medicine to R.I., Japan Society for Promotion of Science grants (24390141 and 26257504) to A.K., Health Labour Science Research Grant to A.K., and Japanese Society for the Promotion of Science Core-to-Core Program B, Asia-Africa Science Platforms to A.K.	Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876; Miotto O, 2013, NAT GENET, V45, P648, DOI 10.1038/ng.2624; O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4; Dondorp AM, 2011, NEW ENGL J MED, V365, P1073, DOI 10.1056/NEJMp1108322; Chang HH, 2013, P NATL ACAD SCI USA, V110, P20129, DOI 10.1073/pnas.1319857110; Flegg JA, 2013, AM J TROP MED HYG, V89, P857, DOI 10.4269/ajtmh.13-0129; Isozumi R, 2014, PARASITOL INT; Minakawa N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032725; Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011; Noor AM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-180; Plowe CV, 2014, NATURE, V505, P30, DOI 10.1038/nature12845; Sakihama N, 2001, EXP PARASITOL, V97, P50, DOI 10.1006/expr.2000.4591; Zhou GF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020318	14	5	5	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	MAR	2015	21	3					490	492		10.3201/eid2103.140898		3	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CC3SI	WOS:000350269300020		
J	Kutsuna, S; Kato, Y; Moi, ML; Kotaki, A; Ota, M; Shinohara, K; Kobayashi, T; Yamamoto, K; Fujiya, Y; Mawatari, M; Sato, T; Kunimatsu, J; Takeshita, N; Hayakawa, K; Kanagawa, S; Takasaki, T; Ohmagari, N				Kutsuna, Satoshi; Kato, Yasuyuki; Moi, Meng Ling; Kotaki, Akira; Ota, Masayuki; Shinohara, Koh; Kobayashi, Tetsuro; Yamamoto, Kei; Fujiya, Yoshihiro; Mawatari, Momoko; Sato, Tastuya; Kunimatsu, Junwa; Takeshita, Nozomi; Hayakawa, Kayoko; Kanagawa, Shuzo; Takasaki, Tomohiko; Ohmagari, Norio			Autochthonous Dengue Fever, Tokyo, Japan, 2014	EMERGING INFECTIOUS DISEASES			English	Article							MOSQUITO AEDES-ALBOPICTUS; INFECTION; INVASION; TRAVELER	After 70 years with no confirmed autochthonous cases of dengue fever in Japan, 19 cases were reported during August-September 2014. Dengue virus serotype 1 was detected in 18 patients. Phylogenetic analysis of the envelope protein genome sequence from 3 patients revealed 100% identity with the strain from the first patient (2014) in Japan.	[Kutsuna, Satoshi; Kato, Yasuyuki; Ota, Masayuki; Shinohara, Koh; Kobayashi, Tetsuro; Yamamoto, Kei; Fujiya, Yoshihiro; Mawatari, Momoko; Sato, Tastuya; Kunimatsu, Junwa; Takeshita, Nozomi; Hayakawa, Kayoko; Kanagawa, Shuzo; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Moi, Meng Ling; Kotaki, Akira; Takasaki, Tomohiko] Natl Inst Infect Dis, Tokyo, Japan	Kutsuna, S (reprint author), Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	sonare.since1192@gmail.com			Ministry of Health, Labour and Welfare, Japan [H24-shinkou-ippan-013, H26-shinkou-jitsuyouka-007]	This work was partly supported by funding from the Research on Emerging and Re-emerging Infectious Diseases grant by the Ministry of Health, Labour and Welfare, Japan (H24-shinkou-ippan-013 and H26-shinkou-jitsuyouka-007). The funders had no role in the study's design, data collection, data analysis, decision to publish, or preparation of the manuscript.	Effler PV, 2005, EMERG INFECT DIS, V11, P742; Kobayashi M, 2014, INT J INFECT DIS, V26, P135, DOI 10.1016/j.ijid.2014.06.005; Moi ML, 2011, J INFECT DIS, V203, P1405, DOI 10.1093/infdis/jir053; Xu GZ, 2007, AM J TROP MED HYG, V76, P1182; Sukehiro N, 2013, JPN J INFECT DIS, V66, P189; Arima Y, 2014, W PACIFIC SURVEILLAN, P5; Guzmán M G, 1987, Bull Pan Am Health Organ, V21, P270; Hotta Susumu, 1998, Medical Entomology and Zoology, V49, P267; Kojima G, 2014, EMERG INFECT DIS, V2015, P21; Ministry of Health Labour and Welfare of Japan, DENG FEV; MORI A, 1981, Tropical Medicine, V23, P79; Nihei N, 2014, GEOSPATIAL HEALTH, V8, P417; Schmidt-Chanasit J, 2014, EUROSURVEILLANCE, V19, P20681; Takasaki Tomohiko, 2011, Trop Med Health, V39, P13, DOI 10.2149/tmh.2011-S07; World Health Organization, 1997, DENG HAEM FEV DIAGN	15	2	2	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	MAR	2015	21	3					517	520		10.3201/eid2103.141662		4	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CC3SI	WOS:000350269300027		
J	Aung, WW; Okada, K; Na-Ubol, M; Natakuathung, W; Sandar, T; Oo, NAT; Aye, MM; Hamada, S				Aung, Wah Wah; Okada, Kazuhisa; Na-Ubol, Mathukorn; Natakuathung, Wirongrong; Sandar, Toe; Oo, Nan Aye Thidar; Aye, Mya Mya; Hamada, Shigeyuki			Cholera in Yangon, Myanmar, 2012-2013	EMERGING INFECTIOUS DISEASES			English	Letter							VIBRIO-CHOLERAE; COMPARATIVE GENOMICS; BANGLADESH		[Aung, Wah Wah; Oo, Nan Aye Thidar; Aye, Mya Mya] Minist Hlth, Dept Med Res Lower Myanmar, Yangon, Myanmar; [Okada, Kazuhisa; Na-Ubol, Mathukorn; Natakuathung, Wirongrong; Hamada, Shigeyuki] Thailand Japan Res Collaborat Ctr Emerging & Reem, Nonthaburi, Thailand; [Okada, Kazuhisa; Hamada, Shigeyuki] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan; [Sandar, Toe] Univ Med, Yangon, Myanmar	Okada, K (reprint author), Osaka Univ, Microbial Dis Res Inst, Osaka, Japan.	kazuhisa@biken.osaka-u.ac.jp					ALBERT MJ, 1993, LANCET, V342, P387; Stine OC, 2008, EMERG INFECT DIS, V14, P831, DOI 10.3201/eid1405.071116; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Bhattacharya T, 2006, ENVIRON MICROBIOL, V8, P526, DOI 10.1111/j.1462-2920.2005.00932.x; Reimer AR, 2011, EMERG INFECT DIS, V17, P2113, DOI 10.3201/eid1711.110794; Grim CJ, 2010, J BACTERIOL, V192, P3524, DOI 10.1128/JB.00040-10; Safa A, 2010, TRENDS MICROBIOL, V18, P46, DOI 10.1016/j.tim.2009.10.003; FUKUDA JM, 1995, J PEDIATR-US, V126, P882, DOI 10.1016/S0022-3476(95)70201-6; Okada K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030863; Than-Htain-Win, 2011, P S EFF ENV CHANG HL, P40	10	0	0	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	MAR	2015	21	3					543	544		10.3201/eid2103.141309		2	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CC3SI	WOS:000350269300038		
J	Okadera, T; Geng, Y; Fujita, T; Dong, HJ; Liu, Z; Yoshida, N; Kanazawa, T				Okadera, Tomohiro; Geng, Yong; Fujita, Tsuyoshi; Dong, Huijuan; Liu, Zhu; Yoshida, Noboru; Kanazawa, Takaaki			Evaluating the water footprint of the energy supply of Liaoning Province, China: A regional input-output analysis approach	ENERGY POLICY			English	Article						Water-energy nexus; Energy supply; Water footprint; Regional input-output approach; Liaoning Province; China	NUCLEAR-POWER-PLANT; VIRTUAL WATER; SCENARIO ANALYSIS; CONSUMPTION; RESOURCES; TRADE; BIOENERGY; IMPACT; FLOWS; NEXUS	Water and energy are important resources for regional economies and are inextricably and reciprocally linked. Global water and energy demand will increase significantly by 2030 while climate change will worsen water availability. Thus, it is important to ensure a sustainable energy supply despite the increasing severity of water resource constraints. Numerous studies have analyzed water requirements to produce energy from production perspectives. However, energy is generally supplied by both internal and external producers. Thus, it is necessary to consider the availability of water to produce energy from consumption perspectives also. We evaluate the water footprint of the energy supply of Liaoning Province, China. We apply the standard top-down approach using an input-output framework. We estimate the water footprint of the energy supply of Liaoning Province at 854 million m(3) in 2002, with 47% of water used for electricity and heating. Our results reveal that energy supply could depend on water resources in neighboring provinces; external producers met 80% of the water footprint of energy supply, although only 35% of energy supply was imported. If Liaoning Province decreased its external dependency, withdrawal of available water resources within the province would increase from 86% to 91%. To guarantee future regional energy security, it is important to manage water resources effectively through water-efficient electricity generation and by allocating water resources among sectors. (C) 2014 Elsevier Ltd. All rights reserved.	[Okadera, Tomohiro] Natl Inst Environm Studies, Ctr Reg Environm Res, Tsukuba, Ibaraki 3058506, Japan; [Dong, Huijuan; Liu, Zhu] Chinese Acad Sci, Inst Appl Ecol, Shenyang 110016, Liaoning, Peoples R China; [Fujita, Tsuyoshi; Dong, Huijuan] Natl Inst Environm Studies, Ctr Social Environm Res, Tsukuba, Ibaraki 3058506, Japan; [Yoshida, Noboru] Wakayama Univ, Fac Syst Engn, Wakayama 6408510, Japan; [Kanazawa, Takaaki] Wakayama Univ, Fac Econ, Wakayama 6408510, Japan; [Geng, Yong] Shanghai Jiao Tong Univ, Sch Environm Sci & Engn, Shanghai 200240, Peoples R China	Okadera, T (reprint author), Natl Inst Environm Studies, Ctr Reg Environm Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	okadera@nies.go.jp; ygeng@sjtu.edu.cn; fujita77@nies.go.jp; donghuijuan@iae.ac.cn; liuzhu@iae.ac.cn; yoshida@sys.wakayama-u.ac.jp; kanazawa@eco.wakayama-u.ac.jp			Environment Research and Technology Development Fund "Planning and evaluation system for resource circulation in Asian cities based on Japanese environmental technologies and policies" [K113002]; Natural Science Foundation of China [71325006, 713111101, 71033004, 71311140172]	This study was funded by the Environment Research and Technology Development Fund "Planning and evaluation system for resource circulation in Asian cities based on Japanese environmental technologies and policies" (K113002) and Natural Science Foundation of China (71325006, 713111101, 71033004 and 71311140172).	Allan J.A., 1997, VIRTUAL WATER LONG T; Cazcarro I, 2011, ECON SYST RES, V23, P409, DOI 10.1080/09535314.2011.611794; Oki T, 2004, WATER SCI TECHNOL, V49, P203; Ma J, 2006, PHILOS T R SOC B, V361, P835, DOI 10.1098/rstb.2005.1644; Carrillo AMR, 2009, ENERG POLICY, V37, P4303, DOI 10.1016/j.enpol.2009.05.074; Rijsberman FR, 2006, AGR WATER MANAGE, V80, P5, DOI 10.1016/j.agwat.2005.07.001; Hubacek K, 2005, J IND ECOL, V9, P187, DOI 10.1162/1088198054084572; Zhao X, 2009, ECOL MODEL, V220, P245, DOI 10.1016/j.ecolmodel.2008.09.016; Hubacek K, 2009, J CLEAN PROD, V17, P1241, DOI 10.1016/j.jclepro.2009.03.011; Ridoutt BG, 2010, GLOBAL ENVIRON CHANG, V20, P113, DOI 10.1016/j.gloenvcha.2009.08.003; Peters GP, 2008, ECOL ECON, V65, P13, DOI 10.1016/j.ecolecon.2007.10.014; Stone KC, 2010, BIORESOURCE TECHNOL, V101, P2014, DOI 10.1016/j.biortech.2009.10.037; Gerbens-Leenes PW, 2009, ECOL ECON, V68, P1052, DOI 10.1016/j.ecolecon.2008.07.013; Chapagain AM, 2011, ECOL ECON, V70, P749, DOI 10.1016/j.ecolecon.2010.11.012; Siddiqi A, 2011, ENERG POLICY, V39, P4529, DOI 10.1016/j.enpol.2011.04.023; Gheewala SH, 2011, BIOFUEL BIOPROD BIOR, V5, P353, DOI 10.1002/bbb.295; King CW, 2008, ENVIRON SCI TECHNOL, V42, P7866, DOI 10.1021/es800367m; Pfister S, 2009, ENVIRON SCI TECHNOL, V43, P4098, DOI 10.1021/es802423e; Zhang ZY, 2011, ECON SYST RES, V23, P431, DOI 10.1080/09535314.2011.636733; Feng KS, 2011, ECON SYST RES, V23, P371, DOI 10.1080/09535314.2011.638276; Allan JA, 1998, GROUND WATER, V36, P545, DOI 10.1111/j.1745-6584.1998.tb02825.x; GLEICK PH, 1994, ANNU REV ENERG ENV, V19, P267; Gerbens-Leenes W, 2009, P NATL ACAD SCI USA, V106, P10219, DOI 10.1073/pnas.0812619106; Chapagain AK, 2007, ECOL ECON, V64, P109, DOI 10.1016/j.ecolecon.2007.02.022; Okadera T, 2006, ECOL ECON, V58, P221, DOI 10.1016/j.ecolecon.2005.07.005; Sovacool BK, 2009, ENERG POLICY, V37, P2763, DOI 10.1016/j.enpol.2009.03.012; Mulder K, 2010, AMBIO, V39, P30, DOI 10.1007/s13280-009-0003-x; Chapagain AK, 2006, ECOL ECON, V60, P186, DOI 10.1016/j.ecolecon.2005.11.027; Guan D, 2008, J ENVIRON MANAGE, V88, P1300, DOI 10.1016/j.jenvman.2007.07.010; Geng Y, 2010, INT J SUST DEV WORLD, V17, P172, DOI 10.1080/13504500903549528; Feng KS, 2012, APPL GEOGR, V32, P691, DOI 10.1016/j.apgeog.2011.08.004; Berndes G, 2002, GLOBAL ENVIRON CHANG, V12, P253, DOI 10.1016/S0959-3780(02)00040-7; Dong HJ, 2013, SCI TOTAL ENVIRON, V442, P215, DOI 10.1016/j.scitotenv.2012.10.049; Scott CA, 2011, ENERG POLICY, V39, P6622, DOI 10.1016/j.enpol.2011.08.013; Hoekstra AY, 2005, GLOBAL ENVIRON CHANG, V15, P45, DOI 10.1016/j.gloenvcha.2004.06.004; Chiu YW, 2009, ENVIRON SCI TECHNOL, V43, P2688, DOI 10.1021/es8031067; Geng Y, 2006, INT J SUST DEV WORLD, V13, P37, DOI 10.1080/13504500609469660; Subhadra BG, 2011, APPL ENERG, V88, P3515, DOI 10.1016/j.apenergy.2010.12.051; Lenzen M, 2013, ECOL ECON, V94, P78, DOI 10.1016/j.ecolecon.2013.06.018; Huang F, 2010, AGR WATER MANAGE, V97, P1259, DOI 10.1016/j.agwat.2010.02.017; Cazcarro I, 2010, J IND ECOL, V14, P496, DOI 10.1111/j.1530-9290.2010.00230.x; Yu Y, 2010, ECOL ECON, V69, P1140, DOI 10.1016/j.ecolecon.2009.12.008; Chapagain AK, 2009, J ENVIRON MANAGE, V90, P1219, DOI 10.1016/j.jenvman.2008.06.006; Hoekstra AY, 2007, WATER RESOUR MANAG, V21, P35, DOI 10.1007/s11269-006-9039-x; Madden N, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/3/035006; Hoekstra AY, 2009, ECOL ECON, V68, P1963, DOI 10.1016/j.ecolecon.2008.06.021; Guan D, 2007, ECOL ECON, V61, P159, DOI 10.1016/j.ecolecon.2006.02.022; Astrauskas A, 1998, ITAL J ZOOL, V65, P461; Bureau of Statistics Liaoning Province, 2003, STAT YB LIAON 2003; Bureau of Statistics Liaoning Province, 2011, STAT YB LIAON 2011; Cazcarro I., 2013, SUSTAINABILITY PRACT, P119; China Electric Power Editorial Committee, 2011, CHIN EL POW YB 2011; [Department of Industry and Transport Statistics National Bureau of Statistics Energy Bureau National Development and Reform Commision], 2004, CHIN EN STAT YB 2000; [Department of National Accounts National Bureau of Statistics of China], 2008, REG INP OUTP TABL CH; Editorial Board of China Environment Yearbook, 2003, CHIN ENV YB 2003; Fridley D., 2008, CHINA ENERGY DATABOO; Gheewala SH, 2013, BIORESOURCE TECHNOL, V150, P457, DOI 10.1016/j.biortech.2013.07.052; Harto C, 2010, ENERG POLICY, V38, P4933, DOI 10.1016/j.enpol.2010.03.074; Hoekstra AY, 2008, GLOBALIZATION WATER; Hoekstra A.Y., 2002, VALUE WATER RES REPO, V11; Hoekstra AY, 2007, ECOL ECON, V64, P143, DOI 10.1016/j.ecolecon.2007.02.023; Hussain KJ, 2010, ENVIRON MONIT ASSESS, V163, P185, DOI 10.1007/s10661-009-0826-8; International Atomic Energy Agency, 2013, POW REACT INF SYST R; International Energy Agency, 2012, WAT EN WORLD EN OUTL; Kohli A., 2011, COOLING WATER ENERGY; Lenzen M., 2001, ECON SYST RES, V13, P65, DOI DOI 10.1080/09535310120026256; Lenzen M, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007649; Lenzen M, 2001, WATER POLICY, V3, P321, DOI DOI 10.1016/S1366-7017(01)00072-1; Li S., 2010, EXPANDED REGIONAL IN; Li T, 2011, MAR ECOL PROG SER, V424, P75, DOI 10.3354/meps08974; Lopez-Morales C, 2011, ECON SYST RES, V23, P387, DOI 10.1080/09535314.2011.635138; Mayer-Pinto M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047871; Miller R E, 2009, INPUT OUTPUT ANAL FD; Ministry of Agriculture Forestry and Fisheries, 2007, STAND DES PLAN REN P; Ministry of Water Resources, 2003, CHIN WAT RES B 2002; Ministry of Water Resources, 2008, CHIN WAT RES B 2007; Ministry of Water Resources, 2001, CHIN WAT RES B 2000; Ministry of Water Resources, 1998, CHIN WAT RES B 1997; Ministry of Water Resources, 2009, CHIN WAT RES B 2009; National Intelligence Council, 2012, GLOB TREND 2030; Okadera T, 2014, ENERGY, V77, P49, DOI 10.1016/j.energy.2014.03.113; Okadera T., 2014, ECON SYST RES, P444; Pacific Institute, 2011, WAT DAT WORLDS WAT; Pfister S, 2009, P NATL ACAD SCI USA, V106, pE93, DOI 10.1073/pnas.0908069106; Renault D., 2003, VALUE WATER RES REPO; Sovacool B. K., 2009, ENERGY LAW J, V30, P11; Sovacool Benjamin K., 2009, J ENVIRON LAW, V34, P333; SURESH K, 1993, HYDROBIOLOGIA, V268, P109, DOI 10.1007/BF00006881; Teixeira TP, 2012, HYDROBIOLOGIA, V684, P161, DOI 10.1007/s10750-011-0980-1; Tseng LC, 2011, HYDROBIOLOGIA, V666, P301, DOI 10.1007/s10750-011-0616-5; Turner-Tomaszewicz C, 2012, COAST MANAGE, V40, P73, DOI 10.1080/08920753.2012.640267; United Nations, 1999, HDB INP OUTP TABL CO; Watkins K., 2006, HUMAN DEV REPORT 200; World Bank, 2012, WORLD DEV INC GDP; Zargar S, 2006, J ENVIRON BIOL, V27, P191	95	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0301-4215	1873-6777		ENERG POLICY	Energy Policy	MAR	2015	78						148	157		10.1016/j.enpol.2014.12.029		10	Energy & Fuels; Environmental Sciences; Environmental Studies	Energy & Fuels; Environmental Sciences & Ecology	CB6IX	WOS:000349731800014		
J	Murayama, K; Oike, Y; Furumi, S; Takeuchi, M; Noguchi, K; Tanaka, K				Murayama, Koichi; Oike, Yasuaki; Furumi, Seiichi; Takeuchi, Masayuki; Noguchi, Keiichi; Tanaka, Ken			Enantioselective Synthesis, Crystal Structure, and Photophysical Properties of a 1,1 '- Bitriphenylene-Based Sila[7]helicene	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Luminescence; Helicenes; Triphenylenes; Cycloaddition; Rhodium	CIRCULARLY-POLARIZED LUMINESCENCE; CATALYZED 2+2+2 CYCLOADDITION; CROSS-CONJUGATED OLIGOTHIOPHENES; ONE HUNDRED YEARS; ASYMMETRIC-SYNTHESIS; STEREOSELECTIVE SYNTHESES; CHIROPTICAL PROPERTIES; HELICAL CHIRALITY; CARBON-SULFUR; MOLECULES	A 1,1'-bitriphenylene-based sila[7]helicene was synthesized with a high ee value by enantioselective double [2+2+2] cycloaddition of a biaryl-linked tetrayne with a silicon-linked bis(propargylic alcohol) as a key step. This sila[7]helicene exhibited a high tolerance toward racemization, which could be explained by the X-ray crystal structure analysis. With respect to the photophysical properties, this sila[7]helicene exhibited a relatively high fluorescence quantum yield and circularly polarized luminescence activity.	[Murayama, Koichi; Oike, Yasuaki; Tanaka, Ken] Tokyo Univ Agr & Technol, Fac Engn, Dept Appl Chem, Koganei, Tokyo 1848588, Japan; [Furumi, Seiichi] Tokyo Univ Sci, Fac Sci, Dept Appl Chem, Shinjuku Ku, Tokyo 1628601, Japan; [Takeuchi, Masayuki] Natl Inst Mat Sci, Organ Mat Grp, Tsukuba, Ibaraki 3050047, Japan; [Noguchi, Keiichi] Tokyo Univ Agr & Technol, Instrumentat Anal Ctr, Koganei, Tokyo 1848588, Japan; [Tanaka, Ken] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Appl Chem, Meguro Ku, Tokyo 1528550, Japan; [Tanaka, Ken] Japan Sci & Technol Agcy JST, ACT C, Kawaguchi, Saitama 3320012, Japan	Tanaka, K (reprint author), Tokyo Univ Agr & Technol, Fac Engn, Dept Appl Chem, Koganei, Tokyo 1848588, Japan.	ktanaka@apc.titech.ac.jp			ACT-C from Japan Science and Technology Agency (JST, Japan)	This work was supported partly by ACT-C from Japan Science and Technology Agency (JST, Japan). We thank Nanotechnology Platform Project of MEXT, Japan. We also thank Mr. Yuta Miyauchi (TUAT) for his valuable assistance, Takasago International Corporation for the gift of Segphos, and Umicore for generous support in supplying the rhodium complex.	Wang EG, 2008, J MATER CHEM, V18, P797, DOI 10.1039/b716607a; Mo YQ, 2009, J POLYM SCI POL CHEM, V47, P3286, DOI 10.1002/pola.23393; Heller B, 2007, CHEM SOC REV, V36, P1085, DOI 10.1039/b607877j; Saleh N, 2014, CHEM SCI, V5, P3680, DOI 10.1039/c4sc01404a; Nakano K, 2005, ANGEW CHEM INT EDIT, V44, P7136, DOI 10.1002/anie.200502855; Kuninobu Y, 2013, ANGEW CHEM INT EDIT, V52, P1520, DOI 10.1002/anie.201207723; Grandbois A, 2008, CHEM-EUR J, V14, P9323, DOI 10.1002/chem.200801033; Mo YQ, 2005, CHEM COMMUN, P4925, DOI 10.1039/b507518a; Gingras M, 2013, CHEM SOC REV, V42, P968, DOI 10.1039/c2cs35154d; Tanaka K, 2009, ANGEW CHEM INT EDIT, V48, P5470, DOI 10.1002/anie.200901962; Dreher SD, 1999, J ORG CHEM, V64, P3671, DOI 10.1021/jo990065o; Rajca A, 2004, J AM CHEM SOC, V126, P15211, DOI 10.1021/ja0462530; Tobisu M, 2009, J AM CHEM SOC, V131, P7506, DOI 10.1021/ja9022978; Gingras M, 2013, CHEM SOC REV, V42, P1007, DOI 10.1039/c2cs35111k; Wang E, 2007, J POLYM SCI POL CHEM, V45, P4941, DOI 10.1002/pola.22243; Shintani R, 2012, J AM CHEM SOC, V134, P7305, DOI 10.1021/ja302278s; Sawada Y, 2012, J AM CHEM SOC, V134, P4080, DOI 10.1021/ja300278e; Li LC, 2010, TETRAHEDRON LETT, V51, P622, DOI 10.1016/j.tetlet.2009.11.074; Chan KL, 2005, J AM CHEM SOC, V127, P7662, DOI 10.1021/ja0508065; Urbano A, 2013, ORG BIOMOL CHEM, V11, P699, DOI 10.1039/c2ob27108g; Fukawa N, 2010, ORG LETT, V12, P1324, DOI 10.1021/ol100227k; Tsumatori H, 2010, ORG LETT, V12, P2362, DOI 10.1021/ol100701w; Kimura Y, 2014, ANGEW CHEM INT EDIT, V53, P8480, DOI 10.1002/anie.201404810; Tanaka K, 2009, CHEM-ASIAN J, V4, P508, DOI 10.1002/asia.200800378; Goto K, 2012, ANGEW CHEM INT EDIT, V51, P10333, DOI 10.1002/anie.201204863; Ureshino T, 2010, J AM CHEM SOC, V132, P14324, DOI 10.1021/ja107698p; Keyworth CW, 2011, J MATER CHEM, V21, P11800, DOI 10.1039/c1jm11242b; Chen JW, 2007, MACROMOL RAPID COMM, V28, P1714, DOI 10.1002/marc.200700326; Miyasaka M, 2005, J AM CHEM SOC, V127, P13806, DOI 10.1021/ja055414c; Morisaki Y, 2014, CHEM-EUR J, V20, P8386, DOI 10.1002/chem.201402930; Shibata T, 2012, CHEM COMMUN, V48, P1311, DOI 10.1039/c1cc16762f; Shibata T, 2008, ORG BIOMOL CHEM, V6, P1317, DOI 10.1039/b720031e; Tanaka K, 2007, J AM CHEM SOC, V129, P12078, DOI 10.1021/ja074914y; Morisaki Y, 2014, J AM CHEM SOC, V136, P3350, DOI 10.1021/ja412197j; Maeda H, 2011, J AM CHEM SOC, V133, P9266, DOI 10.1021/ja203206g; Shibata Y, 2012, SYNTHESIS-STUTTGART, V44, P323, DOI 10.1055/s-0031-1289665; Amako T, 2014, CHEM COMMUN, V50, P12836, DOI 10.1039/c4cc04228j; Sehnal P, 2009, P NATL ACAD SCI USA, V106, P13169, DOI 10.1073/pnas.0902612106; Shimizu M, 2008, ANGEW CHEM INT EDIT, V47, P9760, DOI 10.1002/anie.200804146; Salim M, 2011, TETRAHEDRON LETT, V52, P4518, DOI 10.1016/j.tetlet.2011.06.033; Liang Y, 2011, J AM CHEM SOC, V133, P9204, DOI 10.1021/ja2024959; Latorre A, 2011, CHEM COMMUN, V47, P8103, DOI 10.1039/c1cc12921j; Han SD, 2002, ANGEW CHEM INT EDIT, V41, P3227, DOI 10.1002/1521-3773(20020902)41:17<3227::AID-ANIE3227>3.0.CO;2-T; Kumar J, 2013, CHEM-EUR J, V19, P14090, DOI 10.1002/chem.201302146; Han SD, 2002, ANGEW CHEM INT EDIT, V41, P3223, DOI 10.1002/1521-3773(20020902)41:17<3223::AID-ANIE3223>3.0.CO;2-G; Kaseyama T, 2011, ANGEW CHEM INT EDIT, V50, P3684, DOI 10.1002/anie.201007849; Oyama H, 2013, ORG LETT, V15, P2104, DOI 10.1021/ol4005036; Teply F, 2003, J ORG CHEM, V68, P5193, DOI 10.1021/jo034369t; Amemiya R, 2008, CHEM REC, V8, P116, DOI 10.1002/tcr.20142; Carreno MC, 2003, CHEM-EUR J, V9, P4118, DOI 10.1002/chem.200304835; Shen Y, 2012, CHEM REV, V112, P1463, DOI 10.1021/cr200087r; Yabusaki Y, 2010, CHEM-EUR J, V16, P5581, DOI 10.1002/chem.200903408; Nakamura K, 2014, J AM CHEM SOC, V136, P5555, DOI 10.1021/ja500841f; Chan KL, 2005, CHEM COMMUN, P5766, DOI 10.1039/b511208g; Caeiro J, 2006, ADV SYNTH CATAL, V348, P2466, DOI 10.1002/adsc.200600319; Carreno MC, 2005, CHEM COMMUN, P611, DOI 10.1039/b413879a; Carreno MC, 2008, CHEM-EUR J, V14, P603, DOI 10.1002/chem.200700762; Cizkova M, 2014, EUR J ORG CHEM, P5681, DOI 10.1002/ejoc.201402746; Crittall MR, 2012, CHEM COMMUN, V48, P11181, DOI 10.1039/c2cc35583c; DORE A, 1995, TETRAHEDRON-ASYMMETR, V6, P779, DOI 10.1016/0957-4166(95)00074-Y; Goto K., 2012, ANGEW CHEM, V124, P10479; Gottarelli G, 1996, J ORG CHEM, V61, P2013, DOI 10.1021/jo951823n; Han S., 2002, ANGEW CHEM, V114, P3357, DOI 10.1002/1521-3757(20020902)114:17<3357::AID-ANGE3357>3.0.CO;2-J; Han S., 2002, ANGEW CHEM, V114, P3361, DOI 10.1002/1521-3757(20020902)114:17<3361::AID-ANGE3361>3.0.CO;2-G; Heller B, 2013, J ORGANOMET CHEM, V723, P98, DOI 10.1016/j.jorganchem.2012.07.005; Hoffmann N, 2014, J PHOTOCH PHOTOBIO C, V19, P1, DOI 10.1016/j.jphotochemrev.2013.11.001; Jancarik A., 2013, ANGEW CHEM, V125, P10154; Jancarik A, 2013, ANGEW CHEM INT EDIT, V52, P9970, DOI 10.1002/anie.201301739; Kaseyama T., 2011, ANGEW CHEM, V123, P3768; Kimura Y., 2014, ANGEW CHEM, V126, P8620; Kotzner L., 2014, ANGEW CHEM, V126, P5303; Kotzner L, 2014, ANGEW CHEM INT EDIT, V53, P5202, DOI 10.1002/anie.201400474; Kuninobu Y., 2013, ANGEW CHEM, V125, P1560; Maeda H, 2013, CHEM-EUR J, V19, P16263, DOI 10.1002/chem.201301737; Matsuda T, 2007, ORG LETT, V9, P133, DOI 10.1021/ol062732n; McDowell JJ, 2013, MACROMOLECULES, V46, P6794, DOI 10.1021/ma401346y; McDowell JJ, 2014, ACS APPL MATER INTER, V6, P83, DOI 10.1021/am4025406; Montalti M., 2006, HDB PHOTOCHEMISTRY; Murayama K, 2013, J ORG CHEM, V78, P6202, DOI 10.1021/jo4008892; Nakano K, 2012, ANGEW CHEM INT EDIT, V51, P695, DOI 10.1002/anie.201106157; Nakano K., 2005, ANGEW CHEM, V117, P7298, DOI 10.1002/ange.200502855; Nakano K., 2012, ANGEW CHEM, V124, P719; Nakao Y, 2006, PURE APPL CHEM, V78, P435, DOI 10.1351/pac200678020435; Cossu S, 1997, TETRAHEDRON, V53, P6073, DOI 10.1016/S0040-4020(97)00268-8; Peng ZL, 2013, CHEM REC, V13, P28, DOI 10.1002/tcr.201200010; Pusztai E, 2013, ORGANOMETALLICS, V32, P6871, DOI 10.1021/om4005803; Pusztai E, 2013, ORGANOMETALLICS, V32, P2529, DOI 10.1021/om300891n; Rajca A., 2007, FUNCTIONAL ORGANIC M, P543; Salim M, 2011, TETRAHEDRON LETT, V52, P6591, DOI 10.1016/j.tetlet.2011.09.126; Salim M, 2013, HETEROCYCLES, V87, P547, DOI 10.3987/COM-12-12640; Schmuck C, 2003, ANGEW CHEM INT EDIT, V42, P2448, DOI 10.1002/anie.200201625; Schmuck C., 2003, ANGEW CHEM, V115, P2552, DOI 10.1002/ange.200201625; Shimizu M, 2011, SCI CHINA CHEM, V54, P1937, DOI 10.1007/s11426-011-4396-6; Shimizu M., 2008, ANGEW CHEM, V120, P9906, DOI 10.1002/ange.200804146; Stara IG, 2005, ORG LETT, V7, P2547, DOI 10.1021/ol047311p; Stara I. G., 2010, SCI SYNTHESIS B, V45b, P885; Stara IG, 1999, TETRAHEDRON LETT, V40, P1993, DOI 10.1016/S0040-4039(99)00099-4; Tanaka K., 2009, ANGEW CHEM, V121, P5578; Tanaka K, 2007, SYNLETT, P1977, DOI 10.1055/s-2007-984541; Urbano A., 2003, ANGEW CHEM, V115, P4116, DOI 10.1002/ange.200301667; Urbano A, 2003, ANGEW CHEM INT EDIT, V42, P3986, DOI 10.1002/anie.200301667	101	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	MAR	2015		7					1409	1414		10.1002/ejoc.201403565		6	Chemistry, Organic	Chemistry	CB9ST	WOS:000349973500003		
J	Sakai, N; Matsushita, Y; Konakahara, T; Ogiwara, Y; Hirano, K				Sakai, Norio; Matsushita, Yohei; Konakahara, Takeo; Ogiwara, Yohei; Hirano, Keisuke			One-Pot Preparation of Alkyl Iodides from Esters by Indium-Catalyzed Reductive Cleavage of a Carbon-Oxygen Bond	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Indium; Iodine; Esters; Nucleophilic substitution; Reduction; Polymers	CARBOXYLIC-ACIDS; SELECTIVE SYNTHESIS; ORGANIC HALIDES; DEOXYGENATION; ALDEHYDES; BROMIDES; BROMINATION; KETONES; ETHERS; POLYMETHYLHYDROSILOXANE	We describe the indium-catalyzed reductive iodination of aliphatic and aromatic esters with iodine and 1,1,3,3-tetramethyldisiloxane (TMDS). This reducing procedure accommodates a variety of esters, including esters containing alkyl groups, halogens, a hydroxy group, a thioether, and an alkene moiety. Also, this procedure was applied to the cleavage of carbon-oxygen bonds in acrylate polymers.	[Sakai, Norio; Matsushita, Yohei; Konakahara, Takeo; Ogiwara, Yohei] Tokyo Univ Sci RIKADAI, Fac Sci & Technol, Dept Pure & Appl Chem, Noda, Chiba 2788510, Japan; [Hirano, Keisuke] Nitto Denko Corp, Funct Base Prod Sect, Toyohashi, Aichi 4413194, Japan	Sakai, N (reprint author), Tokyo Univ Sci RIKADAI, Fac Sci & Technol, Dept Pure & Appl Chem, Noda, Chiba 2788510, Japan.	sakachem@rs.noda.tus.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) [25410120]	This work was partially supported by a Grant-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (No. 25410120). We deeply thank Shin-Etsu Chemical Co. Ltd. for the gift of hydrosilanes.	AIZPURUA JM, 1984, TETRAHEDRON LETT, V25, P1103, DOI 10.1016/S0040-4039(01)80113-1; AIZPURUA JM, 1986, CAN J CHEM, V64, P2342, DOI 10.1139/v86-386; Sakai N, 2007, J ORG CHEM, V72, P5920, DOI 10.1021/jo070814z; Sakai N, 2008, TETRAHEDRON LETT, V49, P6873, DOI 10.1016/j.tetlet.2008.09.086; Das B, 2007, TETRAHEDRON LETT, V48, P6681, DOI 10.1016/j.tetlet.2007.07.125; Onishi Y, 2002, J AM CHEM SOC, V124, P13690, DOI 10.1021/ja0283246; KEINAN E, 1990, J ORG CHEM, V55, P2927, DOI 10.1021/jo00296a068; Yadav JS, 2005, TETRAHEDRON LETT, V46, P2687, DOI 10.1016/j.tetlet.2005.02.068; Sakai N, 2011, TETRAHEDRON LETT, V52, P3133, DOI 10.1016/j.tetlet.2011.04.029; Tsuchimoto T, 2009, ORG LETT, V11, P2129, DOI 10.1021/ol900651u; Li ZF, 2007, ORG PREP PROCED INT, V39, P608; Sakai N, 2011, ADV SYNTH CATAL, V353, P3397, DOI 10.1002/adsc.201100524; Miura K, 2007, J ORG CHEM, V72, P787, DOI 10.1021/jo061880o; Moriya T, 2013, J ORG CHEM, V78, P10642, DOI 10.1021/jo401529j; Moriya T, 2012, ORG LETT, V14, P4842, DOI 10.1021/ol302168q; Kabalka GW, 2000, TETRAHEDRON LETT, V41, P5161, DOI 10.1016/S0040-4039(00)00811-X; Larock R. C., 1999, COMPREHENSIVE ORGANI; Miura K, 2004, SYNLETT, P1985, DOI 10.1055/s-2004-830862; Miyai T, 1999, SYNLETT, P182; Moriya T, 2013, SYNTHESIS-STUTTGART, V45, P3233, DOI 10.1055/s-0033-1339903; Pehlivan L, 2012, EUR J ORG CHEM, P4689, DOI 10.1002/ejoc.201200727; REDDY CK, 1992, TETRAHEDRON, V48, P8329; Ruso Jayaraman Sembian, 2014, [Journal of the Korean Chemical Society, 대한화학회지], V58, P39, DOI 10.5012/jkcs.2014.58.1.39; Sakai N, 2008, SYNTHESIS-STUTTGART, P3533, DOI 10.1055/s-0028-1083191; Sakai N, 2005, TETRAHEDRON LETT, V46, P6407, DOI 10.1016/j.tetlet.2005.07.118; Sakai N, 2011, EUR J ORG CHEM, P3178, DOI 10.1002/ejoc.201100161; Sakai N, 2014, EUR J ORG CHEM, P5078, DOI 10.1002/ejoc.201402544	27	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	MAR	2015		7					1591	1595		10.1002/ejoc.201403539		5	Chemistry, Organic	Chemistry	CB9ST	WOS:000349973500026		
J	Ikeuchi, M; Izumi, M; Aso, K; Sugimura, N; Kato, T; Tani, T				Ikeuchi, M.; Izumi, M.; Aso, K.; Sugimura, N.; Kato, T.; Tani, T.			Effects of intra-articular hyaluronic acid injection on immunohistochemical characterization of joint afferents in a rat model of knee osteoarthritis	EUROPEAN JOURNAL OF PAIN			English	Article							IODOACETATE-INDUCED OSTEOARTHRITIS; CENTRAL-NERVOUS-SYSTEM; GENE-RELATED PEPTIDE; SENSORY NEURONS; RADIOGRAPHIC SEVERITY; CENTRAL SENSITIZATION; RHEUMATOID-ARTHRITIS; DISEASE PROGRESSION; SYNOVIAL JOINTS; PAIN MODEL	BackgroundIntra-articular hyaluronic acid (HA) injection, known as viscosupplementation, is a widely used therapy for pain relief in knee osteoarthritis (OA). Long-term clinical efficacy of HA has been reported in spite of a relatively short residence time. Herein, we evaluated our hypothesis that intra-articular HA injection could reduce the OA-associated changes in joint afferents. MethodsOA was induced by intra-articular injection of mono-iodoacetate in rats. Animals in the OA+HA group were given three weekly intra-articular HA injections. Pain-related behaviours, including weight-bearing asymmetry and mechanical hyperalgesia of the paw, knee joint histology and immunohistochemistry of joint afferents identified by retrograde labelling, were compared between groups (naive, OA and OA+HA). ResultsOA rats showed pain-related behaviours and up-regulation of pain-related neurochemical markers [calcitonin gene-related peptide (CGRP), tyrosine receptor kinase A (TrkA) and acid-sensing ion channel 3 (ASIC3)] in joint afferents. HA injections reduced not only the severity of OA and pain behaviours but also OA-associated neurochemical changes in joint afferents. The differences between OA and OA+HA were statistically significant in CGRP (6110% vs. 51 +/- 10%; p=0.0406) but not significant in TrkA (62 +/- 10% vs. 54 +/- 9%; p=0.0878) and ASIC3 (38 +/- 9% vs. 32 +/- 8%; p=0.3681). ConclusionIntra-articular HA injections reduced the severity of OA, decreased mechanical hyperalgesia of the paw, but not weight-bearing asymmetry, and attenuated OA-associated up-regulation of CGRP, but not TrkA and ASIC3, in joint afferents. The modulatory effects of HA on joint afferents is one of the underlying mechanisms of the gap between HA residence time and duration of clinical efficacy.	[Ikeuchi, M.; Izumi, M.; Aso, K.; Sugimura, N.; Kato, T.; Tani, T.] Kochi Univ, Kochi Med Sch, Dept Orthopaed Surg, Nankoku, Kochi, Japan	Ikeuchi, M (reprint author), Kochi Univ, Kochi Med Sch, Dept Orthopaed Surg, Nankoku, Kochi, Japan.	ikeuchim@kochi-u.ac.jp			Setsuro Fujii Memorial Foundation; Osaka Foundation for Promotion of Fundamental Medical Research	This work was supported in part by The Setsuro Fujii Memorial Foundation and The Osaka Foundation for Promotion of Fundamental Medical Research.	ABATANGELO G, 1989, CLIN ORTHOP RELAT R, P278; Mannoni A, 2003, ANN RHEUM DIS, V62, P576, DOI 10.1136/ard.62.6.576; Moreland LW, 2003, ARTHRITIS RES THER, V5, P54, DOI 10.1186/ar623; Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063-4584(03)0163-8; AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; Andrianakos AA, 2006, J RHEUMATOL, V33, P2507; Hochman JR, 2010, ARTHRIT CARE RES, V62, P1019, DOI 10.1002/acr.20142; Divine Jon G, 2007, Clin Orthop Relat Res, V455, P113, DOI 10.1097/BLO.0b013e31802f5421; [Anonymous], 2004, CLIN ORTHOP S, DOI DOI 10.1097/01.BLO.0000143804.26638.82; Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80; VANDERSLUIJS JA, 1992, J ORTHOPAED RES, V10, P58, DOI 10.1002/jor.1100100107; Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188; Schaible HG, 2012, CURR RHEUMATOL REP, V14, P549, DOI 10.1007/s11926-012-0279-x; Saxler G, 2007, EUR J PAIN, V11, P67, DOI 10.1016/j.ejpain.2005.12.011; Fernihough J, 2005, NEUROSCI LETT, V388, P75, DOI 10.1016/j.neulet.2005.06.044; Finan PH, 2013, ARTHRITIS RHEUM-US, V65, P363, DOI 10.1002/art.34646; Ferreira-Gomes J, 2010, ARTHRITIS RHEUM-US, V62, P3677, DOI 10.1002/art.27713; Arendt-Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003; Gwilym SE, 2009, ARTHRIT RHEUM-ARTHR, V61, P1226, DOI 10.1002/art.24837; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Tsai WY, 2013, CONNECT TISSUE RES, V54, P49, DOI 10.3109/03008207.2012.734877; Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003; Im HJ, 2010, ARTHRITIS RHEUM-US, V62, P2995, DOI 10.1002/art.27608; Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008; Yoshioka M, 1997, OSTEOARTHR CARTILAGE, V5, P251, DOI 10.1016/S1063-4584(97)80021-0; Mapp PI, 2013, OSTEOARTHR CARTILAGE, V21, P1336, DOI 10.1016/j.joca.2013.06.031; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Ashraf S, 2011, ANN RHEUM DIS, V70, P523, DOI 10.1136/ard.2010.137844; Gomis A, 2007, PAIN, V130, P126, DOI 10.1016/j.pain.2006.11.012; Imamura M, 2008, ARTHRIT RHEUM-ARTHR, V59, P1424, DOI 10.1002/art.24120; Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004; Murphy SL, 2011, ARTHRIT CARE RES, V63, P1543, DOI 10.1002/acr.20583; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2; BROWN TJ, 1991, EXP PHYSIOL, V76, P125; Chandran P, 2009, EUR J PHARMACOL, V613, P39, DOI 10.1016/j.ejphar.2009.04.009; Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023; FRASER JRE, 1993, SEMIN ARTHRITIS RHEU, V22, P9; Hanesch U, 1995, J NEUROSCI METH, V63, P55, DOI 10.1016/0165-0270(95)00086-0; ISHIDAYAMAMOTO A, 1989, PROG NEUROBIOL, V33, P335, DOI 10.1016/0301-0082(89)90006-3; Izumi M, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-77; KALBHEN DA, 1987, J RHEUMATOL, V14, P130; Kidd Bruce, 2012, HSS J, V8, P26, DOI 10.1007/s11420-011-9263-7; Kobayashi K, 2003, J VET MED SCI, V65, P1195, DOI 10.1292/jvms.65.1195; Lee YC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3306; Leveille SG, 2004, CURR OPIN RHEUMATOL, V16, P114, DOI 10.1097/00002281-200403000-00007; Li J, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3887; Molliver DC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-35; Murphy SL, 2012, CURR RHEUMATOL REP, V14, P576, DOI 10.1007/s11926-012-0285-z; Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-134; Parks E.L., 2011, EUR J PAIN, V15, pe1; Plaas A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3286; Schuelert N, 2009, NEUROSCI LETT, V465, P184, DOI 10.1016/j.neulet.2009.08.063; Sluka KA, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-26; Zavan B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055510	54	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAR	2015	19	3					334	340		10.1002/ejp.551		7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	CC6HK	WOS:000350465800006		
J	Kim, SK; Wang, XY; Ando, S; Wang, XG				Kim, Seong-Ku; Wang, Xingyuan; Ando, Shinji; Wang, Xiaogong			Highly transparent triethoxysilane-terminated copolyimide and its SiO2 composite with enhanced thermal stability and reduced thermal expansion	EUROPEAN POLYMER JOURNAL			English	Article						Transparent polyimide; Thermal stable polyimide; Hybrid PI/silica composite; Sol-gel method; Organic-inorganic composite	SILICA HYBRID MATERIALS; LOW DIELECTRIC-CONSTANT; SOL-GEL PROCESS; THIN-FILMS; MECHANICAL-PROPERTIES; TERNARY COMPOSITES; LINEAR POLYIMIDES; CARBON NANOTUBES; BARRIER PROPERTY; NANOCOMPOSITE	A highly transparent and colorless copolyimide was synthesized to contain electron withdrawing sulfone and fluorine groups. Then, the triethoxysilane terminal groups were introduced by reacting the anhydride end groups of the polymer with (3-aminopropyl)-triethoxysilane. Based on the triethoxysilane-terminated copolyimide, a series of composites of the copolyimide (PI6FDA-TFDB-mBAPS(Si)) with inorganic SiO2 network was successfully fabricated in order to satisfy the requirements for transparent insulators with high thermal stability. Because the hybrid with inorganic SiO2 networks, the composite (PI6FDA-TFDB-mBAPS(Si)-SiO2) can complementarily improve the thermal resistant drawbacks of organic systems. As a result, the composite films exhibit small values of the coefficient of thermal expansion (CTE) with the increasing SiO2 content. The coefficient of thermal expansion (CTE) of the hybrid PI6FDA-TFDB-mBAPS(Si)-SiO2-40% film is 14.4 ppm degrees C-1 in the temperature range from 80 to 170 degrees C. Compared to a value of 34.7 ppm degrees C-1 for the pristine PI, a 57% reduction is achieved for the composite. The composite possesses the glass transition temperature (T-g) of 276.0 degrees C and shows good optical transmittance of 94% at the wavelength of 450 nm. The incorporation of cross-linked SiO2 networks by using the triethoxysilane-terminated PI preserves the high transparency and enhances the thermal stability for the composite films. Due to these optimized properties, the composite can show potential applications in the micro-flexible transparent electronic devices such as transparent insulating panel of advanced transparent display devices and transparent flexible circuit board. (C) 2015 Elsevier Ltd. All rights reserved.	[Kim, Seong-Ku; Wang, Xingyuan; Wang, Xiaogong] Tsinghua Univ, Dept Chem Engn, Lab Adv Mat MOE, Beijing 100084, Peoples R China; [Ando, Shinji] Tokyo Inst Technol, Dept Chem & Mat Sci, Meguro Ku, Tokyo 1528552, Japan	Ando, S (reprint author), Tokyo Inst Technol, Dept Chem & Mat Sci, Meguro Ku, Ookayama 2-12-1-E4-5, Tokyo 1528552, Japan.	wxg-dce@mail.tsinghua.edu.cn	ANDO, Shinji/D-6280-2011	ANDO, Shinji/0000-0002-3508-035X	National Basic Research Program of China (973 Program) [2011CB606102]	The financial support from National Basic Research Program of China (973 Program) under Project 2011CB606102 is gratefully acknowledged.	Al Arbash A, 2006, INT J POLYM MATER, V55, P103, DOI 10.1080/009140390916477; Al Arbash A, 2006, J NANOMATER, DOI 10.1155/JNM/2006/58648; Ando S., 2009, P SOC PHOTO-OPT INS, V7213; Wang HT, 2004, MACROMOL MATER ENG, V289, P793, DOI 10.1002/mame.200400002; Min CK, 2008, COMPOS SCI TECHNOL, V68, P1570, DOI 10.1016/j.compscitech.2007.09.021; Tsai MH, 2001, POLYMER, V42, P4197, DOI 10.1016/S0032-3861(00)00805-3; Liaw DJ, 2012, PROG POLYM SCI, V37, P907, DOI 10.1016/j.progpolymsci.2012.02.005; Paul DR, 2010, PROG POLYM SCI, V35, P893, DOI 10.1016/j.progpolymsci.2010.03.004; Choi J, 2001, J AM CHEM SOC, V123, P11420, DOI 10.1021/ja0107201; Musto P, 2004, POLYMER, V45, P1697, DOI 10.1016/j.polymer.2003.12.044; SCHUBERT U, 1995, CHEM MATER, V7, P2010, DOI 10.1021/cm00059a007; Liu JG, 2008, CHEM MATER, V20, P273, DOI 10.1021/cm071430s; Ling QD, 2006, J AM CHEM SOC, V128, P8732, DOI 10.1021/ja062489n; Tseng IH, 2014, ACS APPL MATER INTER, V6, P13098, DOI 10.1021/am502962b; Sekitani T, 2010, NAT MATER, V9, P1015, DOI [10.1038/nmat2896, 10.1038/NMAT2896]; SROOG CE, 1965, J POLYM SCI PART A, V3, P1373, DOI 10.1002/pol.1965.100030410; Kim S, 2014, RSC ADV, V4, P27267, DOI 10.1039/c4ra02956a; Jiang XW, 2005, POLYMER, V46, P7418, DOI 10.1016/j.polymer.2005.05.127; Choi MC, 2008, PROG POLYM SCI, V33, P581, DOI 10.1016/j.progpolymsci.2007.11.004; Hill D, 2005, MACROMOLECULES, V38, P7670, DOI 10.1021/ma0509210; Cho JH, 2008, NAT MATER, V7, P900, DOI 10.1038/nmat2291; Yorifuji D, 2011, J MATER CHEM, V21, P4402, DOI 10.1039/c0jm04243a; Cheng CF, 2006, MACROMOLECULES, V39, P7583, DOI 10.1021/ma060990u; Park JU, 2007, NAT MATER, V6, P782, DOI 10.1038/nmat1974; Matsuda S, 2005, ADV MATER, V17, P2221, DOI 10.1002/adma.200500655; Tseng IH, 2012, MATER CHEM PHYS, V136, P247, DOI 10.1016/j.matchemphys.2012.06.061; Chen BK, 2004, J APPL POLYM SCI, V94, P382, DOI 10.1002/app.20947; Borgert MT, 1908, J AM CHEM SOC, V30, P1135; Chang CC, 2003, J POLYM RES-TAIWAN, V10, P1, DOI 10.1023/A:1023994403763; Huang SH, 2006, EUR POLYM J, V42, P140, DOI 10.1016/j.eurpolymj.2005.06.032; Kim S, 2014, RSC ADV, V4, P42737, DOI 10.1039/c4ra06546h; Koros W.J., 1988, PROG POLYM SCI, V13, P339, DOI 10.1016/0079-6700(88)90002-0; Meador MA, 1998, ANNU REV MATER SCI, V28, P599, DOI 10.1146/annurev.matsci.28.1.599; MORIKAWA A, 1992, POLYM J, V24, P107, DOI 10.1295/polymj.24.107; MORIKAWA A, 1992, J MATER CHEM, V2, P679, DOI 10.1039/jm9920200679; Numata S, 1987, MATER RES SOC S P, V108, P113, DOI 10.1557/PROC-108-113; Pinel E, 2002, MACROMOLECULES, V35, P10198, DOI 10.1021/ma020942j; Sysel P, 1997, POLYM J, V29, P607, DOI 10.1295/polymj.29.607; Wahab MA, 2003, POLYMER, V44, P4705, DOI 10.1016/S0032-3861(03)00429-4; WANG SH, 1994, J MACROMOL SCI PURE, VA31, P411; Yamashina N, 2012, J PHOTOPOLYM SCI TEC, V25, P385, DOI 10.2494/photopolymer.25.385	41	4	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0014-3057	1873-1945		EUR POLYM J	Eur. Polym. J.	MAR	2015	64						206	214		10.1016/j.eurpolymj.2015.01.012		9	Polymer Science	Polymer Science	CC7CK	WOS:000350525100021		
J	Okita, N; Tsuchiya, T; Fukushima, M; Itakura, K; Yuguchi, K; Narita, T; Hashizume, Y; Sudo, Y; Chiba, T; Shimokawa, I; Higami, Y				Okita, Naoyuki; Tsuchiya, Takuro; Fukushima, Mayumi; Itakura, Kaho; Yuguchi, Keiko; Narita, Takumi; Hashizume, Yukari; Sudo, Yuka; Chiba, Takuya; Shimokawa, Isao; Higami, Yoshikazu			Chronological analysis of caloric restriction-induced alteration of fatty acid biosynthesis in white adipose tissue of rats	EXPERIMENTAL GERONTOLOGY			English	Article						Caloric restriction; Adipose tissue; Fatty acid biosynthesis; SREBP1c	GROWTH-FACTOR-I; GENE-EXPRESSION PROFILE; INSULIN-RECEPTOR; MICE; METABOLISM; ADIPONECTIN; SUPPRESSION; PREVENTION; LONGEVITY; RESPONSES	The beneficial actions of caloric restriction (CR) could be mediated in part by metabolic remodeling of white adipose tissue (WAT). Recently, we suggested that CR for 6 months increased the expressions of proteins involved in de novo fatty acid (FA) biosynthesis in WAT of 9-month-old rats. Herein, we compared the CR-induced chronological alterations of the expression of mRNAs and/or proteins involved in FA biosynthesis in the WAT and liver of rats subjected to CR starting from 3 months of age and their age-matched controls fed ad libitum. The findings suggested that CR was more effective on FA biosynthesis in WAT than in liver. In WAT, CR markedly increased the expressions of mRNAs and/or proteins involved in FA biosynthesis, including sterol regulatory element-binding protein 1c (SREBP1c), a master transcriptional regulator of FA biosynthesis, throughout the experimental period. Interestingly, the CR-enhanced upregulation was temporally attenuated at 5 months of age. CR markedly increased the nuclear phosphorylated form of Akt only at 3.5 months of age. In contrast, CR significantly reduced the expression of leptin at 9 months of age. The CR-induced upregulation was not observed in obese fa/fa Zucker rats homozygous for nonfunctional leptin receptor. Collectively, these data indicate that the V-shaped chronological alterations in WAT are regulated via SREBP1c, which is probably activated by CR duration-dependent modulation of both insulin and leptin signaling. (C) 2015 Elsevier Inc. All rights reserved.	[Okita, Naoyuki; Tsuchiya, Takuro; Fukushima, Mayumi; Itakura, Kaho; Yuguchi, Keiko; Narita, Takumi; Hashizume, Yukari; Sudo, Yuka; Higami, Yoshikazu] Tokyo Univ Sci, Fac Pharmaceut Sci, Mol Pathol & Metab Dis, Noda, Chiba 2788510, Japan; [Okita, Naoyuki] Sasaki Fdn, Sasaki Inst, Dept Internal Med Res, Tokyo, Japan; [Chiba, Takuya; Shimokawa, Isao] Nagasaki Univ, Grad Sch Biomed Sci, Dept Invest Pathol, Nagasaki 852, Japan; [Chiba, Takuya] Waseda Univ, Fac Human Sci, Dept Hlth Sci & Social Welf, Tokorozawa, Saitama, Japan	Higami, Y (reprint author), Tokyo Univ Sci, Fac Pharmaceut Sci, Mol Pathol & Metab Dis, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	higami@rs.noda.tus.ac.jp	Okita, Naoyuki/B-9600-2012	Okita, Naoyuki/0000-0002-1694-2129	Japan Society for the Promotion of Science [19590396]; Ministry of Health, Labour and Welfare; National Cancer Center Research and Development Fund, Japan [23-A-2]	We thank all members of the Molecular Pathology and Metabolic Disease and the Animal Center of the Faculty of Pharmaceutical Sciences, Tokyo University of Science, for their cooperation. This work was partially supported by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19590396), a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare, and the National Cancer Center Research and Development Fund (23-A-2), Japan.	Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Katic M, 2007, AGING CELL, V6, P827, DOI 10.1111/j.1474-9726.2007.00346.x; WISE EM, 1964, P NATL ACAD SCI USA, V52, P1255, DOI 10.1073/pnas.52.5.1255; Torres-Leal FL, 2010, CELL BIOCHEM FUNCT, V28, P623, DOI 10.1002/cbf.1706; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Otabe S, 2007, AM J PHYSIOL-ENDOC M, V293, pE210, DOI 10.1152/ajpendo.00645.2006; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Sekiya M, 2007, J LIPID RES, V48, P1581, DOI 10.1194/jlr.M700033-JLR200; Masternak MM, 2012, AGING CELL, V11, P73, DOI 10.1111/j.1474-9726.2011.00763.x; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Soukas A, 2000, GENE DEV, V14, P963; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Oka S, 2012, CIRC RES, V111, P611, DOI 10.1161/CIRCRESAHA.111.247932; Okita N, 2012, MECH AGEING DEV, V133, P255, DOI 10.1016/j.mad.2012.02.003; [Anonymous], 1970, GENES DEV, V18, P1970; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Bluher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5; Osborne TF, 2009, GENE DEV, V23, P2578, DOI 10.1101/gad.1854309; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Frayn KN, 2002, DIABETOLOGIA, V45, P1201, DOI 10.1007/s00125-002-0873-y; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Chiba T, 2009, MOL CELL ENDOCRINOL, V309, P17, DOI 10.1016/j.mce.2009.05.001; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Argmann C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000752; Chujo Y, 2013, AGE, V35, P1143, DOI 10.1007/s11357-012-9439-1; DeClercq Vanessa, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P228, DOI 10.2174/187152908785849080; Higami Yoshikazu, 2004, FASEB Journal, V18, P415; Higami Y, 2005, ADV CLIN CHEM, V39, P211, DOI 10.1016/S0065-2423(04)39008-6; Higami Y, 2006, J GERONTOL A-BIOL, V61, P1099; Wetter TJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE728; Yamaza H, 2004, EXP GERONTOL, V39, P269, DOI 10.1016/j.exger.2003.11.001; Yamaza H, 2007, J GERONTOL A-BIOL, V62, P27; Zhu M, 2007, EXP GERONTOL, V42, P733, DOI 10.1016/j.exger.2007.05.011	35	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	MAR	2015	63						59	66		10.1016/j.exger.2015.01.043		8	Geriatrics & Gerontology	Geriatrics & Gerontology	CC5HF	WOS:000350389000008		
J	Ogoh, S; Sato, K; Okazaki, K; Miyamoto, T; Hirasawa, A; Sadamoto, T; Shibasaki, M				Ogoh, Shigehiko; Sato, Kohei; Okazaki, Kazunobu; Miyamoto, Tadayoshi; Hirasawa, Ai; Sadamoto, Tomoko; Shibasaki, Manabu			Blood flow in internal carotid and vertebral arteries during graded lower body negative pressure in humans	EXPERIMENTAL PHYSIOLOGY			English	Article							HEAD-UP TILT; DYNAMIC CEREBRAL AUTOREGULATION; ORTHOSTATIC STRESS; VASOVAGAL SYNCOPE; ACUTE HYPOTENSION; PHYSICAL-FITNESS; TOLERANCE; EXERCISE; VOLUME; RESPONSES	New Findings What is the central question of this study? Recently, the heterogeneity of the cerebral arterial circulation has been argued. Orthostatic tolerance may be associated with an orthostatic stress-induced change in blood flow in vertebral arteries rather than in internal carotid arteries, because vertebral arteries supply blood to the medulla oblongata, which is the location of important cardiac, vasomotor and respiratory control centres. What is the main finding and its importance? The effect of graded orthostatic stress on vertebral artery blood flow is different from that on internal carotid artery blood flow. This response allows for the possibility that orthostatic tolerance may be associated with haemodynamic changes in posterior rather than anterior cerebral blood flow. Recently, the heterogeneity of the cerebral arterial circulation has been argued, but the characteristics of vertebral artery (VA) and internal carotid artery (ICA) blood flow during graded orthostatic stress remain unknown. We hypothesized that the change in blood flow in VA is not similar to that in ICA blood flow during graded orthostatic stress. We measured blood flows in both ICA and VA during graded lower body negative pressure (LBNP; -20, -35and -50mmHg) by using two colour-coded ultrasound systems. The effect of graded orthostatic stress on the VA blood flow was different from that on the ICA blood flow (LBNPxartery, P=0.006). The change in ICA blood flow was associated with the level of LBNP (r = 0.287, P=0.029), and a reduction in ICA blood flow from pre-LBNP was observed during -50mmHg LBNP (from 411 +/- 35 to 311 +/- 40mlmin(-1), P=0.044) without symptoms of presyncope. In contrast, VA blood flow was unchanged during graded LBNP compared with the baseline (P=0.597) relative to the reduction in ICA blood flow and thus there was no relationship between VA blood flow and the level of LBNP (r=0.167, P=0.219). These findings suggest that the change in ICA blood flow is due to the level of LBNP during graded orthostatic stress, but the change in VA blood flow is different from that in ICA blood flow across the different levels of LBNP. These findings provide the possibility that posterior cerebral blood flow decreases only during severe orthostatic stress and is therefore more likely to be linked with orthostatic tolerance.	[Ogoh, Shigehiko; Hirasawa, Ai] Toyo Univ, Dept Biomed Engn, Kawagoe, Saitama 3508585, Japan; [Sato, Kohei; Sadamoto, Tomoko] Japan Womens Coll Phys Educ, Res Inst Phys Fitness, Tokyo, Japan; [Okazaki, Kazunobu] Osaka City Univ, Grad Sch Med, Dept Environm Physiol Exercise, Osaka 558, Japan; [Miyamoto, Tadayoshi] Morinomiya Univ Med Sci, Osaka, Japan; [Shibasaki, Manabu] Nara Womens Univ, Dept Environm Hlth, Nara 630, Japan	Ogoh, S (reprint author), Toyo Univ, Dept Biomed Engn, 2100 Kujirai, Kawagoe, Saitama 3508585, Japan.	ogoh@toyo.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [80553841]	This study was supported in part by a Grant-in-Aid for Scientific Research (No. 80553841) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Carey BJ, 2001, CIRCULATION, V104, P898, DOI 10.1161/hc3301.094908; Thomas KN, 2009, J APPL PHYSIOL, V107, P506, DOI 10.1152/japplphysiol.91650.2008; Sato K, 2010, J APPL PHYSIOL, V109, P864, DOI 10.1152/japplphysiol.01359.2009; Zhang R, 1998, J APPL PHYSIOL, V85, P1113; Sato K, 2012, EXP PHYSIOL, V97, P1272, DOI 10.1113/expphysiol.2012.064774; Wilson TE, 2006, AM J PHYSIOL-REG I, V291, pR1443, DOI 10.1152/ajpregu.00712.2005; LEVINE BD, 1991, CIRCULATION, V84, P1016; Smit AAJ, 1999, J PHYSIOL-LONDON, V519, P1, DOI 10.1111/j.1469-7793.1999.0001o.x; Ichikawa D, 2013, SCAND J MED SCI SPOR, V23, pE320, DOI 10.1111/sms.12082; Ogoh S, 2011, CLIN PHYSIOL FUNCT I, V31, P445, DOI 10.1111/j.1475-097X.2011.01040.x; Shin HK, 1999, ARCH NEUROL-CHICAGO, V56, P1353, DOI 10.1001/archneur.56.11.1353; Ogoh S, 2013, J CEREBR BLOOD F MET, V33, P1915, DOI 10.1038/jcbfm.2013.149; Ogoh S, 2003, J PHYSIOL-LONDON, V551, P601, DOI 10.1113/jphysiol.2003.046029; van Lieshout JJ, 2003, J APPL PHYSIOL, V94, P833, DOI 10.1152/japplphysiol.00260.2002; Deegan BM, 2010, J APPL PHYSIOL, V109, P1424, DOI 10.1152/japplphysiol.01262.2009; RAVEN PB, 1993, MED SCI SPORT EXER, V25, P713; SCHONING M, 1994, STROKE, V25, P17; Sato K, 2011, J PHYSIOL-LONDON, V589, P2847, DOI 10.1113/jphysiol.2010.204461; LEVINE BD, 1994, CIRCULATION, V90, P298; Ogoh S, 2013, CLIN SCI, V125, P37, DOI 10.1042/CS20120335; Ogoh S, 2008, STROKE, V39, P1979, DOI 10.1161/STROKEAHA.107.510008; Cooper VL, 2002, CLIN SCI, V103, P221; Sato K, 2012, J PHYSIOL-LONDON, V590, P3277, DOI 10.1113/jphysiol.2012.230425; Tatu L, 1996, NEUROLOGY, V47, P1125; Carey BJ, 2001, CLIN SCI, V101, P351, DOI 10.1042/CS20010021; CONVERTINO VA, 1987, EXERCISE SPORT SCI R, V15, P223; Cooper VL, 2001, EXP PHYSIOL, V86, P677, DOI 10.1113/eph8602213; Deegan BM, 2010, IEEE ENG MED BIO, P2505, DOI 10.1109/IEMBS.2010.5626647; Immink RV, 2006, EUR J APPL PHYSIOL, V96, P609, DOI 10.1007/s00421-006-0136-6; JOHNSON JM, 1973, J APPL PHYSIOL, V35, P798; KLEIN KE, 1969, AEROSPACE MED, V40, P998; LEVINE BD, 1993, MED SCI SPORT EXER, V25, P727; Low DA, 2009, AM J PHYSIOL-REG I, V296, pR1598, DOI 10.1152/ajpregu.90900.2008; Lucas RAI, 2013, AM J PHYSIOL-REG I, V305, pR604, DOI 10.1152/ajpregu.00052.2013; Madsen P, 1998, AVIAT SPACE ENVIR MD, V69, P781; Miyamoto T, 2014, AM J PHYSIOL-HEART C, V306, pH1669, DOI 10.1152/ajpheart.00987.2013; Ogoh S, 2010, J PHYSIOL-LONDON, V588, P365, DOI 10.1113/jphysiol.2009.180844; RAVEN PB, 1984, J APPL PHYSIOL, V56, P138; Schoning M, 1996, J CEREBR BLOOD F MET, V16, P523; SMITH ML, 1988, J APPL PHYSIOL, V64, P585; STEVENS GHJ, 1992, MED SCI SPORT EXER, V24, P1235	41	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0670	1469-445X		EXP PHYSIOL	Exp. Physiol.	MAR	2015	100	3					259	266		10.1113/expphysiol.2014.083964		8	Physiology	Physiology	CC6ED	WOS:000350456900007		
J	Kadoguchi, T; Kinugawa, S; Takada, S; Fukushima, A; Furihata, T; Homma, T; Masaki, Y; Mizushima, W; Nishikawa, M; Takahashi, M; Yokota, T; Matsushima, S; Okita, K; Tsutsui, H				Kadoguchi, Tomoyasu; Kinugawa, Shintaro; Takada, Shingo; Fukushima, Arata; Furihata, Takaaki; Homma, Tsuneaki; Masaki, Yoshihiro; Mizushima, Wataru; Nishikawa, Mikito; Takahashi, Masashige; Yokota, Takashi; Matsushima, Shouji; Okita, Koichi; Tsutsui, Hiroyuki			Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle	EXPERIMENTAL PHYSIOLOGY			English	Article							LOWERED EXERCISE CAPACITY; CHRONIC HEART-FAILURE; TYPE-2 DIABETIC MICE; CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR-I; MYOCARDIAL-INFARCTION; INDEPENDENT MECHANISM; AMBULATORY PATIENTS; INSULIN-RESISTANCE; KNOCKOUT MICE	New findings What is the central question of this study? Does angiotensinII directly induce skeletal muscle abnormalities? What is the main finding and its importance? AngiotensinII induces skeletal muscle abnormalities and reduced exercise capacity. Mitochondrial dysfunction and a decreased number of oxidative fibres are manifest early, while muscle atrophy is seen later. Thus, angiotensinII may play an important role in the skeletal muscle abnormalities observed in a wide variety of diseases. Skeletal muscle abnormalities, such as mitochondrial dysfunction, a decreased percentage of oxidative fibres and atrophy, are the main cause of reduced exercise capacity observed in ageing and various diseases, including heart failure. The renin-angiotensin system, particularly angiotensinII (AngII), is activated in the skeletal muscle in these conditions. Here, we examined whether AngII could directly induce these skeletal muscle abnormalities and investigated their time course. AngiotensinII (1000ngkg(-1)min(-1)) or vehicle was administered to male C57BL/6J mice (10-12weeks of age) via subcutaneously implanted osmotic minipumps for 1 or 4weeks. AngiotensinII significantly decreased body and hindlimb skeletal muscle weights compared with vehicle at 4weeks. In parallel, muscle cross-sectional area was also decreased in the skeletal muscle at 4weeks. Muscle RING finger-1 and atrogin-1 were significantly increased in the skeletal muscle from mice treated with AngII. In addition, cleaved caspase-3 and terminal deoxynucleotidyl trasferase-mediated dUTP nick-positive nuclei were significantly increased in mice treated with AngII at 1 and 4weeks, respectively. Mitochondrial oxidative enzymes, such as citrate synthase, complexI and complexIII activities were significantly decreased in the skeletal muscle from mice treated AngII at 1 and 4weeks. NAD(P)H oxidase-derived superoxide production was increased. NADH staining revealed that typeI fibres were decreased and typeIIb fibres increased in mice treated with AngII at 1week. The work and running distance evaluated by a treadmill test were significantly decreased in mice treated with AngII at 4weeks. Thus, AngII could directly induce the abnormalities in skeletal muscle function and structure.	[Kadoguchi, Tomoyasu; Kinugawa, Shintaro; Takada, Shingo; Fukushima, Arata; Furihata, Takaaki; Homma, Tsuneaki; Masaki, Yoshihiro; Mizushima, Wataru; Nishikawa, Mikito; Takahashi, Masashige; Yokota, Takashi; Matsushima, Shouji; Tsutsui, Hiroyuki] Hokkaido Univ, Grad Sch Med, Dept Cardiovasc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Okita, Koichi] Hokusho Univ, Grad Sch Lifelong Sport, Ebetsu, Hokkaido, Japan	Kinugawa, S (reprint author), Hokkaido Univ, Grad Sch Med, Dept Cardiovasc Med, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	tuckahoe@med.hokudai.ac.jp			Ministry of Education, Science, and Culture [24390192, 26350879]	This study was supported by grants from the Ministry of Education, Science, and Culture (24390192, 26350879).	Song YH, 2005, J CLIN INVEST, V115, P451, DOI 10.1172/JCI200522324; Odden MC, 2004, J AM SOC NEPHROL, V15, P2908, DOI 10.1097/01.ASN.0000143743.78092.E3; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Takada S, 2014, EUR J PHARMACOL, V740, P690, DOI 10.1016/j.ejphar.2014.06.008; Brink M, 1996, J CLIN INVEST, V97, P2509, DOI 10.1172/JCI118698; Clavel S, 2006, MECH AGEING DEV, V127, P794, DOI 10.1016/j.mad.2006.07.005; Andersen JL, 2003, SCAND J MED SCI SPOR, V13, P40, DOI 10.1034/j.1600-0838.2003.00299.x; Dunant P, 2003, MOL THER, V8, P80, DOI 10.1016/S01525-0016(03)00129-1; Houmard JA, 1998, J APPL PHYSIOL, V85, P1337; Dai DF, 2011, CIRC RES, V108, P837, DOI 10.1161/CIRCRESAHA.110.232306; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147; Hirabayashi K, 2014, INT J CARDIOL, V176, P1110, DOI 10.1016/j.ijcard.2014.07.113; Frontera WR, 2000, J APPL PHYSIOL, V88, P1321; Schulze PC, 2005, CIRC RES, V97, P418, DOI 10.1161/01.RES.0000179580.72375.c2; Tamaki M, 2014, KIDNEY INT, V85, P1330, DOI 10.1038/ki.2013.473; MANCINI DM, 1991, CIRCULATION, V83, P778; Ohta Y, 2011, AM J PHYSIOL-HEART C, V300, pH1637, DOI 10.1152/ajpheart.01185.2009; DREXLER H, 1992, CIRCULATION, V85, P1751; Basso N, 2007, AM J PHYSIOL-HEART C, V293, pH1351, DOI 10.1152/ajpheart.00393.2007; Inoue N, 2012, AM J PHYSIOL-HEART C, V302, pH1202, DOI 10.1152/ajpheart.00534.2011; Zoll J, 2006, J APPL PHYSIOL, V101, P385, DOI 10.1152/japplphysiol.01486.2005; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Suga T, 2014, ENDOCRINOLOGY, V155, P68, DOI 10.1210/en.2013-1382; Chabi B, 2008, AGING CELL, V7, P2, DOI 10.1111/j.1474-9726.2007.00347.x; Kinugawa S, 2005, CIRCULATION, V111, P1480, DOI 10.1161/01.CIR.0000159261.11520.63; Gielen S, 2012, CIRCULATION, V125, P2716, DOI 10.1161/CIRCULATIONAHA.111.047381; Okita K, 2013, CIRC J, V77, P293, DOI 10.1253/circj.CJ-12-1235; Ribisl PM, 2007, DIABETES CARE, V30, P2679, DOI 10.2337/dc06-2487; Yoshida T, 2010, AM J PHYSIOL-HEART C, V298, pH1565, DOI 10.1152/ajpheart.00146.2010; Harada K, 1999, CIRCULATION, V100, P2093; Wei YZ, 2006, J BIOL CHEM, V281, P35137, DOI 10.1074/jbc.M601320200; SULLIVAN MJ, 1990, CIRCULATION, V81, P518; Takada S, 2013, J APPL PHYSIOL, V114, P844, DOI 10.1152/japplphysiol.00053.2012; Yokota T, 2009, AM J PHYSIOL-HEART C, V297, pH1069, DOI 10.1152/ajpheart.00267.2009; Banas K, 2011, AM J PHYSIOL-REG I, V301, pR916, DOI 10.1152/ajpregu.00663.2010; Blough ER, 2000, J APPL PHYSIOL, V88, P1265; Burniston JG, 2005, EXP PHYSIOL, V90, P755, DOI 10.1113/expphysiol.2005.030908; Fukushima A, 2014, AM J PHYSIOL-ENDOC M, V307, pE503, DOI 10.1152/ajpendo.00449.2013; Gilliam-Davis S, 2007, AM J PHYSIOL-HEART C, V293, pH1327, DOI 10.1152/ajpheart.00457.2007; Kerner J, 2001, AM J PHYSIOL-ENDOC M, V281, pE1054; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC806, DOI 10.1152/ajpcell.00129.2003; Libera L D, 1999, Am J Physiol, V277, pC982; Maxwell AJ, 1998, CIRCULATION, V98, P369; Sriram S, 2014, MOL ENDOCRINOL, V28, P317, DOI 10.1210/me.2013-1179	44	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0958-0670	1469-445X		EXP PHYSIOL	Exp. Physiol.	MAR	2015	100	3					312	322		10.1113/expphysiol.2014.084095		11	Physiology	Physiology	CC6ED	WOS:000350456900012		
J	Tu, CY; Tian, YJ; Hsieh, CH				Tu, Chen-Yi; Tian, Yongjun; Hsieh, Chih-Hao			Effects of climate on temporal variation in the abundance and distribution of the demersal fish assemblage in the Tsushima Warm Current region of the Japan Sea	FISHERIES OCEANOGRAPHY			English	Article						abundance; climate variability; decadal; demersal species; geographical affinity; geographical distribution; interannual; Japan Sea; life history trait	SOUTHERN CALIFORNIA REGION; WESTERN NORTH PACIFIC; MARINE FISHES; COMMUNITY STRUCTURE; ARCTIC OSCILLATION; CHANGE IMPACTS; 4 DECADES; VARIABILITY; SHIFTS; RECRUITMENT	In the present study, we examined the effects of climate on temporal variation in the abundance and geographical distribution of demersal fishes at both interannual and decadal scales in the Tsushima Warm Current region of the Japan Sea using single-trawler fishery data (1972-2002). This single-trawler fishery targeted multiple species with different geographical affinities and life history traits. Thus, these data were suitable for examining the biological mechanisms that underlie how species respond to climate variability. Our results indicate that the distributional changes of species in response to decadal climate variability are best explained by asymptotic length, which indicates that warming has greater negative effects on larger fishes in the Japan Sea. However, none of the variables examined (including geographical affinity, asymptotic length and age at maturation) could explain the shift in abundance at interannual or decadal scales. It should be noted that life history traits and geographical affinities only provide partial explanations of the responses of species to environmental variability, thereby suggesting that other factors, such as interactions among species, may be involved in mediating species responses.	[Tu, Chen-Yi; Hsieh, Chih-Hao] Natl Taiwan Univ, Inst Oceanog, Taipei 10617, Taiwan; [Tian, Yongjun] Fishery Res Agcy, Japan Sea Natl Fisheries Res Inst, Chuo Ku, Niigata 9518121, Japan; [Hsieh, Chih-Hao] Natl Taiwan Univ, Inst Ecol & Evolutionary Biol, Taipei 10617, Taiwan	Tian, YJ (reprint author), Fishery Res Agcy, Japan Sea Natl Fisheries Res Inst, Chuo Ku, Suidou Cho, Niigata 9518121, Japan.	yjtian@affrc.go.jp	Hsieh, Chih-hao/B-3797-2008	Hsieh, Chih-hao/0000-0001-5935-7272	Japan Fisheries Agency; National Taiwan University; Ministry of Science and Technology of Taiwan	This study was partly supported by the Japan Fisheries Agency, National Taiwan University, and Ministry of Science and Technology of Taiwan. We are grateful for discussions in the Stock Assessment and Management Group of Japan Sea National Fisheries Research Institute during the development of this manuscript. We thank two anonymous reviewers and the editor of FO for their comments and suggestions, and Dr D. Cushley of International Science Editing Company for the English proofreading.	Chen IC, 2011, SCIENCE, V333, P1024, DOI 10.1126/science.1206432; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; Doney SC, 2012, ANNU REV MAR SCI, V4, P11, DOI 10.1146/annurev-marine-041911-111611; Portner HO, 2010, J FISH BIOL, V77, P1745, DOI 10.1111/j.1095-8649.2010.02783.x; Beaugrand G, 2003, NATURE, V426, P661, DOI 10.1038/nature02164; Walther GR, 2010, PHILOS T R SOC B, V365, P2019, DOI 10.1098/rstb.2010.0021; Nye JA, 2009, MAR ECOL PROG SER, V393, P111, DOI 10.3354/meps08220; Zani S, 1998, COMPUT STAT DATA AN, V28, P257, DOI 10.1016/S0167-9473(98)00040-1; Rijnsdorp AD, 2009, ICES J MAR SCI, V66, P1570, DOI 10.1093/icesjms/fsp056; Mantua NJ, 2002, J OCEANOGR, V58, P35, DOI 10.1023/A:1015820616384; Lehodey P, 2006, J CLIMATE, V19, P5009, DOI 10.1175/JCLI3898.1; Chiba S, 2008, PROG OCEANOGR, V77, P112, DOI 10.1016/j.pocean.2008.03.004; MacNeil MA, 2010, PHILOS T R SOC B, V365, P3753, DOI 10.1098/rstb.2010.0289; Engelhard GH, 2011, ICES J MAR SCI, V68, P1090, DOI 10.1093/icesjms/fsr031; Perry AL, 2005, SCIENCE, V308, P1912, DOI 10.1126/science.1111322; Hsieh CH, 2006, NATURE, V443, P859, DOI 10.1038/nature05232; Hsieh CH, 2009, GLOBAL CHANGE BIOL, V15, P2137, DOI 10.1111/j.1365-2486.2009.01875.x; Hsieh CH, 2008, CAN J FISH AQUAT SCI, V65, P947, DOI 10.1139/F08-017; Pinsky ML, 2013, SCIENCE, V341, P1239, DOI 10.1126/science.1239352; Minobe S, 2004, J PHYS OCEANOGR, V34, P2382, DOI 10.1175/JPO2627.1; Dulvy NK, 2008, J APPL ECOL, V45, P1029, DOI 10.1111/j.1365-2664.2008.01488.x; Hsieh CH, 2010, AQUAT SCI, V72, P165, DOI 10.1007/s00027-009-0122-2; MINAMI T, 1992, NETH J SEA RES, V29, P35, DOI 10.1016/0077-7579(92)90006-Z; Branch TA, 2006, CAN J FISH AQUAT SCI, V63, P1647, DOI 10.1139/F06-072; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; Marchal P, 2007, FISH RES, V83, P33, DOI 10.1016/j.fishres.2006.08.025; van der Veer HW, 2000, ICES J MAR SCI, V57, P202, DOI 10.1006/jmsc.1999.0523; Hollowed AB, 2013, ICES J MAR SCI, V70, P1023, DOI 10.1093/icesjms/fst081; Tian YJ, 2011, FISH RES, V112, P140, DOI 10.1016/j.fishres.2011.01.034; GIBSON RN, 1994, NETH J SEA RES, V32, P191, DOI 10.1016/0077-7579(94)90040-X; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0; Hsieh CH, 2005, NATURE, V435, P336, DOI 10.1038/nature03553; Mueter FJ, 2008, ECOL APPL, V18, P309, DOI 10.1890/07-0564.1; Mair L, 2012, GLOBAL CHANGE BIOL, V18, P2439, DOI 10.1111/j.1365-2486.2012.02730.x; Morita K, 2010, OIKOS, V119, P1265, DOI 10.1111/j.1600-0706.2009.18125.x; Hixon MA, 2005, ECOLOGY, V86, P2847, DOI 10.1890/04-1455; Narimatsu Y, 2007, FISHERIES SCI, V73, P55, DOI 10.1111/j.1444-2906.2007.01301.x; Burrows MT, 2011, SCIENCE, V334, P652, DOI 10.1126/science.1210288; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Ottersen G, 2010, J MARINE SYST, V79, P343, DOI 10.1016/j.jmarsys.2008.12.013; Hsieh CH, 2005, PROG OCEANOGR, V67, P160, DOI 10.1016/j.pocean.2005.05.002; Chiba S, 2005, FISH OCEANOGR, V14, P401, DOI 10.1111/j.1365-2419.2005.00355.x; Chiba S, 2002, MAR ECOL PROG SER, V231, P23, DOI 10.3354/meps231023; Cui YL, 2010, J OCEANOGR, V66, P337; FUJIOKA T, 1990, NIPPON SUISAN GAKK, V56, P1553; Fujiwara K., 2014, MARINE FISHERIES STO, P1242; HANAWA K, 1988, J METEOROL SOC JPN, V66, P445; Isobe A, 2007, J CLIMATE, V20, P5707, DOI 10.1175/2007JCLI1779.1; Ives AR, 2006, ECOL APPL, V16, P20, DOI 10.1890/04-0702; Katoh O., 2006, B COASTAL OCEANOGRAP, V44, P19; Kawamura S, 2009, B NIIGATA PREF FISH, V2, P3; Keller AA, 2013, DEEP-SEA RES PT I, V77, P23, DOI 10.1016/j.dsr.2013.03.003; MacCall A. D, 1990, DYNAMIC GEOGRAPHY MA; Matsukura R., 2014, MARINE FISHERIES STO, P1269; Minami T, 1986, B JAP SEA REG FISH R, V36, P39; Misu H., 1974, TSUSHIMA WARM CURREN, P91; Naganuma Kosuke, 2000, Bulletin of the Japan Sea National Fisheries Research Institute, V50, P1; Nakagawa M., 2014, MARINE FISHERIES STO, P1459; Nishimura S., 1968, PUBLICATIONS SETO MA, V15, P329; Ogata T., 1980, DEMERSAL FISH RESOUR, P229; Politis D. N., 2004, ECON REV, V23, P53, DOI DOI 10.1081/ETC-120028836; Poloczanska ES, 2013, NATURE CLIMATE CHANG, V3, P1; RAO CR, 1948, MATH P CAMBRIDGE PHI, V44, P50, DOI DOI 10.1017/S0305004100023987; Tian YJ, 2008, PROG OCEANOGR, V77, P127, DOI 10.1016/j.pocean.2008.03.007; Tian YJ, 2006, PROG OCEANOGR, V68, P217, DOI 10.1016/j.pocean.2006.02.009; Tominaga O., 1991, B JAPAN SEA FISHERIE, V41, P11; Uehara S., 2014, MARINE FISHERIES STO, P1428; VansPutten I. E., 2012, FISH FISH, V13, P216; Watanabe Y. W., 2003, GEOPHYS RES LETT, V30, P10	70	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1054-6006	1365-2419		FISH OCEANOGR	Fish Oceanogr.	MAR	2015	24	2					177	189		10.1111/fog.12101		13	Fisheries; Oceanography	Fisheries; Oceanography	CC7KE	WOS:000350545400006		
J	Alabia, ID; Saitoh, SI; Mugo, R; Igarashi, H; Ishikawa, Y; Usui, N; Kamachi, M; Awaji, T; Seito, M				Alabia, Irene D.; Saitoh, Sei-Ichi; Mugo, Robinson; Igarashi, Hiromichi; Ishikawa, Yoichi; Usui, Norihisa; Kamachi, Masafumi; Awaji, Toshiyuki; Seito, Masaki			Seasonal potential fishing ground prediction of neon flying squid (Ommastrephes bartramii) in the western and central North Pacific	FISHERIES OCEANOGRAPHY			English	Article						maximum entropy model; neon flying squid; North Pacific; potential fishing ground; satellite data	RECRUITMENT VARIABILITY; OCEANOGRAPHIC REGIME; INTERMEDIATE WATER; CATCH DATA; HABITAT; OCEAN; DISTRIBUTIONS; FISHERIES; ABUNDANCE; CEPHALOPODA	We explored the seasonal potential fishing grounds of neon flying squid (Ommastrephes bartramii) in the western and central North Pacific using maximum entropy (MaxEnt) models fitted with squid fishery data as response and environmental factors from remotely sensed [sea surface temperature (SST), sea surface height (SSH), eddy kinetic energy (EKE), wind stress curl (WSC) and numerical model-derived sea surface salinity (SSS)] covariates. The potential squid fishing grounds from January-February (winter) and June-July (summer) 2001-2004 were simulated separately and covered the near-coast (winter) and offshore (summer) forage areas off the Kuroshio-Oyashio transition and subarctic frontal zones. The oceanographic conditions differed between regions and were regulated by the inherent seasonal variability and prevailing basin dynamics. The seasonal and spatial extents of potential squid fishing grounds were largely explained by SST (7-17 degrees C in the winter and 11-18 degrees C in the summer) and SSS (33.8-34.8 in the winter and 33.7-34.3 in the summer). These ocean properties are water mass tracers and define the boundaries of the North Pacific hydrographic provinces. Mesoscale variability in the upper ocean inferred from SSH and EKE were also influential to squid potential fishing grounds and are presumably linked to the augmented primary productivity from nutrient enhancement and entrainment of passive plankton. WSC, however, has the least model contribution to squid potential fishing habitat relative to the other environmental factors examined. Findings of this work underpin the importance of SST and SSS as robust predictors of the seasonal squid potential fishing grounds in the western and central North Pacific and highlight MaxEnt's potential for operational fishery application.	[Alabia, Irene D.; Saitoh, Sei-Ichi] Hokkaido Univ, Grad Sch Fisheries Sci, Lab Marine Environm & Resource Sensing, Hakodate, Hokkaido 0418611, Japan; [Mugo, Robinson] Reg Ctr Mapping Resources Dev SERVIR, Nairobi, Kenya; [Igarashi, Hiromichi; Ishikawa, Yoichi] Japan Agcy Marine Earth Sci & Technol JAMSTEC, Data Res Ctr Marine Earth Sci, Yokohama, Kanagawa 2360001, Japan; [Usui, Norihisa; Kamachi, Masafumi] Meteorol Res Inst, Oceanog Res Dept, Tsukuba, Ibaraki 3050052, Japan; [Awaji, Toshiyuki] Kyoto Univ, Grad Sch Sci Div Earth & Planetary Sci, Sakyo Ward, Kyoto 6068502, Japan; [Seito, Masaki] Aomori Prefectural Ind Technol Res Ctr, Aomori 0300113, Japan	Alabia, ID (reprint author), Hokkaido Univ, Grad Sch Fisheries Sci, Lab Marine Environm & Resource Sensing, 3-1-1 Minato Cho, Hakodate, Hokkaido 0418611, Japan.	irenealabia@salmon.fish.hokudai.ac.jp			Research on Climate Change Adaptation (RECCA) Project of the Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT)	This work was supported by the Research on Climate Change Adaptation (RECCA) Project of the Grant-in-Aid from the Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT). We are grateful to two anonymous reviewers for their constructive comments on the earlier version of this manuscript. The authors also acknowledge the following agencies for providing the data used in our analyses: Aomori Prefectural Industrial Technology Research Center for the squid fishery data; Physical Oceanography Distributed Archive Center (PODACC) at the Jet Propulsion Laboratory (JPL) for the AVHRR-OI SST; NOAA Environmental Research Division's Data Access Program (ERDDAP) for the QuikSCAT-derived WSC data and Archiving Validation and Interpretation of Satellite Data (AVISO) for SSH and geostrophic velocity data.	Tian SQ, 2009, FISH RES, V95, P181, DOI 10.1016/j.fishres.2008.08.012; Shanks AL, 2005, ECOL MONOGR, V75, P505, DOI 10.1890/05-0309; Bakun A, 2006, SCI MAR, V70, P105; Mugo R, 2010, FISH OCEANOGR, V19, P382, DOI 10.1111/j.1365-2419.2010.00552.x; TALLEY LD, 1993, J PHYS OCEANOGR, V23, P517, DOI 10.1175/1520-0485(1993)023<0517:DAFONP>2.0.CO;2; Gong CX, 2012, J OCEAN U CHINA, V11, P241, DOI 10.1007/s11802-012-1898-6; Yasuda I, 2003, J OCEANOGR, V59, P389, DOI 10.1023/A:1025580313836; Ready J, 2010, ECOL MODEL, V221, P467, DOI 10.1016/j.ecolmodel.2009.10.025; Scharffenberg MG, 2010, J GEOPHYS RES-OCEANS, V115, DOI 10.1029/2008JC005242; Ichii T, 2004, FISH OCEANOGR, V13, P295, DOI 10.1111/j.1365-2419.2004.00293.x; Watanabe H, 2004, MAR ECOL PROG SER, V266, P173, DOI 10.3354/meps266173; TALLEY LD, 1995, J PHYS OCEANOGR, V25, P475, DOI 10.1175/1520-0485(1995)025<0475:NPIWIT>2.0.CO;2; Zainuddin M, 2006, DEEP-SEA RES PT II, V53, P419, DOI 10.1016/j.dsr2.2006.01.007; Ichii T, 2009, MAR ECOL PROG SER, V378, P1, DOI 10.3354/meps07873; Waluda CM, 2001, MAR BIOL, V139, P671; Yatsu A, 2000, FISH OCEANOGR, V9, P163, DOI 10.1046/j.1365-2419.2000.00130.x; Usui N, 2006, ADV SPACE RES, V37, P806, DOI 10.1016/j.asr.2005.09.022; Zwolinski JP, 2011, ICES J MAR SCI, V68, P867, DOI 10.1093/icesjms/fsr038; Kappes MA, 2010, PROG OCEANOGR, V86, P246, DOI 10.1016/j.pocean.2010.04.012; Pearson RG, 2007, J BIOGEOGR, V34, P102, DOI 10.1111/j.1365-2699.2006.01594.x; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Bower JR, 2005, FISH RES, V76, P39, DOI 10.1016/j.fishres.2005.05.009; Phillips SJ, 2009, ECOL APPL, V19, P181, DOI 10.1890/07-2153.1; Morgan SG, 2009, MAR ECOL PROG SER, V394, P79, DOI 10.3354/meps08216; MacLeod CD, 2008, HYDROBIOLOGIA, V612, P21, DOI 10.1007/s10750-008-9491-0; Mugo RM, 2014, DEEP-SEA RES PT II, V107, P29, DOI 10.1016/j.dsr2.2013.11.005; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Manderson J, 2011, MAR ECOL PROG SER, V438, P1, DOI 10.3354/meps09308; Kai ET, 2009, P NATL ACAD SCI USA, V106, P8245, DOI 10.1073/pnas.0811034106; Watanabe H, 2008, J MAR BIOL ASSOC UK, V88, P381, DOI 10.1017/S0025315408000635; Hermosilla C, 2011, HYDROBIOLOGIA, V670, P35, DOI 10.1007/s10750-011-0671-y; Jones MC, 2012, ECOL MODEL, V225, P133, DOI 10.1016/j.ecolmodel.2011.11.003; Hirzel AH, 2001, ECOL MODEL, V145, P111, DOI 10.1016/S0304-3800(01)00396-9; Brunetti N. E., 2004, REV INVESTIGACION DE, V16, P51; Canty A.J., 2002, R NEWS, V2, P2; Cao J, 2009, MAR ECOL PROG SER, V381, P119, DOI 10.3354/meps07969; Chavanne CP, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL045057; Chen CS, 2010, ICES J MAR SCI, V67, P1336, DOI 10.1093/icesjms/fsq063; Chen X. J., 2006, J JIMEI U, V11, P40; Chen XJ, 2011, CHIN J OCEANOL LIMN, V29, P493, DOI 10.1007/s00343-011-0058-y; Chen XJ, 2008, FISH RES, V89, P211, DOI 10.1016/j.fishres.2007.10.012; Dell J, 2011, FISH OCEANOGR, V20, P383, DOI 10.1111/j.1365-2419.2011.00591.x; Gallaway BJ, 2003, N AM J FISH MANAGE, V23, P581, DOI 10.1577/1548-8675(2003)023<0581:DOASEL>2.0.CO;2; Ignell S. E., 1991, U S DEP COMMER, P89; Lefkaditou E, 2008, HYDROBIOLOGIA, V612, P71, DOI 10.1007/s10750-008-9490-1; Liu H. S., 2002, J ZHANJIANG OCEAN U, V22, P29; Morris L, 2006, ICES J MAR SCI, V63, P1590, DOI 10.1016/j.icesjms.2006.06.008; Murata M., 1998, INT S LARG PEL SQUID, P13; Roden G. I., 1991, NOAA TECH REP NMFS, V105, P1; Rodhouse PG, 2001, FISH RES, V54, P3, DOI 10.1016/S0165-7836(01)00370-8; Roper C. F. E., 1984, FAO FISH SYNOPSES, V125, P1; Shao Q. Q., 2005, OCEANOL LIMNOL SIN, V5, P111; Steele J. H., 2010, ELEMENTS PHYS OCEANO, V1; Syfert MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055158; Tian SQ, 2009, CHIN J OCEANOL LIMN, V27, P729, DOI 10.1007/s00343-009-9199-7; Waluda CM, 2006, MAR ECOL PROG SER, V310, P25, DOI 10.3354/meps310025; Yatsu Akihiko, 1996, Bulletin of the National Research Institute of Far Seas Fisheries, V33, P123; Yatsu A., 1997, CONTRIBUTIONS FISHER, V36, P53	58	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1054-6006	1365-2419		FISH OCEANOGR	Fish Oceanogr.	MAR	2015	24	2					190	203		10.1111/fog.12102		14	Fisheries; Oceanography	Fisheries; Oceanography	CC7KE	WOS:000350545400007		
J	Cachet, T; Brevard, H; Cantergiani, E; Chaintreau, A; Demyttenaere, J; French, L; Gassenmeier, K; Joulain, D; Koenig, T; Leijs, H; Liddle, P; Loesing, G; Marchant, M; Saito, K; Scanlan, F; Schippa, C; Scotti, A; Sekiya, F; Sherlock, A; Smith, T				Cachet, T.; Brevard, H.; Cantergiani, E.; Chaintreau, A.; Demyttenaere, J.; French, L.; Gassenmeier, K.; Joulain, D.; Koenig, T.; Leijs, H.; Liddle, P.; Loesing, G.; Marchant, M.; Saito, K.; Scanlan, F.; Schippa, C.; Scotti, A.; Sekiya, F.; Sherlock, A.; Smith, T.			Determination of volatile 'restricted substances' in flavourings and their volatile raw materials by GC-MS	FLAVOUR AND FRAGRANCE JOURNAL			English	Article						gas chromatography; mass spectrometry; selected-ion monitoring; flavourings; restricted substances; quantitative analysis	VANILLA EXTRACT PRODUCTS; LIQUID-CHROMATOGRAPHY; ETHYL VANILLIN; FOOD-PRODUCTS; SOFT DRINKS; COUMARIN; SAFROLE; QUANTIFICATION; QUANTITATION; ASARONE	Many flavour regulations around the world contain a list of so-called restricted substances' (RS), i.e. substances that occur naturally in source materials for flavourings and food ingredients with flavouring properties, but whose presence in certain foods is restricted and/or for which maximum levels are set, for example, the European regulation 1334/2008. Only a few publications refer to the determination of RS in compound flavourings or their raw materials, and the latter only concern the analysis of one or two individual RS in single essential oils. The Working Group on Methods of Analysis of the International Organization of the Flavor Industry (IOFI) has developed a method for the rapid routine determination of -asarone, coumarin, menthofuran, methylchavicol, methyleugenol, pulegone, safrole and - and -thujones in flavourings and their raw materials by gas chromatography-mass spectrometry (GC-MS), using selected-ion monitoring and internal standards. The method has been evaluated by nine flavour-industry laboratories using a complex surrogate flavouring containing all of the above analytes, at concentrations that would be likely to produce levels in finished foods of around typical maximum limits for these RS. Results were obtained from a total of 15 columns and sets of analytical conditions, using 11 GC/MS instruments, with in each case a determination of the analyte in two versions of the flavouring. With reproducibility relative standard deviations (RSDR) of less than about 20%, and recoveries of 80-120%, the method performance can be considered as satisfactory for rapid routine checks on the levels of restricted substances in compound flavourings. The method is intended for flavour-industry laboratories in order for them to fulfil their obligation to inform food-industry clients of the amounts of these substances in commercial flavourings, but is not intended for their analysis in finished foods. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Cachet, T.; Brevard, H.; Cantergiani, E.; Chaintreau, A.; Demyttenaere, J.; French, L.; Gassenmeier, K.; Joulain, D.; Koenig, T.; Leijs, H.; Liddle, P.; Loesing, G.; Marchant, M.; Saito, K.; Scanlan, F.; Schippa, C.; Scotti, A.; Sekiya, F.; Sherlock, A.; Smith, T.] IOFI Int Org Flavor Ind Working Grp Methods Anal, Osaka, Japan	Cachet, T (reprint author), IOFI Int Org Flavor Ind Working Grp Methods Anal, Osaka, Japan.	tcachet@iofiorg.org					Analytical Methods Committee, 1981, ANALYST, V106, P448; Analytical Methods Committee Royal Society of Chemistry Essential Oils Subcommittee, 2002, ANALYST, V127, P428; de Jager LS, 2007, J CHROMATOGR A, V1145, P83, DOI 10.1016/j.chroma.2007.01.039; De Jager LS, 2008, FOOD CHEM, V107, P1701, DOI 10.1016/j.foodchem.2007.09.070; VANDENDOOL H, 1963, J CHROMATOGR, V11, P463, DOI 10.1016/S0021-9673(01)80947-X; Tissot E, 2012, FLAVOUR FRAG J, V27, P290, DOI 10.1002/ffj.3098; [Anonymous], 1988, Z LEBENSM UNTERS FOR, V186, P36; Sproll C, 2008, FOOD CHEM, V109, P462, DOI 10.1016/j.foodchem.2007.12.068; Chaintreau A, 2003, J AGR FOOD CHEM, V51, P6398, DOI 10.1021/jf030363t; Archer W., 1988, J CHROMATOGR, V438, P117; Avila M, 2009, J CHROMATOGR A, V1216, P7179, DOI 10.1016/j.chroma.2009.08.053; Choong YM, 2001, J FOOD DRUG ANAL, V9, P27; Dawidowicz L., 2012, FOOD CONTROL, V25, P197; International Organization of the Flavor Industry, 2012, FLAVOUR FRAG J, V27, P224; Cachet T, 2011, FLAVOUR FRAG J, V26, P297, DOI 10.1002/ffj.2061; LANDER V, 1990, Z LEBENSM UNTERS FOR, V190, P410, DOI 10.1007/BF01202558; Micali Giuseppe, 1995, Flavour and Fragrance Journal, V10, P329, DOI 10.1002/ffj.2730100508; MICALI G, 1980, J CHROMATOGR, V194, P245, DOI 10.1016/S0021-9673(00)87304-5; Otto Frank, 2001, Advances in Food Sciences, V23, P31; Raffo A, 2013, FOOD CHEM TOXICOL, V59, P626, DOI 10.1016/j.fct.2013.06.058; Scotter M., 2011, SIMULTANEOUS DISTILL; Siano F, 2005, FOOD ADDIT CONTAM, V22, P197, DOI 10.1080/02652030500041581; Siano F, 2003, FOOD CHEM, V81, P469, DOI 10.1016/S0308-8146(03)00004-9; Walch SG, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-44; 2002, OFFIC J EUR COMMUN L, V221, P8; 2008, OFFIC J EUR COMMUN L, V354, P34	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0882-5734	1099-1026		FLAVOUR FRAG J	Flavour Frag. J.	MAR	2015	30	2					160	164		10.1002/ffj.3222		5	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CB9RE	WOS:000349969000004		
J	Wakabayashi, M; Wakabayashi, H; Norenberg, S; Kubota, K; Engel, KH				Wakabayashi, Motoko; Wakabayashi, Hidehiko; Noerenberg, Svenja; Kubota, Kikue; Engel, Karl-Heinz			Comparison of odour thresholds and odour qualities of the enantiomers of 4-mercapto-2-alkanones and 4-acetylthio-2-alkanones	FLAVOUR AND FRAGRANCE JOURNAL			English	Article						4-mercapto-2-alkanone; 4-acetylthio-2-alkanone; absolute configuration; odour threshold; odour property; flavour	H-1-NMR ANISOTROPY METHOD; VAR. SAUVIGNON BLANC; SENSORY PROPERTIES; COMBINATORIAL SYNTHESIS; 2-METHOXY-2-(1-NAPHTHYL)PROPIONIC ACID; 3-MERCAPTOHEXYL ACETATE; ABSOLUTE-CONFIGURATIONS; FLAVOR COMPOUNDS; IDENTIFICATION; VOLATILE	4-Mercapto-2-alkanones constitute a class of naturally occurring polyfunctional thiols; 4-mercapto-2-heptanone, for example, has been reported in cooked red bell pepper. The objective of this study was to determine the impact of the chain length on the odour thresholds and the odour qualities of the enantiomers of these chiral volatiles. 4-Acetylthio-2-pentanone and 4-acetylthio-2-hexanone and the corresponding 4-mercapto-2-alkanones were synthesized by the addition of thioacetic acid to 3-alkene-2-ones and subsequent lipase-catalysed hydrolysis. The absolute configurations and the gas chromatography (GC) elution order of the enantiomers on a chiral stationary phase were determined on the basis of H-1 NMR anisotropy effects in combination with lipase-catalysed enantioselective hydrolysis. These compounds were included into a homologous series of 4-mercapto-2-alkanones and 4-acetylthio-2-alkanones exhibiting alkyl carbon chain lengths from 5 to 10. The odour thresholds of the enantiomers were compared using capillary gas chromatography-olfactometry (GC-O). The odour thresholds of the mercapto-compounds were consistently lower than those of the corresponding acetylthio-compounds. Both series of compounds exhibited minima of the odour thresholds at alkyl carbon chain lengths of 7 and 8, respectively. Odour thresholds of the (S)-enantiomers of 4-mercapto-2-hexanone and 4-acetylthio-2-hexanone were significantly lower than those of the corresponding (R)-enantiomers. The (S)-enantiomers of the mercapto-compounds had more fruity and pleasant notes than the (R)-enantiomers. Although the number of judges was limited, the comparative data demonstrate the impact of the chain length on odour thresholds and odour qualities of members of a homologous series and underline the role of the configurations for the sensory properties of chiral volatiles. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Wakabayashi, Motoko; Kubota, Kikue] Ochanomizu Univ, Grad Sch Humanities & Sci, Dept Food & Nutr Sci, Bunkyo Ku, Tokyo 1128610, Japan; [Wakabayashi, Motoko] Nihon Univ, Grad Sch Appl Life Sci, Fujisawa, Kanagawa 2520880, Japan; [Wakabayashi, Hidehiko; Noerenberg, Svenja; Engel, Karl-Heinz] Tech Univ Munich, Lehrstuhl Allgemeine Lebensmitteltechnol, D-85350 Freising Weihenstephan, Germany; [Kubota, Kikue] Tokyo Univ Agr, Nodai Res Inst, Setagaya Ku, Tokyo 1568502, Japan	Wakabayashi, M (reprint author), Nihon Univ, Grad Sch Appl Life Sci, 1866 Kameino, Fujisawa, Kanagawa 2520880, Japan.	wakabayashi.motoko@nihon-u.ac.jp					ANNUNZIATA R, 1992, J ORG CHEM, V57, P456, DOI 10.1021/jo00028a015; HOFMANN T, 1995, J AGR FOOD CHEM, V43, P2187, DOI 10.1021/jf00056a042; Bouchilloux P, 1998, J AGR FOOD CHEM, V46, P3095, DOI 10.1021/jf971027d; Tominaga T, 1998, FLAVOUR FRAG J, V13, P159, DOI 10.1002/(SICI)1099-1026(199805/06)13:3<159::AID-FFJ709>3.3.CO;2-Z; Taji H, 2002, CHIRALITY, V14, P81, DOI 10.1002/chir.10038; Harada N, 2000, TETRAHEDRON-ASYMMETR, V11, P1249, DOI 10.1016/S0957-4166(00)00053-7; Tominaga T, 1996, VITIS, V35, P207; RAKELS JLL, 1993, ENZYME MICROB TECH, V15, P1051, DOI 10.1016/0141-0229(93)90053-5; ULLRICH F, 1987, Z LEBENSM UNTERS FOR, V184, P277, DOI 10.1007/BF01027663; ENGEL KH, 1991, J AGR FOOD CHEM, V39, P2249, DOI 10.1021/jf00012a030; Tominaga T, 2006, J AGR FOOD CHEM, V54, P7251, DOI 10.1021/jf061566v; Blank I., 2002, ACS SYM SER, V826, P25; Boelens Mans H., 1993, Perfumer and Flavorist, V18, P29; Boelens M. H., 1986, DEV FOOD FLAVOURS, P23; Carrapiso A. I., 2002, J AGR FOOD CHEM, V50, P2000; GRAYSON DH, 1986, J CHEM SOC PERK T 1, P2137, DOI 10.1039/p19860002137; LAMPARSK.D, 1971, TETRAHEDRON LETT, P3323; Luntzel CS, 2000, J AGR FOOD CHEM, V48, P424; MUSSINAN CJ, 1994, ACS SYM SER, V564, P1; Naef R, 2008, J AGR FOOD CHEM, V56, P517, DOI 10.1021/jf072493y; Norenberg S, 2013, J AGR FOOD CHEM, V61, P2062, DOI 10.1021/jf305447e; Polster J., 2011, P 9 WARTB S FLAV CHE, P69; Robert F, 2004, J AGR FOOD CHEM, V52, P3525, DOI [10.1021/jf0498968, 10.1021/f0498968]; Rowe D. J., 2002, P202, DOI 10.1039/9781847550071-00202; Schieberle P., 2001, ACS SYM SER, V794, P109, DOI 10.1021/bk-2001-0794.ch009; Steinhaus M, 2008, J AGR FOOD CHEM, V56, P4120, DOI 10.1021/jf8005245; Stoffelsma J., 1977, J. Pypker. United States Patent, Patent No. 4053656; SUNDT E, 1971, HELV CHIM ACTA, V54, P1801, DOI 10.1002/hlca.19710540708; Tan YX, 2004, J AGR FOOD CHEM, V52, P3057, DOI 10.1021/jf035149j; van de Waal M, 2002, HELV CHIM ACTA, V85, P1246; Vermeulen C, 2003, J AGR FOOD CHEM, V51, P3618, DOI 10.1021/jf021138z; Vermeulen C, 2003, J AGR FOOD CHEM, V51, P3623, DOI 10.1021/jf0212340; Vermeulen C, 2002, J AGR FOOD CHEM, V50, P5654, DOI 10.1021/jf020468g; Vermeulen C, 2006, COMB CHEM HIGH T SCR, V9, P583, DOI 10.2174/138620706778249712; Wakabayashi H, 2003, J AGR FOOD CHEM, V51, P4349, DOI 10.1021/jf030166u; Wakabayashi M, 2011, EUR FOOD RES TECHNOL, V232, P753, DOI 10.1007/s00217-011-1440-x; WEBER B, 1992, Z LEBENSM UNTERS FOR, V195, P426, DOI 10.1007/BF01191710; Widder S, 2000, J AGR FOOD CHEM, V48, P418, DOI 10.1021/jf9908291	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0882-5734	1099-1026		FLAVOUR FRAG J	Flavour Frag. J.	MAR	2015	30	2					171	178		10.1002/ffj.3228		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	CB9RE	WOS:000349969000006		
J	Hamada, S; Wilk, R; Logan, A; Minard, S; Trubek, A				Hamada, Shingo; Wilk, Richard; Logan, Amanda; Minard, Sara; Trubek, Amy			The Future of Food Studies	FOOD CULTURE & SOCIETY			English	Article						food studies; interdisciplinary; transdisciplinarity; food pedagogy; curriculum development; higher education		The use of food as a core mode of exploring and explaining the world has expanded remarkably quickly in the past ten years, with food studies programming in particular gaining ground in institutional learning arrangements during the last three. Establishing a new field and creating relevant educational programming carries its associated struggles, practicalities and initial successes. To this end, this report highlights five of the most pressing themes to emerge from the 2013 "Future of Food Studies" interdisciplinary workshop, namely: (1) locating food studies in the institutional culture; (2) training undergraduate and graduate students within and beyond disciplinarily; (3) establishing food studies labs and pedagogy; (4) engaging the public beyond the campus; and (5) funding strategies for research and training. Participants agreed on the relevancy of food studies to future learning, teaching and research agendas and argued that food studies could not prosper without a commitment to transgressing conventional institutional and philosophical boundaries. At a time when the value of higher education is under intense scrutiny we acknowledge the need to make food studies a paradigm capable of providing students with the necessary skills for post-graduate employment.	[Hamada, Shingo] Res Inst Humanity & Nat, Kita Ku, Kyoto 6060014, Japan; [Wilk, Richard; Minard, Sara] Indiana Univ, Dept Anthropol, Bloomington, IN 47405 USA; [Logan, Amanda] Northwestern Univ, Dept Anthropol, Evanston, IL 60201 USA; [Trubek, Amy] Dept Nutr & Food Sci, Burlington, VT 05401 USA	Hamada, S (reprint author), Res Inst Humanity & Nat, Kita Ku, Kyoto 6060014, Japan.	hamadas@chikyu.ac.jp; wilkr@indiana.edu; amanda.logan@northwestern.edu; sminard@indiana.edu; amy.trubek@uvm.edu					Alkon AH, 2011, FOOD HEALTH ENVIRON, P1; Barlett Peggy, 2009, ANTHR CLIMATE CHANGE, P356; Belasco W., 2008, FOOD KEY CONCEPTS; Belasco W., 1993, APPETITE CHANGE COUN; Counihan Carole, 2012, FOOD CULTURE READER; Gottwarld Franz-Theo., 2010, FOOD ETHICS; Guthman J, 2004, CAL STUD CRIT HUM GE, V11, P1; Long LM, 2004, CULINARY TOURISM; Mintz Sidney W., 1986, SWEETNESS POWER PLAC; Nestle M, 2002, FOOD POLITICS FOOD I; Nestle M, 2010, FOOD CULT SOC, V13, P159, DOI 10.2752/175174410X12633934462999; Nichter Mimi, 2002, FAT TALK WHAT GIRLS; Santich B., 2004, International Journal of Hospitality Management, V23, P15, DOI 10.1016/S0278-4319(03)00069-0; Trubek AB, 2008, CAL STUD FOOD CULT, V20, P1; Universita degli Studi di Scienze Gastronomiche (UNISG), 2012, HIST MISS; Williams-Forson Psyche, 2011, TAKING FOOD PUBLIC R	16	0	0	BLOOMSBURY PUBLISHING  PLC	LONDON	50 BEDFORD SQ, LONDON, WC1B 3DP, ENGLAND	1552-8014	1751-7443		FOOD CULT SOC	Food Cult. Soc.	MAR	2015	18	1					167	186		10.2752/175174415X14101814953846		20	Sociology	Sociology	CC7BU	WOS:000350523500009		
J	Nagaoka, T; Kawakubo, Y				Nagaoka, Tomohito; Kawakubo, Yoshinori			Using the petrous part of the temporal bone to estimate fetal age at death	FORENSIC SCIENCE INTERNATIONAL			English	Article						Forensic science; Forensic anthropology population data; Fetal age at death; Petrous part; Regression equation; Bayesian estimation	INFANT SACRIFICE; LENGTH; OSSIFICATION; CARTHAGE; CENTERS; GROWTH; PERIOD	Little is understood about the age-related changes in the petrous part of the temporal bone in fetal life. The purposes of this study were to examine documented skeletal remains of Japanese fetuses, to measure the length of the petrous part, and to develop diagnostic standards for fetal age-at-death estimation that could be applied to poorly preserved skeletons. The results indicated that it is possible to use a regression equation to estimate age at death directly from the length of the petrous part of the temporal bone. The application of the present method to a different population led to a fetal age-at-death estimation with an error of less than 1 month. We also used the Bayesian estimation, which yielded posterior probabilities of age, conditional on being of a particular length of the petrous part. The reference table of estimated gestational age may provide an easy-to-use indicator of the fetal age at death. In conclusion, measurement of the petrous part of the temporal bone may offer a new methodological basis for forensic and bioarchaeological diagnoses of fetuses. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Nagaoka, Tomohito] St Marianna Univ, Sch Med, Dept Anat, Kawasaki, Kanagawa 2168511, Japan; [Kawakubo, Yoshinori] Saga Med Sch, Dept Biol Anthropol & Anat, Saga 8498501, Japan	Nagaoka, T (reprint author), St Marianna Univ, Sch Med, Dept Anat, Miyamae Ward, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	nagaoka@marianna-u.ac.jp					Adalian P, 2001, J FORENSIC SCI, V46, P215; BOCQUETAPPEL JP, 1982, J HUM EVOL, V11, P321, DOI 10.1016/S0047-2484(82)80023-7; HADLOCK FP, 1982, AM J ROENTGENOL, V138, P875; Tocheri MW, 2005, INT J OSTEOARCHAEOL, V15, P326, DOI 10.1002/oa.784; SCHEUER JL, 1980, ANN HUM BIOL, V7, P257, DOI 10.1080/03014468000004301; Goto Rie, 2007, Journal of Physiological Anthropology, V26, P253, DOI 10.2114/jpa2.26.253; Lewis ME, 2007, AM J PHYS ANTHROPOL, V134, P117, DOI 10.1002/ajpa.20643; GARN SM, 1979, AM J PHYS ANTHROPOL, V51, P665, DOI 10.1002/ajpa.1330510416; QUEENAN JT, 1980, AM J OBSTET GYNECOL, V138, P297; Noback CR, 1954, AM J PHYS ANTHROP-NE, V12, P63, DOI 10.1002/ajpa.1330120118; Balthazard T., 1921, ANN MED LEGALE, V1, P37; Carneiro C., 2013, FORENSIC SCI INT, V231; Castellana C., 2001, J FORENSIC SCI, V117, P31; Chamberlain A. T, 2006, DEMOGRAPHY ARCHAEOLO; Chervenak FA, 1998, AM J OBSTET GYNECOL, V178, P678, DOI 10.1016/S0002-9378(98)70477-6; Doubilet P.M., 2000, ULTRASONOGRAPHY OBST; Fazekas IGY, 1978, FORENSIC FETAL OSTEO; Gowland R.L., 2002, J ARCHAEOL SCI, V29, P679; Hadlock F.P., 1994, ULTRASONOGRAPHY OBST, P86; Hill AH, 1939, AM J PHYS ANTHROPOL, V24, P251, DOI 10.1002/ajpa.1330240315; Huxley AK, 1998, J FORENSIC SCI, V43, P423; JEANTY P, 1984, J ULTRAS MED, V3, P75; JEANTY P, 1981, RADIOLOGY, V140, P165; KONIGSBERG LW, 1992, AM J PHYS ANTHROPOL, V89, P235, DOI 10.1002/ajpa.1330890208; Kosa F., 1989, AGE MARKERS HUMAN SK, P21; LOGAN WILLIAM H. G., 1933, JOUR AMER DENTAL ASSOC, V20, P379; MATSUSHITA K, 1995, TOHOKU J EXP MED, V176, P109, DOI 10.1620/tjem.176.109; Nagaoka T, 2012, ANTHROPOL SCI, V120, P115, DOI 10.1537/ase.1107312; Nagaoka T, 2012, INT J LEGAL MED, V126, P703, DOI 10.1007/s00414-012-0718-2; Perini Talita Adão, 2005, Rev Bras Med Esporte, V11, P81, DOI 10.1590/S1517-86922005000100009; Scheuer L., 2000, DEV JUVENILE OSTEOLO; Schour I, 1937, J DENT RES, V16, P349; SCHOUR I., 1941, JOUR AMER DENTAL ASSOC, V28, P1153; Schwartz JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009177; Schwartz JH, 2012, ANTIQUITY, V86, P738; Sherwood RJ, 2000, AM J PHYS ANTHROPOL, V113, P305, DOI 10.1002/1096-8644(200011)113:3<305::AID-AJPA3>3.0.CO;2-R; Smith P, 2013, ANTIQUITY, V87, P1191; Ubelaker D.H., 1989, HUMAN SKELETAL REMAI; Ulijaszek SJ, 1994, ANTHROPOMETRY INDIVI, P30	39	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	MAR	2015	248									10.1016/j.forsciint.2015.01.009		7	Medicine, Legal	Legal Medicine	CB9PA	WOS:000349962800029		
J	Tsujikawa, K; Yamamuro, T; Kuwayama, K; Kanamori, T; Iwata, YT; Inoue, H				Tsujikawa, Kenji; Yamamuro, Tadashi; Kuwayama, Kenji; Kanamori, Tatsuyuki; Iwata, Yuko T.; Inoue, Hiroyuki			Instability of the hydrochloride salts of cathinone derivatives in air	FORENSIC SCIENCE INTERNATIONAL			English	Article						Cathinone; alpha-Pyrrolidinoheptanophenone; Oxidative decomposition; Dealkylation	DESIGNER DRUGS; STABILITY	We observed the decomposition of the hydrochloride salt of alpha-pyrrolidinoheptanophenone (alpha-PHPP-HCl), a newly distributed pyrrolidine-type cathinone derivative when 2.5 ng of this substance was placed in glass test tubes and stored in a refrigerator for 3 days. To further investigate this phenomenon, we studied the (i) time course of the residual ratios of alpha-PHPP-HCl when a small amount (10 mu g) of alpha-PHPP-HCl was stored in glass vials in air at room temperature; (ii) identification of the decomposition products of alpha-PHPP-HCl; (iii) effect of air on the decomposition process; (iv) effect of the added amounts of alpha-PHPP-HCl on its decomposition; and (v) comparison of the stability between various cathinone derivatives and their decomposition products. The decomposition of alpha-PHPP-HCl occurred in air and increased with time. Two possible decomposition products, alpha-(2 ''-oxopyrrolidino)heptanophenone and alpha-PHPP-N-oxide, were identified. These products were formed by oxygen in air because the yield significantly decreased by storing them in a vacuum desiccator. With the decrease in the amount of alpha-PHPP-HCl, the residual ratios decreased and amount of the decomposition products increased. This indicates that the decomposition of alpha-PHPP-HCl occurred on the upper surface of the samples. The hydrochloride salts of other cathinone derivatives were also unstable in air, and the residual ratios observed were different depending on the compounds. The pyrrolidine-type cathinone derivatives afforded two types of decomposition products, which were presumed to be 2 ''-oxo and N-oxide derivatives, similar to alpha-PHPP-HCl. In contrast, secondary amine-type cathinone derivatives showed different decomposition patterns, possibly including the dealkylated derivative. These findings may be very useful for the future toxicological analysis of cathinone derivatives. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Tsujikawa, Kenji; Yamamuro, Tadashi; Kuwayama, Kenji; Kanamori, Tatsuyuki; Iwata, Yuko T.; Inoue, Hiroyuki] Natl Res Inst Police Sci, Chem Sect 1, Kashiwa, Chiba 2770882, Japan	Tsujikawa, K (reprint author), Natl Res Inst Police Sci, Chem Sect 1, 6-3-1 Kashiwanoha, Kashiwa, Chiba 2770882, Japan.	tujikawa@nrips.go.jp					ALEKSANDROV AL, 1980, B ACAD SCI USSR CH+, V29, P1740, DOI 10.1007/BF00949211; [Anonymous], TECHN B AL, VAL-116; Tsujikawa K, 2012, FORENSIC SCI INT, V220, P103, DOI 10.1016/j.forsciint.2012.02.005; KISAKI T, 1978, BEITR TABAKFORSCH, V9, P308; Gannett PM, 2001, J ANAL TOXICOL, V25, P88; Johnson RD, 2013, J ANAL TOXICOL, V37, P51, DOI 10.1093/jat/bks138; Maisonneuve B., KIRK OTHMER ENCY CHE, DOI [10.1002/0471238961.0113091413010919.a01, DOI 10.1002/0471238961.0113091413010919.A01]; Saal C., AM PHARM REV; Shima N, 2014, FORENSIC TOXICOL, V32, P59, DOI 10.1007/s11419-013-0202-9; Uchiyama N, 2014, FORENSIC SCI INT, V243, P1, DOI 10.1016/j.forsciint.2014.03.013; Wang CC, 2012, J ANAL TOXICOL, V36, P327, DOI 10.1093/jat/bks033	11	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	MAR	2015	248						48	54		10.1016/j.forsciint.2014.12.016		7	Medicine, Legal	Legal Medicine	CB9PA	WOS:000349962800009		
J	Kirinoki, M; Hitosugi, M; Kato-Hayashi, N; Iwasa, M; Chigusa, Y				Kirinoki, M.; Hitosugi, M.; Kato-Hayashi, N.; Iwasa, M.; Chigusa, Y.			Discovery of Liopiophila varipes and Protopiophila contecta (Diptera: Piophilidae) from human cadavers	FORENSIC SCIENCE INTERNATIONAL			English	Article						Liopiophila varipes; Piophila casei; Protopiophila contecta; Piophilidae; Forensic entomology	FORENSIC ENTOMOLOGY; HUMAN CORPSES; PIG CARRION; HAWAIIAN-ISLANDS; IDENTIFICATION; SUCCESSION; MEGASTIGMATA; PORTUGAL; THAILAND; MALAYSIA	Here, we present two cases in which larvae of the family Piophilidae were detected in human cadavers. Both cases were found in Tochigi Prefecture, which is located in the middle of Honshu Island, Japan. Case 1: A corpse was found hanging in the sun lounge of a house. Dipteran larvae were collected from inside the spinal canal, despite no visible breach on the skin. The adults derived from these larvae were identified as Piophila casei (Linnaeus, 1758) and Liopiophila varipes (Meigen, 1830). Case 2: Skeletal human remains were found in a mountainous forest. Dipteran larvae were detected in the bone marrow cavity of a tibial section during autopsy. One adult fly derived from the larvae was identified as Protopiophila contecta (Walker, 1860). This is the first report of the identification of L. varipes and P. contecta in human cadavers. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Kirinoki, M.; Kato-Hayashi, N.; Chigusa, Y.] Dokkyo Med Univ, Lab Trop Med & Parasitol, Mibu, Tochigi 3210293, Japan; [Hitosugi, M.] Dokkyo Med Univ, Dept Legal Med, Sch Med, Mibu, Tochigi 3210293, Japan; [Iwasa, M.] Obihiro Univ Agr & Vet Med, Entomol Lab, Obihiro, Hokkaido 0808555, Japan	Kirinoki, M (reprint author), Dokkyo Med Univ, Lab Trop Med & Parasitol, Mibu, Tochigi 3210293, Japan.	kirinoki@dokkyomed.ac.jp			Dokkyo Medical University [2009-02-1]	This work was supported by Dokkyo Medical University, Project Research Grant (No. 2009-02-1). The authors wish to thank Ms. Yumie Tsunoda, a technical staff member at the Department of Legal Medicine, School of Medicine, Dokkyo Medical University, for her valuable support. We would like to thank Editage (www.editage.jp) for English language editing. The authors would like to thank Mr. William Hassett, Lecturer at Division of Language Education, Dokkyo Medical University, for the English language review.	Anderson GS, 1995, CAN SOC FORENSIC SCI, V28, P277; Martin-Vega D, 2011, FORENSIC SCI INT, V212, P1, DOI 10.1016/j.forsciint.2011.06.016; Boehme P, 2012, PARASITOL RES, V110, P2325, DOI 10.1007/s00436-011-2767-8; Martin-Vega D, 2011, MED VET ENTOMOL, V25, P64, DOI 10.1111/j.1365-2915.2010.00907.x; Wells JD, 2001, J FORENSIC SCI, V46, P1098; Carvalho LML, 2000, MEM I OSWALDO CRUZ, V95, P135, DOI 10.1590/S0074-02762000000100023; Benecke M, 1998, J FORENSIC SCI, V43, P797; Oliva A, 2001, FORENSIC SCI INT, V120, P145, DOI 10.1016/S0379-0738(01)00423-6; Velasquez Y, 2010, MED VET ENTOMOL, V24, P293, DOI 10.1111/j.1365-2915.2010.00879.x; Horenstein MB, 2010, MED VET ENTOMOL, V24, P16, DOI 10.1111/j.1365-2915.2009.00854.x; Lefebvre F, 2009, ANN SOC ENTOMOL FR, V45, P377; Wolff M, 2001, FORENSIC SCI INT, V120, P53, DOI 10.1016/S0379-0738(01)00422-4; Kumara TK, 2009, TROP BIOMED, V26, P73; Sukontason K, 2007, PARASITOL RES, V101, P1417, DOI 10.1007/s00436-007-0659-8; Anton E, 2011, MED VET ENTOMOL, V25, P353, DOI 10.1111/j.1365-2915.2011.00975.x; Bonduriansky R, 1995, CAN ENTOMOL, V127, P859; Caine LM, 2009, FORENSIC SCI INT, V184, pE21, DOI 10.1016/j.forsciint.2008.10.016; Castro CPE, 2012, MED VET ENTOMOL, V26, P417, DOI 10.1111/j.1365-2915.2012.01031.x; CASTRO CPE, 2010, GRAELLSIA, V66, P101, DOI DOI 10.3989/graellsia.2010.v66.013; Castro CPE, 2012, FORENSIC SCI INT, V214, P23, DOI 10.1016/j.forsciint.2011.07.009; de Pablo R. Ramos, 2006, INT C SER, V1288, P864; Diaz S., 2005, LIST TERRESTRIAL FAU, P210; GOFF ML, 1987, AM J FOREN MED PATH, V8, P45, DOI 10.1097/00000433-198703000-00011; GOFF ML, 1991, J FORENSIC SCI, V36, P607; Hennig W., 1943, FLIEGEN PALAEARKTISC, V5, P1; Iwasa Mitsuhiro, 1998, Medical Entomology and Zoology, V49, P33; Kehlmaier Christian, 1998, Boletim do Museu Municipal do Funchal, V50, P71; Kirinoki Masashi, 2010, Medical Entomology and Zoology, V61, P115; Marchenko MI, 2001, FORENSIC SCI INT, V120, P89, DOI 10.1016/S0379-0738(01)00416-9; Martin-Vega Daniel, 2010, Beitrage zur Entomofaunistik, V11, P9; Matuszewski K. S., 2008, FORENSIC SCI INT, V180, P61; Matuszewski S., 2013, INT J LEGAL MED, V128, P1013; MCALPINE JF, 1977, MEM ENTOMOL SOC CAN, P1; MCALPINE J F, 1978, Annals of the Natal Museum, V23, P455; Nazni WA, 2008, TROP BIOMED, V25, P173; Nielsen P., 1954, ZOOL ICELAND, V3, P79; Nuorteva P., 1977, FORENSIC MED STUDY T, V2, P1072; Russo A, 2006, ENVIRON ENTOMOL, V35, P194; Saigusa K., 2006, RES PRACT FORMS MED, V49, P173; Salona MI, 2010, J FORENSIC SCI, V55, P1652, DOI 10.1111/j.1556-4029.2010.01506.x; SMITH K G V, 1975, Entomologist's Gazette, V26, P277; Smith K. G. V., 1989, HDB IDENTIFICATIO 14, V10; Smith K.G.V., 1986, MANUAL FORENSIC ENTO, VBritish Museum; Sukontason K, 2001, J MED ENTOMOL, V38, P746, DOI 10.1603/0022-2585-38.5.746; Syed A., 1994, Journal of the Entomological Society of British Columbia, V91, P55; Wallman JF, 2001, FORENSIC SCI INT, V120, P60, DOI 10.1016/S0379-0738(01)00426-1; Wells J. D., 2010, FORENSIC ENTOMOLOGY, P437; ZUSKA JAN, 1965, ACTA ENTOMOL BOHEMOSLOV, V62, P141	48	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	MAR	2015	248						E8	E12		10.1016/j.forsciint.2014.12.026		5	Medicine, Legal	Legal Medicine	CB9PA	WOS:000349962800002		
J	Munakata, S; Tashiro, Y; Nishida, C; Sato, A; Komiyama, H; Shimazu, H; Dhahri, D; Salama, Y; Eiamboonsert, S; Takeda, K; Yagita, H; Tsuda, Y; Okada, Y; Nakauchi, H; Sakamoto, K; Heissig, B; Hattori, K				Munakata, Shinya; Tashiro, Yoshihiko; Nishida, Chiemi; Sato, Aki; Komiyama, Hiromitsu; Shimazu, Hiroshi; Dhahri, Douaa; Salama, Yousef; Eiamboonsert, Salita; Takeda, Kazuyoshi; Yagita, Hideo; Tsuda, Yuko; Okada, Yoshio; Nakauchi, Hiromitsu; Sakamoto, Kazuhiro; Heissig, Beate; Hattori, Koichi			Inhibition of Plasmin Protects Against Colitis in Mice by Suppressing Matrix Metalloproteinase 9-Mediated Cytokine Release From Myeloid Cells	GASTROENTEROLOGY			English	Article						IBD; Mouse Model; Plasminogen; UC	INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; VERSUS-HOST-DISEASE; ULCERATIVE-COLITIS; TISSUE REGENERATION; SELECTIVE PLASMIN; ACID THERAPY; FACTOR-ALPHA; FIBRINOLYSIS; COAGULATION	BACKGROUND & AIMS: Activated proteases such as plasmin and matrix metalloproteinases (MMPs) are activated in intestinal tissues of patients with active inflammatory bowel diseases. We investigated the effect of plasmin on the progression of acute colitis. METHODS: Colitis was induced in Mmp9(-/-), Plg(-/-), and C57BL/6 (control) mice by the administration of dextran sulfate sodium, trinitrobenzene sulfonic acid, or CD40 antibody. Plasmin was inhibited in control mice by intraperitoneal injection of YO-2, which blocks its active site. Mucosal and blood samples were collected and analyzed by reverse-transcription polymerase chain reaction and immunohistochemical analyses, as well as for mucosal inflammation and levels of cytokines and chemokines. RESULTS: Circulating levels of plasmin were increased in mice with colitis, compared with controls. Colitis did not develop in control mice injected with YO-2 or in Plg(-/-) mice. Colons from these mice had reduced infiltration of Gr1+ neutrophils and F4/80+ macrophages, and reduced levels of inflammatory cytokines and chemokines. Colonic inflammation and colitis induction required activation of endogenous MMP9. After colitis induction, mice given YO-2, Plg(-/-) mice, and Mmp9(-/-) mice had reduced serum levels of tumor necrosis factor and C-X-C motif chemokine ligand 5, compared with control mice. CONCLUSIONS: In mice, plasmin induces a feedback mechanism in which activation of the fibrinolytic system promotes the development of colitis via activation of MMP9 or proteolytic enzymes. The proteolytic environment stimulates the influx of myeloid cells into the colonic epithelium and the production of tumor necrosis factor and C-X-C motif chemokine ligand 5. In turn, myeloid CD11b+ cells release the urokinase plasminogen activator, which accelerates plasmin production. Disruption of the plasmin-induced chronic inflammatory circuit therefore might be a strategy for colitis treatment.	[Munakata, Shinya; Tashiro, Yoshihiko; Nishida, Chiemi; Sato, Aki; Komiyama, Hiromitsu; Shimazu, Hiroshi; Dhahri, Douaa; Salama, Yousef; Eiamboonsert, Salita; Nakauchi, Hiromitsu; Heissig, Beate; Hattori, Koichi] Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Minato Ku, Tokyo 1088639, Japan; [Munakata, Shinya; Tashiro, Yoshihiko; Komiyama, Hiromitsu; Sakamoto, Kazuhiro] Juntendo Univ, Sch Med, Dept Coloproctol Surg, Bunkyo Ku, Tokyo 113, Japan; [Takeda, Kazuyoshi; Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; [Heissig, Beate; Hattori, Koichi] Juntendo Univ, Sch Med, Atopy Allergy Ctr, Bunkyo Ku, Tokyo 113, Japan; [Tsuda, Yuko; Okada, Yoshio] Kobe Gakuin Univ, Fac Pharmaceut Sci, Nishi Ku, Kobe, Hyogo 65121, Japan	Hattori, K (reprint author), Univ Tokyo, Inst Med Sci, Ctr Stem Cell Biol & Regenerat Med, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	khattori@ims.u-tokyo.ac.jp			Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology; Mitsubishi Pharma Research Foundation; Program for Improvement of the Research Environment for Young Researchers - Special Coordination Funds for Promoting Science and Technology of the Ministry of Education, Culture, Sports, Science and Technology	Supported by grants from the Japan Society for the Promotion of Science and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (K.H., B.H., Y.T.); Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology (K.H.); the Mitsubishi Pharma Research Foundation (K.H); Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (B.H.); and the Program for Improvement of the Research Environment for Young Researchers (B.H.) funded by the Special Coordination Funds for Promoting Science and Technology of the Ministry of Education, Culture, Sports, Science and Technology.	Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; Lijnen HR, 1998, THROMB HAEMOSTASIS, V79, P1171; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra020831; Jarnerot G, 2005, GASTROENTEROLOGY, V128, P1805, DOI 10.1053/j.gasto.2005.03.003; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Neurath MF, 1997, EUR J IMMUNOL, V27, P1743, DOI 10.1002/eji.1830270722; Song J, 2013, J IMMUNOL, V190, P401, DOI 10.4049/jimmunol.1202286; Okada Y, 2000, CHEM PHARM BULL, V48, P1964; Zou T, 2006, J NEUROPATH EXP NEUR, V65, P78, DOI 10.1097/01.jnen.0000195942.25163.f5; Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Naito Y, 2004, INFLAMM RES, V53, P462, DOI 10.1007/s00011-004-1281-1; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Tashiro Y, 2012, BLOOD, V119, P6382, DOI 10.1182/blood-2011-12-399659; Fisher JF, 2006, CANCER METAST REV, V25, P115, DOI 10.1007/s10555-006-7894-9; Sans M, 1999, GASTROENTEROLOGY, V116, P874, DOI 10.1016/S0016-5085(99)70070-3; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; Heissig B, 2012, INT J HEMATOL, V95, P131, DOI 10.1007/s12185-012-1016-y; Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P1593, DOI 10.1053/j.gastro.2004.02.070; Heissig B, 2007, CELL STEM CELL, V1, P658, DOI 10.1016/j.stem.2007.10.012; Mei JJ, 2012, J CLIN INVEST, V122, P974, DOI 10.1172/JCI60588; Peterson JT, 2004, HEART FAIL REV, V9, P63, DOI 10.1023/B:HREV.0000011395.11179.af; COOPER HS, 1993, LAB INVEST, V69, P238; Cayatte Corinne, 2012, Clin Transl Gastroenterol, V3, pe10, DOI 10.1038/ctg.2012.2; DOE WF, 1982, CLIN EXP IMMUNOL, V48, P256; Hattori K, 1997, BLOOD, V90, P542; Heissig B, 2010, HISTOL HISTOPATHOL, V25, P765; HOLLANDERS D, 1982, POSTGRAD MED J, V58, P87; Kolho KL, 2014, INT J COLORECTAL DIS, V29, P43, DOI 10.1007/s00384-013-1775-9; Koutroubakis IE, 2005, NAT CLIN PRACT GASTR, V2, P266, DOI 10.1038/ncpgasthep0190; Kume K, 2007, INTERNAL MED, V46, P1323, DOI 10.2169/internalmedicine.46.0237; Lee E, 2002, BIOCHEM PHARMACOL, V63, P1315, DOI 10.1016/S0006-2952(02)00866-3; Mao JW, 2012, WORLD J GASTROENTERO, V18, P7063, DOI 10.3748/wjg.v18.i47.7063; Ohki M, 2010, BLOOD, V115, P4302, DOI 10.1182/blood-2009-08-236851; SALTER RH, 1970, GUT, V11, P585, DOI 10.1136/gut.11.7.585; Sato A, 2015, LEUKEMIA, V29, P145, DOI 10.1038/leu.2014.151; SOUTO JC, 1994, FIBRINOLYSIS, V8, P359, DOI 10.1016/0268-9499(94)90004-3; van Bodegraven AA, 2002, EUR J GASTROEN HEPAT, V14, P413, DOI 10.1097/00042737-200204000-00014; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; Vrij AA, 2003, PATHOPHYSIOL HAEMO T, V33, P75, DOI 10.1159/000073850	41	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	MAR	2015	148	3					565	+		10.1053/j.gastro.2014.12.001		18	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CB9QX	WOS:000349968200028		
J	Asakura, T; Ogura, K; Goshima, Y				Asakura, Taro; Ogura, Ken-ichi; Goshima, Yoshio			IRE-1/XBP-1 pathway of the unfolded protein response is required for properly localizing neuronal UNC-6/Netrin for axon guidance in C. elegans	GENES TO CELLS			English	Article							PLASMA-CELL DIFFERENTIATION; TRANSCRIPTION FACTOR XBP-1; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; GLUTAMATE-RECEPTOR; MESSENGER-RNA; UNC-6; STRESS; LOCALIZATION; MIGRATIONS	During developing nervous system, neurons project axons to their targets precisely. In this process, axon guidance molecules provide positional information to the axons. Therefore, the spatially and temporally controlled localization of the axon guidance molecules is required for the proper structure formation of the complex nervous system. In C.elegans, UNC-6/Netrin is a secreted protein that elicits both attractive and repulsive response in axon guidance. UNC-6/Netrin secreted from ventral cells may establish a concentration gradient from the ventral to the dorsal side of the animal, thus providing dorso-ventral positional information. However, the mechanisms specifying positional information of UNC-6/Netrin are largely unknown. Here, we show that the ire-1/xbp-1 pathway of the unfolded protein response (UPR) is required for axonal distribution of UNC-6/Netrin in the ventral neurons. In addition, the ire-1/xbp-1 pathway is also required for dorso-ventral axon guidance mediated by UNC-6/Netrin. Our results suggest that the ire-1/xbp-1 pathway of the UPR is crucial for establishing positional information of UNC-6/Netrin. We propose that the proper secretion of UNC-6/Netrin from the ventral neurons requires the activity of IRE-1.	[Asakura, Taro; Ogura, Ken-ichi; Goshima, Yoshio] Yokohama City Univ, Grad Sch Med, Dept Mol Pharmacol & Neurobiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Ogura, K (reprint author), Yokohama City Univ, Grad Sch Med, Dept Mol Pharmacol & Neurobiol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	kenogura@med.yokohama-cu.ac.jp; goshima@med.yokohama-cu.ac.jp			NIH Office of Research Infrastructure Programs [P40 OD010440]; Ministry of Education, Science, Sports and Culture; Yokohama Foundation for Advancement of Medical Science	We thank William Wadsworth, Takeshi Ishihara, Ji Ying Sze and Andrew Fire for plasmid clones; Kumiko Fujita, Hiroshi Matsuoka and Wataru Okubo for technical support; and members of the Goshima laboratory for suggestions and helpful discussions. Some strains were provided by the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440). This work was supported by Grants-in-aid for Scientific Research in a Priority Area (Y.G. and K.O.) from the Ministry of Education, Science, Sports and Culture, and the Yokohama Foundation for Advancement of Medical Science (T.A. and K.O.).	Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ogura K, 2012, DEV GROWTH DIFFER, V54, P390, DOI 10.1111/j.1440-169X.2012.01349.x; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; MELLO CC, 1991, EMBO J, V10, P3959; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Sarin S, 2008, NAT METHODS, V5, P865, DOI [10.1038/nmeth.1249, 10.1038/NMETH.1249]; McNally K, 2006, J CELL BIOL, V175, P881, DOI 10.1083/jcb.200608117; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Von Stetina SE, 2007, GENE DEV, V21, P332, DOI 10.1101/gad.1502107; Davis MW, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-118; Mori K, 2009, J BIOCHEM, V146, P743, DOI 10.1093/jb/mvp166; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Ogura K, 2010, DEVELOPMENT, V137, P1657, DOI 10.1242/dev.050708; BRENNER S, 1974, GENETICS, V77, P71; Asakura T, 2010, GENETICS, V185, P573, DOI 10.1534/genetics.110.116293; Asakura T, 2007, DEV BIOL, V304, P800, DOI 10.1016/j.ydbio.2007.01.028; Kolodkin AL, 2011, COLD SPRING HARB PER, V3, P1; Moore KA, 2012, ANNU REV GENET, V46, P165, DOI 10.1146/annurev-genet-110711-155644; Richardson C. E., 2011, PLOS GENET, V11; Rolls MM, 2002, MOL BIOL CELL, V13, P1778, DOI 10.1091/mbc.01-10-0514; Safra M., 2013, J CELL SCI, V6, P1208; Shim J, 2004, MOL BIOL CELL, V15, P4818, DOI 10.1091/mbc.E04-02-0108; Shioi G, 2001, GENETICS, V157, P1611; Wadsworth WG, 2002, TRENDS NEUROSCI, V25, P423, DOI 10.1016/S0166-2236(02)02206-3	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					153	159		10.1111/gtc.12206		7	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100001		
J	Ruan, K; Yamamoto, TG; Asakawa, H; Chikashige, Y; Masukata, H; Haraguchi, T; Hiraoka, Y				Ruan, Kun; Yamamoto, Takaharu G.; Asakawa, Haruhiko; Chikashige, Yuji; Masukata, Hisao; Haraguchi, Tokuko; Hiraoka, Yasushi			Meiotic nuclear movements in fission yeast are regulated by the transcription factor Mei4 downstream of a Cds1-dependent replication checkpoint pathway	GENES TO CELLS			English	Article							S-PHASE CHECKPOINT; SCHIZOSACCHAROMYCES-POMBE; RIBONUCLEOTIDE REDUCTASE; DNA-REPLICATION; MEIOSIS; CHROMOSOMES; PROPHASE; RECOMBINATION; DYNAMICS; BOUQUET	In meiosis, the fission yeast nucleus displays an elongated morphology, moving back and forth within the cell; these nuclear movements continue for approximately 2h before meiotic nuclear divisions. Meiotic DNA replication occurs in an early phase of the nuclear movements and is followed by meiotic prophase. Here we report that in mutants deficient in meiotic DNA replication, the duration of nuclear movements is strikingly prolonged to four to 5h. We found that this prolongation was caused by the Cds1-dependent replication checkpoint, which represses expression of the mei4(+) gene encoding a meiosis-specific transcription factor. In the absence of Mei4, nuclear movements persisted for more than 8h. In contrast, overproduction of Mei4 accelerated termination of nuclear movements to approximately 30min. These results show that Mei4 is involved in the termination of nuclear movements and that Mei4-mediated regulatory pathways link a DNA replication checkpoint to the termination of nuclear movements.	[Ruan, Kun; Asakawa, Haruhiko; Haraguchi, Tokuko; Hiraoka, Yasushi] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; [Yamamoto, Takaharu G.; Chikashige, Yuji; Haraguchi, Tokuko; Hiraoka, Yasushi] Natl Inst Informat & Communicat Technol, Adv ICT Res Inst Kobe, Nishi Ku, Kobe, Hyogo 6512492, Japan; [Masukata, Hisao] Osaka Univ, Grad Sch Sci, Dept Biol Sci, Toyonaka, Osaka 5600043, Japan	Hiraoka, Y (reprint author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	hiraoka@fbs.osaka-u.ac.jp			JSPS; MEXT	We thank Chizuru Ohtsuki for technical assistance and Kayoko Tanaka for providing plasmids. This work was supported by grants from JSPS and MEXT (to H.A., T.H., and Y.H.).	Kakui Y, 2013, NAT CELL BIOL, V15, P786, DOI 10.1038/ncb2782; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1039/nature02312; Abe H, 2000, GENETICS, V154, P1497; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Yamamoto A, 2001, BIOESSAYS, V23, P526, DOI 10.1002/bies.1072; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Asakawa H, 2010, CURR BIOL, V20, P1919, DOI 10.1016/j.cub.2010.09.070; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Ding DQ, 2006, J CELL BIOL, V174, P499, DOI 10.1083/jcb.200605074; GRALLERT B, 1991, CURR GENET, V20, P199, DOI 10.1007/BF00326233; Chikashige Y, 2004, GENES CELLS, V9, P671, DOI 10.1111/j.1365-2443.2004.00760.x; Nestoras K, 2010, GENE DEV, V24, P1145, DOI 10.1101/gad.561910; Horie S, 1998, MOL CELL BIOL, V18, P2118; Hiraoka Y, 2009, DEV CELL, V17, P598, DOI 10.1016/j.devcel.2009.10.014; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Ding DQ, 1998, J CELL SCI, V111, P701; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; YAMAGISHI M, 1988, GENE, V74, P503; Sato M, 2005, YEAST, V22, P583, DOI 10.1002/yea.1233; Hakansson P, 2006, J BIOL CHEM, V281, P1778; Ding DQ, 2004, DEV CELL, V6, P329, DOI 10.1016/S1534-5807(04)00059-0; Harper L, 2004, J CELL SCI, V117, P4025, DOI 10.1242/jcs.01363; IINO Y, 1995, GENETICS, V140, P1235; Harigaya Y, 2006, NATURE, V442, P45, DOI 10.1038/nature04881; Furnari B, 1999, MOL BIOL CELL, V10, P833; Meister P, 2007, EMBO J, V26, P1315, DOI 10.1038/sj.emboj.7601538; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Liu C, 2005, EMBO J, V24, P3940, DOI 10.1038/sj.emboj.7600854; Pankratz DG, 2005, MOL BIOL CELL, V16, P1651, DOI 10.1091/mbc.E04-10-0934; Wei N, 2008, TRENDS BIOCHEM SCI, V33, P592, DOI 10.1016/j.tibs.2008.09.004; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; [Anonymous], 1991, METHOD ENZYMOL; Yamamoto A, 1999, J CELL BIOL, V145, P1233, DOI 10.1083/jcb.145.6.1233; Funaya C, 2012, CURR BIOL, V22, P562, DOI 10.1016/j.cub.2012.02.042; Chikashige Y, 2007, CHROMOSOMA, V116, P497, DOI 10.1007/s00412-007-0114-8; Ding DQ, 2010, FEBS J, V277, P565, DOI 10.1111/j.1742-4658.2009.07501.x; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Miyoshi T, 2012, MOL CELL, V47, P722, DOI 10.1016/j.molcel.2012.06.023; Murakami-Tonami Y, 2007, P NATL ACAD SCI USA, V104, P14688, DOI 10.1073/pnas.0702906104; Nordlund Pär, 2006, Annu Rev Biochem, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Ogino K, 2006, J BIOL CHEM, V281, P1338, DOI 10.1074/jbc.M505767200; ROBINOW CF, 1977, GENETICS, V87, P491; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-7	46	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					160	172		10.1111/gtc.12207		13	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100002		
J	Iida, T; Mutoh, R; Onai, K; Morishita, M; Furukawa, Y; Namba, K; Ishiura, M				Iida, Takahiro; Mutoh, Risa; Onai, Kiyoshi; Morishita, Megumi; Furukawa, Yukio; Namba, Keiichi; Ishiura, Masahiro			Importance of the monomer-dimer-tetramer interconversion of the clock protein KaiB in the generation of circadian oscillations in cyanobacteria	GENES TO CELLS			English	Article							CRYSTAL-STRUCTURE; ATPASE ACTIVITY; IN-VITRO; PHOSPHORYLATION; COMPLEX; DYNAMICS; MECHANISM; BINDING; SYSTEM; DOMAIN	The molecular machinery of the cyanobacterial circadian clock oscillator consists of three proteins, KaiA, KaiB and KaiC, which interact with each other to generate circadian oscillations in the presence of ATP (the in vitro KaiABC clock oscillator). KaiB comprises four subunits organized as a dimer of dimers. Our previous study suggested that, on interaction with KaiC, the tetrameric KaiB molecule dissociates into two molecules of dimeric KaiB. It is uncertain whether KaiB also exists as a monomer and whether the KaiB monomer can drive normal circadian oscillation. To address these questions, we constructed a new KaiB oligomer mutant with an N-terminal deletion, KaiB(10-108). KaiB(10-108) was a monomer at 4 degrees C but a dimer at 35 degrees C. KaiB(10-108) was able to drive normal clock oscillation in an in vitro reconstituted KaiABC clock oscillator at 25 degrees C, but it was not able to drive normal circadian gene expression rhythms in cyanobacterial cells at 41 degrees C. Wild-type KaiB existed in equilibrium between a dimer and tetramer at lower KaiB concentrations or in the presence of 1m NaCl. Our findings suggest that KaiB is in equilibrium between a monomer, dimer and tetramer in cyanobacterial cells.	[Iida, Takahiro; Mutoh, Risa; Onai, Kiyoshi; Morishita, Megumi; Ishiura, Masahiro] Nagoya Univ, Ctr Gene Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Iida, Takahiro; Mutoh, Risa; Ishiura, Masahiro] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; [Furukawa, Yukio; Namba, Keiichi] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Ishiura, M (reprint author), Nagoya Univ, Ctr Gene Res, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	ishiura@gene.nagoya-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT); Global Center of Excellence grant from MEXT; Japan Society for the Promotion of Science for Young Scientists	We thank Satoko Ogawa and Kumiko Tanaka for technical support. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) to M.I. As a research assistant, T.I. was supported by a Global Center of Excellence grant from MEXT. R.M. was supported by Research Fellowships from the Japan Society for the Promotion of Science for Young Scientists. Development of the high-sensitivity bioluminescence monitoring apparatus CL96S-4 was supported by SENTAN, JST. The CL96S-4 apparatus is commercially available through Churitsu Electric Corp. (Nagoya, Japan).	Akiyama S, 2008, MOL CELL, V29, P703, DOI 10.1016/j.molcel.2008.01.015; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Egli M, 2012, BIOCHEMISTRY-US, V51, P1547, DOI 10.1021/bi201525n; Pattanayek R, 2008, EMBO J, V27, P1767, DOI 10.1038/emboj.2008.104; Mutoh R, 2010, GENES CELLS, V15, P269, DOI 10.1111/j.1365-2443.2009.01377.x; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Nishiwaki T, 2012, J BIOL CHEM, V287, P18030, DOI 10.1074/jbc.M112.350660; Okamoto K, 2005, ANAL BIOCHEM, V340, P193, DOI 10.1016/j.ab.2004.11.007; Iwase R, 2005, J BIOL CHEM, V280, P43141, DOI 10.1074/jbc.M503360200; Hayashi F, 2006, BIOCHEM BIOPH RES CO, V348, P864, DOI 10.1016/j.bbrc.2006.07.143; GROBBELAAR N, 1986, FEMS MICROBIOL LETT, V37, P173, DOI 10.1111/j.1574-6968.1986.tb01788.x; YAMAOKA T, 1978, PLANT CELL PHYSIOL, V19, P943; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Hitomi K, 2005, J BIOL CHEM, V280, P19127, DOI 10.1074/jbc.M411284200; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Terauchi K, 2007, P NATL ACAD SCI USA, V104, P16377, DOI 10.1073/pnas.0706292104; Takai N, 2006, P NATL ACAD SCI USA, V103, P12109, DOI 10.1073/pnas.0602955103; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; Nakajima M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451; Villarreal SA, 2013, J MOL BIOL, V425, P3311, DOI 10.1016/j.jmb.2013.06.018; Kageyama H, 2006, MOL CELL, V23, P161, DOI 10.1016/j.molcel.2006.05.039; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; Murakami R, 2012, J BIOL CHEM, V287, P29506, DOI 10.1074/jbc.M112.349092; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Hayashi F, 2004, BIOCHEM BIOPH RES CO, V316, P195, DOI 10.1016/j.bbrc.2004.02.034; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; [Anonymous], 1990, METHOD ENZYMOL; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Murakami R, 2008, GENES CELLS, V13, P387, DOI 10.1111/j.1365-2443.2008.01174.x; Mutoh R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080200; Onai Kiyoshi, 2004, Journal of Bacteriology, V186, P4972, DOI 10.1128/JB.186.15.4972-4977.2004; Valencia S. J., 2012, GENES CELLS, V17, P398, DOI DOI 10.1111/J.1365-2443.2012.01597.X	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					173	190		10.1111/gtc.12211		18	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100003		
J	Kikuchi, Y; Umemura, H; Nishitani, S; Iida, S; Fukasawa, R; Hayashi, H; Hirose, Y; Tanaka, A; Sugasawa, K; Ohkuma, Y				Kikuchi, Yuko; Umemura, Hiroyasu; Nishitani, Saori; Iida, Satoshi; Fukasawa, Rikiya; Hayashi, Hiroto; Hirose, Yutaka; Tanaka, Aki; Sugasawa, Kaoru; Ohkuma, Yoshiaki			Human mediator MED17 subunit plays essential roles in gene regulation by associating with the transcription and DNA repair machineries	GENES TO CELLS			English	Article							RNA-POLYMERASE-II; HEAD MODULE; IN-VIVO; CHROMATIN ARCHITECTURE; PREINITIATION COMPLEX; KINASE SUBUNIT; NEGATIVE ROLE; TFB1 SUBUNIT; TFIIH; BINDING	In eukaryotes, holo-Mediator consists of four modules: head, middle, tail, and CDK/Cyclin. The head module performs an essential function involved in regulation of RNA polymerase II (Pol II). We studied the human head module subunit MED17 (hMED17). Recent structural studies showed that yeast MED17 may function as a hinge connecting the neck and movable jaw regions of the head module to the fixed jaw region. Luciferase assays in hMED17-knockdown cells showed that hMED17 supports transcriptional activation, and pulldown assays showed that hMED17 interacted with Pol II and the general transcription factors TFIIB, TBP, TFIIE, and TFIIH. In addition, hMED17 bound to a DNA helicase subunit of TFIIH, XPB, which is essential for both transcription and nucleotide excision repair (NER). Because hMED17 associates with p53 upon UV-C irradiation, we treated human MCF-7 cells with either UV-C or the MDM2 inhibitor Nutlin-3. Both treatments resulted in accumulation of p53 in the nucleus, but hMED17 remained concentrated in the nucleus in response to UV-C. hMED17 colocalized with the NER factors XPB and XPG following UV-C irradiation, and XPG and XPB bound to hMED17 in vitro. These findings suggest that hMED17 may play essential roles in switching between transcription and NER.	[Kikuchi, Yuko; Umemura, Hiroyasu; Nishitani, Saori; Iida, Satoshi; Fukasawa, Rikiya; Hayashi, Hiroto; Hirose, Yutaka; Tanaka, Aki; Ohkuma, Yoshiaki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Lab Gene Regulat, Toyama 930, Japan; [Sugasawa, Kaoru] Kobe Univ, Biosignal Res Ctr, Org Adv Sci & Technol, Kobe, Hyogo 657, Japan	Ohkuma, Y (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Lab Gene Regulat, Toyama 930, Japan.	ohkumay@pha.u-toyama.ac.jp			MEXT KAKENHI from the Ministry of Education, Science, and Culture of Japan [17054022, 24118003, 25131704]; Natural Sciences from the Mitsubishi Foundation; Astellas Foundation for Research on Metabolic Disorders	We thank Tadashi Furumoto for technical advice on the UV treatments and luciferase studies and Shotaro Wani for the immunostaining studies. We also thank all of our laboratory members for helpful discussions. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas (Y.O., MEXT KAKENHI Grant Number: 17054022) and Grants-in-Aid for Scientific Research on Innovative Areas (Y.O., MEXT KAKENHI Grant Number: 24118003 and 25131704) from the Ministry of Education, Science, and Culture of Japan, and by foundation research grants for the Natural Sciences from the Mitsubishi Foundation (Y.O.) and the Astellas Foundation for Research on Metabolic Disorders (Y.O.).	Mittler G, 2003, EMBO J, V22, P6494, DOI 10.1093/emboj/cdg619; Lafrance-Vanasse J, 2012, NUCLEIC ACIDS RES, V40, P5739, DOI 10.1093/nar/gks194; Compe E, 2012, NAT REV MOL CELL BIO, V13, P343, DOI 10.1038/nrm3350; Esnault C, 2008, MOL CELL, V31, P337, DOI 10.1016/j.molcel.2008.06.021; Tsai KL, 2014, CELL, V157, P1430, DOI 10.1016/j.cell.2014.05.015; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Dowen JM, 2013, STEM CELL REP, V1, P371, DOI 10.1016/j.stemcr.2013.09.002; Poss ZC, 2013, CRIT REV BIOCHEM MOL, V48, P575, DOI 10.3109/10409238.2013.840259; Okuda M, 2008, EMBO J, V27, P1161, DOI 10.1038/emboj.2008.47; Grunberg S, 2012, NAT STRUCT MOL BIOL, V19, P788, DOI 10.1038/nsmb.2334; Robinson PJJ, 2012, P NATL ACAD SCI USA, V109, P17931, DOI 10.1073/pnas.1215241109; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Lacombe T, 2013, NUCLEIC ACIDS RES, V41, P9651, DOI 10.1093/nar/gkt701; Linder T, 2006, BIOCHEM BIOPH RES CO, V349, P948, DOI 10.1016/j.bbrc.2006.08.099; Furumoto T, 2007, GENES CELLS, V12, P119, DOI 10.1111/j.1365-2443.2007.01036.x; Lariviere L, 2012, NATURE, V492, P448, DOI 10.1038/nature11670; Conaway RC, 2011, CURR OPIN GENET DEV, V21, P225, DOI 10.1016/j.gde.2011.01.013; Cai G, 2010, NAT STRUCT MOL BIOL, V17, P273, DOI 10.1038/nsmb.1757; Tsutsui T, 2008, GENES CELLS, V13, P817, DOI 10.1111/j.1365-2443.2008.01208.x; Tsai KL, 2013, NAT STRUCT MOL BIOL, V20, P611, DOI 10.1038/nsmb.2549; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Takagi Y, 2006, MOL CELL, V23, P355, DOI 10.1016/j.molcel.2006.06.007; He QY, 2008, J BIOL CHEM, V283, P5276, DOI 10.1074/jbc.M708266200; Wang XJ, 2013, PROTEIN CELL, V4, P911, DOI 10.1007/s13238-013-3069-y; Meyer KD, 2010, NAT STRUCT MOL BIOL, V17, P753, DOI 10.1038/nsmb.1816; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; Imasaki T, 2011, NATURE, V475, P240, DOI 10.1038/nature10162; Soutourina J, 2011, SCIENCE, V331, P1451, DOI 10.1126/science.1200188; Lafrance-Vanasse J, 2013, NUCLEIC ACIDS RES, V41, P2736, DOI 10.1093/nar/gks1321; He Y, 2013, NATURE, V495, P481, DOI 10.1038/nature11991; Di Lello P, 2008, P NATL ACAD SCI USA, V105, P106, DOI 10.1073/pnas.0707892105; Tsutsui T, 2011, GENES CELLS, V16, P1208, DOI 10.1111/j.1365-2443.2011.01565.x; Eyboulet F, 2013, GENE DEV, V27, P2549, DOI 10.1101/gad.225813.113; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Kumafuji M, 2014, GENES CELLS, V19, P582, DOI 10.1111/gtc.12155; Lariviere L., 2012, CURR OPIN CELL BIOL, V24, P1; Lehmann A R, 1977, Essays Biochem, V13, P71; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					191	202		10.1111/gtc.12210		12	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100004		
J	Tanaka, A; Akimoto, Y; Kobayashi, S; Hisatake, K; Hanaoka, F; Ohkuma, Y				Tanaka, Aki; Akimoto, Yusuke; Kobayashi, Satoko; Hisatake, Koji; Hanaoka, Fumio; Ohkuma, Yoshiaki			Association of the winged helix motif of the TFIIE alpha subunit of TFIIE with either the TFIIE beta subunit or TFIIB distinguishes its functions in transcription	GENES TO CELLS			English	Article							RNA-POLYMERASE-II; DOUBLE-STRANDED DNA; BASAL TRANSCRIPTION; PREINITIATION COMPLEX; TERMINAL DOMAIN; INITIATION; ELONGATION; PHOSPHORYLATION; TRANSITION; MECHANISM	In eukaryotes, the general transcription factor TFIIE consists of two subunits, and , and plays essential roles in transcription. Structure-function studies indicate that TFIIE has three-winged helix (WH) motifs, with one in TFIIE and two in TFIIE. Recent studies suggested that, by binding to the clamp region of RNA polymerase II, TFIIE-WH promotes the conformational change that transforms the promoter-bound inactive preinitiation complex to the active complex. Here, to elucidate its roles in transcription, functional analyses of point-mutated human TFIIE-WH proteins were carried out. In vitro transcription analyses identified two classes of mutants. One class was defective in transcription initiation, and the other was defective in the transition from initiation to elongation. Analyses of the binding of this motif to other general transcription factors showed that the former class was defective in binding to the basic helix-loop-helix motif of TFIIE and the latter class was defective in binding to the N-terminal cyclin homology region of TFIIB. Furthermore, TFIIE-WH bound to the TFIIH XPB subunit at a third distinct region. Therefore, these results provide further insights into the mechanisms underlying RNA polymerase II activation at the initial stages of transcription.	[Tanaka, Aki; Akimoto, Yusuke; Kobayashi, Satoko; Ohkuma, Yoshiaki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Lab Gene Regulat, Toyama 930, Japan; [Hisatake, Koji] Univ Tsukuba, Dept Biochem, Grad Sch Comprehens Human Sci, Ibaraki, Japan; [Hisatake, Koji] Toyama Univ, Inst Basic Med Sci, Toyama 930, Japan; [Hanaoka, Fumio] Gakushuin Univ, Fac Sci, Tokyo 171, Japan	Ohkuma, Y (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Lab Gene Regulat, Toyama 930, Japan.	ohkumay@pha.u-toyama.ac.jp			Japan Society for the Promotion of Science (JSPS) (JSPS KAKENHI) [24118003, 25131704, 21790066]	We thank Dr Sohail Malik, Dr Kosuke Morikawa and Dr Masahiko Okuda for their critical reading of this manuscript, Tomomichi Watanabe for constructing the WH region point mutants of hTFIIE alpha, and Dr Aya Fukuda and Dr Tomoyoshi Nakadai for TFIIB constructs. We also thank our colleagues at the University of Toyama for helpful discussions. This work was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas from Japan Society for the Promotion of Science (JSPS) to Y.O. (JSPS KAKENHI Grant No. 24118003 and 25131704), and in part by Grant-in-Aid for Young Scientists (B) from JSPS to A.T. (JSPS KAKENHI Grant No. 21790066).	Ibrahim BS, 2009, P NATL ACAD SCI USA, V106, P13242, DOI 10.1073/pnas.0904309106; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Bell SD, 2001, BIOCHEM SOC T, V29, P392, DOI 10.1042/BST0290392; Grohmann D, 2011, MOL CELL, V43, P263, DOI 10.1016/j.molcel.2011.05.030; Vannini A, 2012, MOL CELL, V45, P439, DOI 10.1016/j.molcel.2012.01.023; Okuda M, 2008, EMBO J, V27, P1161, DOI 10.1038/emboj.2008.47; Grunberg S, 2012, NAT STRUCT MOL BIOL, V19, P788, DOI 10.1038/nsmb.2334; Cramer P, 2001, SCIENCE, V292, P1863, DOI 10.1126/science.1059493; Okuda M, 2000, EMBO J, V19, P1346, DOI 10.1093/emboj/19.6.1346; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; Lefevre S, 2011, NAT STRUCT MOL BIOL, V18, P352, DOI 10.1038/nsmb.1996; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Thomas MC, 2006, CRIT REV BIOCHEM MOL, V41, P105, DOI 10.1080/10409230600648736; He Y, 2013, NATURE, V495, P481, DOI 10.1038/nature11991; Carter R, 2010, MOL BIOL EVOL, V27, P1035, DOI 10.1093/molbev/msp316; Chen HT, 2007, NAT STRUCT MOL BIOL, V14, P696, DOI 10.1038/nsmb1272; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Hayashi K, 2005, GENES CELLS, V10, P207, DOI 10.1111/j.1365-2443.2005.00833.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810; Holstege FCP, 1996, EMBO J, V15, P1666; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Luo J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.008318; Murakami K, 2013, SCIENCE, V342, P709, DOI 10.1126/science.1238724; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; Okamoto T, 1998, J BIOL CHEM, V273, P19866, DOI 10.1074/jbc.273.31.19866; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Tanaka A, 2009, GENES CELLS, V14, P395, DOI 10.1111/j.1365-2443.2008.01278.x; Watanabe T, 2003, MOL CELL BIOL, V23, P2914, DOI 10.1128/MCB.23.8.2914-2926.2003; Yamamoto S, 2001, MOL CELL BIOL, V21, P1, DOI 10.1128/MCB.21.1.1-15.2001; ZDZIENICKA MZ, 1986, MUTAT RES, V166, P59, DOI 10.1016/0167-8817(86)90041-6	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					203	216		10.1111/gtc.12212		14	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100005		
J	Uebi, T; Umeda, M; Imai, T				Uebi, Tatsuya; Umeda, Makoto; Imai, Takeshi			Estrogen induces estrogen receptor alpha expression and hepatocyte proliferation in the livers of male mice	GENES TO CELLS			English	Article							HEPATIC REGENERATION; PARTIAL-HEPATECTOMY; SELECTIVE ABLATION; RAT-LIVER; ER-BETA; MOUSE; TAMOXIFEN; SITE; ADIPOCYTES; WHITE	Estrogens play pivotal roles in sexual development, growth, reproduction, and sex differentiation and have been implicated in a number of physiological processes in various tissues. Most of the effects of estrogens are mediated by the estrogen receptors alpha (ER), beta (ER), and G protein-coupled receptor 30 (GPR30). The liver is known to be a target tissue for estrogen signaling, but the physiological role of this signaling is not well characterized. Through analyses of an estradiol (E2)-treated hepatocyte cell line and mice, we showed that E2 signaling controls hepatocyte proliferation. Importantly, our data showed that the E2 signaling that is mediated through ER is crucial for efficient liver regeneration after partial hepatectomy (PH). PH rapidly induced marked increases in circulating E2 and ER transcripts in periportal hepatocytes, well before the onset of hepatocyte proliferation. Taken together, our results indicate that increased E2 is one of the initiating signals that trigger liver regeneration. We suggest that E2 treatment could be beneficial for stimulating liver regeneration in humans.	[Uebi, Tatsuya; Umeda, Makoto; Imai, Takeshi] Natl Ctr Geriatr & Gerontol, Dept Aging Intervent, Obu 4748511, Japan	Imai, T (reprint author), Natl Ctr Geriatr & Gerontol, Dept Aging Intervent, Obu 4748511, Japan.	dai.ncgg@gmail.com			Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Science and Technology Agency (JST)	We are grateful to our department members in the NCGG for helpful discussions. This work was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Science and Technology Agency (JST) to TI.	Higgins GM, 1931, ARCH PATHOL, V12, P186; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; FRANCAVILLA A, 1986, GASTROENTEROLOGY, V91, P1263; FISHER B, 1984, CANCER RES, V44, P2410; Ciana P, 2003, NAT MED, V9, P82, DOI 10.1038/nm809; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Niederreither K, 2002, MECH DEVELOP, V110, P165, DOI 10.1016/S0925-4773(01)00561-5; Dupont S, 2000, DEVELOPMENT, V127, P4277; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; Antal MC, 2012, P NATL ACAD SCI USA, V109, P19822, DOI 10.1073/pnas.1217668109; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Adlanmerini M, 2014, P NATL ACAD SCI USA, V111, pE283, DOI 10.1073/pnas.1322057111; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Imai T, 2004, P NATL ACAD SCI USA, V101, P4543, DOI 10.1073/pnas.0400356101; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Chimento Adele, 2014, Front Endocrinol (Lausanne), V5, P30, DOI 10.3389/fendo.2014.00030; Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; DOLLE P, 1989, EMBO J, V8, P1507; Fahey S. M. L., 1994, LONG TERM TAMOXIFEN, P27; Ferri D, 2005, BIOL CELL, V97, P277, DOI 10.1042/BC20040154; FRANCAVILLA A, 1989, HEPATOLOGY, V9, P614, DOI 10.1002/hep.1840090417; FRANCAVILLA A, 1989, DIGEST DIS SCI, V34, P818, DOI 10.1007/BF01540264; Imai T, 2000, GENESIS, V26, P147, DOI 10.1002/(SICI)1526-968X(200002)26:2<147::AID-GENE15>3.0.CO;2-3; Imai Takeshi, 2003, Keio Journal of Medicine, V52, P198; KAHN D, 1988, J LAB CLIN MED, V112, P644; KAHN D, 1989, DIGEST DIS SCI, V34, P27, DOI 10.1007/BF01536150; Moverare-Skrtic S, 2014, P NATL ACAD SCI USA, V111, P1180, DOI 10.1073/pnas.1322910111; STEER CJ, 1995, FASEB J, V9, P1396; Uebi T., 2013, J BIOSCI MED, V1, P1; Umeda M., 2013, J BIOSCI MED, V1, P5; Umeda M., 2013, J BIOSCI MED, V1, P11; Vacca M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104449; Vaucher L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092425	37	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					217	223		10.1111/gtc.12214		7	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100006		
J	Kobayashi, S; Yamashita, T; Ohneda, K; Nagano, M; Kimura, K; Nakai, H; Poellinger, L; Ohneda, O				Kobayashi, Satomi; Yamashita, Toshiharu; Ohneda, Kinuko; Nagano, Masumi; Kimura, Kenichi; Nakai, Hideto; Poellinger, Lorenz; Ohneda, Osamu			Hypoxia-inducible factor-3 alpha promotes angiogenic activity of pulmonary endothelial cells by repressing the expression of the VE-cadherin gene	GENES TO CELLS			English	Article							PAS DOMAIN PROTEIN; RESPIRATORY-DISTRESS-SYNDROME; TRANSCRIPTION FACTOR ETS-1; IN-VIVO EVIDENCE; VASCULAR INTEGRITY; UP-REGULATION; HIF-2-ALPHA; HOMEOSTASIS; INHIBITION; FACTOR-1	The variants of the hypoxia-inducible factor-3 gene HIF-3 and NEPAS are known to repress the transcriptional activities driven by HIF-1 and HIF-2. Although NEPAS has been shown to play an important role in vascular remodeling during lung development, little is known about the roles of HIF-3 in adult lung function. Here, we examined pulmonary endothelial cells (ECs) isolated from wild-type (WT) and HIF-3 functional knockout (KO) mice. The expression levels of angiogenic factors (Flk1, Ang2 and Tie2) were significantly greater in the HIF-3 KO ECs than those in the WT ECs irrespective of oxygen tension. However, the HIF-3 KO ECs showed impaired proliferative and angiogenic activities. The impaired EC function was likely due to the excess vascular endothelial (VE)-cadherin, an inhibitor of Flk1/PI3 kinase/Akt signaling, as treatment of the cells to a neutralizing antibody partly restored the phenotype of the HIF-3 KO ECs. Importantly, we found that the mRNA levels of HIF-2 and Ets-1 were significantly increased by HIF-3 ablation. Given that both factors are known to activate the VE-cadherin gene, the transcriptional repression of these factors by HIF-3 might be important for silencing the irrelevant expression of the VE-cadherin gene. Collectively, these data show novel and unique roles of HIF-3 for angiogenic gene regulation in pulmonary ECs.	[Kobayashi, Satomi; Yamashita, Toshiharu; Nagano, Masumi; Kimura, Kenichi; Ohneda, Osamu] Univ Tsukuba, Grad Sch Comprehens Human Sci, Lab Regenerat Med & Stem Cell Biol, Tsukuba, Ibaraki 3058575, Japan; [Ohneda, Kinuko] Takasaki Univ Hlth & Welf, Mol Pathophysiol Lab, Takasaki, Gumma 3700033, Japan; [Nakai, Hideto] Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; [Poellinger, Lorenz] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Ohneda, O (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Lab Regenerat Med & Stem Cell Biol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	oohneda@md.tsukuba.ac.jp			Japan Society for the Promotion of Science; Japanese Ministry of Education, Culture, Sports, Science, and Technology	This work was supported by grants-in-aid from the Japan Society for the Promotion of Science and the Japanese Ministry of Education, Culture, Sports, Science, and Technology.	Nagano M, 2007, BLOOD, V110, P151, DOI 10.1182/blood-2006-10-047092; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; YANAI N, 1991, EXP CELL RES, V197, P50, DOI 10.1016/0014-4827(91)90478-D; Jiang BH, 1996, J BIOL CHEM, V271, P17771; Shimoda LA, 2011, AM J RESP CRIT CARE, V183, P152, DOI 10.1164/rccm.201009-1393PP; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7; Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Krotova K, 2010, AM J PHYSIOL-CELL PH, V299, pC1541, DOI 10.1152/ajpcell.00068.2010; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Abraham S, 2009, CURR BIOL, V19, P668, DOI 10.1016/j.cub.2009.02.057; Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Yu EZ, 2004, LAB INVEST, V84, P553, DOI 10.1038/labinvest.3700071; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Lampugnani MG, 2006, J CELL BIOL, V174, P593, DOI 10.1083/jcb.200602080; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Sato M, 2002, AM J RESP CELL MOL, V26, P127; Daly C, 2006, P NATL ACAD SCI USA, V103, P15491, DOI 10.1073/pnas.0607538103; Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Makino Y, 2007, J BIOL CHEM, V282, P14073, DOI 10.1074/jbc.M700732200; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Grover TR, 2007, AM J PHYSIOL-LUNG C, V292, pL1345, DOI 10.1152/ajplung.00372.2006; Heikkila M, 2011, CELL MOL LIFE SCI, V68, P3885, DOI 10.1007/s00018-011-0679-5; Herwig MC, 2013, PATHOBIOLOGY, V80, P245, DOI 10.1159/000347062; Huang YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057695; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; Ohneda O, 1998, BLOOD, V92, P908; Pirotte S, 2011, BLOOD, V117, P2515, DOI 10.1182/blood-2010-08-298810; Rounds S., 2009, PULMONARY ENDOTHELIU, pxvii; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; Thebaud B, 2010, PVRI REV, V2, P62; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Yamashita T, 2008, MOL CELL BIOL, V28, P1285, DOI 10.1128/MCB.01332-07	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					224	241		10.1111/gtc.12215		18	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100007		
J	Koiwai, K; Kubota, T; Watanabe, N; Hori, K; Koiwai, O; Masai, H				Koiwai, Kotaro; Kubota, Takashi; Watanabe, Nobuhisa; Hori, Katsutoshi; Koiwai, Osamu; Masai, Hisao			Definition of the transcription factor TdIF1 consensus-binding sequence through genomewide mapping of its binding sites	GENES TO CELLS			English	Article							QUANTITATIVE PROTEOMICS REVEALS; ALPHA-INDUCED APOPTOSIS; 132 KDA TREP-132; NF-KAPPA-B; TNF-ALPHA; TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE; REGULATING PROTEIN; GENE-EXPRESSION; TDT ACTIVITY; CHIP-SEQ	TdIF1 was originally identified as a protein that directly binds to terminal deoxynucleotidyltransferase, TdT. Through in vitro selection assays (SELEX), we recently showed that TdIF1 recognizes both AT-tract and a specific DNA sequence motif, 5-TGCATG-3, and can up-regulate the expression of RAB20 through the latter motif. However, whether TdIF1 binds to these sequences in the cells has not been clear and its other target genes remain to be identified. Here, we determined in vivo TdIF1-binding sequences (TdIF1-invivoBMs) on the human chromosomes through ChIP-seq analyses. The result showed a 160-base pair cassette containing AT-tract similar to palindrome (inverted repeat)similar to AT-tract' as a likely target sequence of TdIF1. Interestingly, the core sequence of the palindrome in the TdIF1-invivoBMs shares significant similarity to the above 5-TGCATG-3 motif determined by SELEX in vitro. Furthermore, spacer sequences between AT-tract and the palindrome contain many potential transcription factor binding sites. In luciferase assays, TdIF1 can up-regulate transcription activity of the promoters containing the TdIF1-invivoBM, and this effect is mainly through the palindrome. Clusters of this motif were found in the potential target genes. Gene ontology analysis and RT-qPCR showed the enrichment of some candidate targets of TdIF1 among the genes involved in the regulation of ossification. Potential modes of transcription activation by TdIF1 are discussed.	[Koiwai, Kotaro; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Tokyo 1568506, Japan; [Kubota, Takashi; Koiwai, Osamu] Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan; [Watanabe, Nobuhisa; Hori, Katsutoshi] Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Koiwai, K (reprint author), Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Tokyo 1568506, Japan.	koiwai-kt@igakuken.or.jp; masai-hs@igakuken.or.jp					Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Ryu YS, 2011, J BIOL CHEM, V286, P25729, DOI 10.1074/jbc.M111.241893; Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Li LP, 2009, J COMPUT BIOL, V16, P317, DOI 10.1089/cmb.2008.16TT; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Segre CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848; Park J, 2012, HEPATOLOGY, V56, P831, DOI 10.1002/hep.25726; Pagliuca FW, 2011, MOL CELL, V43, P406, DOI 10.1016/j.molcel.2011.05.031; Kim C, 2013, FEBS LETT, V587, P3853, DOI 10.1016/j.febslet.2013.10.018; Lee JH, 2011, CLIN CANCER RES, V17, P7551, DOI 10.1158/1078-0432.CCR-11-1026; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Manelli F, 2000, TRENDS ENDOCRIN MET, V11, P79, DOI 10.1016/S1043-2760(00)00234-4; Lee YH, 2012, INT IMMUNOPHARMACOL, V12, P547, DOI 10.1016/j.intimp.2012.01.011; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Takahashi K, 2006, J IMMUNOL, V177, P4605; Ganti R, 2006, MODERN PATHOL, V19, P1213, DOI 10.1038/modpathol.3800636; Brown-Endres L, 2012, CANCER RES, V72, P2373, DOI 10.1158/0008-5472.CAN-11-3369; Fujisaki S, 2006, GENES CELLS, V11, P47, DOI 10.1111/j.1365-2443.2005.00916.x; Gizard F, 2002, J BIOL CHEM, V277, P39144, DOI 10.1074/jbc.M205786200; Gizard F, 2005, MOL CELL BIOL, V25, P4335, DOI 10.1128/MCB.25.11.4335-4348.2005; Gizard F, 2002, ENDOCR RES, V28, P559, DOI 10.1081/ERC-120016841; Gizard F, 2001, J BIOL CHEM, V276, P33881, DOI 10.1074/jbc.M100113200; Hao Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002065; Hayano T, 2009, GENES CELLS, V14, P1415, DOI 10.1111/j.1365-2443.2009.01358.x; Ku WC, 2009, MOL CELL PROTEOMICS, V8, P2034, DOI 10.1074/mcp.M900013-MCP200; Kubota T, 2007, GENES CELLS, V12, P941, DOI 10.1111/j.1365-2443.2007.01105.x; Kubota T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066710; Maezawa S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039511; Maezawa S, 2008, GENES CELLS, V13, P439, DOI 10.1111/j.1365-2443.2008.01179.x; Oleaga C, 2012, BIOCHEM PHARMACOL, V84, P1581, DOI 10.1016/j.bcp.2012.09.014; Orso F, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-355; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237; Yamamoto K, 2012, THYROID, V22, P516, DOI 10.1089/thy.2011.0222; Yamashita N, 2001, GENES CELLS, V6, P641, DOI 10.1046/j.1365-2443.2001.00449.x; Yoda M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054412; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	40	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1356-9597	1365-2443		GENES CELLS	Genes Cells	MAR	2015	20	3					242	254		10.1111/gtc.12216		13	Cell Biology; Genetics & Heredity	Cell Biology; Genetics & Heredity	CC6US	WOS:000350505100008		
J	Watanabe, Y; Yamamoto, H; Oikawa, R; Toyota, M; Yamamoto, M; Kokudo, N; Tanaka, S; Arii, S; Yotsuyanagi, H; Koike, K; Itoh, F				Watanabe, Yoshiyuki; Yamamoto, Hiroyuki; Oikawa, Ritsuko; Toyota, Minoru; Yamamoto, Masakazu; Kokudo, Norihiro; Tanaka, Shinji; Arii, Shigeki; Yotsuyanagi, Hiroshi; Koike, Kazuhiko; Itoh, Fumio			DNA methylation at hepatitis B viral integrants is associated with methylation at flanking human genomic sequences	GENOME RESEARCH			English	Article							HEPATOCELLULAR-CARCINOMA PATIENTS; EPSTEIN-BARR-VIRUS; LIVER-CANCER; EPIGENETIC MECHANISMS; RECURRENT MUTATIONS; TRANSGENIC MICE; HBX GENE; AMPLIFICATION; CELLS; RISK	Integration of DNA viruses into the human genome plays an important role in various types of tumors, including hepatitis B virus (HBV)-related hepatocellular carcinoma. However, the molecular details and clinical impact of HBV integration on either human or HBV epigenomes are unknown. Here, we show that methylation of the integrated HBV DNA is related to the methylation status of the flanking human genome. We developed a next-generation sequencing-based method for structural methylation analysis of integrated viral genomes (denoted G-NaVI). This method is a novel approach that enables enrichment of viral fragments for sequencing using unique baits based on the sequence of the HBV genome. We detected integrated HBV sequences in the genome of the PLC/PRF/5 cell line and found variable levels of methylation within the integrated HBV genomes. Allele-specific methylation analysis revealed that the HBV genome often became significantly methylated when integrated into highly methylated host sites. After integration into unmethylated human genome regions such as promoters, however, the HBV DNA remains unmethylated and may eventually play an important role in tumorigenesis. The observed dynamic changes in DNA methylation of the host and viral genomes may functionally affect the biological behavior of HBV. These findings may impact public health given that millions of people worldwide are carriers of HBV. We also believe our assay will be a powerful tool to increase our understanding of the various types of DNA virus-associated tumorigenesis.	[Watanabe, Yoshiyuki; Yamamoto, Hiroyuki; Oikawa, Ritsuko; Itoh, Fumio] St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa 2168511, Japan; [Watanabe, Yoshiyuki] Kawasaki Rinko Gen Hosp, Internal Med, Kawasaki, Kanagawa 2100806, Japan; [Toyota, Minoru] Sapporo Med Univ, Sch Med, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; [Yamamoto, Masakazu] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo 1628666, Japan; [Kokudo, Norihiro] Univ Tokyo 1138655, Grad Sch Med, Hepatobiliary Pancreat Surg Div, Artificial Organ & Transplantat Div, Tokyo, Japan; [Tanaka, Shinji; Arii, Shigeki] Tokyo Med & Dent Univ, Grad Sch, Dept Hepatobiliary Pancreat Surg, Tokyo 1130034, Japan; [Yotsuyanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Infect Dis, Tokyo 1138655, Japan; [Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan	Yamamoto, H (reprint author), St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa 2168511, Japan.	h-yama@marianna-u.ac.jp			Japan Society for the Promotion of Science (JSPS) (JSPS KAKENHI) [23590964]	We thank Drs. K. Watashi and T. Wakita for cell lines and Drs. T. Takayama, K. Takasaki, and S. Kawasaki for clinical samples. We also thank Drs. N. Matsumoto and N. Yamada-Ohkawa, as well as other members of the laboratory, for advice and suggestions. A part of the data used for this research was originally obtained by a research project of Hiroyuki Yamamoto and Yoshiyuki Watanabe led by Professor Fumio Itoh and is available at the website of the NBDC/JST (http://biosciencedbc.jp/en/). This work was supported in part by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (JSPS KAKENHI grant no. 23590964 to H. Yotsuyanagi).	Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Adey A, 2013, NATURE, V500, P207, DOI 10.1038/nature12064; Doerfler W, 2008, EPIGENETICS-US, V3, P125; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; Hilleman MR, 2004, P NATL ACAD SCI USA, V101, P14560, DOI 10.1073/pnas.0404758101; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Toh ST, 2013, CARCINOGENESIS, V34, P787, DOI 10.1093/carcin/bgs406; Nakagawa H, 2013, CANCER LETT, V340, P234, DOI 10.1016/j.canlet.2012.10.035; Oishi Y, 2012, TUMOR BIOL, V33, P383, DOI 10.1007/s13277-011-0278-y; Igarashi S, 2010, CLIN CANCER RES, V16, P5114, DOI 10.1158/1078-0432.CCR-10-0581; Lau CC, 2014, CANCER CELL, V25, P335, DOI 10.1016/j.ccr.2014.01.030; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Fernandez AF, 2009, GENOME RES, V19, P438, DOI 10.1101/gr.083550.108; Li SY, 2013, CANCER LETT, V340, P247, DOI 10.1016/j.canlet.2012.09.027; Jiang ZS, 2012, GENOME RES, V22, P593, DOI 10.1101/gr.133926.111; Mirabello L, 2012, JNCI-J NATL CANCER I, V104, P556, DOI 10.1093/jnci/djs135; Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1016/0270-9139(94)90277-1; Toyota M, 1999, CANCER RES, V59, P2307; Gatza ML, 2005, ENVIRON MOL MUTAGEN, V45, P304, DOI 10.1002/em.20088; MINAMI M, 1995, GENOMICS, V29, P403; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Tao Q, 2003, CLIN IMMUNOL, V109, P53, DOI 10.1016/S1521-6616(03)00198-0; Ding D, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003065; Doerfler W, 2001, Dev Biol (Basel), V106, P89; Durbin R, 1998, BIOL SEQUENCE ANAL; Furey TS, 2003, HUM MOL GENET, V12, P1037, DOI 10.1093/hmg/ddg113; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74; OREND G, 1991, J VIROL, V65, P4301; Schriml LM, 1999, BIOTECHNIQUES, V27, P608; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; Speel EJM, 1997, J HISTOCHEM CYTOCHEM, V45, P1439; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Watanabe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023320; Yamada Yoichi, 2011, BMC Res Notes, V4, P179, DOI 10.1186/1756-0500-4-179	38	1	1	COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT	COLD SPRING HARBOR	1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	1088-9051	1549-5469		GENOME RES	Genome Res.	MAR	2015	25	3					328	337		10.1101/gr.175240.114		10	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity	CC7DA	WOS:000350526700003		
J	Takashima, Y; Terada, M; Kawabata, M; Suzuki, A				Takashima, Yasuo; Terada, Maiko; Kawabata, Masuyo; Suzuki, Atsushi			Dynamic Three-Dimensional Morphogenesis of Intrahepatic Bile Ducts in Mouse Liver Development	HEPATOLOGY			English	Article							OVARIAN-CANCER; CELLS; CHOLANGIOCARCINOMA; EXPRESSION; MODEL; DIFFERENTIATION; TUBULOGENESIS; PATHOGENESIS; HEPATOCYTES; PARAMETERS	During liver development, biliary epithelial cells differentiated from bipotential hepatic progenitor cells (hepatoblasts) form a cell layer, called the ductal plate surrounding portal veins (PVs), and develop into intrahepatic bile ducts (IBDs) following developmental programs. Because IBDs make duct structures in the liver, it is necessary to perform sequential and three-dimensional (3D) analyses from the early stages of liver development to address the process of morphogenesis in detail. However, to date, the development of IBDs has mainly been investigated using tissue sections in two-dimensional planes, and examinations of the 3D morphogenesis and quantitative analyses based on morphometrics have not been performed. Therefore, in this study, we simulated the solid structures of IBDs from mouse embryos to adults in silico, analyzed the subjects for the length and number of developing duct structures, number of predicted connections, and discrete distance from the PV, and examined the developmental process of the IBD in detail in a quantitative manner. Conclusions: Through quantitative analyses with spatiotemporal observations using a 3D structural reconstruction model and morphometrics, we succeeded in constructing a 3D dynamic model of bile duct formation. Because the 3D reconstruction technique used in this study is available for analyzing solid structures in tissues that are difficult to approach, it shows promise for wide use in the fields of biology and medicine. (Hepatology 2015;61:1003-1011)	[Takashima, Yasuo; Terada, Maiko; Kawabata, Masuyo; Suzuki, Atsushi] Kyushu Univ, Med Inst Bioregulat, Div Organogenesis & Regenerat, Fukuoka 8128582, Japan; [Suzuki, Atsushi] Japan Sci & Technol Agcy, CREST, Saitama, Japan	Suzuki, A (reprint author), Kyushu Univ, Med Inst Bioregulat, Div Organogenesis & Regenerat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	suzukicks@bioreg.kyushu-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Health Labor Sciences Research Grant in Japan; Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency	This work was supported, in part, by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Health Labor Sciences Research Grant in Japan, and the Core Research for Evolutional Science and Technology Program of the Japan Science and Technology Agency.	Aiba Y, 2014, LIVER INT, V34, P679, DOI 10.1111/liv.12296; Lawrenson K, 2010, NEOPLASIA, V12, P317, DOI 10.1593/neo.91948; Raynaud P, 2011, INT J BIOCHEM CELL B, V43, P245, DOI 10.1016/j.biocel.2009.07.020; Tsunoda T, 2011, ANTICANCER RES, V31, P2453; Rizvi I, 2013, PHOTOCHEM PHOTOBIOL, V89, P942, DOI 10.1111/php.12065; Erturk A, 2012, NAT PROTOC, V7, P1983, DOI 10.1038/nprot.2012.119; Lammert F, 2000, J HEPATOL, V33, P1012, DOI 10.1016/S0168-8278(00)80139-7; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Si-Tayeb K, 2010, DEV CELL, V18, P175, DOI 10.1016/j.devcel.2010.01.011; Antoniou A, 2009, GASTROENTEROLOGY, V136, P2325, DOI 10.1053/j.gastro.2009.02.051; Lee JM, 2013, LAB INVEST, V93, P528, DOI 10.1038/labinvest.2013.41; Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305; Carpentier R, 2011, GASTROENTEROLOGY, V141, P1432, DOI 10.1053/j.gastro.2011.06.049; Zong YW, 2009, DEVELOPMENT, V136, P1727, DOI 10.1242/dev.029140; Glidden MD, 2012, THERANOSTICS, V2, P827, DOI 10.7150/thno.4334; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; Claude M, 2009, PALAEONTOL ELECTRON, V12, p12A; Clemente G, 2010, J VISC SURG, V147, pE175, DOI 10.1016/j.jviscsurg.2010.06.005; Diken Z, 2014, AM J PERINAT, V31, P1, DOI 10.1055/s-0033-1333673; Douhara Akitoshi, 2013, World J Gastrointest Oncol, V5, P181, DOI 10.4251/wjgo.v5.i8.181; Ehlken H, 2013, DIGEST DIS, V31, P118, DOI 10.1159/000347206; Erturk A, 2012, NAT MED, V18, P166, DOI 10.1038/nm.2600; Godlewski G, 2004, SURG RADIOL ANAT, V26, P359, DOI 10.1007/s00276-004-0239-x; Holzinger F, 1999, ANN ONCOL, V10, P122, DOI 10.1023/A:1008321710719; Lesurtel M, 2002, Eur J Gastroenterol Hepatol, V14, P1025, DOI 10.1097/00042737-200209000-00016; Marmaras A, 2010, CYTOSKELETON, V67, P224, DOI 10.1002/cm.20438; Stalling D, 2005, VISUALIZATION HDB, V38, P749; Tsunoda T, 2010, NEOPLASIA, V12, P397, DOI 10.1593/neo.10170; Vestentoft Peter Siig, 2013, Fibrogenesis Tissue Repair, V6, P21, DOI 10.1186/1755-1536-6-21; Vestentoft PS, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-56; Zachow S, 2007, 3D RECONSTRUCTION IN, P1; Zhu QN, 2013, PEERJ, V1, DOI 10.7717/peerj.143	32	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	MAR	2015	61	3					1003	1011		10.1002/hep.27436		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC2BS	WOS:000350150300030		
J	Namikoshi, T; Odahara, K; Wakino, A; Murata, M; Watanabe, S				Namikoshi, Takeshi; Odahara, Keita; Wakino, Akira; Murata, Miki; Watanabe, Shinji			Preparation of aliphatic-aromatic polyimide particles by polycondensation of diethyl hexafluoroisopropylidenediphthalate and diaminooctane in ethylene glycol	HIGH PERFORMANCE POLYMERS			English	Article						Aliphatic-aromatic polyimide; nylon salt-type monomer; confetti-shaped particles; ethylene glycol; rod-shaped particles	HIGH-PRESSURE SYNTHESIS; SEEDED DISPERSION POLYMERIZATION; REACTION-INDUCED CRYSTALLIZATION; PYROMELLITIC ACID; SALT MONOMERS; DIAMINES; POLYPYROMELLITIMIDES; COPOLYMERIZATION; NANOPARTICLES; MICROSPHERES	Polycondensation of nylon salt-type monomer composed of diethyl hexafluoroisopropylidenediphthalate and diaminooctane was performed at 130 degrees C in ethylene glycol to form confetti-shaped particles. Before the polycondensation, the salt monomer solution was homogeneous. As the polycondensation proceeded, the solution became turbid and polyimide particles grew to around 7 m for 8 h. After the polycondensation, small particles precipitated and got deposited onto large particles to form confetti-shaped particles. Rod-shaped particles were also formed by the polycondensation at low monomer concentration in a long reaction time. They were found to be crystalline in form.	[Namikoshi, Takeshi; Odahara, Keita; Wakino, Akira; Murata, Miki; Watanabe, Shinji] Kitami Inst Technol, Dept Mat Sci & Engn, Kitami, Hokkaido 0908507, Japan	Watanabe, S (reprint author), Kitami Inst Technol, Dept Mat Sci & Engn, 165 Koen Cho, Kitami, Hokkaido 0908507, Japan.	watash@mail.kitami-it.ac.jp					Zhao GF, 2007, CHEM MATER, V19, P1901, DOI 10.1021/cm062709w; Huang Y, 2011, MACROMOLECULES, V44, P2404, DOI 10.1021/ma200169w; Chai ZK, 2003, J POLYM SCI POL PHYS, V41, P159, DOI 10.1002/polb.10368; Aranaz I, 2011, POLYMER, V52, P2991, DOI 10.1016/j.polymer.2011.05.027; Bamnolker H, 1996, J POLYM SCI POL CHEM, V34, P1857; Chen MQ, 2001, CHEM LETT, P1306; Evans JR, 1985, J POLYM SCI POL CHEM, V38, P971; Huang HF, 2010, J POLYM SCI POL CHEM, V48, P5198, DOI 10.1002/pola.24319; Imai Y, 1998, J POLYM SCI POL CHEM, V36, P1341, DOI 10.1002/(SICI)1099-0518(199806)36:8<1341::AID-POLA17>3.0.CO;2-6; Imai Y, 1996, J POLYM SCI POL CHEM, V34, P701, DOI 10.1002/(SICI)1099-0518(199603)34:4<701::AID-POLA18>3.0.CO;2-S; Inoue T, 1997, MACROMOLECULES, V30, P1921, DOI 10.1021/ma9615563; Inoue T, 1997, MACROMOL CHEM PHYSIC, V198, P519, DOI 10.1002/macp.1997.021980224; ITOYA K, 1994, MACROMOLECULES, V27, P4101, DOI 10.1021/ma00093a011; KONING C, 1994, POLYMER, V35, P4889, DOI 10.1016/0032-3861(94)90748-X; KORSHAK VV, 1980, J POLYM SCI POL PHYS, V18, P247, DOI 10.1002/pol.1980.180180208; KUMAGAI Y, 1995, POLYMER, V36, P2827, DOI 10.1016/0032-3861(95)93663-7; Kumagai Y, 2000, J POLYM SCI POL CHEM, V38, P1391, DOI 10.1002/(SICI)1099-0518(20000415)38:8<1391::AID-POLA23>3.0.CO;2-Y; Nguyen D, 2010, LANGMUIR, V26, P6086, DOI 10.1021/la100357q; Ni XW, 2009, J APPL POLYM SCI, V113, P3671, DOI 10.1002/app.30365; Shi S, 2011, J APPL POLYM SCI, V120, P501, DOI 10.1002/app.33173; Taniguchi T, 2012, J COLLOID INTERF SCI, V368, P107, DOI 10.1016/j.jcis.2011.11.077; TSENG CM, 1986, J POLYM SCI POL CHEM, V24, P2995, DOI 10.1002/pola.1986.080241126; Unterlass MM, 2011, POLYM CHEM-UK, V2, P1744, DOI 10.1039/c1py00109d; Wakabayashi K, 2008, MACROMOLECULES, V41, P1168, DOI 10.1021/ma702030u; Wakabayashi K, 2008, MACROMOLECULES, V41, P4607, DOI 10.1021/ma800874w; Watanabe S, 2012, HIGH PERFORM POLYM, V24, P710, DOI 10.1177/0954008312450594; Zhao GF, 2009, POLYM ADVAN TECHNOL, V20, P43, DOI 10.1002/pat.1278	27	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0954-0083	1361-6412		HIGH PERFORM POLYM	High Perform. Polym.	MAR	2015	27	2					183	190		10.1177/0954008314542474		8	Polymer Science	Polymer Science	CC6CY	WOS:000350453500007		
J	Louthrenoo, W; Kasitanon, N; Wangkaew, S; Kuwata, S; Takeuchi, F				Louthrenoo, Worawit; Kasitanon, Nuntana; Wangkaew, Suparaporn; Kuwata, Shoji; Takeuchi, Fujio			Distribution of HLA-DR alleles among Thai patients with rheumatoid arthritis	HUMAN IMMUNOLOGY			English	Article						HLA; Polymorphism; MHC class II; Genetic; Rheumatoid arthritis	CYCLIC CITRULLINATED PEPTIDE; HLA-DRB1 SHARED EPITOPE; SINGAPOREAN CHINESE; SUSCEPTIBILITY; ASSOCIATION; GENES; MANIFESTATIONS; HLA-DRB1-ASTERISK-0405; POLYMORPHISM; POPULATIONS	Objective: This study was performed to investigate the association between the HLA-DR series and rheumatoid arthritis (RA) in a Thai population. Methods: HLA-DR subtypes were determined in 100 Thai RA patients and 99 healthy controls (HC). HLA-DR typing was performed using INNO-LiPA HLA-DRB Decoder kits (Innogenetics) and reconfirmed using MICRO SSP HLA DNA Typing kits (One Lambda) for DRB1*02 and *04. Results: When compared with the HC, the RA patients had higher allele frequency (AF) of DRB1*04:05 (15.00% vs 7.07%, p = 0.016, pc = NS, OR = 2.319, 95%CI = 1.189-4.522) and DRB1*10:01 (3.00% vs 0%, p = 0.030, pc = NS), respectively. The DRB1*09:01 was slightly higher in the RA patients, without statistical significance. The AF of the shared epitope (SE) alleles (HLA-DRB1*01:01, *04:01, *04:05 and *10:01) was significantly higher in the RA patients (18.50% vs 7.58%, p = 0.002, pc = 0.046, OR = 2.769, 95%CI = 1.466-5.231, 99%CI = 1.201-6.388). The AF of HLA-DRB4*01 also increased significantly more in the RA patients (40.50% vs 25.76%, p = 0.002, pc = 0.002, OR = 1.962, 95%CI = 1.282-3.003, 99%CI = 1.121-3.433). The HLA-DRB3*03:01 was significantly lower in the RA patients (6.00% vs 14.14%, p = 0.008, pc = 0.023, OR = 0.388, 95%CI = 0.191-0.786, 99%CI = 0.153-0.982). Conclusion: In the presence of SE, the DRB1*04:05 and HLA-DRB4*01 were associated with RA, and the DRB3*03:01 would be a protective allele against RA in a Thai population. (C) 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.	[Louthrenoo, Worawit; Kasitanon, Nuntana; Wangkaew, Suparaporn] Chiang Mai Univ, Fac Med, Dept Internal Med, Div Rheumatol, Chiang Mai 50200, Thailand; [Kuwata, Shoji] Teikyo Univ, Sch Med, Chiba Med Ctr, Dept Internal Med 3, Chiba, Japan; [Takeuchi, Fujio] Univ Tokyo, Fac Med, Dept Internal Med Allergy & Rheumatol, Tokyo 113, Japan	Louthrenoo, W (reprint author), Chiang Mai Univ, Fac Med, Dept Internal Med, Div Rheumatol, Chiang Mai 50200, Thailand.	worawit.louthrenoo@cmu.ac.th			Faculty of Medicine, Chiang Mai University Endowment Fund [01-2004]; Ministry of Education, Culture, Sport, Science and Technology of Japan [17406026]	This study was supported partially by the Faculty of Medicine, Chiang Mai University Endowment Fund, no. 01-2004 (Dr. Louthrenoo) and Grants-in-Aid for Science Research from the Ministry of Education, Culture, Sport, Science and Technology of Japan, no. 17406026 (Dr. Takeuchi and Dr. Kuwata).	Andersson Goran, 1998, Frontiers in Bioscience, V3, pD739; Mitsunaga S, 2012, TISSUE ANTIGENS, V80, P16, DOI 10.1111/j.1399-0039.2012.01872.x; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; Lee HS, 2004, ARTHRITIS RHEUM, V50, P3468, DOI 10.1002/art.20608; Turesson C, 2005, ARTHRITIS RES THER, V7, pR1386, DOI 10.1186/ar1837; Kong KF, 2002, AUTOIMMUNITY, V35, P235, DOI 10.1080/08916930290024179; Padyukov L, 2004, ARTHRITIS RHEUM, V50, P3085, DOI 10.1002/art.20553; Kurko J, 2013, CLIN REV ALLERG IMMU, V45, P170, DOI 10.1007/s12016-012-8346-7; Holoshitz J, 2010, CURR OPIN RHEUMATOL, V22, P293, DOI 10.1097/BOR.0b013e328336ba63; Karlson EW, 2010, ANN RHEUM DIS, V69, P54, DOI 10.1136/ard.2008.102962; Furuya T, 2007, CLIN EXP RHEUMATOL, V25, P219; Jun KR, 2007, J KOREAN MED SCI, V22, P973, DOI 10.3346/jkms.2007.22.6973; Bang SY, 2010, ARTHRITIS RHEUM-US, V62, P369, DOI 10.1002/art.27272; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CHAN SH, 1994, BRIT J RHEUMATOL, V33, P713; Chun-Lai T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021069; Del Rincon I, 2003, ARTHRIT RHEUM-ARTHR, V49, P200, DOI 10.1002/art.11000; Gregersen Peter K, 2010, Bull NYU Hosp Jt Dis, V68, P179; Hameed K, 1997, BRIT J RHEUMATOL, V36, P1184; Hirankarn N, 2007, RHEUMATOL INT, V28, P161, DOI 10.1007/s00296-007-0392-8; Huizinga TW, 2005, ARTHRITIS RHEUM, V52, P3433; Kochi Y, 2004, ARTHRITIS RHEUM, V50, P63, DOI 10.1002/art.11366; Koh WH, 1997, J RHEUMATOL, V24, P629; Lin L, 2007, BIOCHEM CELL BIOL, V85, P227, DOI 10.1139/O06-204; Liu SC, 2007, J RHEUMATOL, V34, P674; Liu X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071373; Pimtanothai Nattiya, 2002, Journal of the Medical Association of Thailand, V85, pS366; Prasannavar DJ, 2013, RHEUMATOL INT; Song EY, 2002, TISSUE ANTIGENS, V59, P475, DOI 10.1034/j.1399-0039.2002.590604.x; Stephens HAF, 2000, HUM IMMUNOL, V61, P1039, DOI 10.1016/S0198-8859(00)00172-5; Takeuchi F, 1996, CLIN EXP RHEUMATOL, V14, P17; Taneja V, 1996, HUM IMMUNOL, V46, P35, DOI 10.1016/0198-8859(95)00165-4; WATANABE Y, 1989, J EXP MED, V169, P2263, DOI 10.1084/jem.169.6.2263	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0198-8859	1879-1166		HUM IMMUNOL	Hum. Immunol.	MAR	2015	76	2-3					113	117		10.1016/j.humimm.2015.01.018		5	Immunology	Immunology	CC7EP	WOS:000350530800008		
J	Kon, M; Suzuki, E; Dung, VC; Hasegawa, Y; Mitsui, T; Muroyas, K; Ueoka, K; Igarashi, N; Nagasaki, K; Oto, Y; Hamajima, T; Yoshino, K; Igarashi, M; Kato-Fukui, Y; Nakabayashi, K; Hayashi, K; Hata, K; Matsubara, Y; Moriya, K; Ogata, T; Nonomura, K; Fukami, M				Kon, M.; Suzuki, E.; Dung, V. C.; Hasegawa, Y.; Mitsui, T.; Muroyas, K.; Ueoka, K.; Igarashi, N.; Nagasaki, K.; Oto, Y.; Hamajima, T.; Yoshino, K.; Igarashi, M.; Kato-Fukui, Y.; Nakabayashi, K.; Hayashi, K.; Hata, K.; Matsubara, Y.; Moriya, K.; Ogata, T.; Nonomura, K.; Fukami, M.			Molecular basis of non-syndromic hypospadias: systematic mutation screening and genome-wide copy-number analysis of 62 patients	HUMAN REPRODUCTION			English	Article						copy-number; hypospadias; mutation; polymorphism; susceptibility	ANDROGEN RECEPTOR GENE; DIFFERENT PHENOTYPES; CHINESE PATIENTS; RISK-FACTORS; DICENTRIC-Y; PREVALENCE; POLYMORPHISMS; SEQUENCE; COHORT; MAMLD1	STUDY QUESTION: What percentage of cases with non-syndromic hypospadias can be ascribed to mutations in known causative/candidate/susceptibility genes or submicroscopic copy-number variations (CNVs) in the genome? SUMMARY ANSWER: Monogenic and digenic mutations in known causative genes and cryptic CNVs account for >10% of cases with non-syndromic hypospadias. While known susceptibility polymorphisms appear to play a minor role in the development of this condition, further studies are required to validate this observation. WHAT IS KNOWN ALREADY: Fifteen causative, three candidate, and 14 susceptible genes, and a few submicroscopic CNVs have been implicated in non-syndromic hypospadias. STUDY DESIGN, SIZE, DURATION: Systematic mutation screening and genome-wide copy-number analysis of 62 patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study group consisted of 57 Japanese and five Vietnamese patients with non-syndromic hypospadias. Systematic mutation screening was performed for 25 known causative/candidate/susceptibility genes using a next-generation sequencer. Functional consequences of nucleotide alterations were assessed by in silico assays. The frequencies of polymorphisms in the patient group were compared with those in the male general population. CNVs were analyzed by array-based comparative genomic hybridization and characterized by fluorescence in situ hybridization. MAIN RESULTS AND THE ROLE OF CHANCE: Seven of 62 patients with anterior or posterior hypospadias carried putative pathogenic mutations, such as hemizygous mutations in AR, a heterozygous mutation in BNC2, and homozygous mutations in SRD5A2 and HSD3B2. Two of the seven patients had mutations in multiple genes. We did not find any rare polymorphisms that were abundant specifically in the patient group. One patient carried mosaic dicentric Y chromosome. LIMITATIONS, REASONS FOR CAUTION: The patient group consisted solely of Japanese and Vietnamese individuals and clinical and hormonal information of the patients remained rather fragmentary. In addition, mutation analysis focused on protein-altering substitutions. WIDER IMPLICATIONS OF THE FINDINGS: Our data provide evidence that pathogenic mutations can underlie both mild and severe hypospadias and that HSD3B2 mutations cause non-syndromic hypospadias as a sole clinical manifestation. Most importantly, this is the first report documenting possible oligogenicity of non-syndromic hypospadias.	[Kon, M.; Suzuki, E.; Igarashi, M.; Kato-Fukui, Y.; Ogata, T.; Fukami, M.] Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Tokyo 1578535, Japan; [Kon, M.; Mitsui, T.; Moriya, K.; Nonomura, K.] Hokkaido Univ, Grad Sch Med, Dept Renal & Genitourinary Surg, Sapporo, Hokkaido 0608638, Japan; [Dung, V. C.] Vietnam Natl Hosp Pediat, Dept Endocrinol, Hanoi, Vietnam; [Hasegawa, Y.] Tokyo Metropolitan Childrens Med Ctr, Dept Endocrinol & Metab, Tokyo 1838561, Japan; [Muroyas, K.] Kanagawa Childrens Med Ctr, Dept Endocrinol & Metab, Yokohama, Kanagawa 2320066, Japan; [Ueoka, K.] Natl Ctr Child Hlth & Dev, Div Urol, Tokyo 1578535, Japan; [Igarashi, N.] Toyama Prefectural Cent Hosp, Dept Pediat, Toyama 9300975, Japan; [Nagasaki, K.] Niigata Univ, Sch Med, Dept Pediat, Niigata 9518510, Japan; [Oto, Y.] Dokkyo Med Univ, Koshigaya Hosp, Dept Pediat, Koshigaya 3430845, Japan; [Hamajima, T.] Aichi Childrens Hlth & Med Ctr, Div Endocrinol & Metab, Obu 4748710, Japan; [Yoshino, K.] Aichi Childrens Hlth & Med Ctr, Dept Urol, Obu 4748710, Japan; [Nakabayashi, K.; Hayashi, K.; Hata, K.] Natl Res Inst Child Hlth & Dev, Maternal Fetal Biol, Tokyo 1578535, Japan; [Matsubara, Y.] Natl Res Inst Child Hlth & Dev, Tokyo 1578535, Japan; [Ogata, T.] Hamamatsu Univ Sch Med, Dept Pediat, Hamamatsu, Shizuoka 4313192, Japan	Fukami, M (reprint author), Natl Res Inst Child Hlth & Dev, Dept Mol Endocrinol, Tokyo 1578535, Japan.	fukami-m@ncchd.go.jp			Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare; National Center for Child Health and Development; Takeda Foundation	This study was funded by the Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology; by the Grant-in-Aid from the Japan Society for the Promotion of Science; by the Grants from the Ministry of Health, Labour and Welfare, from the National Center for Child Health and Development and from the Takeda Foundation.	Albers N, 1997, J PEDIATR-US, V131, P386, DOI 10.1016/S0022-3476(97)80063-7; Kurahashi N, 2004, J EPIDEMIOL, V14, P73, DOI 10.2188/jea.14.73; Fukami M, 2008, J BIOL CHEM, V283, P5525; Nassar N, 2007, ARCH DIS CHILD, V92, P580, DOI 10.1136/adc.2006.112862; Cooper GM, 2011, NAT GENET, V43, P838, DOI 10.1038/ng.909; Sasaki G, 2003, J CLIN ENDOCR METAB, V88, P3431, DOI 10.1210/jc.2002-021415; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Kalfa N, 2011, J PEDIATR UROL, V7, P585, DOI 10.1016/j.jpurol.2011.09.005; Audi L, 2010, J CLIN ENDOCR METAB, V95, P1876, DOI 10.1210/jc.2009-2146; van Rooij IALM, 2013, BJU INT, V112, P121, DOI 10.1111/j.1464-410X.2012.11745.x; van der Zanden LFM, 2012, HUM REPROD UPDATE, V18, P260, DOI 10.1093/humupd/dms002; Fredell L, 2002, J UROLOGY, V167, P1423, DOI 10.1016/S0022-5347(05)65334-7; Blaschko SD, 2012, DIFFERENTIATION, V84, P261, DOI 10.1016/j.diff.2012.06.003; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Wang YP, 2004, EUR J HUM GENET, V12, P706, DOI 10.1038/sj.ejhg.5201232; Schnack TH, 2008, AM J EPIDEMIOL, V167, P251, DOI 10.1093/aje/kwm317; Kohler B, 2009, EUR J ENDOCRINOL, V161, P237, DOI 10.1530/EJE-09-0067; Weidner IS, 1999, J UROLOGY, V161, P1606, DOI 10.1016/S0022-5347(05)68992-6; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Makridakis NM, 2000, PHARMACOGENETICS, V10, P407, DOI 10.1097/00008571-200007000-00004; Melo KFS, 2003, J CLIN ENDOCR METAB, V88, P3241, DOI 10.1210/jc.2002-021658; Boehmer ALM, 2001, J UROLOGY, V165, P1246, DOI 10.1016/S0022-5347(05)66505-6; Brouwers MM, 2010, BJU INT, V105, P254, DOI 10.1111/j.1464-410X.2009.08772.x; Chen TJ, 2007, EUR J HUM GENET, V15, P23, DOI 10.1038/sj.ejhg.5201722; Codner E, 2004, J CLIN ENDOCR METAB, V89, P957, DOI 10.1210/jc.2002-020873; DRUMMONDBORG M, 1988, J PEDIATR-US, V113, P469, DOI 10.1016/S0022-3476(88)80630-9; Kalfa N, 2008, J UROLOGY, V180, P2183, DOI 10.1016/j.juro.2008.07.066; Kojima Y, 2001, J UROLOGY, V165, P1244, DOI 10.1016/S0022-5347(05)66502-0; Sata F, 2010, J SEX MED, V7, P2729, DOI 10.1111/j.1743-6109.2009.01641.x; Serrano T, 2013, HUM REPROD, V28, P1974, DOI 10.1093/humrep/det111; STOLL C, 1990, J MED GENET, V27, P559, DOI 10.1136/jmg.27.9.559; Tannour-Louet M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015392; Wu WH, 2002, J UROLOGY, V168, P229, DOI 10.1016/S0022-5347(05)64898-7	33	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	MAR	2015	30	3					499	506		10.1093/humrep/deu364		8	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CC2AV	WOS:000350147900002		
J	Suzuki, N; Yoshioka, N; Takae, S; Sugishita, Y; Tamura, M; Hashimoto, S; Morimoto, Y; Kawamura, K				Suzuki, Nao; Yoshioka, Nobuhito; Takae, Seido; Sugishita, Yodo; Tamura, Midori; Hashimoto, Shu; Morimoto, Yoshiharu; Kawamura, Kazuhiro			Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency	HUMAN REPRODUCTION			English	Article						ovarian tissue vitrification; infertility treatment; primary ovarian insufficiency; in vitro activation; Akt stimulation	HIGHLY EFFICIENT VITRIFICATION; HUMAN OOCYTES; CRYOPRESERVATION; TRANSPLANTATION; AUTOTRANSPLANTATION; FOLLICLES; FAILURE; EXPRESSION; PREGNANCY; WOMAN	STUDY QUESTION: Is ovarian tissue cryopreservation using vitrification followed by in vitro activation (IVA) of dormant follicles a potential approach for infertility treatment of patients with primary ovarian insufficiency (POI)? SUMMARY ANSWER: Our vitrification approach followed by IVA treatment is a potential infertility therapy for POI patients whose ovaries contain residual follicles. WHAT IS KNOWN ALREADY: Akt (protein kinase B) stimulators [PTEN (phosphatase with TENsin homology deleted in chromosome 10) inhibitor and phosphatidyinositol-3-kinase (PI3 kinase) stimulator] activate dormant primordial follicles in vitro and ovarian fragmentation disrupts the Hippo signaling pathway, leading to the promotion of follicle growth. We treated POI patients with a combination of ovarian vitrification, fragmentation and drug treatment, followed by auto-transplantation, and reported successful follicle growth and pregnancies. STUDY DESIGN, SIZE, DURATION: Prospective clinical study of 37 infertile women with POI between 12 August 2011 and 1 November 2013. We enrolled 10 new patients since the previous publication. PARTICIPANTS/MATERIALS, SETTING, METHODS: POI patients were originally selected based on a history of amenorrhea for more than 1 year and elevated serum FSH levels of >40 mIU/ml (n = 31) but this was later changed to >4 months, age <40 years and serum FSH levels of >35 mIU/ml (n = 6) (mean 71.8 +/- 30.8, range 35.5-197.6) so as to include patients with a shorter duration of amenorrhea. Under laparoscopic surgery, ovariectomy was performed and ovarian cortices were dissected into strips for vitrification. Some pieces were examined histologically. After warming, two to three strips were fragmented into smaller cubes before culturing with Akt stimulators for 2 days. After washing, ovarian cubes were transplanted beneath the serosa of Fallopian tubes under laparoscopic surgery. Follicle growth was monitored by ultrasound and serum estrogen levels. After oocyte retrieval from mature follicles, IVF was performed. MAIN RESULTS AND THE ROLE OF CHANCE: Among 37 patients, 54% had residual follicles based on histology. Among patients with follicles, 9 out of 20 showed follicle growth in auto-grafts with 24 oocytes retrieved from six patients. Following IVF and embryo transfer into four patients, three pregnancies were detected based on serum hCG, followed by one miscarriage and two successful deliveries. For predicting IVA success, we found that routine histological analyses of ovarian cortices and shorter duration from initial POI diagnosis to ovariectomy are valid parameters. LIMITATIONS, REASONS FOR CAUTION: Although our findings suggest that the present vitrification protocol is effective for ovarian tissue cryopreservation, we have not compared the potential of vitrification and slow freezing in follicle growth after grafting. We chose the serosa of Fallopian tubes as the auto-grating site due to its high vascularity and the ease to monitor follicle growth. Future studies are needed to evaluate the best auto-grafting sites for ovarian tissues. Also, future studies are needed to identify biological markers to indicate the presence of residual follicles in POI to predict IVA treatment outcome. WIDER IMPLICATIONS OF THE FINDINGS: In POI patients, ovarian reserve, namely the pool of residual follicles, continues to diminish with age. If one ovary is cryopreserved at an earlier stage of POI, patients could undergo additional non-invasive infertility treatments before the final decision for the IVA treatment. Furthermore, in the cases of unmarried POI patients, cryopreservation of ovarian tissues allows their fertility preservation until they desire to bear children.	[Suzuki, Nao; Yoshioka, Nobuhito; Takae, Seido; Sugishita, Yodo; Tamura, Midori; Kawamura, Kazuhiro] St Marianna Univ, Sch Med, Dept Obstet & Gynecol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Hashimoto, Shu; Morimoto, Yoshiharu] IVF Namba Clin, Osaka, Osaka 5500015, Japan	Kawamura, K (reprint author), St Marianna Univ, Sch Med, Dept Obstet & Gynecol, Miyamae Ku, 2-6-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	kazuhironanami@gmail.com			Smoking Research Foundation; Takeda Science Foundation;  [24390376];  [24659722];  [26114510]	This work was supported by Grant-In-Aid for Scientific Research (Research B: 24390376, Challenging Exploratory Research: 24659722, and Innovative Areas, Mechanisms regulating gamete formation in animals: 26114510) and by research funds from the Smoking Research Foundation, and the Takeda Science Foundation. None of the authors have a conflict of interest.	Loren AW, 2013, J CLIN ONCOL, V31, P2500, DOI 10.1200/JCO.2013.49.2678; NELSON LM, 1994, J CLIN ENDOCR METAB, V79, P1470, DOI 10.1210/jc.79.5.1470; De Vos M, 2010, LANCET, V376, P911, DOI 10.1016/S0140-6736(10)60355-8; Suzuki N, 2012, HUM REPROD, V27, P2420, DOI 10.1093/humrep/des178; von Wolff M, 2009, EUR J CANCER, V45, P1547, DOI 10.1016/j.ejca.2009.01.029; Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110; Demeestere I, 2009, HUM REPROD UPDATE, V15, P649, DOI 10.1093/humupd/dmp021; Jeong K, 2012, MINERVA MED, V103, P37; Katayama KP, 2003, FERTIL STERIL, V80, P223, DOI 10.1016/S0015-0282(03)00551-X; Andersen CY, 2012, FUTURE ONCOL, V8, P595, DOI [10.2217/fon.12.47, 10.2217/FON.12.47]; Meirow D, 2005, NEW ENGL J MED, V353, P318, DOI 10.1056/NEJMc055237; Amorim CA, 2011, REPROD BIOMED ONLINE, V23, P160, DOI 10.1016/j.rbmo.2011.04.005; Gamzatova Z, 2014, GYNECOL ENDOCRINOL, V30, P43, DOI 10.3109/09513590.2014.945789; Kuwayama M, 2007, THERIOGENOLOGY, V67, P73, DOI 10.1016/j.theriogenology.2006.09.014; Nelson LM, 2009, NEW ENGL J MED, V360, P606, DOI 10.1056/NEJMcp0808697; Taylor RN, 2002, ANN NY ACAD SCI, V955, P89; Weenen C, 2004, MOL HUM REPROD, V10, P77, DOI 10.1093/molehr/gah015; MCGRATH SA, 1995, MOL ENDOCRINOL, V9, P131, DOI 10.1210/me.9.1.131; Li J, 2010, P NATL ACAD SCI USA, V107, P10280, DOI 10.1073/pnas.1001198107; Hashimoto S, 2010, REPROD BIOMED ONLINE, V21, P501, DOI 10.1016/j.rbmo.2010.04.029; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Broekmans FJ, 2009, ENDOCR REV, V30, P465, DOI 10.1210/er.2009-0006; Kagawa N, 2009, REPROD BIOMED ONLINE, V18, P568; Donnez J, 2010, CLIN OBSTET GYNECOL, V53, P787, DOI 10.1097/GRF.0b013e3181f97a55; Grynberg M, 2012, FERTIL STERIL, V97, P1260, DOI 10.1016/j.fertnstert.2012.04.042; Callejo J, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-33; Ishizuka B, 1997, FERTIL STERIL, V68, P931, DOI 10.1016/S0015-0282(97)00338-5; Kolp LA, 2011, FERTIL STERIL, V95, P1879, DOI 10.1016/j.fertnstert.2011.02.049; Kuwayama M, 2005, REPROD BIOMED ONLINE, V11, P300; MENON V, 1983, BRIT J OBSTET GYNAEC, V90, P539, DOI 10.1111/j.1471-0528.1983.tb08964.x; Taylor RN, 2002, ANN NY ACAD SCI, V955, P396; Taylor RN, 2002, ANN NY ACAD SCI, V955, P118	32	12	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	MAR	2015	30	3					608	615		10.1093/humrep/deu353		8	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CC2AV	WOS:000350147900013		
J	Okamoto, M; Nasu, K; Abe, W; Aoyagi, Y; Kawano, Y; Kai, K; Moriyama, M; Narahara, H				Okamoto, M.; Nasu, K.; Abe, W.; Aoyagi, Y.; Kawano, Y.; Kai, K.; Moriyama, M.; Narahara, H.			Enhanced miR-210 expression promotes the pathogenesis of endometriosis through activation of signal transducer and activator of transcription 3	HUMAN REPRODUCTION			English	Article						endometriosis; microRNA; signal transducer and activator of transcription 3; vascular endothelial growth factor	MICRORNA EXPRESSION; STROMAL CELLS; GENE-EXPRESSION; INHIBITS PROLIFERATION; POSSIBLE MECHANISM; DOWN-REGULATION; IN-VITRO; HYPOXIA; APOPTOSIS; CANCER	STUDY QUESTION: What are the roles of the microRNA miR-210-an miRNA that is up-regulated in endometriotic cyst stromal cells (ECSCs)-in the pathogenesis of endometriosis? SUMMARY ANSWER: Up-regulated miR-210 expression in ECSCs is involved in their proliferation, resistance to apoptosis and angiogenesis through signal transducer and activator of transcription (STAT) 3. WHAT IS KNOWN ALREADY: In the pathogenesis of endometriosis, a number of roles for microRNAs (miRNAs) are becoming apparent. STUDY DESIGN, SIZE, DURATION: ECSCs and normal endometrial stromal cells (NESCs) were isolated from ovarian endometriotic tissues (patients aged 24-40 years undergoing salpingo-oophorectomy or evisceration for the treatment of ovarian endometriotic cysts, n = 10) and the eutopic endometrial tissues without endometriosis (premenopausal patients aged 35-45 years undergoing hysterectomies for subserousal leiomyoma, n = 13), respectively. PARTICIPANTS/MATERIALS, SETTING, METHODS: We used a global gene expression microarray technique to identify downstream targets of miR-210, and we assessed the functions of miR-210 in the pathogenesis of endometriosis by using the miR-210-transfected NESCs. MAIN RESULTS AND THE ROLE OF CHANCE: Gene expression microarray analysis revealed that one of the key target molecules of miR-210 is STAT3. In the NESCs, in comparison to the control, miR-210 transfection resulted in the induction of cell proliferation (P<0.0005), the production of vascular endothelial cell growth factor (VEGF) (P<0.0005) and the inhibition of apoptosis (P<0.05) through STAT3 activation [increased levels of mRNA (P<0.0005), and protein (P<0.005)]. In the ECSCs, inhibitors of STAT3 inhibited the cell proliferation and VEGF production (P<0.05), and induced the apoptosis of these cells (P<0.05). LIMITATIONS, REASONS FOR CAUTION: The roles of aberrant miR-210 expression were investigated only in the stromal component of ectopic and eutopic endometrium. Control endometrial tissues were obtained from premenopausal patients who had subserosal leiomyoma and NESC gene expression patterns may be altered in these women. Furthermore, the effects of STAT3 inhibitors were evaluated only in ECSCs and not in NESCs. WIDER IMPLICATIONS OF THE FINDINGS: The present findings indicate that miR-210 induces NESCs to differentiate into the endometriotic phenotype and we speculate that up-regulated miR-210 expression in ECSCs is involved in the creation of the endometriosis-specific cellular dysfunctions through epigenetic mechanisms. The data indicate that STAT3 inhibitors may be promising candidates for the treatment of endometriosis.	[Okamoto, M.; Nasu, K.; Abe, W.; Aoyagi, Y.; Kawano, Y.; Kai, K.; Narahara, H.] Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu, Oita 8795593, Japan; [Nasu, K.] Oita Univ, Fac Med, Support Syst Community Med, Div Obstet & Gynecol, Yufu, Oita 8795593, Japan; [Moriyama, M.] Oita Univ, Fac Med, Dept Mol Pathol, Yufu, Oita 8795593, Japan	Nasu, K (reprint author), Oita Univ, Fac Med, Dept Obstet & Gynecol, Hasama Machi, Yufu, Oita 8795593, Japan.	nasu@oita-u.ac.jp			Japan Society for the Promotion of Science [13237327, 25861500, 23592407]	This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (no. 13237327 to K.N., no. 25861500 to Y.K. and no. 23592407 to H.N.).	Hawkins SM, 2011, MOL ENDOCRINOL, V25, P821, DOI 10.1210/me.2010-0371; Gee HE, 2010, CANCER-AM CANCER SOC, V116, P2148, DOI 10.1002/cncr.25009; Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5; Lu L, 2013, MOL CELL BIOCHEM, V381, P273, DOI 10.1007/s11010-013-1711-x; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Zhang Z, 2009, CELL CYCLE, V8, P2756; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Nasu K, 2014, FRONT BIOSCI-LANDMRK, V19, P1202; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Hemida MG, 2010, MOL DIAGN THER, V14, P271, DOI 10.2165/11539540-000000000-00000; Braza-Boils A, 2014, HUM REPROD, V29, P978, DOI 10.1093/humrep/deu019; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Toloubeydokhti T, 2008, REPROD SCI, V15, P993, DOI 10.1177/1933719108324132; Ferrajoli A, 2007, CANCER RES, V67, P11291, DOI 10.1158/0008-5472.CAN-07-0593; Kuokkanen S, 2010, BIOL REPROD, V82, P791, DOI 10.1095/biolreprod.109.081059; Pan Q, 2007, MOL HUM REPROD, V13, P797, DOI 10.1093/molehr/gam063; Fletcher S, 2009, CHEMBIOCHEM, V10, P1959, DOI 10.1002/cbic.200900172; Filigheddu N, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/369549; Shi XY, 2014, INT J MOL MED, V33, P59, DOI 10.3892/ijmm.2013.1536; Nasu K, 2011, J OBSTET GYNAECOL RE, V37, P683, DOI 10.1111/j.1447-0756.2011.01663.x; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Teague EMCO, 2010, HUM REPROD UPDATE, V16, P142, DOI 10.1093/humupd/dmp034; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Gambari R, 2011, BIOCHEM PHARMACOL, V82, P1416, DOI 10.1016/j.bcp.2011.08.007; Abe W, 2013, HUM REPROD, V28, P750, DOI 10.1093/humrep/des446; Donnez J, 1998, HUM REPROD, V13, P1686, DOI 10.1093/humrep/13.6.1686; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Burney RO, 2009, MOL HUM REPROD, V15, P625, DOI 10.1093/molehr/gap068; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Nishida M, 2004, J CLIN ENDOCR METAB, V89, P5094, DOI 10.1210/jc.2004-0354; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Adammek M, 2013, FERTIL STERIL, V99, P1346, DOI 10.1016/j.fertnstert.2012.11.055; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Nasu K, 2011, REPROD SCI, V18, P206, DOI 10.1177/1933719110392059; Teague EMCO, 2009, MOL ENDOCRINOL, V23, P265, DOI 10.1210/me.2008-0387; Committee of the American Society for Reproductive Medicine, 2004, FERTIL STERIL, V81, P1441; Furqan M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-90; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hsu CY, 2014, J PATHOL, V232, P330, DOI 10.1002/path.4295; Karmon AE, 2014, HUM REPROD UPDATE, V20, P670, DOI 10.1093/humupd/dmu017; Kota SK, 2010, DRUG DISCOV TODAY, V15, P733, DOI 10.1016/j.drudis.2010.07.003; Langleben A, 2013, J CLIN ONCOL S, V31; Laurie SA, 2014, J CLIN ONCOL S, V32; Lin SC, 2012, J CLIN ENDOCR METAB, V97, pE1515, DOI 10.1210/jc.2012-1450; Lin SC, 2014, J CLIN ENDOCR METAB, V99, pE427, DOI 10.1210/jc.2013-3717; Shen LC, 2013, J CLIN ENDOCR METAB, V98, P1575, DOI 10.1210/jc.2012-3010; Stephen YC, 2010, CELL CYCLE, V9, P1072; Yuk CC, 2012, MICROCIRCULATION, V19, P215	49	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	MAR	2015	30	3					632	641		10.1093/humrep/deu332		10	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CC2AV	WOS:000350147900016		
J	Cai, K; Zhang, RY; Wonham, WM				Cai, Kai; Zhang, Renyuan; Wonham, W. M.			Relative Observability of Discrete-Event Systems and Its Supremal Sublanguages	IEEE TRANSACTIONS ON AUTOMATIC CONTROL			English	Article						Automata; discrete-event systems; partially-observed supervisory control; regular languages; relative observability; supremal relatively observable sublanguage	DECENTRALIZED SUPERVISORY CONTROL; ARCHITECTURE; FORMULAS	We identify a new observability concept, called relative observability, in supervisory control of discrete-event systems under partial observation. A fixed, ambient language is given, relative to which observability is tested. Relative observability is stronger than observability, but enjoys the important property that it is preserved under set union; hence there exists the supremal relatively observable sublanguage of a given language. Relative observability is weaker than normality, and thus yields, when combined with controllability, a generally larger controlled behavior; in particular, no constraint is imposed that only observable controllable events may be disabled. We design new algorithms which compute the supremal relatively observable (and controllable) sublanguage of a given language, which is generally larger than the normal counterpart. We demonstrate the new observability concept and algorithms with a Guideway and an AGV example.	[Cai, Kai] Osaka City Univ, Osaka 5588585, Japan; [Zhang, Renyuan] Northwestern Polytech Univ, Dept Traff & Control Engn, Xian 710072, Peoples R China; [Wonham, W. M.] Univ Toronto, Dept Elect & Comp Engn, Toronto, ON M5S 3G4, Canada	Cai, K (reprint author), Osaka City Univ, Urban Res Plaza, Osaka 5588585, Japan.	kai.cai@info.eng.osaka-cu.ac.jp; ryzhang@nwpu.edu.cn; wonham@control.utoronto.ca		Zhang, Renyuan/0000-0002-4142-5166	Program to Disseminate Tenure Tracking System, MEXT, Japan; Fundamental Research Funds for the Central Universities, China [3102014JCQ01069]; Natural Sciences and Engineering Research Council, Canada [7399]	This work was supported in part by the Program to Disseminate Tenure Tracking System, MEXT, Japan, the Fundamental Research Funds for the Central Universities, China, under Grant 3102014JCQ01069, and the Natural Sciences and Engineering Research Council, Canada, under Grant 7399. Recommended by Associate Editor D. Hristu-Varsakelis.	CIESLAK R, 1988, IEEE T AUTOMAT CONTR, V33, P249, DOI 10.1109/9.402; RUDIE K, 1992, IEEE T AUTOMAT CONTR, V37, P1692, DOI 10.1109/9.173140; Takai S, 2006, DISCRETE EVENT DYN S, V16, P257, DOI 10.1007/s10626-006-8136-6; Marchand H, 2001, IEEE DECIS CONTR P, P2335, DOI 10.1109/CDC.2001.980609; LIN F, 1995, IEEE T AUTOMAT CONTR, V40, P558, DOI 10.1109/9.376081; WONHAM WM, 1987, SIAM J CONTROL OPTIM, V25, P637, DOI 10.1137/0325036; Ushio T, 1999, IEICE T FUND ELECTR, VE82A, P1965; Komenda J, 2005, DISCRETE EVENT DYN S, V15, P257, DOI 10.1007/s10626-005-2868-6; CHO HJ, 1989, MATH SYST THEORY, V22, P177, DOI 10.1007/BF02088297; FA JH, 1993, SYST CONTROL LETT, V20, P11, DOI 10.1016/0167-6911(93)90082-H; Feng L, 2008, IEEE T AUTOMAT CONTR, V53, P1449, DOI 10.1109/TAC.2008.927679; Yoo TS, 2002, DISCRETE EVENT DYN S, V12, P335, DOI 10.1023/A:1015625600613; BenHadjAlouane N, 1996, DISCRETE EVENT DYN S, V6, P379, DOI 10.1007/BF01797138; BRANDT RD, 1990, SYST CONTROL LETT, V15, P111, DOI 10.1016/0167-6911(90)90004-E; Cai K., 2013, RELATIVE OBSERVABILI; Cassandras C. C., 2007, INTRO DISCRETE EVENT; Cho H., 1989, MATH CONTROL SIGNAL, V2, P47, DOI 10.1007/BF02551361; Davey B. A., 1990, INTRO LATTICES ORDER; Heymann M., 1994, Discrete Event Dynamic Systems: Theory & Applications, V4, DOI 10.1007/BF01438708; HOLLOWAY LE, 1990, IEEE T AUTOMAT CONTR, V35, P514, DOI 10.1109/9.53517; Komenda J., 2011, SYST CONTROL LETT, V55, P1627; KUMAR R, 1993, IEEE T AUTOMAT CONTR, V38, P232, DOI 10.1109/9.250512; Li Y., 1988, P 27 IEEE C DEC CONT, P203; LIN F, 1988, INFORM SCIENCES, V44, P173, DOI 10.1016/0020-0255(88)90001-1; LIN F, 1990, IEEE T AUTOMAT CONTR, V35, P1330, DOI 10.1109/9.61009; Su R, 2010, IEEE T AUTOMAT CONTR, V55, P1627, DOI 10.1109/TAC.2010.2042342; Takai S, 2003, SYST CONTROL LETT, V49, P191, DOI 10.1016/S0167-6911(02)00322-5; Tsitsiklis J. N., 1989, Mathematics of Control, Signals, and Systems, V2, DOI 10.1007/BF02551817; Wonham W. M., 2014, SUPERVISORY CONTROL; Wonham W. M., 2014, DESIGN SOFTWARE XPTC	30	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9286	1558-2523		IEEE T AUTOMAT CONTR	IEEE Trans. Autom. Control	MAR	2015	60	3					659	670		10.1109/TAC.2014.2341891		12	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CC2WP	WOS:000350206000005		
J	Jiang, YZ; Chung, FL; Ishibuchi, H; Deng, ZH; Wang, ST				Jiang, Yizhang; Chung, Fu-Lai; Ishibuchi, Hisao; Deng, Zhaohong; Wang, Shitong			Multitask TSK Fuzzy System Modeling by Mining Intertask Common Hidden Structure	IEEE TRANSACTIONS ON CYBERNETICS			English	Article						Common hidden structure; fuzzy modeling; multitask learning; Takagi-Sugeno-Kang (TSK) fuzzy systems	SUPPORT VECTOR REGRESSION; MULTIPLE TASKS; CLASSIFICATION; APPROXIMATION; FRAMEWORK; MACHINES; DESIGN	The classical fuzzy system modeling methods implicitly assume data generated from a single task, which is essentially not in accordance with many practical scenarios where data can be acquired from the perspective of multiple tasks. Although one can build an individual fuzzy system model for each task, the result indeed tells us that the individual modeling approach will get poor generalization ability due to ignoring the intertask hidden correlation. In order to circumvent this shortcoming, we consider a general framework for preserving the independent information among different tasks and mining hidden correlation information among all tasks in multitask fuzzy modeling. In this framework, a low-dimensional subspace (structure) is assumed to be shared among all tasks and hence be the hidden correlation information among all tasks. Under this framework, a multitask Takagi-Sugeno-Kang (TSK) fuzzy system model called MTCS-TSK-FS (TSK-FS for multiple tasks with common hidden structure), based on the classical L2-norm TSK fuzzy system, is proposed in this paper. The proposed model can not only take advantage of independent sample information from the original space for each task, but also effectively use the intertask common hidden structure among multiple tasks to enhance the generalization performance of the built fuzzy systems. Experiments on synthetic and real-world datasets demonstrate the applicability and distinctive performance of the proposed multitask fuzzy system model in multitask regression learning scenarios.	[Jiang, Yizhang; Deng, Zhaohong; Wang, Shitong] Jiangnan Univ, Sch Digital Media, Wuxi 214122, Peoples R China; [Chung, Fu-Lai] Hong Kong Polytech Univ, Dept Comp, Hong Kong, Hong Kong, Peoples R China; [Ishibuchi, Hisao] Osaka Prefecture Univ, Dept Comp Sci & Intelligent Syst, Osaka 5998531, Japan	Jiang, YZ (reprint author), Jiangnan Univ, Sch Digital Media, Wuxi 214122, Peoples R China.	7121606003@vip.jiangnan.edu.cn; cskchung@comp.polyu.edu.hk; hisaoi@cs.osakafu-u.ac.jp; dzh666828@aliyun.com; wxwangst@aliyun.com	Ishibuchi, Hisao/B-3599-2009	Ishibuchi, Hisao/0000-0001-9186-6472	Hong Kong Polytechnic University [G-UA68]; National Natural Science Foundation of China [61170122, 61272210]; Natural Science Foundation of Jiangsu Province [BK201221834]; JiangSu 333 Expert Engineering [BRA2011142]; Fundamental Research Funds for the Central Universities [JUDCF13030]; Ministry of Education Program for New Century Excellent Talents [NCET-120882]; Postgraduate Student's Creative Research Fund of Jiangsu Province [CXZZ13_0760]	This work was supported in part by the Hong Kong Polytechnic University under Grant G-UA68, in part by the National Natural Science Foundation of China under Grant 61170122 and Grant 61272210, in part by the Natural Science Foundation of Jiangsu Province under Grant BK201221834, in part by JiangSu 333 Expert Engineering under Grant BRA2011142, in part by the Fundamental Research Funds for the Central Universities under Grant JUDCF13030, in part by the Ministry of Education Program for New Century Excellent Talents under Grant NCET-120882, and in part by 2013 Postgraduate Student's Creative Research Fund of Jiangsu Province under Grant CXZZ13_0760.	Alcala-Fdez J., 2011, MULTIPLE VALUED LOGI, V17, P255; Caruana R, 1997, MACH LEARN, V28, P41, DOI 10.1023/A:1007379606734; JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541; Deng ZH, 2011, IEEE T FUZZY SYST, V19, P210, DOI 10.1109/TFUZZ.2010.2091961; Deng ZH, 2013, IEEE T NEUR NET LEAR, V24, P1200, DOI 10.1109/TNNLS.2013.2253617; Solnon M, 2012, J MACH LEARN RES, V13, P2773; Ando RK, 2005, J MACH LEARN RES, V6, P1817; Obozinski G, 2010, STAT COMPUT, V20, P231, DOI 10.1007/s11222-008-9111-x; Yuan XT, 2010, PROC CVPR IEEE, P3493, DOI 10.1109/CVPR.2010.5539967; Zhang Y, 2009, LECT NOTES ARTIF INT, V5782, P617; Evgeniou T, 2005, J MACH LEARN RES, V6, P615; Keshavan RH, 2010, J MACH LEARN RES, V11, P2057; [Anonymous], 2004, P 21 INT C MACH LEAR; Deng ZH, 2010, PATTERN RECOGN, V43, P767, DOI 10.1016/j.patcog.2009.09.010; Argyriou A, 2008, MACH LEARN, V73, P243, DOI 10.1007/s10994-007-5040-8; Zhang J, 2008, MACH LEARN, V73, P221, DOI 10.1007/s10994-008-5050-1; Gao Q, 2012, IEEE T SYST MAN CY B, V42, P1143, DOI 10.1109/TSMCB.2012.2187442; Cortez P, 2009, DECIS SUPPORT SYST, V47, P547, DOI 10.1016/j.dss.2009.05.016; Juang CF, 2009, FUZZY SET SYST, V160, P2486, DOI 10.1016/j.fss.2008.11.022; Leski JM, 2005, IEEE T FUZZY SYST, V13, P181, DOI 10.1109/TFUZZ.2004.840094; Ji Y, 2013, PATTERN RECOGN, V46, P914, DOI 10.1016/j.patcog.2012.08.010; Gu QQ, 2009, IEEE DATA MINING, P159, DOI 10.1109/ICDM.2009.32; Su XJ, 2012, IEEE T SYST MAN CY B, V42, P1574, DOI 10.1109/TSMCB.2012.2195723; Tsang IWH, 2006, IEEE T NEURAL NETWOR, V17, P1126, DOI 10.1109/TNN.2006.878123; Wang H, 2011, 2011 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), P557; Juang CF, 2007, IEEE T SYST MAN CY A, V37, P1077, DOI 10.1109/TSMCA.2007.904579; Yeh IC, 2007, CEMENT CONCRETE COMP, V29, P474, DOI 10.1016/j.cemconcomp.2007.02.001; Astrom K. J., 1992, Journal of Process Control, V2, DOI 10.1016/0959-1524(92)85001-D; Bakker B, 2003, J MACH LEARN RES, V4, P83, DOI DOI 10.1162/153244304322765658; Bezdek J. C., 1981, PATTERN RECOGNITION; Cai F, 2009, P INT JOINT C NEUR N, P418; Caponnetto A, 2008, J MACH LEARN RES, V9, P1615; Cavallanti G., 2008, P COLT; Chen J., 2009, P 26 ANN INT C MACH, P18; Chung FL, 2009, IEEE T FUZZY SYST, V17, P995, DOI 10.1109/TFUZZ.2009.2020154; Del Buono N, 2004, LECT NOTES COMPUT SC, V3044, P988; Deng ZH, 2013, IEEE T FUZZY SYST, V21, P597, DOI 10.1109/TFUZZ.2012.2212444; Edelman A, 1998, SIAM J MATRIX ANAL A, V20, P303, DOI 10.1137/S0895479895290954; Evgeniou T., 2004, P 10 ACM SIGKDD INT, P109, DOI 10.1145/1014052.1014067; Fang J, 2008, IEEE SIGNAL PROC LET, V15, P593, DOI 10.1109/LSP.2008.2001967; Gu Q., 2011, P AAAI; Han S., 2012, P IEEE ICML JUN, P1463; Hsieh C.-J., 2008, P ICML HELS FINL; Ito K, 2003, IEEE IJCNN, P2077; Jacob L., 2008, ADV NEURAL INFORM PR, V21, P745; Ji SW, 2010, ACM T KNOWL DISCOV D, V4, DOI 10.1145/1754428.1754431; Kim D., 2010, P 27 INT C MACH LEAR, P519; Kim S., 2010, P 27 INT C MACH LEAR, V10, P543; Kinoshita S, 1957, J GEN APPL MICROBIOL, V3, P193, DOI 10.2323/jgam.3.193; Kong S., 2012, P 21 INT C PATT REC, P771; Pan S.J., 2008, P 23 NAT C ART INT, V2, P677; Parameswaran S., 2010, P ADV NEUR INF PROC, V23, P1867; Puniyani K., 2010, BIOINFORMATICS, V26, P208; Sonbol AH, 2012, IEEE T SYST MAN CY B, V42, P702, DOI 10.1109/TSMCB.2011.2174151; Sun S., 2008, P 19 INT C PATT REC, P1; TAKAGI T, 1985, IEEE T SYST MAN CYB, V15, P116; Xie S., 2012, P 21 INT C PATT REC, P2954; Yeh I.-C., 2009, CONSTRUCT MAT, V162, P11; Zhang ZH, 2012, PATTERN RECOGN, V45, P465, DOI 10.1016/j.patcog.2011.05.011; Zhou J., 2011, P ADV NEUR INF PROC, V24, P702; Zhou J., 2011, P 17 ACM SIGKDD INT, P814	61	5	6	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2168-2267	2168-2275		IEEE T CYBERNETICS	IEEE T. Cybern.	MAR	2015	45	3					548	561		10.1109/TCYB.2014.2330844		14	Computer Science, Artificial Intelligence; Computer Science, Cybernetics	Computer Science	CC2AN	WOS:000350146900017		
J	Oodate, Y; Tanimoto, Y; Tanoue, H; Kikuchihara, H; Mattausch, HJ; Miura-Mattausch, M				Oodate, Yuhei; Tanimoto, Yuta; Tanoue, Hiroshi; Kikuchihara, Hideyuki; Mattausch, Hans Juergen; Miura-Mattausch, Mitiko			Compact Modeling of the Transient Carrier Trap/Detrap Characteristics in Polysilicon TFTs	IEEE TRANSACTIONS ON ELECTRON DEVICES			English	Article						Capture cross section; compact model; frequency dependence; thin-film transistor (TFT); time constant; transient characteristics; trap density	THIN-FILM TRANSISTORS; FIELD-EFFECT TRANSISTORS; CIRCUIT SIMULATION; MOSFET MODEL; DEVICES	An investigation of the carrier trapping influence on device characteristics in poly-Si thin-film transistors (TFTs) is reported. Particular focus is laid on the transient characteristics, which is influenced by the carrier trapping during the device operation. On the basis of these features, a compact model for TFT-circuit simulation has been developed, which considers the dynamically changing time constant of the carrier trapping in the framework of a complete surface-potential description, thus enabling modeling the dynamically varying trapped carrier density. The compact model is verified against measured characteristics of repeated switching.	[Oodate, Yuhei; Tanimoto, Yuta; Tanoue, Hiroshi; Kikuchihara, Hideyuki; Mattausch, Hans Juergen; Miura-Mattausch, Mitiko] Hiroshima Univ, Grad Sch Adv Sci Matter, Higashihiroshima 7398511, Japan	Oodate, Y (reprint author), Hiroshima Univ, Grad Sch Adv Sci Matter, Higashihiroshima 7398511, Japan.	m120617@hiroshima-u.ac.jp; y-tanimoto@hiroshima-u.ac.jp; hiroshi-tanoue@hiroshima-u.ac.jp; kikuchihara532@hiroshima-u.ac.jp; hjm@hiroshima-u.ac.jp; mmm@hiroshima-u.ac.jp					Lin YY, 1997, IEEE T ELECTRON DEV, V44, P1325, DOI 10.1109/16.605476; Meng ZG, 2000, IEEE T ELECTRON DEV, V47, P404; [Anonymous], 2012, ALTAS US MAN; Horowitz G, 1998, ADV MATER, V10, P365, DOI 10.1002/(SICI)1521-4095(199803)10:5<365::AID-ADMA365>3.0.CO;2-U; Maiti TK, 2014, IEEE T SEMICONDUCT M, V27, P159, DOI 10.1109/TSM.2014.2304736; Miyano S, 2008, SISPAD: 2008 INTERNATIONAL CONFERENCE ON SIMULATION OF SEMICONDUCTOR PROCESSES AND DEVICES, P373; Navarro D, 2006, IEEE T ELECTRON DEV, V53, P2025, DOI [10.1109/TED.2006.880827, 10.1109/ted.2006.880827]; BURNS JR, 1969, RCA REV, V30, P15; CHEN JW, 1981, IEEE T ELECTRON DEV, V28, P299; CHOI JY, 1991, IEEE T ELECTRON DEV, V38, P1384, DOI 10.1109/16.81630; delaBardonnie M, 1997, J NON-CRYST SOLIDS, V216, P209, DOI 10.1016/S0022-3093(97)00187-7; DIMITRIADIS CA, 1993, J APPL PHYS, V74, P2919, DOI 10.1063/1.354648; Grasser T, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.245318; Ikeda H, 2004, JPN J APPL PHYS 1, V43, P477, DOI 10.1143/JJAP.43.477; Jacunski MD, 1996, IEEE T ELECTRON DEV, V43, P1433, DOI 10.1109/16.535329; Jin JW, 2013, J DISP TECHNOL, V9, P871, DOI 10.1109/JDT.2013.2250912; Jyumonji M, 2004, JPN J APPL PHYS 1, V43, P739, DOI 10.1143/JJAP.43.739; Kimura M, 2001, J APPL PHYS, V89, P596, DOI 10.1063/1.1329141; Lee IC, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4724314; LEROUX T, 1986, SOLID STATE ELECTRON, V29, P47, DOI 10.1016/0038-1101(86)90197-8; Ma C., 2013, P IEEE IRPS; Miura-Mattausch M., 2008, PHYS MODELING MOSFET; MiuraMattausch M, 1996, IEEE T COMPUT AID D, V15, P1, DOI 10.1109/43.486267; Nakahagi T., 2011, P 2011 ANN C EXP APP, P171; Oodate Y., 2012, P INT C SIM SEM PROC, P71; Potbhare S., 2007, P SISPAD SEP, P177; Sugiyama D., 2011, THESIS HIROSHIMA U H; Tanoue H., 2013, P IEEE INT REL PHYS; Tsuji H., 2006, IEDM, P1; VANBERKEL C, 1989, J APPL PHYS, V66, P4488, DOI 10.1063/1.343947; WERNER J, 1985, PHYS REV B, V31, P6881, DOI 10.1103/PhysRevB.31.6881; Wu I. W., 1995, SID, P19; Yamaguchi K, 2001, J APPL PHYS, V89, P590, DOI 10.1063/1.1319322	33	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9383	1557-9646		IEEE T ELECTRON DEV	IEEE Trans. Electron Devices	MAR	2015	62	3					862	868		10.1109/TED.2015.2388799		7	Engineering, Electrical & Electronic; Physics, Applied	Engineering; Physics	CC4OF	WOS:000350332000026		
J	Patrashin, M; Sekine, N; Kasamatsu, A; Watanabe, I; Hosako, I; Takahashi, T; Sato, M; Nakasha, Y; Hara, N				Patrashin, Mikhail; Sekine, Norihiko; Kasamatsu, Akifumi; Watanabe, Issei; Hosako, Iwao; Takahashi, Tsuyoshi; Sato, Masaru; Nakasha, Yasuhiro; Hara, Naoki			GaAsSb/InAlAs/InGaAs Tunnel Diodes for Millimeter Wave Detection in 220-330-GHz Band	IEEE TRANSACTIONS ON ELECTRON DEVICES			English	Article						Backward diode; millimeter wave and terahertz detectors; semiconductor nanostructures; tunnel diode; tunneling	BACKWARD DIODES	We report on high-frequency performance and temperature stability of zero-bias GaAsSb/InAlAs/InGaAs tunnel diodes for millimeter-wave detection in 220-330-GHz band. The average voltage sensitivity of 1400 V/W has been achieved in 0.8 x 0.8 mu m(2) mesa devices at room temperature. Measured current-voltage characteristics revealed a superior temperature stability of the devices compared with Schottky barrier diodes. The expected sensitivity variations over a temperature range from T = 17-300 K are 1.7 dB.	[Patrashin, Mikhail; Sekine, Norihiko; Kasamatsu, Akifumi; Watanabe, Issei; Hosako, Iwao] Natl Inst Informat & Commun Technol, Terahertz & Millemeter Waves ICT Lab, Koganei, Tokyo 1848795, Japan; [Takahashi, Tsuyoshi; Sato, Masaru; Nakasha, Yasuhiro; Hara, Naoki] Fujitsu Labs Ltd, Atsugi, Kanagawa 2430197, Japan	Patrashin, M (reprint author), Natl Inst Informat & Commun Technol, Terahertz & Millemeter Waves ICT Lab, 4-2-1 Nukuikitamachi, Koganei, Tokyo 1848795, Japan.	mikhail@nict.go.jp; nsekine@nict.go.jp; kasa@nict.go.jp; issei@nict.go.jp; hosako@nict.go.jp; takahashi.tsuyo@jp.fujitsu.com; sato.masaru@jp.fujitsu.com; nakasha-y@jp.fujitsu.com; hara.naoki@jp.fujitsu.com					COWLEY AM, 1966, IEEE T MICROW THEORY, VMT14, P588, DOI 10.1109/TMTT.1966.1126337; Liu L, 2010, IEEE MICROW WIREL CO, V20, P504, DOI 10.1109/LMWC.2010.2055553; Moyer HP, 2008, IEEE MICROW WIREL CO, V18, P686, DOI 10.1109/LMWC.2008.2003471; Fay P, 2011, PROC SPIE, V8031, DOI 10.1117/12.883677; Patrashin M., 2012, P 37 INT C INFR MILL, P1; Patrashin M., 2014, P 26 INT C IND PHOSP, P1; Schulman JN, 2001, IEEE ELECTR DEVICE L, V22, P200, DOI 10.1109/55.919228; Su N, 2007, IEEE ELECTR DEVICE L, V28, P336, DOI 10.1109/LED.2007.895377; Sze S., 1981, PHYS SEMICONDUCTOR D; Takahashi T, 2009, ELECTRON LETT, V45, P1269, DOI 10.1049/el.2009.2496; Takahashi T, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.104101; Takahashi T., 2012, P INT C IND PHOSPH R, P95	12	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9383	1557-9646		IEEE T ELECTRON DEV	IEEE Trans. Electron Devices	MAR	2015	62	3					1068	1071		10.1109/TED.2015.2393358		4	Engineering, Electrical & Electronic; Physics, Applied	Engineering; Physics	CC4OF	WOS:000350332000056		
J	Okamoto, Y; Nakagawa, T; Aoki, T; Ikeda, M; Kozuma, M; Osada, T; Kurokawa, Y; Ikeda, T; Yamade, N; Okazaki, Y; Miyairi, H; Fujita, M; Koyama, J; Yamazaki, S				Okamoto, Yuki; Nakagawa, Takashi; Aoki, Takeshi; Ikeda, Masataka; Kozuma, Munehiro; Osada, Takeshi; Kurokawa, Yoshiyuki; Ikeda, Takayuki; Yamade, Naoto; Okazaki, Yutaka; Miyairi, Hidekazu; Fujita, Masahiro; Koyama, Jun; Yamazaki, Shunpei			A Boosting Pass Gate With Improved Switching Characteristics and No Overdriving for Programmable Routing Switch Based on Crystalline In-Ga-Zn-O Technology	IEEE TRANSACTIONS ON VERY LARGE SCALE INTEGRATION (VLSI) SYSTEMS			English	Article						Boosting effect; field-programmable gate array (FPGA); In-Ga-Zn-O (IGZO); oxide semiconductor; programmable logic device; programmable switch; reconfigurable system	TRANSISTOR; MEMORY	A boosting pass gate (BPG) suitable for a programmable routing switch including a c-axis aligned crystal In-Ga-Zn-O (CAAC-IGZO) field effect transistor (FET) is proposed. The CAAC-IGZO is one of crystalline oxide semiconductors (OS). The proposed BPG (OS-based BPG, OS BPG) has a combination of a pass gate (PG) and a configuration memory (CM) cell utilizing a CAAC-IGZO FET with extremely low OFF-state current and a storage capacitor. This OS BPG achieves a routing switch with fewer transistors than a conventional routing switch having a combination of a PG and an static RAM (SRAM) cell. Owing to the boosting effect, the switching characteristics, at not only positive transition but also negative transition of input signals, of the OS BPG are improved without using overdriving. In circuits fabricated with a hybrid process of a CMOSFET and a CAAC-IGZO FET with gate lengths of 0.5 and 1.0 mu m, the net delays of the OS BPG, 75 and 58 ns, at driving voltages of 2.0 and 2.5 V have been found to be less than those of the conventional routing switch (SRAM-based PG, SRAM PG) by about 79% and 62%, respectively. It has also been confirmed that a field-programmable gate array (FPGA) chip utilizing the OS BPG as a routing switch reduces the layout areas of routing switches and the whole chip by 61% and 22%, respectively, and increases the maximum operating frequencies at driving voltage of 2.0 and 2.5 V by about 2.8 times and 1.6 times of those of the FPGA chip utilizing the SRAM PG as a routing switch.	[Okamoto, Yuki; Nakagawa, Takashi; Aoki, Takeshi; Ikeda, Masataka; Kozuma, Munehiro; Osada, Takeshi; Kurokawa, Yoshiyuki; Ikeda, Takayuki; Yamade, Naoto; Okazaki, Yutaka; Miyairi, Hidekazu; Koyama, Jun; Yamazaki, Shunpei] Semicond Energy Lab Co Ltd, Atsugi, Kanagawa 2430036, Japan; [Fujita, Masahiro] Univ Tokyo, VLSI Design & Educ Ctr, Tokyo 1130032, Japan	Okamoto, Y (reprint author), Semicond Energy Lab Co Ltd, Atsugi, Kanagawa 2430036, Japan.	yo1273@sel.co.jp					Amano S., 2010, SID S, V43, P626; Inoue H, 2012, IEEE J SOLID-ST CIRC, V47, P2258, DOI 10.1109/JSSC.2012.2198969; Sekine Y, 2011, ECS TRANSACTIONS, V37, P77, DOI 10.1149/1.3600726; [Anonymous], 2006, STRAT DEV HDB; Masui S, 2003, IEEE J SOLID-ST CIRC, V38, P715, DOI 10.1109/JSSC.2003.810034; Aoki T., 2011, P VLSI TECHN S, P174; Chun KC, 2011, IEEE J SOLID-ST CIRC, V46, P1495, DOI 10.1109/JSSC.2011.2128150; Eslami F., 2011, P IEEE INT C FPL APP, P453; Fujii K, 2003, IEICE T ELECTRON, VE86C, P604; Ishimaru K, 2008, SOLID STATE ELECTRON, V52, P1266, DOI 10.1016/j.sse.2008.04.034; Kuon I., 2008, FPGA ARCHITECTURE SU; Lemieux G., 2004, DESIGN INTERCONNECTI; Lewis D., 2012, P IEEE IEDM DEC, P565; Liauw Young Yang, 2012, IEEE INT C SOL STAT, P406; Miyamura M., 2011, IEEE ISSCC, P228; Ohmaru T., 2012, P SSDM SEP, P1144; Rabaey J. M., 2001, LOW ENERGY FPGAS ARC; Suzuki D., 2010, P INT C SOL STAT DEV, P1146; Suzuki D, 2009, 2009 SYMPOSIUM ON VLSI CIRCUITS, DIGEST OF TECHNICAL PAPERS, P80; Tada M., 2011, P IEEE IEDM DEC, P689; Tamura H., 2011, SID S, V42, P729; Tanabe T., 2012, SID S, V43, P88; Trimberger S., 1994, FIELD PROGRAMMABLE G; Tsubuku M., 2013, SID S, V44, P166; Yamazaki S., 2011, P INT WORKSH PRIV SE; Yamazaki S., 2012, SID S, V43, P183	26	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-8210	1557-9999		IEEE T VLSI SYST	IEEE Trans. Very Large Scale Integr. (VLSI) Syst.	MAR	2015	23	3					422	434		10.1109/TVLSI.2014.2316871		13	Computer Science, Hardware & Architecture; Engineering, Electrical & Electronic	Computer Science; Engineering	CC2XO	WOS:000350208700002		
J	Kurahara, LH; Sumiyoshi, M; Aoyagi, K; Hiraishi, K; Nakajima, K; Nakagawa, M; Hu, YP; Inoue, R				Kurahara, Lin Hai; Sumiyoshi, Miho; Aoyagi, Kunihiko; Hiraishi, Keizo; Nakajima, Kyoko; Nakagawa, Midori; Hu, Yaopeng; Inoue, Ryuji			Intestinal Myofibroblast TRPC6 Channel May Contribute to Stenotic Fibrosis in Crohn's Disease	INFLAMMATORY BOWEL DISEASES			English	Article						Crohn's disease; intestinal fibrosis; myofibroblasts; TRPC6	TGF-BETA; MOLECULAR-MECHANISMS; RECEPTOR EXPRESSION; ALPHA; ACTIVATION; CELLS; COLLAGEN; MATRIX; FIBROGENESIS; ANGIOTENSIN	Background:Intestinal fibrosis is a frequent complication of Crohn's disease (CD) and often leads to detrimental stricture formation. Myofibroblasts play active roles in mediating fibrotic changes in various tissues. We investigated whether transient receptor potential channels in intestinal myofibroblasts are involved in CD-associated intestinal fibrosis.Methods:An intestinal myofibroblast cell line (InMyoFibs) was stimulated with transforming growth factor-1 (TGF-1) to model excessive fibrosis. Biopsy samples from nonstenotic or stenotic intestinal regions from patients with CD were used for quantitative comparisons of transient receptor potential channel and fibrosis-associated factor expression levels.Results:TGF-1 treatment transformed spindle-shaped InMyoFibs into filament-shaped cells with enhanced -actin stress fiber formation, transient receptor potential canonical (TRPC) 4 and TRPC6 messenger RNA and protein expression, and basal- and agonist-induced Ca2+ influxes. TGF-1 also enhanced the formation of TRPC6/smooth muscle -actin, TRPC6/N-cadherin, and TRPC4/N-cadherin coimmunoprecipitates. Inhibition of TRPC6 in InMyoFibs by RNA interference or dominant-negative mutations suppressed TGF-1-induced Ca2+ influxes, stress fiber formation, and smooth muscle -actin expression, but increased COL1A1, interleukin (IL)-10, and IL-11 expression, as well as Smad-2, ERK, and p38-MAPK phosphorylation. Similar increases in phosphorylation levels were observed with TRPC and calcineurin inhibitors. In stenotic areas in patients with CD, TRPC6, ACTA2 (smooth muscle -actin), CDH2 (N-cadherin), COL1A1, IL-10, and IL-11 were significantly increased.Conclusions:These results suggest that augmented Ca2+ influxes due to TRPC6 upregulation facilitate stress fiber formation and strengthen cell-cell interactions by negatively regulating the synthesis of antifibrotic factors in TGF-1-treated myofibroblasts. Similar changes observed in stenotic areas of patients with CD suggest the therapeutic significance of targeting TRPC6.	[Kurahara, Lin Hai; Sumiyoshi, Miho; Hiraishi, Keizo; Nakagawa, Midori; Hu, Yaopeng; Inoue, Ryuji] Fukuoka Univ, Sch Med, Dept Physiol, Fukuoka 8140180, Japan; [Aoyagi, Kunihiko] Fukuoka Univ, Sch Med, Dept Gastroenterol, Fukuoka 8140180, Japan; [Nakajima, Kyoko] Fukuoka Univ, Sch Med, Joint Lab Frontier Med Sci, Fukuoka 8140180, Japan	Kurahara, LH (reprint author), Fukuoka Univ, Sch Med, Dept Physiol, Fukuoka 8140180, Japan.	hailin@fukuoka-u.ac.jp			MEXT [22790677, 25860571]; MEXT-supported Program supporting research activities of female researchers; Kaibara Morikazu Medical Science Promotion Foundation; Clinical Research Foundation; Central Research Institute of Fukuoka University	Supported by an MEXT-supported (B) 22790677, (B) 25860571; an MEXT-supported Program supporting research activities of female researchers; the Kaibara Morikazu Medical Science Promotion Foundation; the Clinical Research Foundation; and the Central Research Institute of Fukuoka University.	Davis J, 2012, DEV CELL, V23, P705, DOI 10.1016/j.devcel.2012.08.017; Chiasson VL, 2012, KIDNEY INT, V82, P857, DOI 10.1038/ki.2012.104; Aoki H, 2006, AM J PHYSIOL-CELL PH, V290, pC1100, DOI 10.1152/ajpcell.00465.2005; Inoue R, 2009, CIRC RES, V104, P1399, DOI 10.1161/CIRCRESAHA.108.193227; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Hinz B, 2004, MOL BIOL CELL, V15, P4310, DOI 10.1091/mbc.E04-05-0386; Inoue R, 2006, CIRC RES, V99, P119, DOI 10.1161/01.RES.0000233356.10630.8a; Akool ES, 2008, J IMMUNOL, V181, P2831; Du JY, 2010, CIRC RES, V106, P992, DOI 10.1161/CIRCRESAHA.109.206771; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Biancheri P, 2014, CYTOKINE GROWTH F R, V25, P45, DOI 10.1016/j.cytogfr.2013.11.001; Kawarabayashi Y, 2012, MOL ENDOCRINOL, V26, P846, DOI 10.1210/me.2011-1259; Di Sabatino A, 2009, GUT, V58, P777, DOI 10.1136/gut.2008.149096; Ehrlich HP, 2006, CELL BIOCHEM FUNCT, V24, P63, DOI 10.1027/cbf.1188; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; Speca S, 2012, WORLD J GASTROENTERO, V18, P3635, DOI 10.3748/wjg.v18.i28.3635; Graziani A, 2010, J BIOL CHEM, V285, P4213, DOI 10.1074/jbc.M109.060301; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Rieder F, 2007, GUT, V56, P130, DOI 10.1136/gut.2006.090456; Shi JH, 2013, ARCH DERMATOL RES, V305, P341, DOI 10.1007/s00403-013-1314-0; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Bettenworth Dominik, 2014, Fibrogenesis Tissue Repair, V7, P5, DOI 10.1186/1755-1536-7-5; Biancheri Paolo, 2013, Fibrogenesis Tissue Repair, V6, P13, DOI 10.1186/1755-1536-6-13; Burke JP, 2011, INFLAMM BOWEL DIS, V17, P1665, DOI 10.1002/ibd.21543; Condino G, 2013, DIGEST LIVER DIS, V45, P258, DOI 10.1016/j.dld.2012.10.009; Fichtner-Feigl S, 2008, GASTROENTEROLOGY, V135, P2003, DOI 10.1053/j.gastro.2008.08.055; Hai L, 2011, AM J PHYSIOL-GASTR L, V301, pG356, DOI 10.1152/ajpgi.00354.2010; Hinz Boris, 2010, F1000 Biol Rep, V2, P78, DOI 10.3410/B2-78; Ina K, 2011, HISTOL HISTOPATHOL, V26, P855; Kido S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013090; Kulkarni AA, 2011, PLOS ONE, V6; Latella G, 2013, EUR REV MED PHARMACO, V17, P1283; Medina C, 2011, J PATHOL, V224, P461, DOI 10.1002/path.2870; Meier JKH, 2011, INFLAMM BOWEL DIS, V17, P202, DOI 10.1002/ibd.21344; Nishida M, 2007, J BIOL CHEM, V282, P23117, DOI 10.1074/jbc.M611780200; Stangou M, 2011, J NEPHROL, V24, P106, DOI 10.5301/JN.2010.5094; Valentich JD, 1997, AM J PHYSIOL-CELL PH, V272, pC1513	42	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1078-0998	1536-4844		INFLAMM BOWEL DIS	Inflamm. Bowel Dis.	MAR	2015	21	3					496	506		10.1097/MIB.0000000000000295		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC3JM	WOS:000350243600003		
J	Komatsu, T; Sowa, T; Kino, A; Fujinaga, T				Komatsu, Teruya; Sowa, Terumasa; Kino, Atsunari; Fujinaga, Takuji			The importance of pleural integrity for effective and safe thoracic paravertebral block: a retrospective comparative study on postoperative pain control by paravertebral block	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Paravertebral block; Pleural disruption; Thoracic analgesia; Postoperative pain management	INTERCOSTAL NERVE BLOCK; POSTTHORACOTOMY PAIN; EPIDURAL ANALGESIA; RANDOMIZED-TRIALS; THORACOTOMY; RELIEF; EFFICACY; SURGERY; BUPIVACAINE; 0.5-PERCENT	OBJECTIVES: Recently, paravertebral block (PVB) has been reported to be an effective analgesic modality for post-thoracotomy pain, but there is no consensus on how thoracic PVB can be more effective. Our hypothesis that intact pleura has a significant impact on the analgesic effectiveness of thoracic PVB was evaluated. METHODS: Data of patients who underwent general thoracic surgery [thoracotomy or video-assisted thoracic surgery (VATS)] and paravertebral catheterization at Nagara Medical Center between April 2010 and March 2013 were collected. To compare the frequency of nonsteroidal anti-inflammatory drugs taken as well as the usage of rescue pain medications between patients with pleural disruption and those without, data were analysed after matching on propensity scores. Covariates for match estimation were age, sex, body mass index, American Society of Anesthesiologists score, diagnosis, operative details and local anaesthesia infused. RESULTS: There were 278 patients who underwent general thoracic surgery and paravertebral catheterization. The propensity scorematching process created 78 matched patients with pleural disruption and those without. Based on the propensity score matching, a significant increase in the frequency of non-steroidal anti-inflammatory drugs taken on postoperative day 1 and in the usage of rescue drugs was observed in patients with pleural disruption. CONCLUSIONS: According to our analysis, creating a sub-pleural space without pleural disruption is essential for quality thoracic PVB.	[Komatsu, Teruya; Sowa, Terumasa] Kyoto Univ Hosp, Dept Gen Thorac Surg, Kyoto 6068507, Japan; [Kino, Atsunari] Nagara Med Ctr, Dept Anesthesiol, Gifu, Japan; [Fujinaga, Takuji] Nagara Med Ctr, Dept Gen Thorac Surg, Gifu, Japan	Komatsu, T (reprint author), Kyoto Univ Hosp, Dept Thorac Surg, Sakyo Ku, 54 Kawaharacho, Kyoto 6068507, Japan.	tk.thoracic@gmail.com					Andreetti C, 2014, EUR J CARDIO-THORAC, V46, P907, DOI 10.1093/ejcts/ezu092; Muehling BM, 2008, EUR J CARDIO-THORAC, V34, P174, DOI 10.1016/j.ejcts.2008.04.009; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI [10.1213/01.ane.0000333274.63501.ff, 10.1213/ane.0b013e31817e7b40]; SABANATHAN S, 1988, ANN THORAC SURG, V46, P425; Kotze A, 2009, BRIT J ANAESTH, V103, P626, DOI 10.1093/bja/aep272; Burlacu CL, 2007, REGION ANESTH PAIN M, V32, P136, DOI 10.1016/j.rapm.2006.11.011; Davies RG, 2006, BRIT J ANAESTH, V96, P418, DOI 10.1093/bja/ael020; Fagenholz PJ, 2012, BRIT J ANAESTH, V109, P260, DOI 10.1093/bja/aes126; Raveglia F, 2014, J THORAC CARDIOV SUR, V147, P469, DOI 10.1016/j.jtcvs.2013.09.024; ARLOCK P, 1982, ACTA PHARMACOL TOX, V51, P12; Cheema S, 2003, ANAESTHESIA, V58, P684, DOI 10.1046/j.1365-2044.2003.03189_1.x; Detterbeck FC, 2005, ANN THORAC SURG, V80, P1550, DOI 10.1016/j.athoracsur.2004.11.051; Elsayed H, 2012, J CARDIOTHOR VASC AN, V26, P78, DOI 10.1053/j.jvca.2011.09.019; Fibla JJ, 2008, EUR J CARDIO-THORAC, V33, P430, DOI 10.1016/j.ejcts.2007.12.003; Gulbahara G, 2010, EUR J CARDIO-THORAC, V37, P467, DOI 10.1016/j.ejcts.2009.05.057; Kaiser AM, 1998, ANN THORAC SURG, V66, P367, DOI 10.1016/S0003-4975(98)00448-2; Karmakar MK, 2000, BRIT J ANAESTH, V84, P263; Komatsu T, 2014, ANN THORAC CARDIOVAS, V20, P113, DOI 10.5761/atcs.oa.12.01999; Marret E, 2005, ANN THORAC SURG, V79, P2109, DOI 10.1016/j.athorascur.2004.07.030; Messina M, 2009, MINERVA ANESTESIOL, V75, P616; Novak-Jankovic V, 2011, COLLEGIUM ANTROPOL, V35, P595; SABANATHAN S, 1995, ANN THORAC SURG, V59, P1261, DOI 10.1016/0003-4975(95)00058-S; Scarci M, 2010, INTERACT CARDIOV TH, V10, P92, DOI 10.1510/icvts.2009.221127; Thavaneswaran P, 2010, ANESTH ANALG, V110, P1740, DOI 10.1213/ANE.0b013e3181da82c8	24	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	MAR	2015	20	3					296	299		10.1093/icvts/ivu395		4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CC2TB	WOS:000350196400002		
J	Hamaji, M; Kojima, F; Koyasu, S; Nobashi, T; Tsuruyama, T; Date, H; Nakamura, T				Hamaji, Masatsugu; Kojima, Fumitsugu; Koyasu, Sho; Nobashi, Tomomi; Tsuruyama, Tatsuaki; Date, Hiroshi; Nakamura, Tatsuo			A rigid and bioabsorbable material for anterior chest wall reconstruction in a canine model	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Chest wall; Sternum; Prosthesis	COMPUTED-TOMOGRAPHY; MALIGNANT-TUMORS; RESECTION; DEFECTS; MESH; BIOMATERIALS; EXPERIENCE; FRACTURES; FIXATION; IMPLANTS	OBJECTIVES: The optimal material for anterior chest wall reconstruction following chest wall resection remains controversial. The aim of this experimental study was to evaluate short-term, morphological and histological outcomes of anterior chest wall reconstruction with a rigid and bioabsorbable material in a canine model. METHODS: Twenty adult beagle dogs underwent anterior chest wall resection. In the experimental group (n = 10), the anterior chest wall was reconstructed with a rigid and bioabsorbable material composed of poly-L-lactide acid matrix (60 wt%) and uncalcined and unsintered hydroxyapatite particles (40 wt%), whereas in the control group it was (n = 10) reconstructed with dual polypropylene mesh sheets. Short-term complication rates were compared with chi(2) test. Postoperative sternal deviations were evaluated with sternal alignment angles using computed tomography and multiplanar reconstruction and were compared with Mann-Whitney U-test immediately after reconstruction, and at 1, 3, 6, 9 and 12 months postoperatively. Histological findings of the regenerated chest wall tissue were obtained after staining with haematoxylin and eosin and Elastica van Gieson (EVG) and compared at 3, 6, 9 and 12 months. RESULTS: There was not a significant difference in the short-term postoperative complication rate (P = 0.53) and the complication rate was 20% (wound infection, n = 1 and lethal mediastinitis, n = 1) in the control group and 10% (wound infection, n = 1) in the experimental group. The postoperative sternal deviation was significantly less remarkable at 1 month (123.3 +/- 32.2 degrees vs 159.4 +/- 19.7 degrees, P = 0.027), 3 months (109.8 +/- 34.7 degrees vs 150.9 +/- 34.2 degrees, P = 0.039) and 12 months (61 +/- 15.6 degrees vs 170.3 +/- 6.6 degrees, P = 0.046) in the experimental group than in the control group, whereas no significant difference was noted immediately after reconstruction (165.7 +/- 6.4 degrees vs 168.4 +/- 9.1 degrees, P = 0.50). Histological findings showed dense connective tissue in the regenerated chest wall in both groups and showed chondroblasts in the regenerated chest wall tissue at 3 and 6 months only in the experimental group. CONCLUSIONS: Our results suggest that anterior chest wall reconstruction with a rigid and bioabsorbable material is feasible and may be a valuable alternative to reconstruction with a non-rigid and non-absorbable material.	[Hamaji, Masatsugu; Kojima, Fumitsugu; Nakamura, Tatsuo] Kyoto Univ, Grad Sch Med, Dept Bioartificial Organs, Kyoto 6068507, Japan; [Hamaji, Masatsugu; Kojima, Fumitsugu; Date, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan; [Koyasu, Sho; Nobashi, Tomomi] Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Kyoto 6068507, Japan; [Tsuruyama, Tatsuaki] Kyoto Univ, Grad Sch Med, Ctr Anat Pathol & Forens Med Res, Kyoto 6068507, Japan	Hamaji, M (reprint author), Kyoto Univ, Inst Frontier Med Sci, Dept Bioartificial Organs, Sakyo Ku, 54 Kawaracho, Kyoto 6068507, Japan.	mhamaji@kuhp.kyoto-u.ac.jp					Aghajanzadeh Manoucheher, 2010, J Thorac Dis, V2, P81; Martini N, 1996, J THORAC CARDIOV SUR, V111, P96, DOI 10.1016/S0022-5223(96)70405-1; Sakai A, 2012, J BONE JOINT SURG AM, V94A, P1597, DOI 10.2106/JBJS.J.01673; Marulli G, 2014, EUR J CARDIO-THORAC, V45, pE194, DOI 10.1093/ejcts/ezu095; Bille A, 2012, INTERACT CARDIOV TH, V15, P588, DOI 10.1093/icvts/ivs327; Weyant MJ, 2006, ANN THORAC SURG, V81, P279, DOI 10.1016/j.athoracsur.2005.07.001; Miller DL, 2013, ANN THORAC SURG, V95, P1050, DOI 10.1016/j.athoracsur.2012.11.024; Chapelier AR, 2004, ANN THORAC SURG, V77, P1001, DOI 10.1016/j.athoracsur.2003.08.053; Mansour KA, 2002, ANN THORAC SURG, V73, P1720, DOI 10.1016/S0003-4975(02)03527-0; Shikinami Y, 1999, BIOMATERIALS, V20, P859, DOI 10.1016/S0142-9612(98)00241-5; Berthet JP, 2012, EUR J CARDIO-THORAC, V42, P444, DOI 10.1093/ejcts/ezs028; Briccoli A, 2002, EUR J SURG, V168, P494, DOI 10.1080/110241502321116523; Butterworth JA, 2013, J AM COLL SURGEONS, V217, P306, DOI 10.1016/j.jamcollsurg.2013.02.014; Hamaji Masatsugu, 2009, Interact Cardiovasc Thorac Surg, V9, P559, DOI 10.1510/icvts.2009.212506; Ishii S, 2003, J BIOMED MATER RES B, V66B, P539, DOI 10.1002/jbm.b.10027; Moroi A, 2013, IMPLANT DENT, V22, P255, DOI 10.1097/ID.0b013e31828336be; PUMA F, 1992, ANN THORAC SURG, V53, P408; Qin X, 2008, EUR J CARDIO-THORAC, V34, P870, DOI 10.1016/j.ejcts.2008.06.038; Rocco G, 2012, ANN THORAC SURG, V94, pE109, DOI 10.1016/j.athoracsur.2012.08.029; RUDOLPHY VJ, 1991, ANN THORAC SURG, V52, P821; Schulze RKW, 2010, CLIN ORAL IMPLAN RES, V21, P100, DOI 10.1111/j.1600-0501.2009.01817.x; Tuggle DW, 2004, J PEDIATR SURG, V39, P626, DOI 10.1016/j.jpedsurg.2003.12.032; Ueki K, 2011, J CRANIO MAXILL SURG, V39, P237, DOI 10.1016/j.jcms.2010.06.008	23	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	MAR	2015	20	3					322	328		10.1093/icvts/ivu416		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CC2TB	WOS:000350196400007		
J	Makita, N; Hizukuri, Y; Yamashiro, K; Murakawa, M; Hayashi, Y				Makita, Naoyuki; Hizukuri, Yoshiyuki; Yamashiro, Kyoko; Murakawa, Masao; Hayashi, Yasuhiro			IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration	INTERNATIONAL IMMUNOLOGY			English	Article						CCL24; eosinophil infiltration; IL-4; IL-10; M2a macrophage	ALTERNATIVELY ACTIVATED MACROPHAGES; HELMINTH INFECTION; TH2 RESPONSES; IN-VITRO; INFLAMMATION; DIFFERENTIATION; POLARIZATION; RECRUITMENT; EXPRESSION; MOLECULES	M2 macrophages have been subdivided into subtypes such as IL-4-induced M2a and IL-10-induced M2c in vitro. Although it was reported that IL-10 stimulation leads to an increase in IL-4Ra, the effect of IL-4 and IL-10 in combination with macrophage subtype differentiation remains unclear. Thus, we sought to clarify whether IL-10 enhanced the M2 phenotype induced by IL-4. In this study, we showed that IL-10 enhanced IL-4Ra expression in M-CSF-induced bone marrow-derived macrophages (BMDMs). Global gene expression analysis of M2 macrophages induced by IL-4, IL-10 or IL-4 + IL-10 showed that IL-10 enhanced gene expression of M2a markers induced by IL-4 in M-CSF-induced BMDMs. Moreover, IL-4 and IL-10 synergistically induced CCL24 (Eotaxin-2) production. Enhanced CCL24 expression was also observed in GM-CSF-induced BMDMs and zymosan-elicited, thioglycolate-elicited and naive peritoneal macrophages. CCL24 is a CCR3 agonist and an eosinophil chemoattractant. In vitro, IL-4 + IL-10-stimulated macrophages produced a large amount of CCL24 and increased eosinophil migration, which was inhibited by anti-CCL24 antibody. We also showed that IL-4 + IL-10-stimulated (but not IL-4 or IL-10 alone) macrophages transferred into the peritoneum of C57BL/6J mice increased eosinophil infiltration into the peritoneal cavity. These results demonstrate that IL-4 + IL-10-simulated macrophages have enhanced M2a macrophage-related gene expression, CCL24 production and eosinophil infiltration-inducing activity, thereby suggesting their contribution to eosinophil-related diseases.	[Makita, Naoyuki; Murakawa, Masao] Asubio Pharma Co Ltd, Fac Exploratory Pharmacol, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Hizukuri, Yoshiyuki; Yamashiro, Kyoko; Hayashi, Yasuhiro] Asubio Pharma Co Ltd, Fac Exploratory Technol, Chuo Ku, Kobe, Hyogo 6500047, Japan	Hayashi, Y (reprint author), Asubio Pharma Co Ltd, Fac Exploratory Technol, Chuo Ku, 6-4-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	hayashi.yasuhiro.ej@asubio.co.jp					STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712; Schopf LR, 2002, J IMMUNOL, V168, P2383; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Deng B, 2012, J IMMUNOL, V189, P3669, DOI 10.4049/jimmunol.1103180; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Faith A, 2012, ALLERGY, V67, P1007, DOI 10.1111/j.1398-9995.2012.02852.x; Martinez FO, 2006, J IMMUNOL, V177, P7303; Svensson J, 2011, J IMMUNOL, V187, P3671, DOI 10.4049/jimmunol.1100130; Navarro-Xavier RA, 2010, J IMMUNOL, V184, P1516, DOI 10.4049/jimmunol.0902866; Muller U, 2007, J IMMUNOL, V179, P5367; Schebesch C, 1997, IMMUNOLOGY, V92, P478, DOI 10.1046/j.1365-2567.1997.00371.x; Houser BL, 2011, J IMMUNOL, V186, P2633, DOI 10.4049/jimmunol.1003153; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Hutchins AP, 2013, BRIEF FUNCT GENOMICS, V12, P489, DOI 10.1093/bfgp/elt028; Fleetwood AJ, 2007, J IMMUNOL, V178, P5245; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Han HW, 2013, J IMMUNOL, V190, P904, DOI 10.4049/jimmunol.1201808; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Siddiqui S, 2013, CELL IMMUNOL, V281, P159, DOI 10.1016/j.cellimm.2013.03.001; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Pope SM, 2005, J IMMUNOL, V175, P5341; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Kharraz Y, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/491497; Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426; Edwards JP, 2009, J IMMUNOL, V182, P1929, DOI 10.4049/jimmunol.0802703; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sadik CD, 2012, J LEUKOCYTE BIOL, V91, P207, DOI 10.1189/jlb.0811402; Biswas A, 2011, EUR J IMMUNOL, V41, P992, DOI 10.1002/eji.201040940; Breslin WL, 2013, J IMMUNOL METHODS, V390, P1, DOI 10.1016/j.jim.2011.03.005; Feng YH, 2012, J ZHEJIANG UNIV-SC B, V13, P386, DOI 10.1631/jzus.B1100218; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Fu CL, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-72; Fujieda Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066270; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Luna-Gomes T, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00027; McBride JM, 2002, CELL IMMUNOL, V215, P162, DOI 10.1016/S0008-8749(02)00007-2; Radinger M, 2004, J ALLERGY CLIN IMMUN, V113, P1109, DOI 10.1016/j.jaci.2004.03.022; Zhang SY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000648	40	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0953-8178	1460-2377		INT IMMUNOL	Int. Immunol.	MAR	2015	27	3					131	141		10.1093/intimm/dxu090		11	Immunology	Immunology	CC2WX	WOS:000350206800002		
J	Maruyama, S; Kanoh, M; Matsumoto, A; Kuwahara, M; Yamashita, M; Asano, Y				Maruyama, Saho; Kanoh, Makoto; Matsumoto, Akira; Kuwahara, Makoto; Yamashita, Masakatsu; Asano, Yoshihiro			A novel function of interferon regulatory factor-1: inhibition of T(h)2 cells by down-regulating the Il4 gene during Listeria infection	INTERNATIONAL IMMUNOLOGY			English	Article						IL-1; interferon regulatory factor-1; Listeria monocytogenes; silencer; T-h subset	MAJOR HISTOCOMPATIBILITY COMPLEX; HELPER TYPE-1 CELLS; T-CELLS; MONOCLONAL-ANTIBODY; TRANSCRIPTION FACTORS; RECEPTOR LIGATION; IMMUNE-RESPONSE; CUTTING EDGE; IFN; INDUCTION	Infection with certain pathogens induces a shift of the T-h subset balance to a T(h)1 dominant state. This, in turn, results in the suppression of T(h)2 responses. We focused on the involvement of interferon regulatory factor-1 (IRF-1) in the suppression of T(h)2 cells during Listeria infection. We found that the inhibition of IL-4 production by T(h)2 cells is mediated by a soluble factor (LmSN) produced by Listeria-infected antigen-presenting cells. The inhibition is not observed with T cells from Irf1 gene-targeted mice. IRF-1 suppresses transcription of the Il4 gene in T(h)2 cells. Under the influence of the LmSN, IRF-1 binds to the 3 ' untranslated region (UTR) region of the Il4 gene and down-regulates Il4 gene transcription. Finally, we identified IL-1 alpha and IL-1 beta as the mediator of the LmSN activity. Signaling through IL-1R induces the stabilization and/or nuclear translocation of IRF-1. We propose that IRF-1 functions to induce the T-cell subset shift via a novel mechanism. Under the influence of IL-1, IRF-1 translocates into the nucleus and acts on the 3 ' UTR region of the Il4 gene, thus inhibiting its transcription in T(h)2 cells. As a result, the immune system shifts predominantly to a T(h)1 response during Listeria infection, resulting in effective protection of the host.	[Maruyama, Saho; Kuwahara, Makoto; Yamashita, Masakatsu; Asano, Yoshihiro] Ehime Univ, Grad Sch Med, Dept Immunol, Toon, Ehime 7910295, Japan; [Kanoh, Makoto; Matsumoto, Akira; Yamashita, Masakatsu; Asano, Yoshihiro] Ehime Univ, Grad Sch Med, Dept Infect & Host Defenses, Toon, Ehime 7910295, Japan; [Kuwahara, Makoto] Ehime Univ Hosp, Translat Res Ctr, Toon, Ehime 7910295, Japan	Maruyama, S (reprint author), Ehime Univ, Grad Sch Med, Dept Immunol, Toon, Ehime 7910295, Japan.	saho@m.ehime-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [14207012, 24659476]	Ministry of Education, Culture, Sports, Science and Technology of Japan (14207012 and 24659476).	ABE R, 1995, J IMMUNOL, V154, P985; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Blanch VJ, 1999, J IMMUNOL, V162, P1232; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Vegran F, 2014, NAT IMMUNOL, V15, P758, DOI 10.1038/ni.2925; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Ansel KM, 2004, NAT IMMUNOL, V5, P1251, DOI 10.1038/ni1135; Kubo M, 1997, EMBO J, V16, P4007, DOI 10.1093/emboj/16.13.4007; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; GELLER DA, 1993, SURGERY, V114, P235; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Okamoto M, 2009, NAT IMMUNOL, V10, P872, DOI 10.1038/ni.1747; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; Elser B, 2002, IMMUNITY, V17, P703, DOI 10.1016/S1074-7613(02)00471-5; Croft M, 2009, NAT REV IMMUNOL, V9, P271, DOI 10.1038/nri2526; Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456; Wei G, 2011, IMMUNITY, V35, P299, DOI 10.1016/j.immuni.2011.08.007; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; ASANO Y, 1983, J EXP MED, V158, P1178, DOI 10.1084/jem.158.4.1178; ASANO Y, 1982, J EXP MED, V156, P350, DOI 10.1084/jem.156.2.350; Feng CG, 1999, INT IMMUNOL, V11, P1185, DOI 10.1093/intimm/11.8.1185; Freudenberg MA, 2002, J IMMUNOL, V169, P1665; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Kanoh M, 2002, INT IMMUNOL, V14, P567, DOI 10.1093/intimm/dxf024; KISHIMOTO H, 1995, J EXP MED, V182, P1997, DOI 10.1084/jem.182.6.1997; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Maruyama S, 2003, J IMMUNOL, V170, P997; MATSUOKA S, 1995, J EXP MED, V181, P2007, DOI 10.1084/jem.181.6.2007; McElligott DL, 1997, J IMMUNOL, V159, P4180; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; SANO K, 1987, J EXP MED, V165, P1284, DOI 10.1084/jem.165.5.1284	44	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0953-8178	1460-2377		INT IMMUNOL	Int. Immunol.	MAR	2015	27	3					143	152		10.1093/intimm/dxu092		10	Immunology	Immunology	CC2WX	WOS:000350206800003		
J	Okada, S; Shimada, J; Ito, K; Kato, D				Okada, Satoru; Shimada, Junichi; Ito, Kazuhiro; Kato, Daishiro			A touch panel surgical navigation system with automatic depth perception	INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY			English	Article						Touch panel navigation; Surgical navigation; Robotic surgery; Trajectory; Depth perception; Hand-eye coordination	INSTRUMENTS; TRACKING	A touch panel navigation system may be used to enhance endoscopic surgery, especially for cauterization. We developed and tested the in vitro performance of a new touch panel navigation (TPN) system. This TPN system uses finger motion trajectories on a touch panel to control an argon plasma coagulation (APC) attached to a robot arm. Thermal papers with printed figures were soaked in saline for repeated recording and analysis of cauterized trajectory. A novice and an expert surgeon traced squares and circles displayed on the touch panel and cauterized them using the APC. Sixteen novices and eight experts cauterized squares and circles using both conventional endoscopic and TPN procedures. Six novices cauterized arcs using the endoscopic and TPN procedures 20 times a day for 5 consecutive days. For square shapes, the offset was 5.5 mm with differences between the novice and the expert at 2 of 16 points. For circles, the offset was 5.0 mm and did not differ at any point. Task completion time for the TPN procedure was significantly longer than that for the endoscopic procedure for both squares and circles. For squares, the distance from the target for the TPN procedure was significantly smaller than that for the endoscopic procedure. For circles, the distance did not differ. There was no difference in task completion time and distance between the novices and the experts. Task completion time and distance improved significantly for the endoscopic procedure but not for the TPN procedure. A new TPN system enabled the surgeons to accomplish continuous 3D positioning of the surgical device with automatic depth perception using finger tracing on a 2D monitor. This technology is promising for application in surgical procedures that require precise control of cauterization.	[Okada, Satoru; Shimada, Junichi; Ito, Kazuhiro; Kato, Daishiro] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg, Div Chest Surg,Kamigyo Ku, Kyoto 6028566, Japan	Shimada, J (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Surg, Div Chest Surg,Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	shimajun@beige.plala.or.jp			Japan Society for the Promotion of Science [17209047, 22390270]	This study was financially supported by a Grant-in-Aid for Scientific Research (A) (No. 17209047) and (B) (No. 22390270) from the Japan Society for the Promotion of Science.	Chandra V, 2010, SURGERY, V147, P830, DOI 10.1016/j.surg.2009.11.002; Loukas C, 2013, INT J MED ROBOT COMP, V9, pE34, DOI 10.1002/rcs.1485; Loulmet D, 1999, J THORAC CARDIOV SUR, V118, P4, DOI 10.1016/S0022-5223(99)70133-9; Voros S, 2007, INT J ROBOT RES, V26, P1173, DOI 10.1177/0278364907083395; Tonet O, 2007, COMPUT AIDED SURG, V12, P35, DOI 10.1080/10929080701210782; Krupa A, 2003, IEEE T ROBOTIC AUTOM, V19, P842, DOI 10.1109/TRA.2003.817086; Zaitsev M, 2006, NEUROIMAGE, V31, P1038, DOI 10.1016/j.neuroimage.2006.01.039; Yamaguchi S, 2011, SURG ENDOSC, V25, P771, DOI 10.1007/s00464-010-1251-3; [Anonymous], 2009, The da Vinci Surgical System, Patent No. 20090187288; Anthony RL, 2004, ANN SURG, V239, P14, DOI [10.1097/01.sla.0000103020.19595.7d, DOI 10.1097/01.SLA.0000103020.19595.7D]; Lawton V, 2003, STUD HLTH TECHNOL IN, V94, P373; Michael D, 2004, CURR PROB SURG, V41, P752; Schulder M, 2001, J NEUROSURG, V94, P936, DOI 10.3171/jns.2001.94.6.0936; Shimada J, 2012, PROC INFO COMMUN, V3, P92; Shimada J, 2012, INT J CARS S1, p[7, S173]; Shin Sangkyun, 2011, Stud Health Technol Inform, V163, P581; Uemura M, 2014, J SURG RES, V188, P8, DOI 10.1016/j.jss.2013.12.009	17	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	MAR	2015	10	3					243	251		10.1007/s11548-014-1080-2		9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CC3HX	WOS:000350238700001		
J	Doke, T; Liang, JT; Onogi, S; Nakajima, Y				Doke, Takehito; Liang, Jack T.; Onogi, Shinya; Nakajima, Yoshikazu			Fluoroscopy-based laser guidance system for linear surgical tool insertion depth control	INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY			English	Article						Percutaneous surgery; Laser guidance system; Fluoroscopic navigation; Computer aided surgery; Surgical navigation	IMAGE OVERLAY; SURGERY; NAVIGATION	In most orthopedic surgeries, knowing how far to insert surgical tools is crucial. The objective of this study was to provide guidance information on depth without tracking surgical tools. A previously developed laser guidance system for linear surgical tool insertion uses two laser beams that display the insertion point and orientation on the skin surface. However, the system only provides 4 degrees of freedom guidance (an entry point on the planned pathway line and the orientation) but do not inform surgeons on the ideal insertion depth. A 5-DOF guidance method was developed to provide guidance information by direct projection onto the surgical area using laser beams without tracking markers. A position and orientation guidance performed by two laser beams and depth guidance performed by a single laser beam are appeared on the surgical area in turn. However, depth point appears on the surgical tool side face with some error because of tool radius. Using the actual depth position, insertion path vector and location of the laser sources, the correct depth point on the tool's surface is calculated by the proposed method. So, this system can indicate and navigate the 5-DOF which is planning path and the correct depth point. An evaluation of the accuracy of depth guidance revealed a depth guidance error of mm and results from phantom target insertions revealed overall system accuracies of mm, . In addition, overall system accuracies of application feasibility experiment under the X-ray condition were . A new surgical tool depth insertion method was developed using a fluorolaser guidance system. This tool informs surgeons of the surgical tool tip depth assuming that the insertion point and orientation are correct. The new method was tested successfully in vitro.	[Doke, Takehito; Liang, Jack T.; Nakajima, Yoshikazu] Univ Tokyo, Grad Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan; [Onogi, Shinya] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn, Tokyo, Japan	Doke, T (reprint author), Univ Tokyo, Grad Sch Engn, Bunkyo Ku, Room 307,Takeda Sentanchi Bldg,Yayoi 2-11-16, Tokyo 1138656, Japan.	doke@image.t.u-tokyo.ac.jp					Ferreira SLC, 2007, ANAL CHIM ACTA, V597, P179, DOI 10.1016/j.aca.2007.07.011; Fichtinger G, 2005, IEEE T BIO-MED ENG, V52, P1415, DOI 10.1109/TBME.2005.851493; Schick U, 2002, MINIM INVAS NEUROSUR, V45, P139, DOI 10.1055/s-2002-34345; Marmurek J, 2006, ST HEAL T, V119, P367; Liao H, 2008, LECT NOTES COMPUT SC, V5128, P367; Belkoff SM, 2003, SPINE, V28, P1555, DOI 10.1097/00007632-200307150-00015; Fuchs H, 1996, LECT NOTES COMPUT SC, V1131, P591; Abumi K, 2000, SPINE, V25, P962, DOI 10.1097/00007632-200004150-00011; Volonte F, 2011, J HEPATO-BIL-PAN SCI, V18, P506, DOI 10.1007/s00534-011-0385-6; Haigron P, 2004, IEEE T MED IMAGING, V23, P1380, DOI 10.1109/TMI.2004.836869; Blackwelll M, 1998, LECT NOTES COMPUT SC, V1496, P232; Gavaghan K, 2001, SPINE, V26, P347; Gavaghan K, 2012, INT J COMPUT ASS RAD, V7, P547, DOI 10.1007/s11548-011-0660-7; Glossop N, 2002, LECT NOTES COMPUT SC, V2879, P239; Hofstetter R, 1999, Comput Aided Surg, V4, P65, DOI 10.3109/10929089909148161; Hussman KL, 1998, STEREOT FUNCT NEUROS, V71, P62, DOI 10.1159/000029649; Lavallee S, 1996, COMPUTER ASSISTED SP; Liang JT, 2012, INT J COMPUT ASS RAD, V7, P931, DOI 10.1007/s11548-012-0743-0; Lim S, 2010, JPN SOC COMP AID SUR, V12, P511; MALIK JM, 1995, ACTA NEUROCHIR, V132, P138, DOI 10.1007/BF01404862; Nakajima Y, 2004, INT CONGR SER, V1268, P449, DOI 10.1016/j.ics.2004.03.127; Nakajima Y, 2012, IEEE T BIOMED ENG, V60, P1467; Navab N, 1999, LECT NOTES COMPUT SC, V1679, P688; Nitta Norihisa, 2007, Radiat Med, V25, P187, DOI 10.1007/s11604-006-0116-0; Sasama T, 2002, LNCS, V2489, P25, DOI [10.1007/3-540-45787-9_16, DOI 10.1007/3-540-45787-9_16]; Tonetti J, 2001, Comput Aided Surg, V6, P204, DOI 10.3109/10929080109146084	26	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1861-6410	1861-6429		INT J COMPUT ASS RAD	Int. J. Comput. Assist. Radiol. Surg.	MAR	2015	10	3					275	283		10.1007/s11548-014-1079-8		9	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CC3HX	WOS:000350238700004		
J	Kawasaki, K; Yamanishi, K; Yamada, H				Kawasaki, Kaori; Yamanishi, Kiyofumi; Yamada, Hidekazu			Age-related morphometric changes of inner structures of the skin assessed by in vivo reflectance confocal microscopy	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article								BackgroundIn vivo reflectance confocal microscopy is a useful technique for non-invasive biometry of cutaneous inner structures. In this study, the changes in the inner structures were examined in a wide age range of healthy Japanese using this technique. Materials and methodsSkin on the flexor side of the arm and on the face, which represent sun-protected and sun-exposed sites of the skin, respectively, was examined in 52 healthy Japanese subjects aged 6months-81years old using a reflectance confocal microscope Vivascope((R)) 3000. ResultsThe size of granular cells increased with age and was larger in the group aged over 50years than in the young group aged 18-21years old, at both sites. The size of prickle cells also increased with age in the face but not in the arm. The size of dermal papillae measured at depths of 50m (Z=50m) and 80m (Z=80m) from the surface decreased with age. The size at Z=80m was smaller in the older group than in the younger group at both sites. However, the mean size of granular cells and dermal papillae was smaller in the face than in the arm. The number of dermal papillae decreased with age in the arm at Z=50m and in the face at Z=80m. ConclusionsSkin aging may be reflected in the size of granular and prickle cells and dermal papillae, and the extent varies in each sun-exposed or sun-protected skin site.	[Kawasaki, Kaori; Yamanishi, Kiyofumi; Yamada, Hidekazu] Hyogo Coll Med, Dept Dermatol, Nishinomiya, Hyogo 6638501, Japan; [Kawasaki, Kaori; Yamada, Hidekazu] Kinki Univ, Sch Med, Nara Hosp, Dept Dermatol, Ikoma, Japan; [Kawasaki, Kaori; Yamada, Hidekazu] Kinki Univ, Antiaging Ctr, Ikoma, Japan	Yamada, H (reprint author), Kinki Univ, Sch Med, Nara Hosp, Dept Dermatol, 1248-1 Otoda Cho, Nara 6300293, Japan.	yamadahi@med.kindai.ac.jp					Callaghan T. M., 2008, International Journal of Cosmetic Science, V30, P323, DOI 10.1111/j.1468-2494.2008.00455.x; Huzaira M, 2001, J INVEST DERMATOL, V116, P846, DOI 10.1046/j.0022-202x.2001.01337.x; Gonzalez S., 2008, International Journal of Cosmetic Science, V30, P1, DOI 10.1111/j.1468-2494.2008.00406.x; Baillie L, 2011, BRIT J DERMATOL, V165, P735, DOI 10.1111/j.1365-2133.2011.10416.x; Kohl E, 2011, J EUR ACAD DERMATOL, V25, P873, DOI 10.1111/j.1468-3083.2010.03963.x; Wurm EMT, 2012, BRIT J DERMATOL, V167, P270, DOI 10.1111/j.1365-2133.2012.10943.x; Baumann L, 2007, J PATHOL, V211, P241, DOI 10.1002/path.2098; BHAWAN J, 1995, J CUTAN PATHOL, V22, P154, DOI 10.1111/j.1600-0560.1995.tb01399.x; Lagarrigue SG, 2012, EXP DERMATOL, V21, P281, DOI 10.1111/j.1600-0625.2012.01451.x; Sauermann K, 2002, SKIN RES TECHNOL, V8, P52	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAR	2015	54	3					295	301		10.1111/ijd.12220		7	Dermatology	Dermatology	CC3ZQ	WOS:000350290400019		
J	Miura, T; Matsumura, N; Hiraiwa, T; Yamamoto, T				Miura, Takako; Matsumura, Natsuko; Hiraiwa, Tomoko; Yamamoto, Toshiyuki			Post-herpetic eosinophilic papules and plaques	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							ZOSTER		[Miura, Takako; Matsumura, Natsuko; Hiraiwa, Tomoko; Yamamoto, Toshiyuki] Fukushima Med Univ, Dept Dermatol, Fukushima, Japan	Miura, T (reprint author), Fukushima Med Univ, Dept Dermatol, Fukushima, Japan.	toyamade@fmu.ac.jp					Mitsuhashi Y, 1997, BRIT J DERMATOL, V136, P465, DOI 10.1111/j.1365-2133.1997.tb14966.x; Mochizuki M, 1999, INT ARCH ALLERGY IMM, V120, P19, DOI 10.1159/000053587; Ruocco V, 2012, ACTA DERM-VENEREOL, V92, P378, DOI 10.2340/00015555-1284; Ruocco V, 2002, J AM ACAD DERMATOL, V46, P90, DOI 10.1067/mjd.2002.118362; Zhang MF, 2011, J DERMATOL, V38, P1158, DOI 10.1111/j.1346-8138.2011.01289.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAR	2015	54	3					E82	E84		10.1111/ijd.12647		3	Dermatology	Dermatology	CC3ZQ	WOS:000350290400004		
J	Uchiyama, M; Tsuboi, R; Kusunoki, T				Uchiyama, Masaki; Tsuboi, Ryoji; Kusunoki, Toshio			A case of recurrent facial herpes simplex mimicking hydroa vacciniforme	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							VIRUS		[Uchiyama, Masaki; Tsuboi, Ryoji] Tokyo Med Univ, Dept Dermatol, Tokyo 1608402, Japan; [Kusunoki, Toshio] Tetsugakudou Kusunoki Dermatol Clin, Tokyo, Japan	Uchiyama, M (reprint author), Tokyo Med Univ, Dept Dermatol, Tokyo 1608402, Japan.	sky777xyz@yahoo.co.jp					Cho KH, 2004, BRIT J DERMATOL, V151, P372, DOI 10.1111/j.1365-2133.2004.06038.x; Iwatsuki K, 2006, ARCH DERMATOL, V142, P587, DOI 10.1001/archderm.142.5.587; ERAMO LR, 1986, ARCH DERMATOL, V122, P1310, DOI 10.1001/archderm.122.11.1310; van der Molen RG, 2001, HUM IMMUNOL, V62, P589, DOI 10.1016/S0198-8859(01)00248-8; WHEELER CE, 1960, ARCH DERMATOL, V82, P590	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	MAR	2015	54	3					E84	E85		10.1111/ijd.12671		2	Dermatology	Dermatology	CC3ZQ	WOS:000350290400005		
J	Yin, FW; Liu, XY; Fan, XR; Zhou, DY; Xu, WS; Zhu, BW; Murata, YY				Yin, Fa-Wen; Liu, Xiao-Yang; Fan, Xin-Ru; Zhou, Da-Yong; Xu, Wen-Si; Zhu, Bei-Wei; Murata, Yoshi-Yuki			Extrusion of Antarctic krill (Euphausia superba) meal and its effect on oil extraction	INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY			English	Article						Extraction; separation; extrusion; fatty acid; krill meal; oils; phospholipids	LIPID COMPLEX-FORMATION; SINGLE-SCREW EXTRUSION; FATTY-ACIDS; FISH-OIL; RATS; SUPPLEMENTATION; TRIAL; FEED; DIET	Antarctic krill meal as well as mixed krill meal and starches were extruded through a twin-screw extruder. The extrudates were hard and porous agglomerates. The pellets still showed intact structure without obvious disintegration in response to hexane extraction. The oil recovery rates for raw krill meal and the extrudate of single krill meal were 55.08% and 59.08%, respectively. For extrudates, oil recovery rate increased along with the increasing additive amount of starches, with a maximum of 83.13%. Oil extracted from raw krill meal contained 49.30% of triglycerides (TG), 44.16% of phospholipids (PL), 1.45% of free fatty acids (FFA) and 4.69% of cholesterols (CHO). Meanwhile, polyunsaturated fatty acids (PUFA), monounsaturated fatty acids (MUFA) and saturated fatty acids (SFA) account for 20.89%, 37.84% and 41.27% of the total fatty acids, respectively. By contrast, oils extracted from extrudates contained more TG but less PL and more SFA but less PUFA.	[Yin, Fa-Wen; Liu, Xiao-Yang; Fan, Xin-Ru; Zhou, Da-Yong; Xu, Wen-Si; Zhu, Bei-Wei] Dalian Polytech Univ, Sch Food Sci & Technol, Dalian 116034, Peoples R China; [Yin, Fa-Wen; Liu, Xiao-Yang; Zhou, Da-Yong; Xu, Wen-Si; Zhu, Bei-Wei] Natl Engn Res Ctr Seafood, Dalian 116034, Peoples R China; [Murata, Yoshi-Yuki] Okayama Univ, Dept Biol Resources Chem, Fac Agr, Okayama 7008530, Japan	Liu, XY (reprint author), Dalian Polytech Univ, Sch Food Sci & Technol, Dalian 116034, Peoples R China.	690848382@qq.com			National High Technology Research and Development Program of China (863 Program) [2011AA090801, 2011 AA100803]; Organization Project for National Engineering Research Center of Seafood - Ministry of Science and Technology of the People's Republic of China [2012FU125X03]	This work was financially supported by 'The National High Technology Research and Development Program of China (863 Program) (No. 2011AA090801; 2011 AA100803)' and 'Organization Project for National Engineering Research Center of Seafood funded by Ministry of Science and Technology of the People's Republic of China (No. 2012FU125X03)'.	Ali-Nehari A, 2012, KOREAN J CHEM ENG, V29, P329, DOI 10.1007/s11814-011-0186-2; Ali-Nehari A, 2012, KOREAN J CHEM ENG, V29, P918, DOI 10.1007/s11814-011-0273-4; Vigerust NF, 2013, EUR J NUTR, V52, P1315, DOI 10.1007/s00394-012-0441-2; BHATNAGAR S, 1994, CEREAL CHEM, V71, P582; Sorensen M, 2010, AQUAC RES, V41, P419, DOI 10.1111/j.1365-2109.2009.02346.x; Gigliotti JC, 2011, FOOD CHEM, V125, P1028, DOI 10.1016/j.foodchem.2010.10.013; Grimstad T, 2012, SCAND J GASTROENTERO, V47, P49, DOI 10.3109/00365521.2011.634025; Rossmeisl M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038834; Jeong WS, 2001, J FOOD SCI, V66, P278, DOI 10.1111/j.1365-2621.2001.tb11332.x; Konagai C, 2013, CLIN INTERV AGING, V8, P1247, DOI 10.2147/CIA.S50349; Thachil MT, 2014, INT J FOOD SCI TECH, V49, P309, DOI 10.1111/ijfs.12333; Hansen JO, 2010, AQUACULTURE, V310, P164, DOI 10.1016/j.aquaculture.2010.10.003; Tandy S, 2009, J AGR FOOD CHEM, V57, P9339, DOI 10.1021/jf9016042; AOAC Official Method of Analysis, 2005, 98110 AOAC INT; AOAC Official Method of Analysis, 2000, 95208 AOAC INT; AOAC Official Method of Analysis, 2000, 92039 AOAC INT; AOAC Official Method of Analysis, 2000, 93808 AOAC INT; Baeverfjord G, 2006, AQUACULTURE, V261, P1335, DOI 10.1016/j.aquaculture.2006.08.033; Cripps GC, 1999, MAR ECOL PROG SER, V181, P177, DOI 10.3354/meps181177; Fosshaug LE, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-245; Guy R., 2001, EXTRUSION COOKING TE, P5, DOI 10.1533/9781855736313.1.5; Ho C. T., 1992, FOOD EXTRUSION SCI T, P415; IZZO MT, 1989, CEREAL CHEM, V66, P47; Kraugerud OF, 2011, ANIM FEED SCI TECH, V163, P244, DOI 10.1016/j.anifeedsci.2010.11.010; Li DM, 2013, J SCI FOOD AGR, V93, P2669, DOI 10.1002/jsfa.6072; Moraru C.I., 2003, COMPREHENSIVE REV FO, V2, P147, DOI DOI 10.1111/J.1541-4337.2003.TB00020.X; Nichols PD, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-2; Pfennig A., 2011, IND SCALE NATURAL PR, P202; Ramprasath VR, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-178; RITTNER H, 1984, J AM OIL CHEM SOC, V61, P1200, DOI 10.1007/BF02636250; YAMAGUCHI K, 1986, J AGR FOOD CHEM, V34, P904, DOI 10.1021/jf00071a034	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0950-5423	1365-2621		INT J FOOD SCI TECH	Int. J. Food Sci. Technol.	MAR	2015	50	3					633	639		10.1111/ijfs.12673		7	Food Science & Technology	Food Science & Technology	CB9OD	WOS:000349960200009		
J	Takata, A; Terauchi, M; Hiramitsu, S; Uno, M; Wakana, K; Kubota, T				Takata, Aiko; Terauchi, Masakazu; Hiramitsu, Shiro; Uno, Masaya; Wakana, Kimio; Kubota, Toshiro			Dkk-3 Induces Apoptosis Through Mitochondrial and Fas Death Receptor Pathways in Human Mucinous Ovarian Cancer Cells	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Ovarian cancer; Wnt signaling; Caspase; Tumor suppressor; Proapoptotic	BETA-CATENIN; SUPPRESSOR GENE; RENAL-CANCER; DICKKOPF-3; OVEREXPRESSION; REIC/DKK-3; PROLIFERATION; CARCINOMA; GROWTH; EXPRESSION	Objective: Dkk-3 is a Wnt signaling inhibitor that is frequently inactivated in human cancers. Dkk-3 possesses an antiproliferative activity and induces apoptosis in tumor cells, suggesting that it functions as a tumor suppressor. In this study, we investigated the molecular function of Dkk-3 in human ovarian cancer cells. Methods: We assessed the levels of Dkk-3 protein expression in human mucinous and clear cell ovarian cancer cells, and compared cell viabilities between cell lines that expressed Dkk-3 and those that did not, as well as between cells that expressed Dkk-3 and those whose expression of Dkk-3 was reduced by small interfering RNA. We also evaluated the characteristic fragmentation of DNA to detect apoptosis in Dkk-3-deficient cells. To further investigate the molecular mechanisms of apoptosis, we assessed the expression of molecules involved in apoptosis signaling pathways in Dkk-3-deficient cells. Results: The expression of the Dkk-3 protein was observed in most of the ovarian cancer cell lines tested. Dkk-3-deficient cells showed faster growth than Dkk-3-replete cells. The characteristic fragmentation of DNA was not observed in Dkk-3-deficient cells, which showed decreased levels of expression in caspase-3, activated caspase-9, Bax, p53, activated caspase-8, and Fas/CD95, as well as an increase in Bcl-2 expression. Conclusions: Although Dkk-3 expression was observed in most of human ovarian cancer cell lines, Dkk-3 has a tumor-suppressive function and a proapoptotic effect, inducing apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer MCAS cells.	[Takata, Aiko; Hiramitsu, Shiro; Uno, Masaya; Wakana, Kimio; Kubota, Toshiro] Tokyo Med & Dent Univ, Dept Comprehens Reprod Med, Tokyo 1138510, Japan; [Terauchi, Masakazu] Tokyo Med & Dent Univ, Dept Womens Hlth, Tokyo 1138510, Japan; [Uno, Masaya] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Gynecol, Tokyo, Japan	Terauchi, M (reprint author), Tokyo Med & Dent Univ, Dept Womens Hlth, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138510, Japan.	teragyne@tmd.ac.jp	Terauchi, Masakazu/D-9831-2013	Terauchi, Masakazu/0000-0001-5577-0094			Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661; Jung IL, 2010, INT J MOL MED, V26, P33, DOI 10.3892/ijmm_00000431; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Leung F, 2013, CLIN BIOCHEM, V46, P1462, DOI 10.1016/j.clinbiochem.2013.03.010; Gatcliffe TA, 2008, INT J GYNECOL CANCER, V18, P954, DOI 10.1111/j.1525-1438.2007.01127.x; Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507; Yang ZR, 2012, WORLD J GASTROENTERO, V18, P1590, DOI 10.3748/wjg.v18.i14.1590; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; You A, 2011, J CANCER RES CLIN, V137, P621, DOI 10.1007/s00432-010-0916-6; Fatima S, 2012, ONCOGENE, V31, P4233, DOI 10.1038/onc.2011.580; Hirata H, 2009, CLIN CANCER RES, V15, P5678, DOI 10.1158/1078-0432.CCR-09-0558; Hirata H, 2009, CANCER, V115, P4488, DOI 10.1002/cncr.24491; Mizobuchi Y, 2008, NEURO-ONCOLOGY, V10, P244, DOI 10.1215/15228517-2008-016; Glinka A, 1998, NATURE, V391, P357; Dellinger TH, 2012, GYNECOL ONCOL, V126, P259, DOI 10.1016/j.ygyno.2012.04.026; Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Katase N, 2008, ONCOL RES, V17, P273; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Gloss BS, 2014, CANC LETT, V342, P257; Gu YM, 2011, WORLD J GASTROENTERO, V17, P3810, DOI 10.3748/wjg.v17.i33.3810; Hiramitsu S, 2013, ENDOCRINOLOGY, V154, P4618, DOI 10.1210/en.2013-1387; Jiang T, 2010, J OBSTET GYNAECOL RE, V36, P769, DOI 10.1111/j.1447-0756.2010.01234.x; Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58; Muhlmann G, 2010, VIRCHOWS ARCH, V456, P635, DOI 10.1007/s00428-010-0926-4; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Yoshikawa N, 2014, J GYNECOL ONCOL, V25, P118, DOI 10.3802/jgo.2014.25.2.118	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	MAR	2015	25	3					372	379		10.1097/IGC.0000000000000340		8	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CC1SM	WOS:000350123800006		
J	Kobayashi, Y; Nakamura, K; Nomura, H; Banno, K; Irie, H; Adachi, M; Iida, M; Umene, K; Nogami, Y; Masuda, K; Kisu, I; Ueki, A; Yamagami, W; Kataoka, F; Hirasawa, A; Tominaga, E; Susumu, N; Aoki, D				Kobayashi, Yusuke; Nakamura, Kanako; Nomura, Hiroyuki; Banno, Kouji; Irie, Haruko; Adachi, Masataka; Iida, Miho; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kisu, Iori; Ueki, Arisa; Yamagami, Wataru; Kataoka, Fumio; Hirasawa, Akira; Tominaga, Eiichiro; Susumu, Nobuyuki; Aoki, Daisuke			Clinicopathologic Analysis With Immunohistochemistry for DNA Mismatch Repair Protein Expression in Synchronous Primary Endometrial and Ovarian Cancers	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Synchronous primary endometrial and ovarian cancers; DNA mismatch repair proteins; Lynch syndrome; Bethesda guideline	NONPOLYPOSIS COLORECTAL-CANCER; LYNCH-SYNDROME; MICROSATELLITE INSTABILITY; PRIMARY MALIGNANCIES; INCREASED RISK; CARCINOMAS; MUTATION; TRACT; WOMEN; ADENOCARCINOMA	Objective: Synchronous primary endometrial and ovarian cancers have been an important topic in clinical medicine because it is sometimes difficult to distinguish whether there are 2 primary tumors or a single primary tumor and an associated metastasis. In addition, although these tumors are recommended for either immunohistochemistry for DNA mismatch repair (MMR) proteins or a microsatellite instability test in the Bethesda guidelines as Lynch syndrome-associated cancers, few studies have completed these analyses. In this study, we characterized the clinicopathologic features and the expression pattern of MMR proteins in synchronous primary endometrial and ovarian cancers. Methods: Clinicopathologic features and the expression pattern of MMR proteins (MLH1, MSH2, and MSH6) were characterized and analyzed in 32 synchronous primary endometrial and ovarian cancers. Results: Most synchronous cancers are endometrioid type (endometrioid/endometrioid) (n = 24, 75%), grade 1 (n = 19, 59.4%), and diagnosed as stage I (n = 15, 46.9%) in both endometrium and ovary. It is worth mentioning that 75% of the patients (n = 24) had endometriosis, which was more common (n = 21, 87.5%) in endometrioid/endometrioid cancers, whereas only 3 cases (37.5%) were of different histology (P = 0.018). Loss of expression of at least 1 MMR protein was observed in 17 (53.1%) of the endometrial tumors and in 10 (31.3%) of ovarian tumors. Only 4 cases (12.5%) that had specific MMR protein loss showed the same type of loss for both endometrial and ovarian tumors, in which 3 of the cases were losses in MLH1. One case showed concordant MSH6 protein loss, although the cases did not meet the Amsterdam criteria II. Conclusions: These results suggest that most synchronous primary endometrial ovarian cancers are not hereditary cancers caused by germ line mutations but rather sporadic cancers.	[Kobayashi, Yusuke; Nakamura, Kanako; Nomura, Hiroyuki; Banno, Kouji; Irie, Haruko; Adachi, Masataka; Iida, Miho; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kisu, Iori; Ueki, Arisa; Yamagami, Wataru; Kataoka, Fumio; Hirasawa, Akira; Tominaga, Eiichiro; Susumu, Nobuyuki; Aoki, Daisuke] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 1608582, Japan	Banno, K (reprint author), Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kbanno@z7.keio.jp	Adachi, Masataka/M-3477-2015	Adachi, Masataka/0000-0003-2974-8795			Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; Singh N, 2010, HISTOPATHOLOGY, V56, P277, DOI 10.1111/j.1365-2559.2009.03367.x; Nelson GS, 2013, GYNECOL ONCOL, V131, P309, DOI 10.1016/j.ygyno.2013.08.003; Barrow E, 2009, CLIN GENET, V75, P141, DOI 10.1111/j.1399-0004.2008.01125.x; Ramus SJ, 2008, CLIN CANCER RES, V14, P5840, DOI 10.1158/1078-0432.CCR-08-0373; Kadyrov FA, 2006, CELL, V126, P297, DOI 10.1016/j.cell.2006.05.039; Rodolakis A, 2012, ARCH GYNECOL OBSTET, V285, P817, DOI 10.1007/s00404-011-2046-z; Lim YK, 2011, J GYNECOL ONCOL, V22, P239, DOI 10.3802/jgo.2011.22.4.239; Jascur T, 2006, INT J CANCER, V119, P2030, DOI 10.1002/ijc.22023; Munksgaard PS, 2012, GYNECOL ONCOL, V124, P164, DOI 10.1016/j.ygyno.2011.10.001; Watson P, 2008, INT J CANCER, V123, P444, DOI 10.1002/ijc.23508; Niskakoski A, 2013, INT J CANCER, V133, P2596, DOI 10.1002/ijc.28287; Goodfellow PJ, 2003, P NATL ACAD SCI USA, V100, P5908, DOI 10.1073/pnas.1030231100; Shia J, 2013, MODERN PATHOL, V26, P131, DOI 10.1038/modpathol.2012.138; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Herrinton LJ, 2001, ANN EPIDEMIOL, V11, P529, DOI 10.1016/S1047-2797(01)00237-X; ULBRIGHT TM, 1985, HUM PATHOL, V16, P28, DOI 10.1016/S0046-8177(85)80210-0; Tong SY, 2008, EUR J OBSTET GYN R B, V136, P78, DOI 10.1016/j.ejogrb.2006.09.010; Zaino R, 2001, GYNECOL ONCOL, V83, P355, DOI 10.1006/gyno.2001.6400; Senter L, 2008, GASTROENTEROLOGY, V135, P419, DOI 10.1053/j.gastro.2008.04.026; Buis CCM, 2013, HUM REPROD, V28, P3358, DOI 10.1093/humrep/det340; Aysal A, 2012, AM J SURG PATHOL, V36, P163, DOI 10.1097/PAS.0b013e31823bc434; Chiang YC, 2008, INT J GYNECOL CANCER, V18, P159, DOI 10.1111/j.1525-1438.2007.00975.x; Hemminki K, 2003, CANCER, V97, P2432, DOI 10.1002/cncr.11372; Kawaguchi M, 2009, INT J ONCOL, V35, P977, DOI 10.3892/ijo_00000411; Nishimura N, 2005, J OBSTET GYNAECOL RE, V31, P120, DOI 10.1111/j.1447-0756.2005.00256.x; Scully RE, 1996, ATLAS TUMOR PATHOL 3, P125; Segev Y, 2013, INT J GYNECOL CANCER, V23, P1010, DOI 10.1097/IGC.0b013e31829a5527; Shia J, J MOL DIAGN; Soliman PT, GYNECOL ONCOL; van Niekerk CC, 2007, MODERN PATHOL, V20, P384, DOI 10.1038/modpathol.3800752	31	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	MAR	2015	25	3					440	446		10.1097/IGC.0000000000000377		7	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CC1SM	WOS:000350123800014		
J	Tanaka, T; Terai, Y; Ono, YJ; Fujiwara, S; Tanaka, Y; Sasaki, H; Tsunetoh, S; Kanemura, M; Ohmichi, M				Tanaka, Tomohito; Terai, Yoshito; Ono, Yoshihiro J.; Fujiwara, Satoe; Tanaka, Yoshimichi; Sasaki, Hiroshi; Tsunetoh, Satoshi; Kanemura, Masanori; Ohmichi, Masahide			Genitofemoral Neuropathy After Pelvic Lymphadenectomy in Patients With Uterine Corpus Cancer	INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER			English	Article						Genitofemoral neuropathy; Pelvic lymphadenectomy; Pelvic surgery; Nerve injury	ENDOMETRIAL CANCER; PARAAORTIC LYMPHADENECTOMY; SURVIVAL; BIPOLAR; ADENOCARCINOMA; RADIOTHERAPY; SURGERY	Objective: The aim of this study was to estimate the incidence, etiology, and outcomes of genitofemoral neuropathy after pelvic lymphadenectomy (PLD) for uterine corpus cancer. Materials and Methods: The medical records of women who underwent PLD for uterine corpus cancer between June 2001 and June 2013 were reviewed. Information regarding neuropathy was directly reported by each subject. Results: Thirty-two of 300 patients undergoing PLD during the defined period experienced postoperative neuropathy due to genitofemoral nerve injury, for an incidence of 10.7%. The patients treated with PLD with para-aortic lymphadenectomy (PALD) exhibited a lower rate of genitofemoral neuropathy than those treated without PALD (4.3% vs 13.5%, P = 0.01). The laparoscopy group displayed a higher rate of genitofemoral neuropathy than the laparotomy group (19.1% vs 9.1%, P = 0.04). A total of 81.3% of the patients experienced a full recovery, with a medium time to resolution of 6 months (3-12 months). The administration of adjuvant chemotherapy, including paclitaxel, did not extend the time to recovery. Conclusions: Neuropathy resulting from genitofemoral nerve injury is not infrequent; however, most of the patients recover completely. In this study, the use of laparoscopic procedures increased the incidence of genitofemoral neuropathy, whereas that of PALD did not.	[Tanaka, Tomohito; Terai, Yoshito; Ono, Yoshihiro J.; Fujiwara, Satoe; Tanaka, Yoshimichi; Sasaki, Hiroshi; Tsunetoh, Satoshi; Kanemura, Masanori; Ohmichi, Masahide] Osaka Med Coll, Dept Obstet & Gynecol, Takatsuki, Osaka 5698686, Japan	Tanaka, T (reprint author), Osaka Med Coll, Dept Obstet & Gynecol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.	gyn123@poh.osaka-med.ac.jp					Ko R, 2010, BJU INT, V105, P1314, DOI 10.1111/j.1464-410X.2009.08907.x; Cragun JM, 2005, J CLIN ONCOL, V23, P3668, DOI 10.1200/JCO.2005.04.144; Larson DM, 1998, OBSTET GYNECOL, V91, P355, DOI 10.1016/S0029-7844(97)00698-4; Trimble EL, 1998, GYNECOL ONCOL, V71, P340, DOI 10.1006/gyno.1998.5254; Cardosi RJ, 2002, OBSTET GYNECOL, V100, P240, DOI 10.1016/S0029-7844(02)02052-5; KILGORE LC, 1995, GYNECOL ONCOL, V56, P29, DOI 10.1006/gyno.1995.1005; Apok V, 2011, Pract Neurol, V11, P100, DOI 10.1136/jnnp.2011.242222; AYHAN A, 1994, INT J GYNECOL CANCER, V4, P306, DOI 10.1046/j.1525-1438.1994.04050306.x; BAGGISH MS, 1995, FERTIL STERIL, V63, P422; Bohrer JC, 2009, AM J OBSTET GYNECOL, V201; Brzeziński Jan, 2011, Pol Przegl Chir, V83, P355, DOI 10.2478/v10035-011-0056-y; Cibula D, 2010, GYNECOL ONCOL, V116, P33, DOI 10.1016/j.ygyno.2009.09.003; DeLancey JOL, 2008, LINDES OPERATIVE GYN, P110; Fanning J, 2001, GYNECOL ONCOL, V82, P371, DOI 10.1006/gyno.2001.6276; Lo KWK, 2003, INT J GYNECOL CANCER, V13, P863, DOI 10.1111/j.1525-1438.2003.13320.x; SIEGEL JH, 1994, AM J GASTROENTEROL, V89, P1827; Takeshima N, 1996, OBSTET GYNECOL, V88, P280, DOI 10.1016/0029-7844(96)00115-9; Yenen MC, 2003, EUR J GYNAECOL ONCOL, V24, P327	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1048-891X	1525-1438		INT J GYNECOL CANCER	Int. J. Gynecol. Cancer	MAR	2015	25	3					533	536		10.1097/IGC.0000000000000335		4	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	CC1SM	WOS:000350123800027		
J	Morikawa, M; Kuramoto, A; Nakayama, M; Oguchi, H; Hasegawa, M; Funakoshi, T; Furukawa, S; Hirayama, E; Kanagawa, T; Kaji, T; Kasai, M; Konishi, Y; Yamamoto, S; Itakura, A; Maeda, M; Kobayashi, T; Minakami, H				Morikawa, Mamoru; Kuramoto, Akitaka; Nakayama, Masaki; Oguchi, Hidenori; Hasegawa, Masaaki; Funakoshi, Toru; Furukawa, Seishi; Hirayama, Emi; Kanagawa, Takeshi; Kaji, Takashi; Kasai, Mayumi; Konishi, Yasuhiro; Yamamoto, Shin-ichi; Itakura, Atsuo; Maeda, Makoto; Kobayashi, Takao; Minakami, Hisanori			Intraoperative red cell salvage during obstetric surgery in 50 Japanese women	INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS			English	Article						Adverse events; Allogeneic blood transfusion; Amniotic fluid embolism; Autologous donation; Intraoperative cell salvage; Pregnancy	ANTERIOR UTERINE WALL; BLOOD-TRANSFUSION; CESAREAN-SECTION; PLACENTA PREVIA; FUNDAL INCISION; JEHOVAH-WITNESS; HYSTERECTOMY; ACCRETA	Objective: To determine the clinical usefulness of intraoperative cell salvage (ICS) in obstetrics. Methods: A retrospective analysis was performed using data for 50 patients who had received ICS blood during obstetric surgery at 13 Japanese facilities between January 1, 2007 and December 31, 2013. The frequencies of ICS-associated adverse events, allogeneic blood transfusion (ABT), and preoperative autologous donation (PAD) were assessed. Results: Placenta previa was the indication for ICS in 42 (84%) women. The ICS blood was reinfused in all women (median 366 mL; range 80 to at least 3715). No ICS-associated adverse events occurred. The median estimated blood loss (EBL) was 2171 mL (range 574-47 000); 27 (54%) women lost at least 2000 mL. ABT was not used in 33 (66%) women. Among 26 women who lost at least 2000 mL of blood and were included in analyses, 12 (44%) did not receive ABT. EBL was linearly correlated with the total volume of transfused blood (P < 0.001). Conclusion: ICS caused no adverse events among women at elevated risk of peripartum hemorrhage and might be safe for use in obstetrics. (C) 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.	[Morikawa, Mamoru; Minakami, Hisanori] Hokkaido Univ Hosp, Dept Obstet, Sapporo, Hokkaido 060, Japan; [Kuramoto, Akitaka] Kumamoto City Hosp, Dept Obstet & Gynecol, Kumamoto, Japan; [Nakayama, Masaki] Yokohama Rosai Hosp, Dept Obstet & Gynecol, Yokohama, Kanagawa, Japan; [Oguchi, Hidenori] Toyota Mem Hosp, Dept Obstet & Gynecol, Toyota, Japan; [Hasegawa, Masaaki] Kurashiki Cent Hosp, Dept Obstet & Gynecol, Kurashiki, Okayama, Japan; [Funakoshi, Toru] Hyogo Prefectural Kobe Childrens Hosp, Dept Obstet & Gynecol, Kobe, Hyogo, Japan; [Furukawa, Seishi] Miyazaki Univ Hosp, Dept Obstet & Gynecol, Miyazaki, Japan; [Hirayama, Emi] Sapporo City Hosp, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Kanagawa, Takeshi] Osaka Univ Hosp, Dept Obstet & Gynecol, Suita, Osaka, Japan; [Kaji, Takashi] Tokushima Univ Hosp, Dept Obstet & Gynecol, Tokushima, Japan; [Kasai, Mayumi] Iwate Cent Prefectural Hosp, Dept Obstet & Gynecol, Morioka, Iwate, Japan; [Konishi, Yasuhiro] Saiseikai Yokohamashi Tobu Hosp, Dept Obstet & Gynecol, Yokohama, Kanagawa, Japan; [Yamamoto, Shin-ichi] Kariya Toyota Gen Hosp, Dept Obstet & Gynecol, Kariya, Aichi, Japan; [Itakura, Atsuo] Juntendo Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan; [Maeda, Makoto] Mie Chuo Med Ctr, Dept Obstet & Gynecol, Tsu, Mie, Japan; [Kobayashi, Takao] Hamamatsu Med Ctr, Dept Obstet & Gynecol, Hamamatsu, Shizuoka, Japan	Morikawa, M (reprint author), Hokkaido Univ, Dept Obstet, Grad Sch Med, Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.	mmamoru@med.hokudai.ac.jp			Japan Society of Obstetrical, Gynecological, and Neonatal Hematology	The present study received financial support from the Japan Society of Obstetrical, Gynecological, and Neonatal Hematology.	American College of Obstetricians and Gynecologists, 2006, OBSTET GYNECOL, V108, P1039; Kotsuji F, 2013, BJOG-INT J OBSTET GY, V120, P1144, DOI 10.1111/1471-0528.12252; de Souza A, 2003, BJOG-INT J OBSTET GY, V110, P524, DOI 10.1016/S1470-0328(02)01661-0; Sreelakshmi TR, 2010, ANAESTHESIA, V65, P742, DOI 10.1111/j.1365-2044.2009.06190.x; Nagy CJ, 2008, INT J OBSTET ANESTH, V17, P159, DOI 10.1016/j.ijoa.2007.07.005; Kessack LK, 2010, ANAESTHESIA, V65, P745, DOI 10.1111/j.1365-2044.2010.06301.x; Liumbruno GM, 2011, EUR J OBSTET GYN R B, V159, P19, DOI 10.1016/j.ejogrb.2011.06.011; Clark SL, 2014, OBSTET GYNECOL, V123, P337, DOI 10.1097/AOG.0000000000000107; Esper SA, 2011, BLOOD TRANSFUS-ITALY, V9, P139, DOI 10.2450/2011.0081-10; Benson MD, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/946576; Sahin S, 2014, ARCH GYNECOL OBSTET, V289, P953, DOI 10.1007/s00404-013-3079-2; Ansar A, 2014, JCPSP-J COLL PHYSICI, V24, P318, DOI 04.2014/JCPSP.318322; Araki Yoshiyuki, 2009, Masui, V58, P499; King M, 2009, INT J OBSTET ANESTH, V18, P111, DOI 10.1016/j.ijoa.2008.07.010; Koai E, 2014, OBSTET GYNECOL, V123, p60S, DOI 10.1097/01.AOG.0000447362.62858.67; McDonnell NJ, 2010, ANAESTH INTENS CARE, V38, P492; Nishida R, 2013, J OBSTET GYNAECOL RE, V39, P91, DOI 10.1111/j.1447-0756.2012.01921.x; Parry N, 2010, INT J OBSTET ANESTH, V19, P238, DOI 10.1016/j.ijoa.2009.09.001; Pasternak J, 2014, BLOOD TRANSFUS-ITALY, V12, pS182, DOI 10.2450/2012.0069-12; Provan D, 1999, BRIT MED J, V318, P1435; Rainaldi MP, 1998, BRIT J ANAESTH, V80, P195; Rebarber A, 1998, AM J OBSTET GYNECOL, V179, P715, DOI 10.1016/S0002-9378(98)70070-5; The Association of Anaesthetists of Great Britain and Ireland, 2009, BLOOD TRANSF AN INTR; Thomas D, 2005, INT J OBSTET ANESTH, V14, P48, DOI 10.1016/j.ijoa.2004.09.001; Wright JD, 2011, AM J OBSTET GYNECOL, V205	25	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0020-7292	1879-3479		INT J GYNECOL OBSTET	Int. J. Gynecol. Obstet.	MAR	2015	128	3					256	259		10.1016/j.ijgo.2014.09.008		4	Obstetrics & Gynecology	Obstetrics & Gynecology	CC1JG	WOS:000350096400016		
J	Arraut, I				Arraut, Ivan			On the black holes in alternative theories of gravity: The case of nonlinear massive gravity	INTERNATIONAL JOURNAL OF MODERN PHYSICS D			English	Article						Modified gravity; massive gravity; Vainshtein mechanism; Vainshtein radius; Schwarzschild de-Sitter space	DE-SITTER; CREATION	I derive general conditions in order to explain the origin of the Vainshtein radius inside dRGT. The set of equations, which I have called "Vainshtein" conditions are extremal conditions of the dynamical metric (g(mu nu)) containing all the degrees of freedom of the theory. The Vainshtein conditions are able to explain the coincidence between the Vainshtein radius in dRGT and the scale r(0) = (3/2 r(s)r(Lambda)(2))(1/3), obtained naturally from the Schwarzschild de-Sitter (S-dS) space inside general relativity (GR). In GR, this scale was interpreted as the maximum distance in order to get bound orbits. The same scale corresponds to the static observer position if we want to define the black hole temperature in an asymptotically de-Sitter space. In dRGT, the scale marks a limit after which the extra degrees of freedom of the theory become relevant.	[Arraut, Ivan] Osaka Univ, Dept Phys, Toyonaka, Osaka 5600043, Japan; [Arraut, Ivan] KEK, Inst Particle & Nucl Studies, Ctr Theory, Tsukuba, Ibaraki 3050801, Japan	Arraut, I (reprint author), Osaka Univ, Dept Phys, Toyonaka, Osaka 5600043, Japan.				MEXT (The Ministry of Education, Culture, Sports, Science and Technology) in Japan; KEK Theory Center	The author would like to thank Gia Dvali for a very useful discussion during the Karl Schwarzschildmeeting 2013 organized in FIAS, Frankfurt/Germany. This work is supported by MEXT (The Ministry of Education, Culture, Sports, Science and Technology) in Japan and KEK Theory Center.	Capozziello S, 2011, PHYS REP, V509, P167, DOI 10.1016/j.physrep.2011.09.003; de Rham C, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.231101; Hinterbichler K, 2012, REV MOD PHYS, V84, P671, DOI 10.1103/RevModPhys.84.671; Capozziello S, 2007, CLASSICAL QUANT GRAV, V24, P2153, DOI 10.1088/0264-9381/24/8/013; GIBBONS GW, 1977, PHYS REV D, V15, P2738, DOI 10.1103/PhysRevD.15.2738; Bertolami O, 2007, PHYS REV D, V75, DOI 10.1103/PhysRevD.75.104016; Antolinez A. B., 2006, CLASSICAL QUANTUM GR, V23, P485; Arraut I, 2009, CLASSICAL QUANT GRAV, V26, DOI 10.1088/0264-9381/26/12/125006; Arraut I., ARXIV12056905V3GRQC; Arraut I., ARXIV13050475GRQC; Arraut I, 2011, CENT EUR J PHYS, V9, P926, DOI 10.2478/s11534-010-0147-0; Babichev E, 2013, CLASSICAL QUANT GRAV, V30, DOI 10.1088/0264-9381/30/18/184001; BARROW JD, 1983, J PHYS A-MATH GEN, V16, P2757, DOI 10.1088/0305-4470/16/12/022; BAZANSKI SL, 1986, NUOVO CIMENTO B, V91, P126, DOI 10.1007/BF02722226; Bousso R, 1996, PHYS REV D, V54, P6312, DOI 10.1103/PhysRevD.54.6312; GINSPARG P, 1983, NUCL PHYS B, V222, P245, DOI 10.1016/0550-3213(83)90636-3; Kodama H, 2014, PROG THEOR EXP PHYS, DOI 10.1093/ptep/ptu016; Koyama K, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.131101; Nieuwenhuizen TM, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.024038; Stuchlik Z, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.064001; Stuchlik Z, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.044006; STUCHLIK Z, 1983, B ASTRON I CZECH, V34, P129	22	1	1	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0218-2718	1793-6594		INT J MOD PHYS D	Int. J. Mod. Phys. D	MAR	2015	24	3							1550022	10.1142/S0218271815500224		16	Astronomy & Astrophysics	Astronomy & Astrophysics	CC1PI	WOS:000350113100005		
J	Hasegawa, T; Tateishi, C; Asai, M; Imai, Y; Okamoto, N; Shioyasono, A; Kimoto, A; Akashi, M; Suzuki, H; Furudoi, S; Komori, T				Hasegawa, T.; Tateishi, C.; Asai, M.; Imai, Y.; Okamoto, N.; Shioyasono, A.; Kimoto, A.; Akashi, M.; Suzuki, H.; Furudoi, S.; Komori, T.			Retrospective study of changes in the sensitivity of the oral mucosa: sagittal split ramus osteotomy (SSRO) versus intraoral vertical ramus osteotomy (IVRO)	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						sensitivity; neurosensory disturbance; sagittal split ramus osteotomy; intraoral vertical ramus osteotomy; Semmes-Weinstein pressure aesthesiometer	INFERIOR ALVEOLAR NERVE; NEUROSENSORY DISTURBANCE; MANDIBULAR PROGNATHISM; ORTHOGNATHIC SURGERY; SENSIBILITY; RECOVERY; LIP	We investigated changes in the sensitivity of cutaneous points and the oral mucosa after sagittal split ramus osteotomy (SSRO) and assessed the differences between SSRO and intraoral vertical ramus osteotomy (IVRO). The subjects included in this study were 46 patients with mandibular progmathism who underwent IVRO (88 rami) and 30 patients who underwent SSRO (59 rami). An objective evaluation of the neurosensory status of each patient was completed preoperatively and at 1, 4, 8, 12, and 24 weeks postoperatively. Other variables studied for each patient included sex, age, magnitude of mandibular setback, and amount of blood loss during surgery. We found that a neurosensory recovery occurred earlier in the oral mucosa than at cutaneous points. The number of oral mucosa points showing reduced neurosensory function and neurosensory disturbance after SSRO was significantly higher than after IVRO at 1, 4, and 8 weeks (P < 0.05). The nerve recovery observed after SSRO was delayed for a longer period than that noted in our previous study of IVRO. In conclusion, we found changes in sensitivity at cutaneous points and the oral mucosa after SSRO and assessed the differences between SSRO and IVRO.	[Hasegawa, T.; Tateishi, C.; Asai, M.; Imai, Y.; Okamoto, N.; Shioyasono, A.; Kimoto, A.; Akashi, M.; Suzuki, H.; Furudoi, S.; Komori, T.] Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kobe, Hyogo 6500017, Japan	Hasegawa, T (reprint author), Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hasetaku@med.kobe-u.ac.jp					Al-Bishri A, 2005, INT J ORAL MAX SURG, V34, P247, DOI 10.1016/j.ijom.2004.06.009; Westermark A, 1998, BRIT J ORAL MAX SURG, V36, P429, DOI 10.1016/S0266-4356(98)90458-2; Villarroel MF, 2007, LEPROSY REV, V78, P102; Monnazzi MS, 2012, J ORAL MAXIL SURG, V70, P696, DOI 10.1016/j.joms.2011.02.071; WALTER JM, 1979, J ORAL SURG, V37, P410; EPKER BN, 1977, J ORAL SURG, V35, P157; Westermark A, 1998, BRIT J ORAL MAX SURG, V36, P425, DOI 10.1016/S0266-4356(98)90457-0; Bell JA, 1987, REHABILITATION HAND, P273; Bell-Krotoski J., 1990, J HAND THER, V3, P26; DAL PONT G, 1961, J Oral Surg Anesth Hosp Dent Serv, V19, P42; GALLO WJ, 1976, J ORAL SURG, V34, P178; Ghali GE, 2000, J ORAL MAXIL SURG, V58, P313, DOI 10.1016/S0278-2391(00)90063-6; GHALI GE, 1989, J ORAL MAXIL SURG, V47, P1074, DOI 10.1016/0278-2391(89)90184-5; HALL HD, 1987, J ORAL MAXIL SURG, V45, P684, DOI 10.1016/0278-2391(87)90308-9; Hasegawa T, 2013, INT J ORAL MAX SURG, V42, P1454, DOI 10.1016/j.ijom.2013.04.008; Hunsuck E E, 1968, J Oral Surg, V26, P250; JONES D L, 1990, International Journal of Adult Orthodontics and Orthognathic Surgery, V5, P35; KARAS ND, 1990, J ORAL MAXIL SURG, V48, P124; Kobayashi A, 2006, J ORAL MAXIL SURG, V64, P778, DOI 10.1016/j.joms.2006.01.009; MACINTOSH RB, 1981, J MAXILLOFAC SURG, V9, P151, DOI 10.1016/S0301-0503(81)80036-7; NAPLES RJ, 1994, ORAL SURG ORAL MED O, V77, P318, DOI 10.1016/0030-4220(94)90189-9; Nesari S, 2005, INT J ORAL MAX SURG, V34, P495, DOI 10.1016/j.ijom.2004.10.021; NISHIOKA GJ, 1987, J ORAL MAXIL SURG, V45, P20, DOI 10.1016/0278-2391(87)90081-4; Rajchel J, 1986, INT J ADULT ORTHOD O, V1, P37; ROSENBERG A, 1994, J CRANIO MAXILL SURG, V22, P286, DOI 10.1016/S1010-5182(05)80078-2; Schuchardt K, 1942, DTSCH ZAHN MUND KIEF, V9, P73; Terry BC, 1991, SURG ORTHODONTIC TRE, P264; TRAUNER R, 1957, Oral Surg Oral Med Oral Pathol, V10, P787, DOI 10.1016/0030-4220(57)90105-6; TRAUNER R, 1957, Oral Surg Oral Med Oral Pathol, V10, P677, DOI 10.1016/S0030-4220(57)80063-2; ZAYTOUN HS, 1986, J ORAL MAXIL SURG, V44, P193, DOI 10.1016/0278-2391(86)90107-2	30	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	MAR	2015	44	3					349	355		10.1016/j.ijom.2014.10.016		7	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CC7DJ	WOS:000350527600009		
J	Imai, Y; Hasegawa, T; Takeda, D; Akashi, M; Komori, T				Imai, Y.; Hasegawa, T.; Takeda, D.; Akashi, M.; Komori, T.			The osteogenic activity of human mandibular fracture haematoma-derived progenitor cells is affected by bisphosphonate in vitro	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						mandibular fracture; haematoma; bisphosphonate; alendronate; risedronate; osteogenic activity	GENE-EXPRESSION; HUMAN OSTEOBLASTS; BONE; RATS; PROLIFERATION; DIFFERENTIATION; OSTEONECROSIS; IMPLANTS; PROFILE; JAWS	It is known that bisphosphonates (BPs) suppress the activity of osteoclasts; however, it has not been reported whether BPs affect the potential of human mandibular fracture haematoma-derived cells (MHCs) for bone differentiation. In this study, we examined whether the degree of bone differentiation changes following the administration of BP in vitro. The effects of alendronate and risedronate (10(-8) to 10(-7) M (mol/l)) on cell proliferation were evaluated at 4 and 8 days, after which BP treatment was applied for 4, 8, 14, and 20 days prior to assessing the alkaline phosphatase (ALP) activity and performing the mineralization assay. Alendronate 10(-8) and 10(-7) M and risedronate 10(-7) M decreased the degree of cell proliferation on day 8 (P < 0.05). Using an ELISA, the ALP activity of the control, alendronate 10(-8) M, risedronate 10(-8) M, and risedronate 10(-7) M groups were 112.1 +/- 10.2%, 156.1 +/- 24.3%, 138.8 +/- 16.5%, and 133.3 +/- 10.3%, respectively, at 14 days after treatment (day 0 in each group was considered to be 100%). ALP activity was significantly higher in the alendronate 10(-8) M and risedronate 10(-8) and 10(-7) M groups than in the control group (P = 0.010, 0.014, and 0.009, respectively). It is possible that BPs increase the potential of MHCs for osteogenic differentiation depending on the concentration of the drug.	[Imai, Y.; Hasegawa, T.; Takeda, D.; Akashi, M.; Komori, T.] Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kobe, Hyogo 6500017, Japan	Hasegawa, T (reprint author), Kobe Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	hasetaku@med.kobe-u.ac.jp			Eisai Co. Ltd.	This work was supported by a grant from Eisai Co. Ltd.	Acil Y, 2012, J CRANIOMAXILLOFAC S, V40, P229; ALBERIUS P, 1991, J CRANIO MAXILL SURG, V19, P15, DOI 10.1016/S1010-5182(05)80266-5; Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010; Corrado A, 2010, CLIN EXP RHEUMATOL, V28, P873; Simon MJK, 2010, CLIN ORAL INVEST, V14, P51, DOI 10.1007/s00784-009-0312-2; Kimmel DB, 2007, J DENT RES, V86, P1022; Fournier P, 2002, CANCER RES, V62, P6538; Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049; Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784-009-0365-2; Astrand J, 2004, J ORTHOPAED RES, V22, P244, DOI 10.1016/j.orthres.2003.08.008; Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026; von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059; Yoshinari M, 2002, BIOMATERIALS, V23, P2879, DOI 10.1016/S0142-9612(01)00415-X; Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456; Lam DK, 2007, J CAN DENT ASSOC, V73, P417; Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223-008-9104-y; Reinholz GG, 2000, CANCER RES, V60, P6001; Enjuanes A, 2010, ENDOCRINE, V37, P180, DOI 10.1007/s12020-009-9285-9; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; Greiner SH, 2008, ACTA ORTHOP, V79, P717, DOI 10.1080/17453670810016768; Hasegawa T, 2012, J ORAL MAXIL SURG, V70, P599, DOI 10.1016/j.joms.2011.03.043; Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ; Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746-160X-6-12; Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2001.1679; Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776	25	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	MAR	2015	44	3					412	416		10.1016/j.ijom.2014.10.015		5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	CC7DJ	WOS:000350527600019		
J	Moriyama, K; Furuno, N; Yamakawa, N				Moriyama, Kei; Furuno, Naoko; Yamakawa, Naoki			Crystal face identification by Raman microscopy for assessment of crystal habit of a drug	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Raman spectroscopy; Crystal habit; Phenytoin; Crystal structure; X-ray	ACTIVE PHARMACEUTICAL INGREDIENTS; CRYSTALLIZATION CONDITIONS; DIFFERENT SOLVENTS; SPECTROSCOPY; PHENYTOIN; SPECTRA	Crystal habit is one of the key crystallographic characteristics of active pharmaceutical ingredients (APIs), especially those that are poorly soluble. X-ray powder diffraction has commonly been used to assess crystal habit; however, it can only provide macro-information regarding crystal habit for a whole powder sample, not for individual crystals. We describe an approach that uses Raman microscopy for the identification of crystal faces to assess crystal habit at the individual particle level. An antiepileptic agent, phenytoin, was used as the model substance. Phenytoin crystals form a primitive orthorhombic cell. Raman microscopy was used to identify three different patterns of Raman spectra, corresponding to the crystallographic axis that was parallel to the polarization direction of the excitation laser. Thus, a combination of Raman spectra, in which the polarization direction was horizontal and vertical to the morphologically long axis of the crystal, characterized the crystal face. Phenytoin crystals were prepared under various conditions, and the horizontal/vertical combinations of Raman spectra were recorded for individual crystals. The dominantly exposed crystal faces for each condition were identified. This analytical method enables micro-view assessments of crystal habit, which are helpful for identifying the habits of APIs alone and in formulations. (C) 2015 Elsevier B.V. All rights reserved.	[Moriyama, Kei; Furuno, Naoko; Yamakawa, Naoki] Shujitsu Univ, Sch Pharm, Naka Ku, Okayama 7038516, Japan	Moriyama, K (reprint author), Shujitsu Univ, Sch Pharm, Naka Ku, 1-6-1 Nishigawara, Okayama 7038516, Japan.	moriyama@shujitsu.ac.jp					Widjaja E, 2011, EUR J PHARM SCI, V42, P45, DOI 10.1016/j.ejps.2010.10.004; Erdemir D, 2007, CURR OPIN DRUG DISC, V10, P746; Adhiyaman R, 2006, INT J PHARMACEUT, V321, P27, DOI 10.1016/j.ijpharm.2006.04.021; Blagden N, 2007, ADV DRUG DELIVER REV, V59, P617, DOI 10.1016/j.addr.2007.05.011; Sasic S, 2005, ANALYST, V130, P1530, DOI 10.1039/b506523b; Kuminek G, 2013, J PHARMACEUT BIOMED, V78-79, P105, DOI 10.1016/j.jpba.2013.02.001; Henson MJ, 2006, APPL SPECTROSC, V60, P1247; de Veij M, 2009, J RAMAN SPECTROSC, V40, P297, DOI 10.1002/jrs.2125; Sasic S, 2006, APPL SPECTROSC, V60, P494, DOI 10.1366/000370206777412103; Gordon KC, 2011, INT J PHARMACEUT, V417, P151, DOI 10.1016/j.ijpharm.2010.12.030; Shah B, 2006, J PHARM SCI-US, V95, P1641, DOI 10.1002/jps.20644; Nokhodchi A, 2003, INT J PHARMACEUT, V250, P85, DOI 10.1016/S0378-5173(02)00488-X; Lu J, 2009, CURR MED CHEM, V16, P884; Furuyama N, 2008, INT J PHARM, V361, P12, DOI 10.1016/j.ijpharm.2008.05.009; Llinas A, 2008, DRUG DISCOV TODAY, V13, P198, DOI 10.1016/j.drudis.2007.11.006; Fini G, 2004, J RAMAN SPECTROSC, V35, P335, DOI 10.1002/jrs.1161; Hedoux A, 2011, INT J PHARMACEUT, V417, P17, DOI 10.1016/j.ijpharm.2011.01.031; CAMERMAN A, 1971, ACTA CRYSTALL B-STRU, VB 27, P2205, DOI 10.1107/S0567740871005570; CHATTOPADHYAY TK, 1993, J CRYST SPECTROSC, V23, P149, DOI 10.1007/BF01195449; Connolly B, 2010, ANAL BIOCHEM, V399, P48, DOI 10.1016/j.ab.2009.10.033; Gunasekaran S, 2006, SPECTROCHIM ACTA A, V65, P1041, DOI 10.1016/j.saa.2006.01.037; Haaser M, 2011, J PHARM SCI-US, V100, P4452, DOI 10.1002/jps.22609; Hubert S, 2011, INT J PHARMACEUT, V420, P76, DOI 10.1016/j.ijpharm.2011.08.028	23	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	MAR 1	2015	480	1-2					101	106		10.1016/j.ijpharm.2015.01.031		6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CC6CS	WOS:000350452900012		
J	Miyamoto, N; Kawakami, Y				Miyamoto, N.; Kawakami, Y.			No Graduated Pressure Profile in Compression Stockings Still Reduces Muscle Fatigue	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						compression garments; treadmill running; magnetic resonance imaging; triceps surae; tibialis anterior	MAGNETIC-RESONANCE; SKELETAL-MUSCLE; LOWER-LIMB; EXERCISE; GARMENTS; HEMODYNAMICS; PERFORMANCE; RECOVERY; PH	Most sporting compression stockings possess a graduated pressure profile. However, it remains unclear whether the graduated pressure profile is an essential feature for reducing the development of muscle fatigue. This study sought to examine the effect of the pressure profile of compression stockings on the degree of muscle fatigue of lower leg muscles induced by submaximal running exercise. 15 male subjects performed 30-min treadmill running in 1 control and 4 compression stocking conditions with the following profiles; 1) graduated low pressure, 2) graduated high pressure, 3) uniform pressure distribution, and 4) localized pressure just over the gastrocnemius muscle belly. Before and immediately after the exercise, T2-weighted magnetic resonance images of the right lower leg were obtained without testing garments. T2 values of the triceps surae and tibialis anterior were calculated from the images. T2 was significantly increased after the running in all conditions. The magnitude of T2 increase was significantly greater in the control than in other 3 conditions except for the one with graduated low pressure, whereas there were no significant differences among the latter 3 conditions. The findings suggest that a graduated pressure profile is not an essential feature of compression stockings for reducing the development of muscle fatigue during submaximal running exercise.	[Miyamoto, N.] Natl Inst Fitness & Sports Kanoya, Dept Sports & Life Sci, Kanoya 8912393, Japan; [Kawakami, Y.] Waseda Univ, Fac Sport Sci, Saitama, Japan	Miyamoto, N (reprint author), Natl Inst Fitness & Sports Kanoya, Dept Sports & Life Sci, 1 Shiromizu, Kanoya 8912393, Japan.	miyamoto@nifs-k.ac.jp					Akima H, 1999, MED SCI SPORT EXER, V31, P588, DOI 10.1097/00005768-199904000-00016; Bovenschen HJ, 2013, J ATHL TRAINING, V48, P226, DOI 10.4085/1062-6050-48.1.26; Doan BK, 2003, J SPORT SCI, V21, P601, DOI 10.1080/0264041031000101971; Harriss DJ, 2013, INT J SPORTS MED, V34, P1025, DOI 10.1055/s-0033-1358756; Kraemer WJ, 2010, J STRENGTH COND RES, V24, P804, DOI 10.1519/JSC.0b013e3181d33025; Ibegbuna V, 2003, J VASC SURG, V37, P420, DOI 10.1067/mva.2003.104; [Anonymous], 1996, J STRENGTH COND RES; Westerblad H, 1997, J PHYSIOL-LONDON, V500, P193; Bringard A, 2006, INT J SPORTS MED, V27, P373, DOI 10.1055/s-2005-865718; LAWRENCE D, 1980, BRIT J SURG, V67, P119, DOI 10.1002/bjs.1800670214; Vandenborne K, 2000, EUR J APPL PHYSIOL, V82, P76, DOI 10.1007/s004210050654; Liu R, 2008, ADV THER, V25, P465, DOI 10.1007/s12325-008-0058-2; Wakahara T, 2012, EUR J APPL PHYSIOL, V112, P1569, DOI 10.1007/s00421-011-2121-y; MacRae BA, 2011, SPORTS MED, V41, P815, DOI 10.2165/11591420-000000000-00000; Scanlan AT, 2008, INTJ SPORT PHYSIOL, V3, P424; ADAMS GR, 1992, J APPL PHYSIOL, V73, P1578; CHENG HA, 1995, J APPL PHYSIOL, V79, P1370; DAWSON MJ, 1978, NATURE, V274, P861; EDGERTON VR, 1975, HISTOCHEM J, V7, P259, DOI 10.1007/BF01003594; FLECKENSTEIN JL, 1991, J APPL PHYSIOL, V71, P961; Goh SS, 2011, EUR J APPL PHYSIOL, V111, P819, DOI 10.1007/s00421-010-1705-2; JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3; Kraemer WJ, 1998, SPORTS MED TRAIN REH, V8, P163; Maton B, 2006, EUR J APPL PHYSIOL, V97, P432, DOI 10.1007/s00421-006-0187-8; Matsumoto N, 2013, J TRAIN SCI EXERC SP, V25, P55; Miyamoto N, MED SCI SPO IN PRESS; Miyamoto N, 2011, J ELECTROMYOGR KINES, V21, P249, DOI 10.1016/j.jelekin.2010.08.006; Rassier DE, 2002, J APPL PHYSIOL, V92, P1293, DOI 10.1152/japplphysiol.00912.2001	28	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAR	2015	36	3					220	225		10.1055/s-0034-1390495		6	Sport Sciences	Sport Sciences	CC7TM	WOS:000350571300006		
J	Tanaka, Y; Maeda, Y; Yang, TC; Ando, T; Tauchi, Y; Miyanaga, H				Tanaka, Y.; Maeda, Y.; Yang, T. -C.; Ando, T.; Tauchi, Y.; Miyanaga, H.			Prevention of Orofacial Injury via the Use of Mouthguards among Young Male Rugby Players	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						athletic injuries; injury prevention; dentistry; teeth; facial bones; rugby	SPORT ACTIVITIES; DENTAL INJURIES; TRAUMA; BASKETBALL; CHILDREN; DESIGN; TURKEY; RATES	The purpose of this study was to examine factors hindering the use of mouthguards and the incidence of orofacial injury among young male rugby players. 69 high school rugby players (Group 1) and 431 medical student rugby players (Group 2) participated in this study. Participants in Group 1 used custom-made mouthguards fabricated according to a standardized method, whereas participants in Group 2 used custom-made or over-the-counter mouthguards of their choice. The factors associated with orofacial injury were assessed by logistic regression analysis, while factors hindering mouthguard use were assessed by multinomial logistic regression analysis. All data were obtained from a questionnaire developed by the Japanese Academy of Sports Dentistry. We found that breathing problems were the main factor contributing to the reduced frequency of mouthguard use. In both groups, a significant negative association was observed between the frequency of mouthguard use and the risk of orofacial injury. The group using standardized custom-made mouthguards reported fewer complaints about breathing problems and a higher frequency of mouthguard use. The results of this study suggest that increasing the frequency of mouthguard use would reduce the risk of orofacial injury among young male rugby players. We also conclude that users of custom-made mouthguards complain less frequently of breathing difficulties.	[Tanaka, Y.; Maeda, Y.; Ando, T.; Tauchi, Y.; Miyanaga, H.] Osaka Univ, Grad Sch Dent, Dept Prosthodont Gerodontol & Oral Rehabil, Suita, Osaka 5650871, Japan; [Yang, T. -C.] Natl Taiwan Univ, Sch Dent, Dept Prosthodont, Taipei 10764, Taiwan	Tanaka, Y (reprint author), Osaka Univ, Grad Sch Dent, Dept Prosthodont Gerodontolgy & Oral Rehabil, Yamadaoka 1-8, Suita, Osaka 5650871, Japan.	yutotanaka.0106@gmail.com			Japan Society for the Promotion of Science [24792079]	The authors would like to thank all the participants and volunteers who took part in this study. The authors would like to express their gratitude to Shinsuke Matsuda for technical suggestions on fabricating mouthguards. We are also grateful to Kazutomo Yagi, Sayaka Yamasaki, Maiko Sugie, Toru Kimura, Junpei Kida, Shunta Miwa, Tohru Suganami, Noritaka Yoshino, Rikako Takashima, Kayo Fukuzaki, Kazuhiro Murakami, and Manami Abe for their help with data collection. This study was supported by a Grant-in-Aid for Scientific Research (24792079) from the Japan Society for the Promotion of Science. The authors declare no conflicts of interest with respect to the authorship and/or publication of this article. The results of the present study do not constitute endorsement by the American College of Sports Medicine.	ADA Council on Access, 2006, J AM DENT ASSOC, V137, P1712; Harriss DJ, 2013, INT J SPORTS MED, V34, P1025, DOI 10.1055/s-0033-1358756; Frontera RR, 2011, DENT TRAUMATOL, V27, P208, DOI 10.1111/j.1600-9657.2009.00781.x; Cohenca N, 2007, J AM DENT ASSOC, V138, P1121; Maeda Y, 2009, DENT TRAUMATOL, V25, P556, DOI 10.1111/j.1600-9657.2009.00822.x; Knapik JJ, 2007, SPORTS MED, V37, P117, DOI 10.2165/00007256-200737020-00003; Gebauer DP, 2011, CLIN J SPORT MED, V21, P95, DOI 10.1097/JSM.0b013e31820428b0; Biagi R, 2010, EUR J PAEDIATR DENT, V11, P66; Cetinbas T, 2006, DENT TRAUMATOL, V22, P127, DOI 10.1111/j.1600-9657.2006.00397.x; GARON MW, 1986, J AM DENT ASSOC, V112, P663; HAYRINENIMMONEN R, 1990, ENDOD DENT TRAUMATOL, V6, P208; JOHNSEN D C, 1991, Dental Clinics of North America, V35, P657; Kumamoto David, 2005, J Calif Dent Assoc, V33, P463; Kumamoto David P, 2004, Gen Dent, V52, P270; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lieger O, 2006, DENT TRAUMATOL, V22, P1, DOI 10.1111/j.1600-9657.2006.00328.x; Maeda Y, 2006, BRIT J SPORT MED, V40, P1006, DOI 10.1136/bjsm.2006.030874; Maestrello Christopher L., 1999, Pediatric Dentistry, V21, P340; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; O'Malley Margaret, 2012, J Ir Dent Assoc, V58, P205; Onyeaso CO, 2004, J NATL MED ASSOC, V96, P240; Duymus ZY, 2009, DENT TRAUMATOL, V25, P318, DOI 10.1111/j.1600-9657.2009.00769.x	22	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAR	2015	36	3					254	261		10.1055/s-0034-1390498		8	Sport Sciences	Sport Sciences	CC7TM	WOS:000350571300011		
J	Veszteg, RF; Funaki, Y; Tanaka, A				Veszteg, Robert Ferenc; Funaki, Yukihiko; Tanaka, Aiji			The impact of the Tohoku earthquake and tsunami on social capital in Japan: Trust before and after the disaster	INTERNATIONAL POLITICAL SCIENCE REVIEW			English	Article						earthquake; Japan; social capital; survey; trust; trust game	RECIPROCITY	We report empirical results related to trust and trustworthiness based on a representative web survey carried out in March 2011 in Japan. Although it initially was intended as a pilot, our survey is unique and unrepeatable because the massive Tohoku earthquake that hit Japan in spring 2011 occurred during the data-collection process and created a natural experiment. Apart from exploring changes originated by the disaster, the novelty of our approach lies in using a multipurpose questionnaire assembled by researchers with diverse interests from different academic areas that allows for exploring political and other social correlates of the economic concepts of trust and trustworthiness as measured by the game-theoretical trust game.	[Veszteg, Robert Ferenc] Waseda Univ, Expt Econ, Sch Polit Sci & Econ, Tokyo 1698050, Japan; [Funaki, Yukihiko] Waseda Univ, Econ & Game Theory, Sch Polit Sci & Econ, Tokyo 1698050, Japan; [Tanaka, Aiji] Waseda Univ, Polit Sci, Sch Polit Sci & Econ, Tokyo 1698050, Japan	Veszteg, RF (reprint author), Waseda Univ, Sch Polit Sci & Econ, Shinjuku Ku, 1-6-1 Nishiwaseda, Tokyo 1698050, Japan.	rveszteg@aoni.waseda.jp					Airo Hino, 2013, YORONCHOSA ATARASHI; Alberto Chong, 2011, TRUST TRUSTWOR UNPUB; Aldrich D. P., 2012, BUILDING RESILIENCE; Angus Campbell, 1966, REV FRANCAISE SOCIOL, V7, P579; Dohmen T, 2008, ECON INQ, V46, P84, DOI 10.1111/j.1465-7295.2007.00082.x; LaPorta R, 1997, AM ECON REV, V87, P333; Tierney K, 2006, ANN AM ACAD POLIT SS, V604, P57, DOI 10.1177/0002716205285589; Bowles S, 2002, ECON J, V112, pF419, DOI 10.1111/1468-0297.00077; Johnson ND, 2012, ECON LETT, V116, P210, DOI 10.1016/j.econlet.2012.02.010; Fafchamps M, 2006, J DEV STUD, V42, P1180, DOI 10.1080/00220380600884126; Fehr E, 2009, J EUR ECON ASSOC, V7, P235; Johnson ND, 2011, J ECON PSYCHOL, V32, P865, DOI 10.1016/j.joep.2011.05.007; Ermisch J, 2009, J R STAT SOC A STAT, V172, P749; Alesina A, 2002, J PUBLIC ECON, V85, P207, DOI 10.1016/S0047-2727(01)00084-6; Rubinstein A, 2007, ECON J, V117, P1243, DOI 10.1111/j.1468-0297.2007.02081.x; Bellemare C, 2007, EUR ECON REV, V51, P183, DOI 10.1016/j.euroecorev.2006.03.006; Zak PJ, 2001, ECON J, V111, P295, DOI 10.1111/1468-0297.00609; Bacharach M., 2001, TRUST SOC, V2, P148; Bardsley N., 2009, EXPT EC RETHINKING R; BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Bowles S, 2004, ROUNDTABLE SER BEHAV, P1; Bradley Richardson, 1984, POLITICS IN JAPAN; Camerer C., 2003, BEHAV GAME THEORY EX; Campbell A., 1960, AM VOTER; Cassar A, 2011, TRUST RISK TIME PREF; Cavallo E., 2011, INT REV ENV RESOURCE, V5, P63; Chaudhuri A., 2009, EXPT EC PLAYING FAIR; Denisa Fedakova, 2007, IMPACT NATURAL DISAS; Diamond J., 2010, NATURAL EXPT HIST; DOWNS ANTHONY, 1957, EC THEORY DEMOCRACY; Drabek T. E., 1986, HUMAN SYSTEM RESPONS; Druckman James N., 2011, CAMBRIDGE HDB EXPT P; Ellis PD, 2010, ESSENTIAL GUIDE TO EFFECT SIZES: STATISTICAL POWER, META-ANALYSIS AND THE INTERPRETATION OF RESEARCH RESULTS, P1, DOI 10.1017/CBO9780511761676; Erikson K., 1994, NEW SPECIES TROUBLE; Ernest Fehr, 2003, NATION WIDE LAB EXAM; Fischer H. W., 1998, RESPONSE DISASTER FA; Fukuyama F., 1995, TRUST SOCIAL VIRTUES; Glaeser EL, 2000, Q J ECON, V115, P811, DOI 10.1162/003355300554926; Herbert Weisberg, 1980, POLITICAL BEHAV, V2, P33; Ichiro Miyake, 1998, SEITO SHIJI KOZO; Ichiro Miyake, 1985, SEITO SHIJI BUNSEKI; John Ermisch, 2006, PEOPLES TRUST DESIGN; Joji Watanuki, 1991, THE JAPANESE VOTER; Joji Watanuki, 1967, PARTY SYSTEMS VOTER; Kenneth Arrow, 1972, PHILOS PUBLIC AFF, V1, P343; Louis De Allesi, 1975, AM ECON REV, V65, P127; Michele Belot M, 2010, WHO SHOULD BE CALLED; Monica Capra, 2008, ATTITUDINAL BEHAV ME; Nakagawa Yuko, 2004, INT J MASS EMERGENCI, V22, P5; Philip Converse, 1969, COMP POLIT STUD, V2, P139; Putnam R., 1993, AM PROSPECT, V13, P35; Ranney A., 1962, ESSAYS BEHAV STUDY P; Richard Katz, 1979, COMP POLIT, V10, P147; Richardson Bradley, 1974, POLITICAL CULTURE JA; Ron Dore, 1958, CITY LIFE JAPAN STUD; Shinbun Asahi, 2011, ASAHI SHINBUN   0429, P29; Shinbun Yomiuri, 2011, YOMIURI SHINBUN 0329, P30; Sniderman P. M., 2011, CAMBRIDGE HDB EXPT P; Sweet Stephen, 1998, INT J MASS EMERGENCI, V16, P321; Weisberg H.F., 1996, INTRO SURVEY RES POL; Wilson R. K., 2011, CAMBRIDGE HDB EXPT P; YAMAGISHI T, 1994, MOTIV EMOTION, V18, P129, DOI 10.1007/BF02249397	62	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0192-5121	1460-373X		INT POLIT SCI REV	Int. Polit. Sci. Rev.	MAR	2015	36	2					119	138		10.1177/0192512113509501		20	Political Science	Government & Law	CC4GR	WOS:000350310800001		
J	Yamano, H; Iryu, Y				Yamano, Hiroya; Iryu, Yasufumi			Carbonate sedimentation on Pacific coral reefs Preface	ISLAND ARC			English	Editorial Material									[Yamano, Hiroya] Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; [Iryu, Yasufumi] Tohoku Univ, Inst Geol & Paleontol, Grad Sch Sci, Sendai, Miyagi 9808578, Japan	Yamano, H (reprint author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	hyamano@nies.go.jp					Hongo C, 2015, ISL ARC, V24, P31, DOI 10.1111/iar.12090; Humblet M, 2015, ISL ARC, V24, P16, DOI 10.1111/iar.12077; Asami R, 2015, ISL ARC, V24, P61, DOI 10.1111/iar.12076; Fujita K, 2015, ISL ARC, V24, P47, DOI 10.1111/iar.12069; Fujita K., 2015, ISLAND ARC IN PRESS; Yamano H, 2015, ISL ARC, V24, P4, DOI 10.1111/iar.12085	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		1	3		10.1111/iar.12101		3	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200001		
J	Yamano, H; Cabioch, G; Pelletier, B; Chevillon, C; Tachikawa, H; Lefevre, J; Marchesiello, P				Yamano, Hiroya; Cabioch, Guy; Pelletier, Bernard; Chevillon, Christophe; Tachikawa, Hiroyuki; Lefevre, Jerome; Marchesiello, Patrick			Modern carbonate sedimentary facies on the outer shelf and slope around New Caledonia	ISLAND ARC			English	Article						carbonate sediment; coral reef; rimmed shelf; New Caledonia	GREAT BARRIER-REEF; SOUTHWEST PACIFIC; RYUKYU ISLANDS; SEA; ENVIRONMENTS; EASTERN; LAGOON; AUSTRALIA; ARAGONITE; TRANSPORT	We investigated surface carbonate sediments at 33 sites on the outer shelf and slope around New Caledonia (163 degrees-167 degrees E, 20 degrees-23 degrees S), at water depths of 75-720m. Four carbonate sedimentary facies are recognized on the basis of sediment size fractions and predominant constituents: Facies 1, encrusted grains (rhodoliths and macroids), bryozoa, and benthic foraminifera; Facies 2, bryozoa, benthic foraminifera, and mud; Facies 3, plankton and mud; and Facies 4, ahermatypic corals. Facies distributions were constrained primarily by water depth, and secondarily by local seafloor geomorphology that, in some areas, allows transport of sediments to deeper water. Because the dominant facies (Facies 1 and 3), as well as lagoon and basin facies, are distributed worldwide at similar latitudes, facies around New Caledonia can be considered as representative of carbonate sedimentary facies distributed in tropical-subtropical regions.	[Yamano, Hiroya] Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; [Yamano, Hiroya; Cabioch, Guy; Pelletier, Bernard; Chevillon, Christophe; Lefevre, Jerome; Marchesiello, Patrick] Inst Rech Dev, Noumea 98848, New Caledonia; [Chevillon, Christophe] Direct Environm, Noumea 98846, New Caledonia; [Tachikawa, Hiroyuki] Chiba Prefectural Museum, Chiba 2995242, Japan; [Lefevre, Jerome; Marchesiello, Patrick] Univ Toulouse, LEGOS, Toulouse, France	Yamano, H (reprint author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	hyamano@nies.go.jp	LEFEVRE, Jerome/L-8569-2015		IRD; Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad	This paper is dedicated to Guy Cabioch, who was an excellent carbonate sedimentologist. We thank the crew of the IRD R/V ALIS and Dominique Chardon for assisting with sampling during the research cruise. Angelo Di Matteo sieved the samples. Jean-Pierre Debenay and Kazuhiko Fujita contributed to the identification of larger benthic foraminifera. Comments from Editor Yasufumi Iryu and an anonymous reviewer helped improve the paper. HY thanks the IRD staff, especially Serge Andrefouet, Dominique Ponton, Jocelyne Ferraris, and Fabrice Colin, for providing excellent working conditions during his stay in New Caledonia. This research was supported mainly by IRD and in part by a Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad (to HY).	Alory G, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2005JC003401; Amante C., 2009, NGDC24 NOAA; Andrefouet S, 2006, P 10 INT COR REEF S, V2, P1732; Andrefouet S, 2009, CORAL REEFS, V28, P691, DOI 10.1007/s00338-009-0503-y; Shchepetkin AF, 2005, OCEAN MODEL, V9, P347, DOI 10.1016/j.ocemod.2004.08.002; BERGER WH, 1978, DEEP-SEA RES, V25, P447, DOI 10.1016/0146-6291(78)90552-0; Cox AT, 2001, J GEOPHYS RES-OCEANS, V106, P2313, DOI 10.1029/2001JC000301; SWIFT SA, 1977, J GEOL, V85, P301; Guillemot N, 2010, CORAL REEFS, V29, P445, DOI 10.1007/s00338-010-0587-4; Henin C, 2005, MAR FRESHWATER RES, V56, P1005, DOI 10.1071/MF04266; Balsam WL, 2003, DEEP-SEA RES PT I, V50, P1421, DOI 10.1016/j.dsr.2003.06.001; Ouillon S, 2004, CORAL REEFS, V23, P109, DOI 10.1007/s00338-003-0352-z; Schmuker B, 2002, MAR MICROPALEONTOL, V46, P387, DOI 10.1016/S0377-8398(02)00082-8; Couvelard X, 2008, J PHYS OCEANOGR, V38, P2185, DOI 10.1175/2008JPO3903.1; MARSHALL JF, 1988, CORAL REEFS, V6, P139, DOI 10.1007/BF00302010; BETZER PR, 1984, SCIENCE, V226, P1074, DOI 10.1126/science.226.4678.1074; BITOUN G., 1982, TRAVAUX DOCUMENTS OR, V147, P505; BYRNE RH, 1984, NATURE, V312, P321, DOI 10.1038/312321a0; Cabioch G, 1999, OCEANOL ACTA, V22, P567, DOI 10.1016/S0399-1784(00)88948-3; Chevillon C, 1996, CORAL REEFS, V15, P199, DOI 10.1007/BF01145892; Chevillon C., 1988, P 6 INT COR REEF S T, V3, P425; Chevillon C., 1988, P 6 COR REEF S, V2, P589; COTILLON P, 1989, OCEANOL ACTA, V12, P131; Coudray J., 1976, RECHERCHES NEOGENE Q; DEBENAY JP, 1987, J COASTAL RES, V3, P77; Flamand B, 2008, MAR GEOL, V250, P157, DOI 10.1016/j.margeo.2007.12.002; Ginsburg R.N., 1974, GEOLOGY CONTINENTAL, P137; Gischler E, 2006, FACIES, V52, P341, DOI 10.1007/s10347-005-0031-3; Guevel D., 1983, ANN HYDROGRAPHIQUES, V11, P33; Hallock P, 1987, PALEOCEANOGRAPHY, V2, P457, DOI 10.1029/PA002i005p00457; HALLOCK P, 1988, GEOLOGY, V16, P1104, DOI 10.1130/0091-7613(1988)016<1104:POTNRE>2.3.CO;2; Harris PT, 1996, MAR GEOL, V129, P313, DOI 10.1016/0025-3227(96)83350-0; IRYU Y, 1995, SEDIMENT GEOL, V99, P243, DOI 10.1016/0037-0738(95)00047-C; James N. P., 1979, SEAWARD MARGIN BELIZ; Lambert B., 1991, ENV CARBONATE BATHYA; LIU JD, 1989, MAR GEOL, V87, P207, DOI 10.1016/0025-3227(89)90062-5; Marchesiello P, 2010, MAR POLLUT BULL, V61, P432, DOI 10.1016/j.marpolbul.2010.06.043; MARSHALL J F, 1978, BMR (Bureau of Mineral Resources) Journal of Australian Geology and Geophysics, V3, P85; Matsuda S, 2011, MAR GEOL, V282, P215, DOI 10.1016/j.margeo.2011.02.013; Pelletier B., 2002, CARTOGRAPHIE SONDEUR, V16, P1; Pelletier B., 2006, RAPPORTS MISSIONS SC, V68, P1; PRAGER E J, 1989, Palaios, V4, P310, DOI 10.2307/3514555; READ JF, 1985, AAPG BULL, V69, P1; ROUX M, 1991, B SOC GEOL FR, V162, P675; SCOFFIN TP, 1985, CORAL REEFS, V4, P81, DOI 10.1007/BF00300866; TSUJI Y, 1993, MAR GEOL, V113, P255, DOI 10.1016/0025-3227(93)90021-M; Tucker M. E., 1990, CARBONATE SEDIMENTOL; Uchupi E., 1968, US GEOLOGICAL SURV C, pC1; Vanney J. R., 1991, ENV CARBONATE BATHYL, P38; Vega A., 2006, ATLAS HYDRODYNAMIQUE; Yamano H, 2002, MAR GEOL, V185, P233, DOI 10.1016/S0025-3227(02)00188-3; Yamano H, 2014, GEOMORPHOLOGY, V222, P39, DOI 10.1016/j.geomorph.2014.03.002	52	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		4	15		10.1111/iar.12085		12	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200002		
J	Humblet, M; Hongo, C; Sugihara, K				Humblet, Marc; Hongo, Chuki; Sugihara, Kaoru			An identification guide to some major Quaternary fossil reef-building coral genera (Acropora, Isopora, Montipora, and Porites)	ISLAND ARC			English	Article						Acropora; cross section; internal structure; Isopora; Montipora; Porites; quaternary corals; taxonomic identification	PAPUA-NEW-GUINEA; SEA-LEVEL RISE; NETHERLANDS-ANTILLES; HUON PENINSULA; PACIFIC; ASSEMBLAGES; RECORD; MICROSTRUCTURE; SYSTEMATICS; ATLANTIC	Fossil coral identification is essential for paleoenvironment and sea level reconstructions and in paleoecological and evolutionary studies. It follows the taxonomy of their modern analogues and therefore is based on the external skeleton macromorphology. However, for geologists examining outcrops or drill cores, identification largely relies on cross sections. The coral surface is usually obscured by encrusters or by sediments, or because corals are broken or eroded. It is therefore important to understand the relationship between the internal structure of corals and their surface morphology. We provide a comprehensive description of the internal structure of four common coral genera (Acropora, Isopora, Montipora, and Porites). This identification guide is addressed to reef geologists who wish to identify Quaternary reef corals at the generic level based on cross sections. The massive basal part of Acropora is composed of an interbranch space filled with a highly regular mesh-like network of skeletal elements parallel and perpendicular to growth direction. Corallites have conspicuous dissepiments with a ladder-like appearance in longitudinal section. Corallites of Isopora are structurally similar but they do not show the same differentiation into axial and radial corallites. Corallites are generally sinuous and the coenosteum is less regular. Montipora has smaller corallites which appear as tubes lined with spiny septa. The coenosteum is characterized by long rod-like skeletal elements parallel to growth direction projecting upward at the colony surface to form spinules or larger ornementations. These vertical rods are connected laterally by short bar-like skeletal elements. In Porites, the size of corallites is similar to Montipora but they are juxtaposed and completely filled with skeletal elements. Longitudinal cross sections display a dense network of corallites' skeletal components parallel and perpendicular to growth direction. This new taxonomic guide provides a useful reference material for those who attempt to identify reef-building corals in the fossil record.	[Humblet, Marc] Nagoya Univ, Sch Environm Studies, Dept Earth & Planetary Sci, Nagoya, Aichi 4648601, Japan; [Hongo, Chuki] Univ Ryukyus, Dept Phys & Earth Sci, Fac Sci, Nishihara, Okinawa 9030213, Japan; [Sugihara, Kaoru] Natl Inst Environm Studies, Ctr Environm Biol & Ecosyst Studies, Tsukuba, Ibaraki 3058506, Japan	Humblet, M (reprint author), Nagoya Univ, Sch Environm Studies, Dept Earth & Planetary Sci, Nagoya, Aichi 4648601, Japan.	humblet.marc@f.mbox.nagoya-u.ac.jp			JSPS Research Fellowships for Young Scientists [24.4044]	M.H. would like to express his gratitude to Professor Toru Nakamori of Tohoku University and Dr. Jody Webster of Sydney University for sharing their experience regarding the taxonomic identification of Quaternary reef corals during numerous very enjoyable discussions on the subject. Financial support for this research was awarded to C.H. by JSPS Research Fellowships for Young Scientists (24.4044).	Fukami H, 2004, NATURE, V427, P832, DOI 10.1038/nature02339; Budd AF, 2009, ACTA ZOOL-STOCKHOLM, V90, P142, DOI 10.1111/j.1463-6395.2008.00345.x; Wallace CC, 2007, CORAL REEFS, V26, P231, DOI 10.1007/s00338-007-0203-4; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Budd AF, 2011, J MORPHOL, V272, P66, DOI 10.1002/jmor.10899; Pandolfi JM, 1996, PALEOBIOLOGY, V22, P152; Cabioch G, 1999, QUATERNARY SCI REV, V18, P1681, DOI 10.1016/S0277-3791(99)00014-1; Gladfelter EH, 2007, CORAL REEFS, V26, P883, DOI 10.1007/s00338-007-0278-y; Abbey E, 2011, GLOBAL PLANET CHANGE, V76, P1, DOI 10.1016/j.gloplacha.2010.11.005; Budd AF, 2000, CORAL REEFS, V19, P25, DOI 10.1007/s003380050222; Deschamps P, 2012, NATURE, V483, P559, DOI 10.1038/nature10902; Stanley GD, 2003, EARTH-SCI REV, V60, P195, DOI 10.1016/S0012-8252(02)00104-6; SCOFFIN TP, 1992, CORAL REEFS, V11, P57, DOI 10.1007/BF00357423; Fukami H, 2000, ZOOL SCI, V17, P689, DOI 10.2108/zsj.15.689; CHAPPELL J, 1991, NATURE, V349, P147, DOI 10.1038/349147a0; BARNES DJ, 1988, J EXP MAR BIOL ECOL, V121, P37, DOI 10.1016/0022-0981(88)90022-6; Bayer F. M., 1956, TREATISE INVERTEBRAT, P1; BROMLEY RG, 1978, PALAEOGEOGR PALAEOCL, V23, P169, DOI 10.1016/0031-0182(78)90093-7; Budd AF, 2008, PALAEONTOLOGY, V51, P1387, DOI 10.1111/j.1475-4983.2008.00820.x; Cabioch G, 2003, QUATERNARY SCI REV, V22, P1771, DOI 10.1016/S0277-3791(03)00170-7; Done T.J., 1983, PERSPECTIVES CORAL R, P95; Fukami H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003222; Humblet M, 2009, MAR GEOL, V259, P1, DOI 10.1016/j.margeo.2008.12.002; Iryu Y., 2006, FIELD EXCURSION GUID, P1; Latipov Y. Y., 1998, SCLERACTINIAN CORAL; Nothdurft LD, 2007, FACIES, V53, P1, DOI 10.1007/s10347-006-0090-0; Omata T, 2006, GLOBAL PLANET CHANGE, V53, P137, DOI 10.1016/j.gloplacha.2006.01.009; Pandolfi JM, 2011, CORAL REEFS: AN ECOSYSTEM IN TRANSITION, P13, DOI 10.1007/978-94-007-0114-4_2; Pandolfi JM, 2001, ECOL MONOGR, V71, P49, DOI 10.1890/0012-9615(2001)071[0049:CSOPCR]2.0.CO;2; Priess K, 2000, MAR BIOL, V136, P19, DOI 10.1007/s002270050003; TITLYANOV EA, 1991, CORAL REEFS, V10, P133, DOI 10.1007/BF00572172; Veron J. E. N., 1977, AUSTR I MARINE SCI M, V3; Veron J. E. N., 1982, AUSTR I MARINE SCI M, V5; Veron J. E. N., 1984, AUSTR I MARINE SCI M, V6; Veron J.E.N., 2000, CORALS WORLD; Wallace CC, 1999, STAGHORN CORALS WORL; Webster JM, 2011, P INTEGR OCEAN DRILL, P325, DOI [doi: 10.2204/iodp.proc.325.2011, DOI 10.2204/IODP.PROC.325.2011]; Wells J.W., 1956, TREATISE INVERTEBR F, P328	38	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		16	30		10.1111/iar.12077		15	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200003		
J	Hongo, C; Wirrmann, D				Hongo, Chuki; Wirrmann, Denis			Preliminary identification of key coral species from New Caledonia (Southwest Pacific Ocean), their significance to reef formation, and responses to environmental change	ISLAND ARC			English	Article						barrier reef; coral reef; Holocene; key coral species; New Caledonia	GREAT-BARRIER-REEF; SEA-LEVEL CHANGES; DEVELOPMENT PATTERNS; FRINGING REEFS; SW PACIFIC; RECONSTRUCTIONS; ECOLOGY; CLIMATE; WESTERN; MODEL	The recognition of key coral species (KCS) in the geological record, i.e. those that contribute to reef formation and maintenance of coral reef ecosystems, is important for understanding the development and evolution of reef ecosystems and for forecasting their responses to climate change and anthropogenic impacts in the near future. This study examined the contribution to reef formation and maintenance of KCS from Pleistocene and Holocene barrier reefs in New Caledonia, based on analyses of six cores retrieved from three different reefs: Islets Kendec, Amedee, and Bayes. Our results indicate that at least 19 genera and 33 species of corals contributed to reef formation and maintenance during the Holocene in New Caledonia. Among them, Goniastrea retiformis, Isopora palifera, Dipsastraea pallida/speciosa complex, corymbose Acropora sp., massive Porites sp., and encrusting Porites sp. were KCS during the Holocene. This observation suggests that KCS will potentially contribute to the formation and persistence of reefs in the near future under conditions of estimated global sea-level rise of 0.2-0.6m/100 years. However, the distributions and abundances of these species are currently decreasing. This study emphasizes the need for further research on the restoration and conservation of potential KCS.	[Hongo, Chuki] Univ Ryukyus, Dept Phys & Earth Sci, Nishihara, Okinawa 9030213, Japan; [Wirrmann, Denis] IRD, France Nord, Unit Paleoproxus 182, LOCEAN,UMR 71059, F-93143 Bondy, France; [Wirrmann, Denis] Inst Pierre Simon Laplace, F-93143 Bondy, France	Hongo, C (reprint author), Univ Ryukyus, Dept Phys & Earth Sci, 1 Senbaru, Nishihara, Okinawa 9030213, Japan.	g123001@sci.u-ryukyu.ac.jp			Fukada Geological Institute; JSPS KAKENHI [24.4044]; ORSTOM/IRD; Research Unit 055 PALEOTROPIQUE; PALEOPROXUS program (LOCEAN UMR 7159, CNRS-IRD-UPMC-MNHN, France)	The authors are deeply grateful to Guy Cabioch for his invaluable work in the field and laboratory, without which we would have been unable to develop our study. We thank the IRD team at Noumea for logistical assistance and analyses of cores. This research was supported by the Fukada Geological Institute, JSPS KAKENHI (Grant-in-Aid for JSPS Fellows) Grant Number 24.4044, ORSTOM/IRD (1990-2000) and Research Unit 055 PALEOTROPIQUE (2000-2008), and the PALEOPROXUS program (LOCEAN UMR 7159, CNRS-IRD-UPMC-MNHN, France). We thank Yasufumi Iryu (Associate editor) and three anonymous reviewers for comments that significantly improved the clarity of the manuscript.	Andrefouet S, 2009, CORAL REEFS, V28, P691, DOI 10.1007/s00338-009-0503-y; Fabricius KE, 2005, MAR POLLUT BULL, V50, P125, DOI 10.1016/j.marpolbul.2004.11.028; CABIOCH G, 1995, CORAL REEFS, V14, P131, DOI 10.1007/BF00367230; Hongo C, 2012, QUATERNARY SCI REV, V35, P82, DOI 10.1016/j.quascirev.2012.01.011; PAINE RT, 1969, AM NAT, V103, P91, DOI 10.1086/282586; O'Leary MJ, 2013, NAT GEOSCI, V6, P796, DOI [10.1038/ngeo1890, 10.1038/NGEO1890]; De'ath G, 2012, P NATL ACAD SCI USA, V109, P17995, DOI 10.1073/pnas.1208909109; Thompson WG, 2003, EARTH PLANET SC LETT, V210, P365, DOI 10.1016/S0012-821X(03)00121-3; Frank N, 2006, EARTH PLANET SC LETT, V249, P274, DOI 10.1016/j.epsl.2006.07.029; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Montaggioni LF, 2011, MAR GEOL, V280, P57, DOI 10.1016/j.margeo.2010.12.001; Hongo C, 2011, MAR GEOL, V279, P162, DOI 10.1016/j.margeo.2010.10.023; Montaggioni LF, 1997, SEDIMENTOLOGY, V44, P1053; Guillemot N, 2010, CORAL REEFS, V29, P445, DOI 10.1007/s00338-010-0587-4; Cabioch G, 1999, QUATERNARY SCI REV, V18, P1681, DOI 10.1016/S0277-3791(99)00014-1; Blanchon P, 2009, NATURE, V458, P881, DOI 10.1038/nature07933; Quinn TM, 1998, PALEOCEANOGRAPHY, V13, P412, DOI 10.1029/98PA00401; Chazottes V, 2009, PALAEOGEOGR PALAEOCL, V280, P456, DOI 10.1016/j.palaeo.2009.06.033; Kopp RE, 2009, NATURE, V462, P863, DOI 10.1038/nature08686; Webster JM, 2003, SEDIMENT GEOL, V159, P61, DOI 10.1016/S0037-0738(03)00095-2; Reynolds RW, 2002, J CLIMATE, V15, P1609, DOI 10.1175/1520-0442(2002)015<1609:AIISAS>2.0.CO;2; Montaggioni LF, 2005, EARTH-SCI REV, V71, P1, DOI 10.1016/j.earscirev.2005.01.002; Meehl GA, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Budd AF, 2012, ZOOL J LINN SOC-LOND, V166, P465, DOI 10.1111/j.1096-3642.2012.00855.x; HIGHSMITH RC, 1979, J EXP MAR BIOL ECOL, V37, P105, DOI 10.1016/0022-0981(79)90089-3; BALTZER F, 1970, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V271, P2251; Burke L, 2011, REEFS RISK REVISITED; CABIOCH G, 1989, CR ACAD SCI II, V308, P419; Cabioch G, 1999, OCEANOL ACTA, V22, P567, DOI 10.1016/S0399-1784(00)88948-3; Cabioch Guy, 2011, P717, DOI 10.1007/978-90-481-2639-2_117; Cabioch G, 2008, PALAEOGEOGR PALAEOCL, V268, P91, DOI 10.1016/j.palaeo.2008.07.014; Cabioch G., 2002, SCI TERRE GEOLOGIE G, V47, P1; Cabioch G, 2003, SEDIMENT GEOL, V159, P43, DOI 10.1016/S0037-0738(03)00094-0; Cabioch G., 1995, SCI TERRE GEOLOGIE G, V33, P1; Devantier L., 2008, IUCN 2012 IUCN RED L, P2; Dickinson WR, 2013, QUATERNARY RES, V80, P125, DOI 10.1016/j.yqres.2013.04.007; Finlay H. J., 1939, Transactions and Proceedings of the Royal Society of New Zealand, V69, P89; Gomez E. D., 1985, P 5 INT COR REEF C, V6, P199; Hopley D, 2007, GEOMORPHOLOGY OF THE GREAT BARRIER REEF: DEVELOPMENT, DIVERSITY, AND CHANGE, P1, DOI 10.1017/CBO9780511535543; Korstian CF, 1924, ECOLOGY, V5, P101, DOI 10.2307/1929170; Krebs C. J., 1994, ECOLOGY; Montaggioni LF, 2009, DEV MARINE GEOL, V5, P1; Naval Hydrographic and Oceanographic Service, 2012, OUVR MAR REF ALT MAR; Remy R, 2011, QUATERNARY SCI REV, V30, P2827, DOI 10.1016/j.quascirev.2011.06.019; Richards Z., 2008, IUCN 2012 IUCN RED L, P2; SAMPSON ARTHUR W., 1939, BOT REV, V5, P155, DOI 10.1007/BF02878423; Sheppard CRC, 2009, BIO HABIT, P1, DOI 10.1093/acprof:oso/9780198566359.001.0001; Spalding M.D., 2001, WORLD ATLAS CORAL RE; Veron J.E.N., 2000, CORALS WORLD; Veron JEN, 1995, CORALS SPACE TIME; Wirrmann D, 2011, QUATERNARY RES, V76, P229, DOI 10.1016/j.yqres.2011.04.007; Woodroffe C. D., 2013, ENCY QUATERNARY SCI, V4, P409; Yamano H, 2014, GEOMORPHOLOGY, V222, P39, DOI 10.1016/j.geomorph.2014.03.002; YOUNG DD, 1980, AM BIOL TEACH, V42, P312	54	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		31	46		10.1111/iar.12090		16	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200004		
J	Fujita, K; Omori, A				Fujita, Kazuhiko; Omori, Akitoshi			Modern and Pleistocene large-sized benthic foraminifers from Tahiti, French Polynesia, collected during IODP Expedition 310	ISLAND ARC			English	Article						benthic foraminifer; depositional environment; Expedition 310; Integrated Ocean Drilling Program; Marine Isotope Stage 3; Pleistocene; Tahiti	SEA-LEVEL; ENVIRONMENTAL SIGNIFICANCE; LAST DEGLACIATION; SESOKO ISLAND; REEF; PACIFIC; CORALS; MICROBIALITES; HISTORY; SLOPES	This paper reports the fauna and distribution of large-sized benthic foraminifers (LsBFs; defined as benthic foraminifers >0.5mm in size) from surface sediments collected around Tahiti, French Polynesia, as well as from the Pleistocene deposits drilled off the Tiarei area, Tahiti, during Integrated Ocean Drilling Program (IODP) Expedition 310. At least 6 and 22 genera of living and dead tests of LsBFs, respectively, were identified from modern surface sediments. Foraminiferal abundance in surface sediments depends mainly on the water depth and substratum type. The taxonomic composition of dead LsBF assemblages varies with depositional environments and water depths. Back-reef lagoon assemblages are dominated by Schlumbergerina alveoliniformis, whereas fore-reef slope and shelf assemblages are dominated by Amphistegina spp. The relative abundance of Amphistegina lessonii decreases with increasing water depth. On the shelf, A.lessonii is replaced by Amphistegina bicirculata and Planostegina sp. Pleistocene samples consisting mainly of volcaniclastic sandstone/siltstone and skeletal grainstone contained very small numbers and low species diversity of fossil LsBFs. Amphistegina lobifera, Heterostegina depressa, and Eponides repandus were commonly found in the Pleistocene samples. The taxonomic compositions showed little variation within holes. The Pleistocene assemblages were compositionally similar to those found in modern fore-reef slope environments of <30m depth. Combined results of coral U/Th ages and paleoenvironmental interpretations from in situ corals and LsBFs indicate that the Pleistocene sequence in the Tiarei area was deposited in a fore-reef slope environment during Marine Isotope Stage 3.	[Fujita, Kazuhiko; Omori, Akitoshi] Univ Ryukyus, Dept Phys & Earth Sci, Nishihara, Okinawa 9030213, Japan	Fujita, K (reprint author), Univ Ryukyus, Dept Phys & Earth Sci, Senbaru 1, Nishihara, Okinawa 9030213, Japan.	fujitaka@sci.u-ryukyu.ac.jp			KAKENHI [18340163]; Advanced Earth Science and Technology Organization; Onshore Science Party	This research used samples and data provided by the IODP. This work was supported by a KAKENHI (18340163) and by the Advanced Earth Science and Technology Organization. We are grateful to Kaoru Sugihara and Tsutomu Yamada for collecting modern surface sediments around Tahiti, to the co-chief scientists Gilbert Camoin and Yasufumi Iryu, the staff scientist David McInroy, and all Science Party colleagues, especially Guy Cabioch, for their collaboration during the Onshore Science Party. The Bremen Core Repository team, especially Walter Hale, Ursula Rohl, and Alex Wulbers, are also acknowledged for their support during the Onshore Science Party. We thank Johann Hohenegger for his constructive suggestions on the manuscript.	Hohenegger J, 2004, J FORAMIN RES, V34, P9, DOI 10.2113/0340009; Montaggioni LF, 1997, GEOLOGY, V25, P555, DOI 10.1130/0091-7613(1997)025<0555:CRORGO>2.3.CO;2; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; Thomas AL, 2009, SCIENCE, V324, P1186, DOI 10.1126/science.1168754; Camoin GF, 2012, GEOLOGY, V40, P643, DOI 10.1130/G32057.1; VENECPEYRE MT, 1991, CORAL REEFS, V9, P193, DOI 10.1007/BF00290421; Camoin GF, 1999, SEDIMENT GEOL, V126, P271, DOI 10.1016/S0037-0738(99)00045-7; Deschamps P, 2012, NATURE, V483, P559, DOI 10.1038/nature10902; Li QY, 1996, MAR GEOL, V129, P285, DOI 10.1016/0025-3227(96)83349-4; Camoin G, 2006, SEDIMENT GEOL, V185, P277, DOI 10.1016/j.sedgeo.2005.12.018; Yordanova EK, 2002, FACIES, V46, P169, DOI 10.1007/BF02668080; Bicchi E, 2002, CORAL REEFS, V21, P275, DOI 10.1007/s00338-002-0245-6; Cabioch G, 1999, SEDIMENTOLOGY, V46, P985; Camoin G, 2007, SCI DRILLING, V5, P4, DOI DOI 10.2204/IODP.SD.5.01.2007; Camoin G. F., 2007, P INTEGRATED OCEAN D, V310; Fujita K., 2006, P 10 INT COR REEF S, P528; Fujita K, 2009, CORAL REEFS, V28, P29, DOI 10.1007/s00338-008-0441-0; Fujita K, 2010, MAR GEOL, V271, P149, DOI 10.1016/j.margeo.2010.01.019; HALLOCK P, 1986, Palaios, V1, P55, DOI 10.2307/3514459; Hohenegger Johann, 1994, Marine Ecology, V15, P291, DOI 10.1111/j.1439-0485.1994.tb00059.x; Hohenegger J, 1999, MAR MICROPALEONTOL, V36, P109, DOI 10.1016/S0377-8398(98)00030-9; Iryu Y, 2010, ISL ARC, V19, P690, DOI 10.1111/j.1440-1738.2010.00737.x; Marie P., 1940, B MUSEUM NATL HIST 2, V2, P348; Menabreaz L, 2010, EARTH PLANET SC LETT, V294, P58, DOI 10.1016/j.epsl.2010.03.002; Renema W, 2013, MAR MICROPALEONTOL, V101, P68, DOI 10.1016/j.marmicro.2013.03.002; Rivers JM, 2009, SEDIMENT GEOL, V213, P113, DOI 10.1016/j.sedgeo.2008.11.008; Salvat B., 1981, P 4 INT COR REEF S M, V2, P767; Hallock P, 1999, MODERN FORAMINIFERA, P123; Thomas AL, 2012, MAR GEOL, V295, P86, DOI 10.1016/j.margeo.2011.12.006; Venec-Peyre M. T., 1985, P 5 INT COR REEF C T, V5, P227; Venec-Peyre M. T., 1988, REV PALEOBIOL, V2, P903; VENECPEYRE MT, 1987, CORAL REEFS, V5, P205, DOI 10.1007/BF00300966	32	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		47	60		10.1111/iar.12069		14	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200005		
J	Asami, R; Konishi, M; Tanaka, K; Uemura, R; Furukawa, M; Shinjo, R				Asami, Ryuji; Konishi, Mika; Tanaka, Kentaro; Uemura, Ryu; Furukawa, Masahide; Shinjo, Ryuichi			Late Holocene coral reef environment recorded in Tridacnidae shells from archaeological sites in Okinawa-jima, subtropical southwestern Japan	ISLAND ARC			English	Article						archaeological sites; coral reef; fossil giant clams; Okinawa-jima; oxygen isotopic composition; salinity; water temperature	SURFACE-TEMPERATURE; RYUKYU ISLANDS; ASIAN MONSOON; GIANT CLAMS; NEW-GUINEA; PALEOCLIMATE RECONSTRUCTION; ISOTOPE FRACTIONATION; NORTHWEST PACIFIC; STABLE-ISOTOPES; OXYGEN	Seasonally resolved records of carbon and oxygen isotopic composition (O-18) in fossil shells of giant clams (Tridacnidae) recovered from the Kogachibaru Shell Mound (26 degrees 26N, 127 degrees 49E) and the Second Aragusuku-Shichabaru Ruin (26 degrees 18N, 127 degrees 46E) in Okinawa-jima, southwestern Japan, were investigated to reconstruct subtropical coral reef environments of the past. The samples, mainly composed of aragonite shells with limited amounts of diagenetically-altered calcite cements, were selected for geochemical analyses. The radiocarbon dating of the samples for stable isotope analyses yields about 4000yr cal. BP for the Kogachibaru Shell Mound and about 1900-1700yr cal. BP for the Second Aragusuku-Shichabaru Ruin, respectively, that correspond to the early and middle Shell Mound periods in Okinawa-jima. These show good agreement with the respective ages inferred from excavation. The shell O-18 values roughly show seasonal variations, coincident with the occurrence of annual growth bands. Applying corrections for the effect of diagenetic alteration, the averages of annual, summer, and winter O-18 values of fossil shells were significantly lower (by 0.1-0.7 parts per thousand) than those of aragonite theoretically precipitated in present-day coral reef water of Okinawa-jima. These results demonstrate that annual mean seawater temperature and salinity at the sites where the Tridacnida spp. lived were about 1-3 degrees C higher and/or about 1-2 lower than at present. This variation cannot be fully explained by global climate change, sea level change, and topographic growth of coral reef. Therefore, it is likely that the giant clams lived in extremely small and/or closed coral-reef lagoons with less water circulation where seawater is highly susceptible to insolation-induced temperature increase and input of fresh water; the effect could be enhanced by the fisheries lifestyle that stonewalling would be constructed at shallow waters through the use of tidal variation during the early and middle Shell Mound period in Okinawa-jima.	[Asami, Ryuji; Konishi, Mika; Tanaka, Kentaro; Furukawa, Masahide; Shinjo, Ryuichi] Univ Ryukyus, Dept Phys & Earth Sci, Fac Sci, Nishihara, Okinawa 9030213, Japan; [Tanaka, Kentaro] Hokkaido Univ, Grad Sch Sci, Dept Nat Hist Sci, Sapporo, Hokkaido 0600810, Japan; [Uemura, Ryu] Univ Ryukyus, Dept Chem Biol & Marine Sci, Fac Sci, Nishihara, Okinawa 9030213, Japan	Asami, R (reprint author), Univ Ryukyus, Dept Phys & Earth Sci, Fac Sci, 1 Senbaru, Nishihara, Okinawa 9030213, Japan.	asami@sci.u-ryukyu.ac.jp		Uemura, Ryu/0000-0002-4236-0085	Japan Society for the Promotion of Science [23740385]; Rising Star Program for Subtropical Island Sciences of University of the Ryukyus; International Research Hub Project for Climate Change and Coral Reef/Island Dynamics of University of the Ryukyus	We gratefully acknowledge H. Nakaza of Okinawa Prefectural Archaeological Center and C. Katagiri of Okinawa Prefectural Museum for assistance in the use of samples, Y. Nakano of the University of the Ryukyus for providing unpublished data of seawater temperature, and M. Chinen for help in sample preparation. We are grateful to the editor and two anonymous reviewers for constructive comments to improve our manuscript. We also thank H. Yamano, L. Montaggioni, and Y. Iryu for setting up the opportunity of a special issue 'Carbonate sedimentation in Pacific coral reefs' in memory of Guy Cabioch. This study was financially supported by Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (23740385 to RA), the Rising Star Program for Subtropical Island Sciences of University of the Ryukyus, and the International Research Hub Project for Climate Change and Coral Reef/Island Dynamics of University of the Ryukyus.	Abram NJ, 2001, CORAL REEFS, V20, P221; AHARON P, 1983, NATURE, V304, P720, DOI 10.1038/304720a0; AHARON P, 1991, CORAL REEFS, V10, P71, DOI 10.1007/BF00571826; Fairbanks RG, 1997, CORAL REEFS, V16, pS93, DOI 10.1007/s003380050245; Muller A, 2001, GEOPHYS RES LETT, V28, P4471, DOI 10.1029/2001GL013577; Batenburg SJ, 2011, PALAEOGEOGR PALAEOCL, V306, P75, DOI 10.1016/j.palaeo.2011.03.031; PATZOLD J, 1991, CORAL REEFS, V10, P65, DOI 10.1007/BF00571825; Partin JW, 2007, NATURE, V449, P452, DOI 10.1038/nature06164; Abe O, 2009, ISOT ENVIRON HEALT S, V45, P247, DOI 10.1080/10256010903083847; Kim ST, 2007, GEOCHIM COSMOCHIM AC, V71, P4704, DOI 10.1016/j.gca.2007.04.019; Welsh K, 2011, EARTH PLANET SC LETT, V307, P266, DOI 10.1016/j.epsl.2011.05.032; AHARON P, 1986, PALAEOGEOGR PALAEOCL, V56, P337, DOI 10.1016/0031-0182(86)90101-X; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; BONHAM K, 1965, SCIENCE, V149, P300, DOI 10.1126/science.149.3681.300; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; Reimer PJ, 2009, RADIOCARBON, V51, P1111; Elliot M, 2009, PALAEOGEOGR PALAEOCL, V280, P132, DOI 10.1016/j.palaeo.2009.06.007; Suzuki A, 2001, GEOPHYS RES LETT, V28, P3685, DOI 10.1029/2001GL013482; GROSSMAN EL, 1986, CHEM GEOL, V59, P59, DOI 10.1016/0009-2541(86)90044-6; Griffiths ML, 2010, EARTH PLANET SC LETT, V295, P30, DOI 10.1016/j.epsl.2010.03.018; Stott L, 2004, NATURE, V431, P56, DOI 10.1038/nature02903; McGregor HV, 2003, GEOCHIM COSMOCHIM AC, V67, P2147, DOI 10.1016/S0016-7037(02)01050-5; Wang YJ, 2005, SCIENCE, V308, P854, DOI 10.1126/science.1106296; Asami R, 2009, EARTH PLANET SC LETT, V288, P96, DOI 10.1016/j.epsl.2009.09.011; JONES DS, 1986, SCIENCE, V231, P46, DOI 10.1126/science.231.4733.46; Aubert A, 2009, CORAL REEFS, V28, P989, DOI 10.1007/s00338-009-0538-0; Craig H., 1965, MARINE GEOCHEMISTRY, P227; Division Cultural Assets, 1987, 84 CULT ASS DIV OK P, V84; HENOCQUE Y, 1980, B SOC ZOOL FR, V105, P309; Kawana T., 1996, B ED U RYUKYU, V48, P1; Kawana T., 2002, B FACULTY ED U RYUKY, V60, P235; Kuroda T., 1996, J GEOGR, V105, P328; Mitsuguchi T., 1998, P 3 INT MAR SCI S CO, P50; Morimoto M, 2007, QUATERNARY RES, V67, P204, DOI 10.1016/j.yqres.2006.12.005; Nakano Yoshikatsu, 1993, Galaxea, V11, P163; Nakano Yoshikatsu, 1993, Galaxea, V11, P157; Nitta J., 2003, HIST OKINAWA PREFECT, P183; Oba T., 1988, ASIAN MARINE GEOLOGY, P169; Okai T., 2004, CHIKYUKAGAKU, V38, P281; Okinawa Prefectural Archaeological Center, 2006, 35 OK PREF ARCH CTR, V35; PANNELLA G, 1968, Journal of Paleontology, V42, P64; Ramsey BC, 2009, RADIOCARBON, V51, P337; ROMANEK C S, 1989, Palaios, V4, P402, DOI 10.2307/3514585; ROSEWATER JOSEPH, 1965, INDO PACIFIC MOLLUSCA, V1, P347; Seki A, 2012, GEOCHEM J, V46, pE27; Stichler W., 1995, IAEATECDOC825, P67; Sun YB, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001061; Takamiya H., 1999, NANTO BUNKA, V18, P1; Takamiya H., 2004, GUSUKU BUNKA WO KATA, P401; Uemura R, 2012, J HYDROL, V475, P314, DOI 10.1016/j.jhydrol.2012.10.014; Watanabe T, 1999, J GEOPHYS RES-OCEANS, V104, P20667, DOI 10.1029/1999JC900097; Watanabe T, 2004, PALAEOGEOGR PALAEOCL, V212, P343, DOI 10.1016/j.palaeo.2004.07.001; Yoneda M., 2010, KAGAKU, V80, P383	53	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1038-4871	1440-1738		ISL ARC	Isl. Arc.	MAR	2015	24	1			SI		61	72		10.1111/iar.12076		12	Geosciences, Multidisciplinary	Geology	CC3YU	WOS:000350288200006		
J	Li, YJ; Gu, LJ; Han, Y; Xie, J; Wang, HL; Lv, W; Song, XJ; Li, YL; Iwamoto, A; Ishida, T; Li, TS				Li, Yijia; Gu, Lijun; Han, Yang; Xie, Jing; Wang, Huanling; Lv, Wei; Song, Xiaojing; Li, Yanling; Iwamoto, Aikichi; Ishida, Takaomi; Li, Taisheng		CACT0810 Grp	HIV-1 Subtype B/B ' and Baseline Drug Resistance Mutation Are Associated With Virologic Failure: A Multicenter Cohort Study in China	JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES			English	Article						HIV-1; subtypes; transmitted drug resistance; virologic responses; immunologic responses	ACTIVE ANTIRETROVIRAL THERAPY; NON-B SUBTYPES; IMMUNOLOGICAL RESPONSE; CRF01-AE; TYPE-1; INDIVIDUALS; TRANSMISSION; REGIMEN; IMPACT	Background:Distribution of HIV-1 subtypes, transmitted drug resistance (TDR)/drug resistance mutation (DRM), and their impact on response to combination antiretroviral therapy remain poorly understood in China.Methods:We analyzed data from our multicenter cohort study with 444 antiretroviral-naive participants recruited between 2008 and 2010. HIV-1 subtype and tropism were determined by V3 sequencing, and TDR/DRM was determined by Pol sequencing. Virologic and immunologic responses were monitored over 96 weeks of follow-up. The initial combination antiretroviral therapy regimen for all patients was nevirapine + lamivudine + zidovudine or stavudine. Analysis 1 included patients who finished 96 weeks of follow-up (n = 379), and analysis 2 included all 444 patients.Results:Subtype B/B was associated with higher prevalence of TDR/DRM to nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors. Median time to HIV-1 suppression was 18 weeks in all 3 subtype groups. In Cox proportional models for viral suppression, neither viral tropism nor HIV-1 subtypes had any impact on viral suppression; however, subtypes CRF01_AE and C/CRF07_BC/CRF08_BC were associated with lower risk of virologic failure compared with subtype B/B, with adjusted hazard ratio of 0.11 (P = 0.032) and 0.06 (P = 0.036), respectively in analysis 1, 0.42 (P = 0.047) and 0.22 (P = 0.008), respectively in analysis 2. This association was attenuated by adding DRM profiles to multivariate regression models. Neither subtype nor HIV-1 tropism affected immunologic response.Conclusions:HIV-1 subtype tended to be associated with virologic but not immunologic response; this effect could be ascribed to baseline DRM.	[Li, Yijia; Han, Yang; Xie, Jing; Wang, Huanling; Lv, Wei; Song, Xiaojing; Li, Yanling; Li, Taisheng] Beijing Union Med Coll Hosp, Dept Infect Dis, Beijing 100730, Peoples R China; [Gu, Lijun; Iwamoto, Aikichi; Ishida, Takaomi] Univ Tokyo, Inst Med Sci, Res Ctr Asian Infect Dis, Tokyo, Japan; [Gu, Lijun; Iwamoto, Aikichi; Ishida, Takaomi] Chinese Acad Sci, Japan China Joint Lab Mol Immunol & Mol Microbiol, Inst Microbiol, Beijing, Peoples R China	Li, TS (reprint author), Beijing Union Med Coll Hosp, Dept Infect Dis, Shuafuyuan 1, Beijing 100730, Peoples R China.	litsh@263.net			National Natural Science Foundation of China [81071372]; National Key Technologies R&D Program for the 12th Five-year Plan [2012ZX10001003-001]; Key Clinical Program of the Ministry of Health; Chinese Ministry of Human Resources and Social Security; Ministry of Education, Culture, Sports, Science and Technology for Program of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID)	Supported by grants from National Natural Science Foundation of China (grant 81071372), National Key Technologies R&D Program for the 12th Five-year Plan (grant 2012ZX10001003-001), and Key Clinical Program of the Ministry of Health (2010-2012) (T.L.). J.X. is currently receiving Grant of Chinese Ministry of Human Resources and Social Security (2011). A. I. is currently receiving a contract research fund from the Ministry of Education, Culture, Sports, Science and Technology for Program of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID).	Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; Scherrer AU, 2011, CLIN INFECT DIS, V53, P1143, DOI 10.1093/cid/cir669; Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914; Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68; Oyomopito RA, 2013, JAIDS-J ACQ IMM DEF, V62, P293, DOI 10.1097/QAI.0b013e31827a2e8f; Marozsan AJ, 2005, J VIROL, V79, P7121, DOI 10.1128/JVI.79.11.7121-7134.2005; Geretti AM, 2009, CLIN INFECT DIS, V48, P1296, DOI 10.1086/598502; Chaix ML, 2013, CLIN INFECT DIS, V56, P880, DOI 10.1093/cid/cis999; Wittkop L, 2011, LANCET INFECT DIS, V11, P363, DOI 10.1016/S1473-3099(11)70032-9; Abecasis AB, 2009, J VIROL, V83, P12917, DOI 10.1128/JVI.01022-09; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; Wang WH, 2008, AIDS RES HUM RETROV, V24, P1245, DOI 10.1089/aid.2008.0095; Bannister WP, 2006, ANTIVIR THER, V11, P707; Atlas A, 2005, AIDS RES HUM RETROV, V21, P221, DOI 10.1089/aid.2005.21.221; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Brenner BG, 2007, CURR OPIN HIV AIDS, V2, P94, DOI 10.1097/COH.0b013e32801682e2; Cao Y, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-301; Chen JHK, 2009, JAIDS-J ACQ IMM DEF, V51, P530, DOI 10.1097/QAI.0b013e3181aac516; Fleury HJ, 2006, AIDS RES HUM RETROV, V22, P357, DOI 10.1089/aid.2006.22.357; Frater AJ, 2002, AIDS, V16, P1139, DOI 10.1097/00002030-200205240-00007; Han XX, 2010, JAIDS-J ACQ IMM DEF, V53, pS27, DOI 10.1097/QAI.0b013e3181c7d5bf; Hartzell JD, 2007, JAIDS-J ACQ IMM DEF, V44, P411, DOI 10.1097/QAI.0b013e31802f83a6; He X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047289; Holguin A, 2006, AIDS REV, V8, P98; Kinomoto M, 2005, CLIN INFECT DIS, V41, P243, DOI 10.1086/431197; Li TS, 2014, CHINESE MED J-PEKING, V127, P59, DOI 10.3760/cma.j.issn.0366-6999.20132557; Li XS, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0089462, 10.4161/psb.29462]; Li YJ, 2014, AIDS, V28, P521, DOI 10.1097/QAD.0000000000000125; Liao LJ, 2012, CLIN INFECT DIS, V54, pS320, DOI 10.1093/cid/cir1016; Ministry of Health of People's Republic of China, 2012 CHIN AIDS RESP; Neogi U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039819; Su Bo, 2003, AIDS (Hagerstown), V17, P2515, DOI 10.1097/00002030-200311210-00015; Touloumi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071174; Wang HL, 2012, AIDS, V26, P1755, DOI 10.1097/QAD.0b013e328355ced2; Zhang Y, 2006, PLOS MED, V3, P2065, DOI 10.1371/journal.pmed.0030443	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1525-4135	1077-9450		JAIDS-J ACQ IMM DEF	JAIDS	MAR 1	2015	68	3					289	297		10.1097/QAI.0000000000000473		9	Immunology; Infectious Diseases	Immunology; Infectious Diseases	CC3JZ	WOS:000350245400013		
J	Kodaira, T; Nishimura, Y; Kagami, Y; Ito, Y; Shikama, N; Ishikura, S; Hiraoka, M				Kodaira, Takeshi; Nishimura, Yasumasa; Kagami, Yoshikazu; Ito, Yoshinori; Shikama, Naoto; Ishikura, Satoshi; Hiraoka, Masahiro			Definitive radiotherapy for head and neck squamous cell carcinoma: update and perspectives on the basis of EBM	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Review						intensity modulated radiotherapy; chemoradiotherapy; altered fractionated radiotherapy	INTENSITY-MODULATED RADIOTHERAPY; LOCALLY ADVANCED HEAD; QUALITY-OF-LIFE; PHASE-III TRIAL; STAGE NASOPHARYNGEAL CARCINOMA; PROSPECTIVE CLINICAL-TRIAL; ADVANCED LARYNGEAL-CANCER; RADIATION-THERAPY; INDUCTION CHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS	Radiotherapy plays an essential role in the management of head and neck squamous cell carcinoma. Radiotherapy has a distinct advantage over surgical procedures in that it could achieve organ and function preservation with an efficacy similar to that of surgical series. To improve the clinical outcomes achievable by radiotherapy, altered fractionated radiotherapy has been prospectively tested for early and intermediate risk diseases, and was previously shown to be beneficial for local control and survival. Radiotherapy alone is insufficient for locally advanced disease; therefore, concurrent chemoradiotherapy is typically performed and plays an important role. A meta-analysis (Level Ia) revealed that the concurrent use of platinum agents appeared to improve tumor control and survival; however, this was accompanied by increases in the rates of both acute and late toxicities. Regarding radiation techniques, intensity modulated radiotherapy evolved in the 1990s, and has been globally used to treat head and neck squamous cell carcinoma patients. Intensity modulated radiotherapy reduces the exposure of normal tissue to radiation while preserving excellent dose coverage to the target volume; therefore, the rate of late toxicities especially xerostomia is minimized. Small size randomized studies and a meta-analysis have provided evidence to support the benefits of intensity modulated radiotherapy over two-dimensional or three-dimensional radiation therapy. Intensity modulated radiotherapy can also preserve quality of life following definitive chemoradiotherapy. Further improvements using intensity modulated proton therapy are warranted.	[Kodaira, Takeshi] Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan; [Nishimura, Yasumasa] Kinki Univ, Dept Radiat Oncol, Fac Med, Osaka, Japan; [Kagami, Yoshikazu] Showa Univ, Sch Med, Dept Radiol, Tokyo 142, Japan; [Ito, Yoshinori] Natl Canc Ctr, Dept Radiat Oncol, Tokyo, Japan; [Shikama, Naoto] Saitama Med Univ, Dept Radiat Oncol, Int Med Ctr, Saitama, Japan; [Ishikura, Satoshi] Koshigaya Municipal Hosp, Dept Radiol, Saitama, Japan; [Hiraoka, Masahiro] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan	Kodaira, T (reprint author), Aichi Canc Ctr Hosp, Dept Radiat Oncol, Nagoya, Aichi, Japan.	109103@aichi-cc.jp			Ministry of Health, Labor and Welfare of Japan [20S-5, 20S-6, 17-17, 16-12, 17S-5 H21-018, H23-009, H24-007, H26-090]; National Cancer Center Research and Development Funds [23-A-16, 23-A-21, 26-A-4]	The work was partially supported by Health Sciences Research Grants for a Grant-in-Aid for Cancer Research (20S-5, 20S-6, 17-17, 16-12, 17S-5 H21-018, H23-009, H24-007, H26-090) from the Ministry of Health, Labor and Welfare of Japan and the National Cancer Center Research and Development Funds (23-A-16, 23-A-21 and 26-A-4).	Al-Mamgani A, 2013, RADIOTHER ONCOL, V106, P69, DOI 10.1016/j.radonc.2012.12.006; Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633; Klein J, 2014, ORAL ONCOL, V50, P254, DOI 10.1016/j.oraloncology.2014.01.015; Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054; Rainsbury JW, 2013, HEAD NECK-J SCI SPEC, V35, P1048, DOI 10.1002/hed.22950; Lefebvre JL, 2013, J CLIN ONCOL, V31, P853, DOI 10.1200/JCO.2012.42.3988; Vergeer MR, 2009, INT J RADIAT ONCOL, V74, P1, DOI 10.1016/j.ijrobp.2008.07.059; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Marta GN, 2014, RADIOTHER ONCOL, V110, P9, DOI 10.1016/j.radonc.2013.11.010; Fakhry C, 2008, J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; FEIN DA, 1993, INT J RADIAT ONCOL, V25, P605; Ang KK, 2010, ONCOLOGIST, V15, P25, DOI 10.1634/theoncologist.2010-S3-25; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Blanchard P, 2013, J CLIN ONCOL, V31, P2854, DOI 10.1200/JCO.2012.47.7802; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Resto VA, 2008, HEAD NECK-J SCI SPEC, V30, P222, DOI 10.1002/hed.20681; Hayakawa K, 1996, LARYNGOSCOPE, V106, P1545, DOI 10.1097/00005537-199612000-00020; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Graff P, 2007, INT J RADIAT ONCOL, V67, P1309, DOI 10.1016/j.ijrobp.2006.11.012; Moon SH, 2014, RADIOTHER ONCOL, V110, P98, DOI 10.1016/j.radonc.2013.09.016; Hitt R, 2014, ANN ONCOL, V25, P216, DOI 10.1093/annonc/mdt461; Gupta T, 2012, RADIOTHER ONCOL, V104, P343, DOI 10.1016/j.radonc.2012.07.001; Mendenhall WM, 2001, J CLIN ONCOL, V19, P4029; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Garden AS, 2013, INT J RADIAT ONCOL, V85, P941, DOI 10.1016/j.ijrobp.2012.08.004; Machtay M, 2008, J CLIN ONCOL, V26, P3582, DOI 10.1200/JCO.2007.14.8841; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Nishimura Y, 1996, RADIOTHER ONCOL, V40, P225, DOI 10.1016/0167-8140(96)01796-3; Denaro N, 2014, RADIOTHER ONCOL, V110, P16, DOI 10.1016/j.radonc.2013.08.016; Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4; WITHERS HR, 1988, ACTA ONCOL, V27, P131; Ramaekers BLT, 2011, CANCER TREAT REV, V37, P185, DOI 10.1016/j.ctrv.2010.08.004; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Cellai E, 2005, INT J RADIAT ONCOL, V63, P1378, DOI 10.1016/j.ijrobp.2005.05.018; Eisbruch A, 2010, INT J RADIAT ONCOL, V76, P1333, DOI 10.1016/j.ijrobp.2009.04.011; van der Laan HP, 2013, ACTA ONCOL, V52, P561, DOI 10.3109/0284186X.2012.692885; Levendag PC, 2007, RADIOTHER ONCOL, V85, P64, DOI 10.1016/j.radonc.2007.07.009; Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097; Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013; Tribius S, 2011, CANCER TREAT REV, V37, P511, DOI 10.1016/j.ctrv.2011.01.004; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; van de Water TA, 2011, ONCOLOGIST, V16, P366, DOI 10.1634/theoncologist.2010-0171; Huang K, 2008, CANCER-AM CANCER SOC, V113, P497, DOI 10.1002/cncr.23578; Caglar HB, 2008, INT J RADIAT ONCOL, V72, P1110, DOI 10.1016/j.ijrobp.2008.02.048; Roe JWG, 2010, ORAL ONCOL, V46, P727, DOI 10.1016/j.oraloncology.2010.07.012; Masterson L, 2014, EUR J CANCER, V50, P2636, DOI 10.1016/j.ejca.2014.07.001; Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; O'Rorke MA, 2012, ORAL ONCOL, V48, P1191, DOI 10.1016/j.oraloncology.2012.06.019; Chao KSC, 2001, RADIOTHER ONCOL, V61, P275, DOI 10.1016/S0167-8140(01)00449-2; van der Voet JCM, 1998, INT J RADIAT ONCOL, V42, P247, DOI 10.1016/S0360-3016(98)00226-0; Trotti A, 2014, INT J RADIAT ONCOL, V89, P958, DOI 10.1016/j.ijrobp.2014.04.041; Paccagnella A, 2010, ANN ONCOL, V21, P1515, DOI 10.1093/annonc/mdp573; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Caudell JJ, 2009, INT J RADIAT ONCOL, V73, P410, DOI 10.1016/j.ijrobp.2008.04.048; Richard JM, 1998, ORAL ONCOL, V34, P224, DOI 10.1016/S1368-8375(97)00090-0; Yamazaki H, 2006, INT J RADIAT ONCOL, V64, P77, DOI 10.1016/j.ijrobp.2005.06.014; Schwartz DL, 2013, RADIOTHER ONCOL, V106, P80, DOI 10.1016/j.radonc.2012.10.010; Haddad R, 2013, LANCET ONCOL, V14, P257, DOI 10.1016/S1470-2045(13)70011-1; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bratengeier K, 2007, RADIOTHER ONCOL, V84, P298, DOI 10.1016/j.radonc.2007.06.018; Chen JQ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-15; Fang FM, 2010, RADIOTHER ONCOL, V97, P263, DOI 10.1016/j.radonc.2010.05.022; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Huang TL, 2010, QUAL LIFE RES, V19, P1243, DOI 10.1007/s11136-010-9688-3; Inoue T., 1995, Strahlentherapie und Onkologie, V171, P475; Kunieda F, 2014, JPN J CLIN ONCOL, V44, P770, DOI 10.1093/jjco/hyu067; Nakamura K, 2008, JPN J CLIN ONCOL, V38, P387, DOI 10.1093/jjco/hyn025; Nichols AC, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-133; Nishimura Y, 2010, JPN J CLIN ONCOL, V40, P130, DOI 10.1093/jjco/hyp136; Petrelli F, 2014, ORAL ONCOL, V50, P1041, DOI 10.1016/j.oraloncology.2014.08.005; Prades JM, 2010, ACTA OTO-LARYNGOL, V130, P150, DOI 10.3109/00016480902914080; ROBERTSON AG, 1993, EUR J CANCER, V29A, P501, DOI 10.1016/S0959-8049(05)80139-X; RUDOLTZ MS, 1993, INT J RADIAT ONCOL, V26, P767; Sanders IW, 2014, SCOT MED J, V59, P50, DOI 10.1177/0036933013518153; Scott-Brown M, 2010, RADIOTHER ONCOL, V97, P249, DOI 10.1016/j.radonc.2010.08.004; WOLF GT, 1991, NEW ENGL J MED, V324, P1685; Tribius S, 2013, DTSCH ARZTEBLATT INT, V110, P184; Wu QW, 2003, INT J RADIAT ONCOL, V56, P573, DOI 10.1016/S0360-3016(02)04617-5; Yang HH, 2013, INT J RADIAT ONCOL, V85, pE47, DOI 10.1016/j.ijrobp.2012.09.033; Yeung AR, 2012, HEAD NECK-J SCI SPEC, V34, P613, DOI 10.1002/hed.21993	82	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					235	243		10.1093/jjco/hyu209		9	Oncology	Oncology	CC3DR	WOS:000350225700001		
J	Yoshizaki, T; Kondo, S; Murono, S; Endo, K; Tsuji, A; Nakanishi, Y; Nakanishi, S; Sugimoto, H; Hatano, M; Ueno, T; Wakisaka, N				Yoshizaki, Tomokazu; Kondo, Satoru; Murono, Shigeyuki; Endo, Kazuhira; Tsuji, Akira; Nakanishi, Yosuke; Nakanishi, Sayaka; Sugimoto, Hisashi; Hatano, Miyako; Ueno, Takayoshi; Wakisaka, Naohiro			Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Review						head and neck; radiation oncology; H & N-RadOncol; nasopharyngeal carcinoma	EPSTEIN-BARR-VIRUS; COMPARING NEOADJUVANT CHEMOTHERAPY; CONCURRENT CISPLATIN-RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIALS; ADJUVANT CHEMOTHERAPY; ALTERNATING CHEMORADIOTHERAPY; ADVANCED HEAD; STAGE-III; PHASE-III	Since the publication of Intergroup Study 0099, representing a superiority of concurrent chemoradiotherapy with cisplatin followed by adjuvant chemotherapy to radiotherapy alone for the treatment of locoregionally advanced nasopharyngeal carcinoma, an efficacy of concurrent setting of cisplatin-based chemotherapy with radiotherapy has been repeatedly validated. In meanwhile, the role of adjuvant part of the protocol has been controversial. There is an increasing evidence for the positive role of neoadjuvant chemotherapy with following concurrent chemoradiotherapy whereas favorable contribution was not proven in the last century. This article reviews the role of chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.	[Yoshizaki, Tomokazu; Kondo, Satoru; Murono, Shigeyuki; Endo, Kazuhira; Tsuji, Akira; Nakanishi, Yosuke; Nakanishi, Sayaka; Sugimoto, Hisashi; Hatano, Miyako; Ueno, Takayoshi; Wakisaka, Naohiro] Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, Kanazawa, Ishikawa 9208640, Japan	Yoshizaki, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Div Otolaryngol Head & Neck Surg, Kanazawa, Ishikawa 9208640, Japan.	tomoy@med.kanazawa-u.ac.jp			JSPS KAKENHI [26293367, 24689064]	This work was supported by JSPS KAKENHI Grant Number 26293367, 24689064.	Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Leung SF, 2003, CANCER, V98, P288, DOI 10.1002/cncr.11496; Ang KK, 2004, J CLIN ONCOL, V22, P4657, DOI 10.1200/JCO.2004.07.962; Chi KH, 2002, INT J RADIAT ONCOL, V52, P1238, DOI 10.1016/S0360-3016(01)02781-X; Hareyama M, 2002, CANCER, V94, P2217, DOI 10.1002/cncr.10473; Kong L, 2013, CANCER-AM CANCER SOC, V119, P4111, DOI 10.1002/cncr.28324; Yoshizaki T, 2012, AURIS NASUS LARYNX, V39, P137, DOI 10.1016/j.anl.2011.02.012; Chan ATC, 2005, J NATL CANCER I, V97, P536, DOI 10.1093/jnci/dji084; Yeo W, 1998, EUR J CANCER, V34, P2027, DOI 10.1016/S0959-8049(98)00280-9; Loong HH, 2012, RADIOTHER ONCOL, V104, P300, DOI 10.1016/j.radonc.2011.12.022; Liang ZG, 2013, ASIAN PAC J CANCER P, V14, P515, DOI 10.7314/APJCP.2013.14.1.515; Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310; Chan ATC, 2002, J NATL CANCER I, V94, P1614; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; Ma J, 2001, J CLIN ONCOL, V19, P1350; Huguenin P, 2004, J CLIN ONCOL, V22, P4665, DOI 10.1200/JCO.2004.12.193; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Lee AWM, 2010, J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Yoshizaki T, 2013, CANCER LETT, V337, P1, DOI 10.1016/j.canlet.2013.05.018; Chen L, 2012, LANCET ONCOL, V13, P163, DOI 10.1016/S1470-2045(11)70320-5; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Chow E, 2002, RADIOTHER ONCOL, V63, P269, DOI 10.1016/S0167-8140(02)00132-9; Chua DTT, 2002, INT J RADIAT ONCOL, V53, P334, DOI 10.1016/S0360-3016(02)02710-4; Dogan S, 2014, HEAD NECK-J SCI SPEC, V36, P511, DOI 10.1002/hed.23318; Fareed MM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-318; Fuwa N, 2001, JPN J CLIN ONCOL, V31, P589, DOI 10.1093/jjco/hye135; Goto Y, 2013, J RADIAT RES, V54, P98, DOI 10.1093/jrr/rrs071; Hong RL, 2004, CANCER, V100, P1429, DOI 10.1002/cncr.20129; Isobe K, 2003, JPN J CLIN ONCOL, V33, P497, DOI 10.1093/jjco/hyg094; Kondo S, 2004, CANCER SCI, V95, P508, DOI 10.1111/j.1349-7006.2004.tb03241.x; Liang ZG, 2012, ASIAN PAC J CANCER P, V13, P5747, DOI 10.7314/APJCP.2012.13.11.5747; Niu XS, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-226; Tan EH, 1999, INT J RADIAT ONCOL, V45, P597, DOI 10.1016/S0360-3016(99)00210-2; Ueno T, 2014, ANN OTO RHINOL LARYN, V123, P509, DOI 10.1177/0003489414525122; Yoshizaki Tomokazu, 2005, P171	36	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					244	247		10.1093/jjco/hyu212		4	Oncology	Oncology	CC3DR	WOS:000350225700002		
J	Harada, A; Sasaki, R; Miyawaki, D; Yoshida, K; Nishimura, H; Ejima, Y; Kitajima, K; Saito, M; Otsuki, N; Nibu, KI				Harada, Aya; Sasaki, Ryohei; Miyawaki, Daisuke; Yoshida, Kenji; Nishimura, Hideki; Ejima, Yasuo; Kitajima, Kazuhiro; Saito, Miki; Otsuki, Naoki; Nibu, Ken-Ichi			Treatment outcomes of the patients with early glottic cancer treated with initial radiotherapy and salvaged by conservative surgery	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						glottic cancer; radiotherapy; salvage therapy; organ preservation	SQUAMOUS-CELL CARCINOMA; SUPRACRICOID PARTIAL LARYNGECTOMY; RADIATION-THERAPY; LOCAL-CONTROL; ANTERIOR COMMISSURE; DEFINITIVE RADIOTHERAPY; NEOPLASTIC INVASION; PROGNOSTIC-FACTORS; VOICE QUALITY; FRACTION SIZE	Objective: This retrospective study analyzed the oncological and treatment outcomes of the patients with T1-T2N0 glottic cancer, who were treated with radiotherapy as initial treatment and salvaged by conservative surgery for radiation failure. Methods: Between May 1999 and December 2010, 115 patients with glottic laryngeal cancer were treated at Kobe University Hospital. At presentation, 54 patients had stage T1a disease, 26 had stage T1b disease and 35 had stage T2 disease. Seventy-nine patients were treated with conventional radiotherapy and 36 patients were treated with hyperfractionated radiotherapy as initial treatment. Results: Median duration of follow-up was 61 months. Five-year local control rates of radiotherapy were 92% in T1a, 83% in T1b and 86% in T2. Of 12 patients who developed local recurrence, larynx was successfully preserved in 3 patients by laryngomicrosurgery, 7 patients by vertical partial laryngectomy and one patient by subtotal laryngectomy. Ultimate 5-year laryngeal preservation rate and local control rate of all cases were 99 and 100%, respectively. Conclusions: Present results suggest that initial treatment with radiotherapy salvaged by organ preservation surgery is an effective strategy for laryngeal preservation in the treatment of T1-T2N0 glottic laryngeal cancer.	[Harada, Aya; Sasaki, Ryohei; Miyawaki, Daisuke; Yoshida, Kenji; Nishimura, Hideki; Ejima, Yasuo] Kobe Univ, Grad Sch Med, Div Radiat Oncol, Kobe, Hyogo 6500017, Japan; [Kitajima, Kazuhiro] Kobe Univ, Grad Sch Med, Dept Radiol, Kobe, Hyogo 6500017, Japan; [Saito, Miki; Otsuki, Naoki; Nibu, Ken-Ichi] Kobe Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kobe, Hyogo 6500017, Japan	Sasaki, R (reprint author), Kobe Univ, Grad Sch Med, Div Radiat Oncol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	rsasaki@med.kobe-u.ac.jp		Ejima, Yasuo/0000-0002-1533-7891			Colasanto JM, 2004, CANCER J, V10, P61, DOI 10.1097/00130404-200401000-00012; Garden AS, 2003, INT J RADIAT ONCOL, V55, P322, DOI 10.1016/S0360-3016(02)03938-X; Marshak G, 1999, INT J RADIAT ONCOL, V43, P1009, DOI 10.1016/S0360-3016(98)00547-1; Le QTX, 1997, INT J RADIAT ONCOL, V39, P115, DOI 10.1016/S0360-3016(97)00284-8; FEIN DA, 1993, INT J RADIAT ONCOL, V25, P605; Chen MF, 2003, ANN OTO RHINOL LARYN, V112, P904; Laccourreye O, 1997, AM J OTOLARYNG, V18, P385, DOI 10.1016/S0196-0709(97)90058-2; Krengli M, 2004, ACTA ONCOL, V43, P284, DOI 10.1080/02841860410026233; Mendenhall WM, 2001, J CLIN ONCOL, V19, P4029; Nozaki M, 2000, ANTICANCER RES, V20, P1121; Jin J, 2002, INT J RADIAT ONCOL, V54, P471, DOI 10.1016/S0360-3016(02)02920-6; Toma M, 2002, ARCH OTOLARYNGOL, V128, P909; Mendenhall WM, 2004, CANCER, V100, P1786, DOI 10.1002/cncr.20181; Zouhair A, 2004, STRAHLENTHER ONKOL, V180, P84, DOI 10.1007/s00066-004-1164-y; Tateya I, 2006, EUR ARCH OTO-RHINO-L, V263, P144, DOI 10.1007/s00405-005-0978-2; Cellai E, 2005, INT J RADIAT ONCOL, V63, P1378, DOI 10.1016/j.ijrobp.2005.05.018; Rifai M, 2000, AM J OTOLARYNG, V21, P294, DOI 10.1053/ajot.2000.16159; Becker M, 2000, EUR J RADIOL, V33, P216, DOI 10.1016/S0720-048X(99)00144-8; Becker M, 2008, RADIOLOGY, V249, P551, DOI 10.1148/radiol.2492072183; Bron L, 2000, LARYNGOSCOPE, V110, P627, DOI 10.1097/00005537-200004000-00017; Bradley PJ, 2006, EUR ARCH OTO-RHINO-L, V263, P879, DOI 10.1007/s00405-006-0138-3; Yamazaki H, 2006, INT J RADIAT ONCOL, V64, P77, DOI 10.1016/j.ijrobp.2005.06.014; Back Gary, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P85, DOI 10.1097/01.moo.0000156168.63204.70; BENNINGER MS, 1994, LARYNGOSCOPE, V104, P294; BILLER HF, 1970, LARYNGOSCOPE, V80, P249, DOI 10.1288/00005537-197002000-00009; Chera BS, 1998, INT J RADIAT ONCOL, V78, P461; Fernandes R, 2006, J LARYNGOL OTOL, V120, P857, DOI 10.1017/S0022215106001939; HOWELLBURKE D, 1990, ARCH OTOLARYNGOL, V116, P830; Lesnicar H, 1996, INT J RADIAT ONCOL, V36, P1025, DOI 10.1016/S0360-3016(96)00423-3; Lohynska R, 2005, NEOPLASMA, V52, P483; Maheshwar AA, 2001, J LARYNGOL OTOL, V115, P298; MCGUIRT WF, 1994, ARCH OTOLARYNGOL, V120, P951; Medini E, 1998, AM J CLIN ONCOL-CANC, V21, P302, DOI 10.1097/00000421-199806000-00021; Murakami R, 2000, AM J NEURORADIOL, V21, P1320; Nur Demiral Ayse, 2005, Tumori, V91, P182; PARSONS JT, 1993, HEAD NECK-J SCI SPEC, V15, P87, DOI 10.1002/hed.2880150202; Reddy SP, 2007, INT J RADIAT ONCOL, V69, P1389, DOI 10.1016/j.ijrobp.2007.05.077; Reddy SP, 1998, RADIOTHER ONCOL, V47, P161; SHAHA AR, 1982, AM J SURG, V144, P456, DOI 10.1016/0002-9610(82)90422-6; Thariat J, 2004, Cancer Radiother, V8, P288, DOI 10.1016/S1278-3218(04)00088-5; TONVAN J, 1991, AM J SURG, V162, P337, DOI 10.1016/0002-9610(91)90143-2; Wang CC, 1987, COMPREHENSIVE MANAGE, P906	42	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					248	255		10.1093/jjco/hyu203		8	Oncology	Oncology	CC3DR	WOS:000350225700003		
J	Tokito, T; Murakami, H; Mori, K; Osaka, I; Takahashi, T				Tokito, Takaaki; Murakami, Haruyasu; Mori, Keita; Osaka, Iwao; Takahashi, Toshiaki			Implementation status and explanatory analysis of early advance care planning for Stage IV non-small cell lung cancer patients	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						advance care planning; lung cancer; do-not-attempt-resuscitation; prognosis; supportive care	RANDOMIZED CONTROLLED-TRIAL; OF-LIFE DISCUSSIONS; PALLIATIVE CARE; END; PROGNOSIS; INFORMATION; TALKING; VIDEO; WANT	Objective: The American Society of Clinical Oncology published the goals of individualized care including advance care planning for advanced cancer patients in 2011. However, no data are available on the implementation status of advance care planning. Methods: We retrospectively reviewed the electronic medical records and informed consent forms of consecutive Stage IV non-small cell lung cancer patients treated with chemotherapy between January 2010 and December 2012 at our institution. Two outcomes were defined to investigate the advance care planning implementation status: C-D, the duration from the last day of chemotherapy to death and D-D, that from the day of confirmed do-not-attempt-resuscitation order to death. Results: The study included 136 eligible patients. The advance care planning implementation status in participating patients was as follows: 96 (70%) patients received information on 'incurable disease before first-line chemotherapy', 69 (50%) were informed about 'supportive care before first-line chemotherapy', whereas 43 (32%) learned about their prognosis. The do-not-attempt-resuscitation decision was reflected in 29 patients' will (21%). The median C-D was 64 days. Receipt of <= 2 chemotherapy regimens and provision of prognosis information to patients were significantly associated with long C-D in multivariate analysis. The median D-D was 25 days. Provision of information on supportive care before first-line chemotherapy and provision of prognosis information to patients were significantly associated with long D-D in multivariate analysis. Conclusions: Our results suggest that there is possible benefit from providing information on supportive care before first-line chemotherapy and informing patients about their prognosis in prolonging the duration of supportive care.	[Tokito, Takaaki; Osaka, Iwao] Shizuoka Canc Ctr, Div Palliat Med, Nagaizumi, Shizuoka, Japan; [Tokito, Takaaki] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka 8300011, Japan; [Murakami, Haruyasu; Takahashi, Toshiaki] Shizuoka Canc Ctr, Div Thorac Oncol, Nagaizumi, Shizuoka, Japan; [Mori, Keita] Shizuoka Canc Ctr, Clin Trial Coordinat Off, Nagaizumi, Shizuoka, Japan	Tokito, T (reprint author), Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	tokitou_takaaki@kurume-u.ac.jp					Temel JS, 2013, J CLIN ONCOL, V31, P710, DOI 10.1200/JCO.2012.43.2203; Mack JW, 2012, J CLIN ONCOL, V30, P2715, DOI 10.1200/JCO.2012.42.4564; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Lo B, 1999, ANN INTERN MED, V130, P744; Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744; El-Jawahri A, 2010, J CLIN ONCOL, V28, P305, DOI 10.1200/JCO.2009.24.7502; Temel JS, 2011, J CLIN ONCOL, V29, P2319, DOI 10.1200/JCO.2010.32.4459; van Vliet LM, 2013, J CLIN ONCOL, V31, P3242, DOI 10.1200/JCO.2012.45.5865; Back AL, 2006, J CLIN ONCOL, V24, P4209, DOI 10.1200/JCO2006.06.007; Singer PA, 1996, CAN MED ASSOC J, V155, P1689; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Stein RA, 2013, J CLIN ONCOL, V31, P3403, DOI 10.1200/JCO.2011.40.8872; Mack JW, 2012, ANN INTERN MED, V156, P204, DOI 10.7326/0003-4819-156-3-201202070-00008; Back AL, 2009, MASTERING COMMUNICAT; Back AL, 2006, J CLIN ONCOL, V24, P4214, DOI 10.1200/JCO.2006.06.008; Detering KM, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1345; Fu SQ, 2012, J CLIN ONCOL, V30, P2891, DOI 10.1200/JCO.2011.38.0758; Greer JA, 2011, J CLIN ONCOL, V30, P394; Kizawa Y, 2013, AM J HOSP PALLIAT ME, V30, P664, DOI 10.1177/1049909112462860; National Comprehensive Cancer Network, 2014, PRACT GUID ONC PALL; National Consensus Project for Quality Palliative Care, 2013, CLIN PRACT GUID QUAL	21	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					261	266		10.1093/jjco/hyu207		6	Oncology	Oncology	CC3DR	WOS:000350225700005		
J	Kondo, T; Nakazawa, H; Oya, M; Kimura, G; Fujii, Y; Hatano, T; Kawata, N; Kume, H; Morita, M; Nakajima, K; Ohno, Y; Okegawa, T; Takahashi, S; Wakumoto, Y; Horie, S				Kondo, Tsunenori; Nakazawa, Hayakazu; Oya, Mototsugu; Kimura, Go; Fujii, Yasuhisa; Hatano, Takashi; Kawata, Nozomu; Kume, Haruki; Morita, Masashi; Nakajima, Koichi; Ohno, Yoshio; Okegawa, Takatsugu; Takahashi, Shunji; Wakumoto, Yoshiaki; Horie, Shigeo			Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						carcinoma; renal cell; sorafenib; prognosis; neoplasm; metastasis; real-world practice	RANDOMIZED PHASE-3 TRIAL; EXPANDED-ACCESS; SURVIVAL; SAFETY; TOLERABILITY; CYTOKINE; AXITINIB; THERAPY	Objective: Result of clinical trial for registration purpose is often difficult to generalize because of its limited population in number and inclusion criteria. Methods: To understand the efficacy of sorafenib under daily medical practice, we retrospectively investigated therapeutic outcomes of 175 Japanese patients with advanced renal cell carcinoma treated with sorafenib at 15 centers. Results: The objective response rate and disease control rate were 15.4 and 77.1%, respectively, being similar to those in the Phase II study in Japanese patients (19.4 and 73.6 months). Any tumor shrinkage was observed with 53% of patients, while tumor control without growth was in 61%. Lung lesions were more sensitive to sorafenib than other lesions, in terms of any tumor shrinkage (54%) and the extent of maximal shrinkage, while tumor control was better in lymph node metastases (77%) than in lung (69%). Liver was worse in any tumor shrinkage (35%), tumor control (55%) and the extent of tumor growth. Slightly, shorter median overall survival of 21.1 months compared with Phase II clinical trial (25.3 months) is likely to be attributable to different patient population, because median overall survival was improved to 26.4 months when the population was matched to that in Phase II trial. Univariate and multivariate analyses identified prognostic factors for worse overall survival, including intermediate and poor Memorial Sloan-Kettering Cancer Center risk, Eastern Cooperative Oncology Group performance status >= 1, the presence of non-clear cell component and the presence of liver metastasis. Conclusions: In conclusion, the present study confirmed the efficacy of sorafenib in the real-world setting on advanced renal cell carcinoma.	[Kondo, Tsunenori] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan; [Nakazawa, Hayakazu] TokyoWomens Med Univ, Dept Urol, Med Ctr East, Tokyo, Japan; [Oya, Mototsugu] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan; [Kimura, Go] Nippon Med Sch, Dept Urol, Tokyo 113, Japan; [Fujii, Yasuhisa] Tokyo Med & Dent Univ, Dept Urol, Grad Sch, Tokyo, Japan; [Hatano, Takashi] JR Tokyo Gen Hosp, Dept Urol, Tokyo, Japan; [Kawata, Nozomu] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Kume, Haruki] Univ Tokyo, Dept Urol, Tokyo, Japan; [Morita, Masashi] Showa Univ, Dept Urol, Koto Toyosu Hosp, Tokyo, Japan; [Nakajima, Koichi] Toho Univ, Dept Urol, Sch Med, Tokyo, Japan; [Ohno, Yoshio] Tokyo Med Univ, Dept Urol, Tokyo 1608402, Japan; [Okegawa, Takatsugu] Kyorin Univ, Dept Urol, Tokyo, Japan; [Takahashi, Shunji] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan; [Wakumoto, Yoshiaki; Horie, Shigeo] Juntendo Univ, Grad Sch Med, Dept Urol, Tokyo, Japan	Kondo, T (reprint author), 8-1 Kawada Cho,Shinjuku Ku, Tokyo 1628666, Japan.	tkondo@kc.twmu.ac.jp					Akaza Hideyuki, 2006, Int J Clin Oncol, V11, P434, DOI 10.1007/s10147-006-0596-z; Molina AM, 2008, CLIN GENITOURIN CANC, V6, pS7, DOI 10.3816/CGC.2008.s.002; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Procopio G, 2013, BRIT J CANCER, V108, P311, DOI 10.1038/bjc.2012.543; Fossa SD, 2000, SEMIN ONCOL, V27, P187; Drucker BJ, 2005, CANCER TREAT REV, V31, P536, DOI 10.1016/j.ctrv.2005.07.009; Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7; Stadler WM, 2010, CANCER-AM CANCER SOC, V116, P1272, DOI 10.1002/cncr.24864; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Akaza H, 2007, JPN J CLIN ONCOL, V37, P755, DOI 10.1093/jjco/hym095; Marumo K, 2007, INT J UROL, V14, P479, DOI 10.1111/j.1442-2042.2007.01739.x; Naito S, 2011, BJU INT, V108, P1813, DOI 10.1111/j.1464-410X.2011.10281.x; Beck J, 2011, ANN ONCOL, V22, P1812, DOI 10.1093/annonc/mdq651; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342; Bellmunt J, 2010, BJU INT, V107, P1190; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Kawashima A, 2011, EUR J CANCER, V47, P1521, DOI 10.1016/j.ejca.2011.04.001; Ueda T, 2010, INT J UROL, V17, P811, DOI 10.1111/j.1442-2042.2010.02604.x	20	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					274	280		10.1093/jjco/hyu200		7	Oncology	Oncology	CC3DR	WOS:000350225700007		
J	Kakutani, S; Fukuhara, H; Taguchi, S; Nagata, M; Niimi, A; Hattori, M; Miyazaki, H; Fujimura, T; Nakagawa, T; Kume, H; Igawa, Y; Homma, Y				Kakutani, Shigenori; Fukuhara, Hiroshi; Taguchi, Satoru; Nagata, Masayoshi; Niimi, Aya; Hattori, Mami; Miyazaki, Hideyo; Fujimura, Tetsuya; Nakagawa, Tohru; Kume, Haruki; Igawa, Yasuhiko; Homma, Yukio			Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						bladder cancer; urothelial carcinoma; metastatic urothelial carcinoma; salvage chemotherapy	TRANSITIONAL-CELL CARCINOMA; LONG-TERM-SURVIVAL; PHASE-II; PROGNOSTIC-FACTORS; PLUS CISPLATIN; BLADDER-CANCER; GEMCITABINE; THERAPY; MULTICENTER; METHOTREXATE	Objective: The aim of this study was to evaluate the efficacy and toxicity of the combination of docetaxel, ifosfamide and cisplatin as salvage chemotherapy after failure of standard cisplatin-based regimens for metastatic urothelial carcinoma. Methods: We prospectively administered docetaxel, ifosfamide and cisplatin chemotherapy to patients with metastatic urothelial carcinoma refractory to standard cisplatin-based regimens from 2003 to 2013. Patients who had received only adjuvant and/or neoadjuvant chemotherapy were excluded. Eligible patients received every 28 days docetaxel 60 mg/m(2) on Day 1, ifosfamide 1.0 g/m(2) on Days 2-6 and cisplatin 20 mg/m(2) on Days 2-6. The primary endpoints were progression-free survival and overall survival, calculated from the start of docetaxel, ifosfamide and cisplatin chemotherapy. Secondary endpoints included objective response and related toxicity. Results: Twenty-six cases received a median of 3.0 cycles of docetaxel, ifosfamide and cisplatin chemotherapy (interquartile range: 2-5), resulting in a median progression-free survival of 3 months (interquartile range: 2-9.5 months) and median overall survival of 8.5 months (interquartile range: 6.5-18.75 months), respectively. Of 26 patients, seven (27%) achieved major treatment responses, with one complete response (4%) and six partial responses (23%). Most of Grade 3/4 toxicities were hematologic events, including leukopenia (77%), anemia (54%) and thrombocytopenia (46%). No death from toxicity was observed. Conclusions: Our results indicate that docetaxel, ifosfamide and cisplatin chemotherapy is a tolerable and moderately active regimen for metastatic urothelial carcinoma after failure of standard cisplatin-based regimens.	[Kakutani, Shigenori; Fukuhara, Hiroshi; Taguchi, Satoru; Nagata, Masayoshi; Niimi, Aya; Hattori, Mami; Miyazaki, Hideyo; Fujimura, Tetsuya; Nakagawa, Tohru; Kume, Haruki; Igawa, Yasuhiko; Homma, Yukio] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo 1138655, Japan	Kume, H (reprint author), Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	KUMEH-URO@h.u-tokyo.ac.jp					Krege S, 2001, J UROLOGY, V165, P67, DOI 10.1097/00005392-200101000-00017; Yafi FA, 2011, CURR ONCOL, V18, pE25; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Sternberg CN, 2001, CANCER, V92, P2993, DOI 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2; Matsuda A, 2014, JPN J CLIN ONCOL, V44, P388, DOI 10.1093/jjco/hyu003; de Wit R, 1998, BRIT J CANCER, V78, P1342, DOI 10.1038/bjc.1998.681; Sonpavde G, 2010, LANCET ONCOL, V11, P861, DOI 10.1016/S1470-2045(10)70086-3; Kitamura H, 2011, CANCER SCI, V102, P1171, DOI 10.1111/j.1349-7006.2011.01909.x; von der Maase H, 2000, J CLIN ONCOL, V18, P3068; Bajorin DF, 1999, J CLIN ONCOL, V17, P3173; Sengelov L, 1998, J CLIN ONCOL, V16, P3392; Dimopoulos MA, 1998, UROLOGY, V52, P56, DOI 10.1016/S0090-4295(98)00150-2; Takahashi S, 2005, JPN J CLIN ONCOL, V35, P79, DOI 10.1093/jjco/hyi023; [Anonymous], 2014, NCCN GUID VERS 1 201; Sonpavde G, 2013, EUR UROL, V63, P717, DOI 10.1016/j.eururo.2012.11.042; del Muro XG, 2002, BRIT J CANCER, V86, P326, DOI 10.1038/sj/bjc/6600121; Dimopoulos MA, 1999, ANN ONCOL, V10, P1385, DOI 10.1023/A:1008379500436; Ferlay J, 2013, IARC CANC BASE; Lerner SP, 2011, CAMPBELL WALSH UROLO, P2370; National Cancer Institute, 1999, COMM TOX CRIT VERS 2; Pagliaro LC, 2002, J CLIN ONCOL, V20, P2965, DOI 10.1200/JCO.2002.11.114; Suyama T, 2009, JPN J CLIN ONCOL, V39, P244, DOI 10.1093/jjco/hyp003; Taguchi S, 2013, JPN J CLIN ONCOL, V43, P923, DOI 10.1093/jjco/hyt096; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Witjes JA, 2014, EAU GUIDELINE, V12, P64	26	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					281	285		10.1093/jjco/hyu201		5	Oncology	Oncology	CC3DR	WOS:000350225700008		
J	Takada, S; Hoshino, Y; Ito, H; Masugi, Y; Terauchi, T; Endo, K; Kimata, M; Furukawa, J; Shinozaki, H; Kobayashi, K; Ogata, Y				Takada, Satoshi; Hoshino, Yoshinori; Ito, Homare; Masugi, Yohei; Terauchi, Toshiaki; Endo, Kazuhiro; Kimata, Masaru; Furukawa, Junji; Shinozaki, Hiroharu; Kobayashi, Kenji; Ogata, Yoshiro			Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						bevacizumab; intestinal perforation; necrosis; metastatic colorectal cancer; 5-fluorouracil	CELL LUNG-CANCER; COLORECTAL-CANCER; PERFORATION; COMPLICATIONS; FLUOROURACIL; LEUCOVORIN; MECHANISMS; THERAPY; TRIAL	Recently, bevacizumab has become a key drug for treatment of metastatic colorectal cancer. Molecularly targeted agents such as bevacizumab can cause life-threatening adverse effects, though they are generally considered less toxic than cytotoxic drugs. Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy. Microscopic findings revealed extensive mucosal necrosis in the resected colon specimen and necrosis at the muscularis propria of the descending colon. Pathological findings suggested that the mucosal damage induced by chemotherapy may be exacerbated by treatment with bevacizumab, resulting in extensive necrosis.	[Takada, Satoshi; Hoshino, Yoshinori; Terauchi, Toshiaki; Endo, Kazuhiro; Kimata, Masaru; Furukawa, Junji; Shinozaki, Hiroharu; Kobayashi, Kenji; Ogata, Yoshiro] Saiseikai Utsunomiya Hosp, Dept Surg, Utsunomiya, Tochigi, Japan; [Hoshino, Yoshinori] Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Utsunomiya, Tochigi 3210974, Japan; [Ito, Homare] Jichi Med Univ, Dept Surg, Shimotsuke, Japan; [Masugi, Yohei] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Utsunomiya, Tochigi 3210974, Japan	Hoshino, Y (reprint author), Keio Univ, Sch Med, Dept Surg, Saiseikai Utsunomiya Hosp, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan.	ymailbiz@gmail.com					Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356; Pavlidis ET, 2013, WORLD J GASTROENTERO, V19, P5051, DOI 10.3748/wjg.v19.i31.5051; Gray J, 2007, J THORAC ONCOL, V2, P571, DOI 10.1097/JTO.0b013e31805fea51; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Schellhaas E, 2009, INVEST NEW DRUG, V27, P184, DOI 10.1007/s10637-008-9162-z; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Saif MW, 2007, ANN SURG ONCOL, V14, P1860, DOI 10.1245/s10434-006-9337-9; August DA, 2008, J SURG ONCOL, V97, P180, DOI 10.1002/jso.20938; Borzomati Domenico, 2013, Updates Surg, V65, P121, DOI 10.1007/s13304-013-0207-2; Hapani S, 2009, LANCET ONCOL, V10, P559; Heinzerling John H, 2006, Curr Surg, V63, P334, DOI 10.1016/j.cursur.2006.06.002; Kamba T, 2006, AM J PHYSIOL-HEART C, V290, P560; Keefe DM, 2007, CURR OPIN ONCOL, V19, P323, DOI 10.1097/CCO.0b013e3281214412; Lecarpentier E, 2011, INVEST NEW DRUG, V29, P1500, DOI 10.1007/s10637-010-9505-4; Liu SV, 2012, J CLIN PHARM THER, V37, P607, DOI 10.1111/j.1365-2710.2012.01343.x; Lordick F, 2006, INT J RADIAT ONCOL, V64, P1295, DOI 10.1016/j.ijrobp.2005.12.004; MILLES SS, 1962, GASTROENTEROLOGY, V43, P391; Neufeld G, 2001, Surg Oncol Clin N Am, V10, P339; Walraven M, 2011, ANGIOGENESIS, V14, P135, DOI 10.1007/s10456-010-9197-6; Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2	21	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					286	290		10.1093/jjco/hyu206		5	Oncology	Oncology	CC3DR	WOS:000350225700009		
J	Sagawa, M; Kobayashi, T; Uotani, C; Kibe, Y; Tanaka, M; Machida, Y; Motono, N; Maeda, S; Usuda, K				Sagawa, Motoyasu; Kobayashi, Takeshi; Uotani, Chika; Kibe, Yoshinori; Tanaka, Makoto; Machida, Yuichiro; Motono, Nozomu; Maeda, Sumiko; Usuda, Katsuo			A survey about further work-up for cases with positive sputum cytology during lung cancer mass screening in Ishikawa Prefecture, Japan: a retrospective analysis about quality assurance of lung cancer screening	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						cancer screening; sputum cytology; further work-up; quality assurance; bronchoscopic examination	EFFICACY; PROGRAM	Objective: In cancer screening programs, performing appropriate further work-up is essential. In order to elucidate whether the further work-up for the subjects with positive screening results by sputum cytology was performed appropriately, the present study was conducted as the first large-scale thorough survey in Japan. Methods: All of the lung cancer screening records from 2007 to 2012 in Ishikawa Prefecture were reviewed. Additional investigations about the further work-up were performed. Results: In total, 2 234 984 people were invited to undergo lung cancer screening, and 494 424 people participated in the screening. Of these, 25 264 people underwent sputum cytology, and 68 positive cases were identified. Three of these 68 cases did not undergo further work-up, and another three cases had already been diagnosed to have lung cancer. Forty-five of the remaining 62 cases did not have suspicious chest shadows, and bronchoscopic examinations were performed in 36 cases. Seventeen of these 36 cases were diagnosed as having cancer, whereas none of the nine cases who did not receive the examination was diagnosed (P = 0.038). A bronchoscopic examination was not performed due to other medical conditions in three cases, due to the patient's refusal in another three cases and in the remaining three cases, the reasons were unknown. Conclusion: The participation rate for further work-up was very high. However, there are some issues to be resolved regarding the transmission of information. With our new registered hospital system, the quality assurance of our screening program will be improved.	[Sagawa, Motoyasu; Tanaka, Makoto; Machida, Yuichiro; Motono, Nozomu; Maeda, Sumiko; Usuda, Katsuo] Kanazawa Med Univ, Dept Thorac Surg, Uchinada, Ishikawa 9200293, Japan; [Sagawa, Motoyasu; Kobayashi, Takeshi; Uotani, Chika] Prefectural Comm Management Canc Screening Syst, Lung Canc Screening Div Ishikawa, Kanazawa, Ishikawa, Japan; [Kobayashi, Takeshi] Ishikawa Med Ctr Canc & Cardiovasc Dis, Kanazawa, Ishikawa, Japan; [Uotani, Chika; Kibe, Yoshinori] Ishikawa Hlth Serv Assoc, Kanazawa, Ishikawa, Japan; [Uotani, Chika] Kanazawa Med Assoc, Kanazawa, Ishikawa, Japan	Sagawa, M (reprint author), Kanazawa Med Univ, Dept Thorac Surg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	sagawam@kanazawa-med.ac.jp			Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology; National Cancer Center Research and Development Fund, Japan	This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology and a Grant-in-Aid from the National Cancer Center Research and Development Fund, Japan.	Sagawa M, 2003, LUNG CANCER-J IASLC, V41, P29, DOI 10.1016/S0169-5002(03)00197-1; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; Doria-Rose VP, 2009, CANCER-AM CANCER SOC, V115, P5007, DOI 10.1002/cncr.24545; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; NAKADA T, 1987, TOHOKU J EXP MED, V152, P173, DOI 10.1620/tjem.152.173; Nakayama T, 2002, EUR J CANCER, V38, P1380, DOI 10.1016/S0959-8049(02)00083-7; Nishii K, 2001, LUNG CANCER-J IASLC, V34, P325, DOI 10.1016/S0169-5002(01)00270-7; Okamoto T, 1999, LUNG CANCER, V25, P77; SACCOMAN.G, 1965, ACTA CYTOL, V9, P413; Sagawa M, 2009, LUNG CANCER, V63, P291, DOI 10.1016/j.lungcan.2008.05.012; Sagawa M, 2003, ANTICANCER RES, V23, P597; Sagawa M, 2001, CANCER, V92, P588, DOI 10.1002/1097-0142(20010801)92:3<588::AID-CNCR1358>3.0.CO;2-8; SOBUE T, 1992, INT J CANCER, V50, P230, DOI 10.1002/ijc.2910500212; Tockman MS, 1985, LUNG CANCER CONT ISS, V3, P25; Tsukada H, 2001, BRIT J CANCER, V85, P1326, DOI 10.1054/bjoc.2001.2060	15	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					297	302		10.1093/jjco/hyu214		6	Oncology	Oncology	CC3DR	WOS:000350225700011		
J	Koizumi, W; Morita, S; Sakata, Y				Koizumi, Wasaburo; Morita, Satoshi; Sakata, Yuh			A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						gastric cancer; nab-paclitaxel; Phase III; second-line chemotherapy; weekly	NANOPARTICLE FORMULATION; 2ND-LINE CHEMOTHERAPY; SUPPORTIVE CARE; ABI-007; PLUS	Paclitaxel is an agent widely used in second-line chemotherapy for advanced gastric cancer. The aim of this trial is to evaluate the efficacy and safety of 3-weekly or weekly doses of nanoparticle albumin-bound-paclitaxel compared with weekly doses of Cremophor-based paclitaxel in patients with unresectable or recurrent gastric cancer refractory to first-line chemotherapy comprising fluoropyrimidines. A total of 730 patients will be enrolled from 72 institutions. The primary endpoint is the overall survival, and the secondary endpoints are progression-free survival, time to treatment failure, overall response rate, disease control rate, quality of life (by using the EQ-5D system) and safety.	[Koizumi, Wasaburo] Kitasato Univ, Sch Med, Dept Gastroenterol, Sagamihara, Kanagawa 2288520, Japan; [Morita, Satoshi] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Kyoto, Japan; [Sakata, Yuh] Misawa City Hosp, Misawa, Aomori, Japan	Koizumi, W (reprint author), Kitasato Univ, Sch Med, Dept Gastroenterol, 2-1-1 Asamizodai, Sagamihara, Kanagawa 2288520, Japan.	koizumi@med.kitasato-u.ac.jp			Taiho Pharmaceutical Co., Ltd.	This study is sponsored by Taiho Pharmaceutical Co., Ltd. Funding to pay the Open Access publication charges for this article was provided by Taiho Pharmaceutical Co., Ltd.	Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI [10.1016/S1470-2045(08)70035-4, 10.1016/S1470-204S(08)70035-4]; Ibrahim NK, 2002, CLIN CANCER RES, V8, P1038; Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1; Sasaki Y, 2014, CANCER SCI, V105, P812, DOI 10.1111/cas.12419; GOEDDE HW, 1992, HUM GENET, V88, P344; Nyman DW, 2005, J CLIN ONCOL, V23, P7785, DOI 10.1200/JCO.2004.00.6148; Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7; Kang JH, 2012, J CLIN ONCOL, V30, P1513, DOI 10.1200/JCO.2011.39.4585; Thuss-Patience PC, 2011, EUR J CANCER, V47, P2306, DOI 10.1016/j.ejca.2011.06.002; Center for Cancer Control and Information Services National Cancer Center, 2014, CANC STAT JAP 2013; Hironaka S, 2014, J CLIN ONCOL, V31, P4438; Hironaka Shuichi, 2006, Gastric Cancer, V9, P14, DOI 10.1007/s10120-005-0351-6; International Agency for Research on Cancer, 2014, GLOBOCAN 2008 CANC I; Takiuchi H, 2010, J CLIN ONCOL S, V28, p15S	14	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					303	306		10.1093/jjco/hyu205		4	Oncology	Oncology	CC3DR	WOS:000350225700012		
J	Tanakaya, K; Furukawa, Y; Nakamura, Y; Hirata, K; Tomita, N; Tamura, K; Sugano, K; Ishioka, C; Yoshida, T; Ishida, H; Watanabe, T; Sugihara, K				Tanakaya, Kohji; Furukawa, Yoichi; Nakamura, Yusuke; Hirata, Keiji; Tomita, Naohiro; Tamura, Kazuo; Sugano, Kokichi; Ishioka, Chikashi; Yoshida, Teruhiko; Ishida, Hideyuki; Watanabe, Toshiaki; Sugihara, Kenichi		Japanese Soc Canc Colon Rectum	Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						Lynch syndrome; smoking; colorectal cancer; multiple cancer; male	RISK; MORTALITY	The positive correlation between smoking and cancer risk is well estimated in sporadic colorectal cancer, whereas little is known with regard to Lynch syndrome-associated colorectal cancer. A total of 118 familial colorectal cancer patients from the Hereditary Nonpolyposis Colorectal Cancer Registry and Genetic Testing Project of the Japanese Society for Cancer of the Colon and Rectum, were assessed to determine whether smoking alters the incidence of multiple colorectal cancers. In male patients with Lynch syndrome (n = 29), the incidence of multiple colorectal cancers in patients who had ever smoked (smoking duration: median of 19 years) was higher than that in those who never smoked (58.8% vs. 10.0%, P = 0.02). The cumulative risk for metachronous colorectal cancer was significantly higher in male Lynch syndrome patients who had previously smoked than in those who had never smoked (P = 0.03). Our data suggest that long-term cigarette smoking might be a strong risk factor for the development of multiple colorectal cancers in male Lynch syndrome patients.	[Tanakaya, Kohji] Iwakuni Clin Ctr, Dept Surg, Iwakuni, Japan; [Furukawa, Yoichi] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Genome Res, Tokyo, Japan; [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med, Tokyo, Japan; [Hirata, Keiji] Univ Occupat & Environm Hlth, Dept Surg 1, Kitakyushu, Fukuoka 807, Japan; [Tomita, Naohiro] Hyogo Med Univ, Dept Surg, Nishinomiya, Hyogo 663, Japan; [Tamura, Kazuo] Kinki Univ, Grad Sch Sci & Engn Res, Sci, Higashiosaka, Osaka 577, Japan; [Sugano, Kokichi] Tochigi Canc Ctr, Canc Prevent Unit, Oncogene Res Unit, Utsunomiya, Tochigi, Japan; [Ishioka, Chikashi] Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan; [Yoshida, Teruhiko] Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; [Ishida, Hideyuki] Saitama Med Univ, Saitama Med Ctr, Dept Digest Tract & Gen Surg, Kawagoe, Saitama 3508550, Japan; [Watanabe, Toshiaki] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan; [Sugihara, Kenichi] Tokyo Med & Dent Univ, Dept Surg Oncol, Grad Sch, Tokyo, Japan	Ishida, H (reprint author), Saitama Med Univ, Saitama Med Ctr, Dept Digest Tract & Gen Surg, Kawagoe, Saitama 3508550, Japan.	05hishi@saitama-med.ac.jp			Ministry of Health, Labor and Welfare; Japanese Society for Cancer of the Colon and Rectum	The present study was supported in part by a grant-in-aid for Cancer Research from the Ministry of Health, Labor and Welfare, and by the Japanese Society for Cancer of the Colon and Rectum.	BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684; Katanoda K, 2013, JPN J CLIN ONCOL, V43, P492, DOI 10.1093/jjco/hyt038; Pande M, 2010, CLIN CANCER RES, V16, P1331, DOI 10.1158/1078-0432.CCR-09-1877; Warthin AS, 1913, ARCH INTERN MED, V12, P546; Hannan LM, 2009, CANCER EPIDEM BIOMAR, V18, P3362, DOI 10.1158/1055-9965.EPI-09-0661; Otani T, 2003, CANCER EPIDEM BIOMAR, V12, P1492; Parry S, 2011, GUT, V60, P950, DOI 10.1136/gut.2010.228056; Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356; Brand RM, 2006, WORLD J GASTROENTERO, V12, P4485; Diergaarde B, 2007, CLIN GASTROENTEROL H, V5, P736, DOI 10.1016/j.cgh.2007.02.019; Okayama A, 2007, ASIAN PAC J CANCER P, V8, P191; Lynch HT, 2003, NEW ENGL J MED, V348, P919; van Duijnhoven FJB, 2013, FAM CANCER, V12, P285, DOI 10.1007/s10689-013-9645-8	13	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					307	310		10.1093/jjco/hyu218		4	Oncology	Oncology	CC3DR	WOS:000350225700013		
J	Nishiwaki, S				Nishiwaki, Satoshi			Pros and cons of legislation on allogeneic hematopoietic stem cell transplantation	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Letter							BLOOD		[Nishiwaki, Satoshi] Minist Hlth Labour & Welf, Hlth Serv Bur, Off Transplantat Med, Tokyo 1008916, Japan	Nishiwaki, S (reprint author), Minist Hlth Labour & Welf, Hlth Serv Bur, Off Transplantat Med, Chiyoda Ku, 1-2-2 Kasumigaseki, Tokyo 1008916, Japan.	n-3104@tf7.so-net.ne.jp					Weinberg PD, 2002, ANN INTERN MED, V136, P312; [Anonymous], 2012, ACT APPROPRIATE PROV; [Anonymous], 2005, TRANSFUSION MED REV, V19, P66; Rene R, 2012, HEMOVIGILANCE EFFECT, DOI [10.1002/9781118338179, DOI 10.1002/9781118338179]	4	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAR	2015	45	3					311	312		10.1093/jjco/hyu225		2	Oncology	Oncology	CC3DR	WOS:000350225700014		
J	Du, YH; Matsuzawa, H; Zhou, ML				Du, Yihong; Matsuzawa, Hiroshi; Zhou, Maolin			Spreading speed and profile for nonlinear Stefan problems in high space dimensions	JOURNAL DE MATHEMATIQUES PURES ET APPLIQUEES			English	Article						Nonlinear Stefan problem; Spreading speed; Logarithmic shift	FREE-BOUNDARY; DIFFUSION EQUATION; MODEL	We consider nonlinear diffusion problems of the form u(t) = Delta u + f(u) with Stefan type free boundary conditions, where the nonlinear term f(u) is of monostable, bistable or combustion type. Such problems are used as an alternative model (to the corresponding Cauchy problem) to describe the spreading of a biological or chemical species, where the free boundary represents the expanding front. We are interested in its long-time spreading behavior which, by recent results of Du, Matano and Wang [10], is largely determined by radially symmetric solutions. Therefore we will examine the radially symmetric case, where the equation is satisfied in vertical bar x vertical bar < h(t), with vertical bar x vertical bar = h(t) the free boundary. We assume that spreading happens, namely lim(t ->infinity) h(t) = infinity, lim(t ->infinity) u(t, vertical bar x vertical bar) = 1. For the case of one space dimension (N = 1), Du and Lou [8] proved that lim(t ->infinity) h(t)/t = c* for some c* > 0. Subsequently, sharper estimate of the spreading speed was obtained by the authors of the current paper in [11], in the form that lim(t ->infinity) [h(t) - c*t] = (H) over cap is an element of R-1. In this paper, we consider the case N >= 2 and show that a logarithmic shifting occurs, namely there exists c(*) > 0 independent of N such that lim(t ->infinity) [h(t) - c*t + (N - 1)c(*) log t] = (h) over cap is an element of R-1. At the same time, we also obtain a rather clear description of the spreading profile of u(t,r). These results reveal striking differences from the spreading behavior modeled by the corresponding Cauchy problem. (C) 2014 Elsevier Masson SAS. All rights reserved.	[Du, Yihong] Univ New England, Sch Sci & Technol, Armidale, NSW 2351, Australia; [Matsuzawa, Hiroshi] Numazu Natl Coll Technol, Numazu, Shizuoka 4108501, Japan; [Zhou, Maolin] Univ Tokyo, Grad Sch Math Sci, Tokyo 1538914, Japan	Du, YH (reprint author), Univ New England, Sch Sci & Technol, Armidale, NSW 2351, Australia.	ydu@turing.une.edu.au; hmatsu@numazu-ct.ac.jp; zhouml@ms.u-tokyo.ac.jp			Australian Research Council [DP120100727]; Institute of National Colleges of Technology Japan Overseas Research Scholars Program; JSPS [23740137]	Y. Du was supported by the Australian Research Council (DP120100727), and H. Matsuzawa was supported by the Institute of National Colleges of Technology Japan Overseas Research Scholars Program and by JSPS Grants-in-Aid for Young Scientists (B) (No. 23740137).	Du YH, 2011, J DIFFER EQUATIONS, V250, P4336, DOI 10.1016/j.jde.2011.02.011; Du YH, 2014, ARCH RATION MECH AN, V212, P957, DOI 10.1007/s00205-013-0710-0; ARONSON DG, 1978, ADV MATH, V30, P33, DOI 10.1016/0001-8708(78)90130-5; Weinberger HF, 2002, J MATH BIOL, V45, P511, DOI 10.1007/s00285-002-0169-3; FIFE PC, 1977, ARCH RATION MECH AN, V65, P335; Du YH, 2010, SIAM J MATH ANAL, V42, P377, DOI 10.1137/090771089; Bunting G, 2012, NETW HETEROG MEDIA, V7, P583, DOI 10.3934/nhm.2012.7.583; Hamel F, 2013, NETW HETEROG MEDIA, V8, P275, DOI 10.3934/nhm.2013.8.275; GARTNER J, 1982, MATH NACHR, V105, P317, DOI 10.1002/mana.19821050117; Du YH, 2014, SIAM J MATH ANAL, V46, P375, DOI 10.1137/130908063; Du YH, 2012, J DIFFER EQUATIONS, V253, P996, DOI 10.1016/j.jde.2012.04.014; Aronson D G, 1975, LECT NOTES MATH, V446, P5; BRAMSON M, 1983, MEM AM MATH SOC, V44, P1; Du Y., J EUR MATH IN PRESS; Du Y., PREPRINT; Ducrot A., 2014, T AM MATH S IN PRESS; Fisher R A, 1937, ANN EUGEN, V7, P335; Friedman A., 1964, PARABOLIC DIFFERENTI; JONES CKRT, 1983, J DIFFER EQUATIONS, V49, P142, DOI 10.1016/0022-0396(83)90023-2; Kanel Ja.I., 1964, MAT SBORNIK, V65, P398; Kolmogorov A N, 1937, B MGU A, V1, P1; Ladyzenskaja O. A., 1968, LINEAR QUASILINEAR E; LAU KS, 1985, J DIFFER EQUATIONS, V59, P44, DOI 10.1016/0022-0396(85)90137-8; Lieberman G. M., 1996, 2 ORDER PARABOLIC DI; Uchiyama K, 1978, J MATH KYOTO U, V18, P453; Uchiyama K., 1983, ARCH RATIONAL MECH A, V90, P291	26	2	2	GAUTHIER-VILLARS/EDITIONS ELSEVIER	PARIS	23 RUE LINOIS, 75015 PARIS, FRANCE	0021-7824	1776-3371		J MATH PURE APPL	J. Math. Pures Appl.	MAR	2015	103	3					741	787		10.1016/j.matpur.2014.07.008		47	Mathematics, Applied; Mathematics	Mathematics	CC7DZ	WOS:000350529200004		
J	Morimoto, Y; Wang, S; Yang, T				Morimoto, Yoshinori; Wang, Shuaikun; Yang, Tong			A new characterization and global regularity of infinite energy solutions to the homogeneous Boltzmann equation	JOURNAL DE MATHEMATIQUES PURES ET APPLIQUEES			English	Article						Boltzmann equation; Infinite energy solution; Maxwellian molecule; Smoothing effect	GAS	The purpose of this paper is to introduce a new characterization of the characteristic functions for the study on the measure valued solution to the homogeneous Boltzmann equation so that it precisely captures the moment constraint in physics. This significantly improves the previous result by Cannone and Karch (2010) [2] in the sense that the new characterization gives a complete description of infinite energy solutions for the Maxwellian cross section. In addition, the global in time smoothing effect of the infinite energy solution is justified as for the finite energy solution except for a single Dirac mass initial datum. (C) 2014 Elsevier Masson SAS. All rights reserved.	[Morimoto, Yoshinori] Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan; [Wang, Shuaikun; Yang, Tong] City Univ Hong Kong, Dept Math, Hong Kong, Hong Kong, Peoples R China	Yang, T (reprint author), City Univ Hong Kong, Dept Math, Hong Kong, Hong Kong, Peoples R China.	morimoto@math.h.kyoto-u.ac.jp; shuaiwang4-c@my.cityu.edu.hk; matyang@cityu.edu.hk			Japan Society of the Promotion of Science [25400160]; General Research Fund of Hong Kong, CityU [104511]; Shanghai Jiao Tong University	The research of the first author was supported in part by Grant-in-Aid for Scientific Research No. 25400160, Japan Society of the Promotion of Science. The research of the third author was supported in part by the General Research Fund of Hong Kong, CityU No. 104511, and the Shanghai Jiao Tong University.	Cannone M, 2010, COMMUN PUR APPL MATH, V63, P747; Alexandre R, 2000, ARCH RATION MECH AN, V152, P327, DOI 10.1007/s002050000083; Villani C, 1998, ARCH RATION MECH AN, V143, P273, DOI 10.1007/s002050050106; Morimoto Y, 2009, DISCRETE CONT DYN S, V24, P187, DOI 10.3934/dcds.2009.24.187; Toscani G, 1999, J STAT PHYS, V94, P619, DOI 10.1023/A:1004589506756; Morimoto Y, 2012, KINET RELAT MOD, V5, P551, DOI 10.3934/krm.2012.5.551; Carlen EA, 1999, COMMUN MATH PHYS, V199, P521, DOI 10.1007/s002200050511; Gabetta E., 1995, J STAT PHYS, V81, P901; Morimoto Y., 2014, ANN I H POINCARE ANA; Villani C, 2003, GRADUATE STUDIES MAT, V58; Villani C, 2002, HDB MATH FLUID DYNAM	11	0	0	GAUTHIER-VILLARS/EDITIONS ELSEVIER	PARIS	23 RUE LINOIS, 75015 PARIS, FRANCE	0021-7824	1776-3371		J MATH PURE APPL	J. Math. Pures Appl.	MAR	2015	103	3					809	829		10.1016/j.matpur.2014.09.002		21	Mathematics, Applied; Mathematics	Mathematics	CC7DZ	WOS:000350529200006		
J	Feng, Y; Sun, J; Chen, P				Feng, Yu; Sun, Jian; Chen, Peng			Vehicle trajectory reconstruction using automatic vehicle identification and traffic count data	JOURNAL OF ADVANCED TRANSPORTATION			English	Article						traffic network; automatic vehicle identification; particle filter; trajectory reconstruction; OD estimation	APPROXIMATION METHOD; DESTINATION; MATRIX	The origin-destination (OD) matrix and the vehicle trajectory data are critical to transportation planning, design, and operation management. On the basis of the deployment of automatic vehicle identification (AVI) technology in urban traffic networks in China, this study proposed a vehicle trajectory reconstruction method for a large-scale network by using AVI and traditional detector data. Particle filter theory was employed as the framework for this method that combines five spatial-temporal trajectory correction factors (i.e., the path consistency, the AVI measurability criterion, the travel time consistency, the gravity flow model, and the path-link flow matching model) to estimate the trajectory of a vehicle. The probabilities of the most likely trajectories are updated by the Bayesian method to approximate the true' trajectory. The traffic network in the Beijing Olympic Park was selected as the test bed and was simulated by using VISSIM to create a complete set of vehicle trajectories. The accuracy of the resulting trajectory reconstruction exceeds 90% when the AVI coverage is only 50%, assuming an AVI detection error of 5% for a closed network and an open network. The average relative error of a static OD matrix is 11.05%. Although the accuracy of reconstruction exceeds 80% when the AVI coverage is between 50% and 40%, the accuracy of a defective product-OD matrix decreases rapidly. The proposed method yields high estimation accuracy for the full trajectories of individual vehicles and the OD matrix, which demonstrates significant potential for traffic-related applications. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Feng, Yu; Sun, Jian] Tongji Univ, Dept Traff Engn, Shanghai 200092, Peoples R China; [Feng, Yu; Sun, Jian] Tongji Univ, Minist Educ, Key Lab Rd & Traff Engn, Shanghai 200092, Peoples R China; [Chen, Peng] Nagoya Univ, Dept Civil Engn, Nagoya, Aichi 4648601, Japan	Sun, J (reprint author), Tongji Univ, Dept Transportat Engn, Shanghai 200092, Peoples R China.	sunjian@tongji.edu.cn			Natural Science Foundation of China [51238008, 50948056]; Research and Operation Expenses of Central University	The authors would like to thank the Natural Science Foundation of China (51238008, 50948056) and the Research and Operation Expenses of Central University for supporting this research.	Parry K, 2012, TRANSPORT RES B-METH, V46, P175, DOI 10.1016/j.trb.2011.09.009; Barcelo J, 2010, TRANSP RES RECORD, P19, DOI 10.3141/2175-03; Salmond DJ, 2001, P AMER CONTR CONF, P3755, DOI 10.1109/ACC.2001.946220; Jiang DD, 2011, COMPUT ELECTR ENG, V37, P1106, DOI 10.1016/j.compeleceng.2011.06.009; Castillo E, 2008, TRANSPORT RES B-METH, V42, P455, DOI 10.1016/j.trb.2007.09.004; Castillo E, 2008, COMPUT-AIDED CIV INF, V23, P189, DOI 10.1111/j.1467-8667.2008.00526.x; CREMER M, 1987, TRANSPORT RES B-METH, V21, P117, DOI 10.1016/0191-2615(87)90011-7; Chen A, 2009, TRANSPORT RES B-METH, V43, P852, DOI 10.1016/j.trb.2009.02.007; Ashoks K, 1996, THESIS MIT; Bonsall P, 1997, TRANSPORT RES C-EMER, V5, P371, DOI 10.1016/S0968-090X(98)00003-5; Dixons MP, 2002, J COMPUTER AIDED CIV, V17, P7; Herreras JC, 2008, 87 TRANSP RES BOARD; Hues C, 2001, IEEE WORKSH MULT TRA, P61; Jayakrishnan R., 1994, Transportation Research Part C (Emerging Technologies), V2C, DOI 10.1016/0968-090X(94)90005-1; Kwons J, 2006, TRANSPORT RES REC, V1923, P119; Lees S., 2011, J ADV TRANSPORT, V45, P143; Lis R, 2006, J TRANSPORTATION ENG, V132, P540; Michaels B, 1991, TRANSPORTATION RES B, V25, P13; MUSSONE Lorenzo, 2010, [交通运输系统工程与信息, Journal of Transporation Systems Engineering & Information Technology], V10, P88; Teknomo K, 2014, J ADV TRANSPORT, V48, P608, DOI 10.1002/atr.1214; Tobiass P, 2013, TRANSPORT RES C-EMER, V31, P131; Van der Merwes R, 2000, UNSCENTED PARTICLE F; Van der Zijpps N, 1997, TRANSPORT RES REC, V1607, P1; VansZuylen H. J., 1980, TRANSPORTATION RES B, V14, P281; YANG H, 1994, TRANSPORT RES B-METH, V28, P23, DOI 10.1016/0191-2615(94)90029-9; Yang Xiao-jun, 2006, Control Theory & Applications, V23; Zhang Fei, 2010, Journal of Southeast University (Natural Science Edition), V40, DOI 10.3969/j.issn.1001-0505.2010.02.020; Zhous XS, 2006, IEEE T INTELL TRANSP, V17, P105	28	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0197-6729	2042-3195		J ADV TRANSPORT	J. Adv. Transp.	MAR	2015	49	2			SI		174	194		10.1002/atr.1260		21	Engineering, Civil; Transportation Science & Technology	Engineering; Transportation	CC9CW	WOS:000350666300002		
J	Toshima, H; Yoshinaga, J; Shiraishi, H; Ito, Y; Kamijima, M; Ueyama, J				Toshima, Hiroki; Yoshinaga, Jun; Shiraishi, Hiroaki; Ito, Yuki; Kamijima, Michihiro; Ueyama, Jun			Comparison of Different Urine Pretreatments for Biological Monitoring of Pyrethroid Insecticides	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SEMEN QUALITY; MASS-SPECTROMETRY; HORMONE-LEVELS; METABOLITES; EXPOSURE; POPULATION; MEN	During a cross-validation practice of urinary analysis of pyrethroid insecticide metabolite (3-phenoxybenzoic acid, 3-PBA) by two laboratories (Lab A and Lab B), difference in 3-PBA concentration was noticed. The analytical methods used in the exercise were enzymatic deconjugation (glucuronidase/sulfatase) followed by solid phase extraction and isotope dilution LC-MS-MS determination (Lab A) and acidic deconjugation followed by liquid-liquid extraction and gas chromatography-mass spectrometry determination (Lab B). A significant difference was found for one of the five samples: lower value was obtained in Lab A. Use of acidic deconjugation in Lab A resulted in comparable value with the analytical result for this sample originally obtained in Lab B. The comparison was extended to 42 urine samples taken from Japanese males in Lab A by using the two different deconjugation methods and LC-MS-MS determination. Significantly lower value was obtained for enzymatic deconjugation in some of the 42 urine samples. The results suggested the presence of other conjugated species of 3-PBA than glucuronide and sulfate in human urine. Although the overall agreement between the values obtained by the deconjugation methods was fair, it appears that urine samples should be pretreated by acidic deconjugation for the analysis in biological monitoring of pyrethroid exposure.	[Toshima, Hiroki; Yoshinaga, Jun] Univ Tokyo, Dept Environm Studies, Kashiwa, Chiba 2778563, Japan; [Shiraishi, Hiroaki] Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan; [Ito, Yuki; Kamijima, Michihiro] Nagoya City Univ, Grad Sch Med Sci, Dept Occupat & Environm Hlth, Nagoya, Aichi 4678601, Japan; [Ueyama, Jun] Nagoya Univ, Dept Pathophysiol Lab Sci, Field Radiol & Med Lab Sci, Nagoya, Aichi 4618673, Japan	Yoshinaga, J (reprint author), Univ Tokyo, Dept Environm Studies, Kashiwanoha 5-1-5, Kashiwa, Chiba 2778563, Japan.	junyosh@k.u-tokyo.ac.jp					Baker SE, 2004, ARCH ENVIRON CON TOX, V46, P281, DOI 10.1007/s00244-003-3044-3; Leng G, 2005, J CHROMATOGR B, V814, P285, DOI 10.1016/j.jchromb.2004.10.044; Toshima H, 2012, INT J HYG ENVIR HEAL, V215, P502, DOI 10.1016/j.ijheh.2011.09.005; Barr DB, 2007, ANAL BIOANAL CHEM, V389, P811, DOI 10.1007/s00216-007-1463-0; Becker K, 2006, INT J HYG ENVIR HEAL, V209, P221, DOI 10.1016/j.ijheh.2005.12.002; Meeker JD, 2009, REPROD TOXICOL, V27, P155, DOI 10.1016/j.reprotox.2008.12.012; Barr DB, 2010, ENVIRON HEALTH PERSP, V118, P742, DOI 10.1289/ehp.0901275; Fortin MC, 2008, ENVIRON RES, V107, P343, DOI 10.1016/j.envres.2008.03.002; Imai K, 2014, REPROD TOXICOL, V43, P38, DOI 10.1016/j.reprotox.2013.10.010; Wielgomas B, 2013, INT J HYG ENVIR HEAL, V216, P295, DOI 10.1016/j.ijheh.2012.09.001; Ueyama J, 2009, ENVIRON RES, V109, P175, DOI 10.1016/j.envres.2008.09.006; Schettgen T, 2002, J CHROMATOGR B, V778, P121, DOI 10.1016/S0378-4347(01)00452-2; Baker SE, 2000, J EXPO ANAL ENV EPID, V10, P789; Han Y, 2008, CHEMOSPHERE, V72, P785, DOI 10.1016/j.chemosphere.2008.03.058; IPCS, 1990, IPCS ENV HLTH CRIT; Ji GX, 2011, REPROD TOXICOL, V31, P171, DOI 10.1016/j.reprotox.2010.10.005; Meeker JD, 2008, HUM REPROD, V23, P1932, DOI 10.1093/humrep/den242; Qi X., 2013, INT J HYG ENVIR HEAL, V215, P487; Ueyama J, 2010, J PESTIC SCI, V35, P87, DOI 10.1584/jpestics.R10-01; Xia YK, 2008, FERTIL STERIL, V89, P1743, DOI 10.1016/j.fertnstert.2007.05.049; Yoshinaga J, 2014, ANDROLOGY-US, V2, P416, DOI 10.1111/j.2047-2927.2014.00202.x	21	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2015	39	2					133	136		10.1093/jat/bku142		4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	CC3BL	WOS:000350219100009		
J	Morimoto, N; Suwa, G; Nishimura, T; de Leon, MSP; Zollikofer, CPE; Lovejoy, CO; Nakatsukasa, M				Morimoto, Naoki; Suwa, Gen; Nishimura, Takeshi; de Leon, Marcia S. Ponce; Zollikofer, Christoph P. E.; Lovejoy, C. Owen; Nakatsukasa, Masato			Let bone and muscle talk together: a study of real and virtual dissection and its implications for femoral musculoskeletal structure of chimpanzees	JOURNAL OF ANATOMY			English	Article						comparative anatomy; femoropelvic musculature; gluteus maximus; great ape; Pan troglodytes	HUMAN GLUTEUS MAXIMUS; ARDIPITHECUS-RAMIDUS; HOMINID BIPEDALITY; MORPHOLOGY; MORPHOGENESIS; MUSCULATURE; EVOLUTION; VIRTOPSY; WALKING; HUMANS	Proximal femoral morphology and associated musculature are of special relevance to the understanding of hominoid locomotor systems. Knowledge of bone-muscle correspondence in extant hominoids forms an important comparative basis for inferring structure-function relationships in fossil hominids. However, there is still a lack of consensus on the correspondence between muscle attachment sites and surface morphology of the proximal femoral diaphysis in chimpanzees. Two alternative observations have been proposed regarding the attachment site positions of gluteus maximus (GM) and vastus lateralis (VL) relative to two prominent surface features of the proximal femoral diaphysis, the lateral spiral pilaster and the inferolateral fossa. Here, we use a combination of virtual and physical dissection in an attempt to identify the exact correspondence between muscle attachment sites and osteological features in two specimens of Pan troglodytes verus. The results show that the insertion of the GM tendon is consistently inferolateral to the lateral spiral pilaster, and that a part of the inferolateral fossa consistently forms the attachment site of the VL muscular fibers. While overall musculoskeletal features are similar in the two specimens examined in this study, GM and VL exhibit different degrees of segregation at the level of the inferolateral fossa. One specimen exhibited tendinous GM fibers penetrating the posteromedial part of VL, with both GM and VL inserting at the inferolateral fossa. In the other specimen, GM and VL were separated by a lateral intermuscular septum, which inserted into the inferolateral fossa. Variation of proximal femoral muscle attachments in chimpanzees is thus greater than previously thought. Our results indicate that a conspicuous osteological feature such as the inferolateral fossa does not necessarily correspond to the attachment site of a single muscle, but could serve as a boundary region between two muscles. Caution is thus warranted when interpreting the surface topography of muscle attachment sites and inferring locomotor functions.	[Morimoto, Naoki; Nakatsukasa, Masato] Kyoto Univ, Grad Sch Sci, Lab Phys Anthropol, Kyoto 6068502, Japan; [Suwa, Gen] Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo, Japan; [Nishimura, Takeshi] Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan; [de Leon, Marcia S. Ponce; Zollikofer, Christoph P. E.] Univ Zurich, Inst Anthropol, Zurich, Switzerland; [Lovejoy, C. Owen] Kent State Univ, Sch Biomed Sci, Dept Anthropol, Kent, OH 44242 USA	Morimoto, N (reprint author), Kyoto Univ, Grad Sch Sci, Lab Phys Anthropol, Sakyo Ku, Kyoto 6068502, Japan.	morimoto@anthro.zool.kyoto-u.ac.jp			Swiss National Science Foundation [3100A0-109344/1]; Japan Society for Promotion of Science (JSPS) [251133, 24000015, 26251048]; cooperative research program of primate research institute of Kyoto University	We are grateful to Tobe Zoo, Tenoji Zoo, Higashiyama Zoo, the GAIN (Great Ape Information Network) project of Japan, and Primate Research Institute of Kyoto University, Japan (KUPRI) for data of Rimi and Sakura. We also thank anonymous reviewers for their valuable comments and suggestions. Grant sponsor: Swiss National Science Foundation: no. 3100A0-109344/1; Japan Society for Promotion of Science (JSPS): no.251133, no.24000015, no.26251048. This study was supported by cooperative research program of primate research institute of Kyoto University.	Almecija S, 2013, NAT COMMUN, V4, P1; Bramble DM, 2004, NATURE, V432, P345, DOI 10.1038/nature03052; Lovejoy CO, 2009, SCIENCE, V326, P100, DOI 10.1126/science.1175833; Lieberman DE, 2006, J EXP BIOL, V209, P2143, DOI 10.1242/jeb.02255; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; Pickford M, 2002, C R PALEVOL, V1, P191, DOI 10.1016/S1631-0683(02)00028-3; Lovejoy CO, 2002, AM J PHYS ANTHROPOL, V119, P97, DOI 10.1002/ajpa.10111; Thali Michael J., 2007, Legal Medicine, V9, P100, DOI 10.1016/j.legalmed.2006.11.011; Cox PG, 2011, ANAT REC, V294, P915, DOI 10.1002/ar.21381; Jeffery NS, 2011, J BIOMECH, V44, P189, DOI 10.1016/j.jbiomech.2010.08.027; Lovejoy CO, 2005, GAIT POSTURE, V21, P95, DOI 10.1016/j.gaitpost.2004.01.001; Carrier DR, 2011, P NATL ACAD SCI USA, V108, P18631, DOI 10.1073/pnas.1105277108; Beddard FE, 1893, T ZOOL SOC LONDON, V13, P177; Champneys F, 1871, J Anat Physiol, V6, P176; Crass E, 1952, THESIS U WISCONSIN; Hepburn D, 1892, J Anat Physiol, V26, P324; Lovejoy CO, 2009, SCIENCE, V326, DOI 10.1126/science.1175831; MARZKE MW, 1988, AM J PHYS ANTHROPOL, V77, P519, DOI 10.1002/ajpa.1330770412; Morimoto N, 2011, ANAT REC, V294, P1433, DOI 10.1002/ar.21424; Morimoto N, 2011, ANAT REC, V294, P589, DOI 10.1002/ar.21346; Primrose A, 1898, T CAN I, V6, P507; Raven H, 1950, ANATOMY GORILLA; Schleip Robert, 2012, J Bodyw Mov Ther, V16, P496, DOI 10.1016/j.jbmt.2012.08.001; SIGMON BA, 1974, J HUM EVOL, V3, P161, DOI 10.1016/0047-2484(74)90197-3; STERN JT, 1972, AM J PHYS ANTHROPOL, V36, P315, DOI 10.1002/ajpa.1330360303; STERN JT, 1981, AM J PHYS ANTHROPOL, V55, P153; Suwa G, 2012, ANAT REC, V295, P2039, DOI 10.1002/ar.22604; Thali MJ, 2009, VIRTOPSY APPROACH; Thorpe SKS, 1999, AM J PHYS ANTHROPOL, V110, P179, DOI 10.1002/(SICI)1096-8644(199910)110:2<179::AID-AJPA5>3.0.CO;2-Z; TICHY M, 1985, ANAT EMBRYOL, V173, P275, DOI 10.1007/BF00316309; Uhlmann K, 1968, HDB PRIMATENKUNDE; Voronov AV, 2003, HUM PHYSL, V29, P201, DOI 10.1023/A:1022954929403; Wood C. D., 1982, ATLAS PRIMATE GROSS	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	MAR	2015	226	3					258	267		10.1111/joa.12270		10	Anatomy & Morphology	Anatomy & Morphology	CC1QC	WOS:000350115400006		
J	Nishino, T; Okamoto, K				Nishino, Takeshi; Okamoto, Ken			Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout	JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY			English	Review						Xanthine oxidase; Uric acid; Allopurinol; Febuxostat; Gout	MONONUCLEAR MOLYBDENUM ENZYMES; NITRIC-OXIDE SYNTHASE; AMINO-ACID-SEQUENCE; URIC-ACID; CRYSTAL-STRUCTURE; ENDOTHELIAL DYSFUNCTION; RHODOBACTER-CAPSULATUS; SUBSTRATE ORIENTATION; ALDEHYDE OXIDASE; ACTIVE-SITE	Xanthine oxidoreductase (XOR), which is widely distributed from humans to bacteria, has a key role in purine catabolism, catalyzing two steps of sequential hydroxylation from hypoxanthine to xanthine and from xanthine to urate at its molybdenum cofactor (Moco). Human XOR is considered to be a target of drugs not only for therapy of hyperuricemia and gout, but also potentially for a wide variety of other diseases. In this review, we focus on studies of XOR inhibitors and their implications for understanding the chemical nature and reaction mechanism of the Moco active site of XOR. We also discuss further experimental or clinical studies that would be helpful to clarify remaining issues.	[Nishino, Takeshi; Okamoto, Ken] Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyou Ku, Tokyo 1138602, Japan; [Nishino, Takeshi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan	Nishino, T (reprint author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyou Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	nishino@nms.ac.jp					Al-Eisa A. A., 2002, International Urology and Nephrology, V33, P3, DOI 10.1023/A:1014419830292; Andrade SLA, 2000, EUR J BIOCHEM, V267, P2054, DOI 10.1046/j.1432-1327.2000.01209.x; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Jones RM, 1999, INORG CHEM, V38, P4963, DOI 10.1021/ic990154j; Obermayr RP, 2008, J AM SOC NEPHROL, V19, P2407, DOI 10.1681/ASN.2008010080; Fukunari A, 2004, J PHARMACOL EXP THER, V311, P519, DOI 10.1124/jpet.104.070433; Singh H, 2014, BIOORG MED CHEM LETT, V24, P4192, DOI 10.1016/j.bmcl.2014.07.041; SATO A, 1995, J BIOL CHEM, V270, P2818; Woodward OM, 2009, P NATL ACAD SCI USA, V106, P10338, DOI 10.1073/pnas.0901249106; Enomoto A, 2002, NATURE, V417, P447; Cao HN, 2010, J BIOL CHEM, V285, P28044, DOI 10.1074/jbc.M110.128561; ELION GB, 1966, BIOCHEM PHARMACOL, V15, P863, DOI 10.1016/0006-2952(66)90163-8; Metz S, 2009, J AM CHEM SOC, V131, P14885, DOI 10.1021/ja9045394; Page CC, 1999, NATURE, V402, P47; Nishino T, 2008, FEBS J, V275, P3278, DOI 10.1111/j.1742-4658.2008.06489.x; Agarwal A, 2011, CRIT REV BIOTECHNOL, V31, P264, DOI 10.3109/07388551.2010.527823; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6; Yamaguchi Y, 2007, J BIOCHEM, V141, P513, DOI 10.1093/jb/mvm053; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Moriwaki Y, 1999, HISTOL HISTOPATHOL, V14, P1321; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; HUNT J, 1992, J BIOL CHEM, V267, P21479; Angermuller S, 2009, HISTOCHEM CELL BIOL, V131, P459, DOI 10.1007/s00418-009-0563-7; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; ARELLANO F, 1993, ANN PHARMACOTHER, V27, P337; Sathisha KR, 2011, BIOORGAN MED CHEM, V19, P211, DOI 10.1016/j.bmc.2010.11.034; Chen ZY, 2014, J SEP SCI, V37, P2253, DOI 10.1002/jssc.201400342; BALDWIN JJ, 1975, J MED CHEM, V18, P895, DOI 10.1021/jm00243a007; Guan Q, 2014, EUR J MED CHEM, V85, P508, DOI 10.1016/j.ejmech.2014.08.014; Ichida K, 2012, INT J MOL SCI, V13, P15475, DOI 10.3390/ijms131115475; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; NISHINO T, 1994, J BIOCHEM-TOKYO, V116, P1; Sharma S, 2014, BIOORG MED CHEM LETT, V24, P495, DOI 10.1016/j.bmcl.2013.12.031; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; SAITO T, 1989, J BIOL CHEM, V264, P10015; OKAMOTO K, 1995, J BIOL CHEM, V270, P7816; Iwasaki T, 2000, J BIOCHEM, V127, P771; Khosla UM, 2005, KIDNEY INT, V67, P1739, DOI 10.1111/j.1523-1755.2005.00273.x; Nossaman VE, 2010, CARDIOL REV, V18, P190, DOI 10.1097/CRD.0b013e3181c8e14a; Webb AJ, 2008, CIRC RES, V103, P957, DOI 10.1161/CIRCRESAHA.108.175810; Coelho C, 2012, J BIOL CHEM, V287, P40690, DOI 10.1074/jbc.M112.390419; MASSEY V, 1970, J BIOL CHEM, V245, P6595; SPECTOR T, 1970, BIOCHEM BIOPH RES CO, V38, P583, DOI 10.1016/0006-291X(70)90621-2; SPECTOR T, 1968, BIOCHEM BIOPH RES CO, V32, P1039, DOI 10.1016/0006-291X(68)90134-4; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; STIRPE F, 1969, J BIOL CHEM, V244, P3855; ICHIKAWA M, 1992, J HISTOCHEM CYTOCHEM, V40, P1097; Okamoto K, 2010, J AM CHEM SOC, V132, P17080, DOI 10.1021/ja1077574; Baker JE, 2007, J MOL CELL CARDIOL, V43, P437, DOI 10.1016/j.yjymc.2007.07.057; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HILLE R, 1995, FASEB J, V9, P995; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Alderman M, 2004, CURR MED RES OPIN, V20, P369, DOI 10.1185/030079904125002982; Lim FPL, 2014, EUR J MED CHEM, V85, P371, DOI 10.1016/j.ejmech.2014.07.112; Choi HK, 2007, ARTHRIT RHEUM-ARTHR, V57, P109, DOI 10.1002/art.22466; Khanna D, 2012, ARTHRIT CARE RES, V64, P1431, DOI 10.1002/acr.21772; Tajima S, 2004, FRONT BIOSCI-LANDMRK, V9, P1374, DOI 10.2741/1345; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Hille R, 2013, DALTON T, V42, P3029, DOI 10.1039/c2dt32376a; MASSEY V, 1970, J BIOL CHEM, V245, P2837; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Hille R, 2014, CHEM REV, V114, P3963, DOI 10.1021/cr400443z; Maia LB, 2011, J BIOL INORG CHEM, V16, P443, DOI 10.1007/s00775-010-0741-z; Matsumoto K, 2011, J PHARMACOL EXP THER, V336, P95, DOI 10.1124/jpet.110.174540; Okamoto K, 2008, NUCLEOS NUCLEOT NUCL, V27, P888, DOI 10.1080/15257770802146577; AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Okamoto K, 2003, J BIOL CHEM, V278, P1848, DOI 10.1074/jbc.M208307200; Rock KL, 2013, NAT REV RHEUMATOL, V9, P13, DOI 10.1038/nrrheum.2012.143; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279; Hille R, 2011, COORDIN CHEM REV, V255, P1179, DOI 10.1016/j.ccr.2010.11.034; Kumar R, 2011, EXPERT OPIN THER PAT, V21, P1071, DOI 10.1517/13543776.2011.577417; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Hille R, 2005, ARCH BIOCHEM BIOPHYS, V433, P107, DOI 10.1016/j.abb.2004.08.012; Pauff JM, 2008, J BIOL CHEM, V283, P4818, DOI 10.1074/jbc.M707918200; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Kanellis J, 2005, SEMIN NEPHROL, V25, P39, DOI 10.1016/j.semnephrol.2004.09.007; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; Arikyants N, 2007, PEDIATR NEPHROL, V22, P310, DOI 10.1007/s00467-006-0267-3; Asai R, 2007, J BIOCHEM, V141, P525, DOI 10.1093/jb/mvm054; Ball EG, 1939, J BIOL CHEM, P51; Bayse CA, 2009, DALTON T, P2306, DOI 10.1039/b821878a; Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913; BORDAS J, 1980, BIOCHEM J, V191, P499; BRADBURY MG, 1995, PEDIATR NEPHROL, V9, P476; Bray RC, 1975, ENZYMES, P299, DOI 10.1016/S1874-6047(08)60229-2; Cantu-Medellin N, 2013, REDOX BIOL, V1, P353, DOI 10.1016/j.redox.2013.05.002; Corte E D, 1972, Biochem J, V126, P739; Dietzel U, 2009, J BIOL CHEM, V284, P8759, DOI 10.1074/jbc.M808114200; Dixon M, 1927, BIOCHEM J, V21, P840; EDMONDSO.D, 1972, J BIOL CHEM, V247, P1597; Garattini E, 2013, EXPERT OPIN DRUG DIS, V8, P641, DOI 10.1517/17460441.2013.788497; Gargah Tahar, 2010, Saudi J Kidney Dis Transpl, V21, P328; Glatigny A, 1998, J MOL BIOL, V278, P431, DOI 10.1006/jmbi.1998.1707; Godber Ben, 1997, Biochemical Society Transactions, V25, p519S; Godber BLJ, 2005, BIOCHEM J, V388, P501; Grassi Davide, 2014, Curr Pharm Des, V20, P6089; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887; Hall J, 2014, J BIOL CHEM, V289, P32121, DOI 10.1074/jbc.M114.603456; Hopkins FG, 1920, BIOCHEM J, P721; Hung SI, 2005, P NATL ACAD SCI USA, V102, P6237, DOI 10.1073/pnas.0502360102; Ichida K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1756; Ichida K, 2001, BIOCHEM BIOPH RES CO, V282, P1194, DOI 10.1006/bbrc.2001.4719; Kaya MO, 2014, J ENZYM INHIB MED CH, DOI [10.3109/ 14756366.201 4.920837, DOI 10.3109/14756366.201]; Kikuchi H, 2012, SCI REP-UK, V2, DOI 10.1038/srep00331; Kiss A, 1999, UROL INT, V63, P242, DOI 10.1159/000030458; KRENITSKY TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P108, DOI 10.1016/0003-9861(86)90539-4; Kucera J, 1997, J SMALL ANIM PRACT, V38, P302, DOI 10.1111/j.1748-5827.1997.tb03471.x; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MacDonald TM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005354; Mahro M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082285; Maiti NC, 2003, J BIOL INORG CHEM, V8, P327, DOI 10.1007/s00775-002-0418-3; Marelja Z, 2014, J EXP BIOL, V217, P2201, DOI 10.1242/jeb.102129; Masuda T, 2014, FREE RADICAL BIO MED, V69, P300, DOI 10.1016/j.freeradbiomed.2014.01.016; Matsuo H, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000237; Metz S, 2010, J PHYS CHEM B, V114, P1506, DOI 10.1021/jp909999s; Miranda M, 2010, J VET MED SCI, V72, P921; MORIWAKI Y, 1993, BIOCHIM BIOPHYS ACTA, V1164, P327, DOI 10.1016/0167-4838(93)90266-T; Nepali K, 2011, BIOORGAN MED CHEM, V19, P1950, DOI 10.1016/j.bmc.2011.01.058; Mai TTN, 2013, NAT PROD RES, V27, P61, DOI 10.1080/14786419.2011.652960; NISHINO T, 1986, J BIOL CHEM, V261, P1242; NISHINO T, 1983, P NATL ACAD SCI-BIOL, V80, P1826, DOI 10.1073/pnas.80.7.1826; NISHINO T, 1981, FEBS LETT, V131, P369, DOI 10.1016/0014-5793(81)80406-1; Niu YF, 2011, CHEM-BIOL INTERACT, V189, P161, DOI 10.1016/j.cbi.2010.12.004; PALMER G, 1969, J BIOL CHEM, V244, P2614; Perticone F, 2013, INT J CARDIOL, V167, P232, DOI 10.1016/j.ijcard.2011.12.065; RAJAGOPA.KV, 1967, J BIOL CHEM, V242, P4097; RAJAGOPALAN KV, 1993, ADV EXP MED BIOL, V338, P355; SATO S, 1991, ADV EXP MED BIOL, V309, P135; Scriver C. R., 2001, METABOLIC MOL BASES; SEEGMILLER J. E., 1965, ARTHRITIS RHEUM, V8, P714, DOI 10.1002/art.1780080431; Shi DH, 2014, EUR J MED CHEM, V75, P289, DOI 10.1016/j.ejmech.2014.01.058; Shimo T, 2011, DRUG CHEM TOXICOL, V34, P192, DOI 10.3109/01480545.2010.500291; SILIPO C, 1976, J MED CHEM, V19, P62, DOI 10.1021/jm00223a014; Simmonds HA, 1995, METABOLIC BASIS INHE, P1781; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Spanou C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032214; SPRINGER RH, 1976, J MED CHEM, V19, P291, DOI 10.1021/jm00224a017; Thomas N, 1996, J Assoc Physicians India, V44, P203; Tsuchida S, 2007, J FELINE MED SURG, V9, P503, DOI 10.1016/j.jfms.2007.03.012; vanZuilen CD, 1997, VET QUART, V19, P172; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WORTMANN RL, 1985, J RHEUMATOL, V12, P540	145	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0949-8257	1432-1327		J BIOL INORG CHEM	J. Biol. Inorg. Chem.	MAR	2015	20	2					195	207		10.1007/s00775-014-1210-x		13	Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear	Biochemistry & Molecular Biology; Chemistry	CC3GZ	WOS:000350236100003		
J	Quam, DJ; Gundert, TJ; Ellwein, L; Larkee, CE; Hayden, P; Migrino, RQ; Otake, H; LaDisa, JF				Quam, David J.; Gundert, Timothy J.; Ellwein, Laura; Larkee, Christopher E.; Hayden, Paul; Migrino, Raymond Q.; Otake, Hiromasa; LaDisa, John F., Jr.			Immersive Visualization for Enhanced Computational Fluid Dynamics Analysis	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							PULSE PRESSURE METHOD; WALL SHEAR-STRESS; VIRTUAL-REALITY; BLOOD-FLOW; CAROTID BIFURCATION; STENT IMPLANTATION; IN-VIVO; ARTERIAL COMPLIANCE; CORONARY-ARTERY; PULSATILE FLOW	Modern biomedical computer simulations produce spatiotemporal results that are often viewed at a single point in time on standard 2D displays. An immersive visualization environment (IVE) with 3D stereoscopic capability can mitigate some shortcomings of 2D displays via improved depth cues and active movement to further appreciate the spatial localization of imaging data with temporal computational fluid dynamics (CFD) results. We present a semi-automatic workflow for the import, processing, rendering, and stereoscopic visualization of high resolution, patient-specific imaging data, and CFD results in an IVE. Versatility of the workflow is highlighted with current clinical sequelae known to be influenced by adverse hemodynamics to illustrate potential clinical utility.	[Quam, David J.; Gundert, Timothy J.; Ellwein, Laura; LaDisa, John F., Jr.] Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA; [Larkee, Christopher E.] Marquette Univ, Coll Engn, MARquette Visualizat Lab MARVL, Milwaukee, WI 53233 USA; [Hayden, Paul] Discovery World Pier Wisconsin, Milwaukee, WI 53202 USA; [Migrino, Raymond Q.] Phoenix VA Hlth Care Syst, Phoenix, AZ 85012 USA; [Migrino, Raymond Q.; LaDisa, John F., Jr.] Med Coll Wisconsin, Div Cardiovasc Med, Milwaukee, WI 53226 USA; [Otake, Hiromasa] Kobe Univ, Grad Sch Med, Kobe, Hyogo 657, Japan; [LaDisa, John F., Jr.] Marquette Univ, MARquette Visualizat Lab MARVL, Milwaukee, WI 53233 USA; [LaDisa, John F., Jr.] Marquette Univ, Med Coll Wisconsin, Lab Translat Expt & Computat Cardiovasc Res, Milwaukee, WI 53233 USA	LaDisa, JF (reprint author), Marquette Univ, Dept Biomed Engn, Milwaukee, WI 53233 USA.	dj.quam@gmail.com; timothy.gundert@gmail.com; laura.ellwein@gmail.com; christopher.larkee@marquette.edu; haydenp@discoveryworld.org; Raymond.migrino@va.gov; hiro_yuki15@yahoo.co.jp		Fix, Laura/0000-0001-8680-8585	Marquette University Department of Biomedical Engineering	The authors wish to thank Steve Atwell and Paul Krajniak of Discovery World at Pier Wisconsin for their support during development and presentation of the current results within the HIVE and Josh Hughey for technical assistance. The authors gratefully acknowledge Mark Bowers, Leanne Harmann, Robert Prost, Anil Vamsi Doppalapudi, Tayyab Mohyuddin, and Osama Zaidat for their contributions related to the LCCA data shown here. The authors similarly acknowledge Bon-Kwon Koo, Toshiro Shinke, Yasuhiro Honda, and Junya Shite for their contributions related to the LCX data shown here. Funding was provided by the Marquette University Department of Biomedical Engineering to David Quam.	Wendell DC, 2013, MED ENG PHYS, V35, P723, DOI 10.1016/j.medengphy.2012.07.015; CRUZNEIRA C, 1992, COMMUN ACM, V35, P64, DOI 10.1145/129888.129892; Zhao SZ, 2000, J BIOMECH, V33, P975, DOI 10.1016/S0021-9290(00)00043-9; GOW BS, 1974, J BIOMECH, V7, P389, DOI 10.1016/0021-9290(74)90001-3; Holdsworth DW, 1999, PHYSIOL MEAS, V20, P219, DOI 10.1088/0967-3334/20/3/301; LaDisa JF, 2010, MED PHYS, V37, P784, DOI 10.1118/1.3292631; Williams AR, 2010, J APPL PHYSIOL, V109, P532, DOI 10.1152/japplphysiol.00086.2010; Kerwin WS, 2008, J MAGN RESON IMAGING, V28, P987, DOI 10.1002/jmri.21529; Slater M, 1997, PRESENCE-TELEOP VIRT, V6, P603; Gnasso A, 1997, STROKE, V28, P993; PRESSON CC, 1987, MEM COGNITION, V15, P225, DOI 10.3758/BF03197720; Votanopoulos K, 2008, WORLD J SURG, V32, P110, DOI 10.1007/s00268-007-9253-6; Stone PH, 2003, CURR OPIN CARDIOL, V18, P458, DOI 10.1097/00001573-200311000-00007; MOORE JE, 1994, ATHEROSCLEROSIS, V110, P225, DOI 10.1016/0021-9150(94)90207-0; Marshall I, 2004, J BIOMECH, V37, P679, DOI 10.1016/j.jbiomech.2003.09.032; Vignon-Clementel IE, 2006, COMPUT METHOD APPL M, V195, P3776, DOI 10.1016/j.cma.2005.04.014; Boejen A, 2011, SURG ONCOL, V20, P185, DOI 10.1016/j.suronc.2010.07.004; Dede C, 2009, SCIENCE, V323, P66, DOI 10.1126/science.1167311; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Farooq V, 2011, CIRC-CARDIOVASC INTE, V4, P195, DOI 10.1161/CIRCINTERVENTIONS.110.959882; van Dam A, 2000, IEEE COMPUT GRAPH, V20, P26, DOI 10.1109/38.888006; Papafaklis MI, 2010, JACC-CARDIOVASC INTE, V3, P1181, DOI 10.1016/j.jcin.2010.08.018; Yarnykh VL, 2006, J MAGN RESON IMAGING, V23, P691, DOI 10.1002/jmri.20562; Steinman DAH, 2007, LEONARDO, V40, P71, DOI 10.1162/leon.2007.40.1.71; Aumuller M., 2008, COVISE COLLABORATIVE; Chaudhry A, 1999, ANN ROY COLL SURG, V81, P281; Chu JCH, 2009, J APPL CLIN MED PHYS, V10, P115, DOI 10.1120/jacmp.v10i3.2902; Drascic D., 1989, IEEE INT C SYST MAN, P1244; Ellwein LM, 2011, CARDIOVASC ENG TECHN, V2, P212, DOI DOI 10.1007/S13239-011-0047-5; Esmaily-Moghadam M, 2013, COMPUT MECH, V52, P1141, DOI 10.1007/s00466-013-0868-1; Forsberg AS, 2000, IEEE VISUAL, P457, DOI 10.1109/VISUAL.2000.885731; Gascon J., 2011, SIACG 2011 IB AM S C; Gundert TJ, 2013, J MED DEVICES, V7, DOI 10.1115/1.4023413; Gundert TJ, 2011, ANN BIOMED ENG, V39, P1423, DOI 10.1007/s10439-010-0238-5; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Jordan JA, 2001, SURG ENDOSC-ULTRAS, V15, P1080, DOI 10.1007/s004640000374; Justice J., 2009, EON STUDIO 7; Kitware Inc., 2012, PAR; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293; LaDisa John F Jr, 2005, Biomed Eng Online, V4, P59, DOI 10.1186/1475-925X-4-59; Leigh J, 2006, FUTURE GENER COMP SY, V22, P964, DOI 10.1016/j.future.2006.03.009; Muller J., 2005, Computer Methods in Biomechanics and Biomedical Engineering, V8, P295, DOI 10.1080/10255840500264742; Murata A, 2010, JACC-CARDIOVASC IMAG, V3, P76, DOI 10.1016/j.jcmg.2009.09.018; NICHOLLS SC, 1989, STROKE, V20, P175; PHILLIPS DJ, 1983, ULTRASOUND MED BIOL, V9, P39, DOI 10.1016/0301-5629(83)90108-4; Quam D. J., 2011, BIOM ENG SOC BMES AN, P56; Quam D. J., 2012, THESIS MARQUETTE U M; Reda K., 2013, P IEEE S LARG SCAL D, P59; Sahni O, 2006, COMPUT METHOD APPL M, V195, P5634, DOI 10.1016/j.cma.2005.10.018; Schroeder W., 2006, VISUALIZATION TOOLKI; STEINKE W, 1990, ATHEROSCLEROSIS, V84, P121, DOI 10.1016/0021-9150(90)90081-S; Stergiopulos N, 1999, AM J PHYSIOL-HEART C, V276, pH424; STERGIOPULOS N, 1994, ANN BIOMED ENG, V22, P392, DOI 10.1007/BF02368245; VANHUIS GA, 1987, AM J PHYSIOL, V253, pH317; Ward J. W., 2007, STUDIES HLTH TECHNOL	55	0	0	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	MAR	2015	137	3							031004	10.1115/1.4029017		12	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CC7TZ	WOS:000350572600005		
J	Takamizawa, K				Takamizawa, Keiichi			Biaxial Contractile Mechanics of Common Carotid Arteries of Rabbit	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						vasoactive mechanics; common carotid artery; strain energy function	STRAIN-ENERGY DENSITY; SMOOTH-MUSCLE; CORONARY-ARTERY; TENSION; WALL; VASOACTIVITY; FORMULATION; SEGMENTS; MODEL; RAT	Few multiaxial constitutive laws under the vasoactive condition have been proposed as compared with those under the passive condition. The biaxial isometric properties of vasoactive rabbit arteries were studied, although the constitutive law was not proposed. The purpose of the present study is also to describe the multiaxial active mechanical properties of arteries. A novel strain energy function for the active stress has been proposed. This function is simple and may describe the multiaxial characteristics of constricted vessels. Although this study used mean stress and mean stretch ratio to determine the mechanical properties of vessels, a triaxial constitutive law of constricted vessels may be developed. There remains the subject of residual strains under active condition. If this problem will be solved, the accurate stress analysis under vasoactive conditions is possible.	Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, Suita, Osaka 5658565, Japan	Takamizawa, K (reprint author), Natl Cerebral & Cardiovasc Ctr Res Inst, Dept Biomed Engn, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	keiichi.takamizawa@gmail.com					Holzapfel GA, 2000, J ELASTICITY, V61, P1, DOI 10.1023/A:1010835316564; ARNER A, 1982, CIRC RES, V50, P812; FUNG YC, 1979, AM J PHYSIOL, V237, pH620; Holzapfel GA, 2002, EUR J MECH A-SOLID, V21, P441, DOI 10.1016/S0997-7538(01)01206-2; Holzapfel GA, 2005, AM J PHYSIOL-HEART C, V289, pH2048, DOI 10.1152/ajpheart.00934.2004; HERLIHY JT, 1980, AM J PHYSIOL, V238, pH107; TAKAMIZAWA K, 1987, J BIOMECH, V20, P7, DOI 10.1016/0021-9290(87)90262-4; CAREW TE, 1968, CIRC RES, V23, P61; Rachev A, 1999, ANN BIOMED ENG, V27, P459, DOI 10.1114/1.191; Bol M., 2013, COMPUTER MODELS BIOM, P63; COX RH, 1978, AM J PHYSIOL, V234, pH280; DOBRIN PB, 1973, AM J PHYSIOL, V225, P659; HERLIHY JT, 1973, CIRC RES, V33, P275; Humphrey D. J., 2002, CARDIOVASCULAR SOLID; Huo YL, 2013, J APPL PHYSIOL, V114, P1451, DOI 10.1152/japplphysiol.01237.2012; Huo YL, 2012, AM J PHYSIOL-HEART C, V302, pH2058, DOI 10.1152/ajpheart.00758.2011; Muratada S. C., 2010, BIOMECH MODELL MECHA, V9, P749; Muratada S. C., 2012, J THEOR BIOL, V297, P176; OHHASHI T, 1980, BLOOD VESSELS, V17, P16; PATEL DJ, 1969, CIRC RES, V24, P1; TAKAMIZAWA K, 1992, AM J PHYSIOL, V263, pH30; TODD ME, 1983, CIRC RES, V53, P319; VAISHNAV RN, 1973, CIRC RES, V32, P577; Wagner HP, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003873; Zulliger MA, 2004, AM J PHYSIOL-HEART C, V287, pH1335, DOI 10.1152/ajpheart.00094.2004	25	0	0	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	MAR	2015	137	3							031010	10.1115/1.4028988		5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	CC7TZ	WOS:000350572600011		
J	Shimada, R; Nemoto, S; Ozawa, H; Katsumata, T				Shimada, Ryo; Nemoto, Shintaro; Ozawa, Hideki; Katsumata, Takahiro			Surgical Treatment of a Mycotic Pseudoaneurysm of the Transverse Arch Using a Rifampicin-Impregnated Dacron Patch in an Infant	JOURNAL OF CARDIAC SURGERY			English	Article							AORTA; ANEURYSMS; CHILDREN	We describe a case of successful treatment of mycotic pseudoaneurysm of the transverse aortic arch in a male infant. The aneurysm was resected and the defect was repaired using a patch made from a rifampicin-impregnated Dacron graft. doi: 10.1111/jocs.12492 (J Card Surg 2015;30:281-283)	[Shimada, Ryo; Nemoto, Shintaro; Ozawa, Hideki; Katsumata, Takahiro] Osaka Med Coll, Dept Thorac & Cardiovasc Surg, Takatsuki, Osaka 5698686, Japan	Nemoto, S (reprint author), Osaka Med Coll, Dept Thorac & Cardiovasc Surg, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.	snemoto@poh.osaka-med.ac.jp					BERGSLAND J, 1984, ANN THORAC SURG, V37, P314; LACHAPELLE K, 1994, J VASC SURG, V19, P675; Malec E, 2003, PEDIATR CARDIOL, V24, P89, DOI 10.1007/s00246-0020210-8; Barth H, 2000, PEDIATR CARDIOL, V21, P263, DOI 10.1007/s002460010054; Uchida N, 2012, ANN THORAC SURG, V93, P438, DOI 10.1016/j.athoracsur.2011.07.050	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0886-0440	1540-8191		J CARDIAC SURG	J. Card. Surg.	MAR	2015	30	3					281	283		10.1111/jocs.12492		3	Cardiac & Cardiovascular Systems; Surgery	Cardiovascular System & Cardiology; Surgery	CC7MF	WOS:000350551200016		
J	Ueno, Y; Koike, M; Shimada, Y; Shimura, H; Hira, K; Tanaka, R; Uchiyama, Y; Hattori, N; Urabe, T				Ueno, Yuji; Koike, Masato; Shimada, Yoshiaki; Shimura, Hideki; Hira, Kenichiro; Tanaka, Ryota; Uchiyama, Yasuo; Hattori, Nobutaka; Urabe, Takao			L-carnitine enhances axonal plasticity and improves white-matter lesions after chronic hypoperfusion in rat brain	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						axonal outgrowth; chronic hypoperfusion; L-carnitine; oxidative steess; stroke	CHRONIC CEREBRAL HYPOPERFUSION; ACETYL-L-CARNITINE; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; MITOCHONDRIAL DYSFUNCTION; IN-VIVO; MODEL; STROKE; INJURY; MECHANISMS	Chronic cerebral hypoperfusion causes white-matter lesions (WMLs) with oxidative stress and cognitive impairment. However, the biologic mechanisms that regulate axonal plasticity under chronic cerebral hypoperfusion have not been fully investigated. Here, we investigated whether L-carnitine, an antioxidant agent, enhances axonal plasticity and oligodendrocyte expression, and explored the signaling pathways that mediate axonal plasticity in a rat chronic hypoperfusion model. Adult male Wistar rats subjected to ligation of the bilateral common carotid arteries (LBCCA) were treated with or without L-carnitine. L-carnitine-treated rats exhibited significantly reduced escape latency in the Morris water maze task at 28 days after chronic hypoperfusion. Western blot analysis indicated that L-carnitine increased levels of phosphorylated high-molecular weight neurofilament (pNFH), concurrent With a reduction in phosphorylated phosphatase tensin homolog deleted on chromosome 10 (PTEN), and increased phosphorylated Akt and mammalian target of rapannycin (mTOR) at 28 days after chronic hypoperfusion. L-carnitine reduced lipid peroxidation and oxidative DNA damage, and enhanced oligodendrocyte marker expression and myelin sheath thickness after chronic hypoperfusion. L-carnitine regulates the PTEN/Akt/mTOR signaling pathway, and enhances axonal plasticity while concurrently ameliorating oxidative stress and increasing oligodendrocyte myelination of axons, thereby improving WMLs and cognitive impairment in a rat chronic hypoperfusion model.	[Ueno, Yuji; Shimura, Hideki; Urabe, Takao] Juntendo Univ, Urayasu Hosp, Dept Neurol, Chiba, Japan; [Ueno, Yuji; Shimada, Yoshiaki; Hira, Kenichiro; Tanaka, Ryota; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan; [Uchiyama, Yasuo] Juntendo Univ, Sch Med, Dept Cell Biol & Neurosci, Tokyo 1138421, Japan; [Uchiyama, Yasuo] Juntendo Univ, Grad Sch Med, Dept Cellular & Mol Neuropathol, Tokyo 1138421, Japan	Ueno, Y (reprint author), Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yuji-u@juntendo.ac.jp			High Technology Research Center grant; Ministry of Education, Culture, Sports, Science, and Technology, Japan; Foundation for Strategic Research Projects in Private Universities from MEXT [S1311011]; Comprehensive Brain Science Network (CBSN)	This study was supported in part by a High Technology Research Center grant and a grant-in-aid for exploratory research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. This study was also supported in part by a Grant-in-Aid (S1311011) from the Foundation for Strategic Research Projects in Private Universities from MEXT. This study was also supported in part by the Comprehensive Brain Science Network (CBSN).	Al-Majed AA, 2006, CLIN EXP PHARMACOL P, V33, P725; Andreozzi GM, 2002, CLIN DRUG INVEST, V22, P15, DOI 10.2165/00044011-200222001-00003; Zhang Y, 2013, J NEUROSCI, V33, P6885, DOI 10.1523/JNEUROSCI.5180-12.2013; Manning SM, 2008, J NEUROSCI, V28, P6670, DOI 10.1523/JNEUROSCI.1702-08.2008; Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Watanabe T, 2006, STROKE, V37, P1539, DOI 10.1161/01.STR.0000221783.08037.a9; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; Wang T, 2009, FREE RADICAL BIO MED, V47, P229, DOI 10.1016/j.freeradbiomed.2009.02.027; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Ueno Y, 2012, STROKE, V43, P2221, DOI 10.1161/STROKEAHA.111.646224; Lolic MM, 1997, ANN EMERG MED, V29, P758, DOI 10.1016/S0196-0644(97)70197-5; Carrasco P, 2012, J BIOL CHEM, V287, P21224, DOI 10.1074/jbc.M111.337493; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Ueno Y, 2009, NEUROSCIENCE, V162, P317, DOI 10.1016/j.neuroscience.2009.04.065; Miki K, 2009, J NEUROSCI RES, V87, P1270, DOI 10.1002/jnr.21925; McCracken E, 2000, J CEREBR BLOOD F MET, V20, P1529; Lescuyer P, 2003, PROTEOMICS, V3, P157, DOI 10.1002/pmic.200390024; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Sanchez I, 2000, J CELL BIOL, V151, P1013, DOI 10.1083/jcb.151.5.1013; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Ek CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043484; Delaney CL, 2013, ATHEROSCLEROSIS, V229, P1, DOI 10.1016/j.atherosclerosis.2013.03.004; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dewar D, 2003, J CEREB BLOOD FLOW M, V23, P2632; Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007; Jellinger KA, 2007, ACTA NEUROPATHOL, V113, P349, DOI 10.1007/s00401-006-0185-2; lliceto S, 1995, J AM COLL CARDIOL, V26, P380; Rau TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040881; Ringseis R, 2013, EUR J NUTR, V52, P1421, DOI 10.1007/s00394-013-0511-0; ROE CR, 1982, LANCET, V1, P1411; ROSENTHAL RE, 1992, STROKE, V23, P1312; SCHOLTE HR, 1978, NEW ENGL J MED, V299, P1079; Terasaki Y, 2014, CURR MED CHEM, V21, P2035	39	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2015	35	3					382	391		10.1038/jcbfm:2014.210		10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CC5IZ	WOS:000350393600007		
J	Jamshidi, A; Kurumisawa, K; Nawa, T; Hamzah, MO				Jamshidi, Ali; Kurumisawa, Kiyofumi; Nawa, Toyoharu; Hamzah, Meor Othman			Analysis of structural performance and sustainability of airport concrete pavements incorporating blast furnace slag	JOURNAL OF CLEANER PRODUCTION			English	Article						Cleaner infrastructures; Millennium Development Goals (MDGs); Europe Horizon 2020; Sustainable design	CEMENT; ASPHALT	In this study, the effects of various blast furnace slag (BFS) contents on the performance of cement pastes and pavement were investigated at two levels, the micro and the macro. At the micro level, the strength and chemical properties of cement pastes containing various percentages of BFS and subjected to different water curing periods were evaluated. At the macro level, the structural and sustainability performance of airport concrete pavements were studied. In this regard, several structural design charts were developed to determine the thickness of the concrete slab required to withstand traffic loadings for various versions of aircraft design and subgrade strengths. The sustainability of the concrete pavements was assessed in terms of fuel requirements and greenhouse gas (GHG) emissions. In addition, a simple graphical method was proposed for comparing structural and environmental performance of concrete pavements with respect to BFS content, subgrade strength, different versions of the aircraft design, fuel requirements and GHG emissions for pavement construction. Based on the results obtained using the proposed method and the structural and sustainability analyses, scenarios are suggested for choosing preliminary BFS content. (C) 2014 Elsevier Ltd. All rights reserved.	[Jamshidi, Ali; Kurumisawa, Kiyofumi; Nawa, Toyoharu] Hokkaido Univ, Fac Engn, Kita Ku, Sapporo, Hokkaido 0608628, Japan; [Hamzah, Meor Othman] Univ Sains Malaysia, Sch Civil Engn, Nibong Tebal 14300, P Pinang, Malaysia	Jamshidi, A (reprint author), Hokkaido Univ, Fac Engn, Kita Ku, Kita 13,Nishi 8, Sapporo, Hokkaido 0608628, Japan.	Alij_ep@yahoo.com		Jamshidi, Ali/0000-0001-7691-1730	Hokkaido University; Japan Society for the Promotion Science (JSPS) [26.04058]	The authors would like to acknowledge the Hokkaido University, which funded the reported research through the Research University Grant Scheme. Many thanks are also due to the Sustainable Resources Division of Faculty of Engineering at the Hokkaido University. Also, the authors would like to acknowledge the Japan Society for the Promotion Science (JSPS) Fellows (grant number: 26.04058).	Jamshidi A, 2013, CONSTR BUILD MATER, V38, P530, DOI 10.1016/j.conbuildmat.2012.08.015; Vatopoulos K, 2012, J CLEAN PROD, V32, P251, DOI 10.1016/j.jclepro.2012.03.013; Blankendaal T, 2014, J CLEAN PROD, V66, P27, DOI 10.1016/j.jclepro.2013.10.012; Zapata P, 2005, J INFRASTRUCT SYST, V11, P9, DOI 10.1061/(ASCE)1076-0342(2005)11:1(9); [Anonymous], 2009, PAV DAT BOEING 777, V777, P125; Mothe MG, 2011, J THERM ANAL CALORIM, V106, P679, DOI 10.1007/s10973-011-1386-z; Mokhtari A, 2013, J MATER CIVIL ENG, V25, P419, DOI 10.1061/(ASCE)MT.1943-5533.0000584; Josa A, 2004, CEMENT CONCRETE RES, V34, P1313, DOI 10.1016/j.cemconres.2003.12.020; Balim C., 2009, ADV SOFTW ENG, V40, P334; Cazacliu B, 2010, J CLEAN PROD, V18, P1320, DOI 10.1016/j.jclepro.2010.04.022; Chakraborty S., 2011, ASSESSMENT CIVIL ENG; Department for Environment Food and Rural Affairs (DEFRA), 2010, GUID GHGS CALC VERS; Department of Trade and Industry (DTI), 2006, DIG UK EN STAT; European Commission Directorate-General Environment (ECD-GE), 2013, ENVF1ETU20110044 ECD; Gartner E., 2011, CEMENT CONCRETE RES, V41, P36; Henry M., 2014, J CONST BUILD MAT, V67, P399; Hudson S.W., 1987, BRIDGE MANAGEMENT SY; Kurumisawa K., 2012, CEM SCI CONCR TECHNO, V66, P127; Kurumisawa K, 2012, CEMENT CONCRETE COMP, V34, P408, DOI 10.1016/j.cemconcomp.2011.11.011; Marie I., 2012, J CLEAN PROD, V37, P171; Packard R.G, 1973, DESIGN CONCRETE AIRP; Termkhajornkit P, 2006, CEMENT CONCRETE COMP, V28, P781, DOI 10.1016/j.cemconcomp.2006.05.018; Torgal FP, 2011, ECO-EFFICIENT CONSTRUCTION AND BUILDING MATERIALS, P1; Torgal F.-P., 2013, J CONST BUILD MAT, V40, P729; Torgal F.-P, 2014, J CONST BUILD MAT, V51, P151; TSI, 1980, 706 TSI; Uddin W., 2013, PUBLIC INFRASTRUCTUR; Yoder E. J., 1975, PRINCIPLES PAVEMENT	28	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-6526	1879-1786		J CLEAN PROD	J. Clean Prod.	MAR 1	2015	90						195	210		10.1016/j.jclepro.2014.11.046		16	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CC1EM	WOS:000350084000021		
J	Dong, L; Dong, HJ; Fujita, T; Geng, Y; Fujii, M				Dong, Liang; Dong, Huijuan; Fujita, Tsuyoshi; Geng, Yong; Fujii, Minoru			Cost-effectiveness analysis of China's Sulfur dioxide control strategy at the regional level: regional disparity, inequity and future challenges	JOURNAL OF CLEANER PRODUCTION			English	Article						Cost-effectiveness; SO2 control; Regional disparity; China	INDUSTRIAL SO2 EMISSION; POLLUTION-CONTROL; AIR-POLLUTANTS; POWER-PLANTS; POLICY; REDUCTION; CITY; MITIGATION; BENEFITS; LESSONS	Sulfur dioxide (SO2) is still the critical environmental issue in China. The central government adopts the top-down strategy for SO2 control. However, due to its large size and imbalanced economic development, regional disparity exists and inequity is generated. Under this condition, it requires a region-specific control policy to reach the SO2 mitigation target effectively and efficiently. To date, there have been few studies in this area. Consequently, this study investigates the regional disparity of SO2 emission, reduction potential and abatement cost in China's 32 regions by employing the GAINS China model, and analyzes the inequity issues and policy challenges. Results show that up to 2030, applying with flue gas desulfurization (FGD) and limestone injection technology (LINJ), China's SO2 emissions would be reduced by 51.33% as compared to no policy scenario. Regional disparity is evident in term of reduction potential and unit abatement cost. Regions with larger scale of industry and power generation (e.g. eastern areas) and lower quality of coal (e.g. Heilongjiang province) present a larger reduction potential and lower unit abatement cost. What is more, as the result of the imbalance between middle-western and eastern regions, inequity is highlighted. Certain poor areas (like Guizhou province) have to deal with heavy SO2 emissions and higher abatement cost per GDP with their limited budgets. Future challenges of promoting cost-effective pollution control strategy considering regional condition are discussed in-depth. Our findings are critical for relative flexible policy making. (C) 2015 Elsevier Ltd. All rights reserved.	[Dong, Liang; Dong, Huijuan; Fujita, Tsuyoshi; Fujii, Minoru] Natl Inst Environm Studies, Ctr Social & Environm Syst Res, Tsukuba, Ibaraki 3058506, Japan; [Dong, Liang; Fujita, Tsuyoshi] Nagoya Univ, Grad Sch Environm Studies, Chikusa Ku, Nagoya, Aichi 4648601, Japan; [Dong, Huijuan; Geng, Yong] Shanghai Jiao Tong Univ, Sch Environm Sci & Engn, Shanghai 200240, Peoples R China	Dong, L (reprint author), Natl Inst Environm Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	dong.liang@nies.go.jp; fujita77@nies.go.jp			Environment Research and Technology Development Fund [S-7-2, K113002, 2-1404, 3k143016]; Ministry of the Environment, Japan; National Natural Science Foundation of China [71325006, 71033004, 71311140172, 713111101]	This research was supported by the Environment Research and Technology Development Fund (S-7-2; K113002; 2-1404 and 3k143016), the Ministry of the Environment, Japan. Professor Yong Geng is supported by National Natural Science Foundation of China (71325006, 71033004, 71311140172, 713111101). The efforts of editors and reviewers are sincerely acknowledged.	Amann M., 2007, 5 NEC IIASA; Amann Markus, 2004, REGIONAL AIR POLLUTI; Chen AP, 2010, CHINA ECON REV, V21, P2, DOI 10.1016/j.chieco.2009.11.005; Schreifels JJ, 2012, ENERG POLICY, V48, P779, DOI 10.1016/j.enpol.2012.06.015; Zhang XY, 2012, ATMOS ENVIRON, V46, P590, DOI 10.1016/j.atmosenv.2011.03.004; Aunan K, 2004, ENERG POLICY, V32, P567, DOI 10.1016/S0301-4215(03)00156-3; Su SS, 2011, ENVIRON SCI TECHNOL, V45, P8403, DOI 10.1021/es201656f; Kanada M, 2013, ENERG POLICY, V61, P1322, DOI 10.1016/j.enpol.2013.05.105; Jiang P, 2013, J CLEAN PROD, V58, P130, DOI 10.1016/j.jclepro.2013.07.042; Zhang XH, 2011, ENERG POLICY, V39, P7432, DOI 10.1016/j.enpol.2011.09.011; Streets DG, 2000, ATMOS ENVIRON, V34, P363, DOI 10.1016/S1352-2310(99)00167-3; Fang M, 2009, ATMOS ENVIRON, V43, P79, DOI 10.1016/j.atmosenv.2008.09.064; Shrestha RM, 1997, ENERG ECON, V19, P355, DOI 10.1016/S0140-9883(96)01002-X; Zhao Y, 2008, ATMOS ENVIRON, V42, P8442, DOI 10.1016/j.atmosenv.2008.08.021; Tian HZ, 2013, ATMOS ENVIRON, V69, P273, DOI 10.1016/j.atmosenv.2012.12.033; Zhang KM, 2008, J ENVIRON MANAGE, V88, P1249, DOI 10.1016/j.jenvman.2007.06.019; Kim BG, 2001, ATMOS ENVIRON, V35, P727, DOI 10.1016/S1352-2310(00)00344-7; Gao CL, 2009, ENVIRON MANAGE, V43, P447, DOI 10.1007/s00267-008-9252-x; Liu F, 2013, J CLEAN PROD, V58, P25, DOI 10.1016/j.jclepro.2013.03.024; BP, 2011, BP WORLD EN STAT 201; Chae Y, 2003, CLIM POLICY, V3, pS57, DOI 10.1016/j.clipol.2003.10.005; Chen AP, 2010, J COMP ECON, V38, P189, DOI 10.1016/j.jce.2009.12.003; Dong YL, 2011, J CLEAN PROD, V19, P1306, DOI 10.1016/j.jclepro.2011.03.015; Fan S., 2011, REV DEV FINANCE, V1, P47, DOI DOI 10.1016/J.RDF.2010.10.001; Fujii H, 2013, J CLEAN PROD, V59, P22, DOI 10.1016/j.jclepro.2013.06.059; Geng Y, 2003, ENVIRON MANAGE, V31, P784, DOI 10.1007/s00267-002-2854-9; Geng Y, 2012, ENVIRON SCI TECHNOL, V46, P107, DOI 10.1021/es204293x; Hao Jiming, 2007, Frontiers of Environmental Science and Engineering in China, V1, DOI 10.1007/s11783-007-0024-2; He G, 2012, ENV DEV, V3, P25; He J, 2010, ECOL ECON, V69, P868, DOI 10.1016/j.ecolecon.2009.10.012; He J, 2005, CHINA ECON REV, V16, P364, DOI 10.1016/j.chieco.2005.03.005; Huang YX, 2010, ENERG POLICY, V38, P7531, DOI 10.1016/j.enpol.2010.07.046; IIASA, 2008, GAINS AS SCEN COST E; IIASA, 2008, GAINS AS TOOL COMB A; Kanada M, 2013, J CLEAN PROD, V58, P92, DOI 10.1016/j.jclepro.2013.04.015; Liangxiong H., 2011, ENERGY PROCEDIA, V5, P1008; Lin BQ, 2011, ENERGY, V36, P3120, DOI 10.1016/j.energy.2011.03.001; Ma LW, 2012, ENERGY, V40, P174, DOI 10.1016/j.energy.2012.02.013; Ma SH, 2012, J IND ECOL, V16, P506, DOI 10.1111/j.1530-9290.2011.00418.x; Qian JJ, 1998, ENERG POLICY, V26, P345; Wang JN, 2012, ENVIRON SCI TECHNOL, V46, P4263, DOI 10.1021/es301226n; Yu FX, 2011, ENERG POLICY, V39, P1586, DOI 10.1016/j.enpol.2010.12.034; Zhang ZX, 2007, ENERG POLICY, V35, P3547, DOI 10.1016/j.enpol.2007.02.002	43	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-6526	1879-1786		J CLEAN PROD	J. Clean Prod.	MAR 1	2015	90						345	359		10.1016/j.jclepro.2014.10.101		15	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CC1EM	WOS:000350084000033		
J	Takeuchi, S; Takasato, Y; Masaoka, H; Nagatani, K; Otani, N; Wada, K; Mori, K				Takeuchi, Satoru; Takasato, Yoshio; Masaoka, Hiroyuki; Nagatani, Kimihiro; Otani, Naoki; Wada, Kojiro; Mori, Kentaro			Decompressive craniectomy for arteriovenous malformation-related intracerebral hemorrhage	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Arteriovenous malformation; Complication; Decompressive craniectomy; Intracerebral hemorrhage; Stroke; Surgery	MIDDLE CEREBRAL-ARTERY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; COMMUNITY STROKE PROJECT; MALIGNANT INFARCTION; SURGICAL-TREATMENT; HEAD-INJURY; ICH SCORE; HEMICRANIECTOMY; SURGERY; HYDROCEPHALUS	Arteriovenous malformation (AVM)-related intracerebral hemorrhage (ICH) is the cause of approximately 2-3% of ICH and is an important factor in the significant morbidity and mortality in patients with AVM. Decompressive craniectomy (DC) is a surgical procedure to relieve malignant elevation of intracranial pressure. The use of DC to treat patients with AVM-ICH has been much less common. The present study describes our experience with DC for AVM-ICH and discusses the safety of this procedure. The present retrospective analysis compared 12 consecutive patients treated with DC for AVM-ICH with 23 patients treated with DC for hypertensive ICH. Nine patients were male and three were female, aged from 11 to 53 years (mean, 31.7 years). Hematoma volumes ranged from 50 to 106 ml (mean, 75.8 ml). The outcomes were good recovery in one patient, moderate disability in three, severe disability in seven, and vegetative state in one. Complications after DC included subdural hygroma in four patients, hydrocephalus in one, intracranial infection in two, and intracranial hemorrhage in one. No significant difference was found in the incidence of complications between DC for large AVM-ICH and DC for hypertensive ICH. In conclusion, the present study found no significant difference in the incidence of complications between DC for large AVM-ICH and DC for hypertensive ICH. Further investigations including a prospective randomized trial are needed to confirm the safety and efficacy of DC for the treatment of large AVMICH. (C) 2014 Elsevier Ltd. All rights reserved.	[Takeuchi, Satoru; Nagatani, Kimihiro; Otani, Naoki; Wada, Kojiro; Mori, Kentaro] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; [Takasato, Yoshio; Masaoka, Hiroyuki] Natl Hosp Org Disaster Med Ctr, Dept Neurosurg, Tachikawa, Tokyo, Japan	Takeuchi, S (reprint author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	s.takeuchi@room.ocn.ne.jp					Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Hemphill JC, 2001, STROKE, V32, P891; Fung C, 2012, STROKE, V43, P3207, DOI 10.1161/STROKEAHA.112.666537; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Kim KT, 2009, ACTA NEUROCHIR, V151, P21, DOI 10.1007/s00701-008-0164-6; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; DIERSSEN G, 1983, ACTA NEUROCHIR, V69, P53, DOI 10.1007/BF02055853; Rahme R, 2011, ACTA NEUROCHIR, V153, P897, DOI 10.1007/s00701-010-0927-8; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; DENNIS MS, 1993, STROKE, V24, P796; Murthy JMK, 2005, NEUROCRIT CARE, V2, P258, DOI 10.1385/Neurocrit.Care2005;2:258-262; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Maira G, 2002, NEUROL RES, V24, P54, DOI 10.1179/016164102101199549; Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Brown RD, 1996, NEUROLOGY, V46, P949; Choi JH, 2006, STROKE, V37, P1243, DOI 10.1161/01.STR.0000217970.18319.7d; Appelboom G, 2012, WORLD NEUROSURG, V78, P646, DOI 10.1016/j.wneu.2011.12.001; Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244; De Bonis P, 2013, CLIN NEUROL NEUROSUR, V115, P1308, DOI 10.1016/j.clineuro.2012.12.011; Kothari Rashmi U., 1996, Stroke, V27, P1304; Otani N, 2008, CEREBROVASC DIS, V26, P612, DOI 10.1159/000165115; PAPO I, 1979, NEUROSURGERY, V4, P504; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Takeuchi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12424; Takeuchi S, 2013, CLIN NEUROL NEUROSUR, V115, P317, DOI 10.1016/j.clineuro.2012.05.026; Takeuchi S, 2012, J TRAUMA ACUTE CARE, V73, P1254, DOI 10.1097/TA.0b013e318265cc14; Takeuchi S, 2012, CLIN NEUROL NEUROSUR, V114, P1312, DOI 10.1016/j.clineuro.2012.03.044; Takeuchi S, 2013, J CLIN NEUROSCI, V20, P377, DOI 10.1016/j.jocn.2012.03.035; van Beijnum Janneke, 2009, Brain, V132, P537, DOI 10.1093/brain/awn318	33	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2015	22	3					483	487		10.1016/j.jocn.2014.08.033		5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CC6YN	WOS:000350515000009		
J	Sako, W; Murakami, N; Izumi, Y; Kaji, R				Sako, Wataru; Murakami, Nagahisa; Izumi, Yuishin; Kaji, Ryuji			Val66Met polymorphism of brain-derived neurotrophic factor is associated with idiopathic dystonia	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Brain-derived neurotrophic factor; Dystonia; G196A; Meta-analysis; Polymorphism; Val66Met	CRANIAL-CERVICAL DYSTONIA; FACTOR GENE; VA166MET POLYMORPHISM; HIPPOCAMPAL ACTIVITY; COMMON POLYMORPHISM; HUMAN-MEMORY; BDNF; PLASTICITY; RISK	The Val66Met (G196A; rs6265) single nucleotide polymorphism of brain-derived neurotrophic factor (BDNF) affects morphology and neuronal activity, and is expected to be associated with central nervous system disorders. However, it remains controversial whether Val66Met polymorphism is a risk factor for idiopathic dystonia. We aimed to clarify the impact of BDNF polymorphism on idiopathic dystonia. A literature search of PubMed was carried out. A random-effects model was employed for the meta-analysis. A pooled odds ratio (OR) was calculated along with 95% confidence intervals (CI) to reflect the risk of idiopathic dystonia in each genotype (GG, AG, AA) or minor allele. The proportion of variation due to heterogeneity was computed and expressed as I-2. Five case-control studies, comprising a total sample size of 1804 subjects (784 idiopathic dystonia patients, 1020 normal controls), were included in this meta-analysis. AA genotype was significantly more frequent in patients with idiopathic dystonia (OR = 1.47, 95% CI 1.09-1.99, p = 0.01, four studies, n = 1716). This finding was derived from homogeneous studies (p = 0.97, I-2 = 0%). Our meta-analysis has revealed a significant overall effect of the AA genotype on the development of idiopathic dystonia. (C) 2014 Elsevier Ltd. All rights reserved.	[Sako, Wataru] Feinstein Inst Med Res, Ctr Neurosci, Manhasset, NY 11030 USA; [Murakami, Nagahisa; Izumi, Yuishin; Kaji, Ryuji] Univ Tokushima, Grad Sch Med Sci, Inst Hlth Biosci, Dept Clin Neurosci, Tokushima 770, Japan	Sako, W (reprint author), Feinstein Inst Med Res, Ctr Neurosci, 350 Community Dr, Manhasset, NY 11030 USA.	dwsako@yahoo.co.jp					Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Wang C, 2014, J NEUROSCI, V34, P2645, DOI 10.1523/JNEUROSCI.3501-13.2014; Hariri AR, 2003, J NEUROSCI, V23, P6690; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Martella G, 2009, BRAIN, V132, P2336, DOI 10.1093/brain/awp194; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Rodriguez S, 2009, AM J EPIDEMIOL, V169, P505, DOI 10.1093/aje/kwn359; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Chen YP, 2013, PARKINSONISM RELAT D, V19, P1043, DOI 10.1016/j.parkreldis.2013.06.004; Cramer SC, 2010, NEUROSCI LETT, V468, P42, DOI 10.1016/j.neulet.2009.10.059; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fahn S, 1998, Adv Neurol, V78, P1; Groen JL, 2012, MOVEMENT DISORD, V27, P796, DOI 10.1002/mds.24922; Groen JL, 2013, MOVEMENT DISORD, V28, P827, DOI 10.1002/mds.25381; Hashimoto R, 2008, NEUROSCI RES, V61, P360, DOI 10.1016/j.neures.2008.04.003; Lau J, 1997, ANN INTERN MED, V127, P820; Ma LY, 2013, NEUROSCI LETT, V533, P100, DOI 10.1016/j.neulet.2012.11.037; Martino D, 2009, EUR J NEUROL, V16, P949, DOI 10.1111/j.1468-1331.2009.02633.x; Newman JRB, 2012, PARKINSONISM RELAT D, V18, P351, DOI 10.1016/j.parkreldis.2011.11.024; Svetel MV, 2013, ACTA NEUROL BELG, V113, P243, DOI 10.1007/s13760-013-0183-9	23	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2015	22	3					575	577		10.1016/j.jocn.2014.08.014		3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CC6YN	WOS:000350515000027		
J	Sasagawa, Y; Tachibana, O; Nakagawa, A; Koya, D; Iizuka, H				Sasagawa, Yasuo; Tachibana, Osamu; Nakagawa, Atsushi; Koya, Daisuke; Iizuka, Hideaki			Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						GnRH agonist; Gonadotropin secreting adenomas; Pituitary apoplexy	PROSTATE-CANCER; LEUPROLIDE; GOSERELIN; THERAPY	Gonadotropin-releasing hormone (GnRH) agonists are widely used in hormone therapy for prostate cancer. We report a patient with pituitary apoplexy following this therapy as a rare complication and review the related literature. A 62-year-old man presented with elevated prostate specific antigen. Transrectal ultrasound guided biopsy of the prostate gland revealed adenocarcinoma. Whole-body F-18-fluorodeoxyglucose (FDG) positron emission tomography/CT scan showed FDG-uptake in the pituitary region. MRI also demonstrated a pituitary tumor, diagnosed as an incidental non-functioning adenoma. The patient received his first dose of GnRH agonist (leuprolide 11.25 mg) against prostate cancer. He complained of a severe headache 10 minutes after leuprolide administration and suffered from right third nerve palsy in the next 48 hours. MRI demonstrated a high intensity area on T1-weighted images, diagnosed as pituitary apoplexy. The patient underwent transsphenoidal surgery. Pathology revealed predominantly necrotic tissue and a gonadotropin secreting pituitary adenoma. Overall, 15 patients, including ours, have been reported with pituitary apoplexy after GnRH agonists with pathologic gonadotropin secreting adenoma. Fourteen of 15 patients were male. Pituitary apoplexy developed within 4 hours after administration of the agents in 8/15 patients. The combined data suggest that GnRH agonists have the potential to precipitate pituitary apoplexy in men with gonadotropin secreting adenoma. Therefore, prior to GnRH agonist therapy for prostate cancer, a known pituitary adenoma should be treated. Otherwise, the patients should be cautiously observed for any symptomatic change following drug administration. (C) 2014 Elsevier Ltd. All rights reserved.	[Sasagawa, Yasuo; Tachibana, Osamu; Iizuka, Hideaki] Kanazawa Med Univ, Dept Neurosurg, Uchinada, Ishikawa 9200293, Japan; [Nakagawa, Atsushi; Koya, Daisuke] Kanazawa Med Univ, Dept Endocrinol & Diabet, Uchinada, Ishikawa 9200293, Japan	Sasagawa, Y (reprint author), Kanazawa Med Univ, Dept Neurosurg, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	yacchan1218@yahoo.co.jp					ANDO S, 1995, LANCET, V345, P458, DOI 10.1016/S0140-6736(95)90443-3; Ito Y, 2011, INT J UROL, V18, P83, DOI 10.1111/j.1442-2042.2010.02676.x; Guerra Y, 2010, PITUITARY, V13, P54, DOI 10.1007/s11102-009-0202-2; Van Poppel H, 2012, INT J UROL, V19, P594, DOI 10.1111/j.1442-2042.2012.02997.x; CHANSON P, 1995, J CLIN ENDOCR METAB, V80, P2267, DOI 10.1210/jc.80.7.2267; Engel G, 2003, J ADOLESCENT HEALTH, V32, P89, DOI 10.1016/S1054-139X(02)00372-5; Blaut K, 2006, NEUROENDOCRINOL LETT, V27, P569; Davis Anu, 2006, Pituitary, V9, P263, DOI 10.1007/s11102-006-8616-6; Eaton HJ, 2001, INTERN MED J, V31, P313, DOI 10.1046/j.1445-5994.2001.00065.x; Hands Kathleen E, 2007, Endocr Pract, V13, P642; Massoud W, 2006, INT J UROL, V13, P303, DOI 10.1111/j.1442-2042.2006.01278.x; Morsi A, 1996, CLIN ENDOCRINOL, V44, P121, DOI 10.1046/j.1365-2265.1996.644465.x; Reznik Y, 1997, J ENDOCRINOL INVEST, V20, P566; Sinnadurai M, 2010, J CLIN NEUROSCI, V17, P1201, DOI 10.1016/j.jocn.2010.01.012; Spengos K, 2002, CEREBROVASC DIS, V14, P272, DOI 10.1159/000065664	15	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2015	22	3					601	603		10.1016/j.jocn.2014.08.015		3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CC6YN	WOS:000350515000035		
J	Takase, M; Teraoka, S; Kousuke, Y				Takase, Miyuki; Teraoka, Sachiko; Kousuke, Yabase			Investigating the adequacy of the Competence-Turnover Intention Model: how does nursing competence affect nurses' turnover intention?	JOURNAL OF CLINICAL NURSING			English	Article						affective organisational commitment; exhaustion; nurses; nursing competence; organisational rewards; turnover intention	LEADER-MEMBER EXCHANGE; PERCEIVED ORGANIZATIONAL SUPPORT; DEMANDS-RESOURCES MODEL; WORK ABILITY; JOB DEMANDS; EMOTIONAL EXHAUSTION; PSYCHOLOGICAL CONTRACTS; NORMATIVE COMMITMENT; BURNOUT; METAANALYSIS	Aims and objectivesThe aim of this study was to test the adequacy of the Competence-Turnover Intention Model, which was developed to identify how nursing competence could affect nurses' turnover intention (nurses' intention to voluntarily leave an organisation). BackgroundRecent studies have suggested that the level of nursing competence is negatively related to nurses' intention to leave their jobs, suggesting that a lack of competence threatens both the quality and quantity of the nursing workforce. However, the mechanism of how nursing competence affects nurses' turnover intention has not been explored previously. DesignA cross-sectional survey design was used. MethodsSurveys were distributed to 1337 Japanese registered nurses/midwives in October, 2013. The adequacy of the model was analysed using structural equation modelling. ResultsIn total, 766 questionnaires were returned, with a return rate of 57%. The model fitted well with the data. The results showed that the level of nursing competence was related positively to the quantity of organisational rewards they felt they had received, and negatively related to the level of exhaustion they experienced. Moreover, the perceived organisational rewards and exhaustion were correlated with nurses' turnover intention through affective commitment. ConclusionsThe Competence-Turnover Intention Model is useful for explaining how nursing competence impacts on their turnover intention. Relevance to clinical practiceClinical implications derived from the findings are that: promoting nursing competence is key to improving not only the quality of care provided by nurses, but also to retaining the nursing workforce, and the model can be used to develop strategies that would mitigate their turnover intention.	[Takase, Miyuki] Hiroshima Univ, Inst Biomed Hlth Sci, Hiroshima, Hiroshima 7348551, Japan; [Teraoka, Sachiko] Yasuda Womens Univ, Sch Nursing, Hiroshima, Hiroshima, Japan; [Kousuke, Yabase] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Hiroshima 7348551, Japan	Takase, M (reprint author), Hiroshima Univ, Inst Biomed Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima, Hiroshima 7348551, Japan.	mtakase@hiroshima-u.ac.jp					Dulebohn JH, 2012, J MANAGE, V38, P1715, DOI 10.1177/0149206311415280; Vandenberghe C, 2009, J OCCUP ORGAN PSYCH, V82, P331, DOI 10.1348/096317908X312641; Heidemeier H, 2009, J APPL PSYCHOL, V94, P353, DOI 10.1037/0021-9010.94.2.353; Tourigny L, 2013, INT J HUM RESOUR MAN, V24, P514, DOI 10.1080/09585192.2012.694109; Settoon RP, 1996, J APPL PSYCHOL, V81, P219, DOI 10.1037/0021-9010.81.3.219; Takase M, 2011, NURS HEALTH SCI, V13, P396, DOI 10.1111/j.1442-2018.2011.00631.x; Takase M, 2013, J CLIN NURS, V22, P1400, DOI 10.1111/j.1365-2702.2012.04239.x; Hu Q, 2011, J VOCAT BEHAV, V79, P181, DOI 10.1016/j.jvb.2010.12.009; Schaufeli WB, 2004, J ORGAN BEHAV, V25, P293, DOI 10.1002/job.248; Hakanen JJ, 2008, WORK STRESS, V22, P224, DOI 10.1080/02678370802379432; McNeese-Smith DK, 2003, J NURS ADMIN, V33, P260, DOI 10.1097/00005110-200305000-00002; KISHTON JM, 1994, EDUC PSYCHOL MEAS, V54, P757, DOI 10.1177/0013164494054003022; Meyer JP, 2002, J VOCAT BEHAV, V61, P20, DOI 10.1006/jvbe.2001.1842; Ladebo OJ, 2009, S AFR J PSYCHOL, V39, P46; Camerino D, 2008, INT J NURS STUD, V45, P1645, DOI 10.1016/j.ijnurstu.2008.03.002; Kowalski C, 2010, J CLIN NURS, V19, P1654, DOI 10.1111/j.1365-2702.2009.02989.x; Jourdain G, 2010, INT J NURS STUD, V47, P709, DOI 10.1016/j.ijnurstu.2009.11.007; Ng TWH, 2007, J VOCAT BEHAV, V70, P336, DOI 10.1016/j.jvb.2006.10.002; Brower HH, 2000, LEADERSHIP QUART, V11, P227, DOI 10.1016/S1048-9843(00)00040-0; Liden RC, 1998, J MANAGE, V24, P43, DOI 10.1016/S0149-2063(99)80053-1; Hall RJ, 1999, ORGAN RES METHODS, V2, P233, DOI 10.1177/109442819923002; Demerouti E, 2001, J APPL PSYCHOL, V86, P499, DOI 10.1037//0021-9010.86.3.499; Henderson DJ, 2008, J APPL PSYCHOL, V93, P1208, DOI 10.1037/a0012678; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Camerino D, 2006, J ADV NURS, V56, P542, DOI 10.1111/j.1365-2648.2006.04046.x; Kravits K, 2010, APPL NURS RES, V23, P130, DOI 10.1016/j.apnr.2008.08.002; Somers MJ, 2009, J VOCAT BEHAV, V74, P75, DOI 10.1016/j.jvb.2008.10.006; Bakker AB, 2005, J OCCUP HEALTH PSYCH, V10, P170, DOI 10.1037/1076-8998.10.2.170; Coffman DL, 2005, MULTIVAR BEHAV RES, V40, P235, DOI 10.1207/s15327906mbr4002_4; Demerouti E, 2010, J OCCUP HEALTH PSYCH, V15, P209, DOI 10.1037/a0019408; Hau KT, 2004, BRIT J MATH STAT PSY, V57, P327, DOI 10.1111/j.2044-8317.2004.tb00142.x; Chan ZCY, 2013, J NURS MANAGE, V21, P605, DOI 10.1111/j.1365-2834.2012.01437.x; O'Driscoll MP, 1999, APPL PSYCHOL-INT REV, V48, P197, DOI 10.1111/j.1464-0597.1999.tb00058.x; Brunetto Y, 2013, J NURS MANAGE, V21, P827, DOI 10.1111/jonm.12111; Axley Lawrette, 2008, Nurs Forum, V43, P214, DOI 10.1111/j.1744-6198.2008.00115.x; Bakker A. B., 2007, J MANAGERIAL PSYCHOL, V22, P309, DOI DOI 10.1108/02683940710733115; Blau P. M., 1964, EXCHANGE POWER SOCIA; Bogaert P, 2013, INT J NURS STUD, V50, P1667; Chiu MC, 2007, NURS OUTLOOK, V55, P318, DOI 10.1016/j.outlook.2007.07.002; Derycke H, 2012, J ADV NURS, V68, P1556, DOI 10.1111/j.1365-2648.2012.05961.x; DesGieter S, 2010, J ADV NURS, V66, P911; desJonge J, 2000, SOC SCI MED, V50, P1317; GOULDNER AW, 1960, AM SOCIOL REV, V25, P161, DOI 10.2307/2092623; Jepsen DM, 2012, PSYCHOL REP, V110, P820, DOI 10.2466/01.07.21.28.PR0.110.3.820-838; Jin J, 2012, J VOCAT BEHAV, V80, P326, DOI 10.1016/j.jvb.2011.10.007; Kline R. B., 2010, PRINCIPLES PRACTICE; Laschinger HKS, 2009, J NURS MANAGE, V17, P302, DOI DOI 10.1111/J.1365-2834.2009.00999.X; Maertz CP, 2012, HUM RESOUR MANAGE-US, V51, P71, DOI 10.1002/hrm.20464; McInnis KJ, 2009, J VOCAT BEHAV, V74, P165, DOI 10.1016/j.jvb.2008.12.007; Ministry of Internal Affairs and Communications, 2012, AV AG YEARS SERV MON; Newman A, 2012, INT J HUM RESOUR MAN, V23, P349, DOI 10.1080/09585192.2011.561229; Partnership Nursing System, 2012, NEW MED WORLD WEEKL, P1; Pullon S, 2008, J INTERPROFESSIONAL, V22, P133, DOI 10.1080/13561820701795069; ROUSSEAU DM, 1990, J ORGAN BEHAV, V11, P389, DOI 10.1002/job.4030110506; Somers MJ, 2010, J OCCUP ORGAN PSYCH, V83, P443, DOI 10.1348/096317909X424060; Takase M, 2011, J JAPAN SOC NURSING, V34, P103; Takase M, 2012, INT J NURS STUD, V49, P1521, DOI 10.1016/j.ijnurstu.2012.08.003; Tilley DDS, 2008, J CONTIN EDUC NURS, V39, P58; Veld M, 2014, J ADV NURS, V70, P855, DOI 10.1111/jan.12247	59	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	MAR	2015	24	5-6					805	816		10.1111/jocn.12711		12	Nursing	Nursing	CC4WE	WOS:000350354700018		
J	Takahashi, T; Mamada, A; Breakspear, S; Itou, T; Tanji, N				Takahashi, Toshie; Mamada, Akira; Breakspear, Steven; Itou, Takashi; Tanji, Noriyuki			Age-dependent changes in damage processes of hair cuticle	JOURNAL OF COSMETIC DERMATOLOGY			English	Article						hair; cuticle; age; cmc; weathering	18-METHYLEICOSANOIC ACID; SURFACE; DIAMETER; DENSITY; FIBERS; 18-MEA	Background Human hair cuticle is always exposed to various stresses and then gradually lost in daily life. There are two typical patterns of cuticle damage: type L, where the cell membrane complex, the structure located between cuticle cells, is split and the cuticle lifts up, and type E, where the fragile substructure of the cuticle cell (endocuticle) is damaged so that its rugged residue is exposed. We previously reported that type L damage preferentially occurs in the case of Japanese females in their 20s to 40s. Aims This study aims to elucidate the age-dependent change of cuticle and its effect on hair properties. Methods Hair fibers collected from Japanese females (ranging from 10 to 70 years old) were evaluated in the aspects of inclination for each type of damage, resistance of cuticle against grooming stresses and content of fatty acid 18-MEA on hair surface. Results It was revealed that the dominant damage pattern shifts from type L to E with aging. Furthermore, the cuticle becomes gradually less resistant to daily grooming stress. The dominance of type E damage accelerates cuticle loss. Reduction of 18-MEA on weathered hair is accelerated with aging on elder hair. Conclusions It has been reported that various age-dependent changes of whole hair shaft, such as diameter, density, elasticity, etc., occur in the age range of 40s and 50s. In this study, it was revealed that cuticle becomes more fragile and the hair surface properties deteriorate in the same age range.	[Takahashi, Toshie; Mamada, Akira; Breakspear, Steven; Itou, Takashi; Tanji, Noriyuki] Kao Corp, R&D, Dev Res, Hair Care Prod Res, Tokyo, Japan; [Takahashi, Toshie] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan	Takahashi, T (reprint author), 2-1-3 Bunka Sumida Ku, Tokyo 1318501, Japan.	takahashi.toshie@kao.co.jp					Birch MP, 2001, BRIT J DERMATOL, V144, P297, DOI 10.1046/j.1365-2133.2001.04018.x; Robbins C, 2012, BRIT J DERMATOL, V167, P324, DOI 10.1111/j.1365-2133.2012.11010.x; TATE ML, 1993, J SOC COSMET CHEM, V44, P347; Breakspear S, 2005, J STRUCT BIOL, V149, P235, DOI 10.1016/j.jsb.2004.10.003; Takahashi T, 2006, J COSMET SCI, V57, P327; Robbins C, 2009, J COSMET SCI, V60, P437; ROGERS GE, 1959, ANN NY ACAD SCI, V83, P378; Jones LN, 1997, MICRON, V28, P469, DOI 10.1016/S0968-4328(97)00039-5; Habe T, 2011, SURF INTERFACE ANAL, V43, P410, DOI 10.1002/sia.3407; Kim SN, 2013, BRIT J DERMATOL, V168, P1215, DOI 10.1111/bjd.12185; Mamada A, 2007, J COSMET SCI, V58, P485; Nagase S, 2009, J COSMET SCI, V60, P637; Natarajan U, 2010, J COSMET SCI, V61, P467; Okamoto M, 2012, SURF INTERFACE ANAL, V44, P736, DOI 10.1002/sia.3878; Okamoto M, 2011, SURF INTERFACE ANAL, V43, P298, DOI 10.1002/sia.3406; Otsuka H, 1988, KOSHOKAISHI, V12, P192; Rogers G, 2009, EXP DERMATOL, V18, P541, DOI 10.1111/j.1600-0625.2008.00825.x; Rogers GE, 2004, INT J DEV BIOL, V48, P163, DOI 10.1387/ijdb.15272381; Smith JR, 2005, MICRON, V36, P261, DOI 10.1016/j.micron.2004.11.004; Swift JA, 1999, J COSMET SCI, V50, P23; SWIFT JA, 1974, J SOC COSMET CHEM, V25, P13; Yoshida S, 2011, ADV PLANAR LIP BILAY, V13, P1, DOI 10.1016/B978-0-12-387721-5.00001-8	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1473-2130	1473-2165		J COSMET DERMATOL-US	J. Cosmet. Dermatol.	MAR	2015	14	1					2	8		10.1111/jocd.12129		7	Dermatology	Dermatology	CC6MT	WOS:000350479900002		
J	Iinuma, T; Arai, Y; Abe, Y; Takayama, M; Fukumoto, M; Fukui, Y; Iwase, T; Takebayashi, T; Hirose, N; Gionhaku, N; Komiyama, K				Iinuma, T.; Arai, Y.; Abe, Y.; Takayama, M.; Fukumoto, M.; Fukui, Y.; Iwase, T.; Takebayashi, T.; Hirose, N.; Gionhaku, N.; Komiyama, K.			Denture Wearing during Sleep Doubles the Risk of Pneumonia in the Very Elderly	JOURNAL OF DENTAL RESEARCH			English	Article						oral hygiene; very old; infection; Candida albicans; pneumonitis; interleukin-6	OLDEST-OLD SURVEY; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; TOTAL HEALTH; ORAL-HEALTH; STOMATITIS; MORTALITY; HYGIENE; TABLETS; CANDIDA	Poor oral health and hygiene are increasingly recognized as major risk factors for pneumonia among the elderly. To identify modifiable oral health-related risk factors, we prospectively investigated associations between a constellation of oral health behaviors and incident pneumonia in the community-living very elderly (i.e., 85 years of age or older). At baseline, 524 randomly selected seniors (228 men and 296 women; mean age, 87.8 years) were examined for oral health status and oral hygiene behaviors as well as medical assessment, including blood chemistry analysis, and followed up annually until first hospitalization for or death from pneumonia. During a 3-year follow-up period, 48 events associated with pneumonia (20 deaths and 28 acute hospitalizations) were identified. Among 453 denture wearers, 186 (40.8%) who wore their dentures during sleep were at higher risk for pneumonia than those who removed their dentures at night (log rank P = 0.021). In a multivariate Cox model, both perceived swallowing difficulties and overnight denture wearing were independently associated with an approximately 2.3-fold higher risk of the incidence of pneumonia (for perceived swallowing difficulties, hazard ratio [HR], 2.31; and 95% confidence interval [CI], 1.11-4.82; and for denture wearing during sleep, HR, 2.38; and 95% CI, 1.25-4.56), which was comparable with the HR attributable to cognitive impairment (HR, 2.15; 95% CI, 1.06-4.34), history of stroke (HR, 2.46; 95% CI, 1.13-5.35), and respiratory disease (HR, 2.25; 95% CI, 1.20-4.23). In addition, those who wore dentures during sleep were more likely to have tongue and denture plaque, gum inflammation, positive culture for Candida albicans, and higher levels of circulating interleukin-6 as compared with their counterparts. This study provided empirical evidence that denture wearing during sleep is associated not only with oral inflammatory and microbial burden but also with incident pneumonia, suggesting potential implications of oral hygiene programs for pneumonia prevention in the community.	[Iinuma, T.; Fukumoto, M.; Fukui, Y.; Gionhaku, N.] Nihon Univ, Sch Dent, Dept Complete Denture Prosthodont, Tokyo 101, Japan; [Arai, Y.; Abe, Y.; Hirose, N.] Keio Univ, Sch Med, Ctr Supercentenarian Res, Tokyo, Japan; [Takayama, M.] Keio Univ, Sch Med, Ctr Prevent Med, Tokyo, Japan; [Iwase, T.; Komiyama, K.] Nihon Univ, Sch Dent, Dept Pathol, Tokyo 101, Japan; [Takebayashi, T.] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo, Japan	Iinuma, T (reprint author), Nihon Univ, Sch Dent, Dept Complete Denture Prosthodont, Tokyo 101, Japan.	iinuma.toshimitsu@nihon-u.ac.jp; yasumich@z6.keio.jp			Japan Society for the Promotion of Science [21390245, 20590706, 21590775, 24590898, 22593247, 26463194]; Sato from Nihon University School of Dentistry; Japan Health Foundation for the Prevention of Chronic Disease and the Improvement of QOL of Patients; Foundation for Total Health Promotion; Univers Foundation; Chiyoda Mutual Life Foundation	We thank the participants for their time and personal information and Ms. Miho Shimura for her kind assistance. In addition to the authors, the following contributed to data acquisition as TOOTH investigators: Ken Yamamura, MD, PhD; Yoshinori Ebihara, MD, PhD; Kenichiro Shimizu, MD, PhD; Susumu Nakazawa, MD; Kensuke Nishio, DDS, PhD; Kentaro Urata, DDS; Mitsuru Maruno, DDS; Reio Ito, DDS; and Midori Takayama, PhD. This study was funded by grants from the Grants-in-Aid for Scientific Research (B) (No. 21390245) and (C) (Nos. 20590706, 21590775, 24590898, 22593247, 26463194) from Japan Society for the Promotion of Science, by a grant from the Sato from Nihon University School of Dentistry, by a grant from Japan Health Foundation for the Prevention of Chronic Disease and the Improvement of QOL of Patients, by a grant from the Foundation for Total Health Promotion, by The Univers Foundation, and by the Chiyoda Mutual Life Foundation. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Adachi M, 2002, ORAL SURG ORAL MED O, V94, P191, DOI 10.1067/moe.2002.123493; AMBJORNSEN E, 1982, ACTA ODONTOL SCAND, V40, P203, DOI 10.3109/00016358209019813; Pires FR, 2002, J ORAL REHABIL, V29, P1115, DOI 10.1046/j.1365-2842.2002.00947.x; Awano S, 2008, J DENT RES, V87, P334; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251; Janssens JP, 2004, LANCET INFECT DIS, V4, P112, DOI 10.1016/S1473-3099(04)00931-4; Shulman JD, 2005, J ORAL PATHOL MED, V34, P340, DOI 10.1111/j.1600-0714.2005.00287.x; Emami E, 2013, J DENT, V41, P703, DOI 10.1016/j.jdent.2013.05.017; Compagnoni MA, 2007, J ORAL REHABIL, V34, P600, DOI 10.1111/j.1365-2842.2007.01754.x; Marcenes W, 2013, J DENT RES, V92, P592, DOI 10.1177/0022034513490168; Iinuma T, 2012, J AM GERIATR SOC, V60, P68, DOI 10.1111/j.1532-5415.2011.03780.x; Arai Y, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-35; Baran I, 2009, ARCH GERONTOL GERIAT, V49, P237, DOI 10.1016/j.archger.2008.08.010; Duyck J, 2013, J DENT, V41, P1281, DOI 10.1016/j.jdent.2013.08.002; EICHNER K, 1990, Stomatologie der DDR, V40, P321; Evren BA, 2011, ARCH GERONTOL GERIAT, V53, P252, DOI 10.1016/j.archger.2010.12.016; Felton DA, 2011, J PROSTHODONT, V20, P1, DOI 10.1111/j.1532-849X.2010.00674.x; Fenlon M R, 1998, Eur J Prosthodont Restor Dent, V6, P145; Hyogo Dental Association, 1996, GREAT HANSHIN AWAJI, V33, P41; Ikebe K, 2006, J ORAL REHABIL, V33, P36, DOI 10.1111/j.1365-2842.2006.01527.x; Japanese School Dental Association, 2007, ACT GUID SCH DENT, P43; Jose A, 2010, J PROSTHODONT, V19, P252, DOI 10.1111/j.1532-849X.2009.00561.x; Juthani-Mehta M, 2013, J AM GERIATR SOC, V61, P1111, DOI 10.1111/jgs.12325; Kurozumi A, 2010, ANN JPN PROSTHDONT S, V2, P260; Silva-Lovato CH, 2010, J APPL ORAL SCI, V18, P560, DOI 10.1590/S1678-77572010000600005; Sumi Yasunori, 2003, Gerodontology, V20, P84, DOI 10.1111/j.1741-2358.2003.00084.x; Takamiya AS, 2011, GERODONTOLOGY, V28, P91, DOI 10.1111/j.1741-2358.2010.00369.x; VIGILD M, 1987, COMMUNITY DENT ORAL, V15, P309, DOI 10.1111/j.1600-0528.1987.tb01741.x; Wang Jing, 2006, Gerodontology, V23, P157, DOI 10.1111/j.1741-2358.2006.00130.x	30	3	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-0345	1544-0591		J DENT RES	J. Dent. Res.	MAR	2015	94	3		1			28S	36S		10.1177/0022034514552493		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CC4GA	WOS:000350308700006		
J	Asai, K; Yamori, M; Yamazaki, T; Yamaguchi, A; Takahashi, K; Sekine, A; Kosugi, S; Matsuda, F; Nakayama, T; Bessho, K				Asai, K.; Yamori, M.; Yamazaki, T.; Yamaguchi, A.; Takahashi, K.; Sekine, A.; Kosugi, S.; Matsuda, F.; Nakayama, T.; Bessho, K.		Nagahama Study Grp	Tooth Loss and Atherosclerosis: The Nagahama Study	JOURNAL OF DENTAL RESEARCH			English	Article						arterial stiffness; epidemiology; inflammation; periodontal disease; cross-sectional analysis; cardiovascular diseases	CORONARY-HEART-DISEASE; ANKLE VASCULAR INDEX; PULSE-WAVE VELOCITY; PERIODONTAL-DISEASE; CARDIOVASCULAR-DISEASE; ARTERIAL STIFFNESS; RISK; CAVI; ASSOCIATIONS; HEALTH	Several epidemiologic studies have suggested that oral disease is a risk factor for cardiovascular disease (CVD). However, whether a clinically significant association exists between the 2 disorders remains controversial. Here, we investigated the association between tooth loss, as an indicator of oral disease, and arterial stiffness, as a marker of atherosclerosis, in Japanese adults. Cross-sectional data were collected for 8,124 persons aged 30 to 75 y with no history of tooth loss for noninflammatory reasons, such as orthodontic treatment, malposition, and trauma. Participants received a comprehensive dental examination and extensive in-person measurements of CVD risk factors, and arterial stiffness was evaluated using the cardio-ankle vascular index (CAVI). We examined the association between CAVI and tooth loss using general linear models with adjustment for age, sex, body mass index, smoking status, hemoglobin A1c, and a history of insulin or hypoglycemic medication depending on the model. In addition, we performed an analysis that included interaction terms of the centered variables tooth loss, sex, and age. The results of the multiple regression analysis that included the interaction terms detected that the relationship between CAVI and tooth loss was dependent on sex, with only men showing a positive correlation ( for interaction = 0.04; 95% confidence interval, 0.02-0.06). The findings from this study suggest that a linear relationship exists between tooth loss and degree of arterial stiffness and that the association differed depending on sex.	[Asai, K.; Yamori, M.; Yamazaki, T.; Yamaguchi, A.; Takahashi, K.; Bessho, K.] Kyoto Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kyoto, Japan; [Sekine, A.] Kyoto Univ, Grad Sch Med, EBM Res Ctr, Kyoto, Japan; [Kosugi, S.] Kyoto Univ, Grad Sch Med, Dept Biomed Eth, Kyoto, Japan; [Matsuda, F.] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto, Japan; [Nakayama, T.] Kyoto Univ, Sch Publ Hlth, Dept Hlth Informat, Kyoto, Japan	Yamori, M (reprint author), Kyoto Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kyoto, Japan.	yamori@kuhp.kyoto-u.ac.jp		Kadotani, Hiroshi/0000-0001-7474-3315	Ministry of Education, Culture, Sports, Science and Technology of Japan; Takeda Science Foundation; Kyoto University; 8020 Promotion Foundation; Ministry of Health, Labour and Welfare, Japan	The authors cordially thank the participants of the Nagahama Study, staff of the Nagahama City Office, and the Kohoku Medical Association, Kohoku Dental Association, Nagahama City Hospital, Nagahama Red Cross Hospital, Nagahama Kohoku City Hospital, Non-profit Organization "Zero-ji Club for Health Promotion," and the Lion Foundation for Dental Health for providing clinical support. The Nagahama Study is in part supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan and by the Takeda Science Foundation. Finally, this study would not have been possible without the effort of all who have contributed to the establishment of the Nagahama Study project. This study was partially supported by grants-in-aid from the following organizations: Kyoto University (2006), Takeda Science Foundation (2008), the 8020 Promotion Foundation (2011), and the Ministry of Health, Labour and Welfare, Japan (2009-2013). The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.	Tu YK, 2007, HEART, V93, P1098, DOI 10.1136/hrt.2006.097410; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Beck JD, 2001, ARTERIOSCL THROM VAS, V21, P1816, DOI 10.1161/hq1101.097803; Desvarieux M, 2004, STROKE, V35, P2029, DOI 10.1161/01.STR.0000136767.71518.36; Yambe T, 2004, BIOMED PHARMACOTHER, V58, pS95, DOI 10.1016/S0753-3322(04)80015-5; Hujoel PP, 2000, JAMA-J AM MED ASSOC, V284, P1406, DOI 10.1001/jama.284.11.1406; Takaki A, 2008, HYPERTENS RES, V31, P1347, DOI 10.1291/hypres.31.1347; Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3; Desvarieux M, 2003, STROKE, V34, P2120, DOI 10.1161/01.STR.0000085086.50957.22; Shirai K, 2011, J ATHEROSCLER THROMB, V18, P924; Dietrich T, 2008, CIRCULATION, V117, P1668, DOI 10.1161/CIRCULATIONAHA.107.711507; NICHOLS WW, 1985, AM J CARDIOL, V55, P1179, DOI 10.1016/0002-9149(85)90659-9; Okura T, 2007, HYPERTENS RES, V30, P335, DOI 10.1291/hypres.30.335; Kadota K, 2008, CIRC J, V72, P304, DOI 10.1253/circj.72.304; Demmer RT, 2008, COMMUNITY DENT ORAL, V36, P493, DOI 10.1111/j.1600-0528.2008.00435.x; Kim HD, 2010, J PERIODONTOL, V81, P658, DOI 10.1902/jop.2010.090614; Ylostalo PV, 2006, J CLIN PERIODONTOL, V33, P92, DOI 10.1111/j.1600.051X2005.00875.x; Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101; KANNEL WB, 1976, ANN INTERN MED, V85, P447; Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186; Kagamimori S, 2009, SOC SCI MED, V68, P2152, DOI 10.1016/j.socscimed.2009.03.030; Pussinen PJ, 2003, ARTERIOSCL THROM VAS, V23, P1250, DOI 10.1161/01.ATV.0000072969.71452.87; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beck J D, 1998, Ann Periodontol, V3, P127, DOI 10.1902/annals.1998.3.1.127; Choe H, 2009, ATHEROSCLEROSIS, V203, P550, DOI 10.1016/j.atherosclerosis.2008.07.017; Colhoun HM, 2008, J PERIODONTAL RES, V43, P103, DOI 10.1111/j.1600-0765.2007.01001.x; de Oliveira C, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2451; Herzberg MC, 1996, J PERIODONTOL, V67, P1138; Houshmand M, 2012, J CLIN PERIODONTOL, V39, P635, DOI 10.1111/j.1600-051X.2012.01892.x; Hujoel PP, 2001, J AM DENT ASSOC, V132, P883; Lahelma E, 2010, HEALTH PLACE, V16, P61, DOI 10.1016/j.healthplace.2009.08.004; Lavelle Chris, 2002, J Can Dent Assoc, V68, P176; Sako H, 2009, CIRC J, V73, P1151; Senba T, 2008, J OCCUP HEALTH, V50, P283, DOI 10.1539/joh.L7066; Tabara Y, 2013, INT J CARDIOL, V168, P2673, DOI 10.1016/j.ijcard.2013.03.028	35	2	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0022-0345	1544-0591		J DENT RES	J. Dent. Res.	MAR	2015	94	3		1			52S	58S		10.1177/0022034514559127		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CC4GA	WOS:000350308700009		
J	Sekioka, R; Tanaka, M; Nishimura, T; Itoh, H				Sekioka, Risa; Tanaka, Masami; Nishimura, Takeshi; Itoh, Hiroshi			Serum total bilirubin concentration is negatively associated with increasing severity of retinopathy in patients with type 2 diabetes mellitus	JOURNAL OF DIABETES AND ITS COMPLICATIONS			English	Article						Total bilirubin; Diabetic retinopathy; Type 2 diabetes mellitus; Hypertension; Human	ADHESION MOLECULES; METABOLIC SYNDROME; ANTIOXIDANT; MEN; RAT	Aims: Serum bilirubin concentration is associated with diabetic retinopathy in patients with type 2 diabetes. This study investigated the relationships between serum bilirubin concentration and the severity of diabetic retinopathy. In addition, the importance of bilirubin was compared with factors that were previously shown to be associated with the incidence of diabetic retinopathy. Methods: A total of 674 patients with type 2 diabetes were investigated in this cross-sectional study. Serum total bilirubin concentration was compared between patients with and without diabetic retinopathy, and according to the severity of retinopathy. Univariate and multivariate analyses were performed to evaluate the association of retinopathy with total bilirubin concentration, duration of diabetes, body mass index, systolic blood pressure, and haemoglobin A1c. Results: Serum total bilirubin concentration was significantly lower in patients with retinopathy than in those without Patients with severer retinopathy showed lower total bilirubin concentration, longer diabetes duration, and higher systolic blood pressure. These three parameters were independent explanatory factors for diabetic retinopathy. Conclusions: Total bilirubin concentration is lower in patients with type 2 diabetes complicated with severer retinopathy. Thus, bilirubin might protect against retinopathy in patients with type 2 diabetes. (C) 2015 Elsevier Inc. All rights reserved.	[Sekioka, Risa; Tanaka, Masami; Nishimura, Takeshi; Itoh, Hiroshi] Keio Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Nephrol,Shinjuku Ku, Tokyo 1608582, Japan	Sekioka, R (reprint author), Keio Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Nephrol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	r-sekioka@tenor.ocn.ne.jp; tana176k@a7.keio.jp; t-nishimura128@z6.keio.jp; hiito@z8.keio.jp			Takeda; MSD; Sanofi-Aventis; Astellas; Daiichi Sankyo	Hiroshi ITOH has received compensation from NIPRO, lecture fees from Takeda and MSD, and scholarship grants from Sanofi-Aventis, Astellas, Takeda, MSD, and Daiichi Sankyo. The other authors have no conflict of interest.	Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Novotny L, 2003, EXP BIOL MED, V228, P568; Horio M, 2010, AM J KIDNEY DIS, V56, P32, DOI 10.1053/j.ajkd.2010.02.344; Fujii M, 2010, KIDNEY INT, V78, P905, DOI 10.1038/ki.2010.265; Limb GA, 1999, INVEST OPHTH VIS SCI, V40, P2453; Sedlak TW, 2009, P NATL ACAD SCI USA, V106, P5171, DOI 10.1073/pnas.0813132106; Mazzone GL, 2009, BIOCHEM BIOPH RES CO, V386, P338, DOI 10.1016/j.bbrc.2009.06.029; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Kawasaki R, 2011, DIABETOLOGIA, V54, P2288, DOI 10.1007/s00125-011-2199-0; Chan KH, 2013, DIABETOLOGIA, V56, P724, DOI 10.1007/s00125-012-2818-4; Cui Y, 2006, EXP EYE RES, V83, P807, DOI 10.1016/j.exer.2006.03.024; HAMMES HP, 1994, DIABETOLOGIA, V37, P32; Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631; Yasuda M, 2011, OPHTHALMOLOGY, V118, P1423, DOI 10.1016/j.ophtha.2010.12.009; Cho Ho Chan, 2011, Diabetes Metab J, V35, P595, DOI 10.4093/dmj.2011.35.6.595; Davis MD, 1997, INT TXB DIABETES MEL, P1413; Ellis EA, 2000, FREE RADICAL BIO MED, V28, P91, DOI 10.1016/S0891-5849(99)00216-6; Hernandez C, 2005, DIABETIC MED, V22, P719, DOI 10.1111/j.1464-5491.2005.01538.x; Inoguchi T., 2007, JAMA-J AM MED ASSOC, V298, P1396; Kim ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109251; Lee MJ, 2014, DIABETES METAB, V40, P305, DOI 10.1016/j.diabet.2014.04.006; Najam SS, 2014, J DIABETES, V6, P221, DOI 10.1111/1753-0407.12085; Seino Y., 2010, J DIABETES INVEST, V19, P212; Takayanagi R., 2010, J CLIN BIOCHEM NUTR, V48, P72, DOI 10.3164/jcbn.11-014FR; UK Prospective Diabetes Study Group, 1998, BMJ-BRIT MED J, V317, P703, DOI DOI 10.1136/BMJ.317.7160.703; Vitek L, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00055	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1056-8727	1873-460X		J DIABETES COMPLICAT	J. Diabetes Complications	MAR	2015	29	2					218	221		10.1016/j.jdiacomp.2014.12.002		4	Endocrinology & Metabolism	Endocrinology & Metabolism	CC7EX	WOS:000350531600011		
J	Katome, T; Namekata, K; Mitamura, Y; Semba, K; Egawa, M; Naito, T; Harada, C; Harada, T				Katome, Takashi; Namekata, Kazuhiko; Mitamura, Yoshinori; Semba, Kentaro; Egawa, Mariko; Naito, Takeshi; Harada, Chikako; Harada, Takayuki			Expression of intraocular peroxisome proliferator-activated receptor gamma in patients with proliferative diabetic retinopathy	JOURNAL OF DIABETES AND ITS COMPLICATIONS			English	Article						Angiogenesis; Diabetic retinopathy; Exosomes; Peroxisome proliferator-activated receptor gamma; Vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOTACTIC PROTEIN-1; BREAST-CANCER CELLS; II TYPE-1 RECEPTOR; PPAR-GAMMA; EPIRETINAL MEMBRANES; KAPPA-B; INFLAMMATION; LIGANDS; NEOVASCULARIZATION	Aims: To determine whether peroxisome proliferator-activated receptor gamma (PPAR gamma), which is recognized as a component of the exosomes circulating in plasma, is expressed intraocularly in patients with proliferative diabetic retinopathy (PDR). Methods: The concentrations of PPAR gamma and vascular endothelial growth factor (VEGF) in the aqueous humor and vitreous of 50 eyes with PDR and 38 control eyes were determined by ELISA. The levels of the mRNA and protein of PPAR gamma were determined in proliferative membranes from 12 PDR and 5 control eyes by quantitative RT-PCR and immunohistochemical analyses. Results: PPAR gamma was detected in the culture media of human umbilical vein endothelial cells indicating that PPAR gamma can be released into the extracellular fluid. The PPAR gamma concentrations in the aqueous humor and vitreous fluid were significantly higher in PDR patients than in controls (P < 0.0005). There was a significant positive correlation between the PPAR gamma and VEGF concentrations (P < 0.0005). The level of PPAR gamma increased as the clinical stage advanced. The expressions of the mRNA and protein of PPAR gamma were higher in the membranes of PDR than those of controls. Anti-VEGF therapy significantly reduced the VEGF concentration (P < 0.0001) but not the PPAR gamma concentration. Conclusions: PPAR gamma may play an important role in the pathogenesis of PDR. (C) 2015 Elsevier Inc. All rights reserved.	[Katome, Takashi; Mitamura, Yoshinori; Semba, Kentaro; Egawa, Mariko; Naito, Takeshi; Harada, Takayuki] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Ophthalmol, Tokushima 7708503, Japan; [Katome, Takashi; Namekata, Kazuhiko; Semba, Kentaro; Harada, Chikako; Harada, Takayuki] Tokyo Metropolitan Inst Med Sci, Visual Res Project, Tokyo 113, Japan	Mitamura, Y (reprint author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Ophthalmol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	ymitaymitaymita@yahoo.co.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Funding Program for Next Generation World-Leading Researchers (NEXT Program)	There are no conflicts of interest. This study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (T. Katome, K. Namekata, Y. Mitamura, C. Harada, T. Harada), and the Funding Program for Next Generation World-Leading Researchers (NEXT Program) (T. Harada).	Abu El-Asrar AM, 2007, BRIT J OPHTHALMOL, V91, P822, DOI 10.1136/bjo.2006.109876; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Sassa Y, 2004, DIABETES, V53, P1222, DOI 10.2337/diabetes.53.5.1222; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309; Terrasi M, 2013, J CELL PHYSIOL, V228, P1368, DOI 10.1002/jcp.24295; SMIDDY WE, 1989, OPHTHALMOLOGY, V96, P811; Imayama I, 2006, CARDIOVASC RES, V72, P184, DOI 10.1016/j.cardiores.2006.07.014; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Szeles L, 2007, BBA-MOL CELL BIOL L, V1771, P1014, DOI 10.1016/j.bbalip.2007.02.005; Uchiyama M, 2013, MOL VIS, V19, P2135; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65; Biscetti F, 2013, MOL CELL ENDOCRINOL, V381, P80, DOI 10.1016/j.mce.2013.07.011; Biscetti F, 2008, DIABETES, V57, P1394, DOI 10.2337/db07-0765; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Biscetti F, 2009, NUTR METAB CARDIOVAS, V19, P751, DOI 10.1016/j.numecd.2009.04.011; Rosen ED, 2001, J BIOL CHEM, V276, P37731; Looze C, 2009, BIOCHEM BIOPH RES CO, V378, P433, DOI 10.1016/j.bbrc.2008.11.050; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Burgos R, 2000, DIABETES CARE, V23, P80, DOI 10.2337/diacare.23.1.80; Harada T, 2002, DIABETES CARE, V25, P1060, DOI 10.2337/diacare.25.6.1060; Katome T., 2012, DIABETES RES CLIN PR, V98, P9; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546; Mitamura Y, 2003, DIABETOLOGIA, V46, P699, DOI 10.1007/s00125-003-1084-x; Mitamura Yoshinori, 2005, Curr Diabetes Rev, V1, P73, DOI 10.2174/1573399052952596; Mitamura Y, 2001, OPHTHALMOLOGICA, V215, P415, DOI 10.1159/000050900; Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709; Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P4342, DOI 10.1167/iovs.06-1473; Pershadsingh HA, 2008, PPAR RES, DOI 10.1155/2008/164273; Talbert DR, 2008, BREAST CANCER RES TR, V108, P23, DOI 10.1007/s10549-007-9575-y; Tashimo A, 2004, DIABETIC MED, V21, P1292, DOI 10.1111/j.1464-5491.2004.01334.x; Yoshida-Hata Natsuyo, 2010, Diabetes Res Clin Pract, V87, pe26, DOI 10.1016/j.diabres.2009.12.008	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1056-8727	1873-460X		J DIABETES COMPLICAT	J. Diabetes Complications	MAR	2015	29	2					275	281		10.1016/j.jdiacomp.2014.10.010		7	Endocrinology & Metabolism	Endocrinology & Metabolism	CC7EX	WOS:000350531600020		
J	Takahashi, N; Miura, H; Narita, M; Nishijima, N; Magara, Y				Takahashi, Naohiko; Miura, Haruo; Narita, Mitsuhiro; Nishijima, Noriyo; Magara, Yohei			Development of Scallop Cut Type Damper Seal for Centrifugal Compressors	JOURNAL OF ENGINEERING FOR GAS TURBINES AND POWER-TRANSACTIONS OF THE ASME			English	Article						damper seal; bulk flow analysis; CFD; rotordynamic characteristics; compressor; stability		This paper deals with a new type of damper seal developed for a high-pressure centrifugal compressor. Honeycomb seals and hole pattern seals are popularly used as damper seals and provide superior rotordynamic damping characteristics. Honeycomb seals are expensive because the manufacturing process is complex. Hole pattern seals are easier to manufacture, but they are still expensive. Use of a scallop pattern is one way to reduce manufacturing cost and time. A new seal that has a scallop pattern and small teeth on the stator surface is proposed. This pattern is cut on the stator surface using a disk type tool. To estimate the rotordynamic coefficients of this new seal, a bulk flow model code that is based on a two-control-volume model developed by Matsuda for labyrinth seals was newly developed. This model uses the Hirs model for the viscous shear stresses. The friction factor coefficients for the rotor surface, the stator surface, and the surface between the two-control-volumes were determined by computational fluid dynamics (CFD) steady analysis. The rotordynamic coefficients can also be obtained by using CFD perturbation analysis. The high accuracy of the bulk flow model was demonstrated by comparing its results with CFD perturbation analysis results. In the perturbation analysis, the whirling motion was treated as a steady-state problem by using a rotating frame of reference. For the damper seal, the rotor surface and its neighboring region were treated with a rotating frame of reference and the neighboring region of the stator was treated with a stationary frame of reference. The damping property of the new seal was evaluated by conducting rotor stability tests using a high-pressure compressor with an electromagnetic exciter. The new seal equipped with swirl brakes was used for the balance piston of the compressor. Stability was evaluated by exciting the rotor during operation and identifying the eigenvalues of the rotor. The experimental results showed that the new seal increases damping. Comparison of the damping effect with calculations based on the bulk flow analysis showed good agreement.	[Takahashi, Naohiko] Hitachi Ltd, Turbomachinery R&D Ctr, Infrastruct Syst Co, Tsuchiura, Ibaraki 3000013, Japan; [Miura, Haruo; Narita, Mitsuhiro] Hitachi Ltd, Compressor Div, Infrastruct Syst Co, Tsuchiura, Ibaraki 3000013, Japan; [Nishijima, Noriyo] Hitachi Ltd, Planning Off, Hitachi Res Lab, Hitachi, Ibaraki 3191292, Japan; [Magara, Yohei] Hitachi Ltd, Reliabil Sci Res Dept, Hitachi Res Lab, Hitachinaka, Ibaraki 3120034, Japan	Takahashi, N (reprint author), Hitachi Ltd, Turbomachinery R&D Ctr, Infrastruct Syst Co, 603 Kandatsu Machi, Tsuchiura, Ibaraki 3000013, Japan.	naohiko.takahashi.qb@hitachi-pt.com; haruo.miura.wm@hitachi-pt.com; mitsuhiro.narita.nq@hitachi-pt.com; noriyo.nishijima.sj@hitachi.com; yohei.magara.bc@hitachi.com					Migliorini PJ, 2012, J TRIBOL-T ASME, V134, DOI 10.1115/1.4006407; Camatti M., 2003, P 32 TURB S TURB LAB, P39; Chochua G., 2002, THESIS U FLORIDA GAI; Hirs G. G., 1973, ASME, V94, P137; Kleynhans G. F., 1996, THESIS TEXAS A M U C; Komodori K., 1973, NONCONTACT SEALING T; Matsuda M., 2006, 7 IFTOMM C ROT DYANM; Scharrer J., 1987, THESIS TEXAS A M U C; Shultz R. R., 1996, United States Patent, Patent No. 5540447; Takahashi N, 2012, J ENG GAS TURB POWER, V134, DOI 10.1115/1.4004439; Vance J., 2010, MACHINERY VIBRATION	11	0	0	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0742-4795	1528-8919		J ENG GAS TURB POWER	J. Eng. Gas. Turbines Power-Trans. ASME	MAR	2015	137	3							032509	10.1115/1.4028448		9	Engineering, Mechanical	Engineering	CC1ZV	WOS:000350144900021		
J	Okabe, T				Okabe, Takahiro			Initial profile for the slow decay of the Navier-Stokes flow in the half-space	JOURNAL OF EVOLUTION EQUATIONS			English	Article						Stokes flow; Navier-Stokes flow; Energy decay; Lower bound	LARGE-TIME BEHAVIOR; WEAK SOLUTIONS; L2 DECAY; ENERGY CONCENTRATION; ASYMPTOTIC-BEHAVIOR; GENERAL DOMAINS; EQUATIONS; RN+	We consider the lower bound of the energy decay of the Navier-Stokes flow in the half-space . We investigate the initial profile which cases the slow decay of the energy of solution and consider the application for the concentration phenomenon of the energy into the lower spectral bounds.	Hirosaki Univ, Dept Math Educ, Hirosaki, Aomori 0368560, Japan	Okabe, T (reprint author), Hirosaki Univ, Dept Math Educ, Hirosaki, Aomori 0368560, Japan.	okabe@cc.hirosaki-u.ac.jp			 [25800070]	The author would like to thank Professor Takayuki Kobayashi and Professor Takayuki Kubo for their preprints. This work partially was supported by Grant-in-Aid for Young Scientists (B) 25800070.	BORCHERS W, 1990, ACTA MATH-DJURSHOLM, V165, P189, DOI 10.1007/BF02391905; Carpio A, 1996, SIAM J MATH ANAL, V27, P449, DOI 10.1137/S0036141093256782; KOZONO H, 1989, J DIFFER EQUATIONS, V79, P79, DOI 10.1016/0022-0396(89)90114-9; SCHONBEK ME, 1992, INDIANA U MATH J, V41, P809, DOI 10.1512/iumj.1992.41.41042; KAJIKIYA R, 1986, MATH Z, V192, P135, DOI 10.1007/BF01162027; WIEGNER M, 1987, J LOND MATH SOC, V35, P303; SCHONBEK ME, 1985, ARCH RATION MECH AN, V88, P209, DOI 10.1007/BF00752111; BORCHERS W, 1988, MATH ANN, V282, P139, DOI 10.1007/BF01457017; Fujigaki Y., 2002, INT MATH SER N Y, V1, P91; Fujigaki Y, 2001, SIAM J MATH ANAL, V33, P523, DOI 10.1137/S0036141000367072; Kobayashi T., PREPRINT; Leray J, 1934, ACTA MATH-DJURSHOLM, V63, P193, DOI 10.1007/BF02547354; MASUDA K, 1984, TOHOKU MATH J, V36, P623, DOI 10.2748/tmj/1178228767; Miyakawa T., 2001, METHODS APPL ANAL, V8, P121; Miyakawa T., 2001, MATH BOHEM, V126, P443; Okabe T., PREPRINT; Okabe T, 2009, J DIFFER EQUATIONS, V246, P895, DOI 10.1016/j.jde.2008.07.037; Okabe T, 2013, J MATH ANAL APPL, V401, P534, DOI 10.1016/j.jmaa.2012.12.033; Schonbek M. E., 1991, J AM MATH SOC, V4, P423, DOI 10.2307/2939262; SCHONBEK ME, 1986, COMMUN PART DIFF EQ, V11, P733, DOI 10.1080/03605308608820443; Skalak Z, 2010, J MATH FLUID MECH, V12, P503, DOI 10.1007/s00021-009-0300-y; Skalak Z, 2009, NONLINEAR ANAL-THEOR, V71, P593, DOI 10.1016/j.na.2008.10.095; Skalak Z., 2009, ANN U FERRARA, V55, P377; Skalak Z., 2010, DISCRETE CONTIN DY S, V3, P361; Skalak Z, 2011, ZAMM-Z ANGEW MATH ME, V91, P724, DOI 10.1002/zamm.200900399; Skalak Z., PREPRINT; Skalak Z, 2009, NONLINEAR ANAL-THEOR, V71, pE2070, DOI 10.1016/j.na.2009.03.063; UKAI S, 1987, COMMUN PUR APPL MATH, V40, P611, DOI 10.1002/cpa.3160400506	28	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1424-3199	1424-3202		J EVOL EQU	J. Evol. Equ.	MAR	2015	15	1					149	163		10.1007/s00028-014-0254-2		15	Mathematics, Applied; Mathematics	Mathematics	CC4SC	WOS:000350342600007		
J	Asthana, AK; Friedman, AB; Maconi, G; Maaser, C; Kucharzik, T; Watanabe, M; Gibson, PR				Asthana, Anil Kumar; Friedman, Antony B.; Maconi, Giovanni; Maaser, Christian; Kucharzik, Torsten; Watanabe, Mamoru; Gibson, Peter R.			The failure of gastroenterologists to apply intestinal ultrasound in inflammatory bowel disease in the Asia-Pacific: A need for action	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Review						abdominal abscess; computerized tomography; Crohn's disease; disease assessment; fistula; imaging modalities; intestinal ultrasound; magnetic resonance imaging; stricture; ulcerative colitis	SUPERIOR MESENTERIC-ARTERY; SUSPECTED CROHNS-DISEASE; COMPUTED-TOMOGRAPHY; DOPPLER SONOGRAPHY; TRANSABDOMINAL ULTRASONOGRAPHY; TRANSPERINEAL ULTRASONOGRAPHY; RADIATION-EXPOSURE; DIAGNOSTIC-TOOL; COMPLICATIONS; RECURRENCE	Intestinal ultrasound (IUS) is a cheap, noninvasive, risk-free procedure that is significantly underutilized in the diagnosis and management of patients with inflammatory bowel disease (IBD) in the Asia-Pacific region. More cost-effective methods of monitoring disease activity are required in light of the increasing global burden of IBD (especially in Asia), the advent of personalized medicine, and the rising cost of healthcare. IUS is a prime example of a technique that meets these needs. Its common clinical applications include assessing the activity and complications of IBD. In continental Europe, countries such as Germany and Italy use this imaging tool as the standard of care and have integrated it into management protocols. There are formal training programs in these countries to train gastroenterologists in IUS, and it is used in an outpatient setting during patient consultations. Barriers to its use in the Asia-Pacific region include lack of experience and research data, and there are few established centers with active training programs. These concerns can be addressed by investing more in IUS service provision and by increasing allocation of resources toward local research and training. Increased uptake of IUS will ultimately benefit patients with IBD.	[Asthana, Anil Kumar; Friedman, Antony B.; Gibson, Peter R.] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic 3004, Australia; [Asthana, Anil Kumar; Friedman, Antony B.; Gibson, Peter R.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maconi, Giovanni] Luigi Sacco Univ Hosp, Dept Biomed & Clin Sci, Gastroenterol Unit, Milan, Italy; [Maaser, Christian; Kucharzik, Torsten] Univ Teaching Hosp Lueneburg, Dept Gen Internal Med & Gastroenterol, Luneburg, Germany; [Watanabe, Mamoru] Tokyo Med & Dent Univ, Grad Sch Med Sci, Dept Gastroenterol, Tokyo, Japan	Asthana, AK (reprint author), Alfred Hosp, Dept Gastroenterol, 55 Commercial Rd, Melbourne, Vic 3004, Australia.	dranilasthana@gmail.com					Allen PB, 2011, INFLAMM BOWEL DIS, V17, P1987, DOI 10.1002/ibd.21598; Andreoli A, 1998, AM J GASTROENTEROL, V93, P1117; Suri S, 1999, ACTA RADIOL, V40, P422; Prideaux L, 2012, J GASTROEN HEPATOL, V27, P1266, DOI 10.1111/j.1440-1746.2012.07150.x; Piscaglia F, 2012, ULTRASCHALL MED, V33, P33, DOI 10.1055/s-0031-1281676; Arora G, 2009, GASTROINTEST ENDOSC, V69, P654, DOI 10.1016/j.gie.2008.09.008; Plaikner M, 2014, TECH COLOPROCTOL, V18, P165, DOI 10.1007/s10151-013-1031-x; Panes J, 2013, J CROHNS COLITIS, V7, P556, DOI 10.1016/j.crohns.2013.02.020; Drews BH, 2009, EUR RADIOL, V19, P1379, DOI 10.1007/s00330-008-1290-5; Fraquelli M, 2008, DIGEST LIVER DIS, V40, P860, DOI 10.1016/j.dld.2008.04.006; [Anonymous], 2014, BEST PRACT RES CLIN, V28, P363; Smith LA, 2012, WORLD J GASTROENTERO, V18, P6782, DOI 10.3748/wjg.v18.i46.6782; van Randen A, 2011, EUR RADIOL, V21, P1535, DOI 10.1007/s00330-011-2087-5; Wilson J, 2010, INFLAMM BOWEL DIS, V16, P1550, DOI 10.1002/ibd.21209; Pascu M, 2004, INFLAMM BOWEL DIS, V10, P373, DOI 10.1097/00054725-200407000-00008; Neye H, 2004, DIGEST DIS, V22, P67, DOI 10.1159/000078737; Moreno N, 2014, J CROHNS COLITIS, V8, P1079, DOI 10.1016/j.crohns.2014.02.008; Parente F, 2004, GUT, V53, P1652, DOI 10.1136/gut.2004.041038; Shabana WM, 2008, AM J ROENTGENOL, V190, P736, DOI 10.2214/AJR.07.3115; Maconi G, 2008, INFLAMM BOWEL DIS, V14, P1555, DOI 10.1002/ibd.20515; Bouguen G, 2015, CLIN GASTROENTEROL H, V13, P1042, DOI 10.1016/j.cgh.2013.09.006; Rigazio C, 2009, SCAND J GASTROENTERO, V44, P585, DOI 10.1080/00365520802705992; Horsthuis K, 2008, RADIOLOGY, V247, P64, DOI 10.1148/radiol.2471070611; Stewart LK, 2001, AM J ROENTGENOL, V177, P627; Panes J, 2011, ALIMENT PHARM THER, V34, P125, DOI 10.1111/j.1365-2036.2011.04710.x; Martinez MJ, 2009, ABDOM IMAGING, V34, P141, DOI 10.1007/s00261-008-9365-y; Strobel D, 2011, WORLD J GASTROENTERO, V17, P3192, DOI 10.3748/wjg.v17.i27.3192; Gasche C, 1999, GUT, V44, P112; Maconi G, 2009, AM J ROENTGENOL, V193, P700, DOI 10.2214/AJR.08.1979; [Anonymous], LANDESARZTEKAMMER TS; BOZKURT T, 1994, J CLIN ULTRASOUND, V22, P85, DOI 10.1002/jcu.1870220204; Butcher RO, 2012, SCAND J GASTROENTERO, V47, P1192, DOI 10.3109/00365521.2012.706829; Byrne MF, 2001, CLIN RADIOL, V56, P973, DOI 10.1053/crad.2001.0794; Calabrese E, 2009, INFLAMM BOWEL DIS, V15, P1635, DOI 10.1002/ibd.20948; Calabrese E, 2012, INT J INFLAM, V2012; Chatu S, 2012, ALIMENT PHARM THER, V35, P529, DOI 10.1111/j.1365-2036.2011.04975.x; Di Sabatino A, 2004, DIGEST DIS, V22, P63, DOI 10.1159/000078736; Han Kimyoung, 2013, J Prev Med Public Health, V46, P300, DOI 10.3961/jpmph.2013.46.6.300; HATA J, 1992, AM J GASTROENTEROL, V87, P443; Karoui S, 2010, J CROHNS COLITIS, V4, P334, DOI 10.1016/j.crohns.2009.12.011; Kohn A, 1999, INFLAMM BOWEL DIS, V5, P153; Maconi G, 2014, J CROHNS COLITIS, V8, P1684, DOI 10.1016/j.crohns.2014.08.005; Maconi G, 1998, GUT, V43, P645; Maconi G, 2003, Ann Ital Chir, V74, P651; Maconi G, 1996, DIGEST DIS SCI, V41, P1643, DOI 10.1007/BF02087914; Maconi G, 2013, INFLAMM BOWEL DIS, V19, P2737, DOI 10.1097/01.MIB.0000436274.95722.e5; Maconi G, 2011, DIGEST LIVER DIS, V43, P165, DOI 10.1016/j.dld.2010.05.017; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Migaleddu V, 2009, GASTROENTEROLOGY, V137, P43, DOI 10.1053/j.gastro.2009.03.062; Monteleone M, 2013, J CROHNS COLITIS, V7, pS64; Monteleone MFA, 2013, ECCO; Mosli MH, 2014, AM J GASTROENTEROL, V109, P994, DOI 10.1038/ajg.2014.110; Nevler A, 2013, COLORECTAL DIS, V15, P1011, DOI 10.1111/codi.12204; Pallotta N, 2012, INFLAMM BOWEL DIS, V18, P74, DOI 10.1002/ibd.21678; Parente F, 2009, DIGEST DIS, V27, P285, DOI 10.1159/000228562; Parente F, 2010, AM J GASTROENTEROL, V105, P1150, DOI 10.1038/ajg.2009.672; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; PERA A, 1988, DIGESTION, V41, P180; SHERIDAN MB, 1993, CLIN RADIOL, V48, P402, DOI 10.1016/S0009-9260(05)81109-2; SOLVIG J, 1995, ABDOM IMAGING, V20, P323, DOI 10.1007/BF00203364; SONNENBERG A, 1982, GASTROENTEROLOGY, V83, P430; VANOOSTAYEN JA, 1994, RADIOLOGY, V193, P551; Welfare AIoHa, 2014, HLTH WELFARE EXPENDI, V51	63	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2015	30	3					446	452		10.1111/jgh.12871		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC1YE	WOS:000350140500008		
J	Yamasaki, Y; Nouso, K; Miyahara, K; Wada, N; Dohi, C; Morimoto, Y; Kinugasa, H; Takeuchi, Y; Yasunaka, T; Kuwaki, K; Onishi, H; Ikeda, F; Miyake, Y; Nakamura, S; Shiraha, H; Takaki, A; Iwasaki, Y; Amano, M; Nishimura, SI; Yamamoto, K				Yamasaki, Yasushi; Nouso, Kazuhiro; Miyahara, Koji; Wada, Nozomu; Dohi, Chihiro; Morimoto, Yuki; Kinugasa, Hideaki; Takeuchi, Yasuto; Yasunaka, Tetsuya; Kuwaki, Kenji; Onishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Iwasaki, Yoshiaki; Amano, Maho; Nishimura, Shin-Ichiro; Yamamoto, Kazuhide			Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						diagnosis; non-alcoholic steatohepatitis; serum glycan	FATTY LIVER-DISEASE; ASIA-PACIFIC REGION; FUCOSYL-TRANSFERASE; PANCREATIC-CANCER; SCORING SYSTEM; N-GLYCANS; BIOMARKER; FIBROSIS; GLYCOME	Background and AimsSerum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non-alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non-alcoholic steatohepatitis (NASH) from simple steatosis (SS). MethodsWe collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high-throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined. ResultsAmong the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis. ConclusionWe clearly demonstrated whole-serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.	[Yamasaki, Yasushi; Nouso, Kazuhiro; Miyahara, Koji; Wada, Nozomu; Dohi, Chihiro; Morimoto, Yuki; Kinugasa, Hideaki; Takeuchi, Yasuto; Yasunaka, Tetsuya; Kuwaki, Kenji; Onishi, Hideki; Ikeda, Fusao; Miyake, Yasuhiro; Nakamura, Shinichiro; Shiraha, Hidenori; Takaki, Akinobu; Iwasaki, Yoshiaki; Yamamoto, Kazuhide] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Okayama 7008558, Japan; [Nouso, Kazuhiro; Onishi, Hideki; Ikeda, Fusao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Hepatol, Okayama, Okayama 7008558, Japan; [Amano, Maho; Nishimura, Shin-Ichiro] Hokkaido Univ, Fac Adv Life Sci, Field Drug Discovery Res, Sapporo, Hokkaido, Japan; [Amano, Maho; Nishimura, Shin-Ichiro] Hokkaido Univ, Grad Sch Life Sci, Sapporo, Hokkaido, Japan; [Amano, Maho; Nishimura, Shin-Ichiro] Med Chem Pharmaceut Co Ltd, Sapporo, Hokkaido, Japan	Nouso, K (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Hepatol, Kita Ku, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan.	nouso@cc.okayama-u.ac.jp			Japan Society for the Promotion of Science [KAKENHI 23590976]; Japan Science and Technology Agency (JST); Ministry of Education, Culture, Science, and Technology, Japan	This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI 23590976), and partly supported by a grant for Development of Systems and Technology for Advanced Measurement and Analysis (SENTAN) and The Matching Program for Innovations in Future Drug Discovery and Medical Care from the Japan Science and Technology Agency (JST) and the Ministry of Education, Culture, Science, and Technology, Japan.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Chitturi S, 2007, J GASTROEN HEPATOL, V22, P778, DOI 10.1111/j.1440-1746.2007.05001.x; Okuyama N, 2006, INT J CANCER, V118, P2803, DOI 10.1002/ijc.21728; Vernon G, 2011, ALIMENT PHARM THER, V34, P274, DOI 10.1111/j.1365-2036.2011.04724.x; Nouso K, 2013, J GASTROENTEROL, V48, P1171, DOI 10.1007/s00535-012-0732-7; Amarapurkar DN, 2007, J GASTROEN HEPATOL, V22, P788, DOI 10.1111/j.1440-1746.2007.05042.x; Nishimura SI, 2011, ADV CARBOHYD CHEM BI, V65, P219, DOI 10.1016/B978-0-12-385520-6.00005-4; Klein A, 2010, PROTEOM CLIN APPL, V4, P372, DOI 10.1002/prca.200900151; Sumida Y, 2011, J GASTROENTEROL, V46, P257, DOI 10.1007/s00535-010-0305-6; Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Diab DL, 2008, CLIN GASTROENTEROL H, V6, P1249, DOI 10.1016/j.cgh.2008.07.016; Nakagawa T, 2006, J BIOL CHEM, V281, P29797, DOI 10.1074/jbc.M605697200; Blomme B, 2009, J HEPATOL, V50, P592, DOI 10.1016/j.jhep.2008.12.010; Kamada Y, 2013, PROTEOM CLIN APPL, V7, P648, DOI 10.1002/prca.201200137; Bekesova S, 2012, J PROTEOMICS, V75, P2216, DOI 10.1016/j.jprot.2012.01.024; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Vanderschaeghe D, 2009, MOL CELL PROTEOMICS, V8, P986, DOI 10.1074/mcp.M800470-MCP200; Blomme B, 2012, DIGEST LIVER DIS, V44, P315, DOI 10.1016/j.dld.2011.10.015; CAMPION B, 1989, EUR J BIOCHEM, V184, P405, DOI 10.1111/j.1432-1033.1989.tb15032.x; Javaud C, 2003, GENETICA, V118, P157, DOI 10.1023/A:1024101625214; Kamada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066328; Miyahara K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074861; Miyahara K, 2014, HEPATOLOGY, V59, P355, DOI 10.1002/hep.26531; Wang W, 2001, GLYCOBIOLOGY, V11, P165, DOI 10.1093/glycob/11.2.165	27	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2015	30	3					528	534		10.1111/jgh.12726		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC1YE	WOS:000350140500018		
J	Hashimoto, Y; Hamaguchi, M; Kojima, T; Ohshima, Y; Ohbora, A; Kato, T; Nakamura, N; Fukui, M				Hashimoto, Yoshitaka; Hamaguchi, Masahide; Kojima, Takao; Ohshima, Yasuhiro; Ohbora, Akihiro; Kato, Takahiro; Nakamura, Naoto; Fukui, Michiaki			The modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						epidemiology; fatty liver; NAFLD; obesity	SERUM ALANINE AMINOTRANSFERASE; METABOLIC SYNDROME; UNITED-STATES; DISEASE; RISK; METAANALYSIS; ASSOCIATION; ADIPONECTIN; PREVALENCE; LIGHT	Background and AimRecent cross-sectional studies have been reported the possibility that light to moderate alcohol consumption might be negatively associated with fatty liver. However, there has been no large-scale longitudinal study addressing an impact of alcohol consumption on a development of fatty liver diagnosed by ultrasonography. Thus, we investigated the impact of alcohol consumption on a natural history of fatty liver. MethodsWe analyzed 5437 apparently healthy Japanese who received the health checkup programs repeatedly over 10 years. In this study, we used a standardized questionnaire for addressing the medical history and lifestyle and used a standardized ultrasonographic diagnosis for fatty liver. The total amount of alcohol consumed per week was calculated and classified into four grades; none or minimal, light, moderate, or heavy alcohol consumption (<40, 40-140, 140-280 or >280g/week, respectively). The hazard risks of alcohol consumption for the development of fatty liver were calculated by Cox hazard model after adjusting age, BMI, and parameters for lifestyle. ResultsDuring 10 years of follow-up, fatty liver was continuously diagnosed just in 10% of men and 20% of women with fatty liver at the baseline. In men, the adjusted hazard risks of light and moderate alcohol consumption for the development of fatty liver were 0.72 (95% confidence interval 0.60-0.86, P<0.001) and 0.69 (0.57-0.84, P<0.001), respectively. However, they were not significant in women. ConclusionsThe newly onset of fatty liver was significantly repressed in apparently healthy men who consume light to moderate alcohol.	[Hashimoto, Yoshitaka; Hamaguchi, Masahide; Nakamura, Naoto; Fukui, Michiaki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kyoto 6028566, Japan; [Kojima, Takao; Ohshima, Yasuhiro; Ohbora, Akihiro; Kato, Takahiro] Asahi Univ, Murakami Mem Hosp, Dept Gastroenterol, Gifu, Japan	Hamaguchi, M (reprint author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Endocrinol & Metab, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	seele@koto.kpu-m.ac.jp		Hamaguchi, Masahide/0000-0002-8651-4445	Japan Society for the Promotion of Science [23790791, 26860502]	Financial support. This study was funded in part by Young Scientists (B) from Japan Society for the Promotion of Science, no. 23790791 and 26860502. The funders did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Ekstedt M, 2009, SCAND J GASTROENTERO, V44, P366, DOI 10.1080/00365520802555991; Hernaez R, 2011, HEPATOLOGY, V54, P1082, DOI 10.1002/hep.24452; Hamaguchi M, 2005, ANN INTERN MED, V143, P722; Agarwal DP, 2002, ALCOHOL ALCOHOLISM, V37, P409, DOI 10.1093/alcalc/37.5.409; Omagari K, 2002, J GASTROEN HEPATOL, V17, P1098, DOI 10.1046/j.1440-1746.2002.02846.x; Nakajima T, 2004, HEPATOLOGY, V40, P972, DOI 10.1002/hep.20399; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; Siler SQ, 1999, AM J CLIN NUTR, V70, P928; AARON DJ, 1995, AM J EPIDEMIOL, V142, P191; Koppes LLJ, 2005, DIABETES CARE, V28, P719, DOI 10.2337/diacare.28.3.719; Nishiyama Y, 2012, J HEPATOL, V56, P441, DOI 10.1016/j.jhep.2011.07.024; Dunn W, 2012, J HEPATOL, V57, P384, DOI 10.1016/j.jhep.2012.03.024; Wong VWS, 2012, GUT, V61, P409, DOI 10.1136/gutjnl-2011-300342; Centis E, 2010, DIGEST DIS, V28, P267, DOI 10.1159/000282101; Hashimoto E, 2011, J GASTROENTEROL, V46, P63, DOI 10.1007/s00535-010-0311-8; Gunji T, 2009, AM J GASTROENTEROL, V104, P2189, DOI 10.1038/ajg.2009.361; Pischon T, 2005, AM J CLIN NUTR, V81, P780; Hamaguchi M, 2012, WORLD J GASTROENTERO, V18, P156, DOI 10.3748/wjg.v18.i2.156; Sierksma A, 2004, DIABETES CARE, V27, P184, DOI 10.2337/diacare.27.1.184; Mendez-Sanchez N, 2007, LIVER INT, V27, P423, DOI 10.1111/j.1478-3231.2007.01483.x; Howard AA, 2004, ANN INTERN MED, V140, P211; Hamaguchi M, 2012, WORLD J GASTROENTERO, V18, P237, DOI 10.3748/wjg.v18.i3.237; Ryu S, 2007, CLIN CHEM, V53, P71, DOI 10.1373/clinchem.2006.078980; Bedogni G, 2007, HEPATOLOGY, V46, P1387, DOI 10.1002/hep.21827; Ruhl CE, 2005, CLIN GASTROENTEROL H, V3, P1260, DOI 10.1016/S1542-3565(05)00743-3; Harrison SA, 2007, GUT, V56, P1760, DOI 10.1136/gut.2006.112094; Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295; Suzuki A, 2007, AM J GASTROENTEROL, V102, P1912, DOI 10.1111/j.1572-0241.2007.01274.x; Hamaguchi M, 2007, AM J GASTROENTEROL, V102, P2708, DOI 10.1111/j.1572-0241.2007.01526.x; Moriya A, 2011, ALIMENT PHARM THER, V33, P378, DOI 10.1111/j.1365-2036.2010.04520.x; Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Bellentani S, 1997, GUT, V41, P845; Fukui M, 2005, DIABETIC MED, V22, P1446, DOI 10.1111/j.1464-5491.2005.01629.x; Gutierrez-Grobe Ylse, 2010, Ann Hepatol, V9, P402; Hamaguchi M, 2013, WORLD J GASTROENTERO, V19, P5393, DOI 10.3748/wjg.v19.i32.5393; Ioannou GN, 2006, HEPATOLOGY, V43, P1145, DOI 10.1002/hep.21171; Liangpunsakul S, 2012, AM J GASTROENTEROL, V107, P976, DOI [10.1038/ajg.2012.20, 10.1030/ajg.2012.20]; McCullough Arthur J, 2004, Clin Liver Dis, V8, P521, DOI 10.1016/j.cld.2004.04.004; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Ronksley PE, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d671; Senmaru T, 2013, METABOLISM, V62, P851, DOI 10.1016/j.metabol.2012.12.007; Sookoian S, 2013, GUT, V63, P530	44	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2015	30	3					546	552		10.1111/jgh.12786		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC1YE	WOS:000350140500021		
J	Matsushita, H; Miyake, Y; Takaki, A; Yasunaka, T; Koike, K; Ikeda, F; Shiraha, H; Nouso, K; Yamamoto, K				Matsushita, Hiroshi; Miyake, Yasuhiro; Takaki, Akinobu; Yasunaka, Tetsuya; Koike, Kazuko; Ikeda, Fusao; Shiraha, Hidenori; Nouso, Kazuhiro; Yamamoto, Kazuhide			TLR4, TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis: Relationship with clinical characteristics	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						biliary epithelial cell; cholangiocarcinoma; inflammasome; innate immunity; primary sclerosing cholangitis; toll-like receptor	INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; HEPATIC EXPRESSION; CIRRHOSIS; ACTIVATION; BILE; IDENTIFICATION; CONTRIBUTES; MANAGEMENT; DIAGNOSIS	Background and AimInappropriate innate immune responses have been suggested to contribute to the pathogenesis of primary sclerosing cholangitis (PSC). We evaluated the associations of expressions of toll-like receptor (TLR) 4, TLR9, and nucleotide-binding oligomerization domain-containing protein (NOD)-like receptor family pyrin domain containing 3 (NLRP3) in the biliary epithelial cells (BECs) with clinical features of PSC patients. MethodsWe retrospectively evaluated the expressions of TLR4, TLR9, and NLRP3 in the intrahepatic BECs by immunohistochemical staining in 21 PSC patients and 10 normal controls. In PSC, 17 patients underwent liver biopsy, and, in the other four patients, liver specimens were obtained at the time of liver transplantation. ResultsTLR9 expressions in BECs were higher in PSC patients than in normal controls. TLR9 expressions were correlated with Ludwig fibrosis scores in PSC patients. TLR4 and NLRP3 expressions were similar between PSC patients and normal controls. Seventeen PSC patients undergoing liver biopsy were followed up during a median period of 55.7 months. Four reached to liver transplantation and four developed cholangiocarcinoma. Patients developing cholangiocarcinoma showed lower NLRP3 expressions than the others. Patients reaching to liver transplantation showed higher TLR9 expressions. Expression levels of TLR9 and NLRP3 were not correlated with liver biochemical tests and Mayo risk scores. ConclusionsIn PSC, excessive immune responses through TLR9 signaling may be associated with the disease progression. Insufficient immune response through NLRP3 signaling may be associated with the development of cholangiocarcinoma. Evaluation of TLR9 and NLRP3 expressions in BECs may be useful for predicting the prognosis as an auxiliary marker.	[Matsushita, Hiroshi; Miyake, Yasuhiro; Takaki, Akinobu; Yasunaka, Tetsuya; Koike, Kazuko; Ikeda, Fusao; Shiraha, Hidenori; Nouso, Kazuhiro; Yamamoto, Kazuhide] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Kita Ku, Okayama 7008558, Japan	Miyake, Y (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	miyake43@md.okayama-u.ac.jp					Hiramatsu K, 2000, J HEPATOL, V33, P9, DOI 10.1016/S0168-8278(00)80153-1; Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592; Sasatomi K, 1998, J HEPATOL, V29, P409, DOI 10.1016/S0168-8278(98)80058-5; Janse M, 2011, HEPATOLOGY, V53, P1977, DOI 10.1002/hep.24307; Singh S, 2013, CLIN GASTROENTEROL H, V11, P898, DOI 10.1016/j.cgh.2013.02.016; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Boonstra K, 2012, INFLAMM BOWEL DIS, V18, P2270, DOI 10.1002/ibd.22938; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Benias PC, 2012, CLIN RES HEPATOL GAS, V36, P448, DOI 10.1016/j.clinre.2012.07.001; Wu JB, 2013, J IMMUNOL, V190, P3590, DOI 10.4049/jimmunol.1200860; Rojo OP, 2007, INFLAMM BOWEL DIS, V13, P269, DOI 10.1002/ibd.20019; Boberg KM, 2011, BEST PRACT RES CL GA, V25, P753, DOI 10.1016/j.bpg.2011.10.002; Chapman R, 2010, HEPATOLOGY, V51, P660, DOI 10.1002/hep.23294; Rudolph G, 2009, J HEPATOL, V51, P149, DOI 10.1016/j.jhep.2009.01.023; Mueller T, 2011, LIVER INT, V31, P1574, DOI 10.1111/j.1478-3231.2011.02635.x; Biondo C, 2011, EUR J IMMUNOL, V41, P1969, DOI 10.1002/eji.201141490; Hoque R, 2011, GASTROENTEROLOGY, V141, P358, DOI 10.1053/j.gastro.2011.03.041; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Ishii Y, 2013, INT J ONCOL, V43, P1073, DOI 10.3892/ijo.2013.2038; Szabo G, 2012, J HEPATOL, V57, P642, DOI 10.1016/j.jhep.2012.03.035; LaRusso NF, 2006, HEPATOLOGY, V44, P746, DOI 10.1002/hep.21337; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; Gitter AH, 2001, GASTROENTEROLOGY, V121, P1320, DOI 10.1053/gast.2001.29694; Harada K, 2001, J PATHOL, V193, P218, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH776>3.0.CO;2-H; Karrar A, 2007, GASTROENTEROLOGY, V132, P1504, DOI 10.1053/j.gastro.2007.01.039; Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125; Kulaksiz H, 2006, J HEPATOL, V45, P711, DOI 10.1016/j.jhep.2006.07.022; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; Navaneethan U, 2012, ALIMENT PHARM THER, V35, P1045, DOI 10.1111/j.1365-2036.2012.05063.x; Nilsson HO, 2000, J CLIN MICROBIOL, V38, P1072; Sanchez-Munoz F, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-138; Tanaka A, 2014, J HEPATO-BIL-PAN SCI, V21, P43, DOI 10.1002/jhbp.50; Wang AP, 2005, J AUTOIMMUN, V25, P85, DOI 10.1016/j.jaut.2005.05.003; Watanabe A, 2009, AM J PHYSIOL-GASTR L, V296, pG1248, DOI 10.1152/ajpgi.90223.2008	35	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2015	30	3					600	608		10.1111/jgh.12711		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC1YE	WOS:000350140500028		
J	Honda, Y; Takahashi, S; Zhang, Y; Ono, A; Murakami, E; Shi, N; Kawaoka, T; Miki, D; Tsuge, M; Hiraga, N; Abe, H; Ochi, H; Imamura, M; Aikata, H; Chayama, K				Honda, Yohji; Takahashi, Shoichi; Zhang, Yizhou; Ono, Atsushi; Murakami, Eisuke; Shi, Niu; Kawaoka, Tomokazu; Miki, Daiki; Tsuge, Masataka; Hiraga, Nobuhiko; Abe, Hiromi; Ochi, Hidenori; Imamura, Michio; Aikata, Hiroshi; Chayama, Kazuaki			The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						apoptosis; bisphosphonate; Ras and RhoA; zoledronic acid	BREAST-CANCER CELLS; BONE METASTASES; IN-VITRO; 3RD-GENERATION BISPHOSPHONATE; EXTRAHEPATIC METASTASES; APOPTOSIS; INHIBITION; MANAGEMENT; PROSTATE; DISEASE	Background and AimZoledronic acid (ZOL) is a nitrogen-containing bisphosphonate and is used to reduce cancer-induced osteolysis. We reported previously that ZOL delayed both the growth and pain progression of bone metastases from hepatocellular carcinoma. The present study was designed to evaluate the effects of ZOL on hepatoma cell lines and the molecular mechanisms of such effects. MethodsCell viability assay, scratch assay, immunohistochemistry, Western blotting, and flow cytometry analysis were performed using Huh7 and HepG2 cells treated with and without ZOL. ResultsZOL reduced cell growth in a dose-dependent manner and prevented cell migration when used at a concentration exceeding 10M. Immunohistochemistry showed that the inhibitory effects of ZOL on hepatoma cell progression was not due to the suppression of Ras and RhoA expression but due to inhibition of their translocation from the cytosol to the cell membrane, which terminates mevalonate pathway. Immunoblotting and flow cytometry showed that ZOL inhibited the mitogen-activated protein kinase pathway (MAPK) and induced apoptosis of hepatoma cells. ConclusionsOur results indicated that ZOL prevented cell growth and metastasis based on direct antitumor effects in hepatoma cells. The use of ZOL could not only suppress the progression to bone metastatic lesions but also prevented growth of primary hepatocellular carcinoma.	[Honda, Yohji; Takahashi, Shoichi; Zhang, Yizhou; Ono, Atsushi; Murakami, Eisuke; Shi, Niu; Kawaoka, Tomokazu; Miki, Daiki; Tsuge, Masataka; Hiraga, Nobuhiko; Abe, Hiromi; Ochi, Hidenori; Imamura, Michio; Aikata, Hiroshi; Chayama, Kazuaki] Hiroshima Univ, Dept Med & Mol Sci, Hiroshima 7348551, Japan	Takahashi, S (reprint author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	shoichit@hiroshima-u.ac.jp					Aft RL, 2012, BRIT J CANCER, V107, P7, DOI 10.1038/bjc.2012.210; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Uka K, 2007, WORLD J GASTROENTERO, V13, P414; Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520; Boissier S, 2000, CANCER RES, V60, P2949; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z; Kamada K, 2002, AM J SURG, V184, P284, DOI 10.1016/S0002-9610(02)00933-9; Hiraga T, 2001, CANCER RES, V61, P4418; Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Kodama H, 2007, ONCOLOGY-BASEL, V72, P285, DOI 10.1159/000113040; Katyal S, 2000, RADIOLOGY, V216, P698; Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200; Neville-Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602; Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305; Uka K, 2007, J GASTROENTEROL, V42, P845, DOI 10.1007/s00535-007-2099-8; Arii S, 2010, HEPATOL RES, V40, P667, DOI 10.1111/j.1872-034X.2010.00673.x; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105; Bloomfield DJ, 1998, J CLIN ONCOL, V16, P1218; Boissier S, 1997, CANCER RES, V57, P3890; Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814; Danoyelle C, 2003, BRIT J CANCER, V88, P1631; Katamura Y, 2010, HEPATOL RES, V40, P1195, DOI 10.1111/j.1872-034X.2010.00729.x; Kimura S, 2004, INT J HEMATOL, V79, P37, DOI 10.1007/BF02983531; Nakano M, 2010, HEPATOL RES, V40, P989, DOI 10.1111/j.1872-034X.2010.00706.x; Natsuizaka M, 2005, J GASTROEN HEPATOL, V20, P1782; Okita K, 2006, J GASTROENTEROL, V41, P100, DOI 10.1007/s00535-005-1763-0; Rossi S, 1996, AM J ROENTGENOL, V167, P759; Senaratne SG, 2000, BRIT J CANCER, V82, P1459; Seong J, 2005, LIVER INT, V25, P261, DOI 10.1111/j.1478-3231.2005.01094.x; Yeh KY, 1998, J IMMUNOL, V160, P5773; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2015	30	3					619	627		10.1111/jgh.12715		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CC1YE	WOS:000350140500030		
J	Akamaru, Y; Takahashi, T; Nishida, T; Omori, T; Nishikawa, K; Mikata, S; Yamamura, N; Miyazaki, S; Noro, H; Takiguchi, S; Mori, M; Doki, Y				Akamaru, Yusuke; Takahashi, Tsuyoshi; Nishida, Toshirou; Omori, Takeshi; Nishikawa, Kazuhiro; Mikata, Shoki; Yamamura, Noriyuki; Miyazaki, Satoru; Noro, Hiroshi; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro			Effects of Daikenchuto, a Japanese Herb, on Intestinal Motility After Total Gastrectomy: a Prospective Randomized Trial	JOURNAL OF GASTROINTESTINAL SURGERY			English	Article						Daikenchuto; Total gastrectomy; Intestinal motility; Bristol scale; Gas volume score (GVS)	DAI-KENCHU-TO; IRRITABLE-BOWEL-SYNDROME; GUINEA-PIG ILEUM; KAMPO MEDICINE; POSTOPERATIVE ILEUS; RATING-SCALE; TRANSIT; RESECTION; DISEASE; TANG	This study aimed to assess the efficacy of daikenchuto (DKT), a commonly prescribed, traditional Japanese herbal medicine, on postoperative intestinal dysfunction after gastric cancer surgery. Patients with gastric cancer scheduled for a total gastrectomy were randomly assigned before surgery to receive either no treatment (n = 40; control group) or DKT (7.5 g/day, t.i.d.) for 3 months (n = 41) postoperatively. We examined gastrointestinal motility, stool attributes, the quantity of bowel gas, the quality of life, and the incidence of postoperative ileus. During the hospital stay, significant differences were observed between the DKT group and controls in the number of stools per day (1.1 +/- 0.6 vs 0.8 +/- 0.4, respectively; P = 0.037) and stool consistencies (Bristol scale ratings were 3.7 +/- 0.8 vs 3.1 +/- 0.8, respectively; P = 0.041). The DKT group showed significant reductions in gas volume scores, calculated from abdominal radiographs, at 7 days, 1 month, and 3 months after surgery. The groups did not show significant differences in quality of life scores (based on the Gastrointestinal Symptom Rating Scale) or in the incidence of postoperative ileus. DKT improved bowel movements, stool properties, and bowel gas. These results suggested that DKT promoted early postoperative bowel functions after total gastrectomy.	[Akamaru, Yusuke] Japan Community Healthcare Org, Osaka Hosp, Dept Surg, Fukushima Ku, Osaka, Japan; [Takahashi, Tsuyoshi; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka, Japan; [Nishida, Toshirou] Natl Canc Ctr Hosp East, Dept Surg, Kashiwa, Chiba, Japan; [Nishida, Toshirou; Omori, Takeshi] Osaka Police Hosp, Dept Surg, Tennouji Ku, Osaka, Japan; [Nishikawa, Kazuhiro] Osaka Gen Med Ctr, Depatrment Surg, Sumiyoshi Ku, Osaka, Japan; [Mikata, Shoki] Osaka Rosai Hosp, Dept Surg, Kita Ku, Sakai, Osaka, Japan; [Yamamura, Noriyuki] Rinku Gen Med Ctr, Dept Surg, Izumisano, Osaka, Japan; [Miyazaki, Satoru] Kinan Hosp, Dept Surg, Tanabe, Wakayama, Japan; [Noro, Hiroshi] Otemae Hosp, Dept Surg, Chuo Ku, Osaka, Japan	Takahashi, T (reprint author), Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, 2-2,E2 Yamadaoka, Suita, Osaka, Japan.	ttakahashi2@gesurg.med.osaka-u.ac.jp			Tsumura & Co., Tokyo, Japan	This study was supported by a grant-in-aid from Tsumura & Co., Tokyo, Japan.	Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; Revicki DA, 1998, QUAL LIFE RES, V7, P75; Yoshikawa K, 2012, SURG TODAY, V42, P646, DOI 10.1007/s00595-011-0094-4; Satoh K, 2001, JPN J PHARMACOL, V86, P32, DOI 10.1254/jjp.86.32; Itoh T, 2002, J INT MED RES, V30, P428; Endo S, 2006, AM J SURG, V192, P9, DOI 10.1016/j.amjsurg.2006.01.022; Hayakawa Terumasa, 1999, Journal of Smooth Muscle Research, V35, P47; Hayakawa Terumasa, 1999, Journal of Smooth Muscle Research, V35, P55; Hiura Y, 2013, SURG TODAY, V43, P527, DOI 10.1007/s00595-012-0253-2; Kehlet H, 2001, AM J SURG, V182, p3S, DOI 10.1016/S0002-9610(01)00781-4; Koide A, 2000, AM J GASTROENTEROL, V95, P1735; Maeda Koutarou, 2013, Nihon Geka Gakkai Zasshi, V114, P232; Manabe N, 2010, AM J PHYSIOL-GASTR L, V298, pG970, DOI 10.1152/ajpgi.00043.2010; Nakamura T, 2002, JPN J PHARMACOL, V88, P217, DOI 10.1254/jjp.88.217; Nishi M, 2012, HEPATO-GASTROENTEROL, V59, P2290, DOI 10.5754/hge10115; Oikawa T, 2009, EVID-BASED COMPL ALT, V6, P375, DOI 10.1093/ecam/nem101; Satoh K, 2001, DIGEST DIS SCI, V46, P250, DOI 10.1023/A:1005636412287; Satoh K, 2003, J ETHNOPHARMACOL, V86, P37, DOI 10.1016/S0378-8741(03)00038-2; Satoh K, 2001, BIOL PHARM BULL, V24, P1122, DOI 10.1248/bpb.24.1122; Shibata C, 1999, SURGERY, V126, P918; Shimada M, 2014, INT J CLIN ONCOL; Suzuki H, 2009, NEUROGASTROENT MOTIL, V21, P688, DOI 10.1111/j.1365-2982.2009.01290.x; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Yaegashi M, 2014, HEPATO-GASTROENTEROL, V61, P85, DOI 10.5754/hge13806; Yasunaga H., 2011, EVID-BASED COMPL ALT, V2011; Youn YH, 2011, DIGEST DIS SCI, V56, P2059, DOI 10.1007/s10620-011-1569-2	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1091-255X	1873-4626		J GASTROINTEST SURG	J. Gastrointest. Surg.	MAR	2015	19	3					467	472		10.1007/s11605-014-2730-y		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CB9PV	WOS:000349965000011		
J	Moriya, K; Yoshizu, T; Maki, Y; Tsubokawa, N; Narisawa, H; Endo, N				Moriya, K.; Yoshizu, T.; Maki, Y.; Tsubokawa, N.; Narisawa, H.; Endo, N.			Clinical outcomes of early active mobilization following flexor tendon repair using the six-strand technique: short- and long-term evaluations	JOURNAL OF HAND SURGERY-EUROPEAN VOLUME			English	Article						Early active mobilization; flexor tendon injury; long-term outcomes; repair; six-strand technique	ZONE-II; DIGITORUM PROFUNDUS; FLEXION; MOTION; FINGERS; SURGERY	We evaluated the factors influencing outcomes of flexor tendon repair in 112 fingers using a six-strand suture with the Yoshizu #1 technique and early postoperative active mobilization in 101 consecutive patients. A total of 32 fingers had injuries in Zone I, 78 in Zone II, and two in Zone III. The mean follow-up period was 6 months; 16 patients (19 fingers) participated in long-term follow-up of 2 to 16 years. The total active motion was 230 degrees SD 29 degrees; it correlated negatively with age. The total active motion was 231 degrees SD 28 degrees after repair of the lacerated flexor digitorum superficialis tendon, and was 205 degrees SD 37 degrees after excision of the flexor digitorum superficialis tendon ends (p=0.0093). A total of 19 fingers showed no significant increases in total active motion more than 2 years after surgery. The rupture rate was 5.4% in our patients and related to surgeons' level of expertise. Five out of six ruptured tendons were repaired by inexperienced surgeons. Level of Evidence IV	[Moriya, K.; Yoshizu, T.; Maki, Y.; Tsubokawa, N.; Narisawa, H.] Niigata Hand Surg Fdn, Seiro, Niigata 9570117, Japan; [Endo, N.] Niigata Univ, Grad Sch Med & Dent Sci, Div Orthopaed Surg, Niigata, Japan	Moriya, K (reprint author), Niigata Hand Surg Fdn, Suwayama 997, Seiro, Niigata 9570117, Japan.	kmoriya@k8.dion.ne.jp					Tang JB, 2014, J HAND SURG-EUR VOL, V39, P107, DOI 10.1177/1753193413500768; Kitsis CK, 1998, J HAND SURG-BRIT EUR, V23B, P344, DOI 10.1016/S0266-7681(98)80055-7; AMADIO PC, 1985, J HAND SURG-AM, V10A, P626; Hwang MD, 2009, J HAND SURG-AM, V34A, P700, DOI 10.1016/j.jhsa.2008.12.003; Tang JB, 2005, HAND CLIN, V21, P199, DOI 10.1016/j.hcl.2004.11.005; Imaeda T, 2006, J ORTHOP SCI, V11, P248, DOI 10.1007/s00776-006-1013-1; STRICKLAND JW, 1980, J HAND SURG-AM, V5, P537; Elliot D, 2003, HAND CLIN, V19, P495, DOI 10.1016/S0749-0712(03)00028-3; Tang JB, 2013, HAND CLIN, V29, P251, DOI 10.1016/j.hcl.2013.02.007; Becker H, 1979, J Hand Surg Am, V4, P454; BRANDSMA JW, 1992, J HAND SURG-BRIT EUR, V17B, P625, DOI 10.1016/0266-7681(92)90187-7; CULLEN KW, 1989, J HAND SURG-BRIT EUR, V14B, P392, DOI 10.1016/0266-7681(89)90153-8; Duran RE, 1975, AAOS S TEND SURG HAN, P105; Dy CJ, 2012, J HAND SURG-AM, V37A, P543, DOI 10.1016/j.jhsa.2011.11.006; EJESKAR A, 1981, HAND, V13, P223, DOI 10.1016/S0072-968X(81)80001-0; Elliot D, 2013, Indian J Plast Surg, V46, P312, DOI 10.4103/0970-0358.118610; GAULT DT, 1987, J HAND SURG-BRIT EUR, V12B, P321, DOI 10.1016/0266-7681(87)90181-1; Jones P, 2005, ANN RHEUM DIS, V64, P226, DOI 10.1136/ard.2003.016444; Kleinert H E, 1973, Orthop Clin North Am, V4, P865; Kusano N, 1999, J HAND SURG-BRIT EUR, V24B, P152, DOI 10.1054/jhsb.1998.0174; Moiemen NS, 2000, J HAND SURG-BRIT EUR, V25B, P78, DOI 10.1054/jhsb.1999.0319; Orkar KS, 2012, J HAND SURG-EUR VOL, V37E, P20, DOI 10.1177/1753193411413661; Osada D, 2006, J HAND SURG-AM, V31A, P987, DOI 10.1016/j.jhsa.2006.03.012; Riaz M, 1999, J HAND SURG-BRIT EUR, V24B, P157, DOI 10.1054/jhsb.1998.0175; SAVAGE R, 1989, J HAND SURG-BRIT EUR, V14B, P396, DOI 10.1016/0266-7681(89)90154-X; SILFVERSKIOLD KL, 1994, J HAND SURG-AM, V19A, P53, DOI 10.1016/0363-5023(94)90224-0; SILFVERSKIOLD KL, 1992, J HAND SURG-AM, V17A, P122, DOI 10.1016/0363-5023(92)90127-B; Simmons BP, 1981, HAND, V1, P377; Strickland JW, 1997, TENDON NERVE SURG HA, P353; Tang JB, 2012, TENDON SURG HAND, P81; TANG JB, 1994, J HAND SURG-BRIT EUR, V19B, P699, DOI 10.1016/0266-7681(94)90238-0; Tang JB, 2013, PLASTIC SURG, V6, P178; Yoshizu T, 1996, J MUSCULOSKELET SYST, V9, P881; Zhao CF, 2002, J HAND SURG-AM, V27A, P316, DOI 10.1053/jhsu.2002.31729	34	2	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1753-1934	2043-6289		J HAND SURG-EUR VOL	J. Hand Surg.-Eur. Vol.	MAR	2015	40	3					250	258		10.1177/1753193414551682		9	Orthopedics; Surgery	Orthopedics; Surgery	CC1RA	WOS:000350118500005		
J	Usami, S; Kawahara, S; Yamaguchi, Y; Hirase, T				Usami, S.; Kawahara, S.; Yamaguchi, Y.; Hirase, T.			Homodigital artery flap reconstruction for fingertip amputation: a comparative study of the oblique triangular neurovascular advancement flap and the reverse digital artery island flap	JOURNAL OF HAND SURGERY-EUROPEAN VOLUME			English	Article						Fingertip defect; homodigital artery flap; oblique triangular flap; reverse digital artery island flap	INJURIES; RESTORATION; REPAIR	This fingertip reconstruction study retrospectively compared sensory recovery and active range of motion outcomes in neurovascular island advancement and reverse digital artery island flaps. Seventeen oblique triangular flaps and 14 reverse digital artery island flaps were performed for nail bed level fingertip amputations (Ishikawa subzone II). There was no significant difference between the two procedures in the Semmes-Weinstein monofilament test and range of motion results. For static and moving two-point discrimination tests, however, those with a reverse digital artery island flap required a longer period for sensory recovery compared to those with an oblique triangular advancement flap. This trend equilibrated at 12 months after surgery showing no significant difference in both static and moving two-point discrimination tests between the procedures.	[Usami, S.; Kawahara, S.; Yamaguchi, Y.] Takatsuki Orthopaed Hosp, Tokyo Hand Surg & Sports Med Inst, Dept Orthopaed Surg, Hachioji, Tokyo 1920002, Japan; [Hirase, T.] Yotsuya Med Cube Hand Surg & Microsurg Ctr, Tokyo, Japan	Usami, S (reprint author), Takatsuki Orthopaed Hosp, Tokyo Hand Surg & Sports Med Inst, Dept Orthopaed Surg, 360 Takatsukicho, Hachioji, Tokyo 1920002, Japan.	s-usaplas@mail.goo.ne.jp					Borman H, 2000, ANN PLAS SURG, V45, P24, DOI 10.1097/00000637-200045010-00005; Varitimidis SE, 2005, J HAND SURG-BRIT EUR, V30B, P338, DOI 10.1016/j.jhsb.2005.04.014; Iwasawa M, 2011, J PLAST RECONSTR AES, V64, P1300, DOI 10.1016/j.bjps.2011.04.026; Sano K, 2008, J HAND SURG-AM, V33A, P1088, DOI 10.1016/j.jhsa.2008.02.022; EVANS DM, 1988, BRIT J PLAST SURG, V41, P105, DOI 10.1016/0007-1226(88)90035-5; KOJIMA T, 1990, BRIT J PLAST SURG, V43, P290, DOI 10.1016/0007-1226(90)90074-A; Han SK, 2004, PLAST RECONSTR SURG, V113, P1753, DOI 10.1097/01.PRS.0000117298.52225.43; VENKATASWAMI R, 1980, PLAST RECONSTR SURG, V66, P296, DOI 10.1097/00006534-198008000-00026; Lemmon JA, 2008, PLAST RECONSTR SURG, V122, p105E, DOI 10.1097/PRS.0b013e3181823be0; DELLON ES, 1995, J HAND SURG-BRIT EUR, V20B, P44, DOI 10.1016/S0266-7681(05)80015-4; Fakin RM, 2014, J HAND SURG-EUR VOL, V39, P499, DOI 10.1177/1753193413489794; Han SK, 1998, PLAST RECONSTR SURG, V101, P1006, DOI 10.1097/00006534-199804040-00018; Hoigne D, 2014, J HAND SURG-EUR VOL, V39, P505, DOI 10.1177/1753193413489639; Ishikawa K, 1990, J JAPAN SOC RECONSTR, V3, P54; LAI CS, 1993, BRIT J PLAST SURG, V46, P483, DOI 10.1016/0007-1226(93)90222-W; Lanzetta M, 1995, J HAND SURG-BRIT EUR, V20B, P824, DOI 10.1016/S0266-7681(95)80056-5; Ozaksar K, 2010, J Hand Surg Eur Vol, V35, P125, DOI 10.1177/1753193409337957; Ozcelik IB, 2008, MICROSURG, V28, P524, DOI 10.1002/micr.20543; SAPP JW, 1993, J HAND SURG-AM, V18A, P528, DOI 10.1016/0363-5023(93)90107-E	19	1	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1753-1934	2043-6289		J HAND SURG-EUR VOL	J. Hand Surg.-Eur. Vol.	MAR	2015	40	3					291	297		10.1177/1753193413515134		7	Orthopedics; Surgery	Orthopedics; Surgery	CC1RA	WOS:000350118500012		
J	Wakayama, T; Nakata, H; Kumchantuek, T; Gewaily, MS; Iseki, S				Wakayama, Tomohiko; Nakata, Hiroki; Kumchantuek, Tewarat; Gewaily, Mahmoud Saad; Iseki, Shoichi			Identification of 5-Bromo-2 '-Deoxyuridine-Labeled Cells during Mouse Spermatogenesis by Heat-Induced Antigen Retrieval in Lectin Staining and Immunohistochemistry	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						5-bromo-2'-deoxyuridine; DNA replication; spermatogenesis; heat-induced antigen retrieval; immunohistochemistry; lectin histochemistry	PARAFFIN-EMBEDDED TISSUES; SPERMATOGONIAL STEM-CELLS; SERTOLI-CELLS; IMMUNOGLOBULIN SUPERFAMILY; SEMINIFEROUS EPITHELIUM; MONOCLONAL-ANTIBODY; NEUROTROPHIC FACTOR; CYCLE PROPERTIES; DNA-SYNTHESIS; IN-VIVO	DNA replication occurs during S-phase in spermatogonia and preleptotene spermatocytes during spermatogenesis. 5-Bromo-2'-deoxyuridine (BrdU) is incorporated into synthesized DNA and is detectable in the nucleus by immunohistochemistry (IHC). To identify BrdU-labeled spermatogenic cells, the spermatogenic stages must be determined by visualizing acrosomes and detecting cell type-specific marker molecules in the seminiferous tubules. However, the antibody reaction with BrdU routinely requires denaturation of the DNA, which is achieved by pretreating tissue sections with hydrochloric acid; however, this commonly interferes with further histochemical approaches. Therefore, we examined optimal methods for pretreating paraffin sections of the mouse testis to detect incorporated BrdU by an antibody and, at the same time, visualize acrosomes with peanut agglutinin (PNA) or detect several marker molecules with antibodies. We found that the use of heat-induced antigen retrieval (HIAR), which consisted of heating at 95C in 20 mM Tris-HCl buffer (pH 9.0) for 15 min, was superior to the use of 2 N hydrochloric acid for 90 min at room temperature in terms of the quality of subsequent PNA-lectin histochemistry with double IHC for BrdU and an appropriate stage marker protein. With this method, we identified BrdU-labeled spermatogenic cells during mouse spermatogenesis as A1 spermatogonia through to preleptotene spermatocytes.	[Wakayama, Tomohiko; Nakata, Hiroki; Kumchantuek, Tewarat; Iseki, Shoichi] Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan; [Gewaily, Mahmoud Saad] Kafrelsheikh Univ, Dept Anat & Embryol, Fac Vet Med, Kafr Al Sheikh, Egypt	Wakayama, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	twaka@staff.kanazawa-u.ac.jp			Japanese Ministry of Education, Science and Culture [25460241]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work described herein was supported in part by grants from the Japanese Ministry of Education, Science and Culture to TW (25460241).	MAGAUD JP, 1989, J HISTOCHEM CYTOCHEM, V37, P1517; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; Grasso M, 2012, REPRODUCTION, V143, P325, DOI 10.1530/REP-11-0385; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Yamashita S, 2007, PROG HISTOCHEM CYTO, V41, P141, DOI 10.1016/j.proghi.2006.09.001; Baker PJ, 1999, EUR J BIOCHEM, V260, P911, DOI 10.1046/j.1432-1327.1999.00245.x; Naughton CK, 2006, BIOL REPROD, V74, P314, DOI 10.1095/biolreprod.105.047365; Pileri SA, 1997, J PATHOL, V183, P116; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Wakayama T, 2007, BIOL REPROD, V76, P1081, DOI 10.1095/biolreprod.106.058974; DOBSON MJ, 1994, J CELL SCI, V107, P2749; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Tang XB, 2007, J NEUROSCI, V27, P5837, DOI 10.1523/JNEUROSCI.5048-06.2007; Yomogida K, 2003, BIOL REPROD, V69, P1303, DOI 10.1095/biolreprod.103.015958; Kerr JB, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P827; de Rooij DG, 2001, REPRODUCTION, V121, P347, DOI 10.1530/rep.0.1210347; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Yamashita S, 2005, J HISTOCHEM CYTOCHEM, V53, P13, DOI 10.1369/jhc.4C6323.2005; Maekawa M, 1996, ARCH HISTOL CYTOL, V59, P1, DOI 10.1679/aohc.59.1; Aviles M, 1997, HISTOCHEM J, V29, P583, DOI 10.1023/A:1026432211012; Blanco-Rodriguez J, 2003, REPRODUCTION, V126, P661, DOI 10.1530/reprod/126.5.661; Emoto K, 2005, J HISTOCHEM CYTOCHEM, V53, P1311, DOI 10.1369/jhc.5C6627.2005; HUCKINS C, 1971, CELL TISSUE KINET, V4, P139, DOI 10.1111/j.1365-2184.1971.tb01524.x; HUCKINS C, 1971, CELL TISSUE KINET, V4, P313, DOI 10.1111/j.1365-2184.1971.tb01543.x; Imai T, 2004, MOL CELL ENDOCRINOL, V214, P107, DOI 10.1016/j.mce.2003.10.065; Kim SH, 2004, J MOL HISTOL, V35, P403; Koruji M, 2012, CELL J, V14, P82; Krenacs L, 2010, METHODS MOL BIOL, V588, P103, DOI 10.1007/978-1-59745-324-0_14; MALI P, 1987, ANDROLOGIA, V19, P644; Meistrich Marvin L, 2013, Methods Mol Biol, V927, P299; Munoz-Velasco I, 2013, J HISTOCHEM CYTOCHEM, V61, P680, DOI 10.1369/0022155413496639; NAGASHIMA T, 1985, ACTA NEUROPATHOL, V67, P155; Nakata H, 2012, ACTA HISTOCHEM CYTOC, V45, P47, DOI 10.1267/ahc.11057; Petersen M, 2012, APPL IMMUNOHISTO M M, V20, P614, DOI 10.1097/PAI.0b013e31824f70d8; Salmand PA, 2008, BIOL REPROD, V79, P1092, DOI 10.1095/biolreprod.108.070334; SHI SR, 1992, J HISTOCHEM CYTOCHEM, V40, P787; Shi SR, 1999, J HISTOCHEM CYTOCHEM, V47, P463; Szasz F, 2000, MOL REPROD DEV, V55, P289, DOI 10.1002/(SICI)1098-2795(200003)55:3<289::AID-MRD7>3.0.CO;2-K; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Wenz JR, 1998, TISSUE CELL, V30, P492, DOI 10.1016/S0040-8166(98)80028-1; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	43	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	MAR	2015	63	3					190	205		10.1369/0022155414564870		16	Cell Biology	Cell Biology	CC6RT	WOS:000350495900004		
J	Fujita, H; Hatanaka, Y; Sutoh, Y; Suzuki, Y; Oba, K; Hatanaka, KC; Mitsuhashi, T; Otsuka, N; Fugo, K; Kasahara, M; Matsuno, Y				Fujita, Hiromi; Hatanaka, Yutaka; Sutoh, Yoichi; Suzuki, Yuta; Oba, Koji; Hatanaka, Kanako C.; Mitsuhashi, Tomoko; Otsuka, Noriyuki; Fugo, Kazunori; Kasahara, Masanori; Matsuno, Yoshihiro			Immunohistochemical Validation and Expression Profiling of NKG2D Ligands in a Wide Spectrum of Human Epithelial Neoplasms	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						NKG2D ligands; immunohistochemistry; epithelial neoplasms	I-RELATED CHAIN; DELTA T-CELLS; CANCER PATIENTS; NK CELLS; RECEPTOR; IMMUNORECEPTOR; COSTIMULATION; CYTOTOXICITY; ACTIVATION; MOLECULES	The MHC class I-chain-related proteins (MICs) and the UL16-binding proteins (ULBPs) are inducible stress response molecules that work as activators of a specific receptor, NKG2D, which is expressed on effector cells, such as NK cells and subsets of T cells. In this study, we sought to explore the biological significance of NKG2D ligands in human neoplasms by comprehensively examining the immunohistochemical expression profile of NKG2D ligands in a variety of human epithelial neoplasms. Following careful validation of the immunohistochemical specificity and availability of anti-human ULBP antibodies for formalin-fixed paraffin-embedded (FFPE) materials, the expression of NKG2D ligands was analyzed in FFPE tissue microarrays comprising 22 types of epithelial neoplastic tissue with their non-neoplastic counterpart from various organs. Hierarchical cluster analysis demonstrated a positive relationship among ULBP2/6, ULBP3, ULBP1, and ULBP5, whose expression patterns were similar across all of the neoplastic tissues examined. In contrast, MICA/B, as well as ULBP4, did not appear to be related to any other ligand. These expression profiles of NKG2D ligands in human neoplasms based on well-validated specific antibodies, followed by hierarchical cluster analysis, should help to clarify some functional aspects of these molecules in cancer biology, and also provide a path to the development of novel tumor-type-specific treatment strategies.	[Fujita, Hiromi; Hatanaka, Yutaka; Hatanaka, Kanako C.; Mitsuhashi, Tomoko; Matsuno, Yoshihiro] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 0608648, Japan; [Oba, Koji] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 0608648, Japan; [Fujita, Hiromi; Otsuka, Noriyuki; Fugo, Kazunori; Kasahara, Masanori] Hokkaido Univ, Grad Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan	Matsuno, Y (reprint author), Hokkaido Univ Hosp, Dept Surg Pathol, Kita Ku, Kita 14,Nishi 5, Sapporo, Hokkaido 0608648, Japan.	ymatsuno@med.hokudai.ac.jp	Kasahara, Masanori/G-7651-2011		Ministry of Education, Culture, Sports, Science and Technology of Japan [24590441]	This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Research Project No. 24590441).	Textor S, 2008, INT J CANCER, V123, P2343, DOI 10.1002/ijc.23733; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Eagle RA, 2006, HUM IMMUNOL, V67, P159, DOI 10.1016/j.humimm.2006.02.015; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Radosavljevic M, 2002, GENOMICS, V79, P114, DOI 10.1006/geno.2001.6673; Coudert JD, 2006, SEMIN CANCER BIOL, V16, P333, DOI 10.1016/j.semcancer.2006.07.008; Vetter CS, 2002, J INVEST DERMATOL, V118, P600, DOI 10.1046/j.1523-1747.2002.01700.x; Takada A, 2008, J IMMUNOL, V180, P1678; McGilvray RW, 2010, INT J CANCER, V127, P1412, DOI 10.1002/ijc.25156; McGilvray RW, 2009, CLIN CANCER RES, V15, P6993, DOI 10.1158/1078-0432.CCR-09-0991; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Chalupny NJ, 2003, BIOCHEM BIOPH RES CO, V305, P129, DOI 10.1016/S0006-291X(03)00714-9; Watson NFS, 2006, INT J CANCER, V118, P1445, DOI 10.1002/ijc.21510; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Friese MA, 2003, CANCER RES, V63, P8996; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Eagle RA, 2009, EUR J IMMUNOL, V39, P3207, DOI 10.1002/eji.200939502; Whang MI, 2009, J IMMUNOL, V182, P4557, DOI 10.4049/jimmunol.0802439; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Pende D, 2002, CANCER RES, V62, P6178; Ehrlich LIR, 2005, J IMMUNOL, V174, P1922; Raffaghello L, 2004, NEOPLASIA, V6, P558, DOI 10.1593/neo.04316; Wu J, 1999, SCIENCE, V285, P730, DOI 10.1126/science.285.5428.730; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Bacon L, 2004, J IMMUNOL, V173, P1078; Castriconi R, 2007, EUR J IMMUNOL, V37, P3190, DOI 10.1002/eji.200737546; Eagle RA, 2009, PLOS ONE, V4, P1; Henriksen KL, 2007, J CLIN PATHOL, V60, P397, DOI 10.1136/jcp.2005.034447; Inagaki A, 2009, INT J CANCER, V125, P212, DOI 10.1002/ijc.24351	33	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	MAR	2015	63	3					217	227		10.1369/0022155414563800		11	Cell Biology	Cell Biology	CC6RT	WOS:000350495900006		
J	Wu, J; Carlock, C; Zhou, C; Nakae, S; Hicks, J; Adams, HP; Lou, YH				Wu, Jean; Carlock, Colin; Zhou, Cindy; Nakae, Susumu; Hicks, John; Adams, Henry P.; Lou, Yahuan			IL-33 Is Required for Disposal of Unnecessary Cells during Ovarian Atresia through Regulation of Autophagy and Macrophage Migration	JOURNAL OF IMMUNOLOGY			English	Article							OXIDATIVE STRESS; LIPOFUSCIN; EXPRESSION; DISEASE; TISSUE; BRAIN; ACCUMULATION; POPULATION; CYTOKINES; RESPONSES	Physiological processes such as ovarian follicle atresia generate large amounts of unnecessary cells or tissue detritus, which needs to be disposed of rapidly. IL-33 is a member of the IL-1 cytokine gene family. Constitutive expression of IL-33 in a wide range of tissues has hinted at its role beyond immune defense. We have previously reported a close correlation between IL-33 expression patterns and ovarian atresia. In this study, we demonstrated that IL-33 is required for disposal of degenerative tissue during ovarian atresia using Il33(-/-) mice. Deletion of the Il33 gene impaired normal disposal of atretic follicles, resulting in massive accumulations of tissue wastes abundant with aging-related catabolic wastes such as lipofuscin. Accumulation of tissue wastes in Il33(-/-) mice, in turn, accelerated ovarian aging and functional decline. Thus, their reproductive life span was shortened to two thirds of that for Il33(+/-) littermates. IL-33 orchestrated disposal mechanism through regulation of autophagy in degenerating tissues and macrophage migration into the tissues. Our study provides direct evidence supporting an expanded role of IL-33 in tissue integrity and aging through regulating disposal of unnecessary tissues or cells.	[Wu, Jean; Carlock, Colin; Zhou, Cindy; Lou, Yahuan] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost Sci, Sch Dent, Houston, TX 77054 USA; [Nakae, Susumu] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo 1578535, Japan; [Hicks, John] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Adams, Henry P.] Univ Texas MD Anderson Canc Ctr, Dept Dev Biol, Houston, TX 77030 USA	Lou, YH (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Biomed Sci, Sch Dent, Room 5326,Behav & Biomed Sci Bldg,1941 East Rd, Houston, TX 77054 USA.	yahuan.lou@uth.tmc.edu			National Institutes of Health [R01 HD049613, R01 DK077857]	This work was supported by National Institutes of Health Grants R01 HD049613 and R01 DK077857 (to Y.L.). The Il33<SUP>-/-</SUP> colony was maintained through institutional bridging funding.	Stroikin Y, 2004, EUR J CELL BIOL, V83, P583, DOI 10.1078/0171-9335-00433; Ichimura Y, 2000, NATURE, V408, P488; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868; Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435; Choi JY, 2010, FERTIL STERIL, V93, P2532, DOI 10.1016/j.fertnstert.2009.11.021; Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2; Harris J, 2011, CYTOKINE, V56, P140, DOI 10.1016/j.cyto.2011.08.022; Bhuiyan MS, 2013, J CLIN INVEST, V123, P5284, DOI 10.1172/JCI70877; Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Yasuoka S, 2011, BRAIN RES, V1385, P8, DOI 10.1016/j.brainres.2011.02.045; MOCHIZUKI Y, 1995, ZOOL SCI, V12, P283; Shelling AN, 2010, REPRODUCTION, V140, P633, DOI 10.1530/REP-09-0567; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; PEDERSEN T, 1968, J REPROD FERTIL, V17, P555; Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008; Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; STOJANOVIC A, 1994, DEMENTIA, V5, P229, DOI 10.1159/000106728; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; HSUEH AJW, 1994, ENDOCR REV, V15, P707, DOI 10.1210/er.15.6.707; Zhou C, 2009, J IMMUNOL, V182, P596; Faddy MJ, 2000, MOL CELL ENDOCRINOL, V163, P43, DOI 10.1016/S0303-7207(99)00238-5; Chapuis J, 2009, MOL PSYCHIATR, V14, P1004, DOI 10.1038/mp.2009.10; Hudson CA, 2008, J LEUKOCYTE BIOL, V84, P631, DOI 10.1189/jlb.1207830; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Carlock C, 2013, REPRODUCTION, V146, P491, DOI 10.1530/REP-13-0134; Carlock CI, 2014, J IMMUNOL, V193, P161, DOI 10.4049/jimmunol.1400381; Escobar Sanchez M. L., 2012, EUR J HISTOCHEM, V56, pe17; Georgakopoulou EA, 2013, AGING-US, V5, P37; Gray Douglas A, 2005, Sci Aging Knowledge Environ, V2005, pre1, DOI 10.1126/sageke.2005.5.re1; Wu J, 2010, J LEUKOCYTE BIOL, V88, P849, DOI 10.1189/jlb.0310133	38	1	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAR 1	2015	194	5					2140	2147		10.4049/jimmunol.1402503		8	Immunology	Immunology	CC0KI	WOS:000350023900015		
J	Metz, PJ; Arsenio, J; Kakaradov, B; Kim, SH; Remedios, KA; Oakley, K; Akimoto, K; Ohno, S; Yeo, GW; Chang, JT				Metz, Patrick J.; Arsenio, Janilyn; Kakaradov, Boyko; Kim, Stephanie H.; Remedios, Kelly A.; Oakley, Katherine; Akimoto, Kazunori; Ohno, Shigeo; Yeo, Gene W.; Chang, John T.			Regulation of Asymmetric Division and CD8(+) T Lymphocyte Fate Specification by Protein Kinase C zeta and Protein Kinase C lambda/i	JOURNAL OF IMMUNOLOGY			English	Article							ALLERGIC AIRWAY INFLAMMATION; B-CELL DIVISION; TRANSCRIPTION FACTOR; CUTTING EDGE; EFFECTOR DIFFERENTIATION; PROTECTIVE IMMUNITY; SYNAPSE FORMATION; IN-VIVO; MEMORY; EXPRESSION	During an immune response against a microbial pathogen, activated naive T lymphocytes give rise to effector cells that provide acute host defense and memory cells that provide long-lived immunity. It has been shown that T lymphocytes can undergo asymmetric division, enabling the daughter cells to inherit unequal amounts of fate-determining proteins and thereby acquire distinct fates from their inception. In this study, we show that the absence of the atypical protein kinase C (PKC) isoforms, PKC zeta and PKCl/i, disrupts asymmetric CD8(+) T lymphocyte division. These alterations were associated with aberrant acquisition of a pre-effector transcriptional program, detected by single-cell gene expression analyses, in lymphocytes that had undergone their first division in vivo and enhanced differentiation toward effector fates at the expense of memory fates. Together, these results demonstrate a role for atypical PKC in regulating asymmetric division and the specification of divergent CD8(+) T lymphocyte fates early during an immune response.	[Metz, Patrick J.; Arsenio, Janilyn; Kim, Stephanie H.; Remedios, Kelly A.; Oakley, Katherine; Chang, John T.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Kakaradov, Boyko; Yeo, Gene W.] Univ Calif San Diego, Stem Cell & Bioinformat Programs, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Kakaradov, Boyko; Yeo, Gene W.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA; [Akimoto, Kazunori; Ohno, Shigeo] Yokohama City Univ, Sch Med, Dept Mol Biol, Yokohama, Kanagawa 2360027, Japan; [Yeo, Gene W.] Natl Univ Singapore, Dept Physiol, Singapore 119077, Singapore; [Yeo, Gene W.] Agcy Sci Technol & Res, Mol Engn Lab, Singapore 138632, Singapore; [Yeo, Gene W.] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore 138632, Singapore	Chang, JT (reprint author), Univ Calif San Diego, 9500 Gilman Dr,0063, La Jolla, CA 92093 USA.	changj@ucsd.edu			National Institutes of Health [DK093507, OD008469, AI095277, HG004659, NS075449]; University of California San Diego Digestive Diseases Research Development Center Grant [DK80506]; California Institute for Regenerative Medicine [RB1-01413, RB3-05009]; University of California San Diego Neuroscience Microscopy Shared Facility [P30 NS047101]	This work was supported by National Institutes of Health Grants DK093507, OD008469, and AI095277 (to J.T.C.) and Grants HG004659 and NS075449 (to G.W.Y.), University of California San Diego Digestive Diseases Research Development Center Grant DK80506, California Institute for Regenerative Medicine Grants RB1-01413 and RB3-05009 (to G.W.Y.), and University of California San Diego Neuroscience Microscopy Shared Facility Grant P30 NS047101. B.K. is a National Science Foundation Graduate Research Fellow. G.W.Y. is a recipient of the Alfred P. Sloan Research Fellowship. J.T.C. is a Howard Hughes Medical Institute Physician-Scientist Early Career Awardee.	Fooksman DR, 2010, ANNU REV IMMUNOL, V28, P79, DOI 10.1146/annurev-immunol-030409-101308; Yao SY, 2013, IMMUNITY, V39, P833, DOI 10.1016/j.immuni.2013.10.007; Raczkowski F, 2013, P NATL ACAD SCI USA, V110, P15019, DOI 10.1073/pnas.1309378110; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Obar JJ, 2010, P NATL ACAD SCI USA, V107, P193, DOI 10.1073/pnas.0909945107; Jung YW, 2010, J IMMUNOL, V185, P5315, DOI 10.4049/jimmunol.1001948; Obar JJ, 2010, ANN NY ACAD SCI, V1183, P251, DOI 10.1111/j.1749-6632.2009.05126.x; Blair DA, 2011, J IMMUNOL, V187, P2310, DOI 10.4049/jimmunol.1100363; Arsenio J, 2014, NAT IMMUNOL, V15, P365, DOI 10.1038/ni.2842; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Kalia V, 2010, IMMUNITY, V32, P91, DOI 10.1016/j.immuni.2009.11.010; Martin P, 2005, P NATL ACAD SCI USA, V102, P9866, DOI 10.1073/pnas.0501202102; Plumlee CR, 2013, IMMUNITY, V39, P347, DOI 10.1016/j.immuni.2013.07.014; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Real E, 2007, J IMMUNOL, V179, P5649; King CG, 2012, IMMUNITY, V37, P709, DOI 10.1016/j.immuni.2012.06.021; Olson JA, 2013, IMMUNITY, V38, P1250, DOI 10.1016/j.immuni.2013.05.009; Soloff RS, 2004, J IMMUNOL, V173, P3250; Thaunat O, 2012, SCIENCE, V335, P475, DOI 10.1126/science.1214100; Ciocca ML, 2012, J IMMUNOL, V188, P4145, DOI 10.4049/jimmunol.1200176; Joshi NS, 2007, IMMUNITY, V27, P281, DOI 10.1016/j.immuni.2007.07.010; Mach N, 2000, CANCER RES, V60, P3239; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Gerlach C, 2010, J EXP MED, V207, P1235, DOI 10.1084/jem.20091175; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002; Man K, 2013, NAT IMMUNOL, V14, P1155, DOI 10.1038/ni.2710; Intlekofer AM, 2007, J EXP MED, V204, P2015, DOI 10.1084/jem.20070841; Bertrand F, 2010, J IMMUNOL, V185, P2887, DOI 10.4049/jimmunol.1000739; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Bertrand F, 2013, P NATL ACAD SCI USA, V110, P6073, DOI 10.1073/pnas.1218640110; Haring JS, 2006, IMMUNITY, V25, P19, DOI 10.1016/j.immuni.2006.07.001; Badovinac VP, 2007, J IMMUNOL, V179, P53; Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009; Stemberger C, 2007, IMMUNITY, V27, P985, DOI 10.1016/j.immuni.2007.10.012; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Atwood SX, 2009, CURR BIOL, V19, P723, DOI 10.1016/j.cub.2009.03.056; Oliaro J, 2010, J IMMUNOL, V185, P367, DOI 10.4049/jimmunol.0903627; Hikono H, 2007, J EXP MED, V204, P1625, DOI 10.1084/jem.20070322; Barnett BE, 2012, SCIENCE, V335, P342, DOI 10.1126/science.1213495; Grayson JM, 2000, J IMMUNOL, V164, P3950; Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Chang JT, 2011, IMMUNITY, V34, P492, DOI 10.1016/j.immuni.2011.03.017; Clarke SRM, 2000, IMMUNOL CELL BIOL, V78, P110, DOI 10.1046/j.1440-1711.2000.00889.x; Hawkins ED, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2796; Koike C, 2005, J NEUROSCI, V25, P10290, DOI 10.1523/JNEUROSCI.3657-05.2005; Miyagawa F, 2012, P NATL ACAD SCI USA, V109, P12123, DOI 10.1073/pnas.1201453109; Prehoda KE, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001388; Yamashita YM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001313; Yang JQ, 2009, P NATL ACAD SCI USA, V106, P1099, DOI 10.1073/pnas.0805907106	56	3	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAR 1	2015	194	5					2249	2259		10.4049/jimmunol.1401652		11	Immunology	Immunology	CC0KI	WOS:000350023900025		
J	Mckay, JT; Egan, RP; Yammani, RD; Chen, LP; Shin, T; Yagita, H; Haas, KM				McKay, Jerome T.; Egan, Ryan P.; Yammani, Rama D.; Chen, Lieping; Shin, Tahiro; Yagita, Hideo; Haas, Karen M.			PD-1 Suppresses Protective Immunity to Streptococcus pneumoniae through a B Cell-Intrinsic Mechanism	JOURNAL OF IMMUNOLOGY			English	Article							INDEPENDENT TYPE-2 ANTIGENS; IN-VIVO; PNEUMOCOCCAL POLYSACCHARIDES; RESPONSES; MICE; EXPRESSION; INFECTION; INNATE; IGG3; ANTIBODIES	Despite the emergence of the programmed cell death 1 (PD-1): PD-1 ligand (PD-L) regulatory axis as a promising target for treating multiple human diseases, remarkably little is known about how this pathway regulates responses to extracellular bacterial infections. We found that PD-1 2(-/-) mice, as well as wild-type mice treated with a PD-1 blocking Ab, exhibited significantly increased survival against lethal Streptococcus pneumoniae infection following either priming with low-dose pneumococcal respiratory infection or S. pneumoniae-capsular polysaccharide immunization. Enhanced survival in mice with disrupted PD-1: PD-L interactions was explained by significantly increased proliferation, isotype switching, and IgG production by pneumococcal capsule-specific B cells. Both PD-L, B7-H1 and B7-DC, contributed to PD-1-mediated suppression of protective capsule-specific IgG. Importantly, PD-1 was induced on capsule-specific B cells and suppressed IgG production and protection against pneumococcal infection in a B cell-intrinsic manner. To our knowledge, these results provide the first demonstration of a physiologic role for B cell-intrinsic PD-1 expression in vivo. In summary, our study reveals that B cell-expressed PD-1 plays a central role in regulating protection against S. pneumoniae, and thereby represents a promising target for bolstering immunity to encapsulated bacteria.	[McKay, Jerome T.; Egan, Ryan P.; Yammani, Rama D.; Haas, Karen M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27101 USA; [Chen, Lieping] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06519 USA; [Shin, Tahiro] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan	Haas, KM (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, 575 North Patterson Ave, Winston Salem, NC 27101 USA.	kmhaas@wakehealth.edu			National Institutes of Health [R21AI095800, R56AI08654]; American Cancer Society [RSG-12-170-01-LIB]; National Institutes of Health Training [AI007401]; National Cancer Institute Cancer Center Support Grant [P30CA012197]	This work was supported by National Institutes of Health Grants R21AI095800 and R56AI08654, American Cancer Society Grant RSG-12-170-01-LIB, and National Institutes of Health Training Grant AI007401 (to J.T.M.). This work was also supported by shared resources provided by National Cancer Institute Cancer Center Support Grant P30CA012197.	Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990; Tomayko MM, 2010, J IMMUNOL, V185, P7146, DOI 10.4049/jimmunol.1002163; Lazar-Molnar E, 2010, P NATL ACAD SCI USA, V107, P13402, DOI 10.1073/pnas.1007394107; Brown KE, 2010, CURR OPIN IMMUNOL, V22, P397, DOI 10.1016/j.coi.2010.03.007; Haas KM, 2014, J INFECT DIS, V209, P87, DOI 10.1093/infdis/jit442; Haas KM, 2006, J IMMUNOL, V177, P3063; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Yammani RD, 2013, J IMMUNOL, V190, P3100, DOI 10.4049/jimmunol.1203058; Haas KM, 2005, IMMUNITY, V23, P7, DOI 10.1016/j.immuni.2005.04.011; Kawamoto S, 2012, SCIENCE, V336, P485, DOI 10.1126/science.1217718; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; Zhong XM, 2007, EUR J IMMUNOL, V37, P2405, DOI 10.1002/eji.200737461; Haas KM, 2009, J IMMUNOL, V183, P3661, DOI 10.4049/jimmunol.0901218; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Dong HD, 2004, IMMUNITY, V20, P327, DOI 10.1016/S1074-7613(04)00050-0; BRILES DE, 1992, INFECT IMMUN, V60, P111; Barber DL, 2011, J IMMUNOL, V186, P1598, DOI 10.4049/jimmunol.1003304; Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877; Haas KM, 2002, IMMUNITY, V17, P713, DOI 10.1016/S1074-7613(02)00483-1; Nishimura H, 1998, INT IMMUNOL, V10, P1563, DOI 10.1093/intimm/10.10.1563; Sen G, 2005, J IMMUNOL, V175, P3084; Titanji K, 2010, J CLIN INVEST, V120, P3878, DOI 10.1172/JCI43271; Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828; Weber S, 2012, INFECT IMMUN, V80, P1314, DOI 10.1128/IAI.06081-11; BRILES DE, 1981, NATURE, V294, P88, DOI 10.1038/294088a0; Deenick EK, 1999, J IMMUNOL, V163, P4707; Garau J, 2007, CLIN INFECT DIS, V45, P52, DOI 10.1086/518576; Gonzalez-Fernandez A, 2008, VACCINE, V26, P292, DOI 10.1016/j.vaccine.2007.11.042; Harms G, 1996, INFECT IMMUN, V64, P4220; HUMPHREY JH, 1981, EUR J IMMUNOL, V11, P212, DOI 10.1002/eji.1830110310; Kalka-Moll WM, 2002, J IMMUNOL, V169, P6149; Kovarik J, 2001, IMMUNOLOGY, V102, P67, DOI 10.1046/j.1365-2567.2001.01158.x; Maruya Mikako, 2013, Gut Microbes, V4, P165, DOI 10.4161/gmic.23595; McLay J, 2002, J IMMUNOL, V168, P3437; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Rush JS, 2005, P NATL ACAD SCI USA, V102, P13242, DOI 10.1073/pnas.0502779102; Shin T, 2005, J EXP MED, V201, P1531, DOI 10.1084/jem.20050072; Tian H, 2009, INFECT IMMUN, V77, P1502, DOI 10.1128/IAI.01075-08; Wang SDA, 2011, CURR TOP MICROBIOL, V344, P245, DOI 10.1007/82_2010_81; YIN JZ, 1989, J BIOL RESP MODIF, V8, P190; Zhong XM, 2004, INT IMMUNOL, V16, P1181, DOI 10.1093/intimm/dxh121	45	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	MAR 1	2015	194	5					2289	2299		10.4049/jimmunol.1401673		11	Immunology	Immunology	CC0KI	WOS:000350023900029		
J	Yokoi, K; Akiyama, K; Kaneshiro, E; Higuchi, T; Shimada, Y; Kobayashi, H; Akiyama, M; Otsu, M; Nakauchi, H; Ohashi, T; Ida, H				Yokoi, Kentaro; Akiyama, Kazumasa; Kaneshiro, Eiko; Higuchi, Takashi; Shimada, Yohta; Kobayashi, Hiroshi; Akiyama, Masaharu; Otsu, Makoto; Nakauchi, Hiromitsu; Ohashi, Toya; Ida, Hiroyuki			Effect of donor chimerism to reduce the level of glycosaminoglycans following bone marrow transplantation in a murine model of mucopolysaccharidosis type II	JOURNAL OF INHERITED METABOLIC DISEASE			English	Article							ENZYME REPLACEMENT THERAPY; HEMATOPOIETIC-CELL TRANSPLANTATION; INHERITED METABOLIC DISEASES; HUNTER-SYNDROME; MOUSE MODEL; MPS-II; GUIDELINES; MANAGEMENT; CHILDREN; EFFICACY	Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficient activity of the iduronate-2-sulfatase. This leads to accumulation of glycosaminoglycans (GAGs) in the lysosomes of various cells. Although it has been proposed that bone marrow transplantation (BMT) may have a beneficial effect for patients with MPS II, the requirement for donor-cell chimerism to reduce GAG levels is unknown. To address this issue, we transplanted various ratios of normal and MPS II bone marrow cells in a mouse model of MPS II and analyzed GAG accumulation in various tissues. Chimerism of whole leukocytes and each lineage of BMT recipients' peripheral blood was similar to infusion ratios. GAGs were significantly reduced in the liver, spleen, and heart of recipients. The level of GAG reduction in these tissues depends on the percentage of normal-cell chimerism. In contrast to these tissues, a reduction in GAGs was not observed in the kidney and brain, even if 100 % donor chimerism was achieved. These observations suggest that a high degree of chimerism is necessary to achieve the maximum effect of BMT, and donor lymphocyte infusion or enzyme replacement therapy might be considered options in cases of low-level chimerism in MPS II patients.	[Yokoi, Kentaro; Kaneshiro, Eiko; Kobayashi, Hiroshi; Akiyama, Masaharu; Ohashi, Toya; Ida, Hiroyuki] Jikei Univ, Sch Med, Dept Pediat, Minato Ku, Tokyo 1058461, Japan; [Yokoi, Kentaro; Akiyama, Kazumasa; Higuchi, Takashi; Shimada, Yohta; Kobayashi, Hiroshi; Ohashi, Toya; Ida, Hiroyuki] Jikei Univ, Sch Med, Res Ctr Med Sci, Div Gene Therapy, Tokyo 1058461, Japan; [Otsu, Makoto; Nakauchi, Hiromitsu] Univ Tokyo, Inst Med Sci, Ctr Stem Cell & Regenerat Med, Div Stem Cell Therapy, Tokyo, Japan	Yokoi, K (reprint author), Jikei Univ, Sch Med, Dept Pediat, Minato Ku, 3-25-8 Nishishimbashi, Tokyo 1058461, Japan.	kenta451@jikei.ac.jp			KAKENHI Grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology [25860884]	The authors thank Joseph Muenzer of the University of North Carolina at Chapel Hill for providing the MPS II mice. We also thank Taku Sato of Tokyo Medical and Dental University for helping with the flow cytometry study. Finally, we thank the members of the Laboratory Animal Facility at The Jikei University School of Medicine for help with the animal studies. This work was supported by a KAKENHI Grant (No. 25860884) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Muenzer J, 2002, ACTA PAEDIATR, V91, P98, DOI 10.1080/080352502762458012; Vellodi A, 1999, J INHERIT METAB DIS, V22, P638, DOI 10.1023/A:1005525931994; Boelens JJ, 2013, BLOOD, V121, P3981, DOI 10.1182/blood-2012-09-455238; Higuchi T, 2012, MOL GENET METAB, V107, P122, DOI 10.1016/j.ymgme.2012.05.005; Peters C, 2003, BONE MARROW TRANSPL, V31, P229, DOI 10.1038/sj.bmt.1703839; Akiyama K, 2014, MOL GENET METAB, V111, P139, DOI 10.1016/j.ymgme.2013.09.013; Burton BK, 2011, MOL GENET METAB, V103, P113, DOI 10.1016/j.ymgme.2011.02.018; Tanaka A, 2012, MOL GENET METAB, V107, P513, DOI 10.1016/j.ymgme.2012.09.004; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Muenzer J, 2011, GENET MED, V13, P102, DOI 10.1097/GIM.0b013e318206786f; Muenzer J, 2009, PEDIATRICS, V123, P19, DOI 10.1542/peds.2008-0416; Wynn RF, 2009, J PEDIATR-US, V154, P609, DOI 10.1016/j.jpeds.2008.11.005; Soper BW, 2001, BLOOD, V97, P1498, DOI 10.1182/blood.V97.5.1498; Araya K, 2009, MOL GENET METAB, V98, P255, DOI 10.1016/j.ymgme.2009.05.006; Enquist IB, 2009, STEM CELLS, V27, P744, DOI 10.1634/stemcells.2008-0844; Garcia AR, 2007, MOL GENET METAB, V91, P183, DOI 10.1016/j.ymgme.2007.03.003; Garcia AR, 2007, J INHERIT METAB DIS, V30, P924; Guffon N, 2009, J PEDIATR-US, V154, P733, DOI 10.1016/j.jpeds.2008.11.041; Hansen MD, 2008, BONE MARROW TRANSPL, V41, P349, DOI 10.1038/sj.bmt.1705926; Ito K, 2004, BRIT J DERMATOL, V151, P207, DOI 10.1111/j.1365.2133.2004.05944.x; Link Bianca, 2010, Orthop Rev (Pavia), V2, pe16, DOI 10.4081/or.2010.e16; Muenzer J, 2009, PEDIATRICS, V124, pE1228, DOI 10.1542/peds.2008-0999; Mullen CA, 2000, BONE MARROW TRANSPL, V25, P1093, DOI 10.1038/sj.bmt.1702397; Prasad V, 2008, BONE MARROW TRANSPL, V41, P99, DOI 10.1038/sj.bmt.1705970; Sato Y, 2013, PEDIATR CARDIOL, V34, P2077, DOI 10.1007/s00246-013-0653-0; Scarpa M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-72; Simonaro CM, 2008, AM J PATHOL, V172, P112; Yokoi T, 2011, J GENE MED, V13, P262, DOI 10.1002/jgm.1566	28	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0141-8955	1573-2665		J INHERIT METAB DIS	J. Inherit. Metab. Dis.	MAR	2015	38	2					333	340		10.1007/s10545-014-9800-x		8	Endocrinology & Metabolism; Genetics & Heredity	Endocrinology & Metabolism; Genetics & Heredity	CC4XU	WOS:000350360200015		
